<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="0" size="13" family="Times" color="#000000"/>
	<fontspec id="1" size="16" family="Times" color="#000000"/>
	<fontspec id="2" size="13" family="Times" color="#000000"/>
	<fontspec id="3" size="14" family="Times" color="#000000"/>
<text top="795" left="1095" width="10" height="17" font="0">1 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="91" left="105" width="982" height="16" font="1"><b>2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease Data Supplements </b></text>
<text top="111" left="417" width="357" height="14" font="2"><b>(Section numbers correspond to the full-text guideline.) </b></text>
<text top="124" left="594" width="3" height="17" font="2"><b> </b></text>
<text top="146" left="526" width="142" height="16" font="1"><b>Table of Contents </b></text>
<text top="162" left="86" width="3" height="17" font="2"><b> </b></text>
<text top="179" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#3">Evidence Table 1. Nonrandomized Trials, Observational Studies, and/or Registries of History for Clinical Assessment for PAD–Section 2.1. ........................................................................... 3</a></text>
<text top="181" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#3"> </a></text>
<text top="197" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#9">Evidence Table 2. Nonrandomized Trials, Observational Studies, and/or Registries of Physical Examination for Clinical Assessment for PAD–Section 2.1. .................................................... 9</a></text>
<text top="198" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#9"> </a></text>
<text top="214" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#12">Evidence Table 3. RCTs of Resting ABI for Diagnosing PAD–Section 3.1. ................................................................................................................................................................................. 12</a></text>
<text top="216" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#12"> </a></text>
<text top="231" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#13">Evidence Table 4. Nonrandomized Trials, Observational Studies, and/or Registries of Resting ABI for Diagnosing PAD–Section 3.1. .................................................................................... 13</a></text>
<text top="233" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#13"> </a></text>
<text top="248" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#23">Evidence Table 5. Nonrandomized Trials, Observational Studies, and/or Registries of Physiological Testing–Section 3.2. ...................................................................................................... 23</a></text>
<text top="250" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#23"> </a></text>
<text top="266" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#28">Evidence Table 6. Nonrandomized Trials, Observational Studies, and/or Registries of Imaging for Anatomic Assessment (Ultrasound, CTA, MRA, Angiography)–Section 3.3. ................... 28</a></text>
<text top="267" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#28"> </a></text>
<text top="283" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#34">Evidence Table 7. RCTs of Imaging for Anatomic Assessment (Ultrasound, CTA, MRA, Angiography)–Section 3.3. ............................................................................................................... 34</a></text>
<text top="284" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#34"> </a></text>
<text top="300" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#37">Evidence Table 8. Nonrandomized Trials, Observational Studies, and/or Registries for Abdominal Aortic Aneurysm–Section 4.1. .......................................................................................... 37</a></text>
<text top="302" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#37"> </a></text>
<text top="317" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#38">Evidence Table 9. Nonrandomized Trials, Observational Studies, and/or Registries of Coronary Artery Disease Screening in PAD–Section 4.2. ................................................................... 38</a></text>
<text top="319" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#38"> </a></text>
<text top="334" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#39">Evidence Table 10. RCTs for CAD Screening in PAD–Section 4.2. ............................................................................................................................................................................................ 39</a></text>
<text top="336" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#39"> </a></text>
<text top="352" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#39">Evidence Table 11. Nonrandomized Trials, Observational Studies, and/or Registries of Screening in Carotid Artery Disease–Section 4.3. ............................................................................. 39</a></text>
<text top="353" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#39"> </a></text>
<text top="369" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#40">Evidence Table 12. Nonrandomized Trials, Observational Studies, and/or Registries for Renal Artery Disease–Section 4.4. ................................................................................................... 40</a></text>
<text top="371" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#40"> </a></text>
<text top="386" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#41">Evidence Table 13. RCTs Evaluating Antiplatelet Agents– Section 5.1. ..................................................................................................................................................................................... 41</a></text>
<text top="388" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#41"> </a></text>
<text top="403" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#56">Evidence Table 14. Nonrandomized Trials, Observational Studies, and/or Registries of Antiplatelet Agents–Section 5.2. ........................................................................................................ 56</a></text>
<text top="405" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#56"> </a></text>
<text top="420" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#56">Evidence Table 15. Randomized Trials Comparing Statin Agents–Section 5.2. ......................................................................................................................................................................... 56</a></text>
<text top="422" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#56"> </a></text>
<text top="438" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#59">Evidence Table 16. Nonrandomized Trials, Observational Studies, and/or Registries of Statin Agents–Section 5.2.................................................................................................................. 59</a></text>
<text top="439" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#59"> </a></text>
<text top="455" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#61">Evidence Table 17. RCTs for Antihypertensive Agents– Section 5.3. ......................................................................................................................................................................................... 61</a></text>
<text top="457" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#61"> </a></text>
<text top="472" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#64">Evidence Table 18. Nonrandomized Trials, Observational Studies, and/or Registries of Antihypertensive Agents–Section 5.3. ............................................................................................... 64</a></text>
<text top="474" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#64"> </a></text>
<text top="489" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#64">Evidence Table 19. RCTs for Smoking Cessation–Section 5.4. .................................................................................................................................................................................................. 64</a></text>
<text top="491" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#64"> </a></text>
<text top="507" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#67">Evidence Table 20. Nonrandomized Trials, Observational Studies, and/or Registries of Smoking Cessation–Section 5.4. ....................................................................................................... 67</a></text>
<text top="508" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#67"> </a></text>
<text top="524" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#68">Evidence Table 21. RCTs Evaluating Glycemic Control in Patients with PAD and Diabetes Mellitus–Section 5.5. .................................................................................................................... 68</a></text>
<text top="525" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#68"> </a></text>
<text top="541" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#69">Evidence Table 22. Nonrandomized Trials, Observational Studies, and/or Registries of Glycemic Control–Section 5.5. ........................................................................................................... 69</a></text>
<text top="543" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#69"> </a></text>
<text top="558" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#71">Evidence Table 23. RCTs Evaluating Oral Anticoagulation–Section 5.6. .................................................................................................................................................................................... 71</a></text>
<text top="560" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#71"> </a></text>
<text top="575" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#73">Evidence Table 24. Nonrandomized Trials, Observational Studies, and/or Registries of Oral Anticoagulation–Section 5.6....................................................................................................... 73</a></text>
<text top="577" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#73"> </a></text>
<text top="593" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#74">Evidence Table 25. RCTs and Observational Studies of Cilostazol–Section 5.7. ....................................................................................................................................................................... 74</a></text>
<text top="594" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#74"> </a></text>
<text top="610" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#77">Evidence Table 26. Nonrandomized Trials, Observational Studies, and/or Registries of Pentoxifylline–Section 5.8. ................................................................................................................. 77</a></text>
<text top="611" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#77"> </a></text>
<text top="627" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#79">Evidence Table 27. Systematic Review of Chelation Therapy–Section 5.9. ................................................................................................................................................................................ 79</a></text>
<text top="629" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#79"> </a></text>
<text top="644" left="80" width="981" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#79">Evidence Table 28. Nonrandomized Trials, Observational Studies, and/or Registries of Homocysteine Lowering Therapy for Lower Extremity PAD in Patients with Diabetes Mellitus–</a></text>
<text top="661" left="188" width="913" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#79">Section 5.10.1. .............................................................................................................................................................................................................................................. 79</a></text>
<text top="663" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#79"> </a></text>
<text top="679" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#80">Evidence Table 29. RCTs Comparing Additional Medical Therapies of Homocysteine Lowering Therapy for Lower Extremity PAD–Section 5.10.1. ............................................................... 80</a></text>
<text top="680" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#80"> </a></text>
<text top="696" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#81">Evidence Table 30. RCTs for Influenza Vaccination–Section 5.10.2. .......................................................................................................................................................................................... 81</a></text>
<text top="698" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#81"> </a></text>
<text top="713" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#82">Evidence Table 31. Nonrandomized Trials for Influenza Vaccination–Section 5.10.2. ................................................................................................................................................................ 82</a></text>
<text top="715" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#82"> </a></text>
<text top="730" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#82">Evidence Table 32. RCTs for Exercise Therapy–Section 6. ........................................................................................................................................................................................................ 82</a></text>
<text top="732" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#82"> </a></text>
<text top="747" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#91">Evidence Table 33. Nonrandomized Trials, Observational Studies, and/or Registries for Exercise Therapy–Section 6. ............................................................................................................ 91</a></text>
<text top="749" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#91"> </a></text>
<text top="765" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#92">Evidence Table 34. Nonrandomized Trials and Observational Studies of Minimizing Tissue Loss in Patients with PAD–Section 7. ......................................................................................... 92</a></text>
<text top="766" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#92"> </a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="4" size="13" family="Times" color="#000000"/>
	<fontspec id="5" size="11" family="Times" color="#000000"/>
<text top="795" left="1095" width="10" height="17" font="0">2 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#96">Data Supplement 34a. Functions of a Multidisciplinary Foot Care / Amputation Prevention Team–Section 7. ........................................................................................................................... 96</a></text>
<text top="88" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#96"> </a></text>
<text top="104" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#97">Evidence Table 35. RCTs Comparing Endovascular Treatment and Endovascular Versus Noninvasive Treatment of Claudication–Section 8.1. .................................................................... 97</a></text>
<text top="105" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#97"> </a></text>
<text top="121" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#120">Evidence Table 36. Nonrandomized Trials, Observational Studies, and/or Registries of Endovascular and Endovascular Versus Noninvasive Treatment of Claudication–Section 8.1. ..... 120</a></text>
<text top="122" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#120"> </a></text>
<text top="138" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#123">Evidence Table 37. RCTs Evaluating Surgical Treatment for Claudication–Section 8.1.2. ....................................................................................................................................................... 123</a></text>
<text top="140" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#123"> </a></text>
<text top="155" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#129">Evidence Table 38. Nonrandomized Trials, Observational Studies, and/or Registries of Surgical Treatment for Claudication–Section 8.1.2. ......................................................................... 129</a></text>
<text top="157" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#129"> </a></text>
<text top="172" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#143">Evidence Table 39. RCTs Comparing Endovascular Revascularization for Chronic CLI–Section 8.2. ..................................................................................................................................... 143</a></text>
<text top="174" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#143"> </a></text>
<text top="190" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#151">Evidence Table 40. Nonrandomized Trials, Observational Studies, and/or Registries of Endovascular Revascularization for Chromic CLI–Section 8.2.1. .................................................... 151</a></text>
<text top="191" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#151"> </a></text>
<text top="207" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#157">Evidence Table 41. RCTs of Surgical Revascularization for Chronic CLI–Section 8.2. ............................................................................................................................................................. 157</a></text>
<text top="209" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#157"> </a></text>
<text top="224" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#162">Evidence Table 42. Nonrandomized Trials, Observational Studies, and/or Registries for Surgical Revascularization for Chronic CLI–Section 8.2. ............................................................... 162</a></text>
<text top="226" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#162"> </a></text>
<text top="241" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#167">Evidence Table 43. RCT Comparing Prostanoids for End-Stage Peripheral Artery Disease–Section 8.2.3. ............................................................................................................................ 167</a></text>
<text top="243" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#167"> </a></text>
<text top="258" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#167">Evidence Table 44. Nonrandomized Trials, Observational Studies, and/or Registries for Would Healing Therapies for CLI–Section 8.2.3. ............................................................................ 167</a></text>
<text top="260" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#167"> </a></text>
<text top="276" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#169">Evidence Table 45. Nonrandomized Trials, Observational Studies, and/or Registries of Acute Limb Ischemia–Section 9.1.................................................................................................... 169</a></text>
<text top="277" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#169"> </a></text>
<text top="293" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#171">Evidence Table 46. Nonrandomized Trials, Observational studies, and/or Registries Comparing Evaluating Noninvasive Testing and Angiography for ALI–Section 9.1. ............................ 171</a></text>
<text top="295" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#171"> </a></text>
<text top="310" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#172">Evidence Table 47. RCTs of Revascularization Strategy for ALI–Section 9.2.2. ....................................................................................................................................................................... 172</a></text>
<text top="312" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#172"> </a></text>
<text top="327" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#175">Evidence Table 48. Nonrandomized Trials, Observational Studies, and/or Registries of Clinical Presentation of ALI–Section 9.2.2. ...................................................................................... 175</a></text>
<text top="329" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#175"> </a></text>
<text top="345" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#177">Evidence Table 49. Nonrandomized Trials, Observational Studies, and/or Registries of Diagnostic Evaluation of the Cause of ALI–Section 9.2.2. ............................................................... 177</a></text>
<text top="346" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#177"> </a></text>
<text top="362" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#178">Evidence Table 50. Nonrandomized Trials, Observational Studies, and/or Registries of Revascularization Strategy for ALI–Section 9.2.2............................................................................ 178</a></text>
<text top="364" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#178"> </a></text>
<text top="379" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#181">Evidence Table 51. RCTs for Longitudinal Follow-Up–Section 10. ........................................................................................................................................................................................... 181</a></text>
<text top="381" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#181"> </a></text>
<text top="396" left="80" width="1021" height="17" font="0"><a href="2016_LEPAD_Data_Supplement.html#182">Evidence Table 52. Nonrandomized Trials, Observational Studies, and/or Registries for Longitudinal Follow-Up–Section 10. ............................................................................................... 182</a></text>
<text top="398" left="1101" width="4" height="16" font="3"><a href="2016_LEPAD_Data_Supplement.html#182"> </a></text>
<text top="413" left="80" width="66" height="17" font="0">References </text>
<text top="413" left="188" width="913" height="17" font="0"> ........................................................................................................................................................................................................................ <b>Error! Bookmark not defined.</b></text>
<text top="415" left="1101" width="4" height="16" font="3"> </text>
<text top="435" left="86" width="5" height="16" font="1"><b> </b></text>
<text top="474" left="86" width="274" height="16" font="1"><b>Methodology and Evidence Review </b></text>
<text top="512" left="86" width="979" height="14" font="0">The recommendations listed in this guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from </text>
<text top="529" left="86" width="995" height="14" font="0">research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare </text>
<text top="546" left="86" width="987" height="14" font="0">Research and Quality, and other selected databases relevant to this guideline, was conducted from January through September 2015. Key search words included but </text>
<text top="564" left="86" width="1005" height="14" font="0">were not limited to the following: <i>acute limb ischemia, angioplasty, ankle-brachial index, anticoagulation, antiplatelet therapy, atypical leg symptoms, blood pressure </i></text>
<text top="581" left="86" width="987" height="14" font="4"><i>lowering/hypertension, bypass graft/bypass grafting/surgical bypass, cilostazol, claudication/intermittent claudication, critical limb ischemia/severe limb ischemia, </i></text>
<text top="598" left="86" width="989" height="14" font="4"><i>diabetes, diagnostic testing, endovascular therapy, exercise rehabilitation/exercise therapy/exercise training/supervised exercise, lower extremity/foot wound/ulcer, </i></text>
<text top="615" left="86" width="983" height="14" font="4"><i>peripheral artery disease/peripheral arterial disease/peripheral vascular disease/lower extremity arterial disease, smoking/smoking cessation, statin, stenting, </i>and<i> </i></text>
<text top="633" left="86" width="1004" height="14" font="4"><i>vascular surgery</i>. Additional relevant studies published through September 2016, during the guideline writing process, were also considered by the writing committee, </text>
<text top="650" left="86" width="314" height="14" font="0">and added to the evidence tables when appropriate.  </text>
<text top="651" left="400" width="3" height="12" font="5"><i> </i></text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="6" size="13" family="Times" color="#0000ff"/>
	<fontspec id="7" size="13" family="Symbol" color="#000000"/>
<text top="795" left="1095" width="10" height="17" font="0">3 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="974" height="21" font="1"><b>Evidence Table 1. Nonrandomized Trials, Observational Studies, and/or Registries of History for Clinical Assessment for PAD–Section 2.1. </b></text>
<text top="108" left="110" width="38" height="17" font="2"><b>Study </b></text>
<text top="125" left="98" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="142" left="105" width="48" height="17" font="2"><b>Author; </b></text>
<text top="159" left="113" width="30" height="17" font="2"><b>Year </b></text>
<text top="177" left="97" width="62" height="17" font="2"><b>Published </b></text>
<text top="108" left="231" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="125" left="258" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="108" left="454" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="108" left="657" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="125" left="664" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="142" left="716" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="108" left="928" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="125" left="955" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="195" left="88" width="53" height="17" font="0">Rose GA </text>
<text top="212" left="88" width="46" height="17" font="0">1962(1) </text>
<text top="229" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13974778">13974778 </a></text>
<text top="246" left="88" width="3" height="17" font="0"> </text>
<text top="195" left="182" width="211" height="17" font="2"><b>Study type:</b> Cross-sectional study pts </text>
<text top="212" left="182" width="193" height="17" font="0">with and without claudication given </text>
<text top="229" left="182" width="215" height="17" font="0">claudication questionnaire; validated to </text>
<text top="246" left="182" width="215" height="17" font="0">clinical Dx of IC. Study also validated a </text>
<text top="263" left="182" width="185" height="17" font="0">questionnaire for angina pectoris. </text>
<text top="281" left="182" width="3" height="17" font="0"> </text>
<text top="298" left="182" width="197" height="17" font="2"><b>Size:</b> n=37 pts with “undoubted” IC; </text>
<text top="315" left="182" width="159" height="17" font="0">n=18 controls; total n=55 pts </text>
<text top="332" left="182" width="3" height="17" font="0"> </text>
<text top="350" left="182" width="212" height="17" font="2"><b>Questionnaire</b>: IC defined as leg pain </text>
<text top="367" left="182" width="206" height="17" font="0">that met all of the following elements: </text>
<text top="384" left="182" width="7" height="18" font="7"></text>
<text top="385" left="189" width="191" height="17" font="0"> Site must include 1 or both calves </text>
<text top="402" left="182" width="7" height="18" font="7"></text>
<text top="403" left="189" width="203" height="17" font="0"> Must be provoked by either hurrying </text>
<text top="421" left="182" width="191" height="17" font="0">or walking up hill (or by walking on </text>
<text top="438" left="182" width="205" height="17" font="0">level for those who never walk uphill) </text>
<text top="455" left="182" width="7" height="18" font="7"></text>
<text top="456" left="189" width="133" height="17" font="0"> Must never start at rest </text>
<text top="474" left="182" width="7" height="18" font="7"></text>
<text top="475" left="189" width="187" height="17" font="0"> Must make the pt stop or slacken </text>
<text top="492" left="182" width="30" height="17" font="0">pace </text>
<text top="509" left="182" width="7" height="18" font="7"></text>
<text top="510" left="189" width="178" height="17" font="0"> Must disappear on a majority of </text>
<text top="528" left="182" width="123" height="17" font="0">occasions in ≤10 min  </text>
<text top="545" left="182" width="7" height="18" font="7"></text>
<text top="546" left="189" width="201" height="17" font="0"> Must never disappear while walking </text>
<text top="563" left="182" width="56" height="17" font="0">continues </text>
<text top="195" left="412" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="212" left="412" width="7" height="18" font="7"></text>
<text top="213" left="419" width="130" height="17" font="0"> “Most” IC/PAD pts had </text>
<text top="230" left="412" width="168" height="17" font="0">angiograms; non-PAD pts had </text>
<text top="247" left="412" width="137" height="17" font="0">other causes of leg pain; </text>
<text top="265" left="412" width="7" height="18" font="7"></text>
<text top="266" left="419" width="184" height="17" font="0"> IC group mean age 57.1 y; other </text>
<text top="283" left="412" width="180" height="17" font="0">leg pain group mean age 48.2 y. </text>
<text top="300" left="412" width="3" height="17" font="0"> </text>
<text top="317" left="412" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="195" left="621" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="212" left="621" width="7" height="18" font="7"></text>
<text top="213" left="628" width="217" height="17" font="0"> 34/37 claudicants met criteria for IC by </text>
<text top="230" left="621" width="165" height="17" font="0">questionnaire (92% sensitive)<b> </b></text>
<text top="247" left="621" width="7" height="18" font="7"></text>
<text top="248" left="628" width="216" height="17" font="0"> Of 18 other leg pain controls none met </text>
<text top="266" left="621" width="206" height="17" font="0">criteria for IC by questionnaire (100% </text>
<text top="283" left="621" width="49" height="17" font="0">specific) </text>
<text top="195" left="884" width="7" height="18" font="7"></text>
<text top="196" left="891" width="180" height="17" font="0"> Put forth a concept of classic IC </text>
<text top="213" left="884" width="7" height="18" font="7"></text>
<text top="214" left="891" width="206" height="17" font="0"> Very small sample size for validation </text>
<text top="231" left="884" width="188" height="17" font="0">of questionnaire. Highly restrictive </text>
<text top="249" left="884" width="198" height="17" font="0">definition of IC (will exclude pts with </text>
<text top="266" left="884" width="132" height="17" font="0">atypical leg symptoms). </text>
<text top="283" left="884" width="7" height="18" font="7"></text>
<text top="284" left="891" width="158" height="17" font="0"> High specificity for IC/PAD.  </text>
<text top="301" left="884" width="7" height="18" font="7"></text>
<text top="302" left="891" width="193" height="17" font="0"> Later studies reported much lower </text>
<text top="320" left="884" width="210" height="17" font="0">sensitivity of this questionnaire (68%), </text>
<text top="337" left="884" width="100" height="17" font="0">specificity (100%) </text>
<text top="354" left="884" width="204" height="17" font="4"><i>Richard JL, Ducimetiere P, Elgrishi I, </i></text>
<text top="371" left="884" width="196" height="17" font="4"><i>et al. Rev Epidemiol Med Sci Sante </i></text>
<text top="389" left="884" width="109" height="17" font="4"><i>Publ 1972 (French) </i></text>
<text top="581" left="88" width="56" height="17" font="0">Leng GC, </text>
<text top="598" left="88" width="70" height="17" font="0">Fowkes FG  </text>
<text top="615" left="88" width="46" height="17" font="0">1992(2) </text>
<text top="633" left="88" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1474406">1474406</a></text>
<text top="633" left="136" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1474406"> </a></text>
<text top="650" left="88" width="3" height="17" font="0"> </text>
<text top="581" left="182" width="205" height="17" font="2"><b>Study type:</b> Cross-sectional study of </text>
<text top="598" left="182" width="159" height="17" font="0">questionnaire vs. MD clinical </text>
<text top="615" left="182" width="185" height="17" font="0">assessment/ABI±exercise. Study </text>
<text top="633" left="182" width="209" height="17" font="0">developed modification of Rose/WHO </text>
<text top="650" left="182" width="206" height="17" font="0">Questionnaire (phase I/development) </text>
<text top="667" left="182" width="164" height="17" font="0">and validated the subsequent </text>
<text top="684" left="182" width="211" height="17" font="0">Edinburgh Claudication Questionnaire </text>
<text top="701" left="182" width="114" height="17" font="0">(phase II/validation). </text>
<text top="719" left="182" width="3" height="17" font="0"> </text>
<text top="736" left="182" width="201" height="17" font="2"><b>Size:</b> Phase I (development) n=647; </text>
<text top="753" left="182" width="213" height="17" font="0">586 with claudication/PAD and 61 with </text>
<text top="770" left="182" width="194" height="17" font="0">other leg pain. Phase II (validation) </text>
<text top="581" left="412" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="598" left="412" width="7" height="18" font="7"></text>
<text top="599" left="419" width="172" height="17" font="0"> Pts with leg symptoms seen in </text>
<text top="617" left="412" width="135" height="17" font="0">Vascular Clinic who had </text>
<text top="634" left="412" width="128" height="17" font="0">undergone ABI (Phase </text>
<text top="651" left="412" width="92" height="17" font="0">I/development).  </text>
<text top="668" left="412" width="7" height="18" font="7"></text>
<text top="669" left="419" width="177" height="17" font="0"> Vascular clinic pts with leg pain </text>
<text top="687" left="412" width="178" height="17" font="0">and community pts seeing a GP </text>
<text top="704" left="412" width="116" height="17" font="0">(Phase II/validation). </text>
<text top="721" left="412" width="3" height="17" font="0"> </text>
<text top="738" left="412" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="581" left="621" width="52" height="17" font="2"><b>Results: </b></text>
<text top="598" left="621" width="7" height="18" font="7"></text>
<text top="599" left="628" width="190" height="17" font="0"> Performance of WHO/Rose in the </text>
<text top="617" left="621" width="241" height="17" font="0">dataset—Sensitivity 60%; specificity of 91% </text>
<text top="634" left="621" width="7" height="18" font="7"></text>
<text top="635" left="628" width="226" height="17" font="0"> Does the pain every disappear while still </text>
<text top="652" left="621" width="216" height="17" font="0">walking, poorest performing element of </text>
<text top="669" left="621" width="69" height="17" font="0">WHO/Rose  </text>
<text top="687" left="621" width="7" height="18" font="7"></text>
<text top="688" left="628" width="214" height="17" font="0"> Edinburgh Claudication Questionnaire </text>
<text top="705" left="621" width="241" height="17" font="0">performance vs. ABI/clinical assessment by </text>
<text top="722" left="621" width="51" height="17" font="0">clinician: </text>
<text top="740" left="621" width="7" height="18" font="7"></text>
<text top="741" left="628" width="208" height="17" font="0"> Sensitivity: 91.3% community, 82.8% </text>
<text top="758" left="621" width="80" height="17" font="0">vascular clinic </text>
<text top="775" left="621" width="7" height="18" font="7"></text>
<text top="776" left="628" width="205" height="17" font="0"> Specificity: 99.3% community, 100% </text>
<text top="581" left="884" width="7" height="18" font="7"></text>
<text top="582" left="891" width="208" height="17" font="0"> Identified key issues with WHO/Rose </text>
<text top="599" left="884" width="200" height="17" font="0">Questionnaire to develop Edinburgh </text>
<text top="617" left="884" width="154" height="17" font="0">Claudication Questionnaire. </text>
<text top="634" left="884" width="158" height="17" font="0">Maintained 5 questions from </text>
<text top="651" left="884" width="144" height="17" font="0">WHO/Rose (or with minor </text>
<text top="668" left="884" width="198" height="17" font="0">modification), removed 2 questions, </text>
<text top="685" left="884" width="215" height="17" font="0">diagram included for pts to localize site </text>
<text top="703" left="884" width="197" height="17" font="0">of pain (front and back of both legs) </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1095" width="10" height="17" font="0">4 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="182" width="206" height="17" font="0">n=350; 50 vascular clinic pts and 300 </text>
<text top="104" left="182" width="148" height="17" font="0">community pts—also did a </text>
<text top="122" left="182" width="112" height="17" font="0">reproducibility study<b> </b></text>
<text top="87" left="621" width="80" height="17" font="0">vascular clinic </text>
<text top="104" left="621" width="7" height="18" font="7"></text>
<text top="105" left="628" width="213" height="17" font="0"> PPV: 91% community, 100% vascular </text>
<text top="123" left="621" width="31" height="17" font="0">clinic </text>
<text top="140" left="621" width="7" height="18" font="7"></text>
<text top="141" left="628" width="238" height="17" font="0"> NPV: 99% community, 81% vascular clinic<b> </b></text>
<text top="159" left="88" width="75" height="17" font="0">Criqui MH, et </text>
<text top="176" left="88" width="20" height="17" font="0">al.  </text>
<text top="194" left="88" width="46" height="17" font="0">1996(3) </text>
<text top="211" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9546918">9546918 </a></text>
<text top="228" left="88" width="3" height="17" font="0"> </text>
<text top="159" left="182" width="205" height="17" font="2"><b>Study type:</b> Cross-sectional study of </text>
<text top="176" left="182" width="199" height="17" font="0">modified WHO/ROSE questionnaire </text>
<text top="194" left="182" width="136" height="17" font="0">(San Diego Claudication </text>
<text top="211" left="182" width="200" height="17" font="0">Questionnaire) vs. ABI/TBI/posterior </text>
<text top="228" left="182" width="98" height="17" font="0">tibial flow velocity </text>
<text top="245" left="182" width="3" height="17" font="0"> </text>
<text top="262" left="182" width="168" height="17" font="2"><b>Size:</b> n=508 pts (980 limbs for </text>
<text top="280" left="182" width="52" height="17" font="0">analysis) </text>
<text top="159" left="412" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="176" left="412" width="7" height="18" font="7"></text>
<text top="177" left="419" width="176" height="17" font="0"> Pts seen during preceding 10 y </text>
<text top="195" left="412" width="195" height="17" font="0">at San Diego VA Hospital or UCSD </text>
<text top="212" left="412" width="161" height="17" font="0">Medical Center vascular labs </text>
<text top="229" left="412" width="113" height="17" font="0">invited to participate </text>
<text top="246" left="412" width="7" height="18" font="7"></text>
<text top="247" left="419" width="88" height="17" font="0"> Mean age 68 y </text>
<text top="265" left="412" width="7" height="18" font="7"></text>
<text top="266" left="419" width="161" height="17" font="0"> Vascular lab studies used to </text>
<text top="283" left="412" width="110" height="17" font="0">characterize pts as: </text>
<text top="300" left="412" width="117" height="17" font="0">Optimal (no disease) </text>
<text top="318" left="412" width="103" height="17" font="0">Borderline Normal </text>
<text top="335" left="412" width="117" height="17" font="0">Isolated small vessel </text>
<text top="352" left="412" width="127" height="17" font="0">Isolated posterior tibial </text>
<text top="369" left="412" width="167" height="17" font="0">Moderate PAD (ABI 0.61–0.9) </text>
<text top="386" left="412" width="130" height="17" font="0">Severe PAD (ABI &lt;0.6) </text>
<text top="404" left="412" width="3" height="17" font="0"> </text>
<text top="421" left="412" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="159" left="621" width="213" height="17" font="2"><b>Results: </b>Questionnaire identified wide </text>
<text top="176" left="621" width="182" height="17" font="0">spectrum of clinical sx in pts with </text>
<text top="194" left="621" width="232" height="17" font="0">documented PAD, including no sx, pain at </text>
<text top="211" left="621" width="248" height="17" font="0">rest, noncalf pain, nonRose calf claudication, </text>
<text top="228" left="621" width="123" height="17" font="0">Rose calf claudication </text>
<text top="159" left="884" width="7" height="18" font="7"></text>
<text top="160" left="891" width="135" height="17" font="0"> San Diego Claudication </text>
<text top="177" left="884" width="202" height="17" font="0">Questionnaire accounts for right and </text>
<text top="195" left="884" width="204" height="17" font="0">left leg symptoms separately (as well </text>
<text top="212" left="884" width="214" height="17" font="0">as both legs) and included buttock and </text>
<text top="229" left="884" width="64" height="17" font="0">thigh pain.  </text>
<text top="246" left="884" width="7" height="18" font="7"></text>
<text top="247" left="891" width="170" height="17" font="0"> Questionnaire allows for more </text>
<text top="265" left="884" width="202" height="17" font="0">variation of sx and pts leg symptoms </text>
<text top="282" left="884" width="203" height="17" font="0">can be categorized as: No pain, pain </text>
<text top="299" left="884" width="195" height="17" font="0">at rest, non-calf, non-Rose calf and </text>
<text top="316" left="884" width="66" height="17" font="0">Rose (calf). </text>
<text top="334" left="884" width="7" height="18" font="7"></text>
<text top="335" left="891" width="202" height="17" font="0"> Study recognized wider spectrum of </text>
<text top="352" left="884" width="207" height="17" font="0">leg sx in PAD including leg sx not c/w </text>
<text top="369" left="884" width="163" height="17" font="0">WHO/Rose and also non-calf </text>
<text top="386" left="884" width="212" height="17" font="0">symptoms—early concept of “atypical” </text>
<text top="404" left="884" width="77" height="17" font="0">leg sx in PAD </text>
<text top="439" left="88" width="64" height="17" font="0">McDermott </text>
<text top="456" left="88" width="57" height="17" font="0">MM, et al. </text>
<text top="473" left="88" width="46" height="17" font="0">1999(4) </text>
<text top="490" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10030313">10030313 </a></text>
<text top="508" left="88" width="3" height="17" font="0"> </text>
<text top="439" left="182" width="205" height="17" font="2"><b>Study type: </b>Cross-sectional study of </text>
<text top="456" left="182" width="214" height="17" font="0">pts with and without PAD administered </text>
<text top="473" left="182" width="213" height="17" font="0">San Diego Claudication questionnaire, </text>
<text top="490" left="182" width="92" height="17" font="0">ABI assessment </text>
<text top="508" left="182" width="3" height="17" font="0"> </text>
<text top="525" left="182" width="214" height="17" font="2"><b>Size:</b> n=268 pts (137 known PAD from </text>
<text top="542" left="182" width="185" height="17" font="0">vascular lab; 26 known PAD from </text>
<text top="559" left="182" width="184" height="17" font="0">general medical practice; 105 pts </text>
<text top="576" left="182" width="79" height="17" font="0">without PAD) <b> </b></text>
<text top="439" left="412" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="456" left="412" width="7" height="18" font="7"></text>
<text top="457" left="419" width="145" height="17" font="0"> Pts with and without PAD </text>
<text top="474" left="412" width="161" height="17" font="0">identified from (vascular. lab, </text>
<text top="492" left="412" width="131" height="17" font="0">general medical clinics) </text>
<text top="509" left="412" width="7" height="18" font="7"></text>
<text top="510" left="419" width="143" height="17" font="0"> PAD defined as ABI &lt;0.9 </text>
<text top="527" left="412" width="3" height="17" font="0"> </text>
<text top="544" left="412" width="180" height="17" font="2"><b>Exclusion criteria:</b> Low MMSE, </text>
<text top="562" left="412" width="171" height="17" font="0">nursing home residents, wheel-</text>
<text top="579" left="412" width="183" height="17" font="0">chair bound, pts with major lower </text>
<text top="596" left="412" width="189" height="17" font="0">extremity amputation, non-English </text>
<text top="613" left="412" width="183" height="17" font="0">speakers, life expectancy &lt;6 mo, </text>
<text top="630" left="412" width="154" height="17" font="0">noncompressible ABI &gt;1.50<b> </b></text>
<text top="439" left="621" width="52" height="17" font="2"><b>Results: </b></text>
<text top="456" left="621" width="7" height="18" font="7"></text>
<text top="457" left="628" width="215" height="17" font="0"> Grouped pts according to 4 categories </text>
<text top="474" left="621" width="186" height="17" font="0">based on San Diego Claudication </text>
<text top="492" left="621" width="83" height="17" font="0">Questionnaire: </text>
<text top="509" left="621" width="169" height="17" font="0">1. No exertional leg symptoms </text>
<text top="526" left="621" width="78" height="17" font="0">2. IC (classic) </text>
<text top="543" left="621" width="196" height="17" font="0">3. Atypical exertional leg symptoms </text>
<text top="560" left="621" width="79" height="17" font="0">4. Pain at rest </text>
<text top="578" left="621" width="7" height="18" font="7"></text>
<text top="579" left="628" width="215" height="17" font="0"> Among N=137 PAD pts identified from </text>
<text top="596" left="621" width="72" height="17" font="0">vascular lab: </text>
<text top="613" left="621" width="219" height="17" font="0">15.3% had no exertional leg symptoms; </text>
<text top="630" left="621" width="130" height="17" font="0">28.5% had IC (classic); </text>
<text top="648" left="621" width="223" height="17" font="0">25.5% atypical exertional leg symptoms; </text>
<text top="665" left="621" width="106" height="17" font="0">30.7% pain at rest. </text>
<text top="682" left="621" width="7" height="18" font="7"></text>
<text top="683" left="628" width="184" height="17" font="0"> Among PAD pts (n=163), factors </text>
<text top="700" left="621" width="249" height="17" font="0">significantly associated absence of exertional </text>
<text top="718" left="621" width="222" height="17" font="0">leg sx: older age, male sex, DM, PAD pt </text>
<text top="735" left="621" width="243" height="17" font="0">recruited from general medicine clinic rather </text>
<text top="752" left="621" width="96" height="17" font="0">than vascular lab </text>
<text top="769" left="621" width="7" height="18" font="7"></text>
<text top="770" left="628" width="186" height="17" font="0"> Among PAD pts (N=163). factors </text>
<text top="439" left="884" width="7" height="18" font="7"></text>
<text top="440" left="891" width="200" height="17" font="0"> Further validated wider spectrum of </text>
<text top="457" left="884" width="188" height="17" font="0">lower extremity sx among pts with </text>
<text top="474" left="884" width="86" height="17" font="0">confirmed PAD </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1095" width="10" height="17" font="0">5 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="621" width="220" height="17" font="0">significantly associated with classical IC </text>
<text top="104" left="621" width="236" height="17" font="0">lower ABI, PAD recruited from vascular lab </text>
<text top="122" left="621" width="191" height="17" font="0">rather than general medicine clinic<b> </b></text>
<text top="139" left="88" width="64" height="17" font="0">McDermott </text>
<text top="157" left="88" width="57" height="17" font="0">MM, et al. </text>
<text top="174" left="88" width="46" height="17" font="0">2001(5) </text>
<text top="191" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11585483">11585483 </a></text>
<text top="208" left="88" width="3" height="17" font="0"> </text>
<text top="139" left="182" width="205" height="17" font="2"><b>Study type: </b>Cross-sectional study of </text>
<text top="157" left="182" width="193" height="17" font="0">pts with and without PAD identified </text>
<text top="174" left="182" width="200" height="17" font="0">from 3 medical centers in same city. </text>
<text top="191" left="182" width="187" height="17" font="0">Pts underwent functional capacity </text>
<text top="208" left="182" width="196" height="17" font="0">assessments (6min walk, 4 M walk, </text>
<text top="226" left="182" width="204" height="17" font="0">chair raises), assessment of physical </text>
<text top="243" left="182" width="155" height="17" font="0">activity, ABI, questionnaires </text>
<text top="260" left="182" width="3" height="17" font="0"> </text>
<text top="277" left="182" width="199" height="17" font="2"><b>Size:</b> n=590 pts (460 with PAD; 130 </text>
<text top="294" left="182" width="75" height="17" font="0">without PAD) </text>
<text top="139" left="412" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="157" left="412" width="7" height="18" font="7"></text>
<text top="158" left="419" width="145" height="17" font="0"> Pts with and without PAD </text>
<text top="175" left="412" width="180" height="17" font="0">identified from 3 medical centers </text>
<text top="192" left="412" width="167" height="17" font="0">(vascular lab, general medical </text>
<text top="210" left="412" width="51" height="17" font="0">practice) </text>
<text top="227" left="412" width="7" height="18" font="7"></text>
<text top="228" left="419" width="171" height="17" font="0"> PAD confirmed with study ABI </text>
<text top="245" left="412" width="196" height="17" font="0">(average leg pressure method) and </text>
<text top="262" left="412" width="99" height="17" font="0">required ABI &lt;0.9 </text>
<text top="280" left="412" width="3" height="17" font="0"> </text>
<text top="297" left="412" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="314" left="412" width="7" height="18" font="7"></text>
<text top="315" left="419" width="163" height="17" font="0"> “PAD” pts with normal ABI at </text>
<text top="332" left="412" width="57" height="17" font="0">study visit </text>
<text top="350" left="412" width="7" height="18" font="7"></text>
<text top="351" left="419" width="59" height="17" font="0"> Dementia </text>
<text top="368" left="412" width="7" height="18" font="7"></text>
<text top="369" left="419" width="137" height="17" font="0"> Nursing home residents </text>
<text top="386" left="412" width="7" height="18" font="7"></text>
<text top="387" left="419" width="106" height="17" font="0"> Wheelchair bound </text>
<text top="405" left="412" width="7" height="18" font="7"></text>
<text top="406" left="419" width="170" height="17" font="0"> Pts with major lower extremity </text>
<text top="423" left="412" width="64" height="17" font="0">amputation </text>
<text top="440" left="412" width="7" height="18" font="7"></text>
<text top="441" left="419" width="124" height="17" font="0"> Recent major surgery </text>
<text top="459" left="412" width="7" height="18" font="7"></text>
<text top="460" left="419" width="127" height="17" font="0"> Non-English speakers<b> </b></text>
<text top="139" left="621" width="52" height="17" font="2"><b>Results: </b></text>
<text top="157" left="621" width="218" height="17" font="0">Grouped pts according to 6 types of leg </text>
<text top="174" left="621" width="186" height="17" font="0">symptoms in 4 overall categories: </text>
<text top="191" left="621" width="78" height="17" font="0">1. IC (classic) </text>
<text top="208" left="621" width="246" height="17" font="0">2. Atypical exertional leg pain (carry on/stop) </text>
<text top="226" left="621" width="249" height="17" font="0">3. No exertional leg pain (active/inactive walk </text>
<text top="243" left="621" width="122" height="17" font="0">&gt;6 blocks/wk Yes/No) </text>
<text top="260" left="621" width="190" height="17" font="0">4. Leg pain on exertion and at rest </text>
<text top="277" left="621" width="7" height="18" font="7"></text>
<text top="278" left="628" width="155" height="17" font="0"> Among confirmed PAD pts: </text>
<text top="296" left="621" width="71" height="17" font="0">32% had IC; </text>
<text top="313" left="621" width="207" height="17" font="0">19% leg pain on exertion and at rest;  </text>
<text top="330" left="621" width="232" height="17" font="0">29% atypical exertional leg pain (9% carry </text>
<text top="347" left="621" width="86" height="17" font="0">on; 20% stop);  </text>
<text top="365" left="621" width="152" height="17" font="0">20% no exertional leg pain. </text>
<text top="382" left="621" width="7" height="18" font="7"></text>
<text top="383" left="628" width="193" height="17" font="0"> PAD pts in the non-IC groups also </text>
<text top="400" left="621" width="246" height="17" font="0">demonstrated functional impairment in terms </text>
<text top="417" left="621" width="155" height="17" font="0">of 6 min walk, 4 meter walk. </text>
<text top="434" left="621" width="7" height="18" font="7"></text>
<text top="436" left="628" width="195" height="17" font="0"> No exertional leg pain/inactive and </text>
<text top="453" left="621" width="234" height="17" font="0">exertional and rest pain groups with worse </text>
<text top="470" left="621" width="186" height="17" font="0">functional capacity than IC group. </text>
<text top="487" left="621" width="7" height="18" font="7"></text>
<text top="488" left="628" width="236" height="17" font="0"> Atypical exertional leg pain/carry on group </text>
<text top="506" left="621" width="239" height="17" font="0">with better outcomes on 6 min walk than IC </text>
<text top="523" left="621" width="38" height="17" font="0">group. </text>
<text top="140" left="884" width="7" height="18" font="7"></text>
<text top="141" left="891" width="196" height="17" font="0"> More data on wide spectrum of leg </text>
<text top="158" left="884" width="155" height="17" font="0">sx among pts with PAD and </text>
<text top="175" left="884" width="161" height="17" font="0">demonstration that functional </text>
<text top="192" left="884" width="202" height="17" font="0">impairment is common regardless of </text>
<text top="210" left="884" width="123" height="17" font="0">type of leg symptoms. </text>
<text top="541" left="88" width="75" height="17" font="0">Hirsch AT, et </text>
<text top="558" left="88" width="20" height="17" font="0">al.  </text>
<text top="575" left="88" width="46" height="17" font="0">2001(6) </text>
<text top="593" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11560536">11560536 </a></text>
<text top="610" left="88" width="3" height="17" font="0"> </text>
<text top="541" left="182" width="172" height="17" font="2"><b>Study type: </b>Multi-center cross-</text>
<text top="558" left="182" width="183" height="17" font="0">sectional study conducted at 350 </text>
<text top="575" left="182" width="182" height="17" font="0">primary care practices in the US. </text>
<text top="593" left="182" width="3" height="17" font="0"> </text>
<text top="610" left="182" width="190" height="17" font="0">Pts enrolled underwent San Diego </text>
<text top="627" left="182" width="200" height="17" font="0">Claudication Questionnaire, medical </text>
<text top="644" left="182" width="215" height="17" font="0">and CV Hx/risk factor assessment, BP, </text>
<text top="661" left="182" width="152" height="17" font="0">anthropomorphics, and ABI </text>
<text top="679" left="182" width="76" height="17" font="0">assessment.  </text>
<text top="696" left="182" width="3" height="17" font="0"> </text>
<text top="713" left="182" width="190" height="17" font="0">Pts. identified as having PAD (and </text>
<text top="730" left="182" width="195" height="17" font="0">their providers) further asked about </text>
<text top="747" left="182" width="148" height="17" font="0">awareness of the PAD Dx. </text>
<text top="765" left="182" width="3" height="17" font="0"> </text>
<text top="541" left="412" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="558" left="412" width="7" height="18" font="7"></text>
<text top="559" left="419" width="187" height="17" font="0"> Age ≥70 y; Age 50–69 y with DM </text>
<text top="576" left="412" width="178" height="17" font="0">or at least 10 pack-year tobacco </text>
<text top="594" left="412" width="18" height="17" font="0">Hx </text>
<text top="611" left="412" width="7" height="18" font="7"></text>
<text top="612" left="419" width="189" height="17" font="0"> PAD (lower leg pressure method) </text>
<text top="629" left="412" width="179" height="17" font="0">defined as ABI ≤0.9 in either leg </text>
<text top="646" left="412" width="3" height="17" font="0"> </text>
<text top="664" left="412" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="541" left="621" width="52" height="17" font="2"><b>Results: </b></text>
<text top="558" left="621" width="7" height="18" font="7"></text>
<text top="559" left="628" width="237" height="17" font="0"> Prevalence of PAD in this cohort was 29% </text>
<text top="577" left="621" width="7" height="18" font="7"></text>
<text top="578" left="628" width="212" height="17" font="0"> Among 1865 pts with PAD (mean ABI </text>
<text top="595" left="621" width="35" height="17" font="0">0.78): </text>
<text top="612" left="621" width="177" height="17" font="0">5.5%–15.3% Rose claudication; </text>
<text top="629" left="621" width="164" height="17" font="0">46.3%–61.7% atypical leg sx; </text>
<text top="646" left="621" width="127" height="17" font="0">23.3%–48.3% no pain; </text>
<text top="664" left="621" width="240" height="17" font="0">**rates reported for new Dx/prior Dx and for </text>
<text top="681" left="621" width="141" height="17" font="0">PAD only and PAD+CVD </text>
<text top="541" left="884" width="7" height="18" font="7"></text>
<text top="542" left="891" width="196" height="17" font="0"> More data on wide spectrum of leg </text>
<text top="559" left="884" width="160" height="17" font="0">sx among pts with PAD; only </text>
<text top="576" left="884" width="170" height="17" font="0">approximately 5%–15% of ABI </text>
<text top="594" left="884" width="209" height="17" font="0">confirmed PAD pts have classic Rose </text>
<text top="611" left="884" width="193" height="17" font="0">claudication. Majority have atypical </text>
<text top="628" left="884" width="174" height="17" font="0">non-Rose leg sx or no leg pain. </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="8" size="13" family="Times" color="#000000"/>
<text top="795" left="1095" width="10" height="17" font="0">6 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="182" width="172" height="17" font="2"><b>Size:</b> n=6,979 (1865 had PAD)<b> </b></text>
<text top="105" left="88" width="70" height="17" font="0">Khan NA, et </text>
<text top="122" left="88" width="16" height="17" font="0">al. </text>
<text top="139" left="88" width="46" height="17" font="0">2006(7) </text>
<text top="157" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16449619">16449619 </a></text>
<text top="174" left="88" width="3" height="17" font="0"> </text>
<text top="105" left="182" width="187" height="17" font="2"><b>Study type:</b> Systematic review of </text>
<text top="122" left="182" width="202" height="17" font="0">studies that evaluated element of Hx </text>
<text top="139" left="182" width="206" height="17" font="0">and/or physical examination for Dx of </text>
<text top="157" left="182" width="199" height="17" font="0">PAD in pts with and without disease </text>
<text top="174" left="182" width="3" height="17" font="0"> </text>
<text top="191" left="182" width="161" height="17" font="2"><b>Size:</b> Total of 6,272 pts in 11 </text>
<text top="208" left="182" width="154" height="17" font="0">diagnostic accuracy studies </text>
<text top="105" left="412" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="122" left="412" width="7" height="18" font="7"></text>
<text top="123" left="419" width="176" height="17" font="0"> Studies published from 1/1966–</text>
<text top="141" left="412" width="41" height="17" font="0">3/2005 </text>
<text top="158" left="412" width="7" height="18" font="7"></text>
<text top="159" left="419" width="165" height="17" font="0"> 51 potential articles identified </text>
<text top="176" left="412" width="167" height="17" font="0">from MEDLINE and Cochrane </text>
<text top="194" left="412" width="60" height="17" font="0">databases </text>
<text top="211" left="412" width="7" height="18" font="7"></text>
<text top="212" left="419" width="157" height="17" font="0"> Exam maneuvers had to be </text>
<text top="229" left="412" width="96" height="17" font="0">described clearly </text>
<text top="246" left="412" width="7" height="18" font="7"></text>
<text top="247" left="419" width="180" height="17" font="0"> PAD Dx confirmed by reference </text>
<text top="265" left="412" width="139" height="17" font="0">standard: ABI, duplex, or </text>
<text top="282" left="412" width="65" height="17" font="0">angiogram  </text>
<text top="299" left="412" width="7" height="18" font="7"></text>
<text top="300" left="419" width="181" height="17" font="0"> Data could be extracted into a 2 </text>
<text top="318" left="412" width="50" height="17" font="0">x 2 table </text>
<text top="335" left="412" width="7" height="18" font="7"></text>
<text top="336" left="419" width="178" height="17" font="0"> 17 studies met inclusion criteria </text>
<text top="353" left="412" width="154" height="17" font="0">(11 on diagnostic accuracy) </text>
<text top="370" left="412" width="3" height="17" font="0"> </text>
<text top="387" left="412" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="105" left="621" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="122" left="621" width="186" height="17" font="8"><i><b>Hx – Symptoms of claudication </b></i></text>
<text top="140" left="621" width="7" height="18" font="7"></text>
<text top="141" left="628" width="235" height="17" font="0"> Presence of claudication ↑ likelihood PAD </text>
<text top="158" left="621" width="196" height="17" font="0">(LR PAD: 3.30; 95% CI: 2.30–4.80) </text>
<text top="175" left="621" width="7" height="18" font="7"></text>
<text top="176" left="628" width="210" height="17" font="0"> Absence of claudication did not lower </text>
<text top="194" left="621" width="245" height="17" font="0">likelihood of any PAD, but lowered likelihood </text>
<text top="211" left="621" width="218" height="17" font="0">of moderate to severe PAD (ABI &lt;0.70) </text>
<text top="228" left="621" width="171" height="17" font="0">(LR: 0.57; 95% CI: 0.43–0.76)) </text>
<text top="105" left="884" width="7" height="18" font="7"></text>
<text top="106" left="891" width="197" height="17" font="0"> Presence of claudication increases </text>
<text top="123" left="884" width="165" height="17" font="0">likelihood of PAD. Absence of </text>
<text top="141" left="884" width="207" height="17" font="0">claudication does not lower likelihood </text>
<text top="158" left="884" width="174" height="17" font="0">of PAD, but lowers likelihood of </text>
<text top="175" left="884" width="141" height="17" font="0">moderate to severe PAD. </text>
<text top="405" left="88" width="77" height="17" font="0">Grøndal N, et </text>
<text top="423" left="88" width="16" height="17" font="0">al. </text>
<text top="440" left="88" width="46" height="17" font="0">2015(8) </text>
<text top="457" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25923784">25923784</a></text>
<text top="457" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25923784"> </a></text>
<text top="474" left="88" width="3" height="17" font="0"> </text>
<text top="405" left="182" width="204" height="17" font="2"><b>Study type:</b> Danish intervention arm </text>
<text top="423" left="182" width="94" height="17" font="0">of screening trial </text>
<text top="440" left="182" width="3" height="17" font="0"> </text>
<text top="457" left="182" width="171" height="17" font="2"><b>Size:</b> n=25,083 men who were </text>
<text top="474" left="182" width="216" height="17" font="0">screened for AAA. 18,749 attended the </text>
<text top="492" left="182" width="147" height="17" font="0">screening (uptake 74.7%). </text>
<text top="405" left="412" width="195" height="17" font="2"><b>Inclusion criteria:</b> Men age 65–74 </text>
<text top="423" left="412" width="172" height="17" font="0">y who were screened for AAA.  </text>
<text top="440" left="412" width="3" height="17" font="0"> </text>
<text top="457" left="412" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="407" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="405" left="628" width="6" height="18" font="7"></text>
<text top="407" left="634" width="203" height="17" font="2"><b> endpoint:</b> Prevalence of PAD in pts </text>
<text top="424" left="621" width="107" height="17" font="0">screened for AAA.  </text>
<text top="441" left="621" width="3" height="17" font="0"> </text>
<text top="458" left="621" width="234" height="17" font="2"><b>Results:</b> AAA was diagnosed in 3.3% and </text>
<text top="476" left="621" width="83" height="17" font="0">PAD in 10.9%. </text>
<text top="405" left="884" width="7" height="18" font="7"></text>
<text top="407" left="891" width="200" height="17" font="0"> The prevalence of AAA in Denmark </text>
<text top="424" left="884" width="205" height="17" font="0">has declined in the past decade from </text>
<text top="441" left="884" width="83" height="17" font="0">4.0% to 3.3%.  </text>
<text top="458" left="884" width="7" height="18" font="7"></text>
<text top="459" left="891" width="204" height="17" font="0"> 10.9% of men undergoing screening </text>
<text top="477" left="884" width="128" height="17" font="0">for AAA also had PAD. </text>
<text top="510" left="88" width="74" height="17" font="0">Wassel et al. </text>
<text top="527" left="88" width="46" height="17" font="0">2011(9) </text>
<text top="544" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21920269">21920269</a></text>
<text top="544" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21920269"> </a></text>
<text top="561" left="88" width="3" height="17" font="0"> </text>
<text top="510" left="182" width="211" height="17" font="2"><b>Study type:</b> Observational population-</text>
<text top="527" left="182" width="178" height="17" font="0">based study of current or former </text>
<text top="544" left="182" width="168" height="17" font="0">employees of the University of </text>
<text top="561" left="182" width="174" height="17" font="0">California, San Diego, and their </text>
<text top="578" left="182" width="212" height="17" font="0">significant others, as well as 193 other </text>
<text top="596" left="182" width="211" height="17" font="0">volunteers and their significant others. </text>
<text top="613" left="182" width="3" height="17" font="0"> </text>
<text top="630" left="182" width="100" height="17" font="2"><b>Size:</b> n=2,404 pts </text>
<text top="510" left="412" width="157" height="17" font="2"><b>Inclusion criteria: </b>Men and </text>
<text top="527" left="412" width="140" height="17" font="0">women age 19–91 y who </text>
<text top="544" left="412" width="188" height="17" font="0">completed the baseline visit in the </text>
<text top="561" left="412" width="161" height="17" font="0">San Diego Population Study  </text>
<text top="578" left="412" width="3" height="17" font="0"> </text>
<text top="596" left="412" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="511" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="510" left="628" width="6" height="18" font="7"></text>
<text top="511" left="634" width="236" height="17" font="2"><b> endpoint:</b> Prevalence of PAD in the study </text>
<text top="528" left="621" width="60" height="17" font="0">population </text>
<text top="545" left="621" width="3" height="17" font="0"> </text>
<text top="562" left="621" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="580" left="621" width="7" height="18" font="7"></text>
<text top="581" left="628" width="222" height="17" font="0"> Family hx of PAD was significant, when </text>
<text top="598" left="621" width="229" height="17" font="0">adjusting for SBP, DBP, and dyslipidemia </text>
<text top="615" left="621" width="214" height="17" font="0">(OR: 1.83; 95% CI: 1.03–3.26; p=0.04) </text>
<text top="632" left="621" width="7" height="18" font="7"></text>
<text top="633" left="628" width="236" height="17" font="0"> Family hx of PAD was strongly associated </text>
<text top="651" left="621" width="120" height="17" font="0">with severe prevalent </text>
<text top="668" left="621" width="246" height="17" font="0">PAD (OR: 2.42; 95% CI: 1.13–5.23; p=0.02). </text>
<text top="685" left="621" width="7" height="18" font="7"></text>
<text top="686" left="628" width="228" height="17" font="0"> Parental hx of PAD was significant when </text>
<text top="703" left="621" width="229" height="17" font="0">adjusting for SBP, DBP, and dyslipidemia </text>
<text top="721" left="621" width="214" height="17" font="0">(OR: 1.83; 95% CI: 1.00–3.41; p=0.05) </text>
<text top="738" left="621" width="7" height="18" font="7"></text>
<text top="739" left="628" width="183" height="17" font="0"> Parental hx of PAD was strongly </text>
<text top="756" left="621" width="182" height="17" font="0">associated with severe prevalent </text>
<text top="773" left="621" width="253" height="17" font="0">PAD (OR: 2.91; 95%CI: 1.33–6.40; p=0.008).  </text>
<text top="510" left="884" width="24" height="17" font="0">N/A </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1095" width="10" height="17" font="0">7 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="88" width="66" height="17" font="0">Clark CE et </text>
<text top="104" left="88" width="23" height="17" font="0">al.,  </text>
<text top="122" left="88" width="53" height="17" font="0">2012(10) </text>
<text top="139" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22293369">22293369</a></text>
<text top="139" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22293369"> </a></text>
<text top="156" left="88" width="3" height="17" font="0"> </text>
<text top="87" left="182" width="150" height="17" font="2"><b>Study type:</b> Meta-analysis </text>
<text top="104" left="182" width="3" height="17" font="0"> </text>
<text top="122" left="182" width="106" height="17" font="2"><b>Size:</b> n=20 studies </text>
<text top="87" left="412" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="104" left="412" width="7" height="18" font="7"></text>
<text top="105" left="419" width="186" height="17" font="0"> Cohort or cross-sectional studies </text>
<text top="123" left="412" width="191" height="17" font="0">of differences in BP between arms </text>
<text top="140" left="412" width="7" height="18" font="7"></text>
<text top="141" left="419" width="64" height="17" font="0"> Age ≥18 y </text>
<text top="158" left="412" width="7" height="18" font="7"></text>
<text top="159" left="419" width="189" height="17" font="0"> Data for central vascular disease, </text>
<text top="177" left="412" width="81" height="17" font="0">PVD, or death </text>
<text top="194" left="412" width="3" height="17" font="0"> </text>
<text top="211" left="412" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="228" left="412" width="7" height="18" font="7"></text>
<text top="229" left="419" width="81" height="17" font="0"> Case reports  </text>
<text top="88" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="628" width="6" height="18" font="7"></text>
<text top="88" left="634" width="91" height="17" font="2"><b> endpoint:</b> PVD </text>
<text top="106" left="621" width="3" height="17" font="0"> </text>
<text top="123" left="621" width="52" height="17" font="2"><b>Results: </b></text>
<text top="140" left="621" width="7" height="18" font="7"></text>
<text top="141" left="628" width="224" height="17" font="0"> Significant association of a difference of </text>
<text top="158" left="621" width="237" height="17" font="0">≥10 mmHg and SS (risk ratio: 8.8; 95% CI: </text>
<text top="176" left="621" width="56" height="17" font="0">3·6–21.2) </text>
<text top="193" left="621" width="7" height="18" font="7"></text>
<text top="194" left="628" width="210" height="17" font="0"> Significant association in noninvasive </text>
<text top="211" left="621" width="226" height="17" font="0">studies of a difference of ≥15 mmHg and </text>
<text top="228" left="621" width="206" height="17" font="0">PVD (risk ratio: 2.5, 95% CI: 1.6–3.8) </text>
<text top="246" left="621" width="242" height="17" font="0">(sensitivity: 15%; 95% CI: 9–23) (specificity: </text>
<text top="263" left="621" width="120" height="17" font="0">96%; 95% CI: 94–98) </text>
<text top="280" left="621" width="7" height="18" font="7"></text>
<text top="281" left="628" width="210" height="17" font="0"> Significant association in noninvasive </text>
<text top="298" left="621" width="226" height="17" font="0">studies of a difference of ≥15 mmHg and </text>
<text top="316" left="621" width="230" height="17" font="0">pre-existing cerebrovascular disease (risk </text>
<text top="333" left="621" width="246" height="17" font="0">ratio: 1.6, 95% CI: 1.1–2.48) (sensitivity: 8%; </text>
<text top="350" left="621" width="245" height="17" font="0">95% CI: 2–26) (specificity: 93%; 95% CI: 86–</text>
<text top="367" left="621" width="21" height="17" font="0">97) </text>
<text top="384" left="621" width="7" height="18" font="7"></text>
<text top="385" left="628" width="210" height="17" font="0"> Significant association in noninvasive </text>
<text top="403" left="621" width="226" height="17" font="0">studies of a difference of ≥15 mmHg and </text>
<text top="420" left="621" width="232" height="17" font="0">cardiovascular mortality (HR: 1.7, 95% CI: </text>
<text top="437" left="621" width="52" height="17" font="0">1.1–2.5)  </text>
<text top="454" left="621" width="7" height="18" font="7"></text>
<text top="455" left="628" width="210" height="17" font="0"> Significant association in noninvasive </text>
<text top="473" left="621" width="243" height="17" font="0">studies of a difference of ≥15 mmHg and all-</text>
<text top="490" left="621" width="230" height="17" font="0">cause mortality (HR: 1.6; 95% CI: 1.1–2.3 </text>
<text top="507" left="621" width="7" height="18" font="7"></text>
<text top="508" left="628" width="231" height="17" font="0"> Significant association of ≥10 mmHg and </text>
<text top="526" left="621" width="241" height="17" font="0">PVD (RR: 2.4; 95% CI: 1.5–3.9) (sensitivity: </text>
<text top="543" left="621" width="241" height="17" font="0">32%; 95%CI: 23–41) (specificity: 91%, 95% </text>
<text top="560" left="621" width="61" height="17" font="0">CI: 86–94) </text>
<text top="87" left="884" width="7" height="18" font="7"></text>
<text top="88" left="891" width="196" height="17" font="0"> A difference in SBP of ≥10 mm Hg </text>
<text top="106" left="884" width="214" height="17" font="0">or of ≥15 mm Hg, between arms might </text>
<text top="123" left="884" width="198" height="17" font="0">help to identify pts who need further </text>
<text top="140" left="884" width="122" height="17" font="0">vascular assessment. </text>
<text top="157" left="884" width="7" height="18" font="7"></text>
<text top="158" left="891" width="204" height="17" font="0"> A difference of ≥15 mm Hg could be </text>
<text top="176" left="884" width="196" height="17" font="0">a useful indicator of risk of vascular </text>
<text top="193" left="884" width="107" height="17" font="0">disease and death. </text>
<text top="578" left="88" width="80" height="17" font="0">Singh S et al., </text>
<text top="595" left="88" width="53" height="17" font="0">2015(11) </text>
<text top="612" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26160261">26160261</a></text>
<text top="612" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26160261"> </a></text>
<text top="630" left="88" width="3" height="17" font="0"> </text>
<text top="578" left="182" width="201" height="17" font="2"><b>Study type:</b> Meta-analysis of cohort </text>
<text top="595" left="182" width="42" height="17" font="0">studies </text>
<text top="612" left="182" width="3" height="17" font="0"> </text>
<text top="630" left="182" width="110" height="17" font="2"><b>Size:</b> n=18 cohorts  </text>
<text top="578" left="412" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="595" left="412" width="7" height="18" font="7"></text>
<text top="596" left="419" width="129" height="17" font="0"> Studies measuring BP </text>
<text top="614" left="412" width="169" height="17" font="0">simultaneously in arms or legs </text>
<text top="631" left="412" width="7" height="18" font="7"></text>
<text top="632" left="419" width="133" height="17" font="0"> Studies reporting CAD, </text>
<text top="649" left="412" width="172" height="17" font="0">cerebrovascular disease, PAD, </text>
<text top="666" left="412" width="173" height="17" font="0">subclavian stenosis, survival or </text>
<text top="684" left="412" width="176" height="17" font="0">mortality, and other relevant CV </text>
<text top="701" left="412" width="116" height="17" font="0">indices or outcomes. </text>
<text top="718" left="412" width="3" height="17" font="0"> </text>
<text top="735" left="412" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="752" left="412" width="7" height="18" font="7"></text>
<text top="754" left="419" width="158" height="17" font="0"> Studies that did not report a </text>
<text top="771" left="412" width="194" height="17" font="0">dichotomous outcome defined by a </text>
<text top="579" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="578" left="628" width="6" height="18" font="7"></text>
<text top="579" left="634" width="206" height="17" font="2"><b> endpoint:</b> Prevelance of PAD, CAD, </text>
<text top="596" left="621" width="202" height="17" font="0">cerebrovascular disease, subclavian </text>
<text top="614" left="621" width="202" height="17" font="0">stenosis, all-cause, and CV mortality </text>
<text top="631" left="621" width="3" height="17" font="0"> </text>
<text top="648" left="621" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="665" left="621" width="7" height="18" font="7"></text>
<text top="666" left="628" width="241" height="17" font="0"> Significant association between IASBPD of </text>
<text top="684" left="621" width="224" height="17" font="0">≥10 mmHg and PAD (RR: 2.22; 95% CI: </text>
<text top="701" left="621" width="248" height="17" font="0">1.41–3.5; p=0.0006) (sensitivity: 16.6%; 95% </text>
<text top="718" left="621" width="228" height="17" font="0">CI: 6.7–35.4) (specificity: 91.9%; 95% CI: </text>
<text top="735" left="621" width="62" height="17" font="0">83.1–96.3) </text>
<text top="752" left="621" width="7" height="18" font="7"></text>
<text top="754" left="628" width="232" height="17" font="0"> Significant association of PAD at cutoff of </text>
<text top="771" left="621" width="225" height="17" font="0">15 mmHg (RR: 1.91; 95% CI: 1.28–2.84; </text>
<text top="578" left="884" width="7" height="18" font="7"></text>
<text top="579" left="891" width="205" height="17" font="0"> Inter-arm and leg BP differences are </text>
<text top="596" left="884" width="203" height="17" font="0">predictors of PAD. The IASBPD may </text>
<text top="614" left="884" width="193" height="17" font="0">be associated subclavian stenosis, </text>
<text top="631" left="884" width="200" height="17" font="0">high left ventricular mass effect, and </text>
<text top="648" left="884" width="161" height="17" font="0">higher brachial–ankle PWVs. </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1095" width="10" height="17" font="0">8 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="412" width="155" height="17" font="0">specific BP difference cutoff<b> </b></text>
<text top="87" left="621" width="226" height="17" font="0">p=0.001) (sensitivity: 25.1%; 95% CI 7.9–</text>
<text top="104" left="621" width="254" height="17" font="0">56.7) (specificity: 88.2%; 95% CI: 71.7–95.7).  </text>
<text top="122" left="621" width="7" height="18" font="7"></text>
<text top="123" left="628" width="226" height="17" font="0"> Significant association between inter-leg </text>
<text top="140" left="621" width="237" height="17" font="0">BP difference of ≥15 mmHg and PAD (RR: </text>
<text top="157" left="621" width="157" height="17" font="0">11.87; 95% CI: 7.64–18.44). </text>
<text top="174" left="621" width="7" height="18" font="7"></text>
<text top="175" left="628" width="238" height="17" font="0"> IASBPD of ≥10 mmHg was not associated </text>
<text top="193" left="621" width="220" height="17" font="0">with carotid-femoral PWV (standardized </text>
<text top="210" left="621" width="235" height="17" font="0">mean difference: 0.26; 95% CI: 0.15–0.68; </text>
<text top="227" left="621" width="232" height="17" font="0">p=0.21). One study demonstrated positive </text>
<text top="244" left="621" width="242" height="17" font="0">association between IASBPD of ≥10 mmHg </text>
<text top="262" left="621" width="239" height="17" font="0">and brachial ankle PWV (adjusted OR from </text>
<text top="279" left="621" width="229" height="17" font="0">multivariate model: 1.001; 95% CI: 1.000–</text>
<text top="296" left="621" width="97" height="17" font="0">1.001; p=0.022).  </text>
<text top="313" left="621" width="7" height="18" font="7"></text>
<text top="314" left="628" width="210" height="17" font="0"> Significant association of inter-leg BP </text>
<text top="332" left="621" width="209" height="17" font="0">difference of ≥15 mm Hg or more and </text>
<text top="349" left="621" width="226" height="17" font="0">brachial–ankle PWV (standardized mean </text>
<text top="366" left="621" width="200" height="17" font="0">difference: 0.68; 95% CI: 0.37–0.99; </text>
<text top="383" left="621" width="63" height="17" font="0">p=0.0001). </text>
<text top="401" left="88" width="68" height="17" font="0">Shadman R </text>
<text top="418" left="88" width="37" height="17" font="0">et al.,  </text>
<text top="436" left="88" width="53" height="17" font="0">2004(12) </text>
<text top="453" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15358030">15358030</a></text>
<text top="453" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15358030"> </a></text>
<text top="470" left="88" width="3" height="17" font="0"> </text>
<text top="401" left="182" width="208" height="17" font="2"><b>Study type:</b> Review of cohort studies </text>
<text top="418" left="182" width="3" height="17" font="0"> </text>
<text top="436" left="182" width="179" height="17" font="2"><b>Size:</b> n=4 cohorts with 4,223 pts </text>
<text top="453" left="182" width="201" height="17" font="0">(2,975 from 2 free-living cohorts and </text>
<text top="470" left="182" width="161" height="17" font="0">1,248 from 2 clinical cohorts) </text>
<text top="401" left="412" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="418" left="412" width="55" height="17" font="0">Cohort A: </text>
<text top="436" left="412" width="7" height="18" font="7"></text>
<text top="437" left="419" width="174" height="17" font="0"> Geographic defined population </text>
<text top="454" left="412" width="33" height="17" font="0">study </text>
<text top="471" left="412" width="7" height="18" font="7"></text>
<text top="472" left="419" width="189" height="17" font="0"> Part of the Lipid Research Clinics </text>
<text top="490" left="412" width="80" height="17" font="0">protocol study </text>
<text top="507" left="412" width="3" height="17" font="0"> </text>
<text top="524" left="412" width="55" height="17" font="0">Cohort B: </text>
<text top="541" left="412" width="7" height="18" font="7"></text>
<text top="542" left="419" width="150" height="17" font="0"> Randomly selected from a </text>
<text top="560" left="412" width="193" height="17" font="0">database of UCSD employees and </text>
<text top="577" left="412" width="49" height="17" font="0">spouses </text>
<text top="594" left="412" width="3" height="17" font="0"> </text>
<text top="611" left="412" width="56" height="17" font="0">Cohort C: </text>
<text top="629" left="412" width="7" height="18" font="7"></text>
<text top="630" left="419" width="140" height="17" font="0"> Pt population in Chicago </text>
<text top="647" left="412" width="3" height="17" font="0"> </text>
<text top="664" left="412" width="56" height="17" font="0">Cohort D: </text>
<text top="681" left="412" width="7" height="18" font="7"></text>
<text top="682" left="419" width="170" height="17" font="0"> Pts who visited the San Diego </text>
<text top="700" left="412" width="180" height="17" font="0">Vererans Administration Medical </text>
<text top="717" left="412" width="179" height="17" font="0">Centor or UCSD Medical Center </text>
<text top="734" left="412" width="167" height="17" font="0">vascular laboratories between </text>
<text top="751" left="412" width="65" height="17" font="0">1990–1994 </text>
<text top="769" left="412" width="3" height="17" font="0"> </text>
<text top="402" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="401" left="628" width="6" height="18" font="7"></text>
<text top="402" left="634" width="161" height="17" font="2"><b> endpoint:</b> Prevelance of SS </text>
<text top="420" left="621" width="3" height="17" font="0"> </text>
<text top="437" left="621" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="454" left="621" width="7" height="18" font="7"></text>
<text top="455" left="628" width="227" height="17" font="0"> SS was significantly (p&lt;0.05) associated </text>
<text top="472" left="621" width="207" height="17" font="0">with past smoking (OR: 1.80), current </text>
<text top="490" left="621" width="224" height="17" font="0">smoking (OR: 2.61), and higher levels of </text>
<text top="507" left="621" width="167" height="17" font="0">SBP (OR:1.90 per 20 mm Hg) </text>
<text top="524" left="621" width="7" height="18" font="7"></text>
<text top="525" left="628" width="216" height="17" font="0"> Significant association between higher </text>
<text top="542" left="621" width="216" height="17" font="0">levels of HDL and SS (OR: 0.87 per 10 </text>
<text top="560" left="621" width="38" height="17" font="0">mg/dl) </text>
<text top="577" left="621" width="7" height="18" font="7"></text>
<text top="578" left="628" width="215" height="17" font="0"> Significant association of SS and PAD </text>
<text top="595" left="621" width="113" height="17" font="0">(OR: 5.11, p&lt;0.001) </text>
<text top="401" left="884" width="7" height="18" font="7"></text>
<text top="402" left="891" width="208" height="17" font="0">SS is correlated with current and past </text>
<text top="420" left="884" width="196" height="17" font="0">smoking histories, SBP, HDL levels </text>
<text top="437" left="884" width="204" height="17" font="0">(inversely), and the presence of PAD </text>
<text top="454" left="884" width="7" height="18" font="7"></text>
<text top="455" left="891" width="201" height="17" font="0"> bilateral brachial BP measurements </text>
<text top="472" left="884" width="199" height="17" font="0">should routinely be performed in pts </text>
<text top="490" left="884" width="196" height="17" font="0">with an elevated risk profile, both to </text>
<text top="507" left="884" width="207" height="17" font="0">screen for SS, and to avoid missing a </text>
<text top="524" left="884" width="172" height="17" font="0">hypertension or PAD diagnosis </text>
<text top="541" left="884" width="168" height="17" font="0">because of unilateral pressure </text>
<text top="558" left="884" width="194" height="17" font="0">measurement in an obstructed arm </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="9" size="13" family="Times" color="#ff0000"/>
<text top="795" left="1095" width="10" height="17" font="0">9 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="412" width="3" height="17" font="0"> </text>
<text top="104" left="412" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="122" left="412" width="128" height="17" font="0">Cohort A: Missing data </text>
<text top="139" left="412" width="3" height="17" font="0"> </text>
<text top="156" left="412" width="79" height="17" font="0">Cohort B: N/A </text>
<text top="173" left="412" width="3" height="17" font="0"> </text>
<text top="190" left="412" width="56" height="17" font="0">Cohort C: </text>
<text top="208" left="412" width="7" height="18" font="7"></text>
<text top="209" left="419" width="106" height="17" font="0"> Wheelchair bound </text>
<text top="226" left="412" width="7" height="18" font="7"></text>
<text top="227" left="419" width="155" height="17" font="0"> Hx Foot or leg amputations </text>
<text top="244" left="412" width="7" height="18" font="7"></text>
<text top="245" left="419" width="137" height="17" font="0"> Nursing home residents </text>
<text top="263" left="412" width="7" height="18" font="7"></text>
<text top="264" left="419" width="126" height="17" font="0"> Non-English speaking </text>
<text top="281" left="412" width="7" height="18" font="7"></text>
<text top="282" left="419" width="76" height="17" font="0"> Hx dementia </text>
<text top="300" left="412" width="3" height="17" font="0"> </text>
<text top="317" left="412" width="80" height="17" font="0">Cohort D: N/A </text>
<text top="335" left="86" width="1016" height="17" font="0">ABI indicates ankle-brachial index; BP, blood pressure; CI, confidence interval; CV, cardiovascularular; DBP, diastolic blood pressure; GP, general practitioner; HR, hazard ratio; IASBPD, </text>
<text top="352" left="86" width="1005" height="17" font="0">inter-arm systolic blood pressure; IC, intermittent claudication; LR, likelihood ratio; MMSE, Mini-Mental State Examination; N/A, not applicable; NPV, negative predictive value; OR, odds </text>
<text top="369" left="86" width="974" height="17" font="0">ratio; PAD, peripheral artery disease; PPV, positive predictive value; pt, patient; PVD, peripheral vascular disease; PWV, pulse wave velocity; RR, relative risk; SBP, systolic blood </text>
<text top="386" left="86" width="918" height="17" font="0">pressure; SS, subclavian artery stenosis; TBI, toe-brachial index; UCSD, University of California, San Diego; VA, veterans affairs; and WHO, World Health Organization. </text>
<text top="404" left="86" width="3" height="17" font="9"> </text>
<text top="421" left="86" width="3" height="17" font="9"> </text>
<text top="438" left="86" width="989" height="21" font="1"><b>Evidence Table 2. Nonrandomized Trials, Observational Studies, and/or Registries of Physical Examination for Clinical Assessment for PAD–</b></text>
<text top="459" left="86" width="86" height="21" font="1"><b>Section 2.1. </b></text>
<text top="480" left="110" width="38" height="17" font="2"><b>Study </b></text>
<text top="497" left="98" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="514" left="105" width="48" height="17" font="2"><b>Author; </b></text>
<text top="532" left="114" width="30" height="17" font="2"><b>Year </b></text>
<text top="549" left="97" width="62" height="17" font="2"><b>Published </b></text>
<text top="480" left="188" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="497" left="214" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="480" left="370" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="480" left="596" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="497" left="603" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="514" left="655" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="480" left="908" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="497" left="935" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="567" left="88" width="66" height="17" font="0">Khan NA et </text>
<text top="584" left="88" width="16" height="17" font="0">al. </text>
<text top="601" left="88" width="46" height="17" font="0">2006(7) </text>
<text top="619" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16449619">16449619 </a></text>
<text top="636" left="88" width="3" height="17" font="0"> </text>
<text top="567" left="182" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="584" left="182" width="116" height="17" font="0">Systematic review of </text>
<text top="601" left="182" width="123" height="17" font="0">studies that evaluated </text>
<text top="619" left="182" width="118" height="17" font="0">element of Hx and/or </text>
<text top="636" left="182" width="118" height="17" font="0">physical examination </text>
<text top="653" left="182" width="111" height="17" font="0">for Dx of PAD in pts </text>
<text top="670" left="182" width="92" height="17" font="0">with and without </text>
<text top="687" left="182" width="46" height="17" font="0">disease </text>
<text top="705" left="182" width="3" height="17" font="0"> </text>
<text top="722" left="182" width="117" height="17" font="2"><b>Study size:</b> n=6,272 </text>
<text top="739" left="182" width="109" height="17" font="0">pts in 11 diagnostic </text>
<text top="756" left="182" width="95" height="17" font="0">accuracy studies </text>
<text top="567" left="324" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="584" left="324" width="7" height="18" font="7"></text>
<text top="585" left="331" width="176" height="17" font="0"> Studies published from 1/1966–</text>
<text top="602" left="324" width="41" height="17" font="0">3/2005 </text>
<text top="620" left="324" width="7" height="18" font="7"></text>
<text top="621" left="331" width="193" height="17" font="0"> 51 potential articles identified from </text>
<text top="638" left="324" width="199" height="17" font="0">MEDLINE and Cochrane databases </text>
<text top="655" left="324" width="7" height="18" font="7"></text>
<text top="656" left="331" width="157" height="17" font="0"> Exam maneuvers had to be </text>
<text top="674" left="324" width="96" height="17" font="0">described clearly </text>
<text top="691" left="324" width="7" height="18" font="7"></text>
<text top="692" left="331" width="180" height="17" font="0"> PAD Dx confirmed by reference </text>
<text top="709" left="324" width="204" height="17" font="0">standard: ABI, duplex, or angiogram  </text>
<text top="726" left="324" width="7" height="18" font="7"></text>
<text top="728" left="331" width="190" height="17" font="0"> Data could be extracted into a 2 x </text>
<text top="745" left="324" width="40" height="17" font="0">2 table </text>
<text top="762" left="324" width="7" height="18" font="7"></text>
<text top="763" left="331" width="178" height="17" font="0"> 17 studies met inclusion criteria </text>
<text top="567" left="540" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="584" left="540" width="133" height="17" font="8"><i><b>Physical Examination  </b></i></text>
<text top="601" left="540" width="83" height="17" font="2"><b>Skin changes </b></text>
<text top="619" left="540" width="184" height="17" font="0">Skin cool to touch in affected leg: </text>
<text top="636" left="540" width="7" height="18" font="7"></text>
<text top="637" left="547" width="187" height="17" font="0"> LR PAD: 5.90; 95% CI 4.10–8.60 </text>
<text top="654" left="540" width="94" height="17" font="0">Leg wound/sore: </text>
<text top="671" left="540" width="7" height="18" font="7"></text>
<text top="672" left="547" width="198" height="17" font="0"> LR PAD: 5.90; 95% CI: 2.60–13.40 </text>
<text top="690" left="540" width="90" height="17" font="0">Discolored skin: </text>
<text top="707" left="540" width="7" height="18" font="7"></text>
<text top="708" left="547" width="191" height="17" font="0"> LR PAD: 2.80; 95% CI: 2.40–3.30 </text>
<text top="725" left="540" width="260" height="17" font="0">Absence of cool skin, wound/sore did not lower </text>
<text top="742" left="540" width="97" height="17" font="0">likelihood of PAD </text>
<text top="760" left="540" width="39" height="17" font="2"><b>Bruits </b></text>
<text top="777" left="540" width="115" height="17" font="0">Presence of ≥1 bruit </text>
<text top="567" left="844" width="7" height="18" font="7"></text>
<text top="568" left="851" width="226" height="17" font="0"> In general, presence of physical findings </text>
<text top="585" left="844" width="153" height="17" font="0">increases likelihood of PAD </text>
<text top="603" left="844" width="7" height="18" font="7"></text>
<text top="604" left="851" width="243" height="17" font="0"> Entirely normal pulse exam and absence of </text>
<text top="621" left="844" width="208" height="17" font="0">any bruits decrease likelihood of PAD </text>
<text top="638" left="844" width="7" height="18" font="7"></text>
<text top="639" left="851" width="243" height="17" font="0"> Sensitivities/specificities not reported in this </text>
<text top="656" left="844" width="39" height="17" font="0">review </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">10 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="324" width="154" height="17" font="0">(11 on diagnostic accuracy) </text>
<text top="104" left="324" width="3" height="17" font="0"> </text>
<text top="122" left="324" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="87" left="540" width="7" height="18" font="7"></text>
<text top="88" left="547" width="191" height="17" font="0"> LR PAD: 5.60; 95% CI: 4.70–6.70 </text>
<text top="106" left="540" width="190" height="17" font="0">Over iliac, femoral, popliteal artery </text>
<text top="123" left="540" width="200" height="17" font="0">Absence of a bruit over all 3 arteries </text>
<text top="140" left="540" width="7" height="18" font="7"></text>
<text top="141" left="547" width="191" height="17" font="0"> LR PAD: 0.39; 95% CI: 0.34–0.45 </text>
<text top="158" left="540" width="95" height="17" font="2"><b>Pulse Palpation </b></text>
<text top="176" left="540" width="133" height="17" font="0">Any* pulse abnormality  </text>
<text top="193" left="540" width="7" height="18" font="7"></text>
<text top="194" left="547" width="191" height="17" font="0"> LR PAD: 4.70; 95% CI: 2.20–9.90 </text>
<text top="211" left="540" width="93" height="17" font="0">Absent/reduced  </text>
<text top="228" left="540" width="165" height="17" font="0">*any=femoral/popliteal/DP/PT </text>
<text top="246" left="540" width="191" height="17" font="0">Absence of any pulse abnormality: </text>
<text top="263" left="540" width="7" height="18" font="7"></text>
<text top="264" left="547" width="191" height="17" font="0"> LR PAD: 0.38; 95% CI: 0.23–0.64 </text>
<text top="281" left="540" width="270" height="17" font="0">Abnormal dorsalis pedis pulse less diagnostically </text>
<text top="298" left="540" width="229" height="17" font="0">useful than abnormal femoral or PT pulse </text>
<text top="316" left="540" width="7" height="18" font="7"></text>
<text top="317" left="547" width="215" height="17" font="0"> DP not palpable in 8.1% of healthy pts </text>
<text top="334" left="540" width="7" height="18" font="7"></text>
<text top="335" left="547" width="214" height="17" font="0"> PT not palpable in 2.9% of healthy pts </text>
<text top="352" left="540" width="3" height="17" font="0"> </text>
<text top="370" left="540" width="89" height="17" font="2"><b>Capillary Refill </b></text>
<text top="387" left="540" width="157" height="17" font="0">Abnormal capillary refill time </text>
<text top="404" left="540" width="187" height="17" font="0">LR PAD: 1.90; 95% CI: 1.20–3.20 </text>
<text top="421" left="540" width="129" height="17" font="0">Prolonged venous refill </text>
<text top="438" left="540" width="237" height="17" font="0">LR mod/sev PAD: 3.60; 95% CI: 1.90–6.80 </text>
<text top="456" left="540" width="3" height="17" font="0"> </text>
<text top="473" left="540" width="283" height="17" font="0">Normal venous refill time not informative to r/o PAD </text>
<text top="491" left="88" width="75" height="17" font="0">Cournot M et </text>
<text top="508" left="88" width="16" height="17" font="0">al. </text>
<text top="525" left="88" width="53" height="17" font="0">2007(13) </text>
<text top="542" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18154997">18154997 </a></text>
<text top="560" left="88" width="3" height="17" font="0"> </text>
<text top="491" left="182" width="74" height="17" font="2"><b>Study type:</b>  </text>
<text top="508" left="182" width="7" height="18" font="7"></text>
<text top="509" left="189" width="121" height="17" font="0"> Part of the EVADEC, </text>
<text top="526" left="182" width="104" height="17" font="0">prospective cohort </text>
<text top="544" left="182" width="122" height="17" font="0">study (cross-sectional </text>
<text top="561" left="182" width="119" height="17" font="0">analysis). Pts with no </text>
<text top="578" left="182" width="109" height="17" font="0">known vascularular </text>
<text top="595" left="182" width="107" height="17" font="0">disease underwent </text>
<text top="612" left="182" width="118" height="17" font="0">physical examination </text>
<text top="630" left="182" width="65" height="17" font="0">followed by </text>
<text top="647" left="182" width="112" height="17" font="0">vascularular studies </text>
<text top="664" left="182" width="92" height="17" font="0">(carotid, femoral </text>
<text top="681" left="182" width="92" height="17" font="0">ultrasound, ABI) </text>
<text top="699" left="182" width="7" height="18" font="7"></text>
<text top="700" left="189" width="53" height="17" font="0"> Physical </text>
<text top="717" left="182" width="119" height="17" font="0">examination included </text>
<text top="734" left="182" width="102" height="17" font="0">pulse assessment </text>
<text top="751" left="182" width="124" height="17" font="0">(present/absent), bruit </text>
<text top="769" left="182" width="122" height="17" font="0">assessment using the </text>
<text top="491" left="324" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="508" left="324" width="7" height="18" font="7"></text>
<text top="509" left="331" width="144" height="17" font="0"> 18–90 y (mean age 52 y) </text>
<text top="526" left="324" width="7" height="18" font="7"></text>
<text top="527" left="331" width="91" height="17" font="0"> No known CVD </text>
<text top="545" left="324" width="7" height="18" font="7"></text>
<text top="546" left="331" width="27" height="17" font="0"> Asx </text>
<text top="563" left="324" width="3" height="17" font="0"> </text>
<text top="580" left="324" width="176" height="17" font="2"><b>Exclusion criteria:</b> CV disease </text>
<text top="598" left="324" width="192" height="17" font="0">identified by medical record review </text>
<text top="491" left="540" width="51" height="17" font="2"><b>Results</b>  </text>
<text top="508" left="540" width="274" height="17" font="0">14.5% of pts had any bruit or absent PT/DP pulse </text>
<text top="525" left="540" width="76" height="17" font="4"><i>Femoral bruit </i></text>
<text top="543" left="540" width="7" height="18" font="7"></text>
<text top="544" left="547" width="276" height="17" font="0"> +LR ipsilateral ABI &lt;0.9: 2.90; 95% CI: 1.63–5.16 </text>
<text top="561" left="540" width="7" height="18" font="7"></text>
<text top="562" left="547" width="272" height="17" font="0"> -LR ipsialteral ABI &lt;0.9: 0.93; 95% CI: 0.88–0.98 </text>
<text top="579" left="540" width="97" height="17" font="4"><i>Absent PT pulse  </i></text>
<text top="596" left="540" width="7" height="18" font="7"></text>
<text top="597" left="547" width="276" height="17" font="0"> +LR ipsilateral ABI &lt;0.9: 1.80; 95% CI: 1.08–3.01 </text>
<text top="615" left="540" width="7" height="18" font="7"></text>
<text top="616" left="547" width="272" height="17" font="0"> -LR ipsilateral ABI &lt;0.9: 0.94; 95% CI: 0.88–1.01 </text>
<text top="633" left="540" width="95" height="17" font="4"><i>Absent DP pulse </i></text>
<text top="650" left="540" width="7" height="18" font="7"></text>
<text top="651" left="547" width="276" height="17" font="0"> +LR ipsilateral ABI &lt;0.9: 2.01; 95% CI: 1.17–3.45 </text>
<text top="669" left="540" width="7" height="18" font="7"></text>
<text top="670" left="547" width="272" height="17" font="0"> -LR ipsilateral ABI &lt;0.9: 0.94; 95% CI: 0.88–1.00 </text>
<text top="687" left="540" width="85" height="17" font="4"><i>Absent DP+PT </i></text>
<text top="704" left="540" width="7" height="18" font="7"></text>
<text top="705" left="547" width="276" height="17" font="0"> +LR ipsilateral ABI &lt;0.9: 3.57; 95% CI: 1.93–6.60 </text>
<text top="723" left="540" width="7" height="18" font="7"></text>
<text top="724" left="547" width="272" height="17" font="0"> -LR ipsilateral ABI &lt;0.9: 0.93; 95% CI: 0.97–1.00 </text>
<text top="741" left="540" width="211" height="17" font="0">Interaction term for DM not significant  </text>
<text top="758" left="540" width="287" height="17" font="0">Interobserver agreement 97% for femoral bruit; 92% </text>
<text top="775" left="540" width="178" height="17" font="0">PT palpation; 92% DP palpation </text>
<text top="491" left="844" width="233" height="17" font="0">Both presence of femoral bruit and absent </text>
<text top="508" left="844" width="241" height="17" font="0">pulses increase likelihood of PAD in asx pts </text>
<text top="525" left="844" width="139" height="17" font="0">without known PAD/CVD </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">11 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="182" width="106" height="17" font="0">bell of stethoscope </text>
<text top="104" left="182" width="3" height="17" font="0"> </text>
<text top="122" left="182" width="122" height="17" font="2"><b>Size:</b> n=2,736 eligible </text>
<text top="139" left="182" width="20" height="17" font="0">pts </text>
<text top="156" left="182" width="3" height="17" font="2"><b> </b></text>
<text top="173" left="182" width="82" height="17" font="2"><b>Interobserver </b></text>
<text top="190" left="182" width="119" height="17" font="2"><b>variability substudy </b></text>
<text top="208" left="182" width="75" height="17" font="2"><b>size:</b> 500 pts </text>
<text top="87" left="540" width="252" height="17" font="0">Also reported on carotid bruit for Dx of carotid </text>
<text top="104" left="540" width="271" height="17" font="0">stenosis/plaque/increased IMT (did not affect LR) </text>
<text top="226" left="88" width="60" height="17" font="0">Armstrong </text>
<text top="243" left="88" width="54" height="17" font="0">DW et al. </text>
<text top="260" left="88" width="53" height="17" font="0">2010(14) </text>
<text top="277" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21165366">21165366 </a></text>
<text top="294" left="88" width="3" height="17" font="0"> </text>
<text top="226" left="182" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="243" left="182" width="79" height="17" font="0">Retrospective </text>
<text top="260" left="182" width="116" height="17" font="0">database analysis of </text>
<text top="277" left="182" width="107" height="17" font="0">pts who underwent </text>
<text top="294" left="182" width="81" height="17" font="0">ABI and had a </text>
<text top="312" left="182" width="118" height="17" font="0">physical examination </text>
<text top="329" left="182" width="105" height="17" font="0">documented in the </text>
<text top="346" left="182" width="121" height="17" font="0">CARDIOfile database </text>
<text top="363" left="182" width="101" height="17" font="0">between 12.2005–</text>
<text top="381" left="182" width="101" height="17" font="0">2.2010 at a single </text>
<text top="398" left="182" width="31" height="17" font="0">clinic </text>
<text top="415" left="182" width="3" height="17" font="0"> </text>
<text top="432" left="182" width="122" height="17" font="2"><b>Size:</b> n=1,236 eligible </text>
<text top="449" left="182" width="126" height="17" font="0">pts with complete data </text>
<text top="226" left="324" width="200" height="17" font="2"><b>Inclusion criteria:</b> Pts who had ABI </text>
<text top="243" left="324" width="202" height="17" font="0">performed for suspected PAD or risk </text>
<text top="260" left="324" width="190" height="17" font="0">factors for PAD (Age &gt;70 y, DM or </text>
<text top="277" left="324" width="202" height="17" font="0">smokers ages 50–69 y, intermediate </text>
<text top="294" left="324" width="137" height="17" font="0">Framingham Risk score) </text>
<text top="312" left="324" width="3" height="17" font="0"> </text>
<text top="329" left="324" width="180" height="17" font="2"><b>Exclusion criteria:</b> Pts with ABI </text>
<text top="346" left="324" width="168" height="17" font="0">&gt;1.30 in either leg; incomplete </text>
<text top="363" left="324" width="198" height="17" font="0">physical examination in the databse </text>
<text top="381" left="324" width="3" height="17" font="0"> </text>
<text top="398" left="324" width="67" height="17" font="2"><b>Definitions </b></text>
<text top="415" left="324" width="7" height="18" font="7"></text>
<text top="416" left="331" width="148" height="17" font="0"> PAD defined as ABI ≤0.9  </text>
<text top="433" left="324" width="7" height="18" font="7"></text>
<text top="434" left="331" width="180" height="17" font="0"> Pulses rated 0-3 scale; analysis </text>
<text top="452" left="324" width="104" height="17" font="0">absent vs. present </text>
<text top="469" left="324" width="7" height="18" font="7"></text>
<text top="470" left="331" width="170" height="17" font="0"> Femoral bruits present/absent </text>
<text top="487" left="324" width="7" height="18" font="7"></text>
<text top="488" left="331" width="188" height="17" font="0"> Claudication=leg sx with exercise </text>
<text top="506" left="324" width="140" height="17" font="0">gone within 5 min of rest. </text>
<text top="226" left="540" width="59" height="17" font="2"><b>Results:</b>   </text>
<text top="243" left="540" width="277" height="17" font="0">28.1% of pts had an abnormal ABI in at least 1 leg </text>
<text top="260" left="540" width="37" height="17" font="0">(PAD) </text>
<text top="277" left="540" width="79" height="17" font="4"><i>Femoral bruit  </i></text>
<text top="295" left="540" width="7" height="18" font="7"></text>
<text top="296" left="547" width="146" height="17" font="0"> Sens 36.1%, Spec 92.0% </text>
<text top="313" left="540" width="7" height="18" font="7"></text>
<text top="314" left="547" width="236" height="17" font="0"> PPV 51.1%, NPV 86.2%, Accuracy 81.6% </text>
<text top="331" left="540" width="7" height="18" font="7"></text>
<text top="332" left="547" width="79" height="17" font="0"> +LR PAD 4.5 </text>
<text top="350" left="540" width="7" height="18" font="7"></text>
<text top="351" left="547" width="90" height="17" font="0"> -LR PAD 0.69   </text>
<text top="368" left="540" width="82" height="17" font="4"><i>PT pulse abnl  </i></text>
<text top="385" left="540" width="7" height="18" font="7"></text>
<text top="386" left="547" width="146" height="17" font="0"> Sens 70.0%, Spec 83.4% </text>
<text top="404" left="540" width="7" height="18" font="7"></text>
<text top="405" left="547" width="236" height="17" font="0"> PPV 49.3%, NPV 92.3%, Accuracy 80.9% </text>
<text top="422" left="540" width="7" height="18" font="7"></text>
<text top="423" left="547" width="79" height="17" font="0"> +LR PAD 4.2 </text>
<text top="440" left="540" width="7" height="18" font="7"></text>
<text top="441" left="547" width="83" height="17" font="0"> -LR PAD 0.36 </text>
<text top="459" left="540" width="80" height="17" font="4"><i>DP pulse abnl </i></text>
<text top="476" left="540" width="7" height="18" font="7"></text>
<text top="477" left="547" width="146" height="17" font="0"> Sens 63.9%, Spec 80.6% </text>
<text top="494" left="540" width="7" height="18" font="7"></text>
<text top="495" left="547" width="239" height="17" font="0"> PPV 43.2%, NPV 90.7%,  Accuracy 77.5% </text>
<text top="513" left="540" width="7" height="18" font="7"></text>
<text top="514" left="547" width="79" height="17" font="0"> +LR PAD 3.3 </text>
<text top="531" left="540" width="7" height="18" font="7"></text>
<text top="532" left="547" width="86" height="17" font="0">  -LR PAD 0.45 </text>
<text top="549" left="540" width="280" height="17" font="4"><i>Absent DP and PT pulses+femoral bruit either side </i></text>
<text top="567" left="540" width="206" height="17" font="4"><i>(vs. normal pulses, no femoral bruits) </i></text>
<text top="584" left="540" width="7" height="18" font="7"></text>
<text top="585" left="547" width="146" height="17" font="0"> Sens 58.2%, Spec 98.3% </text>
<text top="602" left="540" width="7" height="18" font="7"></text>
<text top="603" left="547" width="226" height="17" font="0"> PPV 81%, NPV 94.9%, Accuracy 93.8% </text>
<text top="621" left="540" width="7" height="18" font="7"></text>
<text top="622" left="547" width="86" height="17" font="0"> +LR PAD 34.2 </text>
<text top="639" left="540" width="7" height="18" font="7"></text>
<text top="640" left="547" width="86" height="17" font="0">  -LR PAD 0.43 </text>
<text top="226" left="844" width="7" height="18" font="7"></text>
<text top="227" left="851" width="234" height="17" font="0"> Completely normal exam (all ankle pulses </text>
<text top="244" left="844" width="217" height="17" font="0">present and no femoral bruits) has high </text>
<text top="261" left="844" width="184" height="17" font="0">accuracy for normal ABI/no PAD. </text>
<text top="278" left="844" width="7" height="18" font="7"></text>
<text top="279" left="851" width="235" height="17" font="0"> Pulse abnormalities+femoral bruits makes </text>
<text top="297" left="844" width="95" height="17" font="0">Dx of PAD likely. </text>
<text top="314" left="844" width="7" height="18" font="7"></text>
<text top="315" left="851" width="246" height="17" font="0"> Single abnormal physical findings increased </text>
<text top="332" left="844" width="245" height="17" font="0">likelihood of abnormal ABI (specific findings) </text>
<text top="350" left="844" width="7" height="18" font="7"></text>
<text top="351" left="851" width="214" height="17" font="0"> Sensitivity of single abnormal physical </text>
<text top="368" left="844" width="189" height="17" font="0">examination findings lower; not as </text>
<text top="385" left="844" width="234" height="17" font="0">“reassuring” to rule out PAD/abnormal ABI </text>
<text top="658" left="86" width="1015" height="17" font="0">ABI indicates ankle-brachial index; CI indicates confidence interval; CVD, cardiovascularular disease; CV, cardiovascularular; DP, dorsalis pedis; Hx, history; IMT, intima-media thickness; </text>
<text top="675" left="86" width="1008" height="17" font="0">LR, likelihood ratio; PPV, positive predictive value; PAD, peripheral artery disease; PT, posterior tibial; pt, patient; OR, odds ratio; RR, relative risk; sens, sensitivity; and spec, specificity. </text>
<text top="692" left="86" width="3" height="17" font="9"> </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="10" size="13" family="Times" color="#221f1f"/>
<text top="795" left="1088" width="17" height="17" font="0">12 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="510" height="21" font="1"><b>Evidence Table 3. RCTs of Resting ABI for Diagnosing PAD–Section 3.1. </b></text>
<text top="108" left="89" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="125" left="114" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="142" left="92" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="108" left="225" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="125" left="230" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="142" left="224" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="108" left="380" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="108" left="542" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="125" left="560" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="142" left="542" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="159" left="563" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="108" left="723" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="125" left="671" width="210" height="17" font="2"><b>(Absolute Event Rates, P value; OR </b></text>
<text top="142" left="749" width="57" height="17" font="2"><b>or RR; &amp;  </b></text>
<text top="159" left="752" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="109" left="911" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="108" left="972" width="6" height="18" font="7"></text>
<text top="109" left="978" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="126" left="943" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="143" left="951" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="177" left="86" width="96" height="17" font="0">Fowkes FG et al. </text>
<text top="195" left="86" width="53" height="17" font="0">2010(15) </text>
<text top="212" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20197530">20197530 </a></text>
<text top="229" left="86" width="3" height="17" font="0"> </text>
<text top="177" left="203" width="31" height="17" font="2"><b>Aim:</b> </text>
<text top="177" left="233" width="96" height="17" font="10">To determine the </text>
<text top="195" left="203" width="117" height="17" font="10">effectiveness of ASA </text>
<text top="212" left="203" width="126" height="17" font="10">in preventing events in </text>
<text top="229" left="203" width="121" height="17" font="10">people with a low ABI </text>
<text top="246" left="203" width="126" height="17" font="10">identified on screening </text>
<text top="263" left="203" width="122" height="17" font="10">the general population</text>
<text top="263" left="324" width="3" height="17" font="0"> </text>
<text top="281" left="203" width="3" height="17" font="0"> </text>
<text top="298" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="315" left="203" width="3" height="17" font="0"> </text>
<text top="332" left="203" width="100" height="17" font="2"><b>Size:</b> n=3,350 pts </text>
<text top="177" left="344" width="157" height="17" font="2"><b>Inclusion criteria:</b> Men and </text>
<text top="195" left="344" width="114" height="17" font="0">women age 50–75 y </text>
<text top="212" left="344" width="3" height="17" font="0"> </text>
<text top="229" left="344" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="246" left="344" width="7" height="18" font="7"></text>
<text top="247" left="351" width="136" height="17" font="0"> Previous Hx of vascular </text>
<text top="265" left="344" width="124" height="17" font="0">disease, MI, or stroke; </text>
<text top="282" left="344" width="7" height="18" font="7"></text>
<text top="283" left="351" width="135" height="17" font="0"> Currently taking ASA or </text>
<text top="300" left="344" width="51" height="17" font="0">warfarin. </text>
<text top="177" left="540" width="102" height="17" font="2"><b>Intervention:</b> 100 </text>
<text top="195" left="540" width="101" height="17" font="0">mg enteric coated </text>
<text top="212" left="540" width="28" height="17" font="0">ASA </text>
<text top="229" left="540" width="3" height="17" font="0"> </text>
<text top="246" left="540" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="263" left="540" width="48" height="17" font="0">Placebo<b> </b></text>
<text top="178" left="668" width="7" height="17" font="2"><b>1</b></text>
<text top="177" left="675" width="6" height="18" font="7"></text>
<text top="178" left="681" width="72" height="17" font="2"><b> endpoint:</b> C</text>
<text top="178" left="753" width="125" height="17" font="10">omposite of initial fatal </text>
<text top="196" left="668" width="201" height="17" font="10">or nonfatal coronary event, stroke or </text>
<text top="213" left="668" width="213" height="17" font="10">revascularization. (ASA: 13.7; 95% CI: </text>
<text top="230" left="668" width="186" height="17" font="10">11.8–15.9 vs. placebo: 13.3; 95% </text>
<text top="247" left="668" width="176" height="17" font="10">CI: 11.4–15.4, events per 1,000 </text>
<text top="265" left="668" width="188" height="17" font="10">person-y; HR: 1.03; 95% CI: 0.84–</text>
<text top="282" left="668" width="27" height="17" font="10">1.27 </text>
<text top="299" left="668" width="3" height="17" font="10"> </text>
<text top="317" left="668" width="7" height="17" font="2"><b>1</b></text>
<text top="316" left="675" width="6" height="18" font="7"></text>
<text top="317" left="681" width="106" height="17" font="2"><b> Safety endpoint:</b>  </text>
<text top="335" left="668" width="212" height="17" font="0">Major Hemorrhage: ASA: 2.5; 95% CI: </text>
<text top="352" left="668" width="209" height="17" font="0">1.7–3.5 vs. placebo: 1.5; 95% CI: 0.9–</text>
<text top="369" left="668" width="214" height="17" font="0">2.3 per 1,000 person-y; HR: 1.71; 95% </text>
<text top="386" left="668" width="77" height="17" font="0">CI: 0.99–2.97 </text>
<text top="177" left="896" width="7" height="18" font="7"></text>
<text top="178" left="903" width="3" height="17" font="0"> </text>
<text top="178" left="906" width="191" height="17" font="10">Initial vascular events defined as a </text>
<text top="196" left="896" width="198" height="17" font="10">composite of a 1° endpoint event or </text>
<text top="213" left="896" width="100" height="17" font="10">angina, IC, orTIA. </text>
<text top="230" left="896" width="133" height="17" font="10">ASA: 22.8; 95% CI: 20.2</text>
<text top="230" left="1029" width="7" height="17" font="0">–</text>
<text top="230" left="1036" width="46" height="17" font="10">25.6 vs. </text>
<text top="247" left="896" width="152" height="17" font="10">placebo: 22.9; 95% CI: 20.3</text>
<text top="247" left="1048" width="7" height="17" font="0">–</text>
<text top="247" left="1055" width="27" height="17" font="10">25.7 </text>
<text top="265" left="896" width="150" height="17" font="10">events per 1,000 person-y; </text>
<text top="282" left="896" width="161" height="17" font="10">HR: 1.00; 95% CI: 0.85–1.17 </text>
<text top="299" left="896" width="7" height="18" font="7"></text>
<text top="300" left="903" width="3" height="17" font="0"> </text>
<text top="300" left="906" width="104" height="17" font="10">All-cause mortality </text>
<text top="317" left="896" width="193" height="17" font="0">ASA group, 176 deaths (12.8; 95% </text>
<text top="335" left="896" width="192" height="17" font="0">CI: 11.0–14.8 per 1,000 person-y); </text>
<text top="352" left="896" width="184" height="17" font="0">placebo group, 186 deaths (13.5; </text>
<text top="369" left="896" width="71" height="17" font="0">95% CI: 11.6</text>
<text top="369" left="967" width="7" height="17" font="10">–</text>
<text top="369" left="974" width="83" height="17" font="0">15.6 per 1,000 </text>
<text top="386" left="896" width="188" height="17" font="0">person-y; HR: 0.95; 95% CI: 0.77–</text>
<text top="403" left="896" width="32" height="17" font="0">1.16) </text>
<text top="421" left="896" width="7" height="18" font="7"></text>
<text top="422" left="903" width="179" height="17" font="0"> Limitations: higher proportion of </text>
<text top="439" left="896" width="179" height="17" font="0">women, inclusion of pts with DM </text>
<text top="456" left="896" width="162" height="17" font="0">could have influenced results </text>
<text top="474" left="86" width="65" height="17" font="2"><b>POPADAD </b></text>
<text top="492" left="86" width="74" height="17" font="0">Belch J et al. </text>
<text top="509" left="86" width="53" height="17" font="0">2008(16) </text>
<text top="526" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18927173">18927173 </a></text>
<text top="543" left="86" width="3" height="17" font="0"> </text>
<text top="474" left="203" width="106" height="17" font="2"><b>Aim</b>: To determine </text>
<text top="492" left="203" width="99" height="17" font="0">whether ASA and </text>
<text top="509" left="203" width="111" height="17" font="0">antioxidant therapy, </text>
<text top="526" left="203" width="108" height="17" font="0">combined or alone, </text>
<text top="543" left="203" width="102" height="17" font="0">are more effective </text>
<text top="560" left="203" width="87" height="17" font="0">than placebo in </text>
<text top="578" left="203" width="120" height="17" font="0">reducing CVD events </text>
<text top="595" left="203" width="128" height="17" font="0">in pts with DM and Asx </text>
<text top="612" left="203" width="32" height="17" font="0">PAD. </text>
<text top="629" left="203" width="3" height="17" font="0"> </text>
<text top="646" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="664" left="203" width="67" height="17" font="0">Multicenter, </text>
<text top="681" left="203" width="111" height="17" font="0">randomized, double </text>
<text top="698" left="203" width="107" height="17" font="0">blind, 2×2 factorial, </text>
<text top="715" left="203" width="103" height="17" font="0">placebo controlled </text>
<text top="732" left="203" width="27" height="17" font="0">trial. </text>
<text top="750" left="203" width="3" height="17" font="0"> </text>
<text top="767" left="203" width="100" height="17" font="2"><b>Size:</b> n=1,276 pts </text>
<text top="474" left="344" width="166" height="17" font="2"><b>Inclusion criteria</b>: Age ≥40 y </text>
<text top="492" left="344" width="160" height="17" font="0">with type 1 or type 2 DM and </text>
<text top="509" left="344" width="161" height="17" font="0">ABI of ≤0.99 but no Sx CVD. </text>
<text top="526" left="344" width="3" height="17" font="0"> </text>
<text top="543" left="344" width="180" height="17" font="2"><b>Exclusion criteria</b>: People with: </text>
<text top="560" left="344" width="166" height="17" font="0">evidence of Sx vascular CVD; </text>
<text top="578" left="344" width="173" height="17" font="0">ASA or antioxidant therapy use </text>
<text top="595" left="344" width="141" height="17" font="0">on a regular basis; peptic </text>
<text top="612" left="344" width="173" height="17" font="0">ulceration, severe dyspepsia, a </text>
<text top="629" left="344" width="179" height="17" font="0">bleeding disorder, or intolerance </text>
<text top="646" left="344" width="148" height="17" font="0">to ASA; suspected serious </text>
<text top="664" left="344" width="165" height="17" font="0">physical illness (e.g., cancer), </text>
<text top="681" left="344" width="123" height="17" font="0">which could curtail life </text>
<text top="698" left="344" width="168" height="17" font="0">expectancy; psychiatric illness </text>
<text top="715" left="344" width="144" height="17" font="0">(reported by GP); pts with </text>
<text top="732" left="344" width="164" height="17" font="0">congenital heart disease; and </text>
<text top="750" left="344" width="151" height="17" font="0">pts unable to give informed </text>
<text top="767" left="344" width="50" height="17" font="0">consent  </text>
<text top="474" left="540" width="99" height="17" font="2"><b>Intervention and </b></text>
<text top="492" left="540" width="109" height="17" font="2"><b>comparator</b>: Daily, </text>
<text top="509" left="540" width="106" height="17" font="0">100 mg ASA tablet </text>
<text top="526" left="540" width="73" height="17" font="0">+ antioxidant </text>
<text top="543" left="540" width="95" height="17" font="0">capsule (n=320); </text>
<text top="560" left="540" width="85" height="17" font="0">ASA + placebo </text>
<text top="578" left="540" width="95" height="17" font="0">capsule (n=318); </text>
<text top="595" left="540" width="91" height="17" font="0">placebo tablet + </text>
<text top="612" left="540" width="109" height="17" font="0">antioxidant capsule </text>
<text top="629" left="540" width="110" height="17" font="0">(n=320); or placebo </text>
<text top="646" left="540" width="91" height="17" font="0">tablet + placebo </text>
<text top="664" left="540" width="95" height="17" font="0">capsule (n=318). </text>
<text top="475" left="668" width="7" height="17" font="2"><b>1</b></text>
<text top="474" left="675" width="6" height="18" font="7"></text>
<text top="475" left="681" width="66" height="17" font="2"><b> endpoint</b>:  </text>
<text top="493" left="668" width="7" height="18" font="7"></text>
<text top="494" left="675" width="200" height="17" font="0"> Death from CHD or stroke, nonfatal </text>
<text top="511" left="668" width="208" height="17" font="0">MI or stroke, or amputation above the </text>
<text top="528" left="668" width="207" height="17" font="0">ankle for CLI; and death from CHD or </text>
<text top="545" left="668" width="40" height="17" font="0">stroke  </text>
<text top="563" left="668" width="7" height="18" font="7"></text>
<text top="564" left="675" width="182" height="17" font="0"> 116 of 638 1° events in the ASA </text>
<text top="581" left="668" width="199" height="17" font="0">groups compared with 117 of 638 in </text>
<text top="598" left="668" width="210" height="17" font="0">the no ASA groups (18.2% vs. 18.3%) </text>
<text top="615" left="668" width="181" height="17" font="0">HR: 0.98; 95% CI: 0.76–1.26. 43 </text>
<text top="633" left="668" width="214" height="17" font="0">deaths from CHD or stroke occurred in </text>
<text top="650" left="668" width="203" height="17" font="0">the ASA groups compared with 35 in </text>
<text top="667" left="668" width="200" height="17" font="0">the no ASA groups (6.7% vs. 5.5%): </text>
<text top="684" left="668" width="168" height="17" font="0">HR: 1.23; 95% CI: 0.79–1.93). </text>
<text top="702" left="668" width="7" height="18" font="7"></text>
<text top="703" left="675" width="189" height="17" font="0"> No difference in treatment for ABI </text>
<text top="720" left="668" width="35" height="17" font="0">&lt;0.90 </text>
<text top="474" left="896" width="200" height="17" font="2"><b>Adverse effect (effect estimates):  </b></text>
<text top="492" left="896" width="7" height="18" font="7"></text>
<text top="493" left="903" width="125" height="17" font="0"> Malignancy 0.76 (0.52</text>
<text top="493" left="1027" width="7" height="17" font="10">–</text>
<text top="493" left="1034" width="38" height="17" font="0">1.11),  </text>
<text top="510" left="896" width="7" height="18" font="7"></text>
<text top="511" left="903" width="129" height="17" font="0"> GI bleeding, 0.90 (0.53</text>
<text top="511" left="1031" width="7" height="17" font="10">–</text>
<text top="511" left="1038" width="31" height="17" font="0">1.52) </text>
<text top="528" left="896" width="7" height="18" font="7"></text>
<text top="529" left="903" width="120" height="17" font="0"> Dyspepsia 0.77 (0.55</text>
<text top="529" left="1022" width="7" height="17" font="10">–</text>
<text top="529" left="1029" width="38" height="17" font="0">1.08),  </text>
<text top="547" left="896" width="7" height="18" font="7"></text>
<text top="548" left="903" width="100" height="17" font="0"> Allergy 1.14 (0.80</text>
<text top="548" left="1003" width="7" height="17" font="10">–</text>
<text top="548" left="1009" width="35" height="17" font="0">1.63)  </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="11" size="7" family="Times" color="#000000"/>
	<fontspec id="12" size="16" family="Times" color="#000000"/>
<text top="795" left="1088" width="17" height="17" font="0">13 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="86" width="91" height="17" font="0">McDermott, MM </text>
<text top="104" left="86" width="33" height="17" font="0">et al.  </text>
<text top="122" left="86" width="53" height="17" font="0">2013(17) </text>
<text top="139" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821089">23821089</a></text>
<text top="139" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821089"> </a></text>
<text top="156" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="104" left="203" width="109" height="17" font="0">testing efficacy of a </text>
<text top="122" left="203" width="116" height="17" font="0">home-based walking </text>
<text top="139" left="203" width="116" height="17" font="0">exercise intervention </text>
<text top="156" left="203" width="118" height="17" font="0">vs. control in pts with </text>
<text top="173" left="203" width="120" height="17" font="0">PAD with and without </text>
<text top="190" left="203" width="68" height="17" font="0">claudication </text>
<text top="208" left="203" width="3" height="17" font="0"> </text>
<text top="225" left="203" width="93" height="17" font="2"><b>Size:</b> n=194 pts; </text>
<text top="242" left="203" width="81" height="17" font="0">72.2% without </text>
<text top="259" left="203" width="68" height="17" font="0">claudication </text>
<text top="87" left="344" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="104" left="344" width="7" height="18" font="7"></text>
<text top="105" left="351" width="64" height="17" font="0"> Age ≥65 y </text>
<text top="123" left="344" width="7" height="18" font="7"></text>
<text top="124" left="351" width="174" height="17" font="0"> ABI ≤0.9 or 20% post exercise </text>
<text top="141" left="344" width="64" height="17" font="0">drop in ABI </text>
<text top="158" left="344" width="3" height="17" font="0"> </text>
<text top="176" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="193" left="344" width="7" height="18" font="7"></text>
<text top="194" left="351" width="158" height="17" font="0"> Lower extremity amputation </text>
<text top="211" left="344" width="7" height="18" font="7"></text>
<text top="212" left="351" width="168" height="17" font="0"> Inability to walk ≥50 ft without </text>
<text top="230" left="344" width="50" height="17" font="0">stopping </text>
<text top="247" left="344" width="7" height="18" font="7"></text>
<text top="248" left="351" width="141" height="17" font="0"> Inability to attend weekly </text>
<text top="265" left="344" width="51" height="17" font="0">sessions </text>
<text top="282" left="344" width="7" height="18" font="7"></text>
<text top="283" left="351" width="163" height="17" font="0"> Walking impairment not from </text>
<text top="301" left="344" width="29" height="17" font="0">PAD </text>
<text top="318" left="344" width="7" height="18" font="7"></text>
<text top="319" left="351" width="29" height="17" font="0"> CLI  </text>
<text top="87" left="540" width="81" height="17" font="2"><b>Intervention:</b>  </text>
<text top="104" left="540" width="109" height="17" font="0">Home-based group-</text>
<text top="122" left="540" width="106" height="17" font="0">mediated cognitive </text>
<text top="139" left="540" width="105" height="17" font="0">behavioral walking </text>
<text top="156" left="540" width="35" height="17" font="0">group </text>
<text top="173" left="540" width="3" height="17" font="2"><b> </b></text>
<text top="190" left="540" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="208" left="540" width="96" height="17" font="0">Health education </text>
<text top="88" left="668" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="675" width="6" height="18" font="7"></text>
<text top="88" left="681" width="166" height="17" font="2"><b> endpoint: </b>Change in 6-MWT </text>
<text top="106" left="668" width="154" height="17" font="0">between baseline and 6 mo </text>
<text top="123" left="668" width="3" height="17" font="2"><b> </b></text>
<text top="140" left="668" width="191" height="17" font="2"><b>Secondary outcomes: </b>Change in </text>
<text top="157" left="668" width="176" height="17" font="0">treadmill MWT; PFWT; physical </text>
<text top="174" left="668" width="213" height="17" font="0">activity; WIQ scores; PCS and MCS of </text>
<text top="192" left="668" width="37" height="17" font="0">SF-36 </text>
<text top="209" left="668" width="3" height="17" font="0"> </text>
<text top="226" left="668" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="243" left="668" width="47" height="17" font="0">6-MWT: </text>
<text top="261" left="668" width="7" height="18" font="7"></text>
<text top="262" left="675" width="190" height="17" font="0"> Control: 347 m BL vs. 329 m 6mo </text>
<text top="279" left="668" width="7" height="18" font="7"></text>
<text top="280" left="675" width="198" height="17" font="0"> Intervention: 372 m BL vs. 386 m 6 </text>
<text top="297" left="668" width="21" height="17" font="0">mo </text>
<text top="87" left="896" width="7" height="18" font="7"></text>
<text top="88" left="903" width="178" height="17" font="0"> Modest improvement in 6-MWT </text>
<text top="106" left="896" width="194" height="17" font="0">distance after 6 mo of home-based </text>
<text top="123" left="896" width="163" height="17" font="0">exercise in pts with  Asx PAD<b> </b></text>
<text top="337" left="86" width="7" height="17" font="0">1</text>
<text top="338" left="93" width="4" height="11" font="11">o</text>
<text top="337" left="98" width="984" height="17" font="0"> indicates primary; ABI, ankle-brachial index; ASA, aspirin; Asx, asymptomatic; CI, confidence interval; BL, baseline; CVD, cardiovascular disease; CHD, coronary heart disease; GI, </text>
<text top="354" left="86" width="991" height="17" font="0">gastrointestimal; HR, hazard ratio, Hx, history; IC, intermittent claudication; MCS, mental component summary score; MWT, mean walking time; PAD, peripheral artery disease; PCS, </text>
<text top="371" left="86" width="901" height="17" font="0">physical component summary score; PFWT, pain-free walking time; pt, patient; Sx, symptomatic; RCT, randomized controlled trial; and TIA, transient ischemic attack </text>
<text top="389" left="86" width="3" height="17" font="9"> </text>
<text top="406" left="86" width="3" height="17" font="9"> </text>
<text top="423" left="86" width="920" height="21" font="1"><b>Evidence Table 4. Nonrandomized Trials, Observational Studies, and/or Registries of Resting ABI for Diagnosing PAD</b>–<b>Section 3.1. </b></text>
<text top="445" left="93" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="462" left="118" width="48" height="17" font="2"><b>Author; </b></text>
<text top="479" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="445" left="221" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="462" left="248" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="445" left="387" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="445" left="626" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="462" left="634" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="479" left="686" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="445" left="941" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="462" left="969" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="497" left="88" width="92" height="17" font="0">Criqui MH, et al. </text>
<text top="514" left="88" width="53" height="17" font="0">2005(18) </text>
<text top="531" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16246968">16246968</a></text>
<text top="531" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16246968"> </a></text>
<text top="548" left="88" width="3" height="17" font="0"> </text>
<text top="497" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="514" left="209" width="85" height="17" font="0">sectional study </text>
<text top="531" left="209" width="3" height="17" font="0"> </text>
<text top="548" left="209" width="86" height="17" font="2"><b>Size:</b> 2,343 pts </text>
<text top="497" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="514" left="365" width="7" height="18" font="7"></text>
<text top="515" left="371" width="76" height="17" font="0"> Age 29–91 y </text>
<text top="533" left="365" width="7" height="18" font="7"></text>
<text top="534" left="371" width="99" height="17" font="0"> 1 of the following </text>
<text top="551" left="365" width="139" height="17" font="0">ethnicities: Non-Hispanic </text>
<text top="568" left="365" width="146" height="17" font="0">Whites, blacks, Hispanics, </text>
<text top="585" left="365" width="34" height="17" font="0">Asian </text>
<text top="602" left="365" width="3" height="17" font="0"> </text>
<text top="620" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="498" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="497" left="540" width="6" height="18" font="7"></text>
<text top="498" left="546" width="155" height="17" font="2"><b> endpoint:</b> PAD prevalence<b> </b></text>
<text top="515" left="533" width="3" height="17" font="0"> </text>
<text top="532" left="533" width="52" height="17" font="2"><b>Results: </b></text>
<text top="550" left="533" width="7" height="18" font="7"></text>
<text top="551" left="540" width="131" height="17" font="0"> 104 PAD cases (4.4%) </text>
<text top="568" left="533" width="7" height="18" font="7"></text>
<text top="569" left="540" width="353" height="17" font="0"> Blacks had a higher PAD prevalence than Non-Hispanic Whites </text>
<text top="586" left="533" width="113" height="17" font="0">(OR: 2.30; p&gt;0.024) </text>
<text top="604" left="533" width="7" height="18" font="7"></text>
<text top="605" left="540" width="351" height="17" font="0"> Hispanics and Asians has a lower but nonsignificant lower PAD </text>
<text top="622" left="533" width="132" height="17" font="0">prevalence than Whites </text>
<text top="497" left="911" width="7" height="18" font="7"></text>
<text top="498" left="918" width="161" height="17" font="0"> Suggests black ethnicity is a </text>
<text top="515" left="911" width="103" height="17" font="0">risk factor for PAD </text>
<text top="533" left="911" width="7" height="18" font="7"></text>
<text top="534" left="918" width="174" height="17" font="0"> No evidence of blacks being of </text>
<text top="551" left="911" width="167" height="17" font="0">higher susceptibility to CV risk </text>
<text top="568" left="911" width="176" height="17" font="0">factors to explain increased risk </text>
<text top="585" left="911" width="46" height="17" font="0">for PAD </text>
<text top="603" left="911" width="7" height="18" font="7"></text>
<text top="604" left="918" width="175" height="17" font="0"> Low prevalence of PAD (4.4%) </text>
<text top="640" left="88" width="86" height="17" font="0">Selvin E, et al.  </text>
<text top="657" left="88" width="53" height="17" font="0">2004(19) </text>
<text top="674" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15262830">15262830</a></text>
<text top="674" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15262830"> </a></text>
<text top="692" left="88" width="3" height="17" font="0"> </text>
<text top="640" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="657" left="209" width="92" height="17" font="0">sectional survey </text>
<text top="674" left="209" width="3" height="17" font="0"> </text>
<text top="692" left="209" width="100" height="17" font="2"><b>Size:</b> n=2,174 pts </text>
<text top="640" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="657" left="365" width="7" height="18" font="7"></text>
<text top="658" left="371" width="64" height="17" font="0"> Age ≥40 y </text>
<text top="676" left="365" width="7" height="18" font="7"></text>
<text top="677" left="371" width="119" height="17" font="0"> Participants of 1999–</text>
<text top="694" left="365" width="89" height="17" font="0">2000 NHANES  </text>
<text top="711" left="365" width="7" height="18" font="7"></text>
<text top="712" left="371" width="125" height="17" font="0"> Participants with valid </text>
<text top="730" left="365" width="142" height="17" font="0">mean ABI blood pressure </text>
<text top="747" left="365" width="33" height="17" font="0">index </text>
<text top="764" left="365" width="3" height="17" font="0"> </text>
<text top="641" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="640" left="540" width="6" height="18" font="7"></text>
<text top="641" left="546" width="350" height="17" font="2"><b> endpoint:</b> Frequency of detection, pt and physician awareness </text>
<text top="658" left="533" width="200" height="17" font="0">of diagnosis, and treatment intensity<b> </b></text>
<text top="676" left="533" width="3" height="17" font="0"> </text>
<text top="693" left="533" width="52" height="17" font="2"><b>Results: </b></text>
<text top="710" left="533" width="7" height="18" font="7"></text>
<text top="711" left="540" width="343" height="17" font="0"> Prevalence of PAD in adults ≥40 y in U.S. was 4.3% (95% CI: </text>
<text top="728" left="533" width="70" height="17" font="0">3.1%–5.5%) </text>
<text top="746" left="533" width="7" height="18" font="7"></text>
<text top="747" left="540" width="350" height="17" font="0"> Prevalence of PAD in adults ≥70 y in U.S. was 14.5% (95% CI: </text>
<text top="764" left="533" width="84" height="17" font="0">10.8%–18.2%) </text>
<text top="640" left="911" width="7" height="18" font="7"></text>
<text top="641" left="918" width="163" height="17" font="0"> PAD defined as ABI &lt;0.90 in </text>
<text top="658" left="911" width="54" height="17" font="0">either leg </text>
<text top="676" left="911" width="7" height="18" font="7"></text>
<text top="677" left="918" width="154" height="17" font="0"> In the U.S., PAD affects &gt;5 </text>
<text top="694" left="911" width="81" height="17" font="0">million adults.  </text>
<text top="711" left="911" width="7" height="18" font="7"></text>
<text top="712" left="918" width="177" height="17" font="0"> PAD prevalence increases with </text>
<text top="730" left="911" width="188" height="17" font="0">age and disproportionately affects </text>
<text top="747" left="911" width="45" height="17" font="0">blacks.  </text>
<text top="764" left="911" width="7" height="18" font="7"></text>
<text top="765" left="918" width="180" height="17" font="0"> Majority of pt with PAD have ≥1 </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">14 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="365" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="104" left="365" width="7" height="18" font="7"></text>
<text top="105" left="371" width="93" height="17" font="0"> ABI values &gt;1.5 </text>
<text top="123" left="365" width="7" height="18" font="7"></text>
<text top="124" left="371" width="141" height="17" font="0"> Participants with missing </text>
<text top="141" left="365" width="110" height="17" font="0">variables of interest<b> </b></text>
<text top="87" left="533" width="7" height="18" font="7"></text>
<text top="88" left="540" width="328" height="17" font="0"> Black race/ethnicity (OR: 2.83; 95% CI: 1.48–5.42); current </text>
<text top="106" left="533" width="352" height="17" font="0">smoking (OR: 4.46; 95% CI: 2.25–8.84), DM (OR: 2.27; 95% CI: </text>
<text top="123" left="533" width="313" height="17" font="0">1.03–7.12), hypertension (OR: 1.74; 95% CI: 0.97–3.13), </text>
<text top="140" left="533" width="333" height="17" font="0">hypercholesterdemia (OR: 1.68; 95% CI: 1.09–2.57) and low </text>
<text top="157" left="533" width="339" height="17" font="0">kidney function (OR: 2.00; 95% CI: 1.08–3.70) were positively </text>
<text top="174" left="533" width="183" height="17" font="0">associated with PAD prevalence. </text>
<text top="87" left="911" width="93" height="17" font="0">CVD risk factor.  </text>
<text top="104" left="911" width="7" height="18" font="7"></text>
<text top="105" left="918" width="175" height="17" font="0"> Low Prevalence of PAD: 4.3%; </text>
<text top="123" left="911" width="114" height="17" font="0">95% CI: 3.1%–5.5% </text>
<text top="192" left="88" width="94" height="17" font="0">Hirsch AT, et al.  </text>
<text top="210" left="88" width="46" height="17" font="0">2001(6) </text>
<text top="227" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11560536">11560536 </a></text>
<text top="244" left="88" width="3" height="17" font="0"> </text>
<text top="192" left="209" width="74" height="17" font="2"><b>Study type: </b> </text>
<text top="210" left="209" width="7" height="18" font="7"></text>
<text top="211" left="216" width="104" height="17" font="0"> Multi-center cross-</text>
<text top="228" left="209" width="85" height="17" font="0">sectional study </text>
<text top="245" left="209" width="142" height="17" font="0">conducted at 350 primary </text>
<text top="262" left="209" width="137" height="17" font="0">care practices in the US. </text>
<text top="280" left="209" width="7" height="18" font="7"></text>
<text top="281" left="216" width="133" height="17" font="0"> Pts enrolled underwent </text>
<text top="298" left="209" width="132" height="17" font="0">San Diego Claudication </text>
<text top="315" left="209" width="129" height="17" font="0">Questionnaire, medical </text>
<text top="332" left="209" width="120" height="17" font="0">and CV Hx/risk factor </text>
<text top="350" left="209" width="96" height="17" font="0">assessment, BP, </text>
<text top="367" left="209" width="129" height="17" font="0">anthropomorphics, and </text>
<text top="384" left="209" width="99" height="17" font="0">ABI assessment.  </text>
<text top="401" left="209" width="7" height="18" font="7"></text>
<text top="402" left="216" width="97" height="17" font="0"> Pts. identified as </text>
<text top="420" left="209" width="124" height="17" font="0">having PAD (and their </text>
<text top="437" left="209" width="133" height="17" font="0">providers) further asked </text>
<text top="454" left="209" width="131" height="17" font="0">about awareness of the </text>
<text top="471" left="209" width="51" height="17" font="0">PAD Dx. </text>
<text top="488" left="209" width="3" height="17" font="0"> </text>
<text top="506" left="209" width="139" height="17" font="2"><b>Size:</b> n=6,979 pts (1,865 </text>
<text top="523" left="209" width="57" height="17" font="0">had PAD)<b> </b></text>
<text top="192" left="365" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="210" left="365" width="7" height="18" font="7"></text>
<text top="211" left="371" width="140" height="17" font="0"> Age ≥70 y or age 50–69 </text>
<text top="228" left="365" width="129" height="17" font="0">y with DM or Hx of ≥10 </text>
<text top="245" left="365" width="104" height="17" font="0">pack-year tobacco </text>
<text top="262" left="365" width="7" height="18" font="7"></text>
<text top="263" left="371" width="140" height="17" font="0"> PAD (lower leg pressure </text>
<text top="281" left="365" width="132" height="17" font="0">method) defined as ABI </text>
<text top="298" left="365" width="96" height="17" font="0">≤0.9 in either leg </text>
<text top="315" left="365" width="3" height="17" font="0"> </text>
<text top="332" left="365" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="192" left="533" width="52" height="17" font="2"><b>Results: </b></text>
<text top="210" left="533" width="7" height="18" font="7"></text>
<text top="211" left="540" width="237" height="17" font="0"> Prevalence of PAD in this cohort was 29% </text>
<text top="228" left="533" width="7" height="18" font="7"></text>
<text top="229" left="540" width="250" height="17" font="0"> Among 1,865 pts with PAD (mean ABI 0.78): </text>
<text top="246" left="533" width="166" height="17" font="0">5.5–15.3% Rose claudication; </text>
<text top="264" left="533" width="153" height="17" font="0">46.3–61.7% atypical leg sx; </text>
<text top="281" left="533" width="113" height="17" font="0">23.3–48.3% no pain </text>
<text top="298" left="533" width="323" height="17" font="0">**Rates reported for new Dx/prior Dx and for PAD only and </text>
<text top="315" left="533" width="62" height="17" font="0">PAD+CVD </text>
<text top="192" left="911" width="7" height="18" font="7"></text>
<text top="193" left="918" width="176" height="17" font="0"> More data on wide spectrum of </text>
<text top="211" left="911" width="180" height="17" font="0">leg sx among pts with PAD; only </text>
<text top="228" left="911" width="167" height="17" font="0">about 5-15% of ABI confirmed </text>
<text top="245" left="911" width="151" height="17" font="0">PAD pts have classic Rose </text>
<text top="262" left="911" width="182" height="17" font="0">claudication. Many majority have </text>
<text top="280" left="911" width="189" height="17" font="0">atypical non-Rose leg sx or no leg </text>
<text top="297" left="911" width="30" height="17" font="0">pain. </text>
<text top="541" left="88" width="72" height="17" font="0">Guo X, et al. </text>
<text top="558" left="88" width="53" height="17" font="0">2008(20) </text>
<text top="575" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18362433">18362433 </a></text>
<text top="593" left="88" width="3" height="17" font="0"> </text>
<text top="541" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="558" left="209" width="103" height="17" font="0">Observational test </text>
<text top="575" left="209" width="67" height="17" font="0">comparison </text>
<text top="593" left="209" width="3" height="17" font="0"> </text>
<text top="610" left="209" width="90" height="17" font="2"><b>Size:</b> n=298 pts </text>
<text top="541" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="558" left="365" width="7" height="18" font="7"></text>
<text top="559" left="371" width="64" height="17" font="0"> Age ≥35 y </text>
<text top="577" left="365" width="7" height="18" font="7"></text>
<text top="578" left="371" width="148" height="17" font="0"> Cardiology clinic: referrals </text>
<text top="595" left="365" width="81" height="17" font="0">for DSA &amp; ABI </text>
<text top="612" left="365" width="3" height="17" font="0"> </text>
<text top="629" left="365" width="152" height="17" font="2"><b>Exclusion criteria:</b> Severe </text>
<text top="646" left="365" width="108" height="17" font="0">DM &amp; hypertension<b> </b></text>
<text top="664" left="365" width="3" height="17" font="0"> </text>
<text top="681" left="365" width="94" height="17" font="2"><b>Gold standard:</b>  </text>
<text top="698" left="365" width="7" height="18" font="7"></text>
<text top="699" left="371" width="36" height="17" font="0"> DSA. </text>
<text top="716" left="365" width="7" height="18" font="7"></text>
<text top="718" left="371" width="90" height="17" font="0"> Stenosis ≥50% </text>
<text top="735" left="365" width="3" height="17" font="0"> </text>
<text top="752" left="365" width="148" height="17" font="2"><b>ABI method: </b>Oscillometry </text>
<text top="542" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="541" left="540" width="6" height="18" font="7"></text>
<text top="542" left="546" width="346" height="17" font="2"><b> endpoint:</b> Presence of stenosis below aorto-iliac bifurcation in </text>
<text top="559" left="533" width="101" height="17" font="0">leg with lower ABI<b> </b></text>
<text top="576" left="533" width="3" height="17" font="0"> </text>
<text top="594" left="533" width="52" height="17" font="2"><b>Results: </b></text>
<text top="611" left="533" width="7" height="18" font="7"></text>
<text top="612" left="540" width="115" height="17" font="0"> Sensitivity: 76 (N/A) </text>
<text top="629" left="533" width="7" height="18" font="7"></text>
<text top="630" left="540" width="115" height="17" font="0"> Specificity: 90 (N/A) </text>
<text top="648" left="533" width="7" height="18" font="7"></text>
<text top="649" left="540" width="84" height="17" font="0"> PPV: 36 (N/A) </text>
<text top="666" left="533" width="7" height="18" font="7"></text>
<text top="667" left="540" width="85" height="17" font="0"> NPV: 98 (N/A) </text>
<text top="541" left="911" width="7" height="18" font="7"></text>
<text top="542" left="918" width="170" height="17" font="0"> Moderate sensitivity and good </text>
<text top="559" left="911" width="188" height="17" font="0">specificity. No indication of % with </text>
<text top="576" left="911" width="131" height="17" font="0">PAD symptoms but low </text>
<text top="594" left="911" width="181" height="17" font="0">prevalence of PAD on DSA (7%) </text>
<text top="611" left="911" width="146" height="17" font="0">suggests it was negligible. </text>
<text top="628" left="911" width="7" height="18" font="7"></text>
<text top="629" left="918" width="138" height="17" font="0"> 53% had coronary heart </text>
<text top="646" left="911" width="138" height="17" font="0">disease and 13% stroke. </text>
<text top="770" left="88" width="96" height="17" font="0">Aboyans V, et al. </text>
<text top="770" left="209" width="123" height="17" font="2"><b>Study type:</b> Scientific </text>
<text top="770" left="365" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="771" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="770" left="540" width="6" height="18" font="7"></text>
<text top="771" left="546" width="90" height="17" font="2"><b> endpoint:</b> N/A  </text>
<text top="770" left="911" width="7" height="18" font="7"></text>
<text top="771" left="918" width="182" height="17" font="0"> AHA Scientific Statement on the </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">15 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="88" width="53" height="17" font="0">2012(21) </text>
<text top="104" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23159553">23159553</a></text>
<text top="104" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23159553"> </a></text>
<text top="122" left="88" width="3" height="17" font="0"> </text>
<text top="87" left="209" width="57" height="17" font="0">statement </text>
<text top="104" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="209" width="56" height="17" font="2"><b>Size:</b> N/A </text>
<text top="87" left="365" width="3" height="17" font="0"> </text>
<text top="104" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="533" width="3" height="17" font="0"> </text>
<text top="104" left="533" width="76" height="17" font="2"><b>Results:</b> N/A </text>
<text top="87" left="911" width="178" height="17" font="0">measurement and interpretation </text>
<text top="104" left="911" width="57" height="17" font="0">of the ABI </text>
<text top="139" left="88" width="96" height="17" font="0">Aboyans V, et al. </text>
<text top="157" left="88" width="53" height="17" font="0">2008(22) </text>
<text top="174" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18692981">18692981 </a></text>
<text top="191" left="88" width="3" height="17" font="0"> </text>
<text top="139" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="157" left="209" width="52" height="17" font="0">sectional </text>
<text top="174" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="191" left="209" width="90" height="17" font="2"><b>Size:</b> n=510 pts </text>
<text top="139" left="365" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="157" left="365" width="145" height="17" font="0">ambulatory pts presenting </text>
<text top="174" left="365" width="83" height="17" font="0">to vascular lab </text>
<text top="191" left="365" width="3" height="17" font="0"> </text>
<text top="208" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="141" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="140" left="540" width="6" height="18" font="7"></text>
<text top="141" left="546" width="329" height="17" font="2"><b> endpoint:</b> Association of risk factors with ABI &gt;1.4 and ABI </text>
<text top="158" left="533" width="194" height="17" font="0">&lt;0.9 and disease presence by TBI  </text>
<text top="175" left="533" width="3" height="17" font="0"> </text>
<text top="192" left="533" width="343" height="17" font="2"><b>Results:</b> In 84.2% of cases, diabetic limbs with ABI ≥1.40 had </text>
<text top="210" left="533" width="323" height="17" font="0">abnormal results in at least 1 of the 2 noninvasive vascular </text>
<text top="227" left="533" width="308" height="17" font="0">indicators, suggestive of concomitant occlusive disease. </text>
<text top="140" left="911" width="7" height="18" font="7"></text>
<text top="141" left="918" width="79" height="17" font="0"> 50% with DM </text>
<text top="158" left="911" width="7" height="18" font="7"></text>
<text top="159" left="918" width="163" height="17" font="0"> No angiographic correlations </text>
<text top="245" left="88" width="98" height="17" font="0">Schröder F, et al. </text>
<text top="262" left="88" width="53" height="17" font="0">2006(23) </text>
<text top="279" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16950430">16950430</a></text>
<text top="279" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16950430"> </a></text>
<text top="296" left="88" width="3" height="17" font="0"> </text>
<text top="245" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="262" left="209" width="103" height="17" font="0">Observational test </text>
<text top="279" left="209" width="67" height="17" font="0">comparison </text>
<text top="296" left="209" width="3" height="17" font="0"> </text>
<text top="314" left="209" width="90" height="17" font="2"><b>Size: </b>n=216 pts </text>
<text top="245" left="365" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="262" left="365" width="115" height="17" font="0">Attending a vascular </text>
<text top="279" left="365" width="147" height="17" font="0">medicine clinic “suspected </text>
<text top="296" left="365" width="113" height="17" font="0">of having a vascular </text>
<text top="314" left="365" width="108" height="17" font="0">disease. Age &gt;40 y </text>
<text top="331" left="365" width="3" height="17" font="0"> </text>
<text top="348" left="365" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="365" left="365" width="150" height="17" font="0">Previous evidence of PAD, </text>
<text top="382" left="365" width="135" height="17" font="0">obesity, atrial fibrillation, </text>
<text top="400" left="365" width="51" height="17" font="0">ABI &gt;1.3<b> </b></text>
<text top="417" left="365" width="3" height="17" font="0"> </text>
<text top="434" left="365" width="133" height="17" font="2"><b>Gold standard: </b>Duplex </text>
<text top="451" left="365" width="64" height="17" font="0">ultrasound  </text>
<text top="246" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="245" left="540" width="6" height="18" font="7"></text>
<text top="246" left="546" width="149" height="17" font="2"><b> endpoint:</b> Stenosis &gt;70%<b> </b></text>
<text top="263" left="533" width="3" height="17" font="0"> </text>
<text top="280" left="533" width="241" height="17" font="2"><b>Results: </b>High;Low of post/ant tibial arteries </text>
<text top="298" left="533" width="7" height="18" font="7"></text>
<text top="299" left="540" width="120" height="17" font="0"> Sensitivity: 0.68;0.89 </text>
<text top="316" left="533" width="7" height="18" font="7"></text>
<text top="317" left="540" width="120" height="17" font="0"> Specificity: 0.99;0.93 </text>
<text top="334" left="533" width="7" height="18" font="7"></text>
<text top="335" left="540" width="86" height="17" font="0"> PPV 0.99;0.93 </text>
<text top="353" left="533" width="7" height="18" font="7"></text>
<text top="354" left="540" width="90" height="17" font="0"> NPV: 0.74;0.88 </text>
<text top="245" left="911" width="185" height="17" font="0">ABI had good sensitivity and very </text>
<text top="262" left="911" width="174" height="17" font="0">high specificity and PPV. Using </text>
<text top="279" left="911" width="171" height="17" font="0">lower ankle pressure improved </text>
<text top="296" left="911" width="60" height="17" font="0">sensitivity. </text>
<text top="469" left="88" width="96" height="17" font="0">Premalatha G, et </text>
<text top="486" left="88" width="16" height="17" font="0">al. </text>
<text top="504" left="88" width="53" height="17" font="0">2002(24) </text>
<text top="521" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12568206">12568206</a></text>
<text top="521" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12568206"> </a></text>
<text top="538" left="88" width="3" height="17" font="0"> </text>
<text top="469" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="486" left="209" width="103" height="17" font="0">Observational test </text>
<text top="504" left="209" width="67" height="17" font="0">comparison </text>
<text top="521" left="209" width="3" height="17" font="0"> </text>
<text top="538" left="209" width="90" height="17" font="2"><b>Size: </b>n=100 pts </text>
<text top="469" left="365" width="152" height="17" font="2"><b>Inclusion criteria:</b> Pts with </text>
<text top="486" left="365" width="113" height="17" font="0">DM with foot lesions </text>
<text top="504" left="365" width="3" height="17" font="0"> </text>
<text top="521" left="365" width="110" height="17" font="2"><b>Exclusion criteria: </b></text>
<text top="538" left="365" width="142" height="17" font="0">Calcification of peripheral </text>
<text top="555" left="365" width="48" height="17" font="0">arteries <b> </b></text>
<text top="573" left="365" width="3" height="17" font="0"> </text>
<text top="590" left="365" width="133" height="17" font="2"><b>Gold standard: </b>Duplex </text>
<text top="607" left="365" width="61" height="17" font="0">ultrasound </text>
<text top="470" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="469" left="540" width="6" height="18" font="7"></text>
<text top="470" left="546" width="255" height="17" font="2"><b> endpoint:</b> Precise criteria for PAD not stated.<b> </b></text>
<text top="488" left="533" width="3" height="17" font="0"> </text>
<text top="505" left="533" width="52" height="17" font="2"><b>Results: </b></text>
<text top="522" left="533" width="7" height="18" font="7"></text>
<text top="523" left="540" width="96" height="17" font="0"> Sensitivity: 0.71  </text>
<text top="540" left="533" width="7" height="18" font="7"></text>
<text top="541" left="540" width="96" height="17" font="0"> Specificity: 0.89  </text>
<text top="469" left="911" width="181" height="17" font="0">Study in pts with DM with clinical </text>
<text top="486" left="911" width="185" height="17" font="0">suggestion of PAD showing good </text>
<text top="504" left="911" width="168" height="17" font="0">sensitivity and high specificity. </text>
<text top="625" left="88" width="74" height="17" font="0">Allen J, et al. </text>
<text top="642" left="88" width="53" height="17" font="0">1996(25) </text>
<text top="659" left="88" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8638864">8638864</a></text>
<text top="659" left="136" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8638864"> </a></text>
<text top="677" left="88" width="3" height="17" font="0"> </text>
<text top="625" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="642" left="209" width="103" height="17" font="0">Observational test </text>
<text top="659" left="209" width="67" height="17" font="0">comparison </text>
<text top="677" left="209" width="3" height="17" font="0"> </text>
<text top="694" left="209" width="90" height="17" font="2"><b>Size: </b>n=200 pts </text>
<text top="625" left="365" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="642" left="365" width="144" height="17" font="0">Consecutive referrals to a </text>
<text top="659" left="365" width="114" height="17" font="0">vascular laboratory.  </text>
<text top="677" left="365" width="3" height="17" font="0"> </text>
<text top="694" left="365" width="110" height="17" font="2"><b>Exclusion criteria: </b></text>
<text top="711" left="365" width="148" height="17" font="0">Previous vascular surgery. </text>
<text top="728" left="365" width="26" height="17" font="0">DM <b> </b></text>
<text top="745" left="365" width="3" height="17" font="0"> </text>
<text top="763" left="365" width="133" height="17" font="2"><b>Gold standard:</b> Duplex </text>
<text top="626" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="625" left="540" width="6" height="18" font="7"></text>
<text top="626" left="546" width="152" height="17" font="2"><b> endpoint: </b>Stenosis &gt;50% <b> </b></text>
<text top="643" left="533" width="3" height="17" font="0"> </text>
<text top="661" left="533" width="52" height="17" font="2"><b>Results: </b></text>
<text top="678" left="533" width="7" height="18" font="7"></text>
<text top="679" left="540" width="93" height="17" font="0"> Sensitivity: 0.82 </text>
<text top="696" left="533" width="7" height="18" font="7"></text>
<text top="697" left="540" width="93" height="17" font="0"> Specificity: 0.84 </text>
<text top="714" left="533" width="7" height="18" font="7"></text>
<text top="716" left="540" width="55" height="17" font="0"> PPV: 1.0 </text>
<text top="733" left="533" width="7" height="18" font="7"></text>
<text top="734" left="540" width="63" height="17" font="0"> NPV: 0.83 </text>
<text top="625" left="911" width="7" height="18" font="7"></text>
<text top="626" left="918" width="170" height="17" font="0"> Pt symptoms not presented in </text>
<text top="643" left="911" width="164" height="17" font="0">detail but it would appear that </text>
<text top="661" left="911" width="160" height="17" font="0">most were sx pts referred for </text>
<text top="678" left="911" width="75" height="17" font="0">investigation. </text>
<text top="695" left="911" width="7" height="18" font="7"></text>
<text top="696" left="918" width="162" height="17" font="0"> ABI had good sensitivity and </text>
<text top="713" left="911" width="164" height="17" font="0">specificity and excellent PPV. </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">16 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="365" width="61" height="17" font="0">ultrasound </text>
<text top="105" left="88" width="90" height="17" font="0">Lijmer JG, et al. </text>
<text top="122" left="88" width="53" height="17" font="0">1996(26) </text>
<text top="139" left="88" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8795165">8795165</a></text>
<text top="139" left="136" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8795165"> </a></text>
<text top="157" left="88" width="3" height="17" font="0"> </text>
<text top="105" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="122" left="209" width="103" height="17" font="0">Observational test </text>
<text top="139" left="209" width="67" height="17" font="0">comparison </text>
<text top="157" left="209" width="3" height="17" font="0"> </text>
<text top="174" left="209" width="83" height="17" font="2"><b>Size: </b>n=53 pts </text>
<text top="105" left="365" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="122" left="365" width="145" height="17" font="0">Claudication symptoms or </text>
<text top="139" left="365" width="144" height="17" font="0">signs of CLI in referrals to </text>
<text top="157" left="365" width="111" height="17" font="0">vascular laboratory  </text>
<text top="174" left="365" width="3" height="17" font="0"> </text>
<text top="191" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="208" left="365" width="3" height="17" font="0"> </text>
<text top="226" left="365" width="128" height="17" font="2"><b>Gold standard: </b>Digital </text>
<text top="243" left="365" width="135" height="17" font="0">subtraction angiography </text>
<text top="106" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="105" left="540" width="6" height="18" font="7"></text>
<text top="106" left="546" width="152" height="17" font="2"><b> endpoint: </b>Stenosis &gt;50% <b> </b></text>
<text top="123" left="533" width="3" height="17" font="0"> </text>
<text top="141" left="533" width="52" height="17" font="2"><b>Results: </b></text>
<text top="158" left="533" width="7" height="18" font="7"></text>
<text top="159" left="540" width="93" height="17" font="0"> Sensitivity: 0.84 </text>
<text top="176" left="533" width="7" height="18" font="7"></text>
<text top="177" left="540" width="93" height="17" font="0"> Specificity: 0.88 </text>
<text top="105" left="911" width="7" height="18" font="7"></text>
<text top="106" left="918" width="170" height="17" font="0"> Small study but merits include </text>
<text top="123" left="911" width="175" height="17" font="0">some correction for “verification </text>
<text top="141" left="911" width="168" height="17" font="0">bias” in selection of pts having </text>
<text top="158" left="911" width="184" height="17" font="0">angiography and thus included in </text>
<text top="175" left="911" width="57" height="17" font="0">the study. </text>
<text top="192" left="911" width="7" height="18" font="7"></text>
<text top="193" left="918" width="162" height="17" font="0"> ABI had good sensitivity and </text>
<text top="211" left="911" width="60" height="17" font="0">specificity. </text>
<text top="261" left="88" width="82" height="17" font="0">Ankle Brachial </text>
<text top="278" left="88" width="34" height="17" font="0">Index </text>
<text top="295" left="88" width="76" height="17" font="0">Collaboration </text>
<text top="312" left="88" width="53" height="17" font="0">2008(27) </text>
<text top="330" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18612117">18612117 </a></text>
<text top="347" left="88" width="3" height="17" font="0"> </text>
<text top="261" left="209" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="278" left="209" width="49" height="17" font="0">Analysis </text>
<text top="295" left="209" width="3" height="17" font="0"> </text>
<text top="312" left="209" width="123" height="17" font="2"><b>Size:</b> n=16 population </text>
<text top="330" left="209" width="139" height="17" font="0">cohort studies, n=57,294 </text>
<text top="347" left="209" width="20" height="17" font="0">pts </text>
<text top="261" left="365" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="278" left="365" width="150" height="17" font="0">Availability of demographic </text>
<text top="295" left="365" width="155" height="17" font="0">and medical characteristics, </text>
<text top="312" left="365" width="155" height="17" font="0">baseline ABI measurement, </text>
<text top="330" left="365" width="116" height="17" font="0">follow-up data with h </text>
<text top="347" left="365" width="132" height="17" font="0">information on fatal and </text>
<text top="364" left="365" width="90" height="17" font="0">nonfatal events  </text>
<text top="381" left="365" width="3" height="17" font="0"> </text>
<text top="398" left="365" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="416" left="365" width="113" height="17" font="0">Previous Hx of CHD </text>
<text top="262" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="261" left="540" width="6" height="18" font="7"></text>
<text top="262" left="546" width="335" height="17" font="2"><b> endpoint:</b> Change in FRS CV risk prediction with addition of </text>
<text top="279" left="533" width="23" height="17" font="0">ABI </text>
<text top="296" left="533" width="3" height="17" font="0"> </text>
<text top="314" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="331" left="533" width="7" height="18" font="7"></text>
<text top="332" left="540" width="351" height="17" font="0"> Follow-up ranged from 3–6.7 y; 9924 (25% CVD) deaths during </text>
<text top="349" left="533" width="193" height="17" font="0">480,325 person-years of follow-up. </text>
<text top="366" left="533" width="7" height="18" font="7"></text>
<text top="367" left="540" width="348" height="17" font="0"> CV mortality HR for different ABI levels: Reference=1.11–1.20; </text>
<text top="385" left="533" width="354" height="17" font="0">ABI ≤0.60=5.58 for men; 7.04 for women. 19% of men and 36 % </text>
<text top="402" left="533" width="341" height="17" font="0">of women would change risk category with ABI added to FRS. </text>
<text top="261" left="911" width="7" height="18" font="7"></text>
<text top="262" left="918" width="171" height="17" font="0"> ABI provided independent risk </text>
<text top="279" left="911" width="175" height="17" font="0">information and almost doubled </text>
<text top="296" left="911" width="183" height="17" font="0">risk of total mortality CV mortality </text>
<text top="314" left="911" width="182" height="17" font="0">and major coronary events when </text>
<text top="331" left="911" width="113" height="17" font="0">combined with FRS. </text>
<text top="348" left="911" width="7" height="18" font="7"></text>
<text top="349" left="918" width="157" height="17" font="0"> Many men would move to a </text>
<text top="366" left="911" width="172" height="17" font="0">lower risk category, while more </text>
<text top="384" left="911" width="183" height="17" font="0">women would move from a lower </text>
<text top="401" left="911" width="138" height="17" font="0">to a higher risk category. </text>
<text top="434" left="88" width="103" height="17" font="0">Fowkes FG, et al.  </text>
<text top="451" left="88" width="53" height="17" font="0">2014(28) </text>
<text top="468" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24367001">24367001 </a></text>
<text top="485" left="88" width="3" height="17" font="0"> </text>
<text top="434" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="451" left="209" width="3" height="17" font="0"> </text>
<text top="468" left="209" width="110" height="17" font="2"><b>Size:</b> n=18 cohorts, </text>
<text top="485" left="209" width="75" height="17" font="0">n=44,752 pts </text>
<text top="434" left="365" width="152" height="17" font="2"><b>Inclusion criteria:</b> Dataset </text>
<text top="451" left="365" width="154" height="17" font="0">including ABI measurement </text>
<text top="468" left="365" width="119" height="17" font="0">and FRS data points, </text>
<text top="485" left="365" width="144" height="17" font="0">follow-up for mortality and </text>
<text top="503" left="365" width="64" height="17" font="0">CV events. </text>
<text top="520" left="365" width="3" height="17" font="0"> </text>
<text top="537" left="365" width="129" height="17" font="2"><b>Exclusion criteria:</b> Hx </text>
<text top="554" left="365" width="144" height="17" font="0">CHD, invalid ABI, not vital </text>
<text top="571" left="365" width="92" height="17" font="0">status follow-up. </text>
<text top="435" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="434" left="540" width="6" height="18" font="7"></text>
<text top="435" left="546" width="336" height="17" font="2"><b> endpoint:</b> C index (fraction of occasions where the predictor </text>
<text top="452" left="533" width="352" height="17" font="0">score correctly predicts the earlier event for a pair of individuals) </text>
<text top="469" left="533" width="82" height="17" font="0">and NRI score </text>
<text top="486" left="533" width="3" height="17" font="0"> </text>
<text top="504" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="521" left="533" width="7" height="18" font="7"></text>
<text top="522" left="540" width="256" height="17" font="0"> C index for major coronary events, FRS only:  </text>
<text top="539" left="533" width="177" height="17" font="0">   Men: 0.67; 95% CI: 0.6–0.74;  </text>
<text top="557" left="533" width="196" height="17" font="0">   Women: 0.58; 95% CI: 0.49–0.66 </text>
<text top="574" left="533" width="7" height="18" font="7"></text>
<text top="575" left="540" width="81" height="17" font="0"> CV mortality:  </text>
<text top="592" left="533" width="184" height="17" font="0">   Men: 0.68; 95% CI: 0.63–0.74;  </text>
<text top="609" left="533" width="199" height="17" font="0">   Women: 0.45; 95% CI: 0.38–0.52. </text>
<text top="627" left="533" width="7" height="18" font="7"></text>
<text top="628" left="540" width="316" height="17" font="0"> Adding ABI to FRS improves men’s scores modestly and </text>
<text top="645" left="533" width="298" height="17" font="0">women’s scores substantially. Major coronary events:  </text>
<text top="662" left="533" width="184" height="17" font="0">   Men: 0.69; 95% CI: 0.61–0.76;  </text>
<text top="679" left="533" width="216" height="17" font="0">   Women: 0.069; 95% CI: 0.61–0.076.  </text>
<text top="697" left="533" width="7" height="18" font="7"></text>
<text top="698" left="540" width="81" height="17" font="0"> CV mortality:  </text>
<text top="715" left="533" width="184" height="17" font="0">   Men: 0.71; 95% CI: 0.65–0.76;  </text>
<text top="732" left="533" width="196" height="17" font="0">   Women: 0.65; 95% CI: 0.58–0.72 </text>
<text top="749" left="533" width="129" height="17" font="0">Prediction NRI scores:  </text>
<text top="767" left="533" width="7" height="18" font="7"></text>
<text top="768" left="540" width="135" height="17" font="0"> Major coronary events:  </text>
<text top="434" left="911" width="7" height="18" font="7"></text>
<text top="435" left="918" width="129" height="17" font="0"> ABI+FRS model led to </text>
<text top="452" left="911" width="178" height="17" font="0">improved performance mainly in </text>
<text top="469" left="911" width="46" height="17" font="0">women. </text>
<text top="487" left="911" width="7" height="18" font="7"></text>
<text top="488" left="918" width="126" height="17" font="0"> Restricting to those at </text>
<text top="505" left="911" width="154" height="17" font="0">intermediate risk resulted in </text>
<text top="522" left="911" width="160" height="17" font="0">higher NRIs in both men and </text>
<text top="539" left="911" width="43" height="17" font="0">women </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">17 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="533" width="237" height="17" font="0">   Men: 4.3%; 95% CI: 0.0–7.6%; p=0.050;  </text>
<text top="104" left="533" width="266" height="17" font="0">   Women: 9.6%; 95% CI: 6.1%–16.4%; p&lt;0.001 </text>
<text top="122" left="533" width="7" height="18" font="7"></text>
<text top="123" left="540" width="77" height="17" font="0"> CV mortality: </text>
<text top="140" left="533" width="252" height="17" font="0">   Men: 5.7%; 95% CI: 2.7%–7.9%; p&lt;0.001);  </text>
<text top="157" left="533" width="252" height="17" font="0">   Women: 15.7%; CI: 11.3–20.2%; p&lt;0.001).  </text>
<text top="174" left="533" width="7" height="18" font="7"></text>
<text top="175" left="540" width="350" height="17" font="0"> Restricting use of prediction model to those at intermediate risk </text>
<text top="193" left="533" width="341" height="17" font="0">resulted in greater effect (15.9% in men and 23.3% in women) </text>
<text top="211" left="88" width="86" height="17" font="2"><b>GETABI study </b></text>
<text top="228" left="88" width="85" height="17" font="0">Diehm C, et al. </text>
<text top="245" left="88" width="53" height="17" font="0">2009(29) </text>
<text top="262" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19901192">19901192 </a></text>
<text top="280" left="88" width="3" height="17" font="0"> </text>
<text top="211" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="228" left="209" width="70" height="17" font="0">cohort study </text>
<text top="245" left="209" width="3" height="17" font="0"> </text>
<text top="262" left="209" width="107" height="17" font="2"><b>Size:</b> n=6,880 pts;  </text>
<text top="280" left="209" width="111" height="17" font="0">5,392 pts=no PAD;  </text>
<text top="297" left="209" width="106" height="17" font="0">836 pts=asx PAD;  </text>
<text top="314" left="209" width="92" height="17" font="0">593 pts=sx PAD </text>
<text top="211" left="365" width="131" height="17" font="2"><b>Inclusion criteria:</b> Age </text>
<text top="228" left="365" width="142" height="17" font="0">≥65 y, 5 y follow-up data, </text>
<text top="245" left="365" width="124" height="17" font="0">mentally competent to </text>
<text top="262" left="365" width="155" height="17" font="0">cooperate and sign consent </text>
<text top="280" left="365" width="3" height="17" font="0"> </text>
<text top="297" left="365" width="133" height="17" font="2"><b>Exclusion criteria:</b> Life </text>
<text top="314" left="365" width="104" height="17" font="0">expectancy &lt;6 mo </text>
<text top="212" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="211" left="540" width="6" height="18" font="7"></text>
<text top="212" left="546" width="348" height="17" font="2"><b> endpoint:</b> Severe vascular events, CV and all-cause mortality. </text>
<text top="229" left="533" width="3" height="17" font="0"> </text>
<text top="246" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="264" left="533" width="7" height="18" font="7"></text>
<text top="265" left="540" width="122" height="17" font="0"> Mortality (pts /1000):  </text>
<text top="282" left="533" width="96" height="17" font="0">   No PAD: 19.5;  </text>
<text top="299" left="533" width="97" height="17" font="0">   Asx PAD:41.7;  </text>
<text top="316" left="533" width="7" height="18" font="7"></text>
<text top="317" left="540" width="229" height="17" font="0"> HR vs. no PAD: 1.66; 95% CI: 1.38–2.0;  </text>
<text top="335" left="533" width="94" height="17" font="0">   Sx PAD: 53.0;  </text>
<text top="352" left="533" width="7" height="18" font="7"></text>
<text top="353" left="540" width="236" height="17" font="0"> HR vs. no PAD: 1.89; 95% CI; 1.55–2.30.  </text>
<text top="370" left="533" width="7" height="18" font="7"></text>
<text top="371" left="540" width="339" height="17" font="0"> No significant differences between asx and sx PAD groups in </text>
<text top="389" left="533" width="109" height="17" font="0">all-cause mortality.  </text>
<text top="406" left="533" width="7" height="18" font="7"></text>
<text top="407" left="540" width="335" height="17" font="0"> Composite outcome All-cause mortality and Vascular events </text>
<text top="424" left="533" width="66" height="17" font="0">(pts/1000):  </text>
<text top="441" left="533" width="183" height="17" font="0">   No PAD: 27.2, Asx PAD: 60.4;  </text>
<text top="459" left="533" width="215" height="17" font="0">   HR vs. no PAD: 1.81; CI: 1,53–2.14;  </text>
<text top="476" left="533" width="345" height="17" font="0">   Sx PAD 104.7; HR compared to no PAD: 2.66; 95% CI: 2.25–</text>
<text top="493" left="533" width="31" height="17" font="0">3.15. </text>
<text top="510" left="533" width="7" height="18" font="7"></text>
<text top="511" left="540" width="354" height="17" font="0"> Difference between PAD groups also significant (HR: 1.48; 95% </text>
<text top="529" left="533" width="81" height="17" font="0">CI: 1.21–1.80. </text>
<text top="546" left="533" width="7" height="18" font="7"></text>
<text top="547" left="540" width="338" height="17" font="0"> No differences between PAD groups in MI, stroke, peripheral </text>
<text top="564" left="533" width="310" height="17" font="0">amputation. Sig differences in myocardial and peripheral </text>
<text top="582" left="533" width="126" height="17" font="0">revascularualrizations. </text>
<text top="211" left="911" width="7" height="18" font="7"></text>
<text top="212" left="918" width="182" height="17" font="0"> 1 in 5 elderly pts visiting primary </text>
<text top="229" left="911" width="131" height="17" font="0">care clinician had PAD. </text>
<text top="246" left="911" width="7" height="18" font="7"></text>
<text top="247" left="918" width="145" height="17" font="0"> Pts with PD regardless of </text>
<text top="265" left="911" width="183" height="17" font="0">severity had increased risk of CV </text>
<text top="282" left="911" width="170" height="17" font="0">events and death compared to </text>
<text top="299" left="911" width="105" height="17" font="0">those without PAD </text>
<text top="316" left="911" width="7" height="18" font="7"></text>
<text top="317" left="918" width="152" height="17" font="0"> Sx PAD had greater risk of </text>
<text top="335" left="911" width="176" height="17" font="0">composite outcome of all-cause </text>
<text top="352" left="911" width="181" height="17" font="0">death or vascular event than asx </text>
<text top="369" left="911" width="181" height="17" font="0">PAD pts but no greater risk of all-</text>
<text top="386" left="911" width="158" height="17" font="0">cause mortality alone, MI, or </text>
<text top="404" left="911" width="37" height="17" font="0">stroke </text>
<text top="599" left="88" width="98" height="17" font="2"><b>USPSTF</b> <b>Review</b> </text>
<text top="617" left="88" width="71" height="17" font="0">Lin JS, et al. </text>
<text top="634" left="88" width="53" height="17" font="0">2013(30)<b> </b></text>
<text top="651" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24156115">24156115 </a></text>
<text top="668" left="88" width="3" height="17" font="0"> </text>
<text top="599" left="209" width="134" height="17" font="2"><b>Study type:</b> Systematic </text>
<text top="617" left="209" width="98" height="17" font="0">Evidence Review </text>
<text top="634" left="209" width="3" height="17" font="0"> </text>
<text top="651" left="209" width="139" height="17" font="2"><b>Size:</b> n=1 meta-analysis, </text>
<text top="668" left="209" width="115" height="17" font="0">18 population-based </text>
<text top="686" left="209" width="116" height="17" font="0">cohorts (52,510 pts)  </text>
<text top="599" left="365" width="137" height="17" font="2"><b>Inclusion criteria:</b> 3 mo </text>
<text top="617" left="365" width="123" height="17" font="0">follow-up; designed to </text>
<text top="634" left="365" width="146" height="17" font="0">evaluate treatment benefit </text>
<text top="651" left="365" width="152" height="17" font="0">in screen-detected persons </text>
<text top="668" left="365" width="154" height="17" font="0">or populations who had Asx </text>
<text top="686" left="365" width="120" height="17" font="0">or unrecognized PAD </text>
<text top="703" left="365" width="3" height="17" font="0"> </text>
<text top="720" left="365" width="131" height="17" font="2"><b>Exclusion criteria:</b> Pts </text>
<text top="737" left="365" width="48" height="17" font="0">with DM </text>
<text top="599" left="533" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="617" left="533" width="7" height="18" font="7"></text>
<text top="618" left="540" width="322" height="17" font="0"> ABI added to other risk predictors increases but questions </text>
<text top="635" left="533" width="157" height="17" font="0">clinical utility or significance. </text>
<text top="652" left="533" width="7" height="18" font="7"></text>
<text top="653" left="540" width="305" height="17" font="0"> No randomized studies showing improved outcomes in </text>
<text top="671" left="533" width="211" height="17" font="0">response to detection of Asx disease.  </text>
<text top="688" left="533" width="7" height="18" font="7"></text>
<text top="689" left="540" width="323" height="17" font="0"> Benefit of reclassification including ABI may be higher and </text>
<text top="706" left="533" width="365" height="17" font="0">clinically important in older populations at higher risk. May be most </text>
<text top="723" left="533" width="282" height="17" font="0">useful for pts near the thresholds of risk categories. </text>
<text top="741" left="533" width="7" height="18" font="7"></text>
<text top="742" left="540" width="345" height="17" font="0"> Acknowledge the evidence demonstrating increased morbidity </text>
<text top="759" left="533" width="134" height="17" font="0">and mortality in Asx pts. </text>
<text top="599" left="911" width="7" height="18" font="7"></text>
<text top="601" left="918" width="142" height="17" font="0"> Several studies currently </text>
<text top="618" left="911" width="161" height="17" font="0">ongoing that could give more </text>
<text top="635" left="911" width="173" height="17" font="0">definitive answers in the future. </text>
<text top="652" left="911" width="3" height="17" font="0"> </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">18 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="88" width="93" height="17" font="0">Alahdab F, et al. </text>
<text top="104" left="88" width="53" height="17" font="0">2015(31)<b> </b></text>
<text top="122" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25721066">25721066 </a></text>
<text top="139" left="88" width="3" height="17" font="0"> </text>
<text top="87" left="209" width="134" height="17" font="2"><b>Study type:</b> Systematic </text>
<text top="104" left="209" width="44" height="17" font="0">Review </text>
<text top="122" left="209" width="3" height="17" font="0"> </text>
<text top="139" left="209" width="118" height="17" font="2"><b>Size:</b> n=40 individual </text>
<text top="156" left="209" width="118" height="17" font="0">studies, 2 systematic </text>
<text top="173" left="209" width="138" height="17" font="0">reviews, 1 meta-analysis </text>
<text top="87" left="365" width="150" height="17" font="2"><b>Inclusion criteria:</b> Studies </text>
<text top="104" left="365" width="105" height="17" font="0">reporting results of </text>
<text top="122" left="365" width="117" height="17" font="0">screening for asx pts </text>
<text top="139" left="365" width="3" height="17" font="0"> </text>
<text top="156" left="365" width="133" height="17" font="2"><b>Exclusion criteria:</b> Not </text>
<text top="173" left="365" width="150" height="17" font="0">original data, did not report </text>
<text top="190" left="365" width="59" height="17" font="0">on asx pts </text>
<text top="88" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="540" width="6" height="18" font="7"></text>
<text top="88" left="546" width="323" height="17" font="2"><b> endpoint:</b> Multiple that would justify screening for asx pts: </text>
<text top="106" left="533" width="356" height="17" font="0">Accurate test available; disease sufficiently prevalent and mortal; </text>
<text top="123" left="533" width="351" height="17" font="0">screening leads to reduced morbidity and mortality; screening is </text>
<text top="140" left="533" width="65" height="17" font="0">not harmful </text>
<text top="157" left="533" width="3" height="17" font="0"> </text>
<text top="174" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="192" left="533" width="7" height="18" font="7"></text>
<text top="193" left="540" width="351" height="17" font="0"> ABI is adequate test (diagnostic accuracy=0.87; diagnostic OR: </text>
<text top="210" left="533" width="285" height="17" font="0">15.33; 95% CI: 9.39–25.02; pooled sensitivity=75%; </text>
<text top="227" left="533" width="99" height="17" font="0">specificity=86%);  </text>
<text top="244" left="533" width="7" height="18" font="7"></text>
<text top="245" left="540" width="344" height="17" font="0"> PAD is prevalent (average screening yield=17.2%) and mortal </text>
<text top="263" left="533" width="368" height="17" font="0">(pooled HR=2.99 for all-cause mortality and 2.35 for CV mortality).  </text>
<text top="280" left="533" width="7" height="18" font="7"></text>
<text top="281" left="540" width="340" height="17" font="0"> No studies compared screened vs. non screened populations </text>
<text top="298" left="533" width="128" height="17" font="0">for mortality outcomes. </text>
<text top="316" left="533" width="7" height="18" font="7"></text>
<text top="317" left="540" width="278" height="17" font="0"> ABI screening can improve FRS in risk prediction. </text>
<text top="334" left="533" width="7" height="18" font="7"></text>
<text top="335" left="540" width="343" height="17" font="0"> Some evidence that screening can lead to improved morbidity </text>
<text top="352" left="533" width="7" height="18" font="7"></text>
<text top="353" left="540" width="321" height="17" font="0"> Little evidence about potential harm or cost-effectiveness. </text>
<text top="371" left="533" width="351" height="17" font="0">Discussed potential bleeding risk of ASA with no proven benefit  </text>
<text top="87" left="911" width="7" height="18" font="7"></text>
<text top="88" left="918" width="164" height="17" font="0"> Yield of ABI screening text in </text>
<text top="106" left="911" width="187" height="17" font="0">asx pts depends on prevalence of </text>
<text top="123" left="911" width="120" height="17" font="0">traditional risk factors </text>
<text top="140" left="911" width="7" height="18" font="7"></text>
<text top="141" left="918" width="141" height="17" font="0"> No high quality evidence </text>
<text top="158" left="911" width="172" height="17" font="0">supports ‘pt-important’ benefits </text>
<text top="176" left="911" width="130" height="17" font="0">from screening low-risk </text>
<text top="193" left="911" width="61" height="17" font="0">individuals </text>
<text top="210" left="911" width="7" height="18" font="7"></text>
<text top="211" left="918" width="163" height="17" font="0"> High-risk individuals may not </text>
<text top="228" left="911" width="163" height="17" font="0">need screening since there is </text>
<text top="246" left="911" width="168" height="17" font="0">already indication to treat their </text>
<text top="263" left="911" width="26" height="17" font="0">risk  </text>
<text top="389" left="88" width="109" height="17" font="2"><b>Health ABC Study </b></text>
<text top="406" left="88" width="105" height="17" font="0">Hiramoto JS, et al. </text>
<text top="423" left="88" width="53" height="17" font="0">2014(32)<b> </b></text>
<text top="440" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23512905">23512905 </a></text>
<text top="457" left="88" width="3" height="17" font="0"> </text>
<text top="389" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="406" left="209" width="3" height="17" font="0"> </text>
<text top="423" left="209" width="100" height="17" font="2"><b>Size:</b> n=2,797 pts </text>
<text top="389" left="365" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="406" left="365" width="7" height="18" font="7"></text>
<text top="407" left="371" width="76" height="17" font="0"> Age 70–79 y </text>
<text top="424" left="365" width="7" height="18" font="7"></text>
<text top="425" left="371" width="73" height="17" font="0"> No disability </text>
<text top="443" left="365" width="7" height="18" font="7"></text>
<text top="444" left="371" width="131" height="17" font="0"> No functional limitation </text>
<text top="461" left="365" width="7" height="18" font="7"></text>
<text top="462" left="371" width="77" height="17" font="0"> Baseline ABI </text>
<text top="479" left="365" width="79" height="17" font="0">measurement </text>
<text top="497" left="365" width="3" height="17" font="0"> </text>
<text top="514" left="365" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="531" left="365" width="7" height="18" font="7"></text>
<text top="532" left="371" width="110" height="17" font="0"> Self-reported Hx of </text>
<text top="549" left="365" width="68" height="17" font="0">claudication </text>
<text top="567" left="365" width="7" height="18" font="7"></text>
<text top="568" left="371" width="126" height="17" font="0"> LEX revascularization </text>
<text top="390" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="389" left="540" width="6" height="18" font="7"></text>
<text top="390" left="546" width="335" height="17" font="2"><b> endpoint:</b> Development of CV events/mortality, clinical PAD </text>
<text top="407" left="533" width="268" height="17" font="0">(assessed every 6 mo). Median follow-up 9.37 y. </text>
<text top="424" left="533" width="3" height="17" font="0"> </text>
<text top="441" left="533" width="348" height="17" font="2"><b>Results:</b> Baseline low ABI associated with black race, elevated </text>
<text top="459" left="533" width="343" height="17" font="0">SBP, prevalent CVD, and DM. Men had higher incident clinical </text>
<text top="476" left="533" width="351" height="17" font="0">PAD compared to women across all categories of ABI. Men had </text>
<text top="493" left="533" width="327" height="17" font="0">higher rates of CHD death and incident MI except in the 1.3 </text>
<text top="510" left="533" width="349" height="17" font="0">category, where women had higher rates of MI and CHD death. </text>
<text top="528" left="533" width="238" height="17" font="0">Women had higher rates of incident stroke. </text>
<text top="545" left="533" width="61" height="17" font="0">ABI &lt;0.90  </text>
<text top="562" left="533" width="7" height="18" font="7"></text>
<text top="563" left="540" width="79" height="17" font="0"> <b>CHD Death:</b>  </text>
<text top="580" left="533" width="191" height="17" font="0">Men: HR: 4.38; 95% CI: 1.8–10.6;  </text>
<text top="598" left="533" width="217" height="17" font="0">Women HR: 4.96; 95% CI: 1.53–16.01. </text>
<text top="615" left="533" width="7" height="18" font="7"></text>
<text top="616" left="540" width="90" height="17" font="0"> <b>Incident PAD</b>:  </text>
<text top="633" left="533" width="202" height="17" font="0">Men: HR:7.85; 95% CI: 4.44–13.90;  </text>
<text top="650" left="533" width="224" height="17" font="0">Women: HR: 5.56; 95% CI: 2.44–12.67.  </text>
<text top="668" left="533" width="7" height="18" font="7"></text>
<text top="669" left="540" width="52" height="17" font="0"> <b>Stroke</b>:  </text>
<text top="686" left="533" width="198" height="17" font="0">Men: HR: 1.17; 95% CI: 0.56–2.47;  </text>
<text top="703" left="533" width="213" height="17" font="0">Women: HR:2.58; 95% CI: 1.35–4.92;  </text>
<text top="720" left="533" width="7" height="18" font="7"></text>
<text top="721" left="540" width="79" height="17" font="0"> <b>Incident MI:  </b></text>
<text top="739" left="533" width="195" height="17" font="0">Men: HR:2.26; 95% CI: 1.19–4.30; <b> </b></text>
<text top="756" left="533" width="210" height="17" font="0">Women: HR: 2.55; 95% CI: 1.13–5.72 </text>
<text top="773" left="533" width="7" height="18" font="7"></text>
<text top="774" left="540" width="87" height="17" font="0"> <b>Other points:</b>  </text>
<text top="389" left="911" width="7" height="18" font="7"></text>
<text top="390" left="918" width="181" height="17" font="0"> Subclinical PAD seems to affect </text>
<text top="407" left="911" width="144" height="17" font="0">women disproportionately </text>
<text top="424" left="911" width="99" height="17" font="0">compared to men </text>
<text top="441" left="911" width="7" height="18" font="7"></text>
<text top="446" left="918" width="4" height="14" font="0"> </text>
<text top="442" left="923" width="175" height="17" font="0">Higher prevalence of borderline </text>
<text top="460" left="923" width="170" height="17" font="0">ABI in women; associated with </text>
<text top="477" left="923" width="85" height="17" font="0">poor outcomes </text>
<text top="494" left="911" width="7" height="18" font="7"></text>
<text top="495" left="918" width="125" height="17" font="0"> Category of ABI &gt;1.3; </text>
<text top="512" left="911" width="147" height="17" font="0">associated with poorer CV </text>
<text top="530" left="911" width="116" height="17" font="0">outcomes in women  </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">19 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="533" width="333" height="17" font="0">In women with ABI &gt;1.3, Incident MI HR: 9.31; 95% CI: 4.01–</text>
<text top="104" left="533" width="289" height="17" font="0">21.63; Incident stroke HR: 4.81; 95% CI: 2.27–10.30 </text>
<text top="122" left="88" width="86" height="17" font="0">Bundó M, et al. </text>
<text top="139" left="88" width="53" height="17" font="0">2010(33) </text>
<text top="157" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21035692">21035692 </a></text>
<text top="174" left="88" width="3" height="17" font="0"> </text>
<text top="122" left="209" width="127" height="17" font="2"><b>Study type:</b> Follow-up </text>
<text top="139" left="209" width="131" height="17" font="0">observational study (10 </text>
<text top="157" left="209" width="81" height="17" font="0">y, mean 7.7 y) </text>
<text top="174" left="209" width="3" height="17" font="0"> </text>
<text top="191" left="209" width="90" height="17" font="2"><b>Size:</b> n=262 pts </text>
<text top="122" left="365" width="147" height="17" font="2"><b>Inclusion criteria:</b> Type 2 </text>
<text top="139" left="365" width="23" height="17" font="0">DM </text>
<text top="157" left="365" width="3" height="17" font="0"> </text>
<text top="174" left="365" width="128" height="17" font="2"><b>Exclusion criteria:</b> Sx </text>
<text top="191" left="365" width="102" height="17" font="0">PAD or previously </text>
<text top="208" left="365" width="60" height="17" font="0">diagnosed </text>
<text top="123" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="122" left="540" width="6" height="18" font="7"></text>
<text top="123" left="546" width="323" height="17" font="2"><b> endpoint:</b> Mortality (cause of death), CVD, CHD, Disease </text>
<text top="141" left="533" width="349" height="17" font="0">progression (from normal to abnormal, or 15% decrease in ABI) </text>
<text top="158" left="533" width="3" height="17" font="0"> </text>
<text top="175" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="192" left="533" width="7" height="18" font="7"></text>
<text top="193" left="540" width="196" height="17" font="0"> Normal vs. abnormal baseline ABI: </text>
<text top="211" left="533" width="7" height="18" font="7"></text>
<text top="212" left="540" width="152" height="17" font="0"> Mortality: 16.8% vs. 52.8% </text>
<text top="229" left="533" width="7" height="18" font="7"></text>
<text top="230" left="540" width="213" height="17" font="0"> Nonfatal CV Events: 19.4% vs. 38.9% </text>
<text top="248" left="533" width="7" height="18" font="7"></text>
<text top="249" left="540" width="125" height="17" font="0"> CVD: 8.2% vs. 30.6% </text>
<text top="122" left="911" width="7" height="18" font="7"></text>
<text top="123" left="918" width="106" height="17" font="0"> Small sample size </text>
<text top="141" left="911" width="7" height="18" font="7"></text>
<text top="142" left="918" width="177" height="17" font="0"> Significant differences between </text>
<text top="159" left="911" width="131" height="17" font="0">groups in CV outcomes </text>
<text top="267" left="88" width="99" height="17" font="0">TsivgoulisF, et al. </text>
<text top="284" left="88" width="53" height="17" font="0">2012(34) </text>
<text top="301" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22138142">22138142 </a></text>
<text top="318" left="88" width="3" height="17" font="0"> </text>
<text top="267" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="284" left="209" width="136" height="17" font="0">longitudinal cohort study </text>
<text top="301" left="209" width="3" height="17" font="0"> </text>
<text top="318" left="209" width="90" height="17" font="2"><b>Size:</b> n=176 pts </text>
<text top="267" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="284" left="365" width="7" height="18" font="7"></text>
<text top="285" left="371" width="56" height="17" font="0"> Asx PAD </text>
<text top="302" left="365" width="7" height="18" font="7"></text>
<text top="303" left="371" width="141" height="17" font="0"> Acute ischemic stroke or </text>
<text top="321" left="365" width="23" height="17" font="0">TIA </text>
<text top="338" left="365" width="3" height="17" font="0"> </text>
<text top="355" left="365" width="128" height="17" font="2"><b>Exclusion criteria:</b> Sx </text>
<text top="372" left="365" width="29" height="17" font="0">PAD </text>
<text top="268" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="267" left="540" width="6" height="18" font="7"></text>
<text top="268" left="546" width="203" height="17" font="2"><b> endpoint:</b> 30 d recurrence of stroke </text>
<text top="285" left="533" width="3" height="17" font="0"> </text>
<text top="302" left="533" width="348" height="17" font="2"><b>Results:</b> PAD pts had higher 30 d recurrence of stroke (19.2%; </text>
<text top="319" left="533" width="347" height="17" font="0">95% CI: 4.1–34.3; vs. 3.3%: 95% CI: 0.4–6.2. Final multivariate </text>
<text top="337" left="533" width="267" height="17" font="0">analysis HR: 12.46; 95% CI: 2.22–70.0; p=0.004 </text>
<text top="267" left="911" width="7" height="18" font="7"></text>
<text top="268" left="918" width="178" height="17" font="0"> Very small numbers of PAD pts </text>
<text top="285" left="911" width="7" height="18" font="7"></text>
<text top="286" left="918" width="174" height="17" font="0"> Asx PAD pts have higher short </text>
<text top="303" left="911" width="154" height="17" font="0">term risk of recurrent stroke </text>
<text top="390" left="88" width="98" height="17" font="0">Bouisset, F. et al  </text>
<text top="407" left="88" width="53" height="17" font="0">2012(35) </text>
<text top="425" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22513182">22513182 </a></text>
<text top="442" left="88" width="3" height="17" font="0"> </text>
<text top="390" left="209" width="141" height="17" font="2"><b>Study type:</b> Prospective, </text>
<text top="407" left="209" width="136" height="17" font="0">longitudinal cohort study </text>
<text top="425" left="209" width="134" height="17" font="0">(median follow-up 7.2 y; </text>
<text top="442" left="209" width="100" height="17" font="0">range 5.7–8.6 y).  </text>
<text top="459" left="209" width="3" height="17" font="0"> </text>
<text top="476" left="209" width="109" height="17" font="2"><b>Size:</b> n=710 in final </text>
<text top="494" left="209" width="48" height="17" font="0">analysis </text>
<text top="390" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="407" left="365" width="7" height="18" font="7"></text>
<text top="408" left="371" width="144" height="17" font="0"> Nonconsecutive male pts </text>
<text top="426" left="365" width="136" height="17" font="0">age 45–74 y, with stable </text>
<text top="443" left="365" width="37" height="17" font="0">CHD.  </text>
<text top="460" left="365" width="7" height="18" font="7"></text>
<text top="461" left="371" width="142" height="17" font="0"> ABI measured; classified </text>
<text top="479" left="365" width="123" height="17" font="0">as no PAD (n=446) or </text>
<text top="496" left="365" width="154" height="17" font="0">subclinical PAD (n=181), sx </text>
<text top="513" left="365" width="68" height="17" font="0">PAD (n=83) </text>
<text top="530" left="365" width="3" height="17" font="0"> </text>
<text top="547" left="365" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="565" left="365" width="7" height="18" font="7"></text>
<text top="566" left="371" width="136" height="17" font="0"> Acute coronary episode </text>
<text top="583" left="365" width="86" height="17" font="0">within past 7 d  </text>
<text top="600" left="365" width="7" height="18" font="7"></text>
<text top="601" left="371" width="62" height="17" font="0"> Hx cancer </text>
<text top="391" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="390" left="540" width="6" height="18" font="7"></text>
<text top="391" left="546" width="342" height="17" font="2"><b> endpoint:</b> All-cause mortality; prognostic effect of PAD status </text>
<text top="409" left="533" width="317" height="17" font="0">on all-cause death assessed by Cox regression analysis.  </text>
<text top="426" left="533" width="3" height="17" font="0"> </text>
<text top="443" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="460" left="533" width="7" height="18" font="7"></text>
<text top="461" left="540" width="308" height="17" font="0"> Median 7.2 y survival rates No PAD=87.4%; Subclinical </text>
<text top="479" left="533" width="185" height="17" font="0">PAD=78.5%; clinical PAD=70.1% </text>
<text top="496" left="533" width="7" height="18" font="7"></text>
<text top="497" left="540" width="247" height="17" font="0"> Cox regression analysis: Unadjusted model: </text>
<text top="514" left="533" width="7" height="18" font="7"></text>
<text top="515" left="540" width="339" height="17" font="0"> HR for subclinical PAD vs. no PAD: 1.88; 95% CI: 1.27–2.78; </text>
<text top="533" left="533" width="55" height="17" font="0">p=0.001.  </text>
<text top="550" left="533" width="7" height="18" font="7"></text>
<text top="551" left="540" width="319" height="17" font="0"> HR for clinical PAD vs. no PAD: 2.57; 95% CI: 1.62–4.07; </text>
<text top="568" left="533" width="52" height="17" font="0">p&lt;0.001. </text>
<text top="585" left="533" width="3" height="17" font="0"> </text>
<text top="603" left="533" width="95" height="17" font="0">Adjusted model:  </text>
<text top="620" left="533" width="7" height="18" font="7"></text>
<text top="621" left="540" width="339" height="17" font="0"> HR for subclinical PAD vs. no PAD: 1.65; 95% CI: 1.11–2.44; </text>
<text top="638" left="533" width="45" height="17" font="0">p=0.01. </text>
<text top="655" left="533" width="7" height="18" font="7"></text>
<text top="656" left="540" width="319" height="17" font="0"> HR for clinical PAD vs. no PAD: 2.11; 95% CI: 1.28–3.47. </text>
<text top="390" left="911" width="7" height="18" font="7"></text>
<text top="391" left="918" width="179" height="17" font="0"> PAD common in this population </text>
<text top="409" left="911" width="7" height="18" font="7"></text>
<text top="410" left="918" width="174" height="17" font="0"> Detection of subclinical PAD in </text>
<text top="427" left="911" width="181" height="17" font="0">pts with known coronary disease </text>
<text top="444" left="911" width="188" height="17" font="0">provides additional information for </text>
<text top="461" left="911" width="187" height="17" font="0">long-term mortality risk evaluation </text>
<text top="479" left="911" width="7" height="18" font="7"></text>
<text top="480" left="918" width="161" height="17" font="0"> Limitation: Studied only men </text>
<text top="674" left="88" width="70" height="17" font="0">Sen S, et al. </text>
<text top="692" left="88" width="53" height="17" font="0">2009(36) </text>
<text top="709" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19713540">19713540 </a></text>
<text top="726" left="88" width="3" height="17" font="0"> </text>
<text top="674" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="692" left="209" width="112" height="17" font="0">longitudinal hospital-</text>
<text top="709" left="209" width="78" height="17" font="0">based cohort  </text>
<text top="726" left="209" width="3" height="17" font="0"> </text>
<text top="743" left="209" width="90" height="17" font="2"><b>Size:</b> n=102 pts </text>
<text top="674" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="692" left="365" width="7" height="18" font="7"></text>
<text top="693" left="371" width="42" height="17" font="0"> Stroke </text>
<text top="710" left="365" width="7" height="18" font="7"></text>
<text top="711" left="371" width="26" height="17" font="0"> TIA </text>
<text top="728" left="365" width="7" height="18" font="7"></text>
<text top="729" left="371" width="139" height="17" font="0"> Asx PAD vs. normal ABI </text>
<text top="747" left="365" width="3" height="17" font="0"> </text>
<text top="764" left="365" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="676" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="675" left="540" width="6" height="18" font="7"></text>
<text top="676" left="546" width="349" height="17" font="2"><b> endpoint:</b> Composite vascular events including stroke, TIA, MI </text>
<text top="693" left="533" width="181" height="17" font="0">and vascular death median 2.1 y </text>
<text top="710" left="533" width="3" height="17" font="0"> </text>
<text top="727" left="533" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="745" left="533" width="7" height="18" font="7"></text>
<text top="746" left="540" width="193" height="17" font="0"> Asx PAD (26%) vs. no PAD (74%) </text>
<text top="763" left="533" width="230" height="17" font="0">Composite vascular events: 50% vs. 16% </text>
<text top="675" left="911" width="7" height="18" font="7"></text>
<text top="676" left="918" width="142" height="17" font="0"> Small sample, single site </text>
<text top="693" left="911" width="7" height="18" font="7"></text>
<text top="694" left="918" width="172" height="17" font="0"> Pts with stroke or TIA and Asx </text>
<text top="711" left="911" width="179" height="17" font="0">PAD have worse outcomes than </text>
<text top="728" left="911" width="132" height="17" font="0">those without Asx PAD. </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">20 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="365" width="7" height="18" font="7"></text>
<text top="88" left="371" width="41" height="17" font="0"> &lt;18 y  </text>
<text top="106" left="365" width="7" height="18" font="7"></text>
<text top="107" left="371" width="146" height="17" font="0"> Intercerebral hemorrhage </text>
<text top="124" left="365" width="7" height="18" font="7"></text>
<text top="125" left="371" width="40" height="17" font="0"> Coma </text>
<text top="142" left="365" width="7" height="18" font="7"></text>
<text top="143" left="371" width="126" height="17" font="0"> Conditions limiting life </text>
<text top="161" left="365" width="124" height="17" font="0">expectancy to &lt;12 mo </text>
<text top="178" left="365" width="7" height="18" font="7"></text>
<text top="179" left="371" width="50" height="17" font="0"> Sx PAD </text>
<text top="87" left="533" width="7" height="18" font="7"></text>
<text top="88" left="540" width="353" height="17" font="0"> Cumulative event-free survival: 1.6; 95% CI: 1.2–1.9 y vs. 2.5 y; </text>
<text top="106" left="533" width="160" height="17" font="0">95% CI: 2.4–2.6 y; p=0.0001 </text>
<text top="197" left="88" width="96" height="17" font="0">Ratanakorn D, et </text>
<text top="214" left="88" width="16" height="17" font="0">al. </text>
<text top="231" left="88" width="53" height="17" font="0">2012(37)<b> </b></text>
<text top="249" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21236702">21236702</a></text>
<text top="249" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21236702"> </a></text>
<text top="266" left="88" width="3" height="17" font="0"> </text>
<text top="197" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="214" left="209" width="52" height="17" font="0">sectional </text>
<text top="231" left="209" width="3" height="17" font="0"> </text>
<text top="249" left="209" width="117" height="17" font="2"><b>Size:</b> n=747 Thai pts </text>
<text top="197" left="365" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="214" left="365" width="152" height="17" font="0">Consecutive stroke registry </text>
<text top="231" left="365" width="148" height="17" font="0">pts with ischemic stroke or </text>
<text top="249" left="365" width="152" height="17" font="0">TIA within 7 d confirmed by </text>
<text top="266" left="365" width="134" height="17" font="0">CT or MRA; age ≥18 y,  </text>
<text top="283" left="365" width="3" height="17" font="0"> </text>
<text top="300" left="365" width="142" height="17" font="2"><b>Exclusion criteria:</b> Hx of </text>
<text top="318" left="365" width="156" height="17" font="0">previous or current Sx PAD; </text>
<text top="335" left="365" width="152" height="17" font="0">severe disabling stroke; ET </text>
<text top="352" left="365" width="146" height="17" font="0">intubation and mechanical </text>
<text top="369" left="365" width="148" height="17" font="0">ventilation; incomplete ABI </text>
<text top="386" left="365" width="31" height="17" font="0">data. </text>
<text top="198" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="197" left="540" width="6" height="18" font="7"></text>
<text top="198" left="546" width="322" height="17" font="2"><b> endpoint:</b> Prevalence of PAD among total population and </text>
<text top="215" left="533" width="61" height="17" font="0">subgroups </text>
<text top="233" left="533" width="3" height="17" font="0"> </text>
<text top="250" left="533" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="267" left="533" width="7" height="18" font="7"></text>
<text top="268" left="540" width="320" height="17" font="0"> Prevalence of abnormal ABI=18/1%; Multivariate analysis </text>
<text top="285" left="533" width="365" height="17" font="0">abnormal ABI related to female sex (OR: 1.61; 95% CI: 1.09–2.40; </text>
<text top="303" left="533" width="341" height="17" font="0">p=0.017); Age ≥60 y (OR: 3.54; 95% CI: 2.14–5.85; p&lt;0.001); </text>
<text top="320" left="533" width="362" height="17" font="0">Previous ischemic events including CAD (OR: 2.55; 95% CI: 1.47–</text>
<text top="337" left="533" width="341" height="17" font="0">4.43; p=0.001); CVD (OR: 2.15; 95% CI: 1.37–3.55; p=0.002). </text>
<text top="354" left="533" width="7" height="18" font="7"></text>
<text top="355" left="540" width="326" height="17" font="0"> Prevalence in pts ≥60 y =25%; ≥70 y =30%. No significant </text>
<text top="373" left="533" width="361" height="17" font="0">relationship with atherosclerotic risk factors. Strongest prevalence </text>
<text top="390" left="533" width="356" height="17" font="0">of abnormal ABI in large artery disease and cardioembolic stroke </text>
<text top="407" left="533" width="56" height="17" font="0">subtypes. </text>
<text top="197" left="911" width="7" height="18" font="7"></text>
<text top="198" left="918" width="157" height="17" font="0"> Early detection of PAD may </text>
<text top="215" left="911" width="170" height="17" font="0">facilitate treatment and identify </text>
<text top="233" left="911" width="182" height="17" font="0">excess risk of subsequent stroke </text>
<text top="250" left="911" width="109" height="17" font="0">or other CV events. </text>
<text top="425" left="88" width="85" height="17" font="0">Ramos R, et al </text>
<text top="442" left="88" width="53" height="17" font="0">2016(38) </text>
<text top="459" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26868687">26868687</a></text>
<text top="459" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26868687"> </a></text>
<text top="477" left="88" width="3" height="17" font="0"> </text>
<text top="425" left="209" width="114" height="17" font="2"><b>Study Type:</b> Cohort </text>
<text top="442" left="209" width="132" height="17" font="0">design for matched pair </text>
<text top="459" left="209" width="131" height="17" font="0">analysis on the basis of </text>
<text top="477" left="209" width="135" height="17" font="0">study inclusion date and </text>
<text top="494" left="209" width="111" height="17" font="0">propensity for statin </text>
<text top="511" left="209" width="55" height="17" font="0">treatment </text>
<text top="528" left="209" width="3" height="17" font="0"> </text>
<text top="546" left="209" width="128" height="17" font="2"><b>Size</b>: n=5,480 Spanish </text>
<text top="563" left="209" width="133" height="17" font="0">pts from the Information </text>
<text top="580" left="209" width="138" height="17" font="0">System for Development </text>
<text top="597" left="209" width="129" height="17" font="0">of Research in Primary </text>
<text top="614" left="209" width="88" height="17" font="0">Care database. </text>
<text top="425" left="365" width="108" height="17" font="2"><b>Inclusion Criteria:</b> </text>
<text top="442" left="365" width="7" height="18" font="7"></text>
<text top="443" left="371" width="54" height="17" font="0"> 35–85 y  </text>
<text top="461" left="365" width="7" height="18" font="7"></text>
<text top="462" left="371" width="105" height="17" font="0"> ABI measurement </text>
<text top="479" left="365" width="71" height="17" font="0">documented </text>
<text top="496" left="365" width="7" height="18" font="7"></text>
<text top="497" left="371" width="65" height="17" font="0"> ABI&lt;0.95;  </text>
<text top="515" left="365" width="3" height="17" font="0"> </text>
<text top="532" left="365" width="112" height="17" font="2"><b>Exclusion Criteria:</b> </text>
<text top="549" left="365" width="138" height="17" font="0">Previously hx of sx PAD, </text>
<text top="566" left="365" width="85" height="17" font="0">CHD, stroke or </text>
<text top="583" left="365" width="96" height="17" font="0">revascularization </text>
<text top="601" left="365" width="62" height="17" font="0">procedure. </text>
<text top="425" left="533" width="361" height="17" font="2"><b>1ºendpoint: </b>HR of absolute risk reduction in<b> </b>MACE and all-cause </text>
<text top="442" left="533" width="359" height="17" font="0">mortality and 1-year number needed to treat for ‘new’ statin users </text>
<text top="459" left="533" width="199" height="17" font="0">vs. non-statin users followed 2–7 y.  </text>
<text top="477" left="533" width="3" height="17" font="0"> </text>
<text top="494" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="511" left="533" width="7" height="18" font="7"></text>
<text top="512" left="540" width="77" height="17" font="0"> MACE rates  </text>
<text top="530" left="533" width="216" height="17" font="0">New users: 19.7 (95% CI:17.2 to 22.5)  </text>
<text top="547" left="533" width="215" height="17" font="0">Non-users: 24.7 (95% CI: 21.8 to 27.8) </text>
<text top="564" left="533" width="66" height="17" font="0">(20% RRR) </text>
<text top="581" left="533" width="76" height="17" font="0">1 y NNT: 200 </text>
<text top="598" left="533" width="7" height="18" font="7"></text>
<text top="599" left="540" width="138" height="17" font="0"> All-cause mortality rates </text>
<text top="617" left="533" width="216" height="17" font="0">New users: 24.8 (95% CI: 22.0 to 27.8) </text>
<text top="634" left="533" width="215" height="17" font="0">Non-users: 30.3 (95% CI: 27.2 to 33.6) </text>
<text top="651" left="533" width="66" height="17" font="0">(19% RRR) </text>
<text top="668" left="533" width="72" height="17" font="0">1 y NNT 239 </text>
<text top="686" left="533" width="7" height="18" font="7"></text>
<text top="687" left="540" width="188" height="17" font="0"> NNT decreased with ABI cutpoint </text>
<text top="425" left="911" width="7" height="18" font="7"></text>
<text top="426" left="918" width="133" height="17" font="0"> First study to report the </text>
<text top="443" left="911" width="178" height="17" font="0">association between statins and </text>
<text top="461" left="911" width="140" height="17" font="0">both MACE and mortality </text>
<text top="478" left="911" width="180" height="17" font="0">reduction among individuals free </text>
<text top="495" left="911" width="184" height="17" font="0">of clinical CVD, but with asx PAD </text>
<text top="512" left="911" width="96" height="17" font="0">identified by ABI. </text>
<text top="530" left="911" width="7" height="18" font="7"></text>
<text top="531" left="918" width="177" height="17" font="0"> Reduction observed regardless </text>
<text top="548" left="911" width="168" height="17" font="0">of CVD risk scores at baseline </text>
<text top="565" left="911" width="7" height="18" font="7"></text>
<text top="566" left="918" width="161" height="17" font="0"> Absolute reduction in MACE </text>
<text top="583" left="911" width="179" height="17" font="0">and all-cause mortality similar to </text>
<text top="601" left="911" width="188" height="17" font="0">that seen in secondary prevention </text>
<text top="618" left="911" width="46" height="17" font="0">studies. </text>
<text top="705" left="88" width="96" height="17" font="0">Jiménez M, et al. </text>
<text top="722" left="88" width="53" height="17" font="0">2014(39) </text>
<text top="739" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24529125">24529125 </a></text>
<text top="756" left="88" width="3" height="17" font="0"> </text>
<text top="705" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="722" left="209" width="52" height="17" font="0">sectional </text>
<text top="739" left="209" width="3" height="17" font="0"> </text>
<text top="756" left="209" width="142" height="17" font="2"><b>Size:</b> Random population </text>
<text top="773" left="209" width="104" height="17" font="0">sample, n=933 pts </text>
<text top="705" left="365" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="722" left="365" width="145" height="17" font="0">Moderate to high vascular </text>
<text top="739" left="365" width="149" height="17" font="0">risk (REGICOR score &gt;5% </text>
<text top="756" left="365" width="3" height="17" font="0"> </text>
<text top="773" left="365" width="129" height="17" font="2"><b>Exclusion criteria:</b> Hx </text>
<text top="706" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="705" left="540" width="6" height="18" font="7"></text>
<text top="706" left="546" width="221" height="17" font="2"><b> endpoint:</b> Presence of carotid stenosis </text>
<text top="723" left="533" width="3" height="17" font="0"> </text>
<text top="740" left="533" width="338" height="17" font="2"><b>Results:</b> Prevalence of SCCA higher in those with REGICOR </text>
<text top="757" left="533" width="351" height="17" font="0">score &gt;10% and in pts with asx PAD. Asx PAD increased risk of </text>
<text top="775" left="533" width="364" height="17" font="0">SCCA by more than 5-fold. ABI diagnosing SCCA: Sensitivity=0.3; </text>
<text top="705" left="911" width="7" height="18" font="7"></text>
<text top="706" left="918" width="174" height="17" font="0"> ABI emerged as tool to identify </text>
<text top="723" left="911" width="148" height="17" font="0">pts with high risk of having </text>
<text top="740" left="911" width="178" height="17" font="0">subclinical carotid or intracranial </text>
<text top="757" left="911" width="86" height="17" font="0">atherosclerosis </text>
<text top="775" left="911" width="7" height="18" font="7"></text>
<text top="776" left="918" width="133" height="17" font="0"> Helps target screening, </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">21 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="365" width="102" height="17" font="0">stroke, PAD, CAD </text>
<text top="87" left="533" width="311" height="17" font="0">95% CI: 0.18–0.42; specificity=0.95 (95% CI: 0.93-0.96); </text>
<text top="104" left="533" width="356" height="17" font="0">PPV=0.26 (95% CI: 0.15–0.37), NPV= 0.95 (95% CI: 0.94–0.97). </text>
<text top="87" left="911" width="161" height="17" font="0">increasing cost-effectiveness </text>
<text top="122" left="88" width="105" height="17" font="0">McDermott MM, et </text>
<text top="139" left="88" width="16" height="17" font="0">al. </text>
<text top="157" left="88" width="53" height="17" font="0">2000(40) </text>
<text top="174" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10704168">10704168</a></text>
<text top="174" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10704168"> </a></text>
<text top="191" left="88" width="3" height="17" font="0"> </text>
<text top="122" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="139" left="209" width="55" height="17" font="0">sectional  </text>
<text top="157" left="209" width="3" height="17" font="0"> </text>
<text top="174" left="209" width="36" height="17" font="2"><b>Size:</b>  </text>
<text top="191" left="209" width="7" height="18" font="7"></text>
<text top="192" left="216" width="101" height="17" font="0"> Stratified random </text>
<text top="210" left="209" width="107" height="17" font="0">sampling of 32,538 </text>
<text top="227" left="209" width="7" height="18" font="7"></text>
<text top="228" left="216" width="114" height="17" font="0"> Final sample n=574 </text>
<text top="245" left="209" width="42" height="17" font="0">asx pts </text>
<text top="122" left="365" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="139" left="365" width="113" height="17" font="0">Community dwelling </text>
<text top="157" left="365" width="127" height="17" font="0">disabled women ≥65 y </text>
<text top="174" left="365" width="137" height="17" font="0">participating in Women’s </text>
<text top="191" left="365" width="133" height="17" font="0">Health and Aging Study </text>
<text top="208" left="365" width="3" height="17" font="0"> </text>
<text top="226" left="365" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="243" left="365" width="125" height="17" font="0">Mini-mental score &lt;18 </text>
<text top="123" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="122" left="540" width="6" height="18" font="7"></text>
<text top="123" left="546" width="314" height="17" font="2"><b> endpoint:</b> Prevalence of Asx PAD; relationship between </text>
<text top="141" left="533" width="191" height="17" font="0">physical functioning and Asx PAD. </text>
<text top="158" left="533" width="3" height="17" font="0"> </text>
<text top="175" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="192" left="533" width="7" height="18" font="7"></text>
<text top="193" left="540" width="132" height="17" font="0"> ABI&lt;0.90=198 (34.5%) </text>
<text top="211" left="533" width="7" height="18" font="7"></text>
<text top="212" left="540" width="118" height="17" font="0"> ABI&lt;0.50=48 (8.4%) </text>
<text top="229" left="533" width="7" height="18" font="7"></text>
<text top="230" left="540" width="312" height="17" font="0"> Subjective and objective measures of mobility and lower </text>
<text top="248" left="533" width="352" height="17" font="0">extremity function, all statistically lower in Asx PAD compared to </text>
<text top="265" left="533" width="57" height="17" font="0">non-PAD. </text>
<text top="122" left="911" width="7" height="18" font="7"></text>
<text top="123" left="918" width="148" height="17" font="0"> Asx PAD is independently </text>
<text top="141" left="911" width="171" height="17" font="0">associated with impaired lower </text>
<text top="158" left="911" width="120" height="17" font="0">extremity functioning. </text>
<text top="283" left="88" width="86" height="17" font="2"><b>WALCS Study </b></text>
<text top="300" left="88" width="105" height="17" font="0">McDermott MM, et </text>
<text top="317" left="88" width="16" height="17" font="0">al. </text>
<text top="334" left="88" width="46" height="17" font="0">2001(5) </text>
<text top="351" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11585483">11585483</a></text>
<text top="351" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11585483"> </a></text>
<text top="369" left="88" width="3" height="17" font="0"> </text>
<text top="283" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="300" left="209" width="101" height="17" font="0">sectional, new pts </text>
<text top="317" left="209" width="130" height="17" font="0">consecutively identified </text>
<text top="334" left="209" width="140" height="17" font="0">and pts already identified </text>
<text top="351" left="209" width="113" height="17" font="0">with PAD from large </text>
<text top="369" left="209" width="97" height="17" font="0">general medicine </text>
<text top="386" left="209" width="50" height="17" font="0">practice. </text>
<text top="403" left="209" width="3" height="17" font="0"> </text>
<text top="420" left="209" width="36" height="17" font="2"><b>Size:</b>  </text>
<text top="438" left="209" width="7" height="18" font="7"></text>
<text top="439" left="216" width="93" height="17" font="0"> n=430 men and </text>
<text top="456" left="209" width="97" height="17" font="0">women with PAD </text>
<text top="473" left="209" width="7" height="18" font="7"></text>
<text top="474" left="216" width="119" height="17" font="0"> n=130 without PAD.  </text>
<text top="492" left="209" width="84" height="17" font="0">ASX active=63 </text>
<text top="509" left="209" width="94" height="17" font="0">ASX inactive=28 </text>
<text top="283" left="365" width="102" height="17" font="2"><b>Inclusion criteria </b></text>
<text top="300" left="365" width="116" height="17" font="0">Diagnosed with PAD </text>
<text top="317" left="365" width="104" height="17" font="0">(ABI&lt;0.90); ≥55 y  </text>
<text top="334" left="365" width="3" height="17" font="2"><b> </b></text>
<text top="351" left="365" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="369" left="365" width="7" height="18" font="7"></text>
<text top="370" left="371" width="61" height="17" font="0"> ABI &gt;1.5;  </text>
<text top="387" left="365" width="7" height="18" font="7"></text>
<text top="388" left="371" width="77" height="17" font="0"> Normal ABI,  </text>
<text top="405" left="365" width="7" height="18" font="7"></text>
<text top="407" left="371" width="59" height="17" font="0"> Dementia </text>
<text top="424" left="365" width="7" height="18" font="7"></text>
<text top="425" left="371" width="69" height="17" font="0"> Amputation </text>
<text top="442" left="365" width="7" height="18" font="7"></text>
<text top="443" left="371" width="126" height="17" font="0"> Non-English speaking </text>
<text top="461" left="365" width="7" height="18" font="7"></text>
<text top="462" left="371" width="106" height="17" font="0"> Wheelchair bound </text>
<text top="479" left="365" width="7" height="18" font="7"></text>
<text top="480" left="371" width="131" height="17" font="0"> Nursing home resident </text>
<text top="497" left="365" width="7" height="18" font="7"></text>
<text top="498" left="371" width="90" height="17" font="0"> Recent surgery </text>
<text top="284" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="283" left="540" width="6" height="18" font="7"></text>
<text top="284" left="546" width="301" height="17" font="2"><b> endpoint:</b> 6 MWT scores, 7 d physical activity, SPPB, </text>
<text top="301" left="533" width="86" height="17" font="0">Questionnaires </text>
<text top="318" left="533" width="3" height="17" font="0"> </text>
<text top="335" left="533" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="353" left="533" width="7" height="18" font="7"></text>
<text top="354" left="540" width="340" height="17" font="0"> PAD sj. Divided into 6 categories. asx 2 categories: active vs. </text>
<text top="371" left="533" width="45" height="17" font="0">inactive </text>
<text top="388" left="533" width="7" height="18" font="7"></text>
<text top="389" left="540" width="336" height="17" font="0"> 33.3% active and 53.6% inactive PAD pts reported sx during </text>
<text top="407" left="533" width="40" height="17" font="0">6MWT </text>
<text top="424" left="533" width="7" height="18" font="7"></text>
<text top="425" left="540" width="325" height="17" font="0"> All PAD groups had worse functioning that non-PAD group </text>
<text top="442" left="533" width="7" height="18" font="7"></text>
<text top="443" left="540" width="291" height="17" font="0"> Asx inactive functioning similar to claudication group </text>
<text top="461" left="533" width="7" height="18" font="7"></text>
<text top="462" left="540" width="305" height="17" font="0"> Asx inactive functioning poorer than claudication group </text>
<text top="283" left="911" width="24" height="17" font="0">N/A </text>
<text top="527" left="88" width="86" height="17" font="2"><b>WALCS Study </b></text>
<text top="544" left="88" width="101" height="17" font="0">McDermott MM et </text>
<text top="561" left="88" width="20" height="17" font="0">al., </text>
<text top="578" left="88" width="53" height="17" font="0">2004(41) </text>
<text top="596" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15280343">15280343</a></text>
<text top="596" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15280343"> </a></text>
<text top="613" left="88" width="3" height="17" font="0"> </text>
<text top="527" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="544" left="209" width="133" height="17" font="0">cohort study of PAD pts </text>
<text top="561" left="209" width="139" height="17" font="0">with differing types of leg </text>
<text top="578" left="209" width="135" height="17" font="0">symptoms (same cohort </text>
<text top="596" left="209" width="134" height="17" font="0">as above) 2 yr follow-up </text>
<text top="613" left="209" width="3" height="17" font="0"> </text>
<text top="630" left="209" width="36" height="17" font="2"><b>Size:</b>  </text>
<text top="647" left="209" width="7" height="18" font="7"></text>
<text top="648" left="216" width="115" height="17" font="0"> n=417 pts with PAD </text>
<text top="666" left="209" width="7" height="18" font="7"></text>
<text top="667" left="216" width="136" height="17" font="0"> n=259 pts without PAD  </text>
<text top="527" left="365" width="102" height="17" font="2"><b>Inclusion criteria </b></text>
<text top="544" left="365" width="7" height="18" font="7"></text>
<text top="545" left="371" width="61" height="17" font="0"> ABI &lt;0.90 </text>
<text top="562" left="365" width="7" height="18" font="7"></text>
<text top="563" left="371" width="38" height="17" font="0"> ≥55 y </text>
<text top="581" left="365" width="7" height="18" font="7"></text>
<text top="582" left="371" width="146" height="17" font="0"> Non-PAD group identified </text>
<text top="599" left="365" width="124" height="17" font="0">from internal medicine </text>
<text top="616" left="365" width="47" height="17" font="0">practice </text>
<text top="633" left="365" width="3" height="17" font="2"><b> </b></text>
<text top="651" left="365" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="668" left="365" width="7" height="18" font="7"></text>
<text top="669" left="371" width="54" height="17" font="0"> ABI &gt;1.5 </text>
<text top="686" left="365" width="7" height="18" font="7"></text>
<text top="687" left="371" width="70" height="17" font="0"> Normal ABI </text>
<text top="705" left="365" width="7" height="18" font="7"></text>
<text top="706" left="371" width="59" height="17" font="0"> Dementia </text>
<text top="723" left="365" width="7" height="18" font="7"></text>
<text top="724" left="371" width="69" height="17" font="0"> Amputation </text>
<text top="741" left="365" width="7" height="18" font="7"></text>
<text top="743" left="371" width="126" height="17" font="0"> Non-English speaking </text>
<text top="760" left="365" width="7" height="18" font="7"></text>
<text top="761" left="371" width="106" height="17" font="0"> Wheelchair bound </text>
<text top="528" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="527" left="540" width="6" height="18" font="7"></text>
<text top="528" left="546" width="337" height="17" font="2"><b> endpoint:</b> Decline in 6 MWT, Usual pace and fastest-pace 4-</text>
<text top="545" left="533" width="243" height="17" font="0">Meter velocity, summary performance score </text>
<text top="562" left="533" width="3" height="17" font="0"> </text>
<text top="580" left="533" width="344" height="17" font="2"><b>Results:</b> Baseline physical functioning poorer in asx PAD than </text>
<text top="597" left="533" width="352" height="17" font="0">non-PAD; decline greater on all measures. asx PAD has greater </text>
<text top="614" left="533" width="239" height="17" font="0">decline in 6 MWT than pts with claudication </text>
<text top="527" left="911" width="7" height="18" font="7"></text>
<text top="528" left="918" width="160" height="17" font="0"> Asx pts have &gt;2 y decline in </text>
<text top="545" left="911" width="183" height="17" font="0">physical functioning compared to </text>
<text top="562" left="911" width="185" height="17" font="0">asx non-PAD pts. 6 MWT decline </text>
<text top="580" left="911" width="176" height="17" font="0">greater in asx pts that IC group. </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">22 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="365" width="7" height="18" font="7"></text>
<text top="88" left="371" width="131" height="17" font="0"> Nursing home resident </text>
<text top="106" left="365" width="7" height="18" font="7"></text>
<text top="107" left="371" width="90" height="17" font="0"> Recent surgery </text>
<text top="125" left="88" width="86" height="17" font="2"><b>WALCS Study </b></text>
<text top="142" left="88" width="105" height="17" font="0">McDermott MM, et </text>
<text top="159" left="88" width="16" height="17" font="0">al. </text>
<text top="176" left="88" width="53" height="17" font="0">2006(42) </text>
<text top="194" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16389250">16389250</a></text>
<text top="194" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16389250"> </a></text>
<text top="211" left="88" width="3" height="17" font="0"> </text>
<text top="125" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="142" left="209" width="140" height="17" font="0">cohort study with median </text>
<text top="159" left="209" width="104" height="17" font="0">follow-up of 36 mo </text>
<text top="176" left="209" width="3" height="17" font="0"> </text>
<text top="194" left="209" width="121" height="17" font="2"><b>Size:</b> n=417 men and </text>
<text top="211" left="209" width="97" height="17" font="0">women with PAD </text>
<text top="125" left="365" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="142" left="365" width="7" height="18" font="7"></text>
<text top="143" left="371" width="64" height="17" font="0"> Age ≥55 y </text>
<text top="160" left="365" width="7" height="18" font="7"></text>
<text top="161" left="371" width="61" height="17" font="0"> ABI &lt;0.90 </text>
<text top="179" left="365" width="7" height="18" font="7"></text>
<text top="180" left="371" width="146" height="17" font="0"> Non-PAD group identified </text>
<text top="197" left="365" width="124" height="17" font="0">from internal medicine </text>
<text top="214" left="365" width="47" height="17" font="0">practice </text>
<text top="231" left="365" width="3" height="17" font="2"><b> </b></text>
<text top="249" left="365" width="133" height="17" font="2"><b>Exclusion criteria:</b> ABI </text>
<text top="266" left="365" width="101" height="17" font="0">&gt;1.5; Normal ABI, </text>
<text top="283" left="365" width="125" height="17" font="0">dementia, amputation, </text>
<text top="300" left="365" width="120" height="17" font="0">nonEnglish speaking, </text>
<text top="318" left="365" width="147" height="17" font="0">wheelchair bound, nursing </text>
<text top="335" left="365" width="81" height="17" font="0">home resident </text>
<text top="126" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="125" left="540" width="6" height="18" font="7"></text>
<text top="126" left="546" width="337" height="17" font="2"><b> endpoint:</b> Rate of decline in 6 MWT, Usual pace and fastest-</text>
<text top="143" left="533" width="284" height="17" font="0">pace 4-Meter velocity, summary performance score </text>
<text top="160" left="533" width="3" height="17" font="0"> </text>
<text top="177" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="195" left="533" width="7" height="18" font="7"></text>
<text top="196" left="540" width="351" height="17" font="0"> Pts separated into groups based on physical activity level (walk </text>
<text top="213" left="533" width="238" height="17" font="0">3 or more times per wk vs. less frequently). </text>
<text top="230" left="533" width="7" height="18" font="7"></text>
<text top="231" left="540" width="339" height="17" font="0"> Asx PAD pts who walked for exercise 3 or more times per wk </text>
<text top="249" left="533" width="343" height="17" font="0">had less functional decline than those who walked for exercise </text>
<text top="266" left="533" width="86" height="17" font="0">less frequently  </text>
<text top="125" left="911" width="7" height="18" font="7"></text>
<text top="126" left="918" width="137" height="17" font="0"> Greater physical activity </text>
<text top="143" left="911" width="168" height="17" font="0">associated with less decline in </text>
<text top="160" left="911" width="180" height="17" font="0">physical functioning in ASX PAD </text>
<text top="177" left="911" width="23" height="17" font="0">pts. </text>
<text top="353" left="88" width="85" height="17" font="2"><b>WALCS study </b></text>
<text top="370" left="88" width="105" height="17" font="0">McDermott MM, et </text>
<text top="387" left="88" width="16" height="17" font="0">al. </text>
<text top="404" left="88" width="53" height="17" font="0">2010(43) </text>
<text top="421" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20550604">20550604</a></text>
<text top="421" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20550604"> </a></text>
<text top="439" left="88" width="3" height="17" font="0"> </text>
<text top="353" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="370" left="209" width="109" height="17" font="0">observational study </text>
<text top="387" left="209" width="3" height="17" font="0"> </text>
<text top="404" left="209" width="138" height="17" font="2"><b>Size:</b> n=415 pts followed </text>
<text top="421" left="209" width="51" height="17" font="0">up to 7 y </text>
<text top="353" left="365" width="131" height="17" font="2"><b>Inclusion criteria: </b>See </text>
<text top="370" left="365" width="37" height="17" font="0">above </text>
<text top="387" left="365" width="3" height="17" font="0"> </text>
<text top="404" left="365" width="135" height="17" font="2"><b>Exclusion criteria:</b> See </text>
<text top="421" left="365" width="37" height="17" font="0">above </text>
<text top="354" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="353" left="540" width="6" height="18" font="7"></text>
<text top="354" left="546" width="332" height="17" font="2"><b> endpoint:</b> 6 MWT, becoming unable to walk up and down a </text>
<text top="371" left="533" width="337" height="17" font="0">flight of stairs or walk ¼ mile without assistance in pts without </text>
<text top="388" left="533" width="133" height="17" font="0">mobility loss at baseline </text>
<text top="405" left="533" width="3" height="17" font="0"> </text>
<text top="423" left="533" width="346" height="17" font="2"><b>Results:</b> Always asx pts had greater mobility loss than pts with </text>
<text top="440" left="533" width="292" height="17" font="0">claudication (HR: 2.94; 95% CI: 1.39–6.19; p=0.005). </text>
<text top="457" left="533" width="362" height="17" font="0">Asx pts did not demonstrate as much decline in 6MWT as pts with </text>
<text top="474" left="533" width="72" height="17" font="0">claudication. </text>
<text top="353" left="911" width="24" height="17" font="0">N/A </text>
<text top="492" left="88" width="66" height="17" font="2"><b>LIFE study </b></text>
<text top="510" left="88" width="105" height="17" font="0">McDermott MM, et </text>
<text top="527" left="88" width="20" height="17" font="0">al.  </text>
<text top="544" left="88" width="53" height="17" font="0">2013(44) </text>
<text top="561" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24222666">24222666</a></text>
<text top="561" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24222666"> </a></text>
<text top="578" left="88" width="3" height="17" font="0"> </text>
<text top="492" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="510" left="209" width="98" height="17" font="0">sectional study in </text>
<text top="527" left="209" width="111" height="17" font="0">community-dwelling </text>
<text top="544" left="209" width="124" height="17" font="0">sedentary older adults </text>
<text top="561" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="578" left="209" width="100" height="17" font="2"><b>Size:</b> n=1,566 pts </text>
<text top="596" left="209" width="90" height="17" font="0">categorized into </text>
<text top="613" left="209" width="81" height="17" font="0">categories of:  </text>
<text top="630" left="209" width="139" height="17" font="0">Definite PAD , borderline </text>
<text top="647" left="209" width="139" height="17" font="0">PAD, low normal ABI, no </text>
<text top="664" left="209" width="29" height="17" font="0">PAD </text>
<text top="492" left="365" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="510" left="365" width="7" height="18" font="7"></text>
<text top="511" left="371" width="76" height="17" font="0"> Age 70–89 y </text>
<text top="528" left="365" width="7" height="18" font="7"></text>
<text top="529" left="371" width="118" height="17" font="0"> Community-dwelling </text>
<text top="546" left="365" width="7" height="18" font="7"></text>
<text top="547" left="371" width="135" height="17" font="0"> Sedentary (&lt;125 min of </text>
<text top="565" left="365" width="107" height="17" font="0">physical activity/wk </text>
<text top="582" left="365" width="7" height="18" font="7"></text>
<text top="583" left="371" width="122" height="17" font="0"> Functional limitations </text>
<text top="600" left="365" width="3" height="17" font="0"> </text>
<text top="617" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="493" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="492" left="540" width="6" height="18" font="7"></text>
<text top="493" left="546" width="216" height="17" font="2"><b> endpoint:</b> Physical function measures </text>
<text top="511" left="533" width="3" height="17" font="0"> </text>
<text top="528" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="545" left="533" width="7" height="18" font="7"></text>
<text top="546" left="540" width="163" height="17" font="0"> 65% of definite PAD pts asx. </text>
<text top="563" left="533" width="7" height="18" font="7"></text>
<text top="565" left="540" width="353" height="17" font="0"> In asx pts lower ABI values associated with longer 4 meter walk </text>
<text top="582" left="533" width="179" height="17" font="0">time and slower walking velocity </text>
<text top="492" left="911" width="7" height="18" font="7"></text>
<text top="493" left="918" width="180" height="17" font="0"> Lower extremity atherosclerosis </text>
<text top="511" left="911" width="162" height="17" font="0">may be common preventable </text>
<text top="528" left="911" width="177" height="17" font="0">cause of functional limitations in </text>
<text top="545" left="911" width="81" height="17" font="0">older persons. </text>
<text top="562" left="911" width="7" height="18" font="7"></text>
<text top="563" left="918" width="156" height="17" font="0"> Even in individuals who are </text>
<text top="581" left="911" width="183" height="17" font="0">considered functionally impaired, </text>
<text top="598" left="911" width="187" height="17" font="0">low ABI is associated with greater </text>
<text top="615" left="911" width="124" height="17" font="0">functional impairment. </text>
<text top="682" left="88" width="76" height="17" font="0">Niazi K, et al. </text>
<text top="700" left="88" width="53" height="17" font="0">2006(45) </text>
<text top="717" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17039537">17039537</a></text>
<text top="717" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17039537"> </a></text>
<text top="734" left="88" width="3" height="17" font="0"> </text>
<text top="682" left="209" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="700" left="209" width="85" height="17" font="0">sectional study </text>
<text top="717" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="734" left="209" width="117" height="17" font="2"><b>Size:</b> n=107 pts, 208 </text>
<text top="751" left="209" width="32" height="17" font="0">limbs </text>
<text top="682" left="365" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="700" left="365" width="7" height="18" font="7"></text>
<text top="701" left="371" width="148" height="17" font="0"> ABI performed within 30 d </text>
<text top="718" left="365" width="70" height="17" font="0">prior to DSA </text>
<text top="735" left="365" width="3" height="17" font="0"> </text>
<text top="752" left="365" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="770" left="365" width="7" height="18" font="7"></text>
<text top="771" left="371" width="146" height="17" font="0"> Pts with noncompressible </text>
<text top="683" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="682" left="540" width="6" height="18" font="7"></text>
<text top="683" left="546" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="701" left="533" width="3" height="17" font="0"> </text>
<text top="718" left="533" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="735" left="533" width="7" height="18" font="7"></text>
<text top="736" left="540" width="340" height="17" font="0"> Sensitivity of the HAP and LAP ABI for diagnosis of PAD was </text>
<text top="754" left="533" width="152" height="17" font="0">69% and 84%, respectively </text>
<text top="771" left="533" width="7" height="18" font="7"></text>
<text top="772" left="540" width="323" height="17" font="0"> Overall accuracy of HAP and LAP ABI was 72% and 80%, </text>
<text top="682" left="911" width="7" height="18" font="7"></text>
<text top="683" left="918" width="172" height="17" font="0"> LAP ABI has better sensitifvity </text>
<text top="701" left="911" width="129" height="17" font="0">and overall accuracy in </text>
<text top="718" left="911" width="166" height="17" font="0">comparison to the HAP ABI in </text>
<text top="735" left="911" width="92" height="17" font="0">diagnosing PAD </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">23 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="365" width="44" height="17" font="0">vessels </text>
<text top="104" left="365" width="7" height="18" font="7"></text>
<text top="105" left="371" width="61" height="17" font="0"> ABI &gt;1.40 </text>
<text top="87" left="533" width="68" height="17" font="0">respectively </text>
<text top="123" left="80" width="1024" height="17" font="0">ABI indicates ankle-brachial index; ASA, acetylsalicylic acid; asx, asymptomatic; BL, baseline; CAD, coronary artery disease; CHD, coronary heart disease; CI indicates confidence interval; </text>
<text top="141" left="80" width="1004" height="17" font="0">CLI, critical limb ischemia; CT, computed tomography; CVD, cardiovascular disease; CV, cardiovascular; DM, diabetes mellitus; DSA, digital subtraction angiography; ET, endotracheal; </text>
<text top="158" left="80" width="1016" height="17" font="0">FRS, Framingham risk score; HAP, high ankle pressure; HR, hazard ratio; HTN, hypertension; IC, intermittent claudication; LAP, low ankle pressure; MACE, major adverse cardiovascular </text>
<text top="175" left="80" width="1011" height="17" font="0">event; LEX, lower extremity; MCS, mental health composite score; MI, myocardial infarction; MRI, magnetic resonance imaging; MWT, mean walking time; N/A, not applicable; NHANES, </text>
<text top="192" left="80" width="1002" height="17" font="0">National Health and Nutrition Examination Survey; NPV, negative predictive value; NRI, net reclassification improvement; NNT, number needed to treat OR, odds ratio; PAD, peripheral </text>
<text top="210" left="80" width="1014" height="17" font="0">artery disease; PCS, physical composite score, PFWT, pain free walking time; PPV, positive predictive value; pt, patient; RR, relative risk; SBP, systolic blood pressure; SCCA, significant </text>
<text top="227" left="80" width="798" height="17" font="0">stenosis &gt;50%; SF, Short Form; Sx, symptomatic; TIA, transient ischemic attack; US, United States; and WIQ, Walking Impairment Questionnaire. </text>
<text top="244" left="86" width="3" height="17" font="9"> </text>
<text top="261" left="86" width="3" height="17" font="9"> </text>
<text top="278" left="86" width="844" height="21" font="1"><b>Evidence Table 5. Nonrandomized Trials, Observational Studies, and/or Registries of Physiological Testing–Section 3.2. </b></text>
<text top="300" left="90" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="317" left="115" width="48" height="17" font="2"><b>Author; </b></text>
<text top="334" left="93" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="300" left="218" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="317" left="244" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="300" left="417" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="300" left="623" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="317" left="631" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="334" left="682" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="300" left="910" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="317" left="937" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="352" left="88" width="99" height="17" font="0">Rutherford RB, et </text>
<text top="369" left="88" width="16" height="17" font="0">al.<b> </b></text>
<text top="387" left="88" width="53" height="17" font="0">1997(46) </text>
<text top="404" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9308598">9308598 </a></text>
<text top="421" left="88" width="3" height="17" font="0"> </text>
<text top="352" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="369" left="203" width="126" height="17" font="0">Observational study of </text>
<text top="387" left="203" width="129" height="17" font="0">SDP/PVR compared to </text>
<text top="404" left="203" width="112" height="17" font="0">the gold standard of </text>
<text top="421" left="203" width="121" height="17" font="0">angiography for Dx of </text>
<text top="438" left="203" width="29" height="17" font="0">PAD </text>
<text top="455" left="203" width="3" height="17" font="0"> </text>
<text top="473" left="203" width="90" height="17" font="2"><b>Size:</b> n=114 pts </text>
<text top="490" left="203" width="146" height="17" font="0">undergoing SDP/PVR and </text>
<text top="507" left="203" width="71" height="17" font="0">angiography </text>
<text top="352" left="365" width="164" height="17" font="2"><b>Inclusion criteria:</b> 11 normal </text>
<text top="369" left="365" width="191" height="17" font="0">volunteers and 103 pts having had </text>
<text top="387" left="365" width="71" height="17" font="0">angiography </text>
<text top="404" left="365" width="3" height="17" font="0"> </text>
<text top="421" left="365" width="200" height="17" font="2"><b>Exclusion criteria:</b> No angiography </text>
<text top="353" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="352" left="601" width="6" height="18" font="7"></text>
<text top="353" left="607" width="222" height="17" font="2"><b> endpoint:</b> Correct classification of PAD </text>
<text top="371" left="594" width="3" height="17" font="0"> </text>
<text top="388" left="594" width="197" height="17" font="2"><b>Results:</b> 97% of normal limbs were </text>
<text top="405" left="594" width="209" height="17" font="0">correctly classified by SDP/PVR, 86% </text>
<text top="422" left="594" width="224" height="17" font="0">correct classification using either SDP or </text>
<text top="439" left="594" width="29" height="17" font="0">PVR </text>
<text top="352" left="844" width="24" height="17" font="0">N/A </text>
<text top="525" left="88" width="98" height="17" font="0">Eslahpazir BA, et </text>
<text top="542" left="88" width="16" height="17" font="0">al.<b> </b></text>
<text top="559" left="88" width="53" height="17" font="0">2014(47) </text>
<text top="577" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24200144">24200144 </a></text>
<text top="594" left="88" width="3" height="17" font="0"> </text>
<text top="525" left="203" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="542" left="203" width="107" height="17" font="0">healthcare system, </text>
<text top="559" left="203" width="141" height="17" font="0">retrospective cohort of all </text>
<text top="577" left="203" width="103" height="17" font="0">pts with SDP/PVR </text>
<text top="594" left="203" width="119" height="17" font="0">/DWand angiography </text>
<text top="611" left="203" width="112" height="17" font="0">2009–2011 (blinded </text>
<text top="628" left="203" width="93" height="17" font="0">readers for each </text>
<text top="646" left="203" width="61" height="17" font="0">technique) </text>
<text top="663" left="203" width="3" height="17" font="0"> </text>
<text top="680" left="203" width="95" height="17" font="2"><b>Size:</b> n=89 limbs </text>
<text top="525" left="365" width="175" height="17" font="2"><b>Inclusion criteria:</b> Having both </text>
<text top="542" left="365" width="152" height="17" font="0">SDP/PVR and angiography </text>
<text top="559" left="365" width="3" height="17" font="0"> </text>
<text top="577" left="365" width="173" height="17" font="2"><b>Exclusion criteria:</b> Those with </text>
<text top="594" left="365" width="108" height="17" font="0">incomplete reports  </text>
<text top="526" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="525" left="601" width="6" height="18" font="7"></text>
<text top="526" left="607" width="207" height="17" font="2"><b> endpoint:</b> Determination of the most </text>
<text top="543" left="594" width="142" height="17" font="0">accurate diagnostic value </text>
<text top="561" left="594" width="3" height="17" font="0"> </text>
<text top="578" left="594" width="191" height="17" font="2"><b>Results:</b> 66% diagnostic accuracy </text>
<text top="595" left="594" width="186" height="17" font="0">(presence and level of PAD), less </text>
<text top="612" left="594" width="227" height="17" font="0">variability in interpretation using pressure </text>
<text top="629" left="594" width="172" height="17" font="0">than in waveform interpretation </text>
<text top="525" left="844" width="7" height="18" font="7"></text>
<text top="526" left="851" width="236" height="17" font="0"> Readings reflecting incompressibility were </text>
<text top="543" left="844" width="62" height="17" font="0">not utilized </text>
<text top="698" left="88" width="81" height="17" font="0">Ouriel K, et al.<b> </b></text>
<text top="715" left="88" width="53" height="17" font="0">1982(48) </text>
<text top="732" left="88" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7079971">7079971</a></text>
<text top="732" left="136" width="3" height="17" font="2"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7079971"><b> </b></a></text>
<text top="750" left="88" width="3" height="17" font="0"> </text>
<text top="698" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="715" left="203" width="79" height="17" font="0">Observational </text>
<text top="732" left="203" width="3" height="17" font="0"> </text>
<text top="750" left="203" width="118" height="17" font="2"><b>Size:</b> n=218 pts (372 </text>
<text top="767" left="203" width="138" height="17" font="0">limbs) and 25 normal pts </text>
<text top="698" left="365" width="204" height="17" font="2"><b>Inclusion criteria:</b> Able to have ABI, </text>
<text top="715" left="365" width="204" height="17" font="0">treadmill ABI and reactive hyperemia </text>
<text top="732" left="365" width="3" height="17" font="0"> </text>
<text top="750" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="699" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="698" left="601" width="6" height="18" font="7"></text>
<text top="699" left="607" width="216" height="17" font="2"><b> endpoint:</b> Sensitivity and specificity of </text>
<text top="716" left="594" width="152" height="17" font="0">exercise ABI to detect PAD </text>
<text top="734" left="594" width="3" height="17" font="0"> </text>
<text top="751" left="594" width="208" height="17" font="2"><b>Results:</b> 97% and 96% stress testing </text>
<text top="768" left="594" width="228" height="17" font="0">value is in pts with symptoms and normal </text>
<text top="698" left="844" width="24" height="17" font="0">N/A </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">24 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="142" height="17" font="0">and 10 stable claudicants </text>
<text top="87" left="594" width="23" height="17" font="0">ABI </text>
<text top="104" left="594" width="3" height="17" font="0"> </text>
<text top="122" left="88" width="89" height="17" font="0">Aerden D, et al.<b> </b></text>
<text top="139" left="88" width="53" height="17" font="0">2011(49) </text>
<text top="157" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21514102">21514102 </a></text>
<text top="174" left="88" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="139" left="203" width="36" height="17" font="0">study  </text>
<text top="157" left="203" width="3" height="17" font="0"> </text>
<text top="174" left="203" width="103" height="17" font="2"><b>Size: </b>n=187 lower </text>
<text top="191" left="203" width="66" height="17" font="0">extremities  </text>
<text top="122" left="365" width="210" height="17" font="2"><b>Inclusion criteria:</b> Pts in diabetic foot </text>
<text top="139" left="365" width="195" height="17" font="0">clinic with angiography and ABI. All </text>
<text top="157" left="365" width="185" height="17" font="0">with nonhealing foot ulcer and/ or </text>
<text top="174" left="365" width="73" height="17" font="0">absent pulse </text>
<text top="191" left="365" width="3" height="17" font="0"> </text>
<text top="208" left="365" width="185" height="17" font="2"><b>Exclusion criteria:</b> Distal arterial </text>
<text top="226" left="365" width="46" height="17" font="0">bypass  </text>
<text top="123" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="122" left="601" width="6" height="18" font="7"></text>
<text top="123" left="607" width="187" height="17" font="2"><b> endpoint:</b> Correlation of ABI and </text>
<text top="141" left="594" width="217" height="17" font="0">angiography in pts seen in diabetic foot </text>
<text top="158" left="594" width="31" height="17" font="0">clinic </text>
<text top="175" left="594" width="3" height="17" font="0"> </text>
<text top="192" left="594" width="213" height="17" font="2"><b>Results:</b> Correlation between ABI and </text>
<text top="210" left="594" width="223" height="17" font="0">angiographic disease was weak (&lt;0.48). </text>
<text top="227" left="594" width="217" height="17" font="0">ABI could not be determined in 34%. In </text>
<text top="244" left="594" width="222" height="17" font="0">those with calcifications, correlation with </text>
<text top="261" left="594" width="185" height="17" font="0">angiographic severity was worse. </text>
<text top="122" left="844" width="7" height="18" font="7"></text>
<text top="123" left="851" width="244" height="17" font="0"> Arterial calcification evaluated using plain X-</text>
<text top="141" left="844" width="21" height="17" font="0">ray </text>
<text top="158" left="844" width="7" height="18" font="7"></text>
<text top="159" left="851" width="251" height="17" font="0"> Biphasic Doppler signals useful, monophasic </text>
<text top="176" left="844" width="57" height="17" font="0">not useful </text>
<text top="279" left="88" width="83" height="17" font="0">Park SC, et al.<b> </b></text>
<text top="296" left="88" width="53" height="17" font="0">2012(50) </text>
<text top="314" left="88" width="65" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22783531">922783531 </a></text>
<text top="331" left="88" width="3" height="17" font="0"> </text>
<text top="279" left="203" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="296" left="203" width="136" height="17" font="0">analysis of angiography, </text>
<text top="314" left="203" width="112" height="17" font="0">ABI, TBI (many with </text>
<text top="331" left="203" width="44" height="17" font="0">ulcers)  </text>
<text top="348" left="203" width="3" height="17" font="0"> </text>
<text top="365" left="203" width="99" height="17" font="2"><b>Size:</b> n=30 limbs  </text>
<text top="279" left="365" width="204" height="17" font="2"><b>Inclusion criteria:</b> TBI &lt;0.6 or ABI &lt; </text>
<text top="296" left="365" width="129" height="17" font="0">0.9, diabetic gangrene) </text>
<text top="314" left="365" width="3" height="17" font="0"> </text>
<text top="331" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="280" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="279" left="601" width="6" height="18" font="7"></text>
<text top="280" left="607" width="209" height="17" font="2"><b> endpoint:</b> ABI or TBI correlation with </text>
<text top="298" left="594" width="120" height="17" font="0">angiographic disease </text>
<text top="315" left="594" width="3" height="17" font="0"> </text>
<text top="332" left="594" width="212" height="17" font="2"><b>Results:</b> 13 of 30 limbs with abnormal </text>
<text top="349" left="594" width="198" height="17" font="0">TBI, 100% specificity and sensitivity </text>
<text top="279" left="844" width="7" height="18" font="7"></text>
<text top="280" left="851" width="245" height="17" font="0"> Studies with normal population and TBI had </text>
<text top="298" left="844" width="259" height="17" font="0">sparse arterial imaging (did not meet QUADAS </text>
<text top="315" left="844" width="62" height="17" font="0">standards) </text>
<text top="383" left="88" width="96" height="17" font="0">Weinberg I, et al.<b> </b></text>
<text top="400" left="88" width="53" height="17" font="0">2013(51) </text>
<text top="418" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22899598">22899598 </a></text>
<text top="435" left="88" width="3" height="17" font="0"> </text>
<text top="383" left="203" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="400" left="203" width="33" height="17" font="0">study </text>
<text top="418" left="203" width="3" height="17" font="0"> </text>
<text top="435" left="203" width="102" height="17" font="2"><b>Size:</b> n=116 limbs </text>
<text top="383" left="365" width="207" height="17" font="2"><b>Inclusion criteria:</b> Pts with ABI &gt;1.4, </text>
<text top="400" left="365" width="118" height="17" font="0">angiography and TBI </text>
<text top="418" left="365" width="3" height="17" font="0"> </text>
<text top="435" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="384" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="383" left="601" width="6" height="18" font="7"></text>
<text top="384" left="607" width="204" height="17" font="2"><b> endpoint:</b> Angiographic evidence of </text>
<text top="402" left="594" width="104" height="17" font="0">PAD with TBI &lt;0.7 </text>
<text top="419" left="594" width="3" height="17" font="0"> </text>
<text top="436" left="594" width="213" height="17" font="2"><b>Results:</b> 92% of pts with TBI &lt;0.7 had </text>
<text top="453" left="594" width="169" height="17" font="0">angiographic evidence of PAD </text>
<text top="383" left="844" width="7" height="18" font="7"></text>
<text top="384" left="851" width="198" height="17" font="0"> 67% DM and 19% on hemodialysis </text>
<text top="471" left="88" width="88" height="17" font="0">Suominen V, et </text>
<text top="488" left="88" width="16" height="17" font="0">al.<b> </b></text>
<text top="506" left="88" width="53" height="17" font="0">2008(52)<b> </b></text>
<text top="523" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18313338">18313338</a></text>
<text top="523" left="142" width="7" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18313338">  </a></text>
<text top="540" left="88" width="3" height="17" font="0"> </text>
<text top="471" left="203" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="488" left="203" width="146" height="17" font="0">ABI &gt;1.3 and angiography </text>
<text top="506" left="203" width="3" height="17" font="0"> </text>
<text top="523" left="203" width="144" height="17" font="2"><b>Size:</b> n=69 pts of the total </text>
<text top="540" left="203" width="118" height="17" font="0">1,762 pts seen in the </text>
<text top="557" left="203" width="69" height="17" font="0">vascular lab </text>
<text top="471" left="365" width="179" height="17" font="2"><b>Inclusion criteria:</b> TBI, ABI and </text>
<text top="488" left="365" width="71" height="17" font="0">angiography </text>
<text top="506" left="365" width="3" height="17" font="0"> </text>
<text top="523" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="472" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="471" left="601" width="6" height="18" font="7"></text>
<text top="472" left="607" width="210" height="17" font="2"><b> endpoint:</b> Presence of abnormal ABI </text>
<text top="490" left="594" width="232" height="17" font="0">&gt;1.3, TBI &lt;0.6 and angiographic evidence </text>
<text top="507" left="594" width="60" height="17" font="0">of disease </text>
<text top="524" left="594" width="3" height="17" font="0"> </text>
<text top="541" left="594" width="218" height="17" font="2"><b>Results:</b> High sensitivity and specificity </text>
<text top="471" left="844" width="7" height="18" font="7"></text>
<text top="472" left="851" width="216" height="17" font="0"> Larger population with normal ABI and </text>
<text top="490" left="844" width="77" height="17" font="0">abnormal TBI </text>
<text top="575" left="88" width="96" height="17" font="0">Aboyans V, et al. </text>
<text top="592" left="88" width="53" height="17" font="0">2008(22) </text>
<text top="610" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18692981">18692981 </a></text>
<text top="627" left="88" width="3" height="17" font="0"> </text>
<text top="575" left="203" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="592" left="203" width="52" height="17" font="0">sectional </text>
<text top="610" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="627" left="203" width="90" height="17" font="2"><b>Size:</b> n=510 pts </text>
<text top="575" left="365" width="190" height="17" font="2"><b>Inclusion criteria:</b> ambulatory pts </text>
<text top="592" left="365" width="144" height="17" font="0">presenting to vascular lab </text>
<text top="610" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="576" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="575" left="601" width="6" height="18" font="7"></text>
<text top="576" left="607" width="206" height="17" font="2"><b> endpoint:</b> Association of risk factors </text>
<text top="594" left="594" width="221" height="17" font="0">with ABI &gt;1.4 and ABI &lt;0.9 and disease </text>
<text top="611" left="594" width="96" height="17" font="0">presence by TBI  </text>
<text top="628" left="594" width="3" height="17" font="0"> </text>
<text top="645" left="594" width="234" height="17" font="2"><b>Results:</b> In 84.2% of cases, diabetic limbs </text>
<text top="662" left="594" width="229" height="17" font="0">with ABI ≥1.40 had abnormal results in at </text>
<text top="680" left="594" width="202" height="17" font="0">least 1 of the 2 noninvasive vascular </text>
<text top="697" left="594" width="205" height="17" font="0">indicators, suggestive of concomitant </text>
<text top="714" left="594" width="103" height="17" font="0">occlusive disease. </text>
<text top="575" left="844" width="7" height="18" font="7"></text>
<text top="576" left="851" width="79" height="17" font="0"> 50% with DM </text>
<text top="594" left="844" width="7" height="18" font="7"></text>
<text top="595" left="851" width="163" height="17" font="0"> No angiographic correlations </text>
<text top="732" left="88" width="95" height="17" font="0">Wagener JS and </text>
<text top="749" left="88" width="75" height="17" font="0">Hendricker C<b> </b></text>
<text top="766" left="88" width="56" height="17" font="0">1987 (53) </text>
<text top="732" left="203" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="749" left="203" width="99" height="17" font="0">study of repeated </text>
<text top="766" left="203" width="130" height="17" font="0">measurements of TcPO</text>
<text top="772" left="332" width="4" height="11" font="11">2</text>
<text top="766" left="337" width="3" height="17" font="0"> </text>
<text top="732" left="365" width="151" height="17" font="2"><b>Inclusion criteria:</b> Healthy </text>
<text top="749" left="365" width="109" height="17" font="0">nonsmoking adults  </text>
<text top="766" left="365" width="3" height="17" font="0"> </text>
<text top="733" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="732" left="601" width="6" height="18" font="7"></text>
<text top="733" left="607" width="171" height="17" font="2"><b> endpoint:</b> Variability of repeat </text>
<text top="750" left="594" width="57" height="17" font="0">measures </text>
<text top="768" left="594" width="3" height="17" font="0"> </text>
<text top="732" left="844" width="7" height="18" font="7"></text>
<text top="733" left="851" width="235" height="17" font="0"> Mornings and afternoons over 7 d to 7 mo </text>
<text top="750" left="844" width="161" height="17" font="0">with variable inspired oxygen </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">25 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3677809">3677809 </a></text>
<text top="104" left="88" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="104" left="203" width="83" height="17" font="2"><b>Size:</b> n=10 pts </text>
<text top="87" left="365" width="176" height="17" font="2"><b>Exclusion criteria:</b> Respiratory </text>
<text top="104" left="365" width="59" height="17" font="0">symptoms </text>
<text top="87" left="594" width="141" height="17" font="2"><b>Results:</b> Higher for TcPO</text>
<text top="93" left="735" width="4" height="11" font="11">2</text>
<text top="87" left="739" width="59" height="17" font="0"> than Sa O</text>
<text top="93" left="798" width="4" height="11" font="11">2</text>
<text top="87" left="803" width="3" height="17" font="0"> </text>
<text top="104" left="594" width="83" height="17" font="0">pulse oximetry </text>
<text top="122" left="88" width="83" height="17" font="0">Tsai FW, et al. </text>
<text top="139" left="88" width="53" height="17" font="0">2000(54) </text>
<text top="157" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10876204">10876204 </a></text>
<text top="174" left="88" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="137" height="17" font="2"><b>Study type:</b> prospective </text>
<text top="139" left="203" width="142" height="17" font="0">vascular lab pts with SPP </text>
<text top="157" left="203" width="102" height="17" font="0">and toe pressures </text>
<text top="174" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="191" left="203" width="147" height="17" font="2"><b>Size:</b> n=85 limbs, 43 of 53 </text>
<text top="208" left="203" width="68" height="17" font="0">pts with DM </text>
<text top="122" left="365" width="214" height="17" font="2"><b>Inclusion criteria:</b> SPP and TBI in the </text>
<text top="139" left="365" width="69" height="17" font="0">vascular lab </text>
<text top="157" left="365" width="3" height="17" font="0"> </text>
<text top="174" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="123" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="122" left="601" width="6" height="18" font="7"></text>
<text top="123" left="607" width="215" height="17" font="2"><b> endpoint:</b> Correlation of TBI and SPP </text>
<text top="141" left="594" width="3" height="17" font="0"> </text>
<text top="158" left="594" width="226" height="17" font="2"><b>Results:</b> Correlation 0.87 (p&lt;0.01) for all </text>
<text top="122" left="844" width="7" height="18" font="7"></text>
<text top="123" left="851" width="112" height="17" font="0"> Laser Doppler SPP </text>
<text top="141" left="844" width="228" height="17" font="0">do not know if any had ulcers or rest pain </text>
<text top="158" left="844" width="3" height="17" font="0"> </text>
<text top="226" left="88" width="94" height="17" font="0">Yamada T, et al.<b> </b></text>
<text top="244" left="88" width="56" height="17" font="0">2008 (55) </text>
<text top="261" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18241755">18241755 </a></text>
<text top="278" left="88" width="3" height="17" font="0"> </text>
<text top="226" left="203" width="144" height="17" font="2"><b>Study type:</b> retrospective </text>
<text top="244" left="203" width="3" height="17" font="0"> </text>
<text top="261" left="203" width="147" height="17" font="2"><b>Size:</b> n=211 pts (50% with </text>
<text top="278" left="203" width="119" height="17" font="0">DM or hemodialysis)  </text>
<text top="226" left="365" width="175" height="17" font="2"><b>Inclusion criteria:</b> vascular lab </text>
<text top="244" left="365" width="209" height="17" font="0">referral for arterial insufficiency due to </text>
<text top="261" left="365" width="143" height="17" font="0">arteriosclerosis obliterans </text>
<text top="278" left="365" width="95" height="17" font="0">ABP, TBP, TcOO</text>
<text top="284" left="460" width="4" height="11" font="11">2</text>
<text top="278" left="464" width="55" height="17" font="0"> and SPP </text>
<text top="295" left="365" width="3" height="17" font="2"><b> </b></text>
<text top="312" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="227" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="226" left="601" width="6" height="18" font="7"></text>
<text top="227" left="607" width="190" height="17" font="2"><b> endpoint:</b> Ability of test to predict </text>
<text top="245" left="594" width="83" height="17" font="0">wound healing </text>
<text top="262" left="594" width="3" height="17" font="0"> </text>
<text top="279" left="594" width="225" height="17" font="2"><b>Results:</b> Healing more likely at TBP &gt;30 </text>
<text top="296" left="594" width="123" height="17" font="0">and SPP &gt;40 mm Hg, </text>
<text top="314" left="594" width="151" height="17" font="0">Best prediction SPP + TBP </text>
<text top="226" left="844" width="7" height="18" font="7"></text>
<text top="227" left="851" width="202" height="17" font="0"> 26 with ulcer or gangrene leading to </text>
<text top="245" left="844" width="64" height="17" font="0">amputation </text>
<text top="262" left="844" width="7" height="18" font="7"></text>
<text top="263" left="851" width="107" height="17" font="0"> 13% with high ABI </text>
<text top="280" left="844" width="7" height="18" font="7"></text>
<text top="281" left="851" width="228" height="17" font="0"> SPP correlates with ABP, TBP and TcPO</text>
<text top="287" left="1079" width="4" height="11" font="11">2</text>
<text top="281" left="1084" width="3" height="17" font="0"> </text>
<text top="299" left="844" width="7" height="18" font="7"></text>
<text top="300" left="851" width="35" height="17" font="0"> TcPO</text>
<text top="305" left="886" width="4" height="11" font="11">2</text>
<text top="300" left="890" width="195" height="17" font="0"> did not work well to predict healing </text>
<text top="332" left="88" width="101" height="17" font="0">Bosanquet DC, et </text>
<text top="349" left="88" width="16" height="17" font="0">al. </text>
<text top="366" left="88" width="56" height="17" font="0">2014 (56) </text>
<text top="383" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24841052">24841052 </a></text>
<text top="400" left="88" width="3" height="17" font="0"> </text>
<text top="332" left="203" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="349" left="203" width="48" height="17" font="0">analysis </text>
<text top="366" left="203" width="3" height="17" font="0"> </text>
<text top="383" left="203" width="143" height="17" font="2"><b>Size:</b> n=15 cohort studies </text>
<text top="400" left="203" width="146" height="17" font="0">with 1,868 individual limbs </text>
<text top="332" left="365" width="157" height="17" font="2"><b>Inclusion criteria:</b> direct (to </text>
<text top="349" left="365" width="178" height="17" font="0">angiosome) vs. indirect infrapop </text>
<text top="366" left="365" width="96" height="17" font="0">revascularization </text>
<text top="383" left="365" width="3" height="17" font="0"> </text>
<text top="400" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="333" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="332" left="601" width="6" height="18" font="7"></text>
<text top="333" left="607" width="198" height="17" font="2"><b> endpoint:</b> Wound healing and limb </text>
<text top="350" left="594" width="99" height="17" font="0">salvage, mortality </text>
<text top="367" left="594" width="3" height="17" font="0"> </text>
<text top="384" left="594" width="217" height="17" font="2"><b>Results:</b> Direct revascularization of the </text>
<text top="402" left="594" width="235" height="17" font="0">tibial vessels appears to result in improved </text>
<text top="419" left="594" width="209" height="17" font="0">wound healing and limb salvage rates </text>
<text top="436" left="594" width="226" height="17" font="0">compared with indirect revascularization, </text>
<text top="453" left="594" width="235" height="17" font="0">with no effect on mortality or reintervention </text>
<text top="470" left="594" width="34" height="17" font="0">rates. </text>
<text top="332" left="844" width="7" height="18" font="7"></text>
<text top="333" left="851" width="93" height="17" font="0"> Marginal quality </text>
<text top="488" left="88" width="57" height="17" font="0">Carter SA </text>
<text top="506" left="88" width="56" height="17" font="0">1969 (57) </text>
<text top="523" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/5818299">5818299 </a></text>
<text top="540" left="88" width="3" height="17" font="0"> </text>
<text top="488" left="203" width="145" height="17" font="2"><b>Study type:</b> Technique to </text>
<text top="506" left="203" width="95" height="17" font="0">measure systolic </text>
<text top="523" left="203" width="124" height="17" font="0">pressures in the lower </text>
<text top="540" left="203" width="63" height="17" font="0">extremities </text>
<text top="557" left="203" width="3" height="17" font="0"> </text>
<text top="574" left="203" width="102" height="17" font="2"><b>Size:</b> n=288 limbs<b> </b></text>
<text top="488" left="365" width="187" height="17" font="2"><b>Inclusion criteria:</b> 202 limbs with </text>
<text top="506" left="365" width="161" height="17" font="0">disease and 86 limbs without </text>
<text top="523" left="365" width="209" height="17" font="0">angiographically documented disease </text>
<text top="540" left="365" width="3" height="17" font="0"> </text>
<text top="557" left="365" width="213" height="17" font="2"><b>Exclusion criteria:</b> Inability to tolerate </text>
<text top="574" left="365" width="69" height="17" font="0">cuff inflation<b> </b></text>
<text top="489" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="488" left="601" width="6" height="18" font="7"></text>
<text top="489" left="607" width="199" height="17" font="2"><b> endpoint:</b> Ability to determine PAD </text>
<text top="507" left="594" width="189" height="17" font="0">with systolic pressure assessment </text>
<text top="524" left="594" width="3" height="17" font="0"> </text>
<text top="541" left="594" width="206" height="17" font="2"><b>Results:</b> Well tolerated and excellent </text>
<text top="558" left="594" width="157" height="17" font="0">correlation with angiography </text>
<text top="488" left="844" width="7" height="18" font="7"></text>
<text top="489" left="851" width="194" height="17" font="0"> Description of case detail included </text>
<text top="592" left="88" width="81" height="17" font="0">Carter SA and </text>
<text top="610" left="88" width="49" height="17" font="0">Tate RB </text>
<text top="627" left="88" width="56" height="17" font="0">1996 (58)<b> </b></text>
<text top="644" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8752037">8752037 </a></text>
<text top="661" left="88" width="3" height="17" font="0"> </text>
<text top="592" left="203" width="95" height="17" font="2"><b>Study type:</b> Toe </text>
<text top="610" left="203" width="139" height="17" font="0">pressures in consecutive </text>
<text top="627" left="203" width="139" height="17" font="0">pts referred to 1 vascular </text>
<text top="644" left="203" width="20" height="17" font="0">lab </text>
<text top="661" left="203" width="3" height="17" font="0"> </text>
<text top="678" left="203" width="117" height="17" font="2"><b>Size:</b> n=182 pts, 352 </text>
<text top="696" left="203" width="36" height="17" font="0">limbs <b> </b></text>
<text top="592" left="365" width="204" height="17" font="2"><b>Inclusion criteria:</b> Referral to lab for </text>
<text top="610" left="365" width="121" height="17" font="0">segmental pressures  </text>
<text top="627" left="365" width="3" height="17" font="0"> </text>
<text top="644" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="593" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="592" left="601" width="6" height="18" font="7"></text>
<text top="593" left="607" width="167" height="17" font="2"><b> endpoint:</b> Clinical correlation </text>
<text top="611" left="594" width="3" height="17" font="0"> </text>
<text top="628" left="594" width="191" height="17" font="2"><b>Results:</b> Low toe PW amplitude is </text>
<text top="645" left="594" width="220" height="17" font="0">significantly related to the occurrence of </text>
<text top="662" left="594" width="216" height="17" font="0">rest pain, skin breakdown, or both after </text>
<text top="680" left="594" width="228" height="17" font="0">controlling is done for the value of the toe </text>
<text top="697" left="594" width="197" height="17" font="0">pressure and ABI or ankle pressure </text>
<text top="592" left="844" width="7" height="18" font="7"></text>
<text top="593" left="851" width="196" height="17" font="0"> Aim: to test whether addition of the </text>
<text top="611" left="844" width="242" height="17" font="0">measurements of toe PW, which depend on </text>
<text top="628" left="844" width="239" height="17" font="0">distal perfusion, to pressure measurements </text>
<text top="645" left="844" width="258" height="17" font="0">could improve the determination of the severity </text>
<text top="662" left="844" width="239" height="17" font="0">of arterial disease and the presence of CLI. </text>
<text top="715" left="88" width="86" height="17" font="0">Ramsey DE, et </text>
<text top="732" left="88" width="16" height="17" font="0">al. </text>
<text top="749" left="88" width="56" height="17" font="0">1983 (59)<b> </b></text>
<text top="767" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6833352">6833352 </a></text>
<text top="715" left="203" width="95" height="17" font="2"><b>Study type:</b> Toe </text>
<text top="732" left="203" width="146" height="17" font="0">pressures were correlated </text>
<text top="749" left="203" width="119" height="17" font="0">with ankle pressures, </text>
<text top="766" left="203" width="148" height="17" font="0">clinical symptoms, and the </text>
<text top="715" left="365" width="189" height="17" font="2"><b>Inclusion criteria:</b> Pts with ulcers </text>
<text top="732" left="365" width="164" height="17" font="0">presenting to the vascular lab </text>
<text top="749" left="365" width="3" height="17" font="0"> </text>
<text top="766" left="365" width="205" height="17" font="2"><b>Exclusion criteria:</b> Absence of ulcer<b> </b></text>
<text top="716" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="715" left="601" width="6" height="18" font="7"></text>
<text top="716" left="607" width="219" height="17" font="2"><b> endpoint:</b> Relationship of toe pressure </text>
<text top="733" left="594" width="57" height="17" font="0">to healing </text>
<text top="750" left="594" width="3" height="17" font="0"> </text>
<text top="768" left="594" width="184" height="17" font="2"><b>Results:</b> The TBI, arm minus toe </text>
<text top="715" left="844" width="231" height="17" font="0">Toe pressure &gt;30 mm Hg associated with </text>
<text top="732" left="844" width="124" height="17" font="0">good healing potential </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">26 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="88" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="132" height="17" font="0">presence or absence of </text>
<text top="104" left="203" width="119" height="17" font="0">diabetes in 294 limbs </text>
<text top="122" left="203" width="3" height="17" font="0"> </text>
<text top="139" left="203" width="106" height="17" font="2"><b>Size:</b> n=294 limbs <b> </b></text>
<text top="87" left="594" width="221" height="17" font="0">pressure, and the absolute toe pressure </text>
<text top="104" left="594" width="226" height="17" font="0">had an average sensitivity and specificity </text>
<text top="122" left="594" width="218" height="17" font="0">of 85% and 88% for asx limbs and 89% </text>
<text top="139" left="594" width="160" height="17" font="0">and 86% for ischemic limbs.  </text>
<text top="157" left="88" width="83" height="17" font="0">Biancari F and </text>
<text top="174" left="88" width="61" height="17" font="0">Juvonen T </text>
<text top="191" left="88" width="56" height="17" font="0">2014 (60) </text>
<text top="208" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24491282">24491282 </a></text>
<text top="226" left="88" width="3" height="17" font="0"> </text>
<text top="157" left="203" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="174" left="203" width="48" height="17" font="0">analysis </text>
<text top="191" left="203" width="3" height="17" font="0"> </text>
<text top="208" left="203" width="120" height="17" font="2"><b>Size:</b> n=9 studies (no </text>
<text top="226" left="203" width="33" height="17" font="0">RCT)<b> </b></text>
<text top="157" left="365" width="214" height="17" font="2"><b>Inclusion criteria:</b> 715 legs treated by </text>
<text top="174" left="365" width="200" height="17" font="0">direct revascularization according to </text>
<text top="191" left="365" width="207" height="17" font="0">the angiosome principle and 575 legs </text>
<text top="208" left="365" width="200" height="17" font="0">treated by indirect revascularization  </text>
<text top="226" left="365" width="3" height="17" font="0"> </text>
<text top="243" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="158" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="157" left="601" width="6" height="18" font="7"></text>
<text top="158" left="607" width="148" height="17" font="2"><b> endpoint:</b> Wound healing </text>
<text top="175" left="594" width="3" height="17" font="0"> </text>
<text top="192" left="594" width="217" height="17" font="2"><b>Results:</b> Direct revascularization of the </text>
<text top="210" left="594" width="202" height="17" font="0">foot angiosome affected by ischemic </text>
<text top="227" left="594" width="234" height="17" font="0">tissue lesions may improve wound healing </text>
<text top="244" left="594" width="210" height="17" font="0">and limb salvage rates compared with </text>
<text top="261" left="594" width="142" height="17" font="0">indirect revascularization  </text>
<text top="157" left="844" width="7" height="18" font="7"></text>
<text top="158" left="851" width="224" height="17" font="0">Aim: The efficacy of angiosome-targeted </text>
<text top="175" left="844" width="212" height="17" font="0">revascularization to achieve healing of </text>
<text top="192" left="844" width="236" height="17" font="0">ischemic tissue lesions of the foot and limb </text>
<text top="210" left="844" width="138" height="17" font="0">salvage is controversial.  </text>
<text top="279" left="88" width="100" height="17" font="0">Vincent DG, et al. </text>
<text top="296" left="88" width="56" height="17" font="0">1983 (61)<b> </b></text>
<text top="314" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6833348">6833348 </a></text>
<text top="331" left="88" width="3" height="17" font="0"> </text>
<text top="279" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="296" left="203" width="79" height="17" font="0">Observational </text>
<text top="314" left="203" width="3" height="17" font="0"> </text>
<text top="331" left="203" width="102" height="17" font="2"><b>Size:</b> n=219 limbs<b> </b></text>
<text top="279" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="296" left="365" width="7" height="18" font="7"></text>
<text top="297" left="371" width="98" height="17" font="0"> Presence of limb </text>
<text top="315" left="365" width="7" height="18" font="7"></text>
<text top="316" left="371" width="184" height="17" font="0"> Both asx volunteers and pts with </text>
<text top="333" left="365" width="193" height="17" font="0">PAD presenting to the vascular lab </text>
<text top="350" left="365" width="73" height="17" font="0">were studied<b> </b></text>
<text top="280" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="279" left="601" width="6" height="18" font="7"></text>
<text top="280" left="607" width="197" height="17" font="2"><b> endpoint:</b> Diagnostic accuracy toe </text>
<text top="298" left="594" width="98" height="17" font="0">pressure and ABI </text>
<text top="315" left="594" width="3" height="17" font="0"> </text>
<text top="332" left="594" width="204" height="17" font="2"><b>Results:</b> Toe pressure was the most </text>
<text top="349" left="594" width="234" height="17" font="0">reliable indicator of occlusive disease, and </text>
<text top="366" left="594" width="220" height="17" font="0">was able to assess disease distal to the </text>
<text top="384" left="594" width="33" height="17" font="0">ankle </text>
<text top="279" left="844" width="7" height="18" font="7"></text>
<text top="280" left="851" width="230" height="17" font="0"> 5 groups were separated using the ankle-</text>
<text top="298" left="844" width="240" height="17" font="0">brachial and the toe-ankle systolic pressure </text>
<text top="315" left="844" width="228" height="17" font="0">ratios: normal, claudication, limb salvage, </text>
<text top="332" left="844" width="252" height="17" font="0">claudication/incompressible arteries, and limb </text>
<text top="349" left="844" width="179" height="17" font="0">salvage/incompressible arteries. </text>
<text top="402" left="88" width="81" height="17" font="0">Mahe G, et al. </text>
<text top="419" left="88" width="56" height="17" font="0">2015 (62) </text>
<text top="436" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26252297">26252297 </a></text>
<text top="453" left="88" width="3" height="17" font="0"> </text>
<text top="402" left="203" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="419" left="203" width="142" height="17" font="0">analysis of clinical results </text>
<text top="436" left="203" width="3" height="17" font="0"> </text>
<text top="453" left="203" width="87" height="17" font="2"><b>Size:</b> n=12,312 </text>
<text top="470" left="203" width="92" height="17" font="0">consecutive pts <b> </b></text>
<text top="402" left="365" width="197" height="17" font="2"><b>Inclusion criteria:</b> Consecutive pts </text>
<text top="419" left="365" width="133" height="17" font="0">underwent exercise ABI </text>
<text top="436" left="365" width="3" height="17" font="0"> </text>
<text top="453" left="365" width="168" height="17" font="2"><b>Exclusion criteria</b>: Inability to </text>
<text top="470" left="365" width="49" height="17" font="0">exercise<b> </b></text>
<text top="403" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="402" left="601" width="6" height="18" font="7"></text>
<text top="403" left="607" width="216" height="17" font="2"><b> endpoint:</b> Diagnosis of PAD using the </text>
<text top="420" left="594" width="51" height="17" font="0">2 criteria </text>
<text top="437" left="594" width="3" height="17" font="0"> </text>
<text top="454" left="594" width="227" height="17" font="2"><b>Results:</b> Only small overlap between the </text>
<text top="472" left="594" width="172" height="17" font="0">2 populations of PAD identified </text>
<text top="489" left="594" width="3" height="17" font="2"><b> </b></text>
<text top="402" left="844" width="7" height="18" font="7"></text>
<text top="403" left="851" width="239" height="17" font="0"> To determine whether postexercise criteria </text>
<text top="420" left="844" width="250" height="17" font="0">for PAD diagnosis recommended by the AHA </text>
<text top="437" left="844" width="207" height="17" font="0">identifies the same group of PAD pts. </text>
<text top="507" left="88" width="94" height="17" font="0">Nicolaϊ SP, et al.<b> </b></text>
<text top="524" left="88" width="56" height="17" font="0">1990 (63)<b> </b></text>
<text top="541" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19631868">19631868 </a></text>
<text top="559" left="88" width="3" height="17" font="0"> </text>
<text top="507" left="203" width="101" height="17" font="2"><b>Study type:</b> Meta </text>
<text top="524" left="203" width="109" height="17" font="0">regression analysis </text>
<text top="541" left="203" width="3" height="17" font="0"> </text>
<text top="558" left="203" width="146" height="17" font="2"><b>Size:</b> n=8 studies, 658 pts<b> </b></text>
<text top="507" left="365" width="198" height="17" font="2"><b>Inclusion criteria:</b> Trials assessing </text>
<text top="524" left="365" width="181" height="17" font="0">reliability oftreadmill testing were </text>
<text top="541" left="365" width="199" height="17" font="0">identified. Inclusion criteria were the </text>
<text top="558" left="365" width="142" height="17" font="0">use of a C- or G-protocol, </text>
<text top="576" left="365" width="175" height="17" font="0">repetition of this protocol, and a </text>
<text top="593" left="365" width="89" height="17" font="0">retrievable ICC. </text>
<text top="508" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="507" left="601" width="6" height="18" font="7"></text>
<text top="508" left="607" width="222" height="17" font="2"><b> endpoint:</b> Reliability of treadmill testing </text>
<text top="525" left="594" width="3" height="17" font="0"> </text>
<text top="542" left="594" width="179" height="17" font="2"><b>Results:</b> For ICD, the estimated </text>
<text top="560" left="594" width="217" height="17" font="0">reliabilities of the C- and G-protocol (as </text>
<text top="577" left="594" width="210" height="17" font="0">assessed by the ICC) were 0.85 (95% </text>
<text top="594" left="594" width="216" height="17" font="0">confidence interval [CI]: 0.82-0.88) and </text>
<text top="611" left="594" width="213" height="17" font="0">0.83 (95% CI: 0.80-0.85), respectively, </text>
<text top="628" left="594" width="215" height="17" font="0">without dependency of the reliability on </text>
<text top="646" left="594" width="97" height="17" font="0">velocity or grade. </text>
<text top="663" left="594" width="3" height="17" font="2"><b> </b></text>
<text top="507" left="844" width="254" height="17" font="0">For ACD, the reliability was significantly better </text>
<text top="524" left="844" width="241" height="17" font="0">for the G-protocol (0.95, 95% CI: 0.94-0.96) </text>
<text top="541" left="844" width="188" height="17" font="0">than for the C-protocol. Moreover, </text>
<text top="558" left="844" width="253" height="17" font="0">the reliability of the C-protocol was dependent </text>
<text top="576" left="844" width="252" height="17" font="0">on grade of the treadmill (0%, 10%, and 12%) </text>
<text top="593" left="844" width="250" height="17" font="0">with a mean ICC of 0.76 (95% CI: 0.54-0.88), </text>
<text top="610" left="844" width="241" height="17" font="0">0.89 (95% CI: 0.86-0.91), and 0.91 (95% CI </text>
<text top="627" left="844" width="131" height="17" font="0">0.88-0.92), respectively </text>
<text top="681" left="88" width="77" height="17" font="0">Laing SP and </text>
<text top="698" left="88" width="90" height="17" font="0">Greenhalgh RM </text>
<text top="715" left="88" width="56" height="17" font="0">1980 (64) </text>
<text top="733" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7357254">7357254 </a></text>
<text top="750" left="88" width="3" height="17" font="0"> </text>
<text top="681" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="698" left="203" width="79" height="17" font="0">Observational </text>
<text top="715" left="203" width="3" height="17" font="0"> </text>
<text top="732" left="203" width="83" height="17" font="2"><b>Size:</b> n=26 pts<b> </b></text>
<text top="681" left="365" width="204" height="17" font="2"><b>Inclusion criteria:</b> Presentation with </text>
<text top="698" left="365" width="68" height="17" font="0">claudication </text>
<text top="682" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="681" left="601" width="6" height="18" font="7"></text>
<text top="682" left="607" width="210" height="17" font="2"><b> endpoint:</b> Comparison of 2 protocols </text>
<text top="699" left="594" width="3" height="17" font="0"> </text>
<text top="716" left="594" width="228" height="17" font="2"><b>Results:</b> The pts walked for 1 or 2 min at </text>
<text top="734" left="594" width="224" height="17" font="0">4 km/h and 1 or 2 min at 6 km/h, and the </text>
<text top="751" left="594" width="196" height="17" font="0">fall in pressure was the same when </text>
<text top="768" left="594" width="208" height="17" font="0">measured immediately after exercise. </text>
<text top="681" left="844" width="24" height="17" font="0">N/A </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">27 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="88" width="93" height="17" font="0">Raines JK, et al.<b> </b></text>
<text top="104" left="88" width="56" height="17" font="0">1976 (65) </text>
<text top="122" left="88" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1246689">1246689</a></text>
<text top="122" left="136" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1246689"> </a></text>
<text top="139" left="88" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="140" height="17" font="2"><b>Study type:</b> Observation </text>
<text top="104" left="203" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="145" height="17" font="2"><b>Size:</b> n=4,500 procedures<b> </b></text>
<text top="87" left="365" width="210" height="17" font="2"><b>Inclusion criteria:</b> Pts in the vascular </text>
<text top="104" left="365" width="20" height="17" font="0">lab </text>
<text top="88" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="601" width="6" height="18" font="7"></text>
<text top="88" left="607" width="199" height="17" font="2"><b> endpoint:</b> Criteria for management </text>
<text top="106" left="594" width="3" height="17" font="0"> </text>
<text top="123" left="594" width="202" height="17" font="2"><b>Results:</b> Excellent reproducibility for </text>
<text top="140" left="594" width="232" height="17" font="0">physiologic testing including pulse volume </text>
<text top="157" left="594" width="196" height="17" font="0">recording and segmental pressures </text>
<text top="87" left="844" width="24" height="17" font="0">N/A </text>
<text top="175" left="88" width="91" height="17" font="0">Sumner DS and </text>
<text top="192" left="88" width="86" height="17" font="0">Strandness DE </text>
<text top="210" left="88" width="56" height="17" font="0">1969 (66)<b> </b></text>
<text top="227" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/5777227">5777227 </a></text>
<text top="244" left="88" width="3" height="17" font="0"> </text>
<text top="175" left="203" width="140" height="17" font="2"><b>Study type:</b> Observation </text>
<text top="175" left="365" width="202" height="17" font="2"><b>Inclusion criteria:</b> Pts presenting to </text>
<text top="192" left="365" width="183" height="17" font="0">the vascular lab with claudication </text>
<text top="176" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="175" left="601" width="6" height="18" font="7"></text>
<text top="176" left="607" width="206" height="17" font="2"><b> endpoint:</b> Relationship between calf </text>
<text top="194" left="594" width="233" height="17" font="0">blood flow and ankle blood pressure in pts </text>
<text top="211" left="594" width="94" height="17" font="0">with claudication </text>
<text top="228" left="594" width="3" height="17" font="0"> </text>
<text top="245" left="594" width="148" height="17" font="2"><b>Results:</b> Close correlation </text>
<text top="175" left="844" width="24" height="17" font="0">N/A </text>
<text top="263" left="88" width="92" height="17" font="0">Castronuovo JJ, </text>
<text top="280" left="88" width="30" height="17" font="0">et al.<b> </b></text>
<text top="298" left="88" width="53" height="17" font="0">1997(67)<b> </b></text>
<text top="315" left="88" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9357464">9357464 </a></text>
<text top="332" left="88" width="3" height="17" font="0"> </text>
<text top="263" left="203" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="280" left="203" width="106" height="17" font="0">double blind study  </text>
<text top="298" left="203" width="3" height="17" font="0"> </text>
<text top="315" left="203" width="83" height="17" font="2"><b>Size:</b> n=53 pts<b> </b></text>
<text top="263" left="365" width="177" height="17" font="2"><b>Inclusion criteria:</b> Vascular lab </text>
<text top="280" left="365" width="89" height="17" font="0">referrals for CLI </text>
<text top="298" left="365" width="3" height="17" font="0"> </text>
<text top="315" left="365" width="213" height="17" font="2"><b>Exclusion criteria:</b> Sepsis or need for </text>
<text top="332" left="365" width="116" height="17" font="0">guillotine amputation<b> </b></text>
<text top="264" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="263" left="601" width="6" height="18" font="7"></text>
<text top="264" left="607" width="217" height="17" font="2"><b> endpoint:</b> Prediction of wound healing </text>
<text top="281" left="594" width="44" height="17" font="0">by SPP </text>
<text top="299" left="594" width="3" height="17" font="0"> </text>
<text top="316" left="594" width="234" height="17" font="2"><b>Results:</b> SPP measurements identified 31 </text>
<text top="333" left="594" width="218" height="17" font="0">of 32 limbs diagnosed as having CLI by </text>
<text top="350" left="594" width="206" height="17" font="0">clinical evaluation (i.e., group I, those </text>
<text top="368" left="594" width="234" height="17" font="0">limbs that required vascular reconstruction </text>
<text top="385" left="594" width="117" height="17" font="0">or major amputation) </text>
<text top="402" left="594" width="3" height="17" font="2"><b> </b></text>
<text top="263" left="844" width="7" height="18" font="7"></text>
<text top="264" left="851" width="218" height="17" font="0"> DM and wound size similar in 2 groups </text>
<text top="281" left="844" width="7" height="18" font="7"></text>
<text top="283" left="851" width="221" height="17" font="0"> The sensitivity of SPP &lt;30 mm Hg as a </text>
<text top="300" left="844" width="220" height="17" font="0">diagnostic test of CLI was 85%, and the </text>
<text top="317" left="844" width="236" height="17" font="0">specificity was 73%. The overall diagnostic </text>
<text top="334" left="844" width="234" height="17" font="0">accuracy of SPP less than 30 mm Hg as a </text>
<text top="351" left="844" width="238" height="17" font="0">diagnostic test of CLI was 79.3% (p&lt;0.002, </text>
<text top="369" left="844" width="116" height="17" font="0">Fischer's exact test). </text>
<text top="420" left="88" width="94" height="17" font="0">Biotteau E, et al.<b> </b></text>
<text top="437" left="88" width="53" height="17" font="0">2009(68)<b> </b></text>
<text top="454" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20087286">20087286 </a></text>
<text top="472" left="88" width="3" height="17" font="0"> </text>
<text top="420" left="203" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="437" left="203" width="121" height="17" font="0">matched paired study </text>
<text top="454" left="203" width="3" height="17" font="0"> </text>
<text top="472" left="203" width="90" height="17" font="2"><b>Size:</b> n=120 pts<b> </b></text>
<text top="420" left="365" width="202" height="17" font="2"><b>Inclusion criteria:</b> Pts presenting to </text>
<text top="437" left="365" width="197" height="17" font="0">the vascular lab with suspected CLI </text>
<text top="421" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="420" left="601" width="6" height="18" font="7"></text>
<text top="421" left="607" width="221" height="17" font="2"><b> endpoint:</b> Whether a difference can be </text>
<text top="438" left="594" width="161" height="17" font="0">found for chest and foot TcPo</text>
<text top="444" left="755" width="4" height="11" font="11">2</text>
<text top="438" left="760" width="3" height="17" font="0"> </text>
<text top="455" left="594" width="230" height="17" font="0">respectively between pts with and without </text>
<text top="473" left="594" width="222" height="17" font="0">DM referred for clinically suspected CLI. </text>
<text top="490" left="594" width="3" height="17" font="0"> </text>
<text top="507" left="594" width="224" height="17" font="2"><b>Results:</b> TcPo2 is lower at the chest but </text>
<text top="524" left="594" width="231" height="17" font="0">not at the foot level in diabetic than in non-</text>
<text top="542" left="594" width="176" height="17" font="0">diabetic pts with suspected CLI. </text>
<text top="420" left="844" width="7" height="18" font="7"></text>
<text top="421" left="851" width="188" height="17" font="0"> Evenly matched DM and non-DM </text>
<text top="438" left="844" width="7" height="18" font="7"></text>
<text top="439" left="851" width="217" height="17" font="0"> 30 mm Hg threshold applicable to both </text>
<text top="457" left="844" width="66" height="17" font="0">populations </text>
<text top="560" left="88" width="92" height="17" font="0">Bunte MC, et al.<b> </b></text>
<text top="577" left="88" width="53" height="17" font="0">2015(69)<b> </b></text>
<text top="596" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26892836">26892836 </a></text>
<text top="615" left="88" width="3" height="17" font="0"> </text>
<text top="560" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="577" left="203" width="79" height="17" font="0">Observational </text>
<text top="594" left="203" width="3" height="17" font="0"> </text>
<text top="611" left="203" width="132" height="17" font="2"><b>Size:</b> n=89 consecutive </text>
<text top="628" left="203" width="20" height="17" font="0">pts<b> </b></text>
<text top="560" left="365" width="153" height="17" font="2"><b>Inclusion criteria:</b> CLI and </text>
<text top="577" left="365" width="147" height="17" font="0">presentation with rest pain </text>
<text top="560" left="594" width="231" height="17" font="2"><b>Results:</b> Among 31 CLI pts with available </text>
<text top="577" left="594" width="223" height="17" font="0">ABI and TBI results, 19 (61%) had a TBI </text>
<text top="594" left="594" width="217" height="17" font="0">&lt;0.7 <i>and</i> a non-compressible or resting </text>
<text top="611" left="594" width="195" height="17" font="0">ABI &lt;0.9. Conversely, no pts with a </text>
<text top="628" left="594" width="224" height="17" font="0">borderline or normal ABI (0.9–1.4) had a </text>
<text top="646" left="594" width="100" height="17" font="0">normal TBI (≥0.7) </text>
<text top="560" left="844" width="7" height="18" font="7"></text>
<text top="561" left="851" width="218" height="17" font="0"> Among a contemporary, real-world CLI </text>
<text top="578" left="844" width="241" height="17" font="0">population, 29% had near-normal or normal </text>
<text top="595" left="844" width="245" height="17" font="0">ABI, despite having significant infragenicular </text>
<text top="612" left="844" width="94" height="17" font="0">arterial disease.  </text>
<text top="664" left="88" width="77" height="17" font="0">Stein R, et al. </text>
<text top="681" left="88" width="53" height="17" font="0">2006(70) </text>
<text top="698" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16669410">16669410 </a></text>
<text top="715" left="88" width="3" height="17" font="0"> </text>
<text top="664" left="203" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="681" left="203" width="39" height="17" font="0">review </text>
<text top="698" left="203" width="3" height="17" font="0"> </text>
<text top="715" left="203" width="90" height="17" font="2"><b>Size:</b> n=396 pts </text>
<text top="664" left="365" width="187" height="17" font="2"><b>Inclusion criteria:</b> Sx outpatients </text>
<text top="681" left="365" width="157" height="17" font="0">referred for measurement of </text>
<text top="698" left="365" width="207" height="17" font="0">segmental blood pressure, the ABI or </text>
<text top="715" left="365" width="214" height="17" font="0">pulse volume recordings by physicians </text>
<text top="732" left="365" width="202" height="17" font="0">not specialized in the evaluation and </text>
<text top="750" left="365" width="163" height="17" font="0">management of pts with PVD </text>
<text top="665" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="664" left="601" width="6" height="18" font="7"></text>
<text top="665" left="607" width="169" height="17" font="2"><b> endpoint:</b> Diagnostic utility of </text>
<text top="682" left="594" width="235" height="17" font="0">measuring the ABI at rest in pts referred to </text>
<text top="699" left="594" width="219" height="17" font="0">the vascular laboratory for evaluation of </text>
<text top="716" left="594" width="88" height="17" font="0">suspected PAD </text>
<text top="734" left="594" width="3" height="17" font="0"> </text>
<text top="751" left="594" width="228" height="17" font="2"><b>Results:</b> Nearly half of pts referred to the </text>
<text top="768" left="594" width="228" height="17" font="0">outpatient vascular laboratory because of </text>
<text top="664" left="844" width="7" height="18" font="7"></text>
<text top="665" left="851" width="254" height="17" font="0"> Diagnostic accuracy was improved with pulse </text>
<text top="682" left="844" width="200" height="17" font="0">volume recordings and exercise ABI </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">28 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="594" width="221" height="17" font="0">suspected arterial disease had a normal </text>
<text top="104" left="594" width="64" height="17" font="0">resting ABI </text>
<text top="122" left="88" width="92" height="17" font="0">Shishehbor MH, </text>
<text top="139" left="88" width="30" height="17" font="0">et al. </text>
<text top="157" left="88" width="53" height="17" font="0">2016(71) </text>
<text top="174" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26860642">26860642</a></text>
<text top="174" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26860642"> </a></text>
<text top="191" left="88" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="139" left="203" width="79" height="17" font="0">Observational </text>
<text top="157" left="203" width="3" height="17" font="0"> </text>
<text top="174" left="203" width="130" height="17" font="2"><b>Size:</b> n=237 pts; 40 pts </text>
<text top="191" left="203" width="100" height="17" font="0">with available TBI </text>
<text top="122" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="140" left="365" width="7" height="18" font="7"></text>
<text top="141" left="371" width="178" height="17" font="0"> Pts in the IN.PACT DEEP Trial  </text>
<text top="158" left="365" width="7" height="18" font="7"></text>
<text top="159" left="371" width="169" height="17" font="0"> Isolated infrapopliteal disease </text>
<text top="176" left="365" width="7" height="18" font="7"></text>
<text top="177" left="371" width="80" height="17" font="0"> Available ABI </text>
<text top="123" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="122" left="601" width="6" height="18" font="7"></text>
<text top="123" left="607" width="216" height="17" font="2"><b> endpoint:</b> Diagnostic measurement of </text>
<text top="141" left="594" width="223" height="17" font="0">ABI and TBI to diagnose lower extremity </text>
<text top="158" left="594" width="146" height="17" font="0">ulcers and severe disease </text>
<text top="175" left="594" width="3" height="17" font="0"> </text>
<text top="192" left="594" width="218" height="17" font="2"><b>Results:</b> 1/3 of pts with CLI and severe </text>
<text top="210" left="594" width="236" height="17" font="0">isolated infrapopliteal disease have normal </text>
<text top="227" left="594" width="214" height="17" font="0">or incompressible ABIs. Only a few pts </text>
<text top="244" left="594" width="205" height="17" font="0">met the hemodynamic criteria for CLI </text>
<text top="261" left="594" width="211" height="17" font="0">according to cutoffs suggested for ABI </text>
<text top="278" left="594" width="234" height="17" font="0">(6%) and ankle pressure (16%) defined by </text>
<text top="296" left="594" width="111" height="17" font="0">multiple guidelines.  </text>
<text top="122" left="844" width="7" height="18" font="7"></text>
<text top="123" left="851" width="210" height="17" font="0"> Current recommended hemodynamic </text>
<text top="141" left="844" width="253" height="17" font="0">pressures to diagnose CLI are insensitive and </text>
<text top="158" left="844" width="257" height="17" font="0">failed to identify a significant portion of pts with </text>
<text top="175" left="844" width="239" height="17" font="0">lower extremity ulcers and angiographically </text>
<text top="192" left="844" width="250" height="17" font="0">proven severe disease. Toe pressure is more </text>
<text top="210" left="844" width="135" height="17" font="0">sensitive in pts with CLI. </text>
<text top="314" left="80" width="996" height="17" font="0">ABI indicates ankle-brachial index; AHA, American Heart Association; asx, asymptomatic; CLI, critical limb ischemia; DM, diabetes mellitus; ICC, intraclass correlation coefficient; ICD, </text>
<text top="331" left="80" width="985" height="17" font="0">International Classification of Disease; N/A, not applicable; PAD, peripheral artery disease; PVD, peripheral vascular disease; PVR, pulse volume recordings; PW, pulse wave; RCT, </text>
<text top="348" left="80" width="179" height="17" font="0">randomized controlled trial; Sa O</text>
<text top="354" left="259" width="4" height="11" font="11">2</text>
<text top="348" left="263" width="834" height="17" font="0">, oxygen saturation; SDP, segmental Doppler pressure; SPP, skin perfusion pressure; sx, symptomatic; TBI, toe-brachial index; TBP, toe blood pressure; </text>
<text top="365" left="80" width="55" height="17" font="0">and TcPO</text>
<text top="371" left="135" width="4" height="11" font="11">2</text>
<text top="365" left="140" width="192" height="17" font="0">, transcutaneous oxygen pressure. </text>
<text top="382" left="86" width="3" height="17" font="0"> </text>
<text top="400" left="86" width="3" height="17" font="0"> </text>
<text top="417" left="80" width="1016" height="21" font="1"><b>Evidence Table 6. Nonrandomized Trials, Observational Studies, and/or Registries of Imaging for Anatomic Assessment (Ultrasound, CTA, MRA, </b></text>
<text top="438" left="80" width="190" height="21" font="1"><b>Angiography)–Section 3.3. </b></text>
<text top="459" left="89" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="476" left="114" width="48" height="17" font="2"><b>Author; </b></text>
<text top="493" left="92" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="459" left="208" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="476" left="234" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="459" left="400" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="459" left="640" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="476" left="647" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="493" left="699" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="459" left="935" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="476" left="962" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="511" left="86" width="77" height="17" font="2"><b>PIVUS study </b></text>
<text top="529" left="86" width="100" height="17" font="0">Wilkström J, et al. </text>
<text top="546" left="86" width="53" height="17" font="0">2008(72) </text>
<text top="563" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18300136">18300136</a></text>
<text top="563" left="141" width="7" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18300136">  </a></text>
<text top="580" left="86" width="3" height="17" font="0"> </text>
<text top="597" left="86" width="100" height="17" font="0">Wilkström J, et al. </text>
<text top="615" left="86" width="53" height="17" font="0">2009(73) </text>
<text top="632" left="86" width="62" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19446989">19446989  </a></text>
<text top="649" left="86" width="3" height="17" font="6"> </text>
<text top="511" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="529" left="203" width="103" height="17" font="0">Observational test </text>
<text top="546" left="203" width="67" height="17" font="0">comparison<b> </b></text>
<text top="563" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="580" left="203" width="90" height="17" font="2"><b>Size: </b>n=306 pts </text>
<text top="511" left="344" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="529" left="344" width="7" height="18" font="7"></text>
<text top="530" left="351" width="203" height="17" font="0"> General population register Sweden </text>
<text top="547" left="344" width="7" height="18" font="7"></text>
<text top="548" left="351" width="55" height="17" font="0"> Age 70 y </text>
<text top="565" left="344" width="3" height="17" font="0"> </text>
<text top="583" left="344" width="196" height="17" font="2"><b>Exclusion criteria:</b> Unable to have </text>
<text top="600" left="344" width="51" height="17" font="0">WBMRA </text>
<text top="617" left="344" width="3" height="17" font="0"> </text>
<text top="634" left="344" width="90" height="17" font="2"><b>Gold standard</b>: </text>
<text top="651" left="344" width="57" height="17" font="0">WBMRA.  </text>
<text top="669" left="343" width="87" height="17" font="0">Stenosis ≥50% </text>
<text top="686" left="343" width="3" height="17" font="0"> </text>
<text top="703" left="343" width="77" height="17" font="2"><b>ABI method: </b></text>
<text top="720" left="343" width="46" height="17" font="0">Doppler </text>
<text top="512" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="511" left="587" width="6" height="18" font="7"></text>
<text top="512" left="593" width="262" height="17" font="2"><b> endpoint:</b> Presence of stenosis in pelvic or leg </text>
<text top="530" left="581" width="145" height="17" font="0">arteries in right or left legs </text>
<text top="547" left="581" width="3" height="17" font="0"> </text>
<text top="564" left="581" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="581" left="581" width="66" height="17" font="0">Sensitivity:  </text>
<text top="599" left="581" width="7" height="18" font="7"></text>
<text top="600" left="587" width="102" height="17" font="0"> Right: 20 (10, 34) </text>
<text top="617" left="581" width="7" height="18" font="7"></text>
<text top="618" left="587" width="87" height="17" font="0"> Left: 15 (7, 27) </text>
<text top="635" left="581" width="62" height="17" font="0">Specificity: </text>
<text top="653" left="581" width="7" height="18" font="7"></text>
<text top="654" left="587" width="73" height="17" font="0"> 99 (96, 100) </text>
<text top="671" left="581" width="7" height="18" font="7"></text>
<text top="672" left="587" width="73" height="17" font="0"> 99 (96, 100) </text>
<text top="689" left="581" width="31" height="17" font="0">PPV: </text>
<text top="706" left="581" width="7" height="18" font="7"></text>
<text top="708" left="587" width="66" height="17" font="0"> 83 (51, 97) </text>
<text top="725" left="581" width="7" height="18" font="7"></text>
<text top="726" left="587" width="66" height="17" font="0"> 82 (48, 97) </text>
<text top="743" left="581" width="32" height="17" font="0">NPV: </text>
<text top="760" left="581" width="7" height="18" font="7"></text>
<text top="762" left="587" width="66" height="17" font="0"> 84 (79, 88) </text>
<text top="511" left="891" width="7" height="18" font="7"></text>
<text top="512" left="898" width="169" height="17" font="0"> Low sensitivity but good PPV. </text>
<text top="530" left="891" width="7" height="18" font="7"></text>
<text top="531" left="898" width="198" height="17" font="0"> High specificity. Similar results (not </text>
<text top="548" left="891" width="191" height="17" font="0">shown) to detect occlusion, except </text>
<text top="565" left="891" width="61" height="17" font="0">lower PPV </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">29 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="581" width="7" height="18" font="7"></text>
<text top="88" left="587" width="66" height="17" font="0"> 80 (74, 84) </text>
<text top="106" left="86" width="72" height="17" font="0">Guo X, et al. </text>
<text top="123" left="86" width="53" height="17" font="0">2008(20) </text>
<text top="141" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18362433">18362433 </a></text>
<text top="158" left="86" width="3" height="17" font="0"> </text>
<text top="106" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="123" left="203" width="103" height="17" font="0">Observational test </text>
<text top="141" left="203" width="67" height="17" font="0">comparison </text>
<text top="158" left="203" width="3" height="17" font="0"> </text>
<text top="175" left="203" width="90" height="17" font="2"><b>Size:</b> n=298 pts </text>
<text top="106" left="344" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="123" left="344" width="7" height="18" font="7"></text>
<text top="125" left="351" width="64" height="17" font="0"> Age ≥35 y </text>
<text top="142" left="344" width="7" height="18" font="7"></text>
<text top="143" left="351" width="206" height="17" font="0"> Cardiology clinic: referrals for DSA &amp; </text>
<text top="160" left="344" width="23" height="17" font="0">ABI </text>
<text top="177" left="344" width="3" height="17" font="0"> </text>
<text top="195" left="344" width="187" height="17" font="2"><b>Exclusion criteria:</b> Severe DM &amp; </text>
<text top="212" left="344" width="74" height="17" font="0">hypertension<b> </b></text>
<text top="229" left="344" width="3" height="17" font="0"> </text>
<text top="246" left="344" width="94" height="17" font="2"><b>Gold standard:</b>  </text>
<text top="264" left="344" width="7" height="18" font="7"></text>
<text top="265" left="351" width="36" height="17" font="0"> DSA. </text>
<text top="282" left="344" width="7" height="18" font="7"></text>
<text top="283" left="351" width="90" height="17" font="0"> Stenosis ≥50% </text>
<text top="300" left="344" width="3" height="17" font="0"> </text>
<text top="318" left="344" width="77" height="17" font="2"><b>ABI method: </b></text>
<text top="335" left="344" width="71" height="17" font="0">Oscillometry </text>
<text top="107" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="106" left="587" width="6" height="18" font="7"></text>
<text top="107" left="593" width="273" height="17" font="2"><b> endpoint:</b> Presence of stenosis below aorto-iliac </text>
<text top="125" left="581" width="174" height="17" font="0">bifurcation in leg with lower ABI<b> </b></text>
<text top="142" left="581" width="3" height="17" font="0"> </text>
<text top="159" left="581" width="52" height="17" font="2"><b>Results: </b></text>
<text top="176" left="581" width="111" height="17" font="0">Sensitivity: 76 (N/A) </text>
<text top="194" left="581" width="111" height="17" font="0">Specificity: 90 (N/A) </text>
<text top="211" left="581" width="81" height="17" font="0">PPV: 36 (N/A) </text>
<text top="228" left="581" width="81" height="17" font="0">NPV: 98 (N/A) </text>
<text top="106" left="891" width="7" height="18" font="7"></text>
<text top="107" left="898" width="170" height="17" font="0"> Moderate sensitivity and good </text>
<text top="125" left="891" width="188" height="17" font="0">specificity. No indication of % with </text>
<text top="142" left="891" width="208" height="17" font="0">PAD symptoms but low prevalence of </text>
<text top="159" left="891" width="191" height="17" font="0">PAD on DSA (7%) suggests it was </text>
<text top="176" left="891" width="59" height="17" font="0">negligible. </text>
<text top="194" left="891" width="7" height="18" font="7"></text>
<text top="195" left="898" width="190" height="17" font="0"> However 53% had coronary heart </text>
<text top="212" left="891" width="138" height="17" font="0">disease and 13% stroke. </text>
<text top="353" left="86" width="95" height="17" font="0">Clairotte R, et al. </text>
<text top="370" left="86" width="53" height="17" font="0">2009(74) </text>
<text top="387" left="86" width="62" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19366974">19366974  </a></text>
<text top="404" left="86" width="3" height="17" font="0"> </text>
<text top="353" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="370" left="203" width="103" height="17" font="0">Observational test </text>
<text top="387" left="203" width="67" height="17" font="0">comparison </text>
<text top="404" left="203" width="3" height="17" font="0"> </text>
<text top="421" left="203" width="83" height="17" font="2"><b>Size:</b> n=63 pts </text>
<text top="439" left="203" width="3" height="17" font="0"> </text>
<text top="353" left="344" width="221" height="17" font="2"><b>Inclusion criteria</b>: Referrals to clinic for </text>
<text top="370" left="344" width="40" height="17" font="0">duplex </text>
<text top="387" left="344" width="3" height="17" font="0"> </text>
<text top="404" left="344" width="133" height="17" font="2"><b>Exclusion criteria:</b> DM </text>
<text top="421" left="344" width="3" height="17" font="0"> </text>
<text top="439" left="344" width="94" height="17" font="2"><b>Gold standard:</b>  </text>
<text top="456" left="344" width="7" height="18" font="7"></text>
<text top="457" left="351" width="106" height="17" font="0"> Duplex ultrasound </text>
<text top="474" left="344" width="7" height="18" font="7"></text>
<text top="475" left="351" width="209" height="17" font="0"> Velocity ratio ≥2 for stenotic:proximal </text>
<text top="493" left="344" width="57" height="17" font="0">segments </text>
<text top="510" left="344" width="3" height="17" font="0"> </text>
<text top="527" left="344" width="77" height="17" font="2"><b>ABI method: </b></text>
<text top="544" left="344" width="46" height="17" font="0">Doppler </text>
<text top="353" left="581" width="277" height="17" font="2"><b>1° endpoint</b>: Presence of stenosis in iliac to ankle </text>
<text top="370" left="581" width="44" height="17" font="0">arteries </text>
<text top="387" left="581" width="3" height="17" font="2"><b> </b></text>
<text top="404" left="581" width="52" height="17" font="2"><b>Results: </b></text>
<text top="421" left="581" width="111" height="17" font="0">Sensitivity: 73 (N/A) </text>
<text top="439" left="581" width="111" height="17" font="0">Specificity: 98 (N/A) </text>
<text top="456" left="581" width="81" height="17" font="0">PPV: 98 (N/A) </text>
<text top="473" left="581" width="81" height="17" font="0">NPV: 78 (N/A) </text>
<text top="353" left="891" width="7" height="18" font="7"></text>
<text top="354" left="898" width="185" height="17" font="0"> Moderate sensitivity &amp; very good </text>
<text top="371" left="891" width="208" height="17" font="0">specificity. No indication of % pts with </text>
<text top="388" left="891" width="187" height="17" font="0">PAD symptoms but only 14% had </text>
<text top="405" left="891" width="84" height="17" font="0">“clinical PAD”.  </text>
<text top="423" left="891" width="7" height="18" font="7"></text>
<text top="424" left="898" width="183" height="17" font="0"> Duplex ultrasound not ideal gold </text>
<text top="441" left="891" width="58" height="17" font="0">standard.  </text>
<text top="458" left="891" width="7" height="18" font="7"></text>
<text top="459" left="898" width="74" height="17" font="0"> Small study. </text>
<text top="562" left="86" width="99" height="17" font="0">Burbelko M, et al. </text>
<text top="580" left="86" width="53" height="17" font="0">2013(75) </text>
<text top="597" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23188773">23188773 </a></text>
<text top="614" left="86" width="3" height="17" font="0"> </text>
<text top="562" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="580" left="203" width="83" height="17" font="0">Observational  </text>
<text top="597" left="203" width="3" height="17" font="0"> </text>
<text top="614" left="203" width="90" height="17" font="2"><b>Size:</b> n=152 pts </text>
<text top="631" left="203" width="3" height="17" font="0"> </text>
<text top="562" left="344" width="200" height="17" font="2"><b>Inclusion criteria:</b> Underwent MRA </text>
<text top="580" left="344" width="217" height="17" font="0">and DSA of the lower extremities within </text>
<text top="597" left="344" width="31" height="17" font="0">30 d. </text>
<text top="614" left="344" width="3" height="17" font="0"> </text>
<text top="631" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="648" left="344" width="3" height="17" font="0"> </text>
<text top="562" left="581" width="295" height="17" font="2"><b>1° endpoint: </b>Evaluation of stenosis grade and image </text>
<text top="580" left="581" width="39" height="17" font="0">quality </text>
<text top="597" left="581" width="3" height="17" font="2"><b> </b></text>
<text top="614" left="581" width="52" height="17" font="2"><b>Results: </b></text>
<text top="631" left="581" width="100" height="17" font="0">Sensitivity: 73–93 </text>
<text top="648" left="581" width="100" height="17" font="0">Specificity: 64–89 </text>
<text top="562" left="891" width="7" height="18" font="7"></text>
<text top="563" left="898" width="164" height="17" font="0"> CE-MRA demonstrates good </text>
<text top="581" left="891" width="137" height="17" font="0">sensitivity and specificity </text>
<text top="598" left="891" width="7" height="18" font="7"></text>
<text top="599" left="898" width="175" height="17" font="0"> CE-MRA is standardizable and </text>
<text top="616" left="891" width="211" height="17" font="0">shows good inter-observer agreement </text>
<text top="633" left="891" width="7" height="18" font="7"></text>
<text top="635" left="898" width="185" height="17" font="0"> Use of CE-MRA as alternative to </text>
<text top="652" left="891" width="180" height="17" font="0">intra-arterial DSA is well justified </text>
<text top="669" left="891" width="3" height="17" font="0"> </text>
<text top="687" left="86" width="98" height="17" font="0">Shareghi S, et al. </text>
<text top="704" left="86" width="53" height="17" font="0">2010(76) </text>
<text top="721" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19753637">19753637 </a></text>
<text top="739" left="86" width="3" height="17" font="0"> </text>
<text top="687" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="704" left="203" width="79" height="17" font="0">Observational </text>
<text top="721" left="203" width="3" height="17" font="0"> </text>
<text top="739" left="203" width="83" height="17" font="2"><b>Size:</b> n=28 pts </text>
<text top="756" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="687" left="344" width="219" height="17" font="2"><b>Inclusion criteria:</b> consecutive pts with </text>
<text top="704" left="344" width="213" height="17" font="0">sx lower extremity IC and an abnormal </text>
<text top="721" left="344" width="79" height="17" font="0">ABI (ABI&lt;0.9) </text>
<text top="739" left="344" width="3" height="17" font="0"> </text>
<text top="756" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="773" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="687" left="581" width="100" height="17" font="2"><b>1° endpoint:</b> N/A </text>
<text top="704" left="581" width="3" height="17" font="2"><b> </b></text>
<text top="721" left="581" width="52" height="17" font="2"><b>Results: </b></text>
<text top="739" left="581" width="79" height="17" font="0">Sensitivity: 99 </text>
<text top="756" left="581" width="79" height="17" font="0">Specificity: 98 </text>
<text top="687" left="891" width="7" height="18" font="7"></text>
<text top="688" left="898" width="172" height="17" font="0"> MDCT demonstrated accurate </text>
<text top="705" left="891" width="165" height="17" font="0">detection of hemodynamically </text>
<text top="723" left="891" width="171" height="17" font="0">significate disease of the lower </text>
<text top="740" left="891" width="63" height="17" font="0">extremities </text>
<text top="757" left="891" width="3" height="17" font="0"> </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="13" size="13" family="Times" color="#111111"/>
<text top="795" left="1088" width="17" height="17" font="0">30 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="86" width="89" height="17" font="0">De Vries SO, et </text>
<text top="104" left="86" width="16" height="17" font="0">al. </text>
<text top="122" left="86" width="53" height="17" font="0">1996(77) </text>
<text top="139" left="86" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8796687">8796687 </a></text>
<text top="156" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="104" left="203" width="48" height="17" font="0">analysis </text>
<text top="122" left="203" width="3" height="17" font="0"> </text>
<text top="139" left="203" width="105" height="17" font="2"><b>Size:</b> n=14 reports </text>
<text top="156" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="87" left="344" width="109" height="17" font="2"><b>Inclusion criteria</b>:  </text>
<text top="104" left="344" width="7" height="18" font="7"></text>
<text top="105" left="351" width="194" height="17" font="0"> Medline, English-language studies </text>
<text top="123" left="344" width="208" height="17" font="0">published between January 1984 and </text>
<text top="140" left="344" width="64" height="17" font="0">June 1994. </text>
<text top="157" left="344" width="7" height="18" font="7"></text>
<text top="158" left="351" width="150" height="17" font="0"> Additional references from </text>
<text top="176" left="344" width="198" height="17" font="0">bibliographies of review articles and </text>
<text top="193" left="344" width="87" height="17" font="0">original papers. </text>
<text top="210" left="344" width="7" height="18" font="7"></text>
<text top="211" left="351" width="178" height="17" font="0"> Studies pertaining to diagnostic </text>
<text top="228" left="344" width="211" height="17" font="0">performance of duplex or color-guided </text>
<text top="246" left="344" width="207" height="17" font="0">duplex ultrasonography in PAD of the </text>
<text top="263" left="344" width="96" height="17" font="0">lower extremities </text>
<text top="280" left="344" width="7" height="18" font="7"></text>
<text top="281" left="351" width="196" height="17" font="0"> Contrast angiography was used as </text>
<text top="298" left="344" width="98" height="17" font="0">the gold standard </text>
<text top="316" left="344" width="214" height="17" font="0">Significant lesion defined as an arterial </text>
<text top="333" left="344" width="207" height="17" font="0">diameter reduction on angiography of </text>
<text top="350" left="344" width="66" height="17" font="0">50%–100% </text>
<text top="367" left="344" width="7" height="18" font="7"></text>
<text top="368" left="351" width="172" height="17" font="0"> The absolute numbers of True-</text>
<text top="386" left="344" width="211" height="17" font="0">positive, false-negative, true-negative, </text>
<text top="403" left="344" width="202" height="17" font="0">and false-positive observations were </text>
<text top="420" left="344" width="123" height="17" font="0">available or derivable. </text>
<text top="437" left="344" width="3" height="17" font="0"> </text>
<text top="454" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="472" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="87" left="581" width="100" height="17" font="2"><b>1° endpoint:</b> N/A </text>
<text top="104" left="581" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="581" width="52" height="17" font="2"><b>Results: </b></text>
<text top="139" left="581" width="62" height="17" font="0">Sensitivity: </text>
<text top="156" left="581" width="7" height="18" font="7"></text>
<text top="157" left="587" width="70" height="17" font="0"> 83 (Duplex) </text>
<text top="174" left="581" width="7" height="18" font="7"></text>
<text top="175" left="587" width="135" height="17" font="0"> 93 Color guided Duplex </text>
<text top="193" left="581" width="66" height="17" font="0">Specificity:  </text>
<text top="210" left="581" width="7" height="18" font="7"></text>
<text top="211" left="587" width="21" height="17" font="0"> 95 </text>
<text top="87" left="891" width="24" height="17" font="0">N/A </text>
<text top="490" left="86" width="69" height="17" font="0">Ota H, et al. </text>
<text top="507" left="86" width="53" height="17" font="0">2004(78) </text>
<text top="524" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14684540">14684540 </a></text>
<text top="541" left="86" width="3" height="17" font="0"> </text>
<text top="490" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="507" left="203" width="79" height="17" font="0">Observational </text>
<text top="524" left="203" width="3" height="17" font="0"> </text>
<text top="541" left="203" width="129" height="17" font="2"><b>Size: </b>n=27 cases in 24 </text>
<text top="558" left="203" width="20" height="17" font="0">pts </text>
<text top="576" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="490" left="344" width="109" height="17" font="2"><b>Inclusion criteria</b>:  </text>
<text top="507" left="344" width="7" height="18" font="7"></text>
<text top="508" left="351" width="206" height="17" font="0"> Sx lower extremity peripheral arterial </text>
<text top="525" left="344" width="100" height="17" font="0">occlusive disease </text>
<text top="543" left="344" width="7" height="18" font="7"></text>
<text top="544" left="351" width="204" height="17" font="0"> Underwent both MDCT angiography </text>
<text top="561" left="344" width="208" height="17" font="0">and digital subtraction angiography of </text>
<text top="578" left="344" width="183" height="17" font="0">the aortoiliac and lower extremity </text>
<text top="595" left="344" width="44" height="17" font="0">arteries </text>
<text top="612" left="344" width="3" height="17" font="0"> </text>
<text top="630" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="490" left="581" width="100" height="17" font="2"><b>1° endpoint: </b>N/A </text>
<text top="507" left="581" width="3" height="17" font="2"><b> </b></text>
<text top="524" left="581" width="52" height="17" font="2"><b>Results: </b></text>
<text top="541" left="581" width="62" height="17" font="0">Sensitivity: </text>
<text top="559" left="581" width="7" height="18" font="7"></text>
<text top="560" left="587" width="31" height="17" font="0"> 99.2 </text>
<text top="577" left="581" width="66" height="17" font="0">Specificity:  </text>
<text top="594" left="581" width="7" height="18" font="7"></text>
<text top="595" left="587" width="34" height="17" font="0"> 99.1  </text>
<text top="490" left="891" width="7" height="18" font="7"></text>
<text top="491" left="898" width="179" height="17" font="0"> MDCT angiography is a reliable </text>
<text top="508" left="891" width="195" height="17" font="0">method for evaluation the aortoiliac </text>
<text top="525" left="891" width="154" height="17" font="0">and lower extremity arteries </text>
<text top="648" left="86" width="65" height="17" font="0">He C, et al. </text>
<text top="665" left="86" width="53" height="17" font="0">2014(79) </text>
<text top="682" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25252783">25252783 </a></text>
<text top="699" left="86" width="3" height="17" font="0"> </text>
<text top="648" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="665" left="203" width="116" height="17" font="0">(retrospective cohort </text>
<text top="682" left="203" width="37" height="17" font="0">study) </text>
<text top="699" left="203" width="3" height="17" font="0"> </text>
<text top="716" left="203" width="90" height="17" font="2"><b>Size:</b> n=161 pts </text>
<text top="648" left="344" width="222" height="17" font="2"><b>Inclusion criteria:</b> Consecutive pts with </text>
<text top="665" left="344" width="152" height="17" font="0">DM (13 women; mean age, </text>
<text top="682" left="344" width="220" height="17" font="0">69.42±11.04 y) and 101 pts without DM </text>
<text top="699" left="344" width="216" height="17" font="0">(23 women; mean age, 68.50±13.59 y) </text>
<text top="716" left="344" width="220" height="17" font="0">who underwent DSCT and 320-MDCTA </text>
<text top="734" left="344" width="152" height="17" font="0">of the arteries in both legs.  </text>
<text top="751" left="344" width="3" height="17" font="0"> </text>
<text top="768" left="344" width="221" height="17" font="2"><b>Exclusion criteria:</b> Allergy to the iodine </text>
<text top="649" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="648" left="587" width="6" height="18" font="7"></text>
<text top="649" left="593" width="262" height="17" font="2"><b> endpoint:</b> Plaque type, distribution, shape and </text>
<text top="666" left="581" width="291" height="17" font="0">obstructive natures were compared between pts with </text>
<text top="683" left="581" width="89" height="17" font="0">and without DM </text>
<text top="700" left="581" width="3" height="17" font="0"> </text>
<text top="718" left="581" width="263" height="17" font="2"><b>Results:</b> Total of 2898 vascular segments were </text>
<text top="735" left="581" width="278" height="17" font="0">included in the analysis. Plaque and stenosis were </text>
<text top="752" left="581" width="288" height="17" font="0">detected in 681 segments in 60 pts with DM (63.1%) </text>
<text top="769" left="581" width="272" height="17" font="0">and 854 segments in 101 pts without DM (46.9%; </text>
<text top="648" left="891" width="7" height="18" font="7"></text>
<text top="649" left="898" width="3" height="17" font="13"> </text>
<text top="649" left="901" width="170" height="17" font="0">DM is associated with a higher </text>
<text top="666" left="891" width="170" height="17" font="0">incidence of plaque, increased </text>
<text top="683" left="891" width="211" height="17" font="0">incidence of mixed plaques, moderate </text>
<text top="700" left="891" width="200" height="17" font="0">stenosis and localization primarily in </text>
<text top="718" left="891" width="166" height="17" font="0">the distal lower leg segments. </text>
<text top="735" left="891" width="7" height="18" font="7"></text>
<text top="736" left="898" width="3" height="17" font="13"> </text>
<text top="736" left="901" width="174" height="17" font="0">The advanced and noninvasive </text>
<text top="753" left="891" width="178" height="17" font="0">MDCT could be used for routine </text>
<text top="770" left="891" width="185" height="17" font="0">preoperative evaluations of LEA.  </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">31 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="344" width="187" height="17" font="0">contrast agent, liver, kidney or HF </text>
<text top="104" left="344" width="165" height="17" font="0">(Creatinine level ≥120 mol/L), </text>
<text top="122" left="344" width="197" height="17" font="0">pregnancy and leg amputation. The </text>
<text top="139" left="344" width="193" height="17" font="0">vascular exclusion criteria included </text>
<text top="156" left="344" width="208" height="17" font="0">vascular malformations, poor imaging </text>
<text top="173" left="344" width="181" height="17" font="0">and a lumen diameter &lt;1.5 mm.  </text>
<text top="87" left="581" width="294" height="17" font="0">p&lt;0.05). Regarding these plaques, pts with DM had a </text>
<text top="104" left="581" width="289" height="17" font="0">higher incidence of mixed plaques (34.2% vs. 27.1% </text>
<text top="122" left="581" width="289" height="17" font="0">for pts without DM). An increased moderate stenosis </text>
<text top="139" left="581" width="286" height="17" font="0">rate and decreased occlusion rate were observed in </text>
<text top="156" left="581" width="271" height="17" font="0">pts with DM relative to pts without DM (35.8% vs. </text>
<text top="173" left="581" width="293" height="17" font="0">28.3%; and 6.6% vs. 11.4%; respectively). In pts with </text>
<text top="190" left="581" width="289" height="17" font="0">DM, 362 (53.2%) plaques were detected in the distal </text>
<text top="208" left="581" width="288" height="17" font="0">lower leg segments, whereas in pts without DM, 551 </text>
<text top="225" left="581" width="295" height="17" font="0">(64.5%) plaques were found in the proximal upper leg </text>
<text top="242" left="581" width="295" height="17" font="0">segments. The type IV plaque shape, in which the full </text>
<text top="259" left="581" width="292" height="17" font="0">lumen was involved, was detected more frequently in </text>
<text top="276" left="581" width="297" height="17" font="0">pts with DM than in pts without DM (13.1% vs. 8.2%).  </text>
<text top="294" left="86" width="78" height="17" font="0">Philip F, et al. </text>
<text top="312" left="86" width="53" height="17" font="0">2013(80) </text>
<text top="329" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23553996">23553996 </a></text>
<text top="346" left="86" width="3" height="17" font="0"> </text>
<text top="294" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="312" left="203" width="116" height="17" font="0">(retrospective cohort </text>
<text top="329" left="203" width="37" height="17" font="0">study) </text>
<text top="346" left="203" width="3" height="17" font="0"> </text>
<text top="363" left="203" width="83" height="17" font="2"><b>Size:</b> n=83 pts </text>
<text top="294" left="344" width="169" height="17" font="2"><b>Inclusion criteria:</b> MDCT and </text>
<text top="312" left="344" width="138" height="17" font="0">aortography of the pelvic </text>
<text top="329" left="344" width="223" height="17" font="0">vascularulature prior to consideration for </text>
<text top="346" left="344" width="212" height="17" font="0">transcatheter aortic valve replacement </text>
<text top="363" left="344" width="3" height="17" font="0"> </text>
<text top="381" left="344" width="133" height="17" font="2"><b>Exclusion criteria</b>: N/A </text>
<text top="296" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="295" left="587" width="6" height="18" font="7"></text>
<text top="296" left="593" width="247" height="17" font="2"><b> endpoint:</b> Localize the IPA origin, degree of </text>
<text top="313" left="581" width="289" height="17" font="0">stenosis (normal: &lt;50% stenosis or abnormal: &gt;50% </text>
<text top="330" left="581" width="248" height="17" font="0">stenosis or occlusion), normal= and extent of </text>
<text top="347" left="581" width="284" height="17" font="0">calcification, quantified using a nominal scale (0=no </text>
<text top="365" left="581" width="278" height="17" font="0">calcification, 1 ≤25%, 2=25%–50%, 3 ≥50% of the </text>
<text top="382" left="581" width="68" height="17" font="0">IPA length). </text>
<text top="399" left="581" width="3" height="17" font="0"> </text>
<text top="416" left="581" width="269" height="17" font="2"><b>Results:</b> In a pt-based analysis, the sensitivity of </text>
<text top="433" left="581" width="287" height="17" font="0">MDCT for detecting significant proximal IPA disease </text>
<text top="451" left="581" width="277" height="17" font="0">was 100% and, specificity 74%, positive predictive </text>
<text top="468" left="581" width="277" height="17" font="0">valve was 66%, and negative predictive value was </text>
<text top="485" left="581" width="273" height="17" font="0">100%. In assessing the distal IPA and cavernosal </text>
<text top="502" left="581" width="271" height="17" font="0">arteries, the sensitivity was 100%, specificity was </text>
<text top="519" left="581" width="271" height="17" font="0">64%, positive predictive value 89%, and negative </text>
<text top="537" left="581" width="277" height="17" font="0">predictive value of 100%. MDCT used significantly </text>
<text top="554" left="581" width="285" height="17" font="0">more contrast and more radiation than aortography. </text>
<text top="295" left="891" width="7" height="18" font="7"></text>
<text top="296" left="898" width="186" height="17" font="0"> Studies were read independently </text>
<text top="313" left="891" width="67" height="17" font="0">and blinded </text>
<text top="572" left="86" width="57" height="17" font="0">Kayhan A </text>
<text top="589" left="86" width="53" height="17" font="0">2012(81) </text>
<text top="606" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21345629">21345629 </a></text>
<text top="623" left="86" width="3" height="17" font="0"> </text>
<text top="572" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="589" left="203" width="75" height="17" font="0">(prospective) </text>
<text top="606" left="203" width="3" height="17" font="0"> </text>
<text top="623" left="203" width="83" height="17" font="2"><b>Size:</b> n=43 pts </text>
<text top="572" left="344" width="211" height="17" font="2"><b>Inclusion criteria:</b> pts with IC and leg </text>
<text top="589" left="344" width="178" height="17" font="0">pain, diagnosed as mild PAOD,  </text>
<text top="606" left="344" width="3" height="17" font="0"> </text>
<text top="623" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="573" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="572" left="587" width="6" height="18" font="7"></text>
<text top="573" left="593" width="152" height="17" font="2"><b> endpoint:</b> Stenotic lesions </text>
<text top="590" left="581" width="3" height="17" font="0"> </text>
<text top="607" left="581" width="271" height="17" font="2"><b>Results:</b> MDCTA detected obstructed or stenotic </text>
<text top="625" left="581" width="284" height="17" font="0">lesions in 16.8% of arteries, vs. 11.1% compared to </text>
<text top="642" left="581" width="256" height="17" font="0">DUS. When suprapopliteal arteries alone were </text>
<text top="659" left="581" width="271" height="17" font="0">considered, MDCTA detected lesions in 15.0% of </text>
<text top="676" left="581" width="269" height="17" font="0">arteries vs. 11.0% with DUS. When infrapopliteal </text>
<text top="693" left="581" width="265" height="17" font="0">arteries only were considered, MDCTA detected </text>
<text top="711" left="581" width="270" height="17" font="0">lesions in 19.6% of arteries, vs. 11.3% with DUS. </text>
<text top="728" left="581" width="278" height="17" font="0">MDCTA showed 5.7% (95% CI: 3.5%–7.9%) more </text>
<text top="745" left="581" width="285" height="17" font="0">lesions than DUS when all arteries were considered </text>
<text top="762" left="581" width="285" height="17" font="0">together, 8.3% (95% CI: 4.6%–12.0%) more lesions </text>
<text top="572" left="891" width="7" height="18" font="7"></text>
<text top="573" left="898" width="192" height="17" font="0"> 40-row MDCTA may be used as a </text>
<text top="590" left="891" width="197" height="17" font="0">screening tool in pts with mild lower </text>
<text top="607" left="891" width="208" height="17" font="0">extremity PAOD as it is a noninvasive </text>
<text top="625" left="891" width="188" height="17" font="0">and more accurate modality when </text>
<text top="642" left="891" width="108" height="17" font="0">compared to DUS.  </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">32 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="581" width="289" height="17" font="0">when only the infrapopliteal arteries were compared, </text>
<text top="104" left="581" width="283" height="17" font="0">and 4.0% (95% CI: 1.3%–6.8%) more lesions when </text>
<text top="122" left="581" width="284" height="17" font="0">only suprapopliteal arteries were compared (p&lt;0.01 </text>
<text top="139" left="581" width="118" height="17" font="0">for all comparisons).  </text>
<text top="157" left="86" width="86" height="17" font="0">Joshi SB, et al. </text>
<text top="174" left="86" width="53" height="17" font="0">2009(82) </text>
<text top="191" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20083076">20083076 </a></text>
<text top="208" left="86" width="3" height="17" font="0"> </text>
<text top="157" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="174" left="203" width="82" height="17" font="0">(retrospective) </text>
<text top="191" left="203" width="3" height="17" font="0"> </text>
<text top="208" left="203" width="83" height="17" font="2"><b>Size:</b> n=37 pts </text>
<text top="157" left="344" width="197" height="17" font="2"><b>Inclusion criteria:</b> Consecutive pts </text>
<text top="174" left="344" width="212" height="17" font="0">requiring evaluation of aortoiliofemoral </text>
<text top="191" left="344" width="175" height="17" font="0">anatomy prior to cardiovascular </text>
<text top="208" left="344" width="204" height="17" font="0">procedures (pts being considered for </text>
<text top="226" left="344" width="218" height="17" font="0">percutaneous aortic valve intervention.) </text>
<text top="243" left="344" width="3" height="17" font="0"> </text>
<text top="260" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="158" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="157" left="587" width="6" height="18" font="7"></text>
<text top="158" left="593" width="256" height="17" font="2"><b> endpoint:</b> Conventional angiographic and CT </text>
<text top="175" left="581" width="261" height="17" font="0">images were analyzed independently to assess </text>
<text top="192" left="581" width="293" height="17" font="0">suitability for large bore (7 mm diameter) intra-arterial </text>
<text top="210" left="581" width="96" height="17" font="0">catheter access.  </text>
<text top="227" left="581" width="3" height="17" font="0"> </text>
<text top="244" left="581" width="292" height="17" font="2"><b>Results:</b> Excellent CT image quality was achieved in </text>
<text top="261" left="581" width="281" height="17" font="0">34 of 37 pts (92%). The mean contrast dose for CT </text>
<text top="278" left="581" width="256" height="17" font="0">was 12±2 mL. In 9 pts (24%), CT changed the </text>
<text top="296" left="581" width="226" height="17" font="0">assessment of femoral access feasibility. </text>
<text top="313" left="581" width="270" height="17" font="0">Furthermore, in another 7 pts (19%), unfavorable </text>
<text top="330" left="581" width="293" height="17" font="0">anatomy as shown by CT directed the avoidance of a </text>
<text top="347" left="581" width="256" height="17" font="0">particular side. Overall, CT findings altered the </text>
<text top="365" left="581" width="224" height="17" font="0">interventional approach in 16 pts (43%).  </text>
<text top="157" left="891" width="7" height="18" font="7"></text>
<text top="158" left="898" width="162" height="17" font="0"> Purpose was to evaluate the </text>
<text top="175" left="891" width="209" height="17" font="0">feasibility of using ultra-low-dose intra-</text>
<text top="192" left="891" width="214" height="17" font="0">arterial contrast injection for iliofemoral </text>
<text top="210" left="891" width="198" height="17" font="0">CT angiography to follow diagnostic </text>
<text top="227" left="891" width="133" height="17" font="0">cardiac catheterization.  </text>
<text top="244" left="891" width="7" height="18" font="7"></text>
<text top="245" left="898" width="191" height="17" font="0"> 0 to 15 mL of contrast diluted with </text>
<text top="262" left="891" width="176" height="17" font="0">normal saline was injected intra-</text>
<text top="280" left="891" width="215" height="17" font="0">arterially via the pigtail catheter while a </text>
<text top="297" left="891" width="200" height="17" font="0">spiral CT of the abdomen and pelvis </text>
<text top="314" left="891" width="79" height="17" font="0">was acquired  </text>
<text top="331" left="891" width="7" height="18" font="7"></text>
<text top="332" left="898" width="139" height="17" font="0"> There was no significant </text>
<text top="350" left="891" width="213" height="17" font="0">deterioration detected in renal function </text>
<text top="367" left="891" width="194" height="17" font="0">after coronary and CT angiography </text>
<text top="384" left="891" width="193" height="17" font="0">(estimated glomerular filtration rate </text>
<text top="401" left="891" width="188" height="17" font="0">54.8±3.8 mL/min before 53.3±3.9 </text>
<text top="418" left="891" width="128" height="17" font="0">mL/min after, p=0.55).  </text>
<text top="436" left="86" width="102" height="17" font="0">Mesurolle B, et al. </text>
<text top="454" left="86" width="53" height="17" font="0">2004(83) </text>
<text top="471" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15246474">15246474 </a></text>
<text top="488" left="86" width="3" height="17" font="0"> </text>
<text top="436" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="454" left="203" width="75" height="17" font="0">(prospective) </text>
<text top="471" left="203" width="3" height="17" font="0"> </text>
<text top="488" left="203" width="83" height="17" font="2"><b>Size:</b> n=16 pts </text>
<text top="436" left="344" width="223" height="17" font="2"><b>Inclusion criteria:</b> In the assessment of </text>
<text top="454" left="344" width="215" height="17" font="0">occlusive arterial disease of abdominal </text>
<text top="471" left="344" width="178" height="17" font="0">aorta and the lower extremities.  </text>
<text top="488" left="344" width="3" height="17" font="0"> </text>
<text top="505" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="437" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="436" left="587" width="6" height="18" font="7"></text>
<text top="437" left="593" width="269" height="17" font="2"><b> endpoint:</b> Sensitivity and specificity vs. catheter </text>
<text top="455" left="581" width="71" height="17" font="0">angiography </text>
<text top="472" left="581" width="3" height="17" font="0"> </text>
<text top="489" left="581" width="276" height="17" font="2"><b>Results:</b> Overall sensitivity of helical CT was 91% </text>
<text top="506" left="581" width="267" height="17" font="0">and specificity 93%. Segmental analysis found a </text>
<text top="524" left="581" width="267" height="17" font="0">sensitivity of 43% in infrapopliteal arteries, and a </text>
<text top="541" left="581" width="293" height="17" font="0">specificity of 86%. elical CT was inconclusive in 6.2% </text>
<text top="558" left="581" width="287" height="17" font="0">of segments whereas angiography was inconclusive </text>
<text top="575" left="581" width="286" height="17" font="0">in 5%. Overall sensitivity of helical CT was 91% and </text>
<text top="593" left="581" width="243" height="17" font="0">specificity 93%. Segmental analysis found a </text>
<text top="610" left="581" width="267" height="17" font="0">sensitivity of 43% in infrapopliteal arteries, and a </text>
<text top="628" left="581" width="109" height="17" font="0">specificity of 86%.  </text>
<text top="436" left="891" width="7" height="18" font="7"></text>
<text top="437" left="898" width="204" height="17" font="0"> 16 pts underwent both transcatheter </text>
<text top="455" left="891" width="157" height="17" font="0">angiography and helical CT  </text>
<text top="647" left="86" width="97" height="17" font="0">Romano M, et al. </text>
<text top="664" left="86" width="53" height="17" font="0">2004(84) </text>
<text top="682" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15145492">15145492 </a></text>
<text top="699" left="86" width="3" height="17" font="0"> </text>
<text top="647" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="664" left="203" width="75" height="17" font="0">(prospective) </text>
<text top="682" left="203" width="3" height="17" font="0"> </text>
<text top="699" left="203" width="87" height="17" font="2"><b>Size:</b> n=42 pts  </text>
<text top="647" left="344" width="209" height="17" font="2"><b>Inclusion criteria:</b> Untreated pts with </text>
<text top="664" left="344" width="211" height="17" font="0">peripheral vascular occlusive disease  </text>
<text top="682" left="344" width="3" height="17" font="0"> </text>
<text top="699" left="344" width="206" height="17" font="2"><b>Exclusion criteria:</b> Pts with previous </text>
<text top="716" left="344" width="215" height="17" font="0">radiological interventions or surgery for </text>
<text top="733" left="344" width="189" height="17" font="0">their peripheral vascular occlusive </text>
<text top="750" left="344" width="49" height="17" font="0">disease  </text>
<text top="768" left="344" width="3" height="17" font="0"> </text>
<text top="648" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="647" left="587" width="6" height="18" font="7"></text>
<text top="648" left="593" width="273" height="17" font="2"><b> endpoint:</b> Sensitivity and specificity of 4 channel </text>
<text top="665" left="581" width="293" height="17" font="0">MDCTA of the abdominal aorta and lower extremities </text>
<text top="683" left="581" width="163" height="17" font="0">arteries compared with DSA.  </text>
<text top="700" left="581" width="3" height="17" font="0"> </text>
<text top="717" left="581" width="293" height="17" font="2"><b>Results:</b> Overall sensitivity and specificity of MDCTA </text>
<text top="734" left="581" width="269" height="17" font="0">were 93 and 95%, respectively, with positive and </text>
<text top="752" left="581" width="273" height="17" font="0">negative predictive values of 90 and 97%. Overall </text>
<text top="769" left="581" width="252" height="17" font="0">diagnostic accuracy was 94%. Normal arterial </text>
<text top="647" left="891" width="24" height="17" font="0">N/A </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">33 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="581" width="256" height="17" font="0">segments and 100% occlusions were correctly </text>
<text top="104" left="581" width="294" height="17" font="0">identified in all cases by MDCTA. Moderately stenotic </text>
<text top="122" left="581" width="290" height="17" font="0">segments interpretation in the calves appeared to be </text>
<text top="139" left="581" width="270" height="17" font="0">more controversial, but no statistical difference in </text>
<text top="156" left="581" width="259" height="17" font="0">accuracy of MDCTA in the infrapopliteal district </text>
<text top="173" left="581" width="273" height="17" font="0">arteries was noted with respect to accuracy in the </text>
<text top="190" left="581" width="249" height="17" font="0">more proximal arterial bed. Good to excellent </text>
<text top="208" left="581" width="267" height="17" font="0">interobserver and intraobserver agreement were </text>
<text top="225" left="581" width="235" height="17" font="0">observed, with k values greater than 0.80.  </text>
<text top="243" left="86" width="92" height="17" font="0">Martin ML, et al. </text>
<text top="260" left="86" width="53" height="17" font="0">2003(85) </text>
<text top="277" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12646460">12646460 </a></text>
<text top="294" left="86" width="3" height="17" font="0"> </text>
<text top="243" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="260" left="203" width="75" height="17" font="0">(prospective) </text>
<text top="277" left="203" width="3" height="17" font="0"> </text>
<text top="294" left="203" width="83" height="17" font="2"><b>Size:</b> n=41 pts </text>
<text top="243" left="344" width="220" height="17" font="2"><b>Inclusion criteria:</b> Pts referred for DSA </text>
<text top="260" left="344" width="219" height="17" font="0">of the lower extremities for investigation </text>
<text top="277" left="344" width="222" height="17" font="0">of sx atherosclerotic disease of the legs  </text>
<text top="294" left="344" width="3" height="17" font="0"> </text>
<text top="312" left="344" width="199" height="17" font="2"><b>Exclusion criteria:</b> Elevated serum </text>
<text top="329" left="344" width="201" height="17" font="0">creatinine (&gt;120 micro mol/L) levels, </text>
<text top="346" left="344" width="199" height="17" font="0">allergy to contrast material, or acute </text>
<text top="363" left="344" width="174" height="17" font="0">limb-threatening ischemia were </text>
<text top="381" left="344" width="196" height="17" font="0">excluded. Because pts under- went </text>
<text top="398" left="344" width="180" height="17" font="0">MDCT angiography and DSA on </text>
<text top="415" left="344" width="220" height="17" font="0">different days, potential candidates who </text>
<text top="432" left="344" width="205" height="17" font="0">lived more than 1 H from our hospital </text>
<text top="449" left="344" width="141" height="17" font="0">were not asked to enroll.  </text>
<text top="244" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="243" left="587" width="6" height="18" font="7"></text>
<text top="244" left="593" width="255" height="17" font="2"><b> endpoint:</b> Sensitivity and specificity of MDCT </text>
<text top="261" left="581" width="258" height="17" font="0">angiography in showing arterial occlusions and </text>
<text top="278" left="581" width="275" height="17" font="0">stenoses of ≥75%. Intertechnique agreement was </text>
<text top="296" left="581" width="237" height="17" font="0">measured for each anatomic segment, and </text>
<text top="313" left="581" width="267" height="17" font="0">interobserver agreement was calculated for both </text>
<text top="330" left="581" width="265" height="17" font="0">techniques. Agreement was quantified using the </text>
<text top="347" left="581" width="88" height="17" font="0">kappa statistic.  </text>
<text top="365" left="581" width="3" height="17" font="0"> </text>
<text top="382" left="581" width="267" height="17" font="2"><b>Results:</b> The sensitivity and specificity of MDCT </text>
<text top="399" left="581" width="267" height="17" font="0">angiography for depicting arterial occlusions and </text>
<text top="416" left="581" width="295" height="17" font="0">stenoses of at least 75% were 88.6% and 97.7%, and </text>
<text top="433" left="581" width="240" height="17" font="0">92.2% and 96.8%, respectively. Substantial </text>
<text top="451" left="581" width="286" height="17" font="0">intertechnique agreement (kappa &gt;0.4) was present </text>
<text top="468" left="581" width="287" height="17" font="0">in 102 (97.1%) of 105 arterial segments. Substantial </text>
<text top="485" left="581" width="290" height="17" font="0">interobserver agreement was present in 104 (99.0%) </text>
<text top="502" left="581" width="290" height="17" font="0">of 105 comparisons for both MDCT angiography and </text>
<text top="519" left="581" width="291" height="17" font="0">DSA with an average kappa value of 0.84 for CT and </text>
<text top="537" left="581" width="265" height="17" font="0">0.78 for DSA. MDCT angiography showed more </text>
<text top="554" left="581" width="277" height="17" font="0">patent segments than DSA (1,192 vs. 1,091). All 9 </text>
<text top="571" left="581" width="263" height="17" font="0">segments seen on DSA and not seen on MDCT </text>
<text top="588" left="581" width="274" height="17" font="0">angiography were in the calves. Of 110 segments </text>
<text top="605" left="581" width="281" height="17" font="0">seen on MDCT angiography and not seen on DSA, </text>
<text top="623" left="581" width="179" height="17" font="0">100 (90.9%) were in the calves.  </text>
<text top="243" left="891" width="7" height="18" font="7"></text>
<text top="244" left="898" width="202" height="17" font="0"> MDCT angiography was accurate in </text>
<text top="261" left="891" width="178" height="17" font="0">showing arterial atheroocclusive </text>
<text top="278" left="891" width="207" height="17" font="0">disease with reliability similar to DSA. </text>
<text top="296" left="891" width="187" height="17" font="0">MDCT angiography showed more </text>
<text top="313" left="891" width="165" height="17" font="0">vascular segments than DSA, </text>
<text top="330" left="891" width="172" height="17" font="0">particularly within calf vessels.  </text>
<text top="641" left="86" width="89" height="17" font="0">Andreucci M, et </text>
<text top="658" left="86" width="16" height="17" font="0">al. </text>
<text top="675" left="86" width="53" height="17" font="0">2014(86) </text>
<text top="692" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24895606">24895606</a></text>
<text top="692" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24895606"> </a></text>
<text top="710" left="86" width="3" height="17" font="0"> </text>
<text top="641" left="203" width="121" height="17" font="2"><b>Study type:</b> A review </text>
<text top="658" left="203" width="117" height="17" font="0">of the evidence base </text>
<text top="675" left="203" width="125" height="17" font="0">for the adverse effects </text>
<text top="692" left="203" width="87" height="17" font="0">associated with </text>
<text top="710" left="203" width="118" height="17" font="0">radiographic contrast </text>
<text top="727" left="203" width="38" height="17" font="0">drugs. </text>
<text top="744" left="203" width="3" height="17" font="0"> </text>
<text top="761" left="203" width="56" height="17" font="2"><b>Size:</b> N/A<b> </b></text>
<text top="641" left="344" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="658" left="344" width="3" height="17" font="0"> </text>
<text top="675" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="642" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="641" left="587" width="6" height="18" font="7"></text>
<text top="642" left="593" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="659" left="581" width="3" height="17" font="0"> </text>
<text top="676" left="581" width="52" height="17" font="2"><b>Results: </b></text>
<text top="693" left="581" width="7" height="18" font="7"></text>
<text top="694" left="587" width="243" height="17" font="0"> Monitor renal functions for contrast-induced </text>
<text top="712" left="581" width="72" height="17" font="0">nephropathy </text>
<text top="729" left="581" width="7" height="18" font="7"></text>
<text top="730" left="587" width="274" height="17" font="0"> Nephrotoxic meds should be discontinued before </text>
<text top="747" left="581" width="127" height="17" font="0">contrast administration </text>
<text top="765" left="581" width="7" height="18" font="7"></text>
<text top="766" left="587" width="254" height="17" font="0"> Either nonionic iso-osmolar contrast media or </text>
<text top="641" left="891" width="7" height="18" font="7"></text>
<text top="642" left="898" width="167" height="17" font="0"> Important side effects include </text>
<text top="659" left="891" width="185" height="17" font="0">hypersensitivity reactions, thyroid </text>
<text top="676" left="891" width="184" height="17" font="0">dysfunction and contrast-induced </text>
<text top="693" left="891" width="72" height="17" font="0">nephropathy </text>
<text top="711" left="891" width="7" height="18" font="7"></text>
<text top="712" left="898" width="185" height="17" font="0"> The knowledge and screening of </text>
<text top="729" left="891" width="215" height="17" font="0">side effects can allow appreciation and </text>
<text top="746" left="891" width="148" height="17" font="0">then prompt management. </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">34 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="581" width="257" height="17" font="0">nonionic low-osmolar contrast media use to be </text>
<text top="104" left="581" width="44" height="17" font="0">favored </text>
<text top="122" left="581" width="7" height="18" font="7"></text>
<text top="123" left="587" width="137" height="17" font="0"> Lowest dose to be used </text>
<text top="140" left="581" width="7" height="18" font="7"></text>
<text top="141" left="587" width="172" height="17" font="0"> Fluid intake to be encouraged. </text>
<text top="158" left="581" width="7" height="18" font="7"></text>
<text top="159" left="587" width="224" height="17" font="0"> In high-risk pts N-acetylcysteine may be </text>
<text top="177" left="581" width="77" height="17" font="0">administered.<b> </b></text>
<text top="195" left="86" width="82" height="17" font="0">Stacul F, et al. </text>
<text top="212" left="86" width="53" height="17" font="0">2011(87) </text>
<text top="229" left="86" width="55" height="17" font="6"><a href="mailto:http://www.ncbi.nlm.nih.gov/pubmed/21866433">21866433</a></text>
<text top="229" left="141" width="3" height="17" font="0"><a href="mailto:http://www.ncbi.nlm.nih.gov/pubmed/21866433"> </a></text>
<text top="195" left="203" width="74" height="17" font="2"><b>Study type:</b>  </text>
<text top="212" left="203" width="3" height="17" font="0"> </text>
<text top="229" left="203" width="56" height="17" font="2"><b>Size:</b> N/A<b> </b></text>
<text top="195" left="344" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="212" left="344" width="3" height="17" font="0"> </text>
<text top="229" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="196" left="581" width="7" height="17" font="2"><b>1</b></text>
<text top="195" left="587" width="6" height="18" font="7"></text>
<text top="196" left="593" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="213" left="581" width="3" height="17" font="0"> </text>
<text top="230" left="581" width="52" height="17" font="2"><b>Results: </b></text>
<text top="248" left="581" width="7" height="18" font="7"></text>
<text top="249" left="587" width="27" height="17" font="0"> N/A<b> </b></text>
<text top="266" left="581" width="3" height="17" font="2"><b> </b></text>
<text top="195" left="891" width="7" height="18" font="7"></text>
<text top="196" left="898" width="158" height="17" font="0"> Topics reviewed include the </text>
<text top="213" left="891" width="215" height="17" font="0">definition of CIN, the choice of contrast </text>
<text top="230" left="891" width="198" height="17" font="0">medium, the prophylactic measures </text>
<text top="248" left="891" width="202" height="17" font="0">used to reduce the incidence of CIN, </text>
<text top="265" left="891" width="206" height="17" font="0">and the management of pts receiving </text>
<text top="282" left="891" width="58" height="17" font="0">metformin </text>
<text top="300" left="80" width="998" height="17" font="0">ABI indicates ankle-brachial index; CE-MRA, contrast-enhanced MRA; CI, confidence interval; CT, computed tomography; DM, diabetes mellitus; DSA, digital subtraction angiography; </text>
<text top="317" left="80" width="979" height="17" font="0">DSCT, dual source computed tomography; DUS, duplex ultrasonography; IC, intermittent claudication; IPA, internal pudendal artery; LEA, lower extremity atherosclerosis; MDCTA, </text>
<text top="334" left="80" width="1011" height="17" font="0">multidetector computed tomography angiography; MDCT, multidetector computed tomography; N/A, not applicable; NR, nonrandomized; NPV, negative predictive value; PAD, peripheral </text>
<text top="351" left="80" width="891" height="17" font="0">artery disease; PAOD, peripheral arterial occlusive disease; PPV, positive predictive value; pt, patient; and WBMRA, whole-body magnetic resonance angiography. </text>
<text top="369" left="86" width="3" height="17" font="0"> </text>
<text top="386" left="86" width="3" height="17" font="0"> </text>
<text top="403" left="80" width="797" height="21" font="1"><b>Evidence Table 7. RCTs of Imaging for Anatomic Assessment (Ultrasound, CTA, MRA, Angiography)–Section 3.3. </b></text>
<text top="425" left="89" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="442" left="115" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="459" left="93" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="425" left="225" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="442" left="230" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="459" left="224" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="425" left="377" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="425" left="569" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="442" left="587" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="459" left="569" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="476" left="590" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="425" left="785" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="442" left="732" width="210" height="17" font="2"><b>(Absolute Event Rates, P value; OR </b></text>
<text top="459" left="787" width="101" height="17" font="2"><b>or RR; &amp; 95% CI) </b></text>
<text top="426" left="969" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="425" left="1031" width="6" height="18" font="7"></text>
<text top="426" left="1037" width="63" height="17" font="2"><b> Endpoint  </b></text>
<text top="443" left="1009" width="48" height="17" font="2"><b>(if any); </b></text>
<text top="460" left="978" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="477" left="985" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="495" left="88" width="92" height="17" font="0">Meyer BC, et al. </text>
<text top="512" left="88" width="56" height="17" font="0">2012 (88) </text>
<text top="530" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22473508">22473508 </a></text>
<text top="547" left="88" width="3" height="17" font="0"> </text>
<text top="495" left="203" width="116" height="17" font="2"><b>Aim:</b> Compare a CB </text>
<text top="512" left="203" width="128" height="17" font="0">injection protocol using </text>
<text top="530" left="203" width="64" height="17" font="0">high-iodine </text>
<text top="547" left="203" width="124" height="17" font="0">concentration contrast </text>
<text top="564" left="203" width="103" height="17" font="0">medium with a SB </text>
<text top="581" left="203" width="109" height="17" font="0">injection protocol at </text>
<text top="599" left="203" width="118" height="17" font="0">equi-iodine doses for </text>
<text top="616" left="203" width="70" height="17" font="0">run-off CTA. </text>
<text top="633" left="203" width="3" height="17" font="0"> </text>
<text top="650" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="667" left="203" width="95" height="17" font="0">prospective RCT </text>
<text top="685" left="203" width="3" height="17" font="0"> </text>
<text top="702" left="203" width="83" height="17" font="2"><b>Size:</b> n=83 pts </text>
<text top="495" left="344" width="168" height="17" font="2"><b>Inclusion criteria:</b> 64 pts with </text>
<text top="512" left="344" width="175" height="17" font="0">suspected PAD who underwent </text>
<text top="530" left="344" width="144" height="17" font="0">40 or 64-slice run-off CTA </text>
<text top="547" left="344" width="3" height="17" font="0"> </text>
<text top="564" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="495" left="533" width="170" height="17" font="2"><b>Intervention:</b> The CB protocol </text>
<text top="512" left="533" width="163" height="17" font="0">(32 pts, iomeprol 400mgI/mL, </text>
<text top="530" left="533" width="109" height="17" font="0">100 mL, 4 mL/sec)  </text>
<text top="547" left="533" width="3" height="17" font="0"> </text>
<text top="564" left="533" width="169" height="17" font="2"><b>Comparator: </b>The SB protocol </text>
<text top="581" left="533" width="167" height="17" font="0">(32 pts, iomeprol 300 mgI/mL, </text>
<text top="599" left="533" width="112" height="17" font="0">134 mL, 4 mL/sec). <b> </b></text>
<text top="496" left="729" width="7" height="17" font="2"><b>1</b></text>
<text top="495" left="736" width="6" height="18" font="7"></text>
<text top="496" left="742" width="200" height="17" font="2"><b> endpoint:</b> Luminal CD values were </text>
<text top="514" left="729" width="214" height="17" font="0">measured and AO was scored (5-point </text>
<text top="531" left="729" width="170" height="17" font="0">scale). Overall arterial CD was </text>
<text top="548" left="729" width="200" height="17" font="0">significantly higher with the compact </text>
<text top="565" left="729" width="151" height="17" font="0">bolus (CB: 279±57HU, SB: </text>
<text top="583" left="729" width="213" height="17" font="0">234±32HU, p=0.0017). Segmental CD </text>
<text top="600" left="729" width="216" height="17" font="0">was significantly higher (p&lt;0.05) in 7 of </text>
<text top="617" left="729" width="183" height="17" font="0">16 evaluated segments. Patency-</text>
<text top="634" left="729" width="202" height="17" font="0">based comparison revealed superior </text>
<text top="651" left="729" width="187" height="17" font="0">AO in vessels with relevant (50%–</text>
<text top="669" left="729" width="213" height="17" font="0">99%) stenoses (CB: 4.54 vs. SB: 4.18; </text>
<text top="686" left="729" width="189" height="17" font="0">p=0.04). Contrast bolus overriding </text>
<text top="703" left="729" width="185" height="17" font="0">without pathological reasons, i.e., </text>
<text top="720" left="729" width="207" height="17" font="0">acute occlusions, was noted in 1 pt in </text>
<text top="737" left="729" width="182" height="17" font="0">each group. Venous overlay was </text>
<text top="755" left="729" width="191" height="17" font="0">observed less frequently in the CB </text>
<text top="772" left="729" width="202" height="17" font="0">group (CB vs. SB: 12 vs. 19 pts, NS; </text>
<text top="495" left="959" width="7" height="18" font="7"></text>
<text top="496" left="965" width="142" height="17" font="0"> At equi-iodine doses, the </text>
<text top="514" left="959" width="111" height="17" font="0">CB protocol led to a </text>
<text top="531" left="959" width="99" height="17" font="0">quantitatively and </text>
<text top="548" left="959" width="127" height="17" font="0">qualitatively higher AO </text>
<text top="565" left="959" width="112" height="17" font="0">compared to the SB </text>
<text top="583" left="959" width="142" height="17" font="0">protocol. Therefore, a CB </text>
<text top="600" left="959" width="148" height="17" font="0">protocol should be favored </text>
<text top="617" left="959" width="88" height="17" font="0">for run-off CTA. </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">35 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="729" width="202" height="17" font="0">29 of 64 legs [45%] vs. 44 of 64 legs </text>
<text top="104" left="729" width="87" height="17" font="0">[69%]; p=0.01). </text>
<text top="122" left="88" width="81" height="17" font="0">Fraioli F, et al. </text>
<text top="139" left="88" width="53" height="17" font="0">2006(89) </text>
<text top="157" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15988586">15988586 </a></text>
<text top="174" left="88" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="105" height="17" font="2"><b>Aim:</b> Compare the </text>
<text top="139" left="203" width="117" height="17" font="0">influence of radiation </text>
<text top="157" left="203" width="123" height="17" font="0">dose on image quality </text>
<text top="174" left="203" width="83" height="17" font="0">and diagnostic </text>
<text top="191" left="203" width="118" height="17" font="0">accuracy of low dose </text>
<text top="208" left="203" width="111" height="17" font="0">MDCT with DSA for </text>
<text top="226" left="203" width="87" height="17" font="0">the detection of </text>
<text top="243" left="203" width="112" height="17" font="0">aortoiliac and PAD.  </text>
<text top="260" left="203" width="3" height="17" font="0"> </text>
<text top="277" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="294" left="203" width="3" height="17" font="0"> </text>
<text top="312" left="203" width="83" height="17" font="2"><b>Size:</b> n=75 pts </text>
<text top="122" left="344" width="171" height="17" font="2"><b>Inclusion criteria:</b> Onsecutive </text>
<text top="139" left="344" width="131" height="17" font="0">pts, with a clinical Dx of </text>
<text top="157" left="344" width="163" height="17" font="0">obstructive arterial disease of </text>
<text top="174" left="344" width="144" height="17" font="0">the extremities underwent </text>
<text top="191" left="344" width="176" height="17" font="0">MDCT angiography of the aorta </text>
<text top="208" left="344" width="130" height="17" font="0">and peripheral vessels. </text>
<text top="226" left="344" width="3" height="17" font="0"> </text>
<text top="243" left="344" width="146" height="17" font="2"><b>Exclusion criteria:</b> Renal </text>
<text top="260" left="344" width="169" height="17" font="0">insufficiency (serum creatinine </text>
<text top="277" left="344" width="166" height="17" font="0">&gt;2 mg/dl), contra-indication to </text>
<text top="294" left="344" width="166" height="17" font="0">iodinated contrast, respiratory </text>
<text top="312" left="344" width="171" height="17" font="0">failure, congestive heart failure </text>
<text top="329" left="344" width="163" height="17" font="0">and poor general condition of </text>
<text top="346" left="344" width="41" height="17" font="0">the pt.  </text>
<text top="122" left="533" width="178" height="17" font="2"><b>Intervention:</b> Pt population was </text>
<text top="139" left="533" width="151" height="17" font="0">randomly divided into three </text>
<text top="157" left="533" width="177" height="17" font="0">groups of 25 pts. In each group, </text>
<text top="174" left="533" width="157" height="17" font="0">MDCT scanning parameters </text>
<text top="191" left="533" width="167" height="17" font="0">were kept constant, except for </text>
<text top="208" left="533" width="55" height="17" font="0">the mAs.  </text>
<text top="226" left="533" width="3" height="17" font="0"> </text>
<text top="243" left="533" width="165" height="17" font="2"><b>Comparator:</b> 50 mAs vs. 100 </text>
<text top="260" left="533" width="99" height="17" font="0">mAs vs. 130 mAs<b> </b></text>
<text top="123" left="729" width="7" height="17" font="2"><b>1</b></text>
<text top="122" left="736" width="6" height="18" font="7"></text>
<text top="123" left="742" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="141" left="729" width="7" height="18" font="7"></text>
<text top="142" left="736" width="3" height="17" font="13"> </text>
<text top="142" left="739" width="180" height="17" font="0">The dose reduction was 74% for </text>
<text top="159" left="729" width="170" height="17" font="0">group A and 40% for group B.  </text>
<text top="176" left="729" width="7" height="18" font="7"></text>
<text top="177" left="736" width="3" height="17" font="13"> </text>
<text top="177" left="739" width="196" height="17" font="0">The evaluation of the presence and </text>
<text top="195" left="729" width="169" height="17" font="0">degree of stenoses revealed a </text>
<text top="212" left="729" width="204" height="17" font="0">sensitivity, specificity, accuracy, PPV </text>
<text top="229" left="729" width="213" height="17" font="0">and NPV of 96%, 94%, 95%, 83% and </text>
<text top="246" left="729" width="215" height="17" font="0">99% for Group A (50 mAs), 96%, 96%, </text>
<text top="264" left="729" width="206" height="17" font="0">96%, 89% and 99% for Group B (100 </text>
<text top="281" left="729" width="202" height="17" font="0">mAs) and 98%, 96%, 97%, 91% and </text>
<text top="298" left="729" width="205" height="17" font="0">100% for the standard dose protocol, </text>
<text top="315" left="729" width="117" height="17" font="0">Group C (130 mAs). <b> </b></text>
<text top="122" left="959" width="7" height="18" font="7"></text>
<text top="123" left="965" width="10" height="17" font="13"> L</text>
<text top="123" left="976" width="115" height="17" font="0">ow-dose scanning is </text>
<text top="141" left="959" width="107" height="17" font="0">thus a feasible and </text>
<text top="158" left="959" width="140" height="17" font="0">accurate option for 4-row </text>
<text top="175" left="959" width="125" height="17" font="0">CT angiography of the </text>
<text top="192" left="959" width="109" height="17" font="0">peripheral vessels.  </text>
<text top="210" left="959" width="7" height="18" font="7"></text>
<text top="211" left="965" width="3" height="17" font="13"> </text>
<text top="211" left="969" width="133" height="17" font="0">This technique provides </text>
<text top="228" left="959" width="130" height="17" font="0">substantial reduction of </text>
<text top="245" left="959" width="101" height="17" font="0">the radiation dose </text>
<text top="262" left="959" width="133" height="17" font="0">delivered to the pt while </text>
<text top="280" left="959" width="109" height="17" font="0">maintaining optimal </text>
<text top="297" left="959" width="118" height="17" font="0">diagnostic accuracy.  </text>
<text top="314" left="959" width="3" height="17" font="0"> </text>
<text top="364" left="88" width="73" height="17" font="0">Met R, et al.  </text>
<text top="381" left="88" width="53" height="17" font="0">2009(90) </text>
<text top="398" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19176443">19176443 </a></text>
<text top="416" left="88" width="3" height="17" font="0"> </text>
<text top="364" left="203" width="127" height="17" font="2"><b>Aim:</b> To determine the </text>
<text top="381" left="203" width="94" height="17" font="0">accuracy of CTA </text>
<text top="398" left="203" width="112" height="17" font="0">compared with intra-</text>
<text top="416" left="203" width="83" height="17" font="0">arterial DSA in </text>
<text top="433" left="203" width="128" height="17" font="0">differentiating extent of </text>
<text top="450" left="203" width="104" height="17" font="0">disease in pts with </text>
<text top="467" left="203" width="29" height="17" font="0">PAD<b> </b></text>
<text top="485" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="502" left="203" width="102" height="17" font="2"><b>Study type: </b>Meta-</text>
<text top="519" left="203" width="48" height="17" font="0">analysis<b> </b></text>
<text top="536" left="203" width="79" height="17" font="0">CTA vs. DSA  </text>
<text top="553" left="203" width="3" height="17" font="0"> </text>
<text top="571" left="203" width="113" height="17" font="2"><b>Size:</b> n=909 studies </text>
<text top="364" left="344" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="381" left="344" width="7" height="18" font="7"></text>
<text top="382" left="351" width="160" height="17" font="0"> Reviews of effectiveness for </text>
<text top="400" left="344" width="157" height="17" font="0">studies comparing CTA with </text>
<text top="417" left="344" width="144" height="17" font="0">intra-arterial DSA for PAD </text>
<text top="434" left="344" width="7" height="18" font="7"></text>
<text top="435" left="351" width="166" height="17" font="0"> Compared multidetector CTA </text>
<text top="452" left="344" width="123" height="17" font="0">with intra-arterial DSA </text>
<text top="470" left="344" width="171" height="17" font="0">Included at least 10 pts with IC </text>
<text top="487" left="344" width="37" height="17" font="0">or CLI </text>
<text top="504" left="344" width="7" height="18" font="7"></text>
<text top="505" left="351" width="127" height="17" font="0"> Aimed to detect &gt;50% </text>
<text top="522" left="344" width="159" height="17" font="0">stenosis or arterial occlusion </text>
<text top="540" left="344" width="7" height="18" font="7"></text>
<text top="541" left="351" width="161" height="17" font="0"> Presented either 2 x 2 or 3 x </text>
<text top="558" left="344" width="156" height="17" font="0">3 contingency tables (≤50% </text>
<text top="575" left="344" width="166" height="17" font="0">stenosis vs. &gt;50% stenosis or </text>
<text top="593" left="344" width="154" height="17" font="0">occlusion), or provided data </text>
<text top="610" left="344" width="145" height="17" font="0">allowing their construction<b> </b></text>
<text top="627" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="644" left="344" width="131" height="17" font="2"><b>Exclusion criteria:</b> N/A</text>
<text top="645" left="475" width="2" height="11" font="11"> </text>
<text top="365" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="364" left="540" width="6" height="18" font="7"></text>
<text top="365" left="546" width="163" height="17" font="2"><b> endpoint:</b> Sensitivity of CTA </text>
<text top="382" left="533" width="139" height="17" font="0">for detecting PAD (&gt;50% </text>
<text top="400" left="533" width="53" height="17" font="0">stenosis) </text>
<text top="417" left="533" width="3" height="17" font="0"> </text>
<text top="434" left="533" width="159" height="17" font="2"><b>Results:</b> Sensitivity stenosis </text>
<text top="451" left="533" width="178" height="17" font="0">&gt;50% (95%CI: 92–9); specificity </text>
<text top="468" left="533" width="121" height="17" font="0">96%(95% CI: 93–97)  </text>
<text top="364" left="729" width="181" height="17" font="0">CTA had adequate sensitivity for </text>
<text top="381" left="729" width="82" height="17" font="0">detecting PAD </text>
<text top="364" left="959" width="24" height="17" font="0">N/A </text>
<text top="662" left="88" width="101" height="17" font="0">Favaretto E, et al. </text>
<text top="679" left="88" width="53" height="17" font="0">2007(91) </text>
<text top="697" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17443099">17443099 </a></text>
<text top="714" left="88" width="3" height="17" font="0"> </text>
<text top="662" left="203" width="115" height="17" font="2"><b>Aim:</b> Investigate the </text>
<text top="679" left="203" width="112" height="17" font="0">agreement between </text>
<text top="697" left="203" width="118" height="17" font="0">DSA in the diagnosis </text>
<text top="714" left="203" width="66" height="17" font="0">of stenosis <b> </b></text>
<text top="731" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="748" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="765" left="203" width="107" height="17" font="0">Prospective series  </text>
<text top="662" left="344" width="169" height="17" font="2"><b>Inclusion criteria:</b> Lower limb </text>
<text top="679" left="344" width="156" height="17" font="0">artery disease (claudication, </text>
<text top="697" left="344" width="133" height="17" font="0">critical ischemia, or skin </text>
<text top="714" left="344" width="46" height="17" font="0">lesions)<b> </b></text>
<text top="731" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="748" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="663" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="662" left="540" width="6" height="18" font="7"></text>
<text top="663" left="546" width="123" height="17" font="2"><b> endpoint:</b> Diagnostic </text>
<text top="680" left="533" width="174" height="17" font="0">accuracy of duplex for detected </text>
<text top="698" left="533" width="142" height="17" font="0">lesion severity of LE PAD </text>
<text top="715" left="533" width="3" height="17" font="0"> </text>
<text top="732" left="533" width="173" height="17" font="2"><b>Results:</b> Kappa=0.70; 95% CI: </text>
<text top="749" left="533" width="146" height="17" font="0">0.588–0.825 for the whole </text>
<text top="767" left="533" width="159" height="17" font="0">arterial axis. Agreement was </text>
<text top="662" left="729" width="215" height="17" font="0">The sensitivity and specificity of duplex </text>
<text top="679" left="729" width="199" height="17" font="0">compared to angiography is modest </text>
<text top="662" left="959" width="24" height="17" font="0">N/A </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">36 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="94" height="17" font="0">Duplex vs. angio </text>
<text top="104" left="203" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="83" height="17" font="2"><b>Size:</b> n=49 pts </text>
<text top="87" left="533" width="165" height="17" font="0">good for the aorto-iliac district </text>
<text top="104" left="533" width="182" height="17" font="0">(kappa=0.63) with a sensitivity of </text>
<text top="122" left="533" width="164" height="17" font="0">63% and a specificity of 96%, </text>
<text top="139" left="533" width="154" height="17" font="0">and for the femoro-popliteal </text>
<text top="156" left="533" width="151" height="17" font="0">district (kappa=0.70) with a </text>
<text top="173" left="533" width="133" height="17" font="0">sensitivity of 74% and a </text>
<text top="190" left="533" width="116" height="17" font="0">specificity of 83%. In </text>
<text top="208" left="533" width="158" height="17" font="0">infrapopliteal arteries, kappa </text>
<text top="225" left="533" width="150" height="17" font="0">showed a poor agreement. </text>
<text top="243" left="88" width="73" height="17" font="0">Kau T, et al.  </text>
<text top="260" left="88" width="56" height="17" font="0">2011 (92) </text>
<text top="277" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21365195">21365195</a></text>
<text top="277" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21365195"> </a></text>
<text top="294" left="88" width="3" height="17" font="0"> </text>
<text top="243" left="203" width="103" height="17" font="2"><b>Aim:</b> Evaluate the </text>
<text top="260" left="203" width="116" height="17" font="0">accuracy of DE-CTA </text>
<text top="277" left="203" width="105" height="17" font="0">maximum intensity </text>
<text top="294" left="203" width="66" height="17" font="0">projections <b> </b></text>
<text top="312" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="329" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="346" left="203" width="107" height="17" font="0">Prospective series  </text>
<text top="363" left="203" width="102" height="17" font="0">DE-CTA vs. angio </text>
<text top="381" left="203" width="3" height="17" font="0"> </text>
<text top="398" left="203" width="63" height="17" font="2"><b>Size:</b> n=58 </text>
<text top="243" left="344" width="168" height="17" font="2"><b>Inclusion criteria:</b> Pts with sx </text>
<text top="260" left="344" width="153" height="17" font="0">peripheral arterial occlusive </text>
<text top="277" left="344" width="46" height="17" font="0">disease<b> </b></text>
<text top="294" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="312" left="344" width="171" height="17" font="2"><b>Exclusion criteria: </b>in ability to </text>
<text top="329" left="344" width="49" height="17" font="0">get CTA </text>
<text top="244" left="533" width="7" height="17" font="2"><b>1</b></text>
<text top="243" left="540" width="6" height="18" font="7"></text>
<text top="244" left="546" width="123" height="17" font="2"><b> endpoint:</b> Diagnostic </text>
<text top="261" left="533" width="166" height="17" font="0">accuracy of DE-CTA to detect </text>
<text top="278" left="533" width="94" height="17" font="0">stenosis severity </text>
<text top="296" left="533" width="3" height="17" font="0"> </text>
<text top="313" left="533" width="150" height="17" font="2"><b>Results:</b> In DSA, 52.3% of </text>
<text top="330" left="533" width="154" height="17" font="0">segments were significantly </text>
<text top="347" left="533" width="124" height="17" font="0">stenosed or occluded. </text>
<text top="365" left="533" width="158" height="17" font="0">Agreement of DE-CTA MIPs </text>
<text top="382" left="533" width="176" height="17" font="0">with DSA was good in the aorto-</text>
<text top="399" left="533" width="140" height="17" font="0">iliac and femoro-popliteal </text>
<text top="416" left="533" width="119" height="17" font="0">regions (kappa=0.72; </text>
<text top="433" left="533" width="165" height="17" font="0">kappa=0.66), moderate in the </text>
<text top="451" left="533" width="151" height="17" font="0">crural region (kappa=0.55), </text>
<text top="468" left="533" width="123" height="17" font="0">slight in pedal arteries </text>
<text top="485" left="533" width="171" height="17" font="0">(kappa=0.10) and very good in </text>
<text top="502" left="533" width="179" height="17" font="0">bypass segments (kappa=0.81). </text>
<text top="519" left="533" width="174" height="17" font="0">Accuracy was 88%, 78%, 74%, </text>
<text top="537" left="533" width="178" height="17" font="0">55% and 82% for the respective </text>
<text top="554" left="533" width="170" height="17" font="0">territories and moderate (75%) </text>
<text top="571" left="533" width="156" height="17" font="0">overall, with good sensitivity </text>
<text top="588" left="533" width="172" height="17" font="0">(84%) and moderate specificity </text>
<text top="605" left="533" width="179" height="17" font="0">(67%). Sensitivity and specificity </text>
<text top="623" left="533" width="118" height="17" font="0">was 82% and 76% in </text>
<text top="640" left="533" width="182" height="17" font="0">claudicants and 84% and 61% in </text>
<text top="657" left="533" width="71" height="17" font="0">pts with CLI. </text>
<text top="243" left="729" width="215" height="17" font="0">DE-CTA had good diagnostic accuracy </text>
<text top="260" left="729" width="199" height="17" font="0">above the knee. Below the knee the </text>
<text top="277" left="729" width="194" height="17" font="0">diagnostic accuracy was modest at </text>
<text top="294" left="729" width="194" height="17" font="0">best and worse when arteries were </text>
<text top="312" left="729" width="51" height="17" font="0">calcified. </text>
<text top="243" left="959" width="24" height="17" font="0">N/A </text>
<text top="675" left="88" width="92" height="17" font="0">McCullough PA, </text>
<text top="692" left="88" width="53" height="17" font="0">2011(93) </text>
<text top="710" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21609484">21609484</a></text>
<text top="710" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21609484"> </a></text>
<text top="727" left="88" width="3" height="17" font="0"> </text>
<text top="675" left="203" width="100" height="17" font="2"><b>Aim:</b> To compare </text>
<text top="692" left="203" width="118" height="17" font="0">discomfort rates in pt-</text>
<text top="710" left="203" width="106" height="17" font="0">reported outcomes </text>
<text top="727" left="203" width="116" height="17" font="0">related to IOCM with </text>
<text top="744" left="203" width="39" height="17" font="0">LOCM </text>
<text top="761" left="203" width="3" height="17" font="0"> </text>
<text top="675" left="344" width="176" height="17" font="2"><b>Inclusion criteria:</b> Studies with </text>
<text top="692" left="344" width="163" height="17" font="0">intra-arterial administration of </text>
<text top="710" left="344" width="26" height="17" font="0">CM. </text>
<text top="727" left="344" width="3" height="17" font="0"> </text>
<text top="744" left="344" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="761" left="344" width="137" height="17" font="0">Studies with intravenous </text>
<text top="675" left="533" width="174" height="17" font="2"><b>Intervention:</b> IOCM (Iodixanol) </text>
<text top="692" left="533" width="42" height="17" font="0">(3,385) </text>
<text top="710" left="533" width="3" height="17" font="0"> </text>
<text top="727" left="533" width="159" height="17" font="2"><b>Comparator:</b> LOCM (4,796)<b> </b></text>
<text top="676" left="729" width="7" height="17" font="2"><b>1</b></text>
<text top="675" left="736" width="6" height="18" font="7"></text>
<text top="676" left="742" width="70" height="17" font="2"><b> endpoint:</b>   </text>
<text top="693" left="729" width="7" height="18" font="7"></text>
<text top="694" left="736" width="38" height="17" font="0"> Pain:  </text>
<text top="712" left="729" width="217" height="17" font="0">Pts receiving IOCM vs. various LOCMs </text>
<text top="729" left="729" width="208" height="17" font="0">(RD: -0.049; 95% CI: -0.076 – -0.021; </text>
<text top="746" left="729" width="204" height="17" font="0">p=0.001). IOCM was favored over all </text>
<text top="763" left="729" width="216" height="17" font="0">LOCMs combined with a summary RD: </text>
<text top="675" left="959" width="7" height="18" font="7"></text>
<text top="676" left="965" width="112" height="17" font="0"> Cold sensation: NS </text>
<text top="693" left="959" width="57" height="17" font="0">difference </text>
<text top="711" left="959" width="7" height="18" font="7"></text>
<text top="712" left="965" width="142" height="17" font="0"> IOCM was found to have </text>
<text top="729" left="959" width="138" height="17" font="0">less frequent and severe </text>
<text top="746" left="959" width="132" height="17" font="0">pain and warmth during </text>
<text top="763" left="959" width="96" height="17" font="0">administration as </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">37 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="104" left="203" width="116" height="17" font="0">analysis of pooled pt </text>
<text top="122" left="203" width="102" height="17" font="0">outcomes from 22 </text>
<text top="139" left="203" width="35" height="17" font="0">RCTs </text>
<text top="156" left="203" width="3" height="17" font="0"> </text>
<text top="173" left="203" width="80" height="17" font="2"><b>Size:</b> n=8,087 </text>
<text top="190" left="203" width="120" height="17" font="0">(discomfort, n=3,567) </text>
<text top="87" left="344" width="141" height="17" font="0">administration of contrast </text>
<text top="104" left="344" width="172" height="17" font="0">media, reviews, meta analyses </text>
<text top="87" left="729" width="175" height="17" font="0">-0.188; 95% CI: 0.265 – -0.112; </text>
<text top="104" left="729" width="129" height="17" font="0">p&lt;0.001) for incidence. </text>
<text top="122" left="729" width="7" height="18" font="7"></text>
<text top="123" left="736" width="53" height="17" font="0"> Warmth: </text>
<text top="140" left="729" width="185" height="17" font="0">IOCM favored over LOCMs, RD: -</text>
<text top="157" left="729" width="175" height="17" font="0">0.043; 95% CI: -0.074 – -0.011; </text>
<text top="174" left="729" width="52" height="17" font="0">p=0.008) </text>
<text top="87" left="959" width="111" height="17" font="0">compared to LOCM </text>
<text top="208" left="80" width="1008" height="17" font="0">AO indicates Arterial opacification; CB, compact bolus; CD, contrast density; CI, confidence interval; CLI, critical limb ischemia; CTA, computed tomographic angiography; CT, computed </text>
<text top="226" left="80" width="1015" height="17" font="0">tomography; DE-CTA, dual-energy computed tomographic angiography; DSA, digital subtraction angiography; IC, intermittent claudication; IOCM, iso-osmolar contrast media; LOCM, low-</text>
<text top="243" left="80" width="1011" height="17" font="0">osmolar contrast media; mAs, milliamperage second value; MDCT, multiple detector computed tomography; MIPs, maximum intensity projections; NS, not significant; pt, patient; RD, risk </text>
<text top="260" left="80" width="196" height="17" font="0">difference; and SB, standard bolus. </text>
<text top="277" left="80" width="3" height="17" font="0"> </text>
<text top="294" left="80" width="3" height="17" font="0"> </text>
<text top="312" left="86" width="898" height="21" font="1"><b>Evidence Table 8. Nonrandomized Trials, Observational Studies, and/or Registries for Abdominal Aortic Aneurysm–Section 4.1. </b></text>
<text top="333" left="109" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="350" left="134" width="48" height="17" font="2"><b>Author; </b></text>
<text top="367" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="333" left="247" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="350" left="273" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="333" left="416" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="333" left="612" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="350" left="620" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="367" left="672" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="333" left="914" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="350" left="942" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="385" left="95" width="83" height="17" font="0">Sultan S, et al. </text>
<text top="403" left="95" width="53" height="17" font="0">2013(94)<b> </b></text>
<text top="420" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23711680">23711680 </a></text>
<text top="437" left="95" width="3" height="17" font="0"> </text>
<text top="385" left="234" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="403" left="234" width="126" height="17" font="0">sectional single-center </text>
<text top="420" left="234" width="33" height="17" font="0">study </text>
<text top="437" left="234" width="3" height="17" font="0"> </text>
<text top="454" left="234" width="126" height="17" font="2"><b>Size:</b> 328 pts having a </text>
<text top="472" left="234" width="134" height="17" font="0">vascular intervention for </text>
<text top="489" left="234" width="118" height="17" font="0">PAD, AAA, or carotid </text>
<text top="506" left="234" width="49" height="17" font="0">disease  </text>
<text top="385" left="391" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="403" left="391" width="159" height="17" font="0">Intervention for 1 of the PVD </text>
<text top="420" left="391" width="135" height="17" font="0">territories. Poly vascular </text>
<text top="437" left="391" width="152" height="17" font="0">disease defined as disease </text>
<text top="454" left="391" width="90" height="17" font="0">in ≥2 territories. </text>
<text top="472" left="391" width="3" height="17" font="0"> </text>
<text top="489" left="391" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="387" left="566" width="7" height="17" font="2"><b>1</b></text>
<text top="386" left="573" width="6" height="18" font="7"></text>
<text top="387" left="579" width="230" height="17" font="2"><b> endpoint:</b> Prevalence of AAA, CAD, and </text>
<text top="404" left="566" width="200" height="17" font="0">carotid disease in PAD pts receiving </text>
<text top="421" left="566" width="96" height="17" font="0">revascularization </text>
<text top="438" left="566" width="3" height="17" font="0"> </text>
<text top="455" left="566" width="270" height="17" font="2"><b>Results:</b> Poly-vascular bed pts had about 8X the </text>
<text top="473" left="566" width="168" height="17" font="0">risk of carotid disease or AAA. </text>
<text top="386" left="851" width="7" height="18" font="7"></text>
<text top="387" left="857" width="212" height="17" font="0"> Looks at the risk according to multiple </text>
<text top="404" left="851" width="151" height="17" font="0">vascular beds not just PAD </text>
<text top="421" left="851" width="7" height="18" font="7"></text>
<text top="422" left="857" width="233" height="17" font="0"> Can’t discern the risk of AAA or CVD with </text>
<text top="439" left="851" width="62" height="17" font="0">PAD alone </text>
<text top="524" left="95" width="100" height="17" font="0">Kurvers HA, et al. </text>
<text top="541" left="95" width="53" height="17" font="0">2003(95)<b> </b></text>
<text top="558" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12764269">12764269 </a></text>
<text top="576" left="95" width="3" height="17" font="0"> </text>
<text top="524" left="234" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="541" left="234" width="125" height="17" font="0">sectional single center </text>
<text top="558" left="234" width="33" height="17" font="0">study </text>
<text top="576" left="234" width="3" height="17" font="0"> </text>
<text top="593" left="234" width="130" height="17" font="2"><b>Size:</b> n=2,274 vascular </text>
<text top="610" left="234" width="20" height="17" font="0">pts </text>
<text top="524" left="391" width="155" height="17" font="2"><b>Inclusion criteria:</b> Enrolled </text>
<text top="541" left="391" width="152" height="17" font="0">in SMART study referred to </text>
<text top="558" left="391" width="138" height="17" font="0">a vascular center with sx </text>
<text top="576" left="391" width="157" height="17" font="0">peripheral atherosclerosis in </text>
<text top="593" left="391" width="134" height="17" font="0">some arterial territory or </text>
<text top="610" left="391" width="141" height="17" font="0">elevated risk factors (e.g. </text>
<text top="627" left="391" width="30" height="17" font="0">DM)  </text>
<text top="644" left="391" width="3" height="17" font="0"> </text>
<text top="662" left="391" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="525" left="566" width="7" height="17" font="2"><b>1</b></text>
<text top="524" left="573" width="6" height="18" font="7"></text>
<text top="525" left="579" width="255" height="17" font="2"><b> endpoint:</b> Prevalence of AAA &gt;3cm diameter </text>
<text top="542" left="566" width="3" height="17" font="0"> </text>
<text top="559" left="566" width="257" height="17" font="2"><b>Results:</b> Prevalence 6.5% in PAD pts vs. ~1% </text>
<text top="577" left="566" width="236" height="17" font="0">for risk factor only pts. Age &gt;54 y and PAD </text>
<text top="594" left="566" width="248" height="17" font="0">increased prevalence to 9.6%. Prevalence of </text>
<text top="611" left="566" width="157" height="17" font="0">AAA &gt;5cm low in all groups  </text>
<text top="628" left="566" width="3" height="17" font="0"> </text>
<text top="524" left="851" width="7" height="18" font="7"></text>
<text top="525" left="857" width="203" height="17" font="0"> Select sx atherosclerosis population </text>
<text top="680" left="95" width="94" height="17" font="0">Grøndal N, et al. </text>
<text top="697" left="95" width="46" height="17" font="0">2015(8) </text>
<text top="714" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25923784">25923784</a></text>
<text top="714" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25923784"> </a></text>
<text top="731" left="95" width="3" height="17" font="0"> </text>
<text top="680" left="234" width="112" height="17" font="2"><b>Study type:</b> Danish </text>
<text top="697" left="234" width="105" height="17" font="0">intervention arm of </text>
<text top="714" left="234" width="80" height="17" font="0">screening trial </text>
<text top="731" left="234" width="3" height="17" font="0"> </text>
<text top="748" left="234" width="141" height="17" font="2"><b>Size:</b> n=25,083 men who </text>
<text top="766" left="234" width="133" height="17" font="0">were screened for AAA. </text>
<text top="680" left="391" width="157" height="17" font="2"><b>Inclusion criteria:</b> Men age </text>
<text top="697" left="391" width="157" height="17" font="0">65–74 y who were screened </text>
<text top="714" left="391" width="53" height="17" font="0">for AAA.  </text>
<text top="731" left="391" width="3" height="17" font="0"> </text>
<text top="748" left="391" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="681" left="566" width="7" height="17" font="2"><b>1</b></text>
<text top="680" left="573" width="6" height="18" font="7"></text>
<text top="681" left="579" width="257" height="17" font="2"><b> endpoint:</b> Prevalence of PAD in pts screened </text>
<text top="698" left="566" width="53" height="17" font="0">for AAA.  </text>
<text top="715" left="566" width="3" height="17" font="0"> </text>
<text top="732" left="566" width="262" height="17" font="2"><b>Results:</b> AAA was diagnosed in 3.3% and PAD </text>
<text top="750" left="566" width="55" height="17" font="0">in 10.9%. </text>
<text top="680" left="851" width="7" height="18" font="7"></text>
<text top="681" left="857" width="239" height="17" font="0"> The prevalence of AAA has declined in the </text>
<text top="698" left="851" width="182" height="17" font="0">past decade from 4.0% to 3.3%.  </text>
<text top="715" left="851" width="7" height="18" font="7"></text>
<text top="716" left="857" width="250" height="17" font="0"> 10.9% of men undergoing screening for AAA </text>
<text top="734" left="851" width="82" height="17" font="0">also had PAD. </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">38 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="234" width="113" height="17" font="0">1,8749 attended the </text>
<text top="104" left="234" width="101" height="17" font="0">screening (uptake </text>
<text top="122" left="234" width="46" height="17" font="0">74.7%). </text>
<text top="139" left="95" width="102" height="17" font="0">Giugliano G, et al. </text>
<text top="157" left="95" width="53" height="17" font="0">2012(96) </text>
<text top="174" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23173942">23173942</a></text>
<text top="174" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23173942"> </a></text>
<text top="191" left="95" width="3" height="17" font="0"> </text>
<text top="139" left="234" width="138" height="17" font="2"><b>Study type: </b>Prospective </text>
<text top="157" left="234" width="66" height="17" font="0">case series </text>
<text top="174" left="234" width="3" height="17" font="0"> </text>
<text top="191" left="234" width="138" height="17" font="2"><b>Size:</b> n=213 consecutive </text>
<text top="208" left="234" width="23" height="17" font="0">pts <b> </b></text>
<text top="139" left="391" width="130" height="17" font="2"><b>Inclusion criteria:</b> 213 </text>
<text top="157" left="391" width="142" height="17" font="0">consecutive pts with PAD </text>
<text top="174" left="391" width="100" height="17" font="0">screened for AAA </text>
<text top="191" left="391" width="3" height="17" font="0"> </text>
<text top="208" left="391" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="141" left="566" width="7" height="17" font="2"><b>1</b></text>
<text top="140" left="573" width="6" height="18" font="7"></text>
<text top="141" left="579" width="256" height="17" font="2"><b> endpoint:</b> Prevalence of AAA in pts with PAD </text>
<text top="158" left="566" width="3" height="17" font="0"> </text>
<text top="175" left="566" width="254" height="17" font="2"><b>Results:</b> AAA was present in 19 pts (9%) with </text>
<text top="192" left="566" width="213" height="17" font="0">similar prevalence in men and women.<b> </b></text>
<text top="140" left="851" width="7" height="18" font="7"></text>
<text top="141" left="857" width="245" height="17" font="0"> Small study showed that prevalence of AAA </text>
<text top="158" left="851" width="231" height="17" font="0">in pts with PAD is much higher than in the </text>
<text top="175" left="851" width="112" height="17" font="0">general population.  </text>
<text top="192" left="851" width="7" height="18" font="7"></text>
<text top="193" left="857" width="154" height="17" font="0"> Prevalence related to age:  </text>
<text top="211" left="861" width="48" height="17" font="0">&lt;55 y: 0 </text>
<text top="228" left="861" width="79" height="17" font="0">55-64 y: 5.1% </text>
<text top="245" left="861" width="86" height="17" font="0">65-74 y: 11.4% </text>
<text top="262" left="861" width="76" height="17" font="0">&gt;75 y: 15.8% </text>
<text top="280" left="95" width="51" height="17" font="0">Barba A  </text>
<text top="298" left="95" width="53" height="17" font="0">2005(97) </text>
<text top="315" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15963741">15963741 </a></text>
<text top="332" left="95" width="3" height="17" font="0"> </text>
<text top="280" left="234" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="298" left="234" width="141" height="17" font="0">Observational descriptive </text>
<text top="315" left="234" width="33" height="17" font="0">study </text>
<text top="332" left="234" width="3" height="17" font="0"> </text>
<text top="349" left="234" width="125" height="17" font="2"><b>Size:</b> n=1,166 pts with </text>
<text top="366" left="234" width="29" height="17" font="0">PAD<b> </b></text>
<text top="280" left="391" width="140" height="17" font="2"><b>Inclusion criteria:</b> 1,166 </text>
<text top="298" left="391" width="142" height="17" font="0">consecutive pts with PAD </text>
<text top="315" left="391" width="109" height="17" font="0">had AAA screening </text>
<text top="332" left="391" width="3" height="17" font="0"> </text>
<text top="349" left="391" width="143" height="17" font="2"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="281" left="566" width="7" height="17" font="2"><b>1</b></text>
<text top="280" left="573" width="6" height="18" font="7"></text>
<text top="281" left="579" width="256" height="17" font="2"><b> endpoint:</b> Prevalence of AAA in pts with PAD </text>
<text top="299" left="566" width="3" height="17" font="2"><b> </b></text>
<text top="316" left="566" width="262" height="17" font="2"><b>Results:</b> Prevalence of AAA in men was 13.6% </text>
<text top="333" left="566" width="237" height="17" font="0">and in women 4.1% but there were only 73 </text>
<text top="350" left="566" width="50" height="17" font="0">women. <b> </b></text>
<text top="280" left="851" width="7" height="18" font="7"></text>
<text top="281" left="857" width="247" height="17" font="0"> Prevalence of AAA in pts with PAD is higher </text>
<text top="299" left="851" width="172" height="17" font="0">than in the general population.  </text>
<text top="316" left="851" width="7" height="18" font="7"></text>
<text top="317" left="857" width="250" height="17" font="0"> As in other studies, the prevalence of AAA in </text>
<text top="334" left="851" width="183" height="17" font="0">pts with PAD increased with age. </text>
<text top="351" left="851" width="7" height="18" font="7"></text>
<text top="353" left="857" width="228" height="17" font="0"> The prevalence was much higher in men </text>
<text top="370" left="851" width="77" height="17" font="0">than women.  </text>
<text top="388" left="86" width="1015" height="17" font="0">AAA indicates abdominal aortic aneurysm; CAD, coronary artery disease; CVD, cardiovascular disease; N/A, not applicable; PAD, peripheral artery disease; and PVD, peripheral vascular </text>
<text top="405" left="86" width="46" height="17" font="0">disease.</text>
<text top="405" left="132" width="3" height="17" font="9"> </text>
<text top="422" left="86" width="3" height="17" font="0"> </text>
<text top="439" left="86" width="3" height="17" font="0"> </text>
<text top="457" left="80" width="994" height="21" font="1"><b>Evidence Table 9. Nonrandomized Trials, Observational Studies, and/or Registries of Coronary Artery Disease Screening in PAD–Section 4.2. </b></text>
<text top="478" left="105" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="495" left="131" width="48" height="17" font="2"><b>Author; </b></text>
<text top="512" left="108" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="478" left="248" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="495" left="274" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="478" left="407" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="478" left="576" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="495" left="583" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="512" left="635" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="478" left="887" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="495" left="915" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="530" left="88" width="75" height="17" font="0">Lee JY, et al. </text>
<text top="548" left="88" width="53" height="17" font="0">2013(98)<b> </b></text>
<text top="565" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24355120">24355120 </a></text>
<text top="582" left="88" width="3" height="17" font="0"> </text>
<text top="530" left="234" width="111" height="17" font="2"><b>Study type:</b> Cohort </text>
<text top="548" left="234" width="3" height="17" font="0"> </text>
<text top="565" left="234" width="125" height="17" font="2"><b>Size:</b> n=2,424 pts with </text>
<text top="582" left="234" width="139" height="17" font="0">CAD and 119 pts without </text>
<text top="599" left="234" width="131" height="17" font="0">significant CAD on cath </text>
<text top="530" left="392" width="127" height="17" font="2"><b>Inclusion criteria:</b> Pts </text>
<text top="548" left="392" width="91" height="17" font="0">having coronary </text>
<text top="565" left="392" width="71" height="17" font="0">angiography </text>
<text top="582" left="392" width="3" height="17" font="0"> </text>
<text top="599" left="392" width="131" height="17" font="2"><b>Exclusion criteria:</b> Pts </text>
<text top="617" left="392" width="135" height="17" font="0">with known PAD or prior </text>
<text top="634" left="392" width="23" height="17" font="0">ABI </text>
<text top="532" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="531" left="554" width="6" height="18" font="7"></text>
<text top="532" left="560" width="219" height="17" font="2"><b> endpoint:</b> Prevalence of abnormal ABI </text>
<text top="549" left="547" width="183" height="17" font="0">&lt;0.9 or &gt;1.4 and MACE over 3 y. </text>
<text top="566" left="547" width="3" height="17" font="0"> </text>
<text top="583" left="547" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="601" left="547" width="7" height="18" font="7"></text>
<text top="602" left="554" width="229" height="17" font="0"> In CAD pts: 14% had ABI &lt;0.9, vs. 4% in </text>
<text top="619" left="547" width="201" height="17" font="0">pts without CAD. Of the 390 pts with </text>
<text top="636" left="547" width="217" height="17" font="0">abnormal ABI, 130 (33%) had coronary </text>
<text top="653" left="547" width="200" height="17" font="0">revascularization at time of cath. 3 y </text>
<text top="671" left="547" width="224" height="17" font="0">MACE significantly higher with abnormal </text>
<text top="688" left="547" width="179" height="17" font="0">ABI (15.7% vs. 3.3%; p&lt;0.001).  </text>
<text top="705" left="547" width="7" height="18" font="7"></text>
<text top="706" left="554" width="194" height="17" font="0"> Abnormal ABI HR: 1.87 or 2.40 on </text>
<text top="723" left="547" width="162" height="17" font="0">propensity matched analysis. </text>
<text top="531" left="797" width="7" height="18" font="7"></text>
<text top="532" left="803" width="280" height="17" font="0"> Doesn’t really say the prevalence of CAD in all pts </text>
<text top="549" left="797" width="299" height="17" font="0">with abnormal PAD. It looks at a select group who had </text>
<text top="566" left="797" width="300" height="17" font="0">cath and then looks at the impact of PAD on outcomes </text>
<text top="583" left="797" width="51" height="17" font="0">over 3 y. </text>
<text top="601" left="797" width="7" height="18" font="7"></text>
<text top="602" left="803" width="303" height="17" font="0"> Shows prognostic value of low ABI for MACE but does </text>
<text top="619" left="797" width="287" height="17" font="0">not provide information on the value of screening for </text>
<text top="636" left="797" width="133" height="17" font="0">CAD in pts with low ABI </text>
<text top="741" left="88" width="109" height="17" font="0">Moyer VA and U.S. </text>
<text top="758" left="88" width="122" height="17" font="0">Preventative Services </text>
<text top="776" left="88" width="65" height="17" font="0">Task Force </text>
<text top="741" left="234" width="128" height="17" font="2"><b>Study type:</b> Review of </text>
<text top="758" left="234" width="124" height="17" font="0">studies assessing ABI </text>
<text top="776" left="234" width="53" height="17" font="0">and CAD </text>
<text top="741" left="392" width="123" height="17" font="2"><b>Inclusion criteria:</b> All </text>
<text top="758" left="392" width="122" height="17" font="0">studies examining the </text>
<text top="776" left="392" width="107" height="17" font="0">prognostic value of </text>
<text top="742" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="741" left="554" width="6" height="18" font="7"></text>
<text top="742" left="560" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="760" left="547" width="3" height="17" font="0"> </text>
<text top="777" left="547" width="230" height="17" font="2"><b>Results:</b> See box to right. More useful for </text>
<text top="741" left="797" width="7" height="18" font="7"></text>
<text top="742" left="803" width="253" height="17" font="0"> USPSTF summary statement concluding that </text>
<text top="760" left="797" width="309" height="17" font="0">screening for PAD using the ABI in asx individuals is not </text>
<text top="777" left="797" width="57" height="17" font="0">of benefit. </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">39 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="88" width="53" height="17" font="0">2013(99)<b> </b></text>
<text top="104" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24026320">24026320 </a></text>
<text top="122" left="88" width="3" height="17" font="0"> </text>
<text top="87" left="234" width="3" height="17" font="0"> </text>
<text top="104" left="234" width="56" height="17" font="2"><b>Size:</b> N/A </text>
<text top="87" left="392" width="139" height="17" font="0">screening ABI in asx pts. </text>
<text top="104" left="392" width="3" height="17" font="0"> </text>
<text top="122" left="392" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="547" width="235" height="17" font="0">question addressing asx screening with an </text>
<text top="104" left="547" width="23" height="17" font="0">ABI </text>
<text top="87" left="797" width="7" height="18" font="7"></text>
<text top="88" left="803" width="304" height="17" font="0"> They find several studies showing a relationship of low </text>
<text top="106" left="797" width="263" height="17" font="0">ABI to CAD events, but that the NRI is often not </text>
<text top="123" left="797" width="307" height="17" font="0">reported or indicates a change that may not be clinically </text>
<text top="140" left="797" width="58" height="17" font="0">significant </text>
<text top="157" left="797" width="7" height="18" font="7"></text>
<text top="158" left="803" width="298" height="17" font="0"> This is more useful for the assessment of the value of </text>
<text top="176" left="797" width="176" height="17" font="0">screening ABI in asx individuals </text>
<text top="194" left="88" width="71" height="17" font="0">Lin JS, et al. </text>
<text top="211" left="88" width="53" height="17" font="0">2013(30)<b> </b></text>
<text top="228" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24156115">24156115 </a></text>
<text top="245" left="88" width="3" height="17" font="0"> </text>
<text top="194" left="234" width="128" height="17" font="2"><b>Study type:</b> Review of </text>
<text top="211" left="234" width="133" height="17" font="0">studies assessing value </text>
<text top="228" left="234" width="110" height="17" font="0">of ABI in addition to </text>
<text top="245" left="234" width="132" height="17" font="0">Framingham risk score. </text>
<text top="262" left="234" width="3" height="17" font="0"> </text>
<text top="280" left="234" width="87" height="17" font="2"><b>Size:</b> n=52,510 </text>
<text top="194" left="392" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="211" left="392" width="123" height="17" font="0">Studies assessing the </text>
<text top="228" left="392" width="96" height="17" font="0">value of ABI as a </text>
<text top="245" left="392" width="134" height="17" font="0">predictor of CAD events </text>
<text top="262" left="392" width="3" height="17" font="0"> </text>
<text top="280" left="392" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="195" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="194" left="554" width="6" height="18" font="7"></text>
<text top="195" left="560" width="221" height="17" font="2"><b> endpoint:</b> Test characteristics and NRI </text>
<text top="212" left="547" width="3" height="17" font="0"> </text>
<text top="229" left="547" width="219" height="17" font="2"><b>Results:</b> NRI small when adding ABI to </text>
<text top="246" left="547" width="28" height="17" font="0">FRS </text>
<text top="264" left="547" width="3" height="17" font="0"> </text>
<text top="194" left="797" width="7" height="18" font="7"></text>
<text top="195" left="803" width="296" height="17" font="0"> USPSTF analysis supporting the summary statement </text>
<text top="212" left="797" width="62" height="17" font="0">above (99) </text>
<text top="229" left="797" width="3" height="17" font="0"> </text>
<text top="246" left="797" width="7" height="18" font="7"></text>
<text top="247" left="803" width="202" height="17" font="0"> NRI small when adding ABI to FRS  </text>
<text top="265" left="797" width="7" height="18" font="7"></text>
<text top="266" left="803" width="298" height="17" font="0"> This is more useful for the assessment of the value of </text>
<text top="283" left="797" width="176" height="17" font="0">screening ABI in asx individuals </text>
<text top="301" left="80" width="1019" height="17" font="0">ABI indicates ankle-brachial index; asx, asymptomatic; CAD, coronary artery disease; CTA, computed tomographic angiography; CT, computed tomography; FRS, Framingham risk score; </text>
<text top="318" left="80" width="1020" height="17" font="0">HR, hazard ratio; MACE, major adverse cardiovascular events; N/A, not applicable; NRI, net reclassification improvement; PAD, peripheral artery disease, pt, patient; and USPSTF, United </text>
<text top="335" left="80" width="229" height="17" font="0">States Preventative Services Task Force. </text>
<text top="353" left="86" width="3" height="17" font="0"> </text>
<text top="370" left="86" width="3" height="17" font="0"> </text>
<text top="387" left="80" width="457" height="21" font="1"><b>Evidence Table 10. RCTs for CAD Screening in PAD–Section 4.2. </b></text>
<text top="409" left="89" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="426" left="115" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="443" left="93" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="409" left="225" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="426" left="230" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="443" left="224" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="409" left="383" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="409" left="562" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="426" left="580" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="443" left="563" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="460" left="584" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="409" left="748" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="426" left="706" width="188" height="17" font="2"><b>(Absolute Event Rates, P value; </b></text>
<text top="443" left="763" width="79" height="17" font="2"><b>OR or RR; &amp;  </b></text>
<text top="460" left="776" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="410" left="922" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="409" left="983" width="6" height="18" font="7"></text>
<text top="410" left="989" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="427" left="954" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="444" left="962" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="478" left="88" width="100" height="17" font="0">McFalls EO, et al. </text>
<text top="495" left="88" width="59" height="17" font="0">2004(100) </text>
<text top="512" left="88" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15625331">15625331</a></text>
<text top="512" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15625331"> </a></text>
<text top="530" left="88" width="3" height="17" font="0"> </text>
<text top="478" left="203" width="113" height="17" font="2"><b>Study type: </b>RCT of </text>
<text top="495" left="203" width="126" height="17" font="0">cardiac catheterization </text>
<text top="512" left="203" width="75" height="17" font="0">and coronary </text>
<text top="530" left="203" width="114" height="17" font="0">revascularization for </text>
<text top="547" left="203" width="112" height="17" font="0">CAD in high-risk pts </text>
<text top="564" left="203" width="126" height="17" font="0">scheduled for vascular </text>
<text top="581" left="203" width="44" height="17" font="0">surgery </text>
<text top="599" left="203" width="3" height="17" font="0"> </text>
<text top="616" left="203" width="100" height="17" font="2"><b>Size:</b> n=5,859 pts </text>
<text top="478" left="344" width="187" height="17" font="2"><b>Inclusion criteria:</b> Pts scheduled </text>
<text top="495" left="344" width="178" height="17" font="0">for major vascular surgery (AAA </text>
<text top="512" left="344" width="135" height="17" font="0">repair or lower extremity </text>
<text top="530" left="344" width="178" height="17" font="0">operation) who were considered </text>
<text top="547" left="344" width="189" height="17" font="0">at increased risk of cardiovascular </text>
<text top="564" left="344" width="176" height="17" font="0">events according to a risk score </text>
<text top="581" left="344" width="176" height="17" font="0">and the myocardial ischemia on </text>
<text top="599" left="344" width="108" height="17" font="0">noninvasive testing </text>
<text top="616" left="344" width="3" height="17" font="0"> </text>
<text top="633" left="344" width="164" height="17" font="2"><b>Exclusion criteria:</b> Left main </text>
<text top="650" left="344" width="160" height="17" font="0">stenosis &gt;50%, LVEF &lt;20%, </text>
<text top="667" left="344" width="122" height="17" font="0">severe aortic stenosis<b> </b></text>
<text top="478" left="547" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="495" left="547" width="139" height="17" font="0">Revascularization before </text>
<text top="512" left="547" width="129" height="17" font="0">elective major vascular </text>
<text top="530" left="547" width="44" height="17" font="0">surgery </text>
<text top="547" left="547" width="3" height="17" font="0"> </text>
<text top="564" left="547" width="96" height="17" font="2"><b>Comparator: </b>No </text>
<text top="581" left="547" width="134" height="17" font="0">revascularization before </text>
<text top="599" left="547" width="129" height="17" font="0">elective major vascular </text>
<text top="616" left="547" width="44" height="17" font="0">surgery </text>
<text top="479" left="702" width="7" height="17" font="2"><b>1</b></text>
<text top="478" left="709" width="6" height="18" font="7"></text>
<text top="479" left="715" width="172" height="17" font="2"><b> endpoint:</b> Long-term mortality </text>
<text top="496" left="702" width="3" height="17" font="0"> </text>
<text top="514" left="702" width="141" height="17" font="2"><b>Results:</b> No difference in </text>
<text top="531" left="702" width="179" height="17" font="0">outcomes. Mortality at 2.7 y was </text>
<text top="548" left="702" width="109" height="17" font="0">22% in the no-CAD </text>
<text top="565" left="702" width="196" height="17" font="0">revascularization group and 23% in </text>
<text top="583" left="702" width="184" height="17" font="0">the CAD revascularization group. </text>
<text top="600" left="702" width="187" height="17" font="0">30 d postoperative MI=12% in the </text>
<text top="617" left="702" width="184" height="17" font="0">CAD revascularization group and </text>
<text top="634" left="702" width="109" height="17" font="0">14% in the no-CAD </text>
<text top="651" left="702" width="134" height="17" font="0">revascularization group. </text>
<text top="478" left="911" width="7" height="18" font="7"></text>
<text top="479" left="918" width="120" height="17" font="0"> No difference in 30 d </text>
<text top="496" left="911" width="189" height="17" font="0">postoperative MI=12% in the CAD </text>
<text top="514" left="911" width="196" height="17" font="0">revascularization group and 14% in </text>
<text top="531" left="911" width="163" height="17" font="0">the no-CAD revascularization </text>
<text top="548" left="911" width="38" height="17" font="0">group. </text>
<text top="565" left="911" width="7" height="18" font="7"></text>
<text top="566" left="918" width="152" height="17" font="0"> Excludes left main disease </text>
<text top="584" left="911" width="7" height="18" font="7"></text>
<text top="585" left="918" width="172" height="17" font="0"> No advantage to screening for </text>
<text top="602" left="911" width="181" height="17" font="0">CAD in pts having elective major </text>
<text top="619" left="911" width="175" height="17" font="0">vascular surgery on mortality or </text>
<text top="637" left="911" width="140" height="17" font="0">perioperative rates of MI. </text>
<text top="654" left="911" width="3" height="17" font="2"><b> </b></text>
<text top="685" left="80" width="1022" height="17" font="0">AAA indicates abdominal aortic aneurysm; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; pt, patient; and RCT, randomized controlled trial. </text>
<text top="703" left="80" width="3" height="17" font="0"> </text>
<text top="720" left="80" width="3" height="17" font="0"> </text>
<text top="737" left="80" width="952" height="21" font="1"><b>Evidence Table 11. Nonrandomized Trials, Observational Studies, and/or Registries of Screening in Carotid Artery Disease–Section 4.3. </b></text>
<text top="758" left="106" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="776" left="132" width="48" height="17" font="2"><b>Author; </b></text>
<text top="758" left="242" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="776" left="268" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="758" left="434" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="758" left="653" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="776" left="661" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="758" left="931" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="776" left="958" width="75" height="17" font="2"><b>Comment(s) </b></text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">40 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="110" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="87" left="713" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="105" left="88" width="83" height="17" font="0">Sultan S, et al. </text>
<text top="122" left="88" width="53" height="17" font="0">2013(94)<b> </b></text>
<text top="139" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23711680">23711680 </a></text>
<text top="157" left="88" width="3" height="17" font="0"> </text>
<text top="105" left="236" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="122" left="236" width="126" height="17" font="0">sectional single-center </text>
<text top="139" left="236" width="33" height="17" font="0">study </text>
<text top="157" left="236" width="3" height="17" font="0"> </text>
<text top="174" left="236" width="90" height="17" font="2"><b>Size:</b> n=328 pts </text>
<text top="191" left="236" width="99" height="17" font="0">having a vascular </text>
<text top="208" left="236" width="117" height="17" font="0">intervention for PAD, </text>
<text top="226" left="236" width="86" height="17" font="0">AAA, or carotid </text>
<text top="243" left="236" width="49" height="17" font="0">disease  </text>
<text top="105" left="378" width="215" height="17" font="2"><b>Inclusion criteria:</b> Intervention for 1 of </text>
<text top="122" left="378" width="184" height="17" font="0">the PVD territories. Poly vascular </text>
<text top="139" left="378" width="183" height="17" font="0">disease defined as disease in ≥2 </text>
<text top="157" left="378" width="58" height="17" font="0">territories. </text>
<text top="174" left="378" width="3" height="17" font="0"> </text>
<text top="191" left="378" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="106" left="614" width="7" height="17" font="2"><b>1</b></text>
<text top="105" left="621" width="6" height="18" font="7"></text>
<text top="106" left="627" width="230" height="17" font="2"><b> endpoint:</b> Prevalence of AAA, CAD, and </text>
<text top="123" left="614" width="200" height="17" font="0">carotid disease in PAD pts receiving </text>
<text top="141" left="614" width="96" height="17" font="0">revascularization </text>
<text top="158" left="614" width="3" height="17" font="0"> </text>
<text top="175" left="614" width="250" height="17" font="2"><b>Results:</b> Poly-vascular bed pts had about 8X </text>
<text top="192" left="614" width="189" height="17" font="0">the risk of carotid disease or AAA. </text>
<text top="210" left="614" width="3" height="17" font="0"> </text>
<text top="105" left="884" width="7" height="18" font="7"></text>
<text top="106" left="891" width="212" height="17" font="0"> Looks at the risk according to multiple </text>
<text top="123" left="884" width="151" height="17" font="0">vascular beds not just PAD </text>
<text top="141" left="884" width="7" height="18" font="7"></text>
<text top="142" left="891" width="207" height="17" font="0"> Can’t discern the risk of AAA or CVD </text>
<text top="159" left="884" width="87" height="17" font="0">with PAD alone </text>
<text top="261" left="88" width="100" height="17" font="0">Kurvers HA, et al. </text>
<text top="278" left="88" width="53" height="17" font="0">2003(95)<b> </b></text>
<text top="295" left="88" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12764269">12764269 </a></text>
<text top="312" left="88" width="3" height="17" font="0"> </text>
<text top="261" left="236" width="107" height="17" font="2"><b>Study type:</b> Cross-</text>
<text top="278" left="236" width="125" height="17" font="0">sectional single center </text>
<text top="295" left="236" width="33" height="17" font="0">study </text>
<text top="312" left="236" width="3" height="17" font="0"> </text>
<text top="330" left="236" width="80" height="17" font="2"><b>Size:</b> n=2,274 </text>
<text top="347" left="236" width="69" height="17" font="0">vascular pts </text>
<text top="261" left="378" width="214" height="17" font="2"><b>Inclusion criteria:</b> Enrolled in SMART </text>
<text top="278" left="378" width="215" height="17" font="0">study referred to a vascular center with </text>
<text top="295" left="378" width="206" height="17" font="0">sx peripheral atherosclerosis in some </text>
<text top="312" left="378" width="213" height="17" font="0">arterial territory or elevated risk factors </text>
<text top="330" left="378" width="58" height="17" font="0">(e.g. DM)  </text>
<text top="347" left="378" width="3" height="17" font="0"> </text>
<text top="364" left="378" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="262" left="614" width="7" height="17" font="2"><b>1</b></text>
<text top="261" left="621" width="6" height="18" font="7"></text>
<text top="262" left="627" width="230" height="17" font="2"><b> endpoint:</b> Prevalence of carotid stenosis </text>
<text top="279" left="614" width="3" height="17" font="0"> </text>
<text top="296" left="614" width="236" height="17" font="2"><b>Results:</b> Prevalence 12.5% in PAD pts vs. </text>
<text top="314" left="614" width="235" height="17" font="0">~2% for risk factor only pts. Age &gt;54 y and </text>
<text top="331" left="614" width="198" height="17" font="0">PAD increased prevalence to 22%.  </text>
<text top="261" left="884" width="7" height="18" font="7"></text>
<text top="262" left="891" width="203" height="17" font="0"> Select sx atherosclerosis population </text>
<text top="382" left="86" width="1009" height="17" font="0">AAA indicates abdominal aortic aneurysm; ABI, ankle-brachial index; CAD, coronary artery disease; CVD, cardiovascular disease; DM, diabetes mellitus; PAD, peripheral artery disease; </text>
<text top="399" left="86" width="305" height="17" font="0">pt, patient; PVD, peripheral vascular disease; sx, symp. </text>
<text top="399" left="391" width="3" height="17" font="9"> </text>
<text top="416" left="86" width="3" height="17" font="0"> </text>
<text top="434" left="86" width="3" height="17" font="0"> </text>
<text top="451" left="86" width="854" height="21" font="1"><b>Evidence Table 12. Nonrandomized Trials, Observational Studies, and/or Registries for Renal Artery Disease–Section 4.4. </b></text>
<text top="472" left="110" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="490" left="135" width="48" height="17" font="2"><b>Author; </b></text>
<text top="507" left="113" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="472" left="250" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="490" left="276" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="472" left="432" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="472" left="647" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="490" left="654" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="507" left="706" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="472" left="935" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="490" left="962" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="525" left="95" width="80" height="17" font="0">Olin JW, et al. </text>
<text top="542" left="95" width="59" height="17" font="0">1990(101) </text>
<text top="559" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2368764">2368764 </a></text>
<text top="576" left="95" width="3" height="17" font="0"> </text>
<text top="525" left="236" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="542" left="236" width="115" height="17" font="0">center, retrospective </text>
<text top="559" left="236" width="74" height="17" font="0">cohort study  </text>
<text top="576" left="236" width="3" height="17" font="0"> </text>
<text top="593" left="236" width="138" height="17" font="2"><b>Size:</b> n=395 consecutive </text>
<text top="611" left="236" width="23" height="17" font="0">pts  </text>
<text top="525" left="394" width="153" height="17" font="2"><b>Inclusion criteria: </b>Pts who </text>
<text top="542" left="394" width="180" height="17" font="0">underwent catheter angiography </text>
<text top="559" left="394" width="176" height="17" font="0">for evaluation of AAA, Aortoiliac </text>
<text top="576" left="394" width="164" height="17" font="0">Occlusive Disease and PAD.  </text>
<text top="593" left="394" width="3" height="17" font="0"> </text>
<text top="611" left="394" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="526" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="525" left="601" width="6" height="18" font="7"></text>
<text top="526" left="607" width="242" height="17" font="2"><b> endpoint:</b> Prevalence of &gt;50% renal artery </text>
<text top="543" left="594" width="49" height="17" font="0">stenosis </text>
<text top="560" left="594" width="3" height="17" font="0"> </text>
<text top="577" left="594" width="260" height="17" font="2"><b>Results:</b> Prevalence was 38% in pts with AAA, </text>
<text top="595" left="594" width="193" height="17" font="0">33% with AOD and 39% with PAD. </text>
<text top="525" left="891" width="7" height="18" font="7"></text>
<text top="526" left="898" width="165" height="17" font="0"> There is a high prevalence of </text>
<text top="543" left="891" width="202" height="17" font="0">incidental renal artery stenosis in pts </text>
<text top="560" left="891" width="211" height="17" font="0">with atherosclerosis in other locations, </text>
<text top="577" left="891" width="213" height="17" font="0">even in the absence of clinical clues to </text>
<text top="595" left="891" width="78" height="17" font="0">suspect RAS. </text>
<text top="629" left="95" width="118" height="17" font="0">Leertouwer TC, et al. </text>
<text top="646" left="95" width="63" height="17" font="0">2001 (102) </text>
<text top="663" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11260411">11260411 </a></text>
<text top="680" left="95" width="3" height="17" font="0"> </text>
<text top="629" left="236" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="646" left="236" width="115" height="17" font="0">center, retrospective </text>
<text top="663" left="236" width="74" height="17" font="0">cohort study  </text>
<text top="680" left="236" width="3" height="17" font="0"> </text>
<text top="698" left="236" width="138" height="17" font="2"><b>Size:</b> n=386 consecutive </text>
<text top="715" left="236" width="20" height="17" font="0">pts </text>
<text top="629" left="394" width="153" height="17" font="2"><b>Inclusion criteria:</b> Pts who </text>
<text top="646" left="394" width="146" height="17" font="0">underwent catheter based </text>
<text top="663" left="394" width="162" height="17" font="0">angiography for evaluation of </text>
<text top="680" left="394" width="29" height="17" font="0">PAD </text>
<text top="698" left="394" width="3" height="17" font="0"> </text>
<text top="715" left="394" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="630" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="629" left="601" width="6" height="18" font="7"></text>
<text top="630" left="607" width="242" height="17" font="2"><b> endpoint:</b> Prevalence of &gt;50% renal artery </text>
<text top="647" left="594" width="49" height="17" font="0">stenosis </text>
<text top="664" left="594" width="3" height="17" font="0"> </text>
<text top="682" left="594" width="223" height="17" font="2"><b>Results:</b> 126 (33%) had &gt;50% stenosis. </text>
<text top="629" left="891" width="7" height="18" font="7"></text>
<text top="630" left="898" width="186" height="17" font="0"> Incidental renal artery stenosis is </text>
<text top="647" left="891" width="137" height="17" font="0">common in pts with PAD </text>
<text top="664" left="891" width="7" height="18" font="7"></text>
<text top="665" left="898" width="195" height="17" font="0"> Renal replacement therapy did not </text>
<text top="683" left="891" width="163" height="17" font="0">occur in any of these pts thus </text>
<text top="700" left="891" width="204" height="17" font="0">revascularization to prevent ESRD is </text>
<text top="717" left="891" width="140" height="17" font="0">not indicated in most pts. </text>
<text top="735" left="95" width="29" height="17" font="2"><b>CHS </b></text>
<text top="752" left="95" width="97" height="17" font="0">Hansen KJ, et al. </text>
<text top="769" left="95" width="59" height="17" font="0">2002(103) </text>
<text top="735" left="236" width="141" height="17" font="2"><b>Study Type:</b> Multicenter, </text>
<text top="752" left="236" width="136" height="17" font="0">longitudinal cohort study<b> </b></text>
<text top="769" left="236" width="3" height="17" font="2"><b> </b></text>
<text top="735" left="394" width="186" height="17" font="2"><b>Inclusion criteria: </b>Free living pts </text>
<text top="752" left="394" width="141" height="17" font="0">age &gt;65 y were invited to </text>
<text top="769" left="394" width="154" height="17" font="0">undergo renal artery duplex </text>
<text top="736" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="735" left="601" width="6" height="18" font="7"></text>
<text top="736" left="607" width="63" height="17" font="2"><b> endpoint:</b> </text>
<text top="753" left="594" width="245" height="17" font="0">Prevalence of RAS in a free standing elderly </text>
<text top="771" left="594" width="60" height="17" font="0">population </text>
<text top="735" left="891" width="7" height="18" font="7"></text>
<text top="736" left="898" width="70" height="17" font="0"> This is the 1</text>
<text top="737" left="968" width="6" height="11" font="11">st</text>
<text top="736" left="974" width="101" height="17" font="0"> population based </text>
<text top="753" left="891" width="191" height="17" font="0">estimate of the prevalence of RVD </text>
<text top="771" left="891" width="196" height="17" font="0">among free living, elderly black and </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">41 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12218965">12218965 </a></text>
<text top="104" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="236" width="90" height="17" font="2"><b>Size:</b> n=870 pts </text>
<text top="87" left="394" width="64" height="17" font="0">ultrasound<b>  </b></text>
<text top="104" left="394" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="394" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="87" left="594" width="3" height="17" font="0"> </text>
<text top="104" left="594" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="122" left="594" width="7" height="18" font="7"></text>
<text top="123" left="601" width="260" height="17" font="0"> 834 (96%) were technically adequate to define </text>
<text top="140" left="594" width="182" height="17" font="0">the presence or absence of RVD </text>
<text top="157" left="594" width="7" height="18" font="7"></text>
<text top="158" left="601" width="171" height="17" font="0"> Prevalence of RAS was 6.8%. </text>
<text top="176" left="594" width="7" height="18" font="7"></text>
<text top="177" left="601" width="263" height="17" font="0"> No difference in prevalence between white and </text>
<text top="194" left="594" width="59" height="17" font="0">black pts. <b> </b></text>
<text top="87" left="891" width="94" height="17" font="0">white Americans </text>
<text top="212" left="86" width="992" height="17" font="0">AAA indicates; AOD, arterial occlusive disease; ESRD, end-stage renal disease; N/A, not applicable; PAD, peripheral artery disease; pt, patient; RAS, renal artery stenosis; and RVD, </text>
<text top="229" left="86" width="129" height="17" font="0">renal vascular disease. </text>
<text top="246" left="86" width="3" height="17" font="0"> </text>
<text top="264" left="86" width="3" height="17" font="0"> </text>
<text top="281" left="86" width="491" height="21" font="1"><b>Evidence Table 13. RCTs Evaluating Antiplatelet Agents– Section 5.1. </b></text>
<text top="302" left="123" width="38" height="17" font="2"><b>Study </b></text>
<text top="319" left="112" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="337" left="118" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="354" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="302" left="222" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="319" left="227" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="337" left="221" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="302" left="380" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="302" left="549" width="111" height="17" font="2"><b>Study Intervention </b></text>
<text top="319" left="566" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="337" left="549" width="111" height="17" font="2"><b>Study Comparator </b></text>
<text top="354" left="570" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="302" left="755" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="319" left="675" width="267" height="17" font="2"><b>(Absolute Event Rates, P value; OR or RR; &amp;  </b></text>
<text top="337" left="783" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="303" left="958" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="302" left="1020" width="6" height="18" font="7"></text>
<text top="303" left="1026" width="75" height="17" font="2"><b> Endpoint (if </b></text>
<text top="320" left="1013" width="33" height="17" font="2"><b>any); </b></text>
<text top="338" left="974" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="355" left="982" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="373" left="95" width="65" height="17" font="2"><b>POPADAD </b></text>
<text top="390" left="95" width="77" height="17" font="0">Belch J, et al. </text>
<text top="407" left="95" width="53" height="17" font="0">2008(16) </text>
<text top="425" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18927173">18927173 </a></text>
<text top="442" left="95" width="3" height="17" font="0"> </text>
<text top="373" left="203" width="106" height="17" font="2"><b>Aim</b>: To determine </text>
<text top="390" left="203" width="99" height="17" font="0">whether ASA and </text>
<text top="407" left="203" width="111" height="17" font="0">antioxidant therapy, </text>
<text top="425" left="203" width="108" height="17" font="0">combined or alone, </text>
<text top="442" left="203" width="102" height="17" font="0">are more effective </text>
<text top="459" left="203" width="87" height="17" font="0">than placebo in </text>
<text top="476" left="203" width="71" height="17" font="0">reducing the </text>
<text top="493" left="203" width="87" height="17" font="0">development of </text>
<text top="511" left="203" width="83" height="17" font="0">cardiovascular </text>
<text top="528" left="203" width="120" height="17" font="0">events in pts with DM </text>
<text top="545" left="203" width="79" height="17" font="0">and asx PAD. </text>
<text top="562" left="203" width="3" height="17" font="0"> </text>
<text top="579" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="597" left="203" width="67" height="17" font="0">Multicenter, </text>
<text top="614" left="203" width="111" height="17" font="0">randomized, double </text>
<text top="631" left="203" width="107" height="17" font="0">blind, 2×2 factorial, </text>
<text top="648" left="203" width="103" height="17" font="0">placebo controlled </text>
<text top="665" left="203" width="27" height="17" font="0">trial. </text>
<text top="683" left="203" width="3" height="17" font="0"> </text>
<text top="700" left="203" width="100" height="17" font="2"><b>Size:</b> n=1,276 pts </text>
<text top="373" left="338" width="172" height="17" font="2"><b>Inclusion criteria</b>: Aged ≥40 y </text>
<text top="390" left="338" width="177" height="17" font="0">with type 1 or type 2 DM and an </text>
<text top="407" left="338" width="126" height="17" font="0">ABI of ≤0.99 but no sx </text>
<text top="425" left="338" width="132" height="17" font="0">cardiovascular disease  </text>
<text top="442" left="338" width="3" height="17" font="0"> </text>
<text top="459" left="338" width="176" height="17" font="2"><b>Exclusion criteria</b>: People with </text>
<text top="476" left="338" width="185" height="17" font="0">evidence of sx CV disease; those </text>
<text top="493" left="338" width="154" height="17" font="0">who use ASA or antioxidant </text>
<text top="511" left="338" width="182" height="17" font="0">therapy on a regular basis; those </text>
<text top="528" left="338" width="162" height="17" font="0">with peptic ulceration, severe </text>
<text top="545" left="338" width="188" height="17" font="0">dyspepsia, a bleeding disorder, or </text>
<text top="562" left="338" width="168" height="17" font="0">intolerance to ASA; those with </text>
<text top="579" left="338" width="188" height="17" font="0">suspected serious physical illness </text>
<text top="597" left="338" width="196" height="17" font="0">(such as cancer), which might have </text>
<text top="614" left="338" width="153" height="17" font="0">been expected to curtail life </text>
<text top="631" left="338" width="189" height="17" font="0">expectancy; those with psychiatric </text>
<text top="648" left="338" width="163" height="17" font="0">illness (reported by their GP); </text>
<text top="665" left="338" width="150" height="17" font="0">those with congenital heart </text>
<text top="683" left="338" width="187" height="17" font="0">disease; and those unable to give </text>
<text top="700" left="338" width="101" height="17" font="0">informed consent  </text>
<text top="373" left="547" width="99" height="17" font="2"><b>Intervention and </b></text>
<text top="390" left="547" width="109" height="17" font="2"><b>comparator</b>: Daily, </text>
<text top="407" left="547" width="106" height="17" font="0">100 mg ASA tablet </text>
<text top="425" left="547" width="73" height="17" font="0">+ antioxidant </text>
<text top="442" left="547" width="95" height="17" font="0">capsule (n=320), </text>
<text top="459" left="547" width="72" height="17" font="0">ASA tablet + </text>
<text top="476" left="547" width="92" height="17" font="0">placebo capsule </text>
<text top="493" left="547" width="96" height="17" font="0">(n=318), placebo </text>
<text top="511" left="547" width="107" height="17" font="0">tablet + antioxidant </text>
<text top="528" left="547" width="110" height="17" font="0">capsule (n=320), or </text>
<text top="545" left="547" width="91" height="17" font="0">placebo tablet + </text>
<text top="562" left="547" width="92" height="17" font="0">placebo capsule </text>
<text top="579" left="547" width="46" height="17" font="0">(n=318) </text>
<text top="374" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="373" left="682" width="6" height="18" font="7"></text>
<text top="374" left="688" width="66" height="17" font="2"><b> endpoint</b>:  </text>
<text top="391" left="675" width="7" height="18" font="7"></text>
<text top="392" left="682" width="251" height="17" font="0"> Death from coronary heart disease or stroke, </text>
<text top="410" left="675" width="255" height="17" font="0">nonfatal MI or stroke, or amputation above the </text>
<text top="427" left="675" width="248" height="17" font="0">ankle for CLI; and death from CHD or stroke  </text>
<text top="444" left="675" width="7" height="18" font="7"></text>
<text top="445" left="682" width="234" height="17" font="0"> 116 of 638 primary events occurred in the </text>
<text top="462" left="675" width="247" height="17" font="0">ASA groups compared with 117 of 638 in the </text>
<text top="480" left="675" width="245" height="17" font="0">no ASA groups (18.2% vs. 18.3%) HR: 0.98; </text>
<text top="497" left="675" width="246" height="17" font="0">95% CI: 0.76–1.26. 43 deaths from coronary </text>
<text top="514" left="675" width="241" height="17" font="0">heart disease or stroke occurred in the ASA </text>
<text top="531" left="675" width="261" height="17" font="0">groups compared with 35 in the no ASA groups </text>
<text top="548" left="675" width="262" height="17" font="0">(6.7% vs. 5.5%): HR: 1.23; 95% CI: 0.79–1.93). </text>
<text top="566" left="675" width="7" height="18" font="7"></text>
<text top="567" left="682" width="224" height="17" font="0"> No difference in treatment for ABI &lt;0.90 </text>
<text top="373" left="952" width="129" height="17" font="2"><b>Adverse effect (effect </b></text>
<text top="390" left="952" width="72" height="17" font="2"><b>estimates):  </b></text>
<text top="407" left="952" width="7" height="18" font="7"></text>
<text top="408" left="959" width="131" height="17" font="0"> Malignancy 0.76 (0.52–</text>
<text top="426" left="952" width="38" height="17" font="0">1.11),  </text>
<text top="443" left="952" width="7" height="18" font="7"></text>
<text top="444" left="959" width="146" height="17" font="0"> Gastrointestinal bleeding, </text>
<text top="461" left="952" width="94" height="17" font="0">0.90 (0.53–1.52) </text>
<text top="479" left="952" width="7" height="18" font="7"></text>
<text top="480" left="959" width="127" height="17" font="0"> Dyspepsia 0.77 (0.55–</text>
<text top="497" left="952" width="38" height="17" font="0">1.08),  </text>
<text top="514" left="952" width="7" height="18" font="7"></text>
<text top="515" left="959" width="142" height="17" font="0"> Allergy 1.14 (0.80–1.63)  </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="14" size="13" family="Times" color="#201e1e"/>
	<fontspec id="15" size="13" family="Times" color="#1a1717"/>
<text top="795" left="1088" width="17" height="17" font="0">42 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="84" height="17" font="14">Fowkes FG, et </text>
<text top="104" left="95" width="16" height="17" font="14">al. </text>
<text top="122" left="95" width="27" height="17" font="14">2010</text>
<text top="122" left="122" width="22" height="17" font="0">(15)</text>
<text top="122" left="144" width="3" height="17" font="14"> </text>
<text top="139" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20197530">20197530 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="31" height="17" font="2"><b>Aim:</b> </text>
<text top="87" left="233" width="76" height="17" font="14">To determine </text>
<text top="104" left="203" width="109" height="17" font="14">the effectiveness of </text>
<text top="122" left="203" width="102" height="17" font="14">ASA in preventing </text>
<text top="139" left="203" width="118" height="17" font="14">events in people with </text>
<text top="156" left="203" width="108" height="17" font="14">a low ABI identified </text>
<text top="173" left="203" width="94" height="17" font="14">on screening the </text>
<text top="190" left="203" width="108" height="17" font="14">general population. </text>
<text top="190" left="311" width="3" height="17" font="0"> </text>
<text top="208" left="203" width="3" height="17" font="0"> </text>
<text top="225" left="203" width="66" height="17" font="2"><b>Study type</b>:</text>
<text top="225" left="269" width="3" height="17" font="14"> </text>
<text top="242" left="203" width="72" height="17" font="14">Randomized </text>
<text top="259" left="203" width="87" height="17" font="14">Controlled Trial </text>
<text top="259" left="289" width="3" height="17" font="0"> </text>
<text top="276" left="203" width="3" height="17" font="0"> </text>
<text top="294" left="203" width="100" height="17" font="2"><b>Size:</b> n=3,350 pts </text>
<text top="87" left="338" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="104" left="338" width="148" height="17" font="0">Age 50 to 75 with no Hx of </text>
<text top="122" left="338" width="177" height="17" font="0">vascular disease and ABI &lt;0.95 </text>
<text top="139" left="338" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="156" left="338" width="183" height="17" font="14">Hx of MI, stroke, angina, or PAD; </text>
<text top="173" left="338" width="144" height="17" font="14">currently used ASA, other </text>
<text top="190" left="338" width="154" height="17" font="14">antiplatelet or anticoagulant </text>
<text top="208" left="338" width="174" height="17" font="14">agents; had severe indigestion; </text>
<text top="225" left="338" width="195" height="17" font="14">had chronic liver or kidney disease; </text>
<text top="242" left="338" width="191" height="17" font="14">were receiving chemotherapy; had </text>
<text top="259" left="338" width="189" height="17" font="14">contraindications to ASA; and had </text>
<text top="276" left="338" width="144" height="17" font="14">an abnormally high or low </text>
<text top="294" left="338" width="184" height="17" font="14">hematocrit value (measured after </text>
<text top="311" left="338" width="81" height="17" font="14">the screening) </text>
<text top="311" left="419" width="3" height="17" font="0"> </text>
<text top="87" left="547" width="102" height="17" font="2"><b>Intervention:</b> 100 </text>
<text top="104" left="547" width="101" height="17" font="0">mg enteric coated </text>
<text top="122" left="547" width="28" height="17" font="0">ASA </text>
<text top="139" left="547" width="3" height="17" font="0"> </text>
<text top="156" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="173" left="547" width="48" height="17" font="0">Placebo </text>
<text top="88" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="682" width="6" height="18" font="7"></text>
<text top="88" left="688" width="62" height="17" font="2"><b> endpoint</b>: </text>
<text top="88" left="750" width="185" height="17" font="14">Composite of initial (earliest) fatal </text>
<text top="106" left="675" width="212" height="17" font="14">or nonfatal coronary event or stroke or </text>
<text top="123" left="675" width="96" height="17" font="14">revascularization </text>
<text top="123" left="771" width="3" height="17" font="0"> </text>
<text top="140" left="675" width="257" height="17" font="14">No statistically significant difference was found </text>
<text top="157" left="675" width="256" height="17" font="14">between groups (13.7 events per 1000 person-</text>
<text top="174" left="675" width="256" height="17" font="14">years in the ASA group vs. 13.3 in the placebo </text>
<text top="192" left="675" width="165" height="17" font="14">group; HR: 1.03; 95% CI; 0.84</text>
<text top="192" left="840" width="7" height="17" font="0">–</text>
<text top="192" left="847" width="31" height="17" font="14">1.27) </text>
<text top="192" left="878" width="3" height="17" font="0"> </text>
<text top="209" left="675" width="3" height="17" font="0"> </text>
<text top="226" left="675" width="103" height="17" font="2"><b>Safety endpoint:  </b></text>
<text top="243" left="675" width="7" height="18" font="7"></text>
<text top="244" left="682" width="107" height="17" font="0"> Major hemorrhage </text>
<text top="262" left="675" width="7" height="18" font="7"></text>
<text top="263" left="682" width="3" height="17" font="0"> </text>
<text top="263" left="685" width="235" height="17" font="14">Initial event of major hemorrhage requiring </text>
<text top="280" left="675" width="244" height="17" font="14">admission to hospital occurred in 34 pts (2.5 </text>
<text top="297" left="675" width="252" height="17" font="14">per 1000 person-years) in the ASA group and </text>
<text top="314" left="675" width="253" height="17" font="14">20 (1.5 per 1000 person-years) in the placebo </text>
<text top="332" left="675" width="165" height="17" font="14">group (HR: 1.71; 95% CI: 0.99</text>
<text top="332" left="840" width="7" height="17" font="0">–</text>
<text top="332" left="847" width="35" height="17" font="14">2.97). </text>
<text top="332" left="882" width="3" height="17" font="0"> </text>
<text top="87" left="952" width="7" height="18" font="7"></text>
<text top="88" left="959" width="144" height="17" font="14"> All initial vascular events, </text>
<text top="106" left="952" width="154" height="17" font="14">defined as a composite of a </text>
<text top="123" left="952" width="143" height="17" font="14">primary endpoint event or </text>
<text top="140" left="952" width="124" height="17" font="14">angina, IC or transient </text>
<text top="157" left="952" width="108" height="17" font="14">ischemic attack; no </text>
<text top="174" left="952" width="121" height="17" font="14">statistically significant </text>
<text top="192" left="952" width="148" height="17" font="14">difference between groups </text>
<text top="209" left="952" width="123" height="17" font="14">(22.8 events per 1000 </text>
<text top="226" left="952" width="137" height="17" font="14">person-years in the ASA </text>
<text top="243" left="952" width="115" height="17" font="14">group vs. 22.9 in the </text>
<text top="260" left="952" width="140" height="17" font="14">placebo group; HR: 1.00; </text>
<text top="278" left="952" width="71" height="17" font="14">95% CI: 0.85</text>
<text top="278" left="1023" width="7" height="17" font="0">–</text>
<text top="278" left="1030" width="31" height="17" font="14">1.17) </text>
<text top="278" left="1061" width="3" height="17" font="0"> </text>
<text top="295" left="952" width="7" height="18" font="7"></text>
<text top="296" left="959" width="107" height="17" font="14"> All-cause mortality </text>
<text top="296" left="1066" width="3" height="17" font="0"> </text>
<text top="313" left="952" width="146" height="17" font="14">no significant difference in </text>
<text top="330" left="952" width="152" height="17" font="14">all-cause mortality between </text>
<text top="348" left="952" width="156" height="17" font="14">groups (176 vs. 186 deaths, </text>
<text top="365" left="952" width="155" height="17" font="14">respectively; HR: 0.95; 95% </text>
<text top="382" left="952" width="43" height="17" font="14">CI: 0.77</text>
<text top="382" left="995" width="7" height="17" font="0">–</text>
<text top="382" left="1002" width="28" height="17" font="14">1.16)</text>
<text top="382" left="1030" width="3" height="17" font="0"> </text>
<text top="404" left="95" width="40" height="17" font="2"><b>CLIPS </b></text>
<text top="422" left="95" width="83" height="17" font="0">Catalano M, et </text>
<text top="439" left="95" width="16" height="17" font="0">al. </text>
<text top="456" left="95" width="59" height="17" font="0">2007(104) </text>
<text top="473" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17305650">17305650 </a></text>
<text top="491" left="95" width="3" height="17" font="0"> </text>
<text top="404" left="203" width="111" height="17" font="2"><b>Aim:</b> To assess the </text>
<text top="422" left="203" width="114" height="17" font="0">prophylactic efficacy </text>
<text top="439" left="203" width="103" height="17" font="0">of ASA and a high-</text>
<text top="456" left="203" width="93" height="17" font="0">dose antioxidant </text>
<text top="473" left="203" width="112" height="17" font="0">vitamin combination </text>
<text top="491" left="203" width="100" height="17" font="0">in pts with PAD in </text>
<text top="508" left="203" width="116" height="17" font="0">terms of reduction of </text>
<text top="525" left="203" width="90" height="17" font="0">the risk of a first </text>
<text top="542" left="203" width="107" height="17" font="0">vascular event (MI, </text>
<text top="559" left="203" width="90" height="17" font="0">stroke, vascular </text>
<text top="577" left="203" width="88" height="17" font="0">death) and CLI. </text>
<text top="594" left="203" width="3" height="17" font="0"> </text>
<text top="611" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="628" left="203" width="76" height="17" font="0">Randomized, </text>
<text top="645" left="203" width="107" height="17" font="0">placebo-controlled, </text>
<text top="663" left="203" width="111" height="17" font="0">double-blind clinical </text>
<text top="680" left="203" width="118" height="17" font="0">trial with 2x2 factorial </text>
<text top="697" left="203" width="53" height="17" font="0">designs.  </text>
<text top="714" left="203" width="3" height="17" font="0"> </text>
<text top="731" left="203" width="90" height="17" font="2"><b>Size:</b> n=366 pts </text>
<text top="404" left="338" width="189" height="17" font="2"><b>Inclusion criteria:</b> stage I–II PAD </text>
<text top="422" left="338" width="173" height="17" font="0">documented by angiography or </text>
<text top="439" left="338" width="169" height="17" font="0">ultrasound, with ankle/brachial </text>
<text top="456" left="338" width="163" height="17" font="0">index &lt;0.85 or toe index &lt;0.6 </text>
<text top="473" left="338" width="3" height="17" font="0"> </text>
<text top="491" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="508" left="338" width="7" height="18" font="7"></text>
<text top="509" left="344" width="3" height="17" font="0"> </text>
<text top="509" left="348" width="179" height="17" font="15">Fontaine stage III or IV PVD; life </text>
<text top="526" left="338" width="7" height="18" font="7"></text>
<text top="527" left="344" width="12" height="17" font="0"> E</text>
<text top="527" left="356" width="156" height="17" font="15">xpectancy &lt;24 mo; vascular </text>
<text top="544" left="338" width="191" height="17" font="15">surgery or angioplasty in the last 3 </text>
<text top="562" left="338" width="27" height="17" font="15">mo;  </text>
<text top="579" left="338" width="7" height="18" font="7"></text>
<text top="580" left="344" width="12" height="17" font="0"> P</text>
<text top="580" left="356" width="121" height="17" font="15">regnancy or lactation; </text>
<text top="597" left="338" width="7" height="18" font="7"></text>
<text top="598" left="344" width="3" height="17" font="0"> </text>
<text top="598" left="348" width="141" height="17" font="15">Contraindication to ASA;  </text>
<text top="616" left="338" width="7" height="18" font="7"></text>
<text top="617" left="344" width="14" height="17" font="0"> M</text>
<text top="617" left="358" width="146" height="17" font="15">ajor cardiovascular events </text>
<text top="634" left="338" width="165" height="17" font="15">requiring antiplatelet therapy;  </text>
<text top="651" left="338" width="7" height="18" font="7"></text>
<text top="652" left="344" width="12" height="17" font="0"> P</text>
<text top="652" left="356" width="161" height="17" font="15">articipation in another clinical </text>
<text top="670" left="338" width="30" height="17" font="15">trial;  </text>
<text top="687" left="338" width="7" height="18" font="7"></text>
<text top="688" left="344" width="12" height="17" font="0"> U</text>
<text top="688" left="357" width="100" height="17" font="15">ncooperative pts;  </text>
<text top="705" left="338" width="7" height="18" font="7"></text>
<text top="706" left="344" width="11" height="17" font="0"> T</text>
<text top="706" left="355" width="135" height="17" font="15">reatment with drugs that </text>
<text top="724" left="338" width="189" height="17" font="15">interfere with hemostasis, such as </text>
<text top="741" left="338" width="189" height="17" font="15">anticoagulants, antiplatelet agents </text>
<text top="758" left="338" width="153" height="17" font="15">and prostanoids, peripheral </text>
<text top="775" left="338" width="139" height="17" font="15">vasodilators, ASA and/or </text>
<text top="404" left="547" width="99" height="17" font="2"><b>Intervention and </b></text>
<text top="422" left="547" width="104" height="17" font="2"><b>Comparator:</b> Oral </text>
<text top="439" left="547" width="113" height="17" font="0">ASA (100 mg daily), </text>
<text top="456" left="547" width="87" height="17" font="0">oral antioxidant </text>
<text top="473" left="547" width="97" height="17" font="0">vitamins (600 mg </text>
<text top="491" left="547" width="102" height="17" font="0">vitamin E, 250 mg </text>
<text top="508" left="547" width="96" height="17" font="0">vitamin C and 20 </text>
<text top="525" left="547" width="100" height="17" font="0">mg beta-carotene </text>
<text top="542" left="547" width="78" height="17" font="0">daily), both or </text>
<text top="559" left="547" width="41" height="17" font="0">neither </text>
<text top="577" left="547" width="3" height="17" font="0"> </text>
<text top="405" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="404" left="682" width="6" height="18" font="7"></text>
<text top="405" left="688" width="73" height="17" font="2"><b> endpoints:  </b></text>
<text top="423" left="675" width="7" height="18" font="7"></text>
<text top="424" left="682" width="220" height="17" font="0"> Incidence of fatal and nonfatal vascular </text>
<text top="441" left="675" width="246" height="17" font="0">events (MI, stroke and pulmonary embolism) </text>
<text top="458" left="675" width="134" height="17" font="0">and critical leg ischemia </text>
<text top="476" left="675" width="7" height="18" font="7"></text>
<text top="477" left="682" width="3" height="17" font="0"> </text>
<text top="477" left="685" width="221" height="17" font="15">7 of 185 ASA and 20 of 181 placebo pts </text>
<text top="494" left="675" width="256" height="17" font="15">suffered a major vascular event (risk reduction </text>
<text top="511" left="675" width="84" height="17" font="15">64%, p=0.022) </text>
<text top="528" left="675" width="7" height="18" font="7"></text>
<text top="530" left="682" width="3" height="17" font="0"> </text>
<text top="530" left="685" width="214" height="17" font="15">5 ASA and 8 placebo pts, respectively, </text>
<text top="547" left="675" width="245" height="17" font="15">suffered critical leg ischemia (total 12 vs. 28, </text>
<text top="564" left="675" width="52" height="17" font="15">p=0.014) </text>
<text top="581" left="675" width="3" height="17" font="0"> </text>
<text top="598" left="675" width="243" height="17" font="2"><b>Safety endpoint:</b> Incidence of bleeding 4 in </text>
<text top="616" left="675" width="171" height="17" font="0">ASA and 0 in placebo (p=0.99) </text>
<text top="404" left="952" width="7" height="18" font="7"></text>
<text top="405" left="959" width="116" height="17" font="0"> 76% with type 2 DM </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">43 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="338" width="189" height="17" font="15">supplementary vitamins that could </text>
<text top="104" left="338" width="179" height="17" font="15">not be discontinued or had to be </text>
<text top="122" left="338" width="41" height="17" font="15">started.</text>
<text top="122" left="379" width="3" height="17" font="0"> </text>
<text top="141" left="95" width="83" height="17" font="0">Horrocks M, et </text>
<text top="158" left="95" width="16" height="17" font="0">al. </text>
<text top="176" left="95" width="59" height="17" font="0">1997(105) </text>
<text top="193" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9257670">9257670 </a></text>
<text top="210" left="95" width="3" height="17" font="0"> </text>
<text top="141" left="203" width="111" height="17" font="2"><b>Aim:</b> To investigate </text>
<text top="158" left="203" width="84" height="17" font="0">the effects of 2 </text>
<text top="176" left="203" width="99" height="17" font="0">platelet inhibitors, </text>
<text top="193" left="203" width="116" height="17" font="0">ASA and iloprost, on </text>
<text top="210" left="203" width="107" height="17" font="0">platelet uptake and </text>
<text top="227" left="203" width="116" height="17" font="0">restenosis at the site </text>
<text top="244" left="203" width="112" height="17" font="0">of angioplasty in pts </text>
<text top="262" left="203" width="109" height="17" font="0">undergoing femoral </text>
<text top="279" left="203" width="64" height="17" font="0">or popliteal </text>
<text top="296" left="203" width="69" height="17" font="0">angioplasty. </text>
<text top="313" left="203" width="3" height="17" font="0"> </text>
<text top="330" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="348" left="203" width="71" height="17" font="0">Prospective, </text>
<text top="365" left="203" width="68" height="17" font="0">randomized </text>
<text top="382" left="203" width="3" height="17" font="0"> </text>
<text top="399" left="203" width="83" height="17" font="2"><b>Size:</b> n=43 pts </text>
<text top="141" left="338" width="192" height="17" font="2"><b>Inclusion criteria:</b> Pts undergoing </text>
<text top="158" left="338" width="174" height="17" font="0">femoral or popliteal angioplasty </text>
<text top="176" left="338" width="3" height="17" font="0"> </text>
<text top="193" left="338" width="161" height="17" font="2"><b>Exclusion criteria:</b> Bleeding </text>
<text top="210" left="338" width="127" height="17" font="0">disorder, ulcer disease </text>
<text top="141" left="547" width="106" height="17" font="2"><b>Intervention: </b>ASA </text>
<text top="158" left="547" width="109" height="17" font="0">(300 mg/d), iloprost </text>
<text top="176" left="547" width="102" height="17" font="0">(8 H/d IV infusion) </text>
<text top="193" left="547" width="94" height="17" font="0">or no antiplatelet </text>
<text top="210" left="547" width="101" height="17" font="0">medication during </text>
<text top="227" left="547" width="107" height="17" font="0">angioplasty and on </text>
<text top="244" left="547" width="112" height="17" font="0">the subsequent 2 d. </text>
<text top="142" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="141" left="682" width="6" height="18" font="7"></text>
<text top="142" left="688" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="160" left="675" width="7" height="18" font="7"></text>
<text top="161" left="682" width="228" height="17" font="0"> Platelet uptake was measured using 111 </text>
<text top="178" left="675" width="229" height="17" font="0">Indium-labelled platelets. Restenosis was </text>
<text top="195" left="675" width="250" height="17" font="0">assessed by repeat angiography at 3 mo and </text>
<text top="212" left="675" width="172" height="17" font="0">clinical symptoms up to 12 mo. </text>
<text top="230" left="675" width="7" height="18" font="7"></text>
<text top="231" left="682" width="224" height="17" font="0"> Median changes in platelet uptake were </text>
<text top="248" left="675" width="262" height="17" font="0">similar in the 3 treatment groups, but all platelet </text>
<text top="265" left="675" width="255" height="17" font="0">radioactivity ratios &gt;2.0 occurred in the control </text>
<text top="282" left="675" width="250" height="17" font="0">group. Restenosis at 3 mo was observed in 3 </text>
<text top="300" left="675" width="180" height="17" font="0">control, 5 ASA and 1 iloprost pt.  </text>
<text top="317" left="675" width="7" height="18" font="7"></text>
<text top="318" left="682" width="244" height="17" font="0"> Further surgical intervention was performed </text>
<text top="335" left="675" width="248" height="17" font="0">in 3 control and 3 ASA pts, but in none of the </text>
<text top="352" left="675" width="225" height="17" font="0">iloprost pts up to 12 mo after angioplasty </text>
<text top="370" left="675" width="3" height="17" font="0"> </text>
<text top="141" left="952" width="7" height="18" font="7"></text>
<text top="142" left="959" width="137" height="17" font="0"> Limited utility as iloprost </text>
<text top="160" left="952" width="68" height="17" font="0">also utilized </text>
<text top="417" left="95" width="79" height="17" font="0">Minar E, et al. </text>
<text top="435" left="95" width="59" height="17" font="0">1995(106) </text>
<text top="452" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7697845">7697845 </a></text>
<text top="469" left="95" width="3" height="17" font="0"> </text>
<text top="417" left="203" width="120" height="17" font="2"><b>Aim:</b> To compare the </text>
<text top="435" left="203" width="111" height="17" font="0">effects of high-dose </text>
<text top="452" left="203" width="116" height="17" font="0">(1000 mg/d) and low-</text>
<text top="469" left="203" width="121" height="17" font="0">dose (100 mg/d) ASA </text>
<text top="486" left="203" width="119" height="17" font="0">on long-term patency </text>
<text top="503" left="203" width="115" height="17" font="0">after femoropopliteal </text>
<text top="521" left="203" width="69" height="17" font="0">angioplasty. </text>
<text top="538" left="203" width="3" height="17" font="0"> </text>
<text top="555" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="572" left="203" width="72" height="17" font="0">Randomized </text>
<text top="589" left="203" width="3" height="17" font="0"> </text>
<text top="607" left="203" width="90" height="17" font="2"><b>Size:</b> n=216 pts </text>
<text top="417" left="338" width="169" height="17" font="2"><b>Inclusion criteria: </b>Pts treated </text>
<text top="435" left="338" width="164" height="17" font="0">successfully by percutaneous </text>
<text top="452" left="338" width="153" height="17" font="0">transluminal angioplasty for </text>
<text top="469" left="338" width="129" height="17" font="0">femoropopliteal lesions </text>
<text top="486" left="338" width="3" height="17" font="0"> </text>
<text top="503" left="338" width="177" height="17" font="2"><b>Exclusion criteria</b>: Failed PTA, </text>
<text top="521" left="338" width="178" height="17" font="0">recent gastroduodenal ulcer, life </text>
<text top="538" left="338" width="167" height="17" font="0">expectancy &lt;2 y, severe renal </text>
<text top="555" left="338" width="170" height="17" font="0">insufficiency, need for ongoing </text>
<text top="572" left="338" width="178" height="17" font="0">nonsteroidal, unable to consent  </text>
<text top="417" left="547" width="99" height="17" font="2"><b>Intervention and </b></text>
<text top="435" left="547" width="107" height="17" font="2"><b>Comparator</b>: 1000 </text>
<text top="452" left="547" width="87" height="17" font="0">or 100 mg ASA </text>
<text top="469" left="547" width="32" height="17" font="0">daily. </text>
<text top="418" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="417" left="682" width="6" height="18" font="7"></text>
<text top="418" left="688" width="215" height="17" font="2"><b> endpoint:</b> Long-term (24 mo) patency </text>
<text top="436" left="675" width="255" height="17" font="0">36 pts in the high-dose and 36 in the low-dose </text>
<text top="453" left="675" width="262" height="17" font="0">ASA group, developed angiographically verified </text>
<text top="470" left="675" width="250" height="17" font="0">reobstruction within the recanalized segment. </text>
<text top="487" left="675" width="245" height="17" font="0">By intention-to-treat analysis, the cumulative </text>
<text top="505" left="675" width="258" height="17" font="0">patency rates at 24 mo were 62.5% in the high-</text>
<text top="522" left="675" width="241" height="17" font="0">dose and 62.6% in the low-dose ASA group </text>
<text top="539" left="675" width="231" height="17" font="0">(Wilcoxon, p=0.97; log-rank, p=0.97). The </text>
<text top="556" left="675" width="250" height="17" font="0">cumulative survival at 24 mo of follow-up was </text>
<text top="573" left="675" width="247" height="17" font="0">86.6% in the high-dose and 87.7% in the low-</text>
<text top="591" left="675" width="96" height="17" font="0">dose ASA group. </text>
<text top="608" left="675" width="3" height="17" font="0"> </text>
<text top="625" left="675" width="237" height="17" font="2"><b>Safety endpoint:</b> Discontinued therapy for </text>
<text top="642" left="675" width="263" height="17" font="0">gastrointestinal symptoms, 4 in high dose and 0 </text>
<text top="659" left="675" width="65" height="17" font="0">in low dose </text>
<text top="677" left="675" width="256" height="17" font="0">Discontinued therapy 30 high dose and 11 low </text>
<text top="694" left="675" width="80" height="17" font="0">dose (p&lt;0.01) </text>
<text top="417" left="952" width="7" height="18" font="7"></text>
<text top="418" left="959" width="130" height="17" font="0"> 100 mg as effective as </text>
<text top="436" left="952" width="51" height="17" font="0">1000 mg </text>
<text top="453" left="952" width="7" height="18" font="7"></text>
<text top="454" left="959" width="124" height="17" font="0"> Treatment started 3 d </text>
<text top="471" left="952" width="55" height="17" font="0">after PTA </text>
<text top="488" left="952" width="3" height="17" font="0"> </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">44 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="50" height="17" font="2"><b>CAPRIE </b></text>
<text top="104" left="95" width="63" height="17" font="0">1996 (107) </text>
<text top="122" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8918275">8918275 </a></text>
<text top="139" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="111" height="17" font="2"><b>Aim:</b> To assess the </text>
<text top="104" left="203" width="102" height="17" font="0">relative efficacy of </text>
<text top="122" left="203" width="105" height="17" font="0">clopidogrel (75 mg </text>
<text top="139" left="203" width="115" height="17" font="0">once daily) and ASA </text>
<text top="156" left="203" width="111" height="17" font="0">(325 mg once daily) </text>
<text top="173" left="203" width="120" height="17" font="0">in reducing the risk of </text>
<text top="190" left="203" width="120" height="17" font="0">a composite outcome </text>
<text top="208" left="203" width="105" height="17" font="0">cluster of ischemic </text>
<text top="225" left="203" width="75" height="17" font="0">stroke, MI, or </text>
<text top="242" left="203" width="83" height="17" font="0">vascular death </text>
<text top="259" left="203" width="3" height="17" font="0"> </text>
<text top="276" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="294" left="203" width="122" height="17" font="0">Randomized, blinded  </text>
<text top="311" left="203" width="3" height="17" font="0"> </text>
<text top="328" left="203" width="107" height="17" font="2"><b>Size:</b> n=19,185 pts </text>
<text top="87" left="338" width="152" height="17" font="2"><b>Inclusion criteria:</b> Pts with </text>
<text top="104" left="338" width="178" height="17" font="0">atherosclerotic vascular disease </text>
<text top="122" left="338" width="152" height="17" font="0">manifested as either recent </text>
<text top="139" left="338" width="180" height="17" font="0">ischemic stroke, recent MI, or sx </text>
<text top="156" left="338" width="29" height="17" font="0">PAD </text>
<text top="173" left="338" width="3" height="17" font="0"> </text>
<text top="190" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="208" left="338" width="7" height="18" font="7"></text>
<text top="209" left="344" width="63" height="17" font="0"> Age &lt;21 y </text>
<text top="226" left="338" width="7" height="18" font="7"></text>
<text top="227" left="344" width="174" height="17" font="0"> Severe cerebral deficit likely to </text>
<text top="244" left="338" width="160" height="17" font="0">lead to pt being bedridden or </text>
<text top="262" left="338" width="190" height="17" font="0">demented Carotid endarterectomy </text>
<text top="279" left="338" width="120" height="17" font="0">after qualifying stroke </text>
<text top="296" left="338" width="7" height="18" font="7"></text>
<text top="297" left="344" width="161" height="17" font="0"> Qualifying stroke induced by </text>
<text top="314" left="338" width="144" height="17" font="0">carotid endarterectomy or </text>
<text top="332" left="338" width="71" height="17" font="0">angiography </text>
<text top="349" left="338" width="7" height="18" font="7"></text>
<text top="350" left="344" width="157" height="17" font="0"> Pt unlikely to be discharged </text>
<text top="367" left="338" width="150" height="17" font="0">alone after qualifying event </text>
<text top="384" left="338" width="7" height="18" font="7"></text>
<text top="385" left="344" width="182" height="17" font="0"> Severe comorbidity likely to limit </text>
<text top="403" left="338" width="193" height="17" font="0">pt’s life expectancy to less than 3 y </text>
<text top="420" left="338" width="146" height="17" font="0">Uncontrolled hypertension </text>
<text top="437" left="338" width="7" height="18" font="7"></text>
<text top="438" left="344" width="161" height="17" font="0"> Scheduled for major surgery </text>
<text top="456" left="338" width="7" height="18" font="7"></text>
<text top="457" left="344" width="189" height="17" font="0"> Contraindications to study drugs:  </text>
<text top="474" left="338" width="7" height="18" font="7"></text>
<text top="475" left="344" width="134" height="17" font="0"> Severe renal or hepatic </text>
<text top="492" left="338" width="70" height="17" font="0">insufficiency </text>
<text top="510" left="338" width="7" height="18" font="7"></text>
<text top="511" left="344" width="182" height="17" font="0"> Hemostatic disorder or systemic </text>
<text top="528" left="338" width="50" height="17" font="0">bleeding </text>
<text top="545" left="338" width="7" height="18" font="7"></text>
<text top="546" left="344" width="167" height="17" font="0"> Hx of haemostatic disorder or </text>
<text top="564" left="338" width="101" height="17" font="0">systemic bleeding </text>
<text top="581" left="338" width="7" height="18" font="7"></text>
<text top="582" left="344" width="151" height="17" font="0"> Hx of thrombocytopenia or </text>
<text top="599" left="338" width="68" height="17" font="0">neutropenia </text>
<text top="616" left="338" width="7" height="18" font="7"></text>
<text top="617" left="344" width="180" height="17" font="0"> Hx of drug-induced hematologic </text>
<text top="635" left="338" width="134" height="17" font="0">or hepatic abnormalities </text>
<text top="652" left="338" width="7" height="18" font="7"></text>
<text top="653" left="344" width="178" height="17" font="0"> Known to have abnormal WBC, </text>
<text top="670" left="338" width="155" height="17" font="0">differential, or platelet count </text>
<text top="688" left="338" width="7" height="18" font="7"></text>
<text top="689" left="344" width="182" height="17" font="0"> Anticipated requirement for long-</text>
<text top="706" left="338" width="172" height="17" font="0">term anticoagulants, non-study </text>
<text top="723" left="338" width="159" height="17" font="0">antiplatelet drugs or NSAIDs </text>
<text top="740" left="338" width="140" height="17" font="0">affecting platelet function </text>
<text top="758" left="338" width="7" height="18" font="7"></text>
<text top="759" left="344" width="124" height="17" font="0"> Hx of ASA sensitivity  </text>
<text top="776" left="338" width="174" height="17" font="0">Women of childbearing age not </text>
<text top="87" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="104" left="547" width="99" height="17" font="0">Clopidigrel 75 mg </text>
<text top="122" left="547" width="32" height="17" font="0">per d </text>
<text top="139" left="547" width="3" height="17" font="0"> </text>
<text top="156" left="547" width="105" height="17" font="2"><b>Comparator:</b> ASA </text>
<text top="173" left="547" width="76" height="17" font="0">325 mg per d </text>
<text top="88" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="682" width="6" height="18" font="7"></text>
<text top="88" left="688" width="63" height="17" font="2"><b> endpoint:</b> </text>
<text top="106" left="675" width="7" height="18" font="7"></text>
<text top="107" left="682" width="221" height="17" font="0"> Composite outcome cluster of ischemic </text>
<text top="124" left="675" width="162" height="17" font="0">stroke, MI, or vascular death  </text>
<text top="141" left="675" width="7" height="18" font="7"></text>
<text top="142" left="682" width="230" height="17" font="0"> 1960 first events included in the outcome </text>
<text top="159" left="675" width="250" height="17" font="0">cluster on which an intention-to-treat analysis </text>
<text top="177" left="675" width="260" height="17" font="0">showed that pts treated with clopidogrel had an </text>
<text top="194" left="675" width="241" height="17" font="0">annual 5.32% risk of ischemic stroke, MI, or </text>
<text top="211" left="675" width="235" height="17" font="0">vascular death lower than 5.83% with ASA </text>
<text top="228" left="675" width="250" height="17" font="0">(p=0.043). A relative-risk reduction of 8.7% in </text>
<text top="246" left="675" width="218" height="17" font="0">favor of clopidogrel (95% CI: 0.3–16.5)  </text>
<text top="263" left="675" width="3" height="17" font="0"> </text>
<text top="280" left="675" width="234" height="17" font="2"><b>Safety endpoint:</b> Bleeding similar in the 2 </text>
<text top="297" left="675" width="41" height="17" font="0">groups </text>
<text top="314" left="675" width="3" height="17" font="0"> </text>
<text top="87" left="952" width="7" height="18" font="7"></text>
<text top="88" left="959" width="105" height="17" font="0"> Reported adverse </text>
<text top="106" left="952" width="103" height="17" font="0">experiences in the </text>
<text top="123" left="952" width="156" height="17" font="0">clopidogrel and ASA groups </text>
<text top="140" left="952" width="112" height="17" font="0">judged to be severe </text>
<text top="157" left="952" width="138" height="17" font="0">included rash (0.26% vs. </text>
<text top="174" left="952" width="156" height="17" font="0">0.10%), diarrhea (0.23% vs. </text>
<text top="192" left="952" width="81" height="17" font="0">0.11%), upper </text>
<text top="209" left="952" width="146" height="17" font="0">gastrointestinal discomfort </text>
<text top="226" left="952" width="107" height="17" font="0">(0.97% vs. 1.22%), </text>
<text top="243" left="952" width="133" height="17" font="0">intracranial hemorrhage </text>
<text top="260" left="952" width="132" height="17" font="0">(0.33% vs. 0·47%), and </text>
<text top="278" left="952" width="156" height="17" font="0">gastrointestinal hemorrhage </text>
<text top="295" left="952" width="107" height="17" font="0">(0.52% vs. 0.72%), </text>
<text top="312" left="952" width="155" height="17" font="0">respectively. There were 10 </text>
<text top="329" left="952" width="100" height="17" font="0">(0.10%) pts in the </text>
<text top="347" left="952" width="123" height="17" font="0">clopidogrel group with </text>
<text top="364" left="952" width="131" height="17" font="0">significant reductions in </text>
<text top="381" left="952" width="120" height="17" font="0">neutrophils (&lt;1.2 × 10</text>
<text top="382" left="1072" width="4" height="11" font="11">9</text>
<text top="381" left="1076" width="18" height="17" font="0">/L) </text>
<text top="398" left="952" width="149" height="17" font="0">and 16 (0.17%) in the ASA </text>
<text top="415" left="952" width="42" height="17" font="0">group.  </text>
<text top="433" left="952" width="7" height="18" font="7"></text>
<text top="434" left="959" width="126" height="17" font="0"> Marginally statistically </text>
<text top="451" left="952" width="148" height="17" font="0">significant result (p=0.043) </text>
<text top="468" left="952" width="118" height="17" font="0">was observed for the </text>
<text top="485" left="952" width="124" height="17" font="0">primary endpoint, with </text>
<text top="503" left="952" width="146" height="17" font="0">statistical heterogeneity of </text>
<text top="520" left="952" width="145" height="17" font="0">treatment effect (p=0.042) </text>
<text top="537" left="952" width="138" height="17" font="0">being observed between </text>
<text top="554" left="952" width="153" height="17" font="0">the 3 predefined subgroups </text>
<text top="571" left="952" width="137" height="17" font="0">of pts with recent stroke, </text>
<text top="589" left="952" width="145" height="17" font="0">MI, or PVD. Only the PVD </text>
<text top="606" left="952" width="148" height="17" font="0">subgroup clearly benefited </text>
<text top="623" left="952" width="146" height="17" font="0">from clopidogrel over ASA </text>
<text top="640" left="952" width="139" height="17" font="0">the use of clopidogrel vs. </text>
<text top="657" left="952" width="35" height="17" font="0">ASA.  </text>
<text top="675" left="952" width="3" height="17" font="0"> </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="16" size="13" family="Times" color="#282222"/>
	<fontspec id="17" size="13" family="Times" color="#252525"/>
<text top="795" left="1088" width="17" height="17" font="0">45 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="338" width="153" height="17" font="0">using reliable contraception </text>
<text top="104" left="338" width="178" height="17" font="0">Currently receiving investigation </text>
<text top="122" left="338" width="28" height="17" font="0">drug </text>
<text top="139" left="338" width="7" height="18" font="7"></text>
<text top="140" left="344" width="153" height="17" font="0"> Previously entered in other </text>
<text top="157" left="338" width="105" height="17" font="0">clopidogrel studies </text>
<text top="174" left="338" width="196" height="17" font="0">Geographic or other factors making </text>
<text top="192" left="338" width="168" height="17" font="0">study participation impractical  </text>
<text top="210" left="95" width="73" height="17" font="2"><b>CHARISMA  </b></text>
<text top="227" left="95" width="83" height="17" font="0">Cacoub PP, et </text>
<text top="244" left="95" width="16" height="17" font="0">al. </text>
<text top="261" left="95" width="59" height="17" font="0">2009(108) </text>
<text top="278" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19136484">19136484 </a></text>
<text top="296" left="95" width="3" height="17" font="0"> </text>
<text top="210" left="203" width="107" height="17" font="2"><b>Aim: </b>To determine </text>
<text top="227" left="203" width="121" height="17" font="0">whether clopidogrel + </text>
<text top="244" left="203" width="120" height="17" font="0">ASA provides greater </text>
<text top="261" left="203" width="101" height="17" font="0">protection against </text>
<text top="278" left="203" width="117" height="17" font="0">major cardiovascular </text>
<text top="296" left="203" width="95" height="17" font="0">events than ASA </text>
<text top="313" left="203" width="92" height="17" font="0">alone in pts with </text>
<text top="330" left="203" width="32" height="17" font="0">PAD. </text>
<text top="347" left="203" width="3" height="17" font="0"> </text>
<text top="365" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="382" left="203" width="114" height="17" font="0">Substudy of Bhatt et </text>
<text top="399" left="203" width="54" height="17" font="0">al., 2007. </text>
<text top="416" left="203" width="113" height="17" font="0">Post hoc analysis of </text>
<text top="433" left="203" width="107" height="17" font="0">pt subgroup from a </text>
<text top="451" left="203" width="103" height="17" font="0">larger randomized </text>
<text top="468" left="203" width="23" height="17" font="0">trial </text>
<text top="485" left="203" width="3" height="17" font="0"> </text>
<text top="502" left="203" width="100" height="17" font="2"><b>Size:</b> n=3,096 pts </text>
<text top="210" left="338" width="166" height="17" font="2"><b>Inclusion criteria:</b> Sx (2,838) </text>
<text top="227" left="338" width="172" height="17" font="16">current IC together with an ABI </text>
<text top="244" left="338" width="196" height="17" font="16">≤0.85, or a Hx of IC together with a </text>
<text top="261" left="338" width="158" height="17" font="16">previous related intervention </text>
<text top="278" left="338" width="181" height="17" font="16">(amputation, surgical or catheter-</text>
<text top="296" left="338" width="195" height="17" font="16">based peripheral revascularization) </text>
<text top="313" left="338" width="98" height="17" font="0">or asx (258) PAD </text>
<text top="313" left="435" width="84" height="17" font="16">ABI, 0.90 were </text>
<text top="330" left="338" width="152" height="17" font="16">identified among those with </text>
<text top="347" left="338" width="109" height="17" font="16">multiple risk factors </text>
<text top="347" left="446" width="3" height="17" font="0"> </text>
<text top="365" left="338" width="3" height="17" font="0"> </text>
<text top="382" left="338" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="382" left="448" width="64" height="17" font="17">Taking oral </text>
<text top="399" left="338" width="164" height="17" font="17">antithrombotic medications or </text>
<text top="416" left="338" width="162" height="17" font="17">NSAIDs on a long-term basis </text>
<text top="433" left="338" width="157" height="17" font="17">(although cyclooxygenase-2 </text>
<text top="451" left="338" width="196" height="17" font="17">inhibitors were permitted). Pts were </text>
<text top="468" left="338" width="193" height="17" font="17">also excluded if, in the judgment of </text>
<text top="485" left="338" width="141" height="17" font="17">the investigator, they had </text>
<text top="502" left="338" width="145" height="17" font="17">established indications for </text>
<text top="519" left="338" width="167" height="17" font="17">clopidogrel therapy (such as a </text>
<text top="537" left="338" width="187" height="17" font="17">recent acute coronary syndrome). </text>
<text top="554" left="338" width="150" height="17" font="17">Pts who were scheduled to </text>
<text top="571" left="338" width="185" height="17" font="17">undergo a revascularization were </text>
<text top="588" left="338" width="159" height="17" font="17">not allowed to enroll until the </text>
<text top="605" left="338" width="177" height="17" font="17">procedure had been completed; </text>
<text top="623" left="338" width="168" height="17" font="17">such pts were excluded if they </text>
<text top="640" left="338" width="149" height="17" font="17">were considered to require </text>
<text top="657" left="338" width="187" height="17" font="17">clopidogrel after revascularization.</text>
<text top="657" left="524" width="7" height="17" font="0">  </text>
<text top="210" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="227" left="547" width="104" height="17" font="0">Clopidogrel + ASA </text>
<text top="244" left="547" width="3" height="17" font="0"> </text>
<text top="261" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="278" left="547" width="87" height="17" font="0">Placebo + ASA </text>
<text top="211" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="210" left="682" width="6" height="18" font="7"></text>
<text top="211" left="688" width="223" height="17" font="2"><b> endpoint:</b> Among the pts with PAD, the </text>
<text top="228" left="675" width="224" height="17" font="0">primary endpoint occurred in 7.6% in the </text>
<text top="245" left="675" width="225" height="17" font="0">clopidogrel + ASA group and 8.9% in the </text>
<text top="262" left="675" width="257" height="17" font="0">placebo + ASA group (HR: 0.85; 95% CI: 0.66–</text>
<text top="280" left="675" width="251" height="17" font="0">1.08; p=0.18). In these pts, the rate of MI was </text>
<text top="297" left="675" width="256" height="17" font="0">lower in the dual antiplatelet arm than the ASA </text>
<text top="314" left="675" width="250" height="17" font="0">alone arm: 2.3% vs. 3.7% (HR: 0.63; 95% CI: </text>
<text top="331" left="675" width="218" height="17" font="0">0.42–0.96; p=0.029), as was the rate of </text>
<text top="348" left="675" width="251" height="17" font="0">hospitalization for ischemic events: 16.5% vs. </text>
<text top="366" left="675" width="266" height="17" font="0">20.1% (HR: 0.81; 95% CI: 0.68–0.95; p=0.011).  </text>
<text top="383" left="675" width="3" height="17" font="0"> </text>
<text top="400" left="675" width="257" height="17" font="2"><b>Safety endpoint:</b> The rates of severe, fatal, or </text>
<text top="417" left="675" width="247" height="17" font="0">moderate bleeding did not differ between the </text>
<text top="434" left="675" width="260" height="17" font="0">groups, whereas minor bleeding was increased </text>
<text top="452" left="675" width="247" height="17" font="0">with clopidogrel: 34.4% vs. 20.8% (OR: 1.99; </text>
<text top="469" left="675" width="161" height="17" font="0">95% CI: 1.69–2.34; p&lt;0.001) </text>
<text top="486" left="675" width="3" height="17" font="0"> </text>
<text top="210" left="952" width="7" height="18" font="7"></text>
<text top="211" left="959" width="146" height="17" font="0"> Positive subgroups within </text>
<text top="228" left="952" width="152" height="17" font="0">negative trials are often the </text>
<text top="245" left="952" width="132" height="17" font="0">result of confounding or </text>
<text top="262" left="952" width="137" height="17" font="0">bias, especially post-hoc </text>
<text top="280" left="952" width="111" height="17" font="0">defined subgroups.  </text>
<text top="297" left="952" width="7" height="18" font="7"></text>
<text top="298" left="959" width="128" height="17" font="16">The rate of the primary </text>
<text top="315" left="952" width="131" height="17" font="16">safety endpoint (severe </text>
<text top="332" left="952" width="154" height="17" font="16">bleeding) was 1.7% in each </text>
<text top="350" left="952" width="124" height="17" font="16">treatment group (p 1⁄4 </text>
<text top="367" left="952" width="35" height="17" font="16">0.90). </text>
<text top="367" left="987" width="3" height="17" font="0"> </text>
<text top="675" left="95" width="70" height="17" font="2"><b>CHARISMA </b></text>
<text top="692" left="95" width="85" height="17" font="0">Bhatt DL, et al. </text>
<text top="710" left="95" width="59" height="17" font="0">2007(109) </text>
<text top="727" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17498584">17498584 </a></text>
<text top="744" left="95" width="3" height="17" font="0"> </text>
<text top="675" left="203" width="107" height="17" font="2"><b>Aim:</b> To determine </text>
<text top="692" left="203" width="91" height="17" font="0">whether there is </text>
<text top="710" left="203" width="117" height="17" font="0">benefit of clopidoprel </text>
<text top="727" left="203" width="62" height="17" font="0">+ ASA in a </text>
<text top="744" left="203" width="94" height="17" font="0">subpopulation of </text>
<text top="761" left="203" width="68" height="17" font="0">CHARISMA </text>
<text top="675" left="338" width="195" height="17" font="2"><b>Inclusion criteria:</b> “CAPRIE-like” if </text>
<text top="692" left="338" width="140" height="17" font="0">they were enrolled with a </text>
<text top="710" left="338" width="191" height="17" font="0">documented prior MI, documented </text>
<text top="727" left="338" width="182" height="17" font="0">prior ischemic stroke, or sx PAD  </text>
<text top="744" left="338" width="3" height="17" font="0"> </text>
<text top="761" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="675" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="692" left="547" width="104" height="17" font="0">Clopidogrel + ASA </text>
<text top="710" left="547" width="3" height="17" font="0"> </text>
<text top="727" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="744" left="547" width="87" height="17" font="0">Placebo + ASA </text>
<text top="676" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="675" left="682" width="6" height="18" font="7"></text>
<text top="676" left="688" width="246" height="17" font="2"><b> endpoint:</b> The rate of cardiovascular death, </text>
<text top="693" left="675" width="230" height="17" font="0">MI, or stroke was significantly lower in the </text>
<text top="711" left="675" width="244" height="17" font="0">clopidogrel + ASA arm than in the placebo + </text>
<text top="728" left="675" width="241" height="17" font="0">ASA arm: 7.3% vs. 8.8% (HR 0.83; 95% CI: </text>
<text top="745" left="675" width="111" height="17" font="0">0.72–0.96; p=0.01)  </text>
<text top="762" left="675" width="3" height="17" font="0"> </text>
<text top="675" left="952" width="7" height="18" font="7"></text>
<text top="676" left="959" width="146" height="17" font="0"> Positive subgroups within </text>
<text top="693" left="952" width="152" height="17" font="0">negative trials are often the </text>
<text top="711" left="952" width="132" height="17" font="0">result of confounding or </text>
<text top="728" left="952" width="137" height="17" font="0">bias, especially post hoc </text>
<text top="745" left="952" width="105" height="17" font="0">defined subgroups </text>
<text top="762" left="952" width="7" height="18" font="7"></text>
<text top="763" left="959" width="111" height="17" font="0"> Hospitalizations for </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">46 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="116" height="17" font="0">(Clopidogrel for High </text>
<text top="104" left="203" width="97" height="17" font="0">Atherothrombotic </text>
<text top="122" left="203" width="103" height="17" font="0">Risk and Ischemic </text>
<text top="139" left="203" width="73" height="17" font="0">Stabilization, </text>
<text top="156" left="203" width="103" height="17" font="0">Management, and </text>
<text top="173" left="203" width="92" height="17" font="0">Avoidance) trial, </text>
<text top="190" left="203" width="117" height="17" font="0">where no statistically </text>
<text top="208" left="203" width="98" height="17" font="0">significant benefit </text>
<text top="225" left="203" width="93" height="17" font="0">was found in the </text>
<text top="242" left="203" width="75" height="17" font="0">overall broad </text>
<text top="259" left="203" width="110" height="17" font="0">population of stable </text>
<text top="276" left="203" width="66" height="17" font="0">pts studied. </text>
<text top="294" left="203" width="3" height="17" font="0"> </text>
<text top="311" left="203" width="122" height="17" font="2"><b>Study type:</b> Post hoc </text>
<text top="328" left="203" width="75" height="17" font="0">analysis of pt </text>
<text top="345" left="203" width="93" height="17" font="0">subgroup from a </text>
<text top="363" left="203" width="103" height="17" font="0">larger randomized </text>
<text top="380" left="203" width="23" height="17" font="0">trial </text>
<text top="397" left="203" width="3" height="17" font="0"> </text>
<text top="414" left="203" width="100" height="17" font="2"><b>Size:</b> n=9,478 pts </text>
<text top="87" left="338" width="7" height="18" font="7"></text>
<text top="88" left="344" width="3" height="17" font="0"> </text>
<text top="88" left="348" width="145" height="17" font="17">Taking oral antithrombotic </text>
<text top="106" left="338" width="185" height="17" font="17">medications or NSAIDs on a long-</text>
<text top="123" left="338" width="115" height="17" font="17">term basis (although </text>
<text top="140" left="338" width="185" height="17" font="17">cyclooxygenase-2 inhibitors were </text>
<text top="157" left="338" width="66" height="17" font="17">permitted).  </text>
<text top="174" left="338" width="7" height="18" font="7"></text>
<text top="175" left="344" width="3" height="17" font="0"> </text>
<text top="175" left="348" width="122" height="17" font="17">In the judgment of the </text>
<text top="193" left="338" width="179" height="17" font="17">investigator, pts had established </text>
<text top="210" left="338" width="187" height="17" font="17">indications for clopidogrel therapy </text>
<text top="227" left="338" width="183" height="17" font="17">(such as a recent acute coronary </text>
<text top="244" left="338" width="68" height="17" font="17">syndrome).  </text>
<text top="262" left="338" width="7" height="18" font="7"></text>
<text top="263" left="344" width="3" height="17" font="0"> </text>
<text top="263" left="348" width="150" height="17" font="17">Pts who were scheduled to </text>
<text top="280" left="338" width="185" height="17" font="17">undergo a revascularization were </text>
<text top="297" left="338" width="159" height="17" font="17">not allowed to enroll until the </text>
<text top="314" left="338" width="177" height="17" font="17">procedure had been completed; </text>
<text top="332" left="338" width="168" height="17" font="17">such pts were excluded if they </text>
<text top="349" left="338" width="149" height="17" font="17">were considered to require </text>
<text top="366" left="338" width="187" height="17" font="17">clopidogrel after revascularization.</text>
<text top="366" left="524" width="3" height="17" font="0"> </text>
<text top="87" left="675" width="103" height="17" font="2"><b>Safety endpoint:  </b></text>
<text top="104" left="675" width="7" height="18" font="7"></text>
<text top="105" left="682" width="218" height="17" font="0"> Moderate bleeding was significantly in- </text>
<text top="123" left="675" width="239" height="17" font="0">creased: 2.0% vs. 1.3% (HR: 1.60; 95% CI: </text>
<text top="140" left="675" width="121" height="17" font="0">1.16–2.20, p=0.004).  </text>
<text top="157" left="675" width="7" height="18" font="7"></text>
<text top="158" left="682" width="250" height="17" font="0"> No significant difference in the rate of severe </text>
<text top="176" left="675" width="242" height="17" font="0">bleeding: 1.7% vs. 1.5% (HR: 1.12; 95% CI: </text>
<text top="193" left="675" width="111" height="17" font="0">0.81–1.53; p=0.50)  </text>
<text top="87" left="952" width="149" height="17" font="0">ischemia were significantly </text>
<text top="104" left="952" width="94" height="17" font="0">decreased in the </text>
<text top="122" left="952" width="139" height="17" font="0">clopidogrel group, 11.4% </text>
<text top="139" left="952" width="145" height="17" font="0">vs. 13.2% (HR: 0.86; 95% </text>
<text top="156" left="952" width="136" height="17" font="0">CI: 0.76–0.96; p=0.008)  </text>
<text top="173" left="952" width="3" height="17" font="0"> </text>
<text top="432" left="95" width="70" height="17" font="2"><b>CHARISMA </b></text>
<text top="449" left="95" width="97" height="17" font="0">Berger PB, et al.  </text>
<text top="467" left="95" width="59" height="17" font="0">2010(110) </text>
<text top="484" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20516378">20516378 </a></text>
<text top="501" left="95" width="3" height="17" font="0"> </text>
<text top="432" left="203" width="107" height="17" font="2"><b>Aim:</b> To determine </text>
<text top="449" left="203" width="102" height="17" font="0">the frequency and </text>
<text top="467" left="203" width="81" height="17" font="0">time course of </text>
<text top="484" left="203" width="111" height="17" font="0">bleeding with DAPT </text>
<text top="501" left="203" width="58" height="17" font="0">in pts with </text>
<text top="518" left="203" width="115" height="17" font="0">established vascular </text>
<text top="535" left="203" width="83" height="17" font="0">disease or risk </text>
<text top="553" left="203" width="112" height="17" font="0">factors only; identify </text>
<text top="570" left="203" width="71" height="17" font="0">correlates of </text>
<text top="587" left="203" width="77" height="17" font="0">bleeding; and </text>
<text top="604" left="203" width="105" height="17" font="0">determine whether </text>
<text top="621" left="203" width="62" height="17" font="0">bleeding is </text>
<text top="639" left="203" width="87" height="17" font="0">associated with </text>
<text top="656" left="203" width="53" height="17" font="0">mortality. </text>
<text top="673" left="203" width="3" height="17" font="0"> </text>
<text top="690" left="203" width="122" height="17" font="2"><b>Study type:</b> Post hoc </text>
<text top="708" left="203" width="103" height="17" font="0">analysis of double-</text>
<text top="725" left="203" width="80" height="17" font="0">blind, placebo-</text>
<text top="742" left="203" width="60" height="17" font="0">controlled, </text>
<text top="759" left="203" width="91" height="17" font="0">randomized trial </text>
<text top="776" left="203" width="3" height="17" font="0"> </text>
<text top="432" left="338" width="185" height="17" font="2"><b>Inclusion criteria:</b> Pts had either </text>
<text top="449" left="338" width="151" height="17" font="0">established stable vascular </text>
<text top="467" left="338" width="187" height="17" font="0">disease or multiple risk factors for </text>
<text top="484" left="338" width="137" height="17" font="0">vascular disease without </text>
<text top="501" left="338" width="111" height="17" font="0">established disease </text>
<text top="518" left="338" width="3" height="17" font="0"> </text>
<text top="535" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="553" left="338" width="7" height="18" font="7"></text>
<text top="554" left="344" width="3" height="17" font="0"> </text>
<text top="554" left="348" width="145" height="17" font="17">Taking oral antithrombotic </text>
<text top="571" left="338" width="185" height="17" font="17">medications or NSAIDs on a long-</text>
<text top="588" left="338" width="115" height="17" font="17">term basis (although </text>
<text top="605" left="338" width="185" height="17" font="17">cyclooxygenase-2 inhibitors were </text>
<text top="623" left="338" width="62" height="17" font="17">permitted). </text>
<text top="640" left="338" width="7" height="18" font="7"></text>
<text top="641" left="344" width="7" height="17" font="0"> I</text>
<text top="641" left="351" width="119" height="17" font="17">n the judgment of the </text>
<text top="658" left="338" width="179" height="17" font="17">investigator, pts had established </text>
<text top="675" left="338" width="187" height="17" font="17">indications for clopidogrel therapy </text>
<text top="693" left="338" width="183" height="17" font="17">(such as a recent acute coronary </text>
<text top="710" left="338" width="68" height="17" font="17">syndrome).  </text>
<text top="727" left="338" width="7" height="18" font="7"></text>
<text top="728" left="344" width="3" height="17" font="0"> </text>
<text top="728" left="348" width="150" height="17" font="17">Pts who were scheduled to </text>
<text top="746" left="338" width="185" height="17" font="17">undergo a revascularization were </text>
<text top="763" left="338" width="159" height="17" font="17">not allowed to enroll until the </text>
<text top="432" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="449" left="547" width="104" height="17" font="0">Clopdiogrel + ASA </text>
<text top="467" left="547" width="3" height="17" font="0"> </text>
<text top="484" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="501" left="547" width="87" height="17" font="0">Placebo + ASA </text>
<text top="433" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="432" left="682" width="6" height="18" font="7"></text>
<text top="433" left="688" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="451" left="675" width="7" height="18" font="7"></text>
<text top="452" left="682" width="239" height="17" font="0"> Bleeding was assessed with the use of the </text>
<text top="469" left="675" width="257" height="17" font="0">Global Utilization of Streptokinase and t-PA for </text>
<text top="486" left="675" width="258" height="17" font="0">Occluded Coronary Arteries (GUSTO) criteria.  </text>
<text top="503" left="675" width="7" height="18" font="7"></text>
<text top="504" left="682" width="226" height="17" font="0"> Severe bleeding occurred in 1.7% of the </text>
<text top="522" left="675" width="212" height="17" font="0">clopidogrel group vs. 1.3% on placebo </text>
<text top="539" left="675" width="261" height="17" font="0">(p=0.087); moderate bleeding occurred in 2.1% </text>
<text top="556" left="675" width="182" height="17" font="0">vs. 1.3%, respectively (p&lt;0.001). </text>
<text top="573" left="675" width="7" height="18" font="7"></text>
<text top="574" left="682" width="243" height="17" font="0"> Moderate bleeding was strongly associated </text>
<text top="592" left="675" width="222" height="17" font="0">with increased mortality on multivariable </text>
<text top="609" left="675" width="48" height="17" font="0">analysis </text>
<text top="626" left="675" width="231" height="17" font="0">(HR: 2.55; 95% CI: 1.71–3.80; p&lt;0.0001)  </text>
<text top="643" left="675" width="3" height="17" font="0"> </text>
<text top="432" left="952" width="7" height="18" font="7"></text>
<text top="433" left="959" width="127" height="17" font="0"> ASA 75 mg to 162 mg </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="18" size="7" family="Times" color="#1a1717"/>
<text top="795" left="1088" width="17" height="17" font="0">47 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="107" height="17" font="2"><b>Size:</b> n=15,603 pts </text>
<text top="87" left="338" width="177" height="17" font="17">procedure had been completed; </text>
<text top="104" left="338" width="168" height="17" font="17">such pts were excluded if they </text>
<text top="122" left="338" width="149" height="17" font="17">were considered to require </text>
<text top="139" left="338" width="187" height="17" font="17">clopidogrel after revascularization.</text>
<text top="139" left="524" width="7" height="17" font="0">  </text>
<text top="173" left="95" width="87" height="17" font="0">Cassar K, et al. </text>
<text top="191" left="95" width="59" height="17" font="0">2005(111) </text>
<text top="208" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15609386">15609386 </a></text>
<text top="225" left="95" width="3" height="17" font="0"> </text>
<text top="173" left="203" width="111" height="17" font="2"><b>Aim:</b> To investigate </text>
<text top="191" left="203" width="117" height="17" font="0">the antiplatelet effect </text>
<text top="208" left="203" width="107" height="17" font="0">of a combination of </text>
<text top="225" left="203" width="115" height="17" font="0">ASA and clopidogrel </text>
<text top="242" left="203" width="111" height="17" font="0">compared with ASA </text>
<text top="259" left="203" width="92" height="17" font="0">alone in pts with </text>
<text top="277" left="203" width="68" height="17" font="0">claudication </text>
<text top="294" left="203" width="65" height="17" font="0">undergoing </text>
<text top="311" left="203" width="77" height="17" font="0">endovascular </text>
<text top="328" left="203" width="96" height="17" font="0">revascularization </text>
<text top="346" left="203" width="3" height="17" font="0"> </text>
<text top="363" left="203" width="113" height="17" font="2"><b>Study type:</b> Double-</text>
<text top="380" left="203" width="97" height="17" font="0">blind randomized </text>
<text top="397" left="203" width="104" height="17" font="0">placebo-controlled </text>
<text top="414" left="203" width="3" height="17" font="0"> </text>
<text top="432" left="203" width="90" height="17" font="2"><b>Size:</b> n=132 pts </text>
<text top="173" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="191" left="338" width="7" height="18" font="7"></text>
<text top="192" left="344" width="148" height="17" font="0"> Pts undergoing lower limb </text>
<text top="209" left="338" width="66" height="17" font="0">angioplasty </text>
<text top="226" left="338" width="7" height="18" font="7"></text>
<text top="227" left="344" width="3" height="17" font="0"> </text>
<text top="227" left="348" width="114" height="17" font="15">Hemoglobin &gt;10 g/L </text>
<text top="245" left="338" width="7" height="18" font="7"></text>
<text top="246" left="344" width="3" height="17" font="0"> </text>
<text top="246" left="348" width="133" height="17" font="15">Platelet count &gt;150 × 10</text>
<text top="247" left="481" width="4" height="11" font="18">9</text>
<text top="246" left="486" width="24" height="17" font="15"> g/L </text>
<text top="263" left="338" width="7" height="18" font="7"></text>
<text top="264" left="344" width="3" height="17" font="0"> </text>
<text top="264" left="348" width="158" height="17" font="15">Aspartate aminotransferase, </text>
<text top="281" left="338" width="122" height="17" font="15">alkaline phosphatase, </text>
<text top="299" left="338" width="171" height="17" font="15">γ-glutamyltransferase &lt;3 times </text>
<text top="316" left="338" width="101" height="17" font="15">upper normal limit </text>
<text top="333" left="338" width="7" height="18" font="7"></text>
<text top="334" left="344" width="3" height="17" font="0"> </text>
<text top="334" left="348" width="186" height="17" font="15">Creatinine &lt;2 times upper normal </text>
<text top="351" left="338" width="25" height="17" font="15">limit </text>
<text top="369" left="338" width="7" height="18" font="7"></text>
<text top="370" left="344" width="3" height="17" font="0"> </text>
<text top="370" left="348" width="121" height="17" font="15">Body mass index &lt;33 </text>
<text top="387" left="338" width="7" height="18" font="7"></text>
<text top="388" left="344" width="3" height="17" font="0"> </text>
<text top="388" left="348" width="72" height="17" font="15">Age 18–80 y </text>
<text top="405" left="338" width="7" height="18" font="7"></text>
<text top="406" left="344" width="3" height="17" font="0"> </text>
<text top="406" left="348" width="185" height="17" font="15">No contraindication to either ASA </text>
<text top="424" left="338" width="77" height="17" font="15">or clopidogrel </text>
<text top="441" left="338" width="3" height="17" font="0"> </text>
<text top="458" left="338" width="107" height="17" font="2"><b>Exclusion criteria:</b></text>
<text top="458" left="444" width="7" height="17" font="15">  </text>
<text top="475" left="338" width="7" height="18" font="7"></text>
<text top="476" left="344" width="3" height="17" font="0"> </text>
<text top="476" left="348" width="177" height="17" font="15">Hx of hematological malignancy </text>
<text top="494" left="338" width="7" height="18" font="7"></text>
<text top="495" left="344" width="3" height="17" font="0"> </text>
<text top="495" left="348" width="148" height="17" font="15">Acute illness within 14 d of </text>
<text top="512" left="338" width="81" height="17" font="15">randomization </text>
<text top="529" left="338" width="7" height="18" font="7"></text>
<text top="530" left="344" width="3" height="17" font="0"> </text>
<text top="530" left="348" width="186" height="17" font="15">Transfusion of whole blood or red </text>
<text top="548" left="338" width="185" height="17" font="15">cells within 14 d or randomization </text>
<text top="565" left="338" width="157" height="17" font="15">Known or suspected drug or </text>
<text top="582" left="338" width="165" height="17" font="15">alcohol abuse On steroids On </text>
<text top="599" left="338" width="188" height="17" font="15">warfarin or heparin Hx of bleeding </text>
<text top="617" left="338" width="175" height="17" font="15">diathesis or coagulopathy Hx of </text>
<text top="634" left="338" width="170" height="17" font="15">severe neutropenia (neutrophil </text>
<text top="651" left="338" width="86" height="17" font="15">count &lt;1.8 × 10</text>
<text top="652" left="423" width="4" height="11" font="18">9</text>
<text top="651" left="427" width="49" height="17" font="15">Ll) Hx of </text>
<text top="668" left="338" width="182" height="17" font="15">thrombocytopenia (platelet count </text>
<text top="685" left="338" width="55" height="17" font="15">&lt;150 × 10</text>
<text top="687" left="393" width="4" height="11" font="18">9</text>
<text top="685" left="397" width="18" height="17" font="15">/L) </text>
<text top="173" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="191" left="547" width="103" height="17" font="0">Clopidogrel 75 mg </text>
<text top="208" left="547" width="90" height="17" font="0">and ASA 75 mg </text>
<text top="225" left="547" width="3" height="17" font="0"> </text>
<text top="242" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="259" left="547" width="100" height="17" font="0">Placebo and ASA </text>
<text top="277" left="547" width="38" height="17" font="0">75 mg </text>
<text top="175" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="173" left="682" width="6" height="18" font="7"></text>
<text top="175" left="688" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="175" left="751" width="187" height="17" font="15">Flow cytometric measurements of </text>
<text top="192" left="675" width="225" height="17" font="15">platelet fibrinogen binding and P-selectin </text>
<text top="209" left="675" width="257" height="17" font="15">expression were taken as measures of platelet </text>
<text top="226" left="675" width="232" height="17" font="15">function at baseline, 12 h after the loading </text>
<text top="243" left="675" width="258" height="17" font="15">dose, and 1 h, 24 h and 30 d after intervention. </text>
<text top="261" left="675" width="219" height="17" font="15">Within 12 h of the loading dose, platelet </text>
<text top="278" left="675" width="211" height="17" font="15">activation in the clopidogrel group had </text>
<text top="295" left="675" width="232" height="17" font="15">decreased (P-selectin by 27.3%, p=0.017; </text>
<text top="312" left="675" width="210" height="17" font="15">fibrinogen binding by 34.7%, p=0.024; </text>
<text top="329" left="675" width="218" height="17" font="15">stimulated fibrinogen binding by 49.2%, </text>
<text top="347" left="675" width="231" height="17" font="15">p&lt;0.001). No change was observed in the </text>
<text top="364" left="675" width="209" height="17" font="15">placebo group. Platelet function in the </text>
<text top="381" left="675" width="257" height="17" font="15">clopidogrel group was significantly suppressed </text>
<text top="398" left="675" width="257" height="17" font="15">compared with baseline at 1 hr, 24 hr and 30 d </text>
<text top="416" left="675" width="235" height="17" font="15">after endovascular intervention (stimulated </text>
<text top="433" left="675" width="263" height="17" font="15">fibrinogen binding by 53.9%, 51.7%, and 57.2% </text>
<text top="450" left="675" width="143" height="17" font="15">respectively; all p&lt;0.001). </text>
<text top="467" left="675" width="3" height="17" font="15"> </text>
<text top="484" left="675" width="207" height="17" font="2"><b>Safety endpoint</b>: 2 pts in each group </text>
<text top="502" left="675" width="235" height="17" font="0">developed a skin rash and 2 in each group </text>
<text top="519" left="675" width="202" height="17" font="0">developed a hematoma at the site of </text>
<text top="536" left="675" width="213" height="17" font="0">radiological access that did not require </text>
<text top="553" left="675" width="260" height="17" font="0">intervention. The number of pts who developed </text>
<text top="570" left="675" width="250" height="17" font="0">bruising at and around the site of access was </text>
<text top="588" left="675" width="250" height="17" font="0">slightly higher in the clopidogrel group (25 vs. </text>
<text top="605" left="675" width="241" height="17" font="0">16) but the difference between the 2 groups </text>
<text top="622" left="675" width="234" height="17" font="0">was not statistically signiﬁcant. 2 pts in the </text>
<text top="639" left="675" width="261" height="17" font="0">clopidogrel group had an ischemic stroke at d 7 </text>
<text top="656" left="675" width="229" height="17" font="0">and d 12 after angioplasty. 1 of these pts, </text>
<text top="674" left="675" width="239" height="17" font="0">however, had stopped taking all medication </text>
<text top="691" left="675" width="228" height="17" font="0">immediately after intervention. Another pt </text>
<text top="708" left="675" width="256" height="17" font="0">developed melena secondary to bleeding from </text>
<text top="725" left="675" width="200" height="17" font="0">multiple small gastric ulcers. Further </text>
<text top="743" left="675" width="205" height="17" font="0">investigation revealed that the pt had </text>
<text top="760" left="675" width="202" height="17" font="0">metastatic colonic cancer. 1 pt in the </text>
<text top="777" left="675" width="214" height="17" font="0">clopidogrel group became hypotensive </text>
<text top="173" left="952" width="7" height="18" font="7"></text>
<text top="175" left="959" width="114" height="17" font="0"> Limited to post PTA </text>
<text top="192" left="952" width="90" height="17" font="0">platelet function </text>
<text top="209" left="952" width="3" height="17" font="0"> </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">48 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="675" width="261" height="17" font="0">immediately after intervention and was found to </text>
<text top="104" left="675" width="262" height="17" font="0">have a retroperitoneal hematoma. This resulted </text>
<text top="122" left="675" width="254" height="17" font="0">in a delay in discharge from hospital of 7 d but </text>
<text top="139" left="675" width="215" height="17" font="0">no surgical intervention was necessary </text>
<text top="157" left="95" width="55" height="17" font="2"><b>CASPAR</b> </text>
<text top="174" left="95" width="80" height="17" font="0">BelchJJ, et al. </text>
<text top="191" left="95" width="59" height="17" font="0">2010(112) </text>
<text top="208" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20678878">20678878 </a></text>
<text top="226" left="95" width="3" height="17" font="0"> </text>
<text top="157" left="203" width="38" height="17" font="2"><b>Aim:</b> T</text>
<text top="157" left="241" width="68" height="17" font="14">o determine </text>
<text top="174" left="203" width="121" height="17" font="14">whether clopidogrel + </text>
<text top="191" left="203" width="83" height="17" font="14">ASA conferred </text>
<text top="208" left="203" width="83" height="17" font="14">benefit on limb </text>
<text top="226" left="203" width="112" height="17" font="14">outcomes over ASA </text>
<text top="243" left="203" width="66" height="17" font="14">alone in pts </text>
<text top="260" left="203" width="101" height="17" font="14">undergoing below-</text>
<text top="277" left="203" width="117" height="17" font="14">knee bypass grafting </text>
<text top="277" left="319" width="3" height="17" font="0"> </text>
<text top="294" left="203" width="3" height="17" font="0"> </text>
<text top="312" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="329" left="203" width="71" height="17" font="0">Prospective, </text>
<text top="346" left="203" width="67" height="17" font="0">multicenter, </text>
<text top="363" left="203" width="112" height="17" font="0">randomized, double-</text>
<text top="381" left="203" width="80" height="17" font="0">blind, placebo-</text>
<text top="398" left="203" width="57" height="17" font="0">controlled </text>
<text top="415" left="203" width="3" height="17" font="0"> </text>
<text top="432" left="203" width="90" height="17" font="2"><b>Size:</b> n=851 pts </text>
<text top="157" left="338" width="192" height="17" font="2"><b>Inclusion criteria:</b> Pts undergoing </text>
<text top="174" left="338" width="194" height="17" font="0">vascular grafting as a treatment for </text>
<text top="191" left="338" width="183" height="17" font="0">PAD were eligible for recruitment </text>
<text top="208" left="338" width="162" height="17" font="0">to the trial 2–4 d after bypass </text>
<text top="226" left="338" width="157" height="17" font="0">surgery. Between 40–80 yr . </text>
<text top="243" left="338" width="3" height="17" font="0"> </text>
<text top="260" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="277" left="338" width="7" height="18" font="7"></text>
<text top="278" left="344" width="180" height="17" font="0"> Onset of PAD symptoms before </text>
<text top="296" left="338" width="92" height="17" font="0">the age of 40 y;  </text>
<text top="313" left="338" width="7" height="18" font="7"></text>
<text top="314" left="344" width="159" height="17" font="0"> Nonatherosclerotic vascular </text>
<text top="331" left="338" width="53" height="17" font="0">disease;  </text>
<text top="348" left="338" width="7" height="18" font="7"></text>
<text top="349" left="344" width="163" height="17" font="0"> Pts receiving aortobifemoral, </text>
<text top="367" left="338" width="144" height="17" font="0">iliac-femoral, or crossover </text>
<text top="384" left="338" width="150" height="17" font="0">(femoral-femoral) grafts, or </text>
<text top="401" left="338" width="123" height="17" font="0">undergoing peripheral </text>
<text top="418" left="338" width="191" height="17" font="0">transcutaneous angioplasty during </text>
<text top="436" left="338" width="105" height="17" font="0">the same surgery;  </text>
<text top="453" left="338" width="7" height="18" font="7"></text>
<text top="454" left="344" width="185" height="17" font="0"> Significant bleeding risk, such as </text>
<text top="471" left="338" width="161" height="17" font="0">current active bleeding at the </text>
<text top="488" left="338" width="75" height="17" font="0">surgical site;  </text>
<text top="506" left="338" width="7" height="18" font="7"></text>
<text top="507" left="344" width="146" height="17" font="0"> Withdrawal of an epidural </text>
<text top="524" left="338" width="170" height="17" font="0">catheter less than 12 hr before </text>
<text top="541" left="338" width="84" height="17" font="0">randomization; </text>
<text top="559" left="338" width="7" height="18" font="7"></text>
<text top="560" left="344" width="184" height="17" font="0"> Peptic ulceration within 12 mo of </text>
<text top="577" left="338" width="87" height="17" font="0">randomization;  </text>
<text top="594" left="338" width="7" height="18" font="7"></text>
<text top="595" left="344" width="174" height="17" font="0"> Previous or current intracranial </text>
<text top="612" left="338" width="200" height="17" font="0">hemorrhage or hemorrhagic stroke;  </text>
<text top="630" left="338" width="7" height="18" font="7"></text>
<text top="631" left="344" width="174" height="17" font="0"> Any Hx of severe spontaneous </text>
<text top="648" left="338" width="57" height="17" font="0">bleeding;  </text>
<text top="665" left="338" width="7" height="18" font="7"></text>
<text top="666" left="344" width="154" height="17" font="0"> Current warfarin therapy or </text>
<text top="684" left="338" width="165" height="17" font="0">anticipated need for warfarin;  </text>
<text top="701" left="338" width="7" height="18" font="7"></text>
<text top="702" left="344" width="132" height="17" font="0"> Concomitant additional </text>
<text top="719" left="338" width="187" height="17" font="0">antiplatelet agents or thrombolytic </text>
<text top="736" left="338" width="44" height="17" font="0">agents  </text>
<text top="157" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="174" left="547" width="114" height="17" font="14">Clopidogrel 75 mg/d </text>
<text top="191" left="547" width="93" height="17" font="14">+ ASA 75 to 100 </text>
<text top="208" left="547" width="27" height="17" font="14">mg/d</text>
<text top="208" left="574" width="3" height="17" font="0"> </text>
<text top="226" left="547" width="3" height="17" font="0"> </text>
<text top="243" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="260" left="547" width="8" height="17" font="0">P</text>
<text top="260" left="555" width="95" height="17" font="14">lacebo + ASA 75 </text>
<text top="277" left="547" width="65" height="17" font="14">to 100 mg/d</text>
<text top="277" left="612" width="3" height="17" font="0"> </text>
<text top="158" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="157" left="682" width="6" height="18" font="7"></text>
<text top="158" left="688" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="175" left="675" width="7" height="18" font="7"></text>
<text top="176" left="682" width="12" height="17" font="0"> C</text>
<text top="176" left="694" width="197" height="17" font="14">omposite of index-graft occlusion or </text>
<text top="194" left="675" width="248" height="17" font="14">revascularization, above-ankle amputation of </text>
<text top="211" left="675" width="146" height="17" font="14">the affected limb, or death </text>
<text top="211" left="821" width="3" height="17" font="0"> </text>
<text top="228" left="675" width="7" height="18" font="7"></text>
<text top="229" left="682" width="3" height="17" font="0"> </text>
<text top="229" left="685" width="253" height="17" font="14">In the overall population, the primary endpoint </text>
<text top="246" left="675" width="242" height="17" font="14">occurred in 149 of 425 pts in the clopidogrel </text>
<text top="264" left="675" width="262" height="17" font="14">group vs. 151 of 426 pts in the placebo (+ ASA) </text>
<text top="281" left="675" width="165" height="17" font="14">group (HR: 0.98; 95% CI: 0.78</text>
<text top="281" left="840" width="7" height="17" font="0">–</text>
<text top="281" left="847" width="59" height="17" font="14">1.23). In a </text>
<text top="298" left="675" width="241" height="17" font="14">prespecified subgroup analysis, the primary </text>
<text top="315" left="675" width="207" height="17" font="14">endpoint was significantly reduced by </text>
<text top="332" left="675" width="240" height="17" font="14">clopidogrel in prosthetic graft pts (HR: 0.65; </text>
<text top="350" left="675" width="71" height="17" font="14">95% CI: 0.45</text>
<text top="350" left="746" width="7" height="17" font="0">–</text>
<text top="350" left="753" width="180" height="17" font="14">0.95; p=0.025) but not in venous </text>
<text top="367" left="675" width="178" height="17" font="14">graft pts (HR: 1.25; 95% CI: 0.94</text>
<text top="367" left="854" width="7" height="17" font="0">–</text>
<text top="367" left="860" width="71" height="17" font="14">1.67; NS). A </text>
<text top="384" left="675" width="222" height="17" font="14">significant statistical interaction between </text>
<text top="401" left="675" width="222" height="17" font="14">treatment effect and graft type observed </text>
<text top="418" left="675" width="60" height="17" font="14">(p=0.008). </text>
<text top="418" left="735" width="3" height="17" font="0"> </text>
<text top="436" left="675" width="3" height="17" font="0"> </text>
<text top="453" left="675" width="103" height="17" font="2"><b>Safety endpoint:  </b></text>
<text top="470" left="675" width="7" height="18" font="7"></text>
<text top="471" left="682" width="151" height="17" font="0"> Severe bleeding (GUSTO) </text>
<text top="489" left="675" width="7" height="18" font="7"></text>
<text top="490" left="682" width="3" height="17" font="0"> </text>
<text top="490" left="685" width="228" height="17" font="14">Although total bleeds were more frequent </text>
<text top="507" left="675" width="223" height="17" font="14">with clopidogrel, there was no significant </text>
<text top="524" left="675" width="263" height="17" font="14">difference between the rates of severe bleeding </text>
<text top="541" left="675" width="255" height="17" font="14">in the clopidogrel and placebo (+ ASA) groups </text>
<text top="558" left="675" width="94" height="17" font="14">(2.1% vs. 1.2%). </text>
<text top="558" left="769" width="3" height="17" font="0"> </text>
<text top="157" left="952" width="7" height="18" font="7"></text>
<text top="158" left="959" width="141" height="17" font="0"> Benefit only in prosthetic </text>
<text top="175" left="952" width="63" height="17" font="0">graft group </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="19" size="13" family="Times" color="#0f0f0f"/>
	<fontspec id="20" size="7" family="Times" color="#0f0f0f"/>
<text top="795" left="1088" width="17" height="17" font="0">49 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="53" height="17" font="2"><b>MIRROR</b> </text>
<text top="104" left="95" width="76" height="17" font="0">Tepe F, et al. </text>
<text top="122" left="95" width="63" height="17" font="0">2012 (113) </text>
<text top="139" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22569995">22569995 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="111" height="17" font="2"><b>Aim:</b> To investigate </text>
<text top="104" left="203" width="114" height="17" font="0">the influence of dual </text>
<text top="122" left="203" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="139" left="203" width="98" height="17" font="0">vs. ASA alone on </text>
<text top="156" left="203" width="72" height="17" font="0">local platelet </text>
<text top="173" left="203" width="120" height="17" font="0">activation and clinical </text>
<text top="190" left="203" width="115" height="17" font="0">endpoints in pts with </text>
<text top="208" left="203" width="96" height="17" font="0">PAD treated with </text>
<text top="225" left="203" width="121" height="17" font="0">endovascular therapy </text>
<text top="242" left="203" width="3" height="17" font="0"> </text>
<text top="259" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="276" left="203" width="117" height="17" font="0">Randomized, double-</text>
<text top="294" left="203" width="80" height="17" font="0">blind, placebo-</text>
<text top="311" left="203" width="57" height="17" font="0">controlled </text>
<text top="328" left="203" width="3" height="17" font="0"> </text>
<text top="345" left="203" width="83" height="17" font="2"><b>Size:</b> n=80 pts </text>
<text top="87" left="338" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="104" left="338" width="7" height="18" font="7"></text>
<text top="105" left="344" width="12" height="17" font="0"> A</text>
<text top="105" left="356" width="112" height="17" font="19">ge &gt;18 y and &lt;90 y. </text>
<text top="123" left="338" width="7" height="18" font="7"></text>
<text top="124" left="344" width="3" height="17" font="0"> </text>
<text top="124" left="348" width="174" height="17" font="19">Chronic PAD in an artery of the </text>
<text top="141" left="338" width="162" height="17" font="19">upper leg (superficial femoral </text>
<text top="158" left="338" width="119" height="17" font="19">artery and/or popliteal</text>
<text top="158" left="456" width="3" height="17" font="0"> </text>
<text top="158" left="460" width="39" height="17" font="19">artery) </text>
<text top="176" left="338" width="121" height="17" font="19">Stage Rutherford 3–5 </text>
<text top="193" left="338" width="3" height="17" font="0"> </text>
<text top="210" left="338" width="118" height="17" font="2"><b>Exclusion criteria:</b> A</text>
<text top="210" left="456" width="53" height="17" font="19">cute limb-</text>
<text top="227" left="338" width="168" height="17" font="19">threatening ischemia requiring </text>
<text top="244" left="338" width="196" height="17" font="19">immediate action and restoration of </text>
<text top="262" left="338" width="134" height="17" font="19">flow within less than 1 hr</text>
<text top="262" left="472" width="7" height="17" font="0">. </text>
<text top="279" left="338" width="7" height="18" font="7"></text>
<text top="280" left="344" width="3" height="17" font="0"> </text>
<text top="280" left="348" width="170" height="17" font="19">Recent major trauma including </text>
<text top="297" left="338" width="169" height="17" font="19">resuscitation, or active internal </text>
<text top="314" left="338" width="167" height="17" font="19">bleeding (e.g. gastrointestinal, </text>
<text top="332" left="338" width="75" height="17" font="19">genitourinary)</text>
<text top="332" left="413" width="3" height="17" font="0"> </text>
<text top="332" left="416" width="3" height="17" font="19"> </text>
<text top="349" left="338" width="7" height="18" font="7"></text>
<text top="350" left="344" width="3" height="17" font="0"> </text>
<text top="350" left="348" width="170" height="17" font="19">Known severe hepatic or renal </text>
<text top="367" left="338" width="191" height="17" font="19">disorder (liver cirrhosis, stage B, C </text>
<text top="384" left="338" width="164" height="17" font="19">or serum creatinine &gt;2.5 mg)  </text>
<text top="402" left="338" width="7" height="18" font="7"></text>
<text top="403" left="344" width="3" height="17" font="0"> </text>
<text top="403" left="348" width="148" height="17" font="19">Hx of bleeding diathesis of </text>
<text top="420" left="338" width="152" height="17" font="19">platelet count &lt;100,000/mm</text>
<text top="421" left="490" width="4" height="11" font="20">3</text>
<text top="420" left="494" width="7" height="17" font="19">. </text>
<text top="437" left="338" width="7" height="18" font="7"></text>
<text top="438" left="344" width="3" height="17" font="0"> </text>
<text top="438" left="348" width="178" height="17" font="19">Cerebrovascular accident within </text>
<text top="456" left="338" width="134" height="17" font="19">2 yr (thrombolysis only). </text>
<text top="473" left="338" width="7" height="18" font="7"></text>
<text top="474" left="344" width="3" height="17" font="0"> </text>
<text top="474" left="348" width="180" height="17" font="19">Recent (within 2 mo) intracranial </text>
<text top="491" left="338" width="174" height="17" font="19">or intraspinal surgery or trauma </text>
<text top="508" left="338" width="103" height="17" font="19">(thrombolysis only)</text>
<text top="508" left="441" width="10" height="17" font="0">.  </text>
<text top="526" left="338" width="7" height="18" font="7"></text>
<text top="527" left="344" width="3" height="17" font="0"> </text>
<text top="527" left="348" width="150" height="17" font="19">Recent (within 2 mo) major </text>
<text top="544" left="338" width="148" height="17" font="19">surgery (thrombolysis only)</text>
<text top="544" left="485" width="3" height="17" font="0"> </text>
<text top="544" left="489" width="3" height="17" font="19"> </text>
<text top="561" left="338" width="7" height="18" font="7"></text>
<text top="562" left="344" width="3" height="17" font="0"> </text>
<text top="562" left="348" width="127" height="17" font="19">Intracranial neoplasms </text>
<text top="580" left="338" width="7" height="18" font="7"></text>
<text top="581" left="344" width="178" height="17" font="19"> Arteriovenous malformations or </text>
<text top="598" left="338" width="60" height="17" font="19">aneurysms</text>
<text top="598" left="398" width="3" height="17" font="0"> </text>
<text top="598" left="401" width="113" height="17" font="19">Severe uncontrolled </text>
<text top="615" left="338" width="155" height="17" font="19">hypertension (systolic blood </text>
<text top="632" left="338" width="175" height="17" font="19">pressure &gt;220 mm hg, diastolic </text>
<text top="650" left="338" width="164" height="17" font="19">blood pressure &gt;100 mm hg)  </text>
<text top="667" left="338" width="7" height="18" font="7"></text>
<text top="668" left="344" width="3" height="17" font="0"> </text>
<text top="668" left="348" width="135" height="17" font="19">Hypertensive or diabetic </text>
<text top="685" left="338" width="68" height="17" font="19">retinopathy  </text>
<text top="702" left="338" width="7" height="18" font="7"></text>
<text top="703" left="344" width="3" height="17" font="0"> </text>
<text top="703" left="348" width="165" height="17" font="19">Other disease with severe life </text>
<text top="721" left="338" width="184" height="17" font="19">limitation (e.g., advanced cancer, </text>
<text top="738" left="338" width="60" height="17" font="19">NYHA IV)  </text>
<text top="755" left="338" width="7" height="18" font="7"></text>
<text top="756" left="344" width="3" height="17" font="0"> </text>
<text top="756" left="348" width="173" height="17" font="19">Known autoimmune disorders.  </text>
<text top="774" left="338" width="7" height="18" font="7"></text>
<text top="775" left="344" width="3" height="17" font="0"> </text>
<text top="775" left="348" width="152" height="17" font="19">Known allergy against ASA </text>
<text top="87" left="547" width="102" height="17" font="2"><b>Intervention:</b> 500 </text>
<text top="104" left="547" width="96" height="17" font="0">mg ASA and 300 </text>
<text top="122" left="547" width="83" height="17" font="0">mg clopidogrel </text>
<text top="139" left="547" width="105" height="17" font="0">before intervention </text>
<text top="156" left="547" width="104" height="17" font="0">followed by a daily </text>
<text top="173" left="547" width="88" height="17" font="0">dose of 100 mg </text>
<text top="190" left="547" width="90" height="17" font="0">ASA and 75 mg </text>
<text top="208" left="547" width="111" height="17" font="0">clopidogrel for 6 mo </text>
<text top="225" left="547" width="3" height="17" font="0"> </text>
<text top="242" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="259" left="547" width="66" height="17" font="0">Clopidogrel </text>
<text top="276" left="547" width="114" height="17" font="0">replaced by placebo </text>
<text top="88" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="682" width="6" height="18" font="7"></text>
<text top="88" left="688" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="106" left="675" width="7" height="18" font="7"></text>
<text top="107" left="682" width="232" height="17" font="0"> Local concentrations of platelet activation </text>
<text top="124" left="675" width="263" height="17" font="0">markers β-thromboglobulin and CD40L, and the </text>
<text top="141" left="675" width="187" height="17" font="0">rate of pt's resistant to clopidogrel </text>
<text top="158" left="675" width="7" height="18" font="7"></text>
<text top="159" left="682" width="3" height="17" font="0"> </text>
<text top="159" left="685" width="247" height="17" font="13">The median peri-interventional concentration </text>
<text top="177" left="675" width="251" height="17" font="13">of β-TG was 224.5 vs. 365.5 (p=0 0.03) in the </text>
<text top="194" left="675" width="196" height="17" font="13">clopidogrel and placebo group. The </text>
<text top="211" left="675" width="240" height="17" font="13">concentration of CD40L was 127 and 206.5 </text>
<text top="228" left="675" width="238" height="17" font="13">(p=0 0.05). 30% of pts who had clopidogrel </text>
<text top="246" left="675" width="257" height="17" font="13">were resistant. 2 clopidogrel and 8 placebo pts </text>
<text top="263" left="675" width="262" height="17" font="13">required TLR (p=0.04). The clopidogrel pts who </text>
<text top="280" left="675" width="261" height="17" font="13">needed revascularisation were both resistant to </text>
<text top="297" left="675" width="66" height="17" font="13">clopidogrel. </text>
<text top="297" left="741" width="3" height="17" font="0"> </text>
<text top="314" left="675" width="3" height="17" font="0"> </text>
<text top="332" left="675" width="100" height="17" font="2"><b>Safety endpoint:</b> </text>
<text top="332" left="775" width="162" height="17" font="13">Minor bleeding complications </text>
<text top="349" left="675" width="238" height="17" font="13">occurred in 1 clopidogrel and 2 placebo pts.</text>
<text top="349" left="913" width="3" height="17" font="0"> </text>
<text top="366" left="675" width="3" height="17" font="0"> </text>
<text top="87" left="952" width="24" height="17" font="0">N/A </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">50 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="338" width="108" height="17" font="19">and/or clopidogrel.  </text>
<text top="104" left="338" width="7" height="18" font="7"></text>
<text top="105" left="344" width="3" height="17" font="0"> </text>
<text top="105" left="348" width="182" height="17" font="19">Childbearing potential or existing </text>
<text top="123" left="338" width="68" height="17" font="19">pregnancy.  </text>
<text top="140" left="338" width="7" height="18" font="7"></text>
<text top="141" left="344" width="3" height="17" font="0"> </text>
<text top="141" left="348" width="172" height="17" font="19">Contraindications to urokinase, </text>
<text top="158" left="338" width="192" height="17" font="19">reteplase, clopidogrel, heparin and </text>
<text top="176" left="338" width="107" height="17" font="19">acetylsalicylic acid. </text>
<text top="193" left="338" width="7" height="18" font="7"></text>
<text top="194" left="344" width="3" height="17" font="0"> </text>
<text top="194" left="348" width="154" height="17" font="19">Pt who has previously been </text>
<text top="211" left="338" width="115" height="17" font="19">included in this trial.  </text>
<text top="228" left="338" width="7" height="18" font="7"></text>
<text top="229" left="344" width="3" height="17" font="0"> </text>
<text top="229" left="348" width="176" height="17" font="19">Pt who requires long-term Cox2 </text>
<text top="247" left="338" width="55" height="17" font="19">inhibition. </text>
<text top="264" left="338" width="7" height="18" font="7"></text>
<text top="265" left="344" width="3" height="17" font="0"> </text>
<text top="265" left="348" width="161" height="17" font="19">Pt who is not able to sign the </text>
<text top="282" left="338" width="126" height="17" font="19">informed consent form </text>
<text top="282" left="463" width="3" height="17" font="0"> </text>
<text top="300" left="95" width="84" height="17" font="0">Bonaca MP, et </text>
<text top="318" left="95" width="16" height="17" font="0">al. </text>
<text top="335" left="95" width="59" height="17" font="0">2013(114) </text>
<text top="352" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23501976">23501976</a></text>
<text top="352" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23501976"> </a></text>
<text top="369" left="95" width="3" height="17" font="0"> </text>
<text top="300" left="203" width="103" height="17" font="2"><b>Aim:</b> The effect of </text>
<text top="318" left="203" width="75" height="17" font="0">vorapaxar on </text>
<text top="335" left="203" width="107" height="17" font="0">cardiovascular and </text>
<text top="352" left="203" width="107" height="17" font="0">peripheral vascular </text>
<text top="369" left="203" width="116" height="17" font="0">outcomes in pts who </text>
<text top="386" left="203" width="117" height="17" font="0">qualified for TRA2°P-</text>
<text top="404" left="203" width="118" height="17" font="0">TIMI 50 with sx PAD. </text>
<text top="421" left="203" width="3" height="17" font="0"> </text>
<text top="438" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="455" left="203" width="117" height="17" font="0">Randomized, double-</text>
<text top="472" left="203" width="80" height="17" font="0">blind, placebo-</text>
<text top="490" left="203" width="83" height="17" font="0">controlled trial  </text>
<text top="507" left="203" width="3" height="17" font="0"> </text>
<text top="524" left="203" width="104" height="17" font="2"><b>Size:</b> n=3,787 pts  </text>
<text top="300" left="338" width="167" height="17" font="2"><b>Inclusion criteria:</b> Hx of IC in </text>
<text top="318" left="338" width="180" height="17" font="0">conjunction with an ABI &lt;0.85 or </text>
<text top="335" left="338" width="189" height="17" font="0">previous revascularization for limb </text>
<text top="352" left="338" width="55" height="17" font="0">ischemia  </text>
<text top="369" left="338" width="3" height="17" font="0"> </text>
<text top="386" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="404" left="338" width="7" height="18" font="7"></text>
<text top="405" left="344" width="182" height="17" font="0"> A planned revascularization that </text>
<text top="422" left="338" width="158" height="17" font="0">had not yet been performed; </text>
<text top="439" left="338" width="7" height="18" font="7"></text>
<text top="440" left="344" width="148" height="17" font="0"> Hx of a bleeding diathesis </text>
<text top="458" left="338" width="7" height="18" font="7"></text>
<text top="459" left="344" width="143" height="17" font="0"> Were receiving vitamin K </text>
<text top="476" left="338" width="105" height="17" font="0">antagonist therapy </text>
<text top="493" left="338" width="7" height="18" font="7"></text>
<text top="494" left="344" width="187" height="17" font="0"> Had active hepatobiliary disease  </text>
<text top="300" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="318" left="547" width="60" height="17" font="0">Vorapaxar </text>
<text top="335" left="547" width="3" height="17" font="0"> </text>
<text top="352" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="369" left="547" width="48" height="17" font="0">Placebo </text>
<text top="301" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="300" left="682" width="6" height="18" font="7"></text>
<text top="301" left="688" width="230" height="17" font="2"><b> endpoint:</b> Primary efficacy endpoint was </text>
<text top="319" left="675" width="220" height="17" font="0">cardiovascular death, MI, or stroke. The </text>
<text top="336" left="675" width="258" height="17" font="0">primary endpoint did not differ significantly with </text>
<text top="353" left="675" width="264" height="17" font="0">vorapaxar (11.3% vs. 11.9%; HR: 0.94; 95% CI: </text>
<text top="370" left="675" width="111" height="17" font="0">0.78–1.14; p=0.53)  </text>
<text top="387" left="675" width="3" height="17" font="0"> </text>
<text top="405" left="675" width="262" height="17" font="2"><b>Safety endpoint:</b> Principal safety endpoint was </text>
<text top="422" left="675" width="257" height="17" font="0">Global Utilization of Streptokinase and t-PA for </text>
<text top="439" left="675" width="264" height="17" font="0">Occluded Coronary Arteries (GUSTO) bleeding. </text>
<text top="456" left="675" width="217" height="17" font="0">Bleeding occurred more frequently with </text>
<text top="474" left="675" width="243" height="17" font="0">vorapaxar compared with placebo (7.4% vs. </text>
<text top="491" left="675" width="255" height="17" font="0">4.5%; HR: 1.62; 95% CI: 1.21–2.18; p=0.001). </text>
<text top="300" left="952" width="7" height="18" font="7"></text>
<text top="301" left="959" width="134" height="17" font="0"> Rates of hospitalization </text>
<text top="319" left="952" width="154" height="17" font="0">for ALI (2.3% vs. 3.9%; HR: </text>
<text top="336" left="952" width="140" height="17" font="0">0.58; 95% CI: 0.39–0.86; </text>
<text top="353" left="952" width="134" height="17" font="0">p=0.006) and peripheral </text>
<text top="370" left="952" width="131" height="17" font="0">artery revascularization </text>
<text top="387" left="952" width="128" height="17" font="0">(18.4% vs. 22.2%; HR: </text>
<text top="405" left="952" width="140" height="17" font="0">0.84; 95% CI: 0.73–0.97; </text>
<text top="422" left="952" width="149" height="17" font="0">p=0.017) were significantly </text>
<text top="439" left="952" width="147" height="17" font="0">lower in pts randomized to </text>
<text top="456" left="952" width="62" height="17" font="0">vorapaxar. </text>
<text top="542" left="95" width="87" height="17" font="0">Strobl FF, et al. </text>
<text top="559" left="95" width="59" height="17" font="0">2013(115) </text>
<text top="576" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24093324">24093324 </a></text>
<text top="594" left="95" width="3" height="17" font="0"> </text>
<text top="542" left="203" width="103" height="17" font="2"><b>Aim:</b> Investigating </text>
<text top="559" left="203" width="101" height="17" font="0">the effects of dual </text>
<text top="576" left="203" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="594" left="203" width="115" height="17" font="0">on TLR after balloon </text>
<text top="611" left="203" width="77" height="17" font="0">angioplasty ± </text>
<text top="628" left="203" width="80" height="17" font="0">stenting in the </text>
<text top="645" left="203" width="87" height="17" font="0">femoropopliteal </text>
<text top="663" left="203" width="51" height="17" font="0">segment </text>
<text top="680" left="203" width="3" height="17" font="0"> </text>
<text top="697" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="714" left="203" width="71" height="17" font="0">Prospective, </text>
<text top="731" left="203" width="107" height="17" font="0">randomized, single-</text>
<text top="749" left="203" width="82" height="17" font="0">center, double-</text>
<text top="766" left="203" width="114" height="17" font="0">blinded and placebo-</text>
<text top="542" left="338" width="180" height="17" font="2"><b>Inclusion criteria:</b> PAD pts with </text>
<text top="559" left="338" width="142" height="17" font="0">TLR after femoropopliteal </text>
<text top="576" left="338" width="144" height="17" font="0">endovascular intervention </text>
<text top="594" left="338" width="3" height="17" font="0"> </text>
<text top="611" left="338" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="542" left="547" width="106" height="17" font="2"><b>Intervention:</b> ASA </text>
<text top="559" left="547" width="87" height="17" font="0">and clopidogrel </text>
<text top="576" left="547" width="3" height="17" font="0"> </text>
<text top="594" left="547" width="105" height="17" font="2"><b>Comparator:</b> ASA<b> </b></text>
<text top="543" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="542" left="682" width="6" height="18" font="7"></text>
<text top="543" left="688" width="219" height="17" font="2"><b> endpoint:</b> At 6 mo, clopidogrel pts had </text>
<text top="560" left="675" width="243" height="17" font="0">significantly lower rates of TLR compared to </text>
<text top="578" left="675" width="256" height="17" font="0">placebo pts [2 (5%) vs. 8 (20%); p=0.04]. After </text>
<text top="595" left="675" width="253" height="17" font="0">stopping clopidogrel/placebo after 6 mo, there </text>
<text top="612" left="675" width="249" height="17" font="0">was no significant difference in TLR at 12 mo </text>
<text top="629" left="675" width="232" height="17" font="0">after treatment [9 (25%) clopidogrel vs. 12 </text>
<text top="646" left="675" width="259" height="17" font="0">(32.4%) placebo; p=0.35]. Mortality was 0 vs. 1 </text>
<text top="664" left="675" width="262" height="17" font="0">in the placebo group at 6 mo (p=0.32) and 0 vs. </text>
<text top="681" left="675" width="115" height="17" font="0">3 at 12 mo (p=0.08). </text>
<text top="542" left="952" width="24" height="17" font="0">N/A </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">51 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="120" height="17" font="0">controlled clinical trial </text>
<text top="104" left="203" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="83" height="17" font="2"><b>Size:</b> n=73 pts </text>
<text top="141" left="95" width="64" height="17" font="0">Antiplatelet </text>
<text top="158" left="95" width="46" height="17" font="0">Trialists </text>
<text top="176" left="95" width="76" height="17" font="0">Collaboration </text>
<text top="193" left="95" width="73" height="17" font="0">(graft arterial </text>
<text top="210" left="95" width="51" height="17" font="0">patency) </text>
<text top="227" left="95" width="63" height="17" font="0">1994 (116) </text>
<text top="244" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8312766">8312766 </a></text>
<text top="262" left="95" width="3" height="17" font="0"> </text>
<text top="141" left="203" width="107" height="17" font="2"><b>Aim:</b> To determine </text>
<text top="158" left="203" width="79" height="17" font="0">the efficacy of </text>
<text top="176" left="203" width="120" height="17" font="0">antiplatelet therapy in </text>
<text top="193" left="203" width="116" height="17" font="0">maintaining vascular </text>
<text top="210" left="203" width="103" height="17" font="0">patency in various </text>
<text top="227" left="203" width="97" height="17" font="0">categories of pts. </text>
<text top="244" left="203" width="3" height="17" font="0"> </text>
<text top="262" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="279" left="203" width="92" height="17" font="0">Overviews of 46 </text>
<text top="296" left="203" width="111" height="17" font="0">RCTs of antiplatelet </text>
<text top="313" left="203" width="104" height="17" font="0">therapy vs. control </text>
<text top="330" left="203" width="76" height="17" font="0">and 14 RCTs </text>
<text top="348" left="203" width="85" height="17" font="0">comparing one </text>
<text top="365" left="203" width="111" height="17" font="0">antiplatelet regimen </text>
<text top="382" left="203" width="74" height="17" font="0">with another. </text>
<text top="399" left="203" width="3" height="17" font="0"> </text>
<text top="417" left="203" width="107" height="17" font="2"><b>Size: </b>n=12,000 pts </text>
<text top="141" left="338" width="184" height="17" font="2"><b>Inclusion criteria:</b> Pts at varying </text>
<text top="158" left="338" width="147" height="17" font="0">degrees of risk of vascular </text>
<text top="176" left="338" width="196" height="17" font="0">occlusion (by virtue of disease or of </text>
<text top="193" left="338" width="185" height="17" font="0">having some vascular procedure) </text>
<text top="210" left="338" width="194" height="17" font="0">were in trials of antiplatelet therapy </text>
<text top="227" left="338" width="164" height="17" font="0">vs. control or trials comparing </text>
<text top="244" left="338" width="165" height="17" font="0">different antiplatelet regimens </text>
<text top="262" left="338" width="3" height="17" font="0"> </text>
<text top="279" left="338" width="170" height="17" font="2"><b>Exclusion criteria:</b> 39 trials of </text>
<text top="296" left="338" width="167" height="17" font="0">antiplatelet therapy vs. control </text>
<text top="313" left="338" width="183" height="17" font="0">were identified among pts having </text>
<text top="330" left="338" width="187" height="17" font="0">peripheral vascular procedures or </text>
<text top="348" left="338" width="187" height="17" font="0">with PVD (see part I) but vascular </text>
<text top="365" left="338" width="138" height="17" font="0">occlusion was monitored </text>
<text top="382" left="338" width="181" height="17" font="0">systematically in only 14 of them </text>
<text top="141" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="158" left="547" width="102" height="17" font="0">Antiplatelt therapy </text>
<text top="176" left="547" width="7" height="17" font="0">  </text>
<text top="193" left="547" width="96" height="17" font="2"><b>Comparator: </b>No </text>
<text top="210" left="547" width="107" height="17" font="0">antiplatelet therapy<b> </b></text>
<text top="142" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="141" left="682" width="6" height="18" font="7"></text>
<text top="142" left="688" width="236" height="17" font="2"><b> endpoint:</b> Antiplatelet therapy produced a </text>
<text top="160" left="675" width="234" height="17" font="0">highly significant (2p &lt;0.0001) reduction in </text>
<text top="177" left="675" width="240" height="17" font="0">vascular occlusion, with similar proportional </text>
<text top="194" left="675" width="230" height="17" font="0">reductions in several different types of pts </text>
<text top="211" left="675" width="238" height="17" font="0">As well as preventing subclinical occlusion, </text>
<text top="228" left="675" width="230" height="17" font="0">antiplatelet therapy produced a significant </text>
<text top="246" left="675" width="245" height="17" font="0">(2p=0.002) reduction of about one quarter in </text>
<text top="263" left="675" width="217" height="17" font="0">the odds of suffering a &#34;vascular event&#34; </text>
<text top="280" left="675" width="223" height="17" font="0">(nonfatal MI, nonfatal stroke, or vascular </text>
<text top="297" left="675" width="42" height="17" font="0">death). </text>
<text top="314" left="675" width="3" height="17" font="0"> </text>
<text top="332" left="675" width="241" height="17" font="2"><b>Safety endpoint:</b> No clear excess bleeding </text>
<text top="141" left="952" width="7" height="18" font="7"></text>
<text top="142" left="959" width="137" height="17" font="0"> Allocation to antiplatelet </text>
<text top="160" left="952" width="150" height="17" font="0">therapy in the 14 trials with </text>
<text top="177" left="952" width="99" height="17" font="0">pts with PAD was </text>
<text top="194" left="952" width="98" height="17" font="0">associated with a </text>
<text top="211" left="952" width="136" height="17" font="0">proportional reduction of </text>
<text top="228" left="952" width="140" height="17" font="0">43% (SD 8%) in vascular </text>
<text top="246" left="952" width="154" height="17" font="0">occlusion, which was highly </text>
<text top="263" left="952" width="139" height="17" font="0">significant. Studies of pts </text>
<text top="280" left="952" width="149" height="17" font="0">with saphenous vein grafts </text>
<text top="297" left="952" width="138" height="17" font="0">or prosthetic implants for </text>
<text top="314" left="952" width="105" height="17" font="0">lower limb disease </text>
<text top="332" left="952" width="129" height="17" font="0">contributed most of the </text>
<text top="349" left="952" width="153" height="17" font="0">data; of the 3 other studies, </text>
<text top="366" left="952" width="146" height="17" font="0">1 assessed the patency of </text>
<text top="383" left="952" width="155" height="17" font="0">native vessels in pts with IC </text>
<text top="401" left="952" width="141" height="17" font="0">and 2 concerned pts who </text>
<text top="418" left="952" width="106" height="17" font="0">had had peripheral </text>
<text top="435" left="952" width="69" height="17" font="0">angioplasty. </text>
<text top="452" left="952" width="7" height="18" font="7"></text>
<text top="453" left="959" width="117" height="17" font="0"> allocation to a mean </text>
<text top="471" left="952" width="138" height="17" font="0">scheduled duration of 19 </text>
<text top="488" left="952" width="142" height="17" font="0">mo of antiplatelet therapy </text>
<text top="505" left="952" width="127" height="17" font="0">produced a substantial </text>
<text top="522" left="952" width="135" height="17" font="0">absolute reduction of 92 </text>
<text top="539" left="952" width="135" height="17" font="0">(SD 15) per 1,000 in the </text>
<text top="557" left="952" width="129" height="17" font="0">risk of peripheral artery </text>
<text top="574" left="952" width="111" height="17" font="0">occlusion (15.7% of </text>
<text top="591" left="952" width="154" height="17" font="0">antiplatelet allocated pts vs. </text>
<text top="608" left="952" width="133" height="17" font="0">24.9% of corresponding </text>
<text top="625" left="952" width="47" height="17" font="0">controls </text>
<text top="643" left="95" width="64" height="17" font="0">Antiplatelet </text>
<text top="661" left="95" width="49" height="17" font="0">Trialists  </text>
<text top="678" left="95" width="59" height="17" font="0">2002(117) </text>
<text top="695" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11786451">11786451 </a></text>
<text top="712" left="95" width="3" height="17" font="0"> </text>
<text top="643" left="203" width="107" height="17" font="2"><b>Aim:</b> To determine </text>
<text top="661" left="203" width="74" height="17" font="0">the effects of </text>
<text top="678" left="203" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="695" left="203" width="101" height="17" font="0">among tps at high </text>
<text top="712" left="203" width="90" height="17" font="0">risk of occlusive </text>
<text top="729" left="203" width="92" height="17" font="0">vascular events. </text>
<text top="747" left="203" width="3" height="17" font="0"> </text>
<text top="764" left="203" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="643" left="338" width="183" height="17" font="2"><b>Inclusion criteria:</b> PAD includes </text>
<text top="661" left="338" width="165" height="17" font="0">those with claudication and/or </text>
<text top="678" left="338" width="154" height="17" font="0">peripheral revascularization </text>
<text top="695" left="338" width="3" height="17" font="0"> </text>
<text top="712" left="338" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="643" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="661" left="547" width="109" height="17" font="0">Antiplatelet therapy </text>
<text top="678" left="547" width="7" height="17" font="0">  </text>
<text top="695" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="712" left="547" width="43" height="17" font="0">Control </text>
<text top="645" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="643" left="682" width="6" height="18" font="7"></text>
<text top="645" left="688" width="240" height="17" font="2"><b> endpoint:</b> Allocation to antiplatelet therapy </text>
<text top="662" left="675" width="256" height="17" font="0">reduced the combined outcome of any serious </text>
<text top="679" left="675" width="250" height="17" font="0">vascular event by about one quarter; nonfatal </text>
<text top="696" left="675" width="262" height="17" font="0">MI was reduced by one third, nonfatal stroke by </text>
<text top="713" left="675" width="262" height="17" font="0">one quarter, and vascular mortality by one sixth </text>
<text top="731" left="675" width="228" height="17" font="0">(with no apparent adverse effect on other </text>
<text top="748" left="675" width="44" height="17" font="0">deaths) </text>
<text top="765" left="675" width="3" height="17" font="0"> </text>
<text top="643" left="952" width="7" height="18" font="7"></text>
<text top="645" left="959" width="125" height="17" font="0"> Among 9,214 pts with </text>
<text top="662" left="952" width="150" height="17" font="0">PAD in 42 trials (compared </text>
<text top="679" left="952" width="139" height="17" font="0">with 4,939 such pts in 33 </text>
<text top="696" left="952" width="145" height="17" font="0">trials previously<b> </b>evaluated </text>
<text top="713" left="952" width="135" height="17" font="0">there was a proportional </text>
<text top="731" left="952" width="138" height="17" font="0">reduction of 23% (8%) in </text>
<text top="748" left="952" width="132" height="17" font="0">serious vascular events </text>
<text top="765" left="952" width="124" height="17" font="0">(p=0.004), with similar </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">52 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="110" height="17" font="0">analysis of RCTs of </text>
<text top="104" left="203" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="122" left="203" width="92" height="17" font="0">for prevention of </text>
<text top="139" left="203" width="119" height="17" font="0">death, MI, and stroke </text>
<text top="156" left="203" width="82" height="17" font="0">in high risk pts </text>
<text top="173" left="203" width="3" height="17" font="0"> </text>
<text top="190" left="203" width="112" height="17" font="2"><b>Size:</b> n=287 studies </text>
<text top="208" left="203" width="119" height="17" font="0">involving 135,000 pts </text>
<text top="225" left="203" width="100" height="17" font="0">in comparisons of </text>
<text top="242" left="203" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="259" left="203" width="83" height="17" font="0">vs. control and </text>
<text top="276" left="203" width="54" height="17" font="0">77,000 in </text>
<text top="294" left="203" width="87" height="17" font="0">comparisons of </text>
<text top="311" left="203" width="111" height="17" font="0">different antiplatelet </text>
<text top="328" left="203" width="54" height="17" font="0">regimens </text>
<text top="87" left="675" width="256" height="17" font="2"><b>Safety endpoint:</b> The proportional increase in </text>
<text top="104" left="675" width="206" height="17" font="0">risk of a major extracranial bleed with </text>
<text top="122" left="675" width="244" height="17" font="0">antiplatelet therapy was about one half (OR: </text>
<text top="139" left="675" width="224" height="17" font="0">1.6; 95% CI: 1.4–1.8), with no significant </text>
<text top="156" left="675" width="252" height="17" font="0">difference between the proportional increases </text>
<text top="173" left="675" width="251" height="17" font="0">observed in each of the 5 high risk categories </text>
<text top="190" left="675" width="33" height="17" font="0">of pts </text>
<text top="87" left="952" width="152" height="17" font="0">benefits among pts with IC, </text>
<text top="104" left="952" width="131" height="17" font="0">those having peripheral </text>
<text top="122" left="952" width="145" height="17" font="0">grafting, and those having </text>
<text top="139" left="952" width="124" height="17" font="0">peripheral angioplasty </text>
<text top="156" left="952" width="7" height="18" font="7"></text>
<text top="157" left="959" width="124" height="17" font="0"> Much of the data was </text>
<text top="174" left="952" width="135" height="17" font="0">from the picotamide trial </text>
<text top="346" left="95" width="82" height="17" font="0">Morrow DA, et </text>
<text top="363" left="95" width="16" height="17" font="0">al. </text>
<text top="381" left="95" width="59" height="17" font="0">2012(118) </text>
<text top="398" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22443427">22443427 </a></text>
<text top="415" left="95" width="3" height="17" font="0"> </text>
<text top="346" left="203" width="112" height="17" font="2"><b>Aim:</b> Determine the </text>
<text top="363" left="203" width="111" height="17" font="0">impact of vorapaxar </text>
<text top="381" left="203" width="70" height="17" font="0">on secondry </text>
<text top="398" left="203" width="75" height="17" font="0">prevention of </text>
<text top="415" left="203" width="96" height="17" font="0">atherothrombotic </text>
<text top="432" left="203" width="40" height="17" font="0">events </text>
<text top="449" left="203" width="3" height="17" font="0"> </text>
<text top="467" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="484" left="203" width="3" height="17" font="0"> </text>
<text top="501" left="203" width="107" height="17" font="2"><b>Size:</b> n=26,449 pts </text>
<text top="346" left="338" width="187" height="17" font="2"><b>Inclusion criteria:</b> Pts who had a </text>
<text top="363" left="338" width="185" height="17" font="0">hx of MI, ischemic stroke, or PAD </text>
<text top="381" left="338" width="3" height="17" font="0"> </text>
<text top="398" left="338" width="161" height="17" font="2"><b>Exclusion criteria:</b> Pts were </text>
<text top="415" left="338" width="181" height="17" font="0">ineligible if they were planning to </text>
<text top="432" left="338" width="154" height="17" font="0">undergo a revascularization </text>
<text top="449" left="338" width="176" height="17" font="0">procedure, had a hx of bleeding </text>
<text top="467" left="338" width="152" height="17" font="0">diathesis, had recent active </text>
<text top="484" left="338" width="191" height="17" font="0">abnormal bleeding, were receiving </text>
<text top="501" left="338" width="193" height="17" font="0">ongoing treatment with warfarin, or </text>
<text top="518" left="338" width="182" height="17" font="0">had active hepatobiliary disease. </text>
<text top="346" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="363" left="547" width="60" height="17" font="0">Vorapaxar </text>
<text top="381" left="547" width="7" height="17" font="0">  </text>
<text top="398" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="415" left="547" width="48" height="17" font="0">Placebo<b> </b></text>
<text top="347" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="346" left="682" width="6" height="18" font="7"></text>
<text top="347" left="688" width="201" height="17" font="2"><b> endpoint:</b> Composite of death from </text>
<text top="365" left="675" width="248" height="17" font="0">cardiovascular causes, MI, or stroke in 1,028 </text>
<text top="382" left="675" width="257" height="17" font="0">pts (9.3%) in the vorapaxar group and in 1,176 </text>
<text top="399" left="675" width="245" height="17" font="0">pts (10.5%) in the placebo group (HR for the </text>
<text top="416" left="675" width="236" height="17" font="0">vorapaxar group: 0.87; 95% CI: 0.80–0.94; </text>
<text top="433" left="675" width="56" height="17" font="0">p&lt;0.001). </text>
<text top="451" left="675" width="3" height="17" font="0"> </text>
<text top="468" left="675" width="261" height="17" font="2"><b>Safety endpoint:</b> There was an increase in the </text>
<text top="485" left="675" width="263" height="17" font="0">rate of intracranial hemorrhage in the vorapaxar </text>
<text top="502" left="675" width="243" height="17" font="0">group (1.0%, vs. 0.5% in the placebo group; </text>
<text top="519" left="675" width="57" height="17" font="0">P&lt;0.001). </text>
<text top="346" left="952" width="7" height="18" font="7"></text>
<text top="347" left="959" width="83" height="17" font="0">3,787 PAD pts </text>
<text top="537" left="95" width="84" height="17" font="0">Bonaca MP, et </text>
<text top="555" left="95" width="16" height="17" font="0">al. </text>
<text top="572" left="95" width="31" height="17" font="0">2013 </text>
<text top="589" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23501976">23501976</a></text>
<text top="589" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23501976"> </a></text>
<text top="537" left="203" width="111" height="17" font="2"><b>Aim: </b>Determine the </text>
<text top="555" left="203" width="105" height="17" font="0">effect of vorapaxar </text>
<text top="572" left="203" width="120" height="17" font="0">on CV and peripheral </text>
<text top="589" left="203" width="106" height="17" font="0">vascular outcomes<b> </b></text>
<text top="606" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="623" left="203" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="641" left="203" width="3" height="17" font="0"> </text>
<text top="658" left="203" width="107" height="17" font="2"><b>Size: </b>n=26,449 pts<b> </b></text>
<text top="537" left="338" width="153" height="17" font="2"><b>Inclusion criteria: </b>Pts who </text>
<text top="555" left="338" width="185" height="17" font="0">qualified for TRA 2°P-TIMI 50 pts </text>
<text top="572" left="338" width="181" height="17" font="0">with a with stable atherosclerotic </text>
<text top="589" left="338" width="178" height="17" font="0">vascular disease and a prior MI, </text>
<text top="606" left="338" width="135" height="17" font="0">ischemic stroke, or PAD </text>
<text top="623" left="338" width="3" height="17" font="2"><b> </b></text>
<text top="641" left="338" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="537" left="547" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="555" left="547" width="64" height="17" font="0">Vorapaxar<b>. </b></text>
<text top="572" left="547" width="109" height="17" font="0">Thienopyridine was </text>
<text top="589" left="547" width="61" height="17" font="0">planned at </text>
<text top="606" left="547" width="94" height="17" font="0">randomization in </text>
<text top="623" left="547" width="61" height="17" font="0">12,410 pts </text>
<text top="641" left="547" width="3" height="17" font="2"><b> </b></text>
<text top="658" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="675" left="547" width="48" height="17" font="0">Placebo<b> </b></text>
<text top="538" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="537" left="682" width="6" height="18" font="7"></text>
<text top="538" left="688" width="193" height="17" font="2"><b> endpoint: </b>CV death, MI, or stroke </text>
<text top="556" left="675" width="3" height="17" font="2"><b> </b></text>
<text top="573" left="675" width="209" height="17" font="2"><b>Safety endpoint: </b>Global Utilization of </text>
<text top="590" left="675" width="257" height="17" font="0">Streptokinase and t-PA for Occluded Coronary </text>
<text top="607" left="675" width="99" height="17" font="0">Arteries bleeding. </text>
<text top="537" left="952" width="107" height="17" font="0">In the PAD Cohort: </text>
<text top="555" left="952" width="7" height="18" font="7"></text>
<text top="556" left="959" width="138" height="17" font="0"> No significant difference </text>
<text top="573" left="952" width="132" height="17" font="0">between vorapaxar and </text>
<text top="590" left="952" width="142" height="17" font="0">comparator for CV death, </text>
<text top="607" left="952" width="133" height="17" font="0">MI, or stroke (11.3% vs. </text>
<text top="625" left="952" width="144" height="17" font="0">11.9%; HR: 0.94; 95% CI: </text>
<text top="642" left="952" width="107" height="17" font="0">0.78–1.14; p=0.53) </text>
<text top="659" left="952" width="7" height="18" font="7"></text>
<text top="660" left="959" width="136" height="17" font="0"> Significantly lower rates </text>
<text top="677" left="952" width="153" height="17" font="0">of hospitalization for ALI for </text>
<text top="695" left="952" width="148" height="17" font="0">vorapaxar group (2.3% vs. </text>
<text top="712" left="952" width="137" height="17" font="0">3.9%; HR: 0.58; 95% CI: </text>
<text top="729" left="952" width="114" height="17" font="0">0.39–0.86; p=0.006) </text>
<text top="746" left="952" width="7" height="18" font="7"></text>
<text top="747" left="959" width="126" height="17" font="0"> Significant increase in </text>
<text top="765" left="952" width="156" height="17" font="0">bleeding in vorapaxar group </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">53 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="952" width="130" height="17" font="0">compared with placebo </text>
<text top="104" left="952" width="138" height="17" font="0">(.4% vs. 4.5%; HR: 1.63; </text>
<text top="122" left="952" width="109" height="17" font="0">95% CI: 1.21–2.18; </text>
<text top="139" left="952" width="56" height="17" font="0">p=0.001). </text>
<text top="173" left="95" width="95" height="17" font="0">Bohula EA, et al.<b> </b></text>
<text top="191" left="95" width="59" height="17" font="0">2015(119) </text>
<text top="208" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26338971">26338971 </a></text>
<text top="225" left="95" width="3" height="17" font="0"> </text>
<text top="173" left="203" width="107" height="17" font="2"><b>Aim: </b>To determine </text>
<text top="191" left="203" width="113" height="17" font="0">whether the efficacy </text>
<text top="208" left="203" width="74" height="17" font="0">and safety of </text>
<text top="225" left="203" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="242" left="203" width="109" height="17" font="0">with vorapaxar was </text>
<text top="259" left="203" width="66" height="17" font="0">modified by </text>
<text top="277" left="203" width="62" height="17" font="0">concurrent </text>
<text top="294" left="203" width="107" height="17" font="0">thienopyridine use.<b> </b></text>
<text top="311" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="328" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="346" left="203" width="117" height="17" font="2"><b>R</b>andomized, double-</text>
<text top="363" left="203" width="80" height="17" font="0">blind, placebo-</text>
<text top="380" left="203" width="83" height="17" font="0">controlled trial  </text>
<text top="397" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="414" left="203" width="107" height="17" font="2"><b>Size: </b>n=16,897 pts<b> </b></text>
<text top="173" left="338" width="187" height="17" font="2"><b>Inclusion criteria: </b>TRA 2°P-TIMI </text>
<text top="191" left="338" width="178" height="17" font="0">50 pts who qualified with a MI in </text>
<text top="208" left="338" width="157" height="17" font="0">the preceding 2 weeks to 12 </text>
<text top="225" left="338" width="164" height="17" font="0">months and was restricted to. </text>
<text top="242" left="338" width="3" height="17" font="2"><b> </b></text>
<text top="259" left="338" width="184" height="17" font="2"><b>Exclusion criteria: </b>Pts without a </text>
<text top="277" left="338" width="183" height="17" font="0">hx of stroke or transient ischemic </text>
<text top="294" left="338" width="187" height="17" font="0">attack given its contraindication in </text>
<text top="311" left="338" width="84" height="17" font="0">that population<b> </b></text>
<text top="173" left="547" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="191" left="547" width="64" height="17" font="0">Vorapaxar<b>. </b></text>
<text top="208" left="547" width="109" height="17" font="0">Thienopyridine was </text>
<text top="225" left="547" width="61" height="17" font="0">planned at </text>
<text top="242" left="547" width="94" height="17" font="0">randomization in </text>
<text top="259" left="547" width="61" height="17" font="0">12,410 pts </text>
<text top="277" left="547" width="3" height="17" font="2"><b> </b></text>
<text top="294" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="311" left="547" width="48" height="17" font="0">Placebo<b> </b></text>
<text top="175" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="173" left="682" width="6" height="18" font="7"></text>
<text top="175" left="688" width="238" height="17" font="2"><b> endpoint: </b>Vorapaxar significantly reduced </text>
<text top="192" left="675" width="258" height="17" font="0">the composite of cardiovascular death, MI, and </text>
<text top="209" left="675" width="263" height="17" font="0">stroke in comparison with placebo regardless of </text>
<text top="226" left="675" width="223" height="17" font="0">planned thienopyridine therapy (planned </text>
<text top="243" left="675" width="248" height="17" font="0">thienopyridine, HR: 0.80; 95% CI: 0.70–0.91; </text>
<text top="261" left="675" width="255" height="17" font="0">p&lt;0.001; no planned thienopyridine, HR: 0.75; </text>
<text top="278" left="675" width="171" height="17" font="0">95% CI: 0.60–0.94; p=0.011; p-</text>
<text top="295" left="675" width="99" height="17" font="0">interaction=0.67). </text>
<text top="312" left="675" width="3" height="17" font="2"><b> </b></text>
<text top="329" left="675" width="253" height="17" font="2"><b>Safety endpoint: </b>Consistent with the findings </text>
<text top="347" left="675" width="232" height="17" font="0">in the overall cohort, these rates reveal an </text>
<text top="364" left="675" width="248" height="17" font="0">increased RR of GUSTO moderate to severe </text>
<text top="381" left="675" width="221" height="17" font="0">bleeding in pts treated with vorapaxar in </text>
<text top="398" left="675" width="252" height="17" font="0">comparison with placebo; however, there was </text>
<text top="416" left="675" width="208" height="17" font="0">no significant modification by planned </text>
<text top="433" left="675" width="259" height="17" font="0">thienopyridine use (planned thienopyridine HR: </text>
<text top="450" left="675" width="255" height="17" font="0">1.50; 95% CI: 1.18–1.89, p&lt;0.001; no planned </text>
<text top="467" left="675" width="244" height="17" font="0">thienopyridine HR: 1.90; 95% CI: 1.17–3.07; </text>
<text top="484" left="675" width="154" height="17" font="0">p=0.009; p-interaction=0.37 </text>
<text top="173" left="952" width="24" height="17" font="0">N/A </text>
<text top="502" left="95" width="84" height="17" font="0">Bonaca<b> </b>MP, et </text>
<text top="520" left="95" width="16" height="17" font="0">al. </text>
<text top="537" left="95" width="59" height="17" font="0">2016(120)<b> </b></text>
<text top="554" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26826179">26826179 </a></text>
<text top="571" left="95" width="3" height="17" font="0"> </text>
<text top="502" left="203" width="82" height="17" font="2"><b>Aim:</b> Evaluate </text>
<text top="520" left="203" width="120" height="17" font="0">the causes, sequelae </text>
<text top="537" left="203" width="117" height="17" font="0">and predictors of ALI </text>
<text top="554" left="203" width="102" height="17" font="0">in a contemporary </text>
<text top="571" left="203" width="101" height="17" font="0">population with sx </text>
<text top="588" left="203" width="100" height="17" font="0">PAD and whether </text>
<text top="606" left="203" width="107" height="17" font="0">PAR-1 antagonism </text>
<text top="623" left="203" width="83" height="17" font="0">with vorapaxar </text>
<text top="640" left="203" width="109" height="17" font="0">reduced ALI overall </text>
<text top="657" left="203" width="90" height="17" font="0">and by etiology. </text>
<text top="674" left="203" width="3" height="17" font="0"> </text>
<text top="692" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="709" left="203" width="81" height="17" font="0">Subgroup of a </text>
<text top="726" left="203" width="91" height="17" font="0">randomized trial </text>
<text top="743" left="203" width="3" height="17" font="0"> </text>
<text top="761" left="203" width="97" height="17" font="2"><b>Size:</b> n=3,787 pts</text>
<text top="762" left="299" width="4" height="16" font="3"> </text>
<text top="502" left="338" width="187" height="17" font="2"><b>Inclusion criteria:</b> TRA 2°P-TIMI </text>
<text top="520" left="338" width="91" height="17" font="0">50 pts with PAD </text>
<text top="537" left="338" width="3" height="17" font="0"> </text>
<text top="554" left="338" width="153" height="17" font="2"><b>Exclusion criteria:</b> AF and </text>
<text top="571" left="338" width="92" height="17" font="0">absence of PAD </text>
<text top="502" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="520" left="547" width="64" height="17" font="0">Vorapaxar  </text>
<text top="537" left="547" width="3" height="17" font="0"> </text>
<text top="554" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="571" left="547" width="48" height="17" font="0">Placebo<b> </b></text>
<text top="503" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="502" left="682" width="6" height="18" font="7"></text>
<text top="503" left="688" width="88" height="17" font="2"><b> endpoint:</b> ALII </text>
<text top="521" left="675" width="237" height="17" font="0">Vorapaxar reduced first ALI events by 41% </text>
<text top="538" left="675" width="262" height="17" font="0">(HR: 0.58; 95%CI: 0.39–0.86; p=0.006), as well </text>
<text top="555" left="675" width="246" height="17" font="0">as total ALI events by 41% (94 events vs. 56 </text>
<text top="572" left="675" width="205" height="17" font="0">events, risk ratio: 0.59; 95% CI: 0.38–</text>
<text top="590" left="675" width="80" height="17" font="0">0.93,p=0.022) </text>
<text top="607" left="675" width="3" height="17" font="0"> </text>
<text top="624" left="675" width="260" height="17" font="2"><b>Safety endpoint:</b> Bleeding (see TRA 2°P-TIMI </text>
<text top="641" left="675" width="21" height="17" font="0">50) </text>
<text top="502" left="952" width="7" height="18" font="7"></text>
<text top="503" left="959" width="125" height="17" font="0"> Most ALI events were </text>
<text top="521" left="952" width="142" height="17" font="0">graft thrombosis or in situ </text>
<text top="538" left="952" width="138" height="17" font="0">native vessel thrombosis </text>
<text top="555" left="952" width="7" height="18" font="7"></text>
<text top="556" left="959" width="137" height="17" font="0"> Effect consistent across </text>
<text top="574" left="952" width="71" height="17" font="0">all etiologies </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">54 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="60" height="17" font="2"><b>PAD from </b></text>
<text top="104" left="95" width="58" height="17" font="2"><b>TRACER  </b></text>
<text top="122" left="95" width="93" height="17" font="0">Jones WS, et al. </text>
<text top="139" left="95" width="59" height="17" font="0">2014(121) </text>
<text top="156" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25262270">25262270 </a></text>
<text top="174" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="97" height="17" font="2"><b>Aim:</b> Investigate  </text>
<text top="104" left="203" width="89" height="17" font="0">the efficacy and </text>
<text top="122" left="203" width="121" height="17" font="0">safety of vorapaxar in </text>
<text top="139" left="203" width="110" height="17" font="0">NSTE ACS pts with </text>
<text top="156" left="203" width="100" height="17" font="0">documented PAD </text>
<text top="173" left="203" width="3" height="17" font="0"> </text>
<text top="190" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="208" left="203" width="101" height="17" font="0">Subgroup of large </text>
<text top="225" left="203" width="91" height="17" font="0">randomized trial </text>
<text top="242" left="203" width="3" height="17" font="0"> </text>
<text top="259" left="203" width="90" height="17" font="2"><b>Size:</b> n=936 pts </text>
<text top="87" left="338" width="180" height="17" font="2"><b>Inclusion criteria:</b> TRACER pts </text>
<text top="104" left="338" width="94" height="17" font="0">with a hx of PAD </text>
<text top="122" left="338" width="3" height="17" font="0"> </text>
<text top="139" left="338" width="184" height="17" font="2"><b>Exclusion criteria:</b> TRACER pts </text>
<text top="156" left="338" width="71" height="17" font="0">without PAD </text>
<text top="87" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="104" left="547" width="53" height="17" font="0">Vorapxar </text>
<text top="122" left="547" width="3" height="17" font="0"> </text>
<text top="139" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="156" left="547" width="48" height="17" font="0">Placebo<b> </b></text>
<text top="88" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="682" width="6" height="18" font="7"></text>
<text top="88" left="688" width="219" height="17" font="2"><b> endpoint:</b> Lower rates of ischemic end </text>
<text top="106" left="675" width="221" height="17" font="0">points, peripheral revascularization, and </text>
<text top="123" left="675" width="222" height="17" font="0">amputation with vorapaxar did not reach </text>
<text top="140" left="675" width="130" height="17" font="0">statistical significance.* </text>
<text top="157" left="675" width="3" height="17" font="0"> </text>
<text top="174" left="675" width="217" height="17" font="2"><b>Safety endpoint:</b> Vorapaxar increased </text>
<text top="192" left="675" width="254" height="17" font="0">bleeding in both pts with and without PAD at a </text>
<text top="209" left="675" width="140" height="17" font="0">similar magnitude of risk. </text>
<text top="87" left="952" width="24" height="17" font="0">N/A </text>
<text top="277" left="95" width="83" height="17" font="0">Katsanos K, et </text>
<text top="294" left="95" width="20" height="17" font="0">al.  </text>
<text top="312" left="95" width="63" height="17" font="0">2015 (122)<b> </b></text>
<text top="329" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26274912">26274912 </a></text>
<text top="346" left="95" width="3" height="17" font="0"> </text>
<text top="277" left="203" width="104" height="17" font="2"><b>Aim:</b> Comparative </text>
<text top="294" left="203" width="109" height="17" font="0">Efficacy and Safety </text>
<text top="312" left="203" width="64" height="17" font="0">of Different </text>
<text top="329" left="203" width="106" height="17" font="0">Antiplatelet Agents </text>
<text top="346" left="203" width="94" height="17" font="0">for Prevention of </text>
<text top="363" left="203" width="120" height="17" font="0">Major Cardiovascular </text>
<text top="381" left="203" width="89" height="17" font="0">Events and Leg </text>
<text top="398" left="203" width="105" height="17" font="0">Amputations in pts </text>
<text top="415" left="203" width="54" height="17" font="0">with PAD<b> </b></text>
<text top="432" left="203" width="3" height="17" font="0"> </text>
<text top="449" left="203" width="102" height="17" font="2"><b>Study type: </b>Meta-</text>
<text top="467" left="203" width="48" height="17" font="0">analysis<b> </b></text>
<text top="484" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="501" left="203" width="107" height="17" font="2"><b>Size: </b>n=34,518 pts<b> </b></text>
<text top="277" left="338" width="168" height="17" font="2"><b>Inclusion criteria: </b>RCT using </text>
<text top="294" left="338" width="184" height="17" font="0">antiplatelet drugs in pts with PAD </text>
<text top="312" left="338" width="3" height="17" font="0"> </text>
<text top="329" left="338" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="277" left="547" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="294" left="547" width="109" height="17" font="0">Antiplatelet therapy<b> </b></text>
<text top="312" left="547" width="3" height="17" font="2"><b> </b></text>
<text top="329" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="346" left="547" width="48" height="17" font="0">Placebo<b> </b></text>
<text top="278" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="277" left="682" width="6" height="18" font="7"></text>
<text top="278" left="688" width="216" height="17" font="2"><b> endpoint: </b>MACE and leg amputations </text>
<text top="296" left="675" width="248" height="17" font="0">A significant MACE reduction was noted with </text>
<text top="313" left="675" width="231" height="17" font="0">Ticagrelor plus aspirin (RR: 0.67; 95%CrI: </text>
<text top="330" left="675" width="244" height="17" font="0">0.46–0.96; NNT=66), Clopidogrel (RR: 0.72; </text>
<text top="347" left="675" width="257" height="17" font="0">95%CrI: 0.58–0.91; NNT=80), Ticlopidine (RR: </text>
<text top="365" left="675" width="217" height="17" font="0">0.75; 95%CrI: 0.58–0.96; NN =87), and </text>
<text top="382" left="675" width="239" height="17" font="0">Clopidogrel plus aspirin (RR: 0.78; 95%CrI: </text>
<text top="399" left="675" width="119" height="17" font="0">0.61–0.99; NNT=98). </text>
<text top="416" left="675" width="3" height="17" font="0"> </text>
<text top="433" left="675" width="253" height="17" font="0">Dual antiplatelet therapy with Clopidogrel plus </text>
<text top="451" left="675" width="259" height="17" font="0">aspirin significantly reduced major amputations </text>
<text top="468" left="675" width="226" height="17" font="0">following leg revascularization (RR: 0.68; </text>
<text top="485" left="675" width="263" height="17" font="0">95%CrI: 0.46–0.99 compared to ASA, NNT=94) </text>
<text top="502" left="675" width="3" height="17" font="2"><b> </b></text>
<text top="519" left="675" width="251" height="17" font="2"><b>Safety endpoint: </b>The risk of severe bleeding </text>
<text top="537" left="675" width="246" height="17" font="0">was significantly higher with Ticlopidine (RR: </text>
<text top="554" left="675" width="259" height="17" font="0">5.03; 95%CrI: 1.23–39.6; NNH=25), Vorapaxar </text>
<text top="571" left="675" width="258" height="17" font="0">(RR: 1.80; 95%CrI: 1.22–2.69; NNH=130), and </text>
<text top="588" left="675" width="255" height="17" font="0">Clopidogrel plus ASA (RR: 1.48; 95%CrI: 1.05-</text>
<text top="605" left="675" width="91" height="17" font="0">2.10; NNT=215) </text>
<text top="277" left="952" width="24" height="17" font="0">N/A </text>
<text top="623" left="95" width="81" height="17" font="0">Magnani G, et </text>
<text top="641" left="95" width="16" height="17" font="0">al. </text>
<text top="658" left="95" width="59" height="17" font="0">2015(123) </text>
<text top="675" left="95" width="58" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25792124">25792124 </a></text>
<text top="692" left="95" width="3" height="17" font="0"> </text>
<text top="623" left="203" width="116" height="17" font="2"><b>Aim:</b> To observe the </text>
<text top="641" left="203" width="119" height="17" font="0">safety and efficacy of </text>
<text top="658" left="203" width="58" height="17" font="0">vorapaxar<b> </b></text>
<text top="675" left="203" width="3" height="17" font="0"> </text>
<text top="692" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="710" left="203" width="117" height="17" font="2"><b>M</b>ultinational, double-</text>
<text top="727" left="203" width="94" height="17" font="0">blinded, placebo-</text>
<text top="744" left="203" width="110" height="17" font="0">controlled TRA 2°P-</text>
<text top="761" left="203" width="68" height="17" font="0">TIMI 50 trial<b> </b></text>
<text top="623" left="338" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="641" left="338" width="7" height="18" font="7"></text>
<text top="642" left="344" width="177" height="17" font="0"> Met TRA 2°P-TIMI 50 inclusion </text>
<text top="659" left="338" width="40" height="17" font="0">criteria </text>
<text top="676" left="338" width="7" height="18" font="7"></text>
<text top="677" left="344" width="189" height="17" font="0"> Hx of spontaneous MI within prior </text>
<text top="695" left="338" width="80" height="17" font="0">2 wk to 12 mo </text>
<text top="712" left="338" width="7" height="18" font="7"></text>
<text top="713" left="344" width="167" height="17" font="0"> Those with symptomatic PAD </text>
<text top="730" left="338" width="174" height="17" font="0">had hx of IC in conjunction with </text>
<text top="747" left="338" width="173" height="17" font="0">either an ABI &lt;0.85 or previous </text>
<text top="765" left="338" width="191" height="17" font="0">revascularization for limb ischemia </text>
<text top="623" left="547" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="641" left="547" width="100" height="17" font="0">Vorapaxar sulfate </text>
<text top="658" left="547" width="103" height="17" font="0">2.5 mg (vorapaxar </text>
<text top="675" left="547" width="81" height="17" font="0">2.08 mg) daily </text>
<text top="692" left="547" width="3" height="17" font="2"><b> </b></text>
<text top="710" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="727" left="547" width="48" height="17" font="0">Placebo<b> </b></text>
<text top="624" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="623" left="682" width="6" height="18" font="7"></text>
<text top="624" left="688" width="216" height="17" font="2"><b> endpoint: </b>Composite endpoints of CV </text>
<text top="642" left="675" width="157" height="17" font="0">death, MI, or stroke, and CV </text>
<text top="659" left="675" width="260" height="17" font="0">death, MI, stroke, or recurrent ischemia leading </text>
<text top="676" left="675" width="199" height="17" font="0">to urgent coronary revascularization </text>
<text top="693" left="675" width="7" height="18" font="7"></text>
<text top="694" left="682" width="247" height="17" font="0"> 3 y KM event rate of CV death, MI, or stroke </text>
<text top="712" left="675" width="186" height="17" font="0">was 7.9% in vorapaxar compared </text>
<text top="729" left="675" width="254" height="17" font="0">with 9.5% in placebo (HR: 0.80; 95% CI: 0.73–</text>
<text top="746" left="675" width="90" height="17" font="0">0.89; p&lt;0.001).  </text>
<text top="763" left="675" width="7" height="18" font="7"></text>
<text top="764" left="682" width="250" height="17" font="0"> 3 y KM event rate of CV death, MI, stroke, or </text>
<text top="623" left="952" width="7" height="18" font="7"></text>
<text top="624" left="959" width="142" height="17" font="0"> Vorapaxar was shown to </text>
<text top="642" left="952" width="134" height="17" font="0">reduce CV death, MI, or </text>
<text top="659" left="952" width="144" height="17" font="0">stroke in the intended use </text>
<text top="676" left="952" width="107" height="17" font="0">and FDA approved </text>
<text top="693" left="952" width="154" height="17" font="0">population (not those with a </text>
<text top="711" left="952" width="75" height="17" font="0">hx of stroke). </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">55 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="104" left="203" width="107" height="17" font="2"><b>Size: </b>n=16,897 pts<b> </b></text>
<text top="87" left="338" width="3" height="17" font="0"> </text>
<text top="104" left="338" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="87" left="675" width="262" height="17" font="0">urgent coronary revascularization was 10.1% in </text>
<text top="104" left="675" width="239" height="17" font="0">vorapaxar and 11.8% in placebo (HR: 0.83; </text>
<text top="122" left="675" width="164" height="17" font="0">95% CI: 0.76–0.90; p&lt;0.001). </text>
<text top="139" left="675" width="7" height="18" font="7"></text>
<text top="140" left="682" width="228" height="17" font="0"> 3 y KM event rate of CV death or MI was </text>
<text top="157" left="675" width="245" height="17" font="0">7.2% in vorapaxar and 8.3% in placebo; HR: </text>
<text top="174" left="675" width="199" height="17" font="0">0.83; 95% CI: 0.75–0.93, p&lt;0.001).  </text>
<text top="192" left="675" width="7" height="18" font="7"></text>
<text top="193" left="682" width="204" height="17" font="0"> 3 y KM event rate of MI was 5.4% in </text>
<text top="210" left="675" width="229" height="17" font="0">vorapaxar and 6.4% in placebo (p&lt;0.001) </text>
<text top="227" left="675" width="7" height="18" font="7"></text>
<text top="228" left="682" width="223" height="17" font="0"> 3 y KM event rate of stroke was 1.2% in </text>
<text top="246" left="675" width="229" height="17" font="0">vorapaxar and 1.6% in placebo (p=0.002) </text>
<text top="263" left="675" width="67" height="17" font="0">individually. </text>
<text top="280" left="675" width="3" height="17" font="2"><b> </b></text>
<text top="297" left="675" width="257" height="17" font="2"><b>Safety endpoint: </b>GUSTO moderate or severe </text>
<text top="314" left="675" width="53" height="17" font="0">bleeding: </text>
<text top="332" left="675" width="7" height="18" font="7"></text>
<text top="333" left="682" width="235" height="17" font="0"> Combined bleeding criteria was 3.7% with </text>
<text top="350" left="675" width="260" height="17" font="0">vorapaxar and 2.4% in placebo (HR, 1.55; 95% </text>
<text top="367" left="675" width="136" height="17" font="0">CI: 1.30–1.86, p&lt;0.001). </text>
<text top="384" left="675" width="7" height="18" font="7"></text>
<text top="385" left="682" width="255" height="17" font="0"> Severe bleeding was 1.3% with vorapaxar vs. </text>
<text top="403" left="675" width="237" height="17" font="0">1.0% with placebo (HR 1.24; 95% CI: 0.92–</text>
<text top="420" left="675" width="77" height="17" font="0">1.66, P=0.16  </text>
<text top="438" left="95" width="92" height="17" font="0">Berger JS et al,  </text>
<text top="455" left="95" width="31" height="17" font="0">2009 </text>
<text top="472" left="95" width="32" height="17" font="0">(124) </text>
<text top="438" left="203" width="107" height="17" font="2"><b>Aim:</b> To determine </text>
<text top="455" left="203" width="113" height="17" font="0">the effect of ASA on </text>
<text top="472" left="203" width="118" height="17" font="0">CV event rates in pts </text>
<text top="490" left="203" width="54" height="17" font="0">with PAD<b> </b></text>
<text top="507" left="203" width="3" height="17" font="0"> </text>
<text top="524" left="203" width="102" height="17" font="2"><b>Study type: </b>Meta-</text>
<text top="541" left="203" width="61" height="17" font="0">analysis of </text>
<text top="558" left="203" width="101" height="17" font="0">prospective RCTs<b> </b></text>
<text top="576" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="593" left="203" width="96" height="17" font="2"><b>Size: </b>n=18 trials, </text>
<text top="610" left="203" width="54" height="17" font="0">5,269 pts<b> </b></text>
<text top="438" left="338" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="455" left="338" width="7" height="18" font="7"></text>
<text top="456" left="344" width="106" height="17" font="0"> Prospective RCTs </text>
<text top="474" left="338" width="7" height="18" font="7"></text>
<text top="475" left="344" width="172" height="17" font="0"> PAD pts assigned to aspirin or </text>
<text top="492" left="338" width="122" height="17" font="0">placebo/control group </text>
<text top="509" left="338" width="7" height="18" font="7"></text>
<text top="510" left="344" width="176" height="17" font="0"> Data on all-cause mortality, CV </text>
<text top="528" left="338" width="157" height="17" font="0">death, MI, stroke, and major </text>
<text top="545" left="338" width="50" height="17" font="0">bleeding </text>
<text top="562" left="338" width="3" height="17" font="0"> </text>
<text top="579" left="338" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="438" left="547" width="106" height="17" font="2"><b>Intervention: </b>ASA </text>
<text top="455" left="547" width="3" height="17" font="2"><b> </b></text>
<text top="472" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="490" left="547" width="88" height="17" font="0">Placebo/control<b> </b></text>
<text top="439" left="675" width="7" height="17" font="2"><b>1</b></text>
<text top="438" left="682" width="6" height="18" font="7"></text>
<text top="439" left="688" width="66" height="17" font="2"><b> endpoint: </b> </text>
<text top="456" left="675" width="7" height="18" font="7"></text>
<text top="457" left="682" width="215" height="17" font="0"> Nonfatal MI, nonfatal stroke, CV death </text>
<text top="475" left="675" width="7" height="18" font="7"></text>
<text top="476" left="682" width="255" height="17" font="0"> Secondary outcomes were all-cause mortality </text>
<text top="493" left="675" width="3" height="17" font="2"><b> </b></text>
<text top="510" left="675" width="184" height="17" font="2"><b>Safety endpoint: </b>Major bleeding </text>
<text top="438" left="952" width="7" height="18" font="7"></text>
<text top="439" left="959" width="140" height="17" font="0"> ASA therapy, alone or in </text>
<text top="456" left="952" width="95" height="17" font="0">combination with </text>
<text top="474" left="952" width="118" height="17" font="0">dipyridomole, had no </text>
<text top="491" left="952" width="129" height="17" font="0">significant effect on CV </text>
<text top="508" left="952" width="40" height="17" font="0">events </text>
<text top="525" left="952" width="7" height="18" font="7"></text>
<text top="526" left="959" width="139" height="17" font="0"> ASA did have significant </text>
<text top="544" left="952" width="151" height="17" font="0">reduction in nonfatal stroke </text>
<text top="561" left="952" width="7" height="18" font="7"></text>
<text top="562" left="959" width="149" height="17" font="0"> No significant outcome for </text>
<text top="579" left="952" width="125" height="17" font="0">MI, CV mortality, or all-</text>
<text top="596" left="952" width="86" height="17" font="0">cause mortality </text>
<text top="628" left="86" width="1017" height="17" font="0">ABI indicates ankle-brachial index; ACS, acute coronary syndrome; ALI, acute limb ischemia; ASA, aspirin; CHD, coronary heart disease; CI indicates confidence interval; CLI, critical limb </text>
<text top="645" left="86" width="948" height="17" font="0">ischemia; CV, cardiovascular; GP, general practitioner; GUSTO, Global Utilization of Streptokinase and t-PA for Occluded; Coronary Arteries HR, hazard ratio; IC, intermittent </text>
<text top="663" left="86" width="993" height="17" font="0">claudication; IV, intravenous; KM, Kaplan-Meier; MACE, major adverse cardiac event; MI, myocardial infarction; N/A, not applicable; NNT, number needed to treat; NS, not significant; </text>
<text top="680" left="86" width="983" height="17" font="0">NYHA, New York Heart Association; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PAD, peripheral artery disease; PTA, percutaneous transluminal angioplasty; pt, </text>
<text top="697" left="86" width="733" height="17" font="0">patient; PVD, peripheral vascular disease; RCT, randomized controlled trial; RR, relative risk; and TLR, target lesion revascularization. </text>
<text top="714" left="86" width="3" height="17" font="0"> </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="21" size="11" family="Times" color="#000000"/>
<text top="795" left="1088" width="17" height="17" font="0">56 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="835" height="21" font="1"><b>Evidence Table 14. Nonrandomized Trials, Observational Studies, and/or Registries of Antiplatelet Agents–Section 5.2. </b></text>
<text top="108" left="112" width="38" height="17" font="2"><b>Study </b></text>
<text top="125" left="103" width="57" height="17" font="2"><b>Acronym </b></text>
<text top="142" left="109" width="47" height="17" font="2"><b>Author  </b></text>
<text top="159" left="116" width="33" height="17" font="2"><b>Year  </b></text>
<text top="108" left="215" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="125" left="220" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="142" left="214" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="108" left="353" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="108" left="505" width="111" height="17" font="2"><b>Study Intervention </b></text>
<text top="125" left="499" width="126" height="17" font="2"><b>(include # patients) /  </b></text>
<text top="142" left="505" width="111" height="17" font="2"><b>Study Comparator </b></text>
<text top="159" left="503" width="115" height="17" font="2"><b>(include # patients) </b></text>
<text top="108" left="751" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="125" left="642" width="326" height="17" font="2"><b>(include Absolute Event Rates, P value; OR or RR; and  </b></text>
<text top="142" left="780" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="109" left="1006" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="108" left="1068" width="6" height="18" font="7"></text>
<text top="109" left="1074" width="3" height="17" font="2"><b> </b></text>
<text top="126" left="990" width="105" height="17" font="2"><b>Endpoint (if any); </b></text>
<text top="143" left="987" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="161" left="994" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="179" left="86" width="78" height="17" font="0">Armstrong EJ </text>
<text top="196" left="86" width="30" height="17" font="0">et al. </text>
<text top="213" left="86" width="59" height="17" font="0">2015(125) </text>
<text top="230" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25864042">25864042</a></text>
<text top="230" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25864042"> </a></text>
<text top="179" left="189" width="116" height="17" font="2"><b>Aim:</b> This study was </text>
<text top="196" left="189" width="132" height="17" font="0">conducted to determine </text>
<text top="213" left="189" width="91" height="17" font="0">whether there is </text>
<text top="230" left="189" width="100" height="17" font="0">additive benefit of </text>
<text top="247" left="189" width="114" height="17" font="0">DAPT with ASA and </text>
<text top="265" left="189" width="121" height="17" font="0">clopidogrel compared </text>
<text top="282" left="189" width="129" height="17" font="0">with ASA monotherapy </text>
<text top="299" left="189" width="102" height="17" font="0">among pts with sx </text>
<text top="316" left="189" width="99" height="17" font="0">peripheral arterial </text>
<text top="333" left="189" width="49" height="17" font="0">disease. </text>
<text top="351" left="189" width="3" height="17" font="0"> </text>
<text top="368" left="189" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="385" left="189" width="117" height="17" font="0">Observational cohort </text>
<text top="402" left="189" width="3" height="17" font="0"> </text>
<text top="419" left="189" width="90" height="17" font="2"><b>Size:</b> n=629 pts </text>
<text top="179" left="338" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="196" left="338" width="7" height="18" font="7"></text>
<text top="197" left="344" width="131" height="17" font="0"> UC Davis PAD registry </text>
<text top="214" left="338" width="7" height="18" font="7"></text>
<text top="215" left="344" width="111" height="17" font="0"> Claudication or CLI </text>
<text top="233" left="338" width="7" height="18" font="7"></text>
<text top="234" left="344" width="116" height="17" font="0"> All had angiography </text>
<text top="251" left="338" width="3" height="17" font="0"> </text>
<text top="268" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="285" left="338" width="7" height="18" font="7"></text>
<text top="286" left="344" width="122" height="17" font="0"> Warfarin use (96 pts) </text>
<text top="304" left="338" width="7" height="18" font="7"></text>
<text top="305" left="344" width="130" height="17" font="0"> No antiplatelet therapy </text>
<text top="322" left="338" width="25" height="17" font="0">(28) </text>
<text top="339" left="338" width="7" height="18" font="7"></text>
<text top="340" left="344" width="104" height="17" font="0"> In registry for ALI, </text>
<text top="358" left="338" width="127" height="17" font="0">carotid artery stenosis, </text>
<text top="375" left="338" width="96" height="17" font="0">subclavian artery </text>
<text top="392" left="338" width="132" height="17" font="0">stenosis, or renal artery </text>
<text top="409" left="338" width="49" height="17" font="0">stenosis </text>
<text top="179" left="493" width="100" height="17" font="2"><b>Groups: </b>348 with </text>
<text top="196" left="493" width="117" height="17" font="0">DAPT, 281 with ASA </text>
<text top="213" left="493" width="26" height="17" font="0">only </text>
<text top="230" left="493" width="3" height="17" font="2"><b> </b></text>
<text top="247" left="493" width="107" height="17" font="0">Record review with </text>
<text top="265" left="493" width="109" height="17" font="0">median follow 3.2 y </text>
<text top="180" left="641" width="7" height="17" font="2"><b>1</b></text>
<text top="179" left="648" width="6" height="18" font="7"></text>
<text top="180" left="654" width="285" height="17" font="2"><b> endpoint:</b> During 3 y of follow-up, 50 events (20%) </text>
<text top="197" left="641" width="290" height="17" font="0">occurred in the DAPT group vs. 59 (29%) in the ASA </text>
<text top="214" left="641" width="321" height="17" font="0">monotherapy group. After propensity weighting, DAPT use </text>
<text top="231" left="641" width="319" height="17" font="0">was associated with a decreased risk of MACEs (adjusted </text>
<text top="249" left="641" width="278" height="17" font="0">HR: 0.65; 95% CI: 0.44–0.96) and overall mortality </text>
<text top="266" left="641" width="306" height="17" font="0">(adjusted HR: 0.55; 95% CI: 0.35–0.89). No association </text>
<text top="283" left="641" width="284" height="17" font="0">was found between DAPT use and the risk of major </text>
<text top="300" left="641" width="311" height="17" font="0">amputation (adjusted HR: 0.69; 95% CI: 0.37–1.29). In a </text>
<text top="317" left="641" width="308" height="17" font="0">subgroup of 94 pts who underwent point-of-care platelet </text>
<text top="335" left="641" width="322" height="17" font="0">function testing, 21% had decreased response to ASA and </text>
<text top="352" left="641" width="276" height="17" font="0">55% had a decreased response to clopidogrel. No </text>
<text top="369" left="641" width="300" height="17" font="0">association was found between a reduced response to </text>
<text top="386" left="641" width="253" height="17" font="0">ASA or clopidogrel and adverse events at 1 y. </text>
<text top="178" left="979" width="22" height="15" font="21">N/A </text>
<text top="437" left="86" width="999" height="17" font="0">ALI indicates acute limb ischemia; ASA, acetylsalicylic acid; CI, confidence interval; CLI, critical limb ischemia; DAPT, dual antiplatelet therapy; HR, hazard ratio; MACE, major adverse </text>
<text top="455" left="86" width="339" height="17" font="0">cardiac event; PAD, peripheral artery disease; and pt, patient. </text>
<text top="472" left="86" width="3" height="17" font="0"> </text>
<text top="489" left="86" width="543" height="21" font="1"><b>Evidence Table 15. Randomized Trials Comparing Statin Agents–Section 5.2. </b></text>
<text top="511" left="87" width="94" height="17" font="2"><b>Study Acronym </b></text>
<text top="528" left="113" width="47" height="17" font="2"><b>Author  </b></text>
<text top="545" left="120" width="33" height="17" font="2"><b>Year  </b></text>
<text top="511" left="219" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="528" left="223" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="545" left="217" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="511" left="367" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="511" left="529" width="111" height="17" font="2"><b>Study Intervention </b></text>
<text top="528" left="523" width="126" height="17" font="2"><b>(include # patients) /  </b></text>
<text top="545" left="529" width="111" height="17" font="2"><b>Study Comparator </b></text>
<text top="562" left="527" width="116" height="17" font="2"><b>(include # patients) </b></text>
<text top="511" left="701" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="528" left="681" width="144" height="17" font="2"><b>(include Absolute Event </b></text>
<text top="545" left="663" width="182" height="17" font="2"><b>Rates, P value; OR or RR; and  </b></text>
<text top="562" left="729" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="512" left="893" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="511" left="955" width="6" height="18" font="7"></text>
<text top="512" left="961" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="529" left="926" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="546" left="933" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="580" left="86" width="32" height="17" font="2"><b>HPS  </b></text>
<text top="597" left="86" width="29" height="17" font="0">HPS </text>
<text top="615" left="86" width="75" height="17" font="0">Collaborative </text>
<text top="632" left="86" width="38" height="17" font="0">Group </text>
<text top="649" left="86" width="59" height="17" font="0">2007(126) </text>
<text top="666" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17398372">17398372</a></text>
<text top="666" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17398372"> </a></text>
<text top="683" left="86" width="3" height="17" font="0"> </text>
<text top="580" left="196" width="127" height="17" font="2"><b>Aim:</b> Assess impact of </text>
<text top="597" left="196" width="113" height="17" font="0">cholesterol-lowering </text>
<text top="615" left="196" width="96" height="17" font="0">therapy on major </text>
<text top="632" left="196" width="96" height="17" font="0">adverse vascular </text>
<text top="649" left="196" width="130" height="17" font="0">events in pts with PAD  </text>
<text top="666" left="196" width="3" height="17" font="0"> </text>
<text top="683" left="196" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="701" left="196" width="118" height="17" font="0">Prospective, blinded, </text>
<text top="718" left="196" width="32" height="17" font="0">RCT. </text>
<text top="735" left="196" width="3" height="17" font="0"> </text>
<text top="752" left="196" width="107" height="17" font="2"><b>Size:</b> n=20,536 pts </text>
<text top="580" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="597" left="338" width="7" height="18" font="7"></text>
<text top="598" left="344" width="76" height="17" font="0"> Age 40–80 y </text>
<text top="616" left="338" width="7" height="18" font="7"></text>
<text top="617" left="344" width="97" height="17" font="0"> Chol &gt;135mg/dL </text>
<text top="634" left="338" width="7" height="18" font="7"></text>
<text top="635" left="344" width="151" height="17" font="0"> PAD, CVD, DM, or HTN (if </text>
<text top="653" left="338" width="86" height="17" font="0">male and &gt;65)  </text>
<text top="670" left="338" width="3" height="17" font="0"> </text>
<text top="687" left="338" width="149" height="17" font="2"><b>Exclusion criteria:</b> If PCP </text>
<text top="704" left="338" width="168" height="17" font="0">feels statin clearly indicated or </text>
<text top="721" left="338" width="139" height="17" font="0">contraindicated; prior MI, </text>
<text top="739" left="338" width="139" height="17" font="0">stroke, or admission with </text>
<text top="756" left="338" width="163" height="17" font="0">angina in previous 6 mo; liver </text>
<text top="773" left="338" width="169" height="17" font="0">dysfunction; renal dysfunction; </text>
<text top="580" left="520" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="597" left="520" width="105" height="17" font="0">Simvastatin 40 mg </text>
<text top="615" left="520" width="49" height="17" font="0">(10,269) </text>
<text top="632" left="520" width="3" height="17" font="0"> </text>
<text top="649" left="520" width="125" height="17" font="2"><b>Comparator:</b> Placebo </text>
<text top="666" left="520" width="49" height="17" font="0">(10,267)<b> </b></text>
<text top="581" left="662" width="7" height="17" font="2"><b>1</b></text>
<text top="580" left="668" width="6" height="18" font="7"></text>
<text top="581" left="675" width="162" height="17" font="2"><b> endpoint:</b> 24% (95% CI: 19–</text>
<text top="599" left="662" width="148" height="17" font="0">28; p&lt;0.0001) proportional </text>
<text top="616" left="662" width="175" height="17" font="0">reduction in the first occurrence </text>
<text top="633" left="662" width="141" height="17" font="0">of a major vascular event </text>
<text top="650" left="662" width="170" height="17" font="0">Those with LEPAD: 22% (95% </text>
<text top="667" left="662" width="119" height="17" font="0">CI: 15–29; p&lt;0.0001) </text>
<text top="685" left="662" width="126" height="17" font="0">proportional reduction  </text>
<text top="702" left="662" width="3" height="17" font="0"> </text>
<text top="720" left="662" width="7" height="17" font="2"><b>1</b></text>
<text top="719" left="668" width="6" height="18" font="7"></text>
<text top="720" left="675" width="114" height="17" font="2"><b> Safety endpoint (if </b></text>
<text top="737" left="662" width="62" height="17" font="2"><b>relevant):</b>  </text>
<text top="755" left="662" width="7" height="18" font="7"></text>
<text top="756" left="668" width="167" height="17" font="0"> CPK elevation &gt;10x ULN in 1 </text>
<text top="773" left="662" width="108" height="17" font="0">out of 10,000 pts/y. </text>
<text top="580" left="857" width="7" height="18" font="7"></text>
<text top="581" left="864" width="232" height="17" font="0"> Comparable proportional reduction in first </text>
<text top="599" left="857" width="187" height="17" font="0">major coronary event, stroke, and </text>
<text top="616" left="857" width="228" height="17" font="0">revascularization (considered separately) </text>
<text top="633" left="857" width="7" height="18" font="7"></text>
<text top="634" left="864" width="206" height="17" font="0"> 16% reduction in peripheral vascular </text>
<text top="651" left="857" width="206" height="17" font="0">events (5%–25%; p=0.006), primarily </text>
<text top="669" left="857" width="184" height="17" font="0">through reduction in noncoronary </text>
<text top="686" left="857" width="102" height="17" font="0">revascularizations </text>
<text top="703" left="857" width="7" height="18" font="7"></text>
<text top="704" left="864" width="219" height="17" font="0"> Statin group: 85% compliant with statin </text>
<text top="721" left="857" width="7" height="18" font="7"></text>
<text top="722" left="864" width="219" height="17" font="0"> Non-statin group: 17% non-study statin </text>
<text top="740" left="857" width="3" height="17" font="0"> </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">57 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="338" width="153" height="17" font="0">muscle disease; concurrent </text>
<text top="104" left="338" width="145" height="17" font="0">Rx (cyclosporine, fibrates, </text>
<text top="122" left="338" width="160" height="17" font="0">niacin); child bearing; severe </text>
<text top="139" left="338" width="104" height="17" font="0">CHF; limitations to </text>
<text top="156" left="338" width="69" height="17" font="0">compliance. </text>
<text top="87" left="662" width="7" height="18" font="7"></text>
<text top="88" left="668" width="120" height="17" font="0"> Mean follow-up 5.0 y </text>
<text top="174" left="86" width="95" height="17" font="0">Mohler ER, et al. </text>
<text top="191" left="86" width="59" height="17" font="0">2003(127) </text>
<text top="208" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12952839">12952839</a></text>
<text top="208" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12952839"> </a></text>
<text top="226" left="86" width="3" height="17" font="0"> </text>
<text top="174" left="196" width="40" height="17" font="2"><b>Aim:</b> D</text>
<text top="174" left="235" width="51" height="17" font="10">etermine </text>
<text top="191" left="196" width="110" height="17" font="10">whether cholesterol </text>
<text top="208" left="196" width="75" height="17" font="10">lowering with </text>
<text top="226" left="196" width="120" height="17" font="10">atorvastatin improves </text>
<text top="243" left="196" width="117" height="17" font="10">walking performance </text>
<text top="260" left="196" width="74" height="17" font="10">in pts with IC </text>
<text top="277" left="196" width="3" height="17" font="0"> </text>
<text top="294" left="196" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="312" left="196" width="118" height="17" font="0">Prospective, blinded, </text>
<text top="329" left="196" width="29" height="17" font="0">RCT </text>
<text top="346" left="196" width="3" height="17" font="0"> </text>
<text top="363" left="196" width="90" height="17" font="2"><b>Size:</b> n=354 pts </text>
<text top="174" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="191" left="338" width="7" height="18" font="7"></text>
<text top="192" left="344" width="63" height="17" font="0"> Age &gt;25 y </text>
<text top="210" left="338" width="7" height="18" font="7"></text>
<text top="211" left="344" width="106" height="17" font="0"> Stable IC for 6 mo </text>
<text top="228" left="338" width="7" height="18" font="7"></text>
<text top="229" left="344" width="62" height="17" font="0"> ABI ≤0.90 </text>
<text top="246" left="338" width="7" height="18" font="7"></text>
<text top="247" left="344" width="148" height="17" font="0"> 20% reduction in ABI post </text>
<text top="265" left="338" width="106" height="17" font="0">exercise (Gardner) </text>
<text top="282" left="338" width="7" height="18" font="7"></text>
<text top="283" left="344" width="65" height="17" font="0"> LDL ≤160. </text>
<text top="300" left="338" width="3" height="17" font="0"> </text>
<text top="318" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="335" left="338" width="7" height="18" font="7"></text>
<text top="336" left="344" width="75" height="17" font="0"> MI, coronary </text>
<text top="353" left="338" width="157" height="17" font="0">revascularization, peripheral </text>
<text top="370" left="338" width="168" height="17" font="0">revascularization within 6 mo.  </text>
<text top="387" left="338" width="7" height="18" font="7"></text>
<text top="389" left="344" width="105" height="17" font="0"> USA within 3 mo.  </text>
<text top="406" left="338" width="7" height="18" font="7"></text>
<text top="407" left="344" width="152" height="17" font="0"> Stroke or TIA within 6 mo.  </text>
<text top="424" left="338" width="7" height="18" font="7"></text>
<text top="425" left="344" width="124" height="17" font="0"> DVT/PE within 3 mo.  </text>
<text top="443" left="338" width="7" height="18" font="7"></text>
<text top="444" left="344" width="133" height="17" font="0"> Current engagement in </text>
<text top="461" left="338" width="137" height="17" font="0">exercise rehab program. </text>
<text top="174" left="520" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="191" left="520" width="106" height="17" font="0">Atorvastatin 10 mg </text>
<text top="208" left="520" width="95" height="17" font="0">daily (120 pts) or </text>
<text top="226" left="520" width="123" height="17" font="0">atorvastatin 80 g daily </text>
<text top="243" left="520" width="52" height="17" font="0">(120 pts) </text>
<text top="260" left="520" width="7" height="17" font="0">  </text>
<text top="277" left="520" width="125" height="17" font="2"><b>Comparator: </b>Placebo </text>
<text top="294" left="520" width="52" height="17" font="0">(114 pts)<b> </b></text>
<text top="175" left="662" width="7" height="17" font="2"><b>1</b></text>
<text top="174" left="668" width="6" height="18" font="7"></text>
<text top="175" left="675" width="169" height="17" font="2"><b> endpoint:</b> Change in MWT at </text>
<text top="192" left="662" width="41" height="17" font="0">12 mo. </text>
<text top="210" left="662" width="7" height="18" font="7"></text>
<text top="211" left="668" width="103" height="17" font="0"> Placebo: 50±12 s </text>
<text top="228" left="662" width="7" height="18" font="7"></text>
<text top="229" left="668" width="105" height="17" font="0"> Atorva 10: 90±18  </text>
<text top="246" left="662" width="7" height="18" font="7"></text>
<text top="247" left="668" width="102" height="17" font="0"> Atorva 80: 90±18 </text>
<text top="265" left="662" width="50" height="17" font="0">(p=0.37) </text>
<text top="174" left="857" width="7" height="18" font="7"></text>
<text top="175" left="864" width="152" height="17" font="0"> Change in PFWT at 12 mo </text>
<text top="192" left="857" width="7" height="18" font="7"></text>
<text top="193" left="864" width="87" height="17" font="0"> Placebo: 39±8 </text>
<text top="211" left="857" width="7" height="18" font="7"></text>
<text top="212" left="864" width="155" height="17" font="0"> Atorva 10: 74±14 (p=0.13)  </text>
<text top="229" left="857" width="7" height="18" font="7"></text>
<text top="230" left="864" width="158" height="17" font="0"> Atorva 80: 81±15 (p=0.025) </text>
<text top="479" left="86" width="42" height="17" font="2"><b>ICPOP </b></text>
<text top="496" left="86" width="86" height="17" font="0">Hiatt WR, et al. </text>
<text top="513" left="86" width="59" height="17" font="0">2010(128) </text>
<text top="531" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20212073">20212073</a></text>
<text top="531" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20212073"> </a></text>
<text top="548" left="86" width="3" height="17" font="0"> </text>
<text top="479" left="196" width="79" height="17" font="2"><b>Aim:</b> Test the </text>
<text top="496" left="196" width="107" height="17" font="0">hypothesis that ER </text>
<text top="513" left="196" width="119" height="17" font="0">Niacin plus lovastatin </text>
<text top="531" left="196" width="83" height="17" font="0">would improve </text>
<text top="548" left="196" width="122" height="17" font="0">exercise performance </text>
<text top="565" left="196" width="111" height="17" font="0">in pts with PAD and </text>
<text top="582" left="196" width="127" height="17" font="0">claudication compared </text>
<text top="599" left="196" width="119" height="17" font="0">with diet intervention. </text>
<text top="617" left="196" width="3" height="17" font="0"> </text>
<text top="634" left="196" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="651" left="196" width="3" height="17" font="0"> </text>
<text top="668" left="196" width="70" height="17" font="2"><b>Size:</b> n=387 </text>
<text top="479" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="496" left="338" width="7" height="18" font="7"></text>
<text top="497" left="344" width="63" height="17" font="0"> Age &gt;40 y </text>
<text top="515" left="338" width="7" height="18" font="7"></text>
<text top="516" left="344" width="57" height="17" font="0"> Stable IC </text>
<text top="533" left="338" width="7" height="18" font="7"></text>
<text top="534" left="344" width="62" height="17" font="0"> ABI ≤0.90 </text>
<text top="551" left="338" width="7" height="18" font="7"></text>
<text top="552" left="344" width="149" height="17" font="0"> 20% reduction in ABI post-</text>
<text top="570" left="338" width="106" height="17" font="0">exercise (Gardner) </text>
<text top="587" left="338" width="7" height="18" font="7"></text>
<text top="588" left="344" width="62" height="17" font="0"> LDL ≤160 </text>
<text top="605" left="338" width="7" height="18" font="7"></text>
<text top="606" left="344" width="88" height="17" font="0"> PWT 1–20 min </text>
<text top="624" left="338" width="7" height="18" font="7"></text>
<text top="625" left="344" width="116" height="17" font="0"> &lt;20% variability in 2 </text>
<text top="642" left="338" width="79" height="17" font="0">assessments. </text>
<text top="659" left="338" width="3" height="17" font="0"> </text>
<text top="676" left="338" width="157" height="17" font="2"><b>Exclusion criteria:</b> Pts with </text>
<text top="694" left="338" width="148" height="17" font="0">CAD or other indication for </text>
<text top="711" left="338" width="122" height="17" font="0">lipid lowering therapy. </text>
<text top="479" left="520" width="105" height="17" font="2"><b>Intervention:</b> Low-</text>
<text top="496" left="520" width="119" height="17" font="0">dose Niacin 1000 mg </text>
<text top="513" left="520" width="119" height="17" font="0">plus lovastatin 40 mg </text>
<text top="531" left="520" width="109" height="17" font="0">or high-dose Niacin </text>
<text top="548" left="520" width="77" height="17" font="0">2000 mg plus </text>
<text top="565" left="520" width="93" height="17" font="0">lovastatin 40 mg </text>
<text top="582" left="520" width="3" height="17" font="0"> </text>
<text top="599" left="520" width="106" height="17" font="2"><b>Comparator:</b> Diet<b>  </b></text>
<text top="480" left="662" width="7" height="17" font="2"><b>1</b></text>
<text top="479" left="668" width="6" height="18" font="7"></text>
<text top="480" left="675" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="497" left="662" width="7" height="18" font="7"></text>
<text top="498" left="668" width="171" height="17" font="0"> Change from baseline in PWT </text>
<text top="516" left="662" width="179" height="17" font="0">and in claudication onset time at </text>
<text top="533" left="662" width="36" height="17" font="0">28 wk </text>
<text top="550" left="662" width="7" height="18" font="7"></text>
<text top="551" left="668" width="163" height="17" font="0"> Diet: 26.5%; 95% CI: 16.4%–</text>
<text top="569" left="662" width="38" height="17" font="0">37.6% </text>
<text top="587" left="662" width="7" height="17" font="0">L</text>
<text top="586" left="668" width="7" height="18" font="7"></text>
<text top="587" left="675" width="163" height="17" font="0"> ow Niacin/Lova: 38.6%; 95% </text>
<text top="604" left="662" width="151" height="17" font="0">CI: 27.6%–50.6%, p=0.096 </text>
<text top="621" left="662" width="7" height="18" font="7"></text>
<text top="622" left="668" width="173" height="17" font="0"> High Niacin/Lova: 37.8%; 95% </text>
<text top="640" left="662" width="151" height="17" font="0">CI: 26.6%–50.1%, p=0.137 </text>
<text top="657" left="662" width="3" height="17" font="0"> </text>
<text top="674" left="662" width="167" height="17" font="2"><b>Safety endpoint:</b> 2/3 of pts in </text>
<text top="691" left="662" width="170" height="17" font="0">each treatment group reported </text>
<text top="709" left="662" width="150" height="17" font="0">drug-related adverse event </text>
<text top="726" left="662" width="150" height="17" font="0">(pruritis, diarrhea, elevated </text>
<text top="743" left="662" width="170" height="17" font="0">blood sugar). Flushing in 54%. </text>
<text top="760" left="662" width="162" height="17" font="0">Serious adverse events were </text>
<text top="479" left="857" width="7" height="18" font="7"></text>
<text top="480" left="864" width="86" height="17" font="0"> Change in ABI </text>
<text top="497" left="857" width="7" height="18" font="7"></text>
<text top="498" left="864" width="196" height="17" font="0"> Walking Impairment Questionnaire </text>
<text top="516" left="857" width="7" height="18" font="7"></text>
<text top="517" left="864" width="140" height="17" font="0"> Composite of CV events </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">58 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="662" width="165" height="17" font="0">similar in all 3 groups (11.2%, </text>
<text top="104" left="662" width="84" height="17" font="0">11.2%, 10.3%) </text>
<text top="128" left="86" width="66" height="17" font="0">Giri J, et al. </text>
<text top="145" left="86" width="59" height="17" font="0">2006(129) </text>
<text top="162" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16516084">16516084</a></text>
<text top="162" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16516084"> </a></text>
<text top="179" left="86" width="3" height="17" font="0"> </text>
<text top="128" left="196" width="107" height="17" font="2"><b>Aim:</b> To determine </text>
<text top="145" left="196" width="116" height="17" font="0">whether statin use is </text>
<text top="162" left="196" width="113" height="17" font="0">associated with less </text>
<text top="179" left="196" width="114" height="17" font="0">annual decline in LE </text>
<text top="196" left="196" width="63" height="17" font="0">functioning </text>
<text top="214" left="196" width="111" height="17" font="0">with/without LEPAD </text>
<text top="231" left="196" width="3" height="17" font="0"> </text>
<text top="248" left="196" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="265" left="196" width="105" height="17" font="0">Prospective cohort </text>
<text top="283" left="196" width="103" height="17" font="0">study (identified in </text>
<text top="300" left="196" width="118" height="17" font="0">noninvasive vascular </text>
<text top="317" left="196" width="101" height="17" font="0">lab between 1998-</text>
<text top="334" left="196" width="103" height="17" font="0">2000 at 3 Chicago </text>
<text top="351" left="196" width="69" height="17" font="0">institutions). </text>
<text top="369" left="196" width="3" height="17" font="0"> </text>
<text top="386" left="196" width="70" height="17" font="2"><b>Size:</b> n=544 </text>
<text top="128" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="145" left="338" width="7" height="18" font="7"></text>
<text top="146" left="344" width="135" height="17" font="0"> PAD group: ABI &lt;0.90.  </text>
<text top="163" left="338" width="7" height="18" font="7"></text>
<text top="164" left="344" width="157" height="17" font="0"> Non-PAD: 1.50 ≥ABI ≥0.90 </text>
<text top="182" left="338" width="3" height="17" font="0"> </text>
<text top="199" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="216" left="338" width="7" height="18" font="7"></text>
<text top="217" left="344" width="79" height="17" font="0"> SNF resident </text>
<text top="234" left="338" width="7" height="18" font="7"></text>
<text top="236" left="344" width="106" height="17" font="0"> Wheelchair bound </text>
<text top="253" left="338" width="7" height="18" font="7"></text>
<text top="254" left="344" width="130" height="17" font="0"> Foot or leg amputation </text>
<text top="271" left="338" width="7" height="18" font="7"></text>
<text top="272" left="344" width="126" height="17" font="0"> Non-English speaking </text>
<text top="290" left="338" width="7" height="18" font="7"></text>
<text top="291" left="344" width="124" height="17" font="0"> Recent major surgery </text>
<text top="308" left="338" width="7" height="18" font="7"></text>
<text top="309" left="344" width="106" height="17" font="0"> Prior vasc surgery </text>
<text top="326" left="338" width="7" height="18" font="7"></text>
<text top="327" left="344" width="70" height="17" font="0"> Normal ABI </text>
<text top="128" left="520" width="98" height="17" font="2"><b>Intervention:</b> On </text>
<text top="145" left="520" width="33" height="17" font="0">statin </text>
<text top="162" left="520" width="7" height="17" font="0">  </text>
<text top="179" left="520" width="117" height="17" font="2"><b>Comparator:</b> Not on </text>
<text top="196" left="520" width="36" height="17" font="0">statin<b>  </b></text>
<text top="129" left="662" width="7" height="17" font="2"><b>1</b></text>
<text top="128" left="668" width="6" height="18" font="7"></text>
<text top="129" left="675" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="146" left="662" width="7" height="18" font="7"></text>
<text top="147" left="668" width="174" height="17" font="2"><b> </b>Pts with PAD using statins had </text>
<text top="164" left="662" width="128" height="17" font="0">less annual decline in:  </text>
<text top="182" left="662" width="7" height="18" font="7"></text>
<text top="183" left="668" width="158" height="17" font="2"><b> </b>Usual-pace walking velocity </text>
<text top="200" left="662" width="132" height="17" font="0">(0.002 vs. -0.024 m/s/y; </text>
<text top="217" left="662" width="52" height="17" font="0">p=0.013) </text>
<text top="234" left="662" width="7" height="18" font="7"></text>
<text top="236" left="668" width="167" height="17" font="2"><b> </b>Rapid-pace walking velocity (-</text>
<text top="253" left="662" width="180" height="17" font="0">0.006 vs. -0.042 m/s/y; p=0.006) </text>
<text top="270" left="662" width="7" height="18" font="7"></text>
<text top="271" left="668" width="173" height="17" font="2"><b> </b>6 min walk performance (-34.5 </text>
<text top="288" left="662" width="126" height="17" font="0">vs. -57.9 ft/y; p=0.088) </text>
<text top="306" left="662" width="7" height="18" font="7"></text>
<text top="307" left="668" width="165" height="17" font="2"><b> </b>Summary performance score </text>
<text top="324" left="662" width="156" height="17" font="0">(-0.152 vs. -0.376; p=0.067) </text>
<text top="341" left="662" width="145" height="17" font="0">compared with non-users. </text>
<text top="358" left="662" width="7" height="18" font="7"></text>
<text top="359" left="668" width="172" height="17" font="2"><b> </b>Among pts without-PAD, there </text>
<text top="377" left="662" width="176" height="17" font="0">were no significant associations </text>
<text top="394" left="662" width="130" height="17" font="0">between statin use and </text>
<text top="411" left="662" width="102" height="17" font="0">functional decline. </text>
<text top="128" left="857" width="24" height="17" font="0">N/A </text>
<text top="429" left="86" width="87" height="17" font="0">West AM, et al. </text>
<text top="446" left="86" width="59" height="17" font="0">2011(130) </text>
<text top="464" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21570685">21570685</a></text>
<text top="464" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21570685"> </a></text>
<text top="481" left="86" width="3" height="17" font="0"> </text>
<text top="429" left="196" width="70" height="17" font="2"><b>Aim:</b> LDL-C </text>
<text top="446" left="196" width="120" height="17" font="0">cholesterol by adding </text>
<text top="464" left="196" width="103" height="17" font="0">ezetimibe to statin </text>
<text top="481" left="196" width="80" height="17" font="0">therapy would </text>
<text top="498" left="196" width="44" height="17" font="0">regress </text>
<text top="515" left="196" width="86" height="17" font="0">atherosclerosis </text>
<text top="532" left="196" width="114" height="17" font="0">measured by MRI in </text>
<text top="550" left="196" width="93" height="17" font="0">the SFA in PAD. </text>
<text top="567" left="196" width="3" height="17" font="0"> </text>
<text top="584" left="196" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="601" left="196" width="111" height="17" font="0">center, prospective, </text>
<text top="619" left="196" width="116" height="17" font="0">RCT, double-blinded </text>
<text top="636" left="196" width="3" height="17" font="0"> </text>
<text top="653" left="196" width="83" height="17" font="2"><b>Size: </b>n=87 pts </text>
<text top="429" left="338" width="157" height="17" font="2"><b>Inclusion criteria:</b> 30–85 y, </text>
<text top="446" left="338" width="105" height="17" font="0">PAD (ABI 0.4–0.9) </text>
<text top="464" left="338" width="3" height="17" font="0"> </text>
<text top="481" left="338" width="169" height="17" font="2"><b>Exclusion criteria:</b> Rest pain, </text>
<text top="498" left="338" width="159" height="17" font="0">CLI, contraindication to MRI, </text>
<text top="515" left="338" width="64" height="17" font="0">pregnancy. </text>
<text top="429" left="520" width="113" height="17" font="2"><b>Intervention:</b> Statin-</text>
<text top="446" left="520" width="118" height="17" font="0">naive (randomized to </text>
<text top="464" left="520" width="79" height="17" font="0">simvastatin or </text>
<text top="481" left="520" width="91" height="17" font="0">simvastatin plus </text>
<text top="498" left="520" width="74" height="17" font="0">ezetimibe) or </text>
<text top="515" left="520" width="109" height="17" font="0">previously on statin </text>
<text top="532" left="520" width="93" height="17" font="0">given open label </text>
<text top="550" left="520" width="56" height="17" font="0">ezetimibe </text>
<text top="567" left="520" width="7" height="17" font="0">  </text>
<text top="584" left="520" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="601" left="520" width="101" height="17" font="0">Simvastatin alone<b> </b></text>
<text top="430" left="662" width="7" height="17" font="2"><b>1</b></text>
<text top="429" left="668" width="6" height="18" font="7"></text>
<text top="430" left="675" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="448" left="662" width="7" height="18" font="7"></text>
<text top="449" left="668" width="172" height="17" font="2"><b> </b>Atherosclerotic plaque volume </text>
<text top="466" left="662" width="182" height="17" font="0">in the proximal 15–20 cm of SFA </text>
<text top="483" left="662" width="159" height="17" font="0">at baseline and annually x 2. </text>
<text top="500" left="662" width="7" height="18" font="7"></text>
<text top="501" left="668" width="150" height="17" font="2"><b> </b>Baseline and y 2 volumes: </text>
<text top="519" left="662" width="7" height="18" font="7"></text>
<text top="520" left="668" width="156" height="17" font="2"><b> </b>S + E (11.5 ± 1.4 vs.10.5 ± </text>
<text top="537" left="662" width="37" height="17" font="0">1.3 cm</text>
<text top="538" left="698" width="4" height="11" font="11">3</text>
<text top="537" left="703" width="63" height="17" font="0">; p=NS) or  </text>
<text top="554" left="662" width="7" height="18" font="7"></text>
<text top="555" left="668" width="154" height="17" font="2"><b> </b>S (11.0 ± 1.5 vs.10.5 ± 1.4 </text>
<text top="573" left="662" width="16" height="17" font="0">cm</text>
<text top="574" left="678" width="4" height="11" font="11">3</text>
<text top="573" left="682" width="46" height="17" font="0">, p=NS) </text>
<text top="590" left="662" width="7" height="18" font="7"></text>
<text top="591" left="668" width="145" height="17" font="2"><b> </b>E (10.0 ± 0.8–10.8 ± 0.9; </text>
<text top="608" left="662" width="45" height="17" font="0">p&lt;0.01) </text>
<text top="429" left="857" width="7" height="18" font="7"></text>
<text top="430" left="864" width="233" height="17" font="2"><b> </b>Only 72 pts at follow-up (2 died, 11 lost to </text>
<text top="448" left="857" width="209" height="17" font="0">follow-up, 2 withdrew prior to baseline </text>
<text top="465" left="857" width="51" height="17" font="0">imaging)<b> </b></text>
<text top="482" left="857" width="7" height="18" font="7"></text>
<text top="483" left="864" width="238" height="17" font="0"> Statin initiation with or without ezetimibe in </text>
<text top="500" left="857" width="231" height="17" font="0">statin-naive pts halted plaque progression </text>
<text top="518" left="857" width="7" height="18" font="7"></text>
<text top="519" left="864" width="211" height="17" font="0"> Ezetimibe added to existing statin still </text>
<text top="536" left="857" width="228" height="17" font="0">resulted in progression of plaque volume; </text>
<text top="553" left="857" width="233" height="17" font="0">ezetimibe’s effect on PAD may depend on </text>
<text top="570" left="857" width="174" height="17" font="0">relative timing of statin therapy. </text>
<text top="588" left="857" width="7" height="18" font="7"></text>
<text top="589" left="864" width="211" height="17" font="2"><b> </b>LDL-C was lowered by the addition of </text>
<text top="606" left="857" width="202" height="17" font="0">ezetimibe in both groups, but did not </text>
<text top="623" left="857" width="208" height="17" font="0">translate to change in plaque volume. </text>
<text top="640" left="857" width="203" height="17" font="0">Study was underpowered to detect a </text>
<text top="658" left="857" width="177" height="17" font="0">difference between S and S + E </text>
<text top="676" left="86" width="79" height="17" font="0">Stoekenbroek </text>
<text top="693" left="86" width="56" height="17" font="0">RM, et al.<b> </b></text>
<text top="710" left="86" width="59" height="17" font="0">2015(131) </text>
<text top="727" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25595417">25595417</a></text>
<text top="727" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25595417"> </a></text>
<text top="744" left="86" width="3" height="17" font="0"> </text>
<text top="676" left="196" width="91" height="17" font="2"><b>Aim:</b> Determine </text>
<text top="693" left="196" width="105" height="17" font="0">whether high-dose </text>
<text top="710" left="196" width="115" height="17" font="0">statin vs. usual dose </text>
<text top="727" left="196" width="80" height="17" font="0">statin reduces </text>
<text top="744" left="196" width="122" height="17" font="0">incidence of PAD and </text>
<text top="762" left="196" width="119" height="17" font="0">CAD outcomes in pts </text>
<text top="676" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="693" left="338" width="7" height="18" font="7"></text>
<text top="694" left="344" width="64" height="17" font="0"> Age ≤80 y </text>
<text top="711" left="338" width="7" height="18" font="7"></text>
<text top="712" left="344" width="109" height="17" font="0"> Confirmed prior MI </text>
<text top="729" left="338" width="3" height="17" font="0"> </text>
<text top="747" left="338" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="676" left="520" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="693" left="520" width="103" height="17" font="0">Atorvastatin 80mg </text>
<text top="710" left="520" width="3" height="17" font="0"> </text>
<text top="727" left="520" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="744" left="520" width="122" height="17" font="0">Simvastatin 20–40mg<b> </b></text>
<text top="677" left="662" width="7" height="17" font="2"><b>1</b></text>
<text top="676" left="668" width="6" height="18" font="7"></text>
<text top="677" left="675" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="694" left="662" width="7" height="18" font="7"></text>
<text top="695" left="668" width="144" height="17" font="0"> No PAD at baseline: new </text>
<text top="712" left="662" width="152" height="17" font="0">clinical Dx of PAD requiring </text>
<text top="729" left="662" width="138" height="17" font="0">diagnostic procedures or </text>
<text top="747" left="662" width="77" height="17" font="0">interventions. </text>
<text top="764" left="679" width="7" height="18" font="7"></text>
<text top="765" left="686" width="115" height="17" font="0"> 2.2% in atorvastatin </text>
<text top="676" left="857" width="7" height="18" font="7"></text>
<text top="680" left="864" width="4" height="14" font="0"> </text>
<text top="677" left="868" width="224" height="17" font="0">Post-hoc evaluation of CAD outcomes in </text>
<text top="694" left="857" width="137" height="17" font="0">pts with PAD at baseline </text>
<text top="711" left="857" width="7" height="18" font="7"></text>
<text top="715" left="864" width="4" height="14" font="0"> </text>
<text top="712" left="868" width="176" height="17" font="0">Baseline PAD in 374 pts (4.2%) </text>
<text top="730" left="857" width="7" height="18" font="7"></text>
<text top="734" left="864" width="4" height="14" font="0"> </text>
<text top="731" left="868" width="213" height="17" font="0">Major coronary events nonsignificantly </text>
<text top="748" left="857" width="215" height="17" font="0">lower in the atorvastatin group (14.4%) </text>
<text top="765" left="857" width="204" height="17" font="0">compared with the simvastatin group </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">59 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="196" width="54" height="17" font="0">with PAD </text>
<text top="104" left="196" width="3" height="17" font="0"> </text>
<text top="122" left="196" width="100" height="17" font="2"><b>Study type:</b> Multi-</text>
<text top="139" left="196" width="105" height="17" font="0">center, RCT, open-</text>
<text top="156" left="196" width="126" height="17" font="0">label, blinded outcome </text>
<text top="173" left="196" width="69" height="17" font="0">assessment </text>
<text top="190" left="196" width="3" height="17" font="0"> </text>
<text top="208" left="196" width="100" height="17" font="2"><b>Size:</b> n=8,888 pts<b> </b></text>
<text top="87" left="679" width="7" height="18" font="7"></text>
<text top="88" left="686" width="113" height="17" font="0"> 3.2% in simvastatin </text>
<text top="106" left="679" width="7" height="18" font="7"></text>
<text top="107" left="686" width="141" height="17" font="0"> (HR: 0.70; 95% CI: 0.53–</text>
<text top="124" left="679" width="83" height="17" font="0">0.91; p=0.007) </text>
<text top="141" left="662" width="7" height="18" font="7"></text>
<text top="142" left="668" width="165" height="17" font="0"> Known PAD at baseline: new </text>
<text top="159" left="662" width="172" height="17" font="0">hospitalization for treatment for </text>
<text top="177" left="662" width="29" height="17" font="0">PAD </text>
<text top="194" left="679" width="7" height="18" font="7"></text>
<text top="195" left="686" width="138" height="17" font="0"> No significant difference </text>
<text top="212" left="679" width="104" height="17" font="0">(18.3% vs. 16.5%)<b> </b></text>
<text top="87" left="857" width="215" height="17" font="0">(20.1%) (HR: 0.68; 95% CI: 0.41–1.11; </text>
<text top="104" left="857" width="52" height="17" font="0">p=0.13).  </text>
<text top="122" left="857" width="7" height="18" font="7"></text>
<text top="126" left="864" width="4" height="14" font="0"> </text>
<text top="123" left="868" width="233" height="17" font="0">Atorvastatin reduced overall CV (p=0.046) </text>
<text top="140" left="857" width="247" height="17" font="0">and coronary events (p=0.004) and coronary </text>
<text top="157" left="857" width="152" height="17" font="0">revascularization (p=0.007) </text>
<text top="230" left="86" width="86" height="17" font="0">Aung PP, et al. </text>
<text top="248" left="86" width="59" height="17" font="0">2007(132) </text>
<text top="265" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17943736">17943736</a></text>
<text top="265" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17943736"> </a></text>
<text top="230" left="196" width="74" height="17" font="2"><b>Aim:</b> Assess </text>
<text top="248" left="196" width="115" height="17" font="0">outcomes with statin </text>
<text top="265" left="196" width="79" height="17" font="0">vs. placebo in </text>
<text top="282" left="196" width="86" height="17" font="0">individuals with </text>
<text top="299" left="196" width="44" height="17" font="0">LEPAD </text>
<text top="316" left="196" width="3" height="17" font="0"> </text>
<text top="334" left="196" width="102" height="17" font="2"><b>Study type: </b>Meta-</text>
<text top="351" left="196" width="111" height="17" font="0">analysis of 18 RCT. </text>
<text top="368" left="196" width="3" height="17" font="0"> </text>
<text top="385" left="196" width="91" height="17" font="2"><b>Size:</b> n=10, 049 </text>
<text top="230" left="338" width="155" height="17" font="2"><b>Inclusion criteria:</b> RCTs of </text>
<text top="248" left="338" width="161" height="17" font="0">lipid-lowering therapy in PAD </text>
<text top="265" left="338" width="93" height="17" font="0">of the lower limb </text>
<text top="282" left="338" width="3" height="17" font="0"> </text>
<text top="299" left="338" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="230" left="520" width="108" height="17" font="2"><b>Intervention:</b> Lipid-</text>
<text top="248" left="520" width="103" height="17" font="0">lowering therapies </text>
<text top="265" left="520" width="3" height="17" font="0"> </text>
<text top="282" left="520" width="125" height="17" font="2"><b>Comparator:</b> Placebo </text>
<text top="231" left="662" width="7" height="17" font="2"><b>1</b></text>
<text top="230" left="668" width="6" height="18" font="7"></text>
<text top="231" left="675" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="249" left="662" width="7" height="18" font="7"></text>
<text top="250" left="668" width="174" height="17" font="0"> Overall mortality: no significant </text>
<text top="267" left="662" width="165" height="17" font="0">difference (OR: 0.86; 95% CI: </text>
<text top="284" left="662" width="62" height="17" font="0">0.49–1.50) </text>
<text top="301" left="662" width="7" height="18" font="7"></text>
<text top="302" left="668" width="163" height="17" font="0"> Total Cardiovascular events: </text>
<text top="320" left="662" width="162" height="17" font="0">no significant difference (OR: </text>
<text top="337" left="662" width="133" height="17" font="0">0.8; 95% CI: 0.59–1.09) </text>
<text top="230" left="857" width="230" height="17" font="0">Subgroup analysis (exclusion of PQRST): </text>
<text top="248" left="857" width="7" height="18" font="7"></text>
<text top="252" left="864" width="4" height="14" font="0"> </text>
<text top="249" left="868" width="154" height="17" font="0">Significant reduction of total </text>
<text top="266" left="857" width="230" height="17" font="0">cardiovascular events (OR: 0.74; 95% CI: </text>
<text top="283" left="857" width="62" height="17" font="0">0.55–0.98) </text>
<text top="300" left="857" width="7" height="18" font="7"></text>
<text top="301" left="864" width="209" height="17" font="0"> Significant reduction of total coronary </text>
<text top="319" left="857" width="209" height="17" font="0">events (OR: 0.76; 95% CI: 0.67–0.87) </text>
<text top="336" left="857" width="7" height="18" font="7"></text>
<text top="337" left="864" width="216" height="17" font="0"> Greatest effectiveness in statin use for </text>
<text top="354" left="857" width="185" height="17" font="0">individuals with LDL ≥3.5 mmol/L </text>
<text top="403" left="86" width="1017" height="17" font="0">ABI indicates ankle-brachial index; CAD, coronary artery disease; CHF, congestive heart failure; CI indicates confidence interval; CLI, critical limb ischemia; CPK, creatine phosphokinase; </text>
<text top="420" left="86" width="993" height="17" font="0">CVD, cardiovascular disease; CV, cardiovascular; DVT/PE, deep vein thrombosis/pulmonary embolism; HR, hazard ratio; HTN, hypertension; IC, intermittent claudication; LDL-C, low-</text>
<text top="438" left="86" width="1014" height="17" font="0">density lipoprotein; LE, lower extremity; LEPAD, lower extremity peripheral artery disease; MI, myocardial infarction; MRI, magnetic resonance imaging; MWT, maximal walking time; N/A, </text>
<text top="455" left="86" width="993" height="17" font="0">not applicable; PAD, peripheral artery disease; PCP, primary care physician; PFWT, pain-free walking time; pt, patient; PWT, peak treadmill walking time; RCT, randomized controlled </text>
<text top="472" left="86" width="893" height="17" font="0">trial; RR, relative risk; SFA, superficial femoral artery; SNF, skilled nursing facility; TIA, transient ischemic attack; ULN, upper limit normal; and USA, unstable angina</text>
<text top="472" left="979" width="7" height="17" font="9">. </text>
<text top="489" left="86" width="4" height="21" font="1"><b> </b></text>
<text top="528" left="86" width="796" height="21" font="1"><b>Evidence Table 16. Nonrandomized Trials, Observational Studies, and/or Registries of Statin Agents–Section 5.2. </b></text>
<text top="549" left="97" width="94" height="17" font="2"><b>Study Acronym </b></text>
<text top="567" left="122" width="47" height="17" font="2"><b>Author  </b></text>
<text top="584" left="129" width="33" height="17" font="2"><b>Year  </b></text>
<text top="549" left="242" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="567" left="246" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="584" left="240" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="549" left="404" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="549" left="576" width="111" height="17" font="2"><b>Study Intervention </b></text>
<text top="567" left="570" width="126" height="17" font="2"><b>(include # patients) /  </b></text>
<text top="584" left="576" width="111" height="17" font="2"><b>Study Comparator </b></text>
<text top="601" left="574" width="116" height="17" font="2"><b>(include # patients) </b></text>
<text top="549" left="748" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="567" left="728" width="144" height="17" font="2"><b>(include Absolute Event </b></text>
<text top="584" left="711" width="182" height="17" font="2"><b>Rates, P value; OR or RR; and  </b></text>
<text top="601" left="776" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="550" left="917" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="549" left="979" width="6" height="18" font="7"></text>
<text top="550" left="985" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="568" left="949" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="585" left="957" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="619" left="86" width="100" height="17" font="2"><b>REACH Registry </b></text>
<text top="636" left="86" width="111" height="17" font="0">Kumbhani DJ, et al.<b> </b></text>
<text top="653" left="86" width="59" height="17" font="0">2014(133) </text>
<text top="671" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24585266">24585266</a></text>
<text top="671" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24585266"> </a></text>
<text top="688" left="86" width="3" height="17" font="0"> </text>
<text top="619" left="214" width="127" height="17" font="2"><b>Aim:</b> Assess impact of </text>
<text top="636" left="214" width="118" height="17" font="0">statin use on primary </text>
<text top="653" left="214" width="130" height="17" font="0">adverse limb outcomes </text>
<text top="671" left="214" width="137" height="17" font="0">at 4 y and composite CV </text>
<text top="688" left="214" width="98" height="17" font="0">death, MI, stroke. </text>
<text top="705" left="214" width="3" height="17" font="0"> </text>
<text top="722" left="214" width="119" height="17" font="2"><b>Study type:</b> Registry </text>
<text top="739" left="214" width="3" height="17" font="0"> </text>
<text top="757" left="214" width="100" height="17" font="2"><b>Size:</b> n=5,861 pts </text>
<text top="619" left="365" width="179" height="17" font="2"><b>Inclusion criteria:</b> Documented </text>
<text top="636" left="365" width="178" height="17" font="0">sx PAD with complete 4 y follow-</text>
<text top="653" left="365" width="21" height="17" font="0">up. </text>
<text top="671" left="365" width="3" height="17" font="0"> </text>
<text top="688" left="365" width="180" height="17" font="2"><b>Exclusion criteria:</b> Not meeting </text>
<text top="705" left="365" width="165" height="17" font="0">inclusion criteria; no follow-up </text>
<text top="722" left="365" width="161" height="17" font="0">data for primary endpoint; no </text>
<text top="739" left="365" width="152" height="17" font="0">documented Hx of PAD; no </text>
<text top="757" left="365" width="176" height="17" font="0">information regarding statin use </text>
<text top="774" left="365" width="75" height="17" font="0">at enrollment </text>
<text top="619" left="567" width="113" height="17" font="2"><b>Intervention:</b> Statin </text>
<text top="636" left="567" width="59" height="17" font="0">use (62%) </text>
<text top="653" left="567" width="7" height="17" font="0">  </text>
<text top="671" left="567" width="96" height="17" font="2"><b>Comparator:</b> No </text>
<text top="688" left="567" width="92" height="17" font="0">statin use (38%)<b> </b></text>
<text top="620" left="709" width="7" height="17" font="2"><b>1</b></text>
<text top="619" left="716" width="6" height="18" font="7"></text>
<text top="620" left="722" width="156" height="17" font="2"><b> endpoint:</b> Primary adverse </text>
<text top="637" left="709" width="146" height="17" font="0">limb outcomes (worsening </text>
<text top="655" left="709" width="168" height="17" font="0">claudication, new CLI, new LE </text>
<text top="672" left="709" width="176" height="17" font="0">revascularization, new ischemic </text>
<text top="689" left="709" width="102" height="17" font="0">amputation) at 4 y </text>
<text top="706" left="712" width="86" height="17" font="0">-  22% in statin </text>
<text top="723" left="712" width="173" height="17" font="0">-  26.2% in no statin (HR: 0.82; </text>
<text top="741" left="724" width="109" height="17" font="0">95% CI: 0.72–0.92; </text>
<text top="758" left="724" width="63" height="17" font="0">p=0.0013)  </text>
<text top="619" left="905" width="7" height="18" font="7"></text>
<text top="620" left="911" width="141" height="17" font="0"> Registry data (undefined </text>
<text top="637" left="905" width="75" height="17" font="0">confounders) </text>
<text top="655" left="905" width="7" height="18" font="7"></text>
<text top="656" left="911" width="153" height="17" font="0"> Need for revascularization, </text>
<text top="673" left="905" width="172" height="17" font="0">worsening claudication may be </text>
<text top="690" left="905" width="200" height="17" font="0">subjectively determined by observer </text>
<text top="707" left="905" width="7" height="18" font="7"></text>
<text top="708" left="911" width="189" height="17" font="0"> More likely on statin if enrolled by </text>
<text top="726" left="905" width="171" height="17" font="0">cardiologist than by provider of </text>
<text top="743" left="905" width="185" height="17" font="0">other specialty (vascular surgery) </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">60 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="86" width="88" height="17" font="0">Vogel TR, et al. </text>
<text top="104" left="86" width="59" height="17" font="0">2013(134) </text>
<text top="122" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24300135">24300135</a></text>
<text top="122" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24300135"> </a></text>
<text top="139" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="214" width="98" height="17" font="2"><b>Aim:</b> To evaluate </text>
<text top="104" left="214" width="72" height="17" font="0">preoperative </text>
<text top="122" left="214" width="133" height="17" font="0">administration of statins </text>
<text top="139" left="214" width="115" height="17" font="0">and longitudinal limb </text>
<text top="156" left="214" width="92" height="17" font="0">salvage after LE </text>
<text top="173" left="214" width="76" height="17" font="0">endovascular </text>
<text top="190" left="214" width="120" height="17" font="0">revascularization and </text>
<text top="208" left="214" width="97" height="17" font="0">LE open surgery. </text>
<text top="225" left="214" width="3" height="17" font="0"> </text>
<text top="242" left="214" width="124" height="17" font="2"><b>Study type:</b> Medicare </text>
<text top="259" left="214" width="97" height="17" font="0">Claims Database </text>
<text top="276" left="214" width="44" height="17" font="0">Review </text>
<text top="294" left="214" width="3" height="17" font="0"> </text>
<text top="311" left="214" width="91" height="17" font="2"><b>Size:</b> n=22,954  </text>
<text top="87" left="365" width="166" height="17" font="2"><b>Inclusion criteria:</b> Age ≥65 y </text>
<text top="104" left="365" width="105" height="17" font="0">with a diagnosis of </text>
<text top="122" left="365" width="189" height="17" font="0">atherosclerosis of LE arteries who </text>
<text top="139" left="365" width="136" height="17" font="0">were hospitalized during </text>
<text top="156" left="365" width="101" height="17" font="0">2007–2008 for LE </text>
<text top="173" left="365" width="96" height="17" font="0">revascularization </text>
<text top="190" left="365" width="3" height="17" font="0"> </text>
<text top="208" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="567" width="98" height="17" font="2"><b>Intervention:</b> On </text>
<text top="104" left="567" width="87" height="17" font="0">statin at time of </text>
<text top="122" left="567" width="96" height="17" font="0">revascularization </text>
<text top="139" left="567" width="49" height="17" font="0">(11,687) </text>
<text top="156" left="567" width="7" height="17" font="0">  </text>
<text top="173" left="567" width="96" height="17" font="2"><b>Comparator:</b> No </text>
<text top="190" left="567" width="33" height="17" font="0">statin<b> </b></text>
<text top="88" left="709" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="716" width="6" height="18" font="7"></text>
<text top="88" left="722" width="154" height="17" font="2"><b> endpoint:</b> 1 y limb salvage </text>
<text top="106" left="709" width="31" height="17" font="0">rates </text>
<text top="123" left="709" width="172" height="17" font="0">Statin: RR=0.82; 95% CI: 0.78–</text>
<text top="140" left="709" width="86" height="17" font="0">0.86; p&lt;0.0001 </text>
<text top="87" left="905" width="24" height="17" font="0">N/A </text>
<text top="329" left="86" width="97" height="17" font="0">Westin GG, et al. </text>
<text top="346" left="86" width="59" height="17" font="0">2014(135) </text>
<text top="363" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24315911">24315911</a></text>
<text top="363" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24315911"> </a></text>
<text top="381" left="86" width="3" height="17" font="0"> </text>
<text top="329" left="214" width="127" height="17" font="2"><b>Aim: </b>To determine the </text>
<text top="346" left="214" width="121" height="17" font="0">associations between </text>
<text top="363" left="214" width="128" height="17" font="0">statin use and MACCE </text>
<text top="381" left="214" width="114" height="17" font="0">and amputation-free </text>
<text top="398" left="214" width="104" height="17" font="0">survival in CLI pts.<b> </b></text>
<text top="415" left="214" width="3" height="17" font="2"><b> </b></text>
<text top="432" left="214" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="449" left="214" width="81" height="17" font="0">center registry </text>
<text top="467" left="214" width="120" height="17" font="0">(retrospective cohort) </text>
<text top="484" left="214" width="3" height="17" font="0"> </text>
<text top="501" left="214" width="124" height="17" font="2"><b>Size:</b> n=380 (between </text>
<text top="518" left="214" width="69" height="17" font="0">2006–2012) </text>
<text top="329" left="365" width="125" height="17" font="2"><b>Inclusion criteria:</b> ≥1 </text>
<text top="346" left="365" width="185" height="17" font="0">presentation with CLI (Rutherford </text>
<text top="363" left="365" width="7" height="17" font="0">4</text>
<text top="363" left="372" width="7" height="17" font="19">–</text>
<text top="363" left="379" width="170" height="17" font="0">6). “On statin” if hospitalization </text>
<text top="381" left="365" width="131" height="17" font="0">data or most recent pre-</text>
<text top="398" left="365" width="174" height="17" font="0">procedure clinic note had statin </text>
<text top="415" left="365" width="149" height="17" font="0">listed (65% of pts enrolled) </text>
<text top="432" left="365" width="3" height="17" font="0"> </text>
<text top="449" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="329" left="567" width="98" height="17" font="2"><b>Intervention:</b> On </text>
<text top="346" left="567" width="107" height="17" font="0">statin (246 or 65%) </text>
<text top="363" left="567" width="3" height="17" font="0"> </text>
<text top="381" left="567" width="96" height="17" font="2"><b>Comparator: </b>No </text>
<text top="398" left="567" width="33" height="17" font="0">statin </text>
<text top="330" left="709" width="7" height="17" font="2"><b>1</b></text>
<text top="329" left="716" width="6" height="18" font="7"></text>
<text top="330" left="722" width="125" height="17" font="2"><b> endpoint:</b> Composite </text>
<text top="347" left="709" width="151" height="17" font="0">MACCE (death, MI, stroke) </text>
<text top="365" left="709" width="131" height="17" font="0">within 1 y of procedure. </text>
<text top="382" left="709" width="3" height="17" font="0"> </text>
<text top="399" left="709" width="175" height="17" font="2"><b>Results:</b> Statin: 18%, no statin: </text>
<text top="416" left="709" width="165" height="17" font="0">23% (HR: 0.53; 95% CI: 0.28–</text>
<text top="433" left="709" width="86" height="17" font="0">0.99; p=0.048)  </text>
<text top="451" left="709" width="167" height="17" font="0">Propensity score to control for </text>
<text top="468" left="709" width="123" height="17" font="0">confounding variables </text>
<text top="485" left="709" width="3" height="17" font="0"> </text>
<text top="329" left="905" width="7" height="18" font="7"></text>
<text top="330" left="911" width="191" height="17" font="0"> Secondary outcomes (1 y): death, </text>
<text top="347" left="905" width="180" height="17" font="0">MI, stroke, ipsilateral LE bypass, </text>
<text top="365" left="905" width="157" height="17" font="0">ipsilateral major amputation, </text>
<text top="382" left="905" width="176" height="17" font="0">amputation-free survival, vessel </text>
<text top="399" left="905" width="195" height="17" font="0">patency (primary, primary assisted, </text>
<text top="416" left="905" width="64" height="17" font="0">secondary) </text>
<text top="433" left="905" width="191" height="17" font="0">Amputation-free survival HR: 0.59; </text>
<text top="451" left="905" width="150" height="17" font="0">95% CI: 0.35–0.98; p=0.04 </text>
<text top="468" left="905" width="140" height="17" font="0">Improved vessel patency </text>
<text top="485" left="905" width="7" height="18" font="7"></text>
<text top="486" left="911" width="181" height="17" font="0"> Pts on statin had higher rates of </text>
<text top="503" left="905" width="169" height="17" font="0">DM, HTN, CAD, CVD, prior MI </text>
<text top="536" left="86" width="100" height="17" font="0">Feringa HH, et al. </text>
<text top="553" left="86" width="59" height="17" font="0">2007(136) </text>
<text top="571" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17360142">17360142</a></text>
<text top="571" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17360142"> </a></text>
<text top="588" left="86" width="3" height="17" font="0"> </text>
<text top="536" left="214" width="106" height="17" font="2"><b>Aim</b>: To determine </text>
<text top="553" left="214" width="116" height="17" font="0">whether higher-dose </text>
<text top="571" left="214" width="126" height="17" font="0">statins and lower dose </text>
<text top="588" left="214" width="127" height="17" font="0">LDL are independently </text>
<text top="605" left="214" width="122" height="17" font="0">associated with better </text>
<text top="622" left="214" width="98" height="17" font="0">outcomes in PAD </text>
<text top="639" left="214" width="3" height="17" font="2"><b> </b></text>
<text top="657" left="214" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="674" left="214" width="111" height="17" font="0">center, prospective, </text>
<text top="691" left="214" width="118" height="17" font="0">observational, cohort </text>
<text top="708" left="214" width="33" height="17" font="0">study </text>
<text top="726" left="214" width="3" height="17" font="0"> </text>
<text top="743" left="214" width="100" height="17" font="2"><b>Size:</b> n=1,374 pts<b> </b></text>
<text top="536" left="365" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="553" left="365" width="7" height="18" font="7"></text>
<text top="555" left="372" width="54" height="17" font="0"> Age ≥18 </text>
<text top="572" left="365" width="7" height="18" font="7"></text>
<text top="573" left="372" width="62" height="17" font="0"> ABI ≤0.90 </text>
<text top="590" left="365" width="3" height="17" font="0"> </text>
<text top="607" left="365" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="625" left="365" width="7" height="18" font="7"></text>
<text top="626" left="372" width="182" height="17" font="0"> MI or coronary revascularization </text>
<text top="643" left="365" width="70" height="17" font="0">in past 6 mo </text>
<text top="660" left="365" width="7" height="18" font="7"></text>
<text top="661" left="372" width="150" height="17" font="0"> Liver disease (Cirrhosis or </text>
<text top="679" left="365" width="53" height="17" font="0">hepatitis)<b> </b></text>
<text top="536" left="567" width="113" height="17" font="2"><b>Intervention:</b> Statin </text>
<text top="553" left="567" width="109" height="17" font="0">therapy (propensity </text>
<text top="571" left="567" width="105" height="17" font="0">analysis applied to </text>
<text top="588" left="567" width="58" height="17" font="0">control for </text>
<text top="605" left="567" width="75" height="17" font="0">confounders) </text>
<text top="537" left="709" width="7" height="17" font="2"><b>1</b></text>
<text top="536" left="716" width="6" height="18" font="7"></text>
<text top="537" left="722" width="167" height="17" font="2"><b> endpoint:</b> All-cause mortality </text>
<text top="555" left="709" width="101" height="17" font="0">and cardiac death </text>
<text top="572" left="709" width="3" height="17" font="0"> </text>
<text top="589" left="709" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="606" left="709" width="7" height="18" font="7"></text>
<text top="607" left="716" width="64" height="17" font="0"> 6 mo LDL: </text>
<text top="625" left="709" width="93" height="17" font="0">   &lt;100 in 30.8% </text>
<text top="642" left="709" width="79" height="17" font="0">   &lt;70 in 9.7% </text>
<text top="659" left="709" width="7" height="18" font="7"></text>
<text top="660" left="716" width="165" height="17" font="0"> Lowest all-cause and cardiac </text>
<text top="677" left="709" width="171" height="17" font="0">mortality (18% and 13%) in pts </text>
<text top="695" left="709" width="162" height="17" font="0">with lowest cholesterol (&lt;70), </text>
<text top="712" left="709" width="164" height="17" font="0">p&lt;0.001; gradually increasing </text>
<text top="729" left="709" width="183" height="17" font="0">with increasing cholesterol levels </text>
<text top="536" left="905" width="198" height="17" font="0">Secondary endpoint: progression to </text>
<text top="553" left="905" width="76" height="17" font="0">kidney failure </text>
<text top="571" left="905" width="162" height="17" font="0">Conclude: pts with ABI &lt;0.90 </text>
<text top="588" left="905" width="119" height="17" font="0">benefit from LDL &lt;70 </text>
<text top="605" left="905" width="107" height="17" font="0">Mean follow-up 6 y </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">61 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="997" height="17" font="0">CAD indicates coronary artery disease; CLI, critical limb ischemia; CVD, cardiovascular disease; CV, cardiovascular; DM, diabetes mellitus; HR, hazard ratio; HTN, hypertension; LDL, </text>
<text top="104" left="86" width="1016" height="17" font="0">low-density lipoprotein; LE, lower extremity; MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction; N/A, not applicable; pt, patient; and RR, relative </text>
<text top="121" left="86" width="26" height="17" font="0">risk. </text>
<text top="153" left="86" width="475" height="21" font="1"><b>Evidence Table 17. RCTs for Antihypertensive Agents– Section 5.3. </b></text>
<text top="174" left="101" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="192" left="126" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="209" left="104" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="174" left="241" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="192" left="246" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="209" left="240" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="174" left="405" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="174" left="596" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="192" left="614" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="209" left="596" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="226" left="617" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="174" left="768" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="192" left="746" width="149" height="17" font="2"><b>(Absolute Event Rates, P </b></text>
<text top="209" left="763" width="118" height="17" font="2"><b>value; OR or RR; &amp;  </b></text>
<text top="226" left="797" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="176" left="922" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="174" left="983" width="6" height="18" font="7"></text>
<text top="176" left="989" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="193" left="954" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="210" left="962" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="244" left="95" width="76" height="17" font="2"><b>HOPE Study </b></text>
<text top="261" left="95" width="78" height="17" font="0">ABI subgroup </text>
<text top="278" left="95" width="105" height="17" font="0">Ostergren J, et al.  </text>
<text top="296" left="95" width="59" height="17" font="0">2004(137) </text>
<text top="313" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14683738">14683738 </a></text>
<text top="330" left="95" width="3" height="17" font="0"> </text>
<text top="244" left="218" width="128" height="17" font="2"><b>Aim:</b> Impact of ramipril </text>
<text top="261" left="218" width="86" height="17" font="0">on CVD events </text>
<text top="278" left="218" width="3" height="17" font="0"> </text>
<text top="296" left="218" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="313" left="218" width="3" height="17" font="0"> </text>
<text top="330" left="218" width="100" height="17" font="2"><b>Size: </b>n=9,297 pts </text>
<text top="347" left="218" width="103" height="17" font="0">overall, 4,051 with </text>
<text top="365" left="218" width="32" height="17" font="0">PAD  </text>
<text top="382" left="218" width="103" height="17" font="0">8,986 pts with ABI </text>
<text top="399" left="218" width="116" height="17" font="0">measured. 3,099 pts </text>
<text top="416" left="218" width="57" height="17" font="0">with PAD  </text>
<text top="244" left="360" width="191" height="17" font="2"><b>Inclusion criteria:</b> Age ≥55 y with </text>
<text top="261" left="360" width="200" height="17" font="0">CVD (CAD, stroke, PAD) or DM+RF </text>
<text top="278" left="360" width="3" height="17" font="0"> </text>
<text top="296" left="360" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="313" left="360" width="7" height="18" font="7"></text>
<text top="314" left="367" width="177" height="17" font="0"> HF or LV dysfunction (EF &lt;0.4) </text>
<text top="244" left="574" width="145" height="17" font="2"><b>Intervention:</b> Ramipril vs. </text>
<text top="261" left="574" width="47" height="17" font="0">placebo </text>
<text top="278" left="574" width="115" height="17" font="0">PAD group (N=1996 </text>
<text top="296" left="574" width="110" height="17" font="0">ramipril vs. N=2085 </text>
<text top="313" left="574" width="54" height="17" font="0">placebo)  </text>
<text top="245" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="244" left="749" width="6" height="18" font="7"></text>
<text top="245" left="756" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="262" left="743" width="7" height="18" font="7"></text>
<text top="264" left="749" width="42" height="17" font="0"> MACE </text>
<text top="281" left="743" width="7" height="18" font="7"></text>
<text top="282" left="749" width="127" height="17" font="0"> Asx PAD: ABI 0.6–0.9 </text>
<text top="299" left="743" width="136" height="17" font="0">15.7 vs. 21.6 0.72 (0.56, </text>
<text top="316" left="743" width="35" height="17" font="0">0.92)  </text>
<text top="334" left="743" width="129" height="17" font="0">&lt;0.6 16.4 vs. 22.0 0.77 </text>
<text top="351" left="743" width="66" height="17" font="0">(0.55, 1.09) </text>
<text top="368" left="743" width="7" height="18" font="7"></text>
<text top="369" left="749" width="149" height="17" font="0"> Clinical PAD 20.1 vs. 25.8 </text>
<text top="386" left="743" width="97" height="17" font="0">0.75 (0.61, 0.92)  </text>
<text top="244" left="911" width="24" height="17" font="0">N/A </text>
<text top="434" left="95" width="38" height="17" font="2"><b>HOPE</b> </text>
<text top="451" left="95" width="80" height="17" font="0">Yusuf S, et al. </text>
<text top="469" left="95" width="59" height="17" font="0">2000(138) </text>
<text top="486" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10639539">10639539</a></text>
<text top="486" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10639539"> </a></text>
<text top="503" left="95" width="3" height="17" font="0"> </text>
<text top="434" left="218" width="111" height="17" font="2"><b>Aim:</b> To investigate </text>
<text top="451" left="218" width="79" height="17" font="0">effect of ACEI </text>
<text top="469" left="218" width="109" height="17" font="0">(Ramipril-10mg) on </text>
<text top="486" left="218" width="122" height="17" font="0">CV events in high risk </text>
<text top="503" left="218" width="125" height="17" font="0">pts ≥55 y with a mean </text>
<text top="520" left="218" width="105" height="17" font="0">entry BP of 139/79 </text>
<text top="537" left="218" width="121" height="17" font="0">mmHg in both groups </text>
<text top="555" left="218" width="3" height="17" font="0"> </text>
<text top="572" left="218" width="126" height="17" font="2"><b>Study type:</b> RCT, 2x2 </text>
<text top="589" left="218" width="86" height="17" font="0">factorial design </text>
<text top="606" left="218" width="3" height="17" font="0"> </text>
<text top="623" left="218" width="100" height="17" font="2"><b>Size:</b> n=9,297 pts<b> </b></text>
<text top="434" left="360" width="187" height="17" font="2"><b>Inclusion criteria:</b> Pts ≥55 y with </text>
<text top="451" left="360" width="194" height="17" font="0">hx of CAD, stroke, PVD or DM with </text>
<text top="469" left="360" width="188" height="17" font="0">either hypertension, elevated total </text>
<text top="486" left="360" width="185" height="17" font="0">cholesterol, low LDL, smoking, or </text>
<text top="503" left="360" width="104" height="17" font="0">micro albuminuria. </text>
<text top="520" left="360" width="3" height="17" font="0"> </text>
<text top="537" left="360" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="555" left="360" width="7" height="18" font="7"></text>
<text top="556" left="367" width="23" height="17" font="0"> HF </text>
<text top="573" left="360" width="7" height="18" font="7"></text>
<text top="574" left="367" width="57" height="17" font="0"> &lt;0.40 EF </text>
<text top="591" left="360" width="7" height="18" font="7"></text>
<text top="593" left="367" width="130" height="17" font="0"> On ACE-I or Vitamin E </text>
<text top="610" left="360" width="7" height="18" font="7"></text>
<text top="611" left="367" width="164" height="17" font="0"> Uncontrolled hypertension or </text>
<text top="628" left="360" width="103" height="17" font="0">overt nephropathy </text>
<text top="645" left="360" width="7" height="18" font="7"></text>
<text top="646" left="367" width="130" height="17" font="0"> Had MI or stroke&lt;4 wk </text>
<text top="434" left="574" width="130" height="17" font="2"><b>Intervention:</b>  Ramipril </text>
<text top="451" left="574" width="85" height="17" font="0">(10mg) (4,645) </text>
<text top="469" left="574" width="3" height="17" font="0"> </text>
<text top="486" left="574" width="125" height="17" font="2"><b>Comparator:</b> Placebo </text>
<text top="503" left="574" width="42" height="17" font="0">(4,652)<b> </b></text>
<text top="435" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="434" left="749" width="6" height="18" font="7"></text>
<text top="435" left="756" width="139" height="17" font="2"><b> endpoint:</b> Composite of </text>
<text top="453" left="743" width="153" height="17" font="0">MI, stroke, or mortality from </text>
<text top="470" left="743" width="66" height="17" font="0">CV causes. </text>
<text top="487" left="743" width="3" height="17" font="0"> </text>
<text top="504" left="743" width="104" height="17" font="2"><b>Results: </b>Endpoint </text>
<text top="521" left="743" width="137" height="17" font="0">reduction Ramipril group </text>
<text top="539" left="743" width="118" height="17" font="0">vs. Placebo (14% vs. </text>
<text top="556" left="743" width="147" height="17" font="0">17.8%; RR: 0.78; CI: 0.70–</text>
<text top="573" left="743" width="83" height="17" font="0">0.86; p&lt;0.001)<b> </b></text>
<text top="434" left="911" width="7" height="18" font="7"></text>
<text top="435" left="918" width="153" height="17" font="0"> Death from cardiac causes </text>
<text top="453" left="911" width="190" height="17" font="0">reduced (6.1% vs. 8.1%; p&lt;0.001) </text>
<text top="470" left="911" width="7" height="18" font="7"></text>
<text top="471" left="918" width="187" height="17" font="0"> Death from MI reduced (9.9% vs. </text>
<text top="488" left="911" width="94" height="17" font="0">12.3%; p&lt;0.001) </text>
<text top="505" left="911" width="7" height="18" font="7"></text>
<text top="506" left="918" width="173" height="17" font="0"> Death from any cause (10.4 % </text>
<text top="524" left="911" width="113" height="17" font="0">vs. 12.2%; p=0.005) </text>
<text top="541" left="911" width="7" height="18" font="7"></text>
<text top="542" left="918" width="142" height="17" font="0"> Ramipril was found to be </text>
<text top="559" left="911" width="172" height="17" font="0">beneficial in the PVD subgroup </text>
<text top="665" left="95" width="72" height="17" font="2"><b>ONTARGET </b></text>
<text top="682" left="95" width="80" height="17" font="0">Yusuf S, et al. </text>
<text top="699" left="95" width="59" height="17" font="0">2008(139) </text>
<text top="716" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18378520">18378520 </a></text>
<text top="733" left="95" width="3" height="17" font="0"> </text>
<text top="665" left="218" width="85" height="17" font="2"><b>Aim:</b> Impact of </text>
<text top="682" left="218" width="126" height="17" font="0">telmisartan vs. ramipril </text>
<text top="699" left="218" width="106" height="17" font="0">vs. combination on </text>
<text top="716" left="218" width="127" height="17" font="0">CVD events in pts with </text>
<text top="733" left="218" width="109" height="17" font="0">vascular disease or </text>
<text top="751" left="218" width="72" height="17" font="0">high-risk DM </text>
<text top="768" left="218" width="3" height="17" font="0"> </text>
<text top="665" left="360" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="682" left="360" width="7" height="18" font="7"></text>
<text top="683" left="367" width="137" height="17" font="0"> Vascular disease (CAD, </text>
<text top="700" left="360" width="187" height="17" font="0">cerebrovascular disease, PAD) or </text>
<text top="717" left="360" width="134" height="17" font="0">DM+end-organ damage </text>
<text top="735" left="360" width="3" height="17" font="0"> </text>
<text top="752" left="360" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="769" left="360" width="7" height="18" font="7"></text>
<text top="770" left="367" width="122" height="17" font="0"> HF or LV dysfunction<b> </b></text>
<text top="665" left="574" width="146" height="17" font="2"><b>Intervention: </b>Telmisartan </text>
<text top="682" left="574" width="138" height="17" font="0">80mg vs. Ramipril 10 vs. </text>
<text top="699" left="574" width="40" height="17" font="0">combo </text>
<text top="716" left="574" width="115" height="17" font="0">PAD group (N=1136 </text>
<text top="733" left="574" width="110" height="17" font="0">ramipril vs. N=1161 </text>
<text top="751" left="574" width="130" height="17" font="0">telmisartan vs. N=1171 </text>
<text top="768" left="574" width="44" height="17" font="0">combo)<b> </b></text>
<text top="666" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="665" left="749" width="6" height="18" font="7"></text>
<text top="666" left="756" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="683" left="743" width="7" height="18" font="7"></text>
<text top="684" left="749" width="46" height="17" font="0"> MACE: </text>
<text top="701" left="743" width="7" height="18" font="7"></text>
<text top="702" left="749" width="120" height="17" font="0"> Overall trial 16.5% in </text>
<text top="720" left="743" width="90" height="17" font="0">Ramipril, 16.7% </text>
<text top="737" left="743" width="105" height="17" font="0">telmisartan, 16.3% </text>
<text top="754" left="743" width="108" height="17" font="0">combination group. </text>
<text top="771" left="743" width="7" height="18" font="7"></text>
<text top="772" left="749" width="135" height="17" font="0"> Ramipril vs. telmisartan </text>
<text top="665" left="911" width="7" height="18" font="7"></text>
<text top="666" left="918" width="170" height="17" font="0"> Increased risk of hypotension, </text>
<text top="683" left="911" width="162" height="17" font="0">syncope, renal dysfunction in </text>
<text top="700" left="911" width="105" height="17" font="0">combination group </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">62 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="218" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="104" left="218" width="3" height="17" font="0"> </text>
<text top="122" left="218" width="100" height="17" font="2"><b>Size: </b>n=8,576 pts </text>
<text top="139" left="218" width="103" height="17" font="0">overall, 3,468 with </text>
<text top="156" left="218" width="32" height="17" font="0">PAD <b> </b></text>
<text top="87" left="743" width="133" height="17" font="0">RR: 1.01; 95% CI: 0.94–</text>
<text top="104" left="743" width="32" height="17" font="0">1.09) </text>
<text top="122" left="743" width="7" height="18" font="7"></text>
<text top="123" left="749" width="139" height="17" font="0"> Combo vs. Ramipril RR: </text>
<text top="140" left="743" width="136" height="17" font="0">0.99; 95% CI: 0.92–1.07 </text>
<text top="174" left="95" width="48" height="17" font="2"><b>INVEST</b> </text>
<text top="191" left="95" width="83" height="17" font="0">PAD subgroup </text>
<text top="208" left="95" width="88" height="17" font="0">Bavry AA, et al. </text>
<text top="226" left="95" width="59" height="17" font="0">2010(140) </text>
<text top="243" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19996066">19996066 </a></text>
<text top="260" left="95" width="3" height="17" font="0"> </text>
<text top="174" left="218" width="114" height="17" font="2"><b>Aim:</b> Compare CCB </text>
<text top="191" left="218" width="76" height="17" font="0">vs. BB based </text>
<text top="208" left="218" width="127" height="17" font="0">treatment regimens for </text>
<text top="226" left="218" width="127" height="17" font="0">HTN in older with CAD </text>
<text top="243" left="218" width="3" height="17" font="0"> </text>
<text top="260" left="218" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="277" left="218" width="121" height="17" font="0">Prespecified post hoc </text>
<text top="294" left="218" width="90" height="17" font="0">analysis of RCT </text>
<text top="312" left="218" width="3" height="17" font="0"> </text>
<text top="329" left="218" width="100" height="17" font="2"><b>Size: </b>n=2,699 pts </text>
<text top="346" left="218" width="126" height="17" font="0">(total trial: 22,576) pts. </text>
<text top="363" left="218" width="117" height="17" font="0">Mean follow-up 2.7 y </text>
<text top="381" left="218" width="100" height="17" font="0">Primary outcome: </text>
<text top="398" left="218" width="102" height="17" font="0">death, MI, stroke.  </text>
<text top="174" left="360" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="191" left="360" width="7" height="18" font="7"></text>
<text top="192" left="367" width="184" height="17" font="0"> PAD+CAD pts (clinician defined) </text>
<text top="210" left="360" width="7" height="18" font="7"></text>
<text top="211" left="367" width="184" height="17" font="0"> Age ≥50 ywith HTN+stable CAD </text>
<text top="228" left="360" width="3" height="17" font="0"> </text>
<text top="245" left="360" width="162" height="17" font="2"><b>Exclusion criteria:</b> Unstable </text>
<text top="262" left="360" width="191" height="17" font="0">angina, angioplasty, CABG, stroke </text>
<text top="280" left="360" width="66" height="17" font="0">within 1 mo </text>
<text top="297" left="360" width="162" height="17" font="0">Sinus bradycardia, sick sinus </text>
<text top="314" left="360" width="103" height="17" font="0">syndrome, AVB &gt;1</text>
<text top="315" left="463" width="6" height="11" font="11">st</text>
<text top="314" left="469" width="45" height="17" font="0"> degree </text>
<text top="331" left="360" width="69" height="17" font="0">Class IV HF </text>
<text top="348" left="360" width="78" height="17" font="0">Creatinine ≥4 </text>
<text top="366" left="360" width="67" height="17" font="0">Liver failure </text>
<text top="174" left="574" width="131" height="17" font="2"><b>Intervention:</b> Intensive </text>
<text top="191" left="574" width="70" height="17" font="0">therapy with </text>
<text top="208" left="574" width="145" height="17" font="0">verapamil±trandolapril vs. </text>
<text top="226" left="574" width="77" height="17" font="0">atenolol±hctz </text>
<text top="243" left="574" width="3" height="17" font="0"> </text>
<text top="175" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="174" left="749" width="6" height="18" font="7"></text>
<text top="175" left="756" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="192" left="743" width="7" height="18" font="7"></text>
<text top="193" left="749" width="103" height="17" font="0"> 16.2% in PAD pts </text>
<text top="211" left="743" width="7" height="18" font="7"></text>
<text top="212" left="749" width="122" height="17" font="0"> Least frequently SBP </text>
<text top="229" left="743" width="124" height="17" font="0">135-145 with j-shaped </text>
<text top="246" left="743" width="66" height="17" font="0">relationship </text>
<text top="264" left="743" width="7" height="18" font="7"></text>
<text top="265" left="749" width="140" height="17" font="0"> No difference between 2 </text>
<text top="282" left="743" width="109" height="17" font="0">types of medication </text>
<text top="299" left="743" width="144" height="17" font="0">strategies (HR: 0.89; 95% </text>
<text top="316" left="743" width="126" height="17" font="0">CI: 0.74–1.07; p=0.21) </text>
<text top="174" left="911" width="7" height="18" font="7"></text>
<text top="175" left="918" width="142" height="17" font="0"> No difference in vascular </text>
<text top="192" left="911" width="172" height="17" font="0">procedures (HR: 0.94; 95% CI: </text>
<text top="210" left="911" width="100" height="17" font="0">0.77–1.13; p=0.5) </text>
<text top="227" left="911" width="7" height="18" font="7"></text>
<text top="228" left="918" width="171" height="17" font="0"> Poor/Fair QoL (HR: 0.87; 95% </text>
<text top="245" left="911" width="126" height="17" font="0">CI: 0.77–0.99; p=0.03) </text>
<text top="416" left="95" width="99" height="17" font="0">Zanchetti A, et al. </text>
<text top="433" left="95" width="59" height="17" font="0">2006(141) </text>
<text top="450" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17053536">17053536 </a></text>
<text top="467" left="95" width="3" height="17" font="0"> </text>
<text top="416" left="218" width="105" height="17" font="2"><b>Aim:</b> Valsartan vs. </text>
<text top="433" left="218" width="63" height="17" font="0">amlodipine </text>
<text top="450" left="218" width="3" height="17" font="2"><b> </b></text>
<text top="467" left="218" width="127" height="17" font="2"><b>Study type:</b> Subgroup </text>
<text top="485" left="218" width="90" height="17" font="0">analysis of PAD </text>
<text top="502" left="218" width="3" height="17" font="0"> </text>
<text top="519" left="218" width="107" height="17" font="2"><b>Size: </b>n=15,245 pts </text>
<text top="536" left="218" width="115" height="17" font="0">CVD events: cardiac </text>
<text top="553" left="218" width="58" height="17" font="0">death, HF </text>
<text top="571" left="218" width="105" height="17" font="0">hospitalization, MI, </text>
<text top="588" left="218" width="107" height="17" font="0">emergency cardiac </text>
<text top="605" left="218" width="96" height="17" font="0">procedure. Mean </text>
<text top="622" left="218" width="90" height="17" font="0">follow-up 4.2 y.  </text>
<text top="416" left="360" width="178" height="17" font="2"><b>Inclusion criteria:</b> Overall trial:  </text>
<text top="433" left="360" width="7" height="18" font="7"></text>
<text top="434" left="367" width="64" height="17" font="0"> Age ≥50 y </text>
<text top="451" left="360" width="7" height="18" font="7"></text>
<text top="452" left="367" width="132" height="17" font="0"> HTN, CVDRF or CVD.  </text>
<text top="470" left="360" width="106" height="17" font="0">Clinical PAD=2114 </text>
<text top="487" left="360" width="3" height="17" font="0"> </text>
<text top="504" left="360" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="521" left="360" width="7" height="18" font="7"></text>
<text top="522" left="367" width="122" height="17" font="0"> Renal artery stenosis </text>
<text top="540" left="360" width="7" height="18" font="7"></text>
<text top="541" left="367" width="167" height="17" font="0"> Coronary revascularization or </text>
<text top="558" left="360" width="103" height="17" font="0">stroke within 3 mo </text>
<text top="575" left="360" width="7" height="18" font="7"></text>
<text top="576" left="367" width="129" height="17" font="0"> Valvular heart disease </text>
<text top="594" left="360" width="7" height="18" font="7"></text>
<text top="595" left="367" width="171" height="17" font="0"> Severe liver or kidney disease </text>
<text top="612" left="360" width="7" height="18" font="7"></text>
<text top="613" left="367" width="23" height="17" font="0"> HF </text>
<text top="630" left="360" width="7" height="18" font="7"></text>
<text top="631" left="367" width="103" height="17" font="0"> Requiring BB use </text>
<text top="416" left="574" width="81" height="17" font="2"><b>Intervention:</b>  </text>
<text top="433" left="574" width="7" height="18" font="7"></text>
<text top="434" left="581" width="141" height="17" font="0"> Valsartan vs. amlodipine </text>
<text top="452" left="574" width="3" height="17" font="0">I</text>
<text top="451" left="577" width="7" height="18" font="7"></text>
<text top="452" left="584" width="144" height="17" font="0"> n PAD subgroup N=1052 </text>
<text top="470" left="574" width="104" height="17" font="0">valsartan, N=1062 </text>
<text top="487" left="574" width="63" height="17" font="0">amlodipine </text>
<text top="417" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="416" left="749" width="6" height="18" font="7"></text>
<text top="417" left="756" width="104" height="17" font="2"><b> endpoint</b>: In PAD </text>
<text top="434" left="743" width="151" height="17" font="0">subgroup: Event rates 13.4 </text>
<text top="451" left="743" width="88" height="17" font="0">vs. 13.6 p=0.63<b> </b></text>
<text top="416" left="911" width="7" height="18" font="7"></text>
<text top="417" left="918" width="155" height="17" font="0"> Amlodipine with greater BP </text>
<text top="434" left="911" width="61" height="17" font="0">decrease.  </text>
<text top="650" left="95" width="85" height="17" font="0">Diehm C, et al. </text>
<text top="667" left="95" width="59" height="17" font="0">2011(142) </text>
<text top="684" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21602713">21602713 </a></text>
<text top="701" left="95" width="3" height="17" font="0"> </text>
<text top="650" left="218" width="104" height="17" font="2"><b>Aim:</b> Nebivolol vs. </text>
<text top="667" left="218" width="87" height="17" font="0">hctz on walking </text>
<text top="684" left="218" width="81" height="17" font="0">capacity in IC  </text>
<text top="701" left="218" width="3" height="17" font="0"> </text>
<text top="718" left="218" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="736" left="218" width="3" height="17" font="0"> </text>
<text top="753" left="218" width="128" height="17" font="2"><b>Size: </b>n=Parallel in 177 </text>
<text top="770" left="218" width="69" height="17" font="0">pts with 127 </text>
<text top="650" left="360" width="176" height="17" font="2"><b>Inclusion criteria:</b> PAD with IC </text>
<text top="667" left="360" width="54" height="17" font="0">with HTN </text>
<text top="684" left="360" width="3" height="17" font="0"> </text>
<text top="701" left="360" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="718" left="360" width="108" height="17" font="0">Inability to exercise </text>
<text top="736" left="360" width="118" height="17" font="0">Poorly controlled DM </text>
<text top="650" left="574" width="142" height="17" font="2"><b>Intervention:</b> Nebivolol 5 </text>
<text top="667" left="574" width="103" height="17" font="0">mg vs. hctz 25 mg </text>
<text top="651" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="650" left="749" width="6" height="18" font="7"></text>
<text top="651" left="756" width="95" height="17" font="2"><b> endpoint: </b>Initial </text>
<text top="668" left="743" width="121" height="17" font="0">claudication distance: </text>
<text top="685" left="743" width="133" height="17" font="0">Increase 28% vs. 26%.  </text>
<text top="650" left="911" width="7" height="18" font="7"></text>
<text top="651" left="918" width="160" height="17" font="0"> No difference in ABI change </text>
<text top="668" left="911" width="94" height="17" font="0">between groups. </text>
<text top="685" left="911" width="7" height="18" font="7"></text>
<text top="686" left="918" width="129" height="17" font="0"> No adverse effects BB </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">63 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="218" width="64" height="17" font="0">completers </text>
<text top="173" left="95" width="76" height="17" font="2"><b>NORMA</b> <b>trial</b> </text>
<text top="191" left="95" width="98" height="17" font="0">Espinola-Klein C, </text>
<text top="208" left="95" width="30" height="17" font="0">et al. </text>
<text top="225" left="95" width="59" height="17" font="0">2011(143) </text>
<text top="242" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21646599">21646599 </a></text>
<text top="259" left="95" width="3" height="17" font="0"> </text>
<text top="173" left="218" width="122" height="17" font="2"><b>Aim:</b> Compare BB on </text>
<text top="191" left="218" width="110" height="17" font="0">walking parameters </text>
<text top="208" left="218" width="3" height="17" font="0"> </text>
<text top="225" left="218" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="242" left="218" width="3" height="17" font="0"> </text>
<text top="259" left="218" width="90" height="17" font="2"><b>Size: </b>n=128 pts </text>
<text top="173" left="360" width="154" height="17" font="2"><b>Inclusion criteria:</b> IC+HTN </text>
<text top="191" left="360" width="3" height="17" font="0"> </text>
<text top="208" left="360" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="225" left="360" width="7" height="18" font="7"></text>
<text top="226" left="367" width="26" height="17" font="0"> CLI </text>
<text top="243" left="360" width="7" height="18" font="7"></text>
<text top="245" left="367" width="111" height="17" font="0"> Inability to exercise </text>
<text top="262" left="360" width="7" height="18" font="7"></text>
<text top="263" left="367" width="122" height="17" font="0"> Contraindications BB </text>
<text top="280" left="360" width="7" height="18" font="7"></text>
<text top="281" left="367" width="86" height="17" font="0"> MI within 6 mo </text>
<text top="299" left="360" width="7" height="18" font="7"></text>
<text top="300" left="367" width="98" height="17" font="0"> Uncontrolled DM </text>
<text top="173" left="574" width="132" height="17" font="2"><b>Intervention:</b> Nebivolol </text>
<text top="191" left="574" width="142" height="17" font="0">5mg vs. metoprolol 95mg </text>
<text top="175" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="173" left="749" width="6" height="18" font="7"></text>
<text top="175" left="756" width="141" height="17" font="2"><b> endpoint: </b>ICD and ACD </text>
<text top="192" left="743" width="142" height="17" font="0">increased in both groups. </text>
<text top="209" left="743" width="127" height="17" font="0">No difference between </text>
<text top="226" left="743" width="44" height="17" font="0">groups.<b> </b></text>
<text top="173" left="911" width="7" height="18" font="7"></text>
<text top="175" left="918" width="160" height="17" font="0"> No difference in ABI change </text>
<text top="192" left="911" width="115" height="17" font="0">between treatments. </text>
<text top="209" left="911" width="7" height="18" font="7"></text>
<text top="210" left="918" width="146" height="17" font="0"> 7 pts with AE bradycardia </text>
<text top="227" left="911" width="155" height="17" font="0">Re-enforces safety BB in IC </text>
<text top="318" left="95" width="96" height="17" font="0">Paravastu SC, et </text>
<text top="335" left="95" width="16" height="17" font="0">al. </text>
<text top="352" left="95" width="101" height="17" font="0">Cochrane Review </text>
<text top="369" left="95" width="59" height="17" font="0">2013(144) </text>
<text top="387" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24027118">24027118 </a></text>
<text top="404" left="95" width="3" height="17" font="0"> </text>
<text top="318" left="218" width="102" height="17" font="2"><b>Aim:</b> BB Safety in </text>
<text top="335" left="218" width="29" height="17" font="0">PAD </text>
<text top="352" left="218" width="3" height="17" font="0"> </text>
<text top="369" left="218" width="127" height="17" font="2"><b>Study type:</b> Update of </text>
<text top="387" left="218" width="49" height="17" font="0">a review </text>
<text top="404" left="218" width="3" height="17" font="0"> </text>
<text top="421" left="218" width="90" height="17" font="2"><b>Size: </b>n=119 pts </text>
<text top="318" left="360" width="145" height="17" font="2"><b>Inclusion criteria:</b> 6 RCT </text>
<text top="335" left="360" width="148" height="17" font="0">comparing BB to placebo.  </text>
<text top="318" left="574" width="117" height="17" font="2"><b>Intervention:</b> BB vs. </text>
<text top="335" left="574" width="47" height="17" font="0">placebo </text>
<text top="319" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="318" left="749" width="6" height="18" font="7"></text>
<text top="319" left="756" width="130" height="17" font="2"><b> endpoint: </b>None of the </text>
<text top="336" left="743" width="148" height="17" font="0">trials showed worsening of </text>
<text top="353" left="743" width="147" height="17" font="0">walking measures with BB<b> </b></text>
<text top="318" left="911" width="7" height="18" font="7"></text>
<text top="319" left="918" width="175" height="17" font="0"> No evidence that BB adversely </text>
<text top="336" left="911" width="172" height="17" font="0">affect walking parameters in IC </text>
<text top="439" left="95" width="53" height="17" font="2"><b>ALLHAT</b> </text>
<text top="456" left="95" width="59" height="17" font="0">2002(145) </text>
<text top="473" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12479763">12479763</a></text>
<text top="473" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12479763"> </a></text>
<text top="491" left="95" width="3" height="17" font="0"> </text>
<text top="439" left="218" width="114" height="17" font="2"><b>Aim:</b> Comparison of </text>
<text top="456" left="218" width="126" height="17" font="0">an alpha blocker, ACE </text>
<text top="473" left="218" width="127" height="17" font="0">inhibitor, or CCB, each </text>
<text top="491" left="218" width="82" height="17" font="0">compared to a </text>
<text top="508" left="218" width="116" height="17" font="0">thiazide-type diuretic </text>
<text top="525" left="218" width="109" height="17" font="0">on non-fatal or fatal </text>
<text top="542" left="218" width="30" height="17" font="0">CHD </text>
<text top="559" left="218" width="3" height="17" font="0"> </text>
<text top="577" left="218" width="102" height="17" font="2"><b>Study type:</b> RCT  </text>
<text top="594" left="218" width="3" height="17" font="0"> </text>
<text top="611" left="218" width="107" height="17" font="2"><b>Size:</b> n=33,357 pts<b> </b></text>
<text top="439" left="360" width="111" height="17" font="2"><b>Inclusion Criteria:</b>  </text>
<text top="456" left="360" width="7" height="18" font="7"></text>
<text top="457" left="367" width="63" height="17" font="0"> Age &gt;50 y </text>
<text top="475" left="360" width="7" height="18" font="7"></text>
<text top="476" left="367" width="174" height="17" font="0"> African American15,085 (35.5) </text>
<text top="493" left="360" width="7" height="18" font="7"></text>
<text top="494" left="367" width="115" height="17" font="0"> White 19,977 (47.0) </text>
<text top="511" left="360" width="7" height="18" font="7"></text>
<text top="512" left="367" width="133" height="17" font="0"> Hispanics 5,299 (12.5)<b>  </b></text>
<text top="530" left="360" width="3" height="17" font="2"><b> </b></text>
<text top="547" left="360" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="439" left="574" width="154" height="17" font="0">Intervention: Chlorthalidone </text>
<text top="456" left="574" width="83" height="17" font="0">vs. Doxazosin, </text>
<text top="473" left="574" width="141" height="17" font="0">Amlopdipine, or Lisinopril </text>
<text top="440" left="743" width="7" height="17" font="2"><b>1</b></text>
<text top="439" left="749" width="6" height="18" font="7"></text>
<text top="440" left="756" width="129" height="17" font="2"><b> endpoint: </b>Nonfatal MI </text>
<text top="457" left="743" width="81" height="17" font="0">and fatal CHD<b> </b></text>
<text top="439" left="911" width="7" height="18" font="7"></text>
<text top="440" left="918" width="188" height="17" font="0"> No difference in primary outcome </text>
<text top="457" left="911" width="153" height="17" font="0">(nonfatal MI and fatal CHD) </text>
<text top="475" left="911" width="3" height="17" font="0"> </text>
<text top="629" left="86" width="1014" height="17" font="0">ABI indicates ankle-brachial index; ACEI, angiotensin converting enzyme inhibitor; AE, adverse event; AVB, atrioventricular block; ACD, absolute claudication distance; ACEi, angiotensin-</text>
<text top="646" left="86" width="996" height="17" font="0">converting-enzyme inhibitor; AE, adverse event; BB, beta blockers; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary arterial disease; CCB, calcium channel </text>
<text top="663" left="86" width="993" height="17" font="0">blockers; CI, confidence interval; CLI, critical limb ischemia; CVD, cardiovascular disease; CVDRF, cardiovascular disease risk factors; CV, cardiovascular; DM, diabetes mellitus; EF, </text>
<text top="681" left="86" width="1004" height="17" font="0">ejection fraction; hctz, hydrochlorothiazide; HF, heart failure; HR, hazard ratio; HTN, hypertension; IC, intermittent claudication; LV, left ventricular; MACE, major adverse cardiovascular </text>
<text top="698" left="86" width="984" height="17" font="0">events; MI, myocardial infarction; PAD, peripheral artery disease; PVD, peripheral vascular disease; QoL, quality of life; RCT, randomized controlled trial; RR, relative risk; and SBP, </text>
<text top="715" left="86" width="132" height="17" font="0">systolic blood pressure. </text>
<text top="732" left="86" width="3" height="17" font="0"> </text>
<text top="749" left="86" width="3" height="17" font="0"> </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">64 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="875" height="21" font="1"><b>Evidence Table 18. Nonrandomized Trials, Observational Studies, and/or Registries of Antihypertensive Agents–Section 5.3. </b></text>
<text top="108" left="109" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="125" left="134" width="48" height="17" font="2"><b>Author; </b></text>
<text top="142" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="108" left="274" width="38" height="17" font="2"><b>Study </b></text>
<text top="125" left="253" width="81" height="17" font="2"><b>Type/Design; </b></text>
<text top="142" left="260" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="108" left="403" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="108" left="605" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="125" left="613" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="142" left="665" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="108" left="908" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="125" left="935" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="160" left="95" width="100" height="17" font="0">Feringa HH, et al. </text>
<text top="177" left="95" width="59" height="17" font="0">2006(146) </text>
<text top="195" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16545650">16545650 </a></text>
<text top="212" left="95" width="3" height="17" font="0"> </text>
<text top="160" left="234" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="177" left="234" width="110" height="17" font="0">Observation Cohort </text>
<text top="195" left="234" width="3" height="17" font="0"> </text>
<text top="212" left="234" width="115" height="17" font="2"><b>Size:</b> 2,420 PAD pts </text>
<text top="160" left="365" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="177" left="365" width="7" height="18" font="7"></text>
<text top="178" left="371" width="176" height="17" font="0"> Referred for Evaluation of PAD </text>
<text top="196" left="365" width="7" height="18" font="7"></text>
<text top="197" left="371" width="55" height="17" font="0"> ABI ≤0.9 </text>
<text top="214" left="365" width="7" height="18" font="7"></text>
<text top="215" left="371" width="109" height="17" font="0"> 77% with ABI ≤0.7 </text>
<text top="233" left="365" width="3" height="17" font="0"> </text>
<text top="250" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="160" left="566" width="245" height="17" font="0">All-cause mortality: 44% at median follow-up </text>
<text top="177" left="566" width="253" height="17" font="0">time of 8 y. MV and propensity score adjusted </text>
<text top="195" left="566" width="232" height="17" font="0">BB HR: 0.68; 95% CI: 0.58–0.80; p&lt;0.001 </text>
<text top="212" left="566" width="244" height="17" font="0">ACEi HR: 0.80; 95% CI: 0.69–0.94; p=0.005 </text>
<text top="229" left="566" width="166" height="17" font="0">Nonsignificant: diuretics, CCB </text>
<text top="160" left="837" width="7" height="18" font="7"></text>
<text top="161" left="844" width="189" height="17" font="0"> Potential for residual confounding </text>
<text top="179" left="837" width="7" height="18" font="7"></text>
<text top="180" left="844" width="230" height="17" font="0"> Supports use of BB, ACEi in clinical PAD </text>
<text top="268" left="95" width="38" height="17" font="2"><b>HOPE</b> </text>
<text top="285" left="95" width="86" height="17" font="0">Sleight P, et al. </text>
<text top="302" left="95" width="59" height="17" font="0">2000(147) </text>
<text top="319" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11967789">11967789</a></text>
<text top="319" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11967789"> </a></text>
<text top="337" left="95" width="3" height="17" font="0"> </text>
<text top="268" left="234" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="285" left="234" width="87" height="17" font="0">Editorial review </text>
<text top="302" left="234" width="3" height="17" font="0"> </text>
<text top="319" left="234" width="100" height="17" font="2"><b>Size:</b> n=9,297 pts </text>
<text top="268" left="365" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="285" left="365" width="3" height="17" font="0"> </text>
<text top="302" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="269" left="566" width="7" height="17" font="2"><b>1</b></text>
<text top="268" left="573" width="6" height="18" font="7"></text>
<text top="269" left="579" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="286" left="566" width="3" height="17" font="0"> </text>
<text top="303" left="566" width="76" height="17" font="2"><b>Results:</b> N/A </text>
<text top="268" left="837" width="7" height="18" font="7"></text>
<text top="269" left="844" width="250" height="17" font="0"> Significant benefits in mortality and morbidity </text>
<text top="286" left="837" width="251" height="17" font="0">from use of Ramipril in subjects at high risk of </text>
<text top="303" left="837" width="269" height="17" font="0">future CV events (ACEi could be offered to wider </text>
<text top="320" left="837" width="215" height="17" font="0">group of pts. including those on Aspirin </text>
<text top="338" left="837" width="73" height="17" font="0">prophylaxis). </text>
<text top="355" left="837" width="7" height="18" font="7"></text>
<text top="356" left="844" width="234" height="17" font="0"> ACEi found to be highly cost effective in a </text>
<text top="373" left="837" width="111" height="17" font="0">preliminary analysis </text>
<text top="391" left="86" width="1003" height="17" font="0">ACEi indicates angiotensin-converting-enzyme inhibitor; BB, beta blocker; CCB, calcium channel blockers; CI, confidence interval; HR, hazard ratio; N/A, not applicable; OR, odds ratio; </text>
<text top="409" left="86" width="172" height="17" font="0">pt, patient; and RR, relative risk</text>
<text top="409" left="258" width="7" height="17" font="9">. </text>
<text top="426" left="86" width="3" height="17" font="0"> </text>
<text top="443" left="86" width="3" height="17" font="0"> </text>
<text top="460" left="86" width="434" height="21" font="1"><b>Evidence Table 19. RCTs for Smoking Cessation–Section 5.4. </b></text>
<text top="482" left="102" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="499" left="127" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="516" left="105" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="482" left="232" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="499" left="236" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="516" left="230" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="482" left="404" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="482" left="610" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="499" left="627" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="516" left="610" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="533" left="631" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="482" left="799" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="499" left="757" width="188" height="17" font="2"><b>(Absolute Event Rates, P value; </b></text>
<text top="516" left="813" width="79" height="17" font="2"><b>OR or RR; &amp;  </b></text>
<text top="533" left="827" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="483" left="973" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="482" left="1034" width="6" height="18" font="7"></text>
<text top="483" left="1040" width="63" height="17" font="2"><b> Endpoint  </b></text>
<text top="500" left="1013" width="48" height="17" font="2"><b>(if any); </b></text>
<text top="517" left="981" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="534" left="989" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="552" left="95" width="92" height="17" font="0">Rigotti NA, et al. </text>
<text top="570" left="95" width="111" height="17" font="0">Helping HAND Trial </text>
<text top="587" left="95" width="59" height="17" font="0">2014(148) </text>
<text top="604" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25138333">25138333 </a></text>
<text top="621" left="95" width="3" height="17" font="0"> </text>
<text top="552" left="220" width="100" height="17" font="2"><b>Aim:</b> To compare </text>
<text top="570" left="220" width="83" height="17" font="0">post discharge </text>
<text top="587" left="220" width="102" height="17" font="0">tobacco cessation </text>
<text top="604" left="220" width="92" height="17" font="0">intervention with </text>
<text top="621" left="220" width="92" height="17" font="0">standard care in </text>
<text top="638" left="220" width="98" height="17" font="0">hospitalized adult </text>
<text top="656" left="220" width="105" height="17" font="0">smokers who want </text>
<text top="673" left="220" width="37" height="17" font="0">to quit </text>
<text top="690" left="220" width="3" height="17" font="0"> </text>
<text top="707" left="220" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="724" left="220" width="103" height="17" font="0">single-center RCT </text>
<text top="742" left="220" width="3" height="17" font="0"> </text>
<text top="759" left="220" width="70" height="17" font="2"><b>Size:</b> n=397 </text>
<text top="776" left="220" width="98" height="17" font="0">hospitalized adult </text>
<text top="552" left="339" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="570" left="339" width="7" height="18" font="7"></text>
<text top="571" left="346" width="63" height="17" font="0"> Age &gt;18 y </text>
<text top="588" left="339" width="7" height="18" font="7"></text>
<text top="589" left="346" width="92" height="17" font="0"> Current smoker </text>
<text top="606" left="339" width="7" height="18" font="7"></text>
<text top="607" left="346" width="68" height="17" font="0"> Plan to quit </text>
<text top="625" left="339" width="7" height="18" font="7"></text>
<text top="626" left="346" width="156" height="17" font="0"> Agree to accept medication </text>
<text top="643" left="339" width="7" height="18" font="7"></text>
<text top="644" left="346" width="189" height="17" font="0"> 38% (N=151) with Circulatory Dx: </text>
<text top="661" left="339" width="197" height="17" font="0">cardiovascular, peripheral vascular, </text>
<text top="679" left="339" width="91" height="17" font="0">cerebrovascular </text>
<text top="696" left="339" width="3" height="17" font="0"> </text>
<text top="713" left="339" width="195" height="17" font="2"><b>Exclusion criteria:</b> LOS &lt;24 H, no </text>
<text top="730" left="339" width="207" height="17" font="0">telephone, substance use (other than </text>
<text top="747" left="339" width="229" height="17" font="0">tobacco, alcohol, marijuana), admitted for </text>
<text top="765" left="339" width="188" height="17" font="0">alcohol or drug overdose, medical </text>
<text top="552" left="594" width="141" height="17" font="2"><b>Intervention:</b> Automated </text>
<text top="570" left="594" width="142" height="17" font="0">voice response calls, free </text>
<text top="587" left="594" width="105" height="17" font="0">smoking cessation </text>
<text top="604" left="594" width="108" height="17" font="0">medication for 90 d </text>
<text top="621" left="594" width="3" height="17" font="0"> </text>
<text top="638" left="594" width="120" height="17" font="2"><b>Comparator:</b> Printed </text>
<text top="656" left="594" width="101" height="17" font="0">recommendations </text>
<text top="553" left="749" width="7" height="17" font="2"><b>1</b></text>
<text top="552" left="756" width="6" height="18" font="7"></text>
<text top="553" left="762" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="571" left="749" width="7" height="18" font="7"></text>
<text top="572" left="756" width="186" height="17" font="0"> Biochemically confirmed tobacco </text>
<text top="589" left="749" width="107" height="17" font="0">abstinence at 6 mo </text>
<text top="606" left="749" width="7" height="18" font="7"></text>
<text top="607" left="756" width="185" height="17" font="0"> 26% vs. 15% (RR: 1.71; 95% CI: </text>
<text top="625" left="749" width="163" height="17" font="0">1.14–2.56; p=0.009) NNT 9.4 </text>
<text top="642" left="749" width="7" height="18" font="7"></text>
<text top="643" left="756" width="183" height="17" font="0"> Subgroup analysis in Circulatory </text>
<text top="660" left="749" width="178" height="17" font="0">disorders showed similar results </text>
<text top="552" left="965" width="7" height="18" font="7"></text>
<text top="553" left="972" width="79" height="17" font="0"> Single-center </text>
<text top="571" left="965" width="7" height="18" font="7"></text>
<text top="572" left="972" width="134" height="17" font="0"> 20% lost to follow-up at </text>
<text top="589" left="965" width="31" height="17" font="0">6 mo </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">65 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="220" width="50" height="17" font="0">smokers </text>
<text top="87" left="339" width="186" height="17" font="0">instability, admitted to obstetric or </text>
<text top="104" left="339" width="224" height="17" font="0">psychiatric units, life expectancy &lt;12 mo </text>
<text top="173" left="95" width="92" height="17" font="0">Rigotti NA, et al. </text>
<text top="190" left="95" width="59" height="17" font="0">2010(149) </text>
<text top="207" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20048210">20048210 </a></text>
<text top="225" left="95" width="3" height="17" font="0"> </text>
<text top="173" left="220" width="98" height="17" font="2"><b>Aim:</b> To evaluate </text>
<text top="190" left="220" width="47" height="17" font="0">effect of </text>
<text top="207" left="220" width="79" height="17" font="0">varenicline on </text>
<text top="225" left="220" width="105" height="17" font="0">smoking cessation </text>
<text top="242" left="220" width="89" height="17" font="0">rates in pts with </text>
<text top="259" left="220" width="36" height="17" font="0">stable </text>
<text top="276" left="220" width="83" height="17" font="0">cardiovascular </text>
<text top="293" left="220" width="49" height="17" font="0">disease. </text>
<text top="311" left="220" width="3" height="17" font="0"> </text>
<text top="328" left="220" width="100" height="17" font="2"><b>Study type:</b> Multi-</text>
<text top="345" left="220" width="66" height="17" font="0">center RCT </text>
<text top="362" left="220" width="3" height="17" font="0"> </text>
<text top="380" left="220" width="90" height="17" font="2"><b>Size:</b> n=714 pts </text>
<text top="173" left="339" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="190" left="339" width="7" height="18" font="7"></text>
<text top="191" left="346" width="76" height="17" font="0"> Age 35–75 y </text>
<text top="209" left="339" width="7" height="18" font="7"></text>
<text top="210" left="346" width="227" height="17" font="0"> Want to quit smoking but had not tried in </text>
<text top="227" left="339" width="57" height="17" font="0">past 3 mo </text>
<text top="244" left="339" width="7" height="18" font="7"></text>
<text top="245" left="346" width="234" height="17" font="0"> Stable CVD (CAD, PAD, Cerebrovascular </text>
<text top="263" left="339" width="141" height="17" font="0">disease). PAD=179, 25% </text>
<text top="280" left="339" width="3" height="17" font="0"> </text>
<text top="297" left="339" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="314" left="339" width="7" height="18" font="7"></text>
<text top="315" left="346" width="221" height="17" font="0"> Cardiovascular intervention within 2 mo </text>
<text top="333" left="339" width="7" height="18" font="7"></text>
<text top="334" left="346" width="150" height="17" font="0"> Uncontrolled hypertension </text>
<text top="351" left="339" width="7" height="18" font="7"></text>
<text top="352" left="346" width="97" height="17" font="0"> Prior amputation </text>
<text top="369" left="339" width="7" height="18" font="7"></text>
<text top="370" left="346" width="95" height="17" font="0"> Class III/IV CHF </text>
<text top="388" left="339" width="7" height="18" font="7"></text>
<text top="389" left="346" width="138" height="17" font="0"> Moderate/severe COPD </text>
<text top="406" left="339" width="7" height="18" font="7"></text>
<text top="407" left="346" width="193" height="17" font="0"> Uncontrolled GI/hepatic/endocrine </text>
<text top="424" left="339" width="46" height="17" font="0">disease </text>
<text top="442" left="339" width="7" height="18" font="7"></text>
<text top="443" left="346" width="141" height="17" font="0"> Severe renal impairment </text>
<text top="460" left="339" width="7" height="18" font="7"></text>
<text top="461" left="346" width="220" height="17" font="0"> Cancer, depression, psychosis, drug or </text>
<text top="478" left="339" width="103" height="17" font="0">alcohol use/abuse </text>
<text top="173" left="594" width="142" height="17" font="2"><b>Intervention:</b> Varenicline </text>
<text top="190" left="594" width="125" height="17" font="0">(0.5 once daily for 3 d, </text>
<text top="207" left="594" width="138" height="17" font="0">0.5 twice a day for 4 d, 1 </text>
<text top="225" left="594" width="120" height="17" font="0">mg twice a day for 12 </text>
<text top="242" left="594" width="26" height="17" font="0">wk)  </text>
<text top="259" left="594" width="3" height="17" font="0"> </text>
<text top="276" left="594" width="125" height="17" font="2"><b>Comparator:</b> Placebo </text>
<text top="174" left="749" width="7" height="17" font="2"><b>1</b></text>
<text top="173" left="756" width="6" height="18" font="7"></text>
<text top="174" left="762" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="191" left="749" width="7" height="18" font="7"></text>
<text top="192" left="756" width="183" height="17" font="0"> 4 wk continuous abstinence rate </text>
<text top="210" left="749" width="7" height="18" font="7"></text>
<text top="211" left="756" width="85" height="17" font="0"> 9–12 wk CAR: </text>
<text top="228" left="749" width="7" height="18" font="7"></text>
<text top="229" left="756" width="196" height="17" font="0"> 47% vs. 13.9% (OR: 6.11; 95% CI: </text>
<text top="246" left="749" width="124" height="17" font="0">4.18–8.93; p&lt;0.0001)  </text>
<text top="264" left="749" width="3" height="17" font="0"> </text>
<text top="281" left="749" width="100" height="17" font="2"><b>Safety endpoint: </b></text>
<text top="298" left="749" width="7" height="18" font="7"></text>
<text top="299" left="756" width="165" height="17" font="0"> SAE 6.5% varenicline vs. 6.0 </text>
<text top="316" left="749" width="47" height="17" font="0">placebo </text>
<text top="334" left="749" width="7" height="18" font="7"></text>
<text top="335" left="756" width="180" height="17" font="0"> No difference in psychiatric AEs </text>
<text top="352" left="749" width="7" height="18" font="7"></text>
<text top="353" left="756" width="161" height="17" font="0"> Non-statistically different but </text>
<text top="370" left="749" width="198" height="17" font="0">higher rate CV events in varenicline </text>
<text top="388" left="749" width="57" height="17" font="0">25 vs. 20  </text>
<text top="173" left="965" width="7" height="18" font="7"></text>
<text top="174" left="972" width="115" height="17" font="0"> 9–52 wk abstinence </text>
<text top="191" left="965" width="135" height="17" font="0">rate: 19.2 vs. 7.2% (OR: </text>
<text top="209" left="965" width="140" height="17" font="0">3.14; 95% CI: 1.93–5.11; </text>
<text top="226" left="965" width="59" height="17" font="0">p&lt;0.0001) </text>
<text top="243" left="965" width="7" height="18" font="7"></text>
<text top="244" left="972" width="111" height="17" font="0"> FDA advisory: may </text>
<text top="261" left="965" width="133" height="17" font="0">increase risk of adverse </text>
<text top="279" left="965" width="122" height="17" font="0">cardiovascular events </text>
<text top="496" left="95" width="108" height="17" font="0">Hennrikus D, et al.  </text>
<text top="514" left="95" width="59" height="17" font="0">2010(150) </text>
<text top="531" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21144971">21144971 </a></text>
<text top="548" left="95" width="3" height="17" font="0"> </text>
<text top="496" left="220" width="98" height="17" font="2"><b>Aim:</b> To evaluate </text>
<text top="514" left="220" width="96" height="17" font="0">intensive tailored </text>
<text top="531" left="220" width="62" height="17" font="0">counseling </text>
<text top="548" left="220" width="85" height="17" font="0">intervention for </text>
<text top="565" left="220" width="105" height="17" font="0">smoking cessation </text>
<text top="582" left="220" width="62" height="17" font="0">in PAD pts </text>
<text top="600" left="220" width="3" height="17" font="0"> </text>
<text top="617" left="220" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="634" left="220" width="3" height="17" font="0"> </text>
<text top="651" left="220" width="90" height="17" font="2"><b>Size:</b> n=124 pts </text>
<text top="496" left="339" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="514" left="339" width="7" height="18" font="7"></text>
<text top="515" left="346" width="213" height="17" font="0"> Primary inclusion criteria were a Dx of </text>
<text top="532" left="339" width="232" height="17" font="0">lower extremity PAD (defined as at least 1 </text>
<text top="549" left="339" width="92" height="17" font="0">of the following:  </text>
<text top="566" left="339" width="7" height="18" font="7"></text>
<text top="567" left="346" width="192" height="17" font="0"> An ABI of &lt;0.90 in at least 1 lower </text>
<text top="585" left="339" width="57" height="17" font="0">extremity; </text>
<text top="602" left="339" width="7" height="18" font="7"></text>
<text top="603" left="346" width="89" height="17" font="0"> A TBI of &lt;0.60. </text>
<text top="620" left="339" width="7" height="18" font="7"></text>
<text top="621" left="346" width="219" height="17" font="0"> Objective evidence of arterial occlusive </text>
<text top="639" left="339" width="211" height="17" font="0">disease in 1 lower extremity by duplex </text>
<text top="656" left="339" width="172" height="17" font="0">ultrasonography, MRA, or CTA </text>
<text top="673" left="339" width="7" height="18" font="7"></text>
<text top="674" left="346" width="204" height="17" font="0"> Prior leg arterial revascularization or </text>
<text top="692" left="339" width="131" height="17" font="0">amputation due to PAD </text>
<text top="709" left="339" width="7" height="18" font="7"></text>
<text top="710" left="346" width="229" height="17" font="0"> Current smoking (defined as smoking ≥1 </text>
<text top="727" left="339" width="160" height="17" font="0">cigarette a day ≥6 d per wk). </text>
<text top="744" left="339" width="7" height="18" font="7"></text>
<text top="745" left="346" width="212" height="17" font="0"> Additional inclusion criteria included a </text>
<text top="763" left="339" width="183" height="17" font="0">desire to quit within the next 30 d </text>
<text top="496" left="594" width="128" height="17" font="2"><b>Intervention:</b> Clinician </text>
<text top="514" left="594" width="92" height="17" font="0">advice, smoking </text>
<text top="531" left="594" width="137" height="17" font="0">counselor, individualized </text>
<text top="548" left="594" width="103" height="17" font="0">letter, motivational </text>
<text top="565" left="594" width="113" height="17" font="0">interview, info about </text>
<text top="582" left="594" width="83" height="17" font="0">pharmacologic </text>
<text top="600" left="594" width="71" height="17" font="0">intervention  </text>
<text top="617" left="594" width="3" height="17" font="0"> </text>
<text top="634" left="594" width="116" height="17" font="2"><b>Comparator:</b> Verbal </text>
<text top="651" left="594" width="130" height="17" font="0">advice, list of programs </text>
<text top="497" left="749" width="7" height="17" font="2"><b>1</b></text>
<text top="496" left="756" width="6" height="18" font="7"></text>
<text top="497" left="762" width="157" height="17" font="2"><b> endpoint:</b> 6 mo biologically </text>
<text top="515" left="749" width="200" height="17" font="0">confirmed smoking cessation 21.3% </text>
<text top="532" left="749" width="197" height="17" font="0">vs. 6.8%; chi-square: 5.21; p=0.023 </text>
<text top="549" left="749" width="3" height="17" font="0"> </text>
<text top="496" left="965" width="24" height="17" font="0">N/A </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">66 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="339" width="7" height="18" font="7"></text>
<text top="88" left="346" width="64" height="17" font="0"> Age ≥18 y </text>
<text top="106" left="339" width="7" height="18" font="7"></text>
<text top="107" left="346" width="187" height="17" font="0"> Ability to speak and write English </text>
<text top="124" left="339" width="7" height="18" font="7"></text>
<text top="125" left="346" width="220" height="17" font="0"> No participation in a smoking cessation </text>
<text top="142" left="339" width="137" height="17" font="0">program in the past 30 d </text>
<text top="160" left="339" width="7" height="18" font="7"></text>
<text top="161" left="346" width="227" height="17" font="0"> Consumption of &lt;21 alcoholic drinks/wk. </text>
<text top="178" left="339" width="3" height="17" font="0"> </text>
<text top="195" left="339" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="213" left="95" width="90" height="17" font="0">Tonstad S et al. </text>
<text top="230" left="95" width="59" height="17" font="0">2003(151) </text>
<text top="248" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12714026">12714026 </a></text>
<text top="265" left="95" width="3" height="17" font="0"> </text>
<text top="213" left="220" width="94" height="17" font="2"><b>Aim:</b> Buproprion </text>
<text top="230" left="220" width="99" height="17" font="0">SR in established </text>
<text top="248" left="220" width="29" height="17" font="0">CVD </text>
<text top="265" left="220" width="3" height="17" font="0"> </text>
<text top="282" left="220" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="299" left="220" width="3" height="17" font="0"> </text>
<text top="316" left="220" width="90" height="17" font="2"><b>Size:</b> n=629 pts </text>
<text top="213" left="339" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="230" left="339" width="7" height="18" font="7"></text>
<text top="231" left="346" width="33" height="17" font="0"> CAD </text>
<text top="249" left="339" width="7" height="18" font="7"></text>
<text top="250" left="346" width="68" height="17" font="0"> PAD (33%) </text>
<text top="267" left="339" width="7" height="18" font="7"></text>
<text top="268" left="346" width="97" height="17" font="0"> HF (Class I or II) </text>
<text top="285" left="339" width="7" height="18" font="7"></text>
<text top="286" left="346" width="180" height="17" font="0"> Adults who smoke average ≥10 </text>
<text top="304" left="339" width="235" height="17" font="0">cigarettes/d during previous 12 mo without </text>
<text top="321" left="339" width="165" height="17" font="0">quit attempt in previous 3 mo. </text>
<text top="338" left="339" width="3" height="17" font="0"> </text>
<text top="355" left="339" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="373" left="339" width="7" height="18" font="7"></text>
<text top="374" left="346" width="49" height="17" font="0"> Seizure </text>
<text top="391" left="339" width="7" height="18" font="7"></text>
<text top="392" left="346" width="177" height="17" font="0"> Renal/hepatic/heme/pulmonary </text>
<text top="409" left="339" width="106" height="17" font="0">neurologic disease </text>
<text top="427" left="339" width="7" height="18" font="7"></text>
<text top="428" left="346" width="62" height="17" font="0"> Psychosis </text>
<text top="445" left="339" width="7" height="18" font="7"></text>
<text top="446" left="346" width="69" height="17" font="0"> Depression </text>
<text top="213" left="594" width="107" height="17" font="2"><b>Intervention:</b> 7 wk </text>
<text top="230" left="594" width="124" height="17" font="0">buproprion 150/d 1–2, </text>
<text top="248" left="594" width="68" height="17" font="0">then 150bid </text>
<text top="265" left="594" width="3" height="17" font="0"> </text>
<text top="282" left="594" width="125" height="17" font="2"><b>Comparator:</b> Placebo </text>
<text top="214" left="749" width="7" height="17" font="2"><b>1</b></text>
<text top="213" left="756" width="6" height="18" font="7"></text>
<text top="214" left="762" width="141" height="17" font="2"><b> endpoint:</b> 4 wk smoking </text>
<text top="231" left="749" width="55" height="17" font="0">cessation </text>
<text top="249" left="749" width="183" height="17" font="0">43% vs. 19% (OR: 3.27; 95% CI: </text>
<text top="266" left="749" width="62" height="17" font="0">2.24–4.84) </text>
<text top="283" left="749" width="3" height="17" font="0"> </text>
<text top="213" left="965" width="24" height="17" font="0">N/A </text>
<text top="464" left="95" width="90" height="17" font="0">Stead LF, et al.  </text>
<text top="481" left="95" width="59" height="17" font="0">2013(152) </text>
<text top="499" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23728631">23728631 </a></text>
<text top="516" left="95" width="3" height="17" font="0"> </text>
<text top="464" left="220" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="481" left="220" width="48" height="17" font="0">analysis </text>
<text top="499" left="220" width="3" height="17" font="0"> </text>
<text top="516" left="220" width="96" height="17" font="2"><b>Size: </b>n=42 trials; </text>
<text top="533" left="220" width="61" height="17" font="0">31,000 pts<b> </b></text>
<text top="464" left="339" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="481" left="339" width="7" height="18" font="7"></text>
<text top="482" left="346" width="152" height="17" font="0"> Trials between 1972–2012 </text>
<text top="500" left="339" width="7" height="18" font="7"></text>
<text top="501" left="346" width="224" height="17" font="0"> Trials of smoking interventions involving </text>
<text top="518" left="339" width="53" height="17" font="0">clinicians </text>
<text top="535" left="339" width="3" height="17" font="0"> </text>
<text top="552" left="339" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="464" left="594" width="129" height="17" font="2"><b>Intervention:</b> Smoking </text>
<text top="481" left="594" width="94" height="17" font="0">cessation advice </text>
<text top="499" left="594" width="3" height="17" font="0"> </text>
<text top="516" left="594" width="101" height="17" font="2"><b>Comparator:</b> N/A </text>
<text top="465" left="749" width="7" height="17" font="2"><b>1</b></text>
<text top="464" left="756" width="6" height="18" font="7"></text>
<text top="465" left="762" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="483" left="749" width="7" height="18" font="7"></text>
<text top="484" left="756" width="174" height="17" font="0"> Brief advice RR: 1.66; 95% CI: </text>
<text top="501" left="749" width="58" height="17" font="0">1.42–1.94 </text>
<text top="518" left="749" width="7" height="18" font="7"></text>
<text top="519" left="756" width="189" height="17" font="0"> Intensive RR: 1.84; 95% CI: 1.60–</text>
<text top="536" left="749" width="27" height="17" font="0">2.13 </text>
<text top="464" left="965" width="7" height="18" font="7"></text>
<text top="465" left="972" width="117" height="17" font="0"> Simple advice has a </text>
<text top="483" left="965" width="138" height="17" font="0">small effect on cessation </text>
<text top="500" left="965" width="31" height="17" font="0">rates </text>
<text top="570" left="95" width="101" height="17" font="0">Prochaska JJ and </text>
<text top="588" left="95" width="52" height="17" font="0">Hilton JF </text>
<text top="605" left="95" width="59" height="17" font="0">2012(153) </text>
<text top="622" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22563098">22563098 </a></text>
<text top="639" left="95" width="3" height="17" font="0"> </text>
<text top="570" left="220" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="588" left="220" width="48" height="17" font="0">analysis </text>
<text top="605" left="220" width="3" height="17" font="0"> </text>
<text top="622" left="220" width="93" height="17" font="2"><b>Size:</b> n=22 trials </text>
<text top="570" left="339" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="588" left="339" width="7" height="18" font="7"></text>
<text top="589" left="346" width="221" height="17" font="0"> RCT adults with varenicline vs. placebo </text>
<text top="606" left="339" width="7" height="18" font="7"></text>
<text top="607" left="346" width="197" height="17" font="0"> 2 with active CVD, 11 with Hx CVD </text>
<text top="624" left="339" width="3" height="17" font="0"> </text>
<text top="642" left="339" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="570" left="594" width="142" height="17" font="2"><b>Intervention: </b>Varenicline<b> </b></text>
<text top="588" left="594" width="3" height="17" font="0"> </text>
<text top="605" left="594" width="125" height="17" font="2"><b>Comparator: </b>Placebo </text>
<text top="572" left="749" width="7" height="17" font="2"><b>1</b></text>
<text top="570" left="756" width="6" height="18" font="7"></text>
<text top="572" left="762" width="189" height="17" font="2"><b> endpoint:</b> CV events during drug </text>
<text top="589" left="749" width="146" height="17" font="0">treatment or within 30 d of </text>
<text top="606" left="749" width="86" height="17" font="0">discontinuation </text>
<text top="623" left="749" width="3" height="17" font="0"> </text>
<text top="640" left="749" width="185" height="17" font="2"><b>Results:</b> RR: 1.40; 95% CI: 0.82–</text>
<text top="658" left="749" width="72" height="17" font="0">2.39; p=0.22 </text>
<text top="570" left="965" width="7" height="18" font="7"></text>
<text top="572" left="972" width="127" height="17" font="0"> Risk of cardiovascular </text>
<text top="589" left="965" width="142" height="17" font="0">SAE with varenicline use: </text>
<text top="606" left="965" width="79" height="17" font="0">meta-analysis </text>
<text top="676" left="95" width="76" height="17" font="0">Mills EJ et al. </text>
<text top="693" left="95" width="59" height="17" font="0">2014(154) </text>
<text top="710" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24323793">24323793 </a></text>
<text top="727" left="95" width="3" height="17" font="0"> </text>
<text top="676" left="220" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="693" left="220" width="48" height="17" font="0">analysis </text>
<text top="710" left="220" width="3" height="17" font="0"> </text>
<text top="727" left="220" width="92" height="17" font="2"><b>Size:</b> n=63 RCT </text>
<text top="676" left="339" width="242" height="17" font="2"><b>Inclusion criteria: </b>RCT of NRT, bupropion, </text>
<text top="693" left="339" width="239" height="17" font="0">and varenicline that reported CVD outcome<b> </b></text>
<text top="710" left="339" width="3" height="17" font="0"> </text>
<text top="727" left="339" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="676" left="594" width="110" height="17" font="2"><b>Intervention:</b> NRT, </text>
<text top="693" left="594" width="142" height="17" font="0">bupropion, or varenicline <b> </b></text>
<text top="710" left="594" width="3" height="17" font="0"> </text>
<text top="727" left="594" width="101" height="17" font="2"><b>Comparator: </b>N/A </text>
<text top="677" left="749" width="7" height="17" font="2"><b>1</b></text>
<text top="676" left="756" width="6" height="18" font="7"></text>
<text top="677" left="762" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="694" left="749" width="7" height="18" font="7"></text>
<text top="695" left="756" width="113" height="17" font="0"> All CVD and MACE </text>
<text top="712" left="749" width="7" height="18" font="7"></text>
<text top="713" left="756" width="193" height="17" font="0"> NRT: RR 1.81; 95% CI: 1.35–2.43 </text>
<text top="731" left="749" width="7" height="18" font="7"></text>
<text top="732" left="756" width="173" height="17" font="0"> Buproprion: RR: 1.03; 95% CI: </text>
<text top="749" left="749" width="58" height="17" font="0">0.71–1.50 </text>
<text top="766" left="749" width="7" height="18" font="7"></text>
<text top="767" left="756" width="174" height="17" font="0"> Varenicline: RR: 1.24; 95% CI: </text>
<text top="676" left="965" width="24" height="17" font="0">N/A </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">67 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="749" width="58" height="17" font="0">0.85–1.81 </text>
<text top="173" left="86" width="960" height="17" font="0">AE indicates adverse event; CAD, coronary arterial disease; CAR, continuous abstinence rate; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive </text>
<text top="191" left="86" width="1010" height="17" font="0">pulmonary disease; CTA, computed tomography angiography; CVD, cardiovascular disease; CV, cardiovascular; FDA, Food and Drug Administration; GI, gastrointestinal; LOS, length of </text>
<text top="208" left="86" width="1015" height="17" font="0">stay; MACE, major adverse cardiovascular event; MRA, magnetic resonance angiogram; N/A, not applicable; NNT, number needed to treat; NRT, nicotine replacement therapy; OR, odds </text>
<text top="225" left="86" width="729" height="17" font="0">ratio; PAD, peripheral artery disease; pt, patient; RCT, randomized controlled trial; RR, relative risk; and SAE, serious adverse event.  </text>
<text top="242" left="86" width="3" height="17" font="0"> </text>
<text top="259" left="86" width="838" height="21" font="1"><b>Evidence Table 20. Nonrandomized Trials, Observational Studies, and/or Registries of Smoking Cessation–Section 5.4. </b></text>
<text top="281" left="109" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="298" left="135" width="48" height="17" font="2"><b>Author; </b></text>
<text top="315" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="281" left="255" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="298" left="281" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="281" left="441" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="281" left="670" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="298" left="678" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="315" left="730" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="281" left="955" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="298" left="982" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="333" left="95" width="75" height="17" font="0">Clair C, et al.<b> </b></text>
<text top="350" left="95" width="59" height="17" font="0">2013(155) </text>
<text top="368" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23483176">23483176 </a></text>
<text top="385" left="95" width="3" height="17" font="0"> </text>
<text top="333" left="235" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="350" left="235" width="142" height="17" font="0">cohort. To investigate the </text>
<text top="368" left="235" width="157" height="17" font="0">impact of weight gain on the </text>
<text top="385" left="235" width="152" height="17" font="0">effect of smoking cessation </text>
<text top="402" left="235" width="140" height="17" font="0">on cardiovascular events </text>
<text top="419" left="235" width="3" height="17" font="0"> </text>
<text top="437" left="235" width="138" height="17" font="2"><b>Size:</b> n=3,251 pts, mean </text>
<text top="454" left="235" width="136" height="17" font="0">follow-up 25 y, 631 CVD </text>
<text top="471" left="235" width="43" height="17" font="0">events. </text>
<text top="333" left="405" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="351" left="405" width="7" height="18" font="7"></text>
<text top="352" left="412" width="144" height="17" font="0"> Longitudinal cohort study </text>
<text top="369" left="405" width="72" height="17" font="0">1984–2011.  </text>
<text top="386" left="405" width="7" height="18" font="7"></text>
<text top="387" left="412" width="167" height="17" font="0"> Self-reported smoking status: </text>
<text top="404" left="405" width="161" height="17" font="0">smoker, recent quitter (&lt;4 y), </text>
<text top="422" left="405" width="123" height="17" font="0">long-term quitter &gt;4 y, </text>
<text top="439" left="405" width="64" height="17" font="0">nonsmoker </text>
<text top="456" left="405" width="7" height="18" font="7"></text>
<text top="457" left="412" width="94" height="17" font="0"> Stratified by DM </text>
<text top="475" left="405" width="3" height="17" font="0"> </text>
<text top="492" left="405" width="177" height="17" font="2"><b>Exclusion criteria:</b> Established </text>
<text top="509" left="405" width="36" height="17" font="0">CVD.  </text>
<text top="334" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="333" left="608" width="6" height="18" font="7"></text>
<text top="334" left="614" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="352" left="601" width="7" height="18" font="7"></text>
<text top="353" left="608" width="299" height="17" font="0"> CVD events (coronary heart disease, cerebrovascular </text>
<text top="370" left="601" width="223" height="17" font="0">disease, PAD, congestive heart failure).  </text>
<text top="387" left="601" width="7" height="18" font="7"></text>
<text top="388" left="608" width="93" height="17" font="0"> PAD events=73 </text>
<text top="406" left="601" width="3" height="17" font="0"> </text>
<text top="423" left="601" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="440" left="601" width="45" height="17" font="0">No DM: </text>
<text top="457" left="601" width="7" height="18" font="7"></text>
<text top="458" left="608" width="253" height="17" font="0"> Recent Quitters RR: 0.61; 95% CI: 0.21–1.78 </text>
<text top="476" left="601" width="7" height="18" font="7"></text>
<text top="477" left="608" width="270" height="17" font="0"> Long-term Quitters RR: 0.29; 95% CI: 0.16–0.52 </text>
<text top="494" left="601" width="26" height="17" font="0">DM: </text>
<text top="511" left="601" width="7" height="18" font="7"></text>
<text top="512" left="608" width="253" height="17" font="0"> Recent Quitters RR: 0.36; 95% CI: 0.04–2.97 </text>
<text top="530" left="601" width="7" height="18" font="7"></text>
<text top="531" left="608" width="270" height="17" font="0"> Long-term Quitters RR: 0.42; 95% CI: 0.16–1.10 </text>
<text top="333" left="932" width="7" height="18" font="7"></text>
<text top="334" left="938" width="169" height="17" font="0">Smoking cessation associated </text>
<text top="352" left="932" width="174" height="17" font="0">with lower CVD rates (including </text>
<text top="369" left="932" width="166" height="17" font="0">PAD) even when adjusting for </text>
<text top="386" left="932" width="72" height="17" font="0">weight gain.  </text>
<text top="549" left="95" width="46" height="17" font="2"><b>VSGNE </b></text>
<text top="566" left="95" width="86" height="17" font="0">Hoel AW, et al. </text>
<text top="583" left="95" width="59" height="17" font="0">2013(156)<b> </b></text>
<text top="600" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23375433">23375433 </a></text>
<text top="618" left="95" width="3" height="17" font="0"> </text>
<text top="549" left="235" width="119" height="17" font="2"><b>Study type:</b> Registry </text>
<text top="566" left="235" width="3" height="17" font="0"> </text>
<text top="583" left="235" width="100" height="17" font="2"><b>Size:</b> n=7,807 pts </text>
<text top="549" left="405" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="566" left="405" width="7" height="18" font="7"></text>
<text top="567" left="412" width="32" height="17" font="0"> CEA </text>
<text top="584" left="405" width="7" height="18" font="7"></text>
<text top="585" left="412" width="77" height="17" font="0"> Carotid stent </text>
<text top="603" left="405" width="7" height="18" font="7"></text>
<text top="604" left="412" width="64" height="17" font="0"> LE bypass </text>
<text top="621" left="405" width="7" height="18" font="7"></text>
<text top="622" left="412" width="66" height="17" font="0"> AAA repair </text>
<text top="639" left="405" width="3" height="17" font="0"> </text>
<text top="657" left="405" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="674" left="405" width="7" height="18" font="7"></text>
<text top="675" left="412" width="130" height="17" font="0"> Lost to follow-up at 1 y </text>
<text top="692" left="405" width="7" height="18" font="7"></text>
<text top="693" left="412" width="165" height="17" font="0"> Lack of smoking status at 1 y </text>
<text top="550" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="549" left="608" width="6" height="18" font="7"></text>
<text top="550" left="614" width="275" height="17" font="2"><b> endpoint:</b> Self-reported smoking cessation at 1 y </text>
<text top="567" left="601" width="3" height="17" font="0"> </text>
<text top="584" left="601" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="602" left="601" width="7" height="18" font="7"></text>
<text top="603" left="608" width="196" height="17" font="0"> 46% pts post LE bypass quit at 1 y </text>
<text top="620" left="601" width="307" height="17" font="0">Variability across treatment center in smoking cessation </text>
<text top="637" left="601" width="90" height="17" font="0">rates 28%–62% </text>
<text top="654" left="601" width="7" height="18" font="7"></text>
<text top="655" left="608" width="283" height="17" font="0"> 78% of surgeons offered pharmacologic therapy or </text>
<text top="673" left="601" width="318" height="17" font="0">referral to smoking cessation program. Rates of cessation </text>
<text top="690" left="601" width="213" height="17" font="0">higher in these surgeons 48% vs. 33% </text>
<text top="549" left="932" width="7" height="18" font="7"></text>
<text top="550" left="938" width="144" height="17" font="0"> Systems of care promote </text>
<text top="567" left="932" width="163" height="17" font="0">smoking cessation in pts with </text>
<text top="584" left="932" width="95" height="17" font="0">vascular disease </text>
<text top="602" left="932" width="7" height="18" font="7"></text>
<text top="603" left="938" width="126" height="17" font="0"> High rates of smoking </text>
<text top="620" left="932" width="129" height="17" font="0">cessation after surgical </text>
<text top="637" left="932" width="65" height="17" font="0">procedures </text>
<text top="711" left="95" width="71" height="17" font="2"><b>ACS/NSQIP </b></text>
<text top="729" left="95" width="107" height="17" font="0">Selvarajah S, et al. </text>
<text top="746" left="95" width="59" height="17" font="0">2014(157) </text>
<text top="763" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24502815">24502815 </a></text>
<text top="711" left="235" width="119" height="17" font="2"><b>Study type:</b> Registry </text>
<text top="729" left="235" width="3" height="17" font="0"> </text>
<text top="746" left="235" width="107" height="17" font="2"><b>Size:</b> n=16,534 pts </text>
<text top="711" left="405" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="729" left="405" width="7" height="18" font="7"></text>
<text top="730" left="412" width="161" height="17" font="0"> Infrainguinal bypass surgery </text>
<text top="747" left="405" width="7" height="18" font="7"></text>
<text top="748" left="412" width="166" height="17" font="0"> Pre-operative smoking status </text>
<text top="765" left="405" width="3" height="17" font="0"> </text>
<text top="712" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="711" left="608" width="6" height="18" font="7"></text>
<text top="712" left="614" width="155" height="17" font="2"><b> endpoint:</b> 30 d graft failure </text>
<text top="730" left="601" width="3" height="17" font="0"> </text>
<text top="747" left="601" width="315" height="17" font="2"><b>Results:</b> Higher early graft failure in active smokers (OR: </text>
<text top="764" left="601" width="185" height="17" font="0">1.21; 95% CI: 1.02–1.43; p=0.03) </text>
<text top="711" left="932" width="7" height="18" font="7"></text>
<text top="712" left="938" width="152" height="17" font="0"> Active smoking associated </text>
<text top="730" left="932" width="127" height="17" font="0">with early graft failure.  </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">68 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="405" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="105" left="95" width="38" height="17" font="2"><b>UCSD </b></text>
<text top="122" left="95" width="111" height="17" font="0">Armstrong EJ, et al.<b> </b></text>
<text top="139" left="95" width="59" height="17" font="0">2014(158) </text>
<text top="157" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25282696">25282696 </a></text>
<text top="174" left="95" width="3" height="17" font="0"> </text>
<text top="105" left="235" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="122" left="235" width="38" height="17" font="0">cohort </text>
<text top="139" left="235" width="3" height="17" font="0"> </text>
<text top="157" left="235" width="90" height="17" font="2"><b>Size:</b> n=204 pts </text>
<text top="105" left="405" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="122" left="405" width="7" height="18" font="7"></text>
<text top="123" left="412" width="152" height="17" font="0"> Peripheral angiography for </text>
<text top="141" left="405" width="105" height="17" font="0">claudication or CLI </text>
<text top="158" left="405" width="7" height="18" font="7"></text>
<text top="159" left="412" width="144" height="17" font="0"> Active smoking at time of </text>
<text top="176" left="405" width="71" height="17" font="0">angiography </text>
<text top="194" left="405" width="89" height="17" font="0">30% quit for 1 y </text>
<text top="211" left="405" width="3" height="17" font="0"> </text>
<text top="228" left="405" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="106" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="105" left="608" width="6" height="18" font="7"></text>
<text top="106" left="614" width="199" height="17" font="2"><b> endpoint:</b> Amputation-free survival </text>
<text top="123" left="601" width="3" height="17" font="0"> </text>
<text top="141" left="601" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="158" left="601" width="7" height="18" font="7"></text>
<text top="159" left="608" width="308" height="17" font="0"> Smoking cessation associated with lower mortality 14% </text>
<text top="176" left="601" width="212" height="17" font="0">vs. 31% (HR: 0.40; 95% CI: 0.18–0.90 </text>
<text top="194" left="601" width="7" height="18" font="7"></text>
<text top="195" left="608" width="282" height="17" font="0"> Higher amputation-free survival 81% vs. 60% (HR: </text>
<text top="212" left="601" width="133" height="17" font="0">0.43; 95% CI: 0.2–0.86) </text>
<text top="105" left="932" width="7" height="18" font="7"></text>
<text top="106" left="938" width="110" height="17" font="0"> Smoking cessation </text>
<text top="123" left="932" width="122" height="17" font="0">associated with better </text>
<text top="141" left="932" width="102" height="17" font="0">outcomes in PAD. </text>
<text top="246" left="95" width="94" height="17" font="2"><b>Scottish Family </b></text>
<text top="263" left="95" width="79" height="17" font="2"><b>Health Study </b></text>
<text top="280" left="95" width="57" height="17" font="0">Lu L, et al </text>
<text top="298" left="95" width="59" height="17" font="0">2013(159) </text>
<text top="315" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23880175">23880175</a></text>
<text top="315" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23880175"> </a></text>
<text top="332" left="95" width="3" height="17" font="0"> </text>
<text top="246" left="235" width="110" height="17" font="2"><b>Study Type: </b>Cross-</text>
<text top="263" left="235" width="122" height="17" font="0">sectional cohort study<b> </b></text>
<text top="280" left="235" width="3" height="17" font="2"><b> </b></text>
<text top="298" left="235" width="128" height="17" font="2"><b>Size: </b>n=5,686 pts, 134 </text>
<text top="315" left="235" width="150" height="17" font="0">(2.4% with PAD defined by </text>
<text top="332" left="235" width="27" height="17" font="0">ABI)<b> </b></text>
<text top="246" left="405" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="263" left="405" width="7" height="18" font="7"></text>
<text top="264" left="412" width="89" height="17" font="0"> Never smokers </text>
<text top="281" left="405" width="7" height="18" font="7"></text>
<text top="283" left="412" width="64" height="17" font="0"> Age ≥18 y </text>
<text top="300" left="405" width="3" height="17" font="0"> </text>
<text top="317" left="405" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="246" left="601" width="295" height="17" font="2"><b>Results: </b>Second-hand smoke exposure (≥40 hrs/wk) </text>
<text top="263" left="601" width="306" height="17" font="0">higher prevalence PAD (OR: 5.56; 95% CI: 1.82–17.06; </text>
<text top="280" left="601" width="52" height="17" font="0">p=0.003)<b> </b></text>
<text top="246" left="932" width="155" height="17" font="0">No cotinine levels available, </text>
<text top="263" left="932" width="86" height="17" font="0">cross-sectional </text>
<text top="350" left="95" width="128" height="17" font="0">Tan CE and Glantz SA </text>
<text top="367" left="95" width="59" height="17" font="0">2012(160) </text>
<text top="384" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23109514">23109514</a></text>
<text top="384" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23109514"> </a></text>
<text top="402" left="95" width="3" height="17" font="0"> </text>
<text top="350" left="235" width="153" height="17" font="2"><b>Study Type: M</b>eta-analysis </text>
<text top="367" left="235" width="132" height="17" font="0">of impact of smoke-free </text>
<text top="384" left="235" width="140" height="17" font="0">laws with coronary, heart </text>
<text top="402" left="235" width="140" height="17" font="0">disease, cerebrovascular </text>
<text top="419" left="235" width="40" height="17" font="0">events </text>
<text top="436" left="235" width="3" height="17" font="0"> </text>
<text top="453" left="235" width="136" height="17" font="2"><b>Size: </b>n=45 studies of 33 </text>
<text top="470" left="235" width="93" height="17" font="0">smoke-free laws<b> </b></text>
<text top="350" left="405" width="150" height="17" font="2"><b>Inclusion criteria: </b>Studies </text>
<text top="367" left="405" width="175" height="17" font="0">published before November 30, </text>
<text top="384" left="405" width="31" height="17" font="0">2011<b> </b></text>
<text top="402" left="405" width="3" height="17" font="2"><b> </b></text>
<text top="419" left="405" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="350" left="601" width="297" height="17" font="2"><b>Results: </b>Smoke-free legislation associated with lower </text>
<text top="367" left="601" width="294" height="17" font="0">hospital admission or death for: coronary events (RR: </text>
<text top="384" left="601" width="312" height="17" font="0">0.84; 95% CI: 0.82–0.88), other heart disease (RR: 0.61; </text>
<text top="402" left="601" width="303" height="17" font="0">95% CI: 0.44–0.85), cerebrovascular events (RR: 0.84; </text>
<text top="419" left="601" width="109" height="17" font="0">95% CI: 0.75–0.94)<b> </b></text>
<text top="350" left="932" width="164" height="17" font="0">Did not ascertain PAD events </text>
<text top="488" left="86" width="1007" height="17" font="0">AAA indicates abdominal aortic aneurysm; ABI, ankle-brachial index; CEA, carotid endarterectomy; CLI, critical limb ischemia; CI, confidence interval; CVD, cardiovascular disease; DM, </text>
<text top="506" left="86" width="791" height="17" font="0">diabetes mellitus; HR, hazard ratio; LE, lower extremity; N/A, not applicable; OR, odds ratio; PAD, peripheral artery disease; and RR, relative risk.</text>
<text top="506" left="877" width="3" height="17" font="9"> </text>
<text top="523" left="86" width="3" height="17" font="0"> </text>
<text top="540" left="86" width="3" height="17" font="0"> </text>
<text top="557" left="86" width="777" height="21" font="1"><b>Evidence Table 21. RCTs Evaluating Glycemic Control in Patients with PAD and Diabetes Mellitus–Section 5.5. </b></text>
<text top="579" left="96" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="596" left="122" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="613" left="99" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="579" left="239" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="596" left="244" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="613" left="237" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="579" left="397" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="579" left="556" width="111" height="17" font="2"><b>Study Intervention </b></text>
<text top="596" left="573" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="613" left="556" width="111" height="17" font="2"><b>Study Comparator </b></text>
<text top="630" left="577" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="579" left="701" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="596" left="684" width="138" height="17" font="2"><b>(Absolute Event Rates, </b></text>
<text top="613" left="690" width="129" height="17" font="2"><b>P value; OR or RR; &amp;  </b></text>
<text top="630" left="729" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="580" left="885" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="579" left="946" width="6" height="18" font="7"></text>
<text top="580" left="952" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="597" left="917" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="614" left="925" width="96" height="17" font="2"><b>Adverse Events </b></text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">69 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="75" height="17" font="2"><b>PROACTIVE</b> </text>
<text top="104" left="95" width="92" height="17" font="0">Dormandy JA et </text>
<text top="122" left="95" width="16" height="17" font="0">al. </text>
<text top="139" left="95" width="59" height="17" font="0">2005(161) </text>
<text top="156" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16214598">16214598 </a></text>
<text top="173" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="209" width="102" height="17" font="2"><b>Aim:</b> To ascertain </text>
<text top="104" left="209" width="116" height="17" font="0">whether pioglitazone </text>
<text top="122" left="209" width="131" height="17" font="0">reduces macrovascular </text>
<text top="139" left="209" width="137" height="17" font="0">morbidty and mortality in </text>
<text top="156" left="209" width="132" height="17" font="0">high-risk pts with type 2 </text>
<text top="173" left="209" width="23" height="17" font="0">DM </text>
<text top="190" left="209" width="3" height="17" font="0"> </text>
<text top="208" left="209" width="113" height="17" font="2"><b>Study type:</b> Double </text>
<text top="225" left="209" width="136" height="17" font="0">blind, placebo controlled </text>
<text top="242" left="209" width="91" height="17" font="0">randomized trial </text>
<text top="259" left="209" width="3" height="17" font="0"> </text>
<text top="276" left="209" width="36" height="17" font="2"><b>Size:  </b></text>
<text top="294" left="209" width="7" height="18" font="7"></text>
<text top="295" left="216" width="71" height="17" font="0"> n=5,238 pts </text>
<text top="312" left="209" width="7" height="18" font="7"></text>
<text top="313" left="216" width="122" height="17" font="0"> PAD subgroup ~20% </text>
<text top="330" left="209" width="118" height="17" font="0">n=1,043 (reported as </text>
<text top="348" left="209" width="107" height="17" font="0">1,274 in 2009 PAD </text>
<text top="365" left="209" width="106" height="17" font="0">subset publication) </text>
<text top="87" left="365" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="104" left="365" width="7" height="18" font="7"></text>
<text top="105" left="371" width="76" height="17" font="0"> Pts with DM  </text>
<text top="123" left="365" width="7" height="18" font="7"></text>
<text top="124" left="371" width="76" height="17" font="0"> Age 35–75 y </text>
<text top="141" left="365" width="7" height="18" font="7"></text>
<text top="142" left="371" width="137" height="17" font="0"> HgB A1c &gt;6.5% despite </text>
<text top="159" left="365" width="142" height="17" font="0">treatment with diet or oral </text>
<text top="177" left="365" width="172" height="17" font="0">agents (with or without insulin). </text>
<text top="194" left="365" width="7" height="18" font="7"></text>
<text top="195" left="371" width="130" height="17" font="0"> Evidence of “extensive </text>
<text top="212" left="365" width="163" height="17" font="0">macrovascular disease” CAD </text>
<text top="230" left="365" width="163" height="17" font="0">or stroke or “objective arterial </text>
<text top="247" left="365" width="140" height="17" font="0">disease in the leg” (PAD) </text>
<text top="264" left="365" width="7" height="18" font="7"></text>
<text top="265" left="371" width="126" height="17" font="0"> PAD defined as major </text>
<text top="282" left="365" width="174" height="17" font="0">amputation or claudication+ABI </text>
<text top="300" left="365" width="28" height="17" font="0">&lt;0.9 </text>
<text top="317" left="365" width="3" height="17" font="0"> </text>
<text top="334" left="365" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="351" left="365" width="7" height="18" font="7"></text>
<text top="352" left="371" width="64" height="17" font="0"> Type I DM </text>
<text top="370" left="365" width="7" height="18" font="7"></text>
<text top="371" left="371" width="100" height="17" font="0"> Pt only on insulin </text>
<text top="388" left="365" width="7" height="18" font="7"></text>
<text top="389" left="371" width="161" height="17" font="0"> Planned coronary/peripheral </text>
<text top="406" left="365" width="96" height="17" font="0">revascularization </text>
<text top="423" left="365" width="7" height="18" font="7"></text>
<text top="425" left="371" width="163" height="17" font="0"> NYHA CHF class II or above </text>
<text top="442" left="365" width="7" height="18" font="7"></text>
<text top="443" left="371" width="137" height="17" font="0"> CLI excluded (rest pain, </text>
<text top="460" left="365" width="144" height="17" font="0">ischemic ulcer, gangrene) </text>
<text top="478" left="365" width="7" height="18" font="7"></text>
<text top="479" left="371" width="94" height="17" font="0"> CKD on dialysis </text>
<text top="496" left="365" width="7" height="18" font="7"></text>
<text top="497" left="371" width="162" height="17" font="0"> Abnormal ALT (&gt; 2.5 x ULN) </text>
<text top="87" left="554" width="105" height="17" font="2"><b>Intervention:</b> Oral </text>
<text top="104" left="554" width="111" height="17" font="0">pioglitazone (15 mg </text>
<text top="122" left="554" width="109" height="17" font="0">qd mo 1; 30 mg mo </text>
<text top="139" left="554" width="107" height="17" font="0">2; 45 qd mo 3-end; </text>
<text top="156" left="554" width="113" height="17" font="0">medication could be </text>
<text top="173" left="554" width="108" height="17" font="0">adjusted if needed) </text>
<text top="190" left="554" width="3" height="17" font="0"> </text>
<text top="208" left="554" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="225" left="554" width="51" height="17" font="0">Placebo  </text>
<text top="88" left="682" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="689" width="6" height="18" font="7"></text>
<text top="88" left="695" width="125" height="17" font="2"><b> endpoint:</b> Composite </text>
<text top="106" left="682" width="106" height="17" font="0">all-cause mortality, </text>
<text top="123" left="682" width="140" height="17" font="0">nonfatal MI, stroke, ACS, </text>
<text top="140" left="682" width="124" height="17" font="0">coronary or peripheral </text>
<text top="157" left="682" width="133" height="17" font="0">revascularization, major </text>
<text top="174" left="682" width="64" height="17" font="0">amputation </text>
<text top="192" left="682" width="3" height="17" font="0"> </text>
<text top="209" left="682" width="129" height="17" font="0">Average follow-up 34.5 </text>
<text top="226" left="682" width="24" height="17" font="0">mo. </text>
<text top="243" left="682" width="3" height="17" font="0"> </text>
<text top="262" left="682" width="7" height="17" font="2"><b>1</b></text>
<text top="261" left="689" width="6" height="18" font="7"></text>
<text top="262" left="695" width="118" height="17" font="2"><b> endpoint:</b> HR: 0.90; </text>
<text top="279" left="682" width="109" height="17" font="0">95% CI: 0.80–1.02; </text>
<text top="296" left="682" width="48" height="17" font="0">p=0.095 </text>
<text top="313" left="682" width="3" height="17" font="0"> </text>
<text top="330" left="682" width="119" height="17" font="2"><b>Safety endpoint:</b> No </text>
<text top="348" left="682" width="99" height="17" font="0">difference in CHF </text>
<text top="365" left="682" width="137" height="17" font="0">admissions or death due </text>
<text top="382" left="682" width="92" height="17" font="0">to CHF between </text>
<text top="399" left="682" width="139" height="17" font="0">pioglitazone and placebo </text>
<text top="417" left="682" width="41" height="17" font="0">groups </text>
<text top="434" left="682" width="3" height="17" font="0"> </text>
<text top="88" left="837" width="7" height="17" font="2"><b>2</b></text>
<text top="87" left="844" width="6" height="18" font="7"></text>
<text top="88" left="850" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="106" left="837" width="7" height="18" font="7"></text>
<text top="107" left="844" width="247" height="17" font="0"> All-cause mortality, non–fatal MI, stroke HR: </text>
<text top="124" left="837" width="188" height="17" font="0">0.84; 95% CI: 0.72–0.98; p=0.027 </text>
<text top="141" left="837" width="7" height="18" font="7"></text>
<text top="142" left="844" width="228" height="17" font="0"> Subgroup analysis for PAD not reported. </text>
<text top="159" left="837" width="3" height="17" font="0"> </text>
<text top="177" left="837" width="67" height="17" font="2"><b>Summary:  </b></text>
<text top="194" left="837" width="7" height="18" font="7"></text>
<text top="195" left="844" width="259" height="17" font="0"> Primary endpoint was negative, but secondary </text>
<text top="212" left="837" width="246" height="17" font="0">endpoint (primary for most studies of MACE) </text>
<text top="230" left="837" width="264" height="17" font="0">positive for reduction in events with pioglitazone </text>
<text top="247" left="837" width="248" height="17" font="0">vs. placebo; no PAD specific data presented, </text>
<text top="264" left="837" width="225" height="17" font="0">though 20% of pt population had sx PAD </text>
<text top="281" left="837" width="7" height="18" font="7"></text>
<text top="282" left="844" width="258" height="17" font="0"> PAD substudy (2009 publication): PAD subset </text>
<text top="300" left="837" width="263" height="17" font="0">had higher event rates than non-PAD subset. In </text>
<text top="317" left="837" width="229" height="17" font="0">subset of pts enrolled with PAD (N=1,274 </text>
<text top="334" left="837" width="254" height="17" font="0">reported), there was no benefit of pioglitazone </text>
<text top="351" left="837" width="232" height="17" font="0">on the primary or secondary endpoint with </text>
<text top="368" left="837" width="243" height="17" font="0">increased rate of LE revascularization in the </text>
<text top="386" left="837" width="256" height="17" font="0">pioglitazone vs. placebo groups (p=0.0077). In </text>
<text top="403" left="837" width="269" height="17" font="0">the subgroup of pts randomized WITHOUT PAD, </text>
<text top="420" left="837" width="239" height="17" font="0">there was a beneficial effect of pioglitazone </text>
<text top="437" left="837" width="37" height="17" font="0">seen.  </text>
<text top="515" left="86" width="1006" height="17" font="0">ABI indicates ankle-brachial index; ACS, acute coronary syndrome; ALT, alanine aminotransferase; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; </text>
<text top="532" left="86" width="985" height="17" font="0">CKD, chronic kidney disease; CLI, critical limb ischemia; DM, diabetes mellitus; HR, hazard ratio; HgB, hemoglobin; LE, lower extremity; MACE, medical adverse cardiac events; MI, </text>
<text top="549" left="86" width="913" height="17" font="0">myocardial infarction; NYHA, New York Heart Association; PAD, peripheral artery disease; pt, patient; RCT, randomized controlled trial, and ULN, upper limit of normal. </text>
<text top="567" left="86" width="3" height="17" font="0"> </text>
<text top="584" left="86" width="3" height="17" font="0"> </text>
<text top="601" left="86" width="823" height="21" font="1"><b>Evidence Table 22. Nonrandomized Trials, Observational Studies, and/or Registries of Glycemic Control–Section 5.5. </b></text>
<text top="622" left="121" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="640" left="146" width="48" height="17" font="2"><b>Author; </b></text>
<text top="657" left="124" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="622" left="275" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="640" left="301" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="622" left="443" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="622" left="650" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="640" left="658" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="657" left="709" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="622" left="941" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="640" left="969" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="675" left="95" width="60" height="17" font="2"><b>PAD-UCD </b></text>
<text top="692" left="95" width="80" height="17" font="0">Singh S, et al.<b> </b></text>
<text top="709" left="95" width="59" height="17" font="0">2014(162)<b> </b></text>
<text top="727" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24939930">24939930</a></text>
<text top="727" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24939930"> </a></text>
<text top="744" left="95" width="3" height="17" font="0"> </text>
<text top="675" left="259" width="150" height="17" font="2"><b>Study type:</b> Observational </text>
<text top="692" left="259" width="142" height="17" font="0">registry of pts undergoing </text>
<text top="709" left="259" width="142" height="17" font="0">interventional procedures </text>
<text top="727" left="259" width="136" height="17" font="0">for CLI or ALI at a single </text>
<text top="744" left="259" width="38" height="17" font="0">center </text>
<text top="761" left="259" width="3" height="17" font="0"> </text>
<text top="675" left="422" width="127" height="17" font="2"><b>Inclusion criteria:</b> Pts </text>
<text top="692" left="422" width="99" height="17" font="0">with PAD within a </text>
<text top="709" left="422" width="135" height="17" font="0">peripheral interventional </text>
<text top="727" left="422" width="140" height="17" font="0">registry with DM with CLI </text>
<text top="744" left="422" width="123" height="17" font="0">or ALI who underwent </text>
<text top="761" left="422" width="140" height="17" font="0">infrapopliteal intervention </text>
<text top="676" left="587" width="7" height="17" font="2"><b>1</b></text>
<text top="675" left="594" width="6" height="18" font="7"></text>
<text top="676" left="600" width="215" height="17" font="2"><b> endpoint:</b> Patency of the target lesion </text>
<text top="693" left="587" width="3" height="17" font="0"> </text>
<text top="710" left="587" width="288" height="17" font="2"><b>Results:</b> Pts with peri-procedural FBG values below </text>
<text top="728" left="587" width="295" height="17" font="0">the median value of 144 mg/dL had improved primary </text>
<text top="745" left="587" width="278" height="17" font="0">patency at 1 yr (46% vs. 16%; HR: 1.82; p=0.005); </text>
<text top="762" left="587" width="297" height="17" font="0">association robust after adjustment for insulin use and </text>
<text top="675" left="905" width="7" height="18" font="7"></text>
<text top="676" left="911" width="165" height="17" font="0"> Observational study provides </text>
<text top="693" left="905" width="175" height="17" font="0">some support for adequate peri-</text>
<text top="710" left="905" width="178" height="17" font="0">procedural glycemic control with </text>
<text top="728" left="905" width="187" height="17" font="0">revascularization for infrapopliteal </text>
<text top="745" left="905" width="192" height="17" font="0">lesions in pts with DM with ALI/CLI </text>
<text top="762" left="905" width="193" height="17" font="0">to prevent MALE, possibly patency </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">70 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="259" width="145" height="17" font="2"><b>Size:</b> n=149 pts, 309 PTA </text>
<text top="104" left="259" width="65" height="17" font="0">procedures </text>
<text top="87" left="422" width="129" height="17" font="0">during the study period </text>
<text top="104" left="422" width="3" height="17" font="0"> </text>
<text top="122" left="422" width="129" height="17" font="2"><b>Exclusion criteria:</b> No </text>
<text top="139" left="422" width="144" height="17" font="0">FBG on day of angiogram </text>
<text top="156" left="422" width="142" height="17" font="0">procedure or within 2 d of </text>
<text top="173" left="422" width="79" height="17" font="0">the procedure </text>
<text top="87" left="587" width="118" height="17" font="0">lesion characteristics </text>
<text top="104" left="587" width="3" height="17" font="0"> </text>
<text top="122" left="587" width="283" height="17" font="0">One yr major adverse limb events lower for pts with </text>
<text top="139" left="587" width="236" height="17" font="0">FBG below median (23% vs. 35%; p=0.05) </text>
<text top="87" left="905" width="70" height="17" font="0">of PTA sites </text>
<text top="191" left="95" width="103" height="17" font="0">Takahara M, et al. </text>
<text top="208" left="95" width="59" height="17" font="0">2010(163) </text>
<text top="226" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20843974">20843974</a></text>
<text top="226" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20843974"> </a></text>
<text top="243" left="95" width="3" height="17" font="0"> </text>
<text top="191" left="259" width="150" height="17" font="2"><b>Study type:</b> Observational </text>
<text top="208" left="259" width="89" height="17" font="0">cohort study vs. </text>
<text top="226" left="259" width="144" height="17" font="0">retrospective chart review </text>
<text top="243" left="259" width="145" height="17" font="0">(study design not clear) at </text>
<text top="260" left="259" width="83" height="17" font="0">a single center </text>
<text top="277" left="259" width="3" height="17" font="0"> </text>
<text top="294" left="259" width="137" height="17" font="2"><b>Size:</b> n=278 pts; 197 pts </text>
<text top="312" left="259" width="48" height="17" font="0">with DM </text>
<text top="191" left="422" width="127" height="17" font="2"><b>Inclusion criteria:</b> Pts </text>
<text top="208" left="422" width="146" height="17" font="0">with PAD undergoing PTA </text>
<text top="226" left="422" width="137" height="17" font="0">for CLI including pts with </text>
<text top="243" left="422" width="95" height="17" font="0">and without DMs </text>
<text top="260" left="422" width="3" height="17" font="0"> </text>
<text top="277" left="422" width="131" height="17" font="2"><b>Exclusion criteria:</b> Pts </text>
<text top="294" left="422" width="124" height="17" font="0">with CLI who were not </text>
<text top="312" left="422" width="132" height="17" font="0">candidates for PTA and </text>
<text top="329" left="422" width="130" height="17" font="0">treated by other means </text>
<text top="192" left="587" width="7" height="17" font="2"><b>1</b></text>
<text top="191" left="594" width="6" height="18" font="7"></text>
<text top="192" left="600" width="275" height="17" font="2"><b> endpoint:</b> Major amputation, mortality (all-cause) </text>
<text top="210" left="587" width="3" height="17" font="0"> </text>
<text top="227" left="587" width="215" height="17" font="2"><b>Results:</b> Average follow-up 90±72 wk. </text>
<text top="244" left="587" width="3" height="17" font="0"> </text>
<text top="261" left="587" width="160" height="17" font="0">Among 287 CLI pts with DM: </text>
<text top="278" left="587" width="295" height="17" font="0">HgB A1c level not associated with increased mortality </text>
<text top="296" left="587" width="3" height="17" font="0"> </text>
<text top="313" left="587" width="267" height="17" font="0">HgBA1c level associated with major amputation, </text>
<text top="330" left="587" width="297" height="17" font="0">adjusted HR: 1.349 per 1% increment; 95% CI: 1.103–</text>
<text top="347" left="587" width="90" height="17" font="0">1.650; p=0.004) </text>
<text top="365" left="587" width="3" height="17" font="0"> </text>
<text top="382" left="587" width="292" height="17" font="0">Association was robust after MV adjustment for other </text>
<text top="399" left="587" width="44" height="17" font="0">factors. </text>
<text top="416" left="587" width="3" height="17" font="0"> </text>
<text top="433" left="587" width="301" height="17" font="0">Increased quartiles of HgB A1C had stepwise increase </text>
<text top="451" left="587" width="292" height="17" font="0">in risk for major amputation, adjust HRs (for Fontaine </text>
<text top="468" left="587" width="155" height="17" font="0">Stage IV, dialysis, infection) </text>
<text top="485" left="587" width="146" height="17" font="0">Quartile         Adjusted HR </text>
<text top="502" left="587" width="81" height="17" font="0">Q1 ≤5.9%     - </text>
<text top="519" left="587" width="224" height="17" font="0">Q2 6–6.7%     2.030 (0.657-6.266, p NS) </text>
<text top="537" left="587" width="242" height="17" font="0">Q3 6.8–7.6%  3.398 (1.227-9.412, p=0.019) </text>
<text top="554" left="587" width="236" height="17" font="0">Q4 ≥7.7%     3.983 (1.398-11.35, p=0.010) </text>
<text top="191" left="905" width="7" height="18" font="7"></text>
<text top="192" left="911" width="159" height="17" font="0"> Another observational study </text>
<text top="210" left="905" width="149" height="17" font="0">providing some support for </text>
<text top="227" left="905" width="187" height="17" font="0">adequate glycemic control among </text>
<text top="244" left="905" width="191" height="17" font="0">PAD pts with DM with CLI who will </text>
<text top="261" left="905" width="170" height="17" font="0">undergo revascularization (pre-</text>
<text top="278" left="905" width="195" height="17" font="0">procedural HgB A1c) to reduce risk </text>
<text top="296" left="905" width="183" height="17" font="0">of amputation---association more </text>
<text top="313" left="905" width="187" height="17" font="0">pronounced for highest quartile of </text>
<text top="330" left="905" width="157" height="17" font="0">HgB A1c vs. lowest quartile. </text>
<text top="347" left="905" width="7" height="18" font="7"></text>
<text top="348" left="911" width="181" height="17" font="0"> No mortality benefit seen over a </text>
<text top="366" left="905" width="187" height="17" font="0">relatively short period of follow-up </text>
<text top="572" left="95" width="115" height="17" font="2"><b>Strong Heart Study </b></text>
<text top="589" left="95" width="101" height="17" font="0">Resnick HE, et al. </text>
<text top="606" left="95" width="59" height="17" font="0">2004(164) </text>
<text top="623" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14970108">14970108</a></text>
<text top="623" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14970108"> </a></text>
<text top="641" left="95" width="3" height="17" font="0"> </text>
<text top="572" left="259" width="150" height="17" font="2"><b>Study type:</b> Observational </text>
<text top="589" left="259" width="70" height="17" font="0">cohort study </text>
<text top="606" left="259" width="3" height="17" font="0"> </text>
<text top="623" left="259" width="128" height="17" font="2"><b>Size:</b> n=4,549 in entire </text>
<text top="641" left="259" width="123" height="17" font="0">cohort; 1,974 with DM </text>
<text top="658" left="259" width="103" height="17" font="0">without prior lower </text>
<text top="675" left="259" width="118" height="17" font="0">extremity amputation </text>
<text top="572" left="422" width="144" height="17" font="2"><b>Inclusion criteria:</b> Native </text>
<text top="589" left="422" width="133" height="17" font="0">Americans age 45–74 y </text>
<text top="606" left="422" width="97" height="17" font="0">seen for baseline </text>
<text top="623" left="422" width="135" height="17" font="0">examination 1989–1992 </text>
<text top="641" left="422" width="144" height="17" font="0">and subsequent follow-up </text>
<text top="658" left="422" width="31" height="17" font="0">visits </text>
<text top="675" left="422" width="3" height="17" font="0"> </text>
<text top="692" left="422" width="131" height="17" font="2"><b>Exclusion criteria:</b> Pts </text>
<text top="710" left="422" width="127" height="17" font="0">without DM; those with </text>
<text top="727" left="422" width="111" height="17" font="0">prior LE amputation </text>
<text top="744" left="422" width="53" height="17" font="0">excluded </text>
<text top="573" left="587" width="7" height="17" font="2"><b>1</b></text>
<text top="572" left="594" width="6" height="18" font="7"></text>
<text top="573" left="600" width="263" height="17" font="2"><b> endpoint:</b> Incident lower extremity amputation  </text>
<text top="590" left="587" width="3" height="17" font="0"> </text>
<text top="607" left="587" width="297" height="17" font="2"><b>Results:</b> After average 8 yr follow-up. Among pts with </text>
<text top="625" left="587" width="281" height="17" font="0">PAD (ABI &lt;0.9), higher HgB A1c increased odds of </text>
<text top="642" left="587" width="281" height="17" font="0">lower extremity amputation. Relationship also seen </text>
<text top="659" left="587" width="258" height="17" font="0">among pts with normal ABI and those with non-</text>
<text top="676" left="587" width="183" height="17" font="0">compressible vessels (ABI &gt;1.4). </text>
<text top="693" left="587" width="3" height="17" font="0"> </text>
<text top="711" left="587" width="284" height="17" font="0">Odds of incident LE amputation among pts with DM </text>
<text top="728" left="587" width="299" height="17" font="0">and PAD (ABI &lt;0.9) or non-compressible vessels (ABI </text>
<text top="745" left="587" width="300" height="17" font="0">≤1.4); reference pts with DM with normal ABI and HgB </text>
<text top="762" left="587" width="112" height="17" font="0">A1c &lt;6.5%* (OR=1)<b> </b></text>
<text top="572" left="905" width="7" height="18" font="7"></text>
<text top="573" left="911" width="163" height="17" font="0"> Epidemiological cohort study </text>
<text top="590" left="905" width="202" height="17" font="0">providing evidence of an association </text>
<text top="607" left="905" width="190" height="17" font="0">between HgBA1c/glycemic control </text>
<text top="625" left="905" width="184" height="17" font="0">and risk of LE amputation among </text>
<text top="642" left="905" width="172" height="17" font="0">pts with DM with PAD and also </text>
<text top="659" left="905" width="203" height="17" font="0">those with non compressible vessels </text>
<text top="676" left="905" width="176" height="17" font="0">(most of whom have PAD when </text>
<text top="693" left="905" width="148" height="17" font="0">assessed by other means) </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">71 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="587" width="3" height="17" font="0"> </text>
<text top="104" left="587" width="174" height="17" font="0">Pts with DM with PAD ABI &lt;0.9 </text>
<text top="122" left="587" width="195" height="17" font="0">HgB A1c Age adjusted OR LE amp </text>
<text top="139" left="587" width="83" height="17" font="0">&lt;6.5%        1.7 </text>
<text top="156" left="587" width="133" height="17" font="0">6.5-9.5%    5.6 (p&lt;0.05) </text>
<text top="173" left="587" width="133" height="17" font="0">&gt;9.5%        8.7 (p&lt;0.05) </text>
<text top="190" left="587" width="3" height="17" font="0"> </text>
<text top="208" left="587" width="210" height="17" font="0">Pts with DM with n/c vessels ABI &gt;1.4 </text>
<text top="225" left="587" width="195" height="17" font="0">HgB A1c Age adjusted OR LE amp </text>
<text top="242" left="587" width="87" height="17" font="0">&lt;6.5%         2.6 </text>
<text top="259" left="587" width="133" height="17" font="0">6.5-9.5%    7.5 (p&lt;0.05) </text>
<text top="276" left="587" width="140" height="17" font="0">&gt;9.5%        10.4 (p&lt;0.05) </text>
<text top="294" left="86" width="984" height="17" font="0">ABI indicates ankle-brachial index; ALI, acute limb ischemia; CI indicates confidence interval; CLI, critical limb ischemia; DM, diabetes mellitus; FBG, fasting blood glucose; HgbA1c, </text>
<text top="312" left="86" width="984" height="17" font="0">hemoglobin A1c; HR, hazard ratio; LE, lower extremity; MALE, major adverse limb event; MV, multivariate; NS, non-significant; OR, odds ratio; PAD, peripheral artery disease; PTA, </text>
<text top="329" left="86" width="388" height="17" font="0">percutaneous transluminal angioplasty; pt, patient; and RR, relative risk</text>
<text top="329" left="475" width="7" height="17" font="9">. </text>
<text top="346" left="86" width="3" height="17" font="0"> </text>
<text top="363" left="86" width="3" height="17" font="0"> </text>
<text top="381" left="86" width="497" height="21" font="1"><b>Evidence Table 23. RCTs Evaluating Oral Anticoagulation–Section 5.6. </b></text>
<text top="402" left="100" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="419" left="125" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="436" left="103" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="402" left="241" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="419" left="246" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="436" left="240" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="402" left="393" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="402" left="556" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="419" left="573" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="436" left="556" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="454" left="577" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="402" left="728" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="419" left="705" width="149" height="17" font="2"><b>(Absolute Event Rates, P </b></text>
<text top="436" left="723" width="118" height="17" font="2"><b>value; OR or RR; &amp;  </b></text>
<text top="454" left="756" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="403" left="908" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="402" left="970" width="6" height="18" font="7"></text>
<text top="403" left="976" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="420" left="941" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="437" left="948" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="472" left="95" width="83" height="17" font="2"><b>WAVE TRIAL  </b></text>
<text top="489" left="95" width="84" height="17" font="0">Anand S, et al. </text>
<text top="506" left="95" width="59" height="17" font="0">2007(165) </text>
<text top="523" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17634457">17634457 </a></text>
<text top="540" left="95" width="3" height="17" font="0"> </text>
<text top="472" left="216" width="82" height="17" font="2"><b>Aim:</b> Evaluate </text>
<text top="489" left="216" width="130" height="17" font="0">anticoagulant agents in </text>
<text top="506" left="216" width="75" height="17" font="0">prevention of </text>
<text top="523" left="216" width="83" height="17" font="0">cardiovascular </text>
<text top="540" left="216" width="111" height="17" font="0">complications in pts </text>
<text top="558" left="216" width="54" height="17" font="0">with PAD </text>
<text top="575" left="216" width="3" height="17" font="0"> </text>
<text top="592" left="216" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="609" left="216" width="3" height="17" font="0"> </text>
<text top="626" left="216" width="100" height="17" font="2"><b>Size:</b> n=2,161 pts </text>
<text top="472" left="362" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="489" left="362" width="7" height="18" font="7"></text>
<text top="490" left="369" width="76" height="17" font="0"> Age 35–85 y </text>
<text top="507" left="362" width="7" height="18" font="7"></text>
<text top="508" left="369" width="92" height="17" font="0"> PAD defined as </text>
<text top="526" left="362" width="165" height="17" font="0">atherosclerosis of the arteries </text>
<text top="543" left="362" width="154" height="17" font="0">of the lower extremities, the </text>
<text top="560" left="362" width="123" height="17" font="0">carotid arteries, or the </text>
<text top="577" left="362" width="106" height="17" font="0">subclavian arteries </text>
<text top="594" left="362" width="3" height="17" font="0"> </text>
<text top="612" left="362" width="110" height="17" font="2"><b>Exclusion criteria: </b></text>
<text top="629" left="362" width="7" height="18" font="7"></text>
<text top="630" left="369" width="101" height="17" font="0"> Indication for oral </text>
<text top="647" left="362" width="132" height="17" font="0">anticoagulant treatment </text>
<text top="664" left="362" width="7" height="18" font="7"></text>
<text top="665" left="369" width="154" height="17" font="0"> Actively bleeding or at high </text>
<text top="683" left="362" width="90" height="17" font="0">risk for bleeding </text>
<text top="700" left="362" width="7" height="18" font="7"></text>
<text top="701" left="369" width="146" height="17" font="0"> Stroke within 6 mo before </text>
<text top="718" left="362" width="61" height="17" font="0">enrollment </text>
<text top="736" left="362" width="7" height="18" font="7"></text>
<text top="737" left="369" width="49" height="17" font="0"> Dialysis </text>
<text top="472" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="489" left="547" width="112" height="17" font="0">Anticoagulation and </text>
<text top="506" left="547" width="63" height="17" font="0">antiplatelet </text>
<text top="523" left="547" width="3" height="17" font="0"> </text>
<text top="540" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="558" left="547" width="98" height="17" font="0">Antiplatelet alone </text>
<text top="473" left="689" width="7" height="17" font="2"><b>1</b></text>
<text top="472" left="695" width="6" height="18" font="7"></text>
<text top="473" left="702" width="138" height="17" font="2"><b> endpoint:</b> MI, stroke, or </text>
<text top="490" left="689" width="170" height="17" font="0">death no difference (12.2% vs. </text>
<text top="507" left="689" width="87" height="17" font="0">13.3%, p=0.48) </text>
<text top="524" left="689" width="3" height="17" font="0"> </text>
<text top="543" left="689" width="7" height="17" font="2"><b>1</b></text>
<text top="542" left="695" width="6" height="18" font="7"></text>
<text top="543" left="702" width="126" height="17" font="2"><b> Safety endpoint:</b> Life </text>
<text top="560" left="689" width="182" height="17" font="0">threatening bleeding significantly </text>
<text top="577" left="689" width="146" height="17" font="0">increased (4.0% vs. 1.2%, </text>
<text top="594" left="689" width="59" height="17" font="0">p&lt;0.0001) </text>
<text top="472" left="884" width="7" height="18" font="7"></text>
<text top="473" left="891" width="128" height="17" font="0"> Mean follow-up 35 mo </text>
<text top="490" left="884" width="3" height="17" font="0"> </text>
<text top="507" left="884" width="67" height="17" font="2"><b>Summary:  </b></text>
<text top="524" left="884" width="7" height="18" font="7"></text>
<text top="525" left="891" width="207" height="17" font="0"> Combination of an anticoagulant and </text>
<text top="543" left="884" width="209" height="17" font="0">antiplatelet therapy not more effective </text>
<text top="560" left="884" width="181" height="17" font="0">than antiplatelet therapy alone in </text>
<text top="577" left="884" width="178" height="17" font="0">preventing major cardiovascular </text>
<text top="594" left="884" width="189" height="17" font="0">complications and associated with </text>
<text top="612" left="884" width="198" height="17" font="0">increase in life-threatening bleeding </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">72 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="70" height="17" font="2"><b>BOA TRIAL </b></text>
<text top="104" left="95" width="59" height="17" font="0">2000(166) </text>
<text top="122" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10665553">10665553 </a></text>
<text top="139" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="216" width="85" height="17" font="2"><b>Aim:</b> Compare </text>
<text top="104" left="216" width="113" height="17" font="0">effectiveness of oral </text>
<text top="122" left="216" width="108" height="17" font="0">anticoagulants with </text>
<text top="139" left="216" width="102" height="17" font="0">ASA in prevention </text>
<text top="156" left="216" width="113" height="17" font="0">infrainguinal bypass-</text>
<text top="173" left="216" width="107" height="17" font="0">graft occlusion and </text>
<text top="190" left="216" width="80" height="17" font="0">clinical events </text>
<text top="208" left="216" width="3" height="17" font="0"> </text>
<text top="225" left="216" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="242" left="216" width="3" height="17" font="0"> </text>
<text top="259" left="216" width="100" height="17" font="2"><b>Size:</b> n=2,690 pts </text>
<text top="87" left="362" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="104" left="362" width="159" height="17" font="0">Infrainguinal bypass for PAD </text>
<text top="122" left="362" width="3" height="17" font="0"> </text>
<text top="139" left="362" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="156" left="362" width="7" height="18" font="7"></text>
<text top="157" left="369" width="133" height="17" font="0"> Contraindication to trial </text>
<text top="174" left="362" width="69" height="17" font="0">medications </text>
<text top="192" left="362" width="7" height="18" font="7"></text>
<text top="193" left="369" width="148" height="17" font="0"> Shortened life expectancy </text>
<text top="210" left="362" width="7" height="18" font="7"></text>
<text top="211" left="369" width="141" height="17" font="0"> MI or stroke 1 mo before </text>
<text top="228" left="362" width="44" height="17" font="0">surgery </text>
<text top="246" left="362" width="7" height="18" font="7"></text>
<text top="247" left="369" width="144" height="17" font="0"> Abnormalities of platelets </text>
<text top="264" left="362" width="7" height="18" font="7"></text>
<text top="265" left="369" width="49" height="17" font="0"> Anemia </text>
<text top="87" left="547" width="128" height="17" font="2"><b>Intervention:</b> Warfarin </text>
<text top="104" left="547" width="3" height="17" font="0"> </text>
<text top="122" left="547" width="105" height="17" font="2"><b>Comparator:</b> ASA </text>
<text top="88" left="689" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="695" width="6" height="18" font="7"></text>
<text top="88" left="702" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="106" left="689" width="7" height="18" font="7"></text>
<text top="107" left="695" width="167" height="17" font="0"> Graft occlusion no difference  </text>
<text top="124" left="689" width="7" height="18" font="7"></text>
<text top="125" left="695" width="167" height="17" font="0"> Vascular death, MI, stroke, or </text>
<text top="142" left="689" width="139" height="17" font="0">amputation no difference </text>
<text top="159" left="689" width="3" height="17" font="0"> </text>
<text top="177" left="689" width="151" height="17" font="2"><b>Safety endpoint:</b> Bleeding </text>
<text top="194" left="689" width="163" height="17" font="0">increased (HR: 1.96; 95% CI: </text>
<text top="211" left="689" width="62" height="17" font="0">1.42–2.71) </text>
<text top="87" left="884" width="7" height="18" font="7"></text>
<text top="88" left="891" width="128" height="17" font="0"> Mean follow-up 21 mo </text>
<text top="106" left="884" width="7" height="18" font="7"></text>
<text top="107" left="891" width="154" height="17" font="0"> Vein graft subset-benefit to </text>
<text top="124" left="884" width="86" height="17" font="0">anticoagulation </text>
<text top="141" left="884" width="3" height="17" font="0"> </text>
<text top="158" left="884" width="67" height="17" font="2"><b>Summary:  </b></text>
<text top="176" left="884" width="7" height="18" font="7"></text>
<text top="177" left="891" width="206" height="17" font="0"> No difference other than in vein graft </text>
<text top="194" left="884" width="183" height="17" font="0">subgroup analysis and increased </text>
<text top="211" left="884" width="128" height="17" font="0">bleeding complications </text>
<text top="283" left="95" width="98" height="17" font="0">Johnson WC and </text>
<text top="300" left="95" width="72" height="17" font="0">Williford WO </text>
<text top="318" left="95" width="59" height="17" font="0">2002(167) </text>
<text top="335" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11877686">11877686 </a></text>
<text top="352" left="95" width="3" height="17" font="0"> </text>
<text top="283" left="216" width="129" height="17" font="2"><b>Aim:</b> Evaluate warfarin </text>
<text top="300" left="216" width="106" height="17" font="0">+ ASA therapy) vs. </text>
<text top="318" left="216" width="132" height="17" font="0">ASA alone on mortality, </text>
<text top="335" left="216" width="120" height="17" font="0">morbidity and bypass </text>
<text top="352" left="216" width="50" height="17" font="0">patency  </text>
<text top="369" left="216" width="3" height="17" font="0"> </text>
<text top="386" left="216" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="404" left="216" width="3" height="17" font="0"> </text>
<text top="421" left="216" width="90" height="17" font="2"><b>Size:</b> n=831 pts </text>
<text top="283" left="362" width="131" height="17" font="2"><b>Inclusion criteria:</b> Any </text>
<text top="300" left="362" width="89" height="17" font="0">bypass for PAD </text>
<text top="318" left="362" width="3" height="17" font="0"> </text>
<text top="335" left="362" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="352" left="362" width="148" height="17" font="0">Contraindication to ASA or </text>
<text top="369" left="362" width="47" height="17" font="0">warfarin </text>
<text top="283" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="300" left="547" width="112" height="17" font="0">Anticoagulation and </text>
<text top="318" left="547" width="63" height="17" font="0">antiplatelet </text>
<text top="335" left="547" width="3" height="17" font="0"> </text>
<text top="352" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="369" left="547" width="98" height="17" font="0">Antiplatelet alone </text>
<text top="284" left="689" width="7" height="17" font="2"><b>1</b></text>
<text top="283" left="695" width="6" height="18" font="7"></text>
<text top="284" left="702" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="301" left="689" width="7" height="18" font="7"></text>
<text top="302" left="695" width="169" height="17" font="0"> Bypass patency no significant </text>
<text top="320" left="689" width="57" height="17" font="0">difference </text>
<text top="337" left="689" width="7" height="18" font="7"></text>
<text top="338" left="695" width="170" height="17" font="0"> 6 mm PTFE bypass subgroup </text>
<text top="355" left="689" width="178" height="17" font="0">analysis significant benefit (71% </text>
<text top="373" left="689" width="96" height="17" font="0">vs. 58%; p=0.02) </text>
<text top="390" left="689" width="3" height="17" font="0"> </text>
<text top="407" left="689" width="100" height="17" font="2"><b>Safety endpoint: </b></text>
<text top="424" left="689" width="7" height="18" font="7"></text>
<text top="425" left="695" width="161" height="17" font="0"> Mortality increased (32% vs. </text>
<text top="443" left="689" width="91" height="17" font="0">23%; p=0.0001) </text>
<text top="460" left="689" width="7" height="18" font="7"></text>
<text top="461" left="695" width="164" height="17" font="0"> Major hemorrhage increased </text>
<text top="478" left="689" width="50" height="17" font="0">(p=0.02) </text>
<text top="283" left="884" width="7" height="18" font="7"></text>
<text top="284" left="891" width="187" height="17" font="0">1/3 of anticoagulation pts stopped </text>
<text top="301" left="884" width="86" height="17" font="0">anticoagulation </text>
<text top="319" left="884" width="3" height="17" font="0"> </text>
<text top="336" left="884" width="67" height="17" font="2"><b>Summary:  </b></text>
<text top="353" left="884" width="7" height="18" font="7"></text>
<text top="354" left="891" width="201" height="17" font="0"> Anticoagulation + ASA compared to </text>
<text top="371" left="884" width="222" height="17" font="0">ASA no difference in overall patency but </text>
<text top="389" left="884" width="165" height="17" font="0">increased mortality and major </text>
<text top="406" left="884" width="73" height="17" font="0">hemorrhage. </text>
<text top="423" left="884" width="7" height="18" font="7"></text>
<text top="424" left="891" width="174" height="17" font="0"> Benefit in subgroup analysis of </text>
<text top="441" left="884" width="137" height="17" font="0">patency for 6 mm PTFE. </text>
<text top="496" left="95" width="88" height="17" font="0">Sarac TP, et al. </text>
<text top="513" left="95" width="59" height="17" font="0">1998(168) </text>
<text top="531" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9737454">9737454 </a></text>
<text top="548" left="95" width="3" height="17" font="0"> </text>
<text top="496" left="216" width="86" height="17" font="2"><b>Aim:</b> Effects of </text>
<text top="513" left="216" width="131" height="17" font="0">anticoagulation therapy </text>
<text top="531" left="216" width="122" height="17" font="0">after autogenous vein </text>
<text top="548" left="216" width="121" height="17" font="0">bypass on duration of </text>
<text top="565" left="216" width="122" height="17" font="0">patency, limb salvage </text>
<text top="582" left="216" width="130" height="17" font="0">rates, and complication </text>
<text top="599" left="216" width="31" height="17" font="0">rates </text>
<text top="617" left="216" width="3" height="17" font="0"> </text>
<text top="634" left="216" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="651" left="216" width="3" height="17" font="0"> </text>
<text top="668" left="216" width="83" height="17" font="2"><b>Size:</b> n=64 pts </text>
<text top="496" left="362" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="513" left="362" width="165" height="17" font="0">Infrainguinal vein bypass high </text>
<text top="531" left="362" width="127" height="17" font="0">risk for graft occlusion  </text>
<text top="548" left="362" width="3" height="17" font="0"> </text>
<text top="565" left="362" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="496" left="547" width="128" height="17" font="2"><b>Intervention:</b> Warfarin </text>
<text top="513" left="547" width="52" height="17" font="0">and ASA </text>
<text top="531" left="547" width="3" height="17" font="0"> </text>
<text top="548" left="547" width="105" height="17" font="2"><b>Comparator:</b> ASA </text>
<text top="565" left="547" width="33" height="17" font="0">alone </text>
<text top="497" left="689" width="7" height="17" font="2"><b>1</b></text>
<text top="496" left="695" width="6" height="18" font="7"></text>
<text top="497" left="702" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="515" left="689" width="7" height="18" font="7"></text>
<text top="516" left="695" width="151" height="17" font="0"> 3 y patency improved (PP: </text>
<text top="533" left="689" width="183" height="17" font="0">74% vs. 51%, p=0.04; PAP: 77% </text>
<text top="550" left="689" width="159" height="17" font="0">vs. 56%, p=0.5; SP: 81% vs. </text>
<text top="567" left="689" width="70" height="17" font="0">56%, p=0.2) </text>
<text top="585" left="689" width="7" height="18" font="7"></text>
<text top="586" left="695" width="149" height="17" font="0"> 3 y limb salvage improved </text>
<text top="603" left="689" width="128" height="17" font="0">(81% vs. 31%; p=0.01) </text>
<text top="620" left="689" width="7" height="18" font="7"></text>
<text top="621" left="695" width="125" height="17" font="0"> Survival no difference </text>
<text top="639" left="689" width="3" height="17" font="0"> </text>
<text top="656" left="689" width="100" height="17" font="2"><b>Safety endpoint: </b></text>
<text top="673" left="689" width="7" height="18" font="7"></text>
<text top="674" left="695" width="163" height="17" font="0"> Postop hematoma increased </text>
<text top="691" left="689" width="138" height="17" font="0">(32% vs. 3.7%, p=0.004) </text>
<text top="709" left="689" width="7" height="18" font="7"></text>
<text top="710" left="695" width="122" height="17" font="0"> No difference in RBC </text>
<text top="727" left="689" width="70" height="17" font="0">transfusions </text>
<text top="496" left="884" width="7" height="18" font="7"></text>
<text top="497" left="891" width="67" height="17" font="0">Small study </text>
<text top="515" left="884" width="7" height="18" font="7"></text>
<text top="516" left="891" width="215" height="17" font="0">Definition of high risk for bypass failure </text>
<text top="533" left="884" width="44" height="17" font="0">unclear </text>
<text top="550" left="884" width="7" height="18" font="7"></text>
<text top="551" left="891" width="150" height="17" font="0">Did not evaluate stroke, MI </text>
<text top="569" left="884" width="3" height="17" font="0"> </text>
<text top="586" left="884" width="67" height="17" font="2"><b>Summary:  </b></text>
<text top="603" left="884" width="7" height="18" font="7"></text>
<text top="604" left="891" width="187" height="17" font="0"> Anticoagulation after vein bypass </text>
<text top="621" left="884" width="185" height="17" font="0">increases the incidence of wound </text>
<text top="639" left="884" width="216" height="17" font="0">hematomas, but improves patency rate </text>
<text top="656" left="884" width="103" height="17" font="0">and limb salvage.  </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">73 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="105" height="17" font="0">Antonicelli R, et al. </text>
<text top="104" left="95" width="59" height="17" font="0">1999(169) </text>
<text top="122" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10492316">10492316 </a></text>
<text top="139" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="216" width="103" height="17" font="2"><b>Aim:</b> Evaluate the </text>
<text top="104" left="216" width="115" height="17" font="0">efficacy of low-dose, </text>
<text top="122" left="216" width="126" height="17" font="0">subcutaneous calcium-</text>
<text top="139" left="216" width="124" height="17" font="0">heparin in comparison </text>
<text top="156" left="216" width="130" height="17" font="0">with placebo in pts with </text>
<text top="173" left="216" width="16" height="17" font="0">IC </text>
<text top="190" left="216" width="3" height="17" font="0"> </text>
<text top="208" left="216" width="102" height="17" font="2"><b>Study type:</b> RCT  </text>
<text top="225" left="216" width="3" height="17" font="0"> </text>
<text top="242" left="216" width="90" height="17" font="2"><b>Size:</b> n=201 pts </text>
<text top="87" left="362" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="104" left="362" width="7" height="18" font="7"></text>
<text top="105" left="369" width="106" height="17" font="0"> Willingness to use </text>
<text top="123" left="362" width="103" height="17" font="0">parenteral therapy </text>
<text top="140" left="362" width="7" height="18" font="7"></text>
<text top="141" left="369" width="140" height="17" font="0"> ≥6 mo Hx of IC who had </text>
<text top="158" left="362" width="149" height="17" font="0">PAD confirmed by Doppler </text>
<text top="176" left="362" width="70" height="17" font="0">examination </text>
<text top="193" left="362" width="3" height="17" font="0"> </text>
<text top="210" left="362" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="104" left="547" width="127" height="17" font="0">Subcutaneous heparin </text>
<text top="122" left="547" width="52" height="17" font="0">and ASA </text>
<text top="139" left="547" width="3" height="17" font="0"> </text>
<text top="156" left="547" width="105" height="17" font="2"><b>Comparator:</b> ASA </text>
<text top="173" left="547" width="33" height="17" font="0">alone </text>
<text top="88" left="689" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="695" width="6" height="18" font="7"></text>
<text top="88" left="702" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="106" left="689" width="7" height="18" font="7"></text>
<text top="107" left="695" width="172" height="17" font="0"> Maximum walking time 40% in </text>
<text top="124" left="689" width="131" height="17" font="0">heparin group and 16% </text>
<text top="141" left="689" width="144" height="17" font="0">in placebo group (p=0.05) </text>
<text top="158" left="689" width="7" height="18" font="7"></text>
<text top="159" left="695" width="169" height="17" font="0"> Pain-free walking time 39% in </text>
<text top="177" left="689" width="144" height="17" font="0">heparin group and 23% in </text>
<text top="194" left="689" width="134" height="17" font="0">placebo group (p=0.09). </text>
<text top="87" left="884" width="7" height="18" font="7"></text>
<text top="88" left="891" width="213" height="17" font="0"> 132 of 201 randomized pts completed </text>
<text top="106" left="884" width="53" height="17" font="0">the study </text>
<text top="123" left="884" width="3" height="17" font="0"> </text>
<text top="140" left="884" width="64" height="17" font="2"><b>Summary: </b></text>
<text top="157" left="884" width="7" height="18" font="7"></text>
<text top="158" left="891" width="141" height="17" font="0"> Treatment with low-dose </text>
<text top="176" left="884" width="187" height="17" font="0">subcutaneous heparin is safe and </text>
<text top="193" left="884" width="163" height="17" font="0">effective in improving walking </text>
<text top="210" left="884" width="72" height="17" font="0">performance </text>
<text top="260" left="86" width="992" height="17" font="0">ASA indicates acetylsalicylic acid; CI, confidence interval; HR, hazard ratio; IC, intermittent claudication; MI, myocardial infarction; N/A, not applicable; PAD, peripheral artery disease; </text>
<text top="277" left="86" width="438" height="17" font="0">PTFE, polytetrafluoroethylene; pt, patient; and RCT, randomized controlled trial. </text>
<text top="294" left="86" width="3" height="17" font="0"> </text>
<text top="312" left="86" width="3" height="17" font="0"> </text>
<text top="329" left="86" width="846" height="21" font="1"><b>Evidence Table 24. Nonrandomized Trials, Observational Studies, and/or Registries of Oral Anticoagulation–Section 5.6. </b></text>
<text top="350" left="108" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="367" left="134" width="48" height="17" font="2"><b>Author; </b></text>
<text top="385" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="350" left="247" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="367" left="273" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="350" left="410" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="350" left="599" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="367" left="607" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="385" left="659" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="350" left="908" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="367" left="935" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="403" left="95" width="125" height="17" font="0">Alonso-Coello P, et al.<b> </b></text>
<text top="420" left="95" width="59" height="17" font="0">2012(170)<b> </b></text>
<text top="437" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22315275">22315275 </a></text>
<text top="454" left="95" width="3" height="17" font="0"> </text>
<text top="403" left="234" width="113" height="17" font="2"><b>Study type:</b> Clinical </text>
<text top="420" left="234" width="142" height="17" font="0">practice guidelines based </text>
<text top="437" left="234" width="120" height="17" font="0">on meta-analysis of 3 </text>
<text top="454" left="234" width="142" height="17" font="0">RCTs evaluating warfarin </text>
<text top="472" left="234" width="123" height="17" font="0">+ ASA vs. ASA alone. </text>
<text top="489" left="234" width="3" height="17" font="0"> </text>
<text top="506" left="234" width="104" height="17" font="2"><b>Size:</b> n=3,048 pts  </text>
<text top="403" left="391" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="420" left="391" width="7" height="18" font="7"></text>
<text top="421" left="398" width="56" height="17" font="0"> Asx PAD </text>
<text top="438" left="391" width="7" height="18" font="7"></text>
<text top="439" left="398" width="50" height="17" font="0"> Sx PAD </text>
<text top="457" left="391" width="7" height="18" font="7"></text>
<text top="458" left="398" width="25" height="17" font="0"> ALI </text>
<text top="475" left="391" width="7" height="18" font="7"></text>
<text top="476" left="398" width="131" height="17" font="0"> Post peripheral arterial </text>
<text top="493" left="391" width="96" height="17" font="0">revascularization </text>
<text top="511" left="391" width="7" height="18" font="7"></text>
<text top="512" left="398" width="95" height="17" font="0"> Carotid stenosis </text>
<text top="529" left="391" width="3" height="17" font="0"> </text>
<text top="546" left="391" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="404" left="554" width="7" height="17" font="2"><b>1</b></text>
<text top="403" left="560" width="6" height="18" font="7"></text>
<text top="404" left="566" width="63" height="17" font="2"><b> endpoint:</b> </text>
<text top="421" left="554" width="7" height="18" font="7"></text>
<text top="422" left="560" width="208" height="17" font="0"> Prevention of cardiovascular disease </text>
<text top="439" left="554" width="7" height="18" font="7"></text>
<text top="440" left="560" width="260" height="17" font="0"> Relief of lower extremity symptoms and critical </text>
<text top="458" left="554" width="52" height="17" font="0">ischemia </text>
<text top="475" left="554" width="3" height="17" font="0"> </text>
<text top="492" left="554" width="229" height="17" font="2"><b>Results:</b> Results failed to demonstrate or </text>
<text top="509" left="554" width="243" height="17" font="0">exclude an effect of warfarin + ASA vs. ASA </text>
<text top="527" left="554" width="233" height="17" font="0">alone on mortality, nonfatal MI, or nonfatal </text>
<text top="544" left="554" width="221" height="17" font="0">stroke. However, there was a significant </text>
<text top="561" left="554" width="263" height="17" font="0">increase in major bleeding events with warfarin. </text>
<text top="403" left="837" width="7" height="18" font="7"></text>
<text top="404" left="844" width="263" height="17" font="0"> Recommend against the use of warfarin + ASA </text>
<text top="421" left="837" width="204" height="17" font="0">in pts with asx or sx PAD (Grade 1B) </text>
<text top="579" left="95" width="94" height="17" font="0">Bedenis R, et al.<b> </b></text>
<text top="596" left="95" width="59" height="17" font="0">2015(171) </text>
<text top="613" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25695213">25695213 </a></text>
<text top="631" left="95" width="3" height="17" font="0"> </text>
<text top="579" left="234" width="127" height="17" font="2"><b>Study type:</b> Cochrane </text>
<text top="596" left="234" width="44" height="17" font="0">Review </text>
<text top="613" left="234" width="3" height="17" font="0"> </text>
<text top="631" left="234" width="144" height="17" font="2"><b>Size: </b>n=1,381 pts in the 3 </text>
<text top="648" left="234" width="130" height="17" font="0">studies included for the </text>
<text top="665" left="234" width="61" height="17" font="0">analysis of </text>
<text top="682" left="234" width="86" height="17" font="0">anticoagulants. </text>
<text top="579" left="391" width="143" height="17" font="2"><b>Inclusion criteria:</b> Lower </text>
<text top="596" left="391" width="142" height="17" font="0">extremity bypass for PAD </text>
<text top="613" left="391" width="3" height="17" font="0"> </text>
<text top="631" left="391" width="137" height="17" font="2"><b>Exclusion criteria:</b> N/A  </text>
<text top="580" left="554" width="7" height="17" font="2"><b>1</b></text>
<text top="579" left="560" width="6" height="18" font="7"></text>
<text top="580" left="566" width="197" height="17" font="2"><b> endpoint:</b> Bypass primary patency </text>
<text top="597" left="554" width="3" height="17" font="0"> </text>
<text top="615" left="554" width="260" height="17" font="2"><b>Results:</b> No difference in primary graft patency </text>
<text top="632" left="554" width="227" height="17" font="0">when ASA or ASA with dipyridamole was </text>
<text top="649" left="554" width="196" height="17" font="0">compared to a vitamin K antagonist </text>
<text top="579" left="837" width="7" height="18" font="7"></text>
<text top="580" left="844" width="258" height="17" font="0"> No patency benefit with use of anticoagulation </text>
<text top="700" left="95" width="83" height="17" font="0">Cosmi B, et al.<b> </b></text>
<text top="718" left="95" width="59" height="17" font="0">2001(172)<b> </b></text>
<text top="735" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11687006">11687006 </a></text>
<text top="752" left="95" width="3" height="17" font="0"> </text>
<text top="700" left="234" width="127" height="17" font="2"><b>Study type:</b> Cochrane </text>
<text top="718" left="234" width="44" height="17" font="0">Review </text>
<text top="735" left="234" width="3" height="17" font="0"> </text>
<text top="752" left="234" width="132" height="17" font="2"><b>Size:</b> n=3 studies in the </text>
<text top="769" left="234" width="106" height="17" font="0">primary analysis; 4 </text>
<text top="700" left="391" width="125" height="17" font="2"><b>Inclusion criteria:</b> IC, </text>
<text top="718" left="391" width="56" height="17" font="0">RCT data </text>
<text top="735" left="391" width="3" height="17" font="0"> </text>
<text top="752" left="391" width="137" height="17" font="2"><b>Exclusion criteria:</b> N/A  </text>
<text top="701" left="554" width="7" height="17" font="2"><b>1</b></text>
<text top="700" left="560" width="6" height="18" font="7"></text>
<text top="701" left="566" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="719" left="554" width="7" height="18" font="7"></text>
<text top="720" left="560" width="154" height="17" font="0"> Maximum walking distance </text>
<text top="737" left="554" width="7" height="18" font="7"></text>
<text top="738" left="560" width="150" height="17" font="0"> Pain-free walking distance </text>
<text top="755" left="554" width="3" height="17" font="0"> </text>
<text top="773" left="554" width="258" height="17" font="2"><b>Results:</b> No benefit of heparin, LMWHs or oral </text>
<text top="700" left="837" width="7" height="18" font="7"></text>
<text top="701" left="844" width="217" height="17" font="0"> No significant difference was observed </text>
<text top="719" left="837" width="255" height="17" font="0">between heparin treatment and control groups </text>
<text top="736" left="837" width="234" height="17" font="0">for pain-free walking distance or maximum </text>
<text top="753" left="837" width="221" height="17" font="0">walking distance at the end of treatment </text>
<text top="770" left="837" width="7" height="18" font="7"></text>
<text top="771" left="844" width="215" height="17" font="0"> Major and minor bleeding events were </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">74 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="234" width="129" height="17" font="0">additional studies were </text>
<text top="104" left="234" width="139" height="17" font="0">included in the sensitivity </text>
<text top="122" left="234" width="48" height="17" font="0">analysis </text>
<text top="87" left="554" width="258" height="17" font="0">anticoagulants has been established for IC. An </text>
<text top="104" left="554" width="240" height="17" font="0">increased risk of major bleeding events has </text>
<text top="122" left="554" width="191" height="17" font="0">been observed especially with oral </text>
<text top="139" left="554" width="264" height="17" font="0">anticoagulants. The use of anticoagulants for IC </text>
<text top="156" left="554" width="213" height="17" font="0">cannot be recommended at this stage. </text>
<text top="87" left="837" width="257" height="17" font="0">significantly more frequent in the group treated </text>
<text top="104" left="837" width="248" height="17" font="0">with oral anticoagulants compared to control, </text>
<text top="122" left="837" width="254" height="17" font="0">with a nonsignificant increase in fatal bleeding </text>
<text top="139" left="837" width="43" height="17" font="0">events. </text>
<text top="174" left="86" width="1004" height="17" font="0">ALI indicates acute limb ischemia; ASA, aspirin; IC, intermittent claudication; LMWH, low molecular weight heparin; N/A, not applicable; PAD, peripheral arterial disease; pt, patient; and </text>
<text top="191" left="86" width="183" height="17" font="0">RCT, randomized controlled trial. </text>
<text top="208" left="86" width="3" height="17" font="0"> </text>
<text top="226" left="86" width="551" height="21" font="1"><b>Evidence Table 25. RCTs and Observational Studies of Cilostazol–Section 5.7. </b></text>
<text top="247" left="99" width="89" height="17" font="2"><b>Study Author;  </b></text>
<text top="264" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="247" left="225" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="264" left="230" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="281" left="224" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="247" left="346" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="247" left="491" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="264" left="509" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="281" left="492" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="299" left="513" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="247" left="728" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="264" left="648" width="267" height="17" font="2"><b>(Absolute Event Rates, P value; OR or RR; &amp;  </b></text>
<text top="281" left="756" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="248" left="952" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="247" left="1013" width="6" height="18" font="7"></text>
<text top="248" left="1019" width="75" height="17" font="2"><b> Endpoint (if </b></text>
<text top="265" left="1007" width="33" height="17" font="2"><b>any); </b></text>
<text top="283" left="968" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="300" left="975" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="318" left="95" width="94" height="17" font="0">Bedenis R, et al. </text>
<text top="335" left="95" width="63" height="17" font="0">2014 (173) </text>
<text top="352" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25358850">25358850 </a></text>
<text top="369" left="95" width="3" height="17" font="0"> </text>
<text top="318" left="203" width="107" height="17" font="2"><b>Aim: </b>To determine </text>
<text top="335" left="203" width="122" height="17" font="0">Cilostazol’s impact on </text>
<text top="352" left="203" width="113" height="17" font="0">claudication walking </text>
<text top="369" left="203" width="112" height="17" font="0">distances, mortality, </text>
<text top="387" left="203" width="126" height="17" font="0">and vascular events in </text>
<text top="404" left="203" width="101" height="17" font="0">pts with stable IC. </text>
<text top="421" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="438" left="203" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="455" left="203" width="127" height="17" font="0">analysis: Double-blind, </text>
<text top="473" left="203" width="122" height="17" font="0">RCTs of cilostazol vs. </text>
<text top="490" left="203" width="115" height="17" font="0">placebo, or vs. other </text>
<text top="507" left="203" width="116" height="17" font="0">antiplatelet agents in </text>
<text top="524" left="203" width="101" height="17" font="0">pts with stable IC. </text>
<text top="542" left="203" width="3" height="17" font="0"> </text>
<text top="559" left="203" width="32" height="17" font="2"><b>Size: </b></text>
<text top="576" left="203" width="7" height="18" font="7"></text>
<text top="577" left="209" width="84" height="17" font="0"> n=15 studies.  </text>
<text top="594" left="203" width="7" height="18" font="7"></text>
<text top="595" left="209" width="71" height="17" font="0"> n=3,718 pts </text>
<text top="318" left="344" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="335" left="344" width="82" height="17" font="0">Cilostazol with </text>
<text top="352" left="344" width="64" height="17" font="0">placebo, or </text>
<text top="369" left="344" width="69" height="17" font="0">medications </text>
<text top="387" left="344" width="103" height="17" font="0">currently known to </text>
<text top="404" left="344" width="94" height="17" font="0">increase walking </text>
<text top="421" left="344" width="73" height="17" font="0">distance e.g. </text>
<text top="438" left="344" width="115" height="17" font="0">pentoxifylline. All pts </text>
<text top="455" left="344" width="114" height="17" font="0">had IC secondary to </text>
<text top="473" left="344" width="32" height="17" font="0">PAD. </text>
<text top="318" left="473" width="109" height="17" font="0">All included studies </text>
<text top="335" left="473" width="112" height="17" font="0">compared cilostazol </text>
<text top="352" left="473" width="143" height="17" font="0">100mg 2x/d with placebo. </text>
<text top="369" left="473" width="116" height="17" font="0">In addition, 2 studies </text>
<text top="387" left="473" width="129" height="17" font="0">compared cilostazol 50 </text>
<text top="404" left="473" width="146" height="17" font="0">mg 2x/d with placebo, and </text>
<text top="421" left="473" width="101" height="17" font="0">1 study compared </text>
<text top="438" left="473" width="125" height="17" font="0">cilostazol 150 mg 2x/d </text>
<text top="455" left="473" width="128" height="17" font="0">with placebo. 3 studies </text>
<text top="473" left="473" width="136" height="17" font="0">compared cilostazol 100 </text>
<text top="490" left="473" width="147" height="17" font="0">mg 2x/d with pentoxifylline </text>
<text top="507" left="473" width="118" height="17" font="0">400 mg 3x/d. 1 study </text>
<text top="524" left="473" width="136" height="17" font="0">compared cilostazol 100 </text>
<text top="542" left="473" width="147" height="17" font="0">mg 2x/d with pentoxifylline </text>
<text top="559" left="473" width="138" height="17" font="0">600 mg 2x/d and 1 study </text>
<text top="576" left="473" width="136" height="17" font="0">compared cilostazol 100 </text>
<text top="593" left="473" width="93" height="17" font="0">mg 2x/d with the </text>
<text top="610" left="473" width="133" height="17" font="0">antiplateletK-134 50 mg </text>
<text top="628" left="473" width="92" height="17" font="0">and 100mg 2x/d </text>
<text top="318" left="635" width="280" height="17" font="0">For 8 studies data were compatible for comparison </text>
<text top="335" left="635" width="268" height="17" font="0">by meta-analysis, but data for 7 studies were too </text>
<text top="352" left="635" width="245" height="17" font="0">heterogeneous to be pooled. For the studies </text>
<text top="369" left="635" width="282" height="17" font="0">included in the meta-analysis, for ICD there was an </text>
<text top="387" left="635" width="280" height="17" font="0">improvement in the cilostazol group for the 100 mg </text>
<text top="404" left="635" width="263" height="17" font="0">and 50 mg 2x/d, compared with placebo (WMD: </text>
<text top="421" left="635" width="242" height="17" font="0">31.41 meters; 95% CI: 22.38–40.45 meters; </text>
<text top="438" left="635" width="257" height="17" font="0">p&lt;0.00001) and (WMD: 19.89 meters; 95% CI: </text>
<text top="455" left="635" width="268" height="17" font="0">9.44–30.34 meters; p=0.0002), respectively. ICD </text>
<text top="473" left="635" width="240" height="17" font="0">was improved in the cilostazol group for the </text>
<text top="490" left="635" width="269" height="17" font="0">comparison of cilostazol 150 mg vs. placebo and </text>
<text top="507" left="635" width="278" height="17" font="0">cilostazol 100 mg vs. pentoxifylline, but only single </text>
<text top="524" left="635" width="264" height="17" font="0">studies were used for these analyses. ACD was </text>
<text top="542" left="635" width="271" height="17" font="0">significantly increased in pts taking cilostazol 100 </text>
<text top="559" left="635" width="284" height="17" font="0">mg and 50 mg 2x/d, compared with placebo (WMD: </text>
<text top="576" left="635" width="242" height="17" font="0">43.12 meters; 95% CI: 18.28–67.96 meters; </text>
<text top="593" left="635" width="250" height="17" font="0">p=0.0007) and (WMD: 32.00 meters; 95% CI: </text>
<text top="610" left="635" width="268" height="17" font="0">14.17–49.83 meters; p=0.0004), respectively. As </text>
<text top="628" left="635" width="288" height="17" font="0">with ICD, ACD was increased in pts taking cilostazol </text>
<text top="645" left="635" width="245" height="17" font="0">150 mg vs. placebo, but with only 1 study an </text>
<text top="662" left="635" width="282" height="17" font="0">association cannot be clearly determined. 2 studies </text>
<text top="679" left="635" width="280" height="17" font="0">comparing cilostazol to pentoxifylline had opposing </text>
<text top="696" left="635" width="277" height="17" font="0">findings, resulting in an imprecise CI (WMD: 13.42 </text>
<text top="714" left="635" width="268" height="17" font="0">meters (95% CI: -43.51 – 70.35 meters; p=0.64). </text>
<text top="731" left="635" width="262" height="17" font="0">ABI was lowered in the cilostazol 100 mg group </text>
<text top="748" left="635" width="280" height="17" font="0">compared with placebo (WMD: 0.06; 95% CI: 0.04–</text>
<text top="765" left="635" width="276" height="17" font="0">0.08; p&lt;0.00001). The single study evaluating ABI </text>
<text top="318" left="938" width="143" height="17" font="0">There was no association </text>
<text top="335" left="938" width="156" height="17" font="0">between treatment type and </text>
<text top="352" left="938" width="157" height="17" font="0">all-cause mortality for any of </text>
<text top="369" left="938" width="152" height="17" font="0">the treatment comparisons, </text>
<text top="387" left="938" width="131" height="17" font="0">but there were very few </text>
<text top="404" left="938" width="120" height="17" font="0">events, and therefore </text>
<text top="421" left="938" width="141" height="17" font="0">inadequately powered. In </text>
<text top="438" left="938" width="124" height="17" font="0">general cilostazol was </text>
<text top="455" left="938" width="165" height="17" font="0">associated with a higher odds </text>
<text top="473" left="938" width="127" height="17" font="0">of headache, diarrhea, </text>
<text top="490" left="938" width="165" height="17" font="0">abnormal stool, dizziness and </text>
<text top="507" left="938" width="66" height="17" font="0">palpitations </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">75 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="635" width="267" height="17" font="0">for the comparison of cilostazol vs. pentoxifylline </text>
<text top="104" left="635" width="135" height="17" font="0">found no change in ABI. </text>
<text top="122" left="95" width="84" height="17" font="0">Dawson DL, et </text>
<text top="139" left="95" width="16" height="17" font="0">al. </text>
<text top="157" left="95" width="63" height="17" font="0">2000 (174) </text>
<text top="174" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11063952">11063952</a></text>
<text top="174" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11063952"> </a></text>
<text top="191" left="95" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="107" height="17" font="2"><b>Aim: </b>To determine </text>
<text top="139" left="203" width="113" height="17" font="0">evaluate the relative </text>
<text top="157" left="203" width="119" height="17" font="0">efficacy and safety of </text>
<text top="174" left="203" width="78" height="17" font="0">cilostazol and </text>
<text top="191" left="203" width="78" height="17" font="0">pentoxifylline. </text>
<text top="208" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="226" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="243" left="203" width="117" height="17" font="0">Randomized, double-</text>
<text top="260" left="203" width="80" height="17" font="0">blind, placebo-</text>
<text top="277" left="203" width="124" height="17" font="0">controlled, multicenter </text>
<text top="294" left="203" width="27" height="17" font="0">trial. </text>
<text top="312" left="203" width="3" height="17" font="0"> </text>
<text top="329" left="203" width="90" height="17" font="2"><b>Size:</b> n=698 pts<b> </b></text>
<text top="122" left="344" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="140" left="344" width="7" height="18" font="7"></text>
<text top="141" left="351" width="74" height="17" font="0"> Moderate-to-</text>
<text top="158" left="344" width="112" height="17" font="0">severe claudication  </text>
<text top="175" left="344" width="7" height="18" font="7"></text>
<text top="176" left="351" width="106" height="17" font="0"> Baseline pain-free </text>
<text top="194" left="344" width="94" height="17" font="0">walking distance </text>
<text top="211" left="344" width="49" height="17" font="0">≥53.6 m </text>
<text top="228" left="344" width="7" height="18" font="7"></text>
<text top="229" left="351" width="103" height="17" font="0"> Baseline maximal </text>
<text top="246" left="344" width="94" height="17" font="0">walking distance </text>
<text top="264" left="344" width="56" height="17" font="0">≤537.6 m </text>
<text top="281" left="344" width="3" height="17" font="0"> </text>
<text top="298" left="344" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="315" left="344" width="7" height="18" font="7"></text>
<text top="316" left="351" width="105" height="17" font="0"> Buerger’s disease </text>
<text top="334" left="344" width="7" height="18" font="7"></text>
<text top="335" left="351" width="90" height="17" font="0"> Critial ischemia </text>
<text top="352" left="344" width="93" height="17" font="0">(category II or III </text>
<text top="369" left="344" width="76" height="17" font="0">chronis lower </text>
<text top="386" left="344" width="109" height="17" font="0">extremity ischemia) </text>
<text top="404" left="344" width="7" height="18" font="7"></text>
<text top="405" left="351" width="94" height="17" font="0"> Lower extremity </text>
<text top="422" left="344" width="41" height="17" font="0">arterial </text>
<text top="439" left="344" width="81" height="17" font="0">reconstruction </text>
<text top="456" left="344" width="64" height="17" font="0">(surgical or </text>
<text top="474" left="344" width="95" height="17" font="0">endovascular) or </text>
<text top="491" left="344" width="89" height="17" font="0">sympathectomy </text>
<text top="508" left="344" width="66" height="17" font="0">within 3 mo </text>
<text top="525" left="344" width="7" height="18" font="7"></text>
<text top="526" left="351" width="70" height="17" font="0"> Prior use of </text>
<text top="544" left="344" width="58" height="17" font="0">cilostrazol </text>
<text top="561" left="344" width="3" height="17" font="0"> </text>
<text top="122" left="473" width="116" height="17" font="2"><b>Study intervention:</b> </text>
<text top="139" left="473" width="144" height="17" font="0">Pentoxifylline or cilostazol </text>
<text top="157" left="473" width="3" height="17" font="0"> </text>
<text top="174" left="473" width="125" height="17" font="2"><b>Comparator:</b> Placebo </text>
<text top="122" left="635" width="269" height="17" font="2"><b>Primary endpoint: </b>Walking ability, measured by </text>
<text top="139" left="635" width="41" height="17" font="0">MWD. <b> </b></text>
<text top="157" left="635" width="7" height="18" font="7"></text>
<text top="158" left="641" width="280" height="17" font="0"> Cilostazol treatment resulted in greater MWD than </text>
<text top="175" left="635" width="285" height="17" font="0">both pentoxifylline and placebo at 24 wk (p&lt;0.001).  </text>
<text top="192" left="635" width="7" height="18" font="7"></text>
<text top="193" left="641" width="212" height="17" font="0"> Pentoxifylline treatment resulted in no </text>
<text top="211" left="635" width="240" height="17" font="0">improvement in MWD compared to placebo </text>
<text top="228" left="635" width="3" height="17" font="0"> </text>
<text top="245" left="635" width="286" height="17" font="2"><b>Secondary endpoints: </b> PFWD and resting Doppler </text>
<text top="262" left="635" width="83" height="17" font="0">limb pressures </text>
<text top="280" left="635" width="7" height="18" font="7"></text>
<text top="281" left="641" width="212" height="17" font="0"> At wk 4 and after, there was a greater </text>
<text top="298" left="635" width="289" height="17" font="0">improvement in PFWD with cilostazol treatment than </text>
<text top="315" left="635" width="96" height="17" font="0">placebo (p&lt;0.01) </text>
<text top="332" left="635" width="7" height="18" font="7"></text>
<text top="333" left="641" width="217" height="17" font="0"> There was no difference in PFWD with </text>
<text top="351" left="635" width="260" height="17" font="0">pentoxifylline treatment compared with placebo </text>
<text top="368" left="635" width="53" height="17" font="0">(p&lt;0.05). </text>
<text top="122" left="938" width="7" height="18" font="7"></text>
<text top="123" left="945" width="136" height="17" font="0"> Withdrawal rates due to </text>
<text top="141" left="938" width="156" height="17" font="0">adverse effects were similar </text>
<text top="158" left="938" width="152" height="17" font="0">among the cilostazol (16%) </text>
<text top="175" left="938" width="119" height="17" font="0">and the pentoxifylline </text>
<text top="192" left="938" width="98" height="17" font="0">treatments (19%) </text>
<text top="210" left="938" width="7" height="18" font="7"></text>
<text top="211" left="945" width="159" height="17" font="0"> Adverse events were higher </text>
<text top="228" left="938" width="166" height="17" font="0">in the active treatment groups </text>
<text top="245" left="938" width="137" height="17" font="0">than in placebo (27% for </text>
<text top="262" left="938" width="103" height="17" font="0">cilostazol; 26% for </text>
<text top="280" left="938" width="124" height="17" font="0">pentoxifylline; 16% for </text>
<text top="297" left="938" width="102" height="17" font="0">placebo; p=0.006) </text>
<text top="314" left="938" width="7" height="18" font="7"></text>
<text top="315" left="945" width="136" height="17" font="0"> Overall results have not </text>
<text top="332" left="938" width="152" height="17" font="0">shown clear evidence of an </text>
<text top="350" left="938" width="132" height="17" font="0">improvement in walking </text>
<text top="367" left="938" width="98" height="17" font="0">performance with </text>
<text top="384" left="938" width="133" height="17" font="0">pentoxifylline treatment. </text>
<text top="579" left="95" width="79" height="17" font="0">Goldenberger </text>
<text top="596" left="95" width="54" height="17" font="0">NA, et al. </text>
<text top="613" left="95" width="63" height="17" font="0">2012 (175) </text>
<text top="630" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22615190">22615190 </a></text>
<text top="648" left="95" width="3" height="17" font="0"> </text>
<text top="579" left="203" width="111" height="17" font="2"><b>Aim: </b>To investigate </text>
<text top="596" left="203" width="122" height="17" font="0">the effect of cilostazol </text>
<text top="613" left="203" width="86" height="17" font="0">+ l-carnitine vs. </text>
<text top="630" left="203" width="105" height="17" font="0">cilostazol alone on </text>
<text top="648" left="203" width="122" height="17" font="0">treadmill performance </text>
<text top="665" left="203" width="36" height="17" font="0">in IC.  </text>
<text top="682" left="203" width="3" height="17" font="0"> </text>
<text top="699" left="203" width="66" height="17" font="2"><b>Secondary</b> </text>
<text top="716" left="203" width="86" height="17" font="2"><b>objectives:</b> To </text>
<text top="734" left="203" width="77" height="17" font="0">evaluate QoL </text>
<text top="751" left="203" width="118" height="17" font="0">measures and safety </text>
<text top="768" left="203" width="116" height="17" font="0">indices with the drug </text>
<text top="579" left="344" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="596" left="344" width="110" height="17" font="0">PAD pts with stable </text>
<text top="613" left="344" width="113" height="17" font="0">IC were randomized </text>
<text top="630" left="344" width="115" height="17" font="0">to either l-carnitine 1 </text>
<text top="648" left="344" width="78" height="17" font="0">g or matching </text>
<text top="665" left="344" width="104" height="17" font="0">placebo 2x/d, on a </text>
<text top="682" left="344" width="81" height="17" font="0">background of </text>
<text top="699" left="344" width="61" height="17" font="0">cilostazol.  </text>
<text top="579" left="473" width="146" height="17" font="0">145 pts met criteria for the </text>
<text top="596" left="473" width="140" height="17" font="0">mITT population and 120 </text>
<text top="613" left="473" width="127" height="17" font="0">pts for the per-protocol </text>
<text top="630" left="473" width="92" height="17" font="0">population. 74 L-</text>
<text top="648" left="473" width="117" height="17" font="0">carnitine/71 placebo. </text>
<text top="579" left="635" width="280" height="17" font="0">In the mITT (n=145), the mean ln<i> </i>ratio in PWT was </text>
<text top="596" left="635" width="234" height="17" font="0">0.241 for cilostazol/l-carnitine vs. 0.134 for </text>
<text top="613" left="635" width="290" height="17" font="0">cilostazol/placebo (p=0.076), corresponding to mean </text>
<text top="630" left="635" width="281" height="17" font="0">increases of 1.99 and 1.36 min, respectively. In the </text>
<text top="648" left="635" width="287" height="17" font="0">per-protocol population (n=120), the mean <i>ln </i>ratio in </text>
<text top="665" left="635" width="290" height="17" font="0">PWT was 0.267 for cilostazol/l-carnitine vs. 0.145 for </text>
<text top="682" left="635" width="164" height="17" font="0">cilostazol/placebo (p=0.048).  </text>
<text top="579" left="938" width="157" height="17" font="0">The per-protocol population, </text>
<text top="596" left="938" width="164" height="17" font="0">the mean <i>ln </i>ratio in PWT was </text>
<text top="613" left="938" width="157" height="17" font="0">significantly increased in the </text>
<text top="630" left="938" width="165" height="17" font="0">cilostazol/l-carnitine group vs. </text>
<text top="648" left="938" width="156" height="17" font="0">the cilostazol/placebo group </text>
<text top="665" left="938" width="167" height="17" font="0">(0.267 vs. 0.145, respectively; </text>
<text top="682" left="938" width="169" height="17" font="0">p=0.048). This represented an </text>
<text top="699" left="938" width="154" height="17" font="0">arithmetic mean increase in </text>
<text top="716" left="938" width="160" height="17" font="0">PWT of 39.2% from baseline </text>
<text top="734" left="938" width="126" height="17" font="0">to d 180 for cilostazol/l-</text>
<text top="751" left="938" width="142" height="17" font="0">carnitine, as compared to </text>
<text top="768" left="938" width="160" height="17" font="0">21.5% for cilostazol/placebo. </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">76 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="77" height="17" font="0">combination.  </text>
<text top="104" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="203" width="82" height="17" font="2"><b>Study type: </b>A </text>
<text top="139" left="203" width="67" height="17" font="0">multicenter, </text>
<text top="156" left="203" width="112" height="17" font="0">randomized, double-</text>
<text top="173" left="203" width="80" height="17" font="0">blind, placebo-</text>
<text top="190" left="203" width="80" height="17" font="0">controlled trial </text>
<text top="208" left="203" width="3" height="17" font="0"> </text>
<text top="225" left="203" width="90" height="17" font="2"><b>Size: </b>n=164 pts </text>
<text top="87" left="938" width="145" height="17" font="0">In the cilostazol/l-carnitine </text>
<text top="104" left="938" width="156" height="17" font="0">group, the mean increase in </text>
<text top="122" left="938" width="148" height="17" font="0">physical functioning on the </text>
<text top="139" left="938" width="138" height="17" font="0">SF-36v2 was also nearly </text>
<text top="156" left="938" width="98" height="17" font="0">double that of the </text>
<text top="173" left="938" width="167" height="17" font="0">cilostazol/placebo group (6.77 </text>
<text top="190" left="938" width="146" height="17" font="0">[16.379] vs. 3.73 [17.566], </text>
<text top="208" left="938" width="128" height="17" font="0">respectively; p=0.066). </text>
<text top="243" left="95" width="79" height="17" font="0">Warner CJ, et </text>
<text top="260" left="95" width="16" height="17" font="0">al. </text>
<text top="277" left="95" width="63" height="17" font="0">2014 (176) </text>
<text top="294" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24468286">24468286 </a></text>
<text top="312" left="95" width="3" height="17" font="0"> </text>
<text top="243" left="203" width="124" height="17" font="2"><b>Aim:</b> MEDLINE (1946-</text>
<text top="260" left="203" width="119" height="17" font="0">2012), and Cochrane </text>
<text top="277" left="203" width="96" height="17" font="0">CENTRAL (1996-</text>
<text top="294" left="203" width="86" height="17" font="0">2012), and trial </text>
<text top="312" left="203" width="125" height="17" font="0">registries searched for </text>
<text top="329" left="203" width="103" height="17" font="0">studies comparing </text>
<text top="346" left="203" width="67" height="17" font="0">cilostazol in </text>
<text top="363" left="203" width="95" height="17" font="0">combination with </text>
<text top="381" left="203" width="121" height="17" font="0">antiplatelet therapy to </text>
<text top="398" left="203" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="415" left="203" width="88" height="17" font="0">alone after PVI. </text>
<text top="432" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="449" left="203" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="467" left="203" width="55" height="17" font="0">analysis:  </text>
<text top="484" left="203" width="3" height="17" font="0"> </text>
<text top="501" left="203" width="100" height="17" font="2"><b>Size:</b> n=1,522 pts </text>
<text top="243" left="344" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="260" left="344" width="7" height="18" font="7"></text>
<text top="261" left="351" width="90" height="17" font="0"> Pts undergoing </text>
<text top="278" left="344" width="77" height="17" font="0">endovascular </text>
<text top="296" left="344" width="55" height="17" font="0">treatment </text>
<text top="313" left="344" width="84" height="17" font="0">(angioplasty or </text>
<text top="330" left="344" width="68" height="17" font="0">stenting) for </text>
<text top="347" left="344" width="88" height="17" font="0">infrainguinal LE </text>
<text top="365" left="344" width="32" height="17" font="0">PVD. </text>
<text top="382" left="344" width="7" height="18" font="7"></text>
<text top="383" left="351" width="95" height="17" font="0"> The intervention </text>
<text top="400" left="344" width="114" height="17" font="0">must be cilostazol in </text>
<text top="417" left="344" width="103" height="17" font="0">the periprocedural </text>
<text top="434" left="344" width="43" height="17" font="0">setting. </text>
<text top="452" left="344" width="7" height="18" font="7"></text>
<text top="453" left="351" width="95" height="17" font="0"> The comparison </text>
<text top="470" left="344" width="96" height="17" font="0">group may be no </text>
<text top="487" left="344" width="74" height="17" font="0">cilostazol, an </text>
<text top="504" left="344" width="63" height="17" font="0">antiplatelet </text>
<text top="522" left="344" width="81" height="17" font="0">medication, or </text>
<text top="539" left="344" width="50" height="17" font="0">placebo. </text>
<text top="556" left="344" width="7" height="18" font="7"></text>
<text top="557" left="351" width="95" height="17" font="0"> ≥6 mo follow-up </text>
<text top="575" left="344" width="7" height="18" font="7"></text>
<text top="576" left="351" width="61" height="17" font="0"> The study </text>
<text top="593" left="344" width="103" height="17" font="0">reported at ≥1 pre-</text>
<text top="610" left="344" width="103" height="17" font="0">specified outcome </text>
<text top="627" left="344" width="57" height="17" font="0">of interest </text>
<text top="645" left="344" width="67" height="17" font="0">(restenosis, </text>
<text top="662" left="344" width="77" height="17" font="0">freedom from </text>
<text top="679" left="344" width="68" height="17" font="0">amputation, </text>
<text top="696" left="344" width="57" height="17" font="0">mortality). </text>
<text top="243" left="473" width="79" height="17" font="0">2 RCTs and 4 </text>
<text top="260" left="473" width="142" height="17" font="0">retrospective cohorts met </text>
<text top="277" left="473" width="149" height="17" font="0">inclusion criteria. 1,522 pts </text>
<text top="294" left="473" width="125" height="17" font="0">included in the review. </text>
<text top="312" left="473" width="124" height="17" font="0">A majority (87%) were </text>
<text top="329" left="473" width="140" height="17" font="0">from retrospective cohort </text>
<text top="346" left="473" width="49" height="17" font="0">studies.  </text>
<text top="363" left="473" width="90" height="17" font="0">All studies were </text>
<text top="381" left="473" width="134" height="17" font="0">conducted in Japan and </text>
<text top="398" left="473" width="140" height="17" font="0">published between 2008–</text>
<text top="415" left="473" width="38" height="17" font="0">2012.  </text>
<text top="432" left="473" width="129" height="17" font="0">All compared cilostazol </text>
<text top="449" left="473" width="131" height="17" font="0">with either no cilostazol </text>
<text top="467" left="473" width="124" height="17" font="0">(n=4) or an alternative </text>
<text top="484" left="473" width="126" height="17" font="0">antiplatelet medication </text>
<text top="501" left="473" width="130" height="17" font="0">(n=2), with both groups </text>
<text top="518" left="473" width="113" height="17" font="0">receiving various co-</text>
<text top="535" left="473" width="145" height="17" font="0">interventions (ASA with or </text>
<text top="553" left="473" width="103" height="17" font="0">without an adjunct </text>
<text top="570" left="473" width="133" height="17" font="0">antiplatelet medication). </text>
<text top="243" left="635" width="252" height="17" font="0">The addition of cilostazol was associated with </text>
<text top="260" left="635" width="289" height="17" font="0">decreased restenosis (RR: 0.71; 95% CI: 0.60–0.84; </text>
<text top="277" left="635" width="273" height="17" font="0">p&lt;0.001), improved amputation-free survival (HR: </text>
<text top="294" left="635" width="275" height="17" font="0">0.63; 95% CI: 0.47–0.85; p=0.002), improved limb </text>
<text top="312" left="635" width="270" height="17" font="0">salvage (HR: 0.42; 95% CI: 0.27–0.66; p&lt;0.001), </text>
<text top="329" left="635" width="225" height="17" font="0">and improved freedom from target lesion </text>
<text top="346" left="635" width="264" height="17" font="0">revascularization (RR: 1.36; 95% CI: 1.14–1.61; </text>
<text top="363" left="635" width="56" height="17" font="0">p&lt;0.001). </text>
<text top="243" left="938" width="136" height="17" font="0">There was no significant </text>
<text top="260" left="938" width="158" height="17" font="0">reduction in mortality among </text>
<text top="277" left="938" width="169" height="17" font="0">those receiving cilostazol (RR: </text>
<text top="294" left="938" width="140" height="17" font="0">0.73; 95% CI: 0.45–1.19; </text>
<text top="312" left="938" width="49" height="17" font="0">p=0.21). </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">77 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="53" height="17" font="2"><b>STOP-IC</b> </text>
<text top="104" left="95" width="70" height="17" font="0">Iida O, et al. </text>
<text top="122" left="95" width="63" height="17" font="0">2013 (177) </text>
<text top="139" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23652861">23652861 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="123" height="17" font="2"><b>Aim:</b> To determine by </text>
<text top="104" left="203" width="127" height="17" font="0">angiographic follow-up </text>
<text top="122" left="203" width="128" height="17" font="0">whether treatment with </text>
<text top="139" left="203" width="101" height="17" font="0">cilostazol reduces </text>
<text top="156" left="203" width="111" height="17" font="0">restenosis at 12 mo </text>
<text top="173" left="203" width="81" height="17" font="0">after PTA with </text>
<text top="190" left="203" width="98" height="17" font="0">provisional nitinol </text>
<text top="208" left="203" width="64" height="17" font="0">stenting for </text>
<text top="225" left="203" width="87" height="17" font="0">femoropopliteal </text>
<text top="242" left="203" width="46" height="17" font="0">disease </text>
<text top="259" left="203" width="3" height="17" font="0"> </text>
<text top="276" left="203" width="70" height="17" font="2"><b>Study type: </b></text>
<text top="294" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="311" left="203" width="123" height="17" font="2"><b>Size: </b>n=152 pts: 75 in </text>
<text top="328" left="203" width="118" height="17" font="0">cilostazol/77 placebo </text>
<text top="87" left="344" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="104" left="344" width="94" height="17" font="0">Within 1 wk after </text>
<text top="122" left="344" width="114" height="17" font="0">randomization, each </text>
<text top="139" left="344" width="114" height="17" font="0">pt was admitted and </text>
<text top="156" left="344" width="114" height="17" font="0">underwent PTA with </text>
<text top="173" left="344" width="98" height="17" font="0">provisional nitinol </text>
<text top="190" left="344" width="50" height="17" font="0">stenting. </text>
<text top="87" left="473" width="146" height="17" font="2"><b>Study intervention:</b> 75 in </text>
<text top="104" left="473" width="54" height="17" font="0">cilostazol </text>
<text top="122" left="473" width="3" height="17" font="0"> </text>
<text top="139" left="473" width="130" height="17" font="2"><b>Study comparator:</b> 77 </text>
<text top="156" left="473" width="47" height="17" font="0">placebo </text>
<text top="87" left="635" width="277" height="17" font="2"><b>Results: </b>During the12 mo follow-up period, 11 pts </text>
<text top="104" left="635" width="284" height="17" font="0">died and 152 pts (80%) had evaluable angiographic </text>
<text top="122" left="635" width="278" height="17" font="0">data at 12 mo. The angiographic restenosis rate at </text>
<text top="139" left="635" width="275" height="17" font="0">12 mo was 20% (15/75) in the cilostazol group vs. </text>
<text top="156" left="635" width="277" height="17" font="0">49% (38/77) in the noncilostazol group (p=0.0001) </text>
<text top="173" left="635" width="93" height="17" font="0">by ITT analysis.  </text>
<text top="87" left="938" width="163" height="17" font="0">The cilostazol group also had </text>
<text top="104" left="938" width="149" height="17" font="0">a significantly higher event-</text>
<text top="122" left="938" width="153" height="17" font="0">free survival at 12 mo (83% </text>
<text top="139" left="938" width="150" height="17" font="0">vs. 71%, p=0.02), although </text>
<text top="156" left="938" width="147" height="17" font="0">cardiovascular event rates </text>
<text top="173" left="938" width="154" height="17" font="0">were similar in both groups. </text>
<text top="346" left="86" width="981" height="17" font="0">ABI indicates ankle-brachial index; ACD, absolute claudication distance; CI, confidence interval; HR, hazard ratio; IC, intermittent claudication; ICD, initial claudication distance; ITT, </text>
<text top="363" left="86" width="1015" height="17" font="0">intent-to-treat; LE, lower extremity; mITT, modified intent-to-treat; MWD, maximal walking distance; PAD, peripheral artery disease; PFWD, pain free walking distance; PTA, percutaneous </text>
<text top="381" left="86" width="916" height="17" font="0">transluminal angioplasty; PVD, peripheral vascular disease; PVI, peripheral vascular intervention; PWT, peak walking time; RCT, randomized controlled trial; and PTFE, </text>
<text top="398" left="86" width="782" height="17" font="0">polytetrafluoroethylene; pt, patient; QoL, quality of life; RCT, randomized controlled trial; RR, relative risk; and WMD, walking maximal distance. </text>
<text top="415" left="86" width="3" height="17" font="0"> </text>
<text top="432" left="86" width="3" height="17" font="0"> </text>
<text top="449" left="86" width="797" height="21" font="1"><b>Evidence Table 26. Nonrandomized Trials, Observational Studies, and/or Registries of Pentoxifylline–Section 5.8. </b></text>
<text top="471" left="123" width="38" height="17" font="2"><b>Study </b></text>
<text top="488" left="112" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="505" left="118" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="522" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="471" left="215" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="488" left="220" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="505" left="214" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="471" left="356" width="45" height="17" font="2"><b>Patient </b></text>
<text top="488" left="345" width="67" height="17" font="2"><b>Population </b></text>
<text top="471" left="450" width="191" height="17" font="2"><b>Study Intervention (# patients) /  </b></text>
<text top="488" left="454" width="180" height="17" font="2"><b>Study Comparator (# patients) </b></text>
<text top="471" left="755" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="488" left="675" width="267" height="17" font="2"><b>(Absolute Event Rates, P value; OR or RR; &amp;  </b></text>
<text top="505" left="783" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="472" left="976" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="471" left="1038" width="6" height="18" font="7"></text>
<text top="472" left="1044" width="60" height="17" font="2"><b> Endpoint </b></text>
<text top="489" left="1016" width="48" height="17" font="2"><b>(if any); </b></text>
<text top="506" left="985" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="524" left="992" width="96" height="17" font="2"><b>Adverse Events </b></text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">78 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="85" height="17" font="0">Salhiyyah K, et </text>
<text top="104" left="95" width="16" height="17" font="0">al. </text>
<text top="122" left="95" width="63" height="17" font="0">2015 (178) </text>
<text top="139" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22258961">22258961</a></text>
<text top="140" left="149" width="7" height="16" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22258961">  </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="107" height="17" font="2"><b>Aim: </b>To determine </text>
<text top="104" left="203" width="79" height="17" font="0">the efficacy of </text>
<text top="122" left="203" width="87" height="17" font="0">pentoxifylline in </text>
<text top="139" left="203" width="77" height="17" font="0">improving the </text>
<text top="156" left="203" width="107" height="17" font="0">walking capacity of </text>
<text top="173" left="203" width="101" height="17" font="0">pts with stable IC<b>  </b></text>
<text top="190" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="208" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="225" left="203" width="96" height="17" font="0">Cochrane review </text>
<text top="242" left="203" width="3" height="17" font="0"> </text>
<text top="259" left="203" width="106" height="17" font="2"><b>Size:</b> n=24 studies </text>
<text top="276" left="203" width="79" height="17" font="0">with 3,377 pts </text>
<text top="294" left="203" width="103" height="17" font="0">(Current until April </text>
<text top="311" left="203" width="35" height="17" font="0">2015) </text>
<text top="87" left="324" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="104" left="324" width="7" height="18" font="7"></text>
<text top="105" left="331" width="75" height="17" font="0"> Double blind </text>
<text top="123" left="324" width="96" height="17" font="0">RCTs comparing </text>
<text top="140" left="324" width="94" height="17" font="0">pentoxifylline vs. </text>
<text top="157" left="324" width="84" height="17" font="0">placebo or any </text>
<text top="174" left="324" width="31" height="17" font="0">other </text>
<text top="192" left="324" width="93" height="17" font="0">pharmacological </text>
<text top="209" left="324" width="67" height="17" font="0">intervention </text>
<text top="226" left="324" width="7" height="18" font="7"></text>
<text top="227" left="331" width="79" height="17" font="0"> Symptoms of </text>
<text top="244" left="324" width="52" height="17" font="0">stable IC </text>
<text top="262" left="324" width="7" height="18" font="7"></text>
<text top="263" left="331" width="98" height="17" font="0"> Fontaine stage II </text>
<text top="280" left="324" width="66" height="17" font="0">due to PAD </text>
<text top="297" left="324" width="3" height="17" font="0"> </text>
<text top="314" left="324" width="62" height="17" font="2"><b>Exclusion </b></text>
<text top="332" left="324" width="95" height="17" font="2"><b>criteria: </b>Pts with </text>
<text top="349" left="324" width="105" height="17" font="0">critical ischemia or </text>
<text top="366" left="324" width="83" height="17" font="0">had previously </text>
<text top="383" left="324" width="108" height="17" font="0">undergone surgical </text>
<text top="401" left="324" width="92" height="17" font="0">or percutaneous </text>
<text top="418" left="324" width="65" height="17" font="0">procedures </text>
<text top="87" left="446" width="7" height="18" font="7"></text>
<text top="88" left="452" width="121" height="17" font="0"> 17 studies compared </text>
<text top="106" left="446" width="146" height="17" font="0">pentoxifylline with placebo </text>
<text top="123" left="446" width="7" height="18" font="7"></text>
<text top="124" left="452" width="179" height="17" font="0"> 1 study compared pentoxifylline </text>
<text top="141" left="446" width="85" height="17" font="0">with flunarizine </text>
<text top="158" left="446" width="7" height="18" font="7"></text>
<text top="159" left="452" width="179" height="17" font="0"> 1 study compared pentoxifylline </text>
<text top="177" left="446" width="65" height="17" font="0">with aspirin </text>
<text top="194" left="446" width="7" height="18" font="7"></text>
<text top="195" left="452" width="179" height="17" font="0"> 1 study compared pentoxifylline </text>
<text top="212" left="446" width="55" height="17" font="0">with GBE </text>
<text top="230" left="446" width="7" height="18" font="7"></text>
<text top="231" left="452" width="179" height="17" font="0"> 1 study compared pentoxifylline </text>
<text top="248" left="446" width="148" height="17" font="0">with nylidrin hydrochloride  </text>
<text top="265" left="446" width="7" height="18" font="7"></text>
<text top="266" left="452" width="189" height="17" font="0"> 2 studies compared pentoxifylline </text>
<text top="284" left="446" width="62" height="17" font="0">with PGE1 </text>
<text top="301" left="446" width="7" height="18" font="7"></text>
<text top="302" left="452" width="179" height="17" font="0"> 1 study compared pentoxifylline </text>
<text top="319" left="446" width="81" height="17" font="0">with nifedipine </text>
<text top="336" left="446" width="7" height="18" font="7"></text>
<text top="337" left="452" width="189" height="17" font="0"> 2 studies compared pentoxifylline </text>
<text top="355" left="446" width="150" height="17" font="0">with cilostazol and placebo </text>
<text top="372" left="446" width="7" height="18" font="7"></text>
<text top="373" left="452" width="179" height="17" font="0"> 1 study compared pentoxifylline </text>
<text top="390" left="446" width="139" height="17" font="0">with iloprost and placebo </text>
<text top="87" left="655" width="297" height="17" font="0">The difference in percentage improvement in TWD for </text>
<text top="104" left="655" width="302" height="17" font="0">pentoxifylline over placebo ranged from 1.2%–155.9%, </text>
<text top="122" left="655" width="282" height="17" font="0">and for PFWD the difference ranged from -33.8% – </text>
<text top="139" left="655" width="265" height="17" font="0">73.9%Testing for statistical significance of these </text>
<text top="156" left="655" width="284" height="17" font="0">results was generally not possible due to the lack of </text>
<text top="173" left="655" width="34" height="17" font="0">data.  </text>
<text top="87" left="972" width="7" height="18" font="7"></text>
<text top="88" left="979" width="81" height="17" font="2"><b> </b>There was no </text>
<text top="106" left="972" width="121" height="17" font="0">statistically significant </text>
<text top="123" left="972" width="94" height="17" font="0">difference in ABI </text>
<text top="140" left="972" width="70" height="17" font="0">between the </text>
<text top="157" left="972" width="98" height="17" font="0">pentoxifylline and </text>
<text top="174" left="972" width="94" height="17" font="0">placebo groups.  </text>
<text top="192" left="972" width="7" height="18" font="7"></text>
<text top="193" left="979" width="105" height="17" font="2"><b> </b>Pentoxifylline was </text>
<text top="210" left="972" width="133" height="17" font="0">generally well tolerated. </text>
<text top="408" left="446" width="191" height="17" font="2"><b>Study intervention:</b> Pentoxifylline </text>
<text top="425" left="446" width="3" height="17" font="0"> </text>
<text top="443" left="446" width="125" height="17" font="2"><b>Comparator:</b> Placebo </text>
<text top="408" left="655" width="7" height="18" font="7"></text>
<text top="409" left="662" width="282" height="17" font="2"><b> </b>Large variability in results. Unable to perform meta-</text>
<text top="427" left="655" width="173" height="17" font="0">analysis because of variability.  </text>
<text top="444" left="655" width="7" height="18" font="7"></text>
<text top="445" left="662" width="227" height="17" font="2"><b> </b>PFWD (11 studies): -33.8%– 73.9% with </text>
<text top="462" left="655" width="75" height="17" font="0">pentoxifylline </text>
<text top="479" left="655" width="7" height="18" font="7"></text>
<text top="480" left="662" width="275" height="17" font="2"><b> </b>TWD (14 studies): 1%–155.9% with pentoxifylline </text>
<text top="498" left="655" width="7" height="18" font="7"></text>
<text top="499" left="662" width="260" height="17" font="2"><b> </b>QoL – SF-36 (3 studies): 2 studies showed not </text>
<text top="516" left="655" width="232" height="17" font="0">difference, one study showed a significant </text>
<text top="533" left="655" width="118" height="17" font="0">improvement in QoL. </text>
<text top="408" left="972" width="24" height="17" font="0">N/A<b> </b></text>
<text top="551" left="446" width="191" height="17" font="2"><b>Study intervention:</b> Pentoxifylline </text>
<text top="569" left="446" width="3" height="17" font="0"> </text>
<text top="586" left="446" width="154" height="17" font="2"><b>Comparator</b>: Active agents </text>
<text top="551" left="655" width="7" height="18" font="7"></text>
<text top="552" left="662" width="297" height="17" font="2"><b> </b>Pentoxifylline showed a larger improvement in PFWD </text>
<text top="570" left="655" width="274" height="17" font="0">when compared with GBE (1 study), buflomedil (1 </text>
<text top="587" left="655" width="159" height="17" font="0">study) and iloprost (1 study). </text>
<text top="604" left="655" width="7" height="18" font="7"></text>
<text top="605" left="662" width="232" height="17" font="2"><b> </b>Cilostazol (2 studies) and PGE1 (2 study) </text>
<text top="622" left="655" width="301" height="17" font="0">showed a larger improvement in PFWD compared with </text>
<text top="640" left="655" width="78" height="17" font="0">pentoxifylline. </text>
<text top="657" left="655" width="7" height="18" font="7"></text>
<text top="658" left="662" width="258" height="17" font="2"><b> </b>For TWD a larger improvement was shown for </text>
<text top="675" left="655" width="286" height="17" font="0">Pentoxifylline showed a larger improvement in TWD </text>
<text top="692" left="655" width="247" height="17" font="0">when compared with nylidrin, GBE and ASA. </text>
<text top="710" left="655" width="261" height="17" font="0">Cilostazol, PGE1 and flunarizine showed larger </text>
<text top="727" left="655" width="286" height="17" font="0">improvements in TWD compared with pentoxifylline. </text>
<text top="744" left="655" width="7" height="18" font="7"></text>
<text top="745" left="662" width="284" height="17" font="2"><b> </b>Pentoxifylline appeared to be well tolerated in most </text>
<text top="551" left="972" width="24" height="17" font="0">N/A<b> </b></text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="22" size="13" family="Times" color="#454545"/>
<text top="795" left="1088" width="17" height="17" font="0">79 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="1004" height="17" font="0">ABI indicates ankle-brachial index; GBE, ginkgo biloba extract; IC, intermittent claudication; PAD, peripheral artery disease; PFWD, pain free walking distance; PGE1, prostaglandin E1; </text>
<text top="104" left="86" width="349" height="17" font="0">pt, patient; QoL, quality of life; and TWD, total walking distance. </text>
<text top="104" left="435" width="3" height="17" font="9"> </text>
<text top="121" left="86" width="3" height="17" font="2"><b> </b></text>
<text top="138" left="86" width="514" height="21" font="1"><b>Evidence Table 27. Systematic Review of Chelation Therapy–Section 5.9. </b></text>
<text top="159" left="99" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="177" left="124" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="194" left="102" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="159" left="233" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="177" left="237" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="194" left="231" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="159" left="397" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="159" left="587" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="177" left="605" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="194" left="588" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="211" left="609" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="159" left="747" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="177" left="731" width="138" height="17" font="2"><b>(Absolute Event Rates, </b></text>
<text top="194" left="737" width="129" height="17" font="2"><b>P value; OR or RR; &amp;  </b></text>
<text top="211" left="776" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="161" left="908" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="160" left="970" width="6" height="18" font="7"></text>
<text top="161" left="976" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="178" left="941" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="195" left="948" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="229" left="95" width="103" height="17" font="0">Villarruz MV, et al. </text>
<text top="246" left="95" width="59" height="17" font="0">2008(179) </text>
<text top="263" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12519577">12519577</a></text>
<text top="263" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12519577"> </a></text>
<text top="281" left="95" width="3" height="17" font="0"> </text>
<text top="229" left="214" width="111" height="17" font="2"><b>Aim:</b> To assess the </text>
<text top="246" left="214" width="90" height="17" font="0">effects of EDTA </text>
<text top="263" left="214" width="110" height="17" font="0">chelation on clinical </text>
<text top="281" left="214" width="98" height="17" font="0">outcomes among </text>
<text top="298" left="214" width="66" height="17" font="0">people with </text>
<text top="315" left="214" width="104" height="17" font="0">atherosclerotic CV </text>
<text top="332" left="214" width="49" height="17" font="0">disease: </text>
<text top="350" left="214" width="3" height="17" font="0"> </text>
<text top="367" left="214" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="384" left="214" width="103" height="17" font="0">Systematic review </text>
<text top="229" left="347" width="185" height="17" font="2"><b>Inclusion criteria:</b> Pts with PVD, </text>
<text top="246" left="347" width="137" height="17" font="0">particularly those with IC </text>
<text top="229" left="572" width="79" height="17" font="0">7 publications </text>
<text top="246" left="572" width="118" height="17" font="0">representing 5 trials.  </text>
<text top="229" left="728" width="7" height="18" font="7"></text>
<text top="230" left="735" width="136" height="17" font="0"> WMD in ABI: 0.01; 95% </text>
<text top="247" left="728" width="92" height="17" font="0">CI: -0.03 – 0.06. </text>
<text top="265" left="728" width="7" height="18" font="7"></text>
<text top="266" left="735" width="100" height="17" font="0"> WMD for walking </text>
<text top="283" left="728" width="142" height="17" font="0">distance: -37.93; 95% CI: </text>
<text top="300" left="728" width="76" height="17" font="0">-90.32 – 0.06 </text>
<text top="317" left="728" width="7" height="18" font="7"></text>
<text top="319" left="735" width="122" height="17" font="0"> WMD for PFWD post-</text>
<text top="336" left="728" width="141" height="17" font="0">treatment: -7.73; 95% CI: </text>
<text top="353" left="728" width="76" height="17" font="0">-22.59 – 7.13 </text>
<text top="229" left="884" width="7" height="18" font="7"></text>
<text top="230" left="891" width="197" height="17" font="0"> Side effects: Faintness: RR: 11.44; </text>
<text top="247" left="884" width="112" height="17" font="0">95% CI: 1.51–86.45 </text>
<text top="265" left="884" width="7" height="18" font="7"></text>
<text top="266" left="891" width="207" height="17" font="0"> Gastrointestinal symptoms RR: 1.63; </text>
<text top="283" left="884" width="105" height="17" font="0">95% CI: 0.67–3.99 </text>
<text top="300" left="884" width="7" height="18" font="7"></text>
<text top="301" left="891" width="200" height="17" font="0"> Proteinuria RR: 2.60; 95% CI: 0.85–</text>
<text top="319" left="884" width="27" height="17" font="0">7.93 </text>
<text top="336" left="884" width="7" height="18" font="7"></text>
<text top="337" left="891" width="187" height="17" font="0"> Hypocalcemia RR: 3.12; 95% CI: </text>
<text top="354" left="884" width="65" height="17" font="0">0.65–14.98 </text>
<text top="402" left="86" width="1002" height="17" font="0">ABI indicates ankle-brachial index; EDTA, ethylene diamine tetraacetic acid; CI, confidence interval; HR, hazard ratio; IC, intermittent claudication; N/A, not applicable; PFWD, pain free </text>
<text top="419" left="86" width="650" height="17" font="0">walking distance; pt, patient; PVD, peripheral vascular disease; RR, relative risk; and WMD, weighted mean difference. </text>
<text top="436" left="86" width="3" height="17" font="0"> </text>
<text top="454" left="86" width="3" height="17" font="0"> </text>
<text top="471" left="86" width="985" height="21" font="1"><b>Evidence Table 28. Nonrandomized Trials, Observational Studies, and/or Registries of Homocysteine Lowering Therapy for Lower Extremity </b></text>
<text top="491" left="86" width="383" height="21" font="1"><b>PAD in Patients with Diabetes Mellitus–Section 5.10.1. </b></text>
<text top="513" left="109" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="530" left="134" width="48" height="17" font="2"><b>Author; </b></text>
<text top="547" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="513" left="264" width="38" height="17" font="2"><b>Study </b></text>
<text top="530" left="242" width="81" height="17" font="2"><b>Type/Design; </b></text>
<text top="547" left="250" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="513" left="407" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="513" left="674" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="530" left="681" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="547" left="733" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="513" left="962" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="530" left="989" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="565" left="95" width="123" height="17" font="0">Khandanpour N, et al. </text>
<text top="582" left="95" width="63" height="17" font="0">2009 (180) </text>
<text top="600" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19560951">19560951</a></text>
<text top="600" left="149" width="3" height="17" font="22"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19560951"> </a></text>
<text top="617" left="95" width="3" height="17" font="0"> </text>
<text top="565" left="234" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="582" left="234" width="93" height="17" font="0">Meta-analysis of </text>
<text top="600" left="234" width="77" height="17" font="0">observational </text>
<text top="617" left="234" width="66" height="17" font="0">studies and </text>
<text top="634" left="234" width="70" height="17" font="0">clinical trials </text>
<text top="651" left="234" width="3" height="17" font="0"> </text>
<text top="668" left="234" width="36" height="17" font="2"><b>Size:</b>  </text>
<text top="686" left="234" width="7" height="18" font="7"></text>
<text top="687" left="241" width="77" height="17" font="0"> n=14 studies </text>
<text top="704" left="234" width="94" height="17" font="0">included in meta-</text>
<text top="721" left="234" width="90" height="17" font="0">analysis (of 214 </text>
<text top="738" left="234" width="79" height="17" font="0">retrieved from </text>
<text top="756" left="234" width="64" height="17" font="0">databases) </text>
<text top="565" left="344" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="582" left="344" width="7" height="18" font="7"></text>
<text top="584" left="351" width="204" height="17" font="2"><b> </b>Reviewed MEDLINE, EMBASE, and </text>
<text top="601" left="344" width="233" height="17" font="0">Cochrane databases for studies published </text>
<text top="618" left="344" width="184" height="17" font="0">between 1950—December, 2007 </text>
<text top="635" left="344" width="7" height="18" font="7"></text>
<text top="636" left="351" width="208" height="17" font="2"><b> </b>Observational meta-analysis: studies </text>
<text top="654" left="344" width="161" height="17" font="0">with measurement of plasma </text>
<text top="671" left="344" width="224" height="17" font="0">homocysteine levels in PAD pts and non-</text>
<text top="688" left="344" width="75" height="17" font="0">PAD controls </text>
<text top="705" left="344" width="7" height="18" font="7"></text>
<text top="706" left="351" width="204" height="17" font="2"><b> </b>Clinical trial meta-analysis: Trials for </text>
<text top="724" left="344" width="226" height="17" font="0">which PAD pts with treated with single or </text>
<text top="741" left="344" width="227" height="17" font="0">combined vitamin therapy (folate, vitamin </text>
<text top="758" left="344" width="129" height="17" font="0">B6 and/or vitamin B12) </text>
<text top="775" left="344" width="7" height="18" font="7"></text>
<text top="776" left="351" width="228" height="17" font="2"><b> </b>PAD defined as ABI &lt;0.9, IC, diminished </text>
<text top="566" left="594" width="7" height="17" font="2"><b>1</b></text>
<text top="565" left="601" width="6" height="18" font="7"></text>
<text top="566" left="607" width="306" height="17" font="2"><b> endpoint:</b> Homocysteine levels in PAD pts vs. controls </text>
<text top="584" left="594" width="3" height="17" font="0"> </text>
<text top="601" left="594" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="618" left="594" width="7" height="18" font="7"></text>
<text top="619" left="601" width="308" height="17" font="0"> PAD pts had higher homocysteine levels than non-PAD </text>
<text top="636" left="594" width="47" height="17" font="0">controls </text>
<text top="654" left="594" width="7" height="18" font="7"></text>
<text top="655" left="601" width="300" height="17" font="0"> Pooled mean difference vs. controls +4.31 micromol/L </text>
<text top="672" left="594" width="172" height="17" font="0">(95% CI: 1.71–6.31; p&lt;0.0001) </text>
<text top="689" left="594" width="7" height="18" font="7"></text>
<text top="690" left="601" width="321" height="17" font="0"> Mean plasma homocysteine levels higher in PAD pts than </text>
<text top="708" left="594" width="327" height="17" font="0">in controls in all 14 studies include in meta-analysis, though </text>
<text top="725" left="594" width="251" height="17" font="0">magnitude of difference varied across studies </text>
<text top="742" left="594" width="7" height="18" font="7"></text>
<text top="743" left="601" width="317" height="17" font="2"><b> </b>Clinical trial meta-analysis unable to be performed due to </text>
<text top="760" left="594" width="330" height="17" font="0">limited study quality and diverse outcomes reported. Among </text>
<text top="565" left="945" width="7" height="18" font="7"></text>
<text top="566" left="952" width="141" height="17" font="0"> Homocysteine levels are </text>
<text top="584" left="945" width="156" height="17" font="0">elevated among PAD pts as </text>
<text top="601" left="945" width="125" height="17" font="0">compared to non-PAD </text>
<text top="618" left="945" width="47" height="17" font="0">controls </text>
<text top="635" left="945" width="7" height="18" font="7"></text>
<text top="636" left="952" width="122" height="17" font="0"> Data lacking to make </text>
<text top="654" left="945" width="153" height="17" font="0">statement regarding benefit </text>
<text top="671" left="945" width="142" height="17" font="0">of homocysteine lowering </text>
<text top="688" left="945" width="156" height="17" font="0">therapy for clinical benefit in </text>
<text top="705" left="945" width="29" height="17" font="0">PAD </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">80 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="344" width="175" height="17" font="0">pedal pulses + angiographically </text>
<text top="104" left="344" width="226" height="17" font="0">demonstrated PAD (obstruction of one at </text>
<text top="122" left="344" width="122" height="17" font="0">least major leg artery) </text>
<text top="139" left="344" width="3" height="17" font="0"> </text>
<text top="156" left="344" width="206" height="17" font="2"><b>Exclusion criteria:</b> Lack of non PAD </text>
<text top="173" left="344" width="222" height="17" font="0">control group, non-English studies, case </text>
<text top="190" left="344" width="180" height="17" font="0">reports, homocysteine levels not </text>
<text top="208" left="344" width="237" height="17" font="0">extractable, non-fasting or post-methionine </text>
<text top="225" left="344" width="207" height="17" font="0">loading homocysteine levels reported </text>
<text top="87" left="594" width="185" height="17" font="0">8 clinical trials, 3 nonrandomized. </text>
<text top="104" left="594" width="7" height="18" font="7"></text>
<text top="105" left="601" width="262" height="17" font="2"><b> </b>All 8 studies demonstrated reduction in plasma </text>
<text top="123" left="594" width="276" height="17" font="0">homocysteine in folate/vitamin intervention groups </text>
<text top="140" left="594" width="7" height="18" font="7"></text>
<text top="141" left="601" width="303" height="17" font="2"><b> </b>One study in meta-analysis which reported on ABI and </text>
<text top="158" left="594" width="319" height="17" font="0">walking distance studied other nutritional supplements not </text>
<text top="176" left="594" width="214" height="17" font="0">homocysteine lowering vitamins alone. </text>
<text top="193" left="594" width="7" height="18" font="7"></text>
<text top="194" left="601" width="300" height="17" font="2"><b> </b>Studies reported other endpoints including endothelial </text>
<text top="211" left="594" width="283" height="17" font="0">function testing, inflammatory and other biomarkers </text>
<text top="243" left="86" width="734" height="17" font="0">ABI indicates ankle-brachial index; CI, confidence interval; IC, intermittent claudication; PAD, peripheral artery disease; and pt, patient. </text>
<text top="260" left="86" width="3" height="17" font="0"> </text>
<text top="277" left="86" width="3" height="17" font="0"> </text>
<text top="294" left="86" width="1012" height="21" font="1"><b>Evidence Table 29. RCTs Comparing Additional Medical Therapies of Homocysteine Lowering Therapy for Lower Extremity PAD–Section 5.10.1. </b></text>
<text top="316" left="96" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="333" left="121" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="350" left="99" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="316" left="225" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="333" left="230" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="350" left="224" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="316" left="394" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="316" left="579" width="111" height="17" font="2"><b>Study Intervention </b></text>
<text top="333" left="597" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="350" left="579" width="111" height="17" font="2"><b>Study Comparator </b></text>
<text top="367" left="600" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="316" left="726" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="333" left="710" width="138" height="17" font="2"><b>(Absolute Event Rates, </b></text>
<text top="350" left="716" width="129" height="17" font="2"><b>P value; OR or RR; &amp;  </b></text>
<text top="367" left="755" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="317" left="897" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="316" left="958" width="6" height="18" font="7"></text>
<text top="317" left="964" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="334" left="929" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="351" left="937" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="385" left="95" width="53" height="17" font="2"><b>HOPE-2</b>  </text>
<text top="403" left="95" width="76" height="17" font="0">Lonn E, et al. </text>
<text top="420" left="95" width="63" height="17" font="0">2006 (181) </text>
<text top="437" left="95" width="3" height="17" font="0"> </text>
<text top="454" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16531613">16531613 </a></text>
<text top="472" left="95" width="3" height="17" font="0"> </text>
<text top="489" left="95" width="49" height="17" font="2"><b>HOPE-2 </b></text>
<text top="506" left="95" width="80" height="17" font="2"><b>Investigators </b></text>
<text top="523" left="95" width="76" height="17" font="0">Lonn E, et al. </text>
<text top="540" left="95" width="59" height="17" font="0">2006(182) </text>
<text top="558" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16450017">16450017 </a></text>
<text top="575" left="95" width="3" height="17" font="0"> </text>
<text top="385" left="209" width="113" height="17" font="2"><b>Aim:</b> Study effect of </text>
<text top="403" left="209" width="42" height="17" font="0">vitamin </text>
<text top="420" left="209" width="107" height="17" font="0">supplementation to </text>
<text top="437" left="209" width="112" height="17" font="0">lower homocysteine </text>
<text top="454" left="209" width="88" height="17" font="0">levels on risk of </text>
<text top="472" left="209" width="94" height="17" font="0">major CV events </text>
<text top="489" left="209" width="86" height="17" font="0">among pts with </text>
<text top="506" left="209" width="95" height="17" font="0">vascular disease </text>
<text top="523" left="209" width="3" height="17" font="0"> </text>
<text top="540" left="209" width="113" height="17" font="2"><b>Study type:</b> Double </text>
<text top="558" left="209" width="79" height="17" font="0">blind, placebo </text>
<text top="575" left="209" width="57" height="17" font="0">controlled </text>
<text top="592" left="209" width="91" height="17" font="0">randomized trial </text>
<text top="609" left="209" width="3" height="17" font="0"> </text>
<text top="626" left="209" width="36" height="17" font="2"><b>Size:</b>  </text>
<text top="644" left="209" width="7" height="18" font="7"></text>
<text top="645" left="216" width="52" height="17" font="0"> n=5,522 </text>
<text top="662" left="209" width="113" height="17" font="0">randomized pts with </text>
<text top="679" left="209" width="29" height="17" font="0">PAD </text>
<text top="696" left="209" width="7" height="18" font="7"></text>
<text top="698" left="216" width="41" height="17" font="0"> n=133 </text>
<text top="715" left="209" width="108" height="17" font="0">claudication (2.4%) </text>
<text top="732" left="209" width="7" height="18" font="7"></text>
<text top="733" left="216" width="95" height="17" font="0"> n=276 with PAD </text>
<text top="750" left="209" width="96" height="17" font="0">revascularization </text>
<text top="768" left="209" width="40" height="17" font="0">(5.0%) </text>
<text top="385" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="403" left="338" width="7" height="18" font="7"></text>
<text top="404" left="345" width="193" height="17" font="2"><b> </b>Age ≥55 y with documented CAD, </text>
<text top="421" left="338" width="220" height="17" font="0">PAD, cerebrovascular disease, or DM + </text>
<text top="438" left="338" width="170" height="17" font="0">at least 1 additional risk factor. </text>
<text top="456" left="338" width="7" height="18" font="7"></text>
<text top="457" left="345" width="191" height="17" font="2"><b> </b>PAD enrollment criteria were prior </text>
<text top="474" left="338" width="182" height="17" font="0">lower extremity revascularization </text>
<text top="491" left="338" width="213" height="17" font="0">(bypass or PTA), claudication with ABI </text>
<text top="508" left="338" width="221" height="17" font="0">≤0.8, documented (leg) arterial stenosis </text>
<text top="526" left="338" width="207" height="17" font="0">≥50% on angiography, prior ischemic </text>
<text top="543" left="338" width="129" height="17" font="0">limb or foot amputation </text>
<text top="560" left="338" width="3" height="17" font="0"> </text>
<text top="577" left="338" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="594" left="338" width="7" height="18" font="7"></text>
<text top="595" left="344" width="183" height="17" font="0"> Use of vitamin supplements with </text>
<text top="613" left="338" width="153" height="17" font="0">significant folic acid content </text>
<text top="630" left="338" width="7" height="18" font="7"></text>
<text top="631" left="344" width="147" height="17" font="0"> Prior adverse reactions to </text>
<text top="648" left="338" width="77" height="17" font="0">folate/B6/B12 </text>
<text top="666" left="338" width="7" height="18" font="7"></text>
<text top="667" left="344" width="202" height="17" font="0"> Planned cardiac/peripheral vascular </text>
<text top="684" left="338" width="161" height="17" font="0">revascularization within 6 mo </text>
<text top="701" left="338" width="7" height="18" font="7"></text>
<text top="702" left="344" width="92" height="17" font="0"> Significant non- </text>
<text top="719" left="338" width="183" height="17" font="0">atherosclerotic/athero-thrombotic </text>
<text top="737" left="338" width="129" height="17" font="0">cardiovascular disease </text>
<text top="754" left="338" width="7" height="18" font="7"></text>
<text top="755" left="344" width="145" height="17" font="0"> Other non-cardiovascular </text>
<text top="772" left="338" width="168" height="17" font="0">comorbidities expected to limit </text>
<text top="385" left="574" width="107" height="17" font="2"><b>Intervention:</b> Folic </text>
<text top="403" left="574" width="109" height="17" font="0">acid 2.5 mg/vitamin </text>
<text top="420" left="574" width="98" height="17" font="0">B6 50 mg/vitamin </text>
<text top="437" left="574" width="79" height="17" font="0">B12 1 mg in a </text>
<text top="454" left="574" width="79" height="17" font="0">combined pill  </text>
<text top="472" left="574" width="7" height="17" font="0">  </text>
<text top="489" left="574" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="506" left="574" width="48" height="17" font="0">Placebo </text>
<text top="387" left="709" width="7" height="17" font="2"><b>1</b></text>
<text top="386" left="716" width="6" height="18" font="7"></text>
<text top="387" left="722" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="404" left="709" width="7" height="18" font="7"></text>
<text top="405" left="716" width="110" height="17" font="2"><b> </b>No improvement in </text>
<text top="422" left="709" width="135" height="17" font="0">composite of death from </text>
<text top="439" left="709" width="105" height="17" font="0">CV cause, MI, and </text>
<text top="457" left="709" width="129" height="17" font="0">stroke with intervention </text>
<text top="474" left="709" width="7" height="18" font="7"></text>
<text top="475" left="716" width="107" height="17" font="2"><b> </b>Event rates 18.8% </text>
<text top="492" left="709" width="133" height="17" font="0">(intervention) vs. 19.8% </text>
<text top="509" left="709" width="114" height="17" font="0">(placebo); RR: 0.95; </text>
<text top="527" left="709" width="109" height="17" font="0">95% CI: 0.84–1.07; </text>
<text top="544" left="709" width="45" height="17" font="0">p=0.41. </text>
<text top="561" left="709" width="7" height="18" font="7"></text>
<text top="562" left="716" width="124" height="17" font="2"><b> </b>“Average follow-up” 5 </text>
<text top="579" left="709" width="10" height="17" font="0">y </text>
<text top="597" left="709" width="3" height="17" font="0"> </text>
<text top="614" left="709" width="119" height="17" font="2"><b>Safety endpoint:</b> No </text>
<text top="631" left="709" width="122" height="17" font="0">SAEs related to study </text>
<text top="648" left="709" width="59" height="17" font="0">treatment. </text>
<text top="386" left="861" width="7" height="18" font="7"></text>
<text top="387" left="868" width="235" height="17" font="0"> Homocysteine decreased in interventional </text>
<text top="404" left="861" width="218" height="17" font="0">arm and increased in placebo arm (-2.4 </text>
<text top="421" left="861" width="178" height="17" font="0">micromol/L vs. +0.8 micromol/L) </text>
<text top="438" left="861" width="7" height="18" font="7"></text>
<text top="439" left="868" width="213" height="17" font="0"> No difference in risk of death between </text>
<text top="457" left="861" width="210" height="17" font="0">groups (RR: 0.96; 95% CI: 0.81–1.13) </text>
<text top="474" left="861" width="7" height="18" font="7"></text>
<text top="475" left="868" width="237" height="17" font="0"> No difference in risk of MI between groups </text>
<text top="492" left="861" width="176" height="17" font="0">(RR: 0.989; 95% CI: 0.85–1.14) </text>
<text top="509" left="861" width="7" height="18" font="7"></text>
<text top="511" left="868" width="199" height="17" font="0"> Decreased RR stroke among those </text>
<text top="528" left="861" width="236" height="17" font="0">randomized to intervention (RR: 0.75; 95% </text>
<text top="545" left="861" width="85" height="17" font="0">CI: 0.59–0.97). </text>
<text top="562" left="861" width="7" height="18" font="7"></text>
<text top="563" left="868" width="225" height="17" font="0"> Increased RR risk of hospitalization with </text>
<text top="581" left="861" width="246" height="17" font="0">unstable angina among those randomized to </text>
<text top="598" left="861" width="236" height="17" font="0">intervention (RR: 1.24; 95% CI: 1.04–1.49) </text>
<text top="615" left="861" width="7" height="18" font="7"></text>
<text top="616" left="868" width="211" height="17" font="0"> All other secondary outcomes with no </text>
<text top="633" left="861" width="243" height="17" font="0">difference in groups (including VTE, cancer) </text>
<text top="651" left="861" width="3" height="17" font="0"> </text>
<text top="668" left="861" width="229" height="17" font="2"><b>Summary:</b> Negative study; no overall CV </text>
<text top="685" left="861" width="240" height="17" font="0">benefit of homocysteine lowering therapy in </text>
<text top="702" left="861" width="215" height="17" font="0">this Westernized population study (US, </text>
<text top="719" left="861" width="243" height="17" font="0">Canada, Brazil, and Europe) which included </text>
<text top="737" left="861" width="151" height="17" font="0">a small subset of PAD pts.  </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">81 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="338" width="215" height="17" font="0">compliance or ability to complete study </text>
<text top="109" left="86" width="996" height="17" font="0">CAD indicates coronary artery disease; CI, confidence interval; CV, cardiovascular; HOPE, Heart Outcomes Prevention Evaluation; PAD, periphery artery disease; PTA, percutaneous </text>
<text top="126" left="86" width="942" height="17" font="0">transluminal angioplasty; pt, patient; RCT, randomized controlled trial; RR, relative risk; SAE, serious adverse event; US, United States; and VTE, venous thromboembolism. </text>
<text top="143" left="86" width="3" height="17" font="0"> </text>
<text top="160" left="86" width="3" height="17" font="0"> </text>
<text top="178" left="86" width="468" height="21" font="1"><b>Evidence Table 30. RCTs for Influenza Vaccination–Section 5.10.2. </b></text>
<text top="199" left="98" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="216" left="124" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="233" left="102" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="199" left="242" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="216" left="247" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="233" left="241" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="199" left="391" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="199" left="542" width="111" height="17" font="2"><b>Study Intervention </b></text>
<text top="216" left="560" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="233" left="542" width="111" height="17" font="2"><b>Study Comparator </b></text>
<text top="251" left="563" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="199" left="703" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="216" left="680" width="149" height="17" font="2"><b>(Absolute Event Rates, P </b></text>
<text top="233" left="698" width="118" height="17" font="2"><b>value; OR or RR; &amp;  </b></text>
<text top="251" left="731" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="200" left="893" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="199" left="955" width="6" height="18" font="7"></text>
<text top="200" left="961" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="217" left="926" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="235" left="933" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="269" left="95" width="61" height="17" font="2"><b>FLUVACS</b> </text>
<text top="286" left="95" width="106" height="17" font="0">Gurfinkel EP, et al. </text>
<text top="303" left="95" width="63" height="17" font="0">2004 (183) </text>
<text top="320" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14683739">14683739 </a></text>
<text top="337" left="95" width="3" height="17" font="0"> </text>
<text top="269" left="214" width="140" height="17" font="2"><b>Aim:</b> To test the effect of </text>
<text top="286" left="214" width="131" height="17" font="0">1 yr benefit of influenza </text>
<text top="303" left="214" width="123" height="17" font="0">vaccination in pts with </text>
<text top="320" left="214" width="112" height="17" font="0">MI and planned PCI </text>
<text top="337" left="214" width="3" height="17" font="0"> </text>
<text top="355" left="214" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="372" left="214" width="3" height="17" font="0"> </text>
<text top="389" left="214" width="135" height="17" font="2"><b>Size: </b>n=301 (200 MI pts </text>
<text top="406" left="214" width="96" height="17" font="0">and 101 PCI pts) </text>
<text top="269" left="366" width="157" height="17" font="2"><b>Inclusion criteria:</b> MI pts or </text>
<text top="286" left="366" width="44" height="17" font="0">PCI pts </text>
<text top="303" left="366" width="3" height="17" font="0"> </text>
<text top="320" left="366" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="337" left="366" width="159" height="17" font="0">Unstable CAD, prior by-bass </text>
<text top="355" left="366" width="131" height="17" font="0">surgery, angioplasty, or </text>
<text top="372" left="366" width="85" height="17" font="0">tissue necrosis </text>
<text top="269" left="540" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="286" left="540" width="98" height="17" font="0">Influenza vaccine </text>
<text top="303" left="540" width="32" height="17" font="0">(151) </text>
<text top="320" left="540" width="3" height="17" font="0"> </text>
<text top="337" left="540" width="96" height="17" font="2"><b>Comparator:</b> No </text>
<text top="355" left="540" width="113" height="17" font="0">vaccination ontop of </text>
<text top="372" left="540" width="114" height="17" font="0">standard medication </text>
<text top="389" left="540" width="32" height="17" font="0">(150) </text>
<text top="270" left="668" width="7" height="17" font="2"><b>1</b></text>
<text top="269" left="675" width="6" height="18" font="7"></text>
<text top="270" left="681" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="287" left="668" width="97" height="17" font="0">Time to first CVD </text>
<text top="304" left="668" width="7" height="18" font="7"></text>
<text top="305" left="675" width="149" height="17" font="0"> At 6 mo: 2% in vaccinated </text>
<text top="323" left="668" width="172" height="17" font="0">intervention group vs. 8% CVD </text>
<text top="340" left="668" width="164" height="17" font="0">in unvaccinated controls (RR: </text>
<text top="357" left="668" width="139" height="17" font="0">0.25; 95% CI: 0.07–0.86; </text>
<text top="374" left="668" width="45" height="17" font="0">p=0.01) </text>
<text top="391" left="668" width="7" height="18" font="7"></text>
<text top="392" left="675" width="142" height="17" font="0"> At 1 yr: 6% in vaccinated </text>
<text top="410" left="668" width="149" height="17" font="0">intervention group vs. 17% </text>
<text top="427" left="668" width="168" height="17" font="0">CVD in unvaccinated controls. </text>
<text top="444" left="668" width="168" height="17" font="0">(RR: 0.34; 95% CI: 0.17–0.71; </text>
<text top="461" left="668" width="52" height="17" font="0">p=0.002) </text>
<text top="269" left="854" width="222" height="17" font="0">Time to first composite triple endpoint of </text>
<text top="286" left="854" width="228" height="17" font="0">CVD, MI, and rehospitalization for severe </text>
<text top="303" left="854" width="234" height="17" font="0">recurrent ischemia at 1 yr was significantly </text>
<text top="320" left="854" width="196" height="17" font="0">decreased in the intervention group </text>
<text top="337" left="854" width="192" height="17" font="0">compared to control group (22% in </text>
<text top="355" left="854" width="224" height="17" font="0">vaccinated intervention group vs. 37% in </text>
<text top="372" left="854" width="238" height="17" font="0">unvaccinated control group; RR: 0.59; 95% </text>
<text top="389" left="854" width="126" height="17" font="0">CI: 0.4–0.86; p=0.004) </text>
<text top="406" left="854" width="7" height="18" font="7"></text>
<text top="407" left="861" width="215" height="17" font="0"> Reduction in RR of CVD in vaccinated </text>
<text top="425" left="854" width="72" height="17" font="0">group at 1 y. </text>
<text top="442" left="854" width="7" height="18" font="7"></text>
<text top="443" left="861" width="201" height="17" font="0"> No PAD specific evidence identified </text>
<text top="479" left="95" width="54" height="17" font="2"><b>FLUCAD</b> </text>
<text top="497" left="95" width="103" height="17" font="0">Ciszewski A, et al. </text>
<text top="514" left="95" width="63" height="17" font="0">2008 (184) </text>
<text top="531" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18187561">18187561</a></text>
<text top="531" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18187561"> </a></text>
<text top="548" left="95" width="3" height="17" font="0"> </text>
<text top="479" left="214" width="131" height="17" font="2"><b>Aim:</b> Determine effects </text>
<text top="497" left="214" width="131" height="17" font="0">of influenza vaccination </text>
<text top="514" left="214" width="121" height="17" font="0">on coronary events in </text>
<text top="531" left="214" width="75" height="17" font="0">pts with CAD </text>
<text top="548" left="214" width="3" height="17" font="0"> </text>
<text top="566" left="214" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="583" left="214" width="3" height="17" font="0"> </text>
<text top="600" left="214" width="112" height="17" font="2"><b>Size:</b> n=658 treated </text>
<text top="617" left="214" width="109" height="17" font="0">CAD pts (477 men) </text>
<text top="479" left="366" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="497" left="366" width="7" height="18" font="7"></text>
<text top="498" left="373" width="76" height="17" font="0"> Age 30–80 y </text>
<text top="515" left="366" width="7" height="18" font="7"></text>
<text top="516" left="373" width="107" height="17" font="0"> CAD confirmed by </text>
<text top="533" left="366" width="133" height="17" font="0">angiography with ≥50% </text>
<text top="551" left="366" width="111" height="17" font="0">stenosis of ≥1 large </text>
<text top="568" left="366" width="142" height="17" font="0">epicardial coronary artery </text>
<text top="585" left="366" width="3" height="17" font="0"> </text>
<text top="602" left="366" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="619" left="366" width="133" height="17" font="0">Congestive heart failure </text>
<text top="637" left="366" width="66" height="17" font="0">NYHA III/IV </text>
<text top="654" left="366" width="7" height="18" font="7"></text>
<text top="655" left="373" width="152" height="17" font="0"> Planned CV surgery within </text>
<text top="672" left="366" width="27" height="17" font="0">6mo </text>
<text top="689" left="366" width="7" height="18" font="7"></text>
<text top="691" left="373" width="121" height="17" font="0"> Evolving renal failure </text>
<text top="708" left="366" width="7" height="18" font="7"></text>
<text top="709" left="373" width="110" height="17" font="0"> Neoplastic disease </text>
<text top="726" left="366" width="7" height="18" font="7"></text>
<text top="727" left="373" width="154" height="17" font="0"> Psycho-organic disorder or </text>
<text top="745" left="366" width="146" height="17" font="0">any factor impeding follow-</text>
<text top="762" left="366" width="17" height="17" font="0">up </text>
<text top="479" left="540" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="497" left="540" width="98" height="17" font="0">Influenza vaccine </text>
<text top="514" left="540" width="32" height="17" font="0">(325) </text>
<text top="531" left="540" width="3" height="17" font="0"> </text>
<text top="548" left="540" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="566" left="540" width="80" height="17" font="0">Placebo (333) </text>
<text top="481" left="668" width="7" height="17" font="2"><b>1</b></text>
<text top="480" left="675" width="6" height="18" font="7"></text>
<text top="481" left="681" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="498" left="668" width="53" height="17" font="0">1 yr CVD </text>
<text top="515" left="668" width="7" height="18" font="7"></text>
<text top="516" left="675" width="144" height="17" font="0"> At 1 y: HR: 1.06; 95% CI: </text>
<text top="533" left="668" width="106" height="17" font="0">0.15–7.56; p=0.95  </text>
<text top="481" left="854" width="7" height="17" font="2"><b>2</b></text>
<text top="480" left="861" width="6" height="18" font="7"></text>
<text top="481" left="867" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="498" left="854" width="7" height="18" font="7"></text>
<text top="499" left="861" width="244" height="17" font="0"> No difference between two groups for CVD, </text>
<text top="516" left="854" width="215" height="17" font="0">acute MI, or coronary revascularization </text>
<text top="533" left="854" width="7" height="18" font="7"></text>
<text top="534" left="861" width="206" height="17" font="0"> At 1 y coronary ischemic events was </text>
<text top="552" left="854" width="248" height="17" font="0">decreased in intervention group compared to </text>
<text top="569" left="854" width="228" height="17" font="0">placebo control group (HR: 0.54; 95% CI: </text>
<text top="586" left="854" width="114" height="17" font="0">0.29–0.99; p=0.047) </text>
<text top="603" left="854" width="3" height="17" font="0"> </text>
<text top="621" left="854" width="243" height="17" font="2"><b>Limitations: </b>Small sample size, effect of flu </text>
<text top="638" left="854" width="224" height="17" font="0">vaccination on restenosis is unknown, pt </text>
<text top="655" left="854" width="78" height="17" font="0">selection bias </text>
<text top="672" left="854" width="3" height="17" font="0"> </text>
<text top="689" left="854" width="7" height="18" font="7"></text>
<text top="691" left="861" width="201" height="17" font="0"> No PAD specific evidence identified </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">82 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="366" width="7" height="18" font="7"></text>
<text top="88" left="373" width="109" height="17" font="0"> Contraindication to </text>
<text top="106" left="366" width="65" height="17" font="0">vaccination </text>
<text top="173" left="86" width="963" height="17" font="0">CAD indicates coronary artery disease; CI, confidence interval; CVD, cardiovascular death; CVD, cardiovascular disease; HR, hazard ratio; ITT, intention to treat; MI, myocardial </text>
<text top="190" left="86" width="795" height="17" font="0">infarction; NYHA, New York Heart Association; PCI, percutaneous intervention; pt, patient; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="207" left="86" width="3" height="17" font="0"> </text>
<text top="225" left="86" width="3" height="17" font="0"> </text>
<text top="242" left="86" width="585" height="21" font="1"><b>Evidence Table 31. Nonrandomized Trials for Influenza Vaccination–Section 5.10.2. </b></text>
<text top="263" left="109" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="280" left="134" width="48" height="17" font="2"><b>Author; </b></text>
<text top="298" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="263" left="248" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="280" left="274" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="263" left="417" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="263" left="616" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="280" left="623" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="298" left="675" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="263" left="918" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="280" left="945" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="316" left="95" width="92" height="17" font="0">Davis MM, et al. </text>
<text top="333" left="95" width="63" height="17" font="0">2006 (185) </text>
<text top="350" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17010820">17010820 </a></text>
<text top="367" left="95" width="3" height="17" font="0"> </text>
<text top="316" left="234" width="117" height="17" font="2"><b>Study type</b>: Science </text>
<text top="333" left="234" width="110" height="17" font="0">Advisory Statement </text>
<text top="350" left="234" width="3" height="17" font="0"> </text>
<text top="367" left="234" width="55" height="17" font="2"><b>Size</b>: N/A </text>
<text top="316" left="392" width="153" height="17" font="2"><b>Inclusion criteria</b>: Cohort , </text>
<text top="333" left="392" width="136" height="17" font="0">case control studies and </text>
<text top="350" left="392" width="35" height="17" font="0">RCTs </text>
<text top="367" left="392" width="3" height="17" font="0"> </text>
<text top="384" left="392" width="133" height="17" font="2"><b>Exclusion criteria</b>: N/A </text>
<text top="316" left="566" width="7" height="18" font="7"></text>
<text top="317" left="573" width="271" height="17" font="2"><b> </b>COR I LOE B recommendation to immunize with </text>
<text top="334" left="566" width="249" height="17" font="0">inactivated vaccine as part of comprehensive </text>
<text top="351" left="566" width="258" height="17" font="0">secondary prevention in persons with coronary </text>
<text top="368" left="566" width="241" height="17" font="0">and other atherosclerotic vascular disease.  </text>
<text top="386" left="566" width="7" height="18" font="7"></text>
<text top="387" left="573" width="160" height="17" font="2"><b> </b>1 RCT (FLUVACS) included </text>
<text top="404" left="566" width="7" height="18" font="7"></text>
<text top="405" left="573" width="240" height="17" font="2"><b> </b>Summary of observational cohort and case </text>
<text top="422" left="566" width="266" height="17" font="0">control studies demonstrating reduced CV event </text>
<text top="440" left="566" width="271" height="17" font="0">rates among pts with cardiovascular disease who </text>
<text top="457" left="566" width="168" height="17" font="0">received influenza vaccination </text>
<text top="316" left="857" width="7" height="18" font="7"></text>
<text top="317" left="864" width="219" height="17" font="0"> Not recommended for persons with CV </text>
<text top="334" left="857" width="203" height="17" font="0">conditions to be immunized with live, </text>
<text top="351" left="857" width="113" height="17" font="0">attenuated vaccine.  </text>
<text top="368" left="857" width="7" height="18" font="7"></text>
<text top="369" left="864" width="226" height="17" font="0"> Immunization coverage levels are below </text>
<text top="387" left="857" width="79" height="17" font="0">national goals </text>
<text top="475" left="86" width="988" height="17" font="0">COR indicates class of recommendation; CV, cardiovascular; LOE, level of evidence; N/A, not applicable; PCI, percutaneous coronary intervention; pt, patient; and RCT, randomized </text>
<text top="492" left="86" width="83" height="17" font="0">controlled trial. </text>
<text top="509" left="86" width="3" height="17" font="0"> </text>
<text top="526" left="86" width="3" height="17" font="0"> </text>
<text top="544" left="86" width="407" height="21" font="1"><b>Evidence Table 32. RCTs for Exercise Therapy–Section 6. </b></text>
<text top="565" left="102" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="582" left="128" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="599" left="105" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="565" left="235" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="582" left="240" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="599" left="233" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="565" left="367" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="565" left="536" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="582" left="554" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="599" left="536" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="617" left="557" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="565" left="722" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="582" left="699" width="149" height="17" font="2"><b>(Absolute Event Rates, P </b></text>
<text top="599" left="717" width="118" height="17" font="2"><b>value; OR or RR; &amp;  </b></text>
<text top="617" left="750" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="566" left="905" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="565" left="966" width="6" height="18" font="7"></text>
<text top="566" left="973" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="583" left="937" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="601" left="945" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="635" left="95" width="92" height="17" font="2"><b>CLEVER 18 mo </b></text>
<text top="652" left="95" width="23" height="17" font="2"><b>F/U</b> </text>
<text top="669" left="95" width="97" height="17" font="0">Murphy TP, et al. </text>
<text top="686" left="95" width="63" height="17" font="0">2015 (186) </text>
<text top="703" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25766947">25766947 </a></text>
<text top="721" left="95" width="3" height="17" font="0"> </text>
<text top="635" left="222" width="92" height="17" font="2"><b>Aim:</b> Report the </text>
<text top="652" left="222" width="88" height="17" font="0">longer-term (18 </text>
<text top="669" left="222" width="103" height="17" font="0">mo) efficacy of SE </text>
<text top="686" left="222" width="103" height="17" font="0">compared with ST </text>
<text top="703" left="222" width="105" height="17" font="0">and OMC included </text>
<text top="721" left="222" width="80" height="17" font="0">printed advice </text>
<text top="738" left="222" width="107" height="17" font="0">about exercise and </text>
<text top="755" left="222" width="109" height="17" font="0">diet. SE and ST pts </text>
<text top="772" left="222" width="76" height="17" font="0">also received </text>
<text top="635" left="344" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="652" left="344" width="7" height="18" font="7"></text>
<text top="653" left="351" width="62" height="17" font="2"><b> </b>Age &gt;40 y </text>
<text top="670" left="344" width="7" height="18" font="7"></text>
<text top="671" left="351" width="142" height="17" font="2"><b> </b>oderate to severe IC due </text>
<text top="689" left="344" width="114" height="17" font="0">to aortoiliac PAD. IC </text>
<text top="706" left="344" width="155" height="17" font="0">defined as ability to walk ≥2 </text>
<text top="723" left="344" width="146" height="17" font="0">min on TM at 2 miles/hr at </text>
<text top="740" left="344" width="124" height="17" font="0">0% grade but &lt;11 min </text>
<text top="757" left="344" width="96" height="17" font="0">(about 5.5 METS </text>
<text top="775" left="344" width="100" height="17" font="0">maximum). ≥50% </text>
<text top="635" left="513" width="148" height="17" font="2"><b>Intervention:</b> OMC, n=22; </text>
<text top="652" left="513" width="135" height="17" font="0">SE, n=44; ST, n=46. SE </text>
<text top="669" left="513" width="155" height="17" font="0">was supervised for 26 wk, 3 </text>
<text top="686" left="513" width="124" height="17" font="0">times/wk, 1 h for 6 mo </text>
<text top="703" left="513" width="133" height="17" font="0">followed by a telephone </text>
<text top="721" left="513" width="123" height="17" font="0">maintenance program </text>
<text top="738" left="513" width="120" height="17" font="0">through 18 mo during </text>
<text top="755" left="513" width="125" height="17" font="0">home-based exercise. </text>
<text top="772" left="513" width="3" height="17" font="0"> </text>
<text top="636" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="635" left="690" width="6" height="18" font="7"></text>
<text top="636" left="696" width="148" height="17" font="2"><b> endpoint:</b> PWT improved </text>
<text top="653" left="683" width="174" height="17" font="0">from baseline to 18 mo for both </text>
<text top="670" left="683" width="180" height="17" font="0">SE (5±5.4 min) and ST (3.2±4.7 </text>
<text top="687" left="683" width="168" height="17" font="0">min) more than OMC (0.2±2.1 </text>
<text top="705" left="683" width="148" height="17" font="0">min); p&lt;0.001 and p&lt;0.04, </text>
<text top="722" left="683" width="175" height="17" font="0">respectively. SE and ST did not </text>
<text top="739" left="683" width="34" height="17" font="0">differ. </text>
<text top="756" left="683" width="3" height="17" font="0"> </text>
<text top="775" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="774" left="690" width="6" height="18" font="7"></text>
<text top="775" left="696" width="154" height="17" font="2"><b> Safety endpoint:</b> All major </text>
<text top="635" left="878" width="7" height="18" font="7"></text>
<text top="636" left="884" width="193" height="17" font="0"> At 18 mo, improvement in disease-</text>
<text top="653" left="878" width="177" height="17" font="0">specific scales (WIQ, PAQ) was </text>
<text top="670" left="878" width="191" height="17" font="0">statistically superior for ST and SE </text>
<text top="687" left="878" width="202" height="17" font="0">compared with OMC, but ST and SE </text>
<text top="705" left="878" width="201" height="17" font="0">differed significantly from each other </text>
<text top="722" left="878" width="211" height="17" font="0">(favoring ST) only for PAQ symptoms, </text>
<text top="739" left="878" width="213" height="17" font="0">PAQ treatment satisfaction, PAQ QoL, </text>
<text top="756" left="878" width="107" height="17" font="0">and PAQ summary </text>
<text top="774" left="878" width="7" height="18" font="7"></text>
<text top="775" left="884" width="206" height="17" font="0"> Mean ABI values were normalized in </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="23" size="13" family="Times" color="#131312"/>
<text top="795" left="1088" width="17" height="17" font="0">83 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="222" width="36" height="17" font="0">OMC. </text>
<text top="104" left="222" width="3" height="17" font="0"> </text>
<text top="122" left="222" width="102" height="17" font="2"><b>Study type: </b>Long-</text>
<text top="139" left="222" width="94" height="17" font="0">term follow-up of </text>
<text top="156" left="222" width="32" height="17" font="0">RCT  </text>
<text top="173" left="222" width="3" height="17" font="0"> </text>
<text top="190" left="222" width="101" height="17" font="2"><b>Size:</b> n=79 of 111 </text>
<text top="208" left="222" width="107" height="17" font="0">pts initially enrolled </text>
<text top="225" left="222" width="60" height="17" font="0">completed </text>
<text top="242" left="222" width="106" height="17" font="0">assessments at 18 </text>
<text top="259" left="222" width="24" height="17" font="0">mo. </text>
<text top="87" left="344" width="7" height="18" font="7"></text>
<text top="88" left="351" width="146" height="17" font="2"><b> </b>Stenosis of distal aorta or </text>
<text top="106" left="344" width="72" height="17" font="0">iliac arteries. </text>
<text top="123" left="344" width="3" height="17" font="0"> </text>
<text top="140" left="344" width="147" height="17" font="2"><b>Exclusion criteria:</b> CLI or </text>
<text top="157" left="344" width="147" height="17" font="0">2 comorbid conditions that </text>
<text top="174" left="344" width="122" height="17" font="0">limited walking ability. </text>
<text top="87" left="513" width="101" height="17" font="2"><b>Comparator:</b> N/A </text>
<text top="87" left="683" width="174" height="17" font="0">adverse events occurred in first </text>
<text top="104" left="683" width="165" height="17" font="0">6 mo and not in the follow-up. </text>
<text top="122" left="683" width="155" height="17" font="0">These included an MI in the </text>
<text top="139" left="683" width="148" height="17" font="0">OMC group; 1 death in SE </text>
<text top="156" left="683" width="133" height="17" font="0">group; and 1 target limb </text>
<text top="173" left="683" width="148" height="17" font="0">revascularization in the ST </text>
<text top="190" left="683" width="42" height="17" font="0">group.  </text>
<text top="87" left="878" width="228" height="17" font="0">the stented pts and changed by 0.00±0.1 </text>
<text top="104" left="878" width="216" height="17" font="0">for OMC, 0.2±0.2 for ST, and 0.00±0.1 </text>
<text top="122" left="878" width="202" height="17" font="0">for SE (p=0.002 for ST vs. OMC and </text>
<text top="139" left="878" width="128" height="17" font="0">p&lt;0.001 for ST vs. SE) </text>
<text top="156" left="878" width="7" height="18" font="7"></text>
<text top="157" left="884" width="222" height="17" font="0"> SE had the advantage of improved limb </text>
<text top="174" left="878" width="220" height="17" font="0">muscle strength, walking efficiency, and </text>
<text top="192" left="878" width="76" height="17" font="0">performance. </text>
<text top="277" left="95" width="57" height="17" font="2"><b>CLEVER</b>  </text>
<text top="294" left="95" width="97" height="17" font="0">Murphy TP, et al. </text>
<text top="312" left="95" width="63" height="17" font="0">2012 (187) </text>
<text top="329" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22090168">22090168 </a></text>
<text top="346" left="95" width="3" height="17" font="0"> </text>
<text top="277" left="222" width="31" height="17" font="2"><b>Aim:</b> </text>
<text top="277" left="252" width="75" height="17" font="23">Compare the </text>
<text top="294" left="222" width="105" height="17" font="23">benefits OMC, SE, </text>
<text top="312" left="222" width="88" height="17" font="23">and ST on both </text>
<text top="329" left="222" width="101" height="17" font="23">walking outcomes </text>
<text top="346" left="222" width="95" height="17" font="23">and measures of </text>
<text top="363" left="222" width="85" height="17" font="23">QoL in pts with </text>
<text top="381" left="222" width="106" height="17" font="23">claudication due to </text>
<text top="398" left="222" width="81" height="17" font="23">aortoiliac PAD.</text>
<text top="398" left="303" width="3" height="17" font="0"> </text>
<text top="415" left="222" width="3" height="17" font="0"> </text>
<text top="432" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="449" left="222" width="3" height="17" font="0"> </text>
<text top="467" left="222" width="90" height="17" font="2"><b>Size:</b> n=111 pts </text>
<text top="277" left="344" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="295" left="344" width="7" height="18" font="7"></text>
<text top="296" left="351" width="63" height="17" font="0"> Age &gt;40 y </text>
<text top="313" left="344" width="7" height="18" font="7"></text>
<text top="314" left="351" width="129" height="17" font="0"> Moderate to severe IC </text>
<text top="331" left="344" width="138" height="17" font="0">due to aortoiliac PAD. IC </text>
<text top="348" left="344" width="150" height="17" font="0">defined as ability to walk at </text>
<text top="366" left="344" width="125" height="17" font="0">least 2 min on TM at 2 </text>
<text top="383" left="344" width="137" height="17" font="0">miles/hr at 0% grade but </text>
<text top="400" left="344" width="144" height="17" font="0">&lt;11 min (about 5.5 METS </text>
<text top="417" left="344" width="68" height="17" font="0">maximum).  </text>
<text top="434" left="344" width="7" height="18" font="7"></text>
<text top="436" left="351" width="134" height="17" font="0"> ≥50% stenosis of distal </text>
<text top="453" left="344" width="122" height="17" font="0">aorta or iliac arteries.  </text>
<text top="470" left="344" width="3" height="17" font="0"> </text>
<text top="487" left="344" width="147" height="17" font="2"><b>Exclusion criteria:</b> CLI or </text>
<text top="504" left="344" width="147" height="17" font="0">2 comorbid conditions that </text>
<text top="522" left="344" width="125" height="17" font="0">limited walking ability.  </text>
<text top="277" left="513" width="148" height="17" font="2"><b>Intervention:</b> OMC, n=22; </text>
<text top="294" left="513" width="135" height="17" font="0">SE, n=44; ST, n=46. SE </text>
<text top="312" left="513" width="155" height="17" font="0">was supervised for 26 wk, 3 </text>
<text top="329" left="513" width="143" height="17" font="0">times/wk, 1 hr for 6 mo. A </text>
<text top="346" left="513" width="148" height="17" font="0">ST/SE group was dropped </text>
<text top="363" left="513" width="116" height="17" font="0">after 8 pt to enhance </text>
<text top="381" left="513" width="126" height="17" font="0">enrollment in the other </text>
<text top="398" left="513" width="130" height="17" font="0">groups. Randomization </text>
<text top="415" left="513" width="83" height="17" font="0">ratio was 2:2:1 </text>
<text top="432" left="513" width="86" height="17" font="0">(ST:SE:OMC).  </text>
<text top="449" left="513" width="3" height="17" font="0"> </text>
<text top="467" left="513" width="101" height="17" font="2"><b>Comparator:</b> N/A </text>
<text top="278" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="277" left="690" width="6" height="18" font="7"></text>
<text top="278" left="696" width="149" height="17" font="2"><b> endpoint:</b> Compared with </text>
<text top="296" left="683" width="154" height="17" font="0">baseline, PWT improved by </text>
<text top="313" left="683" width="164" height="17" font="0">1.2±2.6 min with OMC alone, </text>
<text top="330" left="683" width="142" height="17" font="0">5.8±4.6 min with SE, and </text>
<text top="347" left="683" width="178" height="17" font="0">3.7±4.9 min with ST. Compared </text>
<text top="365" left="683" width="158" height="17" font="0">with OMC alone, SE led to a </text>
<text top="382" left="683" width="164" height="17" font="0">greater mean improvement in </text>
<text top="399" left="683" width="166" height="17" font="0">PWT by 4.6 min (95% CI: 2.7–</text>
<text top="416" left="683" width="173" height="17" font="0">6.5; p&lt;0.001), whereas ST had </text>
<text top="433" left="683" width="156" height="17" font="0">a somewhat smaller relative </text>
<text top="451" left="683" width="176" height="17" font="0">improvement in PWT of 2.5 min </text>
<text top="468" left="683" width="167" height="17" font="0">(95% CI: 0.6–4.4; p=0.022). A </text>
<text top="485" left="683" width="158" height="17" font="0">direct comparison of SE and </text>
<text top="502" left="683" width="118" height="17" font="0">ST showed a greater </text>
<text top="519" left="683" width="180" height="17" font="0">improvement in PWT with SE by </text>
<text top="537" left="683" width="177" height="17" font="0">a mean of 2.1 min (95% CI: 0.0–</text>
<text top="554" left="683" width="69" height="17" font="0">4.2; p=0.04) </text>
<text top="571" left="683" width="3" height="17" font="0"> </text>
<text top="588" left="683" width="179" height="17" font="2"><b>Safety endpoint:</b> 4 SAEs within </text>
<text top="605" left="683" width="165" height="17" font="0">30 d of ST. SAEs noted in the </text>
<text top="623" left="683" width="176" height="17" font="0">18 mo follow-up report that said </text>
<text top="640" left="683" width="165" height="17" font="0">they occurred in the first 6 mo </text>
<text top="657" left="683" width="115" height="17" font="0">were not mentioned. </text>
<text top="277" left="878" width="7" height="18" font="7"></text>
<text top="278" left="884" width="209" height="17" font="0"> ABI improved by 0.29±0.33 in the ST </text>
<text top="296" left="878" width="128" height="17" font="0">group (p&lt;0.0001) only. </text>
<text top="313" left="878" width="7" height="18" font="7"></text>
<text top="314" left="884" width="193" height="17" font="0"> The greatest improvements in self-</text>
<text top="331" left="878" width="213" height="17" font="0">reported QoL were observed in the ST </text>
<text top="348" left="878" width="223" height="17" font="0">cohort despite greater increases in PWT </text>
<text top="366" left="878" width="92" height="17" font="0">in the SE group. </text>
<text top="675" left="95" width="51" height="17" font="2"><b>GOALS</b>  </text>
<text top="692" left="95" width="105" height="17" font="0">McDermott MM, et </text>
<text top="710" left="95" width="16" height="17" font="0">al. </text>
<text top="727" left="95" width="56" height="17" font="0">2013 (17) </text>
<text top="744" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821089">23821089 </a></text>
<text top="761" left="95" width="3" height="17" font="0"> </text>
<text top="675" left="222" width="91" height="17" font="2"><b>Aim:</b> Determine </text>
<text top="692" left="222" width="92" height="17" font="0">whether a home-</text>
<text top="710" left="222" width="81" height="17" font="0">based walking </text>
<text top="727" left="222" width="98" height="17" font="0">exercise program </text>
<text top="744" left="222" width="79" height="17" font="0">using a group-</text>
<text top="761" left="222" width="106" height="17" font="0">mediated cognitive </text>
<text top="675" left="344" width="151" height="17" font="2"><b>Inclusion criteria:</b> Resting </text>
<text top="692" left="344" width="140" height="17" font="0">ABI ≤0.9 or ABI between </text>
<text top="710" left="344" width="133" height="17" font="0">0.91–1 with a 20% drop </text>
<text top="727" left="344" width="127" height="17" font="0">after a heel-rise test or </text>
<text top="744" left="344" width="131" height="17" font="0">medical evidence of LE </text>
<text top="761" left="344" width="110" height="17" font="0">revascularization or </text>
<text top="675" left="513" width="143" height="17" font="2"><b>Intervention:</b> Walking on-</text>
<text top="692" left="513" width="92" height="17" font="0">ground (not TM) </text>
<text top="710" left="513" width="132" height="17" font="0">progressing to 50 min 5 </text>
<text top="727" left="513" width="145" height="17" font="0">times/wk for 6 mo. For pts </text>
<text top="744" left="513" width="152" height="17" font="0">with IC, walk to pain level 4 </text>
<text top="761" left="513" width="148" height="17" font="0">of 5, rest, and resume. For </text>
<text top="676" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="675" left="690" width="6" height="18" font="7"></text>
<text top="676" left="696" width="124" height="17" font="2"><b> endpoint:</b> Exercisers </text>
<text top="693" left="683" width="146" height="17" font="0">increased their 6 min walk </text>
<text top="711" left="683" width="166" height="17" font="0">distance (357.4–399.8 meters </text>
<text top="728" left="683" width="150" height="17" font="0">vs. 353.3–342.2 meters for </text>
<text top="745" left="683" width="180" height="17" font="0">those in the control group; mean </text>
<text top="762" left="683" width="170" height="17" font="0">difference: 53.5; 95% CI: 33.2–</text>
<text top="675" left="878" width="7" height="18" font="7"></text>
<text top="676" left="884" width="219" height="17" font="0"> Maximal TM walking time (intervention, </text>
<text top="693" left="878" width="206" height="17" font="0">7.91–9.44 min vs. control, 7.56–8.09; </text>
<text top="711" left="878" width="196" height="17" font="0">mean difference: 1.01 min; 95% CI: </text>
<text top="728" left="878" width="193" height="17" font="0">0.07–1.95; p=0.04), accelerometer-</text>
<text top="745" left="878" width="201" height="17" font="0">measured physical activity over 7 ds </text>
<text top="762" left="878" width="209" height="17" font="0">(intervention, 778.0–866.1 vs. control, </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">84 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="222" width="60" height="17" font="0">behavioral </text>
<text top="104" left="222" width="81" height="17" font="0">approach, can </text>
<text top="122" left="222" width="103" height="17" font="0">improve functional </text>
<text top="139" left="222" width="73" height="17" font="0">performance </text>
<text top="156" left="222" width="94" height="17" font="0">compared with a </text>
<text top="173" left="222" width="108" height="17" font="0">control group in pts </text>
<text top="190" left="222" width="103" height="17" font="0">with PAD with and </text>
<text top="208" left="222" width="62" height="17" font="0">without IC. </text>
<text top="225" left="222" width="3" height="17" font="0"> </text>
<text top="242" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="259" left="222" width="3" height="17" font="0"> </text>
<text top="276" left="222" width="90" height="17" font="2"><b>Size:</b> n=194 pts </text>
<text top="87" left="344" width="102" height="17" font="0">evidence of PAD.  </text>
<text top="104" left="344" width="3" height="17" font="0"> </text>
<text top="122" left="344" width="129" height="17" font="2"><b>Exclusion criteria:</b> LE </text>
<text top="139" left="344" width="130" height="17" font="0">amputation, wheelchair </text>
<text top="156" left="344" width="132" height="17" font="0">confinement, inability to </text>
<text top="173" left="344" width="123" height="17" font="0">walk 50 ft, walking aid </text>
<text top="190" left="344" width="118" height="17" font="0">except cane, walking </text>
<text top="208" left="344" width="155" height="17" font="0">impairment other than PAD, </text>
<text top="225" left="344" width="140" height="17" font="0">surgery within past 3 mo, </text>
<text top="242" left="344" width="141" height="17" font="0">other major comorbidities </text>
<text top="259" left="344" width="110" height="17" font="0">that would preclude </text>
<text top="276" left="344" width="126" height="17" font="0">unsupervised exercise </text>
<text top="87" left="513" width="144" height="17" font="0">pts without IC, walk at 12–</text>
<text top="104" left="513" width="128" height="17" font="0">14 on Borg RPE scale. </text>
<text top="122" left="513" width="135" height="17" font="0">Using a group-mediated </text>
<text top="139" left="513" width="112" height="17" font="0">cognitive behavioral </text>
<text top="156" left="513" width="143" height="17" font="0">approach, exercisers also </text>
<text top="173" left="513" width="148" height="17" font="0">met once a wk for 90 min.  </text>
<text top="190" left="513" width="3" height="17" font="0"> </text>
<text top="208" left="513" width="116" height="17" font="2"><b>Comparator:</b> Health </text>
<text top="225" left="513" width="156" height="17" font="0">education control group that </text>
<text top="242" left="513" width="137" height="17" font="0">met weekly for 60 min to </text>
<text top="259" left="513" width="126" height="17" font="0">discuss general health </text>
<text top="276" left="513" width="42" height="17" font="0">topics.  </text>
<text top="87" left="683" width="82" height="17" font="0">73.8; p&lt;0.001. </text>
<text top="104" left="683" width="3" height="17" font="0"> </text>
<text top="122" left="683" width="163" height="17" font="2"><b>Safety endpoint:</b> 1 exerciser </text>
<text top="139" left="683" width="174" height="17" font="0">developed dyspnea on exertion </text>
<text top="156" left="683" width="148" height="17" font="0">and subsequently required </text>
<text top="173" left="683" width="155" height="17" font="0">CABG and completed study </text>
<text top="190" left="683" width="82" height="17" font="0">after recovery. </text>
<text top="87" left="878" width="205" height="17" font="0">671.6–645.0; mean difference: 114.7 </text>
<text top="104" left="878" width="196" height="17" font="0">activity units; 95% CI: 12.82–216.5; </text>
<text top="122" left="878" width="160" height="17" font="0">p=0.03), WIQ distance score </text>
<text top="139" left="878" width="226" height="17" font="0">(intervention, 35.3–47.4 vs. control, 33.3–</text>
<text top="156" left="878" width="204" height="17" font="0">34.4; mean difference: 11.1; 95% CI: </text>
<text top="173" left="878" width="199" height="17" font="0">3.9–18.1; p=0.003), and WIQ speed </text>
<text top="190" left="878" width="229" height="17" font="0">score (intervention: 36.1–47.7 vs. control: </text>
<text top="208" left="878" width="215" height="17" font="0">35.3–36.6; mean difference: 10.4; 95% </text>
<text top="225" left="878" width="130" height="17" font="0">CI: 3.4–17.4; p=0.004). </text>
<text top="242" left="878" width="7" height="18" font="7"></text>
<text top="243" left="884" width="217" height="17" font="0"> 1 death from cancer among exercisers </text>
<text top="260" left="878" width="229" height="17" font="0">and 2 deaths from hypertensive CVD and </text>
<text top="278" left="878" width="222" height="17" font="0">CVD with pneumonia, all considered not </text>
<text top="295" left="878" width="77" height="17" font="0">study related. </text>
<text top="313" left="95" width="51" height="17" font="2"><b>GOALS</b>  </text>
<text top="330" left="95" width="105" height="17" font="0">McDermott MM, et </text>
<text top="347" left="95" width="16" height="17" font="0">al. </text>
<text top="365" left="95" width="63" height="17" font="0">2014 (188) </text>
<text top="382" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24850615">24850615 </a></text>
<text top="399" left="95" width="3" height="17" font="0"> </text>
<text top="313" left="222" width="62" height="17" font="2"><b>Aim:</b> 6 mo </text>
<text top="330" left="222" width="81" height="17" font="0">intervention of </text>
<text top="347" left="222" width="63" height="17" font="0">walking vs. </text>
<text top="365" left="222" width="105" height="17" font="0">controls in pts with </text>
<text top="382" left="222" width="78" height="17" font="0">PAD with and </text>
<text top="399" left="222" width="100" height="17" font="0">without IC. This is </text>
<text top="416" left="222" width="109" height="17" font="0">a follow-up study at </text>
<text top="433" left="222" width="100" height="17" font="0">12 mo, 6 mo after </text>
<text top="451" left="222" width="94" height="17" font="0">completing the 6 </text>
<text top="468" left="222" width="87" height="17" font="0">mo intervention </text>
<text top="485" left="222" width="3" height="17" font="0"> </text>
<text top="502" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="519" left="222" width="3" height="17" font="0"> </text>
<text top="537" left="222" width="97" height="17" font="2"><b>Size:</b> Initial study </text>
<text top="554" left="222" width="108" height="17" font="0">enrolled 194 pts, of </text>
<text top="571" left="222" width="59" height="17" font="0">which 178 </text>
<text top="588" left="222" width="100" height="17" font="0">completed testing </text>
<text top="605" left="222" width="104" height="17" font="0">at 6 mo. At 12 mo, </text>
<text top="623" left="222" width="84" height="17" font="0">168 completed </text>
<text top="640" left="222" width="92" height="17" font="0">follow-up testing </text>
<text top="313" left="344" width="151" height="17" font="2"><b>Inclusion criteria:</b> Resting </text>
<text top="330" left="344" width="140" height="17" font="0">ABI ≤0.9 or ABI between </text>
<text top="347" left="344" width="133" height="17" font="0">0.91–1 with a 20% drop </text>
<text top="365" left="344" width="127" height="17" font="0">after a heel-rise test or </text>
<text top="382" left="344" width="131" height="17" font="0">medical evidence of LE </text>
<text top="399" left="344" width="110" height="17" font="0">revascularization or </text>
<text top="416" left="344" width="98" height="17" font="0">evidence of PAD. </text>
<text top="433" left="344" width="3" height="17" font="0"> </text>
<text top="451" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="468" left="344" width="7" height="18" font="7"></text>
<text top="469" left="351" width="86" height="17" font="0"> LE amputation </text>
<text top="486" left="344" width="7" height="18" font="7"></text>
<text top="487" left="351" width="139" height="17" font="0"> Wheelchair confinement </text>
<text top="505" left="344" width="7" height="18" font="7"></text>
<text top="506" left="351" width="118" height="17" font="0"> Inability to walk 50 ft </text>
<text top="523" left="344" width="7" height="18" font="7"></text>
<text top="524" left="351" width="140" height="17" font="0"> Walking aid except cane </text>
<text top="541" left="344" width="7" height="18" font="7"></text>
<text top="542" left="351" width="146" height="17" font="0"> Walking impairment other </text>
<text top="560" left="344" width="56" height="17" font="0">than PAD </text>
<text top="577" left="344" width="7" height="18" font="7"></text>
<text top="578" left="351" width="142" height="17" font="0"> Surgery within past 3 mo </text>
<text top="595" left="344" width="7" height="18" font="7"></text>
<text top="596" left="351" width="148" height="17" font="0"> Other major comorbidities </text>
<text top="614" left="344" width="110" height="17" font="0">that would preclude </text>
<text top="631" left="344" width="126" height="17" font="0">unsupervised exercise </text>
<text top="313" left="513" width="148" height="17" font="2"><b>Intervention:</b> During 6 mo </text>
<text top="330" left="513" width="151" height="17" font="0">phase, exercisers attended </text>
<text top="347" left="513" width="131" height="17" font="0">weekly group sessions, </text>
<text top="365" left="513" width="120" height="17" font="0">which included group-</text>
<text top="382" left="513" width="106" height="17" font="0">mediated cognitive </text>
<text top="399" left="513" width="126" height="17" font="0">behavioral techniques. </text>
<text top="416" left="513" width="121" height="17" font="0">During the next 6 mo, </text>
<text top="433" left="513" width="131" height="17" font="0">exercisers received call </text>
<text top="451" left="513" width="143" height="17" font="0">from their group facilitator </text>
<text top="468" left="513" width="136" height="17" font="0">and were encouraged to </text>
<text top="485" left="513" width="133" height="17" font="0">exercise and keep logs, </text>
<text top="502" left="513" width="135" height="17" font="0">which were sent back to </text>
<text top="519" left="513" width="67" height="17" font="0">study team. </text>
<text top="537" left="513" width="3" height="17" font="0"> </text>
<text top="554" left="513" width="127" height="17" font="2"><b>Comparator:</b> Controls </text>
<text top="571" left="513" width="133" height="17" font="0">received calls related to </text>
<text top="588" left="513" width="120" height="17" font="0">general health topics. </text>
<text top="314" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="313" left="690" width="6" height="18" font="7"></text>
<text top="314" left="696" width="137" height="17" font="2"><b> endpoint:</b> Compared to </text>
<text top="331" left="683" width="166" height="17" font="0">controls, exercisers increased </text>
<text top="348" left="683" width="166" height="17" font="0">their 6 min walk distance from </text>
<text top="366" left="683" width="157" height="17" font="0">baseline to 12 mo follow-up, </text>
<text top="383" left="683" width="151" height="17" font="0">(from 355.4–381.9 m in the </text>
<text top="400" left="683" width="172" height="17" font="0">intervention vs. 353.1–345.6 m </text>
<text top="417" left="683" width="146" height="17" font="0">in the control group; mean </text>
<text top="434" left="683" width="160" height="17" font="0">difference: +34.1 m; 95% CI: </text>
<text top="452" left="683" width="117" height="17" font="0">14.6–53.5; p&lt;0.001)  </text>
<text top="469" left="683" width="3" height="17" font="0"> </text>
<text top="486" left="683" width="166" height="17" font="2"><b>Safety endpoint:</b> No adverse </text>
<text top="503" left="683" width="89" height="17" font="0">events reported </text>
<text top="313" left="878" width="7" height="18" font="7"></text>
<text top="314" left="884" width="191" height="17" font="0"> WIQ speed score increased (from </text>
<text top="331" left="878" width="221" height="17" font="0">36.1–46.5 in exercisers vs. 34.9–36.5 in </text>
<text top="348" left="878" width="225" height="17" font="0">the control group; mean difference: +8.8; </text>
<text top="366" left="878" width="225" height="17" font="0">95% CI: +1.6 – +16.1; p=0.018). Change </text>
<text top="383" left="878" width="190" height="17" font="0">in the WIQ distance score was not </text>
<text top="400" left="878" width="190" height="17" font="0">different between groups at 12 mo </text>
<text top="417" left="878" width="60" height="17" font="0">(p=0.139). </text>
<text top="434" left="878" width="7" height="18" font="7"></text>
<text top="436" left="884" width="159" height="17" font="0"> No adverse events reported </text>
<text top="658" left="95" width="94" height="17" font="0">Collins TC, et al. </text>
<text top="675" left="95" width="63" height="17" font="0">2011 (189) </text>
<text top="692" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21873560">21873560 </a></text>
<text top="710" left="95" width="3" height="17" font="0"> </text>
<text top="658" left="222" width="91" height="17" font="2"><b>Aim:</b> Determine </text>
<text top="675" left="222" width="89" height="17" font="0">the efficacy of a </text>
<text top="692" left="222" width="72" height="17" font="0">home-based </text>
<text top="710" left="222" width="44" height="17" font="0">walking </text>
<text top="727" left="222" width="81" height="17" font="0">intervention to </text>
<text top="744" left="222" width="92" height="17" font="0">improve walking </text>
<text top="761" left="222" width="98" height="17" font="0">ability and QoL in </text>
<text top="658" left="344" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="675" left="344" width="7" height="18" font="7"></text>
<text top="676" left="351" width="64" height="17" font="0"> Age ≥40 y </text>
<text top="693" left="344" width="7" height="18" font="7"></text>
<text top="694" left="351" width="147" height="17" font="0"> With PAD or prior surgery </text>
<text top="712" left="344" width="144" height="17" font="0">for PAD with continued IC </text>
<text top="729" left="344" width="7" height="18" font="7"></text>
<text top="730" left="351" width="92" height="17" font="0"> Type 1 or 2 DM </text>
<text top="747" left="344" width="3" height="17" font="0"> </text>
<text top="765" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="658" left="513" width="155" height="17" font="2"><b>Intervention:</b> All pts in both </text>
<text top="675" left="513" width="148" height="17" font="0">groups received education </text>
<text top="692" left="513" width="110" height="17" font="0">about PAD and self-</text>
<text top="710" left="513" width="150" height="17" font="0">management behaviors for </text>
<text top="727" left="513" width="142" height="17" font="0">DM and CVD risk factors. </text>
<text top="744" left="513" width="151" height="17" font="0">Exercisers participated in a </text>
<text top="761" left="513" width="113" height="17" font="0">home-based routine </text>
<text top="659" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="658" left="690" width="6" height="18" font="7"></text>
<text top="659" left="696" width="169" height="17" font="2"><b> endpoint:</b> The groups did not </text>
<text top="676" left="683" width="180" height="17" font="0">differ in 6 mo change in maximal </text>
<text top="693" left="683" width="143" height="17" font="0">treadmill walking distance </text>
<text top="711" left="683" width="174" height="17" font="0">average: 24.5; SE: 19.6 meters </text>
<text top="728" left="683" width="163" height="17" font="0">vs. maximal treadmill walking </text>
<text top="745" left="683" width="155" height="17" font="0">distance average: 39.2; SE: </text>
<text top="762" left="683" width="117" height="17" font="0">19.6 meters; p=0.60. </text>
<text top="658" left="878" width="7" height="18" font="7"></text>
<text top="659" left="884" width="204" height="17" font="0"> For the exercise and control groups, </text>
<text top="676" left="878" width="201" height="17" font="0">respectively, average walking speed </text>
<text top="693" left="878" width="222" height="17" font="0">scores increased by 5.7 (standard error: </text>
<text top="711" left="878" width="176" height="17" font="0">2.2) units and decreased by 1.9 </text>
<text top="728" left="878" width="216" height="17" font="0">(standard error: 2.8) units (p=0.03); the </text>
<text top="745" left="878" width="224" height="17" font="0">mental health QoL subscale score of the </text>
<text top="762" left="878" width="219" height="17" font="0">SF-36 increased by 3.2 (standard error: </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">85 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="222" width="88" height="17" font="0">people with DM </text>
<text top="104" left="222" width="53" height="17" font="0">and PAD </text>
<text top="122" left="222" width="3" height="17" font="0"> </text>
<text top="139" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="156" left="222" width="3" height="17" font="0"> </text>
<text top="173" left="222" width="90" height="17" font="2"><b>Size:</b> n=145 pts </text>
<text top="87" left="344" width="7" height="18" font="7"></text>
<text top="88" left="351" width="135" height="17" font="0"> No intention to exercise </text>
<text top="106" left="344" width="7" height="18" font="7"></text>
<text top="107" left="351" width="80" height="17" font="0"> No telephone </text>
<text top="124" left="344" width="7" height="18" font="7"></text>
<text top="125" left="351" width="86" height="17" font="0"> LE amputation </text>
<text top="142" left="344" width="7" height="18" font="7"></text>
<text top="143" left="351" width="26" height="17" font="0"> CLI </text>
<text top="161" left="344" width="7" height="18" font="7"></text>
<text top="162" left="351" width="131" height="17" font="0"> LE revascularization in </text>
<text top="179" left="344" width="57" height="17" font="0">past 6 mo </text>
<text top="196" left="344" width="7" height="18" font="7"></text>
<text top="197" left="351" width="116" height="17" font="0"> MI within past 3 mo  </text>
<text top="215" left="344" width="7" height="18" font="7"></text>
<text top="216" left="351" width="142" height="17" font="0"> Comorbidities that would </text>
<text top="233" left="344" width="133" height="17" font="0">preclude participation in </text>
<text top="250" left="344" width="126" height="17" font="0">unsupervised exercise </text>
<text top="267" left="344" width="53" height="17" font="0">program  </text>
<text top="87" left="513" width="156" height="17" font="0">walking program for 3 d and </text>
<text top="104" left="513" width="139" height="17" font="0">1 group exercise session </text>
<text top="122" left="513" width="92" height="17" font="0">per wk for 6 mo. </text>
<text top="139" left="513" width="3" height="17" font="0"> </text>
<text top="156" left="513" width="127" height="17" font="2"><b>Comparator:</b> Controls </text>
<text top="173" left="513" width="156" height="17" font="0">received twice monthly calls </text>
<text top="190" left="513" width="122" height="17" font="0">to discuss their health </text>
<text top="208" left="513" width="57" height="17" font="0">behaviors </text>
<text top="87" left="683" width="3" height="17" font="0"> </text>
<text top="104" left="683" width="119" height="17" font="2"><b>Safety endpoint:</b> No </text>
<text top="122" left="683" width="176" height="17" font="0">unanticipated adverse events in </text>
<text top="139" left="683" width="148" height="17" font="0">either group. Some events </text>
<text top="156" left="683" width="172" height="17" font="0">included general health issues, </text>
<text top="173" left="683" width="174" height="17" font="0">leg bypass surgery, broken hip, </text>
<text top="190" left="683" width="159" height="17" font="0">foot problems, and unable to </text>
<text top="208" left="683" width="163" height="17" font="0">complete treadmill testing but </text>
<text top="225" left="683" width="174" height="17" font="0">these were too few to ascertain </text>
<text top="242" left="683" width="78" height="17" font="0">group effects. </text>
<text top="87" left="878" width="202" height="17" font="0">1.5) and decreased by 2.4 (standard </text>
<text top="104" left="878" width="140" height="17" font="0">error: 1.5) units (p=0.01). </text>
<text top="285" left="95" width="105" height="17" font="0">Gardner AW, et al. </text>
<text top="303" left="95" width="63" height="17" font="0">2011 (190) </text>
<text top="320" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21262997">21262997 </a></text>
<text top="337" left="95" width="3" height="17" font="0"> </text>
<text top="285" left="222" width="85" height="17" font="2"><b>Aim:</b> Compare </text>
<text top="303" left="222" width="63" height="17" font="0">changes in </text>
<text top="320" left="222" width="49" height="17" font="0">exercise </text>
<text top="337" left="222" width="96" height="17" font="0">performance and </text>
<text top="354" left="222" width="93" height="17" font="0">daily ambulatory </text>
<text top="371" left="222" width="108" height="17" font="0">activity in PAD with </text>
<text top="389" left="222" width="89" height="17" font="0">IC after a home-</text>
<text top="406" left="222" width="86" height="17" font="0">based exercise </text>
<text top="423" left="222" width="63" height="17" font="0">program, a </text>
<text top="440" left="222" width="63" height="17" font="0">supervised </text>
<text top="457" left="222" width="102" height="17" font="0">exercise program, </text>
<text top="475" left="222" width="85" height="17" font="0">and usual-care </text>
<text top="492" left="222" width="44" height="17" font="0">control. </text>
<text top="509" left="222" width="3" height="17" font="0"> </text>
<text top="526" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="544" left="222" width="3" height="17" font="0"> </text>
<text top="561" left="222" width="90" height="17" font="2"><b>Size:</b> n=119 pts </text>
<text top="285" left="344" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="303" left="344" width="148" height="17" font="0">Exertional leg pain, resting </text>
<text top="320" left="344" width="147" height="17" font="0">ABI ≤0.9 or ABI ≤.73 after </text>
<text top="337" left="344" width="49" height="17" font="0">exercise </text>
<text top="354" left="344" width="3" height="17" font="0"> </text>
<text top="371" left="344" width="155" height="17" font="2"><b>Exclusion criteria:</b> Inability </text>
<text top="389" left="344" width="112" height="17" font="0">to obtain ABI due to </text>
<text top="406" left="344" width="144" height="17" font="0">noncompressible vessels, </text>
<text top="423" left="344" width="146" height="17" font="0">asx PAD, use of cliostazol </text>
<text top="440" left="344" width="135" height="17" font="0">or pentoxifylline initiated </text>
<text top="457" left="344" width="140" height="17" font="0">within 3 mo before study, </text>
<text top="475" left="344" width="136" height="17" font="0">exercise limited by other </text>
<text top="492" left="344" width="156" height="17" font="0">causes, major comorbidities </text>
<text top="509" left="344" width="132" height="17" font="0">(active cancer, renal, or </text>
<text top="526" left="344" width="72" height="17" font="0">liver disease </text>
<text top="285" left="513" width="117" height="17" font="2"><b>Intervention:</b> 12 wk. </text>
<text top="303" left="513" width="137" height="17" font="0">Home-based exercise of </text>
<text top="320" left="513" width="151" height="17" font="0">intermittent walking to near-</text>
<text top="337" left="513" width="152" height="17" font="0">maximal pain 3 d/wk at self-</text>
<text top="354" left="513" width="130" height="17" font="0">selected pace. Walking </text>
<text top="371" left="513" width="141" height="17" font="0">duration progressed from </text>
<text top="389" left="513" width="135" height="17" font="0">20 min initially to 45 min </text>
<text top="406" left="513" width="106" height="17" font="0">during final 2 wk of </text>
<text top="423" left="513" width="118" height="17" font="0">program. Supervised </text>
<text top="440" left="513" width="151" height="17" font="0">program was performed on </text>
<text top="457" left="513" width="150" height="17" font="0">a treadmill with durations 5 </text>
<text top="475" left="513" width="127" height="17" font="0">min shorter than home-</text>
<text top="492" left="513" width="139" height="17" font="0">based program. Intensity </text>
<text top="509" left="513" width="105" height="17" font="0">set at 40% of peak </text>
<text top="526" left="513" width="130" height="17" font="0">workload from baseline </text>
<text top="544" left="513" width="118" height="17" font="0">exercise test, to near-</text>
<text top="561" left="513" width="131" height="17" font="0">maximal pain, rest, and </text>
<text top="578" left="513" width="126" height="17" font="0">resume exercise. Both </text>
<text top="595" left="513" width="139" height="17" font="0">groups used step activity </text>
<text top="612" left="513" width="116" height="17" font="0">monitors to measure </text>
<text top="630" left="513" width="48" height="17" font="0">walking. </text>
<text top="647" left="513" width="3" height="17" font="0"> </text>
<text top="664" left="513" width="157" height="17" font="2"><b>Comparator:</b> Non-exercise, </text>
<text top="681" left="513" width="104" height="17" font="0">usual care control  </text>
<text top="286" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="285" left="690" width="6" height="18" font="7"></text>
<text top="286" left="696" width="141" height="17" font="2"><b> endpoint:</b> Both exercise </text>
<text top="304" left="683" width="180" height="17" font="0">programs increased claudication </text>
<text top="321" left="683" width="171" height="17" font="0">onset time (p&lt;0.001) and peak </text>
<text top="338" left="683" width="173" height="17" font="0">walking time (p&lt;0.01). Controls </text>
<text top="355" left="683" width="88" height="17" font="0">did not change. </text>
<text top="373" left="683" width="3" height="17" font="0"> </text>
<text top="390" left="683" width="174" height="17" font="2"><b>Safety endpoint:</b> Not specified </text>
<text top="407" left="683" width="155" height="17" font="0">but though no unanticipated </text>
<text top="424" left="683" width="172" height="17" font="0">adverse events in either group. </text>
<text top="441" left="683" width="169" height="17" font="0">Events included stroke (2), leg </text>
<text top="459" left="683" width="181" height="17" font="0">revascularization (2), MI (1), and </text>
<text top="476" left="683" width="172" height="17" font="0">hernia surgery (1). These were </text>
<text top="493" left="683" width="145" height="17" font="0">too few to ascertain group </text>
<text top="510" left="683" width="43" height="17" font="0">effects. </text>
<text top="285" left="878" width="7" height="18" font="7"></text>
<text top="286" left="884" width="186" height="17" font="0"> Home group only increased daily </text>
<text top="304" left="878" width="147" height="17" font="0">average cadence (p&lt;0.01) </text>
<text top="321" left="878" width="3" height="17" font="0"> </text>
<text top="699" left="95" width="95" height="17" font="0">Saxton JM, et al. </text>
<text top="716" left="95" width="63" height="17" font="0">2011 (191) </text>
<text top="734" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21215558">21215558 </a></text>
<text top="751" left="95" width="3" height="17" font="0"> </text>
<text top="699" left="222" width="105" height="17" font="2"><b>Aim:</b> Compare the </text>
<text top="716" left="222" width="92" height="17" font="0">effects of upper- </text>
<text top="734" left="222" width="83" height="17" font="0">and lower-limb </text>
<text top="751" left="222" width="93" height="17" font="0">aerobic exercise </text>
<text top="768" left="222" width="61" height="17" font="0">training on </text>
<text top="699" left="344" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="716" left="344" width="7" height="18" font="7"></text>
<text top="718" left="351" width="108" height="17" font="0"> PAD with IC by Hx </text>
<text top="735" left="344" width="7" height="18" font="7"></text>
<text top="736" left="351" width="55" height="17" font="0"> ABI ≤0.9 </text>
<text top="753" left="344" width="7" height="18" font="7"></text>
<text top="754" left="351" width="103" height="17" font="0"> Symptoms 12 mo </text>
<text top="772" left="344" width="3" height="17" font="0"> </text>
<text top="699" left="513" width="154" height="17" font="2"><b>Intervention:</b> Arm cranking </text>
<text top="716" left="513" width="113" height="17" font="0">at 85%–90% of limb-</text>
<text top="734" left="513" width="137" height="17" font="0">specific maximal oxygen </text>
<text top="751" left="513" width="140" height="17" font="0">uptake, 2 d/wk for 24 wk, </text>
<text top="768" left="513" width="143" height="17" font="0">total time exercise time of </text>
<text top="700" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="699" left="690" width="6" height="18" font="7"></text>
<text top="700" left="696" width="124" height="17" font="2"><b> endpoint:</b> After 6 wk, </text>
<text top="718" left="683" width="171" height="17" font="0">improvements in the perceived </text>
<text top="735" left="683" width="128" height="17" font="0">severity of claudication </text>
<text top="752" left="683" width="155" height="17" font="0">(p=0.023) and stair climbing </text>
<text top="769" left="683" width="157" height="17" font="0">ability (p=0.011) vs. controls </text>
<text top="699" left="878" width="7" height="18" font="7"></text>
<text top="700" left="884" width="186" height="17" font="0"> At 48 and 72 wk, improvement in </text>
<text top="718" left="878" width="204" height="17" font="0">perceptions of walking distance were </text>
<text top="735" left="878" width="211" height="17" font="0">better maintained in upper limb group. </text>
<text top="752" left="878" width="226" height="17" font="0">Improvements in walking speed and stair </text>
<text top="769" left="878" width="225" height="17" font="0">climbing ability were similarly maintained </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">86 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="222" width="91" height="17" font="0">disease-specific </text>
<text top="104" left="222" width="92" height="17" font="0">functional status </text>
<text top="122" left="222" width="105" height="17" font="0">and generic health-</text>
<text top="139" left="222" width="101" height="17" font="0">related QoL in pts </text>
<text top="156" left="222" width="41" height="17" font="0">with IC </text>
<text top="173" left="222" width="3" height="17" font="0"> </text>
<text top="190" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="208" left="222" width="3" height="17" font="0"> </text>
<text top="225" left="222" width="90" height="17" font="2"><b>Size:</b> n=104 pts </text>
<text top="87" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="104" left="344" width="7" height="18" font="7"></text>
<text top="105" left="351" width="129" height="17" font="0"> Revascularization with </text>
<text top="123" left="344" width="64" height="17" font="0">past 12 mo </text>
<text top="140" left="344" width="7" height="18" font="7"></text>
<text top="141" left="351" width="136" height="17" font="0"> Exercise limiting angina </text>
<text top="158" left="344" width="7" height="18" font="7"></text>
<text top="159" left="351" width="33" height="17" font="0"> SOB </text>
<text top="177" left="344" width="7" height="18" font="7"></text>
<text top="178" left="351" width="89" height="17" font="0"> Severe arthritis </text>
<text top="195" left="344" width="7" height="18" font="7"></text>
<text top="196" left="351" width="146" height="17" font="0"> Medications for IC except </text>
<text top="213" left="344" width="97" height="17" font="0">if using long term </text>
<text top="87" left="513" width="152" height="17" font="0">20 min in 40 min session. 2 </text>
<text top="104" left="513" width="157" height="17" font="0">min bouts intermittent with 2 </text>
<text top="122" left="513" width="47" height="17" font="0">min rest </text>
<text top="139" left="513" width="3" height="17" font="0"> </text>
<text top="156" left="513" width="142" height="17" font="2"><b>Comparator:</b> Leg cycling </text>
<text top="173" left="513" width="148" height="17" font="0">using same parameters as </text>
<text top="190" left="513" width="150" height="17" font="0">for arm exercise and a non-</text>
<text top="208" left="513" width="128" height="17" font="0">exercise control group  </text>
<text top="87" left="683" width="178" height="17" font="0">were observed in the upper limb </text>
<text top="104" left="683" width="167" height="17" font="0">group, and an improvement in </text>
<text top="122" left="683" width="180" height="17" font="0">the general health domain of the </text>
<text top="139" left="683" width="141" height="17" font="0">SF-36v2 vs. controls was </text>
<text top="156" left="683" width="181" height="17" font="0">observed in the lower limb group </text>
<text top="173" left="683" width="154" height="17" font="0">(p=0.010). After 24 wk, all 4 </text>
<text top="190" left="683" width="175" height="17" font="0">WIQ domains were improved in </text>
<text top="208" left="683" width="135" height="17" font="0">the upper limb group vs. </text>
<text top="225" left="683" width="179" height="17" font="0">controls (p≤0.05), and 3 of the 4 </text>
<text top="242" left="683" width="175" height="17" font="0">WIQ domains were improved in </text>
<text top="259" left="683" width="167" height="17" font="0">the lower limb group (p&lt;0.05). </text>
<text top="276" left="683" width="3" height="17" font="0"> </text>
<text top="294" left="683" width="174" height="17" font="2"><b>Safety endpoint:</b> Not specified </text>
<text top="311" left="683" width="155" height="17" font="0">but though no unanticipated </text>
<text top="328" left="683" width="172" height="17" font="0">adverse events in either group. </text>
<text top="345" left="683" width="178" height="17" font="0">These were too few to ascertain </text>
<text top="363" left="683" width="78" height="17" font="0">group effects. </text>
<text top="87" left="878" width="200" height="17" font="0">in both exercise groups vs. controls. </text>
<text top="104" left="878" width="225" height="17" font="0">Sustained improvements were also seen </text>
<text top="122" left="878" width="193" height="17" font="0">in both exercise groups vs. control. </text>
<text top="139" left="878" width="3" height="17" font="0"> </text>
<text top="381" left="95" width="105" height="17" font="0">Treat-Jacobson D, </text>
<text top="398" left="95" width="30" height="17" font="0">et al. </text>
<text top="415" left="95" width="63" height="17" font="0">2009 (192) </text>
<text top="432" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19651669">19651669 </a></text>
<text top="449" left="95" width="3" height="17" font="0"> </text>
<text top="381" left="222" width="85" height="17" font="2"><b>Aim:</b> Compare </text>
<text top="398" left="222" width="97" height="17" font="0">effects of aerobic </text>
<text top="415" left="222" width="103" height="17" font="0">arm-ergometry vs. </text>
<text top="432" left="222" width="109" height="17" font="0">treadmill walking or </text>
<text top="449" left="222" width="102" height="17" font="0">usual care in PAD </text>
<text top="467" left="222" width="41" height="17" font="0">with IC </text>
<text top="484" left="222" width="3" height="17" font="0"> </text>
<text top="501" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="518" left="222" width="3" height="17" font="0"> </text>
<text top="535" left="222" width="83" height="17" font="2"><b>Size:</b> n=41 pts </text>
<text top="381" left="344" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="398" left="344" width="91" height="17" font="0">Lifestyle-limiting </text>
<text top="415" left="344" width="155" height="17" font="0">claudication, ABI ≤0.9, drop </text>
<text top="432" left="344" width="114" height="17" font="0">in ABI of ≥10% after </text>
<text top="449" left="344" width="98" height="17" font="0">treadmill walking, </text>
<text top="467" left="344" width="3" height="17" font="0"> </text>
<text top="484" left="344" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="501" left="344" width="131" height="17" font="0">Uncontrolled HBP, CLI, </text>
<text top="518" left="344" width="136" height="17" font="0">exercise limited by other </text>
<text top="535" left="344" width="150" height="17" font="0">health conditions, coronary </text>
<text top="553" left="344" width="155" height="17" font="0">or LE revascularization past </text>
<text top="570" left="344" width="34" height="17" font="0">3 mo  </text>
<text top="381" left="513" width="105" height="17" font="2"><b>Intervention:</b> Arm-</text>
<text top="398" left="513" width="154" height="17" font="0">ergometry at one work level </text>
<text top="415" left="513" width="122" height="17" font="0">below maximal during </text>
<text top="432" left="513" width="115" height="17" font="0">baseline test. 3d/wk, </text>
<text top="449" left="513" width="156" height="17" font="0">exercise for 2 min, rest for 2 </text>
<text top="467" left="513" width="153" height="17" font="0">min for 60 min. Progressive </text>
<text top="484" left="513" width="140" height="17" font="0">increase of exercise over </text>
<text top="501" left="513" width="111" height="17" font="0">12 wk by increasing </text>
<text top="518" left="513" width="126" height="17" font="0">workload and exercise </text>
<text top="535" left="513" width="33" height="17" font="0">bouts </text>
<text top="553" left="513" width="3" height="17" font="0"> </text>
<text top="570" left="513" width="156" height="17" font="2"><b>Comparator:</b> TM walking to </text>
<text top="587" left="513" width="120" height="17" font="0">4/5 claudication, rest, </text>
<text top="604" left="513" width="108" height="17" font="0">exercise. Workload </text>
<text top="621" left="513" width="136" height="17" font="0">increased when pt could </text>
<text top="639" left="513" width="144" height="17" font="0">walk 8 min without having </text>
<text top="656" left="513" width="109" height="17" font="0">to stop due to IC. A </text>
<text top="673" left="513" width="105" height="17" font="0">combination group </text>
<text top="690" left="513" width="112" height="17" font="0">performed both arm </text>
<text top="708" left="513" width="142" height="17" font="0">ergometry and walking. A </text>
<text top="725" left="513" width="135" height="17" font="0">usual care group did not </text>
<text top="742" left="513" width="116" height="17" font="0">receive participate in </text>
<text top="759" left="513" width="133" height="17" font="0">supervised exercise but </text>
<text top="776" left="513" width="137" height="17" font="0">given usual care walking </text>
<text top="382" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="381" left="690" width="6" height="18" font="7"></text>
<text top="382" left="696" width="147" height="17" font="2"><b> endpoint:</b> 12 wk maximal </text>
<text top="399" left="683" width="163" height="17" font="0">walking distance increased in </text>
<text top="416" left="683" width="151" height="17" font="0">the arm-ergometry (+53%), </text>
<text top="433" left="683" width="121" height="17" font="0">treadmill (+69%), and </text>
<text top="451" left="683" width="154" height="17" font="0">combination (+68%) groups </text>
<text top="468" left="683" width="180" height="17" font="0">(p&lt;0.002 vs. control). The 12 wk </text>
<text top="485" left="683" width="145" height="17" font="0">pain free walking distance </text>
<text top="502" left="683" width="174" height="17" font="0">increased in the arm-ergometry </text>
<text top="519" left="683" width="145" height="17" font="0">group (+82%; p=0.025 vs. </text>
<text top="537" left="683" width="160" height="17" font="0">control). Change in PFWD in </text>
<text top="554" left="683" width="160" height="17" font="0">treadmill (+54%; p=0.196 vs. </text>
<text top="571" left="683" width="181" height="17" font="0">control) and combination (+60%; </text>
<text top="588" left="683" width="173" height="17" font="0">p=0.107 vs. control) groups did </text>
<text top="605" left="683" width="183" height="17" font="0">not reach statistical significance.  </text>
<text top="623" left="683" width="3" height="17" font="0"> </text>
<text top="640" left="683" width="174" height="17" font="2"><b>Safety endpoint:</b> Not specified </text>
<text top="657" left="683" width="159" height="17" font="0">with 1 study unrelated injury. </text>
<text top="381" left="878" width="7" height="18" font="7"></text>
<text top="382" left="884" width="195" height="17" font="0"> 24 wk MWD was maintained in the </text>
<text top="399" left="878" width="214" height="17" font="0">arm-ergometry (p=0.009) and treadmill </text>
<text top="416" left="878" width="171" height="17" font="0">(p=0.019) groups, whereas the </text>
<text top="433" left="878" width="229" height="17" font="0">combination group declined (p=0.751) vs. </text>
<text top="451" left="878" width="183" height="17" font="0">control. PFWD improvement was </text>
<text top="468" left="878" width="216" height="17" font="0">maintained in the arm-ergometry group </text>
<text top="485" left="878" width="224" height="17" font="0">after a 12 wk follow-up (+123%; p=0.011 </text>
<text top="502" left="878" width="64" height="17" font="0">vs. control) </text>
<text top="519" left="878" width="7" height="18" font="7"></text>
<text top="521" left="884" width="215" height="17" font="0"> Resting SBP was lower after 12 wk on </text>
<text top="538" left="878" width="214" height="17" font="0">in arm group (-17 mm Hg) vs. controls. </text>
<text top="555" left="878" width="214" height="17" font="0">This was maintained at 24 wk (-11 mm </text>
<text top="572" left="878" width="27" height="17" font="0">Hg). </text>
<text top="589" left="878" width="3" height="17" font="0"> </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">87 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="513" width="62" height="17" font="0">guidelines. </text>
<text top="173" left="95" width="75" height="17" font="0">Mika P, et al. </text>
<text top="191" left="95" width="63" height="17" font="0">2013 (193) </text>
<text top="208" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23117015">23117015</a></text>
<text top="208" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23117015"> </a></text>
<text top="225" left="95" width="3" height="17" font="0"> </text>
<text top="173" left="222" width="100" height="17" font="2"><b>Aim: </b>To compare </text>
<text top="191" left="222" width="72" height="17" font="0">3 mo of SET </text>
<text top="208" left="222" width="73" height="17" font="0">performed to </text>
<text top="225" left="222" width="55" height="17" font="0">moderate </text>
<text top="242" left="222" width="95" height="17" font="0">claudication pain </text>
<text top="259" left="222" width="71" height="17" font="0">vs. pain-free </text>
<text top="277" left="222" width="103" height="17" font="0">walking in pts with </text>
<text top="294" left="222" width="16" height="17" font="0">IC </text>
<text top="311" left="222" width="3" height="17" font="0"> </text>
<text top="328" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="346" left="222" width="3" height="17" font="0"> </text>
<text top="363" left="222" width="83" height="17" font="2"><b>Size:</b> n=60 pts </text>
<text top="173" left="344" width="133" height="17" font="2"><b>Inclusion Criteria: </b>Age </text>
<text top="191" left="344" width="128" height="17" font="0">50–75 y with IC, stable </text>
<text top="208" left="344" width="142" height="17" font="0">medical therapy for 6 mo, </text>
<text top="225" left="344" width="144" height="17" font="0">not taking medications for </text>
<text top="242" left="344" width="46" height="17" font="0">IC pain. </text>
<text top="259" left="344" width="3" height="17" font="0"> </text>
<text top="277" left="344" width="140" height="17" font="2"><b>Exclusion criteria: </b>CVD </text>
<text top="294" left="344" width="148" height="17" font="0">event in prior 1 y, unstable </text>
<text top="311" left="344" width="141" height="17" font="0">angina, impaired function </text>
<text top="328" left="344" width="150" height="17" font="0">status due to cardiac, lung, </text>
<text top="346" left="344" width="112" height="17" font="0">kidney, liver, or joint </text>
<text top="363" left="344" width="145" height="17" font="0">disease, unable to walk at </text>
<text top="380" left="344" width="58" height="17" font="0">3.2 km/hr. </text>
<text top="173" left="513" width="136" height="17" font="2"><b>Intervention: </b>Titled MT. </text>
<text top="191" left="513" width="126" height="17" font="0">SET, 3 times/wk at 3.2 </text>
<text top="208" left="513" width="117" height="17" font="0">km/hr and grade that </text>
<text top="225" left="513" width="148" height="17" font="0">induced IC within 3–5 min. </text>
<text top="242" left="513" width="103" height="17" font="0">Walking done with </text>
<text top="259" left="513" width="156" height="17" font="0">intermittent bouts of walking </text>
<text top="277" left="513" width="144" height="17" font="0">to moderate pain and rest </text>
<text top="294" left="513" width="122" height="17" font="0">until pain abated. The </text>
<text top="311" left="513" width="141" height="17" font="0">session was done initially </text>
<text top="328" left="513" width="147" height="17" font="0">for 35 min and progressed </text>
<text top="346" left="513" width="145" height="17" font="0">by 5 min each 2 wk until a </text>
<text top="363" left="513" width="106" height="17" font="0">total of 60 min was </text>
<text top="380" left="513" width="82" height="17" font="0">accomplished. </text>
<text top="397" left="513" width="3" height="17" font="0"> </text>
<text top="414" left="513" width="141" height="17" font="2"><b>Comparator: </b>Titled PFT. </text>
<text top="432" left="513" width="150" height="17" font="0">The PFT walked until initial </text>
<text top="449" left="513" width="138" height="17" font="0">onset of pain, stopped to </text>
<text top="466" left="513" width="130" height="17" font="0">rest, and then resumed </text>
<text top="483" left="513" width="150" height="17" font="0">walking following the same </text>
<text top="500" left="513" width="138" height="17" font="0">pattern as the MT group. </text>
<text top="175" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="173" left="690" width="6" height="18" font="7"></text>
<text top="175" left="696" width="135" height="17" font="2"><b> endpoint: </b>Post-training </text>
<text top="192" left="683" width="169" height="17" font="0">MWD was prolonged by 100% </text>
<text top="209" left="683" width="163" height="17" font="0">(p&lt;0.001) vs. 98% (p&lt;0.001), </text>
<text top="226" left="683" width="170" height="17" font="0">and PFWT by 120% (p&lt;0.001) </text>
<text top="243" left="683" width="47" height="17" font="0">vs. 93% </text>
<text top="261" left="683" width="162" height="17" font="0">(p&lt;0.001) in the MT group as </text>
<text top="278" left="683" width="122" height="17" font="0">compared to the PFT, </text>
<text top="295" left="683" width="75" height="17" font="0">respectively.  </text>
<text top="312" left="683" width="3" height="17" font="0"> </text>
<text top="329" left="683" width="166" height="17" font="0">Endothelial function assessed </text>
<text top="347" left="683" width="139" height="17" font="0">by flow-mediated dilation </text>
<text top="364" left="683" width="171" height="17" font="0">increased by 56% (p&lt;0.001) in </text>
<text top="381" left="683" width="145" height="17" font="0">the MT group and by 36% </text>
<text top="398" left="683" width="148" height="17" font="0">(p&lt;0.01) in the PFT group. </text>
<text top="416" left="683" width="3" height="17" font="0"> </text>
<text top="433" left="683" width="178" height="17" font="2"><b>Safety endpoint: </b>Not specified. </text>
<text top="450" left="683" width="169" height="17" font="0">Among 8 dropouts/withdrawal, </text>
<text top="467" left="683" width="160" height="17" font="0">none were reported as being </text>
<text top="484" left="683" width="171" height="17" font="0">related to SET in either group.  </text>
<text top="173" left="878" width="7" height="18" font="7"></text>
<text top="175" left="884" width="213" height="17" font="0"> No significant changes in the levels of </text>
<text top="192" left="878" width="216" height="17" font="0">hs-CRP and fibrinogen were seen after </text>
<text top="209" left="878" width="223" height="17" font="0">SET in either group. The smoking status </text>
<text top="226" left="878" width="228" height="17" font="0">and BMI did not change significantly after </text>
<text top="243" left="878" width="204" height="17" font="0">the program in both groups (p&gt;0.05). </text>
<text top="518" left="95" width="46" height="17" font="2"><b>CETAC</b> </text>
<text top="536" left="95" width="86" height="17" font="0">Fakhry F, et al. </text>
<text top="553" left="95" width="63" height="17" font="0">2013 (194) </text>
<text top="570" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23842830">23842830 </a></text>
<text top="587" left="95" width="3" height="17" font="0"> </text>
<text top="518" left="222" width="31" height="17" font="2"><b>Aim:</b> </text>
<text top="518" left="252" width="75" height="17" font="15">Compare the </text>
<text top="536" left="222" width="96" height="17" font="15">long-term clinical </text>
<text top="553" left="222" width="99" height="17" font="15">effectiveness of a </text>
<text top="570" left="222" width="104" height="17" font="15">SET-first or an ER-</text>
<text top="587" left="222" width="79" height="17" font="15">first treatment </text>
<text top="604" left="222" width="105" height="17" font="15">strategy in pts with </text>
<text top="622" left="222" width="16" height="17" font="15">IC.</text>
<text top="622" left="237" width="7" height="17" font="0">  </text>
<text top="639" left="222" width="3" height="17" font="0"> </text>
<text top="656" left="222" width="102" height="17" font="2"><b>Study type:</b> RCT  </text>
<text top="673" left="222" width="3" height="17" font="0"> </text>
<text top="691" left="222" width="90" height="17" font="2"><b>Size:</b> n=151 pts </text>
<text top="518" left="344" width="144" height="17" font="2"><b>Inclusion criteria</b>: Stable </text>
<text top="536" left="344" width="90" height="17" font="0">IC with iliac and </text>
<text top="553" left="344" width="140" height="17" font="0">femoropopliteal disease.  </text>
<text top="570" left="344" width="3" height="17" font="0"> </text>
<text top="587" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="518" left="513" width="127" height="17" font="2"><b>Intervention:</b> 24 wk of </text>
<text top="536" left="513" width="154" height="17" font="0">supervised TM exercise, 30 </text>
<text top="553" left="513" width="132" height="17" font="0">min, 2 d/wk, and 3 d/wk </text>
<text top="570" left="513" width="79" height="17" font="0">walk at home. </text>
<text top="587" left="513" width="3" height="17" font="0"> </text>
<text top="604" left="513" width="155" height="17" font="2"><b>Comparator:</b> Endovascular </text>
<text top="622" left="513" width="152" height="17" font="0">revascularization with initial </text>
<text top="639" left="513" width="152" height="17" font="0">angioplasty and stenting as </text>
<text top="656" left="513" width="48" height="17" font="0">needed  </text>
<text top="520" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="518" left="690" width="6" height="18" font="7"></text>
<text top="520" left="696" width="115" height="17" font="2"><b> endpoint:</b> After 7 y, </text>
<text top="537" left="683" width="129" height="17" font="0">functional performance </text>
<text top="554" left="683" width="165" height="17" font="0">consisting of maximal walking </text>
<text top="571" left="683" width="169" height="17" font="0">distance and pain free walking </text>
<text top="588" left="683" width="156" height="17" font="0">distance (p&lt;0.001) and QoL </text>
<text top="606" left="683" width="163" height="17" font="0">(p≤0.005) had improved after </text>
<text top="623" left="683" width="162" height="17" font="0">both SET and ER. Long-term </text>
<text top="640" left="683" width="130" height="17" font="0">comparison showed no </text>
<text top="657" left="683" width="157" height="17" font="0">differences between the two </text>
<text top="674" left="683" width="139" height="17" font="0">treatments. Except in the </text>
<text top="692" left="683" width="155" height="17" font="0">secondary intervention rate, </text>
<text top="709" left="683" width="165" height="17" font="0">which was significantly higher </text>
<text top="726" left="683" width="161" height="17" font="0">after SET (p=0.001). Yet, the </text>
<text top="743" left="683" width="162" height="17" font="0">total number of endovascular </text>
<text top="761" left="683" width="143" height="17" font="0">and surgical interventions </text>
<text top="518" left="878" width="7" height="18" font="7"></text>
<text top="520" left="884" width="170" height="17" font="0"> The portion of pts not needing </text>
<text top="537" left="878" width="181" height="17" font="0">secondary intervention rate, was </text>
<text top="554" left="878" width="206" height="17" font="0">significantly lower after SET, 47% vs. </text>
<text top="571" left="878" width="206" height="17" font="0">73% with ER (p=0.001). Yet, the total </text>
<text top="588" left="878" width="205" height="17" font="0">number of endovascular and surgical </text>
<text top="606" left="878" width="210" height="17" font="0">interventions (primary and secondary) </text>
<text top="623" left="878" width="205" height="17" font="0">remained higher after ER, 121 vs. 64 </text>
<text top="640" left="878" width="56" height="17" font="0">(p&lt;0.001) </text>
<text top="657" left="878" width="7" height="18" font="7"></text>
<text top="658" left="884" width="223" height="17" font="0"> The cumulative survival probability for 7 </text>
<text top="676" left="878" width="217" height="17" font="0">y was 68% with SET and 74% with ER, </text>
<text top="693" left="878" width="134" height="17" font="15">(HR: 1.35; 95 % CI: 0.67</text>
<text top="693" left="1012" width="7" height="17" font="0">–</text>
<text top="693" left="1018" width="80" height="17" font="15">2.70; p=0.402)</text>
<text top="693" left="1098" width="7" height="17" font="0">  </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="24" size="13" family="Times" color="#1a171c"/>
<text top="795" left="1088" width="17" height="17" font="0">88 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="683" width="137" height="17" font="0">(primary and secondary) </text>
<text top="104" left="683" width="141" height="17" font="0">remained higher after ER </text>
<text top="122" left="683" width="56" height="17" font="0">(p&lt;0.001) </text>
<text top="139" left="683" width="3" height="17" font="0"> </text>
<text top="156" left="683" width="125" height="17" font="2"><b>Safety endpoint:</b> See </text>
<text top="173" left="683" width="117" height="17" font="0">secondary outcomes </text>
<text top="191" left="95" width="93" height="17" font="0">Mazari FA, et al. </text>
<text top="208" left="95" width="63" height="17" font="0">2010 (195) </text>
<text top="226" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19762206">19762206</a></text>
<text top="226" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19762206"> </a></text>
<text top="243" left="95" width="3" height="17" font="0"> </text>
<text top="191" left="222" width="100" height="17" font="2"><b>Aim: </b>To compare </text>
<text top="208" left="222" width="105" height="17" font="0">the 3 mo effects of </text>
<text top="226" left="222" width="86" height="17" font="0">PTA, SET, and </text>
<text top="243" left="222" width="104" height="17" font="0">PTA + SET for the </text>
<text top="260" left="222" width="69" height="17" font="0">treatment of </text>
<text top="277" left="222" width="87" height="17" font="0">femoropopliteal </text>
<text top="294" left="222" width="104" height="17" font="0">disease in pts with </text>
<text top="312" left="222" width="16" height="17" font="0">IC </text>
<text top="329" left="222" width="3" height="17" font="0"> </text>
<text top="346" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="363" left="222" width="3" height="17" font="0"> </text>
<text top="381" left="222" width="90" height="17" font="2"><b>Size:</b> n=178 pts<b> </b></text>
<text top="191" left="344" width="144" height="17" font="2"><b>Inclusion criteria: </b>Stable </text>
<text top="208" left="344" width="148" height="17" font="0">IC and suitable for PTA for </text>
<text top="226" left="344" width="129" height="17" font="0">femoropopliteal lesions </text>
<text top="243" left="344" width="116" height="17" font="0">after 3 mo of optimal </text>
<text top="260" left="344" width="138" height="17" font="0">medical therapy for CVD </text>
<text top="277" left="344" width="113" height="17" font="0">risk factors and DM. </text>
<text top="294" left="344" width="3" height="17" font="0"> </text>
<text top="312" left="344" width="136" height="17" font="2"><b>Exclusion criteria: </b>CLI, </text>
<text top="329" left="344" width="141" height="17" font="0">severe systemic disease, </text>
<text top="346" left="344" width="152" height="17" font="0">inability to tolerate treadmill </text>
<text top="363" left="344" width="144" height="17" font="0">testing, significant cardiac </text>
<text top="381" left="344" width="151" height="17" font="0">ischemia; revascularization </text>
<text top="398" left="344" width="72" height="17" font="0">in prior 6 mo </text>
<text top="191" left="513" width="119" height="17" font="2"><b>Intervention: </b>SET, 3 </text>
<text top="208" left="513" width="108" height="17" font="0">times/wk for 12 wk, </text>
<text top="226" left="513" width="151" height="17" font="0">consisting of circuit training </text>
<text top="243" left="513" width="153" height="17" font="0">that included stepping, heel </text>
<text top="260" left="513" width="146" height="17" font="0">raises, leg press, exercise </text>
<text top="277" left="513" width="148" height="17" font="0">cycle, knee extension, and </text>
<text top="294" left="513" width="105" height="17" font="0">elbow flexion. PTA </text>
<text top="312" left="513" width="115" height="17" font="0">consisting of balloon </text>
<text top="329" left="513" width="157" height="17" font="0">angioplasty and no stenting. </text>
<text top="346" left="513" width="3" height="17" font="0"> </text>
<text top="363" left="513" width="137" height="17" font="2"><b>Comparator: </b>Combined </text>
<text top="381" left="513" width="72" height="17" font="0">PTA + SET<b>.  </b></text>
<text top="192" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="191" left="690" width="6" height="18" font="7"></text>
<text top="192" left="696" width="121" height="17" font="2"><b> endpoint: </b>All groups </text>
<text top="210" left="683" width="177" height="17" font="0">demonstrated significant clinical </text>
<text top="227" left="683" width="164" height="17" font="0">(pt reported walking distance, </text>
<text top="244" left="683" width="156" height="17" font="0">MWD, PFWD, rest and post-</text>
<text top="261" left="683" width="127" height="17" font="0">exercise ABI) and QoL </text>
<text top="278" left="683" width="134" height="17" font="0">improvements (p&lt;0.05). </text>
<text top="296" left="683" width="159" height="17" font="0">Combined therapy produced </text>
<text top="313" left="683" width="170" height="17" font="0">greater improvement in clinical </text>
<text top="330" left="683" width="153" height="17" font="0">outcomes than PTA or SET </text>
<text top="347" left="683" width="164" height="17" font="0">alone (p&lt;0.05) but not in QoL </text>
<text top="365" left="683" width="61" height="17" font="0">measures. </text>
<text top="382" left="683" width="3" height="17" font="0"> </text>
<text top="399" left="683" width="125" height="17" font="2"><b>Safety endpoint: </b>See </text>
<text top="416" left="683" width="172" height="17" font="0">secondary outcomes. No study </text>
<text top="433" left="683" width="131" height="17" font="0">specific adverse events </text>
<text top="451" left="683" width="53" height="17" font="0">reported. </text>
<text top="191" left="878" width="7" height="18" font="7"></text>
<text top="192" left="884" width="215" height="17" font="0"> 21 pts (7%) withdrew, of whom 8 were </text>
<text top="210" left="878" width="200" height="17" font="0">in the SET group, 3 were in the PTA </text>
<text top="227" left="878" width="200" height="17" font="0">group, and 10 were in the combined </text>
<text top="244" left="878" width="176" height="17" font="0">group. 11 pts who had PTA had </text>
<text top="261" left="878" width="159" height="17" font="0">restenosis but none required </text>
<text top="278" left="878" width="99" height="17" font="0">revascularization. </text>
<text top="468" left="95" width="46" height="17" font="2"><b>ERASE </b></text>
<text top="486" left="95" width="86" height="17" font="0">Fakhry F, et al. </text>
<text top="503" left="95" width="63" height="17" font="0">2015 (196) </text>
<text top="520" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26547465">26547465</a></text>
<text top="520" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26547465"> </a></text>
<text top="537" left="95" width="3" height="17" font="0"> </text>
<text top="468" left="222" width="90" height="17" font="2"><b>Aim: </b>To assess </text>
<text top="486" left="222" width="40" height="17" font="0">the 1 y </text>
<text top="503" left="222" width="89" height="17" font="0">effectiveness of </text>
<text top="520" left="222" width="70" height="17" font="0">combination </text>
<text top="537" left="222" width="89" height="17" font="0">therapy of ER + </text>
<text top="555" left="222" width="103" height="17" font="0">SET or SET alone </text>
<text top="572" left="222" width="74" height="17" font="0">in pts with IC </text>
<text top="589" left="222" width="3" height="17" font="0"> </text>
<text top="606" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="623" left="222" width="3" height="17" font="0"> </text>
<text top="641" left="222" width="90" height="17" font="2"><b>Size:</b> n=212 pts </text>
<text top="468" left="344" width="129" height="17" font="2"><b>Inclusion criteria: </b>ABI </text>
<text top="486" left="344" width="156" height="17" font="0">&lt;0.9 or decrease &gt;0.15 with </text>
<text top="503" left="344" width="109" height="17" font="0">exercise, 1 or more </text>
<text top="520" left="344" width="132" height="17" font="0">vascular stenosis at the </text>
<text top="537" left="344" width="145" height="17" font="0">aortoiliac or femropoliteral </text>
<text top="555" left="344" width="148" height="17" font="0">level or both, and impaired </text>
<text top="572" left="344" width="38" height="17" font="0">MWD. </text>
<text top="589" left="344" width="3" height="17" font="0"> </text>
<text top="606" left="344" width="144" height="17" font="2"><b>Exclusion Criteria</b>: Not a </text>
<text top="623" left="344" width="75" height="17" font="0">candidate for </text>
<text top="641" left="344" width="138" height="17" font="0">revascularization or prior </text>
<text top="658" left="344" width="129" height="17" font="0">treatment for the target </text>
<text top="675" left="344" width="103" height="17" font="0">lesions, limited life </text>
<text top="692" left="344" width="108" height="17" font="0">expectancy; limited </text>
<text top="710" left="344" width="144" height="17" font="0">ambulation due to causes </text>
<text top="727" left="344" width="78" height="17" font="0">other than IC. </text>
<text top="468" left="513" width="150" height="17" font="2"><b>Intervention: </b>Combination </text>
<text top="486" left="513" width="142" height="17" font="0">therapy of ER + SET.<b> </b>For </text>
<text top="503" left="513" width="155" height="17" font="0">ER, a stent was used only if </text>
<text top="520" left="513" width="95" height="17" font="0">the initial balloon </text>
<text top="537" left="513" width="111" height="17" font="0">angioplasty was not </text>
<text top="555" left="513" width="117" height="17" font="0">successful. SET was </text>
<text top="572" left="513" width="135" height="17" font="0">started 2–4 wk after ER. </text>
<text top="589" left="513" width="146" height="17" font="0">SET consisted primarily of </text>
<text top="606" left="513" width="111" height="17" font="0">intermittent bouts of </text>
<text top="623" left="513" width="137" height="17" font="0">treadmill walking to near-</text>
<text top="641" left="513" width="155" height="17" font="0">maximum claudication pain. </text>
<text top="658" left="513" width="150" height="17" font="0">Frequency of 2–3 sessions </text>
<text top="675" left="513" width="138" height="17" font="0">for 30–45 min for initial 3 </text>
<text top="692" left="513" width="139" height="17" font="0">mo followed by at least 1 </text>
<text top="710" left="513" width="155" height="17" font="0">session per wk between mo </text>
<text top="727" left="513" width="152" height="17" font="0">3–6 and then 1 session per </text>
<text top="744" left="513" width="81" height="17" font="0">4 wk until 1 y.  </text>
<text top="761" left="513" width="3" height="17" font="0"> </text>
<text top="470" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="468" left="690" width="6" height="18" font="7"></text>
<text top="470" left="696" width="150" height="17" font="2"><b> endpoint: </b>After 1 y, MWD </text>
<text top="487" left="683" width="138" height="17" font="0">increased in both groups </text>
<text top="504" left="683" width="134" height="17" font="0">(p&lt;0.001) with a greater </text>
<text top="521" left="683" width="165" height="17" font="0">improvement in the combined </text>
<text top="539" left="683" width="136" height="17" font="0">therapy group (p&lt;0.001) </text>
<text top="556" left="683" width="3" height="17" font="0"> </text>
<text top="573" left="683" width="125" height="17" font="2"><b>Safety endpoint: </b>See </text>
<text top="590" left="683" width="172" height="17" font="0">secondary outcomes. No study </text>
<text top="607" left="683" width="135" height="17" font="0">specific AE’s discussed. </text>
<text top="468" left="878" width="7" height="18" font="7"></text>
<text top="470" left="884" width="193" height="17" font="0"> After 1 y, PFWD increased in both </text>
<text top="487" left="878" width="175" height="17" font="0">groups (p&lt;0.001) with a greater </text>
<text top="504" left="878" width="209" height="17" font="0">improvement in the combined therapy </text>
<text top="521" left="878" width="101" height="17" font="0">groups (p&lt;0.001). </text>
<text top="521" left="978" width="114" height="17" font="24">Similarly, ABI at rest </text>
<text top="539" left="878" width="214" height="17" font="24">and after exercise showed significantly </text>
<text top="556" left="878" width="220" height="17" font="24">greater improvement in the combination </text>
<text top="573" left="878" width="222" height="17" font="24">therapy group. Also, measures of health-</text>
<text top="590" left="878" width="228" height="17" font="24">related QoL improved in both groups with </text>
<text top="607" left="878" width="205" height="17" font="24">greater improvements with combined </text>
<text top="625" left="878" width="48" height="17" font="24">therapy. </text>
<text top="642" left="878" width="3" height="17" font="24"> </text>
<text top="659" left="878" width="7" height="18" font="7"></text>
<text top="660" left="884" width="204" height="17" font="0"> A higher proportion of pts without an </text>
<text top="677" left="878" width="226" height="17" font="0">additional intervention in the combination </text>
<text top="695" left="878" width="211" height="17" font="0">group (92%) vs. the SET alone (77%), </text>
<text top="712" left="878" width="192" height="17" font="0">HR: 3.2; 95% CI: 1.1–9.2; p=0.005.</text>
<text top="712" left="1069" width="3" height="17" font="24"> </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">89 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="513" width="145" height="17" font="2"><b>Comparator: </b>SET alone. <b> </b></text>
<text top="173" left="95" width="81" height="17" font="0">Guidon M and </text>
<text top="191" left="95" width="55" height="17" font="0">McGee H </text>
<text top="208" left="95" width="63" height="17" font="0">2013 (197) </text>
<text top="225" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22804715">22804715 </a></text>
<text top="242" left="95" width="3" height="17" font="0"> </text>
<text top="173" left="222" width="90" height="17" font="2"><b>Aim:</b> To assess </text>
<text top="191" left="222" width="94" height="17" font="0">the 1 y effects of </text>
<text top="208" left="222" width="93" height="17" font="0">participation in a </text>
<text top="225" left="222" width="98" height="17" font="0">12 wk supervised </text>
<text top="242" left="222" width="98" height="17" font="0">exercise program </text>
<text top="259" left="222" width="73" height="17" font="0">on functional </text>
<text top="277" left="222" width="99" height="17" font="0">capacity and QoL </text>
<text top="294" left="222" width="70" height="17" font="0">for PAD pts  </text>
<text top="311" left="222" width="3" height="17" font="0"> </text>
<text top="328" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="346" left="222" width="3" height="17" font="0"> </text>
<text top="363" left="222" width="83" height="17" font="2"><b>Size:</b> n=44 pts </text>
<text top="173" left="344" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="191" left="344" width="152" height="17" font="0">Fontaine Stage II, ABI &lt;0.9 </text>
<text top="208" left="344" width="130" height="17" font="0">at rest or a decrease of </text>
<text top="225" left="344" width="150" height="17" font="0">ankle pressure by ≥15 mm </text>
<text top="242" left="344" width="96" height="17" font="0">Hg post-exercise </text>
<text top="259" left="344" width="3" height="17" font="0"> </text>
<text top="277" left="344" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="294" left="344" width="113" height="17" font="0">Comorbidities which </text>
<text top="311" left="344" width="140" height="17" font="0">precluded participation in </text>
<text top="328" left="344" width="131" height="17" font="0">exercise, MI past 6 mo, </text>
<text top="346" left="344" width="140" height="17" font="0">acute onset or within one </text>
<text top="363" left="344" width="112" height="17" font="0">mo of IC, lower limb </text>
<text top="380" left="344" width="153" height="17" font="0">revascularization past 6 mo </text>
<text top="173" left="513" width="117" height="17" font="2"><b>Intervention:</b> 2 d/wk </text>
<text top="191" left="513" width="147" height="17" font="0">supervised exercise for 12 </text>
<text top="208" left="513" width="140" height="17" font="0">wk. 30–40 min of aerobic </text>
<text top="225" left="513" width="141" height="17" font="0">exercise using a range of </text>
<text top="242" left="513" width="113" height="17" font="0">equipment including </text>
<text top="259" left="513" width="148" height="17" font="0">treadmill, stepper, elliptical </text>
<text top="277" left="513" width="138" height="17" font="0">trainer, recumbent cycle, </text>
<text top="294" left="513" width="146" height="17" font="0">and arm cycle. Intensity of </text>
<text top="311" left="513" width="146" height="17" font="0">70%–80% of exercise test </text>
<text top="328" left="513" width="154" height="17" font="0">maximum HR. On treadmill, </text>
<text top="346" left="513" width="156" height="17" font="0">walking to leg pain of 3 of 4, </text>
<text top="363" left="513" width="144" height="17" font="0">rest, and resume walking. </text>
<text top="380" left="513" width="99" height="17" font="0">Exercise intensity </text>
<text top="397" left="513" width="141" height="17" font="0">progressed by increasing </text>
<text top="414" left="513" width="104" height="17" font="0">resistance or time. </text>
<text top="432" left="513" width="3" height="17" font="0"> </text>
<text top="449" left="513" width="143" height="17" font="2"><b>Comparator:</b> Usual care, </text>
<text top="466" left="513" width="118" height="17" font="0">general advice about </text>
<text top="483" left="513" width="122" height="17" font="0">exercise and smoking </text>
<text top="500" left="513" width="82" height="17" font="0">cessation, ABI </text>
<text top="518" left="513" width="82" height="17" font="0">measurement  </text>
<text top="175" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="173" left="690" width="6" height="18" font="7"></text>
<text top="175" left="696" width="148" height="17" font="2"><b> endpoint:</b> At 12 wk, there </text>
<text top="192" left="683" width="168" height="17" font="0">was a trend towards improved </text>
<text top="209" left="683" width="147" height="17" font="0">QoL in both groups, with a </text>
<text top="226" left="683" width="114" height="17" font="0">tendency for greater </text>
<text top="243" left="683" width="157" height="17" font="0">improvement in the exercise </text>
<text top="261" left="683" width="157" height="17" font="0">group (p=0.066) and a trend </text>
<text top="278" left="683" width="157" height="17" font="0">towards improved functional </text>
<text top="295" left="683" width="159" height="17" font="0">capacity (WIQ Stair-climbing </text>
<text top="312" left="683" width="173" height="17" font="0">p=0.093) in the exercise group, </text>
<text top="329" left="683" width="170" height="17" font="0">with an increase of 8.55 points </text>
<text top="347" left="683" width="152" height="17" font="0">in the exercise group and a </text>
<text top="364" left="683" width="172" height="17" font="0">decrease of 13.42 points in the </text>
<text top="381" left="683" width="133" height="17" font="0">control group. At 1 y, IC </text>
<text top="398" left="683" width="153" height="17" font="0">Questionnaire scores in the </text>
<text top="416" left="683" width="114" height="17" font="0">exercise group were </text>
<text top="433" left="683" width="181" height="17" font="0">considerably better than those in </text>
<text top="450" left="683" width="172" height="17" font="0">the control group, 27.94±19.83 </text>
<text top="467" left="683" width="152" height="17" font="0">vs. 38.54±24.26 (p=0.058), </text>
<text top="484" left="683" width="158" height="17" font="0">reflecting improved QoL and </text>
<text top="502" left="683" width="138" height="17" font="0">maintenance of benefits. </text>
<text top="519" left="683" width="3" height="17" font="0"> </text>
<text top="536" left="683" width="178" height="17" font="2"><b>Safety endpoint:</b> Not specified. </text>
<text top="553" left="683" width="144" height="17" font="0">2 exercisers and 1 control </text>
<text top="570" left="683" width="180" height="17" font="0">dropped for progression of PAD, </text>
<text top="588" left="683" width="161" height="17" font="0">3 exercisers dropped for non-</text>
<text top="605" left="683" width="181" height="17" font="0">specified medical reasons in first </text>
<text top="622" left="683" width="39" height="17" font="0">12 wk. </text>
<text top="173" left="878" width="24" height="17" font="0">N/A </text>
<text top="640" left="95" width="105" height="17" font="0">Gardner AW, et al. </text>
<text top="657" left="95" width="63" height="17" font="0">2014 (198) </text>
<text top="674" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25237048">25237048 </a></text>
<text top="692" left="95" width="3" height="17" font="0"> </text>
<text top="640" left="222" width="100" height="17" font="2"><b>Aim: </b>To compare </text>
<text top="657" left="222" width="109" height="17" font="0">the 12 wk effects of </text>
<text top="674" left="222" width="93" height="17" font="0">exercise training </text>
<text top="692" left="222" width="105" height="17" font="0">using a step watch </text>
<text top="709" left="222" width="84" height="17" font="0">home-exercise </text>
<text top="726" left="222" width="63" height="17" font="0">program, a </text>
<text top="743" left="222" width="63" height="17" font="0">supervised </text>
<text top="761" left="222" width="102" height="17" font="0">exercise program, </text>
<text top="640" left="344" width="152" height="17" font="2"><b>Inclusion criteria: </b>Sx PAD </text>
<text top="657" left="344" width="133" height="17" font="0">by Hx of ambulatory leg </text>
<text top="674" left="344" width="142" height="17" font="0">pain or pain confirmed by </text>
<text top="692" left="344" width="137" height="17" font="0">treadmill exercise or ABI </text>
<text top="709" left="344" width="151" height="17" font="0">≤0.90 at rest or ≤0.73 after </text>
<text top="726" left="344" width="53" height="17" font="0">exercise. </text>
<text top="743" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="761" left="344" width="133" height="17" font="2"><b>Exclusion criteria: </b>ABI </text>
<text top="640" left="513" width="152" height="17" font="2"><b>Intervention: </b>Home-based </text>
<text top="657" left="513" width="153" height="17" font="0">3 mo of intermittent walking </text>
<text top="674" left="513" width="131" height="17" font="0">(NEXT STEP) o mild-to-</text>
<text top="692" left="513" width="150" height="17" font="0">moderate claudication pain </text>
<text top="709" left="513" width="138" height="17" font="0">3 d/wk, progressing from </text>
<text top="726" left="513" width="131" height="17" font="0">20–45 min/session. Pts </text>
<text top="743" left="513" width="139" height="17" font="0">used step monitor during </text>
<text top="761" left="513" width="155" height="17" font="0">each session. Exercise logs </text>
<text top="641" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="640" left="690" width="6" height="18" font="7"></text>
<text top="641" left="696" width="160" height="17" font="2"><b> endpoint: </b>At 12 wk, change </text>
<text top="658" left="683" width="177" height="17" font="0">scores for COT (p&lt;0.001), PWT </text>
<text top="676" left="683" width="170" height="17" font="0">(p&lt;0.001), 6 min walk distance </text>
<text top="693" left="683" width="136" height="17" font="0">(p=0.028), daily average </text>
<text top="710" left="683" width="137" height="17" font="0">cadence (p=0.011) were </text>
<text top="727" left="683" width="164" height="17" font="0">different among the 3 groups, </text>
<text top="745" left="683" width="153" height="17" font="0">with both walking programs </text>
<text top="762" left="683" width="145" height="17" font="0">showing changes in these </text>
<text top="640" left="878" width="7" height="18" font="7"></text>
<text top="641" left="884" width="198" height="17" font="0"> Time to minimum calf muscle StO2 </text>
<text top="658" left="878" width="213" height="17" font="0">during exercise (p=0.025), large-artery </text>
<text top="676" left="878" width="195" height="17" font="0">elasticity index (p=0.012), and high-</text>
<text top="693" left="878" width="214" height="17" font="0">sensitivity C-reactive protein (p=0.041) </text>
<text top="710" left="878" width="212" height="17" font="0">were also significantly different among </text>
<text top="727" left="878" width="189" height="17" font="0">the 3 groups. Both walking groups </text>
<text top="745" left="878" width="169" height="17" font="0">improved time to minimum StO</text>
<text top="750" left="1046" width="4" height="11" font="11">2</text>
<text top="745" left="1051" width="56" height="17" font="0">. Only the </text>
<text top="762" left="878" width="158" height="17" font="0">NEXT Step home group had </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">90 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="222" width="92" height="17" font="0">and an attention </text>
<text top="104" left="222" width="92" height="17" font="0">control group on </text>
<text top="122" left="222" width="95" height="17" font="0">walking time and </text>
<text top="139" left="222" width="49" height="17" font="0">selected </text>
<text top="156" left="222" width="74" height="17" font="0">physiological </text>
<text top="173" left="222" width="60" height="17" font="0">outcomes.<b> </b></text>
<text top="190" left="222" width="3" height="17" font="2"><b> </b></text>
<text top="208" left="222" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="225" left="222" width="3" height="17" font="2"><b> </b></text>
<text top="242" left="222" width="90" height="17" font="2"><b>Size: </b>n=180 pts<b> </b></text>
<text top="87" left="344" width="94" height="17" font="0">≥1.40; asx PAD; </text>
<text top="104" left="344" width="116" height="17" font="0">medications for PAD </text>
<text top="122" left="344" width="137" height="17" font="0">symptoms, other serious </text>
<text top="139" left="344" width="79" height="17" font="0">comorbidities.<b> </b></text>
<text top="87" left="513" width="132" height="17" font="0">were reviewed by study </text>
<text top="104" left="513" width="133" height="17" font="0">staff, and feedback was </text>
<text top="122" left="513" width="147" height="17" font="0">given to guide subsequent </text>
<text top="139" left="513" width="104" height="17" font="0">exercise sessions. </text>
<text top="156" left="513" width="3" height="17" font="0"> </text>
<text top="173" left="513" width="142" height="17" font="2"><b>Comparator:</b> Supervised </text>
<text top="190" left="513" width="154" height="17" font="0">exercise while wearing step </text>
<text top="208" left="513" width="137" height="17" font="0">activity monitor following </text>
<text top="225" left="513" width="149" height="17" font="0">similar workout protocol as </text>
<text top="242" left="513" width="146" height="17" font="0">home-based group. There </text>
<text top="259" left="513" width="120" height="17" font="0">was also an attention-</text>
<text top="276" left="513" width="129" height="17" font="0">control, light resistance </text>
<text top="294" left="513" width="148" height="17" font="0">exercise group that did not </text>
<text top="311" left="513" width="151" height="17" font="0">walk but performed various </text>
<text top="328" left="513" width="150" height="17" font="0">resistance exercise. These </text>
<text top="345" left="513" width="113" height="17" font="0">pts also wore a step </text>
<text top="363" left="513" width="145" height="17" font="0">monitor to quantify time of </text>
<text top="380" left="513" width="62" height="17" font="0">their visits.<b> </b></text>
<text top="87" left="683" width="138" height="17" font="0">walking parameters from </text>
<text top="104" left="683" width="170" height="17" font="0">baseline. The change for PWT </text>
<text top="122" left="683" width="180" height="17" font="0">in the supervised exercise group </text>
<text top="139" left="683" width="150" height="17" font="0">was greater than the home-</text>
<text top="156" left="683" width="125" height="17" font="0">based group (p&lt;0.05). </text>
<text top="173" left="683" width="3" height="17" font="0"> </text>
<text top="190" left="683" width="178" height="17" font="2"><b>Safety endpoint:</b> Not specified. </text>
<text top="208" left="683" width="162" height="17" font="0">1 stroke and 1 MI in attention </text>
<text top="225" left="683" width="139" height="17" font="0">control group; 1 stroke in </text>
<text top="242" left="683" width="181" height="17" font="0">supervised exercise group; 1 leg </text>
<text top="259" left="683" width="181" height="17" font="0">revascularization in home-based </text>
<text top="276" left="683" width="83" height="17" font="0">walking group. </text>
<text top="87" left="878" width="158" height="17" font="0">improvements from baseline </text>
<text top="104" left="878" width="170" height="17" font="0">in LAEI, and hs-CRP (p&lt;0.05). </text>
<text top="398" left="95" width="111" height="17" font="0">Langbein WE, et al. </text>
<text top="415" left="95" width="63" height="17" font="0">2002 (199) </text>
<text top="432" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12021703">12021703</a></text>
<text top="432" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12021703"> </a></text>
<text top="449" left="95" width="3" height="17" font="0"> </text>
<text top="398" left="222" width="107" height="17" font="2"><b>Aim: </b>To determine </text>
<text top="415" left="222" width="76" height="17" font="0">if polestriding </text>
<text top="432" left="222" width="105" height="17" font="0">exercise increases </text>
<text top="449" left="222" width="103" height="17" font="0">exercise tolerance </text>
<text top="467" left="222" width="102" height="17" font="0">of persons with IC </text>
<text top="484" left="222" width="86" height="17" font="0">pain caused by </text>
<text top="501" left="222" width="32" height="17" font="0">PAD.<b> </b></text>
<text top="518" left="222" width="3" height="17" font="2"><b> </b></text>
<text top="535" left="222" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="553" left="222" width="3" height="17" font="2"><b> </b></text>
<text top="570" left="222" width="83" height="17" font="2"><b>Size: </b>n=52 pts<b> </b></text>
<text top="398" left="344" width="134" height="17" font="2"><b>Inclusion criteria:</b> Pain </text>
<text top="415" left="344" width="141" height="17" font="0">from claudication primary </text>
<text top="432" left="344" width="139" height="17" font="0">limiting factor to maximal </text>
<text top="449" left="344" width="49" height="17" font="0">exercise </text>
<text top="467" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="484" left="344" width="152" height="17" font="2"><b>Exclusion criteria: </b>Severe </text>
<text top="501" left="344" width="139" height="17" font="0">leg pain at rest, ischemic </text>
<text top="518" left="344" width="155" height="17" font="0">ulceration, resting ABI &lt;0.4, </text>
<text top="535" left="344" width="148" height="17" font="0">revascularization in past y, </text>
<text top="553" left="344" width="136" height="17" font="0">current use of vitamin E, </text>
<text top="570" left="344" width="104" height="17" font="0">warafin sodium, or </text>
<text top="587" left="344" width="150" height="17" font="0">pentoxifylline, other factors </text>
<text top="604" left="344" width="91" height="17" font="0">limiting exercise<b> </b></text>
<text top="398" left="513" width="146" height="17" font="2"><b>Intervention: </b>Polestriding </text>
<text top="415" left="513" width="139" height="17" font="0">exercise 3 times/wk for 4 </text>
<text top="432" left="513" width="143" height="17" font="0">wk, twice per wk for 8 wk, </text>
<text top="449" left="513" width="120" height="17" font="0">once per wk for 4 wk. </text>
<text top="467" left="513" width="3" height="17" font="0"> </text>
<text top="484" left="513" width="149" height="17" font="2"><b>Comparator:</b> Nonexercise </text>
<text top="501" left="513" width="40" height="17" font="0">control<b> </b></text>
<text top="399" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="398" left="690" width="6" height="18" font="7"></text>
<text top="399" left="696" width="130" height="17" font="2"><b> endpoint: </b>Polestriding </text>
<text top="416" left="683" width="174" height="17" font="0">improved exercise tolerance on </text>
<text top="433" left="683" width="149" height="17" font="0">the constant work-rate and </text>
<text top="451" left="683" width="146" height="17" font="0">incremental treadmill tests </text>
<text top="468" left="683" width="118" height="17" font="0">(p&lt;0.001). Perceived </text>
<text top="485" left="683" width="125" height="17" font="0">claudication pain were </text>
<text top="502" left="683" width="120" height="17" font="0">significantly less after </text>
<text top="519" left="683" width="176" height="17" font="0">polestriding training program. pt </text>
<text top="537" left="683" width="162" height="17" font="0">perceived distance (p&lt;0.001) </text>
<text top="554" left="683" width="145" height="17" font="0">and walking speed scores </text>
<text top="571" left="683" width="141" height="17" font="0">(p&lt;0.022) on the Walking </text>
<text top="588" left="683" width="131" height="17" font="0">Impairment Questionair </text>
<text top="605" left="683" width="154" height="17" font="0">improved in the polestriding </text>
<text top="623" left="683" width="109" height="17" font="0">trained group only.  </text>
<text top="640" left="683" width="3" height="17" font="0"> </text>
<text top="657" left="683" width="124" height="17" font="2"><b>Safety endpoint:</b> N/A </text>
<text top="399" left="878" width="7" height="17" font="2"><b>2</b></text>
<text top="398" left="884" width="6" height="18" font="7"></text>
<text top="399" left="891" width="200" height="17" font="2"><b> endpoint:</b> No changes in resting or </text>
<text top="416" left="878" width="96" height="17" font="0">postexercise ABI </text>
<text top="675" left="95" width="96" height="17" font="0">Walker RD, et al. </text>
<text top="692" left="95" width="63" height="17" font="0">2000 (200) </text>
<text top="710" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10753273">10753273</a></text>
<text top="710" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10753273"> </a></text>
<text top="727" left="95" width="3" height="17" font="0"> </text>
<text top="675" left="222" width="100" height="17" font="2"><b>Aim: </b>To compare </text>
<text top="692" left="222" width="88" height="17" font="0">effects of upper </text>
<text top="710" left="222" width="109" height="17" font="0">limb (arm cranking) </text>
<text top="727" left="222" width="107" height="17" font="0">and lower-limb (leg </text>
<text top="744" left="222" width="103" height="17" font="0">cranking) exercise </text>
<text top="761" left="222" width="105" height="17" font="0">training on walking </text>
<text top="675" left="344" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="692" left="344" width="125" height="17" font="0">Moderate to severe IC </text>
<text top="710" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="727" left="344" width="110" height="17" font="2"><b>Exclusion criteria: </b></text>
<text top="744" left="344" width="144" height="17" font="0">Claudication of &gt;12 mo or </text>
<text top="761" left="344" width="109" height="17" font="0">revascularization in </text>
<text top="675" left="513" width="132" height="17" font="2"><b>Intervention: </b>An upper-</text>
<text top="692" left="513" width="152" height="17" font="0">limb and lower limb training </text>
<text top="710" left="513" width="130" height="17" font="0">groups 2 d/wk for 6 wk. </text>
<text top="727" left="513" width="126" height="17" font="0">Each group performed </text>
<text top="744" left="513" width="145" height="17" font="0">intermittent 2 min bouts of </text>
<text top="761" left="513" width="148" height="17" font="0">exercise followed by 2 min </text>
<text top="676" left="683" width="7" height="17" font="2"><b>1</b></text>
<text top="675" left="690" width="6" height="18" font="7"></text>
<text top="676" left="696" width="135" height="17" font="2"><b> endpoint: </b>Both training </text>
<text top="693" left="683" width="172" height="17" font="0">groups improved the maximum </text>
<text top="711" left="683" width="154" height="17" font="0">power generated during the </text>
<text top="728" left="683" width="163" height="17" font="0">incremental upper- and lower-</text>
<text top="745" left="683" width="174" height="17" font="0">limb ergometry tests (p&lt;0.001). </text>
<text top="762" left="683" width="165" height="17" font="0">PFWD and MWD improved in </text>
<text top="675" left="878" width="7" height="18" font="7"></text>
<text top="676" left="884" width="216" height="17" font="0"> Improvements in physical function and </text>
<text top="693" left="878" width="209" height="17" font="0">role-limitation-physical domains of the </text>
<text top="711" left="878" width="144" height="17" font="0">SF-36 QoL questionnaire. </text>
<text top="728" left="878" width="7" height="18" font="7"></text>
<text top="729" left="884" width="204" height="17" font="0"> No exercise-related adverse events. </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">91 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="222" width="88" height="17" font="0">distances in pts </text>
<text top="104" left="222" width="97" height="17" font="0">with claudication.<b> </b></text>
<text top="122" left="222" width="3" height="17" font="2"><b> </b></text>
<text top="139" left="222" width="99" height="17" font="2"><b>Study type:</b> RCT<b> </b></text>
<text top="156" left="222" width="3" height="17" font="2"><b> </b></text>
<text top="173" left="222" width="83" height="17" font="2"><b>Size: </b>n=76 pts<b> </b></text>
<text top="87" left="344" width="122" height="17" font="0">previous 12 mo; other </text>
<text top="104" left="344" width="92" height="17" font="0">exercise-limiting </text>
<text top="122" left="344" width="122" height="17" font="0">comorbidities such as </text>
<text top="139" left="344" width="156" height="17" font="0">angina, shortness of breath, </text>
<text top="156" left="344" width="87" height="17" font="0">severe arthritis.<b> </b></text>
<text top="87" left="513" width="148" height="17" font="0">of rest; total exercise of 20 </text>
<text top="104" left="513" width="157" height="17" font="0">min during a 40 min session </text>
<text top="122" left="513" width="3" height="17" font="0"> </text>
<text top="139" left="513" width="134" height="17" font="2"><b>Comparator:</b> Untrained </text>
<text top="156" left="513" width="35" height="17" font="0">group<b> </b></text>
<text top="87" left="683" width="128" height="17" font="0">both groups (p&lt;0.001). </text>
<text top="104" left="683" width="150" height="17" font="0">Improvements were similar </text>
<text top="122" left="683" width="169" height="17" font="0">between the 2 training groups, </text>
<text top="139" left="683" width="162" height="17" font="0">while there was no change in </text>
<text top="156" left="683" width="157" height="17" font="0">the untrained control group.  </text>
<text top="173" left="683" width="3" height="17" font="0"> </text>
<text top="190" left="683" width="124" height="17" font="2"><b>Safety endpoint:</b> N/A </text>
<text top="208" left="86" width="1010" height="17" font="0">ABI indicates ankle-brachial index; ACC, Journal of American College of Cardiology; BMI, body mass index; CABG, coronary artery bypass graft; CI, confidence interval; CLI, critical limb </text>
<text top="226" left="86" width="1004" height="17" font="0">ischemia; COT, claudication onset time; CV, cardiovascular; CVD, cardiovascular disease; ER, endovascular revascularization; HR: hazard ratio; HBP, high blood pressure; HR, hazard </text>
<text top="243" left="86" width="1010" height="17" font="0">ratio; hs-CRP, high-sensitivity C-reactive Protein; IC, intermittent claudication; JAMA, Journal of American Medical Association; LAEI, large artery elasticity; LDL, low density lipoproteins; </text>
<text top="260" left="86" width="977" height="17" font="0">LE, lower extremity; METs, metabolic equivalent; MI, myocardial infarction; MWD, maximal walking distance; N/A, not applicable; OMC, optimal medical care; OR, odds ratio; PAD, </text>
<text top="277" left="86" width="996" height="17" font="0">periphery artery disease; PAQ, personal attributes questionnaire; PFT, pain free time; PFWD, pain free walking distance; PFWT, pain free walking time; PWT, peak walking time; QoL, </text>
<text top="294" left="86" width="997" height="17" font="0">quality of life; RCT, randomized controlled trial; RR, relative risk; RPE, ratings of perceived exertions; SBP, systolic blood pressure;<b> </b>SE, supervised exercise; SET, supervised exercise </text>
<text top="312" left="86" width="189" height="17" font="0">training; SOB, shortness of breath;</text>
<text top="313" left="275" width="4" height="16" font="3"> </text>
<text top="312" left="279" width="21" height="17" font="0">StO</text>
<text top="317" left="300" width="4" height="11" font="11">2</text>
<text top="312" left="305" width="621" height="17" font="0">, tissue oxygen saturation; ST, stent revascularization; TM, treadmill; and WIQ, walking impairment questionnaire. </text>
<text top="329" left="86" width="3" height="17" font="0"> </text>
<text top="346" left="86" width="3" height="17" font="0"> </text>
<text top="363" left="86" width="816" height="21" font="1"><b>Evidence Table 33. Nonrandomized Trials, Observational Studies, and/or Registries for Exercise Therapy–Section 6. </b></text>
<text top="385" left="109" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="402" left="135" width="48" height="17" font="2"><b>Author; </b></text>
<text top="419" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="385" left="245" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="402" left="271" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="385" left="400" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="385" left="582" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="402" left="590" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="419" left="642" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="385" left="897" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="402" left="925" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="437" left="95" width="70" height="17" font="0">Pilz M, et al. </text>
<text top="454" left="95" width="59" height="17" font="0">2014(201) </text>
<text top="472" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24825596">24825596 </a></text>
<text top="489" left="95" width="3" height="17" font="0"> </text>
<text top="437" left="235" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="454" left="235" width="90" height="17" font="0">Nonrandomized </text>
<text top="472" left="235" width="125" height="17" font="0">intervention consisting </text>
<text top="489" left="235" width="114" height="17" font="0">of combined aerobic </text>
<text top="506" left="235" width="116" height="17" font="0">and strength training </text>
<text top="523" left="235" width="132" height="17" font="0">lasting for 6 or 12 mo in </text>
<text top="540" left="235" width="68" height="17" font="0">pts with IC.  </text>
<text top="558" left="235" width="3" height="17" font="0"> </text>
<text top="575" left="235" width="136" height="17" font="2"><b>Size:</b> n=94 pts (n=42 for </text>
<text top="592" left="235" width="125" height="17" font="0">6 mo, n=52 for 12 mo) </text>
<text top="437" left="385" width="135" height="17" font="2"><b>Inclusion criteria:</b> PAD </text>
<text top="454" left="385" width="122" height="17" font="0">Rutherford stage 1–3, </text>
<text top="472" left="385" width="55" height="17" font="0">ABI ≤0.9, </text>
<text top="489" left="385" width="3" height="17" font="0"> </text>
<text top="506" left="385" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="523" left="385" width="133" height="17" font="0">Rutherford stage 0 or 4–</text>
<text top="540" left="385" width="134" height="17" font="0">6, exercise limiting CVD </text>
<text top="558" left="385" width="137" height="17" font="0">or orthopedic conditions, </text>
<text top="575" left="385" width="134" height="17" font="0">only aorto-illiac stenosis </text>
<text top="438" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="437" left="547" width="6" height="18" font="7"></text>
<text top="438" left="553" width="209" height="17" font="2"><b> endpoint:</b> Maximal walking distance, </text>
<text top="455" left="540" width="179" height="17" font="0">walking speed, muscle strength  </text>
<text top="473" left="540" width="3" height="17" font="0"> </text>
<text top="490" left="540" width="263" height="17" font="2"><b>Results:</b> Significant increases in all parameters </text>
<text top="507" left="540" width="256" height="17" font="0">evaluated, but greater benefit was found in the </text>
<text top="524" left="540" width="263" height="17" font="0">12 mo training group. The absolute claudication </text>
<text top="542" left="540" width="233" height="17" font="0">distance increased similarly by 27.5% and </text>
<text top="559" left="540" width="252" height="17" font="0">29.5%, respectively, at 6 and 12 mo a greater </text>
<text top="576" left="540" width="244" height="17" font="0">increase in walking speed (12.1% vs. 5.3%;, </text>
<text top="593" left="540" width="257" height="17" font="0">p&lt;0.001) was seen at 12 vs. 6 mo. All strength </text>
<text top="610" left="540" width="250" height="17" font="0">parameters increased significantly in both the </text>
<text top="628" left="540" width="246" height="17" font="0">groups showing an increase for &#34;pushing&#34; by </text>
<text top="645" left="540" width="254" height="17" font="0">90.0% (6 mo) and 90.2% (12 mo), for &#34;pulling&#34; </text>
<text top="662" left="540" width="247" height="17" font="0">by 64.2% (6 mo) and 75.3% (12 mo), and for </text>
<text top="679" left="540" width="226" height="17" font="0">&#34;tiptoe standing&#34; by 70.5% (group A) and </text>
<text top="696" left="540" width="139" height="17" font="0">113.7% (12 mo; p&lt;0.05). </text>
<text top="437" left="817" width="7" height="18" font="7"></text>
<text top="438" left="824" width="254" height="17" font="0"> Combined exercise increased walking speed, </text>
<text top="455" left="817" width="221" height="17" font="0">MWD, and muscle strength parameters. </text>
<text top="473" left="817" width="7" height="18" font="7"></text>
<text top="474" left="824" width="263" height="17" font="0"> Greater improvements resulted from the 12 mo </text>
<text top="491" left="817" width="49" height="17" font="0">program </text>
<text top="508" left="817" width="7" height="18" font="7"></text>
<text top="509" left="824" width="269" height="17" font="0"> No changes in weight, total cholesterol, or blood </text>
<text top="527" left="817" width="230" height="17" font="0">sugar in the 6 mo group. Total cholesterol </text>
<text top="544" left="817" width="288" height="17" font="0">decreased by -9.4 mg/dL in 12 mo group (p=0.0053) </text>
<text top="561" left="817" width="7" height="18" font="7"></text>
<text top="562" left="824" width="237" height="17" font="0"> Strength exercise involved lower extremity </text>
<text top="579" left="817" width="49" height="17" font="0">exercise </text>
<text top="597" left="817" width="7" height="18" font="7"></text>
<text top="598" left="824" width="280" height="17" font="0"> Though the program was supervised, walking was </text>
<text top="615" left="817" width="265" height="17" font="0">done on a track in a gym rather than treadmill to </text>
<text top="632" left="817" width="286" height="17" font="0">mimic walking in a community setting. Pts were also </text>
<text top="649" left="817" width="269" height="17" font="0">instructed to walk on the weekends on their own. </text>
<text top="714" left="95" width="85" height="17" font="0">Mays RJ, et al. </text>
<text top="732" left="95" width="59" height="17" font="0">2013(202) </text>
<text top="749" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24103409">24103409</a></text>
<text top="749" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24103409"> </a></text>
<text top="766" left="95" width="3" height="17" font="0"> </text>
<text top="714" left="235" width="126" height="17" font="2"><b>Study type: </b>Literature </text>
<text top="732" left="235" width="39" height="17" font="0">review<b> </b></text>
<text top="749" left="235" width="3" height="17" font="2"><b> </b></text>
<text top="766" left="235" width="102" height="17" font="2"><b>Size: </b>n=10 RCTs<b>  </b></text>
<text top="714" left="385" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="732" left="385" width="7" height="18" font="7"></text>
<text top="733" left="392" width="135" height="17" font="0"> PubMed/MEDLINE and </text>
<text top="750" left="385" width="117" height="17" font="0">Cochrane databases </text>
<text top="767" left="385" width="7" height="18" font="7"></text>
<text top="768" left="392" width="101" height="17" font="0"> English language </text>
<text top="716" left="540" width="10" height="17" font="0"> <b>1</b></text>
<text top="714" left="550" width="6" height="18" font="7"></text>
<text top="716" left="556" width="228" height="17" font="2"><b> endpoint: </b>Peak walking performance on </text>
<text top="733" left="540" width="74" height="17" font="0">the treadmill. </text>
<text top="750" left="540" width="3" height="17" font="0"> </text>
<text top="767" left="540" width="252" height="17" font="2"><b>Results: </b>Supervised exercise programs were </text>
<text top="714" left="817" width="7" height="18" font="7"></text>
<text top="716" left="824" width="257" height="17" font="0"> Unstructured recommendations for pts with sx </text>
<text top="733" left="817" width="230" height="17" font="0">PAD to exercise in the community are not </text>
<text top="750" left="817" width="68" height="17" font="0">efficacious.  </text>
<text top="767" left="817" width="7" height="18" font="7"></text>
<text top="768" left="824" width="268" height="17" font="0"> Community walking programs may improve with </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">92 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="385" width="7" height="18" font="7"></text>
<text top="88" left="392" width="98" height="17" font="0"> Used community </text>
<text top="106" left="385" width="142" height="17" font="0">walking programs to treat </text>
<text top="123" left="385" width="90" height="17" font="0">PAD pts with IC </text>
<text top="140" left="385" width="3" height="17" font="2"><b> </b></text>
<text top="157" left="385" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="87" left="540" width="258" height="17" font="0">more effective than community walking studies </text>
<text top="104" left="540" width="264" height="17" font="0">with general recommendations to walk at home. </text>
<text top="122" left="540" width="261" height="17" font="0">Community trials that incorporated more advice </text>
<text top="139" left="540" width="261" height="17" font="0">and feedback for PAD pts in general resulted in </text>
<text top="156" left="540" width="245" height="17" font="0">similar outcomes with no differences in peak </text>
<text top="173" left="540" width="250" height="17" font="0">walking time compared to supervised walking </text>
<text top="190" left="540" width="97" height="17" font="0">exercise groups. <b> </b></text>
<text top="87" left="817" width="170" height="17" font="0">more feedback and monitoring </text>
<text top="208" left="86" width="819" height="17" font="0">CVD indicates cardiovascular disease; IC, intermittent claudication; MWD, maximum walking distance; PAD, peripheral artery disease; and pt, patient. </text>
<text top="226" left="86" width="3" height="17" font="0"> </text>
<text top="243" left="86" width="3" height="17" font="0"> </text>
<text top="260" left="86" width="899" height="21" font="1"><b>Evidence Table 34. Nonrandomized Trials and Observational Studies of Minimizing Tissue Loss in Patients with PAD–Section 7. </b></text>
<text top="281" left="123" width="38" height="17" font="2"><b>Study </b></text>
<text top="299" left="112" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="316" left="118" width="48" height="17" font="2"><b>Author; </b></text>
<text top="333" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="281" left="225" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="299" left="251" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="281" left="427" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="281" left="640" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="299" left="647" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="316" left="699" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="281" left="924" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="299" left="952" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="351" left="95" width="75" height="17" font="0">Crane M and </text>
<text top="368" left="95" width="55" height="17" font="0">Werber B </text>
<text top="385" left="95" width="59" height="17" font="0">1999(203) </text>
<text top="403" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10028467">10028467 </a></text>
<text top="420" left="95" width="3" height="17" font="0"> </text>
<text top="351" left="203" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="368" left="203" width="112" height="17" font="0">retrospective cohort </text>
<text top="385" left="203" width="3" height="17" font="0"> </text>
<text top="403" left="203" width="90" height="17" font="2"><b>Size:</b> n=115 pts </text>
<text top="420" left="203" width="112" height="17" font="0">(55 nonpathway, 60 </text>
<text top="437" left="203" width="53" height="17" font="0">pathway) </text>
<text top="351" left="378" width="193" height="17" font="2"><b>Inclusion criteria:</b> All diabetic foot </text>
<text top="368" left="378" width="175" height="17" font="0">infections 1993 and 1995–1996 </text>
<text top="352" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="351" left="608" width="6" height="18" font="7"></text>
<text top="352" left="614" width="204" height="17" font="2"><b> endpoint:</b> Prevalence of major (leg) </text>
<text top="369" left="601" width="215" height="17" font="0">amputation among those admitted with </text>
<text top="387" left="601" width="49" height="17" font="0">infection </text>
<text top="404" left="601" width="3" height="17" font="0"> </text>
<text top="421" left="601" width="239" height="17" font="2"><b>Results:</b> 23% nonpathway vs. 7% pathway </text>
<text top="351" left="871" width="196" height="17" font="0">Established pathway allows “earlier </text>
<text top="368" left="871" width="207" height="17" font="0">recognition, evaluation and expedient </text>
<text top="385" left="871" width="219" height="17" font="0">treatment of potentially limb-threatening </text>
<text top="403" left="871" width="59" height="17" font="0">infections” </text>
<text top="420" left="871" width="3" height="17" font="0"> </text>
<text top="455" left="95" width="90" height="17" font="0">Larsson J, et al. </text>
<text top="472" left="95" width="59" height="17" font="0">1995(204) </text>
<text top="490" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8542736">8542736 </a></text>
<text top="507" left="95" width="3" height="17" font="0"> </text>
<text top="455" left="203" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="472" left="203" width="112" height="17" font="0">retrospective cohort </text>
<text top="490" left="203" width="3" height="17" font="0"> </text>
<text top="507" left="203" width="108" height="17" font="2"><b>Size:</b> n=200,000 pt </text>
<text top="524" left="203" width="117" height="17" font="0">population with 2.4% </text>
<text top="541" left="203" width="153" height="17" font="0">prevalence of DM (~4,800)  </text>
<text top="455" left="378" width="191" height="17" font="2"><b>Inclusion criteria:</b> “All DM related </text>
<text top="472" left="378" width="201" height="17" font="0">primary amputations from toe to hip” </text>
<text top="490" left="378" width="135" height="17" font="0">between 1982 and 1993<b> </b></text>
<text top="456" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="455" left="608" width="6" height="18" font="7"></text>
<text top="456" left="614" width="185" height="17" font="2"><b> endpoint:</b> Annual incidence (per </text>
<text top="473" left="601" width="231" height="17" font="0">inhabitant) of major and minor amputation </text>
<text top="491" left="601" width="3" height="17" font="0"> </text>
<text top="508" left="601" width="231" height="17" font="2"><b>Results:</b> All amputations=19.1 vs. 9.4 per </text>
<text top="525" left="601" width="254" height="17" font="0">100K; major amputations=16 vs. 3.6 per 100K </text>
<text top="455" left="871" width="198" height="17" font="0">“Multidisciplinary approach plays an </text>
<text top="472" left="871" width="217" height="17" font="0">important role to reduce and maintain a </text>
<text top="490" left="871" width="208" height="17" font="0">low incidence of major amputations in </text>
<text top="507" left="871" width="70" height="17" font="0">diabetic pts” </text>
<text top="559" left="95" width="85" height="17" font="0">Armstrong DG, </text>
<text top="576" left="95" width="30" height="17" font="0">et al. </text>
<text top="593" left="95" width="59" height="17" font="0">2012(205) </text>
<text top="611" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22431496">22431496 </a></text>
<text top="628" left="95" width="3" height="17" font="0"> </text>
<text top="559" left="203" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="576" left="203" width="112" height="17" font="0">retrospective cohort </text>
<text top="593" left="203" width="3" height="17" font="0"> </text>
<text top="611" left="203" width="140" height="17" font="2"><b>Size:</b> n=790 diabetic foot </text>
<text top="628" left="203" width="64" height="17" font="0">operations  </text>
<text top="559" left="378" width="193" height="17" font="2"><b>Inclusion criteria:</b> All diabetic foot </text>
<text top="576" left="378" width="207" height="17" font="0">operations 2006–2008 vs. 2008-2010 </text>
<text top="560" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="559" left="608" width="6" height="18" font="7"></text>
<text top="560" left="614" width="212" height="17" font="2"><b> endpoint:</b> Amputation level, case mix </text>
<text top="577" left="601" width="3" height="17" font="0"> </text>
<text top="595" left="601" width="213" height="17" font="2"><b>Results:</b> 37.5% reduction in transtibial </text>
<text top="612" left="601" width="214" height="17" font="0">amputations; 44% increase in vascular </text>
<text top="629" left="601" width="73" height="17" font="0">interventions </text>
<text top="559" left="871" width="202" height="17" font="0">Interdisciplinary care as a “rapid and </text>
<text top="576" left="871" width="233" height="17" font="0">sustained impact in changing surgery type </text>
<text top="593" left="871" width="217" height="17" font="0">from reactive to proactive” and reduces </text>
<text top="611" left="871" width="105" height="17" font="0">major amputations </text>
<text top="647" left="95" width="83" height="17" font="0">Chung J, et al. </text>
<text top="664" left="95" width="59" height="17" font="0">2015(206) </text>
<text top="682" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25073577">25073577 </a></text>
<text top="699" left="95" width="3" height="17" font="0"> </text>
<text top="647" left="203" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="664" left="203" width="112" height="17" font="0">retrospective cohort </text>
<text top="682" left="203" width="3" height="17" font="0"> </text>
<text top="699" left="203" width="69" height="17" font="2"><b>Size:</b> 85 pts </text>
<text top="647" left="378" width="196" height="17" font="2"><b>Inclusion criteria:</b> “All consecutive </text>
<text top="664" left="378" width="206" height="17" font="0">pts” with R5/6 CLI at a single hospital </text>
<text top="682" left="378" width="86" height="17" font="0">8/2010–6/2012 </text>
<text top="648" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="647" left="608" width="6" height="18" font="7"></text>
<text top="648" left="614" width="217" height="17" font="2"><b> endpoint:</b> 1 y amputation-free survival </text>
<text top="665" left="601" width="3" height="17" font="0"> </text>
<text top="683" left="601" width="251" height="17" font="2"><b>Results:</b> 67 vs. 42% at 1 y; also higher mean </text>
<text top="700" left="601" width="226" height="17" font="0">limb salvage times. Multidisciplinary care </text>
<text top="717" left="601" width="244" height="17" font="0">remained significant on multivariate analysis </text>
<text top="647" left="871" width="171" height="17" font="0">Multidisciplinary care improves </text>
<text top="664" left="871" width="222" height="17" font="0">amputation-free survival in pts with R5/6 </text>
<text top="682" left="871" width="23" height="17" font="0">CLI </text>
<text top="735" left="95" width="88" height="17" font="0">Canavan RJ, et </text>
<text top="752" left="95" width="16" height="17" font="0">al. </text>
<text top="769" left="95" width="59" height="17" font="0">2008(207) </text>
<text top="735" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="752" left="203" width="3" height="17" font="0"> </text>
<text top="769" left="203" width="154" height="17" font="2"><b>Size:</b> n=273,987 population </text>
<text top="735" left="378" width="141" height="17" font="2"><b>Inclusion criteria:</b> All LE </text>
<text top="752" left="378" width="184" height="17" font="0">amputations from 7/1995–6/2000 </text>
<text top="736" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="735" left="608" width="6" height="18" font="7"></text>
<text top="736" left="614" width="225" height="17" font="2"><b> endpoint:</b> Incidence of major and minor </text>
<text top="753" left="601" width="71" height="17" font="0">amputations </text>
<text top="771" left="601" width="3" height="17" font="0"> </text>
<text top="735" left="871" width="224" height="17" font="0">Reduction in major amputations “a result </text>
<text top="752" left="871" width="187" height="17" font="0">of better organized diabetes care” </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">93 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18071005">18071005</a></text>
<text top="87" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18071005"> </a></text>
<text top="104" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="141" height="17" font="0">with 1.94% prevalence of </text>
<text top="104" left="203" width="26" height="17" font="0">DM  </text>
<text top="87" left="601" width="232" height="17" font="2"><b>Results:</b> Decrease in incidence from 564–</text>
<text top="104" left="601" width="254" height="17" font="0">176/100K pts with DM between first and fifth y </text>
<text top="122" left="601" width="204" height="17" font="0">after change; increase in angioplasty </text>
<text top="139" left="601" width="64" height="17" font="0">prevalence </text>
<text top="157" left="95" width="86" height="17" font="0">Williams DT, et </text>
<text top="174" left="95" width="16" height="17" font="0">al. </text>
<text top="191" left="95" width="59" height="17" font="0">2012(208) </text>
<text top="208" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22503433">22503433 </a></text>
<text top="226" left="95" width="3" height="17" font="0"> </text>
<text top="157" left="203" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="174" left="203" width="152" height="17" font="0">retrospective &amp; prospective </text>
<text top="191" left="203" width="44" height="17" font="0">cohorts </text>
<text top="208" left="203" width="3" height="17" font="0"> </text>
<text top="226" left="203" width="139" height="17" font="2"><b>Size:</b> n=220,000 pts with </text>
<text top="243" left="203" width="131" height="17" font="0">4.2% prevalence of DM </text>
<text top="260" left="203" width="42" height="17" font="0">(9,328) </text>
<text top="157" left="378" width="209" height="17" font="2"><b>Inclusion criteria:</b> All DM or PAD pts </text>
<text top="174" left="378" width="179" height="17" font="0">receiving in pt treatment 1/2004–</text>
<text top="191" left="378" width="200" height="17" font="0">12/2005 (before service) vs. 1/2006–</text>
<text top="208" left="378" width="126" height="17" font="0">12/2009 (after service) </text>
<text top="158" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="157" left="608" width="6" height="18" font="7"></text>
<text top="158" left="614" width="225" height="17" font="2"><b> endpoint:</b> Incidence of major and minor </text>
<text top="175" left="601" width="64" height="17" font="0">amputation </text>
<text top="192" left="601" width="3" height="17" font="0"> </text>
<text top="210" left="601" width="235" height="17" font="2"><b>Results:</b> Fewer major amputations among </text>
<text top="227" left="601" width="224" height="17" font="0">DM pts (peak of 24.7 to nadir of 1.07 per </text>
<text top="244" left="601" width="220" height="17" font="0">10,000); decrease in minor amputations<b> </b></text>
<text top="157" left="871" width="156" height="17" font="0">“Formation of a well-defined </text>
<text top="174" left="871" width="209" height="17" font="0">[multidisciplinary] service … has been </text>
<text top="191" left="871" width="204" height="17" font="0">associated with further demonstrable </text>
<text top="208" left="871" width="230" height="17" font="0">reductions in limb loss caused by diabetic </text>
<text top="226" left="871" width="77" height="17" font="0">foot disease.” </text>
<text top="278" left="95" width="90" height="17" font="0">Driver VR, et al. </text>
<text top="295" left="95" width="59" height="17" font="0">2005(209) </text>
<text top="312" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15677774">15677774 </a></text>
<text top="330" left="95" width="3" height="17" font="0"> </text>
<text top="278" left="203" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="295" left="203" width="3" height="17" font="0"> </text>
<text top="312" left="203" width="130" height="17" font="2"><b>Size:</b> n=About 350,000 </text>
<text top="330" left="203" width="154" height="17" font="0">population (4,940 with DM)  </text>
<text top="278" left="378" width="176" height="17" font="2"><b>Inclusion criteria:</b> All in pt LEA </text>
<text top="295" left="378" width="115" height="17" font="0">between 1999–2003 </text>
<text top="279" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="278" left="608" width="6" height="18" font="7"></text>
<text top="279" left="614" width="218" height="17" font="2"><b> endpoint:</b> Incidence of LEA (all levels) </text>
<text top="296" left="601" width="3" height="17" font="0"> </text>
<text top="314" left="601" width="234" height="17" font="2"><b>Results:</b> Decreased amputation incidence </text>
<text top="331" left="601" width="223" height="17" font="0">from 9.9–1.6 per 1K (71% of which were </text>
<text top="348" left="601" width="38" height="17" font="0">minor)<b> </b></text>
<text top="278" left="871" width="231" height="17" font="0">Multidisciplinary care improves outcomes, </text>
<text top="295" left="871" width="155" height="17" font="0">decreases amputation rates </text>
<text top="366" left="95" width="94" height="17" font="0">Wrobel JS, et al. </text>
<text top="383" left="95" width="63" height="17" font="0">2003 (210) </text>
<text top="400" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14578237">14578237 </a></text>
<text top="418" left="95" width="3" height="17" font="0"> </text>
<text top="366" left="203" width="159" height="17" font="2"><b>Study type:</b> Cross-sectional </text>
<text top="383" left="203" width="3" height="17" font="0"> </text>
<text top="400" left="203" width="154" height="17" font="2"><b>Size:</b> n=10 Veterans Affairs </text>
<text top="418" left="203" width="90" height="17" font="0">medical centers </text>
<text top="366" left="378" width="168" height="17" font="2"><b>Inclusion criteria:</b> Surveys of </text>
<text top="383" left="378" width="185" height="17" font="0">general, vascular, and orthopedic </text>
<text top="400" left="378" width="194" height="17" font="0">surgeons; rehabilitation specialists; </text>
<text top="418" left="378" width="171" height="17" font="0">podiatrists; physical therapists; </text>
<text top="435" left="378" width="174" height="17" font="0">pedorthists; orthotists; DM care </text>
<text top="452" left="378" width="147" height="17" font="0">specialists; DM educators; </text>
<text top="469" left="378" width="154" height="17" font="0">dermatologists; wound care </text>
<text top="486" left="378" width="189" height="17" font="0">specialists; and infectious disease </text>
<text top="504" left="378" width="202" height="17" font="0">clinicians; and 10 randomly-selected </text>
<text top="521" left="378" width="126" height="17" font="0">primary care providers </text>
<text top="367" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="366" left="608" width="6" height="18" font="7"></text>
<text top="367" left="614" width="209" height="17" font="2"><b> endpoint:</b> Correlation between lower </text>
<text top="384" left="601" width="172" height="17" font="0">extremity amputation rates and </text>
<text top="402" left="601" width="3" height="17" font="0"> </text>
<text top="419" left="601" width="223" height="17" font="2"><b>Results:</b> Significant negative correlation </text>
<text top="436" left="601" width="247" height="17" font="0">between programming coordination and total </text>
<text top="453" left="601" width="129" height="17" font="0">and minor amputations<b> </b></text>
<text top="366" left="871" width="232" height="17" font="0">Improved programming coordination more </text>
<text top="383" left="871" width="221" height="17" font="0">influential than feedback coordination or </text>
<text top="400" left="871" width="217" height="17" font="0">site rankings on decreasing amputation </text>
<text top="418" left="871" width="31" height="17" font="0">rates </text>
<text top="539" left="95" width="86" height="17" font="0">Vartanian et al. </text>
<text top="558" left="95" width="27" height="17" font="0">2015</text>
<text top="559" left="122" width="39" height="16" font="3"> (211)</text>
<text top="558" left="161" width="3" height="17" font="0"> </text>
<text top="576" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25596408">25596408</a></text>
<text top="576" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25596408"> </a></text>
<text top="593" left="95" width="3" height="17" font="0"> </text>
<text top="539" left="203" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="556" left="203" width="113" height="17" font="0">retrospective review </text>
<text top="573" left="203" width="3" height="17" font="0"> </text>
<text top="591" left="203" width="160" height="17" font="2"><b>Size:</b> n=91 limbs from 89 pts </text>
<text top="539" left="378" width="152" height="17" font="2"><b>Inclusion criteria:</b> Pts with </text>
<text top="556" left="378" width="194" height="17" font="0">neuroischemic wounds treated at a </text>
<text top="573" left="378" width="165" height="17" font="0">signle institutional amputation </text>
<text top="591" left="378" width="191" height="17" font="0">prevention clinic from March 2012–</text>
<text top="608" left="378" width="204" height="17" font="0">July 2013. Pts at highest risk for limb </text>
<text top="625" left="378" width="186" height="17" font="0">loss, defined as ischemic wounds </text>
<text top="642" left="378" width="174" height="17" font="0">(ischemic ulcer or gangrene) or </text>
<text top="659" left="378" width="113" height="17" font="0">diabetic foot ulcers.  </text>
<text top="677" left="378" width="3" height="17" font="0"> </text>
<text top="694" left="378" width="158" height="17" font="2"><b>Exclusion criteria: </b>New pts </text>
<text top="711" left="378" width="205" height="17" font="0">evaluated for benign conditions (e.g., </text>
<text top="728" left="378" width="179" height="17" font="0">arthritis, overuse injuries, simple </text>
<text top="745" left="378" width="187" height="17" font="0">infections in nondiabetics, venous </text>
<text top="763" left="378" width="206" height="17" font="0">ulcers, minor trauma, radiculopathy).  </text>
<text top="540" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="539" left="608" width="6" height="18" font="7"></text>
<text top="540" left="614" width="193" height="17" font="2"><b> endpoint:</b> Time to wound healing, </text>
<text top="557" left="601" width="224" height="17" font="0">reulceration rate, and ambulatory status. </text>
<text top="574" left="601" width="3" height="17" font="0"> </text>
<text top="592" left="601" width="256" height="17" font="2"><b>Results:</b> 67% of wounds were present &gt;6 wks </text>
<text top="609" left="601" width="251" height="17" font="0">before referral. A total of 151 podiatric and 86 </text>
<text top="626" left="601" width="251" height="17" font="0">vascular interventions were prformed, with an </text>
<text top="643" left="601" width="241" height="17" font="0">equal distribution of endovascular and open </text>
<text top="661" left="601" width="244" height="17" font="0">revascularizations. Complete wound healing </text>
<text top="678" left="601" width="256" height="17" font="0">observed in 59% of wounds, and average time </text>
<text top="695" left="601" width="239" height="17" font="0">to full healing was 12 wk. Hindfood wounds </text>
<text top="712" left="601" width="255" height="17" font="0">predictive of failure to heal (OR: 0.21; p &lt;0.01; </text>
<text top="729" left="601" width="113" height="17" font="0">95% CI: 0.06–0.68). </text>
<text top="539" left="871" width="226" height="17" font="0">Multidisciplinary care can help effectively </text>
<text top="556" left="871" width="211" height="17" font="0">heal wounds and maintain ambulatory </text>
<text top="573" left="871" width="185" height="17" font="0">status in pts with limb threatening </text>
<text top="591" left="871" width="228" height="17" font="0">neuroischemic wounds. Hindfoot or ankle </text>
<text top="608" left="871" width="198" height="17" font="0">wounds can adversely influence the </text>
<text top="625" left="871" width="232" height="17" font="0">outcome. Healing can be prolonged and a </text>
<text top="642" left="871" width="198" height="17" font="0">substancial proportion of pts can be </text>
<text top="659" left="871" width="226" height="17" font="0">expected to have a recurrence, therefore </text>
<text top="677" left="871" width="225" height="17" font="0">surveillance is mandatory. A coordinated </text>
<text top="694" left="871" width="228" height="17" font="0">amputation prevention program may help </text>
<text top="711" left="871" width="221" height="17" font="0">to minimize hospital readmissions in the </text>
<text top="728" left="871" width="117" height="17" font="0">high-risk population.  </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">94 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="86" height="17" font="0">Gardner SE, et </text>
<text top="104" left="95" width="16" height="17" font="0">al. </text>
<text top="122" left="95" width="59" height="17" font="0">2009(212) </text>
<text top="139" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147524">19147524</a></text>
<text top="139" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147524"> </a></text>
<text top="87" left="203" width="158" height="17" font="2"><b>Study type:</b> Cross sectional </text>
<text top="104" left="203" width="33" height="17" font="0">study </text>
<text top="122" left="203" width="3" height="17" font="0"> </text>
<text top="139" left="203" width="83" height="17" font="2"><b>Size:</b> n=64 pts </text>
<text top="87" left="378" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="104" left="378" width="7" height="18" font="7"></text>
<text top="105" left="385" width="101" height="17" font="0"> Age ≥18 y of age </text>
<text top="123" left="378" width="7" height="18" font="7"></text>
<text top="124" left="385" width="146" height="17" font="0"> Pts with ≥1 full-thickness, </text>
<text top="141" left="378" width="206" height="17" font="0">nonarterial diabetic foot ulcers from a </text>
<text top="158" left="378" width="172" height="17" font="0">Department of Veterans Affairs </text>
<text top="176" left="378" width="184" height="17" font="0">Medical Center and an academic-</text>
<text top="193" left="378" width="95" height="17" font="0">affiliated hospital </text>
<text top="210" left="378" width="3" height="17" font="0"> </text>
<text top="227" left="378" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="244" left="378" width="7" height="18" font="7"></text>
<text top="245" left="385" width="165" height="17" font="0"> White blood cell count &lt;1500 </text>
<text top="263" left="378" width="48" height="17" font="0">cells/mm</text>
<text top="264" left="427" width="7" height="11" font="11">3 </text>
<text top="280" left="378" width="7" height="18" font="7"></text>
<text top="281" left="385" width="154" height="17" font="0"> Patelet count &lt;125,000/mm</text>
<text top="282" left="539" width="7" height="11" font="11">3 </text>
<text top="298" left="378" width="7" height="18" font="7"></text>
<text top="299" left="385" width="92" height="17" font="0"> Coagulopathies </text>
<text top="317" left="378" width="7" height="18" font="7"></text>
<text top="318" left="385" width="191" height="17" font="0"> Receiving anticoagulation therapy </text>
<text top="88" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="608" width="6" height="18" font="7"></text>
<text top="88" left="614" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="106" left="601" width="7" height="18" font="7"></text>
<text top="107" left="608" width="223" height="17" font="0"> Sensitivity, specificity, and concordance </text>
<text top="124" left="601" width="218" height="17" font="0">probability of each sign as compared to </text>
<text top="141" left="601" width="198" height="17" font="0">microbial load (reference standard), </text>
<text top="158" left="601" width="7" height="18" font="7"></text>
<text top="159" left="608" width="223" height="17" font="0"> Sensitivity, specificity, and concordance </text>
<text top="177" left="601" width="241" height="17" font="0">probability of the IDSA combination of signs </text>
<text top="194" left="601" width="195" height="17" font="0">as compared to microbial load, and </text>
<text top="211" left="601" width="7" height="18" font="7"></text>
<text top="212" left="608" width="219" height="17" font="0"> discriminatory accuracy of a composite </text>
<text top="230" left="601" width="254" height="17" font="0">predictor computed from the classic and signs </text>
<text top="247" left="601" width="252" height="17" font="0">specific to secondary wounds as compared to </text>
<text top="264" left="601" width="83" height="17" font="0">microbial load. </text>
<text top="281" left="601" width="3" height="17" font="0"> </text>
<text top="298" left="601" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="316" left="601" width="7" height="18" font="7"></text>
<text top="317" left="608" width="204" height="17" font="0"> No signs were significant predictors, </text>
<text top="334" left="601" width="221" height="17" font="0">although increasing pain was marginally </text>
<text top="351" left="601" width="168" height="17" font="0">insignificant (c=0.56; p=0.055) </text>
<text top="368" left="601" width="198" height="17" font="0">IDSA combination of signs were not </text>
<text top="386" left="601" width="62" height="17" font="0">significant. </text>
<text top="403" left="601" width="171" height="17" font="0">Composite predictor c=0.783; c</text>
<text top="408" left="771" width="37" height="11" font="11">overfitting </text>
<text top="426" left="601" width="33" height="11" font="11">corrected</text>
<text top="420" left="634" width="198" height="17" font="0">=0.645; SE=0.0483; 95% CI: 0.559–</text>
<text top="437" left="601" width="38" height="17" font="0">0.732. </text>
<text top="87" left="871" width="234" height="17" font="0">Individual signs of infection do not perform </text>
<text top="104" left="871" width="212" height="17" font="0">well nor does the IDSA combination of </text>
<text top="122" left="871" width="32" height="17" font="0">signs </text>
<text top="139" left="871" width="224" height="17" font="0">A composite predictor based on all signs </text>
<text top="156" left="871" width="237" height="17" font="0">provides a moderate level of discrimination </text>
<text top="455" left="95" width="92" height="17" font="0">Lipsky BA, et al. </text>
<text top="472" left="95" width="59" height="17" font="0">2012(213) </text>
<text top="490" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22619242">22619242</a></text>
<text top="490" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22619242"> </a></text>
<text top="455" left="203" width="140" height="17" font="2"><b>Study type:</b> Summary of </text>
<text top="472" left="203" width="148" height="17" font="0">new guidelines for diabetic </text>
<text top="490" left="203" width="79" height="17" font="0">foot infections </text>
<text top="507" left="203" width="3" height="17" font="0"> </text>
<text top="524" left="203" width="56" height="17" font="2"><b>Size:</b> N/A </text>
<text top="455" left="378" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="472" left="378" width="3" height="17" font="0"> </text>
<text top="490" left="378" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="456" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="455" left="608" width="6" height="18" font="7"></text>
<text top="456" left="614" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="474" left="601" width="3" height="17" font="0"> </text>
<text top="491" left="601" width="76" height="17" font="2"><b>Results:</b> N/A </text>
<text top="455" left="871" width="24" height="17" font="0">N/A </text>
<text top="542" left="95" width="93" height="17" font="0">Pickwell K, et al. </text>
<text top="559" left="95" width="59" height="17" font="0">2015(214) </text>
<text top="542" left="203" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="559" left="203" width="33" height="17" font="0">study </text>
<text top="576" left="203" width="3" height="17" font="0"> </text>
<text top="594" left="203" width="90" height="17" font="2"><b>Size:</b> n=575 pts </text>
<text top="542" left="378" width="166" height="17" font="2"><b>Inclusion criteria:</b> Part of the </text>
<text top="559" left="378" width="92" height="17" font="0">Eurodiale study. </text>
<text top="576" left="378" width="3" height="17" font="0"> </text>
<text top="594" left="378" width="207" height="17" font="2"><b>Exclusion criteria: </b>Pts treated in the </text>
<text top="611" left="378" width="192" height="17" font="0">participating centers for an ulcer of </text>
<text top="628" left="378" width="208" height="17" font="0">the ipsilateral foot during the previous </text>
<text top="645" left="378" width="205" height="17" font="0">12 mo and those with life expectancy </text>
<text top="663" left="378" width="30" height="17" font="0">&lt;1  y </text>
<text top="543" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="542" left="608" width="6" height="18" font="7"></text>
<text top="543" left="614" width="234" height="17" font="2"><b> endpoint:</b> Healing of the foot ulcer, major </text>
<text top="560" left="601" width="116" height="17" font="0">amputation, or death </text>
<text top="578" left="601" width="3" height="17" font="0"> </text>
<text top="595" left="601" width="235" height="17" font="2"><b>Results:</b> 159 (28%) pts (126 minor and 33 </text>
<text top="612" left="601" width="229" height="17" font="0">major) within 1 y follow-up; 103 pts (18%) </text>
<text top="629" left="601" width="219" height="17" font="0">underwent amputations proximal to and </text>
<text top="646" left="601" width="108" height="17" font="0">including the hallux </text>
<text top="664" left="601" width="216" height="17" font="0">Incidence of amputation increased with </text>
<text top="681" left="601" width="237" height="17" font="0">redness, periwound or pretibial edema, the </text>
<text top="698" left="601" width="248" height="17" font="0">presence of pus, lymphadenitis/lymphangitis, </text>
<text top="715" left="601" width="252" height="17" font="0">fever (all p&lt;0.01) and elevated CRP (p=0.01). </text>
<text top="542" left="871" width="218" height="17" font="0">Positive probe-to-bone test, deep ulcer, </text>
<text top="559" left="871" width="230" height="17" font="0">elevated CRP levels, and the presence of </text>
<text top="576" left="871" width="190" height="17" font="0">periwound or pretibial edema. The </text>
<text top="594" left="871" width="201" height="17" font="0">presence of increased (non)purulent </text>
<text top="611" left="871" width="164" height="17" font="0">exudate, foul smell, and fever </text>
<text top="628" left="871" width="222" height="17" font="0">independently predicted any amputation </text>
<text top="645" left="871" width="224" height="17" font="0">but not amputations excluding the lesser </text>
<text top="663" left="871" width="211" height="17" font="0">toes are risk factos for lower extremity </text>
<text top="680" left="871" width="232" height="17" font="0">amputation in pts with diabetic foot ulcers. </text>
<text top="733" left="95" width="83" height="17" font="0">Dinh MT, et al. </text>
<text top="750" left="95" width="59" height="17" font="0">2008(215) </text>
<text top="733" left="203" width="150" height="17" font="2"><b>Study type:</b> Meta-analysis </text>
<text top="750" left="203" width="3" height="17" font="0"> </text>
<text top="768" left="203" width="147" height="17" font="2"><b>Size:</b> n=9 articles from the </text>
<text top="733" left="378" width="172" height="17" font="2"><b>Inclusion criteria: </b>studies that </text>
<text top="750" left="378" width="183" height="17" font="0">assess the accuracy of clinical or </text>
<text top="768" left="378" width="182" height="17" font="0">imaging diagnostic modalities for </text>
<text top="734" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="733" left="608" width="6" height="18" font="7"></text>
<text top="734" left="614" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="752" left="601" width="3" height="17" font="0"> </text>
<text top="769" left="601" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="733" left="871" width="182" height="17" font="0">Among the imaging tests that we </text>
<text top="750" left="871" width="216" height="17" font="0">evaluated, MRI was the most accurate. </text>
<text top="768" left="871" width="217" height="17" font="0">However, MRI is costly and may not be </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">95 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="133" height="17" font="0">literature search and 59 </text>
<text top="104" left="203" width="162" height="17" font="0">studies identified by perusing </text>
<text top="122" left="203" width="152" height="17" font="0">reference lists of potentially </text>
<text top="139" left="203" width="90" height="17" font="0">relevant articles </text>
<text top="87" left="378" width="202" height="17" font="0">diagnosis of osteomyelitis in pts with </text>
<text top="104" left="378" width="198" height="17" font="0">diabetes and foot ulcer, and studies </text>
<text top="122" left="378" width="209" height="17" font="0">that used histopathologic examination </text>
<text top="139" left="378" width="198" height="17" font="0">and/or microbiologic culture of bone </text>
<text top="156" left="378" width="196" height="17" font="0">specimens as the reference test for </text>
<text top="173" left="378" width="208" height="17" font="0">diagnosis of osteomyelitis. All pts had </text>
<text top="190" left="378" width="207" height="17" font="0">to participate in the test being studied </text>
<text top="208" left="378" width="157" height="17" font="0">as well as the reference test </text>
<text top="225" left="378" width="3" height="17" font="0"> </text>
<text top="242" left="378" width="135" height="17" font="2"><b>Exclusion criteria: N/A</b> </text>
<text top="87" left="601" width="7" height="18" font="7"></text>
<text top="88" left="608" width="245" height="17" font="0"> A positive probe-to-bone test result in had a </text>
<text top="106" left="601" width="229" height="17" font="0">sensitivity of 0.87 (95% CI: 0.71–0.96) for </text>
<text top="123" left="601" width="248" height="17" font="0">diagnosis of osteomyelitis and a specificity of </text>
<text top="140" left="601" width="251" height="17" font="0">0.91 (95% CI: 0.89–0.92). The likelihood ratio </text>
<text top="157" left="601" width="230" height="17" font="0">for a positive test result was 9.40, and the </text>
<text top="174" left="601" width="242" height="17" font="0">likelihood ratio for a negative test result was </text>
<text top="192" left="601" width="34" height="17" font="0">0.14,  </text>
<text top="209" left="601" width="7" height="18" font="7"></text>
<text top="210" left="608" width="248" height="17" font="0"> The pooled diagnostic OR for exposed bone </text>
<text top="227" left="601" width="232" height="17" font="0">or a positive probe-to-bone test result was </text>
<text top="244" left="601" width="34" height="17" font="0">49.45 </text>
<text top="262" left="601" width="7" height="18" font="7"></text>
<text top="263" left="608" width="247" height="17" font="0"> Sensitivity of plain radiography for diagnosis </text>
<text top="280" left="601" width="243" height="17" font="0">of osteomyelitis was highly variable, ranging </text>
<text top="297" left="601" width="86" height="17" font="0">from 0.28–0.75 </text>
<text top="87" left="871" width="224" height="17" font="0">readily available. Nuclear medicine bone </text>
<text top="104" left="871" width="228" height="17" font="0">scan and indium-labeled leukocyte scans </text>
<text top="122" left="871" width="187" height="17" font="0">had low-to-moderate accuracy for </text>
<text top="139" left="871" width="176" height="17" font="0">detection of osteomyelitis. Plain </text>
<text top="156" left="871" width="222" height="17" font="0">radiographs provided limited information </text>
<text top="315" left="95" width="84" height="17" font="0">Prompers L, et </text>
<text top="332" left="95" width="16" height="17" font="0">al. </text>
<text top="350" left="95" width="59" height="17" font="0">2008(216) </text>
<text top="367" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18297261">18297261</a></text>
<text top="367" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18297261"> </a></text>
<text top="315" left="203" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="332" left="203" width="126" height="17" font="0">cohort study within the </text>
<text top="350" left="203" width="109" height="17" font="0">EURODIALE Study </text>
<text top="367" left="203" width="3" height="17" font="0"> </text>
<text top="384" left="203" width="100" height="17" font="2"><b>Size:</b> n=1,088 pts </text>
<text top="315" left="378" width="166" height="17" font="2"><b>Inclusion criteria:</b> Part of the </text>
<text top="332" left="378" width="109" height="17" font="0">EURODIALE Study </text>
<text top="350" left="378" width="3" height="17" font="0"> </text>
<text top="367" left="378" width="135" height="17" font="2"><b>Exclusion criteria: N/A</b> </text>
<text top="316" left="601" width="7" height="17" font="2"><b>1</b></text>
<text top="315" left="608" width="6" height="18" font="7"></text>
<text top="316" left="614" width="148" height="17" font="2"><b> endpoint:</b> Wound healing </text>
<text top="334" left="601" width="3" height="17" font="0"> </text>
<text top="351" left="601" width="249" height="17" font="2"><b>Results:</b> At 1-y follow up, 23% of pts had not </text>
<text top="368" left="601" width="232" height="17" font="0">healed. Predictors of nonhealing are older </text>
<text top="385" left="601" width="241" height="17" font="0">age, male sex, HF, inability to stand or walk </text>
<text top="402" left="601" width="207" height="17" font="0">without help, ESRD, larger ulcer size, </text>
<text top="420" left="601" width="255" height="17" font="0">peripheral neuropathy, and PAD. Infection is a </text>
<text top="437" left="601" width="220" height="17" font="0">predictor of nonhealing in PAD pts only. </text>
<text top="315" left="871" width="216" height="17" font="0">Predictors of healing differ between pts </text>
<text top="332" left="871" width="211" height="17" font="0">with and without PAD, suggesting that </text>
<text top="350" left="871" width="188" height="17" font="0">diabetic foot ulcers with or without </text>
<text top="367" left="871" width="215" height="17" font="0">concomitant PAD should be defined as </text>
<text top="384" left="871" width="156" height="17" font="0">two separate disease states </text>
<text top="455" left="86" width="974" height="17" font="0">AFS indicates amputation-free survival; CLI, critical or chronic limb ischemia; DM, diabetes mellitus; DR, diabetes-related; ESRD, end stage renal disease; HF, heart failure; IDSA, </text>
<text top="472" left="86" width="1011" height="17" font="0">Infectious Disease Society of America; LEA, lower extremity amputation; LPS, Limb Prevention Service; MDC, multidisciplinary care; NR, nonrandomized; OR, odds ratio; pt, patient; and </text>
<text top="489" left="86" width="94" height="17" font="0">RR, relative risk. </text>
<text top="506" left="86" width="3" height="17" font="0"> </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">96 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="751" height="21" font="1"><b>Data Supplement 34a. Functions of a Multidisciplinary Foot Care / Amputation Prevention Team–Section 7. </b></text>
<text top="108" left="99" width="38" height="17" font="2"><b>Study </b></text>
<text top="125" left="99" width="37" height="17" font="2"><b>Name </b></text>
<text top="108" left="174" width="45" height="17" font="2"><b>Patient </b></text>
<text top="125" left="165" width="63" height="17" font="2"><b>Education </b></text>
<text top="108" left="245" width="112" height="17" font="2"><b>Risk Stratification, </b></text>
<text top="125" left="267" width="67" height="17" font="2"><b>Testing for </b></text>
<text top="142" left="244" width="113" height="17" font="2"><b>Neuropathy and/or </b></text>
<text top="159" left="286" width="29" height="17" font="2"><b>PAD </b></text>
<text top="108" left="373" width="77" height="17" font="2"><b>Prophylactic </b></text>
<text top="125" left="384" width="56" height="17" font="2"><b>Podiatric </b></text>
<text top="142" left="387" width="50" height="17" font="2"><b>Surgery </b></text>
<text top="108" left="471" width="64" height="17" font="2"><b>Protocols, </b></text>
<text top="125" left="467" width="72" height="17" font="2"><b>Algorithms, </b></text>
<text top="142" left="478" width="50" height="17" font="2"><b>Referral </b></text>
<text top="159" left="473" width="60" height="17" font="2"><b>Pathways </b></text>
<text top="108" left="555" width="79" height="17" font="2"><b>Wound Care, </b></text>
<text top="125" left="565" width="58" height="17" font="2"><b>Including </b></text>
<text top="142" left="555" width="79" height="17" font="2"><b>Debridement </b></text>
<text top="159" left="569" width="51" height="17" font="2"><b>in Clinic </b></text>
<text top="108" left="662" width="55" height="17" font="2"><b>Infection </b></text>
<text top="125" left="650" width="79" height="17" font="2"><b>Management </b></text>
<text top="108" left="772" width="37" height="17" font="2"><b>Close </b></text>
<text top="125" left="745" width="91" height="17" font="2"><b>Post-Operative </b></text>
<text top="142" left="757" width="67" height="17" font="2"><b>Monitoring </b></text>
<text top="108" left="859" width="58" height="17" font="2"><b>Orthotics </b></text>
<text top="125" left="875" width="25" height="17" font="2"><b>and </b></text>
<text top="142" left="853" width="70" height="17" font="2"><b>Prosthetics </b></text>
<text top="108" left="1005" width="36" height="17" font="2"><b>Other </b></text>
<text top="177" left="99" width="40" height="17" font="0">Crane  </text>
<text top="197" left="102" width="31" height="17" font="0">1999 </text>
<text top="217" left="89" width="58" height="17" font="0"><a href="http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/?term=10028467">10028467 </a></text>
<text top="237" left="102" width="32" height="17" font="0">(203) </text>
<text top="207" left="194" width="3" height="17" font="0"> </text>
<text top="207" left="299" width="3" height="17" font="0"> </text>
<text top="207" left="410" width="3" height="17" font="0"> </text>
<text top="207" left="497" width="12" height="17" font="0">X </text>
<text top="207" left="593" width="3" height="17" font="0"> </text>
<text top="207" left="687" width="3" height="17" font="0"> </text>
<text top="207" left="788" width="3" height="17" font="0"> </text>
<text top="207" left="886" width="3" height="17" font="0"> </text>
<text top="177" left="938" width="3" height="17" font="0"> </text>
<text top="257" left="100" width="40" height="17" font="0">Driver  </text>
<text top="277" left="102" width="31" height="17" font="0">2005 </text>
<text top="297" left="89" width="58" height="17" font="0"><a href="http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/?term=15677774">15677774 </a></text>
<text top="317" left="102" width="32" height="17" font="0">(209) </text>
<text top="287" left="190" width="12" height="17" font="0">X </text>
<text top="287" left="295" width="12" height="17" font="0">X </text>
<text top="287" left="410" width="3" height="17" font="0"> </text>
<text top="287" left="502" width="3" height="17" font="0"> </text>
<text top="287" left="589" width="12" height="17" font="0">X </text>
<text top="287" left="683" width="12" height="17" font="0">X </text>
<text top="287" left="784" width="12" height="17" font="0">X </text>
<text top="287" left="882" width="12" height="17" font="0">X </text>
<text top="257" left="938" width="122" height="17" font="0">Research; community </text>
<text top="277" left="938" width="108" height="17" font="0">outreach/education </text>
<text top="337" left="93" width="53" height="17" font="0">Williams  </text>
<text top="357" left="102" width="31" height="17" font="0">2012 </text>
<text top="377" left="89" width="58" height="17" font="0"><a href="http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/?term=22503433">22503433 </a></text>
<text top="397" left="102" width="32" height="17" font="0">(208) </text>
<text top="367" left="190" width="12" height="17" font="0">X </text>
<text top="367" left="299" width="3" height="17" font="0"> </text>
<text top="367" left="410" width="3" height="17" font="0"> </text>
<text top="367" left="497" width="12" height="17" font="0">X </text>
<text top="367" left="589" width="12" height="17" font="0">X </text>
<text top="367" left="687" width="3" height="17" font="0"> </text>
<text top="367" left="788" width="3" height="17" font="0"> </text>
<text top="367" left="886" width="3" height="17" font="0"> </text>
<text top="337" left="938" width="123" height="17" font="0">Admission to vascular </text>
<text top="357" left="938" width="163" height="17" font="0">inpatient service for infection; </text>
<text top="377" left="938" width="127" height="17" font="0">multidisciplinary clinics </text>
<text top="417" left="96" width="43" height="17" font="0">Rogers </text>
<text top="437" left="101" width="34" height="17" font="0"> 2010 </text>
<text top="457" left="89" width="58" height="17" font="0"><a href="http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/?term=20804929">20804929 </a></text>
<text top="476" left="102" width="32" height="17" font="0">(217) </text>
<text top="447" left="194" width="3" height="17" font="0"> </text>
<text top="447" left="295" width="12" height="17" font="0">X </text>
<text top="447" left="406" width="12" height="17" font="0">X </text>
<text top="447" left="502" width="3" height="17" font="0"> </text>
<text top="447" left="589" width="12" height="17" font="0">X </text>
<text top="447" left="683" width="12" height="17" font="0">X </text>
<text top="447" left="784" width="12" height="17" font="0">X </text>
<text top="447" left="882" width="12" height="17" font="0">X </text>
<text top="417" left="938" width="123" height="17" font="0">Gait analysis; medical </text>
<text top="437" left="938" width="118" height="17" font="0">management of PAD </text>
<text top="497" left="95" width="49" height="17" font="0">Sumpio  </text>
<text top="517" left="102" width="31" height="17" font="0">2010 </text>
<text top="537" left="89" width="58" height="17" font="0"><a href="http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/20488327">20488327 </a></text>
<text top="556" left="102" width="32" height="17" font="0">(218) </text>
<text top="527" left="194" width="3" height="17" font="0"> </text>
<text top="527" left="295" width="12" height="17" font="0">X </text>
<text top="527" left="406" width="12" height="17" font="0">X </text>
<text top="527" left="502" width="3" height="17" font="0"> </text>
<text top="527" left="589" width="12" height="17" font="0">X </text>
<text top="527" left="683" width="12" height="17" font="0">X </text>
<text top="527" left="784" width="12" height="17" font="0">X </text>
<text top="527" left="882" width="12" height="17" font="0">X </text>
<text top="497" left="938" width="3" height="17" font="0"> </text>
<text top="577" left="89" width="61" height="17" font="0">Fitzgerald  </text>
<text top="597" left="102" width="31" height="17" font="0">2009 </text>
<text top="617" left="89" width="58" height="17" font="0"><a href="http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/?term=19436764">19436764 </a></text>
<text top="636" left="102" width="36" height="17" font="0">(219)  </text>
<text top="607" left="194" width="3" height="17" font="0"> </text>
<text top="607" left="295" width="12" height="17" font="0">X </text>
<text top="607" left="410" width="3" height="17" font="0"> </text>
<text top="607" left="502" width="3" height="17" font="0"> </text>
<text top="607" left="589" width="12" height="17" font="0">X </text>
<text top="607" left="683" width="12" height="17" font="0">X </text>
<text top="607" left="784" width="12" height="17" font="0">X </text>
<text top="607" left="886" width="3" height="17" font="0"> </text>
<text top="577" left="938" width="3" height="17" font="0"> </text>
<text top="667" left="97" width="46" height="17" font="0">Wrobel  </text>
<text top="687" left="102" width="31" height="17" font="0">2006 </text>
<text top="706" left="89" width="58" height="17" font="0"><a href="http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/?term=16649651">16649651 </a></text>
<text top="726" left="102" width="32" height="17" font="0">(220) </text>
<text top="696" left="190" width="12" height="17" font="0">X </text>
<text top="696" left="299" width="3" height="17" font="0"> </text>
<text top="696" left="410" width="3" height="17" font="0"> </text>
<text top="696" left="497" width="12" height="17" font="0">X </text>
<text top="696" left="593" width="3" height="17" font="0"> </text>
<text top="696" left="687" width="3" height="17" font="0"> </text>
<text top="696" left="788" width="3" height="17" font="0"> </text>
<text top="696" left="886" width="3" height="17" font="0"> </text>
<text top="657" left="938" width="129" height="17" font="0">Ease in recruiting staff; </text>
<text top="677" left="938" width="153" height="17" font="0">confidence in staff; clinician </text>
<text top="696" left="938" width="148" height="17" font="0">attendance at diabetic foot </text>
<text top="716" left="938" width="146" height="17" font="0">care education program in </text>
<text top="736" left="938" width="57" height="17" font="0">past 3 yrs </text>
<text top="757" left="86" width="223" height="17" font="0">PAD indicates peripheral artery disease. </text>
<text top="774" left="86" width="3" height="17" font="0"> </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">97 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="3" height="17" font="0"> </text>
<text top="104" left="86" width="989" height="21" font="1"><b>Evidence Table 35. RCTs Comparing Endovascular Treatment and Endovascular Versus Noninvasive Treatment of Claudication–Section 8.1. </b></text>
<text top="125" left="122" width="38" height="17" font="2"><b>Study </b></text>
<text top="142" left="110" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="159" left="117" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="177" left="95" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="125" left="217" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="142" left="222" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="159" left="216" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="125" left="360" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="125" left="518" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="142" left="536" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="159" left="519" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="177" left="540" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="125" left="674" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="142" left="651" width="149" height="17" font="2"><b>(Absolute Event Rates, P </b></text>
<text top="159" left="669" width="118" height="17" font="2"><b>value; OR or RR; &amp;  </b></text>
<text top="177" left="702" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="126" left="871" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="125" left="933" width="6" height="18" font="7"></text>
<text top="126" left="939" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="143" left="904" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="161" left="911" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="195" left="95" width="78" height="17" font="0">Tetteroo E, et </text>
<text top="212" left="95" width="20" height="17" font="0">al.  </text>
<text top="229" left="95" width="59" height="17" font="0">1998(221) </text>
<text top="246" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9643685">9643685</a></text>
<text top="246" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9643685"> </a></text>
<text top="263" left="95" width="3" height="17" font="0"> </text>
<text top="195" left="200" width="91" height="17" font="2"><b>Aim:</b> Determine </text>
<text top="212" left="200" width="98" height="17" font="0">superiority of iliac </text>
<text top="229" left="200" width="82" height="17" font="0">PTAS vs. PTA </text>
<text top="246" left="200" width="3" height="17" font="0"> </text>
<text top="263" left="200" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="281" left="200" width="3" height="17" font="0"> </text>
<text top="298" left="200" width="90" height="17" font="2"><b>Size:</b> n=279 pts </text>
<text top="195" left="331" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="212" left="331" width="7" height="18" font="7"></text>
<text top="213" left="338" width="75" height="17" font="0"> Claudication </text>
<text top="230" left="331" width="7" height="18" font="7"></text>
<text top="231" left="338" width="146" height="17" font="0"> Iliac artery stenosis &lt;5cm </text>
<text top="249" left="331" width="3" height="17" font="0"> </text>
<text top="266" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="283" left="331" width="7" height="18" font="7"></text>
<text top="284" left="338" width="148" height="17" font="0"> Stenosis &gt;10 cm in length </text>
<text top="301" left="331" width="7" height="18" font="7"></text>
<text top="302" left="338" width="151" height="17" font="0"> Arterial occlusion &gt;5 cm in </text>
<text top="320" left="331" width="161" height="17" font="0">length, or ≤5 cm not allowing </text>
<text top="337" left="331" width="154" height="17" font="0">the passage of a guide wire </text>
<text top="354" left="331" width="7" height="18" font="7"></text>
<text top="355" left="338" width="158" height="17" font="0"> Stenosis involving the distal </text>
<text top="373" left="331" width="141" height="17" font="0">aorta; severe comorbidity </text>
<text top="390" left="331" width="129" height="17" font="0">(e.g., severe cardiac or </text>
<text top="407" left="331" width="161" height="17" font="0">cerebrovascular abnormality, </text>
<text top="424" left="331" width="107" height="17" font="0">malignant disease) </text>
<text top="195" left="513" width="113" height="17" font="2"><b>Intervention:</b> PTAS </text>
<text top="212" left="513" width="3" height="17" font="0"> </text>
<text top="229" left="513" width="105" height="17" font="2"><b>Comparator:</b> PTA<b> </b></text>
<text top="196" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="195" left="655" width="6" height="18" font="7"></text>
<text top="196" left="661" width="134" height="17" font="2"><b> endpoint:</b> Reduction in </text>
<text top="213" left="648" width="93" height="17" font="0">symptoms; QoL  </text>
<text top="195" left="817" width="7" height="18" font="7"></text>
<text top="196" left="824" width="204" height="17" font="0"> No difference between groups at 2 y </text>
<text top="213" left="817" width="7" height="18" font="7"></text>
<text top="214" left="824" width="267" height="17" font="0"> Group I=PTAS. Group II=PTA. The mean follow-</text>
<text top="231" left="817" width="273" height="17" font="0">up was 9.3 mo (range 3–24). Initial hemodynamic </text>
<text top="249" left="817" width="278" height="17" font="0">success and complication rates were 119 (81%) of </text>
<text top="266" left="817" width="282" height="17" font="0">149 limbs and 6 (4%) of 143 limbs (group I) vs. 103 </text>
<text top="283" left="817" width="246" height="17" font="0">(82%) of 126 limbs and 10 (7%) of 136 limbs </text>
<text top="300" left="817" width="284" height="17" font="0">(group II), respectively. Clinical success rates at 2 y </text>
<text top="317" left="817" width="275" height="17" font="0">were 29 (78%) of 37 pts and 26 (77%) of 34 pts in </text>
<text top="335" left="817" width="281" height="17" font="0">groups I and II, respectively (p=0.6); however, 43% </text>
<text top="352" left="817" width="226" height="17" font="0">and 35% of the pts, respectively, still had </text>
<text top="369" left="817" width="239" height="17" font="0">symptoms. QoL improved significantly after </text>
<text top="386" left="817" width="282" height="17" font="0">intervention (p&lt;0.05) but no difference between the </text>
<text top="403" left="817" width="263" height="17" font="0">groups during follow-up. 2 y cumulative patency </text>
<text top="421" left="817" width="235" height="17" font="0">rates were similar at 71% vs. 70% (p=0.2), </text>
<text top="438" left="817" width="281" height="17" font="0">respectively, as were reintervention rates at 7% vs. </text>
<text top="455" left="817" width="198" height="17" font="0">4%, respectively (95% CI: 2%–9%). </text>
<text top="473" left="95" width="93" height="17" font="0">Klein WM, et al.  </text>
<text top="490" left="95" width="59" height="17" font="0">2004(222)<b> </b></text>
<text top="508" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15286319">15286319 </a></text>
<text top="525" left="95" width="3" height="17" font="0"> </text>
<text top="473" left="200" width="91" height="17" font="2"><b>Aim:</b> Determine </text>
<text top="490" left="200" width="98" height="17" font="0">superiority of iliac </text>
<text top="508" left="200" width="82" height="17" font="0">PTAS vs. PTA </text>
<text top="525" left="200" width="3" height="17" font="0"> </text>
<text top="542" left="200" width="74" height="17" font="2"><b>Study type:</b>  </text>
<text top="559" left="200" width="3" height="17" font="0"> </text>
<text top="576" left="200" width="90" height="17" font="2"><b>Size:</b> n=279 pts </text>
<text top="473" left="331" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="490" left="331" width="7" height="18" font="7"></text>
<text top="491" left="338" width="75" height="17" font="0"> Claudication </text>
<text top="509" left="331" width="7" height="18" font="7"></text>
<text top="510" left="338" width="146" height="17" font="0"> Iliac artery stenosis &lt;5cm </text>
<text top="527" left="331" width="3" height="17" font="0"> </text>
<text top="544" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="562" left="331" width="7" height="18" font="7"></text>
<text top="563" left="338" width="162" height="17" font="0"> Stenosis of &gt;10 cm in length </text>
<text top="580" left="331" width="7" height="18" font="7"></text>
<text top="581" left="338" width="125" height="17" font="0"> Occlusion of &gt;5 cm in </text>
<text top="598" left="331" width="166" height="17" font="0">length, or of ≤5 cm if it did not </text>
<text top="615" left="331" width="126" height="17" font="0">allow the passage of a </text>
<text top="633" left="331" width="159" height="17" font="0">guidewire; stenosis involving </text>
<text top="650" left="331" width="84" height="17" font="0">the distal aorta </text>
<text top="667" left="331" width="7" height="18" font="7"></text>
<text top="668" left="338" width="159" height="17" font="0"> Or severe comorbidity (e.g., </text>
<text top="685" left="331" width="98" height="17" font="0">severe cardiac or </text>
<text top="703" left="331" width="161" height="17" font="0">cerebrovascular abnormality, </text>
<text top="720" left="331" width="107" height="17" font="0">malignant disease) </text>
<text top="473" left="513" width="113" height="17" font="2"><b>Intervention:</b> PTAS </text>
<text top="490" left="513" width="7" height="17" font="0">  </text>
<text top="508" left="513" width="105" height="17" font="2"><b>Comparator:</b> PTA </text>
<text top="474" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="473" left="655" width="6" height="18" font="7"></text>
<text top="474" left="661" width="119" height="17" font="2"><b> endpoint:</b> Technical </text>
<text top="492" left="648" width="141" height="17" font="0">success and incidence of </text>
<text top="509" left="648" width="78" height="17" font="0">reintervention </text>
<text top="473" left="817" width="7" height="18" font="7"></text>
<text top="474" left="824" width="171" height="17" font="0"> No difference between groups </text>
<text top="492" left="817" width="7" height="18" font="7"></text>
<text top="493" left="824" width="276" height="17" font="0"> Long-term follow-up from above study. The mean </text>
<text top="510" left="817" width="235" height="17" font="0">follow-up period was 5.6 y±1.3 (±standard </text>
<text top="527" left="817" width="265" height="17" font="0">deviation). There were no significant differences </text>
<text top="544" left="817" width="253" height="17" font="0">between primary stent placement and primary </text>
<text top="562" left="817" width="273" height="17" font="0">angioplasty treatment groups in regard to number </text>
<text top="579" left="817" width="263" height="17" font="0">of reinterventions in the treated iliac arteries (33 </text>
<text top="596" left="817" width="243" height="17" font="0">[18%] of 187 segments and 33 [20%] of 169 </text>
<text top="613" left="817" width="283" height="17" font="0">segments, respectively) or in the ipsilateral legs (45 </text>
<text top="630" left="817" width="241" height="17" font="0">[25%] of 181 legs and 50 [30%] of 164 legs, </text>
<text top="648" left="817" width="265" height="17" font="0">respectively). Sex, presence of critical ischemia, </text>
<text top="665" left="817" width="282" height="17" font="0">and length of stenosis were predictors of whether a </text>
<text top="682" left="817" width="200" height="17" font="0">pt would require iliac reintervention.  </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">98 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="78" height="17" font="0">Bosch JL and </text>
<text top="104" left="95" width="68" height="17" font="0">Hunink MG  </text>
<text top="122" left="95" width="59" height="17" font="0">1997(223)<b> </b></text>
<text top="139" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9205227">9205227 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="91" height="17" font="2"><b>Aim:</b> Determine </text>
<text top="104" left="200" width="98" height="17" font="0">superiority of iliac </text>
<text top="122" left="200" width="82" height="17" font="0">PTAS vs. PTA </text>
<text top="139" left="200" width="3" height="17" font="0"> </text>
<text top="156" left="200" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="173" left="200" width="48" height="17" font="0">analysis </text>
<text top="190" left="200" width="3" height="17" font="0"> </text>
<text top="208" left="200" width="90" height="17" font="2"><b>Size:</b> n=301 pts </text>
<text top="87" left="331" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="104" left="331" width="7" height="18" font="7"></text>
<text top="105" left="338" width="111" height="17" font="0"> Claudication of CLI </text>
<text top="123" left="331" width="7" height="18" font="7"></text>
<text top="124" left="338" width="133" height="17" font="0"> Iliac artery involvement </text>
<text top="141" left="331" width="3" height="17" font="0"> </text>
<text top="158" left="331" width="154" height="17" font="2"><b>Exclusion criteria:</b> Studies </text>
<text top="176" left="331" width="155" height="17" font="0">without specified endpoints  </text>
<text top="87" left="513" width="113" height="17" font="2"><b>Intervention:</b> PTAS </text>
<text top="104" left="513" width="3" height="17" font="0"> </text>
<text top="122" left="513" width="105" height="17" font="2"><b>Comparator:</b> PTA </text>
<text top="88" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="655" width="6" height="18" font="7"></text>
<text top="88" left="661" width="119" height="17" font="2"><b> endpoint:</b> Technical </text>
<text top="106" left="648" width="142" height="17" font="0">success; primary patency </text>
<text top="123" left="648" width="3" height="17" font="0"> </text>
<text top="140" left="648" width="150" height="17" font="2"><b>Safety endpoint:</b> Mortality </text>
<text top="157" left="648" width="63" height="17" font="0">and MACE </text>
<text top="87" left="817" width="7" height="18" font="7"></text>
<text top="88" left="824" width="171" height="17" font="0"> No difference between groups </text>
<text top="106" left="817" width="7" height="18" font="7"></text>
<text top="107" left="824" width="274" height="17" font="0"> The immediate technical success rate in the PTA </text>
<text top="124" left="817" width="263" height="17" font="0">group was 91%; the rate was higher in the stent </text>
<text top="141" left="817" width="282" height="17" font="0">group (96%), but the difference was not statistically </text>
<text top="158" left="817" width="271" height="17" font="0">significant [corrected]. Complication and mortality </text>
<text top="176" left="817" width="262" height="17" font="0">rates were not statistically significantly different. </text>
<text top="193" left="817" width="280" height="17" font="0">Analyzed data included technical failures and were </text>
<text top="210" left="817" width="269" height="17" font="0">adjusted for lesion type and disease severity. 4 y </text>
<text top="227" left="817" width="269" height="17" font="0">primary patency rates were 65% for stenoses vs. </text>
<text top="244" left="817" width="272" height="17" font="0">54% for occlusions after PTA to treat claudication </text>
<text top="262" left="817" width="278" height="17" font="0">and were 53% for stenoses vs. 44% for occlusions </text>
<text top="279" left="817" width="259" height="17" font="0">after PTA to treat critical ischemia. These rates </text>
<text top="296" left="817" width="282" height="17" font="0">were 77% for stenoses vs. 61% for occlusions after </text>
<text top="313" left="817" width="270" height="17" font="0">stent placement to treat claudication and 67% for </text>
<text top="330" left="817" width="237" height="17" font="0">stenoses vs. 53% for occlusions after stent </text>
<text top="348" left="817" width="256" height="17" font="0">placement to treat critical ischemia. The risk of </text>
<text top="365" left="817" width="268" height="17" font="0">long-term failure was reduced by 39% after stent </text>
<text top="382" left="817" width="174" height="17" font="0">placement compared with PTA. </text>
<text top="400" left="95" width="88" height="17" font="0">Kashyap VS, et </text>
<text top="417" left="95" width="16" height="17" font="0">al. </text>
<text top="434" left="95" width="59" height="17" font="0">2008(224)<b> </b></text>
<text top="452" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18804943">18804943 </a></text>
<text top="469" left="95" width="3" height="17" font="0"> </text>
<text top="400" left="200" width="110" height="17" font="2"><b>Aim:</b> Iliac occlusive </text>
<text top="417" left="200" width="104" height="17" font="0">disease. PTAS vs. </text>
<text top="434" left="200" width="66" height="17" font="0">aorto-bifem </text>
<text top="452" left="200" width="3" height="17" font="0"> </text>
<text top="469" left="200" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="486" left="200" width="79" height="17" font="0">Retrospective </text>
<text top="503" left="200" width="3" height="17" font="0"> </text>
<text top="521" left="200" width="99" height="17" font="2"><b>Size:</b> PTAS n=83 </text>
<text top="538" left="200" width="117" height="17" font="0">pts vs. ABF n=86 pts </text>
<text top="400" left="331" width="156" height="17" font="2"><b>Inclusion criteria:</b> Sx aorto-</text>
<text top="417" left="331" width="124" height="17" font="0">iliac occlusive disease </text>
<text top="434" left="331" width="154" height="17" font="0">(claudication 53% rest pain, </text>
<text top="452" left="331" width="152" height="17" font="0">28%; tissue loss, 12%; ALI, </text>
<text top="469" left="331" width="25" height="17" font="0">7%) </text>
<text top="486" left="331" width="3" height="17" font="0"> </text>
<text top="503" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="521" left="331" width="7" height="18" font="7"></text>
<text top="522" left="338" width="90" height="17" font="0"> Pts undergoing </text>
<text top="539" left="331" width="161" height="17" font="0">endovascular treatment such </text>
<text top="556" left="331" width="147" height="17" font="0">as PTA or stenting for iliac </text>
<text top="573" left="331" width="59" height="17" font="0">stenoses.  </text>
<text top="591" left="331" width="7" height="18" font="7"></text>
<text top="592" left="338" width="153" height="17" font="0"> Pts with iliac dissection, an </text>
<text top="609" left="331" width="133" height="17" font="0">associated AAA, or iliac </text>
<text top="626" left="331" width="132" height="17" font="0">recanalization before or </text>
<text top="643" left="331" width="121" height="17" font="0">during AAA endograft </text>
<text top="661" left="331" width="64" height="17" font="0">placement. </text>
<text top="400" left="513" width="113" height="17" font="2"><b>Intervention:</b> PTAS </text>
<text top="417" left="513" width="7" height="17" font="0">  </text>
<text top="434" left="513" width="105" height="17" font="2"><b>Comparator:</b> ABF<b> </b></text>
<text top="401" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="400" left="655" width="6" height="18" font="7"></text>
<text top="401" left="661" width="119" height="17" font="2"><b> endpoint:</b> Technical </text>
<text top="418" left="648" width="146" height="17" font="0">success; primary patency; </text>
<text top="436" left="648" width="155" height="17" font="0">secondary patency; survival </text>
<text top="400" left="817" width="7" height="18" font="7"></text>
<text top="401" left="824" width="277" height="17" font="0"> Primary patency at 3 y was significantly higher for </text>
<text top="418" left="817" width="255" height="17" font="0">ABF than for R/PTAS (93% vs. 74%, p=0.002) </text>
<text top="436" left="817" width="7" height="18" font="7"></text>
<text top="437" left="824" width="256" height="17" font="0"> Secondary patency rates (97% vs. 95%), limb </text>
<text top="454" left="817" width="257" height="17" font="0">salvage (98% vs. 98%), and long-term survival </text>
<text top="471" left="817" width="152" height="17" font="0">(80% vs. 80%) were similar </text>
<text top="679" left="95" width="75" height="17" font="2"><b>ABSOLUTE</b>  </text>
<text top="696" left="95" width="91" height="17" font="0">Schillinger M, et </text>
<text top="713" left="95" width="20" height="17" font="0">al.  </text>
<text top="730" left="95" width="59" height="17" font="0">2007(225) </text>
<text top="747" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17502568">17502568 </a></text>
<text top="765" left="95" width="3" height="17" font="0"> </text>
<text top="679" left="200" width="113" height="17" font="2"><b>Aim: </b>SFA PTAS vs. </text>
<text top="696" left="200" width="27" height="17" font="0">PTA<b> </b></text>
<text top="713" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="730" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="747" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="765" left="200" width="90" height="17" font="2"><b>Size: </b>n=104 pts<b> </b></text>
<text top="679" left="331" width="168" height="17" font="2"><b>Inclusion criteria: </b>Rutherford </text>
<text top="696" left="331" width="7" height="17" font="0">3</text>
<text top="696" left="338" width="7" height="17" font="19">–</text>
<text top="696" left="344" width="110" height="17" font="0">5 and SFA stenosis </text>
<text top="713" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="730" left="331" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="747" left="331" width="7" height="18" font="7"></text>
<text top="748" left="338" width="156" height="17" font="0"> Acute CLI, previous bypass </text>
<text top="766" left="331" width="143" height="17" font="0">surgery, or stenting of the </text>
<text top="679" left="513" width="113" height="17" font="2"><b>Intervention: </b>PTAS </text>
<text top="696" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="713" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="680" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="679" left="655" width="6" height="18" font="7"></text>
<text top="680" left="661" width="127" height="17" font="2"><b> endpoint: </b>Restenosis </text>
<text top="697" left="648" width="90" height="17" font="0">by duplex at 2 y </text>
<text top="679" left="817" width="7" height="18" font="7"></text>
<text top="680" left="824" width="266" height="17" font="2"><b> </b>PTAS is superior to PTA for long lesions (lesion </text>
<text top="697" left="817" width="217" height="17" font="0">length 112 mm PTAS and 93 mm PTA) </text>
<text top="714" left="817" width="7" height="18" font="7"></text>
<text top="715" left="824" width="234" height="17" font="0"> Of 104 pts with chronic limb ischemia and </text>
<text top="733" left="817" width="264" height="17" font="0">superficial femoral artery obstructions, 98 (94%) </text>
<text top="750" left="817" width="274" height="17" font="0">could be followed up until 2 y after intervention for </text>
<text top="767" left="817" width="237" height="17" font="0">occurrence of restenosis (&gt;50%) by duplex </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1088" width="17" height="17" font="0">99 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="27" height="17" font="0">SFA </text>
<text top="104" left="331" width="7" height="18" font="7"></text>
<text top="105" left="338" width="155" height="17" font="0"> Untreated inflow disease of </text>
<text top="123" left="331" width="155" height="17" font="0">the ipsilateral pelvic arteries </text>
<text top="140" left="331" width="167" height="17" font="0">(&gt;50% stenosis or occlusions)<b> </b></text>
<text top="87" left="817" width="247" height="17" font="0">ultrasound and for clinical and hemodynamic </text>
<text top="104" left="817" width="261" height="17" font="0">outcome by treadmill walking distance and ABI. </text>
<text top="122" left="817" width="272" height="17" font="0">Restenosis rates at 2 y were 45.7% (21 of 46) vs. </text>
<text top="139" left="817" width="243" height="17" font="0">69.2% (36 of 52) in favor of primary stenting </text>
<text top="156" left="817" width="264" height="17" font="0">compared with balloon angioplasty with optional </text>
<text top="173" left="817" width="270" height="17" font="0">secondary stenting by an ITT analysis (p=0.031). </text>
<text top="190" left="817" width="230" height="17" font="0">Consistently, stenting (whether primary or </text>
<text top="208" left="817" width="258" height="17" font="0">secondary; n=63) was superior to plain balloon </text>
<text top="225" left="817" width="272" height="17" font="0">angioplasty (n=35) with respect to the occurrence </text>
<text top="242" left="817" width="255" height="17" font="0">of restenosis (49.2% vs. 74.3%; p=0.028) by a </text>
<text top="259" left="817" width="266" height="17" font="0">treatment-received analysis. Clinically, pts in the </text>
<text top="276" left="817" width="272" height="17" font="0">primary stent group showed a trend toward better </text>
<text top="294" left="817" width="282" height="17" font="0">treadmill walking capacity (average, 302 vs. 196 m; </text>
<text top="311" left="817" width="268" height="17" font="0">p=0.12) and better ABI values (average, 0.88 vs. </text>
<text top="328" left="817" width="268" height="17" font="0">0.78; p=0.09) at 2 y, respectively. Reintervention </text>
<text top="345" left="817" width="276" height="17" font="0">rates tended to be lower after primary stenting (17 </text>
<text top="363" left="817" width="237" height="17" font="0">of 46 [37.0%] vs. 28 of 52 [53.8%]; p=0.14)<b> </b></text>
<text top="381" left="95" width="36" height="17" font="2"><b>FAST </b></text>
<text top="398" left="95" width="90" height="17" font="0">Krankenberg H, </text>
<text top="415" left="95" width="33" height="17" font="0">et al.  </text>
<text top="432" left="95" width="63" height="17" font="0">2007 (226)<b> </b></text>
<text top="449" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17592075">17592075 </a></text>
<text top="467" left="95" width="3" height="17" font="0"> </text>
<text top="381" left="200" width="105" height="17" font="2"><b>Aim: </b>SFA PTA vs. </text>
<text top="398" left="200" width="36" height="17" font="0">PTAS<b> </b></text>
<text top="415" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="432" left="200" width="102" height="17" font="2"><b>Study type:</b> RCT<b>  </b></text>
<text top="449" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="467" left="200" width="93" height="17" font="2"><b>Size:</b> n=<b> </b>244 pts<b> </b></text>
<text top="381" left="331" width="133" height="17" font="2"><b>Inclusion criteria: </b>SFA </text>
<text top="398" left="331" width="155" height="17" font="0">stenosis and claudication or </text>
<text top="415" left="331" width="23" height="17" font="0">CLI </text>
<text top="432" left="331" width="3" height="17" font="0"> </text>
<text top="449" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="467" left="331" width="7" height="18" font="7"></text>
<text top="468" left="338" width="94" height="17" font="0"> TL that required </text>
<text top="485" left="331" width="157" height="17" font="0">pretreatment with adjunctive </text>
<text top="502" left="331" width="127" height="17" font="0">devices, e.g., lasers or </text>
<text top="519" left="331" width="110" height="17" font="0">debulking catheters </text>
<text top="537" left="331" width="7" height="18" font="7"></text>
<text top="538" left="338" width="155" height="17" font="0"> A TL that extended into the </text>
<text top="555" left="331" width="167" height="17" font="0">popliteal artery; previous stent </text>
<text top="572" left="331" width="152" height="17" font="0">implantation in the targeted </text>
<text top="589" left="331" width="27" height="17" font="0">SFA </text>
<text top="607" left="331" width="7" height="18" font="7"></text>
<text top="608" left="338" width="148" height="17" font="0"> Multiple lesions &gt;10 cm in </text>
<text top="625" left="331" width="37" height="17" font="0">length </text>
<text top="642" left="331" width="7" height="18" font="7"></text>
<text top="643" left="338" width="151" height="17" font="0"> Acute or subacute (≤4 wk) </text>
<text top="661" left="331" width="116" height="17" font="0">thrombotic occlusion </text>
<text top="678" left="331" width="7" height="18" font="7"></text>
<text top="679" left="338" width="157" height="17" font="0"> An untreated ipsilateral iliac </text>
<text top="696" left="331" width="83" height="17" font="0">artery stenosis </text>
<text top="713" left="331" width="7" height="18" font="7"></text>
<text top="714" left="338" width="152" height="17" font="0"> Ongoing dialysis treatment </text>
<text top="732" left="331" width="7" height="18" font="7"></text>
<text top="733" left="338" width="112" height="17" font="0"> Treatment with oral </text>
<text top="750" left="331" width="142" height="17" font="0">anticoagulants other than </text>
<text top="767" left="331" width="107" height="17" font="0">antiplatelet agents. </text>
<text top="381" left="513" width="113" height="17" font="2"><b>Intervention: </b>PTAS </text>
<text top="398" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="415" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="382" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="381" left="655" width="6" height="18" font="7"></text>
<text top="382" left="661" width="119" height="17" font="2"><b> endpoint: </b>Technical </text>
<text top="399" left="648" width="111" height="17" font="0">success, 1 y duplex </text>
<text top="416" left="648" width="59" height="17" font="0">restenosis </text>
<text top="381" left="817" width="7" height="18" font="7"></text>
<text top="382" left="824" width="230" height="17" font="0"> For short lesions mean length 45 mm, no </text>
<text top="399" left="817" width="194" height="17" font="0">difference between PTAS and PTA<b> </b></text>
<text top="416" left="817" width="7" height="18" font="7"></text>
<text top="417" left="824" width="255" height="17" font="0"> Overall, stent fractures were detected in 45 of </text>
<text top="434" left="817" width="233" height="17" font="0">121 treated legs (37.2%). In a stent-based </text>
<text top="452" left="817" width="234" height="17" font="0">analysis, 64 of 261 stents (24.5%) showed </text>
<text top="469" left="817" width="264" height="17" font="0">fractures, which were classified as minor (single </text>
<text top="486" left="817" width="248" height="17" font="0">strut fracture) in 31 cases (48.4%), moderate </text>
<text top="503" left="817" width="251" height="17" font="0">(fracture of &gt;1 strut) in 17 cases (26.6%), and </text>
<text top="521" left="817" width="276" height="17" font="0">severe (complete separation of stent segments) in </text>
<text top="538" left="817" width="269" height="17" font="0">16 cases (25.0%). Fracture rates were 13.2% for </text>
<text top="555" left="817" width="280" height="17" font="0">stented length ≤8 cm, 42.4% for stented length &gt;8–</text>
<text top="572" left="817" width="279" height="17" font="0">16 cm, and 52.0% for stented length &gt;16 cm. In 21 </text>
<text top="589" left="817" width="257" height="17" font="0">cases (32.8%) there was a restenosis of &gt;50% </text>
<text top="607" left="817" width="268" height="17" font="0">diameter reduction at the site of stent fracture. In </text>
<text top="624" left="817" width="267" height="17" font="0">22 cases (34.4%) with stent fracture there was a </text>
<text top="641" left="817" width="273" height="17" font="0">total stent reocclusion. According to Kaplan Meier </text>
<text top="658" left="817" width="272" height="17" font="0">estimates, the primary patency rate at 12 mo was </text>
<text top="675" left="817" width="244" height="17" font="0">significantly lower for pts with stent fractures </text>
<text top="693" left="817" width="166" height="17" font="0">(41.1% vs. 84.3%, p&lt;0.0001). </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">100 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="86" height="17" font="0">Laird JR, et al.  </text>
<text top="104" left="95" width="59" height="17" font="0">2010(227)<b> </b></text>
<text top="122" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20484101">20484101 </a></text>
<text top="139" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="105" height="17" font="2"><b>Aim: </b>SFA SES vs. </text>
<text top="104" left="200" width="27" height="17" font="0">PTA<b> </b></text>
<text top="122" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="139" left="200" width="99" height="17" font="2"><b>Study type:</b> RCT<b> </b></text>
<text top="156" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="173" left="200" width="93" height="17" font="2"><b>Size:</b> n=<b> </b>206 pts<b> </b></text>
<text top="87" left="331" width="158" height="17" font="2"><b>Inclusion criteria: </b>Fem/pop </text>
<text top="104" left="331" width="83" height="17" font="0">artery stenosis </text>
<text top="122" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="139" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="156" left="331" width="7" height="18" font="7"></text>
<text top="157" left="338" width="138" height="17" font="0"> Pts with CLI (Rutherford </text>
<text top="174" left="331" width="67" height="17" font="0">categories 4</text>
<text top="174" left="398" width="7" height="17" font="19">–</text>
<text top="174" left="405" width="14" height="17" font="0">6) </text>
<text top="192" left="331" width="7" height="18" font="7"></text>
<text top="193" left="338" width="160" height="17" font="0"> Sensitivity to contrast media </text>
<text top="210" left="331" width="141" height="17" font="0">that was not amenable to </text>
<text top="227" left="331" width="148" height="17" font="0">pretreatment with steroids, </text>
<text top="244" left="331" width="127" height="17" font="0">antihistamines, or both </text>
<text top="262" left="331" width="7" height="18" font="7"></text>
<text top="263" left="338" width="140" height="17" font="0"> Known allergies to study </text>
<text top="280" left="331" width="137" height="17" font="0">medications or materials </text>
<text top="297" left="331" width="7" height="18" font="7"></text>
<text top="298" left="338" width="118" height="17" font="0"> Renal failure (serum </text>
<text top="316" left="331" width="141" height="17" font="0">creatinine &gt;2.0 mg/dL) or </text>
<text top="333" left="331" width="114" height="17" font="0">hepatic insufficiency </text>
<text top="350" left="331" width="7" height="18" font="7"></text>
<text top="351" left="338" width="155" height="17" font="0"> Previous bypass surgery of </text>
<text top="368" left="331" width="81" height="17" font="0">the target limb </text>
<text top="386" left="331" width="7" height="18" font="7"></text>
<text top="387" left="338" width="113" height="17" font="0"> Extensive PVD that </text>
<text top="404" left="331" width="165" height="17" font="0">precluded safe insertion of an </text>
<text top="421" left="331" width="98" height="17" font="0">introducer sheath </text>
<text top="438" left="331" width="7" height="18" font="7"></text>
<text top="439" left="338" width="151" height="17" font="0"> Aneurysmal disease in the </text>
<text top="457" left="331" width="161" height="17" font="0">vessel segment to be treated </text>
<text top="474" left="331" width="7" height="18" font="7"></text>
<text top="475" left="338" width="155" height="17" font="0"> Thrombus in the area to be </text>
<text top="492" left="331" width="136" height="17" font="0">treated that could not be </text>
<text top="510" left="331" width="50" height="17" font="0">resolved </text>
<text top="527" left="331" width="7" height="18" font="7"></text>
<text top="528" left="338" width="145" height="17" font="0"> Angiographic evidence of </text>
<text top="545" left="331" width="112" height="17" font="0">poor inflow that was </text>
<text top="562" left="331" width="122" height="17" font="0">inadequate to support </text>
<text top="580" left="331" width="162" height="17" font="0">vascular bypass or who were </text>
<text top="597" left="331" width="111" height="17" font="0">receiving dialysis or </text>
<text top="614" left="331" width="157" height="17" font="0">immunosuppressive therapy </text>
<text top="631" left="331" width="81" height="17" font="0">were ineligible </text>
<text top="87" left="513" width="113" height="17" font="2"><b>Intervention: </b>PTAS<b> </b></text>
<text top="104" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="513" width="108" height="17" font="2"><b>Comparator: </b>PTA <b> </b></text>
<text top="88" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="655" width="6" height="18" font="7"></text>
<text top="88" left="661" width="122" height="17" font="2"><b> endpoint: </b>1 y duplex </text>
<text top="106" left="648" width="90" height="17" font="0">derived patency<b> </b></text>
<text top="87" left="817" width="7" height="18" font="7"></text>
<text top="88" left="824" width="238" height="17" font="2"><b> </b>Mean lesion length 71 mm; PTAS superior<b> </b></text>
<text top="106" left="817" width="7" height="18" font="7"></text>
<text top="107" left="824" width="260" height="17" font="0"> A total of 206 pts from 24 centers in the United </text>
<text top="124" left="817" width="269" height="17" font="0">States and Europe with obstructive lesions of the </text>
<text top="141" left="817" width="261" height="17" font="0">superficial femoral artery and proximal popliteal </text>
<text top="158" left="817" width="269" height="17" font="0">artery and IC were randomized to implantation of </text>
<text top="176" left="817" width="234" height="17" font="0">nitinol stents or percutaneous transluminal </text>
<text top="193" left="817" width="269" height="17" font="0">angioplasty. The mean total lesion length was 71 </text>
<text top="210" left="817" width="231" height="17" font="0">mm for the stent group and 64 mm for the </text>
<text top="227" left="817" width="261" height="17" font="0">angioplasty group. Acute lesion success (&lt;30% </text>
<text top="244" left="817" width="275" height="17" font="0">residual stenosis) was superior for the stent group </text>
<text top="262" left="817" width="266" height="17" font="0">compared with the angioplasty group (95.8% vs. </text>
<text top="279" left="817" width="273" height="17" font="0">83.9%; p&lt;0.01). 29 (40.3%) pts in the angioplasty </text>
<text top="296" left="817" width="256" height="17" font="0">group underwent bailout stenting because of a </text>
<text top="313" left="817" width="252" height="17" font="0">suboptimal angiographic result or flow-limiting </text>
<text top="330" left="817" width="261" height="17" font="0">dissection. Bailout stenting was treated as a TL </text>
<text top="348" left="817" width="283" height="17" font="0">revascularization and loss of primary patency in the </text>
<text top="365" left="817" width="228" height="17" font="0">final analysis. At 12 mo, freedom from TL </text>
<text top="382" left="817" width="263" height="17" font="0">revascularization was 87.3% for the stent group </text>
<text top="399" left="817" width="260" height="17" font="0">compared with 45.1% for the angioplasty group </text>
<text top="417" left="817" width="258" height="17" font="0">(p&lt;0.0001). Duplex ultrasound-derived primary </text>
<text top="434" left="817" width="261" height="17" font="0">patency at 12 mo was better for the stent group </text>
<text top="451" left="817" width="256" height="17" font="0">(81.3% vs. 36.7%; p&lt;0.0001). Through 12 mo, </text>
<text top="468" left="817" width="276" height="17" font="0">fractures occurred in 3.1% of stents implanted. No </text>
<text top="485" left="817" width="259" height="17" font="0">stent fractures resulted in loss of patency or TL </text>
<text top="503" left="817" width="99" height="17" font="0">revascularization. </text>
<text top="649" left="95" width="72" height="17" font="0">Dick P, et al. </text>
<text top="666" left="95" width="59" height="17" font="0">2009(228)<b> </b></text>
<text top="684" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19859954">19859954 </a></text>
<text top="701" left="95" width="3" height="17" font="0"> </text>
<text top="649" left="200" width="105" height="17" font="2"><b>Aim: </b>SFA SES vs. </text>
<text top="666" left="200" width="27" height="17" font="0">PTA<b> </b></text>
<text top="684" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="701" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="718" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="735" left="200" width="83" height="17" font="2"><b>Size: </b>n=73 pts<b> </b></text>
<text top="649" left="331" width="133" height="17" font="2"><b>Inclusion criteria: </b>SFA </text>
<text top="666" left="331" width="141" height="17" font="0">stenosis and claudication<b> </b></text>
<text top="684" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="701" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="718" left="331" width="7" height="18" font="7"></text>
<text top="719" left="338" width="61" height="17" font="0"> Acute CLI </text>
<text top="736" left="331" width="7" height="18" font="7"></text>
<text top="737" left="338" width="156" height="17" font="0"> Previous bypass surgery or </text>
<text top="755" left="331" width="108" height="17" font="0">stenting of the SFA </text>
<text top="772" left="331" width="7" height="18" font="7"></text>
<text top="773" left="338" width="155" height="17" font="0"> Untreated inflow disease of </text>
<text top="649" left="513" width="113" height="17" font="2"><b>Intervention: </b>PTAS </text>
<text top="666" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="684" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="650" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="649" left="655" width="6" height="18" font="7"></text>
<text top="650" left="661" width="109" height="17" font="2"><b> endpoint: </b>Primary </text>
<text top="668" left="648" width="47" height="17" font="0">patency<b> </b></text>
<text top="649" left="817" width="7" height="18" font="7"></text>
<text top="650" left="824" width="140" height="17" font="2"><b> </b>PTAS is superior to PTA<b> </b></text>
<text top="668" left="817" width="7" height="18" font="7"></text>
<text top="669" left="824" width="247" height="17" font="0"> Average length of the treated segments was </text>
<text top="686" left="817" width="265" height="17" font="0">98±54 mm and 71±43 mm in the stent and PTA </text>
<text top="703" left="817" width="272" height="17" font="0">groups (p=0.011), respectively. In the PTA group, </text>
<text top="720" left="817" width="272" height="17" font="0">secondary stenting was performed in 10 of 39 pts </text>
<text top="738" left="817" width="252" height="17" font="0">(26%) due to a suboptimal result after balloon </text>
<text top="755" left="817" width="256" height="17" font="0">dilation. Restenosis rates in the stent and PTA </text>
<text top="772" left="817" width="284" height="17" font="0">groups were 21.9% vs. 55.6% (p=0.005) at 6 mo by </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">101 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="155" height="17" font="0">the ipsilateral pelvic arteries </text>
<text top="104" left="331" width="161" height="17" font="0">(&gt;50% stenosis or occlusion) </text>
<text top="122" left="331" width="7" height="18" font="7"></text>
<text top="123" left="338" width="154" height="17" font="0"> Known intolerance of study </text>
<text top="140" left="331" width="168" height="17" font="0">medications or contrast agent. </text>
<text top="87" left="817" width="262" height="17" font="0">CTA, and 2.9% vs. 18.9% (p=0.033), 18.2% vs. </text>
<text top="104" left="817" width="274" height="17" font="0">50.0% (p=0.006), and 34.4% vs. 61.1% (p=0.028) </text>
<text top="122" left="817" width="262" height="17" font="0">at 3, 6, and 12 mo by sonography, respectively. </text>
<text top="139" left="817" width="233" height="17" font="0">Clinically, pts in the stent group reported a </text>
<text top="156" left="817" width="254" height="17" font="0">significantly higher maximum walking capacity </text>
<text top="173" left="817" width="255" height="17" font="0">compared with the PTA group at 6 and 12 mo. </text>
<text top="191" left="95" width="56" height="17" font="2"><b>IN.PACT</b>  </text>
<text top="208" left="95" width="78" height="17" font="0">Tepe G, et al. </text>
<text top="226" left="95" width="59" height="17" font="0">2015(229)<b> </b></text>
<text top="243" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25472980">25472980 </a></text>
<text top="260" left="95" width="3" height="17" font="0"> </text>
<text top="191" left="200" width="107" height="17" font="2"><b>Aim: </b>SFA DCB vs. </text>
<text top="208" left="200" width="27" height="17" font="0">PTA<b> </b></text>
<text top="226" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="243" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="260" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="277" left="200" width="93" height="17" font="2"><b>Size:</b> n=<b> </b>331 pts<b> </b></text>
<text top="191" left="331" width="136" height="17" font="2"><b>Inclusion criteria: </b>IC or </text>
<text top="208" left="331" width="166" height="17" font="0">ischemic rest pain attributable </text>
<text top="226" left="331" width="141" height="17" font="0">to superficial femoral and </text>
<text top="243" left="331" width="78" height="17" font="0">popliteal PAD<b> </b></text>
<text top="260" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="277" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="295" left="331" width="7" height="18" font="7"></text>
<text top="296" left="338" width="142" height="17" font="0"> Lesion and/or occlusions </text>
<text top="313" left="331" width="161" height="17" font="0">located in or extending to the </text>
<text top="330" left="331" width="155" height="17" font="0">popliteal artery or below the </text>
<text top="347" left="331" width="95" height="17" font="0">ankle joint space </text>
<text top="365" left="331" width="7" height="18" font="7"></text>
<text top="366" left="338" width="157" height="17" font="0"> Inflow lesion or occlusion in </text>
<text top="383" left="331" width="149" height="17" font="0">the ipsilateral iliac, SFA, or </text>
<text top="400" left="331" width="156" height="17" font="0">popliteal arteries with length </text>
<text top="417" left="331" width="45" height="17" font="0">≥15 cm </text>
<text top="434" left="331" width="7" height="18" font="7"></text>
<text top="436" left="338" width="129" height="17" font="0"> Significant (≥50% DS) </text>
<text top="453" left="331" width="152" height="17" font="0">inflow lesion or occlusion in </text>
<text top="470" left="331" width="149" height="17" font="0">the ipsilateral iliac, SFA, or </text>
<text top="487" left="331" width="169" height="17" font="0">popliteal arteries left untreated </text>
<text top="505" left="331" width="7" height="18" font="7"></text>
<text top="506" left="338" width="150" height="17" font="0"> Previously implanted stent </text>
<text top="523" left="331" width="161" height="17" font="0">in the TL(s). Aneurysm in the </text>
<text top="540" left="331" width="73" height="17" font="0">target vessel </text>
<text top="557" left="331" width="7" height="18" font="7"></text>
<text top="558" left="338" width="144" height="17" font="0"> Acute thrombus in the TL </text>
<text top="191" left="513" width="107" height="17" font="2"><b>Intervention: </b>DCB </text>
<text top="208" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="226" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="192" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="191" left="655" width="6" height="18" font="7"></text>
<text top="192" left="661" width="100" height="17" font="2"><b> endpoint: </b>12 mo </text>
<text top="210" left="648" width="91" height="17" font="0">primary patency </text>
<text top="191" left="817" width="7" height="18" font="7"></text>
<text top="192" left="824" width="122" height="17" font="2"><b> </b>DCB superior to PTA </text>
<text top="210" left="817" width="7" height="18" font="7"></text>
<text top="211" left="824" width="227" height="17" font="0"> The IN.PACT SFA Trial is a prospective, </text>
<text top="228" left="817" width="254" height="17" font="0">multicenter, single-blinded, randomized trial in </text>
<text top="245" left="817" width="236" height="17" font="0">which 331 pts with IC or ischemic rest pain </text>
<text top="262" left="817" width="283" height="17" font="0">attributable to superficial femoral and popliteal PAD </text>
<text top="280" left="817" width="277" height="17" font="0">were randomly assigned in a 2:1 ratio to treatment </text>
<text top="297" left="817" width="265" height="17" font="0">with DCB or PTA. The primary efficacy endpoint </text>
<text top="314" left="817" width="256" height="17" font="0">was primary patency, defined as freedom from </text>
<text top="331" left="817" width="274" height="17" font="0">restenosis or clinically driven TL revascularization </text>
<text top="348" left="817" width="256" height="17" font="0">at 12 mo. Baseline characteristics were similar </text>
<text top="366" left="817" width="276" height="17" font="0">between the 2 groups. Mean lesion length and the </text>
<text top="383" left="817" width="258" height="17" font="0">percentage of total occlusions for the DCB and </text>
<text top="400" left="817" width="251" height="17" font="0">PTA arms were 8.94±4.89 and 8.81±5.12 cm </text>
<text top="417" left="817" width="227" height="17" font="0">(p=0.82) and 25.8% and 19.5% (p=0.22), </text>
<text top="434" left="817" width="243" height="17" font="0">respectively. DCB resulted in higher primary </text>
<text top="452" left="817" width="277" height="17" font="0">patency vs. PTA (82.2% vs. 52.4%; p&lt;0.001). The </text>
<text top="469" left="817" width="263" height="17" font="0">rate of clinically driven TL revascularization was </text>
<text top="486" left="817" width="275" height="17" font="0">2.4% in the DCB arm in comparison with 20.6% in </text>
<text top="503" left="817" width="264" height="17" font="0">the PTA arm (p&lt;0.001). There was a low rate of </text>
<text top="521" left="817" width="266" height="17" font="0">vessel thrombosis in both arms (1.4% after DCB </text>
<text top="538" left="817" width="249" height="17" font="0">and 3.7% after PTA [p=0.10]). There were no </text>
<text top="555" left="817" width="274" height="17" font="0">device- or procedure-related deaths and no major </text>
<text top="572" left="817" width="70" height="17" font="0">amputations </text>
<text top="590" left="95" width="86" height="17" font="2"><b>DEBATE-SFA</b>  </text>
<text top="607" left="95" width="81" height="17" font="0">Liistro F, et al. </text>
<text top="625" left="95" width="59" height="17" font="0">2013(230)<b> </b></text>
<text top="642" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24239203">24239203 </a></text>
<text top="659" left="95" width="3" height="17" font="0"> </text>
<text top="590" left="200" width="112" height="17" font="2"><b>Aim: </b>PEB+BMS vs. </text>
<text top="607" left="200" width="65" height="17" font="0">PTA+BMS<b>  </b></text>
<text top="625" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="642" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="659" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="676" left="200" width="90" height="17" font="2"><b>Size: </b>n=104 pts<b> </b></text>
<text top="590" left="331" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="607" left="331" width="122" height="17" font="0">Claudication and SFA </text>
<text top="625" left="331" width="49" height="17" font="0">stenosis </text>
<text top="642" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="659" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="676" left="331" width="7" height="18" font="7"></text>
<text top="677" left="338" width="119" height="17" font="0"> Life expectancy &lt;1 y </text>
<text top="695" left="331" width="7" height="18" font="7"></text>
<text top="696" left="338" width="113" height="17" font="0"> Contraindication for </text>
<text top="713" left="331" width="164" height="17" font="0">combined antiplatelet therapy </text>
<text top="730" left="331" width="7" height="18" font="7"></text>
<text top="731" left="338" width="147" height="17" font="0"> Known allergy to nickel or </text>
<text top="749" left="331" width="55" height="17" font="0">paclitaxel </text>
<text top="766" left="331" width="7" height="18" font="7"></text>
<text top="767" left="338" width="152" height="17" font="0"> Need for major amputation </text>
<text top="590" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="607" left="513" width="62" height="17" font="0">PEB+BMS<b> </b></text>
<text top="625" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="642" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="659" left="513" width="61" height="17" font="0">PTA+BMS<b> </b></text>
<text top="591" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="590" left="655" width="6" height="18" font="7"></text>
<text top="591" left="661" width="137" height="17" font="2"><b> endpoint: </b>12 mo binary </text>
<text top="609" left="648" width="59" height="17" font="0">restenosis </text>
<text top="590" left="817" width="7" height="18" font="7"></text>
<text top="591" left="824" width="200" height="17" font="2"><b> </b>PEB+BMS is superior to PTA+BMS </text>
<text top="609" left="817" width="7" height="18" font="7"></text>
<text top="610" left="824" width="269" height="17" font="0"> Mean lesion length was 94±60 vs. 96±69 mm in </text>
<text top="627" left="817" width="255" height="17" font="0">the PEB+BMS and PTA+BMS groups (p=0.8), </text>
<text top="644" left="817" width="266" height="17" font="0">respectively. The primary endpoint occurred in 9 </text>
<text top="661" left="817" width="270" height="17" font="0">(17%) vs. 26 (47.3%) of lesions in the PEB+BMS </text>
<text top="679" left="817" width="269" height="17" font="0">and PTA+BMS groups (p=0.008), respectively. A </text>
<text top="696" left="817" width="251" height="17" font="0">near-significant (p=0.07) 1 y freedom from TL </text>
<text top="713" left="817" width="269" height="17" font="0">revascularization advantage was observed in the </text>
<text top="730" left="817" width="272" height="17" font="0">PEB+BMS group. No major amputation occurred. </text>
<text top="747" left="817" width="271" height="17" font="0">No significant difference was observed according </text>
<text top="765" left="817" width="256" height="17" font="0">to lesion characteristics or technical approach. </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">102 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="135" height="17" font="0">at the time of enrollment </text>
<text top="104" left="331" width="7" height="18" font="7"></text>
<text top="105" left="338" width="117" height="17" font="0"> Failure to recanalize </text>
<text top="123" left="331" width="138" height="17" font="0">intended below-the-knee </text>
<text top="140" left="331" width="150" height="17" font="0">arteries in CLI pts at risk of </text>
<text top="157" left="331" width="98" height="17" font="0">major amputation<b> </b></text>
<text top="175" left="95" width="85" height="17" font="0">Scheinert D, et </text>
<text top="192" left="95" width="20" height="17" font="0">al.  </text>
<text top="210" left="95" width="59" height="17" font="0">2014(231)<b> </b></text>
<text top="227" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24456716">24456716 </a></text>
<text top="244" left="95" width="3" height="17" font="0"> </text>
<text top="175" left="200" width="107" height="17" font="2"><b>Aim: </b>SFA DCB vs. </text>
<text top="192" left="200" width="27" height="17" font="0">PTA </text>
<text top="210" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="227" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="244" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="261" left="200" width="90" height="17" font="2"><b>Size: </b>n=101 pts<b> </b></text>
<text top="175" left="331" width="168" height="17" font="2"><b>Inclusion criteria: </b>Rutherford </text>
<text top="192" left="331" width="38" height="17" font="0">class 2</text>
<text top="192" left="369" width="7" height="17" font="19">–</text>
<text top="192" left="376" width="98" height="17" font="0">5 femoropopliteal </text>
<text top="210" left="331" width="45" height="17" font="0">lesions  </text>
<text top="227" left="331" width="3" height="17" font="0"> </text>
<text top="244" left="331" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="261" left="331" width="7" height="18" font="7"></text>
<text top="262" left="338" width="120" height="17" font="0"> Life expectancy ≤2 y </text>
<text top="280" left="331" width="7" height="18" font="7"></text>
<text top="281" left="338" width="161" height="17" font="0"> Creatinine &gt;2.5 mg/dL or Hx </text>
<text top="298" left="331" width="161" height="17" font="0">of hemorrhagic stroke ≤3 mo </text>
<text top="315" left="331" width="7" height="18" font="7"></text>
<text top="316" left="338" width="151" height="17" font="0"> Previous surgery of the TL </text>
<text top="334" left="331" width="7" height="18" font="7"></text>
<text top="335" left="338" width="116" height="17" font="0"> Previous or planned </text>
<text top="352" left="331" width="103" height="17" font="0">intervention ≤30 d </text>
<text top="369" left="331" width="7" height="18" font="7"></text>
<text top="370" left="338" width="155" height="17" font="0"> Use of adjunctive therapies </text>
<text top="387" left="331" width="163" height="17" font="0">(including glycoprotein IIb/IlIa </text>
<text top="405" left="331" width="57" height="17" font="0">inhibitors) </text>
<text top="422" left="331" width="7" height="18" font="7"></text>
<text top="423" left="338" width="148" height="17" font="0"> Severe lesion calcification </text>
<text top="440" left="331" width="7" height="18" font="7"></text>
<text top="441" left="338" width="136" height="17" font="0"> Sudden symptom onset </text>
<text top="459" left="331" width="7" height="18" font="7"></text>
<text top="460" left="338" width="141" height="17" font="0"> Acute or subacute target </text>
<text top="477" left="331" width="162" height="17" font="0">vessel thrombus or occlusion </text>
<text top="494" left="331" width="7" height="18" font="7"></text>
<text top="495" left="338" width="124" height="17" font="0"> Absence of ≥1 patent </text>
<text top="513" left="331" width="129" height="17" font="0">untreated runoff vessel </text>
<text top="530" left="331" width="7" height="18" font="7"></text>
<text top="531" left="338" width="144" height="17" font="0"> Significant inflow disease<b> </b></text>
<text top="175" left="513" width="107" height="17" font="2"><b>Intervention: </b>DCB<b> </b></text>
<text top="192" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="210" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="176" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="175" left="655" width="6" height="18" font="7"></text>
<text top="176" left="661" width="132" height="17" font="2"><b> endpoint: </b>The primary </text>
<text top="194" left="648" width="150" height="17" font="0">endpoint was angiographic </text>
<text top="211" left="648" width="133" height="17" font="0">late lumen loss at 6 mo. </text>
<text top="228" left="648" width="119" height="17" font="0">Secondary outcomes </text>
<text top="245" left="648" width="150" height="17" font="0">included adjudicated major </text>
<text top="262" left="648" width="129" height="17" font="0">adverse events (death, </text>
<text top="280" left="648" width="152" height="17" font="0">amputation, TL thrombosis, </text>
<text top="297" left="648" width="141" height="17" font="0">reintervention), functional </text>
<text top="314" left="648" width="84" height="17" font="0">outcomes, and </text>
<text top="331" left="648" width="103" height="17" font="0">pharmacokinetics. </text>
<text top="175" left="817" width="7" height="18" font="7"></text>
<text top="176" left="824" width="122" height="17" font="2"><b> </b>DCB superior to PTA </text>
<text top="194" left="817" width="7" height="18" font="7"></text>
<text top="195" left="824" width="257" height="17" font="0"> Demographic, PVD, and lesion characteristics </text>
<text top="212" left="817" width="271" height="17" font="0">were matched, with mean lesion length of 8.1 3.8 </text>
<text top="229" left="817" width="272" height="17" font="0">cm and 42% total occlusions. At 6 mo, late lumen </text>
<text top="246" left="817" width="257" height="17" font="0">loss was 58% lower for the Lutonix DCB group </text>
<text top="264" left="817" width="259" height="17" font="0">(0.46 1.13 mm) than for the control group (1.09 </text>
<text top="281" left="817" width="244" height="17" font="0">1.07 mm; p=0.016). Composite 24 mo major </text>
<text top="298" left="817" width="251" height="17" font="0">adverse events were 39% for the DCB group, </text>
<text top="315" left="817" width="270" height="17" font="0">including 15 TL revascularizations, 1 amputation, </text>
<text top="332" left="817" width="275" height="17" font="0">and 4 deaths vs. 46% for uncoated balloon group, </text>
<text top="350" left="817" width="277" height="17" font="0">with 20 TL revascularizations, 1 thrombosis, and 5 </text>
<text top="367" left="817" width="266" height="17" font="0">deaths. Pharmacokinetics showed biexponential </text>
<text top="384" left="817" width="281" height="17" font="0">decay with peak concentration (Cmax) of 59 ng/mL </text>
<text top="401" left="817" width="265" height="17" font="0">and total observed exposure (AUC(all)) of 73 ng </text>
<text top="418" left="817" width="275" height="17" font="0">h/ml. For successful DCB deployment excluding 8 </text>
<text top="436" left="817" width="269" height="17" font="0">malfunctions, 6 mo late lumen loss was 0.39 mm </text>
<text top="453" left="817" width="277" height="17" font="0">and the 24 mo TL revascularization rate was 24%. </text>
<text top="549" left="95" width="79" height="17" font="0">Werk M, et al. </text>
<text top="566" left="95" width="59" height="17" font="0">2012(232)<b> </b></text>
<text top="583" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23192918">23192918 </a></text>
<text top="601" left="95" width="3" height="17" font="0"> </text>
<text top="549" left="200" width="107" height="17" font="2"><b>Aim: </b>SFA DCB vs. </text>
<text top="566" left="200" width="27" height="17" font="0">PTA </text>
<text top="583" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="601" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="618" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="635" left="200" width="83" height="17" font="2"><b>Size: </b>n=85 pts<b> </b></text>
<text top="549" left="331" width="124" height="17" font="2"><b>Inclusion criteria: </b>Sx </text>
<text top="566" left="331" width="92" height="17" font="0">femoro-popliteal </text>
<text top="583" left="331" width="129" height="17" font="0">atherosclerotic disease </text>
<text top="601" left="331" width="3" height="17" font="0"> </text>
<text top="618" left="331" width="135" height="17" font="2"><b>Exclusion criteria:</b> Key </text>
<text top="635" left="331" width="132" height="17" font="0">exclusion criteria were:  </text>
<text top="652" left="331" width="7" height="18" font="7"></text>
<text top="653" left="338" width="107" height="17" font="0"> Acute thrombus or </text>
<text top="671" left="331" width="164" height="17" font="0">aneurysm in the target vessel </text>
<text top="688" left="331" width="7" height="18" font="7"></text>
<text top="689" left="338" width="155" height="17" font="0"> Failure to cross the TL with </text>
<text top="706" left="331" width="66" height="17" font="0">a guidewire </text>
<text top="723" left="331" width="7" height="18" font="7"></text>
<text top="725" left="338" width="162" height="17" font="0"> Inflow lesions that cannot be </text>
<text top="742" left="331" width="129" height="17" font="0">successfully pretreated </text>
<text top="759" left="331" width="7" height="18" font="7"></text>
<text top="760" left="338" width="149" height="17" font="0"> Significant disease of all 3 </text>
<text top="549" left="513" width="107" height="17" font="2"><b>Intervention: </b>DCB<b> </b></text>
<text top="566" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="583" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="550" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="549" left="655" width="6" height="18" font="7"></text>
<text top="550" left="661" width="132" height="17" font="2"><b> endpoint: </b>The primary </text>
<text top="567" left="648" width="136" height="17" font="0">endpoint was late lumen </text>
<text top="585" left="648" width="141" height="17" font="0">loss at 6 mo assessed by </text>
<text top="602" left="648" width="117" height="17" font="0">blinded angiographic </text>
<text top="619" left="648" width="110" height="17" font="0">corelab quantitative </text>
<text top="636" left="648" width="52" height="17" font="0">analyses </text>
<text top="549" left="817" width="7" height="18" font="7"></text>
<text top="550" left="824" width="133" height="17" font="2"><b> </b>DEB is superior to PTA </text>
<text top="567" left="817" width="7" height="18" font="7"></text>
<text top="568" left="824" width="241" height="17" font="0"> Pts with sx femoro-popliteal atherosclerotic </text>
<text top="586" left="817" width="258" height="17" font="0">disease undergoing percutaneous transluminal </text>
<text top="603" left="817" width="273" height="17" font="0">angioplasty were randomized to paclitaxel-coated </text>
<text top="620" left="817" width="277" height="17" font="0">IN.PACT Pacific or uncoated Pacific balloons. The </text>
<text top="637" left="817" width="250" height="17" font="0">primary endpoint was late lumen loss at 6 mo </text>
<text top="655" left="817" width="232" height="17" font="0">assessed by blinded angiographic corelab </text>
<text top="672" left="817" width="271" height="17" font="0">quantitative analyses. Secondary endpoints were </text>
<text top="689" left="817" width="281" height="17" font="0">binary restenosis and Rutherford class change at 6 </text>
<text top="706" left="817" width="253" height="17" font="0">mo, and TL revascularization + major adverse </text>
<text top="723" left="817" width="281" height="17" font="0">clinical events (major adverse events=death, target </text>
<text top="741" left="817" width="274" height="17" font="0">limb amputation, or TL revascularization) at 6 and </text>
<text top="758" left="817" width="284" height="17" font="0">12 mo. 85 pts (91 cases=interventional procedures) </text>
<text top="775" left="817" width="278" height="17" font="0">were randomized in 3 hospitals (44 to DEB and 47 </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">103 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="118" height="17" font="0">infrapopliteal vessels </text>
<text top="104" left="331" width="7" height="18" font="7"></text>
<text top="105" left="338" width="118" height="17" font="0"> Renal failure (serum </text>
<text top="123" left="331" width="126" height="17" font="0">creatinine &gt;2.0 mg/dL) </text>
<text top="140" left="331" width="7" height="18" font="7"></text>
<text top="141" left="338" width="162" height="17" font="0"> Known intolerance or allergy </text>
<text top="158" left="331" width="116" height="17" font="0">to study medications </text>
<text top="176" left="331" width="7" height="18" font="7"></text>
<text top="177" left="338" width="119" height="17" font="0"> Life expectancy &lt;2 y<b> </b></text>
<text top="87" left="817" width="271" height="17" font="0">to uncoated balloons). Average lesion length was </text>
<text top="104" left="817" width="274" height="17" font="0">7.0±5.3 and 6.6±5.5 cm for DEB and control arm, </text>
<text top="122" left="817" width="271" height="17" font="0">respectively. Procedural success was obtained in </text>
<text top="139" left="817" width="269" height="17" font="0">all cases. 6 mo quantitative angiography showed </text>
<text top="156" left="817" width="270" height="17" font="0">that DEB were associated with significantly lower </text>
<text top="173" left="817" width="277" height="17" font="0">late lumen loss (-0.01 mm; 95% CI: -0.29–0.26 vs. </text>
<text top="190" left="817" width="273" height="17" font="0">0.65 mm; 95% CI: 0.37–0.93; p=0.001) and fewer </text>
<text top="208" left="817" width="238" height="17" font="0">binary restenoses (3 [8.6%] vs. 11 [32.4%]; </text>
<text top="225" left="817" width="263" height="17" font="0">p=0.01). This translated into a clinically relevant </text>
<text top="242" left="817" width="247" height="17" font="0">benefit with significantly fewer major adverse </text>
<text top="259" left="817" width="277" height="17" font="0">events for DEB vs. uncoated balloons up to 12 mo </text>
<text top="276" left="817" width="258" height="17" font="0">(3 [7.1%] vs. 15 [34.9%]; p&lt;0.01) as well as TL </text>
<text top="294" left="817" width="239" height="17" font="0">revascularizations (3 [7.1%] vs. 12 [27.9%]; </text>
<text top="311" left="817" width="49" height="17" font="0">p=0.02). </text>
<text top="329" left="95" width="61" height="17" font="2"><b>VIASTAR</b>  </text>
<text top="346" left="95" width="95" height="17" font="0">Lammer J, et al.  </text>
<text top="363" left="95" width="59" height="17" font="0">2013(233) </text>
<text top="381" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23831445">23831445 </a></text>
<text top="398" left="95" width="3" height="17" font="0"> </text>
<text top="329" left="200" width="107" height="17" font="2"><b>Aim: </b>SFA Viabahn </text>
<text top="346" left="200" width="83" height="17" font="0">vs. nitinol SES </text>
<text top="363" left="200" width="3" height="17" font="0"> </text>
<text top="381" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="398" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="415" left="200" width="90" height="17" font="2"><b>Size: </b>n=141 pts<b> </b></text>
<text top="329" left="331" width="151" height="17" font="2"><b>Inclusion criteria: </b>Sx SFA </text>
<text top="346" left="331" width="52" height="17" font="0">stenosis<b>  </b></text>
<text top="363" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="381" left="331" width="169" height="17" font="2"><b>Exclusion criteria:</b> The major </text>
<text top="398" left="331" width="129" height="17" font="0">exclusion criteria were: </text>
<text top="415" left="331" width="7" height="18" font="7"></text>
<text top="416" left="338" width="137" height="17" font="0"> Untreated inflow lesions </text>
<text top="433" left="331" width="7" height="18" font="7"></text>
<text top="434" left="338" width="139" height="17" font="0"> Any previous stenting or </text>
<text top="452" left="331" width="151" height="17" font="0">surgery in the target artery, </text>
<text top="469" left="331" width="151" height="17" font="0">serum creatinine level &gt;2.5 </text>
<text top="486" left="331" width="38" height="17" font="0">mg/dL </text>
<text top="503" left="331" width="7" height="18" font="7"></text>
<text top="504" left="338" width="68" height="17" font="0"> Septicemia </text>
<text top="522" left="331" width="7" height="18" font="7"></text>
<text top="523" left="338" width="122" height="17" font="0"> Known intolerance to </text>
<text top="540" left="331" width="161" height="17" font="0">heparin, antithrombotic study </text>
<text top="557" left="331" width="134" height="17" font="0">medications, or contrast </text>
<text top="575" left="331" width="40" height="17" font="0">agents<b> </b></text>
<text top="329" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="346" left="513" width="97" height="17" font="0">Viabahn (heparin </text>
<text top="363" left="513" width="44" height="17" font="0">coated) </text>
<text top="381" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="398" left="513" width="105" height="17" font="2"><b>Comparator: </b>SES<b> </b></text>
<text top="330" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="329" left="655" width="6" height="18" font="7"></text>
<text top="330" left="661" width="135" height="17" font="2"><b> endpoint: </b>6 and 12 mo </text>
<text top="347" left="648" width="91" height="17" font="0">primary patency </text>
<text top="329" left="817" width="7" height="18" font="7"></text>
<text top="330" left="824" width="138" height="17" font="2"><b> </b>No significant difference </text>
<text top="347" left="817" width="7" height="18" font="7"></text>
<text top="348" left="824" width="267" height="17" font="0"> Mean±SD lesion length was 19.0±6.3 cm in the </text>
<text top="366" left="817" width="282" height="17" font="0">Viabahn group and 17.3±6.6 cm in the BMS group. </text>
<text top="383" left="817" width="271" height="17" font="0">Major complications within 30 d were observed in </text>
<text top="400" left="817" width="252" height="17" font="0">1.4%. The 12 mo primary patency rates in the </text>
<text top="417" left="817" width="269" height="17" font="0">Viabahn and BMS groups were: ITT 70.9% (95% </text>
<text top="434" left="817" width="257" height="17" font="0">CI: 0.58–0.80) and 55.1% (95% CI: 0.41–0.67) </text>
<text top="452" left="817" width="272" height="17" font="0">(log-rank test p=0.11); TPP 78.1% (95% CI: 0.65–</text>
<text top="469" left="817" width="267" height="17" font="0">0.86) and 53.5% (95% CI: 0.39–0.65) (HR: 2.23; </text>
<text top="486" left="817" width="254" height="17" font="0">95% CI: 1.14–4.34) (log-rank test p=0.009). In </text>
<text top="503" left="817" width="240" height="17" font="0">lesions ≥20 cm, (TASC class D), the 12 mo </text>
<text top="521" left="817" width="270" height="17" font="0">patency rate was significantly longer in VIA pts in </text>
<text top="538" left="817" width="247" height="17" font="0">the ITT analysis (VIA 71.3% vs. BMS 36.8%; </text>
<text top="555" left="817" width="280" height="17" font="0">p=0.01) and the TPP analysis (VIA 73.3% vs. BMS </text>
<text top="572" left="817" width="196" height="17" font="0">33.3%; p=0.004). Freedom from TL </text>
<text top="589" left="817" width="277" height="17" font="0">revascularization was 84.6% for Viabahn (95% CI: </text>
<text top="607" left="817" width="280" height="17" font="0">0.72–0.91) vs. 77.0% for BMS (95% CI: 0.63–0.85; </text>
<text top="624" left="817" width="281" height="17" font="0">p=0.37). The ABI in the Viabahn group significantly </text>
<text top="641" left="817" width="264" height="17" font="0">increased to 0.94±0.23 compared with the BMS </text>
<text top="658" left="817" width="202" height="17" font="0">group (0.85±0.23; p&lt;0.05) at 12 mo. </text>
<text top="676" left="95" width="58" height="17" font="2"><b>VIBRANT </b></text>
<text top="693" left="95" width="89" height="17" font="0">Geraghty PJ, et </text>
<text top="711" left="95" width="20" height="17" font="0">al.  </text>
<text top="728" left="95" width="59" height="17" font="0">2013(234)<b> </b></text>
<text top="745" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23676191">23676191 </a></text>
<text top="762" left="95" width="3" height="17" font="0"> </text>
<text top="676" left="200" width="98" height="17" font="2"><b>Aim: </b>Viabahn vs. </text>
<text top="693" left="200" width="28" height="17" font="0">SES </text>
<text top="711" left="200" width="3" height="17" font="0"> </text>
<text top="728" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="745" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="762" left="200" width="90" height="17" font="2"><b>Size: </b>n=184 pts<b> </b></text>
<text top="676" left="331" width="124" height="17" font="2"><b>Inclusion criteria: </b>Sx </text>
<text top="693" left="331" width="152" height="17" font="0">complex superficial femoral </text>
<text top="711" left="331" width="159" height="17" font="0">artery disease (TASC I class </text>
<text top="728" left="331" width="94" height="17" font="0">C and D lesions, </text>
<text top="745" left="331" width="123" height="17" font="0">accompanied by IC or </text>
<text top="762" left="331" width="106" height="17" font="0">ischemic rest pain) </text>
<text top="676" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="693" left="513" width="122" height="17" font="0">Viabahn (non-heparin </text>
<text top="711" left="513" width="44" height="17" font="0">coated) </text>
<text top="728" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="745" left="513" width="105" height="17" font="2"><b>Comparator: </b>SES<b> </b></text>
<text top="677" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="676" left="655" width="6" height="18" font="7"></text>
<text top="677" left="661" width="140" height="17" font="2"><b> endpoint: </b>Patency, limb </text>
<text top="695" left="648" width="140" height="17" font="0">hemodynamics, and QoL </text>
<text top="712" left="648" width="148" height="17" font="0">were evaluated at 1, 6, 12, </text>
<text top="729" left="648" width="133" height="17" font="0">24, and 36 mo following </text>
<text top="746" left="648" width="70" height="17" font="0">intervention<b>. </b></text>
<text top="676" left="817" width="7" height="18" font="7"></text>
<text top="677" left="824" width="138" height="17" font="2"><b> </b>No significant difference </text>
<text top="695" left="817" width="7" height="18" font="7"></text>
<text top="696" left="824" width="276" height="17" font="0"> The average treated lesion measured 18±8 cm in </text>
<text top="713" left="817" width="273" height="17" font="0">length, and 58.8% of lesions displayed segmental </text>
<text top="730" left="817" width="255" height="17" font="0">or complete occlusion. At 3 y, primary patency </text>
<text top="747" left="817" width="269" height="17" font="0">rates (defined by peak systolic velocity ratio ≤2.0 </text>
<text top="765" left="817" width="266" height="17" font="0">and no TL revascularization) did not significantly </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">104 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="104" left="331" width="165" height="17" font="2"><b>Exclusion criteria:</b> Occluded </text>
<text top="122" left="331" width="163" height="17" font="0">popliteal artery of &lt;1 infrapop </text>
<text top="139" left="331" width="143" height="17" font="0">artery patent to the ankle <b> </b></text>
<text top="87" left="817" width="276" height="17" font="0">differ between pts treated with the VIABAHN stent </text>
<text top="104" left="817" width="265" height="17" font="0">graft and those who received a bare nitinol stent </text>
<text top="122" left="817" width="272" height="17" font="0">(24.2% vs. 25.9%; p=0.392). Stent fractures were </text>
<text top="139" left="817" width="262" height="17" font="0">significantly more common in bare nitinol stents </text>
<text top="156" left="817" width="256" height="17" font="0">(50.0%) than in the VIABAHN endoprostheses </text>
<text top="173" left="817" width="283" height="17" font="0">(2.6%). Primary-assisted patency rates were higher </text>
<text top="190" left="817" width="247" height="17" font="0">in those receiving bare nitinol stents than the </text>
<text top="208" left="817" width="268" height="17" font="0">VIABAHN stent graft (88.8% vs. 69.8%; p=0.04), </text>
<text top="225" left="817" width="259" height="17" font="0">although secondary patency rates did not differ </text>
<text top="242" left="817" width="282" height="17" font="0">between bare nitinol stent and stent graft recipients </text>
<text top="259" left="817" width="242" height="17" font="0">(89.3% vs. 79.5%; p=0.304). There were no </text>
<text top="276" left="817" width="234" height="17" font="0">instances of procedure-related mortality or </text>
<text top="294" left="817" width="271" height="17" font="0">amputation. The hemodynamic improvement and </text>
<text top="311" left="817" width="278" height="17" font="0">quality measures improved equally in both groups.<b> </b></text>
<text top="329" left="95" width="77" height="17" font="0">Saxon RR, et </text>
<text top="346" left="95" width="20" height="17" font="0">al.  </text>
<text top="363" left="95" width="59" height="17" font="0">2008(235)<b> </b></text>
<text top="381" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18503895">18503895 </a></text>
<text top="398" left="95" width="3" height="17" font="0"> </text>
<text top="329" left="200" width="110" height="17" font="2"><b>Aim: </b>SFA: Viabahn </text>
<text top="346" left="200" width="46" height="17" font="0">vs. PTA </text>
<text top="363" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="381" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="398" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="415" left="200" width="90" height="17" font="2"><b>Size: </b>n=197 pts<b> </b></text>
<text top="329" left="331" width="151" height="17" font="2"><b>Inclusion criteria: </b>Sx SFA </text>
<text top="346" left="331" width="29" height="17" font="0">PAD </text>
<text top="363" left="331" width="3" height="17" font="0"> </text>
<text top="381" left="331" width="165" height="17" font="2"><b>Exclusion criteria:</b> Occluded </text>
<text top="398" left="331" width="163" height="17" font="0">popliteal artery of &lt;1 infrapop </text>
<text top="415" left="331" width="140" height="17" font="0">artery patent to the ankle<b> </b></text>
<text top="329" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="346" left="513" width="49" height="17" font="0">Viabahn<b> </b></text>
<text top="363" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="381" left="513" width="105" height="17" font="2"><b>Comparator:</b> PTA<b> </b></text>
<text top="330" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="329" left="655" width="6" height="18" font="7"></text>
<text top="330" left="661" width="140" height="17" font="2"><b> endpoint: </b>12 mo duplex </text>
<text top="347" left="648" width="94" height="17" font="0">primary patency  </text>
<text top="329" left="817" width="7" height="18" font="7"></text>
<text top="330" left="824" width="174" height="17" font="2"><b> </b>Viabahn superior to PTA alone </text>
<text top="347" left="817" width="7" height="18" font="7"></text>
<text top="348" left="824" width="260" height="17" font="0"> The stent-graft group had a significantly higher </text>
<text top="366" left="817" width="266" height="17" font="0">technical success rate (95% vs. 66%, p&lt;0.0001) </text>
<text top="383" left="817" width="251" height="17" font="0">and 1 y primary vessel patency rate at duplex </text>
<text top="400" left="817" width="249" height="17" font="0">ultrasonography (65% vs. 40%, p=0.0003). A </text>
<text top="417" left="817" width="275" height="17" font="0">patency benefit was seen for lesions at least 3 cm </text>
<text top="434" left="817" width="269" height="17" font="0">long. At 12 mo, chronic limb ischemia status was </text>
<text top="452" left="817" width="253" height="17" font="0">15% further improved for the stent-graft group </text>
<text top="469" left="817" width="264" height="17" font="0">(p=0.003). There were no significant differences </text>
<text top="486" left="817" width="245" height="17" font="0">between treatment groups with regard to the </text>
<text top="503" left="817" width="270" height="17" font="0">occurrence of early or late major adverse events.<b> </b></text>
<text top="521" left="95" width="86" height="17" font="0">Kedora J, et al. </text>
<text top="539" left="95" width="59" height="17" font="0">2007(236)<b> </b></text>
<text top="556" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17126520">17126520</a></text>
<text top="556" left="149" width="3" height="17" font="2"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17126520"><b> </b></a></text>
<text top="573" left="95" width="3" height="17" font="0"> </text>
<text top="521" left="200" width="110" height="17" font="2"><b>Aim: </b>SFA: Viabhan </text>
<text top="539" left="200" width="96" height="17" font="0">vs. synthetic fem-</text>
<text top="556" left="200" width="66" height="17" font="0">pop bypass </text>
<text top="573" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="590" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="607" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="625" left="200" width="83" height="17" font="2"><b>Size: </b>n=86 pts<b> </b></text>
<text top="521" left="331" width="124" height="17" font="2"><b>Inclusion criteria: </b>Sx </text>
<text top="539" left="331" width="135" height="17" font="0">femoral-popliteal arterial </text>
<text top="556" left="331" width="103" height="17" font="0">occlusive disease <b> </b></text>
<text top="573" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="590" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="607" left="331" width="7" height="18" font="7"></text>
<text top="608" left="338" width="125" height="17" font="0"> No aorto-iliac disease </text>
<text top="626" left="331" width="7" height="18" font="7"></text>
<text top="627" left="338" width="155" height="17" font="0"> &lt;1 infrapop artery patent to </text>
<text top="644" left="331" width="33" height="17" font="0">ankle<b> </b></text>
<text top="521" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="539" left="513" width="49" height="17" font="0">Viabahn </text>
<text top="556" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="573" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="590" left="513" width="103" height="17" font="0">Synthetic fem-pop </text>
<text top="607" left="513" width="42" height="17" font="0">bypass<b> </b></text>
<text top="625" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="522" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="521" left="655" width="6" height="18" font="7"></text>
<text top="522" left="661" width="140" height="17" font="2"><b> endpoint: </b>12 mo duplex </text>
<text top="540" left="648" width="91" height="17" font="0">primary patency </text>
<text top="521" left="817" width="7" height="18" font="7"></text>
<text top="522" left="824" width="80" height="17" font="2"><b> </b>No difference </text>
<text top="540" left="817" width="7" height="18" font="7"></text>
<text top="541" left="824" width="259" height="17" font="0"> Pts were monitored for a median of 18 mo. No </text>
<text top="558" left="817" width="249" height="17" font="0">statistical difference was found in the primary </text>
<text top="575" left="817" width="280" height="17" font="0">patency (p=0.895) or secondary patency (p=0.861) </text>
<text top="593" left="817" width="273" height="17" font="0">between the 2 treatment groups. Primary patency </text>
<text top="610" left="817" width="271" height="17" font="0">at 3, 6, 9, and 12 mo of follow-up was 84%, 82%, </text>
<text top="627" left="817" width="259" height="17" font="0">75.6%, and 73.5% for the stent graft group and </text>
<text top="644" left="817" width="261" height="17" font="0">90%, 81.8%, 79.7%, and 74.2% for the femoral-</text>
<text top="661" left="817" width="262" height="17" font="0">popliteal surgical group. 13 pts in the stent graft </text>
<text top="679" left="817" width="204" height="17" font="0">group had 14 reinterventions, and 12 </text>
<text top="696" left="817" width="280" height="17" font="0">reinterventions occurred in the surgical group. This </text>
<text top="713" left="817" width="267" height="17" font="0">resulted in secondary patency rates of 83.9% for </text>
<text top="730" left="817" width="260" height="17" font="0">the stent graft group and 83.7% for the surgical </text>
<text top="747" left="817" width="163" height="17" font="0">group at the 12 mo follow-up. </text>
<text top="765" left="95" width="67" height="17" font="2"><b>Zilver PTX  </b></text>
<text top="765" left="200" width="106" height="17" font="2"><b>Aim: </b>SFA DES vs. </text>
<text top="765" left="331" width="124" height="17" font="2"><b>Inclusion criteria: </b>Sx </text>
<text top="765" left="513" width="107" height="17" font="2"><b>Intervention: </b>DES </text>
<text top="766" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="765" left="655" width="6" height="18" font="7"></text>
<text top="766" left="661" width="138" height="17" font="2"><b> endpoint: </b>2 mo rates of </text>
<text top="765" left="817" width="7" height="18" font="7"></text>
<text top="766" left="824" width="168" height="17" font="2"><b> </b>DES is superior to PTA±BMS </text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">105 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="88" height="17" font="0">Dake MD, et al. </text>
<text top="104" left="95" width="59" height="17" font="0">2011(237)<b> </b></text>
<text top="122" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21953370">21953370 </a></text>
<text top="139" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="102" height="17" font="0">PTA w provisional </text>
<text top="104" left="200" width="30" height="17" font="0">BMS </text>
<text top="122" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="139" left="200" width="102" height="17" font="2"><b>Study type: </b>RCT<b>  </b></text>
<text top="156" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="173" left="200" width="90" height="17" font="2"><b>Size: </b>n=474 pts<b> </b></text>
<text top="87" left="331" width="77" height="17" font="0">fem/pop PAD </text>
<text top="104" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="331" width="144" height="17" font="2"><b>Exclusion criteria:</b> Major </text>
<text top="139" left="331" width="151" height="17" font="0">exclusion criteria included:  </text>
<text top="156" left="331" width="7" height="18" font="7"></text>
<text top="157" left="338" width="144" height="17" font="0"> Utreated &gt;50% DS of the </text>
<text top="174" left="331" width="62" height="17" font="0">inflow tract </text>
<text top="192" left="331" width="7" height="18" font="7"></text>
<text top="193" left="338" width="141" height="17" font="0"> Lesion pretreatment with </text>
<text top="210" left="331" width="104" height="17" font="0">adjunctive devices </text>
<text top="227" left="331" width="7" height="18" font="7"></text>
<text top="228" left="338" width="128" height="17" font="0"> Previous target vessel </text>
<text top="246" left="331" width="47" height="17" font="0">stenting<b> </b></text>
<text top="87" left="513" width="72" height="17" font="0">(no polymer) </text>
<text top="104" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="122" left="513" width="117" height="17" font="2"><b>Comparator: </b>PTA w </text>
<text top="139" left="513" width="92" height="17" font="0">provisional BMS<b> </b></text>
<text top="87" left="648" width="128" height="17" font="0">event-free survival and </text>
<text top="104" left="648" width="50" height="17" font="0">patency <b> </b></text>
<text top="87" left="817" width="7" height="18" font="7"></text>
<text top="88" left="824" width="248" height="17" font="0"> Pts were randomly assigned to primary DES </text>
<text top="106" left="817" width="207" height="17" font="0">implantation (n=236) or PTA (n=238). </text>
<text top="123" left="817" width="254" height="17" font="0">Demographics and lesion characteristics were </text>
<text top="140" left="817" width="278" height="17" font="0">similar between groups (eg, average lesion length, </text>
<text top="157" left="817" width="279" height="17" font="0">approximately 65±40 mm). 120 pts had acute PTA </text>
<text top="174" left="817" width="227" height="17" font="0">failure and underwent secondary random </text>
<text top="192" left="817" width="255" height="17" font="0">assignment to provisional DES (n=61) or BMS </text>
<text top="209" left="817" width="278" height="17" font="0">(n=59). Primary endpoints were the 12 mo rates of </text>
<text top="226" left="817" width="280" height="17" font="0">event free survival and patency in the primary DES </text>
<text top="243" left="817" width="268" height="17" font="0">and PTA groups. Compared with the PTA group, </text>
<text top="260" left="817" width="267" height="17" font="0">the primary DES group exhibited superior 12 mo </text>
<text top="278" left="817" width="283" height="17" font="0">event free survival (90.4% vs. 82.6%; p=0.004) and </text>
<text top="295" left="817" width="250" height="17" font="0">primary patency (83.1% vs. 32.8%; p&lt;0.001), </text>
<text top="312" left="817" width="284" height="17" font="0">satisfying the primary hypotheses. In the secondary </text>
<text top="329" left="817" width="269" height="17" font="0">evaluations, (1) the primary DES group exhibited </text>
<text top="347" left="817" width="260" height="17" font="0">superior clinical benefit compared with the PTA </text>
<text top="364" left="817" width="233" height="17" font="0">group (88.3% vs. 75.8%; p&lt;0.001), (2) the </text>
<text top="381" left="817" width="271" height="17" font="0">provisional DES group exhibited superior primary </text>
<text top="398" left="817" width="267" height="17" font="0">patency (89.9% vs. 73.0%; p=0.01) and superior </text>
<text top="415" left="817" width="241" height="17" font="0">clinical benefit (90.5% and 72.3%; p=0.009) </text>
<text top="433" left="817" width="277" height="17" font="0">compared with the provisional BMS group, and (3) </text>
<text top="450" left="817" width="264" height="17" font="0">the stent fracture rate (both DES and BMS) was </text>
<text top="467" left="817" width="77" height="17" font="0">0.9% (4/457). </text>
<text top="485" left="95" width="88" height="17" font="0">Dake MD, et al. </text>
<text top="502" left="95" width="59" height="17" font="0">2015(238)<b> </b></text>
<text top="519" left="95" width="79" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823823/">PMC4823823 </a></text>
<text top="485" left="200" width="106" height="17" font="2"><b>Aim: </b>SFA DES vs. </text>
<text top="502" left="200" width="102" height="17" font="0">PTA w provisional </text>
<text top="519" left="200" width="30" height="17" font="0">BMS </text>
<text top="537" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="554" left="200" width="102" height="17" font="2"><b>Study type: </b>RCT<b>  </b></text>
<text top="571" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="588" left="200" width="90" height="17" font="2"><b>Size: </b>n=474 pts<b> </b></text>
<text top="485" left="331" width="124" height="17" font="2"><b>Inclusion criteria: </b>Sx </text>
<text top="502" left="331" width="77" height="17" font="0">fem/pop PAD </text>
<text top="519" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="537" left="331" width="144" height="17" font="2"><b>Exclusion criteria:</b> Major </text>
<text top="554" left="331" width="151" height="17" font="0">exclusion criteria included:  </text>
<text top="571" left="331" width="7" height="18" font="7"></text>
<text top="572" left="338" width="144" height="17" font="0"> Utreated &gt;50% DS of the </text>
<text top="589" left="331" width="62" height="17" font="0">inflow tract </text>
<text top="607" left="331" width="7" height="18" font="7"></text>
<text top="608" left="338" width="141" height="17" font="0"> Lesion pretreatment with </text>
<text top="625" left="331" width="104" height="17" font="0">adjunctive devices </text>
<text top="642" left="331" width="7" height="18" font="7"></text>
<text top="643" left="338" width="128" height="17" font="0"> Previous target vessel </text>
<text top="661" left="331" width="47" height="17" font="0">stenting<b> </b></text>
<text top="485" left="513" width="107" height="17" font="2"><b>Intervention: </b>DES </text>
<text top="502" left="513" width="72" height="17" font="0">(no polymer) </text>
<text top="519" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="537" left="513" width="117" height="17" font="2"><b>Comparator: </b>PTA w </text>
<text top="554" left="513" width="92" height="17" font="0">provisional BMS<b> </b></text>
<text top="486" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="485" left="655" width="6" height="18" font="7"></text>
<text top="486" left="661" width="138" height="17" font="2"><b> endpoint: </b>2 mo rates of </text>
<text top="503" left="648" width="128" height="17" font="0">event-free survival and </text>
<text top="521" left="648" width="50" height="17" font="0">patency <b> </b></text>
<text top="485" left="817" width="7" height="18" font="7"></text>
<text top="486" left="824" width="273" height="17" font="2"><b> </b>5-y results from Zilver PTX study show long-term </text>
<text top="503" left="817" width="196" height="17" font="0">information previously unavailable.  </text>
<text top="521" left="817" width="7" height="18" font="7"></text>
<text top="522" left="824" width="260" height="17" font="2"><b> </b>Zilver PTX DES provided sustained safety and </text>
<text top="539" left="817" width="250" height="17" font="0">clinical durability in comparison with standard </text>
<text top="556" left="817" width="138" height="17" font="0">endovascular treatments </text>
<text top="679" left="95" width="61" height="17" font="2"><b>SIROCCO</b> </text>
<text top="696" left="95" width="87" height="17" font="0">Duda SH, et al. </text>
<text top="713" left="95" width="59" height="17" font="0">2006(239)<b> </b></text>
<text top="730" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17154704">17154704 </a></text>
<text top="747" left="95" width="3" height="17" font="0"> </text>
<text top="679" left="200" width="109" height="17" font="2"><b>Aim: </b>SFA: DES vs. </text>
<text top="696" left="200" width="30" height="17" font="0">BMS </text>
<text top="713" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="730" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="747" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="765" left="200" width="83" height="17" font="2"><b>Size: </b>n=93 pts<b> </b></text>
<text top="679" left="331" width="152" height="17" font="2"><b>Inclusion criteria: </b>Chronic </text>
<text top="696" left="331" width="129" height="17" font="0">limb ischemia and SFA </text>
<text top="713" left="331" width="164" height="17" font="0">occlusions or stenoses TASC </text>
<text top="730" left="331" width="12" height="17" font="0">C </text>
<text top="747" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="765" left="331" width="156" height="17" font="2"><b>Exclusion criteria:</b> Lesions </text>
<text top="679" left="513" width="107" height="17" font="2"><b>Intervention: </b>DES<b> </b></text>
<text top="696" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="713" left="513" width="111" height="17" font="2"><b>Comparator: </b>BMS <b> </b></text>
<text top="680" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="679" left="655" width="6" height="18" font="7"></text>
<text top="680" left="661" width="115" height="17" font="2"><b> endpoint: </b>Freedom </text>
<text top="697" left="648" width="87" height="17" font="0">from restenosis </text>
<text top="679" left="817" width="7" height="18" font="7"></text>
<text top="680" left="824" width="274" height="17" font="2"><b> </b>No meaningful difference between sirolimus DES </text>
<text top="697" left="817" width="49" height="17" font="0">vs. BMS </text>
<text top="714" left="817" width="7" height="18" font="7"></text>
<text top="715" left="824" width="264" height="17" font="0"> Both the sirolimus-eluting and the bare SMART </text>
<text top="733" left="817" width="234" height="17" font="0">stents were effective in revascularizing the </text>
<text top="750" left="817" width="252" height="17" font="0">diseased SFA and in sustaining freedom from </text>
<text top="767" left="817" width="279" height="17" font="0">restenosis. For both types of stents, improvements </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">106 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="48" height="17" font="0">&gt;20 cm <b> </b></text>
<text top="87" left="817" width="232" height="17" font="0">in ABI and symptoms of claudication were </text>
<text top="104" left="817" width="282" height="17" font="0">maintained over 24 mo (median 24 mo ABI 0.96 for </text>
<text top="122" left="817" width="250" height="17" font="0">the sirolimus group vs. 0.87 for the bare stent </text>
<text top="139" left="817" width="281" height="17" font="0">group, p&gt;0.05). At 24 mo, the restenosis rate in the </text>
<text top="156" left="817" width="269" height="17" font="0">sirolimus group was 22.9% vs. 21.1% in the bare </text>
<text top="173" left="817" width="249" height="17" font="0">stent group (p&gt;0.05). The cumulative in-stent </text>
<text top="190" left="817" width="261" height="17" font="0">restenosis rates according to duplex ultrasound </text>
<text top="208" left="817" width="279" height="17" font="0">were 4.7%, 9.0%, 15.6%, and 21.9%, respectively, </text>
<text top="225" left="817" width="249" height="17" font="0">at 6, 9, 18, and 24 mo; the rates did not differ </text>
<text top="242" left="817" width="262" height="17" font="0">significantly between the treatment groups. The </text>
<text top="259" left="817" width="265" height="17" font="0">TLR rate for the sirolimus group was 6% and for </text>
<text top="276" left="817" width="254" height="17" font="0">the bare stent group 13%; the TVR rates were </text>
<text top="294" left="817" width="256" height="17" font="0">somewhat higher: 13% and 22%, respectively. </text>
<text top="311" left="817" width="269" height="17" font="0">Mortality rates did not differ significantly between </text>
<text top="328" left="817" width="65" height="17" font="0">the groups. </text>
<text top="346" left="95" width="78" height="17" font="0">Tepe G, et al. </text>
<text top="363" left="95" width="59" height="17" font="0">2008(240) </text>
<text top="381" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18272892">18272892 </a></text>
<text top="398" left="95" width="3" height="17" font="0"> </text>
<text top="346" left="200" width="108" height="17" font="2"><b>Aim: </b>SFA: PTA vs. </text>
<text top="363" left="200" width="96" height="17" font="0">PTA with balloon </text>
<text top="381" left="200" width="108" height="17" font="0">dipped in paclitaxel </text>
<text top="398" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="415" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="432" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="449" left="200" width="90" height="17" font="2"><b>Size: </b>n=154 pts </text>
<text top="346" left="331" width="152" height="17" font="2"><b>Inclusion criteria: </b>Pts with </text>
<text top="363" left="331" width="152" height="17" font="0">Rutherford stages 1–5 sx &amp; </text>
<text top="381" left="331" width="142" height="17" font="0">stenosis or occlusion of a </text>
<text top="398" left="331" width="122" height="17" font="0">femoropopliteal artery </text>
<text top="415" left="331" width="3" height="17" font="0"> </text>
<text top="432" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="449" left="331" width="7" height="18" font="7"></text>
<text top="450" left="338" width="145" height="17" font="0"> Poor inflow; absence of a </text>
<text top="468" left="331" width="107" height="17" font="0">patent crural artery </text>
<text top="485" left="331" width="7" height="18" font="7"></text>
<text top="486" left="338" width="145" height="17" font="0"> Acute onset of symptoms </text>
<text top="503" left="331" width="7" height="18" font="7"></text>
<text top="504" left="338" width="66" height="17" font="0"> Pregnancy </text>
<text top="522" left="331" width="7" height="18" font="7"></text>
<text top="523" left="338" width="133" height="17" font="0"> Life expectancy of &gt;1 y </text>
<text top="540" left="331" width="7" height="18" font="7"></text>
<text top="541" left="338" width="115" height="17" font="0"> Contraindications to </text>
<text top="558" left="331" width="111" height="17" font="0">required medication<b> </b></text>
<text top="346" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="363" left="513" width="96" height="17" font="0">Paclitaxel dipped </text>
<text top="381" left="513" width="43" height="17" font="0">balloon </text>
<text top="398" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="415" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="347" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="346" left="655" width="6" height="18" font="7"></text>
<text top="347" left="661" width="138" height="17" font="2"><b> endpoint: </b>Angiographic </text>
<text top="365" left="648" width="156" height="17" font="0">restenosis at 6 mo and TVR </text>
<text top="346" left="817" width="7" height="18" font="7"></text>
<text top="347" left="824" width="81" height="17" font="2"><b> </b>DCB superior </text>
<text top="365" left="817" width="7" height="18" font="7"></text>
<text top="366" left="824" width="275" height="17" font="0"> The mean (±SD) age of the pts was 68±8 y, 24% </text>
<text top="383" left="817" width="248" height="17" font="0">were smokers, and 49% had DM. 27% of the </text>
<text top="400" left="817" width="245" height="17" font="0">lesions were total occlusions, and 36% were </text>
<text top="417" left="817" width="258" height="17" font="0">restenotic lesions. The mean lesion length was </text>
<text top="434" left="817" width="273" height="17" font="0">7.4±6.5 cm. There were no significant differences </text>
<text top="452" left="817" width="259" height="17" font="0">in baseline characteristics between the groups. </text>
<text top="469" left="817" width="268" height="17" font="0">There were no adverse events attributable to the </text>
<text top="486" left="817" width="276" height="17" font="0">paclitaxel-coated balloons. At 6 mo, the mean late </text>
<text top="503" left="817" width="270" height="17" font="0">lumen loss was 1.7±1.8 mm in the control group, </text>
<text top="521" left="817" width="260" height="17" font="0">as compared with 0.4±1.2 mm (p&lt;0.001) in the </text>
<text top="538" left="817" width="271" height="17" font="0">group treated with paclitaxel-coated balloons and </text>
<text top="555" left="817" width="255" height="17" font="0">2.2±1.6 mm (p=0.11) in the group treated with </text>
<text top="572" left="817" width="249" height="17" font="0">paclitaxel in the contrast medium. The rate of </text>
<text top="589" left="817" width="251" height="17" font="0">revascularization of TLs at 6 mo was 20 of 54 </text>
<text top="607" left="817" width="252" height="17" font="0">(37%) in the control group, 2 of 48 (4%) in the </text>
<text top="624" left="817" width="247" height="17" font="0">group treated with paclitaxel-coated balloons </text>
<text top="641" left="817" width="261" height="17" font="0">(p&lt;0.001 vs. control), and 15 of 52 (29%) in the </text>
<text top="658" left="817" width="237" height="17" font="0">group treated with paclitaxel in the contrast </text>
<text top="675" left="817" width="266" height="17" font="0">medium (p=0.41 vs. control); at 24 mo, the rates </text>
<text top="693" left="817" width="280" height="17" font="0">increased to 28 of 54 (52%), 7 of 48 (15%), and 21 </text>
<text top="710" left="817" width="67" height="17" font="0">of 52 (40%) </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">107 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="75" height="17" font="2"><b>EXCITE ISR  </b></text>
<text top="104" left="95" width="90" height="17" font="0">Dippel EJ, et al. </text>
<text top="122" left="95" width="59" height="17" font="0">2015(241)<b> </b></text>
<text top="139" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25499305">25499305 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="86" height="17" font="2"><b>Aim: </b>SFA ISR: </text>
<text top="104" left="200" width="104" height="17" font="0">ELA+PTA vs. PTA </text>
<text top="122" left="200" width="3" height="17" font="0"> </text>
<text top="139" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="156" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="173" left="200" width="90" height="17" font="2"><b>Size: </b>n=250 pts </text>
<text top="87" left="331" width="168" height="17" font="2"><b>Inclusion criteria: </b>Rutherford </text>
<text top="104" left="331" width="109" height="17" font="0">Class 1–4 SFA ISR </text>
<text top="122" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="139" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="156" left="331" width="7" height="18" font="7"></text>
<text top="157" left="338" width="66" height="17" font="0"> Pregnancy </text>
<text top="174" left="331" width="7" height="18" font="7"></text>
<text top="175" left="338" width="25" height="17" font="0"> ALI </text>
<text top="193" left="331" width="7" height="18" font="7"></text>
<text top="194" left="338" width="137" height="17" font="0"> Life expectancy &lt;12 mo </text>
<text top="211" left="331" width="7" height="18" font="7"></text>
<text top="212" left="338" width="152" height="17" font="0"> Cerebrovascular accidents </text>
<text top="230" left="331" width="159" height="17" font="0">or MI 60 d prior to procedure </text>
<text top="247" left="331" width="7" height="18" font="7"></text>
<text top="248" left="338" width="116" height="17" font="0"> Contraindications or </text>
<text top="265" left="331" width="160" height="17" font="0">allergies that could affect the </text>
<text top="282" left="331" width="59" height="17" font="0">procedure </text>
<text top="300" left="331" width="7" height="18" font="7"></text>
<text top="301" left="338" width="76" height="17" font="0"> Uncontrolled </text>
<text top="318" left="331" width="102" height="17" font="0">hypercoagulability </text>
<text top="335" left="331" width="7" height="18" font="7"></text>
<text top="336" left="338" width="137" height="17" font="0"> Systemic infection in TL </text>
<text top="354" left="331" width="7" height="18" font="7"></text>
<text top="355" left="338" width="144" height="17" font="0"> Previous treatment to the </text>
<text top="372" left="331" width="167" height="17" font="0">target vessel within 3 mo prior </text>
<text top="389" left="331" width="105" height="17" font="0">to study procedure </text>
<text top="406" left="331" width="7" height="18" font="7"></text>
<text top="407" left="338" width="129" height="17" font="0"> Serum creatinine ≥2.5 </text>
<text top="425" left="331" width="121" height="17" font="0">mg/dL unless dialysis-</text>
<text top="442" left="331" width="62" height="17" font="0">dependent </text>
<text top="459" left="331" width="7" height="18" font="7"></text>
<text top="460" left="338" width="115" height="17" font="0"> Aneurysm within TL </text>
<text top="478" left="331" width="7" height="18" font="7"></text>
<text top="479" left="338" width="143" height="17" font="0"> DES or covered stents in </text>
<text top="496" left="331" width="38" height="17" font="0">the TL </text>
<text top="513" left="331" width="7" height="18" font="7"></text>
<text top="514" left="338" width="120" height="17" font="0"> Planned or predicted </text>
<text top="531" left="331" width="102" height="17" font="0">cardiac surgery or </text>
<text top="549" left="331" width="115" height="17" font="0">interventions prior to </text>
<text top="566" left="331" width="157" height="17" font="0">completion of 30 d follow-up </text>
<text top="583" left="331" width="7" height="18" font="7"></text>
<text top="584" left="338" width="137" height="17" font="0"> Grade 4/5 stent fracture </text>
<text top="602" left="331" width="129" height="17" font="0">affecting target stent or </text>
<text top="619" left="331" width="152" height="17" font="0">proximal to the target stent.<b> </b></text>
<text top="87" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="104" left="513" width="58" height="17" font="0">ELA+PTA<b> </b></text>
<text top="122" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="139" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="88" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="655" width="6" height="18" font="7"></text>
<text top="88" left="661" width="120" height="17" font="2"><b> endpoint: </b>6 mo TLR </text>
<text top="106" left="648" width="3" height="17" font="0"> </text>
<text top="123" left="648" width="127" height="17" font="2"><b>Safety endpoint: </b>30 d </text>
<text top="140" left="648" width="39" height="17" font="0">MACE<b> </b></text>
<text top="87" left="817" width="7" height="18" font="7"></text>
<text top="88" left="824" width="253" height="17" font="2"><b> </b>ELA+PTA superior to PTA alone for SFA ISR </text>
<text top="106" left="817" width="7" height="18" font="7"></text>
<text top="107" left="824" width="267" height="17" font="0"> Study enrollment was stopped at 250 pts due to </text>
<text top="124" left="817" width="254" height="17" font="0">early efficacy demonstrated at a prospectively-</text>
<text top="141" left="817" width="277" height="17" font="0">specified interim analysis. A total of 169 ELA+PTA </text>
<text top="158" left="817" width="261" height="17" font="0">pts (62.7% male; mean age 68.5±9.8 y) and 81 </text>
<text top="176" left="817" width="254" height="17" font="0">PTA pts (61.7% male; mean age 67.8±10.3 y) </text>
<text top="193" left="817" width="272" height="17" font="0">were enrolled. Mean lesion length was 19.6±12.0 </text>
<text top="210" left="817" width="275" height="17" font="0">cm vs. 19.3±11.9 cm, and 30.5% vs. 36.8% of pts </text>
<text top="227" left="817" width="215" height="17" font="0">exhibited total occlusion. ELA+PTA pts </text>
<text top="244" left="817" width="278" height="17" font="0">demonstrated superior procedural success (93.5% </text>
<text top="262" left="817" width="232" height="17" font="0">vs. 82.7%; p=0.01) with significantly fewer </text>
<text top="279" left="817" width="277" height="17" font="0">procedural complications. ELA+PTA and PTA pt 6-</text>
<text top="296" left="817" width="245" height="17" font="0">mo freedom from TLR was 73.5% vs. 51.8% </text>
<text top="313" left="817" width="257" height="17" font="0">(p&lt;0.005), and 30 d major adverse event rates </text>
<text top="330" left="817" width="250" height="17" font="0">were 5.8% vs. 20.5% (p&lt;0.001), respectively. </text>
<text top="348" left="817" width="276" height="17" font="0">ELA+PTA was associated with a 52% reduction in </text>
<text top="365" left="817" width="199" height="17" font="0">TLR (HR: 0.48; 95% CI: 0.31–0.74).<b> </b></text>
<text top="637" left="95" width="52" height="17" font="2"><b>COBRA </b> </text>
<text top="654" left="95" width="81" height="17" font="0">Banerjee S, et </text>
<text top="671" left="95" width="16" height="17" font="0">al. </text>
<text top="688" left="95" width="59" height="17" font="0">2012(242)<b> </b></text>
<text top="705" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22981558">22981558 </a></text>
<text top="723" left="95" width="3" height="17" font="0"> </text>
<text top="637" left="200" width="116" height="17" font="2"><b>Aim: </b>SFA: PTAS vs. </text>
<text top="654" left="200" width="118" height="17" font="0">PTAS with Cryo PTA </text>
<text top="671" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="688" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="705" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="723" left="200" width="83" height="17" font="2"><b>Size: </b>n=74 pts </text>
<text top="637" left="331" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="654" left="331" width="7" height="18" font="7"></text>
<text top="655" left="338" width="26" height="17" font="0"> DM </text>
<text top="672" left="331" width="7" height="18" font="7"></text>
<text top="673" left="338" width="50" height="17" font="0"> Sx PAD </text>
<text top="691" left="331" width="7" height="18" font="7"></text>
<text top="692" left="338" width="144" height="17" font="0"> Superficial femoral artery </text>
<text top="709" left="331" width="163" height="17" font="0">lesions requiring implantation </text>
<text top="726" left="331" width="155" height="17" font="0">of stents &gt;5 mm in diameter </text>
<text top="743" left="331" width="125" height="17" font="0">and &gt;60 mm in length. </text>
<text top="761" left="331" width="3" height="17" font="0"> </text>
<text top="637" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="654" left="513" width="89" height="17" font="0">Cryoplasty PTA </text>
<text top="671" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="688" left="513" width="105" height="17" font="2"><b>Comparator: </b>PTA<b> </b></text>
<text top="638" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="637" left="655" width="6" height="18" font="7"></text>
<text top="638" left="661" width="137" height="17" font="2"><b> endpoint: </b>12 mo binary </text>
<text top="655" left="648" width="59" height="17" font="0">restenosis </text>
<text top="672" left="648" width="3" height="17" font="0"> </text>
<text top="689" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="637" left="817" width="7" height="18" font="7"></text>
<text top="638" left="824" width="249" height="17" font="2"><b> </b>Post-dilation with cryoplasty balloon reduced </text>
<text top="655" left="817" width="284" height="17" font="0">binary restenosis compared to conventional balloon </text>
<text top="672" left="817" width="66" height="17" font="0">angioplasty </text>
<text top="689" left="817" width="7" height="18" font="7"></text>
<text top="691" left="824" width="268" height="17" font="0"> 74 pts, with 90 stented superficial femoral artery </text>
<text top="708" left="817" width="265" height="17" font="0">lesions, were randomly assigned to post-dilation </text>
<text top="725" left="817" width="259" height="17" font="0">using cryoplasty (n=45 lesions) or conventional </text>
<text top="742" left="817" width="266" height="17" font="0">balloons (n=45 lesions). Mean lesion length was </text>
<text top="759" left="817" width="266" height="17" font="0">148±98 mm, mean stented length was 190±116 </text>
<text top="777" left="817" width="265" height="17" font="0">mm, mean stent diameter was 6.1±0.4 mm, and </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">108 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="104" left="331" width="7" height="18" font="7"></text>
<text top="105" left="338" width="159" height="17" font="0"> Allergic to ASA, clopidogrel, </text>
<text top="123" left="331" width="159" height="17" font="0">or iodine-based radiographic </text>
<text top="140" left="331" width="47" height="17" font="0">contrast </text>
<text top="157" left="331" width="7" height="18" font="7"></text>
<text top="158" left="338" width="132" height="17" font="0"> Had obstructive (≥50% </text>
<text top="176" left="331" width="163" height="17" font="0">diameter stenosis) iliofemoral </text>
<text top="193" left="331" width="81" height="17" font="0">artery disease </text>
<text top="210" left="331" width="7" height="18" font="7"></text>
<text top="211" left="338" width="111" height="17" font="0"> Absence ≥1 vessel </text>
<text top="228" left="331" width="152" height="17" font="0">infrapopliteal run-off. All pts </text>
<text top="246" left="331" width="161" height="17" font="0">had radio-opaque tape in the </text>
<text top="263" left="331" width="155" height="17" font="0">imaging field as a reference </text>
<text top="280" left="331" width="124" height="17" font="0">for determining vessel </text>
<text top="297" left="331" width="69" height="17" font="0">dimensions.<b> </b></text>
<text top="87" left="817" width="254" height="17" font="0">50% of the lesions were total occlusions. Post-</text>
<text top="104" left="817" width="276" height="17" font="0">dilation balloon diameters were 5.23±0.51 mm vs. </text>
<text top="122" left="817" width="272" height="17" font="0">5.51±0.72 mm in the cryoplasty and conventional </text>
<text top="139" left="817" width="275" height="17" font="0">balloon angioplasty groups, respectively (p=0.02). </text>
<text top="156" left="817" width="278" height="17" font="0">At 12 mo, binary restenosis was significantly lower </text>
<text top="173" left="817" width="275" height="17" font="0">in the cryoplasty group (29.3% vs. 55.8%; p=0.01; </text>
<text top="190" left="817" width="169" height="17" font="0">OR: 0.36; 95% CI: 0.15–0.89). </text>
<text top="315" left="95" width="92" height="17" font="0">Whyman MR, et </text>
<text top="332" left="95" width="16" height="17" font="0">al<b>. </b></text>
<text top="350" left="95" width="59" height="17" font="0">1996(243) </text>
<text top="367" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8760978">8760978 </a></text>
<text top="384" left="95" width="3" height="17" font="0"> </text>
<text top="315" left="200" width="112" height="17" font="2"><b>Aim:</b> Compare PTA </text>
<text top="332" left="200" width="81" height="17" font="0">vs. Med Tx for </text>
<text top="350" left="200" width="99" height="17" font="0">treadmill distance </text>
<text top="367" left="200" width="73" height="17" font="0">until onset of </text>
<text top="384" left="200" width="72" height="17" font="0">claudication, </text>
<text top="401" left="200" width="101" height="17" font="0">treadmill MWD, pt </text>
<text top="418" left="200" width="113" height="17" font="0">reported MWD, ABI, </text>
<text top="436" left="200" width="88" height="17" font="0">QoL (NHP) and </text>
<text top="453" left="200" width="100" height="17" font="0">Duplex measured </text>
<text top="470" left="200" width="105" height="17" font="0">extent of occlusive </text>
<text top="487" left="200" width="49" height="17" font="0">disease. </text>
<text top="504" left="200" width="3" height="17" font="0"> </text>
<text top="522" left="200" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="539" left="200" width="3" height="17" font="0"> </text>
<text top="556" left="200" width="104" height="17" font="2"><b>Size:</b> n=62 pts (30 </text>
<text top="573" left="200" width="113" height="17" font="0">PTA+Meds, 32 Med </text>
<text top="591" left="200" width="107" height="17" font="0">Tx ) 47 femoral; 15 </text>
<text top="608" left="200" width="25" height="17" font="0">iliac </text>
<text top="315" left="331" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="332" left="331" width="7" height="18" font="7"></text>
<text top="333" left="338" width="75" height="17" font="0"> Unilateral IC </text>
<text top="351" left="331" width="7" height="18" font="7"></text>
<text top="352" left="338" width="89" height="17" font="0"> Short stenoses </text>
<text top="369" left="331" width="3" height="17" font="0"> </text>
<text top="386" left="331" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="404" left="331" width="7" height="18" font="7"></text>
<text top="405" left="338" width="135" height="17" font="0"> Previous angioplasty or </text>
<text top="422" left="331" width="155" height="17" font="0">arterial surgery to the sx leg </text>
<text top="439" left="331" width="7" height="18" font="7"></text>
<text top="440" left="338" width="86" height="17" font="0"> MI within 6 mo </text>
<text top="458" left="331" width="7" height="18" font="7"></text>
<text top="459" left="338" width="85" height="17" font="0"> Pts taking oral </text>
<text top="476" left="331" width="83" height="17" font="0">anticoagulants </text>
<text top="493" left="331" width="7" height="18" font="7"></text>
<text top="494" left="338" width="144" height="17" font="0"> Duration of symptoms &lt;1 </text>
<text top="512" left="331" width="21" height="17" font="0">mo </text>
<text top="529" left="331" width="7" height="18" font="7"></text>
<text top="530" left="338" width="131" height="17" font="0"> Inability to manage the </text>
<text top="547" left="331" width="120" height="17" font="0">treadmill examination </text>
<text top="564" left="331" width="7" height="18" font="7"></text>
<text top="565" left="338" width="141" height="17" font="0"> Any psychiatric illness or </text>
<text top="583" left="331" width="168" height="17" font="0">other reason making follow-up </text>
<text top="600" left="331" width="42" height="17" font="0">difficult </text>
<text top="315" left="513" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="332" left="513" width="121" height="17" font="0">PTA+medical therapy </text>
<text top="350" left="513" width="3" height="17" font="0"> </text>
<text top="367" left="513" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="384" left="513" width="94" height="17" font="0">Medical therapy  </text>
<text top="401" left="513" width="50" height="17" font="0">(Medical </text>
<text top="418" left="513" width="119" height="17" font="0">therapy=ASA+advise </text>
<text top="436" left="513" width="90" height="17" font="0">on smoking and </text>
<text top="453" left="513" width="53" height="17" font="0">exercise)<b> </b></text>
<text top="316" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="315" left="655" width="6" height="18" font="7"></text>
<text top="316" left="661" width="139" height="17" font="2"><b> endpoint:</b> Max treadmill </text>
<text top="334" left="648" width="156" height="17" font="0">time to onset of claudication </text>
<text top="351" left="648" width="139" height="17" font="0">at 6 mo follow-up p&lt;0.01 </text>
<text top="315" left="817" width="7" height="18" font="7"></text>
<text top="316" left="824" width="240" height="17" font="0"> More PTA pt were asx on treadmill at 6 mo </text>
<text top="334" left="817" width="51" height="17" font="0">(p≤0.01) </text>
<text top="351" left="817" width="7" height="18" font="7"></text>
<text top="352" left="824" width="230" height="17" font="0"> More PTA pt had no claudication at 6 mo </text>
<text top="369" left="817" width="51" height="17" font="0">(p≤0.05) </text>
<text top="386" left="817" width="7" height="18" font="7"></text>
<text top="387" left="824" width="234" height="17" font="0"> ABI higher in PTA group at 6 mo (p≤0.05) </text>
<text top="405" left="817" width="7" height="18" font="7"></text>
<text top="406" left="824" width="271" height="17" font="0"> Lower Nottingham Health Score pain scores at 6 </text>
<text top="423" left="817" width="146" height="17" font="0">mo in PTA group (p≤0.05) </text>
<text top="626" left="95" width="92" height="17" font="0">Whyman MR, et </text>
<text top="643" left="95" width="16" height="17" font="0">al.<b> </b></text>
<text top="660" left="95" width="59" height="17" font="0">1997(244) </text>
<text top="677" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9357454">9357454 </a></text>
<text top="695" left="95" width="3" height="17" font="0"> </text>
<text top="626" left="200" width="117" height="17" font="2"><b>Aim:</b> 2 y follow-up of </text>
<text top="643" left="200" width="70" height="17" font="0">above study </text>
<text top="660" left="200" width="3" height="17" font="0"> </text>
<text top="677" left="200" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="695" left="200" width="3" height="17" font="0"> </text>
<text top="712" left="200" width="104" height="17" font="2"><b>Size:</b> n=62 pts (30 </text>
<text top="729" left="200" width="113" height="17" font="0">PTA+Meds, 32 Med </text>
<text top="746" left="200" width="107" height="17" font="0">Tx ) 47 femoral; 15 </text>
<text top="763" left="200" width="25" height="17" font="0">iliac </text>
<text top="626" left="331" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="643" left="331" width="7" height="18" font="7"></text>
<text top="644" left="338" width="75" height="17" font="0"> Unilateral IC </text>
<text top="661" left="331" width="7" height="18" font="7"></text>
<text top="662" left="338" width="89" height="17" font="0"> Short stenoses </text>
<text top="680" left="331" width="3" height="17" font="0"> </text>
<text top="697" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="714" left="331" width="7" height="18" font="7"></text>
<text top="715" left="338" width="135" height="17" font="0"> Previous angioplasty or </text>
<text top="733" left="331" width="155" height="17" font="0">arterial surgery to the sx leg </text>
<text top="750" left="331" width="7" height="18" font="7"></text>
<text top="751" left="338" width="86" height="17" font="0"> MI within 6 mo </text>
<text top="768" left="331" width="7" height="18" font="7"></text>
<text top="769" left="338" width="85" height="17" font="0"> Pts taking oral </text>
<text top="626" left="513" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="643" left="513" width="121" height="17" font="0">PTA+medical therapy </text>
<text top="660" left="513" width="3" height="17" font="0"> </text>
<text top="677" left="513" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="695" left="513" width="94" height="17" font="0">Medical therapy  </text>
<text top="712" left="513" width="50" height="17" font="0">(Medical </text>
<text top="729" left="513" width="119" height="17" font="0">therapy=ASA+advise </text>
<text top="746" left="513" width="90" height="17" font="0">on smoking and </text>
<text top="763" left="513" width="53" height="17" font="0">exercise)<b> </b></text>
<text top="627" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="626" left="655" width="6" height="18" font="7"></text>
<text top="627" left="661" width="139" height="17" font="2"><b> endpoint:</b> Max treadmill </text>
<text top="644" left="648" width="156" height="17" font="0">time to onset of claudication </text>
<text top="661" left="648" width="86" height="17" font="0">at 2 y follow-up </text>
<text top="679" left="648" width="3" height="17" font="0"> </text>
<text top="696" left="648" width="127" height="17" font="2"><b>Safety endpoint:</b> Non-</text>
<text top="713" left="648" width="49" height="17" font="0">reported </text>
<text top="626" left="817" width="7" height="18" font="7"></text>
<text top="627" left="824" width="277" height="17" font="0"> No difference in pt reported MWD, treadmill onset </text>
<text top="644" left="817" width="268" height="17" font="0">to claudication, treadmill MWD, or ABPI (p&gt;0.05) </text>
<text top="661" left="817" width="7" height="18" font="7"></text>
<text top="662" left="824" width="149" height="17" font="0"> No difference in NHP QoL </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">109 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="83" height="17" font="0">anticoagulants </text>
<text top="104" left="331" width="7" height="18" font="7"></text>
<text top="105" left="338" width="144" height="17" font="0"> Duration of symptoms &lt;1 </text>
<text top="123" left="331" width="21" height="17" font="0">mo </text>
<text top="140" left="331" width="7" height="18" font="7"></text>
<text top="141" left="338" width="131" height="17" font="0"> Inability to manage the </text>
<text top="158" left="331" width="120" height="17" font="0">treadmill examination </text>
<text top="176" left="331" width="7" height="18" font="7"></text>
<text top="177" left="338" width="141" height="17" font="0"> Any psychiatric illness or </text>
<text top="194" left="331" width="168" height="17" font="0">other reason making follow-up </text>
<text top="211" left="331" width="42" height="17" font="0">difficult </text>
<text top="229" left="95" width="85" height="17" font="0">Perkins, JM, et </text>
<text top="246" left="95" width="16" height="17" font="0">al.<b> </b></text>
<text top="264" left="95" width="59" height="17" font="0">2011(245) </text>
<text top="281" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21855020">21855020 </a></text>
<text top="298" left="95" width="3" height="17" font="0"> </text>
<text top="229" left="200" width="108" height="17" font="2"><b>Aim:</b> Compare ABI </text>
<text top="246" left="200" width="71" height="17" font="0">and Walking </text>
<text top="264" left="200" width="111" height="17" font="0">distance in PAD pts </text>
<text top="281" left="200" width="113" height="17" font="0">treated with PTA vs. </text>
<text top="298" left="200" width="93" height="17" font="0">exercise training </text>
<text top="315" left="200" width="3" height="17" font="0"> </text>
<text top="332" left="200" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="350" left="200" width="3" height="17" font="0"> </text>
<text top="367" left="200" width="83" height="17" font="2"><b>Size:</b> n=56 pts </text>
<text top="229" left="331" width="161" height="17" font="2"><b>Inclusion criteria:</b> Unilateral </text>
<text top="246" left="331" width="135" height="17" font="0">claudication lesion(s) on </text>
<text top="264" left="331" width="135" height="17" font="0">angiography suitable for </text>
<text top="281" left="331" width="144" height="17" font="0">angioplasty, as agreed by </text>
<text top="298" left="331" width="144" height="17" font="0">surgeons and radiologists </text>
<text top="315" left="331" width="3" height="17" font="0"> </text>
<text top="332" left="331" width="133" height="17" font="2"><b>Exclusion criteria:</b> Not </text>
<text top="350" left="331" width="101" height="17" font="0">specified in article </text>
<text top="229" left="513" width="105" height="17" font="2"><b>Intervention:</b> PTA </text>
<text top="246" left="513" width="3" height="17" font="0"> </text>
<text top="264" left="513" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="281" left="513" width="94" height="17" font="0">Exercise training </text>
<text top="298" left="513" width="118" height="17" font="0">(Supervised exercise </text>
<text top="315" left="513" width="118" height="17" font="0">classes 2x/wk for the </text>
<text top="332" left="513" width="113" height="17" font="0">first 6 mo. After this, </text>
<text top="350" left="513" width="90" height="17" font="0">attendance was </text>
<text top="367" left="513" width="118" height="17" font="0">required on a regular </text>
<text top="384" left="513" width="103" height="17" font="0">basis according to </text>
<text top="401" left="513" width="98" height="17" font="0">the pt’s progress. </text>
<text top="418" left="513" width="116" height="17" font="0">Each class lasted 30 </text>
<text top="436" left="513" width="98" height="17" font="0">min. Dynamic leg </text>
<text top="453" left="513" width="85" height="17" font="0">exercises were </text>
<text top="470" left="513" width="109" height="17" font="0">performed, with the </text>
<text top="487" left="513" width="111" height="17" font="0">intensity of exercise </text>
<text top="504" left="513" width="119" height="17" font="0">increasing as the pt’s </text>
<text top="522" left="513" width="103" height="17" font="0">exercise tolerance </text>
<text top="539" left="513" width="109" height="17" font="0">improved. Pts were </text>
<text top="556" left="513" width="108" height="17" font="0">also encouraged to </text>
<text top="573" left="513" width="100" height="17" font="0">perform the same </text>
<text top="591" left="513" width="120" height="17" font="0">exercises at home on </text>
<text top="608" left="513" width="92" height="17" font="0">a regular basis)<b> </b> </text>
<text top="230" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="229" left="655" width="6" height="18" font="7"></text>
<text top="230" left="661" width="135" height="17" font="2"><b> endpoint:</b> Better ABI in </text>
<text top="248" left="648" width="134" height="17" font="0">PTA group at 15 mo; no </text>
<text top="265" left="648" width="146" height="17" font="0">difference in ABI, distance </text>
<text top="282" left="648" width="155" height="17" font="0">to claudication or MWD at 6 </text>
<text top="299" left="648" width="62" height="17" font="0">y follow-up </text>
<text top="229" left="817" width="7" height="18" font="7"></text>
<text top="230" left="824" width="70" height="17" font="0"> Small study </text>
<text top="248" left="817" width="7" height="18" font="7"></text>
<text top="249" left="824" width="266" height="17" font="0"> No difference in endpoints at 6 y follow-up (only </text>
<text top="266" left="817" width="119" height="17" font="0">37 pts followed to 6 y </text>
<text top="283" left="817" width="7" height="18" font="7"></text>
<text top="284" left="824" width="177" height="17" font="0"> PTA only (no stents or med Tx) </text>
<text top="626" left="95" width="91" height="17" font="0">Spronk S, et al.  </text>
<text top="643" left="95" width="59" height="17" font="0">2009(246) </text>
<text top="660" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19188327">19188327 </a></text>
<text top="677" left="95" width="3" height="17" font="0"> </text>
<text top="626" left="200" width="100" height="17" font="2"><b>Aim:</b> To compare </text>
<text top="643" left="200" width="91" height="17" font="0">clinical success, </text>
<text top="660" left="200" width="108" height="17" font="0">functional capacity, </text>
<text top="677" left="200" width="105" height="17" font="0">and QoL during 12 </text>
<text top="695" left="200" width="49" height="17" font="0">mo after </text>
<text top="712" left="200" width="110" height="17" font="0">revascularization or </text>
<text top="729" left="200" width="112" height="17" font="0">supervised exercise </text>
<text top="746" left="200" width="118" height="17" font="0">training in pts with IC </text>
<text top="763" left="200" width="3" height="17" font="0"> </text>
<text top="626" left="331" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="643" left="331" width="7" height="18" font="7"></text>
<text top="644" left="338" width="19" height="17" font="0"> IC </text>
<text top="661" left="331" width="7" height="18" font="7"></text>
<text top="662" left="338" width="118" height="17" font="0"> Max PFWD &lt;350 m  </text>
<text top="680" left="331" width="7" height="18" font="7"></text>
<text top="681" left="338" width="54" height="17" font="0"> ABI &lt;0.9 </text>
<text top="698" left="331" width="3" height="17" font="0"> </text>
<text top="715" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="733" left="331" width="7" height="18" font="7"></text>
<text top="734" left="338" width="31" height="17" font="0"> AAA </text>
<text top="751" left="331" width="7" height="18" font="7"></text>
<text top="752" left="338" width="148" height="17" font="0"> Life incapacitating cardiac </text>
<text top="769" left="331" width="145" height="17" font="0">disease (≥NYHA class III) </text>
<text top="626" left="513" width="105" height="17" font="2"><b>Intervention:</b> PTA </text>
<text top="643" left="513" width="118" height="17" font="0">with provisional stent </text>
<text top="660" left="513" width="7" height="17" font="0">  </text>
<text top="677" left="513" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="695" left="513" width="85" height="17" font="0">Hospital based </text>
<text top="712" left="513" width="112" height="17" font="0">supervised exercise </text>
<text top="729" left="513" width="44" height="17" font="0">training<b> </b></text>
<text top="627" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="626" left="655" width="6" height="18" font="7"></text>
<text top="627" left="661" width="138" height="17" font="2"><b> endpoint:</b> Improvement </text>
<text top="644" left="648" width="149" height="17" font="0">in one Rutherford category </text>
<text top="661" left="648" width="3" height="17" font="0"> </text>
<text top="679" left="648" width="100" height="17" font="2"><b>Safety endpoint:</b> </text>
<text top="696" left="648" width="152" height="17" font="0">Functional capacity defined </text>
<text top="713" left="648" width="144" height="17" font="0">in terms of ABI, maximum </text>
<text top="730" left="648" width="153" height="17" font="0">PFD, and MWD SF-36 QoL<b> </b></text>
<text top="626" left="817" width="7" height="18" font="7"></text>
<text top="627" left="824" width="126" height="17" font="0"> At 1 wk endo superior </text>
<text top="644" left="817" width="7" height="18" font="7"></text>
<text top="645" left="824" width="133" height="17" font="0"> By 12 mo no difference </text>
<text top="663" left="817" width="7" height="18" font="7"></text>
<text top="664" left="824" width="272" height="17" font="0"> 2010 correction of statistical methods—better for </text>
<text top="681" left="817" width="240" height="17" font="0">exercise group—still no difference at 12 mo </text>
<text top="698" left="817" width="3" height="17" font="0"> </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">110 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="104" left="200" width="3" height="17" font="0"> </text>
<text top="122" left="200" width="97" height="17" font="2"><b>Size:</b> n=76 endo; </text>
<text top="139" left="200" width="114" height="17" font="0">n=75 hospital based </text>
<text top="156" left="200" width="112" height="17" font="0">supervised exercise </text>
<text top="87" left="331" width="7" height="18" font="7"></text>
<text top="88" left="338" width="131" height="17" font="0"> Multilevel disease (i.e., </text>
<text top="106" left="331" width="154" height="17" font="0">same-side stenoses at both </text>
<text top="123" left="331" width="152" height="17" font="0">the iliac and femoral levels, </text>
<text top="140" left="331" width="97" height="17" font="0">requiring multiple </text>
<text top="157" left="331" width="165" height="17" font="0">revascularization procedures) </text>
<text top="174" left="331" width="7" height="18" font="7"></text>
<text top="175" left="338" width="159" height="17" font="0"> Isolated tibial artery disease </text>
<text top="193" left="331" width="7" height="18" font="7"></text>
<text top="194" left="338" width="157" height="17" font="0"> Lesions deemed unsuitable </text>
<text top="211" left="331" width="156" height="17" font="0">for revascularization (iliac or </text>
<text top="228" left="331" width="163" height="17" font="0">femoropopliteal TASC type D </text>
<text top="246" left="331" width="132" height="17" font="0">and some TASC type B </text>
<text top="263" left="331" width="152" height="17" font="0">and/or C lesions, such as a </text>
<text top="280" left="331" width="125" height="17" font="0">unilateral external iliac </text>
<text top="297" left="331" width="148" height="17" font="0">occlusion that involved the </text>
<text top="314" left="331" width="142" height="17" font="0">origins of the internal iliac </text>
<text top="332" left="331" width="168" height="17" font="0">and/or common femoral artery </text>
<text top="349" left="331" width="155" height="17" font="0">or single or multiple femoral </text>
<text top="366" left="331" width="124" height="17" font="0">popliteal lesions in the </text>
<text top="383" left="331" width="155" height="17" font="0">absence of continuous tibial </text>
<text top="401" left="331" width="168" height="17" font="0">vessels to improve inflow for a </text>
<text top="418" left="331" width="137" height="17" font="0">distal bypass procedure) </text>
<text top="435" left="331" width="7" height="18" font="7"></text>
<text top="436" left="338" width="162" height="17" font="0"> Prior treatment for the lesion </text>
<text top="453" left="331" width="153" height="17" font="0">(including exercise training) </text>
<text top="471" left="95" width="88" height="17" font="0">Spronk S, et al. </text>
<text top="488" left="95" width="59" height="17" font="0">2008(247)<b> </b></text>
<text top="506" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18771879">18771879 </a></text>
<text top="523" left="95" width="3" height="17" font="0"> </text>
<text top="471" left="200" width="60" height="17" font="2"><b>Aim:</b> Cost-</text>
<text top="488" left="200" width="75" height="17" font="0">effectiveness </text>
<text top="506" left="200" width="98" height="17" font="0">analysis of above </text>
<text top="523" left="200" width="33" height="17" font="0">study </text>
<text top="540" left="200" width="3" height="17" font="0"> </text>
<text top="557" left="200" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="575" left="200" width="3" height="17" font="0"> </text>
<text top="592" left="200" width="97" height="17" font="2"><b>Size:</b> n=76 endo; </text>
<text top="609" left="200" width="114" height="17" font="0">n=75 hospital based </text>
<text top="626" left="200" width="112" height="17" font="0">supervised exercise </text>
<text top="471" left="331" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="489" left="331" width="7" height="18" font="7"></text>
<text top="490" left="338" width="19" height="17" font="0"> IC </text>
<text top="507" left="331" width="7" height="18" font="7"></text>
<text top="508" left="338" width="114" height="17" font="0"> Max PFWD &lt;350 m </text>
<text top="525" left="331" width="7" height="18" font="7"></text>
<text top="526" left="338" width="54" height="17" font="0"> ABI &lt;0.9 </text>
<text top="544" left="331" width="3" height="17" font="0"> </text>
<text top="561" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="578" left="331" width="7" height="18" font="7"></text>
<text top="579" left="338" width="31" height="17" font="0"> AAA </text>
<text top="596" left="331" width="7" height="18" font="7"></text>
<text top="597" left="338" width="148" height="17" font="0"> Life incapacitating cardiac </text>
<text top="615" left="331" width="145" height="17" font="0">disease (≥NYHA class III) </text>
<text top="632" left="331" width="7" height="18" font="7"></text>
<text top="633" left="338" width="131" height="17" font="0"> Multilevel disease (i.e., </text>
<text top="650" left="331" width="154" height="17" font="0">same-side stenoses at both </text>
<text top="668" left="331" width="152" height="17" font="0">the iliac and femoral levels, </text>
<text top="685" left="331" width="97" height="17" font="0">requiring multiple </text>
<text top="702" left="331" width="165" height="17" font="0">revascularization procedures) </text>
<text top="719" left="331" width="7" height="18" font="7"></text>
<text top="720" left="338" width="159" height="17" font="0"> Isolated tibial artery disease </text>
<text top="738" left="331" width="7" height="18" font="7"></text>
<text top="739" left="338" width="157" height="17" font="0"> Lesions deemed unsuitable </text>
<text top="756" left="331" width="156" height="17" font="0">for revascularization (iliac or </text>
<text top="773" left="331" width="163" height="17" font="0">femoropopliteal TASC type D </text>
<text top="471" left="513" width="105" height="17" font="2"><b>Intervention:</b> PTA </text>
<text top="488" left="513" width="118" height="17" font="0">with provisional stent </text>
<text top="506" left="513" width="7" height="17" font="0">  </text>
<text top="523" left="513" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="540" left="513" width="85" height="17" font="0">Hospital based </text>
<text top="557" left="513" width="112" height="17" font="0">supervised exercise </text>
<text top="575" left="513" width="44" height="17" font="0">training<b> </b></text>
<text top="472" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="471" left="655" width="6" height="18" font="7"></text>
<text top="472" left="661" width="97" height="17" font="2"><b> endpoint:</b> Mean </text>
<text top="490" left="648" width="126" height="17" font="0">improvement of health-</text>
<text top="507" left="648" width="148" height="17" font="0">related QoL and functional </text>
<text top="524" left="648" width="124" height="17" font="0">capacity over a 12 mo </text>
<text top="541" left="648" width="141" height="17" font="0">period, cumulative 12 mo </text>
<text top="558" left="648" width="126" height="17" font="0">costs, and incremental </text>
<text top="576" left="648" width="90" height="17" font="0">costs per QALY </text>
<text top="593" left="648" width="3" height="17" font="0"> </text>
<text top="610" left="648" width="123" height="17" font="2"><b>Safety endpoint:</b> Not </text>
<text top="627" left="648" width="49" height="17" font="0">reported </text>
<text top="471" left="817" width="7" height="18" font="7"></text>
<text top="472" left="824" width="258" height="17" font="0"> Endo costs more than exercise program when </text>
<text top="490" left="817" width="250" height="17" font="0">adjusted for QALY however this study had no </text>
<text top="507" left="817" width="185" height="17" font="0">difference between QoL at 12 mo </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">111 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="331" width="132" height="17" font="0">and some TASC type B </text>
<text top="104" left="331" width="152" height="17" font="0">and/or C lesions, such as a </text>
<text top="122" left="331" width="125" height="17" font="0">unilateral external iliac </text>
<text top="139" left="331" width="148" height="17" font="0">occlusion that involved the </text>
<text top="156" left="331" width="142" height="17" font="0">origins of the internal iliac </text>
<text top="173" left="331" width="168" height="17" font="0">and/or common femoral artery </text>
<text top="190" left="331" width="155" height="17" font="0">or single or multiple femoral </text>
<text top="208" left="331" width="124" height="17" font="0">popliteal lesions in the </text>
<text top="225" left="331" width="155" height="17" font="0">absence of continuous tibial </text>
<text top="242" left="331" width="168" height="17" font="0">vessels to improve inflow for a </text>
<text top="259" left="331" width="137" height="17" font="0">distal bypass procedure) </text>
<text top="277" left="331" width="7" height="18" font="7"></text>
<text top="278" left="338" width="162" height="17" font="0"> Prior treatment for the lesion </text>
<text top="295" left="331" width="153" height="17" font="0">(including exercise training) </text>
<text top="313" left="95" width="79" height="17" font="0">Gelin J, et al.  </text>
<text top="330" left="95" width="59" height="17" font="0">2001(248) </text>
<text top="347" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11472042">11472042 </a></text>
<text top="365" left="95" width="3" height="17" font="0"> </text>
<text top="313" left="200" width="98" height="17" font="2"><b>Aim: </b>Invasive vs. </text>
<text top="330" left="200" width="112" height="17" font="0">supervised exercise </text>
<text top="347" left="200" width="60" height="17" font="0">vs. control </text>
<text top="365" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="382" left="200" width="98" height="17" font="2"><b>Study type</b>: RCT </text>
<text top="399" left="200" width="73" height="17" font="0">single center </text>
<text top="416" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="433" left="200" width="116" height="17" font="2"><b>Size: </b>Invasive (n=87 </text>
<text top="451" left="200" width="105" height="17" font="0">pts; 17 were endo) </text>
<text top="468" left="200" width="111" height="17" font="0">vs. meds (n=89) vs. </text>
<text top="485" left="200" width="80" height="17" font="0">control (n=89)<b> </b></text>
<text top="313" left="331" width="146" height="17" font="2"><b>Inclusion criteria</b>: IC with </text>
<text top="330" left="331" width="51" height="17" font="0">ABI &lt;0.6 </text>
<text top="347" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="365" left="331" width="167" height="17" font="2"><b>Exclusion criteria:</b> Pts with a </text>
<text top="382" left="331" width="154" height="17" font="0">medical Hx contraindicating </text>
<text top="399" left="331" width="139" height="17" font="0">surgery and/or with other </text>
<text top="416" left="331" width="145" height="17" font="0">disorders severely limiting </text>
<text top="433" left="331" width="131" height="17" font="0">walking evaluation on a </text>
<text top="451" left="331" width="53" height="17" font="0">treadmill  </text>
<text top="313" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="330" left="513" width="92" height="17" font="0">Surgery or endo </text>
<text top="347" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="365" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="382" left="513" width="114" height="17" font="0">Supervised exercise </text>
<text top="399" left="513" width="106" height="17" font="0">(3 30 min sessions </text>
<text top="416" left="513" width="110" height="17" font="0">for 6 mo and then 2 </text>
<text top="433" left="513" width="95" height="17" font="0">sessions per wk) </text>
<text top="451" left="513" width="3" height="17" font="0"> </text>
<text top="468" left="513" width="109" height="17" font="2"><b>Control:</b> Advise on </text>
<text top="485" left="513" width="57" height="17" font="0">risk factor </text>
<text top="502" left="513" width="99" height="17" font="0">management and </text>
<text top="519" left="513" width="44" height="17" font="0">walking </text>
<text top="314" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="313" left="655" width="6" height="18" font="7"></text>
<text top="314" left="661" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="331" left="648" width="123" height="17" font="0">ABI (p&lt;0.01) and max </text>
<text top="348" left="648" width="126" height="17" font="0">treadmill time (p&lt;0.01) </text>
<text top="366" left="648" width="141" height="17" font="0">improved only in invasive </text>
<text top="383" left="648" width="35" height="17" font="0">group </text>
<text top="400" left="648" width="3" height="17" font="0"> </text>
<text top="417" left="648" width="119" height="17" font="2"><b>Safety endpoint: </b>No </text>
<text top="434" left="648" width="140" height="17" font="0">difference in 1 y mortality </text>
<text top="313" left="817" width="7" height="18" font="7"></text>
<text top="314" left="824" width="244" height="17" font="2"><b> </b>Only 59% of exercise pts competed training </text>
<text top="537" left="95" width="74" height="17" font="0">Taft C, et al.<b>  </b></text>
<text top="555" left="95" width="59" height="17" font="0">2001(249) </text>
<text top="572" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11472043">11472043 </a></text>
<text top="589" left="95" width="3" height="17" font="0"> </text>
<text top="537" left="200" width="105" height="17" font="2"><b>Aim: </b>QoL analysis </text>
<text top="555" left="200" width="83" height="17" font="0">of above study </text>
<text top="572" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="589" left="200" width="106" height="17" font="2"><b>Study type: </b>: RCT </text>
<text top="606" left="200" width="73" height="17" font="0">single center </text>
<text top="623" left="200" width="7" height="17" font="2"><b>  </b></text>
<text top="641" left="200" width="116" height="17" font="2"><b>Size: </b>Invasive (n=87 </text>
<text top="658" left="200" width="105" height="17" font="0">pts; 17 were endo) </text>
<text top="675" left="200" width="111" height="17" font="0">vs. Meds (n=89) vs. </text>
<text top="692" left="200" width="86" height="17" font="0">Control (n=89)<b>  </b></text>
<text top="537" left="331" width="146" height="17" font="2"><b>Inclusion criteria</b>: IC with </text>
<text top="555" left="331" width="51" height="17" font="0">ABI &lt;0.6 </text>
<text top="572" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="589" left="331" width="167" height="17" font="2"><b>Exclusion criteria:</b> Pts with a </text>
<text top="606" left="331" width="154" height="17" font="0">medical Hx contraindicating </text>
<text top="623" left="331" width="139" height="17" font="0">surgery and/or with other </text>
<text top="641" left="331" width="145" height="17" font="0">disorders severely limiting </text>
<text top="658" left="331" width="131" height="17" font="0">walking evaluation on a </text>
<text top="675" left="331" width="53" height="17" font="0">treadmill <b> </b></text>
<text top="537" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="555" left="513" width="92" height="17" font="0">Surgery or endo </text>
<text top="572" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="589" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="606" left="513" width="114" height="17" font="0">Supervised exercise </text>
<text top="623" left="513" width="106" height="17" font="0">(3 30 min sessions </text>
<text top="641" left="513" width="110" height="17" font="0">for 6 mo and then 2 </text>
<text top="658" left="513" width="95" height="17" font="0">sessions per wk) </text>
<text top="675" left="513" width="3" height="17" font="0"> </text>
<text top="692" left="513" width="109" height="17" font="2"><b>Control:</b> Advise on </text>
<text top="710" left="513" width="57" height="17" font="0">risk factor </text>
<text top="727" left="513" width="99" height="17" font="0">management and </text>
<text top="744" left="513" width="44" height="17" font="0">walking<b> </b></text>
<text top="538" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="537" left="655" width="6" height="18" font="7"></text>
<text top="538" left="661" width="111" height="17" font="2"><b> endpoint: </b>Invasive </text>
<text top="556" left="648" width="144" height="17" font="0">therapy improved disease </text>
<text top="573" left="648" width="146" height="17" font="0">specific symptoms (waling </text>
<text top="590" left="648" width="139" height="17" font="0">pain) but no difference in </text>
<text top="607" left="648" width="111" height="17" font="0">other aspect of QoL<b> </b></text>
<text top="537" left="817" width="24" height="17" font="0">N/A<b> </b></text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">112 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="45" height="17" font="2"><b>EXACT </b></text>
<text top="104" left="95" width="76" height="17" font="0">Hobbs, et al.<b>  </b></text>
<text top="122" left="95" width="59" height="17" font="0">2006(250) </text>
<text top="139" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16414385">16414385 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="116" height="17" font="2"><b>Aim: </b>Endo vs. Meds<b> </b></text>
<text top="104" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="139" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="156" left="200" width="110" height="17" font="2"><b>Size: </b>Endovascular </text>
<text top="173" left="200" width="113" height="17" font="0">revascularization+be</text>
<text top="190" left="200" width="103" height="17" font="0">st medical therapy </text>
<text top="208" left="200" width="33" height="17" font="0">(n=9) </text>
<text top="225" left="200" width="74" height="17" font="0">Best medical </text>
<text top="242" left="200" width="77" height="17" font="0">therapy (n=7) </text>
<text top="259" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="87" left="331" width="155" height="17" font="2"><b>Inclusion criteria: </b>PAD pts </text>
<text top="104" left="331" width="41" height="17" font="0">with IC </text>
<text top="122" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="139" left="331" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="104" left="513" width="65" height="17" font="0">PTA+meds </text>
<text top="122" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="139" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="156" left="513" width="92" height="17" font="0">Optimal medical </text>
<text top="173" left="513" width="44" height="17" font="0">therapy<b> </b></text>
<text top="88" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="655" width="6" height="18" font="7"></text>
<text top="88" left="661" width="136" height="17" font="2"><b> endpoint: </b>At 6 mo PTA </text>
<text top="106" left="648" width="116" height="17" font="0">group has better ABI </text>
<text top="123" left="648" width="115" height="17" font="0">(p=0.013) and MWD </text>
<text top="140" left="648" width="56" height="17" font="0">(p=0.008) </text>
<text top="87" left="817" width="24" height="17" font="0">N/A<b> </b></text>
<text top="277" left="95" width="57" height="17" font="2"><b>CLEVER  </b></text>
<text top="294" left="95" width="81" height="17" font="0">Murphy TP, et </text>
<text top="312" left="95" width="20" height="17" font="0">al.<b>  </b></text>
<text top="329" left="95" width="59" height="17" font="0">2012(187) </text>
<text top="346" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22090168">22090168 </a></text>
<text top="363" left="95" width="3" height="17" font="0"> </text>
<text top="277" left="200" width="96" height="17" font="2"><b>Aim: </b>Supervised </text>
<text top="294" left="200" width="118" height="17" font="0">exercise vs. stent vs. </text>
<text top="312" left="200" width="34" height="17" font="0">meds </text>
<text top="329" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="346" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="363" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="381" left="200" width="105" height="17" font="2"><b>Size: </b>Meds (n=22) </text>
<text top="398" left="200" width="97" height="17" font="0">vs. SE (n=42) vs. </text>
<text top="415" left="200" width="71" height="17" font="0">stent (N=46)<b> </b></text>
<text top="277" left="331" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="295" left="331" width="7" height="18" font="7"></text>
<text top="296" left="338" width="160" height="17" font="2"><b> </b>Severe IC (defined as ability </text>
<text top="313" left="331" width="156" height="17" font="0">to walk ≥2 but &lt;11 min on a </text>
<text top="330" left="331" width="168" height="17" font="0">graded treadmill test using the </text>
<text top="347" left="331" width="103" height="17" font="0">Gardner protocol)  </text>
<text top="365" left="331" width="7" height="18" font="7"></text>
<text top="366" left="338" width="135" height="17" font="0"> Objective evidence of a </text>
<text top="383" left="331" width="157" height="17" font="0">hemodynamically significant </text>
<text top="400" left="331" width="142" height="17" font="0">aortoiliac arterial stenosis </text>
<text top="417" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="434" left="331" width="147" height="17" font="2"><b>Exclusion criteria:</b> CLI or </text>
<text top="452" left="331" width="137" height="17" font="0">comorbid conditions that </text>
<text top="469" left="331" width="118" height="17" font="0">limited walking ability </text>
<text top="277" left="513" width="77" height="17" font="2"><b>Intervention</b>: </text>
<text top="294" left="513" width="114" height="17" font="0">Supervised exercise<b> </b></text>
<text top="312" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="329" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="346" left="513" width="113" height="17" font="0">Stenting vs. medical </text>
<text top="363" left="513" width="81" height="17" font="0">therapy alone<b>  </b></text>
<text top="278" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="277" left="655" width="6" height="18" font="7"></text>
<text top="278" left="661" width="122" height="17" font="2"><b> endpoint: </b>Change in<b> </b></text>
<text top="296" left="648" width="142" height="17" font="0">peak walking time a 6 mo </text>
<text top="313" left="648" width="121" height="17" font="0">compared to baseline </text>
<text top="330" left="648" width="136" height="17" font="0">(meds 1.2±2.6 mins, SE </text>
<text top="347" left="648" width="152" height="17" font="0">5.8±4.6, ST 3.7±4.9) meds </text>
<text top="365" left="648" width="87" height="17" font="0">vs. SE p&lt;0.001 </text>
<text top="382" left="648" width="106" height="17" font="0">SE vs. ST p=0.022 </text>
<text top="399" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="277" left="817" width="7" height="18" font="7"></text>
<text top="278" left="824" width="253" height="17" font="2"><b> </b>Both SE and ST experienced improvement in </text>
<text top="296" left="817" width="279" height="17" font="0">QoL; peak walking time increase was larger for SE<b> </b></text>
<text top="487" left="95" width="92" height="17" font="2"><b>CLEVER 18 mo </b></text>
<text top="504" left="95" width="23" height="17" font="2"><b>F/U </b></text>
<text top="521" left="95" width="81" height="17" font="0">Murphy TP, et </text>
<text top="539" left="95" width="16" height="17" font="0">al. </text>
<text top="556" left="95" width="59" height="17" font="0">2015(186) </text>
<text top="573" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25766947">25766947 </a></text>
<text top="590" left="95" width="3" height="17" font="0"> </text>
<text top="487" left="200" width="96" height="17" font="2"><b>Aim: </b>Supervised </text>
<text top="504" left="200" width="118" height="17" font="0">exercise vs. stent vs. </text>
<text top="521" left="200" width="34" height="17" font="0">meds </text>
<text top="539" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="556" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT<b> </b></text>
<text top="573" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="590" left="200" width="105" height="17" font="2"><b>Size: </b>Meds (n=22) </text>
<text top="607" left="200" width="97" height="17" font="0">vs. SE (n=42) vs. </text>
<text top="625" left="200" width="69" height="17" font="0">stent (n=46)<b> </b></text>
<text top="487" left="331" width="164" height="17" font="2"><b>Inclusion criteria: </b>Severe IC </text>
<text top="504" left="331" width="159" height="17" font="0">(defined as ability to walk ≥2 </text>
<text top="521" left="331" width="137" height="17" font="0">but &lt;11 min on a graded </text>
<text top="539" left="331" width="127" height="17" font="0">treadmill test using the </text>
<text top="556" left="331" width="124" height="17" font="0">Gardner protocol) and </text>
<text top="573" left="331" width="128" height="17" font="0">objective evidence of a </text>
<text top="590" left="331" width="157" height="17" font="0">hemodynamically significant </text>
<text top="607" left="331" width="142" height="17" font="0">aortoiliac arterial stenosis </text>
<text top="625" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="642" left="331" width="147" height="17" font="2"><b>Exclusion criteria: </b>CLI or </text>
<text top="659" left="331" width="137" height="17" font="0">comorbid conditions that </text>
<text top="676" left="331" width="118" height="17" font="0">limited walking ability<b> </b></text>
<text top="487" left="513" width="77" height="17" font="2"><b>Intervention</b>: </text>
<text top="504" left="513" width="114" height="17" font="0">Supervised exercise<b> </b></text>
<text top="521" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="539" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="556" left="513" width="113" height="17" font="0">Stenting vs. Medical </text>
<text top="573" left="513" width="78" height="17" font="0">therapy alone </text>
<text top="488" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="487" left="655" width="6" height="18" font="7"></text>
<text top="488" left="661" width="122" height="17" font="2"><b> endpoint: </b>Change in </text>
<text top="505" left="648" width="152" height="17" font="0">peak walking time at 18 mo </text>
<text top="522" left="648" width="121" height="17" font="0">compared to baseline </text>
<text top="540" left="648" width="136" height="17" font="0">(meds 0.2±2.1mins, SE <b> </b></text>
<text top="557" left="648" width="142" height="17" font="0">5.0±5.4 min, ST 3.7±4.7) </text>
<text top="574" left="648" width="121" height="17" font="0">meds vs. SE p&lt;0.001 </text>
<text top="591" left="648" width="113" height="17" font="0">meds vs. ST p=0.04 </text>
<text top="609" left="648" width="99" height="17" font="0">SE vs. ST p=0.16<b> </b></text>
<text top="487" left="817" width="24" height="17" font="0">N/A<b> </b></text>
<text top="694" left="95" width="51" height="17" font="2"><b>OBACT  </b></text>
<text top="711" left="95" width="86" height="17" font="0">Nylaende M, et </text>
<text top="729" left="95" width="20" height="17" font="0">al.  </text>
<text top="746" left="95" width="59" height="17" font="0">2007(251) </text>
<text top="763" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17055756">17055756 </a></text>
<text top="694" left="200" width="113" height="17" font="2"><b>Aim: </b>Endo vs. OMT<b> </b></text>
<text top="711" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="729" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="746" left="200" width="73" height="17" font="0">single center </text>
<text top="763" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="694" left="331" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="711" left="331" width="7" height="18" font="7"></text>
<text top="712" left="338" width="125" height="17" font="0"> PAD with disabling IC </text>
<text top="730" left="331" width="7" height="18" font="7"></text>
<text top="731" left="338" width="153" height="17" font="0"> ABI &lt;0.9 and peak walking </text>
<text top="748" left="331" width="94" height="17" font="0">distance &lt;400 m </text>
<text top="765" left="331" width="7" height="18" font="7"></text>
<text top="766" left="338" width="110" height="17" font="0"> Both Aortoiliac and </text>
<text top="694" left="513" width="105" height="17" font="2"><b>Intervention: </b>PTA </text>
<text top="711" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="729" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="746" left="513" width="90" height="17" font="0">Medical therapy<b> </b></text>
<text top="695" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="694" left="655" width="6" height="18" font="7"></text>
<text top="695" left="661" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="713" left="648" width="7" height="18" font="7"></text>
<text top="714" left="655" width="128" height="17" font="0"> PFWD, MWD at 3, 12, </text>
<text top="731" left="648" width="142" height="17" font="0">and 24 mo PFWD, MWD, </text>
<text top="748" left="648" width="144" height="17" font="0">and ABI were improved in </text>
<text top="765" left="648" width="134" height="17" font="0">PTA group compared to </text>
<text top="694" left="817" width="7" height="18" font="7"></text>
<text top="695" left="824" width="251" height="17" font="0"> On QoL questionnaires pain was less in PTA </text>
<text top="713" left="817" width="35" height="17" font="0">group </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">113 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="110" height="17" font="2"><b>Size: </b>Endovascular </text>
<text top="104" left="200" width="113" height="17" font="0">revascularization+op</text>
<text top="122" left="200" width="75" height="17" font="0">timal medical </text>
<text top="139" left="200" width="84" height="17" font="0">therapy (n=28) </text>
<text top="156" left="200" width="92" height="17" font="0">Optimal medical </text>
<text top="173" left="200" width="84" height="17" font="0">therapy (n=28) </text>
<text top="87" left="331" width="140" height="17" font="0">femoropopliteal diseased </text>
<text top="104" left="331" width="138" height="17" font="0">population was included. </text>
<text top="122" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="139" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="156" left="331" width="7" height="18" font="7"></text>
<text top="157" left="338" width="148" height="17" font="0"> Subjective PFWD &gt;400 m </text>
<text top="174" left="331" width="7" height="18" font="7"></text>
<text top="175" left="338" width="26" height="17" font="0"> CLI </text>
<text top="193" left="331" width="7" height="18" font="7"></text>
<text top="194" left="338" width="118" height="17" font="0"> Previous vascular or </text>
<text top="211" left="331" width="121" height="17" font="0">endovascular surgery </text>
<text top="228" left="331" width="7" height="18" font="7"></text>
<text top="229" left="338" width="56" height="17" font="0"> DM ulcer </text>
<text top="247" left="331" width="7" height="18" font="7"></text>
<text top="248" left="338" width="136" height="17" font="0"> Other physical disability </text>
<text top="265" left="331" width="168" height="17" font="0">abrogating organized exercise </text>
<text top="282" left="331" width="7" height="18" font="7"></text>
<text top="283" left="338" width="90" height="17" font="0"> Use of warfarin </text>
<text top="301" left="331" width="7" height="18" font="7"></text>
<text top="302" left="338" width="110" height="17" font="0"> Renal Insufficiency </text>
<text top="87" left="648" width="48" height="17" font="0">Med Tx; </text>
<text top="104" left="648" width="7" height="18" font="7"></text>
<text top="105" left="655" width="130" height="17" font="0"> 24 mo p values PFWD </text>
<text top="123" left="648" width="151" height="17" font="0">p=0.0001, MWD p=0.0009, </text>
<text top="140" left="648" width="82" height="17" font="0">ABI p=0.0013<b>  </b></text>
<text top="320" left="95" width="43" height="17" font="2"><b>MIMIC  </b></text>
<text top="337" left="95" width="68" height="17" font="0">Greenhalgh </text>
<text top="354" left="95" width="59" height="17" font="0">RM, et al.  </text>
<text top="371" left="95" width="59" height="17" font="0">2008(252) </text>
<text top="389" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19022184">19022184 </a></text>
<text top="406" left="95" width="3" height="17" font="0"> </text>
<text top="320" left="200" width="102" height="17" font="2"><b>Aim: </b>Endo vs. SE<b> </b></text>
<text top="337" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="354" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="371" left="200" width="73" height="17" font="0">single center </text>
<text top="389" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="406" left="200" width="110" height="17" font="2"><b>Size: </b>Endovascular </text>
<text top="423" left="200" width="96" height="17" font="0">revascularization </text>
<text top="440" left="200" width="118" height="17" font="0">(n=87) multiple types </text>
<text top="457" left="200" width="98" height="17" font="0">of procedures vs. </text>
<text top="475" left="200" width="114" height="17" font="0">Supervised exercise </text>
<text top="493" left="200" width="97" height="17" font="0">(n=88) Treadmill </text>
<text top="511" left="200" width="98" height="17" font="0">walking training 3 </text>
<text top="529" left="200" width="101" height="17" font="0">times per wk for 6 </text>
<text top="546" left="200" width="21" height="17" font="0">mo<b> </b></text>
<text top="320" left="331" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="337" left="331" width="7" height="18" font="7"></text>
<text top="338" left="338" width="152" height="17" font="0"> PAD pts with IC (ABI &lt;0.9) </text>
<text top="355" left="331" width="7" height="18" font="7"></text>
<text top="356" left="338" width="153" height="17" font="0"> 93 pts with femoropopliteal </text>
<text top="374" left="331" width="164" height="17" font="0">disease, 34 pts with aortoiliac </text>
<text top="391" left="331" width="46" height="17" font="0">disease </text>
<text top="408" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="425" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="443" left="331" width="7" height="18" font="7"></text>
<text top="444" left="338" width="125" height="17" font="0"> Symptoms too mild to </text>
<text top="461" left="331" width="146" height="17" font="0">consider angioplasty or so </text>
<text top="478" left="331" width="157" height="17" font="0">severe that intervention was </text>
<text top="495" left="331" width="62" height="17" font="0">mandatory </text>
<text top="513" left="331" width="7" height="18" font="7"></text>
<text top="514" left="338" width="146" height="17" font="0"> CLI (absolute Doppler BP </text>
<text top="531" left="331" width="147" height="17" font="0">&lt;50 mm hg or presence of </text>
<text top="548" left="331" width="142" height="17" font="0">ulcers or gangrene with a </text>
<text top="566" left="331" width="167" height="17" font="0">Doppler pressure &gt;50 mm hg) </text>
<text top="583" left="331" width="7" height="18" font="7"></text>
<text top="584" left="338" width="153" height="17" font="0"> Concomitant disease (e.g., </text>
<text top="601" left="331" width="152" height="17" font="0">musculoskeletal or cardiac) </text>
<text top="618" left="331" width="137" height="17" font="0">which prohibits exercise. </text>
<text top="320" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="337" left="513" width="62" height="17" font="0">PTA±stent<b> </b></text>
<text top="354" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="371" left="513" width="97" height="17" font="2"><b>Comparator: </b>SE </text>
<text top="389" left="513" width="107" height="17" font="0">once a wk for 6 mo<b> </b></text>
<text top="321" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="320" left="655" width="6" height="18" font="7"></text>
<text top="321" left="661" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="338" left="648" width="7" height="18" font="7"></text>
<text top="339" left="655" width="133" height="17" font="0"> 24 mo average walking </text>
<text top="357" left="648" width="150" height="17" font="0">time and initial claudication </text>
<text top="374" left="648" width="49" height="17" font="0">distance </text>
<text top="391" left="648" width="7" height="18" font="7"></text>
<text top="392" left="655" width="134" height="17" font="0"> Fem-pop disease AWD </text>
<text top="409" left="648" width="148" height="17" font="0">was 38% greater with PTA </text>
<text top="427" left="648" width="123" height="17" font="0">(p=0.04) and ICD was </text>
<text top="444" left="648" width="147" height="17" font="0">longer with PTA (p=0.004) </text>
<text top="461" left="648" width="7" height="18" font="7"></text>
<text top="462" left="655" width="139" height="17" font="0"> Aorto-iliac disease AWD </text>
<text top="479" left="648" width="148" height="17" font="0">was 78% greater with PTA </text>
<text top="497" left="648" width="123" height="17" font="0">(p=0.05) and ICD was </text>
<text top="514" left="648" width="136" height="17" font="0">longer with PTA(p=0.05)<b> </b></text>
<text top="320" left="817" width="24" height="17" font="0">N/A<b> </b></text>
<text top="636" left="95" width="83" height="17" font="0">Kruidenier LM, </text>
<text top="653" left="95" width="30" height="17" font="0">et al. </text>
<text top="671" left="95" width="59" height="17" font="0">2011(253) </text>
<text top="688" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21571547">21571547 </a></text>
<text top="705" left="95" width="3" height="17" font="0"> </text>
<text top="636" left="200" width="82" height="17" font="2"><b>Aim: </b>Endo vs. </text>
<text top="653" left="200" width="56" height="17" font="0">Endo+SE<b> </b></text>
<text top="671" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="688" left="200" width="98" height="17" font="2"><b>Study type</b>: RCT </text>
<text top="705" left="200" width="73" height="17" font="0">single center </text>
<text top="722" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="739" left="200" width="110" height="17" font="2"><b>Size: </b>Endovascular </text>
<text top="757" left="200" width="96" height="17" font="0">revascularization </text>
<text top="774" left="200" width="111" height="17" font="0">(n=35) Consisted of </text>
<text top="636" left="331" width="155" height="17" font="2"><b>Inclusion criteria: </b>PAD pts </text>
<text top="653" left="331" width="94" height="17" font="0">with Rutherford 1</text>
<text top="653" left="424" width="7" height="17" font="19">–</text>
<text top="653" left="431" width="10" height="17" font="0">4<b> </b></text>
<text top="671" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="688" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="705" left="331" width="7" height="18" font="7"></text>
<text top="706" left="338" width="161" height="17" font="0"> Hx of or current participation </text>
<text top="723" left="331" width="100" height="17" font="0">in a SET program </text>
<text top="741" left="331" width="7" height="18" font="7"></text>
<text top="742" left="338" width="143" height="17" font="0"> Serious cardiopulmonary </text>
<text top="759" left="331" width="144" height="17" font="0">comorbidity (NYHA III–IV) </text>
<text top="636" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="653" left="513" width="56" height="17" font="0">Endo+SE<b> </b></text>
<text top="671" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="688" left="513" width="109" height="17" font="2"><b>Comparator: </b>Endo </text>
<text top="637" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="636" left="655" width="6" height="18" font="7"></text>
<text top="637" left="661" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="655" left="648" width="7" height="18" font="7"></text>
<text top="656" left="655" width="128" height="17" font="0"> 6 mo absolute walking </text>
<text top="673" left="648" width="49" height="17" font="0">distance </text>
<text top="690" left="648" width="7" height="18" font="7"></text>
<text top="691" left="655" width="121" height="17" font="0"> Endo+SE superior to </text>
<text top="709" left="648" width="121" height="17" font="0">endo alone (p=0.011) </text>
<text top="636" left="817" width="24" height="17" font="0">N/A </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">114 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="88" left="200" width="94" height="17" font="0">iliac angioplasty </text>
<text top="107" left="200" width="107" height="17" font="0">with selective stent </text>
<text top="124" left="200" width="103" height="17" font="0">placement for iliac </text>
<text top="142" left="200" width="60" height="17" font="0">stenoses, </text>
<text top="160" left="200" width="91" height="17" font="0">angioplasty with </text>
<text top="178" left="200" width="75" height="17" font="0">primary stent </text>
<text top="195" left="200" width="105" height="17" font="0">placement for SFA </text>
<text top="212" left="200" width="70" height="17" font="0">stenoses, or </text>
<text top="229" left="200" width="105" height="17" font="0">recanalization with </text>
<text top="247" left="200" width="75" height="17" font="0">primary stent </text>
<text top="264" left="200" width="103" height="17" font="0">placement for iliac </text>
<text top="281" left="200" width="68" height="17" font="0">and femoral </text>
<text top="298" left="200" width="61" height="17" font="0">occlusions </text>
<text top="315" left="200" width="99" height="17" font="0">Vs. Endovascular </text>
<text top="333" left="200" width="113" height="17" font="0">revascularization+su</text>
<text top="350" left="200" width="99" height="17" font="0">pervised exercise </text>
<text top="367" left="200" width="39" height="17" font="0">(n=35) </text>
<text top="384" left="200" width="74" height="17" font="0">Nonspecified </text>
<text top="401" left="200" width="98" height="17" font="0">exercise program </text>
<text top="419" left="200" width="83" height="17" font="0">2x/wk for 6 mo </text>
<text top="87" left="331" width="7" height="18" font="7"></text>
<text top="88" left="338" width="147" height="17" font="0"> Other serious comorbidity </text>
<text top="106" left="331" width="150" height="17" font="0">preventing physical activity </text>
<text top="123" left="331" width="7" height="18" font="7"></text>
<text top="124" left="338" width="162" height="17" font="0"> Insufficient knowledge of the </text>
<text top="141" left="331" width="90" height="17" font="0">Dutch language </text>
<text top="158" left="331" width="7" height="18" font="7"></text>
<text top="159" left="338" width="124" height="17" font="0"> No insurance for SET </text>
<text top="177" left="331" width="7" height="18" font="7"></text>
<text top="178" left="338" width="152" height="17" font="0"> Major amputation or tissue </text>
<text top="195" left="331" width="29" height="17" font="0">loss. </text>
<text top="437" left="95" width="77" height="17" font="0">Mazari FA, et </text>
<text top="454" left="95" width="16" height="17" font="0">al. </text>
<text top="471" left="95" width="59" height="17" font="0">2012(254) </text>
<text top="488" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22021102">22021102 </a></text>
<text top="505" left="95" width="3" height="17" font="0"> </text>
<text top="437" left="200" width="102" height="17" font="2"><b>Aim: </b>Endo vs. SE </text>
<text top="454" left="200" width="75" height="17" font="0">vs. Endo+SE<b> </b></text>
<text top="471" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="488" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="505" left="200" width="73" height="17" font="0">single center </text>
<text top="523" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="540" left="200" width="110" height="17" font="2"><b>Size: </b>Endovascular </text>
<text top="557" left="200" width="96" height="17" font="0">revascularization </text>
<text top="574" left="200" width="102" height="17" font="0">(n=60), SE (n=60) </text>
<text top="592" left="200" width="78" height="17" font="0">Endovascular </text>
<text top="609" left="200" width="113" height="17" font="0">revascularization+su</text>
<text top="626" left="200" width="99" height="17" font="0">pervised exercise </text>
<text top="643" left="200" width="39" height="17" font="0">(n=58) </text>
<text top="437" left="331" width="160" height="17" font="2"><b>Inclusion criteria: </b>PAD with </text>
<text top="454" left="331" width="137" height="17" font="0">sx unilateral claudication </text>
<text top="471" left="331" width="153" height="17" font="0">suitable for angioplasty and </text>
<text top="488" left="331" width="129" height="17" font="0">femoropopliteal lesions </text>
<text top="505" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="523" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="540" left="331" width="7" height="18" font="7"></text>
<text top="541" left="338" width="96" height="17" font="0"> Critical ischemia </text>
<text top="558" left="331" width="7" height="18" font="7"></text>
<text top="559" left="338" width="134" height="17" font="0"> Incapacitating systemic </text>
<text top="577" left="331" width="46" height="17" font="0">disease </text>
<text top="594" left="331" width="7" height="18" font="7"></text>
<text top="595" left="338" width="156" height="17" font="0"> Inability to tolerate treadmill </text>
<text top="612" left="331" width="40" height="17" font="0">testing </text>
<text top="630" left="331" width="7" height="18" font="7"></text>
<text top="631" left="338" width="152" height="17" font="0"> Ischemic changes on ECG </text>
<text top="648" left="331" width="127" height="17" font="0">during treadmill testing </text>
<text top="665" left="331" width="7" height="18" font="7"></text>
<text top="666" left="338" width="144" height="17" font="0"> Ipsilateral surgery/PTA in </text>
<text top="683" left="331" width="81" height="17" font="0">previous 6 mo </text>
<text top="437" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="454" left="513" width="56" height="17" font="0">Endo+SE<b> </b></text>
<text top="471" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="488" left="513" width="109" height="17" font="2"><b>Comparator: </b>Endo </text>
<text top="505" left="513" width="106" height="17" font="0">alone vs. SE alone<b> </b></text>
<text top="523" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="540" left="513" width="78" height="17" font="0">Endovascular </text>
<text top="557" left="513" width="48" height="17" font="0">therapy: </text>
<text top="574" left="513" width="79" height="17" font="0">Percutaneous </text>
<text top="592" left="513" width="70" height="17" font="0">transluminal </text>
<text top="609" left="513" width="66" height="17" font="0">angioplasty </text>
<text top="626" left="513" width="114" height="17" font="0">Supervised exercise </text>
<text top="643" left="513" width="100" height="17" font="0">therapy: Circuit of </text>
<text top="660" left="513" width="111" height="17" font="0">exercises 3x/ wk for </text>
<text top="678" left="513" width="36" height="17" font="0">12 wk </text>
<text top="695" left="513" width="3" height="17" font="0"> </text>
<text top="712" left="513" width="120" height="17" font="0">Concomitant therapy: </text>
<text top="729" left="513" width="67" height="17" font="0">All pts were </text>
<text top="746" left="513" width="61" height="17" font="0">prescribed </text>
<text top="764" left="513" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="438" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="437" left="655" width="6" height="18" font="7"></text>
<text top="438" left="661" width="128" height="17" font="2"><b> endpoint: </b>ICD, MWD, </text>
<text top="455" left="648" width="127" height="17" font="0">repeat revascular, peri-</text>
<text top="472" left="648" width="140" height="17" font="0">procedural complications<b> </b></text>
<text top="437" left="817" width="7" height="18" font="7"></text>
<text top="438" left="824" width="251" height="17" font="2"><b> </b>No significant difference at 12 mo in ICD and </text>
<text top="455" left="817" width="75" height="17" font="0">MWD or QoL<b> </b></text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">115 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="513" width="70" height="17" font="0">(ASA and/or </text>
<text top="104" left="513" width="120" height="17" font="0">clopidogrel), received </text>
<text top="122" left="513" width="105" height="17" font="0">smoking cessation </text>
<text top="139" left="513" width="107" height="17" font="0">advice and support </text>
<text top="156" left="513" width="102" height="17" font="0">(including nicotine </text>
<text top="173" left="513" width="116" height="17" font="0">replacement therapy </text>
<text top="190" left="513" width="103" height="17" font="0">and NHS smoking </text>
<text top="208" left="513" width="112" height="17" font="0">cessation program), </text>
<text top="225" left="513" width="81" height="17" font="0">and risk factor </text>
<text top="243" left="95" width="77" height="17" font="0">Mazari FA, et </text>
<text top="260" left="95" width="16" height="17" font="0">al<b>. </b></text>
<text top="277" left="95" width="59" height="17" font="0">2010(195) </text>
<text top="294" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19762206">19762206 </a></text>
<text top="312" left="95" width="3" height="17" font="0"> </text>
<text top="243" left="200" width="107" height="17" font="2"><b>Aim: </b>3 mo data for </text>
<text top="260" left="200" width="60" height="17" font="0">above trial </text>
<text top="277" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="294" left="200" width="99" height="17" font="2"><b>Study type:</b> RCT<b> </b></text>
<text top="312" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="329" left="200" width="93" height="17" font="2"><b>Size:</b> n=178 pts <b> </b></text>
<text top="243" left="331" width="160" height="17" font="2"><b>Inclusion criteria: </b>PAD with </text>
<text top="260" left="331" width="137" height="17" font="0">sx unilateral claudication </text>
<text top="277" left="331" width="129" height="17" font="0">suitable for angioplasty </text>
<text top="294" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="312" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="329" left="331" width="7" height="18" font="7"></text>
<text top="330" left="338" width="96" height="17" font="0"> Critical ischemia </text>
<text top="347" left="331" width="7" height="18" font="7"></text>
<text top="348" left="338" width="134" height="17" font="0"> Incapacitating systemic </text>
<text top="366" left="331" width="46" height="17" font="0">disease </text>
<text top="383" left="331" width="7" height="18" font="7"></text>
<text top="384" left="338" width="156" height="17" font="0"> Inability to tolerate treadmill </text>
<text top="401" left="331" width="40" height="17" font="0">testing </text>
<text top="418" left="331" width="7" height="18" font="7"></text>
<text top="419" left="338" width="152" height="17" font="0"> Ischemic changes on ECG </text>
<text top="437" left="331" width="127" height="17" font="0">during treadmill testing </text>
<text top="454" left="331" width="7" height="18" font="7"></text>
<text top="455" left="338" width="144" height="17" font="0"> Ipsilateral surgery/PTA in </text>
<text top="472" left="331" width="81" height="17" font="0">previous 6 mo </text>
<text top="243" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="260" left="513" width="56" height="17" font="0">Endo+SE<b> </b></text>
<text top="277" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="294" left="513" width="81" height="17" font="2"><b>Comparator:  </b></text>
<text top="312" left="513" width="7" height="18" font="7"></text>
<text top="313" left="520" width="108" height="17" font="0"> Endo alone vs. SE </text>
<text top="330" left="513" width="33" height="17" font="0">alone<b> </b></text>
<text top="347" left="513" width="7" height="18" font="7"></text>
<text top="348" left="520" width="81" height="17" font="0"> Endovascular </text>
<text top="366" left="513" width="48" height="17" font="0">therapy: </text>
<text top="383" left="513" width="79" height="17" font="0">Percutaneous </text>
<text top="400" left="513" width="70" height="17" font="0">transluminal </text>
<text top="417" left="513" width="66" height="17" font="0">angioplasty </text>
<text top="434" left="513" width="114" height="17" font="0">Supervised exercise </text>
<text top="452" left="513" width="100" height="17" font="0">therapy: Circuit of </text>
<text top="469" left="513" width="120" height="17" font="0">exercises 3 times per </text>
<text top="486" left="513" width="72" height="17" font="0">wk for 12 wk </text>
<text top="503" left="513" width="7" height="18" font="7"></text>
<text top="504" left="520" width="76" height="17" font="0"> Concomitant </text>
<text top="522" left="513" width="115" height="17" font="0">therapy: All pts were </text>
<text top="539" left="513" width="61" height="17" font="0">prescribed </text>
<text top="556" left="513" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="573" left="513" width="70" height="17" font="0">(ASA and/or </text>
<text top="591" left="513" width="120" height="17" font="0">clopidogrel), received </text>
<text top="608" left="513" width="105" height="17" font="0">smoking cessation </text>
<text top="625" left="513" width="107" height="17" font="0">advice and support </text>
<text top="642" left="513" width="102" height="17" font="0">(including nicotine </text>
<text top="659" left="513" width="116" height="17" font="0">replacement therapy </text>
<text top="677" left="513" width="103" height="17" font="0">and NHS smoking </text>
<text top="694" left="513" width="112" height="17" font="0">cessation program), </text>
<text top="711" left="513" width="81" height="17" font="0">and risk factor<b> </b></text>
<text top="244" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="243" left="655" width="6" height="18" font="7"></text>
<text top="244" left="661" width="128" height="17" font="2"><b> endpoint:</b> ICD, MWD, </text>
<text top="261" left="648" width="127" height="17" font="0">repeat revascular, peri-</text>
<text top="278" left="648" width="140" height="17" font="0">procedural complications<b> </b></text>
<text top="296" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="313" left="648" width="133" height="17" font="2"><b>Safety endpoint: </b>None </text>
<text top="330" left="648" width="49" height="17" font="0">reported<b> </b></text>
<text top="347" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="243" left="817" width="279" height="17" font="0">At 3 mo PTA + SEP provided greater improvement </text>
<text top="260" left="817" width="219" height="17" font="0">in claudication than SEP or PTA alone.  </text>
<text top="277" left="817" width="157" height="17" font="0">See above for 12 mo results </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">116 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="90" height="17" font="0">Nordanstig J, et </text>
<text top="104" left="95" width="16" height="17" font="0">al.<b> </b></text>
<text top="122" left="95" width="59" height="17" font="0">2011(255) </text>
<text top="139" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21397530">21397530 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="114" height="17" font="2"><b>Aim: </b>Invasive+OMT </text>
<text top="104" left="200" width="108" height="17" font="0">vs. optimal medical </text>
<text top="122" left="200" width="13" height="17" font="0">tx </text>
<text top="139" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="156" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="173" left="200" width="64" height="17" font="0">multicenter </text>
<text top="190" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="208" left="200" width="117" height="17" font="2"><b>Size</b>: Inv (n=100) vs. </text>
<text top="225" left="200" width="74" height="17" font="0">OMT(n=101)<b> </b></text>
<text top="87" left="331" width="160" height="17" font="2"><b>Inclusion criteria: </b>IC &gt;6 mo </text>
<text top="104" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="139" left="331" width="7" height="18" font="7"></text>
<text top="140" left="338" width="64" height="17" font="0"> Age ≥85 y </text>
<text top="157" left="331" width="7" height="18" font="7"></text>
<text top="158" left="338" width="73" height="17" font="0"> Incorrect Dx </text>
<text top="176" left="331" width="7" height="18" font="7"></text>
<text top="177" left="338" width="133" height="17" font="0"> Other disorders limiting </text>
<text top="194" left="331" width="117" height="17" font="0">walking performance </text>
<text top="211" left="331" width="7" height="18" font="7"></text>
<text top="212" left="338" width="127" height="17" font="0"> Pts with ≥2 previously </text>
<text top="230" left="331" width="102" height="17" font="0">occluded vascular </text>
<text top="247" left="331" width="90" height="17" font="0">reconstructions. </text>
<text top="87" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="104" left="513" width="83" height="17" font="0">Invasive+OMT<b> </b></text>
<text top="122" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="139" left="513" width="81" height="17" font="2"><b>Comparator:  </b></text>
<text top="156" left="513" width="7" height="18" font="7"></text>
<text top="157" left="520" width="34" height="17" font="0"> OMT<b> </b></text>
<text top="174" left="513" width="7" height="18" font="7"></text>
<text top="175" left="520" width="107" height="17" font="0"> Revascularization: </text>
<text top="193" left="513" width="118" height="17" font="0">In general, aorto-iliac </text>
<text top="210" left="513" width="83" height="17" font="0">TASC A and B </text>
<text top="227" left="513" width="114" height="17" font="0">lesions were treated </text>
<text top="244" left="513" width="109" height="17" font="0">endovascularly and </text>
<text top="262" left="513" width="85" height="17" font="0">TASC C and D </text>
<text top="279" left="513" width="115" height="17" font="0">lesions with surgery. </text>
<text top="296" left="513" width="92" height="17" font="0">Femoropopliteal </text>
<text top="313" left="513" width="120" height="17" font="0">TASC A lesions were </text>
<text top="330" left="513" width="111" height="17" font="0">offered angioplasty, </text>
<text top="348" left="513" width="113" height="17" font="0">whereas TASC BeD </text>
<text top="365" left="513" width="114" height="17" font="0">lesions usually were </text>
<text top="382" left="513" width="122" height="17" font="0">treated surgically. For </text>
<text top="399" left="513" width="75" height="17" font="0">lesions in the </text>
<text top="417" left="513" width="95" height="17" font="0">common femoral </text>
<text top="434" left="513" width="38" height="17" font="0">artery, </text>
<text top="451" left="513" width="114" height="17" font="0">endarterectomy with </text>
<text top="468" left="513" width="90" height="17" font="0">or without patch </text>
<text top="485" left="513" width="91" height="17" font="0">angioplasty was </text>
<text top="503" left="513" width="33" height="17" font="0">used. </text>
<text top="520" left="513" width="7" height="18" font="7"></text>
<text top="521" left="520" width="95" height="17" font="0"> Optimal medical </text>
<text top="538" left="513" width="114" height="17" font="0">therapy: ASA 75 mg </text>
<text top="555" left="513" width="115" height="17" font="0">daily (or ticlopidine if </text>
<text top="573" left="513" width="103" height="17" font="0">contraindication to </text>
<text top="590" left="513" width="118" height="17" font="0">ASA). Smokers were </text>
<text top="607" left="513" width="111" height="17" font="0">offered participation </text>
<text top="624" left="513" width="72" height="17" font="0">in a smoking </text>
<text top="641" left="513" width="100" height="17" font="0">cessation support </text>
<text top="659" left="513" width="73" height="17" font="0">program and </text>
<text top="676" left="513" width="111" height="17" font="0">received verbal and </text>
<text top="693" left="513" width="104" height="17" font="0">written information </text>
<text top="710" left="513" width="74" height="17" font="0">with smoking </text>
<text top="728" left="513" width="98" height="17" font="0">cessation advice. </text>
<text top="745" left="513" width="105" height="17" font="0">Hypertension, DM, </text>
<text top="762" left="513" width="107" height="17" font="0">and hyperlipidemia </text>
<text top="88" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="655" width="6" height="18" font="7"></text>
<text top="88" left="661" width="117" height="17" font="2"><b> endpoint: </b>2 y Mean </text>
<text top="106" left="648" width="145" height="17" font="0">Walking Performance and </text>
<text top="123" left="648" width="27" height="17" font="0">QoL </text>
<text top="140" left="648" width="3" height="17" font="0"> </text>
<text top="157" left="648" width="146" height="17" font="0">MWP was not significantly </text>
<text top="174" left="648" width="144" height="17" font="0">(p=0.104) improved in the </text>
<text top="192" left="648" width="143" height="17" font="0">INV vs. the NON group. 2 </text>
<text top="209" left="648" width="146" height="17" font="0">SF-36 physical subscales, </text>
<text top="226" left="648" width="139" height="17" font="0">Bodily Pain (p&lt;0.01) and </text>
<text top="243" left="648" width="127" height="17" font="0">Role Physical (p&lt;0.05) </text>
<text top="260" left="648" width="152" height="17" font="0">improved significantly more </text>
<text top="278" left="648" width="128" height="17" font="0">in the INV vs. the NON </text>
<text top="295" left="648" width="125" height="17" font="0">group. There were 7% </text>
<text top="312" left="648" width="126" height="17" font="0">crossovers against the </text>
<text top="329" left="648" width="137" height="17" font="0">study protocol in the INV </text>
<text top="347" left="648" width="38" height="17" font="0">group.<b> </b></text>
<text top="87" left="817" width="24" height="17" font="0">N/A<b> </b></text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">117 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="513" width="85" height="17" font="0">were managed </text>
<text top="104" left="513" width="117" height="17" font="0">according to national </text>
<text top="122" left="513" width="62" height="17" font="0">guidelines. </text>
<text top="139" left="513" width="122" height="17" font="0">Verbal training advice </text>
<text top="156" left="513" width="118" height="17" font="0">and a written training </text>
<text top="173" left="513" width="86" height="17" font="0">program for IC. </text>
<text top="190" left="513" width="113" height="17" font="0">Instructed to walk at </text>
<text top="208" left="513" width="100" height="17" font="0">least 1 H/d and to </text>
<text top="225" left="513" width="86" height="17" font="0">walk up to their </text>
<text top="242" left="513" width="118" height="17" font="0">maximal claudication </text>
<text top="259" left="513" width="113" height="17" font="0">distance as often as </text>
<text top="276" left="513" width="86" height="17" font="0">possible and to </text>
<text top="294" left="513" width="119" height="17" font="0">perform an additional </text>
<text top="311" left="513" width="112" height="17" font="0">exercise program at </text>
<text top="328" left="513" width="110" height="17" font="0">home several times </text>
<text top="345" left="513" width="35" height="17" font="0">per d. </text>
<text top="363" left="95" width="46" height="17" font="2"><b>IRONIC </b></text>
<text top="381" left="95" width="90" height="17" font="0">Nordanstig J, et </text>
<text top="398" left="95" width="16" height="17" font="0">al. </text>
<text top="415" left="95" width="59" height="17" font="0">2014(256) </text>
<text top="432" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25095886">25095886</a></text>
<text top="432" left="149" width="7" height="17" font="2"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25095886"><b>  </b></a></text>
<text top="449" left="95" width="3" height="17" font="0"> </text>
<text top="363" left="200" width="114" height="17" font="2"><b>Aim: </b>Invasive+OMT </text>
<text top="381" left="200" width="108" height="17" font="0">vs. optimal medical </text>
<text top="398" left="200" width="13" height="17" font="0">tx </text>
<text top="415" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="432" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="449" left="200" width="81" height="17" font="0">(single center) </text>
<text top="467" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="484" left="200" width="81" height="17" font="2"><b>Size: </b>Invasive </text>
<text top="501" left="200" width="89" height="17" font="0">(n=79) vs. OMT </text>
<text top="518" left="200" width="39" height="17" font="0">(n=79)<b> </b></text>
<text top="363" left="331" width="160" height="17" font="2"><b>Inclusion criteria: </b>IC &gt;6 mo<b> </b></text>
<text top="381" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="398" left="331" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="415" left="331" width="7" height="18" font="7"></text>
<text top="416" left="338" width="118" height="17" font="0"> Very mild symptoms </text>
<text top="433" left="331" width="7" height="18" font="7"></text>
<text top="434" left="338" width="146" height="17" font="0"> Symptoms so severe that </text>
<text top="452" left="331" width="129" height="17" font="0">invasive treatment was </text>
<text top="469" left="331" width="159" height="17" font="0">considered mandatory (main </text>
<text top="486" left="331" width="161" height="17" font="0">criteria according to protocol: </text>
<text top="503" left="331" width="151" height="17" font="0">inability to work because of </text>
<text top="521" left="331" width="154" height="17" font="0">IC, subcritical ischemia with </text>
<text top="538" left="331" width="116" height="17" font="0">occasional rest pain, </text>
<text top="555" left="331" width="156" height="17" font="0">infrarenal aortic thrombosis) </text>
<text top="572" left="331" width="7" height="18" font="7"></text>
<text top="573" left="338" width="153" height="17" font="0"> Weight &gt;120 kg (maximum </text>
<text top="591" left="331" width="146" height="17" font="0">possible load on treadmill) </text>
<text top="608" left="331" width="7" height="18" font="7"></text>
<text top="609" left="338" width="113" height="17" font="0"> ≥2 previously failed </text>
<text top="626" left="331" width="105" height="17" font="0">ipsilateral vascular </text>
<text top="643" left="331" width="73" height="17" font="0">interventions </text>
<text top="363" left="513" width="110" height="17" font="2"><b>Intervention: </b>Endo </text>
<text top="381" left="513" width="106" height="17" font="0">except for TASC D </text>
<text top="398" left="513" width="3" height="17" font="0"> </text>
<text top="415" left="513" width="83" height="17" font="0">79 allocated to </text>
<text top="432" left="513" width="70" height="17" font="0">invasive Rx  </text>
<text top="449" left="513" width="67" height="17" font="0">70 received </text>
<text top="467" left="513" width="70" height="17" font="0">intervention: </text>
<text top="484" left="513" width="7" height="18" font="7"></text>
<text top="485" left="520" width="40" height="17" font="2"><b> </b>52 pts </text>
<text top="502" left="513" width="81" height="17" font="0">Endovascular  </text>
<text top="519" left="513" width="7" height="18" font="7"></text>
<text top="521" left="520" width="71" height="17" font="2"><b> </b>16 pts open </text>
<text top="538" left="513" width="48" height="17" font="0">surgery. </text>
<text top="555" left="513" width="7" height="18" font="7"></text>
<text top="556" left="520" width="74" height="17" font="2"><b> </b>2 pts hybrid  </text>
<text top="573" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="591" left="513" width="108" height="17" font="2"><b>Comparator: </b>OMT<b> </b></text>
<text top="364" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="363" left="655" width="6" height="18" font="7"></text>
<text top="364" left="661" width="99" height="17" font="2"><b> endpoint: </b>SF 36 </text>
<text top="382" left="648" width="80" height="17" font="0">(p&lt;0.001) and </text>
<text top="399" left="648" width="145" height="17" font="0">VascularuQoL (p&lt;0.01) at </text>
<text top="416" left="648" width="118" height="17" font="0">12 mo better with Inv </text>
<text top="363" left="817" width="7" height="18" font="7"></text>
<text top="364" left="824" width="267" height="17" font="2"><b> </b>Distance to onset of claudication better with Inv. </text>
<text top="382" left="817" width="256" height="17" font="0">Invasive (+124 m) vs. the noninvasive (+50 m) </text>
<text top="399" left="817" width="95" height="17" font="0">group (p=0.003)  </text>
<text top="416" left="817" width="7" height="18" font="7"></text>
<text top="417" left="824" width="248" height="17" font="2"><b> </b>No difference Inv vs. Meds for MWD change </text>
<text top="434" left="817" width="7" height="18" font="7"></text>
<text top="436" left="824" width="259" height="17" font="2"><b> </b>Invasive therapy group included 18 pts treated </text>
<text top="453" left="817" width="267" height="17" font="0">with surgical and hybrid approach to invasive Rx </text>
<text top="470" left="817" width="7" height="18" font="7"></text>
<text top="471" left="824" width="215" height="17" font="2"><b> </b>Outcomes not stratified by surgical vs. </text>
<text top="488" left="817" width="145" height="17" font="0">endovsacular procedures. </text>
<text top="506" left="817" width="7" height="18" font="7"></text>
<text top="507" left="824" width="255" height="17" font="0"> Both aortoiliac and femoropoliteal disease pts </text>
<text top="524" left="817" width="282" height="17" font="0">were enrolled. Pragmatic design to include large IC </text>
<text top="541" left="817" width="252" height="17" font="0">population independent of whether surgical or </text>
<text top="558" left="817" width="205" height="17" font="0">endovascular approach was required </text>
<text top="661" left="95" width="92" height="17" font="0">Malgor RD, et al </text>
<text top="679" left="95" width="59" height="17" font="0">2015(257) </text>
<text top="696" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25721067">25721067 </a></text>
<text top="713" left="95" width="3" height="17" font="0"> </text>
<text top="661" left="200" width="82" height="17" font="2"><b>Aim: </b>Endo vs. </text>
<text top="679" left="200" width="104" height="17" font="0">surgical vs. SE vs. </text>
<text top="696" left="200" width="34" height="17" font="0">Meds </text>
<text top="713" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="730" left="200" width="102" height="17" font="2"><b>Study type: </b>Meta-</text>
<text top="747" left="200" width="100" height="17" font="0">analysis of RCTs  </text>
<text top="765" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="661" left="331" width="155" height="17" font="2"><b>Inclusion criteria: </b>RCTs of<b> </b></text>
<text top="679" left="331" width="36" height="17" font="0">IC pts </text>
<text top="696" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="713" left="331" width="144" height="17" font="2"><b>Exclusion criteria: </b>Trials </text>
<text top="730" left="331" width="158" height="17" font="0">exclusively enrolling pts with </text>
<text top="747" left="331" width="151" height="17" font="0">CLI, defined as rest pain or </text>
<text top="765" left="331" width="61" height="17" font="0">tissue loss </text>
<text top="661" left="513" width="110" height="17" font="2"><b>Intervention: </b>Endo </text>
<text top="679" left="513" width="104" height="17" font="0">vs. surgical vs. SE </text>
<text top="696" left="513" width="53" height="17" font="0">vs. Meds </text>
<text top="662" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="661" left="655" width="6" height="18" font="7"></text>
<text top="662" left="661" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="680" left="648" width="7" height="18" font="7"></text>
<text top="681" left="655" width="85" height="17" font="0"> Open surgery, </text>
<text top="698" left="648" width="148" height="17" font="0">endovascular therapy, and </text>
<text top="715" left="648" width="124" height="17" font="0">exercise therapy were </text>
<text top="733" left="648" width="107" height="17" font="0">superior to medical </text>
<text top="750" left="648" width="136" height="17" font="0">management in terms of </text>
<text top="767" left="648" width="118" height="17" font="0">walking distance and </text>
<text top="661" left="817" width="7" height="18" font="7"></text>
<text top="662" left="824" width="198" height="17" font="0"> Minimal data on cost effectiveness. </text>
<text top="680" left="817" width="7" height="18" font="7"></text>
<text top="681" left="824" width="261" height="17" font="0"> Efficacy of surgery, endovascular and exercise </text>
<text top="698" left="817" width="282" height="17" font="0">therapy seemed to be superior to medical mgmt for </text>
<text top="715" left="817" width="216" height="17" font="0">walking distance, pain and claudication </text>
<text top="733" left="817" width="7" height="18" font="7"></text>
<text top="734" left="824" width="269" height="17" font="0"> Evidence is sparse supporting superiority of one </text>
<text top="751" left="817" width="113" height="17" font="0">of three approaches </text>
<text top="768" left="817" width="7" height="18" font="7"></text>
<text top="769" left="824" width="265" height="17" font="0"> Isolated iliac or femorpopliteal disease pts. may </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">118 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="118" height="17" font="2"><b>Size:</b> n=8 systematic </text>
<text top="104" left="200" width="115" height="17" font="0">reviews and 12 trials </text>
<text top="122" left="200" width="104" height="17" font="0">enrolling 1,548 pts </text>
<text top="87" left="648" width="68" height="17" font="0">claudication </text>
<text top="104" left="648" width="3" height="17" font="0"> </text>
<text top="122" left="648" width="52" height="17" font="2"><b>Results: </b></text>
<text top="139" left="648" width="129" height="17" font="0">RCTs for Surgery (with </text>
<text top="156" left="648" width="103" height="17" font="0">physical training):  </text>
<text top="173" left="648" width="7" height="18" font="7"></text>
<text top="174" left="655" width="135" height="17" font="0"> Max. and symptom free </text>
<text top="192" left="648" width="148" height="17" font="0">walking distance improved </text>
<text top="209" left="648" width="140" height="17" font="0">vs. Medical management </text>
<text top="226" left="648" width="131" height="17" font="0">alone or exercise alone </text>
<text top="243" left="648" width="7" height="18" font="7"></text>
<text top="244" left="655" width="144" height="17" font="0"> ABI improved vs. surgery </text>
<text top="262" left="648" width="124" height="17" font="0">alone but not exercise </text>
<text top="279" left="648" width="7" height="18" font="7"></text>
<text top="280" left="655" width="81" height="17" font="0"> Endovascular </text>
<text top="297" left="648" width="139" height="17" font="0">approaches with medical </text>
<text top="314" left="648" width="105" height="17" font="0">mgmt. or exercise: </text>
<text top="332" left="648" width="140" height="17" font="0">Combination of both may </text>
<text top="349" left="648" width="117" height="17" font="0">be a better approach </text>
<text top="366" left="648" width="7" height="18" font="7"></text>
<text top="367" left="655" width="131" height="17" font="0"> Endovascular vs. open </text>
<text top="384" left="648" width="48" height="17" font="0">surgery: </text>
<text top="402" left="648" width="7" height="18" font="7"></text>
<text top="403" left="655" width="147" height="17" font="0"> Studies generally showed </text>
<text top="420" left="648" width="97" height="17" font="0">open bypass had </text>
<text top="437" left="648" width="150" height="17" font="0">significantly longer hospital </text>
<text top="454" left="648" width="134" height="17" font="0">stay, high complications </text>
<text top="472" left="648" width="146" height="17" font="0">and a high 30-d mortality.  </text>
<text top="489" left="648" width="7" height="18" font="7"></text>
<text top="490" left="655" width="148" height="17" font="0"> Some SRs had conflicting </text>
<text top="507" left="648" width="156" height="17" font="0">info about 30-d mortality but </text>
<text top="524" left="648" width="125" height="17" font="0">patency was generally </text>
<text top="542" left="648" width="122" height="17" font="0">better in surgical arm. </text>
<text top="559" left="648" width="7" height="18" font="7"></text>
<text top="560" left="655" width="119" height="17" font="0"> Revasc with medical </text>
<text top="577" left="648" width="101" height="17" font="0">mgmt or exercise: </text>
<text top="595" left="648" width="7" height="18" font="7"></text>
<text top="596" left="655" width="145" height="17" font="0"> Invasive revasc generally </text>
<text top="613" left="648" width="146" height="17" font="0">increased leg BP and flow </text>
<text top="630" left="648" width="144" height="17" font="0">parameters, better SF 36, </text>
<text top="647" left="648" width="140" height="17" font="0">overall QoL score and IC </text>
<text top="665" left="648" width="124" height="17" font="0">distance but not MWD<b> </b></text>
<text top="682" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="699" left="648" width="123" height="17" font="2"><b>Safety endpoint: </b>Not </text>
<text top="716" left="648" width="49" height="17" font="0">reported<b> </b></text>
<text top="87" left="817" width="273" height="17" font="0">do better than combined disease according to the </text>
<text top="104" left="817" width="70" height="17" font="0">limited data.<b> </b></text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">119 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="82" height="17" font="0">Vemulapalli S, </text>
<text top="104" left="95" width="27" height="17" font="0">et al<b> </b></text>
<text top="122" left="95" width="59" height="17" font="0">2015(258) </text>
<text top="139" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25963038">25963038 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="200" width="82" height="17" font="2"><b>Aim: </b>Endo vs. </text>
<text top="104" left="200" width="114" height="17" font="0">surgical vs. exercise </text>
<text top="122" left="200" width="53" height="17" font="0">vs. Meds </text>
<text top="139" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="156" left="200" width="102" height="17" font="2"><b>Study type: </b>Meta-</text>
<text top="173" left="200" width="100" height="17" font="0">analysis of RCTs  </text>
<text top="190" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="208" left="200" width="106" height="17" font="2"><b>Size: </b>n=35 studies </text>
<text top="225" left="200" width="68" height="17" font="0">of 7,475 pts </text>
<text top="87" left="331" width="142" height="17" font="2"><b>Inclusion criteria: </b>IC pts </text>
<text top="104" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="331" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="87" left="513" width="110" height="17" font="2"><b>Intervention: </b>Endo </text>
<text top="104" left="513" width="84" height="17" font="0">vs. surgical vs. </text>
<text top="122" left="513" width="102" height="17" font="0">exercise vs. Meds </text>
<text top="139" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="156" left="513" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="173" left="513" width="96" height="17" font="0">Medication alone<b> </b></text>
<text top="88" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="655" width="6" height="18" font="7"></text>
<text top="88" left="661" width="141" height="17" font="2"><b> endpoint: </b>Only exercise </text>
<text top="106" left="648" width="130" height="17" font="0">improved MWD p=0.01 </text>
<text top="123" left="648" width="120" height="17" font="0">SF-36 improved in all </text>
<text top="140" left="648" width="146" height="17" font="0">groups compared to meds </text>
<text top="157" left="648" width="68" height="17" font="0">(usual care) </text>
<text top="174" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="192" left="648" width="123" height="17" font="2"><b>Safety endpoint: </b>Not </text>
<text top="209" left="648" width="49" height="17" font="0">reported<b> </b></text>
<text top="87" left="817" width="7" height="18" font="7"></text>
<text top="88" left="824" width="212" height="17" font="0"> Authors conclude current RCT data is </text>
<text top="106" left="817" width="265" height="17" font="0">inconclusive to determine superiority for walking </text>
<text top="123" left="817" width="176" height="17" font="0">distance or QoL for claudication </text>
<text top="243" left="95" width="80" height="17" font="0">McPhail IR, et </text>
<text top="260" left="95" width="16" height="17" font="0">al. </text>
<text top="277" left="95" width="59" height="17" font="0">2001(259) </text>
<text top="294" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11300450">11300450</a></text>
<text top="294" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11300450"> </a></text>
<text top="312" left="95" width="3" height="17" font="0"> </text>
<text top="243" left="200" width="105" height="17" font="2"><b>Aim: </b>Compare the </text>
<text top="260" left="200" width="70" height="17" font="0">standard LE </text>
<text top="277" left="200" width="107" height="17" font="0">vascular laboratory </text>
<text top="294" left="200" width="96" height="17" font="0">treatmill exercise </text>
<text top="312" left="200" width="116" height="17" font="0">with the office-based </text>
<text top="329" left="200" width="69" height="17" font="0">active pedal </text>
<text top="346" left="200" width="77" height="17" font="0">plantarflexion </text>
<text top="363" left="200" width="57" height="17" font="0">technique </text>
<text top="381" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="398" left="200" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="415" left="200" width="71" height="17" font="0">Prospective, </text>
<text top="432" left="200" width="68" height="17" font="0">randomized </text>
<text top="449" left="200" width="90" height="17" font="0">crossover study </text>
<text top="467" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="484" left="200" width="111" height="17" font="2"><b>Size: </b>n=50 pts (100 </text>
<text top="501" left="200" width="23" height="17" font="0">LE) </text>
<text top="243" left="331" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="260" left="331" width="7" height="18" font="7"></text>
<text top="261" left="338" width="134" height="17" font="0"> Known or suspected IC </text>
<text top="278" left="331" width="7" height="18" font="7"></text>
<text top="279" left="338" width="141" height="17" font="0"> Referred for LE treadmill </text>
<text top="297" left="331" width="89" height="17" font="0">exercise testing </text>
<text top="314" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="331" left="331" width="113" height="17" font="2"><b>Exclusion criteria: </b> </text>
<text top="348" left="331" width="7" height="18" font="7"></text>
<text top="349" left="338" width="151" height="17" font="0"> Ankle SBP &gt;300 mmHg or </text>
<text top="367" left="331" width="129" height="17" font="0">&gt;50 mmHg higher than </text>
<text top="384" left="331" width="110" height="17" font="0">brachial systolic BP </text>
<text top="401" left="331" width="7" height="18" font="7"></text>
<text top="402" left="338" width="153" height="17" font="0"> CLI and inability to walk on </text>
<text top="420" left="331" width="152" height="17" font="0">a treatmill or perform active </text>
<text top="437" left="331" width="110" height="17" font="0">pedal plantarflexion </text>
<text top="243" left="513" width="115" height="17" font="2"><b>Intervention: </b>Active </text>
<text top="260" left="513" width="110" height="17" font="0">pedal plantarflexion </text>
<text top="277" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="294" left="513" width="96" height="17" font="2"><b>Comparator: </b>LE </text>
<text top="312" left="513" width="99" height="17" font="0">treadmill exercise </text>
<text top="329" left="513" width="40" height="17" font="0">testing<b> </b></text>
<text top="244" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="243" left="655" width="6" height="18" font="7"></text>
<text top="244" left="661" width="133" height="17" font="2"><b> endpoint: </b>Active pedal </text>
<text top="261" left="648" width="135" height="17" font="0">plantarflexion compared </text>
<text top="278" left="648" width="128" height="17" font="0">favorably with treadmill </text>
<text top="296" left="648" width="156" height="17" font="0">exercise for the noninvasive </text>
<text top="313" left="648" width="135" height="17" font="0">objective assessment of </text>
<text top="330" left="648" width="38" height="17" font="0">PAOD </text>
<text top="347" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="365" left="648" width="123" height="17" font="2"><b>Safety endpoint: </b>Not </text>
<text top="382" left="648" width="49" height="17" font="0">reported<b> </b></text>
<text top="243" left="817" width="24" height="17" font="0">N/A </text>
<text top="519" left="95" width="80" height="17" font="0">Schulte KL, et </text>
<text top="536" left="95" width="20" height="17" font="0">al.  </text>
<text top="553" left="95" width="59" height="17" font="0">2015(260) </text>
<text top="571" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26245919">26245919</a></text>
<text top="571" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26245919"> </a></text>
<text top="519" left="200" width="85" height="17" font="2"><b>Aim: </b>Compare </text>
<text top="536" left="200" width="105" height="17" font="0">primary placement </text>
<text top="553" left="200" width="107" height="17" font="0">of a self-expanding </text>
<text top="571" left="200" width="107" height="17" font="0">nitinol stent to PTA </text>
<text top="588" left="200" width="111" height="17" font="0">with bailout stenting </text>
<text top="605" left="200" width="86" height="17" font="0">in infrapopliteal </text>
<text top="622" left="200" width="103" height="17" font="0">arteries of pts with </text>
<text top="639" left="200" width="105" height="17" font="0">severe intermittent </text>
<text top="657" left="200" width="105" height="17" font="0">claudication or CLI </text>
<text top="674" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="691" left="200" width="99" height="17" font="2"><b>Study type: </b>RCT </text>
<text top="708" left="200" width="3" height="17" font="2"><b> </b></text>
<text top="726" left="200" width="83" height="17" font="2"><b>Size: </b>n=92 pts </text>
<text top="519" left="331" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="536" left="331" width="7" height="18" font="7"></text>
<text top="537" left="338" width="145" height="17" font="0"> Pts undergoing treatment </text>
<text top="555" left="331" width="152" height="17" font="0">for infrapopliteal stenosis in </text>
<text top="572" left="331" width="118" height="17" font="0">11 European centers </text>
<text top="589" left="331" width="3" height="17" font="2"><b> </b></text>
<text top="606" left="331" width="113" height="17" font="2"><b>Exclusion criteria: </b> </text>
<text top="623" left="331" width="7" height="18" font="7"></text>
<text top="624" left="338" width="27" height="17" font="0"> N/A </text>
<text top="642" left="331" width="3" height="17" font="0"> </text>
<text top="519" left="513" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="536" left="513" width="120" height="17" font="0">Primary placement of </text>
<text top="553" left="513" width="94" height="17" font="0">a self-expanding </text>
<text top="571" left="513" width="112" height="17" font="0">nitinol stent vs. PTA </text>
<text top="588" left="513" width="115" height="17" font="0">with bailout stenting<b> </b> </text>
<text top="520" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="519" left="655" width="6" height="18" font="7"></text>
<text top="520" left="661" width="130" height="17" font="2"><b> endpoint: </b>Sustainable </text>
<text top="537" left="648" width="143" height="17" font="0">clinical improvement after </text>
<text top="555" left="648" width="120" height="17" font="0">12 mo, defined as ≥1 </text>
<text top="572" left="648" width="118" height="17" font="0">category increase for </text>
<text top="589" left="648" width="156" height="17" font="0">Rutherford category 3 pts, a </text>
<text top="606" left="648" width="137" height="17" font="0">≥2 category increase for </text>
<text top="623" left="648" width="126" height="17" font="0">CLI pts compared with </text>
<text top="641" left="648" width="56" height="17" font="0">baseline.<b>  </b></text>
<text top="658" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="675" left="648" width="130" height="17" font="2"><b>Safety endpoint: </b>TLR, </text>
<text top="692" left="648" width="142" height="17" font="0">mortality, and amputation </text>
<text top="710" left="648" width="124" height="17" font="0">assessed after 12 mo. </text>
<text top="519" left="817" width="7" height="18" font="7"></text>
<text top="520" left="824" width="275" height="17" font="0"> Sustained improvement at 1 y in 74.3% of the pts </text>
<text top="537" left="817" width="267" height="17" font="0">treated with primary stenting and in 68.6% of the </text>
<text top="555" left="817" width="281" height="17" font="0">pts treated with PTA and bailout stenting (p&gt;0.05).  </text>
<text top="572" left="817" width="7" height="18" font="7"></text>
<text top="573" left="824" width="273" height="17" font="0"> Freedom from TLR (76.6% and 77.6%), mortality </text>
<text top="590" left="817" width="252" height="17" font="0">(7.4% vs 2.1%), and amputation [8.9% (major </text>
<text top="607" left="817" width="251" height="17" font="0">6.7%) vs 13.2% (major 8.7%)] at 1 y were not </text>
<text top="625" left="817" width="118" height="17" font="0">significantly different. </text>
<text top="642" left="817" width="7" height="18" font="7"></text>
<text top="643" left="824" width="255" height="17" font="0"> Primary self-expanding nitinol stenting did not </text>
<text top="660" left="817" width="240" height="17" font="0">show statistically different clinical outcomes </text>
<text top="677" left="817" width="214" height="17" font="0">compared to PTA with bailout stenting  </text>
<text top="744" left="86" width="988" height="17" font="0">AAA indicates abdominal aortic aneurysm; ABF, aorto-bifemoral bypass; ABI, ankle-brachial index; ABPI, ankle-brachia pressure index; AFB, aortobifemoral bypass; AIOD, aortoiliac </text>
<text top="761" left="86" width="1018" height="17" font="0">occlusive disease; ALI, acute limb ischemia; ASA, American Society of Anesthesiologist; AUC, appropriate use criteria; AWD, absolute walking distance; BMS, bare metal stent; BP, blood </text>
<text top="778" left="86" width="1012" height="17" font="0">pressure; CI, confidence interval; CLI, critical limb ischemia; CTA, computed tomography angiography; DCB, drug coated balloon; DEB, drug eluting balloon; DES, drug eluting stent; DS, </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">120 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="1012" height="17" font="0">diameter stenosis; ECG, electrocardiogram; ELA, excimer laser antherectomy; HR, hazard ratio; IC, intermittent claudication; ICD, International Classification of Disease; Inv, intervention </text>
<text top="104" left="86" width="1015" height="17" font="0">group; ISR, in stent restenosis; ITT, intention to treat; JACC, Journal of American College of Cardiology; LE, lower extremity; MACE, major adverse cardiac event; MWD, maximal walking </text>
<text top="121" left="86" width="1018" height="17" font="0">distance; MWP, mean walking performance; N/A, not applicable; NEJM, New England Journal of Medicine; NHP, Nottingham Health Score; NYHA, New York Heart Association; OR, odds </text>
<text top="138" left="86" width="1014" height="17" font="0">ratio; OMT, osteopathic manipulative treatment; PAD, periphery artery disease; PEB, paclitaxel eluting balloon; PFWD, pain free walking distance; PTA, percutaneous angioplasty; PTAS, </text>
<text top="155" left="86" width="967" height="17" font="0">percutaneous angioplasty stent; PVD, peripheral vascular disease; QALY, quality adjusted life year; QoL, quality of life; RCT, randomized controlled trail; R/PTAS, recanalization, </text>
<text top="172" left="86" width="821" height="17" font="0">percutaneous transluminal angioplasty, and stenting; RR, relative risk; SE, supervised exercise; SEP, supervised exercise; SES, self-expanding stents;</text>
<text top="172" left="908" width="3" height="17" font="9"> </text>
<text top="172" left="911" width="192" height="17" font="0">SFA, superficial femoral artery, ST </text>
<text top="190" left="86" width="924" height="17" font="0">stent revascularization; TASC, transatlantic inter-society consensus; TL, target lesion; TLR, total lesion revascularization; TPP, treatment per-protocol; TVR, target vessel </text>
<text top="207" left="86" width="255" height="17" font="0">revascularization; and VIA, viabahn treatment. </text>
<text top="224" left="86" width="3" height="17" font="0"> </text>
<text top="241" left="86" width="3" height="17" font="0"> </text>
<text top="258" left="86" width="983" height="21" font="1"><b>Evidence Table 36. Nonrandomized Trials, Observational Studies, and/or Registries of Endovascular and Endovascular Versus Noninvasive </b></text>
<text top="279" left="86" width="276" height="21" font="1"><b>Treatment of Claudication–Section 8.1. </b></text>
<text top="301" left="96" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="318" left="122" width="48" height="17" font="2"><b>Author; </b></text>
<text top="335" left="99" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="301" left="225" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="318" left="251" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="301" left="410" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="301" left="593" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="318" left="600" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="335" left="652" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="301" left="891" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="318" left="918" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="353" left="95" width="101" height="17" font="0">Scheinert D, et al. </text>
<text top="370" left="95" width="63" height="17" font="0">2005 (261) </text>
<text top="387" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15653033">15653033 </a></text>
<text top="405" left="95" width="3" height="17" font="0"> </text>
<text top="353" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="370" left="209" width="122" height="17" font="0">series assessing SES </text>
<text top="387" left="209" width="101" height="17" font="0">fracture incidence </text>
<text top="405" left="209" width="3" height="17" font="0"> </text>
<text top="422" left="209" width="83" height="17" font="2"><b>Size:</b> n=93 pts </text>
<text top="353" left="371" width="159" height="17" font="2"><b>Inclusion criteria:</b> PTAS for </text>
<text top="370" left="371" width="178" height="17" font="0">claudication or chronic ischemia </text>
<text top="387" left="371" width="3" height="17" font="0"> </text>
<text top="405" left="371" width="143" height="17" font="2"><b>Exclusion criteria:</b> None </text>
<text top="422" left="371" width="49" height="17" font="0">reported </text>
<text top="354" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="353" left="581" width="6" height="18" font="7"></text>
<text top="354" left="587" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="371" left="574" width="7" height="18" font="7"></text>
<text top="372" left="581" width="136" height="17" font="0"> Stent fracture incidence </text>
<text top="390" left="574" width="7" height="18" font="7"></text>
<text top="391" left="581" width="123" height="17" font="0"> Restenosis incidence </text>
<text top="408" left="574" width="3" height="17" font="0"> </text>
<text top="425" left="574" width="206" height="17" font="2"><b>Results: </b>The primary patency rate at </text>
<text top="443" left="574" width="200" height="17" font="0">12 mo was significantly lower for pts </text>
<text top="460" left="574" width="210" height="17" font="0">with stent fractures (41.1% vs. 84.3%, </text>
<text top="477" left="574" width="63" height="17" font="0">p&lt;0.0001).<b> </b></text>
<text top="353" left="803" width="7" height="18" font="7"></text>
<text top="354" left="810" width="187" height="17" font="0"> Stent fractures predict restenosis </text>
<text top="371" left="803" width="7" height="18" font="7"></text>
<text top="372" left="810" width="279" height="17" font="0"> Overall, stent fractures were detected in 45 of 121 </text>
<text top="390" left="803" width="291" height="17" font="0">treated legs (37.2%). In a stent-based analysis, 64 of </text>
<text top="407" left="803" width="272" height="17" font="0">261 stents (24.5%) showed fractures, which were </text>
<text top="424" left="803" width="286" height="17" font="0">classified as minor (single strut fracture) in 31 cases </text>
<text top="441" left="803" width="283" height="17" font="0">(48.4%), moderate (fracture of &gt;1 strut) in 17 cases </text>
<text top="459" left="803" width="276" height="17" font="0">(26.6%), and severe (complete separation of stent </text>
<text top="476" left="803" width="286" height="17" font="0">segments) in 16 cases (25.0%). Fracture rates were </text>
<text top="493" left="803" width="278" height="17" font="0">13.2% for stented length ≤8 cm, 42.4% for stented </text>
<text top="510" left="803" width="283" height="17" font="0">length &gt;8–16 cm, and 52.0% for stented length &gt;16 </text>
<text top="527" left="803" width="276" height="17" font="0">cm. In 21 cases (32.8%) there was a restenosis of </text>
<text top="545" left="803" width="303" height="17" font="0">&gt;50% diameter reduction at the site of stent fracture. In </text>
<text top="562" left="803" width="293" height="17" font="0">22 cases (34.4%) with stent fracture there was a total </text>
<text top="579" left="803" width="247" height="17" font="0">stent reocclusion. According to Kaplan Meier </text>
<text top="596" left="803" width="272" height="17" font="0">estimates, the primary patency rate at 12 mo was </text>
<text top="613" left="803" width="286" height="17" font="0">significantly lower for pts with stent fractures (41.1% </text>
<text top="631" left="803" width="123" height="17" font="0">vs. 84.3%; p&lt;0.0001). </text>
<text top="649" left="95" width="88" height="17" font="0">Sakamoto Y, et </text>
<text top="666" left="95" width="16" height="17" font="0">al. </text>
<text top="683" left="95" width="59" height="17" font="0">2013(262) </text>
<text top="700" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23536429">23536429 </a></text>
<text top="718" left="95" width="3" height="17" font="0"> </text>
<text top="649" left="209" width="139" height="17" font="2"><b>Study type:</b> Case series </text>
<text top="666" left="209" width="142" height="17" font="0">evaluating PTAS patency </text>
<text top="683" left="209" width="75" height="17" font="0">for SFA CTO </text>
<text top="700" left="209" width="3" height="17" font="0"> </text>
<text top="718" left="209" width="90" height="17" font="2"><b>Size:</b> n=352 pts </text>
<text top="649" left="371" width="163" height="17" font="2"><b>Inclusion criteria:</b> SFA CTO </text>
<text top="666" left="371" width="101" height="17" font="0">undergoing PTAS </text>
<text top="683" left="371" width="3" height="17" font="0"> </text>
<text top="700" left="371" width="143" height="17" font="2"><b>Exclusion criteria:</b> None </text>
<text top="718" left="371" width="125" height="17" font="0">reported. Lack of CTO </text>
<text top="650" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="649" left="581" width="6" height="18" font="7"></text>
<text top="650" left="587" width="151" height="17" font="2"><b> endpoint:</b> 5 y primary and </text>
<text top="667" left="574" width="213" height="17" font="0">secondary patency rates and the rates </text>
<text top="684" left="574" width="215" height="17" font="0">of freedom from bypass surgery, major </text>
<text top="701" left="574" width="193" height="17" font="0">or minor amputation, and all-cause </text>
<text top="719" left="574" width="34" height="17" font="0">death </text>
<text top="736" left="574" width="3" height="17" font="0"> </text>
<text top="753" left="574" width="198" height="17" font="2"><b>Results: </b>Female gender (OR: 1.95; </text>
<text top="770" left="574" width="199" height="17" font="0">p=0.0051) and mean stent diameter </text>
<text top="649" left="803" width="7" height="18" font="7"></text>
<text top="650" left="810" width="193" height="17" font="0"> Stent diameter predicts restenosis </text>
<text top="667" left="803" width="7" height="18" font="7"></text>
<text top="668" left="810" width="288" height="17" font="0"> Mean age was 72±9 y and 31% were female pts. In </text>
<text top="685" left="803" width="286" height="17" font="0">total, 58% of the pts had DM and 25% were pts with </text>
<text top="703" left="803" width="278" height="17" font="0">CLI. Occluded length was 194±89 mm, mean total </text>
<text top="720" left="803" width="298" height="17" font="0">stent length was 198±7 mm, and mean stent diameter </text>
<text top="737" left="803" width="293" height="17" font="0">was 7.1±0.9 mm. 5 y primary and secondary patency </text>
<text top="754" left="803" width="281" height="17" font="0">rates were 51.8% and 79.5%, respectively, and the </text>
<text top="772" left="803" width="294" height="17" font="0">rates of freedom from bypass surgery, major or minor </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">121 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="574" width="190" height="17" font="0">(OR: 0.77; p=0.0324) were factors </text>
<text top="104" left="574" width="197" height="17" font="0">strongly associated with restenosis. </text>
<text top="87" left="803" width="292" height="17" font="0">amputation, and all-cause death were 96.1%, 96.2%, </text>
<text top="104" left="803" width="265" height="17" font="0">and 78.4%, respectively. Female sex (OR: 1.95; </text>
<text top="122" left="803" width="259" height="17" font="0">p=0.0051) and mean stent diameter (OR: 0.77; </text>
<text top="139" left="803" width="263" height="17" font="0">p=0.0324) were factors strongly associated with </text>
<text top="156" left="803" width="63" height="17" font="0">restenosis. </text>
<text top="174" left="95" width="103" height="17" font="0">Feinglass J, et al.  </text>
<text top="191" left="95" width="59" height="17" font="0">2000(263) </text>
<text top="208" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10642712">10642712 </a></text>
<text top="226" left="95" width="3" height="17" font="0"> </text>
<text top="174" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="191" left="209" width="143" height="17" font="0">Observational multicenter </text>
<text top="208" left="209" width="3" height="17" font="0"> </text>
<text top="226" left="209" width="90" height="17" font="2"><b>Size:</b> n=526 pts </text>
<text top="243" left="209" width="142" height="17" font="0">Majority received medical </text>
<text top="260" left="209" width="17" height="17" font="0">Tx </text>
<text top="277" left="209" width="105" height="17" font="0">60 surgical bypass </text>
<text top="294" left="209" width="86" height="17" font="0">grafting and 44 </text>
<text top="312" left="209" width="92" height="17" font="0">angioplasty only </text>
<text top="174" left="371" width="146" height="17" font="2"><b>Inclusion criteria:</b> IC and </text>
<text top="191" left="371" width="78" height="17" font="0">abnormal ABI </text>
<text top="208" left="371" width="3" height="17" font="0"> </text>
<text top="226" left="371" width="178" height="17" font="2"><b>Exclusion criteria:</b> Evidence of </text>
<text top="243" left="371" width="26" height="17" font="0">CLI  </text>
<text top="175" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="174" left="581" width="6" height="18" font="7"></text>
<text top="175" left="587" width="170" height="17" font="2"><b> endpoint:</b> Invasive group had </text>
<text top="192" left="574" width="204" height="17" font="0">better walking distance and less pain </text>
<text top="210" left="574" width="104" height="17" font="0">at 18 mo follow-up </text>
<text top="227" left="574" width="3" height="17" font="0"> </text>
<text top="244" left="574" width="188" height="17" font="2"><b>Results:</b> The mean ABI improved </text>
<text top="261" left="574" width="212" height="17" font="0">significantly for the pts who underwent </text>
<text top="278" left="574" width="166" height="17" font="0">bypass grafting surgery (0.20; </text>
<text top="296" left="574" width="213" height="17" font="0">p&lt;0.001) and modestly for the pts who </text>
<text top="313" left="574" width="207" height="17" font="0">underwent angioplasty (0.09; p&lt;0.05) </text>
<text top="330" left="574" width="121" height="17" font="0">compared to baseline </text>
<text top="174" left="803" width="7" height="18" font="7"></text>
<text top="175" left="810" width="292" height="17" font="0"> Study exclusion criteria were poorly described or not </text>
<text top="192" left="803" width="66" height="17" font="0">appropriate </text>
<text top="210" left="803" width="7" height="18" font="7"></text>
<text top="211" left="810" width="188" height="17" font="0"> Comparator(s) not well described </text>
<text top="228" left="803" width="7" height="18" font="7"></text>
<text top="229" left="810" width="294" height="17" font="0"> Diagnostic or therapeutic advances have been made </text>
<text top="246" left="803" width="271" height="17" font="0">in routine practice since the study was conducted </text>
<text top="348" left="95" width="95" height="17" font="0">Giuliano G, et al. </text>
<text top="365" left="95" width="63" height="17" font="0">2013 (264) </text>
<text top="382" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22790191">22790191 </a></text>
<text top="400" left="95" width="3" height="17" font="0"> </text>
<text top="348" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="365" left="209" width="117" height="17" font="0">Observational Single </text>
<text top="382" left="209" width="38" height="17" font="0">center </text>
<text top="400" left="209" width="3" height="17" font="0"> </text>
<text top="417" left="209" width="110" height="17" font="2"><b>Size:</b> Endovascular </text>
<text top="434" left="209" width="142" height="17" font="0">revascularization (n=264) </text>
<text top="451" left="209" width="121" height="17" font="0">Conservative medical </text>
<text top="468" left="209" width="91" height="17" font="0">therapy (n=215) </text>
<text top="486" left="209" width="3" height="17" font="0"> </text>
<text top="348" left="371" width="187" height="17" font="2"><b>Inclusion criteria:</b> Fontaine 2 IC, </text>
<text top="365" left="371" width="165" height="17" font="0">ABI &lt;0.9, &gt;50% stenosis in at </text>
<text top="382" left="371" width="94" height="17" font="0">least 1 leg artery </text>
<text top="400" left="371" width="3" height="17" font="0"> </text>
<text top="417" left="371" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="434" left="371" width="7" height="18" font="7"></text>
<text top="435" left="378" width="26" height="17" font="0"> CLI </text>
<text top="452" left="371" width="7" height="18" font="7"></text>
<text top="454" left="378" width="113" height="17" font="0"> Previous lower limb </text>
<text top="471" left="371" width="96" height="17" font="0">revascularization </text>
<text top="488" left="371" width="7" height="18" font="7"></text>
<text top="489" left="378" width="145" height="17" font="0"> Recent acute coronary or </text>
<text top="506" left="371" width="182" height="17" font="0">cerebrovascular ischemic events </text>
<text top="524" left="371" width="39" height="17" font="0">(6 mo) </text>
<text top="541" left="371" width="7" height="18" font="7"></text>
<text top="542" left="378" width="152" height="17" font="0"> Recent coronary or carotid </text>
<text top="559" left="371" width="175" height="17" font="0">revascularization procedures (6 </text>
<text top="576" left="371" width="25" height="17" font="0">mo) </text>
<text top="594" left="371" width="7" height="18" font="7"></text>
<text top="595" left="378" width="174" height="17" font="0"> Abnormal myocardial ischemia </text>
<text top="612" left="371" width="134" height="17" font="0">stress test at enrollment </text>
<text top="629" left="371" width="7" height="18" font="7"></text>
<text top="630" left="378" width="116" height="17" font="0"> Decompensated HF </text>
<text top="648" left="371" width="7" height="18" font="7"></text>
<text top="649" left="378" width="131" height="17" font="0"> Malignant neoplasia or </text>
<text top="666" left="371" width="153" height="17" font="0">significant hepatic, renal, or </text>
<text top="683" left="371" width="123" height="17" font="0">inflammatory disease. </text>
<text top="349" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="348" left="581" width="6" height="18" font="7"></text>
<text top="349" left="587" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="366" left="574" width="7" height="18" font="7"></text>
<text top="367" left="581" width="202" height="17" font="0"> Improved functional status at 21 mo </text>
<text top="385" left="574" width="80" height="17" font="0">in Endo group </text>
<text top="402" left="574" width="7" height="18" font="7"></text>
<text top="403" left="581" width="176" height="17" font="0"> Lower MACE (6.4% vs. 16.3%; </text>
<text top="420" left="574" width="131" height="17" font="0">p=0.003) in endo group </text>
<text top="438" left="574" width="3" height="17" font="0"> </text>
<text top="455" left="574" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="472" left="574" width="198" height="17" font="0">During a median follow-up of 21 mo </text>
<text top="489" left="574" width="159" height="17" font="0">(12.0–29.0), the incidence of </text>
<text top="506" left="574" width="201" height="17" font="0">cardiovascular events was markedly </text>
<text top="524" left="574" width="186" height="17" font="0">lower in PTA compared to MT pts </text>
<text top="541" left="574" width="149" height="17" font="0">(6.4% vs. 16.3%; p=0.003) </text>
<text top="348" left="803" width="7" height="18" font="7"></text>
<text top="349" left="810" width="180" height="17" font="0"> Comparators not well described </text>
<text top="701" left="95" width="90" height="17" font="0">Koivunen K and </text>
<text top="718" left="95" width="76" height="17" font="0">Lukkarinen H </text>
<text top="736" left="95" width="59" height="17" font="0">2008(265) </text>
<text top="753" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18221916">18221916 </a></text>
<text top="770" left="95" width="3" height="17" font="0"> </text>
<text top="701" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="719" left="209" width="119" height="17" font="0">Observational single </text>
<text top="738" left="209" width="38" height="17" font="0">center </text>
<text top="755" left="209" width="3" height="17" font="0"> </text>
<text top="772" left="209" width="110" height="17" font="2"><b>Size:</b> Endovascular </text>
<text top="701" left="371" width="174" height="17" font="2"><b>Inclusion criteria:</b> PAD and IC </text>
<text top="718" left="371" width="3" height="17" font="0"> </text>
<text top="736" left="371" width="152" height="17" font="2"><b>Exclusion criteria:</b> Pts not </text>
<text top="753" left="371" width="104" height="17" font="0">receiving endo Tx  </text>
<text top="702" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="701" left="581" width="6" height="18" font="7"></text>
<text top="702" left="587" width="168" height="17" font="2"><b> endpoint:</b> Nottingham Health </text>
<text top="720" left="574" width="74" height="17" font="0">Profile Score </text>
<text top="737" left="574" width="3" height="17" font="0"> </text>
<text top="754" left="574" width="212" height="17" font="2"><b>Results:</b> 12 mo QoL better in invasive </text>
<text top="771" left="574" width="31" height="17" font="0">arms </text>
<text top="701" left="803" width="7" height="18" font="7"></text>
<text top="702" left="810" width="174" height="17" font="0"> Comparator not well described </text>
<text top="720" left="803" width="7" height="18" font="7"></text>
<text top="721" left="810" width="264" height="17" font="0"> Study did not use a clinically relevant surrogate </text>
<text top="738" left="803" width="51" height="17" font="0">outcome </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">122 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="209" width="135" height="17" font="0">revascularization (n=85) </text>
<text top="104" left="209" width="149" height="17" font="0">Percutaneous transluminal </text>
<text top="122" left="209" width="124" height="17" font="0">angioplasty or surgery </text>
<text top="139" left="209" width="39" height="17" font="0">(n=31) </text>
<text top="156" left="209" width="68" height="17" font="0">Comparator </text>
<text top="173" left="209" width="131" height="17" font="0">Conservative treatment </text>
<text top="190" left="209" width="123" height="17" font="0">(N=64) No description </text>
<text top="208" left="209" width="51" height="17" font="0">provided </text>
<text top="87" left="574" width="3" height="17" font="0"> </text>
<text top="226" left="95" width="90" height="17" font="0">Pell JP and Lee </text>
<text top="243" left="95" width="18" height="17" font="0">AJ </text>
<text top="260" left="95" width="59" height="17" font="0">1997(266) </text>
<text top="277" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9507581">9507581 </a></text>
<text top="294" left="95" width="3" height="17" font="0"> </text>
<text top="226" left="209" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="243" left="209" width="143" height="17" font="0">Observational multicenter </text>
<text top="260" left="209" width="3" height="17" font="0"> </text>
<text top="277" left="209" width="110" height="17" font="2"><b>Size:</b> Endovascular </text>
<text top="294" left="209" width="135" height="17" font="0">revascularization (n=19) </text>
<text top="312" left="209" width="149" height="17" font="0">Percutaneous transluminal </text>
<text top="329" left="209" width="124" height="17" font="0">angioplasty or surgery </text>
<text top="346" left="209" width="39" height="17" font="0">(n=19) </text>
<text top="363" left="209" width="68" height="17" font="0">Comparator </text>
<text top="381" left="209" width="131" height="17" font="0">Conservative treatment </text>
<text top="399" left="209" width="132" height="17" font="0">(n=157) No description </text>
<text top="417" left="209" width="51" height="17" font="0">provided </text>
<text top="226" left="371" width="122" height="17" font="2"><b>Inclusion criteria:</b> IC </text>
<text top="243" left="371" width="3" height="17" font="0"> </text>
<text top="260" left="371" width="137" height="17" font="2"><b>Exclusion criteria:</b> N/A  </text>
<text top="227" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="226" left="581" width="6" height="18" font="7"></text>
<text top="227" left="587" width="123" height="17" font="2"><b> endpoint:</b> 6 mo QOL </text>
<text top="244" left="574" width="3" height="17" font="0"> </text>
<text top="261" left="574" width="189" height="17" font="2"><b>Results:</b> PTA or surgery provided </text>
<text top="278" left="574" width="200" height="17" font="0">improved QOL at 6 mo compared to </text>
<text top="296" left="574" width="90" height="17" font="0">conservative Tx </text>
<text top="226" left="803" width="7" height="18" font="7"></text>
<text top="227" left="810" width="268" height="17" font="0"> Study did not report pts' baseline characteristics </text>
<text top="244" left="803" width="7" height="18" font="7"></text>
<text top="245" left="810" width="249" height="17" font="0"> Study did not report pts' comorbid conditions </text>
<text top="262" left="803" width="7" height="18" font="7"></text>
<text top="263" left="810" width="188" height="17" font="0"> Comparator(s) not well described </text>
<text top="435" left="95" width="93" height="17" font="0">Kalbaugh CA, et </text>
<text top="452" left="95" width="13" height="17" font="0">al </text>
<text top="470" left="95" width="59" height="17" font="0">2006(267) </text>
<text top="487" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16814976">16814976 </a></text>
<text top="504" left="95" width="3" height="17" font="0"> </text>
<text top="435" left="209" width="139" height="17" font="2"><b>Study type:</b> Case series </text>
<text top="452" left="209" width="3" height="17" font="0"> </text>
<text top="470" left="209" width="79" height="17" font="2"><b>Size:</b> IC n=54 </text>
<text top="487" left="209" width="54" height="17" font="0">CLI n=30 </text>
<text top="435" left="371" width="138" height="17" font="2"><b>Inclusion criteria:</b> Endo </text>
<text top="452" left="371" width="121" height="17" font="0">treatment of IC or ALI </text>
<text top="470" left="371" width="3" height="17" font="0"> </text>
<text top="487" left="371" width="143" height="17" font="2"><b>Exclusion criteria:</b> None </text>
<text top="504" left="371" width="53" height="17" font="0">reported  </text>
<text top="436" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="435" left="581" width="6" height="18" font="7"></text>
<text top="436" left="587" width="123" height="17" font="2"><b> endpoint:</b> QoL at 1 y </text>
<text top="454" left="574" width="3" height="17" font="0"> </text>
<text top="471" left="574" width="213" height="17" font="2"><b>Results:</b> Improved QoL in both IC and </text>
<text top="488" left="574" width="143" height="17" font="0">ALI compared to baseline </text>
<text top="435" left="803" width="7" height="18" font="7"></text>
<text top="436" left="810" width="118" height="17" font="0"> No comparative arm </text>
<text top="522" left="95" width="86" height="17" font="0">Sachs T, et al.  </text>
<text top="539" left="95" width="59" height="17" font="0">2011(268) </text>
<text top="556" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21880457">21880457</a></text>
<text top="556" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21880457"> </a></text>
<text top="574" left="95" width="3" height="17" font="0"> </text>
<text top="522" left="209" width="137" height="17" font="2"><b>Aim: </b>Determine national </text>
<text top="539" left="209" width="130" height="17" font="0">estimates for the costs, </text>
<text top="556" left="209" width="139" height="17" font="0">utilization, and outcomes </text>
<text top="574" left="209" width="146" height="17" font="0">of angioplasty and bypass </text>
<text top="591" left="209" width="135" height="17" font="0">graft for the treatment of </text>
<text top="608" left="209" width="72" height="17" font="0">claudication  </text>
<text top="625" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="642" left="209" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="660" left="209" width="48" height="17" font="0">analysis </text>
<text top="677" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="694" left="209" width="114" height="17" font="2"><b>Size: </b>n=563,143 pts<b> </b></text>
<text top="522" left="371" width="153" height="17" font="2"><b>Inclusion criteria: </b>Pts who </text>
<text top="539" left="371" width="168" height="17" font="0">underwent endo or surgery for </text>
<text top="556" left="371" width="154" height="17" font="0">PAD based on ICD-9 codes </text>
<text top="574" left="371" width="3" height="17" font="2"><b> </b></text>
<text top="591" left="371" width="153" height="17" font="2"><b>Exclusion: </b>Atherosclerosis </text>
<text top="608" left="371" width="128" height="17" font="0">unspecified ICD-I code<b> </b></text>
<text top="523" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="522" left="581" width="6" height="18" font="7"></text>
<text top="523" left="587" width="162" height="17" font="2"><b> endpoint:</b> Costs and clinical </text>
<text top="540" left="574" width="57" height="17" font="0">outcomes </text>
<text top="558" left="574" width="3" height="17" font="0"> </text>
<text top="575" left="574" width="188" height="17" font="2"><b>Results:</b> Unclear cost analysis as </text>
<text top="592" left="574" width="213" height="17" font="0">more PTA procedures were performed </text>
<text top="609" left="574" width="202" height="17" font="0">compared to surgery; lower mortality </text>
<text top="626" left="574" width="53" height="17" font="0">with PTA </text>
<text top="644" left="574" width="3" height="17" font="2"><b> </b></text>
<text top="522" left="803" width="281" height="17" font="0">Study limited by methodology; ICD-9 code analysis </text>
<text top="712" left="95" width="100" height="17" font="0">Shammas NW, et </text>
<text top="729" left="95" width="16" height="17" font="0">al. </text>
<text top="746" left="95" width="59" height="17" font="0">2009(269) </text>
<text top="764" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19966364">19966364</a></text>
<text top="764" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19966364"> </a></text>
<text top="712" left="209" width="148" height="17" font="2"><b>Aim: </b>Determine predictors </text>
<text top="729" left="209" width="131" height="17" font="0">of distal embolization in </text>
<text top="746" left="209" width="144" height="17" font="0">pts undergoing LE arterial </text>
<text top="764" left="209" width="135" height="17" font="0">peripheral endovascular </text>
<text top="712" left="371" width="126" height="17" font="2"><b>Inclusion criteria</b>: Pts </text>
<text top="729" left="371" width="123" height="17" font="0">undergoing peripheral </text>
<text top="746" left="371" width="173" height="17" font="0">intervention enrolled in a single </text>
<text top="764" left="371" width="81" height="17" font="0">center registry<b> </b></text>
<text top="713" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="712" left="581" width="6" height="18" font="7"></text>
<text top="713" left="587" width="167" height="17" font="2"><b> endpoint:</b> Predictors of distal </text>
<text top="730" left="574" width="72" height="17" font="0">embolization </text>
<text top="748" left="574" width="3" height="17" font="2"><b> </b></text>
<text top="765" left="574" width="181" height="17" font="2"><b>Results:</b> Prior Hx of amputation; </text>
<text top="712" left="803" width="302" height="17" font="0">Limitation is that this is a single center registry analysis </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">123 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="209" width="40" height="17" font="0">revasc </text>
<text top="104" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="209" width="149" height="17" font="2"><b>Study type: </b>Retrospective </text>
<text top="139" left="209" width="122" height="17" font="0">analysis; case-control </text>
<text top="156" left="209" width="33" height="17" font="0">study<b> </b></text>
<text top="173" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="190" left="209" width="90" height="17" font="2"><b>Size: </b>n=577 pts<b> </b></text>
<text top="87" left="371" width="3" height="17" font="2"><b> </b></text>
<text top="104" left="371" width="148" height="17" font="2"><b>Exclusion: </b>None reported<b> </b></text>
<text top="87" left="574" width="199" height="17" font="0">presence of thrombus, and TASC-D </text>
<text top="104" left="574" width="200" height="17" font="0">lesions predicted distal embolization<b> </b></text>
<text top="208" left="95" width="74" height="17" font="0">Matsi PJ and </text>
<text top="226" left="95" width="73" height="17" font="0">Manninen HI </text>
<text top="243" left="95" width="59" height="17" font="0">1998(270) </text>
<text top="260" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9853140">9853140</a></text>
<text top="260" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9853140"> </a></text>
<text top="277" left="95" width="3" height="17" font="0"> </text>
<text top="208" left="209" width="84" height="17" font="2"><b>Aim:</b> To report </text>
<text top="226" left="209" width="102" height="17" font="0">complications and </text>
<text top="243" left="209" width="149" height="17" font="0">predictors of complications </text>
<text top="260" left="209" width="94" height="17" font="0">in a cohort of pts </text>
<text top="277" left="209" width="135" height="17" font="0">undergoing endo revasc </text>
<text top="294" left="209" width="123" height="17" font="0">for claudication or CLI </text>
<text top="312" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="329" left="209" width="149" height="17" font="2"><b>Study type: </b>Retrospective </text>
<text top="346" left="209" width="48" height="17" font="0">analysis<b> </b></text>
<text top="363" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="381" left="209" width="148" height="17" font="2"><b>Size: </b>n=410 procedures in </text>
<text top="398" left="209" width="44" height="17" font="0">295 pts<b> </b></text>
<text top="208" left="371" width="127" height="17" font="2"><b>Inclusion criteria: </b>Pts </text>
<text top="226" left="371" width="123" height="17" font="0">undergoing peripheral </text>
<text top="243" left="371" width="168" height="17" font="0">intervention at a single center  </text>
<text top="260" left="371" width="3" height="17" font="2"><b> </b></text>
<text top="277" left="371" width="148" height="17" font="2"><b>Exclusion:</b> None reported<b> </b></text>
<text top="209" left="574" width="7" height="17" font="2"><b>1</b></text>
<text top="208" left="581" width="6" height="18" font="7"></text>
<text top="209" left="587" width="167" height="17" font="2"><b> endpoint:</b> Complications and </text>
<text top="227" left="574" width="149" height="17" font="0">predictors of complications </text>
<text top="244" left="574" width="3" height="17" font="2"><b> </b></text>
<text top="261" left="574" width="194" height="17" font="2"><b>Results:</b> More complications in pts </text>
<text top="278" left="574" width="194" height="17" font="0">with occluded arteries compared to </text>
<text top="296" left="574" width="183" height="17" font="0">stenosed arteries; more bleeding </text>
<text top="313" left="574" width="205" height="17" font="0">complications in women; pts with CLI </text>
<text top="330" left="574" width="183" height="17" font="0">had higher mortality compared to </text>
<text top="347" left="574" width="200" height="17" font="0">claudication; mortality was driven by </text>
<text top="365" left="574" width="190" height="17" font="0">CAD and cerebrovascular disease<b> </b></text>
<text top="208" left="803" width="284" height="17" font="0">Limitation is that this is a single center retrospective </text>
<text top="226" left="803" width="48" height="17" font="0">analysis </text>
<text top="416" left="86" width="989" height="17" font="0">ABI indicates ankle-brachial index; ALI, acute limb ischemia; CAD, coronary artery disease; CI, confidence interval; CLI, critical limb ischemia; CTO, chronic total occlusion; HF, heart </text>
<text top="433" left="86" width="1002" height="17" font="0">failure; HR, hazard ratio; IC, intermittent claudication; ICD, International Classification of Diseases; JACC, Journal of American College of Cardiology; LE, lower extremity; MACE, major </text>
<text top="450" left="86" width="1012" height="17" font="0">adverse cardiac event; OR, odds ratio; PAD, periphery artery disease; PTA, percutaneous angioplasty; PTAS, percutaneous angioplasty stent; pt, patient; QoL, quality of life; RR, relative </text>
<text top="467" left="86" width="636" height="17" font="0">risk; SES, self-expanding stents; SFA, superficial femoral artery; and TASC, Trans-Atlantic Inter-Society Consensus. </text>
<text top="485" left="86" width="3" height="17" font="0"> </text>
<text top="502" left="86" width="3" height="17" font="0"> </text>
<text top="519" left="86" width="614" height="21" font="1"><b>Evidence Table 37. RCTs Evaluating Surgical Treatment for Claudication–Section 8.1.2. </b></text>
<text top="540" left="123" width="38" height="17" font="2"><b>Study </b></text>
<text top="558" left="112" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="575" left="118" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="592" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="540" left="239" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="558" left="244" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="575" left="237" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="540" left="417" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="540" left="593" width="111" height="17" font="2"><b>Study Intervention </b></text>
<text top="558" left="610" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="575" left="593" width="111" height="17" font="2"><b>Study Comparator </b></text>
<text top="592" left="614" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="540" left="768" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="558" left="726" width="188" height="17" font="2"><b>(Absolute Event Rates, P value; </b></text>
<text top="575" left="783" width="79" height="17" font="2"><b>OR or RR; &amp;  </b></text>
<text top="592" left="796" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="541" left="932" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="540" left="993" width="6" height="18" font="7"></text>
<text top="541" left="999" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="559" left="964" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="576" left="972" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="610" left="95" width="50" height="17" font="2"><b>IRONIC</b>  </text>
<text top="627" left="95" width="80" height="17" font="0">Nordanstig, et </text>
<text top="644" left="95" width="16" height="17" font="0">al. </text>
<text top="662" left="95" width="59" height="17" font="0">2014(256) </text>
<text top="679" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25095886">25095886 </a></text>
<text top="696" left="95" width="3" height="17" font="0"> </text>
<text top="610" left="203" width="152" height="17" font="2"><b>Aim:</b> Compare invasive vs. </text>
<text top="627" left="203" width="124" height="17" font="0">noninvasive treatment </text>
<text top="644" left="203" width="90" height="17" font="0">strategies for IC </text>
<text top="662" left="203" width="3" height="17" font="0"> </text>
<text top="679" left="203" width="139" height="17" font="2"><b>Study type:</b> RCT (single </text>
<text top="696" left="203" width="105" height="17" font="0">center, open label) </text>
<text top="713" left="203" width="3" height="17" font="0"> </text>
<text top="730" left="203" width="151" height="17" font="2"><b>Size:</b> n=158 pts with stable </text>
<text top="748" left="203" width="151" height="17" font="0">IC (79 allocated to invasive </text>
<text top="765" left="203" width="140" height="17" font="0">Rx 79 to noninvasive Rx) </text>
<text top="610" left="371" width="190" height="17" font="2"><b>Inclusion criteria:</b> Stable (&gt;6 mo) </text>
<text top="627" left="371" width="75" height="17" font="0">IC symptoms </text>
<text top="644" left="371" width="3" height="17" font="0"> </text>
<text top="662" left="371" width="191" height="17" font="2"><b>Exclusion criteria:</b> Mild or severe </text>
<text top="679" left="371" width="59" height="17" font="0">symptoms </text>
<text top="610" left="587" width="81" height="17" font="2"><b>Intervention:</b>  </text>
<text top="627" left="587" width="7" height="18" font="7"></text>
<text top="628" left="594" width="107" height="17" font="0"> Invasive treatment </text>
<text top="646" left="587" width="118" height="17" font="0">(Open surgical repair </text>
<text top="663" left="587" width="118" height="17" font="0">reserved for TASC D </text>
<text top="680" left="587" width="46" height="17" font="0">lesions) </text>
<text top="697" left="587" width="7" height="18" font="7"></text>
<text top="698" left="594" width="87" height="17" font="0"> 79 allocated to </text>
<text top="716" left="587" width="70" height="17" font="0">invasive Rx  </text>
<text top="733" left="587" width="7" height="18" font="7"></text>
<text top="734" left="594" width="70" height="17" font="0"> 70 received </text>
<text top="751" left="587" width="71" height="17" font="0">intervention: </text>
<text top="768" left="587" width="47" height="17" font="0">   52 pts </text>
<text top="611" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="610" left="729" width="6" height="18" font="7"></text>
<text top="611" left="735" width="172" height="17" font="2"><b> endpoint:</b> HRQL assessed by </text>
<text top="628" left="722" width="146" height="17" font="0">SF-36, VascuQol. Greater </text>
<text top="646" left="722" width="144" height="17" font="0">improvement in VascuQol </text>
<text top="663" left="722" width="165" height="17" font="0">improved significantly more in </text>
<text top="680" left="722" width="184" height="17" font="0">invasive group (p&lt;0.01) including </text>
<text top="697" left="722" width="176" height="17" font="0">3/5 domain scores; claudication </text>
<text top="714" left="722" width="195" height="17" font="0">distance improved more in invasive </text>
<text top="732" left="722" width="185" height="17" font="0">group (+124m vs. +50m); change </text>
<text top="749" left="722" width="166" height="17" font="0">in MWD not different between </text>
<text top="766" left="722" width="41" height="17" font="0">groups </text>
<text top="610" left="931" width="7" height="18" font="7"></text>
<text top="611" left="938" width="159" height="17" font="0"> Exclusion criteria somewhat </text>
<text top="628" left="931" width="49" height="17" font="0">arbitrary </text>
<text top="646" left="931" width="7" height="18" font="7"></text>
<text top="647" left="938" width="163" height="17" font="0"> Only 18/158 pts had surgical </text>
<text top="664" left="931" width="151" height="17" font="0">or hybrid procedures (Total </text>
<text top="681" left="931" width="161" height="17" font="0">procedures: 1 aortobifemoral </text>
<text top="698" left="931" width="146" height="17" font="0">bypass, 3 femoral-femoral </text>
<text top="716" left="931" width="157" height="17" font="0">bypass, 8 ccommon femoral </text>
<text top="733" left="931" width="176" height="17" font="0">endarterectomy/profundaplasty, </text>
<text top="750" left="931" width="140" height="17" font="0">5 femoral-popliteal artery </text>
<text top="767" left="931" width="151" height="17" font="0">bypass, 1 distal to popliteal </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">124 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="587" width="81" height="17" font="0">Endovascular  </text>
<text top="104" left="587" width="78" height="17" font="0">   16 pts open </text>
<text top="122" left="587" width="48" height="17" font="0">surgery. </text>
<text top="139" left="587" width="84" height="17" font="0">   2 pts. hybrid  </text>
<text top="156" left="587" width="3" height="17" font="0"> </text>
<text top="173" left="587" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="190" left="587" width="70" height="17" font="0">Noninvasive </text>
<text top="208" left="587" width="112" height="17" font="0">treatment (N=79 pts </text>
<text top="225" left="587" width="57" height="17" font="0">allocated) </text>
<text top="87" left="931" width="47" height="17" font="0">bypass) </text>
<text top="104" left="931" width="7" height="18" font="7"></text>
<text top="105" left="938" width="150" height="17" font="0"> Outcomes not stratified by </text>
<text top="123" left="931" width="141" height="17" font="0">surgical vs. endovsacular </text>
<text top="140" left="931" width="65" height="17" font="0">procedures </text>
<text top="243" left="95" width="75" height="17" font="0">Linni K, et al. </text>
<text top="260" left="95" width="59" height="17" font="0">2014(271) </text>
<text top="277" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25101576">25101576 </a></text>
<text top="294" left="95" width="3" height="17" font="0"> </text>
<text top="243" left="203" width="149" height="17" font="2"><b>Aim:</b> Compare clinical and </text>
<text top="260" left="203" width="144" height="17" font="0">hemodynamic outcome in </text>
<text top="277" left="203" width="154" height="17" font="0">pts undergoing treatment of </text>
<text top="294" left="203" width="153" height="17" font="0">CFA atherosclerotic lesions </text>
<text top="312" left="203" width="127" height="17" font="0">by bioabsorbable stent </text>
<text top="329" left="203" width="144" height="17" font="0">implantation (BASI group) </text>
<text top="346" left="203" width="126" height="17" font="0">or by common femoral </text>
<text top="363" left="203" width="156" height="17" font="0">artery endarterectomy (CFE </text>
<text top="381" left="203" width="42" height="17" font="0">group). </text>
<text top="398" left="203" width="3" height="17" font="0"> </text>
<text top="415" left="203" width="139" height="17" font="2"><b>Study type:</b> RCT (single </text>
<text top="432" left="203" width="105" height="17" font="0">center, open label) </text>
<text top="449" left="203" width="3" height="17" font="0"> </text>
<text top="467" left="203" width="83" height="17" font="2"><b>Size:</b> n=80 pts </text>
<text top="243" left="371" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="260" left="371" width="7" height="18" font="7"></text>
<text top="261" left="378" width="160" height="17" font="0"> Claudication or CLI &gt;2 wk in </text>
<text top="278" left="371" width="48" height="17" font="0">duration </text>
<text top="296" left="371" width="7" height="18" font="7"></text>
<text top="297" left="378" width="149" height="17" font="0"> CFA stenosis or occlusion </text>
<text top="314" left="371" width="7" height="18" font="7"></text>
<text top="315" left="378" width="91" height="17" font="0"> Atherosclerosis </text>
<text top="332" left="371" width="3" height="17" font="0"> </text>
<text top="350" left="371" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="367" left="371" width="7" height="18" font="7"></text>
<text top="368" left="378" width="66" height="17" font="0"> Urgent CLI </text>
<text top="385" left="371" width="7" height="18" font="7"></text>
<text top="386" left="378" width="188" height="17" font="0"> Simultaneous aneurysm repair or </text>
<text top="404" left="371" width="87" height="17" font="0">bypass grafting </text>
<text top="421" left="371" width="7" height="18" font="7"></text>
<text top="422" left="378" width="64" height="17" font="0"> Redo CFE </text>
<text top="439" left="371" width="7" height="18" font="7"></text>
<text top="440" left="378" width="49" height="17" font="0"> Trauma </text>
<text top="458" left="371" width="7" height="18" font="7"></text>
<text top="459" left="378" width="109" height="17" font="0"> Renal insufficiency </text>
<text top="476" left="371" width="7" height="18" font="7"></text>
<text top="477" left="378" width="66" height="17" font="0"> Pregnancy </text>
<text top="243" left="587" width="99" height="17" font="2"><b>Intervention:</b> 1:1 </text>
<text top="260" left="587" width="81" height="17" font="0">randomization </text>
<text top="277" left="587" width="3" height="17" font="0"> </text>
<text top="294" left="587" width="109" height="17" font="2"><b>Comparator:</b> BASI </text>
<text top="312" left="587" width="70" height="17" font="0">implantation </text>
<text top="244" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="243" left="729" width="6" height="18" font="7"></text>
<text top="244" left="735" width="182" height="17" font="2"><b> endpoint:</b> Surgical site infection </text>
<text top="261" left="722" width="194" height="17" font="0">(7 for CFE vs. 0 for BASI, p=0.002) </text>
<text top="243" left="931" width="7" height="18" font="7"></text>
<text top="244" left="938" width="146" height="17" font="0"> Technical success (100% </text>
<text top="261" left="931" width="121" height="17" font="0">CFE vs. 97.5% BASI) </text>
<text top="278" left="931" width="7" height="18" font="7"></text>
<text top="279" left="938" width="157" height="17" font="0"> 30d primary patency (100% </text>
<text top="297" left="931" width="173" height="17" font="0">CFE vs. 92.5% BASI; p=0.038) </text>
<text top="314" left="931" width="7" height="18" font="7"></text>
<text top="315" left="938" width="153" height="17" font="0"> 1 y primary patency (100% </text>
<text top="332" left="931" width="162" height="17" font="0">CFE vs. 80% BASI; p=0.007) </text>
<text top="350" left="931" width="7" height="18" font="7"></text>
<text top="351" left="938" width="169" height="17" font="0"> 1 y secondary patency (100% </text>
<text top="368" left="931" width="156" height="17" font="0">CFE vs. 84% BASI; p=0.01) </text>
<text top="385" left="931" width="7" height="18" font="7"></text>
<text top="386" left="938" width="129" height="17" font="0"> Limb salvage (p=0.51) </text>
<text top="495" left="95" width="94" height="17" font="0">Gabrielli R, et al. </text>
<text top="512" left="95" width="59" height="17" font="0">2012(272) </text>
<text top="530" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23044257">23044257 </a></text>
<text top="547" left="95" width="3" height="17" font="0"> </text>
<text top="495" left="203" width="146" height="17" font="2"><b>Aim:</b> Evaluated outcomes </text>
<text top="512" left="203" width="92" height="17" font="0">of RE vs. ENDO </text>
<text top="530" left="203" width="146" height="17" font="0">interventions on (TASC)-II </text>
<text top="547" left="203" width="142" height="17" font="0">D femoropopliteal lesions </text>
<text top="564" left="203" width="117" height="17" font="0">and identified factors </text>
<text top="581" left="203" width="133" height="17" font="0">predictive of restenosis. </text>
<text top="598" left="203" width="3" height="17" font="0"> </text>
<text top="616" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="633" left="203" width="3" height="17" font="0"> </text>
<text top="650" left="203" width="83" height="17" font="2"><b>Size:</b> n=95 pts </text>
<text top="495" left="371" width="166" height="17" font="2"><b>Inclusion criteria:</b> TASC-II D </text>
<text top="512" left="371" width="184" height="17" font="0">lesions (not claudication-specific) </text>
<text top="530" left="371" width="3" height="17" font="0"> </text>
<text top="547" left="371" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="564" left="371" width="7" height="18" font="7"></text>
<text top="565" left="378" width="191" height="17" font="0"> Previous treatment (endovascular </text>
<text top="582" left="371" width="128" height="17" font="0">intervention or bypass) </text>
<text top="599" left="371" width="7" height="18" font="7"></text>
<text top="601" left="378" width="192" height="17" font="0"> Chronic renal insufficiency (serum </text>
<text top="618" left="371" width="119" height="17" font="0">creatinine 1.5 mg/dL) </text>
<text top="635" left="371" width="7" height="18" font="7"></text>
<text top="636" left="378" width="99" height="17" font="0"> Occlusion of iliac </text>
<text top="653" left="371" width="7" height="18" font="7"></text>
<text top="655" left="378" width="101" height="17" font="0"> Common femoral </text>
<text top="672" left="371" width="7" height="18" font="7"></text>
<text top="673" left="378" width="193" height="17" font="0"> Popliteal arteries (P2-3 segments) </text>
<text top="495" left="587" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="512" left="587" width="47" height="17" font="0">Remote </text>
<text top="530" left="587" width="114" height="17" font="0">endarterectomy with </text>
<text top="547" left="587" width="83" height="17" font="0">distal endpoint </text>
<text top="564" left="587" width="89" height="17" font="0">angioplasty and </text>
<text top="581" left="587" width="88" height="17" font="0">stenting (N=51) </text>
<text top="598" left="587" width="3" height="17" font="0"> </text>
<text top="616" left="587" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="633" left="587" width="61" height="17" font="0">Subintimal </text>
<text top="650" left="587" width="89" height="17" font="0">angioplasty and </text>
<text top="667" left="587" width="88" height="17" font="0">stenting (N=44) </text>
<text top="496" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="495" left="729" width="6" height="18" font="7"></text>
<text top="496" left="735" width="180" height="17" font="2"><b> endpoint:</b> Primary patency was </text>
<text top="513" left="722" width="190" height="17" font="0">76.5% (39 of 51) in RE and 56.8% </text>
<text top="531" left="722" width="189" height="17" font="0">(25 of 44) in ENDO (HR: 2.6; 95% </text>
<text top="548" left="722" width="195" height="17" font="0">CI: 0.99–4.2; p=0.05) at 24 mo and </text>
<text top="565" left="722" width="177" height="17" font="0">was 62.7% (32 of 46) in RE and </text>
<text top="582" left="722" width="175" height="17" font="0">47.7% (21 of 40) in ENDO (HR: </text>
<text top="599" left="722" width="185" height="17" font="0">1.89; 95% CI: 0.94–3.78; p=0.07) </text>
<text top="617" left="722" width="51" height="17" font="0">at 36 mo </text>
<text top="495" left="931" width="7" height="18" font="7"></text>
<text top="496" left="938" width="162" height="17" font="0"> 61% of RE and 52% of endo </text>
<text top="513" left="931" width="127" height="17" font="0">group had Rutherford 4</text>
<text top="513" left="1059" width="7" height="17" font="19">–</text>
<text top="513" left="1066" width="10" height="17" font="0">5 </text>
<text top="531" left="931" width="149" height="17" font="0">ischemia (&lt;50% of pts had </text>
<text top="548" left="931" width="72" height="17" font="0">claudication) </text>
<text top="691" left="95" width="46" height="17" font="2"><b>REVAS</b> </text>
<text top="708" left="95" width="86" height="17" font="0">Gisbertz SS, et </text>
<text top="725" left="95" width="16" height="17" font="0">al. </text>
<text top="743" left="95" width="59" height="17" font="0">2010(273) </text>
<text top="760" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21035693">21035693 </a></text>
<text top="777" left="95" width="3" height="17" font="0"> </text>
<text top="691" left="203" width="144" height="17" font="2"><b>Aim:</b> Compare RSFAE or </text>
<text top="708" left="203" width="148" height="17" font="0">supragenicular bypass, for </text>
<text top="725" left="203" width="140" height="17" font="0">TASC C and D lesions of </text>
<text top="743" left="203" width="48" height="17" font="0">the SFA </text>
<text top="760" left="203" width="3" height="17" font="0"> </text>
<text top="777" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="691" left="371" width="191" height="17" font="2"><b>Inclusion criteria:</b> TASC C and D </text>
<text top="708" left="371" width="107" height="17" font="0">lesions of the SFA  </text>
<text top="725" left="371" width="3" height="17" font="0"> </text>
<text top="743" left="371" width="110" height="17" font="2"><b>Exclusion criteria: </b></text>
<text top="760" left="371" width="7" height="18" font="7"></text>
<text top="761" left="378" width="166" height="17" font="0"> Previous surgery or PTA with </text>
<text top="691" left="587" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="708" left="587" width="44" height="17" font="0">RSFAE </text>
<text top="725" left="587" width="3" height="17" font="0"> </text>
<text top="743" left="587" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="760" left="587" width="86" height="17" font="0">Supragenicular </text>
<text top="777" left="587" width="42" height="17" font="0">bypass </text>
<text top="692" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="691" left="729" width="6" height="18" font="7"></text>
<text top="692" left="735" width="173" height="17" font="2"><b> endpoint:</b> 3 y primary patency </text>
<text top="709" left="722" width="187" height="17" font="0">after 3 y was 47% for RSFAE and </text>
<text top="727" left="722" width="148" height="17" font="0">60% for bypass (p=0.107), </text>
<text top="744" left="722" width="182" height="17" font="0">assisted primary patency was 63 </text>
<text top="761" left="722" width="196" height="17" font="0">and 69% (p=0.406), and secondary </text>
<text top="691" left="931" width="7" height="18" font="7"></text>
<text top="692" left="938" width="132" height="17" font="0"> For venous (n=25) and </text>
<text top="709" left="931" width="164" height="17" font="0">prosthetic grafts (n=30) at 3 y </text>
<text top="727" left="931" width="168" height="17" font="0">primary patency was 65% and </text>
<text top="744" left="931" width="126" height="17" font="0">56 vs. 47% for RSFAE </text>
<text top="761" left="931" width="153" height="17" font="0">(p=0.143), assisted primary </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">125 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="3" height="17" font="0"> </text>
<text top="104" left="203" width="146" height="17" font="2"><b>Size:</b> n=116 pts (77 [66%] </text>
<text top="122" left="203" width="44" height="17" font="0">had IC) </text>
<text top="87" left="371" width="181" height="17" font="0">additional stent placement of the </text>
<text top="104" left="371" width="62" height="17" font="0">target SFA </text>
<text top="122" left="371" width="7" height="18" font="7"></text>
<text top="123" left="378" width="173" height="17" font="0"> An SFA diameter &lt;4 mm. SFA </text>
<text top="140" left="371" width="185" height="17" font="0">occlusion had to start &lt;4 cm from </text>
<text top="157" left="371" width="98" height="17" font="0">the proximal SFA </text>
<text top="87" left="722" width="141" height="17" font="0">patency was 69 and 73% </text>
<text top="104" left="722" width="128" height="17" font="0">(p=0.541), respectively </text>
<text top="87" left="931" width="160" height="17" font="0">patency was 84% and 56 vs. </text>
<text top="104" left="931" width="174" height="17" font="0">63% for RSFAE (p=0.052), and </text>
<text top="122" left="931" width="160" height="17" font="0">secondary patency was 89% </text>
<text top="139" left="931" width="150" height="17" font="0">and 59 vs. 69% for RSFAE </text>
<text top="156" left="931" width="60" height="17" font="0">(p=0.046). </text>
<text top="173" left="931" width="7" height="18" font="7"></text>
<text top="174" left="938" width="136" height="17" font="0"> Pts were randomized to </text>
<text top="192" left="931" width="147" height="17" font="0">RSFAE or bypass with the </text>
<text top="209" left="931" width="148" height="17" font="0">ipsilateral saphenous vein. </text>
<text top="226" left="931" width="171" height="17" font="0">When the saphenous vein was </text>
<text top="243" left="931" width="174" height="17" font="0">not available or not suitable, 23 </text>
<text top="260" left="931" width="157" height="17" font="0">pts received a PTFE bypass </text>
<text top="278" left="95" width="81" height="17" font="0">van Det RJ, et </text>
<text top="296" left="95" width="16" height="17" font="0">al. </text>
<text top="313" left="95" width="59" height="17" font="0">2009(274) </text>
<text top="330" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19231253">19231253 </a></text>
<text top="347" left="95" width="3" height="17" font="0"> </text>
<text top="278" left="203" width="142" height="17" font="2"><b>Aim:</b> To compare ePTFE </text>
<text top="296" left="203" width="133" height="17" font="0">prosthesis and collagen-</text>
<text top="313" left="203" width="111" height="17" font="0">impregnated knitted </text>
<text top="330" left="203" width="142" height="17" font="0">polyester (Dacron) for AK </text>
<text top="347" left="203" width="134" height="17" font="0">femoro-popliteal bypass </text>
<text top="365" left="203" width="38" height="17" font="0">grafts. </text>
<text top="382" left="203" width="3" height="17" font="0"> </text>
<text top="399" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="416" left="203" width="72" height="17" font="0">(multicenter) </text>
<text top="433" left="203" width="3" height="17" font="0"> </text>
<text top="451" left="203" width="147" height="17" font="2"><b>Size:</b> n=228 bypass grafts </text>
<text top="468" left="203" width="101" height="17" font="0">(176 [77%] for IC) </text>
<text top="278" left="371" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="296" left="371" width="7" height="18" font="7"></text>
<text top="297" left="378" width="126" height="17" font="0"> Disabling claudication </text>
<text top="314" left="371" width="7" height="18" font="7"></text>
<text top="315" left="378" width="59" height="17" font="0"> Rest pain </text>
<text top="332" left="371" width="7" height="18" font="7"></text>
<text top="333" left="378" width="122" height="17" font="0"> Tissue loss for whom </text>
<text top="351" left="371" width="185" height="17" font="0">suprageniculate femoral-popliteal </text>
<text top="368" left="371" width="113" height="17" font="0">bypass was feasible </text>
<text top="385" left="371" width="3" height="17" font="0"> </text>
<text top="402" left="371" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="420" left="371" width="7" height="18" font="7"></text>
<text top="421" left="378" width="153" height="17" font="0"> Previous ipsilateral femoro-</text>
<text top="438" left="371" width="114" height="17" font="0">popliteal procedures </text>
<text top="455" left="371" width="7" height="18" font="7"></text>
<text top="456" left="378" width="165" height="17" font="0"> Contraindication to long-term </text>
<text top="474" left="371" width="121" height="17" font="0">anticoagulant therapy </text>
<text top="491" left="371" width="7" height="18" font="7"></text>
<text top="492" left="378" width="185" height="17" font="0"> Life expectancy &gt;1 y and current </text>
<text top="509" left="371" width="176" height="17" font="0">treatment with chemotherapy or </text>
<text top="526" left="371" width="75" height="17" font="0">radiotherapy. </text>
<text top="278" left="587" width="98" height="17" font="2"><b>Intervention:</b> AK </text>
<text top="296" left="587" width="92" height="17" font="0">femoro-popliteal </text>
<text top="313" left="587" width="107" height="17" font="0">bypass grafts were </text>
<text top="330" left="587" width="120" height="17" font="0">randomly allocated to </text>
<text top="347" left="587" width="118" height="17" font="0">either an ePTFE (n Z </text>
<text top="365" left="587" width="121" height="17" font="0">114) or a Dacron (n Z </text>
<text top="382" left="587" width="109" height="17" font="0">114) vascular graft  </text>
<text top="399" left="587" width="3" height="17" font="0"> </text>
<text top="416" left="587" width="101" height="17" font="2"><b>Comparator: </b>N/A<b> </b></text>
<text top="279" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="278" left="729" width="6" height="18" font="7"></text>
<text top="279" left="735" width="136" height="17" font="2"><b> endpoint:</b> After 5 y, the </text>
<text top="297" left="722" width="165" height="17" font="0">primary, primary assisted and </text>
<text top="314" left="722" width="195" height="17" font="0">secondary patency rates were 36% </text>
<text top="331" left="722" width="170" height="17" font="0">(95% CI: 26%–46%), 46% (CI: </text>
<text top="348" left="722" width="167" height="17" font="0">36%–56%) and 51% (95% CI: </text>
<text top="366" left="722" width="175" height="17" font="0">41%–61%) for ePTFE and 52% </text>
<text top="383" left="722" width="191" height="17" font="0">(95% CI: 42%–62%; p=0.04), 66% </text>
<text top="400" left="722" width="184" height="17" font="0">(95% CI: 56%–76%; p=0.01) and </text>
<text top="417" left="722" width="195" height="17" font="0">70% (95% CI: 60–80%; p=0.01) for </text>
<text top="434" left="722" width="174" height="17" font="0">Dacron, respectively. After 10 y </text>
<text top="452" left="722" width="191" height="17" font="0">these rates were respectively 28% </text>
<text top="469" left="722" width="178" height="17" font="0">(95% CI: 18%–38%), 31% (95% </text>
<text top="486" left="722" width="182" height="17" font="0">CI:19%–43%) and 35% (95% CI: </text>
<text top="503" left="722" width="175" height="17" font="0">23%–47%) for ePTFE and 28% </text>
<text top="521" left="722" width="178" height="17" font="0">(95% CI: 18%–38%), 49% (95% </text>
<text top="538" left="722" width="186" height="17" font="0">CI: 37%–61%) and 49% (95% CI: </text>
<text top="555" left="722" width="131" height="17" font="0">37%–61%) for Dacron.  </text>
<text top="278" left="931" width="24" height="17" font="0">N/A </text>
<text top="573" left="95" width="49" height="17" font="2"><b>REVAS</b>  </text>
<text top="590" left="95" width="86" height="17" font="0">Gisbertz SS, et </text>
<text top="607" left="95" width="16" height="17" font="0">al. </text>
<text top="625" left="95" width="59" height="17" font="0">2009(275) </text>
<text top="642" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18990592">18990592 </a></text>
<text top="659" left="95" width="3" height="17" font="0"> </text>
<text top="573" left="203" width="148" height="17" font="2"><b>Aim:</b> Compare RSFAE vs. </text>
<text top="590" left="203" width="126" height="17" font="0">supragenicular bypass </text>
<text top="607" left="203" width="44" height="17" font="0">grafting </text>
<text top="625" left="203" width="3" height="17" font="0"> </text>
<text top="642" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="659" left="203" width="3" height="17" font="0"> </text>
<text top="676" left="203" width="146" height="17" font="2"><b>Size:</b> n=116 pts (77 [66%] </text>
<text top="693" left="203" width="44" height="17" font="0">had IC) </text>
<text top="573" left="371" width="191" height="17" font="2"><b>Inclusion criteria:</b> TASC C and D </text>
<text top="590" left="371" width="103" height="17" font="0">lesions of the SFA </text>
<text top="607" left="371" width="3" height="17" font="0"> </text>
<text top="625" left="371" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="642" left="371" width="7" height="18" font="7"></text>
<text top="643" left="378" width="191" height="17" font="0"> Previous treatment (endovascular </text>
<text top="660" left="371" width="128" height="17" font="0">intervention or bypass) </text>
<text top="677" left="371" width="7" height="18" font="7"></text>
<text top="678" left="378" width="192" height="17" font="0"> Chronic renal insufficiency (serum </text>
<text top="696" left="371" width="119" height="17" font="0">creatinine 1.5 mg/dL) </text>
<text top="713" left="371" width="7" height="18" font="7"></text>
<text top="714" left="378" width="103" height="17" font="0"> Occlusion of iliac, </text>
<text top="731" left="371" width="172" height="17" font="0">common femoral, and popliteal </text>
<text top="749" left="371" width="139" height="17" font="0">arteries (P2-3 segments) </text>
<text top="573" left="587" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="590" left="587" width="44" height="17" font="0">RSFAE </text>
<text top="607" left="587" width="3" height="17" font="0"> </text>
<text top="625" left="587" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="642" left="587" width="86" height="17" font="0">Supragenicular </text>
<text top="659" left="587" width="42" height="17" font="0">bypass </text>
<text top="574" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="573" left="729" width="6" height="18" font="7"></text>
<text top="574" left="735" width="183" height="17" font="2"><b> endpoint:</b> Primary patency after </text>
<text top="591" left="722" width="188" height="17" font="0">1 y follow-up was 61% for RSFAE </text>
<text top="609" left="722" width="172" height="17" font="0">and 73% for bypass (p=0.094). </text>
<text top="626" left="722" width="180" height="17" font="0">Secondary patency was 79% for </text>
<text top="643" left="722" width="189" height="17" font="0">both groups. Subdividing between </text>
<text top="660" left="722" width="163" height="17" font="0">venous (n=25) and prosthetic </text>
<text top="677" left="722" width="167" height="17" font="0">grafts (n=30) shows a primary </text>
<text top="695" left="722" width="140" height="17" font="0">patency of 89% and 63% </text>
<text top="712" left="722" width="155" height="17" font="0">respectively at 1 y follow-up </text>
<text top="729" left="722" width="60" height="17" font="0">(p=0.086). </text>
<text top="573" left="931" width="24" height="17" font="0">N/A </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">126 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="76" height="17" font="0">Ricco JB and </text>
<text top="104" left="95" width="51" height="17" font="0">Probst H </text>
<text top="122" left="95" width="59" height="17" font="0">2008(276) </text>
<text top="139" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17997269">17997269 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="141" height="17" font="2"><b>Aim:</b> Compare crossover </text>
<text top="104" left="203" width="113" height="17" font="0">vs. direct bypass for </text>
<text top="122" left="203" width="132" height="17" font="0">unilateral iliac occlusive </text>
<text top="139" left="203" width="124" height="17" font="0">disease in claudicants </text>
<text top="156" left="203" width="3" height="17" font="0"> </text>
<text top="173" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="190" left="203" width="72" height="17" font="0">(multicenter) </text>
<text top="208" left="203" width="3" height="17" font="0"> </text>
<text top="225" left="203" width="90" height="17" font="2"><b>Size:</b> n=143 pts </text>
<text top="87" left="371" width="186" height="17" font="2"><b>Inclusion criteria:</b> Unilateral iliac </text>
<text top="104" left="371" width="159" height="17" font="0">artery occlusive disease and </text>
<text top="122" left="371" width="120" height="17" font="0">disabling claudication </text>
<text top="139" left="371" width="3" height="17" font="0"> </text>
<text top="156" left="371" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="87" left="587" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="104" left="587" width="102" height="17" font="0">Crossover bypass </text>
<text top="122" left="587" width="41" height="17" font="0">(N=74) </text>
<text top="139" left="587" width="3" height="17" font="0"> </text>
<text top="156" left="587" width="113" height="17" font="2"><b>Comparator:</b> Direct </text>
<text top="173" left="587" width="84" height="17" font="0">bypass (N=69) </text>
<text top="88" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="729" width="6" height="18" font="7"></text>
<text top="88" left="735" width="179" height="17" font="2"><b> endpoint:</b> Primary patency and </text>
<text top="106" left="722" width="185" height="17" font="0">assisted primary patency Primary </text>
<text top="123" left="722" width="176" height="17" font="0">patency at 5 y was higher in the </text>
<text top="140" left="722" width="172" height="17" font="0">direct bypass group than in the </text>
<text top="157" left="722" width="185" height="17" font="0">crossover bypass group (92.7 vs. </text>
<text top="174" left="722" width="181" height="17" font="0">73.2, p=0.001). Assisted primary </text>
<text top="192" left="722" width="191" height="17" font="0">patency and secondary patency at </text>
<text top="209" left="722" width="175" height="17" font="0">5 y were also higher after direct </text>
<text top="226" left="722" width="169" height="17" font="0">bypass than crossover bypass </text>
<text top="243" left="722" width="193" height="17" font="0">(92.7 vs. 84.3, p=0.04 and 97.0 vs. </text>
<text top="260" left="722" width="151" height="17" font="0">89.8, p=0.03, respectively). </text>
<text top="278" left="722" width="166" height="17" font="0">Patency at 5 y after crossover </text>
<text top="295" left="722" width="185" height="17" font="0">bypass was significantly higher in </text>
<text top="312" left="722" width="170" height="17" font="0">pts presenting no or low-grade </text>
<text top="329" left="722" width="136" height="17" font="0">SFA stenosis than in pts </text>
<text top="347" left="722" width="166" height="17" font="0">presenting high-grade (&gt;50%) </text>
<text top="364" left="722" width="179" height="17" font="0">stenosis or occlusion of the SFA </text>
<text top="381" left="722" width="193" height="17" font="0">(74.0% vs. 62.5%, p=0.04). In both </text>
<text top="398" left="722" width="172" height="17" font="0">treatment groups, patency was </text>
<text top="415" left="722" width="159" height="17" font="0">comparable using PTFE and </text>
<text top="433" left="722" width="178" height="17" font="0">polyester grafts. Overall survival </text>
<text top="450" left="722" width="133" height="17" font="0">was 59.5±12% at 10 y.  </text>
<text top="87" left="931" width="24" height="17" font="0">N/A </text>
<text top="468" left="95" width="95" height="17" font="0">Jensen LP, et al. </text>
<text top="485" left="95" width="59" height="17" font="0">2007(277) </text>
<text top="502" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17400486">17400486 </a></text>
<text top="519" left="95" width="3" height="17" font="0"> </text>
<text top="468" left="203" width="144" height="17" font="2"><b>Aim:</b> Compare PTFE and </text>
<text top="485" left="203" width="150" height="17" font="0">polyester grafts for femoral </text>
<text top="502" left="203" width="131" height="17" font="0">to above-knee popliteal </text>
<text top="519" left="203" width="77" height="17" font="0">artery bypass </text>
<text top="537" left="203" width="3" height="17" font="0"> </text>
<text top="554" left="203" width="133" height="17" font="2"><b>Study type:</b> RCT (multi-</text>
<text top="571" left="203" width="116" height="17" font="0">center), Scandinavia </text>
<text top="588" left="203" width="3" height="17" font="0"> </text>
<text top="605" left="203" width="153" height="17" font="2"><b>Size:</b> n=427 pts (270 [65%] </text>
<text top="623" left="203" width="44" height="17" font="0">had IC) </text>
<text top="468" left="371" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="485" left="371" width="7" height="18" font="7"></text>
<text top="486" left="378" width="196" height="17" font="0"> Consecutive pts with chronic lower </text>
<text top="503" left="371" width="78" height="17" font="0">limb ischemia </text>
<text top="521" left="371" width="7" height="18" font="7"></text>
<text top="522" left="378" width="179" height="17" font="0"> Considered suitable for surgical </text>
<text top="539" left="371" width="139" height="17" font="0">revascularization using a </text>
<text top="556" left="371" width="183" height="17" font="0">supragenicular prosthetic bypass </text>
<text top="573" left="371" width="28" height="17" font="0">graft </text>
<text top="591" left="371" width="7" height="18" font="7"></text>
<text top="592" left="378" width="196" height="17" font="0"> Provided the pts consented to take </text>
<text top="609" left="371" width="28" height="17" font="0">part  </text>
<text top="626" left="371" width="3" height="17" font="0"> </text>
<text top="643" left="371" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="661" left="371" width="7" height="18" font="7"></text>
<text top="662" left="378" width="63" height="17" font="0"> Age &lt;18 y </text>
<text top="679" left="371" width="7" height="18" font="7"></text>
<text top="680" left="378" width="57" height="17" font="0"> Pregnant </text>
<text top="697" left="371" width="7" height="18" font="7"></text>
<text top="698" left="378" width="177" height="17" font="0"> Previously enrolled in the study </text>
<text top="716" left="371" width="7" height="18" font="7"></text>
<text top="717" left="378" width="180" height="17" font="0"> Considered impossible to follow </text>
<text top="734" left="371" width="7" height="18" font="7"></text>
<text top="735" left="378" width="172" height="17" font="0"> Informed consent could not be </text>
<text top="752" left="371" width="57" height="17" font="0">obtained.  </text>
<text top="468" left="587" width="112" height="17" font="2"><b>Intervention:</b> 6 mm </text>
<text top="485" left="587" width="86" height="17" font="0">Dacron conduit </text>
<text top="502" left="587" width="3" height="17" font="0"> </text>
<text top="519" left="587" width="111" height="17" font="2"><b>Comparator:</b> 6 mm </text>
<text top="537" left="587" width="78" height="17" font="0">PTFE conduit </text>
<text top="469" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="468" left="729" width="6" height="18" font="7"></text>
<text top="469" left="735" width="173" height="17" font="2"><b> endpoint:</b> 2 y primary patency </text>
<text top="486" left="722" width="181" height="17" font="0">rates for Dacron and PTFE were </text>
<text top="503" left="722" width="183" height="17" font="0">70% and 57% (p=0.02), whereas </text>
<text top="521" left="722" width="188" height="17" font="0">the secondary patency rates were </text>
<text top="538" left="722" width="133" height="17" font="0">76% and 65% (p=0.04), </text>
<text top="555" left="722" width="188" height="17" font="0">respectively. Primary patency at 2 </text>
<text top="572" left="722" width="178" height="17" font="0">y was significantly influenced by </text>
<text top="589" left="722" width="195" height="17" font="0">the number of patent crural vessels </text>
<text top="607" left="722" width="186" height="17" font="0">(2 or 3 67%, 1 50%, p=0.01). At 2 </text>
<text top="624" left="722" width="183" height="17" font="0">y, pts treated for CLI had a major </text>
<text top="641" left="722" width="174" height="17" font="0">amputation more often than pts </text>
<text top="658" left="722" width="157" height="17" font="0">operated on for IC, 10 and 3 </text>
<text top="675" left="722" width="176" height="17" font="0">respectively (p=0.003), and had </text>
<text top="693" left="722" width="195" height="17" font="0">higher mortality rates, 20% and 8% </text>
<text top="710" left="722" width="132" height="17" font="0">respectively (p=0.001).  </text>
<text top="468" left="931" width="7" height="18" font="7"></text>
<text top="469" left="938" width="139" height="17" font="0"> Medical therapy was not </text>
<text top="486" left="931" width="74" height="17" font="0">standardized </text>
<text top="503" left="931" width="7" height="18" font="7"></text>
<text top="504" left="938" width="163" height="17" font="0"> Amputations at 2 y, (major in </text>
<text top="522" left="931" width="148" height="17" font="0">4% and minor in 3%), 30 d </text>
<text top="539" left="931" width="152" height="17" font="0">mortality and complications </text>
<text top="556" left="931" width="148" height="17" font="0">(wound infections: 3% and </text>
<text top="573" left="931" width="152" height="17" font="0">other wound complications: </text>
<text top="591" left="931" width="174" height="17" font="0">13%) occurred equally frequent </text>
<text top="608" left="931" width="85" height="17" font="0">in both groups. </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">127 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="88" height="17" font="0">AbuRahma AF, </text>
<text top="104" left="95" width="30" height="17" font="0">et al. </text>
<text top="122" left="95" width="59" height="17" font="0">1999(278) </text>
<text top="139" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10520903">10520903</a></text>
<text top="139" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10520903"> </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="145" height="17" font="2"><b>Aim:</b> Compare patency of </text>
<text top="104" left="203" width="144" height="17" font="0">PTFE vs. saphenous vein </text>
<text top="122" left="203" width="120" height="17" font="0">grafts for above-knee </text>
<text top="139" left="203" width="42" height="17" font="0">bypass </text>
<text top="156" left="203" width="3" height="17" font="0"> </text>
<text top="173" left="203" width="141" height="17" font="2"><b>Study type:</b> Prospective, </text>
<text top="190" left="203" width="68" height="17" font="0">randomized </text>
<text top="208" left="203" width="3" height="17" font="0"> </text>
<text top="225" left="203" width="134" height="17" font="2"><b>Size:</b> n=43 pts (86 legs) </text>
<text top="87" left="371" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="104" left="371" width="7" height="18" font="7"></text>
<text top="105" left="378" width="172" height="17" font="0"> Bilateral disabling claudication </text>
<text top="123" left="371" width="7" height="18" font="7"></text>
<text top="124" left="378" width="131" height="17" font="0"> Failed medical therapy </text>
<text top="141" left="371" width="7" height="18" font="7"></text>
<text top="142" left="378" width="179" height="17" font="0"> Long SFA occlusion with above-</text>
<text top="159" left="371" width="110" height="17" font="0">knee reconstitution.<b> </b></text>
<text top="177" left="371" width="3" height="17" font="0"> </text>
<text top="194" left="371" width="143" height="17" font="2"><b>Exclusion criteria: </b>None </text>
<text top="211" left="371" width="61" height="17" font="0">mentioned<b> </b></text>
<text top="87" left="587" width="99" height="17" font="2"><b>Intervention:</b> Pts </text>
<text top="104" left="587" width="118" height="17" font="0">received above-knee </text>
<text top="122" left="587" width="106" height="17" font="0">PTFE graft in 1 leg </text>
<text top="139" left="587" width="113" height="17" font="0">and saphenous vein </text>
<text top="156" left="587" width="96" height="17" font="0">graft in the other; </text>
<text top="173" left="587" width="111" height="17" font="0">were randomized in </text>
<text top="190" left="587" width="114" height="17" font="0">terms of the order of </text>
<text top="208" left="587" width="113" height="17" font="0">staged interventions </text>
<text top="225" left="587" width="108" height="17" font="0">(either SV-PTFE or </text>
<text top="242" left="587" width="60" height="17" font="0">PTFE-SV) </text>
<text top="259" left="587" width="3" height="17" font="0"> </text>
<text top="276" left="587" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="294" left="587" width="107" height="17" font="0">Contralateral leg in </text>
<text top="311" left="587" width="101" height="17" font="0">same pts; each pt </text>
<text top="328" left="587" width="110" height="17" font="0">served as their own </text>
<text top="345" left="587" width="40" height="17" font="0">control </text>
<text top="88" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="729" width="6" height="18" font="7"></text>
<text top="88" left="735" width="145" height="17" font="2"><b> endpoint:</b> No statistically </text>
<text top="106" left="722" width="172" height="17" font="0">significant differences between </text>
<text top="123" left="722" width="175" height="17" font="0">primary and secondary patency </text>
<text top="140" left="722" width="187" height="17" font="0">rates for both grafts; however, the </text>
<text top="157" left="722" width="170" height="17" font="0">assisted primary patency rates </text>
<text top="174" left="722" width="171" height="17" font="0">were higher for SVG (p&lt;0.05).<i> </i> </text>
<text top="87" left="931" width="139" height="17" font="0">Standardized antiplatelet </text>
<text top="104" left="931" width="166" height="17" font="0">therapy (ASA 325 mg), but no </text>
<text top="122" left="931" width="176" height="17" font="0">mention of other components of </text>
<text top="139" left="931" width="94" height="17" font="0">medical therapy. </text>
<text top="156" left="931" width="154" height="17" font="0">All PTFE were 8 mm grafts. </text>
<text top="173" left="931" width="3" height="17" font="0"> </text>
<text top="363" left="95" width="94" height="17" font="0">Green RM, et al. </text>
<text top="381" left="95" width="59" height="17" font="0">2000(279) </text>
<text top="398" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10709052">10709052</a></text>
<text top="398" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10709052"> </a></text>
<text top="415" left="95" width="3" height="17" font="0"> </text>
<text top="363" left="203" width="114" height="17" font="2"><b>Aim:</b> Identify factors </text>
<text top="381" left="203" width="110" height="17" font="0">affecting patency of </text>
<text top="398" left="203" width="125" height="17" font="0">prosthetic above-knee </text>
<text top="415" left="203" width="130" height="17" font="0">femoropopliteal bypass </text>
<text top="432" left="203" width="34" height="17" font="0">grafts </text>
<text top="449" left="203" width="3" height="17" font="0"> </text>
<text top="467" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="484" left="203" width="3" height="17" font="0"> </text>
<text top="501" left="203" width="146" height="17" font="2"><b>Size:</b> n=240 pts (59% had </text>
<text top="518" left="203" width="72" height="17" font="0">claudication)<b> </b></text>
<text top="363" left="371" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="381" left="371" width="7" height="18" font="7"></text>
<text top="382" left="378" width="193" height="17" font="0"> An angiographically demonstrated </text>
<text top="399" left="371" width="193" height="17" font="0">superficial femoral artery occlusion </text>
<text top="416" left="371" width="202" height="17" font="0">with reconstitution of a popliteal seg- </text>
<text top="433" left="371" width="118" height="17" font="0">ment above the knee </text>
<text top="451" left="371" width="7" height="18" font="7"></text>
<text top="452" left="378" width="149" height="17" font="0"> Not undergone any earlier </text>
<text top="469" left="371" width="187" height="17" font="0">infrainguinal vascular procedures. </text>
<text top="486" left="371" width="3" height="17" font="0"> </text>
<text top="503" left="371" width="170" height="17" font="2"><b>Exclusion criteria: </b>Adjunctive </text>
<text top="521" left="371" width="196" height="17" font="0">inflow procedures were not allowed </text>
<text top="538" left="371" width="182" height="17" font="0">at the time of the femoropopliteal </text>
<text top="555" left="371" width="200" height="17" font="0">bypass grafting procedure (previous </text>
<text top="572" left="371" width="198" height="17" font="0">aortofemoral, iliofemoral, or femoral-</text>
<text top="589" left="371" width="196" height="17" font="0">femoral bypass grafts were eligible, </text>
<text top="607" left="371" width="57" height="17" font="0">however).<b> </b></text>
<text top="363" left="587" width="117" height="17" font="2"><b>Intervention:</b> Above-</text>
<text top="381" left="587" width="75" height="17" font="0">knee femoral-</text>
<text top="398" left="587" width="92" height="17" font="0">popliteal bypass </text>
<text top="415" left="587" width="3" height="17" font="0"> </text>
<text top="432" left="587" width="109" height="17" font="2"><b>Comparator:</b> Gore-</text>
<text top="449" left="587" width="107" height="17" font="0">tex vs. Hemashield </text>
<text top="467" left="587" width="34" height="17" font="0">grafts<b> </b></text>
<text top="364" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="363" left="729" width="6" height="18" font="7"></text>
<text top="364" left="735" width="152" height="17" font="2"><b> endpoint:</b> No difference in </text>
<text top="382" left="722" width="196" height="17" font="0">primary or secondary patency rates </text>
<text top="399" left="722" width="166" height="17" font="0">at 5 yrs between the 2 grafts. <b> </b></text>
<text top="363" left="931" width="171" height="17" font="0">Primary patency 45% vs. 43%. </text>
<text top="381" left="931" width="156" height="17" font="0">Secondary patency 68% vs. </text>
<text top="398" left="931" width="32" height="17" font="0">68%. </text>
<text top="415" left="931" width="124" height="17" font="0">Risk of graft occlusion </text>
<text top="432" left="931" width="153" height="17" font="0">increased for pts age &lt;65 d </text>
<text top="449" left="931" width="147" height="17" font="0">(HR: 2.1; p=0.001) and for </text>
<text top="467" left="931" width="155" height="17" font="0">grafts with diameters &lt;7mm </text>
<text top="484" left="931" width="122" height="17" font="0">(HR: 1.65; p=0.0219). </text>
<text top="625" left="95" width="74" height="17" font="0">Johnson WC </text>
<text top="642" left="95" width="68" height="17" font="0">and Lee KK </text>
<text top="659" left="95" width="59" height="17" font="0">1999(280) </text>
<text top="676" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10587392">10587392</a></text>
<text top="676" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10587392"> </a></text>
<text top="693" left="95" width="3" height="17" font="0"> </text>
<text top="625" left="203" width="138" height="17" font="2"><b>Aim:</b> To identify whether </text>
<text top="642" left="203" width="135" height="17" font="0">improved patency exists </text>
<text top="659" left="203" width="144" height="17" font="0">with different bypass graft </text>
<text top="676" left="203" width="116" height="17" font="0">materials for pts with </text>
<text top="693" left="203" width="132" height="17" font="0">femoral-popliteal above-</text>
<text top="711" left="203" width="114" height="17" font="0">knee bypass grafts.  </text>
<text top="728" left="203" width="3" height="17" font="0"> </text>
<text top="745" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="762" left="203" width="3" height="17" font="0"> </text>
<text top="625" left="371" width="187" height="17" font="2"><b>Inclusion criteria: </b>Pts scheduled </text>
<text top="642" left="371" width="174" height="17" font="0">for femoral-AK popliteal bypass </text>
<text top="659" left="371" width="187" height="17" font="0">grafting at 20 VA Medical Centers<b> </b></text>
<text top="676" left="371" width="3" height="17" font="0"> </text>
<text top="693" left="371" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="711" left="371" width="7" height="18" font="7"></text>
<text top="712" left="378" width="146" height="17" font="0"> Noncompressible vessels </text>
<text top="729" left="371" width="7" height="18" font="7"></text>
<text top="730" left="378" width="54" height="17" font="0"> ABI &gt;0.9 </text>
<text top="747" left="371" width="7" height="18" font="7"></text>
<text top="748" left="378" width="193" height="17" font="0"> Prior ipsilateral prosthetic fem-pop </text>
<text top="766" left="371" width="171" height="17" font="0">AK or below-knee bypass graft </text>
<text top="625" left="587" width="116" height="17" font="2"><b>Intervention:</b> above-</text>
<text top="642" left="587" width="75" height="17" font="0">knee femoral-</text>
<text top="659" left="587" width="92" height="17" font="0">popliteal bypass </text>
<text top="676" left="587" width="35" height="17" font="0">graft.<b> </b> </text>
<text top="693" left="587" width="3" height="17" font="0"> </text>
<text top="711" left="587" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="728" left="587" width="114" height="17" font="0">externally supported </text>
<text top="745" left="587" width="114" height="17" font="0">PTFE (n=265), HUV </text>
<text top="762" left="587" width="109" height="17" font="0">(n=261), or SV (n = </text>
<text top="626" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="625" left="729" width="6" height="18" font="7"></text>
<text top="626" left="735" width="149" height="17" font="2"><b> endpoint:</b> The cumulative </text>
<text top="643" left="722" width="170" height="17" font="0">assisted primary patency rates </text>
<text top="660" left="722" width="178" height="17" font="0">were similar among the different </text>
<text top="677" left="722" width="178" height="17" font="0">conduit types at 2 yrs (SV: 81%; </text>
<text top="695" left="722" width="191" height="17" font="0">HUV: 70%; PTFE: 69%). After 5 y, </text>
<text top="712" left="722" width="188" height="17" font="0">above-knee SV bypass grafts had </text>
<text top="729" left="722" width="163" height="17" font="0">a significantly (<i>p</i>≤0.01) better </text>
<text top="746" left="722" width="164" height="17" font="0">patency rate (73%) than HUV </text>
<text top="763" left="722" width="185" height="17" font="0">bypass grafts (53%), which had a </text>
<text top="625" left="931" width="172" height="17" font="0">Possible bias against HUV and </text>
<text top="642" left="931" width="173" height="17" font="0">PTFE- pts with prior SV graft in </text>
<text top="659" left="931" width="126" height="17" font="0">ipsilateral leg were not </text>
<text top="676" left="931" width="144" height="17" font="0">excluded, but instead had </text>
<text top="693" left="931" width="167" height="17" font="0">randomization limited to either </text>
<text top="711" left="931" width="82" height="17" font="0">HUV or PTFE. </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">128 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="90" height="17" font="2"><b>Size:</b> n=752 pts<b> </b></text>
<text top="87" left="371" width="109" height="17" font="0">emergency surgery </text>
<text top="104" left="371" width="7" height="18" font="7"></text>
<text top="105" left="378" width="115" height="17" font="0"> &lt;1 y life expectancy </text>
<text top="123" left="371" width="7" height="18" font="7"></text>
<text top="124" left="378" width="123" height="17" font="0"> Oral anticoagulation,  </text>
<text top="141" left="371" width="7" height="18" font="7"></text>
<text top="142" left="378" width="167" height="17" font="0"> Popliteal aneurysmal disease </text>
<text top="160" left="371" width="7" height="18" font="7"></text>
<text top="161" left="378" width="165" height="17" font="0"> Serum creatinine &gt;2.0 mg/dL </text>
<text top="178" left="371" width="7" height="18" font="7"></text>
<text top="179" left="378" width="194" height="17" font="0"> Polycythemia (red blood cell count </text>
<text top="196" left="371" width="141" height="17" font="0">higher than 7.5 × 106/mm</text>
<text top="197" left="512" width="4" height="11" font="11">3</text>
<text top="196" left="516" width="7" height="17" font="0">) </text>
<text top="214" left="371" width="7" height="18" font="7"></text>
<text top="215" left="378" width="133" height="17" font="0"> Platelet count &gt;106/mm</text>
<text top="216" left="511" width="4" height="11" font="11">2</text>
<text top="215" left="516" width="7" height="17" font="0"> <b> </b></text>
<text top="232" left="371" width="7" height="18" font="7"></text>
<text top="233" left="378" width="178" height="17" font="0"> Prior ipsilateral SV bypass graft </text>
<text top="250" left="371" width="127" height="17" font="0">were not excluded, but </text>
<text top="267" left="371" width="193" height="17" font="0">randomization was limited to either </text>
<text top="285" left="371" width="79" height="17" font="0">HUV or PTFE </text>
<text top="87" left="587" width="32" height="17" font="0">226) <b> </b></text>
<text top="87" left="722" width="153" height="17" font="0">significantly (p≤0.01) better </text>
<text top="104" left="722" width="176" height="17" font="0">patency rate than PTFE bypass </text>
<text top="122" left="722" width="77" height="17" font="0">grafts (39%).<b> </b> </text>
<text top="139" left="722" width="3" height="17" font="2"><b> </b></text>
<text top="303" left="95" width="90" height="17" font="0">Klinkert P, et al. </text>
<text top="320" left="95" width="59" height="17" font="0">2003(281) </text>
<text top="337" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12514593">12514593</a></text>
<text top="337" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12514593"> </a></text>
<text top="354" left="95" width="3" height="17" font="0"> </text>
<text top="303" left="203" width="151" height="17" font="2"><b>Aim:</b> To compare vein with </text>
<text top="320" left="203" width="146" height="17" font="0">polytetrafluoroethylene for </text>
<text top="337" left="203" width="143" height="17" font="0">femoropopliteal bypasses </text>
<text top="354" left="203" width="150" height="17" font="0">with the distal anastomosis </text>
<text top="371" left="203" width="88" height="17" font="0">above the knee </text>
<text top="389" left="203" width="3" height="17" font="0"> </text>
<text top="406" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="423" left="203" width="3" height="17" font="0"> </text>
<text top="440" left="203" width="153" height="17" font="2"><b>Size:</b> n=151 bypasses (120 </text>
<text top="457" left="203" width="90" height="17" font="0">for claudication)<b> </b></text>
<text top="303" left="371" width="198" height="17" font="2"><b>Inclusion criteria: </b>Femoropopliteal </text>
<text top="320" left="371" width="193" height="17" font="0">bypass with the distal anastomosis </text>
<text top="337" left="371" width="176" height="17" font="0">to the popliteal artery above the </text>
<text top="354" left="371" width="30" height="17" font="0">knee<b> </b></text>
<text top="371" left="371" width="3" height="17" font="0"> </text>
<text top="389" left="371" width="190" height="17" font="2"><b>Exclusion criteria: </b>Earlier arterial </text>
<text top="406" left="371" width="196" height="17" font="0">bypass graft procedure in the same </text>
<text top="423" left="371" width="186" height="17" font="0">leg or with the greater saphenous </text>
<text top="440" left="371" width="118" height="17" font="0">vein removed earlier.<b> </b></text>
<text top="303" left="587" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="320" left="587" width="118" height="17" font="0">Femoral-AK popliteal </text>
<text top="337" left="587" width="42" height="17" font="0">bypass </text>
<text top="354" left="587" width="3" height="17" font="0"> </text>
<text top="371" left="587" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="389" left="587" width="99" height="17" font="0">Venous vs. PTFE </text>
<text top="406" left="587" width="71" height="17" font="0">graft conduit<b> </b></text>
<text top="304" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="303" left="729" width="6" height="18" font="7"></text>
<text top="304" left="735" width="155" height="17" font="2"><b> endpoint:</b> Primary patency </text>
<text top="321" left="722" width="175" height="17" font="0">rates after 5 yrs were 75.6% for </text>
<text top="338" left="722" width="182" height="17" font="0">venous bypass grafts and 51.9% </text>
<text top="355" left="722" width="147" height="17" font="0">for PTFE grafts (p=0.035). </text>
<text top="373" left="722" width="170" height="17" font="0">Secondary patency rates were </text>
<text top="390" left="722" width="162" height="17" font="0">79.7% for vein and 57.2% for </text>
<text top="407" left="722" width="154" height="17" font="0">PTFE bypasses (p=0 .036).<b> </b></text>
<text top="303" left="931" width="167" height="17" font="0">Reversed vein was used in 75 </text>
<text top="320" left="931" width="138" height="17" font="0">bypass grafts, and 6 mm </text>
<text top="337" left="931" width="54" height="17" font="0">stretched </text>
<text top="354" left="931" width="128" height="17" font="0">polytetrafluoroethylene </text>
<text top="371" left="931" width="141" height="17" font="0">prostheses were used 76 </text>
<text top="389" left="931" width="40" height="17" font="0">times.  </text>
<text top="476" left="95" width="82" height="17" font="0">Veith FJ, et al. </text>
<text top="493" left="95" width="59" height="17" font="0">1986(282) </text>
<text top="510" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3510323">3510323</a></text>
<text top="510" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3510323"> </a></text>
<text top="527" left="95" width="3" height="17" font="0"> </text>
<text top="476" left="203" width="145" height="17" font="2"><b>Aim:</b> Compare patency of </text>
<text top="493" left="203" width="143" height="17" font="0">PTFE vs. saphenous vein </text>
<text top="510" left="203" width="133" height="17" font="0">for infra-inguinal arterial </text>
<text top="527" left="203" width="87" height="17" font="0">reconstructions </text>
<text top="544" left="203" width="3" height="17" font="0"> </text>
<text top="562" left="203" width="140" height="17" font="2"><b>Study type:</b> prospective, </text>
<text top="579" left="203" width="135" height="17" font="0">randomized, multicenter </text>
<text top="596" left="203" width="3" height="17" font="0"> </text>
<text top="613" left="203" width="129" height="17" font="2"><b>Size:</b> n=845 bypasses. </text>
<text top="630" left="203" width="93" height="17" font="0">&lt;20% of pts had </text>
<text top="648" left="203" width="72" height="17" font="0">claudication.<b> </b></text>
<text top="476" left="371" width="184" height="17" font="2"><b>Inclusion criteria: </b>Bypass to the </text>
<text top="493" left="371" width="202" height="17" font="0">popliteal or an infrapopliteal artery to </text>
<text top="510" left="371" width="152" height="17" font="0">control ischemia caused by </text>
<text top="527" left="371" width="86" height="17" font="0">atherosclerosis<b> </b></text>
<text top="544" left="371" width="3" height="17" font="0"> </text>
<text top="562" left="371" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="579" left="371" width="7" height="18" font="7"></text>
<text top="580" left="378" width="174" height="17" font="0"> Bypass for non-PAD diagnosis </text>
<text top="597" left="371" width="7" height="18" font="7"></text>
<text top="598" left="378" width="183" height="17" font="0"> Ability to treat with endovascular </text>
<text top="616" left="371" width="189" height="17" font="0">approach or through deep femoral </text>
<text top="633" left="371" width="187" height="17" font="0">revascularizastion without bypass </text>
<text top="650" left="371" width="7" height="18" font="7"></text>
<text top="651" left="378" width="120" height="17" font="0"> Sequential bypasses </text>
<text top="668" left="371" width="7" height="18" font="7"></text>
<text top="669" left="378" width="100" height="17" font="0"> Composite grafts </text>
<text top="687" left="371" width="7" height="18" font="7"></text>
<text top="688" left="378" width="94" height="17" font="0"> Inadequate vein </text>
<text top="476" left="587" width="113" height="17" font="2"><b>Intervention:</b> PTFE </text>
<text top="493" left="587" width="3" height="17" font="0"> </text>
<text top="510" left="587" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="527" left="587" width="62" height="17" font="0">Autogenus </text>
<text top="544" left="587" width="118" height="17" font="0">saphenous vein graft<b> </b></text>
<text top="477" left="722" width="7" height="17" font="2"><b>1</b></text>
<text top="476" left="729" width="6" height="18" font="7"></text>
<text top="477" left="735" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="494" left="722" width="7" height="18" font="7"></text>
<text top="495" left="729" width="163" height="17" font="0"> Patency and limb salvage by </text>
<text top="512" left="722" width="128" height="17" font="0">distal anastomotic site. </text>
<text top="530" left="722" width="7" height="18" font="7"></text>
<text top="531" left="729" width="177" height="17" font="0"> No difference in 4 y patency for </text>
<text top="548" left="722" width="195" height="17" font="0">above-knee grafts. No difference in </text>
<text top="565" left="722" width="160" height="17" font="0">rates of limb salvage for CLI. </text>
<text top="582" left="722" width="7" height="18" font="7"></text>
<text top="583" left="729" width="132" height="17" font="0"> 4 y primary patency for </text>
<text top="601" left="722" width="159" height="17" font="0">infrapopliteal bypasses were </text>
<text top="618" left="722" width="176" height="17" font="0">inferior for PTFE (49% vs. 12%, </text>
<text top="635" left="722" width="56" height="17" font="0">p&lt;0.001). </text>
<text top="476" left="931" width="172" height="17" font="0">Inadequate vein defined based </text>
<text top="493" left="931" width="166" height="17" font="0">on diameter &lt;3.0 mm for graft </text>
<text top="510" left="931" width="158" height="17" font="0">to tibial artery or &lt;4.0mm for </text>
<text top="527" left="931" width="129" height="17" font="0">graft to popliteal artery. </text>
<text top="706" left="86" width="992" height="17" font="0">ABF indicates aortobifemoral bypass; ABI, ankle-brachial index; AK, above knee; BASI, bioabsorbable stent; CFA, common femoral artery; CFE, common femoral endarterectomy; CI </text>
<text top="723" left="86" width="964" height="17" font="0">indicates confidence interval; CFA, common femoral artery; CFE, common femoral artery endarectomy; CLI, critical limb ischemia; EIA-external iliac artery; ENDO, endovascular </text>
<text top="740" left="86" width="1018" height="17" font="0">interventions; ePTFE, expanded polytetrafluoroethylene; HR, hazard ratio; HUV, human umbilical vein; IC, intermittent claudication; MWD, maximum walking distance; N/A, not applicable; </text>
<text top="757" left="86" width="1007" height="17" font="0">OR, odds ratio; PTA, percutaneous transluminal angioplasty; PTAS, percutaneous transluminal angioplasty stent; PTFE, polytetrafluoroethylene; pt, patient; RCT, randomized controlled </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">129 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="979" height="17" font="0">trail; RE, remote endarterectomy; R/PTAS, percutaneous transluminal angioplasty, and stenting; RR-relative risk; RSFAE, remote superficial artery endarterectomy; SA-RIEA, stent </text>
<text top="104" left="86" width="1014" height="17" font="0">assisted remote iliac endarterectomy; SFA, superficial femoral artery; SIA, subintimal angioplasty; SV, saphenous vein; TASC, transatlantic inter-society consensus; and TL, target lesion. </text>
<text top="121" left="86" width="3" height="17" font="0"> </text>
<text top="138" left="86" width="3" height="17" font="0"> </text>
<text top="155" left="86" width="963" height="21" font="1"><b>Evidence Table 38. Nonrandomized Trials, Observational Studies, and/or Registries of Surgical Treatment for Claudication–Section 8.1.2. </b></text>
<text top="177" left="103" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="194" left="128" width="48" height="17" font="2"><b>Author; </b></text>
<text top="211" left="106" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="177" left="258" width="38" height="17" font="2"><b>Study </b></text>
<text top="194" left="237" width="81" height="17" font="2"><b>Type/Design; </b></text>
<text top="211" left="244" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="177" left="380" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="177" left="599" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="194" left="607" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="211" left="659" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="177" left="914" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="194" left="942" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="229" left="95" width="100" height="17" font="0">Nguyen BN, et al. </text>
<text top="246" left="95" width="59" height="17" font="0">2015(283) </text>
<text top="263" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25702917">25702917 </a></text>
<text top="281" left="95" width="3" height="17" font="0"> </text>
<text top="229" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="246" left="223" width="3" height="17" font="0"> </text>
<text top="263" left="223" width="66" height="17" font="2"><b>Size:</b> 1,843 </text>
<text top="281" left="223" width="65" height="17" font="0">procedures </text>
<text top="229" left="344" width="159" height="17" font="2"><b>Inclusion criteria:</b> Common </text>
<text top="246" left="344" width="156" height="17" font="0">femoral endarterectomies in </text>
<text top="263" left="344" width="96" height="17" font="0">NSQIP database </text>
<text top="281" left="344" width="3" height="17" font="0"> </text>
<text top="298" left="344" width="178" height="17" font="2"><b>Exclusion criteria:</b> Other major </text>
<text top="315" left="344" width="170" height="17" font="0">procedures, hybrid procedures </text>
<text top="230" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="229" left="547" width="6" height="18" font="7"></text>
<text top="230" left="553" width="169" height="17" font="2"><b> endpoint:</b> Operative mortality </text>
<text top="247" left="540" width="3" height="17" font="0"> </text>
<text top="265" left="540" width="293" height="17" font="2"><b>Results: </b>3.4% mortality; mortality predictors included </text>
<text top="282" left="540" width="287" height="17" font="0">age, nonindependent functional status, preoperative </text>
<text top="299" left="540" width="286" height="17" font="0">dialysis, sepsis, emergency status, and ASA class 4 </text>
<text top="316" left="540" width="25" height="17" font="0">or 5 </text>
<text top="229" left="851" width="7" height="18" font="7"></text>
<text top="230" left="857" width="139" height="17" font="0"> Not claudication-specific </text>
<text top="334" left="95" width="72" height="17" font="0">Lo RC, et al.<b> </b></text>
<text top="351" left="95" width="31" height="17" font="0">2014 </text>
<text top="369" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24080134">24080134 </a></text>
<text top="386" left="95" width="32" height="17" font="0">(284) </text>
<text top="334" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="351" left="223" width="3" height="17" font="0"> </text>
<text top="369" left="223" width="104" height="17" font="2"><b>Size:</b> n=1,797,885 </text>
<text top="386" left="223" width="20" height="17" font="0">pts </text>
<text top="334" left="344" width="178" height="17" font="2"><b>Inclusion criteria:</b> Pts admitted </text>
<text top="351" left="344" width="163" height="17" font="0">with IC identified through NIS </text>
<text top="369" left="344" width="178" height="17" font="0">dataset based on ICD-9 primary </text>
<text top="386" left="344" width="139" height="17" font="0">and secondary Dx codes </text>
<text top="403" left="344" width="3" height="17" font="0"> </text>
<text top="420" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="335" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="334" left="547" width="6" height="18" font="7"></text>
<text top="335" left="553" width="281" height="17" font="2"><b> endpoint:</b> In-hospital mortality stratified by gender </text>
<text top="353" left="540" width="3" height="17" font="0"> </text>
<text top="370" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="387" left="540" width="7" height="18" font="7"></text>
<text top="388" left="547" width="217" height="17" font="0"> Mortality lowest among pts undergoing </text>
<text top="405" left="540" width="283" height="17" font="0">endovascular procedures and highest among those </text>
<text top="423" left="540" width="202" height="17" font="0">undergoing open+endo procedures.  </text>
<text top="440" left="540" width="7" height="18" font="7"></text>
<text top="441" left="547" width="280" height="17" font="0"> Women had higher mortality rates than men for all </text>
<text top="458" left="540" width="285" height="17" font="0">procedures (open: 1.0% vs. .7%; OR: 1.37; 95% CI; </text>
<text top="475" left="540" width="297" height="17" font="0">1.25–1.49; p&lt;0.01; endovascular: 0.5% vs. 0.2%; OR; </text>
<text top="493" left="540" width="284" height="17" font="0">1.99; 95% CI: 1.72–2.30; p&lt;0.01; open+endo: 1.8% </text>
<text top="510" left="540" width="261" height="17" font="0">vs. .8%; OR: 2.13; 95% CI: 1.76–2.58; p&lt;0.01). </text>
<text top="334" left="851" width="7" height="18" font="7"></text>
<text top="335" left="857" width="241" height="17" font="0"> Claudication pts were a subgroup analysis, </text>
<text top="353" left="851" width="239" height="17" font="0">but reference provides claudication-specific </text>
<text top="370" left="851" width="233" height="17" font="0">mortality rates stratified by procedure type </text>
<text top="387" left="851" width="7" height="18" font="7"></text>
<text top="388" left="857" width="231" height="17" font="0"> Hypothesis and models based on gender </text>
<text top="405" left="851" width="7" height="18" font="7"></text>
<text top="406" left="857" width="244" height="17" font="0"> In-hospital mortality highest among pts who </text>
<text top="424" left="851" width="199" height="17" font="0">had hybrid (open+endo) procedures </text>
<text top="441" left="851" width="7" height="18" font="7"></text>
<text top="442" left="857" width="213" height="17" font="0"> In-hospital mortality lowest among pts </text>
<text top="459" left="851" width="207" height="17" font="0">undergoing endovascular procedures </text>
<text top="528" left="95" width="100" height="17" font="0">Siracuse JJ, et al. </text>
<text top="545" left="95" width="59" height="17" font="0">2014(285) </text>
<text top="562" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24142958">24142958 </a></text>
<text top="579" left="95" width="3" height="17" font="0"> </text>
<text top="528" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="545" left="223" width="3" height="17" font="0"> </text>
<text top="562" left="223" width="100" height="17" font="2"><b>Size:</b> n=1,513 pts </text>
<text top="579" left="223" width="78" height="17" font="0">from the ACS-</text>
<text top="597" left="223" width="86" height="17" font="0">NSQIP dataset </text>
<text top="614" left="223" width="107" height="17" font="0">(no stratification by </text>
<text top="631" left="223" width="74" height="17" font="0">IC/CLI/other) </text>
<text top="528" left="344" width="180" height="17" font="2"><b>Inclusion criteria:</b> Elective CFE </text>
<text top="545" left="344" width="3" height="17" font="0"> </text>
<text top="562" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="529" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="528" left="547" width="6" height="18" font="7"></text>
<text top="529" left="553" width="140" height="17" font="2"><b> endpoint:</b> 30 d mortality </text>
<text top="546" left="540" width="3" height="17" font="0"> </text>
<text top="563" left="540" width="263" height="17" font="2"><b>Results: </b>Partial- and total-dependent functional </text>
<text top="581" left="540" width="296" height="17" font="0">status (OR: 9.0; 95% CI: 2.8–28.4 and OR: 21.3; 95% </text>
<text top="598" left="540" width="293" height="17" font="0">CI: 3.3–139.4) and dyspnea at rest (OR: 8.2; 95% CI: </text>
<text top="615" left="540" width="163" height="17" font="0">1.2–58.8) predicted mortality  </text>
<text top="528" left="851" width="7" height="18" font="7"></text>
<text top="529" left="857" width="241" height="17" font="0"> No claudication-specific results or ABI data </text>
<text top="546" left="851" width="7" height="18" font="7"></text>
<text top="547" left="857" width="233" height="17" font="0"> Major morbidity (aggregate): Independent </text>
<text top="565" left="851" width="230" height="17" font="0">predictors of morbidity include steroid use </text>
<text top="582" left="851" width="256" height="17" font="0">(OR: 2.4; 95% CI: 1.4–4.1), DM (OR: 1.8; 95% </text>
<text top="599" left="851" width="238" height="17" font="0">CI: 1.3–2.4), and obesity (OR: 1.6; 95% CI: </text>
<text top="616" left="851" width="52" height="17" font="0">1.1–2.4). </text>
<text top="633" left="851" width="7" height="18" font="7"></text>
<text top="635" left="857" width="237" height="17" font="0"> Postoperative morbidities included cardiac </text>
<text top="652" left="851" width="221" height="17" font="0">(1.0%), pulmonary (1.9%), renal (0.4%), </text>
<text top="669" left="851" width="252" height="17" font="0">urinary tract infection (1.7%), thromboembolic </text>
<text top="686" left="851" width="228" height="17" font="0">(0.5%), neurologic (0.4%), sepsis (2.7%), </text>
<text top="703" left="851" width="225" height="17" font="0">superficial (6.3%), and deep surgical site </text>
<text top="721" left="851" width="124" height="17" font="0">complications (2.0%).  </text>
<text top="738" left="851" width="7" height="18" font="7"></text>
<text top="739" left="857" width="243" height="17" font="0"> At least 1 complication, including major and </text>
<text top="756" left="851" width="195" height="17" font="0">minor, was seen in 7.9% of the pts. </text>
<text top="774" left="95" width="85" height="17" font="0">Aihara H, et al. </text>
<text top="774" left="223" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="774" left="344" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="775" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="774" left="547" width="6" height="18" font="7"></text>
<text top="775" left="553" width="155" height="17" font="2"><b> endpoint:</b> Primary patency </text>
<text top="774" left="851" width="7" height="18" font="7"></text>
<text top="775" left="857" width="239" height="17" font="0"> Overall complication rate was 14.4% in the </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">130 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="59" height="17" font="0">2014(286) </text>
<text top="104" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24292129">24292129 </a></text>
<text top="122" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="68" height="17" font="0">pooled data </text>
<text top="104" left="223" width="92" height="17" font="0">registry analysis </text>
<text top="122" left="223" width="45" height="17" font="0">(Japan) </text>
<text top="139" left="223" width="3" height="17" font="0"> </text>
<text top="156" left="223" width="90" height="17" font="2"><b>Size:</b> n=263 pts </text>
<text top="173" left="223" width="68" height="17" font="0">(313 limbs); </text>
<text top="190" left="223" width="104" height="17" font="0">endovascular: 177 </text>
<text top="208" left="223" width="87" height="17" font="0">pts (202 limbs); </text>
<text top="225" left="223" width="83" height="17" font="0">bypass: 86 pts </text>
<text top="242" left="223" width="64" height="17" font="0">(111 limbs) </text>
<text top="87" left="344" width="179" height="17" font="0">Endovascular therapy or bypass </text>
<text top="104" left="344" width="154" height="17" font="0">surgery for claudication and </text>
<text top="122" left="344" width="148" height="17" font="0">TASC C/D femoropopliteal </text>
<text top="139" left="344" width="46" height="17" font="0">disease </text>
<text top="156" left="344" width="3" height="17" font="0"> </text>
<text top="173" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="190" left="344" width="7" height="18" font="7"></text>
<text top="192" left="351" width="107" height="17" font="0"> Hybrid procedures </text>
<text top="209" left="344" width="7" height="18" font="7"></text>
<text top="210" left="351" width="90" height="17" font="0"> Acute ischemia </text>
<text top="227" left="344" width="7" height="18" font="7"></text>
<text top="228" left="351" width="26" height="17" font="0"> CLI </text>
<text top="246" left="344" width="7" height="18" font="7"></text>
<text top="247" left="351" width="63" height="17" font="0"> TASC A/B </text>
<text top="87" left="540" width="3" height="17" font="0"> </text>
<text top="104" left="540" width="290" height="17" font="2"><b>Results: </b>1 and 5 y primary patency rates 82.1% and </text>
<text top="122" left="540" width="286" height="17" font="0">69.4% in the bypass group and 67.8% and 45.2% in </text>
<text top="139" left="540" width="284" height="17" font="0">the endovascular treatment group (p&lt;0.01, log-rank </text>
<text top="156" left="540" width="27" height="17" font="0">test) </text>
<text top="87" left="851" width="238" height="17" font="0">bypass surgery group and 3.5% in the EVT </text>
<text top="104" left="851" width="84" height="17" font="0">group (p&lt;0.01) </text>
<text top="265" left="95" width="79" height="17" font="0">Boufi M, et al. </text>
<text top="282" left="95" width="59" height="17" font="0">2013(287) </text>
<text top="299" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23835109">23835109 </a></text>
<text top="316" left="95" width="3" height="17" font="0"> </text>
<text top="265" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="282" left="223" width="74" height="17" font="0">retrospective </text>
<text top="299" left="223" width="53" height="17" font="0">(France)  </text>
<text top="316" left="223" width="3" height="17" font="0"> </text>
<text top="334" left="223" width="102" height="17" font="2"><b>Size:</b> n=150 limbs </text>
<text top="351" left="223" width="84" height="17" font="0">(82 bypass, 58 </text>
<text top="368" left="223" width="57" height="17" font="0">SIA/stent) </text>
<text top="265" left="344" width="174" height="17" font="2"><b>Inclusion criteria: </b>Claudicants </text>
<text top="282" left="344" width="158" height="17" font="0">with femoropopliteal disease </text>
<text top="299" left="344" width="135" height="17" font="0">treated with above-knee </text>
<text top="316" left="344" width="178" height="17" font="0">femoropopliteal bypass or SIA + </text>
<text top="334" left="344" width="47" height="17" font="0">stenting </text>
<text top="351" left="344" width="3" height="17" font="0"> </text>
<text top="368" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="266" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="265" left="547" width="6" height="18" font="7"></text>
<text top="266" left="553" width="111" height="17" font="2"><b> endpoint:</b> Patency </text>
<text top="283" left="540" width="3" height="17" font="0"> </text>
<text top="300" left="540" width="262" height="17" font="2"><b>Results: </b>24 mo, primary, primary-assisted, and </text>
<text top="318" left="540" width="284" height="17" font="0">secondary patency for bypass vs. SIA+stent groups </text>
<text top="335" left="540" width="257" height="17" font="0">was, respectively, 66.6% vs. 70.1%; 76.5% vs. </text>
<text top="352" left="540" width="168" height="17" font="0">90.1%; and 88.2% vs. 90.1%.  </text>
<text top="265" left="851" width="7" height="18" font="7"></text>
<text top="266" left="857" width="215" height="17" font="0"> No statistical test provided for patency </text>
<text top="283" left="851" width="169" height="17" font="0">difference between treatments </text>
<text top="386" left="95" width="112" height="17" font="0">Sachwani GR, et al. </text>
<text top="403" left="95" width="59" height="17" font="0">2013(288) </text>
<text top="420" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23177535">23177535 </a></text>
<text top="438" left="95" width="3" height="17" font="0"> </text>
<text top="386" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="403" left="223" width="77" height="17" font="0">retrospective  </text>
<text top="420" left="223" width="3" height="17" font="0"> </text>
<text top="438" left="223" width="90" height="17" font="2"><b>Size:</b> n=229 pts </text>
<text top="455" left="223" width="97" height="17" font="0">(66% of ABF and </text>
<text top="472" left="223" width="42" height="17" font="0">71% of </text>
<text top="489" left="223" width="103" height="17" font="0">percutaneous iliac </text>
<text top="506" left="223" width="95" height="17" font="0">stent group were </text>
<text top="524" left="223" width="69" height="17" font="0">claudicants) </text>
<text top="386" left="344" width="148" height="17" font="2"><b>Inclusion criteria:</b> Sx iliac </text>
<text top="403" left="344" width="135" height="17" font="0">artery occlusive disease </text>
<text top="420" left="344" width="150" height="17" font="0">undergoing iliac stenting or </text>
<text top="438" left="344" width="118" height="17" font="0">aortofemoral bypass  </text>
<text top="455" left="344" width="3" height="17" font="0"> </text>
<text top="472" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="387" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="386" left="547" width="6" height="18" font="7"></text>
<text top="387" left="553" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="404" left="540" width="7" height="18" font="7"></text>
<text top="405" left="547" width="51" height="17" font="0"> Patency </text>
<text top="423" left="540" width="7" height="18" font="7"></text>
<text top="424" left="547" width="51" height="17" font="0"> Survival </text>
<text top="441" left="540" width="3" height="17" font="0"> </text>
<text top="458" left="540" width="264" height="17" font="2"><b>Results: </b>At 72 mo, the primary patency for ABF </text>
<text top="476" left="540" width="270" height="17" font="0">bypass was greater than for PCIS (91% vs. 73%; </text>
<text top="493" left="540" width="285" height="17" font="0">p=0.010). Secondary patency rates were equivalent </text>
<text top="510" left="540" width="288" height="17" font="0">in both groups (98% ABF vs. 85% PCIS). Survival in </text>
<text top="527" left="540" width="287" height="17" font="0">the ABF bypass group was significantly greater than </text>
<text top="544" left="540" width="239" height="17" font="0">in the PCIS group (76% vs. 68%; p=0.013). </text>
<text top="386" left="851" width="7" height="18" font="7"></text>
<text top="387" left="857" width="124" height="17" font="0"> Includes pts with CLI  </text>
<text top="404" left="851" width="7" height="18" font="7"></text>
<text top="405" left="857" width="243" height="17" font="0"> Pts in the ABF grafting group were younger </text>
<text top="423" left="851" width="255" height="17" font="0">(age 60±0.9 y vs. age 65±1.2 y; p=0.002) and </text>
<text top="440" left="851" width="240" height="17" font="0">more commonly had a Hx of nicotine abuse </text>
<text top="457" left="851" width="229" height="17" font="0">(97% vs. 86%; p=0.002), COPD (85% vs. </text>
<text top="474" left="851" width="226" height="17" font="0">70%; p=0.02), and a greater incidence of </text>
<text top="492" left="851" width="235" height="17" font="0">superficial femoral artery disease (45% vs. </text>
<text top="509" left="851" width="87" height="17" font="0">24%; p=0.001). </text>
<text top="526" left="851" width="7" height="18" font="7"></text>
<text top="527" left="857" width="234" height="17" font="0"> “Iliac stenting has lower morbidity, shorter </text>
<text top="544" left="851" width="209" height="17" font="0">hospital length of stay, and equivalent </text>
<text top="562" left="851" width="213" height="17" font="0">secondary patency but inferior primary </text>
<text top="579" left="851" width="165" height="17" font="0">patency compared with ABF.” </text>
<text top="597" left="95" width="93" height="17" font="0">Jones WS, et al. </text>
<text top="614" left="95" width="59" height="17" font="0">2013(289) </text>
<text top="631" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23844447">23844447</a></text>
<text top="631" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23844447"> </a></text>
<text top="648" left="95" width="3" height="17" font="0"> </text>
<text top="597" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="614" left="223" width="103" height="17" font="0">Systematic review </text>
<text top="631" left="223" width="47" height="17" font="0">(AHRQ) </text>
<text top="648" left="223" width="3" height="17" font="0"> </text>
<text top="666" left="223" width="106" height="17" font="2"><b>Size: </b>n=83 studies </text>
<text top="683" left="223" width="64" height="17" font="0">contributed </text>
<text top="700" left="223" width="103" height="17" font="0">evidence; 35 were </text>
<text top="717" left="223" width="68" height="17" font="0">claudication </text>
<text top="734" left="223" width="96" height="17" font="0">specific, while 12 </text>
<text top="752" left="223" width="93" height="17" font="0">evaluated mixed </text>
<text top="769" left="223" width="104" height="17" font="0">cohorts of CLI and </text>
<text top="597" left="344" width="159" height="17" font="2"><b>Inclusion criteria: </b>PubMed, </text>
<text top="614" left="344" width="153" height="17" font="0">Embase, and the Cochrane </text>
<text top="631" left="344" width="133" height="17" font="0">Database of Systematic </text>
<text top="648" left="344" width="159" height="17" font="0">Reviews for relevant English </text>
<text top="666" left="344" width="152" height="17" font="0">language studies published </text>
<text top="683" left="344" width="110" height="17" font="0">since January 1995 </text>
<text top="700" left="344" width="3" height="17" font="0"> </text>
<text top="717" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="598" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="597" left="547" width="6" height="18" font="7"></text>
<text top="598" left="553" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="615" left="540" width="3" height="17" font="0"> </text>
<text top="632" left="540" width="278" height="17" font="2"><b>Results: </b>For claudication, data were too sparse to </text>
<text top="650" left="540" width="246" height="17" font="0">definitively conclude which treatment is most </text>
<text top="667" left="540" width="286" height="17" font="0">effective. QoL showed significant improvement from </text>
<text top="684" left="540" width="230" height="17" font="0">cilostazol, exercise training, endovascular </text>
<text top="701" left="540" width="291" height="17" font="0">intervention, and surgical intervention compared with </text>
<text top="718" left="540" width="294" height="17" font="0">usual care. The potential additive effects of combined </text>
<text top="736" left="540" width="297" height="17" font="0">treatment strategies and the timing of these combined </text>
<text top="753" left="540" width="134" height="17" font="0">strategies are unknown. </text>
<text top="597" left="851" width="257" height="17" font="0">Surgery is effective for claudication, but limited </text>
<text top="614" left="851" width="250" height="17" font="0">comparative evidence to support it over other </text>
<text top="631" left="851" width="65" height="17" font="0">treatments. </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">131 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="72" height="17" font="0">claudication. </text>
<text top="105" left="95" width="107" height="17" font="0">Antoniou GA, et al. </text>
<text top="122" left="95" width="59" height="17" font="0">2013(290) </text>
<text top="139" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23159476">23159476</a></text>
<text top="139" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23159476"> </a></text>
<text top="157" left="95" width="3" height="17" font="0"> </text>
<text top="105" left="223" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="122" left="223" width="48" height="17" font="0">analysis </text>
<text top="139" left="223" width="3" height="17" font="0"> </text>
<text top="157" left="223" width="85" height="17" font="2"><b>Size:</b> n=4 RCT </text>
<text top="174" left="223" width="34" height="17" font="0">and 6 </text>
<text top="191" left="223" width="77" height="17" font="0">observational </text>
<text top="208" left="223" width="104" height="17" font="0">studies (2,817 pts; </text>
<text top="226" left="223" width="79" height="17" font="0">139=87 open, </text>
<text top="243" left="223" width="31" height="17" font="0">1430 </text>
<text top="260" left="223" width="94" height="17" font="0">endovascular). 1 </text>
<text top="277" left="223" width="58" height="17" font="0">study was </text>
<text top="294" left="223" width="98" height="17" font="0">claudication only, </text>
<text top="312" left="223" width="91" height="17" font="0">while 4 included </text>
<text top="329" left="223" width="79" height="17" font="0">pts with either </text>
<text top="346" left="223" width="83" height="17" font="0">claudication or </text>
<text top="363" left="223" width="26" height="17" font="0">CLI. </text>
<text top="105" left="344" width="150" height="17" font="2"><b>Inclusion criteria: </b>Studies </text>
<text top="122" left="344" width="161" height="17" font="0">comparing open surgical and </text>
<text top="139" left="344" width="148" height="17" font="0">percutaneous transluminal </text>
<text top="157" left="344" width="158" height="17" font="0">methods for the treatment of </text>
<text top="174" left="344" width="174" height="17" font="0">femoropopliteal arterial disease </text>
<text top="191" left="344" width="3" height="17" font="0"> </text>
<text top="208" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="106" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="105" left="547" width="6" height="18" font="7"></text>
<text top="106" left="553" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="123" left="540" width="3" height="17" font="0"> </text>
<text top="141" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="158" left="540" width="7" height="18" font="7"></text>
<text top="159" left="547" width="274" height="17" font="0"> Endovascular treatment had lower 30 d morbidity </text>
<text top="176" left="540" width="283" height="17" font="0">(OR: 2.93; 95% CI: 1.34–6.41) and higher technical </text>
<text top="194" left="540" width="276" height="17" font="0">failure (OR: 0.10; 95% CI: 0.05–0.22) than bypass </text>
<text top="211" left="540" width="269" height="17" font="0">surgery, whereas no differences in 30 d mortality </text>
<text top="228" left="540" width="293" height="17" font="0">between the 2 groups were identified (OR: 0.92; 95% </text>
<text top="245" left="540" width="88" height="17" font="0">CI: 0.55–1.51).  </text>
<text top="262" left="540" width="7" height="18" font="7"></text>
<text top="263" left="547" width="269" height="17" font="0"> Higher primary patency in the surgical treatment </text>
<text top="281" left="540" width="291" height="17" font="0">arm was found at 1 (OR: 2.42; 95% CI: 1.37–4.28), 2 </text>
<text top="298" left="540" width="295" height="17" font="0">(OR: 2.03; 95% CI: 1.20–3.45), and 3 (OR: 1.48; 95% </text>
<text top="315" left="540" width="179" height="17" font="0">CI: 1.12–1.97) y of intervention.  </text>
<text top="332" left="540" width="7" height="18" font="7"></text>
<text top="333" left="547" width="289" height="17" font="0"> Progression to amputation was found to occur more </text>
<text top="351" left="540" width="297" height="17" font="0">commonly in the endovascular group at the end of the </text>
<text top="368" left="540" width="293" height="17" font="0">second (OR: 0.60; 95% CI: 0.42–0.86) and third (OR; </text>
<text top="385" left="540" width="234" height="17" font="0">0.55; 95% CI: 0.39–0.77) y of intervention. </text>
<text top="402" left="540" width="7" height="18" font="7"></text>
<text top="403" left="547" width="275" height="17" font="0">  Higher amputation free and overall survival rates </text>
<text top="421" left="540" width="297" height="17" font="0">were found in the bypass group at 4 y (OR: 1.31; 95% </text>
<text top="438" left="540" width="266" height="17" font="0">CI: 1.07–1.61 and OR: 1.29; 95% CI: 1.04–1.61, </text>
<text top="455" left="540" width="76" height="17" font="0">respectively).<b> </b></text>
<text top="105" left="851" width="212" height="17" font="0">High level evidence demonstrating the </text>
<text top="122" left="851" width="234" height="17" font="0">superiority of one method over the other is </text>
<text top="139" left="851" width="245" height="17" font="0">lacking. An endovascular first approach may </text>
<text top="157" left="851" width="189" height="17" font="0">be advisable in pts with significant </text>
<text top="174" left="851" width="243" height="17" font="0">comorbidity, whereas for fit pts with a longer </text>
<text top="191" left="851" width="250" height="17" font="0">term perspective a bypass procedure may be </text>
<text top="208" left="851" width="250" height="17" font="0">offered as a first line interventional treatment. </text>
<text top="473" left="95" width="96" height="17" font="0">Malgor RD, et al. </text>
<text top="490" left="95" width="59" height="17" font="0">2012(291) </text>
<text top="508" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22944568">22944568 </a></text>
<text top="525" left="95" width="3" height="17" font="0"> </text>
<text top="473" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="490" left="223" width="77" height="17" font="0">retrospective, </text>
<text top="508" left="223" width="73" height="17" font="0">single center </text>
<text top="525" left="223" width="3" height="17" font="0"> </text>
<text top="542" left="223" width="70" height="17" font="2"><b>Size:</b> n=230 </text>
<text top="559" left="223" width="44" height="17" font="0">pts/262 </text>
<text top="576" left="223" width="65" height="17" font="0">procedures </text>
<text top="473" left="344" width="177" height="17" font="2"><b>Inclusion criteria:</b> Consecutive </text>
<text top="490" left="344" width="28" height="17" font="0">CFE </text>
<text top="508" left="344" width="3" height="17" font="0"> </text>
<text top="525" left="344" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="542" left="344" width="7" height="18" font="7"></text>
<text top="543" left="351" width="105" height="17" font="0"> Hx of infrainguinal </text>
<text top="560" left="344" width="151" height="17" font="0">revascularization, including </text>
<text top="578" left="344" width="148" height="17" font="0">aorto-,axillo-, or iliofemoral </text>
<text top="595" left="344" width="42" height="17" font="0">bypass </text>
<text top="612" left="344" width="7" height="18" font="7"></text>
<text top="613" left="351" width="126" height="17" font="0"> Cross-femoral bypass </text>
<text top="630" left="344" width="7" height="18" font="7"></text>
<text top="631" left="351" width="171" height="17" font="0"> Common femoral interposition </text>
<text top="649" left="344" width="44" height="17" font="0">grafting </text>
<text top="474" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="473" left="547" width="6" height="18" font="7"></text>
<text top="474" left="553" width="271" height="17" font="2"><b> endpoint:</b> Mortality, patency, reintervention, and </text>
<text top="492" left="540" width="288" height="17" font="0">limb salvage; analysis stratified by use of CFE alone </text>
<text top="509" left="540" width="294" height="17" font="0">(Group A) vs. CFE+distal revascularization (Group B) </text>
<text top="526" left="540" width="3" height="17" font="0"> </text>
<text top="543" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="560" left="540" width="7" height="18" font="7"></text>
<text top="561" left="547" width="283" height="17" font="0"> Cumulative 5 y primary patencies for groups A and </text>
<text top="579" left="540" width="235" height="17" font="0">group B were 96% and 92%, respectively.  </text>
<text top="596" left="540" width="7" height="18" font="7"></text>
<text top="597" left="547" width="280" height="17" font="0"> Secondary patency was 100% at both time points. </text>
<text top="614" left="540" width="284" height="17" font="0">Limb salvage was also lower in pts with RC 5 and 6 </text>
<text top="632" left="540" width="101" height="17" font="0">(p=0.01; p=0.02).  </text>
<text top="649" left="540" width="7" height="18" font="7"></text>
<text top="650" left="547" width="267" height="17" font="0"> Overall survival was 93% at 1 y and 77% at 5 y. </text>
<text top="667" left="540" width="274" height="17" font="0">There was no difference in survival between the 2 </text>
<text top="684" left="540" width="44" height="17" font="0">groups. </text>
<text top="473" left="851" width="7" height="18" font="7"></text>
<text top="474" left="857" width="238" height="17" font="0"> Predictors for distal revascularization were </text>
<text top="492" left="851" width="206" height="17" font="0">RC 5 or 6 (p&lt;0.001), TASC D lesions </text>
<text top="509" left="851" width="217" height="17" font="0">(p&lt;0.0001), DM (p=0.04), and being on </text>
<text top="526" left="851" width="86" height="17" font="0">anticoagulation </text>
<text top="543" left="851" width="60" height="17" font="0">(p=0.003). </text>
<text top="560" left="851" width="7" height="18" font="7"></text>
<text top="561" left="857" width="232" height="17" font="0"> 113 (67%) of group A and 37/85 (40%) of </text>
<text top="579" left="851" width="161" height="17" font="0">group B pts were claudicants </text>
<text top="702" left="95" width="96" height="17" font="0">Simons JP, et al. </text>
<text top="720" left="95" width="59" height="17" font="0">2012(292) </text>
<text top="737" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22608039">22608039 </a></text>
<text top="754" left="95" width="3" height="17" font="0"> </text>
<text top="702" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="720" left="223" width="107" height="17" font="0">multicenter registry </text>
<text top="737" left="223" width="90" height="17" font="0">(Vascular Study </text>
<text top="754" left="223" width="79" height="17" font="0">Group of New </text>
<text top="771" left="223" width="56" height="17" font="0">England)  </text>
<text top="702" left="344" width="176" height="17" font="2"><b>Inclusion criteria:</b> Elective and </text>
<text top="720" left="344" width="170" height="17" font="0">urgent infrainguinal LEB for an </text>
<text top="737" left="344" width="156" height="17" font="0">indication of CLI (defined as </text>
<text top="754" left="344" width="181" height="17" font="0">tissue loss or ischemic rest pain) </text>
<text top="771" left="344" width="30" height="17" font="0">or IC </text>
<text top="703" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="702" left="547" width="6" height="18" font="7"></text>
<text top="703" left="553" width="199" height="17" font="2"><b> endpoint:</b> Amputation-free survival </text>
<text top="721" left="540" width="3" height="17" font="0"> </text>
<text top="738" left="540" width="266" height="17" font="2"><b>Results: </b>Pts with IC experienced a lower rate of </text>
<text top="755" left="540" width="271" height="17" font="0">major amputation at 1 y than pts with CLI (2% vs. </text>
<text top="772" left="540" width="91" height="17" font="0">12%; p&lt;0.0001) </text>
<text top="702" left="851" width="7" height="18" font="7"></text>
<text top="703" left="857" width="247" height="17" font="0"> Graft patency was also significantly better in </text>
<text top="721" left="851" width="254" height="17" font="0">the IC group when compared to the CLI group </text>
<text top="738" left="851" width="224" height="17" font="0">(IC: primary 79%, primary-assisted 87%, </text>
<text top="755" left="851" width="239" height="17" font="0">secondary 89%; CLI: primary 66%, primary-</text>
<text top="772" left="851" width="172" height="17" font="0">assisted 75%, secondary 77%) </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">132 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="3" height="17" font="0"> </text>
<text top="104" left="223" width="100" height="17" font="2"><b>Size:</b> n=2,907 pts </text>
<text top="122" left="223" width="107" height="17" font="0">(797 [28%] had IC) </text>
<text top="87" left="344" width="3" height="17" font="0"> </text>
<text top="104" left="344" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="122" left="344" width="7" height="18" font="7"></text>
<text top="123" left="351" width="25" height="17" font="0"> ALI </text>
<text top="140" left="344" width="7" height="18" font="7"></text>
<text top="141" left="351" width="132" height="17" font="0"> Bypass for aneurysmal </text>
<text top="158" left="344" width="46" height="17" font="0">disease </text>
<text top="176" left="344" width="7" height="18" font="7"></text>
<text top="177" left="351" width="130" height="17" font="0"> No specified indication </text>
<text top="195" left="95" width="100" height="17" font="0">Siracuse JJ, et al. </text>
<text top="212" left="95" width="59" height="17" font="0">2012(293) </text>
<text top="229" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22301210">22301210 </a></text>
<text top="246" left="95" width="3" height="17" font="0"> </text>
<text top="195" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="212" left="223" width="77" height="17" font="0">(single center </text>
<text top="229" left="223" width="78" height="17" font="0">retrospective) </text>
<text top="246" left="223" width="3" height="17" font="0"> </text>
<text top="264" left="223" width="90" height="17" font="2"><b>Size:</b> n=218 pts </text>
<text top="281" left="223" width="98" height="17" font="0">(113 bypass, 105 </text>
<text top="298" left="223" width="40" height="17" font="0">PTAS) </text>
<text top="195" left="344" width="150" height="17" font="2"><b>Inclusion criteria:</b> All LEB </text>
<text top="212" left="344" width="170" height="17" font="0">procedures at single center for </text>
<text top="229" left="344" width="68" height="17" font="0">claudication </text>
<text top="246" left="344" width="3" height="17" font="0"> </text>
<text top="264" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="281" left="344" width="7" height="18" font="7"></text>
<text top="282" left="351" width="138" height="17" font="0"> Limb salvage procedure </text>
<text top="299" left="344" width="7" height="18" font="7"></text>
<text top="300" left="351" width="131" height="17" font="0"> Secondary procedures </text>
<text top="196" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="195" left="547" width="6" height="18" font="7"></text>
<text top="196" left="553" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="213" left="540" width="7" height="18" font="7"></text>
<text top="214" left="547" width="88" height="17" font="0"> Complications, </text>
<text top="231" left="540" width="7" height="18" font="7"></text>
<text top="232" left="547" width="68" height="17" font="0"> Restenosis </text>
<text top="250" left="540" width="7" height="18" font="7"></text>
<text top="251" left="547" width="124" height="17" font="0"> Symptom recurrence  </text>
<text top="268" left="540" width="7" height="18" font="7"></text>
<text top="269" left="547" width="92" height="17" font="0"> Reinterventions </text>
<text top="287" left="540" width="7" height="18" font="7"></text>
<text top="288" left="547" width="102" height="17" font="0"> Major amputation </text>
<text top="305" left="540" width="7" height="18" font="7"></text>
<text top="306" left="547" width="53" height="17" font="0"> Mortality </text>
<text top="323" left="540" width="3" height="17" font="0"> </text>
<text top="340" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="358" left="540" width="7" height="18" font="7"></text>
<text top="359" left="547" width="283" height="17" font="0"> Bypass showed improved freedom from restenosis </text>
<text top="376" left="540" width="278" height="17" font="0">(73% vs. 42% at 3 y; HR: 0.4; 95% CI: 0.23–0.71), </text>
<text top="393" left="540" width="292" height="17" font="0">symptom recurrence (70% and 36% at 3 y; HR: 0.37; </text>
<text top="410" left="540" width="280" height="17" font="0">95% CI: 0.2–0.56), and freedom from symptoms at </text>
<text top="428" left="540" width="291" height="17" font="0">last follow-up (83% vs. 49%; HR: 0.18; 95% CI: 0.08–</text>
<text top="445" left="540" width="35" height="17" font="0">0.40). </text>
<text top="462" left="540" width="7" height="18" font="7"></text>
<text top="463" left="547" width="243" height="17" font="0"> Multivariable analysis of all pts showed that </text>
<text top="481" left="540" width="294" height="17" font="0">restenosis was predicted by PTA/S (HR: 2.5; 95% CI: </text>
<text top="498" left="540" width="259" height="17" font="0">1.4–4.4) and TASC D (HR: 3.7; 95% CI: 3.5–9) </text>
<text top="515" left="540" width="49" height="17" font="0">lesions.  </text>
<text top="532" left="540" width="7" height="18" font="7"></text>
<text top="533" left="547" width="287" height="17" font="0"> Recurrence of symptoms was similarly predicted by </text>
<text top="551" left="540" width="291" height="17" font="0">PTA/S (HR: 3.0; 95% CI: 1.8–5) and TASC D lesions </text>
<text top="568" left="540" width="145" height="17" font="0">(HR: 3.1; 95% CI: 1.4–7).  </text>
<text top="195" left="851" width="7" height="18" font="7"></text>
<text top="196" left="857" width="226" height="17" font="0"> Claudication-specific retrospective study </text>
<text top="213" left="851" width="7" height="18" font="7"></text>
<text top="214" left="857" width="221" height="17" font="0"> Bypass grafts were used less for TASC </text>
<text top="231" left="851" width="7" height="18" font="7"></text>
<text top="232" left="857" width="216" height="17" font="0"> A (17% vs. 40%; p&lt;0.01) and more for </text>
<text top="250" left="851" width="249" height="17" font="0">TASC C (36% vs. 11%; p&lt;0.01) and TASC D </text>
<text top="267" left="851" width="167" height="17" font="0">(13% vs. 3%; p&lt;0.01) lesions. </text>
<text top="284" left="851" width="7" height="18" font="7"></text>
<text top="285" left="857" width="228" height="17" font="0"> There was no difference in freedom from </text>
<text top="303" left="851" width="219" height="17" font="0">reintervention (77% vs. 66% at 3 y; NS) </text>
<text top="320" left="851" width="7" height="18" font="7"></text>
<text top="321" left="857" width="243" height="17" font="0"> Statin use postoperatively was predictive of </text>
<text top="338" left="851" width="233" height="17" font="0">patency (HR: 0.6; 95% CI: 0.35–0.97) and </text>
<text top="355" left="851" width="241" height="17" font="0">freedom from recurrent symptoms (HR: 0.6; </text>
<text top="373" left="851" width="113" height="17" font="0">95% CI: 0.36–0.93). </text>
<text top="390" left="851" width="7" height="18" font="7"></text>
<text top="391" left="857" width="249" height="17" font="0"> No differences in perioperative mortality (2% </text>
<text top="408" left="851" width="250" height="17" font="0">vs. 0%; NS) or 3 y mortality (9% vs. 8%; NS). </text>
<text top="586" left="95" width="97" height="17" font="0">Kakkos SK, et al. </text>
<text top="603" left="95" width="59" height="17" font="0">2011(294) </text>
<text top="620" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21865062">21865062 </a></text>
<text top="637" left="95" width="3" height="17" font="0"> </text>
<text top="586" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="603" left="223" width="77" height="17" font="0">(single center </text>
<text top="620" left="223" width="78" height="17" font="0">retrospective) </text>
<text top="637" left="223" width="3" height="17" font="0"> </text>
<text top="655" left="223" width="90" height="17" font="2"><b>Size:</b> n=269 pts </text>
<text top="672" left="223" width="94" height="17" font="0">(86 [32%] for IC) </text>
<text top="586" left="344" width="133" height="17" font="2"><b>Inclusion criteria:</b> AFB </text>
<text top="603" left="344" width="3" height="17" font="0"> </text>
<text top="620" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="587" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="586" left="547" width="6" height="18" font="7"></text>
<text top="587" left="553" width="249" height="17" font="2"><b> endpoint:</b> Long-term survival, complications </text>
<text top="604" left="540" width="3" height="17" font="0"> </text>
<text top="621" left="540" width="280" height="17" font="2"><b>Results:</b> 60% survival at 10 y (vs. 42% for pts with </text>
<text top="639" left="540" width="149" height="17" font="0">Dx other than IC; p=0.013) </text>
<text top="586" left="851" width="7" height="18" font="7"></text>
<text top="587" left="857" width="216" height="17" font="0"> IC associated with improved long-term </text>
<text top="604" left="851" width="222" height="17" font="0">survival vs. CLI or aneurysm Dx, but not </text>
<text top="621" left="851" width="180" height="17" font="0">significant in multivariable model </text>
<text top="639" left="851" width="7" height="18" font="7"></text>
<text top="640" left="857" width="212" height="17" font="0"> No other results were stratified by Dx  </text>
<text top="690" left="95" width="78" height="17" font="0">Simó G, et al. </text>
<text top="707" left="95" width="59" height="17" font="0">2011(295) </text>
<text top="724" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21704539">21704539 </a></text>
<text top="741" left="95" width="3" height="17" font="0"> </text>
<text top="690" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="707" left="223" width="77" height="17" font="0">(single center </text>
<text top="724" left="223" width="78" height="17" font="0">retrospective) </text>
<text top="741" left="223" width="3" height="17" font="0"> </text>
<text top="759" left="223" width="70" height="17" font="2"><b>Size:</b> n=155 </text>
<text top="776" left="223" width="86" height="17" font="0">procedures (79 </text>
<text top="690" left="344" width="159" height="17" font="2"><b>Inclusion criteria:</b> SA-RIEA </text>
<text top="707" left="344" width="3" height="17" font="0"> </text>
<text top="724" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="741" left="344" width="7" height="18" font="7"></text>
<text top="743" left="351" width="156" height="17" font="0"> Long chronic CIA occlusion </text>
<text top="760" left="344" width="7" height="18" font="7"></text>
<text top="761" left="351" width="119" height="17" font="0"> stenotic aorta and/or </text>
<text top="691" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="690" left="547" width="6" height="18" font="7"></text>
<text top="691" left="553" width="111" height="17" font="2"><b> endpoint:</b> Patency </text>
<text top="708" left="540" width="3" height="17" font="0"> </text>
<text top="725" left="540" width="148" height="17" font="2"><b>Results: </b>The 1, 3, and 5 y </text>
<text top="743" left="540" width="272" height="17" font="0">primary, primary-assisted and secondary patency </text>
<text top="760" left="540" width="283" height="17" font="0">rates were 80.2%, 74.7% and 69.3%; 84.8%,82.4% </text>
<text top="777" left="540" width="235" height="17" font="0">and 78.2%; and 86.8%, 84.2% and 79.6%, </text>
<text top="690" left="851" width="7" height="18" font="7"></text>
<text top="691" left="857" width="248" height="17" font="0"> 10 pts required conversion to a conventional </text>
<text top="708" left="851" width="198" height="17" font="0">iliofemoral reconstructive procedure </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">133 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="91" height="17" font="0">[51%] had IC as </text>
<text top="104" left="223" width="59" height="17" font="0">indication) </text>
<text top="87" left="344" width="142" height="17" font="0">aneurysmal degeneration </text>
<text top="104" left="344" width="7" height="18" font="7"></text>
<text top="105" left="351" width="139" height="17" font="0"> Heavily calcified EIAs or </text>
<text top="123" left="344" width="88" height="17" font="0">bilateral lesions </text>
<text top="87" left="540" width="68" height="17" font="0">respectively </text>
<text top="141" left="95" width="90" height="17" font="0">Eugster T, et al. </text>
<text top="158" left="95" width="59" height="17" font="0">2011(296) </text>
<text top="175" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21850598">21850598 </a></text>
<text top="192" left="95" width="3" height="17" font="0"> </text>
<text top="141" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="158" left="223" width="77" height="17" font="0">(single center </text>
<text top="175" left="223" width="78" height="17" font="0">retrospective) </text>
<text top="192" left="223" width="3" height="17" font="0"> </text>
<text top="210" left="223" width="93" height="17" font="2"><b>Size:</b> n=124 pts  </text>
<text top="141" left="344" width="179" height="17" font="2"><b>Inclusion criteria:</b> Pts operated </text>
<text top="158" left="344" width="139" height="17" font="0">on for severe IC (walking </text>
<text top="175" left="344" width="161" height="17" font="0">distance\200 m) ≥y ago after </text>
<text top="192" left="344" width="110" height="17" font="0">failing nonoperative </text>
<text top="210" left="344" width="75" height="17" font="0">management </text>
<text top="227" left="344" width="3" height="17" font="0"> </text>
<text top="244" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="142" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="141" left="547" width="6" height="18" font="7"></text>
<text top="142" left="553" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="159" left="540" width="7" height="18" font="7"></text>
<text top="160" left="547" width="51" height="17" font="0"> Survival </text>
<text top="178" left="540" width="7" height="18" font="7"></text>
<text top="179" left="547" width="120" height="17" font="0"> Primary patency rate </text>
<text top="196" left="540" width="7" height="18" font="7"></text>
<text top="197" left="547" width="169" height="17" font="0"> Assisted primary patency rate </text>
<text top="214" left="540" width="3" height="17" font="0"> </text>
<text top="231" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="249" left="540" width="7" height="18" font="7"></text>
<text top="250" left="547" width="283" height="17" font="0"> In-hospital and 30 d mortality of 0.8%; survival rate </text>
<text top="267" left="540" width="135" height="17" font="0">was 50.3% (SE±5.42%) </text>
<text top="284" left="540" width="7" height="18" font="7"></text>
<text top="285" left="547" width="224" height="17" font="0"> Primary patency rate at 10 y was 63.5% </text>
<text top="303" left="540" width="71" height="17" font="0">(SE±7.50%) </text>
<text top="320" left="540" width="7" height="18" font="7"></text>
<text top="321" left="547" width="233" height="17" font="0"> Assisted-primary patency rate was 87.3% </text>
<text top="338" left="540" width="71" height="17" font="0">(SE±5.19%) </text>
<text top="355" left="540" width="7" height="18" font="7"></text>
<text top="356" left="547" width="249" height="17" font="0"> Patency rates of spliced and nonspliced vein </text>
<text top="374" left="540" width="154" height="17" font="0">bypasses were not different </text>
<text top="141" left="851" width="7" height="18" font="7"></text>
<text top="142" left="857" width="210" height="17" font="0"> In-hospital and 30 d mortality of 0.8% </text>
<text top="392" left="95" width="82" height="17" font="0">Sachs T, et al. </text>
<text top="409" left="95" width="63" height="17" font="0">2011 (268) </text>
<text top="426" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21880457">21880457 </a></text>
<text top="443" left="95" width="3" height="17" font="0"> </text>
<text top="392" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="409" left="223" width="82" height="17" font="0">(NIS database </text>
<text top="426" left="223" width="69" height="17" font="0">1997–2009) </text>
<text top="443" left="223" width="3" height="17" font="0"> </text>
<text top="461" left="223" width="94" height="17" font="2"><b>Size:</b> n=264,231 </text>
<text top="478" left="223" width="92" height="17" font="0">pts (claudication </text>
<text top="495" left="223" width="59" height="17" font="0">subgroup) </text>
<text top="392" left="344" width="178" height="17" font="2"><b>Inclusion criteria:</b> Pts with ICD-</text>
<text top="409" left="344" width="156" height="17" font="0">9 defined Dx atherosclerotic </text>
<text top="426" left="344" width="133" height="17" font="0">disease who underwent </text>
<text top="443" left="344" width="180" height="17" font="0">intervention of angioplasty stent, </text>
<text top="461" left="344" width="119" height="17" font="0">peripheral bypass) or </text>
<text top="478" left="344" width="118" height="17" font="0">aortofemoral bypass  </text>
<text top="495" left="344" width="3" height="17" font="0"> </text>
<text top="512" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="393" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="392" left="547" width="6" height="18" font="7"></text>
<text top="393" left="553" width="208" height="17" font="2"><b> endpoint:</b> Demographics, costs, and </text>
<text top="410" left="540" width="273" height="17" font="0">comorbidities, as well as multivariable adjusted in-</text>
<text top="427" left="540" width="222" height="17" font="0">hospital mortality and major amputation. </text>
<text top="445" left="540" width="3" height="17" font="0"> </text>
<text top="462" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="479" left="540" width="7" height="18" font="7"></text>
<text top="480" left="547" width="276" height="17" font="0"> In-hospital mortality was similar for PTA and BPG </text>
<text top="497" left="540" width="262" height="17" font="0">groups for claudication (0.1% vs. 0.2%; p=0.04) </text>
<text top="515" left="540" width="7" height="18" font="7"></text>
<text top="516" left="547" width="290" height="17" font="0"> Average cost per procedure of PTA was higher than </text>
<text top="533" left="540" width="287" height="17" font="0">BPG for claudication ($13,903 vs. $12,681; p=0.02). </text>
<text top="550" left="540" width="7" height="18" font="7"></text>
<text top="551" left="547" width="241" height="17" font="0"> Number of pts per y undergoing PTA for IC </text>
<text top="569" left="540" width="215" height="17" font="0">increased threefold (15,903 to 46,138)  </text>
<text top="392" left="851" width="24" height="17" font="0">N/A </text>
<text top="586" left="95" width="87" height="17" font="0">Piazza M, et al. </text>
<text top="604" left="95" width="59" height="17" font="0">2011(297) </text>
<text top="621" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21531527">21531527 </a></text>
<text top="638" left="95" width="3" height="17" font="0"> </text>
<text top="586" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="604" left="223" width="77" height="17" font="0">(single center </text>
<text top="621" left="223" width="78" height="17" font="0">retrospective) </text>
<text top="638" left="223" width="3" height="17" font="0"> </text>
<text top="655" left="223" width="90" height="17" font="2"><b>Size:</b> n=162 pts </text>
<text top="673" left="223" width="106" height="17" font="0">(248 limbs) 74% of </text>
<text top="690" left="223" width="90" height="17" font="0">open repair and </text>
<text top="707" left="223" width="79" height="17" font="0">60% of hybrid </text>
<text top="724" left="223" width="85" height="17" font="0">repair pts were </text>
<text top="741" left="223" width="65" height="17" font="0">claudicants </text>
<text top="586" left="344" width="180" height="17" font="2"><b>Inclusion criteria:</b> Hybrid repair </text>
<text top="604" left="344" width="159" height="17" font="0">(combining iliac stenting and </text>
<text top="621" left="344" width="161" height="17" font="0">open CFE) or open aortoiliac </text>
<text top="638" left="344" width="182" height="17" font="0">and femoral reconstruction in pts </text>
<text top="655" left="344" width="180" height="17" font="0">with extensive iliac and common </text>
<text top="673" left="344" width="148" height="17" font="0">femoral occlusive disease  </text>
<text top="690" left="344" width="3" height="17" font="0"> </text>
<text top="707" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="724" left="344" width="7" height="18" font="7"></text>
<text top="725" left="351" width="102" height="17" font="0"> Aortic thrombosis </text>
<text top="743" left="344" width="7" height="18" font="7"></text>
<text top="744" left="351" width="137" height="17" font="0"> Abdominal aortic or iliac </text>
<text top="761" left="344" width="64" height="17" font="0">aneurysms </text>
<text top="588" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="587" left="547" width="6" height="18" font="7"></text>
<text top="588" left="553" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="605" left="540" width="7" height="18" font="7"></text>
<text top="606" left="547" width="158" height="17" font="0"> 30 d mortality and morbidity </text>
<text top="623" left="540" width="7" height="18" font="7"></text>
<text top="624" left="547" width="77" height="17" font="0"> ABI increase </text>
<text top="642" left="540" width="7" height="18" font="7"></text>
<text top="643" left="547" width="109" height="17" font="0"> Long-term patency </text>
<text top="660" left="540" width="7" height="18" font="7"></text>
<text top="661" left="547" width="188" height="17" font="0"> Procedurally related limb salvage </text>
<text top="678" left="540" width="7" height="18" font="7"></text>
<text top="679" left="547" width="91" height="17" font="0"> Overall survival </text>
<text top="697" left="540" width="3" height="17" font="0"> </text>
<text top="714" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="731" left="540" width="7" height="18" font="7"></text>
<text top="732" left="547" width="272" height="17" font="0"> 30 d morbidity (3% vs. 5%, p=0.55) and mortality </text>
<text top="750" left="540" width="274" height="17" font="0">(1.1% vs. 1.4%, p=0.85) were equivalent between </text>
<text top="767" left="540" width="133" height="17" font="0">hybrid and open repair.  </text>
<text top="587" left="851" width="7" height="18" font="7"></text>
<text top="588" left="857" width="239" height="17" font="0"> “Procedurally related” limb salvage is likely </text>
<text top="605" left="851" width="90" height="17" font="0">biased endpoint </text>
<text top="622" left="851" width="7" height="18" font="7"></text>
<text top="623" left="857" width="246" height="17" font="0"> Reported 100% limb salvage rate is atypical </text>
<text top="641" left="851" width="7" height="18" font="7"></text>
<text top="642" left="857" width="234" height="17" font="0"> Multiple selective sub-group tests without  </text>
<text top="659" left="851" width="7" height="18" font="7"></text>
<text top="660" left="857" width="189" height="17" font="0"> Multiple stratified comparisons by </text>
<text top="677" left="851" width="185" height="17" font="0">dichotomized TASC classification </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">134 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="344" width="7" height="18" font="7"></text>
<text top="88" left="351" width="156" height="17" font="0"> Concomitant visceral artery </text>
<text top="106" left="344" width="96" height="17" font="0">revascularization </text>
<text top="123" left="344" width="7" height="18" font="7"></text>
<text top="124" left="351" width="25" height="17" font="0"> ALI </text>
<text top="141" left="344" width="7" height="18" font="7"></text>
<text top="142" left="351" width="138" height="17" font="0"> Pts &lt;40 y with traumatic </text>
<text top="159" left="344" width="165" height="17" font="0">etiology for their disease from </text>
<text top="177" left="344" width="130" height="17" font="0">high performance sport </text>
<text top="194" left="344" width="120" height="17" font="0">(competitive cyclists). </text>
<text top="87" left="540" width="7" height="18" font="7"></text>
<text top="88" left="547" width="290" height="17" font="0"> Primary patency of hybrid vs. open repair at 3 y was </text>
<text top="106" left="540" width="280" height="17" font="0">similar (91% vs. 97%; p=0.29) and was maintained </text>
<text top="123" left="540" width="263" height="17" font="0">after stratification by TASC A/B (89% vs. 100%; </text>
<text top="140" left="540" width="265" height="17" font="0">p=0.38) and TASC C/D (95% vs. 97%; p=0.54).  </text>
<text top="157" left="540" width="7" height="18" font="7"></text>
<text top="158" left="547" width="258" height="17" font="0"> Multivariate analysis for patency indicated that </text>
<text top="176" left="540" width="291" height="17" font="0">major tissue loss (Rutherford class 6) at presentation </text>
<text top="193" left="540" width="289" height="17" font="0">in the hybrid group was predictive of decreased long-</text>
<text top="210" left="540" width="131" height="17" font="0">term patency (p=0.02).  </text>
<text top="227" left="540" width="7" height="18" font="7"></text>
<text top="228" left="547" width="261" height="17" font="0"> Limb salvage at 3 y was 100% in both groups.  </text>
<text top="246" left="540" width="7" height="18" font="7"></text>
<text top="247" left="547" width="270" height="17" font="0"> Overall survival was 74% for OR vs. 40% for HR </text>
<text top="264" left="540" width="60" height="17" font="0">(p=0.007). </text>
<text top="282" left="95" width="104" height="17" font="0">Derksen WJ, et al. </text>
<text top="299" left="95" width="59" height="17" font="0">2010(298) </text>
<text top="316" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20167515">20167515 </a></text>
<text top="334" left="95" width="3" height="17" font="0"> </text>
<text top="282" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="299" left="223" width="70" height="17" font="0">(prospective </text>
<text top="316" left="223" width="42" height="17" font="0">cohort) </text>
<text top="334" left="223" width="3" height="17" font="0"> </text>
<text top="351" left="223" width="104" height="17" font="2"><b>Size:</b> n=90 pts (72 </text>
<text top="368" left="223" width="79" height="17" font="0">[80%] had IC) </text>
<text top="282" left="344" width="150" height="17" font="2"><b>Inclusion criteria:</b> RSFAE </text>
<text top="299" left="344" width="148" height="17" font="0">performed TASC C/D SFA </text>
<text top="316" left="344" width="163" height="17" font="0">obstruction with or without an </text>
<text top="334" left="344" width="115" height="17" font="0">additional open CFE </text>
<text top="351" left="344" width="3" height="17" font="0"> </text>
<text top="368" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="283" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="282" left="547" width="6" height="18" font="7"></text>
<text top="283" left="553" width="223" height="17" font="2"><b> endpoint:</b> Restenosis following RSFAE </text>
<text top="300" left="540" width="3" height="17" font="0"> </text>
<text top="318" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="335" left="540" width="7" height="18" font="7"></text>
<text top="336" left="547" width="268" height="17" font="0"> 57 pts (63%), a restenotic lesion was diagnosed </text>
<text top="353" left="540" width="79" height="17" font="0">within 12 mo.  </text>
<text top="370" left="540" width="7" height="18" font="7"></text>
<text top="371" left="547" width="275" height="17" font="0"> In multivariate analysis, age, duration of ischemic </text>
<text top="389" left="540" width="261" height="17" font="0">walking complaints, and lumen diameter before </text>
<text top="406" left="540" width="282" height="17" font="0">RSFAE were associated with increased restenosis  </text>
<text top="282" left="851" width="7" height="18" font="7"></text>
<text top="283" left="857" width="222" height="17" font="0"> Complicated inclusion/exclusion criteria </text>
<text top="300" left="851" width="179" height="17" font="0">make generalization challenging </text>
<text top="424" left="95" width="101" height="17" font="0">Koscielny A, et al. </text>
<text top="441" left="95" width="59" height="17" font="0">2010(299) </text>
<text top="458" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20101647">20101647 </a></text>
<text top="476" left="95" width="3" height="17" font="0"> </text>
<text top="424" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="441" left="223" width="78" height="17" font="0">(retrospective </text>
<text top="458" left="223" width="78" height="17" font="0">case-control)  </text>
<text top="476" left="223" width="3" height="17" font="0"> </text>
<text top="493" left="223" width="104" height="17" font="2"><b>Size:</b> n=48 pts (24 </text>
<text top="510" left="223" width="85" height="17" font="0">matched pairs) </text>
<text top="424" left="344" width="153" height="17" font="2"><b>Inclusion criteria:</b> Pts with </text>
<text top="441" left="344" width="153" height="17" font="0">peripheral arterial occlusive </text>
<text top="458" left="344" width="111" height="17" font="0">disease undergoing </text>
<text top="476" left="344" width="172" height="17" font="0">femoropopliteal supragenicular </text>
<text top="493" left="344" width="141" height="17" font="0">bypass or profundaplasty </text>
<text top="510" left="344" width="3" height="17" font="0"> </text>
<text top="527" left="344" width="143" height="17" font="2"><b>Exclusion criteria:</b> None </text>
<text top="544" left="344" width="61" height="17" font="0">mentioned </text>
<text top="425" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="424" left="547" width="6" height="18" font="7"></text>
<text top="425" left="553" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="442" left="540" width="7" height="18" font="7"></text>
<text top="443" left="547" width="102" height="17" font="0"> Bypass occlusion </text>
<text top="461" left="540" width="7" height="18" font="7"></text>
<text top="462" left="547" width="97" height="17" font="0"> Surgical revision </text>
<text top="479" left="540" width="7" height="18" font="7"></text>
<text top="480" left="547" width="69" height="17" font="0"> Amputation </text>
<text top="497" left="540" width="7" height="18" font="7"></text>
<text top="498" left="547" width="40" height="17" font="0"> Death </text>
<text top="516" left="540" width="3" height="17" font="0"> </text>
<text top="533" left="540" width="293" height="17" font="2"><b>Results:</b> No significant outcome differences between </text>
<text top="550" left="540" width="279" height="17" font="0">supragenicular bypass surgery orprofundaplasty in </text>
<text top="567" left="540" width="148" height="17" font="0">pts who had surgery for IC </text>
<text top="424" left="851" width="7" height="18" font="7"></text>
<text top="425" left="857" width="204" height="17" font="0"> Mean length of follow-up was 36 mo </text>
<text top="585" left="95" width="90" height="17" font="0">Ballotta E, et al. </text>
<text top="603" left="95" width="59" height="17" font="0">2010(300) </text>
<text top="620" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19828166">19828166 </a></text>
<text top="637" left="95" width="3" height="17" font="0"> </text>
<text top="585" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="603" left="223" width="78" height="17" font="0">(retrospective </text>
<text top="620" left="223" width="73" height="17" font="0">single center </text>
<text top="637" left="223" width="72" height="17" font="0">cohort)(Italy) </text>
<text top="654" left="223" width="3" height="17" font="0"> </text>
<text top="671" left="223" width="90" height="17" font="2"><b>Size:</b> n=117 pts </text>
<text top="689" left="223" width="93" height="17" font="0">(121 procedures </text>
<text top="706" left="223" width="45" height="17" font="0">[60% of </text>
<text top="723" left="223" width="95" height="17" font="0">procedures were </text>
<text top="740" left="223" width="97" height="17" font="0">for claudication])  </text>
<text top="585" left="344" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="603" left="344" width="7" height="18" font="7"></text>
<text top="604" left="351" width="131" height="17" font="0"> CFA occlusive disease </text>
<text top="621" left="344" width="146" height="17" font="0">(isolated or with additional </text>
<text top="638" left="344" width="145" height="17" font="0">infrainguinal lesions in the </text>
<text top="655" left="344" width="89" height="17" font="0">ipsilateral limb)  </text>
<text top="673" left="344" width="7" height="18" font="7"></text>
<text top="674" left="351" width="165" height="17" font="0"> Amenable to endarterectomy </text>
<text top="691" left="344" width="126" height="17" font="0">of the CFA (isolated or </text>
<text top="708" left="344" width="176" height="17" font="0">combined with a profundoplasty </text>
<text top="725" left="344" width="163" height="17" font="0">or with the endarterectomy of </text>
<text top="743" left="344" width="169" height="17" font="0">the superficial or deep femoral </text>
<text top="760" left="344" width="177" height="17" font="0">artery first tract, not &gt;1 cm long) </text>
<text top="777" left="344" width="3" height="17" font="0"> </text>
<text top="586" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="585" left="547" width="6" height="18" font="7"></text>
<text top="586" left="553" width="111" height="17" font="2"><b> endpoint:</b> Patency </text>
<text top="604" left="540" width="3" height="17" font="0"> </text>
<text top="621" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="638" left="540" width="7" height="18" font="7"></text>
<text top="639" left="547" width="275" height="17" font="0"> 7 y PP, APP, and LS rates were 96%, 100%, and </text>
<text top="656" left="540" width="107" height="17" font="0">100%, respectively </text>
<text top="674" left="540" width="7" height="18" font="7"></text>
<text top="675" left="547" width="208" height="17" font="0"> The 7 y rates of freedom from further </text>
<text top="692" left="540" width="278" height="17" font="0">revascularization and survival were 79% and 80%, </text>
<text top="709" left="540" width="72" height="17" font="0">respectively. </text>
<text top="585" left="851" width="7" height="18" font="7"></text>
<text top="586" left="857" width="124" height="17" font="0"> No comparison group </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="25" size="13" family="Times" color="#565656"/>
<text top="795" left="1081" width="24" height="17" font="0">135 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="344" width="180" height="17" font="2"><b>Exclusion criteria:</b> Major tissue </text>
<text top="104" left="344" width="167" height="17" font="0">loss for which a contemporary </text>
<text top="122" left="344" width="165" height="17" font="0">infrainguinal revascularization </text>
<text top="139" left="344" width="85" height="17" font="0">was performed </text>
<text top="157" left="95" width="90" height="17" font="0">Burke CR, et al. </text>
<text top="174" left="95" width="27" height="17" font="0">2010</text>
<text top="174" left="122" width="32" height="17" font="25">(301) </text>
<text top="174" left="154" width="3" height="17" font="0"> </text>
<text top="191" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20122461">20122461 </a></text>
<text top="208" left="95" width="3" height="17" font="0"> </text>
<text top="157" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="174" left="223" width="78" height="17" font="0">(retrospective </text>
<text top="191" left="223" width="77" height="17" font="0">single center) </text>
<text top="208" left="223" width="3" height="17" font="0"> </text>
<text top="226" left="223" width="97" height="17" font="2"><b>Size:</b> n=118 AFB </text>
<text top="243" left="223" width="101" height="17" font="0">and 174 aortoiliac </text>
<text top="260" left="223" width="89" height="17" font="0">angioplasty and </text>
<text top="277" left="223" width="85" height="17" font="0">AS procedures </text>
<text top="157" left="344" width="143" height="17" font="2"><b>Inclusion criteria:</b> All pts </text>
<text top="174" left="344" width="168" height="17" font="0">undergoing treatment AIOD at </text>
<text top="191" left="344" width="144" height="17" font="0">the University of Michigan </text>
<text top="208" left="344" width="172" height="17" font="0">Hospitals between 1997–2007  </text>
<text top="226" left="344" width="3" height="17" font="0"> </text>
<text top="243" left="344" width="143" height="17" font="2"><b>Exclusion criteria:</b> None </text>
<text top="260" left="344" width="61" height="17" font="0">mentioned </text>
<text top="158" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="157" left="547" width="6" height="18" font="7"></text>
<text top="158" left="553" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="175" left="540" width="7" height="18" font="7"></text>
<text top="176" left="547" width="53" height="17" font="0"> Mortality </text>
<text top="194" left="540" width="7" height="18" font="7"></text>
<text top="195" left="547" width="92" height="17" font="0"> Adverse events </text>
<text top="212" left="540" width="3" height="17" font="0"> </text>
<text top="229" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="246" left="540" width="7" height="18" font="7"></text>
<text top="247" left="547" width="284" height="17" font="0"> Long-term mortality, freedom from amputation, and </text>
<text top="265" left="540" width="245" height="17" font="0">freedom from revision procedure of any type </text>
<text top="282" left="540" width="278" height="17" font="0">(endovascular or open) were not different between </text>
<text top="299" left="540" width="48" height="17" font="0">groups.  </text>
<text top="316" left="540" width="7" height="18" font="7"></text>
<text top="317" left="547" width="246" height="17" font="0"> AFB was associated with increased surgical </text>
<text top="335" left="540" width="288" height="17" font="0">complication rates including the need for emergency </text>
<text top="352" left="540" width="282" height="17" font="0">surgery (6.8% and 1.7%; p=0.029), infection/sepsis </text>
<text top="369" left="540" width="287" height="17" font="0">(16.1% and 2.3%; p&lt;0.001), transfusion (16.1% and </text>
<text top="386" left="540" width="271" height="17" font="0">5.7%; p=0.004), and lymph leak (8.5% and 0.6%; </text>
<text top="404" left="540" width="56" height="17" font="0">p=0.001). </text>
<text top="421" left="540" width="7" height="18" font="7"></text>
<text top="422" left="547" width="267" height="17" font="0"> No difference between AFB and AS groups with </text>
<text top="439" left="540" width="295" height="17" font="0">respect to 30 d mortality (0.8% and 1.1%; p=0.64), MI </text>
<text top="456" left="540" width="284" height="17" font="0">(1.7% and 1.1%; p=0.53), cerebrovascular accident </text>
<text top="474" left="540" width="277" height="17" font="0">(0.0% and 1.1%; p=0.35), or renal failure requiring </text>
<text top="491" left="540" width="218" height="17" font="0">hemodialysis (3.4% and 1.2%; p=0.19). </text>
<text top="157" left="851" width="7" height="18" font="7"></text>
<text top="158" left="857" width="224" height="17" font="0"> Large number of statistical comparisons </text>
<text top="175" left="851" width="216" height="17" font="0">without adjustment of significance level </text>
<text top="192" left="851" width="7" height="18" font="7"></text>
<text top="193" left="857" width="239" height="17" font="0"> Not claudication specific (60 % of PTA and </text>
<text top="211" left="851" width="133" height="17" font="0">41% of AFB pts had IC) </text>
<text top="509" left="95" width="81" height="17" font="0">Twine CP and </text>
<text top="526" left="95" width="64" height="17" font="0">McLain AD </text>
<text top="543" left="95" width="59" height="17" font="0">2010(302) </text>
<text top="560" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20464717">20464717</a></text>
<text top="560" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20464717"> </a></text>
<text top="578" left="95" width="3" height="17" font="0"> </text>
<text top="509" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="526" left="223" width="57" height="17" font="0">Cochrane </text>
<text top="543" left="223" width="101" height="17" font="0">systematic review </text>
<text top="560" left="223" width="3" height="17" font="0"> </text>
<text top="578" left="223" width="92" height="17" font="2"><b>Size:</b> n=13 RCT </text>
<text top="595" left="223" width="79" height="17" font="0">with 2,313 pts </text>
<text top="612" left="223" width="105" height="17" font="0">(1955 above knee, </text>
<text top="629" left="223" width="90" height="17" font="0">358 below knee </text>
<text top="646" left="223" width="59" height="17" font="0">bypasses)<b> </b></text>
<text top="509" left="344" width="178" height="17" font="2"><b>Inclusion criteria:</b> Randomized </text>
<text top="526" left="344" width="182" height="17" font="0">trials comparing femoro-popliteal </text>
<text top="543" left="344" width="38" height="17" font="0">grafts. </text>
<text top="560" left="344" width="3" height="17" font="0"> </text>
<text top="578" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="510" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="509" left="547" width="6" height="18" font="7"></text>
<text top="510" left="553" width="87" height="17" font="2"><b> endpoint: </b>N/A<b> </b></text>
<text top="527" left="540" width="3" height="17" font="0"> </text>
<text top="544" left="540" width="291" height="17" font="2"><b>Results: </b>7 graft types were compared (reversed and </text>
<text top="562" left="540" width="281" height="17" font="0">in situ autologous vein, PTFE with and without vein </text>
<text top="579" left="540" width="283" height="17" font="0">cuff, HUV, Dacron and HBD. Above the knee, there </text>
<text top="596" left="540" width="287" height="17" font="0">was a benefit in primary patency for autologous vein </text>
<text top="613" left="540" width="276" height="17" font="0">over PTFE (p=0.0001) and HUV (p=0.0003) by 60 </text>
<text top="630" left="540" width="271" height="17" font="0">mo. Dacron showed primary patency benefit over </text>
<text top="648" left="540" width="253" height="17" font="0">PTFE by 24 mo (p=0.02), continuing to 60 mo </text>
<text top="665" left="540" width="290" height="17" font="0">(p=0.02). HUV also showed benefit over PTFE by 24 </text>
<text top="682" left="540" width="292" height="17" font="0">mo (p=0.0003) in 1 trial. Below the knee, in the 1 trial </text>
<text top="699" left="540" width="287" height="17" font="0">there was a significant benefit in primary patency for </text>
<text top="716" left="540" width="293" height="17" font="0">PTFE with a vein cuff when compared to PTFE alone </text>
<text top="734" left="540" width="280" height="17" font="0">at all time intervals to 24 mo (p=0.03). Limited data </text>
<text top="751" left="540" width="262" height="17" font="0">were available for limb survival. Antiplatelet and </text>
<text top="768" left="540" width="281" height="17" font="0">anticoagulant protocols varied extensively between </text>
<text top="509" left="851" width="250" height="17" font="0">There was a clear primary patency benefit for </text>
<text top="526" left="851" width="246" height="17" font="0">autologous vein when compared to synthetic </text>
<text top="543" left="851" width="231" height="17" font="0">materials for above knee bypasses. In the </text>
<text top="560" left="851" width="256" height="17" font="0">long term (5 y) Dacron confers a small primary </text>
<text top="578" left="851" width="234" height="17" font="0">patency benefit over PTFE for above knee </text>
<text top="595" left="851" width="219" height="17" font="0">bypass. PTFE with a vein cuff improved </text>
<text top="612" left="851" width="230" height="17" font="0">primary patency when compared to PTFE </text>
<text top="629" left="851" width="219" height="17" font="0">alone for below knee bypasses. Further </text>
<text top="646" left="851" width="219" height="17" font="0">randomized data is needed to ascertain </text>
<text top="664" left="851" width="214" height="17" font="0">whether this information translates into </text>
<text top="681" left="851" width="162" height="17" font="0">improvement in limb survival. </text>
</page>
<page number="136" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">136 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="540" width="206" height="17" font="0">trials, and in some cases within trials. </text>
<text top="104" left="540" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="95" width="87" height="17" font="0">Chiesa R, et al. </text>
<text top="139" left="95" width="59" height="17" font="0">2009(303) </text>
<text top="157" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19540713">19540713 </a></text>
<text top="174" left="95" width="3" height="17" font="0"> </text>
<text top="122" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="139" left="223" width="78" height="17" font="0">(retrospective </text>
<text top="157" left="223" width="73" height="17" font="0">single center </text>
<text top="174" left="223" width="45" height="17" font="0">cohort)  </text>
<text top="191" left="223" width="3" height="17" font="0"> </text>
<text top="208" left="223" width="90" height="17" font="2"><b>Size:</b> n=822 pts </text>
<text top="226" left="223" width="87" height="17" font="0">(777 [94%] had </text>
<text top="243" left="223" width="85" height="17" font="0">claudication as </text>
<text top="260" left="223" width="59" height="17" font="0">indication) </text>
<text top="122" left="344" width="177" height="17" font="2"><b>Inclusion criteria:</b> Consecutive </text>
<text top="139" left="344" width="152" height="17" font="0">pts undergoing aortoiliac or </text>
<text top="157" left="344" width="153" height="17" font="0">aortofemoral reconstruction </text>
<text top="174" left="344" width="169" height="17" font="0">employing a bifurcated ePTFE </text>
<text top="191" left="344" width="68" height="17" font="0">stretch graft </text>
<text top="208" left="344" width="3" height="17" font="0"> </text>
<text top="226" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="123" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="122" left="547" width="6" height="18" font="7"></text>
<text top="123" left="553" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="141" left="540" width="7" height="18" font="7"></text>
<text top="142" left="547" width="51" height="17" font="0"> Survival </text>
<text top="159" left="540" width="7" height="18" font="7"></text>
<text top="160" left="547" width="126" height="17" font="0"> Graft-patency survival </text>
<text top="178" left="540" width="7" height="18" font="7"></text>
<text top="179" left="547" width="139" height="17" font="0"> Amputation-free survival </text>
<text top="196" left="540" width="3" height="17" font="0"> </text>
<text top="213" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="230" left="540" width="7" height="18" font="7"></text>
<text top="231" left="547" width="213" height="17" font="0"> 11 y primary graft-patency rate 90.6% </text>
<text top="249" left="540" width="7" height="18" font="7"></text>
<text top="250" left="547" width="248" height="17" font="0"> The secondary rate patency rate was 97.9% </text>
<text top="122" left="851" width="7" height="18" font="7"></text>
<text top="123" left="857" width="235" height="17" font="0"> Amputation-free survival only evaluated in </text>
<text top="141" left="851" width="193" height="17" font="0">subset of pts with CLI as indication </text>
<text top="158" left="851" width="7" height="18" font="7"></text>
<text top="159" left="857" width="241" height="17" font="0"> Primary patency reported was for total 11 y </text>
<text top="176" left="851" width="253" height="17" font="0">duration of study period but mean follow-up of </text>
<text top="194" left="851" width="64" height="17" font="0">only 72 mo </text>
<text top="211" left="851" width="7" height="18" font="7"></text>
<text top="212" left="857" width="229" height="17" font="0"> No survival analysis; descriptive analysis </text>
<text top="229" left="851" width="175" height="17" font="0">without models accounting time </text>
<text top="246" left="851" width="83" height="17" font="0">considerations </text>
<text top="278" left="95" width="104" height="17" font="0">Al-Khoury G, et al. </text>
<text top="295" left="95" width="59" height="17" font="0">2009(304) </text>
<text top="312" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19628359">19628359 </a></text>
<text top="330" left="95" width="3" height="17" font="0"> </text>
<text top="278" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="295" left="223" width="78" height="17" font="0">(retrospective </text>
<text top="312" left="223" width="73" height="17" font="0">single center </text>
<text top="330" left="223" width="42" height="17" font="0">cohort) </text>
<text top="347" left="223" width="3" height="17" font="0"> </text>
<text top="364" left="223" width="83" height="17" font="2"><b>Size:</b> n=95 pts </text>
<text top="381" left="223" width="96" height="17" font="0">(105 limbs); 65% </text>
<text top="398" left="223" width="79" height="17" font="0">of procedures </text>
<text top="416" left="223" width="64" height="17" font="0">done for IC </text>
<text top="278" left="344" width="153" height="17" font="2"><b>Inclusion criteria:</b> Pts who </text>
<text top="295" left="344" width="168" height="17" font="0">underwent an isolated femoral </text>
<text top="312" left="344" width="89" height="17" font="0">endarterectomy </text>
<text top="330" left="344" width="3" height="17" font="0"> </text>
<text top="347" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="279" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="278" left="547" width="6" height="18" font="7"></text>
<text top="279" left="553" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="296" left="540" width="7" height="18" font="7"></text>
<text top="297" left="547" width="230" height="17" font="0"> Change in ABI (based on cut-point of 15) </text>
<text top="315" left="540" width="7" height="18" font="7"></text>
<text top="316" left="547" width="156" height="17" font="0"> Change in Rutherford class </text>
<text top="333" left="540" width="7" height="18" font="7"></text>
<text top="334" left="547" width="114" height="17" font="0"> Repeat intervention </text>
<text top="351" left="540" width="7" height="18" font="7"></text>
<text top="353" left="547" width="51" height="17" font="0"> Patency </text>
<text top="370" left="540" width="3" height="17" font="0"> </text>
<text top="387" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="404" left="540" width="7" height="18" font="7"></text>
<text top="405" left="547" width="217" height="17" font="0"> 83.8% of pts with marked initial clinical </text>
<text top="423" left="540" width="294" height="17" font="0">improvement remained symptom free at 2 y, whereas </text>
<text top="440" left="540" width="295" height="17" font="0">only 28.6% in the group with mild and moderate initial </text>
<text top="457" left="540" width="228" height="17" font="0">response maintained their clinical status.  </text>
<text top="474" left="540" width="7" height="18" font="7"></text>
<text top="475" left="547" width="276" height="17" font="0"> 2 y freedom from repeat intervention was 61.8%.  </text>
<text top="493" left="540" width="7" height="18" font="7"></text>
<text top="494" left="547" width="256" height="17" font="0"> Multivariate analysis revealed that TASC C/ D </text>
<text top="511" left="540" width="287" height="17" font="0">lesions (OR: 9.3; 95% CI: 2.43–35.63; p=0.001) and </text>
<text top="528" left="540" width="281" height="17" font="0">DM (OR: 3.64; 95% CI: 1.01–13.15; p=0.048) were </text>
<text top="546" left="540" width="269" height="17" font="0">predictive of recurrent symptoms while extensive </text>
<text top="563" left="540" width="294" height="17" font="0">endarterectomy and ≥2 vessel tibial runoff decreased </text>
<text top="580" left="540" width="181" height="17" font="0">the need for repeat intervention.  </text>
<text top="597" left="540" width="7" height="18" font="7"></text>
<text top="598" left="547" width="285" height="17" font="0"> Patency was 100% with a mean follow-up of 11 mo </text>
<text top="616" left="540" width="46" height="17" font="0">(1–72).  </text>
<text top="633" left="540" width="7" height="18" font="7"></text>
<text top="634" left="547" width="262" height="17" font="0"> Complete resolution of symptoms was noted in </text>
<text top="651" left="540" width="287" height="17" font="0">73.4% with some clinical improvement noted in 91% </text>
<text top="668" left="540" width="53" height="17" font="0">of limbs.  </text>
<text top="686" left="540" width="7" height="18" font="7"></text>
<text top="687" left="547" width="273" height="17" font="0"> ABI increase achieved in 85.1% with a mean ABI </text>
<text top="704" left="540" width="275" height="17" font="0">increase of 0.27±0.20, and this correlated with ≥2 </text>
<text top="721" left="540" width="297" height="17" font="0">runoff vessels (OR: 0.20; 95% CI: 0.04–0.96; p=0.04). </text>
<text top="278" left="851" width="24" height="17" font="0">N/A </text>
<text top="739" left="95" width="107" height="17" font="0">Goodney PP, et al. </text>
<text top="756" left="95" width="59" height="17" font="0">2009(305) </text>
<text top="773" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19497502">19497502 </a></text>
<text top="739" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="756" left="223" width="70" height="17" font="0">(prospective </text>
<text top="773" left="223" width="103" height="17" font="0">registry) (Vascular </text>
<text top="739" left="344" width="150" height="17" font="2"><b>Inclusion criteria:</b> LEB for </text>
<text top="756" left="344" width="141" height="17" font="0">arterial occlusive disease </text>
<text top="773" left="344" width="3" height="17" font="0"> </text>
<text top="740" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="739" left="547" width="6" height="18" font="7"></text>
<text top="740" left="553" width="255" height="17" font="2"><b> endpoint:</b> Predictors of ambulation status 1 y </text>
<text top="757" left="540" width="86" height="17" font="0">postoperatively </text>
<text top="775" left="540" width="3" height="17" font="0"> </text>
<text top="739" left="851" width="3" height="17" font="0"> </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">137 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="86" height="17" font="0">Study Group of </text>
<text top="104" left="223" width="84" height="17" font="0">New England)  </text>
<text top="122" left="223" width="3" height="17" font="0"> </text>
<text top="139" left="223" width="104" height="17" font="2"><b>Size:</b> n=1,400 pts, </text>
<text top="156" left="223" width="106" height="17" font="0">1561 bypasses (IC </text>
<text top="173" left="223" width="98" height="17" font="0">was indication for </text>
<text top="190" left="223" width="32" height="17" font="0">25%) </text>
<text top="87" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="87" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="104" left="540" width="7" height="18" font="7"></text>
<text top="105" left="547" width="274" height="17" font="0"> Claudicant pts had higher primary (79% vs. 73%; </text>
<text top="123" left="540" width="272" height="17" font="0">p&lt;0.001) and secondary (87% vs. 81%; p&lt;0.001) </text>
<text top="140" left="540" width="281" height="17" font="0">graft patency rates and were more likely to be alive </text>
<text top="157" left="540" width="277" height="17" font="0">and ambulatory 1 y postoperatively (96% vs. 81%; </text>
<text top="174" left="540" width="129" height="17" font="0">p&lt;0.001) than CLI pts.  </text>
<text top="192" left="540" width="7" height="18" font="7"></text>
<text top="193" left="547" width="281" height="17" font="0"> Amputation rates were 12% for CLI pts and 1% for </text>
<text top="210" left="540" width="142" height="17" font="0">claudicant pts (p&lt;0.001).  </text>
<text top="227" left="540" width="7" height="18" font="7"></text>
<text top="228" left="547" width="271" height="17" font="0"> All claudicant pts walked before surgery, and the </text>
<text top="246" left="540" width="264" height="17" font="0">95% who survived 1 y postoperatively remained </text>
<text top="263" left="540" width="71" height="17" font="0">ambulatory.  </text>
<text top="280" left="540" width="7" height="18" font="7"></text>
<text top="281" left="547" width="250" height="17" font="0"> The risk of dying or being nonambulatory 1 y </text>
<text top="298" left="540" width="257" height="17" font="0">postoperatively was increased in pts who were </text>
<text top="316" left="540" width="289" height="17" font="0">nonambulatory preoperatively (HR: 1.5; 95% CI: 1.3–</text>
<text top="333" left="540" width="276" height="17" font="0">1.6; p&lt;0.0001), by increasing age of 70–79 y (HR: </text>
<text top="350" left="540" width="292" height="17" font="0">1.8; 95% CI: 1.2–2.6; p&lt;0.007) and 80-89 y (HR: 2.3; </text>
<text top="367" left="540" width="296" height="17" font="0">95% CI: 1.5–3.7; p&lt;0.0001), by CLI (HR: 2.0; 95% CI: </text>
<text top="384" left="540" width="295" height="17" font="0">1.2–3.4; p&lt;0.007), by postoperative MI (HR: 2.5; 95% </text>
<text top="402" left="540" width="290" height="17" font="0">CI: 1.6–4.1; p&lt;0.001), and by major amputation (HR: </text>
<text top="419" left="540" width="178" height="17" font="0">2.9; 95% CI: 2.1–4.1; p&lt;0.001).  </text>
<text top="436" left="540" width="7" height="18" font="7"></text>
<text top="437" left="547" width="288" height="17" font="0"> Graft thrombosis during follow-up (HR: 1.6; 95% CI: </text>
<text top="454" left="540" width="257" height="17" font="0">1.1–1.8; p&lt;0.003) and living in a nursing home </text>
<text top="472" left="540" width="281" height="17" font="0">preoperatively (HR: 3.5; 95% CI: 1.5–7.8; p&lt;0.003) </text>
<text top="489" left="540" width="282" height="17" font="0">were independently associated with a higher risk of </text>
<text top="506" left="540" width="155" height="17" font="0">being nonambulatory at 1 y. </text>
<text top="524" left="95" width="97" height="17" font="0">Chang RW, et al. </text>
<text top="541" left="95" width="59" height="17" font="0">2008(306) </text>
<text top="558" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18572359">18572359</a></text>
<text top="558" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18572359"> </a></text>
<text top="576" left="95" width="3" height="17" font="0"> </text>
<text top="524" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="541" left="223" width="77" height="17" font="0">(single center </text>
<text top="558" left="223" width="74" height="17" font="0">retrospective </text>
<text top="576" left="223" width="42" height="17" font="0">cohort) </text>
<text top="593" left="223" width="3" height="17" font="0"> </text>
<text top="610" left="223" width="93" height="17" font="2"><b>Size: </b>n=171 pts, </text>
<text top="627" left="223" width="89" height="17" font="0">193 procedures </text>
<text top="645" left="223" width="56" height="17" font="0">(46% had </text>
<text top="662" left="223" width="85" height="17" font="0">claudication as </text>
<text top="679" left="223" width="59" height="17" font="0">indication) </text>
<text top="524" left="344" width="159" height="17" font="2"><b>Inclusion criteria:</b> CFE with </text>
<text top="541" left="344" width="168" height="17" font="0">patch angioplasty and primary </text>
<text top="558" left="344" width="159" height="17" font="0">stenting or stent grafting in a </text>
<text top="576" left="344" width="160" height="17" font="0">single combined hybrid open </text>
<text top="593" left="344" width="177" height="17" font="0">and endovascular procedure for </text>
<text top="610" left="344" width="142" height="17" font="0">treatment of TASC C and </text>
<text top="627" left="344" width="159" height="17" font="0">iliofemoral occlusive disease </text>
<text top="645" left="344" width="3" height="17" font="0"> </text>
<text top="662" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="525" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="524" left="547" width="6" height="18" font="7"></text>
<text top="525" left="553" width="258" height="17" font="2"><b> endpoint:</b> Technical success, clinical success </text>
<text top="542" left="540" width="288" height="17" font="0">(based on AHA classification), ABI change, patency, </text>
<text top="560" left="540" width="167" height="17" font="0">adverse events, length of stay </text>
<text top="577" left="540" width="3" height="17" font="0"> </text>
<text top="594" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="611" left="540" width="7" height="18" font="7"></text>
<text top="612" left="547" width="287" height="17" font="0"> 30 d mortality was 2.3% and 5 y survival was 60%.  </text>
<text top="630" left="540" width="7" height="18" font="7"></text>
<text top="631" left="547" width="252" height="17" font="0"> 5 y primary, primary-assisted, and secondary </text>
<text top="648" left="540" width="276" height="17" font="0">patencies were 60%, 97%, and 98% respectively.  </text>
<text top="665" left="540" width="7" height="18" font="7"></text>
<text top="666" left="547" width="288" height="17" font="0"> Endovascular reintervention was required in 14% of </text>
<text top="684" left="540" width="295" height="17" font="0">pts; inflow surgical procedures were required in 10%.  </text>
<text top="701" left="540" width="7" height="18" font="7"></text>
<text top="702" left="547" width="276" height="17" font="0"> By logistic regression analysis, use of stent grafts </text>
<text top="719" left="540" width="260" height="17" font="0">compared with bare stents was associated with </text>
<text top="736" left="540" width="296" height="17" font="0">significantly higher primary patency (87% 5% vs. 53% </text>
<text top="754" left="540" width="74" height="17" font="0">7%; p&lt;0.01). </text>
<text top="771" left="540" width="7" height="18" font="7"></text>
<text top="772" left="547" width="258" height="17" font="0"> Clinical improvement was seen in 92% of pts.  </text>
<text top="524" left="851" width="24" height="17" font="0">N/A </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">138 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="540" width="7" height="18" font="7"></text>
<text top="88" left="547" width="276" height="17" font="0"> Mean ABI increased from 0.38 0.32 to 0.72 0.24.  </text>
<text top="106" left="540" width="7" height="18" font="7"></text>
<text top="107" left="547" width="260" height="17" font="0"> Median length of stay was 2 d (range, 1–51 d). </text>
<text top="125" left="95" width="87" height="17" font="0">KoivunenK and </text>
<text top="142" left="95" width="76" height="17" font="0">Lukkarinen H </text>
<text top="159" left="95" width="59" height="17" font="0">2008(265) </text>
<text top="176" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18221916">18221916</a></text>
<text top="176" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18221916"> </a></text>
<text top="194" left="95" width="3" height="17" font="0"> </text>
<text top="125" left="223" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="142" left="223" width="66" height="17" font="0">prospective </text>
<text top="159" left="223" width="3" height="17" font="2"><b> </b></text>
<text top="176" left="223" width="90" height="17" font="2"><b>Size:</b> n=180 pts </text>
<text top="194" left="223" width="97" height="17" font="0">(64 conservative, </text>
<text top="211" left="223" width="97" height="17" font="0">85 endovascular, </text>
<text top="228" left="223" width="66" height="17" font="0">31 surgery) </text>
<text top="125" left="344" width="177" height="17" font="2"><b>Inclusion criteria: </b>IC (Fontaine </text>
<text top="142" left="344" width="176" height="17" font="0">II), surgery clinic pt at university </text>
<text top="159" left="344" width="103" height="17" font="0">hospital in Finland </text>
<text top="176" left="344" width="3" height="17" font="2"><b> </b></text>
<text top="194" left="344" width="110" height="17" font="2"><b>Exclusion criteria: </b></text>
<text top="211" left="344" width="180" height="17" font="0">Nonatherosclerotic disease, lack </text>
<text top="228" left="344" width="163" height="17" font="0">of angiographic verification of </text>
<text top="245" left="344" width="72" height="17" font="0">Dx, previous </text>
<text top="262" left="344" width="176" height="17" font="0">surgery/endovascular treatment </text>
<text top="280" left="344" width="53" height="17" font="0">&lt;5 y, CLI </text>
<text top="126" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="125" left="547" width="6" height="18" font="7"></text>
<text top="126" left="553" width="259" height="17" font="2"><b> endpoint:</b> HRQoL (Nottingham Health Profile) </text>
<text top="143" left="540" width="3" height="17" font="2"><b> </b></text>
<text top="160" left="540" width="52" height="17" font="2"><b>Results: </b></text>
<text top="178" left="540" width="7" height="18" font="7"></text>
<text top="179" left="547" width="272" height="17" font="0"> Conservative group's clinical outcomes (ABI, asx </text>
<text top="196" left="540" width="257" height="17" font="0">walking distance) remained stable, while these </text>
<text top="213" left="540" width="295" height="17" font="0">measures improved significantly in the surgery group  </text>
<text top="230" left="540" width="7" height="18" font="7"></text>
<text top="231" left="547" width="277" height="17" font="0"> Conservative group had improved quality of sleep </text>
<text top="249" left="540" width="137" height="17" font="0">and emotional reactions  </text>
<text top="266" left="540" width="7" height="18" font="7"></text>
<text top="267" left="547" width="240" height="17" font="0"> Endo group had significant improvement in </text>
<text top="284" left="540" width="287" height="17" font="0">emotional reactions and energy + reduction in social </text>
<text top="301" left="540" width="282" height="17" font="0">isolation. No significant changes in pain or mobility  </text>
<text top="319" left="540" width="7" height="18" font="7"></text>
<text top="320" left="547" width="269" height="17" font="0"> Surgery group had improvements in sleep, pain, </text>
<text top="337" left="540" width="272" height="17" font="0">emotional reactions, social isolation, and physical </text>
<text top="354" left="540" width="49" height="17" font="0">mobility  </text>
<text top="371" left="540" width="7" height="18" font="7"></text>
<text top="373" left="547" width="228" height="17" font="0"> Large effect size for surgery vs. small for </text>
<text top="390" left="540" width="107" height="17" font="0">conservative, endo </text>
<text top="125" left="851" width="7" height="18" font="7"></text>
<text top="126" left="857" width="219" height="17" font="0"> Pts treated with conservative approach </text>
<text top="143" left="851" width="185" height="17" font="0">exercised more often at baseline  </text>
<text top="160" left="851" width="7" height="18" font="7"></text>
<text top="161" left="857" width="189" height="17" font="0"> Surgery group had more baseline </text>
<text top="179" left="851" width="77" height="17" font="0">hypertension  </text>
<text top="196" left="851" width="7" height="18" font="7"></text>
<text top="197" left="857" width="191" height="17" font="0"> Smoking increased significantly in </text>
<text top="214" left="851" width="186" height="17" font="0">conservative management group  </text>
<text top="408" left="95" width="108" height="17" font="0">Jaquinandi V, et al. </text>
<text top="425" left="95" width="59" height="17" font="0">2007(307) </text>
<text top="442" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17264010">17264010</a></text>
<text top="442" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17264010"> </a></text>
<text top="459" left="95" width="3" height="17" font="0"> </text>
<text top="408" left="223" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="425" left="223" width="66" height="17" font="0">prospective </text>
<text top="442" left="223" width="3" height="17" font="0"> </text>
<text top="459" left="223" width="90" height="17" font="2"><b>Size:</b> n=105 pts </text>
<text top="408" left="344" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="425" left="344" width="7" height="18" font="7"></text>
<text top="426" left="351" width="64" height="17" font="0"> Age ≥18 y </text>
<text top="443" left="344" width="7" height="18" font="7"></text>
<text top="444" left="351" width="161" height="17" font="0"> Had a patent AFB for ≥4 mo </text>
<text top="462" left="344" width="121" height="17" font="0">before his or her visit  </text>
<text top="479" left="344" width="7" height="18" font="7"></text>
<text top="480" left="351" width="144" height="17" font="0"> Able to walk on treadmill  </text>
<text top="497" left="344" width="3" height="17" font="0"> </text>
<text top="515" left="344" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="532" left="344" width="7" height="18" font="7"></text>
<text top="533" left="351" width="61" height="17" font="0"> Acute CLI </text>
<text top="550" left="344" width="7" height="18" font="7"></text>
<text top="551" left="351" width="142" height="17" font="0"> Unstable angina pectoris </text>
<text top="569" left="344" width="7" height="18" font="7"></text>
<text top="570" left="351" width="150" height="17" font="0"> Uncontrolled hypertension </text>
<text top="587" left="344" width="7" height="18" font="7"></text>
<text top="588" left="351" width="160" height="17" font="0"> New York Heart Association </text>
<text top="605" left="344" width="159" height="17" font="0">(NYHA) cardiac insufficiency </text>
<text top="622" left="344" width="135" height="17" font="0">function class of III or IV </text>
<text top="640" left="344" width="7" height="18" font="7"></text>
<text top="641" left="351" width="59" height="17" font="0"> MI ≤3 mo </text>
<text top="658" left="344" width="7" height="18" font="7"></text>
<text top="659" left="351" width="118" height="17" font="0"> Arterial aneurysm or </text>
<text top="676" left="344" width="98" height="17" font="0">pseudoaneurysm </text>
<text top="694" left="344" width="7" height="18" font="7"></text>
<text top="695" left="351" width="151" height="17" font="0"> Major respiratory limitation </text>
<text top="712" left="344" width="98" height="17" font="0">(resting dyspnea) </text>
<text top="729" left="344" width="7" height="18" font="7"></text>
<text top="730" left="351" width="151" height="17" font="0"> Stroke or major neurologic </text>
<text top="748" left="344" width="54" height="17" font="0">disorders </text>
<text top="765" left="344" width="7" height="18" font="7"></text>
<text top="766" left="351" width="123" height="17" font="0"> Lived too far from the </text>
<text top="409" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="408" left="547" width="6" height="18" font="7"></text>
<text top="409" left="553" width="253" height="17" font="2"><b> endpoint:</b> Symptoms based on modified San </text>
<text top="426" left="540" width="276" height="17" font="0">Diego Claudication questionnaire, change in TcPO</text>
<text top="432" left="816" width="4" height="11" font="11">2</text>
<text top="426" left="820" width="3" height="17" font="0"> </text>
<text top="443" left="540" width="204" height="17" font="0">before and after treadmill ambulation </text>
<text top="461" left="540" width="3" height="17" font="0"> </text>
<text top="478" left="540" width="279" height="17" font="2"><b>Results: </b>30 pts reported proximal exercise-related </text>
<text top="495" left="540" width="274" height="17" font="0">pain consistent with vascular criteria by Hx before </text>
<text top="512" left="540" width="290" height="17" font="0">exercise. However, 59 pts (56%) reported symptoms </text>
<text top="530" left="540" width="265" height="17" font="0">compatible with proximal claudication, and TcPO</text>
<text top="535" left="805" width="4" height="11" font="11">2</text>
<text top="530" left="810" width="3" height="17" font="0"> </text>
<text top="547" left="540" width="297" height="17" font="0">values were abnormal on one or both sides in 52. The </text>
<text top="564" left="540" width="282" height="17" font="0">persistence of at least one (prograde or retrograde) </text>
<text top="581" left="540" width="249" height="17" font="0">pathway to the hypogastric circulation did not </text>
<text top="598" left="540" width="248" height="17" font="0">decrease proportion of pts reporting proximal </text>
<text top="616" left="540" width="257" height="17" font="0">claudication by Hx (26%) or on treadmill (55%) </text>
<text top="633" left="540" width="255" height="17" font="0">compared with those with bilateral hypogastric </text>
<text top="650" left="540" width="293" height="17" font="0">occlusion (33% by Hx; p=0.51 compared with at least </text>
<text top="667" left="540" width="281" height="17" font="0">one prograde hypogastric pathway and 61% based </text>
<text top="684" left="540" width="286" height="17" font="0">on treadmill test, p=0.65 compared with at least one </text>
<text top="702" left="540" width="176" height="17" font="0">prograde hypogastric pathway). </text>
<text top="408" left="851" width="24" height="17" font="0">N/A </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">139 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="344" width="65" height="17" font="0">laboratory.  </text>
<text top="105" left="95" width="111" height="17" font="0">Fowkes F and Leng </text>
<text top="122" left="95" width="22" height="17" font="0">GC </text>
<text top="139" left="95" width="59" height="17" font="0">2008(308) </text>
<text top="157" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18425879">18425879</a></text>
<text top="157" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18425879"> </a></text>
<text top="174" left="95" width="3" height="17" font="0"> </text>
<text top="105" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="122" left="223" width="103" height="17" font="0">Systematic review </text>
<text top="139" left="223" width="65" height="17" font="0">(Cochrane) </text>
<text top="157" left="223" width="3" height="17" font="0"> </text>
<text top="174" left="223" width="107" height="17" font="2"><b>Size:</b> n=19 trials (2 </text>
<text top="191" left="223" width="108" height="17" font="0">claudication only, 4 </text>
<text top="208" left="223" width="94" height="17" font="0">with claudication </text>
<text top="226" left="223" width="51" height="17" font="0">and CLI)<b> </b></text>
<text top="105" left="344" width="155" height="17" font="2"><b>Inclusion criteria:</b> RCTs of </text>
<text top="122" left="344" width="180" height="17" font="0">bypass surgery for chronic lower </text>
<text top="139" left="344" width="152" height="17" font="0">limb ischemia vs. any other </text>
<text top="157" left="344" width="55" height="17" font="0">treatment </text>
<text top="174" left="344" width="3" height="17" font="0"> </text>
<text top="191" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="106" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="105" left="547" width="6" height="18" font="7"></text>
<text top="106" left="553" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="123" left="540" width="3" height="17" font="0"> </text>
<text top="141" left="540" width="292" height="17" font="2"><b>Results:</b> Mortality and amputation rates did not differ </text>
<text top="158" left="540" width="259" height="17" font="0">significantly between bypass surgery and PTA; </text>
<text top="175" left="540" width="297" height="17" font="0">primary patency was significantly higher in the bypass </text>
<text top="192" left="540" width="291" height="17" font="0">group after 12 mo (OR: 1.6; 95% CI: 1.0–2.6) but not </text>
<text top="210" left="540" width="248" height="17" font="0">after 4 y (p=0.14). Blood flow restoration was </text>
<text top="227" left="540" width="205" height="17" font="0">significantly greater in bypass than in </text>
<text top="244" left="540" width="283" height="17" font="0">thromboendarterectomy pts (Peto OR: 9.2; 95% CI: </text>
<text top="261" left="540" width="268" height="17" font="0">1.7–50.6); mortality and amputation rates did not </text>
<text top="278" left="540" width="250" height="17" font="0">differ. Bypass surgery outcomes did not differ </text>
<text top="296" left="540" width="287" height="17" font="0">significantly from exercise or spinal cord stimulation.<b> </b></text>
<text top="105" left="851" width="253" height="17" font="0">There is limited evidence for the effectiveness </text>
<text top="122" left="851" width="215" height="17" font="0">of bypass surgery compared with other </text>
<text top="139" left="851" width="256" height="17" font="0">treatments; no studies compared bypass to no </text>
<text top="157" left="851" width="235" height="17" font="0">treatment. Further large trials are required. </text>
<text top="314" left="95" width="97" height="17" font="0">Periera CE, et al. </text>
<text top="331" left="95" width="59" height="17" font="0">2006(309) </text>
<text top="348" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16950427">16950427</a></text>
<text top="348" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16950427"> </a></text>
<text top="365" left="95" width="3" height="17" font="0"> </text>
<text top="314" left="223" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="331" left="223" width="48" height="17" font="0">analysis </text>
<text top="348" left="223" width="3" height="17" font="0"> </text>
<text top="365" left="223" width="106" height="17" font="2"><b>Size:</b> n=73 articles </text>
<text top="382" left="223" width="101" height="17" font="0">included; analysis </text>
<text top="400" left="223" width="49" height="17" font="0">included </text>
<text top="417" left="223" width="69" height="17" font="0">claudication-</text>
<text top="434" left="223" width="99" height="17" font="0">specific subgroup<b> </b></text>
<text top="314" left="344" width="181" height="17" font="2"><b>Inclusion criteria:</b> graft patency </text>
<text top="331" left="344" width="172" height="17" font="0">included as outcome, follow up </text>
<text top="348" left="344" width="166" height="17" font="0">of 1 y for at least some grafts, </text>
<text top="365" left="344" width="166" height="17" font="0">minimum of 30 bypasses in at </text>
<text top="382" left="344" width="145" height="17" font="0">least 1 series when article </text>
<text top="400" left="344" width="176" height="17" font="0">descrbied 2 or more series, and </text>
<text top="417" left="344" width="124" height="17" font="0">publication after 1986  </text>
<text top="434" left="344" width="3" height="17" font="0"> </text>
<text top="451" left="344" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="468" left="344" width="7" height="18" font="7"></text>
<text top="470" left="351" width="126" height="17" font="0"> Clinical symptoms not </text>
<text top="487" left="344" width="57" height="17" font="0">described </text>
<text top="504" left="344" width="7" height="18" font="7"></text>
<text top="505" left="351" width="129" height="17" font="0"> Predominance of blind </text>
<text top="522" left="344" width="155" height="17" font="0">segments of popliteal artery </text>
<text top="540" left="344" width="7" height="18" font="7"></text>
<text top="541" left="351" width="159" height="17" font="0"> Predominance of composite </text>
<text top="558" left="344" width="77" height="17" font="0">bypass grafts </text>
<text top="575" left="344" width="7" height="18" font="7"></text>
<text top="576" left="351" width="169" height="17" font="0"> Predominance of bypasses to </text>
<text top="594" left="344" width="138" height="17" font="0">the infrapopliteal arteries </text>
<text top="611" left="344" width="7" height="18" font="7"></text>
<text top="612" left="351" width="167" height="17" font="0"> Repeat inclusion of bypasses </text>
<text top="629" left="344" width="7" height="18" font="7"></text>
<text top="630" left="351" width="147" height="17" font="0"> Unreliable or unattainable </text>
<text top="648" left="344" width="178" height="17" font="0">reconstruction of life tables from </text>
<text top="665" left="344" width="88" height="17" font="0">graphs or texts. </text>
<text top="315" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="314" left="547" width="6" height="18" font="7"></text>
<text top="315" left="553" width="223" height="17" font="2"><b> endpoint:</b> Pooled primary graft patency </text>
<text top="332" left="540" width="3" height="17" font="0"> </text>
<text top="349" left="540" width="270" height="17" font="2"><b>Results:</b> For claudication-specific meta-analysis, </text>
<text top="366" left="540" width="278" height="17" font="0">pooled primary graft patency was 57.4% for above-</text>
<text top="384" left="540" width="285" height="17" font="0">knee polytetrafluoroethylene, 77.2% for above-knee </text>
<text top="401" left="540" width="295" height="17" font="0">vein, and 64.8% for below-knee vein at 5 y; there was </text>
<text top="418" left="540" width="291" height="17" font="0">a significant difference between above-knee grafts at </text>
<text top="435" left="540" width="270" height="17" font="0">3, 4, and 5 y (p&lt;0.05). The corresponding pooled </text>
<text top="452" left="540" width="267" height="17" font="0">secondary graft patency was 73.2%, 80.1%, and </text>
<text top="470" left="540" width="163" height="17" font="0">79.7%, respectively (p&gt;0.05).<b> </b></text>
<text top="314" left="851" width="232" height="17" font="0">The great saphenous vein performs better </text>
<text top="331" left="851" width="256" height="17" font="0">than polytetrafluoroethylene in femoropopliteal </text>
<text top="348" left="851" width="254" height="17" font="0">bypass grafting and should be used whenever </text>
<text top="365" left="851" width="52" height="17" font="0">possible. </text>
<text top="683" left="95" width="105" height="17" font="0">Rosenthal D, et al. </text>
<text top="700" left="95" width="59" height="17" font="0">2006(310) </text>
<text top="717" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16953157">16953157 </a></text>
<text top="734" left="95" width="3" height="17" font="0"> </text>
<text top="683" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="700" left="223" width="78" height="17" font="0">(retrospective </text>
<text top="717" left="223" width="105" height="17" font="0">multicenter cohort) </text>
<text top="734" left="223" width="3" height="17" font="0"> </text>
<text top="752" left="223" width="90" height="17" font="2"><b>Size:</b> n=210 pts </text>
<text top="769" left="223" width="93" height="17" font="0">(158 [75%] were </text>
<text top="683" left="344" width="153" height="17" font="2"><b>Inclusion criteria:</b> Remote </text>
<text top="700" left="344" width="103" height="17" font="0">superficial femoral </text>
<text top="717" left="344" width="145" height="17" font="0">endarterectomy and distal </text>
<text top="734" left="344" width="179" height="17" font="0">aSpire stenting for TASC D SFA </text>
<text top="752" left="344" width="36" height="17" font="0">lesion </text>
<text top="769" left="344" width="3" height="17" font="0"> </text>
<text top="684" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="683" left="547" width="6" height="18" font="7"></text>
<text top="684" left="553" width="217" height="17" font="2"><b> endpoint:</b> Primary cumulative patency </text>
<text top="701" left="540" width="3" height="17" font="0"> </text>
<text top="718" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="736" left="540" width="7" height="18" font="7"></text>
<text top="737" left="547" width="273" height="17" font="0"> Primary cumulative patency rate by means of life-</text>
<text top="754" left="540" width="288" height="17" font="0">table analysis was 60.6±4.8% (SE) at 33 mo, (mean </text>
<text top="771" left="540" width="142" height="17" font="0">17.1 mo; range 133 mo).  </text>
<text top="683" left="851" width="7" height="18" font="7"></text>
<text top="684" left="857" width="200" height="17" font="0"> Did not stratify results by diagnostic </text>
<text top="701" left="851" width="55" height="17" font="0">indication </text>
<text top="718" left="851" width="7" height="18" font="7"></text>
<text top="719" left="857" width="222" height="17" font="0"> 12 pts (5.7%) had wound complications </text>
<text top="737" left="851" width="3" height="17" font="0"> </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">140 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="69" height="17" font="0">claudicants) </text>
<text top="87" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="540" width="7" height="18" font="7"></text>
<text top="88" left="547" width="286" height="17" font="0"> During follow-up percutaneous transluminal balloon </text>
<text top="106" left="540" width="297" height="17" font="0">and/or stent angioplasty was necessary in 50 pts for a </text>
<text top="123" left="540" width="272" height="17" font="0">primary assisted patency of 70.2±4.8% at 33 mo. </text>
<text top="140" left="540" width="7" height="18" font="7"></text>
<text top="141" left="547" width="174" height="17" font="0"> Mean ABI rose from 0.58–0.95 </text>
<text top="159" left="95" width="90" height="17" font="0">Martin JD, et al. </text>
<text top="176" left="95" width="59" height="17" font="0">2006(311) </text>
<text top="194" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16476609">16476609 </a></text>
<text top="211" left="95" width="3" height="17" font="0"> </text>
<text top="159" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="176" left="223" width="78" height="17" font="0">(retrospective </text>
<text top="194" left="223" width="73" height="17" font="0">single center </text>
<text top="211" left="223" width="42" height="17" font="0">cohort) </text>
<text top="228" left="223" width="3" height="17" font="0"> </text>
<text top="245" left="223" width="90" height="17" font="2"><b>Size:</b> n=133 pts </text>
<text top="262" left="223" width="76" height="17" font="0">(57% had IC) </text>
<text top="159" left="344" width="153" height="17" font="2"><b>Inclusion criteria:</b> Remote </text>
<text top="176" left="344" width="180" height="17" font="0">endarterectomy from an inguinal </text>
<text top="194" left="344" width="111" height="17" font="0">incision for vascular </text>
<text top="211" left="344" width="175" height="17" font="0">reconstruction of &gt;10 cm length </text>
<text top="228" left="344" width="169" height="17" font="0">total occlusions of the external </text>
<text top="245" left="344" width="166" height="17" font="0">iliac and/or superficial femoral </text>
<text top="262" left="344" width="48" height="17" font="0">arteries. </text>
<text top="280" left="344" width="3" height="17" font="0"> </text>
<text top="297" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="160" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="159" left="547" width="6" height="18" font="7"></text>
<text top="160" left="553" width="155" height="17" font="2"><b> endpoint:</b> Primary patency </text>
<text top="177" left="540" width="3" height="17" font="0"> </text>
<text top="195" left="540" width="285" height="17" font="2"><b>Results: </b>Mean follow-up was 19 mo, with a primary </text>
<text top="212" left="540" width="287" height="17" font="0">patency of 70% at 30 mo by life-table analysis. Limb </text>
<text top="229" left="540" width="106" height="17" font="0">salvage was 94%.<b> </b> </text>
<text top="159" left="851" width="7" height="18" font="7"></text>
<text top="160" left="857" width="191" height="17" font="0"> 12% technical failure rate (bypass </text>
<text top="177" left="851" width="130" height="17" font="0">performed in these pts) </text>
<text top="315" left="95" width="72" height="17" font="0">Mori E, et al. </text>
<text top="332" left="95" width="59" height="17" font="0">2002(312) </text>
<text top="349" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11821823">11821823</a></text>
<text top="349" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11821823"> </a></text>
<text top="366" left="95" width="3" height="17" font="0"> </text>
<text top="315" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="332" left="223" width="74" height="17" font="0">(prospective, </text>
<text top="349" left="223" width="81" height="17" font="0">observational) </text>
<text top="366" left="223" width="3" height="17" font="0"> </text>
<text top="384" left="223" width="90" height="17" font="2"><b>Size:</b> n=427 pts </text>
<text top="401" left="223" width="104" height="17" font="0">[surgery=259 (362 </text>
<text top="418" left="223" width="30" height="17" font="0">legs) </text>
<text top="435" left="223" width="104" height="17" font="0">conservative=168] </text>
<text top="315" left="344" width="172" height="17" font="2"><b>Inclusion criteria:</b> Admitted to </text>
<text top="332" left="344" width="100" height="17" font="0">the hospital for IC </text>
<text top="349" left="344" width="3" height="17" font="0"> </text>
<text top="366" left="344" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="316" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="315" left="547" width="6" height="18" font="7"></text>
<text top="316" left="553" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="333" left="540" width="3" height="17" font="0"> </text>
<text top="350" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="368" left="540" width="7" height="18" font="7"></text>
<text top="369" left="547" width="240" height="17" font="0"> Surgery group had significantly better QOL </text>
<text top="386" left="540" width="178" height="17" font="0">improvement than conservative  </text>
<text top="403" left="540" width="7" height="18" font="7"></text>
<text top="404" left="547" width="288" height="17" font="0"> Infrainguinal and conservative were not significantly </text>
<text top="421" left="540" width="51" height="17" font="0">different  </text>
<text top="315" left="851" width="7" height="18" font="7"></text>
<text top="316" left="857" width="217" height="17" font="0"> Inferior 3 and 5 y patency observed for </text>
<text top="333" left="851" width="108" height="17" font="0">below knee bypass </text>
<text top="350" left="851" width="7" height="18" font="7"></text>
<text top="351" left="857" width="167" height="17" font="0"> Recommendation for surgical </text>
<text top="369" left="851" width="252" height="17" font="0">revascularization may be overinterpretation of </text>
<text top="386" left="851" width="43" height="17" font="0">results  </text>
<text top="403" left="851" width="7" height="18" font="7"></text>
<text top="404" left="857" width="169" height="17" font="0"> No defined pharmacotherapy  </text>
<text top="422" left="851" width="7" height="18" font="7"></text>
<text top="423" left="857" width="141" height="17" font="0"> No exercise comparator  </text>
<text top="440" left="851" width="7" height="18" font="7"></text>
<text top="441" left="857" width="246" height="17" font="0"> Does not report adverse events, amputation </text>
<text top="458" left="851" width="31" height="17" font="0">rates </text>
<text top="476" left="95" width="96" height="17" font="0">Feinglass J, et al </text>
<text top="494" left="95" width="59" height="17" font="0">2000(263) </text>
<text top="511" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10642712">10642712</a></text>
<text top="511" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10642712"> </a></text>
<text top="528" left="95" width="3" height="17" font="0"> </text>
<text top="476" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="494" left="223" width="74" height="17" font="0">(prospective, </text>
<text top="511" left="223" width="81" height="17" font="0">observational) </text>
<text top="528" left="223" width="3" height="17" font="0"> </text>
<text top="545" left="223" width="93" height="17" font="2"><b>Size:</b> n=526 pts  </text>
<text top="562" left="223" width="52" height="17" font="0">(104 had </text>
<text top="580" left="223" width="99" height="17" font="0">revascularization, </text>
<text top="597" left="223" width="69" height="17" font="0">including 60 </text>
<text top="614" left="223" width="96" height="17" font="0">bypasses and 44 </text>
<text top="631" left="223" width="79" height="17" font="0">angioplasties) </text>
<text top="476" left="344" width="162" height="17" font="2"><b>Inclusion criteria:</b> Abnormal </text>
<text top="494" left="344" width="112" height="17" font="0">ABI without prior LE </text>
<text top="511" left="344" width="133" height="17" font="0">revascularization or CLI </text>
<text top="528" left="344" width="59" height="17" font="0">symptoms </text>
<text top="545" left="344" width="3" height="17" font="0"> </text>
<text top="562" left="344" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="580" left="344" width="7" height="18" font="7"></text>
<text top="581" left="351" width="129" height="17" font="0"> Prior revascularization </text>
<text top="598" left="344" width="7" height="18" font="7"></text>
<text top="599" left="351" width="59" height="17" font="0"> Rest pain </text>
<text top="616" left="344" width="7" height="18" font="7"></text>
<text top="617" left="351" width="42" height="17" font="0"> Ulcers </text>
<text top="635" left="344" width="7" height="18" font="7"></text>
<text top="636" left="351" width="62" height="17" font="0"> Gangrene </text>
<text top="477" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="476" left="547" width="6" height="18" font="7"></text>
<text top="477" left="553" width="244" height="17" font="2"><b> endpoint:</b> SF-36 physical functioning score </text>
<text top="495" left="540" width="3" height="17" font="0"> </text>
<text top="512" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="529" left="540" width="7" height="18" font="7"></text>
<text top="530" left="547" width="277" height="17" font="0"> Bypass and angioplasty groups maintained highly </text>
<text top="547" left="540" width="280" height="17" font="0">significant improvements in mean physical function </text>
<text top="565" left="540" width="296" height="17" font="0">and walking distance scores, and reported greater leg </text>
<text top="582" left="540" width="131" height="17" font="0">symptom improvement  </text>
<text top="599" left="540" width="7" height="18" font="7"></text>
<text top="600" left="547" width="284" height="17" font="0"> Conditions of unmatched medical management pts </text>
<text top="617" left="540" width="190" height="17" font="0">declined on all outcome measures </text>
<text top="635" left="540" width="7" height="18" font="7"></text>
<text top="636" left="547" width="245" height="17" font="0"> Mean ABI improved significantly for bypass, </text>
<text top="653" left="540" width="139" height="17" font="0">modestly for angioplasty <b> </b></text>
<text top="476" left="851" width="7" height="18" font="7"></text>
<text top="477" left="857" width="245" height="17" font="0"> Pts who underwent angioplasty and surgery </text>
<text top="495" left="851" width="254" height="17" font="0">were classified as surgical bypass (regardless </text>
<text top="512" left="851" width="226" height="17" font="0">if procedures were staged within a single </text>
<text top="529" left="851" width="219" height="17" font="0">admission or separate hospitalizations)  </text>
<text top="546" left="851" width="7" height="18" font="7"></text>
<text top="547" left="857" width="213" height="17" font="0"> Does not include adverse event rates  </text>
<text top="565" left="851" width="7" height="18" font="7"></text>
<text top="566" left="857" width="221" height="17" font="0"> No standardized medical management  </text>
<text top="583" left="851" width="7" height="18" font="7"></text>
<text top="584" left="857" width="177" height="17" font="0"> No mention of exercise therapy </text>
<text top="671" left="95" width="107" height="17" font="0">Pell JP and Lee AJ </text>
<text top="688" left="95" width="59" height="17" font="0">1997(266) </text>
<text top="705" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9507581">9507581</a></text>
<text top="705" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9507581"> </a></text>
<text top="723" left="95" width="3" height="17" font="0"> </text>
<text top="671" left="223" width="92" height="17" font="2"><b>Study type:</b> NR </text>
<text top="688" left="223" width="74" height="17" font="0">(prospective, </text>
<text top="705" left="223" width="81" height="17" font="0">observational) </text>
<text top="723" left="223" width="3" height="17" font="0"> </text>
<text top="740" left="223" width="90" height="17" font="2"><b>Size:</b> n=201 pts </text>
<text top="671" left="344" width="141" height="17" font="2"><b>Inclusion criteria:</b> newly </text>
<text top="688" left="344" width="107" height="17" font="0">referred pts with IC </text>
<text top="705" left="344" width="3" height="17" font="0"> </text>
<text top="723" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="672" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="671" left="547" width="6" height="18" font="7"></text>
<text top="672" left="553" width="135" height="17" font="2"><b> endpoint:</b> QoL (SF-36) </text>
<text top="689" left="540" width="3" height="17" font="0"> </text>
<text top="707" left="540" width="55" height="17" font="2"><b>Results:  </b></text>
<text top="724" left="540" width="7" height="18" font="7"></text>
<text top="725" left="547" width="227" height="17" font="0"> All aspects of QoL deteriorated following </text>
<text top="742" left="540" width="131" height="17" font="0">conservative treatment  </text>
<text top="759" left="540" width="289" height="17" font="0">PTA and reconstruction had significant improvement </text>
<text top="777" left="540" width="297" height="17" font="0">in pain and physical function after adjustment for case </text>
<text top="671" left="851" width="7" height="18" font="7"></text>
<text top="672" left="857" width="237" height="17" font="0"> F/U data available on 81% of 195 pts alive </text>
<text top="689" left="851" width="100" height="17" font="0">at final timepoint.  </text>
<text top="707" left="905" width="88" height="17" font="0">◦10% had PTA  </text>
<text top="724" left="905" width="141" height="17" font="0">◦10% had reconstruction  </text>
<text top="741" left="905" width="169" height="17" font="0">◦76% managed conservatively </text>
<text top="758" left="851" width="7" height="18" font="7"></text>
<text top="759" left="857" width="208" height="17" font="0"> &#34;Conservative management&#34; was not </text>
<text top="777" left="851" width="259" height="17" font="0">defined beyond lack of procedural intervention  </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="26" size="11" family="Times" color="#000000"/>
	<fontspec id="27" size="11" family="Symbol" color="#000000"/>
<text top="795" left="1081" width="24" height="17" font="0">141 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="540" width="23" height="17" font="0">mix<b> </b></text>
<text top="87" left="851" width="7" height="18" font="7"></text>
<text top="88" left="857" width="166" height="17" font="0"> No defined pharmacotherapy </text>
<text top="106" left="851" width="7" height="18" font="7"></text>
<text top="107" left="857" width="218" height="17" font="0"> No exercise therapy comparison group </text>
<text top="125" left="95" width="70" height="17" font="0">Archie JP Jr </text>
<text top="142" left="95" width="59" height="17" font="0">1994(313) </text>
<text top="159" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7811585">7811585</a></text>
<text top="159" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7811585"> </a></text>
<text top="176" left="95" width="3" height="17" font="0"> </text>
<text top="124" left="223" width="82" height="15" font="26"><b>Study type:</b> NR </text>
<text top="140" left="223" width="105" height="15" font="21">(retrospective, single </text>
<text top="155" left="223" width="38" height="15" font="21">center) </text>
<text top="171" left="223" width="3" height="15" font="21"> </text>
<text top="186" left="223" width="63" height="15" font="26"><b>Size:</b> n=312 </text>
<text top="202" left="223" width="101" height="15" font="21">bypasses in 285 pts </text>
<text top="217" left="223" width="79" height="15" font="21">(39% had IC as </text>
<text top="233" left="223" width="54" height="15" font="21">indication) </text>
<text top="124" left="344" width="178" height="15" font="26"><b>Inclusion criteria:</b> Femoropopliteal </text>
<text top="140" left="344" width="175" height="15" font="21">bypass using ipsilateral autologous </text>
<text top="155" left="344" width="170" height="15" font="21">reversed GSV when available and </text>
<text top="171" left="344" width="82" height="15" font="21">PTFE when not. </text>
<text top="186" left="344" width="3" height="15" font="21"> </text>
<text top="202" left="344" width="121" height="15" font="26"><b>Exclusion criteria: </b>N/A </text>
<text top="125" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="124" left="546" width="5" height="16" font="27"></text>
<text top="125" left="552" width="103" height="15" font="26"><b> endpoint:</b> Patency  </text>
<text top="141" left="540" width="3" height="15" font="21"> </text>
<text top="157" left="540" width="269" height="15" font="26"><b>Results: </b>GSV patency superior to PTFE at 3 and 5 yr; </text>
<text top="172" left="540" width="42" height="15" font="21">P&lt;0.01. </text>
<text top="125" left="851" width="7" height="18" font="7"></text>
<text top="126" left="857" width="3" height="17" font="0"> </text>
<text top="127" left="861" width="246" height="15" font="21">Patency for GSV vs. PTFE was 87% vs. 54% at 3 </text>
<text top="143" left="851" width="140" height="15" font="21">yr and 81% vs. 48% at 5 ys. </text>
<text top="159" left="851" width="7" height="18" font="7"></text>
<text top="160" left="857" width="3" height="17" font="0"> </text>
<text top="161" left="861" width="237" height="15" font="21">Above-knee GSV primary patency &gt;below-knee </text>
<text top="177" left="851" width="128" height="15" font="21">GSV &gt;above-knee PTFE. </text>
<text top="192" left="851" width="7" height="18" font="7"></text>
<text top="194" left="857" width="3" height="17" font="0"> </text>
<text top="195" left="861" width="232" height="15" font="21">Overall PTFE failure rate was 3–4 times higher </text>
<text top="211" left="851" width="88" height="15" font="21">than that of GSV. </text>
<text top="249" left="95" width="98" height="17" font="0">Hunink MG, et al. </text>
<text top="267" left="95" width="59" height="17" font="0">1994(314) </text>
<text top="284" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8152359">8152359</a></text>
<text top="284" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8152359"> </a></text>
<text top="301" left="95" width="3" height="17" font="0"> </text>
<text top="249" left="223" width="82" height="15" font="26"><b>Study type:</b> NR </text>
<text top="265" left="223" width="79" height="15" font="21">(meta-analysis) </text>
<text top="280" left="223" width="3" height="15" font="21"> </text>
<text top="296" left="223" width="97" height="15" font="26"><b>Size:</b> n=17 femoral-</text>
<text top="311" left="223" width="82" height="15" font="21">popliteal bypass </text>
<text top="327" left="223" width="65" height="15" font="21">studies were </text>
<text top="342" left="223" width="100" height="15" font="21">included in life table </text>
<text top="358" left="223" width="97" height="15" font="21">analysis of patency </text>
<text top="249" left="344" width="135" height="15" font="26"><b>Inclusion criteria:</b> English </text>
<text top="265" left="344" width="152" height="15" font="21">language articles had to report </text>
<text top="280" left="344" width="174" height="15" font="21">original data, patency based on life </text>
<text top="296" left="344" width="175" height="15" font="21">table or Kaplan-Meier analysis with </text>
<text top="311" left="344" width="151" height="15" font="21">the number at risk or standard </text>
<text top="327" left="344" width="125" height="15" font="21">errors, define patency as </text>
<text top="342" left="344" width="174" height="15" font="21">hemodynamic improvement, report </text>
<text top="358" left="344" width="165" height="15" font="21">the distribution of covariates, and </text>
<text top="373" left="344" width="145" height="15" font="21">not duplicate other published </text>
<text top="389" left="344" width="46" height="15" font="21">material. </text>
<text top="404" left="344" width="3" height="15" font="21"> </text>
<text top="420" left="344" width="155" height="15" font="26"><b>Exclusion criteria: </b>See above </text>
<text top="250" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="249" left="546" width="5" height="16" font="27"></text>
<text top="250" left="552" width="100" height="15" font="26"><b> endpoint:</b> Patency </text>
<text top="266" left="540" width="3" height="15" font="21"> </text>
<text top="281" left="540" width="269" height="15" font="26"><b>Results: </b>Unadjusted pooled 5 yr patency was 45% for </text>
<text top="297" left="540" width="293" height="15" font="21">angioplasty, 73% for bypass surgery using a vein graft, and </text>
<text top="312" left="540" width="276" height="15" font="21">49% for bypass surgery using PTFE graft. Adjusted 5 yr </text>
<text top="328" left="540" width="290" height="15" font="21">primary patencies after surgery varied from 33%–80% with </text>
<text top="343" left="540" width="296" height="15" font="21">the best results being for saphenous vein bypass performed </text>
<text top="359" left="540" width="81" height="15" font="21">for claudication. </text>
<text top="249" left="851" width="226" height="15" font="21">Pooled data included bypasses performed for </text>
<text top="265" left="851" width="220" height="15" font="21">CLI/limb salvage as well as claudication, but </text>
<text top="280" left="851" width="212" height="15" font="21">analysis was stratified based on indication. </text>
<text top="436" left="95" width="107" height="17" font="0">Schweiger H, et al. </text>
<text top="453" left="95" width="59" height="17" font="0">1993(315) </text>
<text top="470" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8230575">8230575</a></text>
<text top="470" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8230575"> </a></text>
<text top="488" left="95" width="3" height="17" font="0"> </text>
<text top="436" left="223" width="82" height="15" font="26"><b>Study type:</b> NR </text>
<text top="451" left="223" width="102" height="15" font="21">(retrospective single </text>
<text top="467" left="223" width="38" height="15" font="21">center) </text>
<text top="482" left="223" width="3" height="15" font="21"> </text>
<text top="498" left="223" width="106" height="15" font="26"><b>Size:</b> n=211 grafts in </text>
<text top="513" left="223" width="87" height="15" font="21">184 pts, 195 legs </text>
<text top="529" left="223" width="71" height="15" font="21">(none had IC) </text>
<text top="436" left="344" width="173" height="15" font="26"><b>Inclusion criteria:</b> Below-popliteal </text>
<text top="451" left="344" width="162" height="15" font="21">(tibial) PTFE grafts implanted for </text>
<text top="467" left="344" width="65" height="15" font="21">limb salvage </text>
<text top="482" left="344" width="3" height="15" font="21"> </text>
<text top="498" left="344" width="121" height="15" font="26"><b>Exclusion criteria: </b>N/A </text>
<text top="437" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="436" left="546" width="5" height="16" font="27"></text>
<text top="437" left="552" width="199" height="15" font="26"><b> endpoint:</b> 5 yr cumulative limb salvage </text>
<text top="452" left="540" width="3" height="15" font="21"> </text>
<text top="468" left="540" width="237" height="15" font="26"><b>Results: </b>5 yr cumulative limb salvage was 51% </text>
<text top="436" left="851" width="7" height="18" font="7"></text>
<text top="437" left="857" width="3" height="17" font="0"> </text>
<text top="438" left="861" width="214" height="15" font="21">2 yr primary/secondary patency 37% / 45% </text>
<text top="454" left="851" width="7" height="18" font="7"></text>
<text top="455" left="857" width="3" height="17" font="0"> </text>
<text top="457" left="861" width="214" height="15" font="21">5 yr primary/secondary patency 23% / 25% </text>
<text top="473" left="851" width="7" height="18" font="7"></text>
<text top="474" left="857" width="3" height="17" font="0"> </text>
<text top="475" left="861" width="202" height="15" font="21">Primary bypass procedures had superior </text>
<text top="491" left="851" width="123" height="15" font="21">outcomes vs. secondary </text>
<text top="507" left="851" width="7" height="18" font="7"></text>
<text top="508" left="857" width="3" height="17" font="0"> </text>
<text top="509" left="861" width="75" height="15" font="21">All pts had CLI </text>
<text top="525" left="851" width="7" height="18" font="7"></text>
<text top="526" left="857" width="3" height="17" font="0"> </text>
<text top="528" left="861" width="143" height="15" font="21">25 limbs had acute ischemia<i> </i></text>
<text top="545" left="95" width="99" height="17" font="0">Baldwin ZK, et al. </text>
<text top="562" left="95" width="59" height="17" font="0">2004(316) </text>
<text top="580" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15111843">15111843</a></text>
<text top="580" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15111843"> </a></text>
<text top="597" left="95" width="3" height="17" font="0"> </text>
<text top="545" left="223" width="63" height="15" font="26"><b>Study type:</b> </text>
<text top="560" left="223" width="103" height="15" font="21">Retrospective single </text>
<text top="576" left="223" width="34" height="15" font="21">center </text>
<text top="592" left="223" width="3" height="15" font="21"> </text>
<text top="607" left="223" width="63" height="15" font="26"><b>Size:</b> n=631 </text>
<text top="622" left="223" width="101" height="15" font="21">infrainguinal bypass </text>
<text top="638" left="223" width="90" height="15" font="21">grafts in 578 legs; </text>
<text top="653" left="223" width="92" height="15" font="21">85% were for CLI. </text>
<text top="545" left="344" width="117" height="15" font="26"><b>Inclusion criteria: </b>N/A </text>
<text top="560" left="344" width="3" height="15" font="21"> </text>
<text top="576" left="344" width="124" height="15" font="26"><b>Exclusion criteria: </b>N/A  </text>
<text top="546" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="545" left="546" width="5" height="16" font="27"></text>
<text top="546" left="552" width="125" height="15" font="26"><b> endpoint:</b> Limb salvage </text>
<text top="562" left="540" width="3" height="15" font="21"> </text>
<text top="577" left="540" width="274" height="15" font="26"><b>Results: </b>Limb salvage rates following graft failure were </text>
<text top="592" left="540" width="291" height="15" font="21">50% at 2 yr. Limb salvage was 100% among pts with IC as </text>
<text top="608" left="540" width="266" height="15" font="21">initial bypass indication. Early graft failure (&lt;30 d) had </text>
<text top="623" left="540" width="87" height="15" font="21">worse prognosis.<b> </b></text>
<text top="639" left="540" width="3" height="15" font="21"> </text>
<text top="545" left="851" width="246" height="15" font="21">“The overall prognosis for limb salvage in pts with </text>
<text top="560" left="851" width="201" height="15" font="21">failed infrainguinal bypass grafts is poor, </text>
<text top="576" left="851" width="232" height="15" font="21">particularly in pts with grafts placed because of </text>
<text top="592" left="851" width="222" height="15" font="21">tissue loss and those with early graft failure.” </text>
<text top="670" left="95" width="86" height="17" font="0">Leng GC, et al. </text>
<text top="687" left="95" width="59" height="17" font="0">1996(317) </text>
<text top="704" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9027521">9027521</a></text>
<text top="704" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9027521"> </a></text>
<text top="721" left="95" width="3" height="17" font="0"> </text>
<text top="670" left="223" width="63" height="15" font="26"><b>Study type:</b> </text>
<text top="685" left="223" width="95" height="15" font="21">Prospective cohort </text>
<text top="701" left="223" width="87" height="15" font="21">study (Edinburgh </text>
<text top="716" left="223" width="68" height="15" font="21">Artery Study) </text>
<text top="732" left="223" width="3" height="15" font="21"> </text>
<text top="747" left="223" width="90" height="15" font="26"><b>Size:</b> n=1,592 pts </text>
<text top="670" left="344" width="160" height="15" font="26"><b>Inclusion criteria:</b> Age 55–74 y </text>
<text top="685" left="344" width="179" height="15" font="21">selected randomly from the age-sex </text>
<text top="701" left="344" width="172" height="15" font="21">registers of 10 general practices in </text>
<text top="716" left="344" width="103" height="15" font="21">Edinburgh, Scotland </text>
<text top="732" left="344" width="3" height="15" font="21"> </text>
<text top="747" left="344" width="121" height="15" font="26"><b>Exclusion criteria: </b>N/A </text>
<text top="671" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="670" left="546" width="5" height="16" font="27"></text>
<text top="671" left="552" width="257" height="15" font="26"><b> endpoint:</b> Incidence and natural hx of claudication; </text>
<text top="686" left="540" width="213" height="15" font="21">incidence of CV events in sx and asx PAD. </text>
<text top="702" left="540" width="3" height="15" font="21"> </text>
<text top="717" left="540" width="295" height="15" font="26"><b>Results:</b>116 new cases of claudication identified (incidence </text>
<text top="733" left="540" width="158" height="15" font="21">of 15.5 per 1,000 person-years) </text>
<text top="670" left="851" width="253" height="15" font="21">Among those with baseline claudication, 28.8% still </text>
<text top="685" left="851" width="223" height="15" font="21">had pain after 5 yr, 8.2% underwent vascular </text>
<text top="701" left="851" width="236" height="15" font="21">surgery or amputation, and 1.4% developed leg </text>
<text top="716" left="851" width="39" height="15" font="21">ulcers.  </text>
<text top="774" left="95" width="98" height="17" font="0">Kannel WB et al.  </text>
<text top="774" left="223" width="82" height="15" font="26"><b>Study type:</b> NR </text>
<text top="774" left="344" width="138" height="15" font="26"><b>Inclusion criteria:</b> General </text>
<text top="775" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="774" left="546" width="5" height="16" font="27"></text>
<text top="775" left="552" width="259" height="15" font="26"><b> endpoint:</b> Incidence of claudication by age and sex </text>
<text top="774" left="851" width="247" height="15" font="21">5,209 pts at the initial examination; of these 4,030 </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">142 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="59" height="17" font="0">1970(318) </text>
<text top="104" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/5444530">5444530</a></text>
<text top="104" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/5444530"> </a></text>
<text top="122" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="101" height="15" font="21">(prospective cohort) </text>
<text top="102" left="223" width="3" height="15" font="21"> </text>
<text top="118" left="223" width="90" height="15" font="26"><b>Size:</b> n=5,209 pts </text>
<text top="87" left="344" width="178" height="15" font="21">population of adult men and women </text>
<text top="102" left="344" width="146" height="15" font="21">(Framingham; 14 y follow up) </text>
<text top="118" left="344" width="3" height="15" font="21"> </text>
<text top="133" left="344" width="162" height="15" font="26"><b>Exclusion criteria: </b>None stated </text>
<text top="87" left="540" width="3" height="15" font="21"> </text>
<text top="102" left="540" width="281" height="15" font="26"><b>Results: </b>79 men and 46 women developed claudication. </text>
<text top="118" left="540" width="296" height="15" font="21">Overall annual incidence per 10,000 was 26 for men and 12 </text>
<text top="133" left="540" width="267" height="15" font="21">for women. No death was attributable to impaired limb </text>
<text top="149" left="540" width="253" height="15" font="21">circulation, and no amputation related to circulatory </text>
<text top="164" left="540" width="212" height="15" font="21">diseased occurred over 14 yr study period. </text>
<text top="87" left="851" width="225" height="15" font="21">returned for the 8 examination covered in this </text>
<text top="102" left="851" width="46" height="15" font="21">analysis. </text>
<text top="181" left="95" width="89" height="17" font="0">Kannel WB and </text>
<text top="198" left="95" width="62" height="17" font="0">Shurtleff D </text>
<text top="215" left="95" width="59" height="17" font="0">1971(319) </text>
<text top="232" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/5119838">5119838</a></text>
<text top="232" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/5119838"> </a></text>
<text top="250" left="95" width="3" height="17" font="0"> </text>
<text top="181" left="223" width="82" height="15" font="26"><b>Study type:</b> NR </text>
<text top="196" left="223" width="101" height="15" font="21">(prospective cohort) </text>
<text top="212" left="223" width="3" height="15" font="21"> </text>
<text top="227" left="223" width="90" height="15" font="26"><b>Size:</b> n=5,209 pts </text>
<text top="181" left="344" width="138" height="15" font="26"><b>Inclusion criteria:</b> General </text>
<text top="196" left="344" width="178" height="15" font="21">population of adult men and women </text>
<text top="212" left="344" width="146" height="15" font="21">(Framingham; 16 y follow up) </text>
<text top="227" left="344" width="3" height="15" font="21"> </text>
<text top="243" left="344" width="162" height="15" font="26"><b>Exclusion criteria: </b>None stated </text>
<text top="182" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="181" left="546" width="5" height="16" font="27"></text>
<text top="182" left="552" width="258" height="15" font="26"><b> endpoint:</b> Adverse cardiovascular events, mortality </text>
<text top="197" left="540" width="3" height="15" font="21"> </text>
<text top="213" left="540" width="247" height="15" font="26"><b>Results: </b>No death in the study group was directly </text>
<text top="228" left="540" width="245" height="15" font="21">attributable to impaired leg circulation. A total of 6 </text>
<text top="244" left="540" width="291" height="15" font="21">amputations occurred. Among those followed for ≥4 y from </text>
<text top="259" left="540" width="285" height="15" font="21">onset of claudication symptoms, 45% had their symptoms </text>
<text top="275" left="540" width="124" height="15" font="21">disappear for at least 4 y </text>
<text top="181" left="851" width="7" height="18" font="7"></text>
<text top="182" left="857" width="3" height="17" font="0"> </text>
<text top="183" left="861" width="230" height="15" font="21">Purpose of study was “to examine in a general </text>
<text top="199" left="851" width="250" height="15" font="21">population the manner in which IC arises, evolves, </text>
<text top="215" left="851" width="213" height="15" font="21">and becomes complicated by more serious </text>
<text top="230" left="851" width="256" height="15" font="21">cardiovascular impairments, and terminates fatally”. </text>
<text top="246" left="851" width="7" height="18" font="7"></text>
<text top="247" left="857" width="3" height="17" font="0"> </text>
<text top="248" left="861" width="232" height="15" font="21">Significant overlap with Kannel 1970 (making it </text>
<text top="264" left="851" width="240" height="15" font="21">challenging to identify distinct findings within this </text>
<text top="279" left="851" width="39" height="15" font="21">report). </text>
<text top="296" left="95" width="56" height="17" font="0">Tillgren C </text>
<text top="313" left="95" width="59" height="17" font="0">1965(320) </text>
<text top="330" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14317326">14317326</a></text>
<text top="330" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14317326"> </a></text>
<text top="347" left="95" width="3" height="17" font="0"> </text>
<text top="296" left="223" width="82" height="15" font="26"><b>Study type:</b> NR </text>
<text top="311" left="223" width="74" height="15" font="21">(retrospective) </text>
<text top="327" left="223" width="3" height="15" font="21"> </text>
<text top="342" left="223" width="26" height="15" font="26"><b>Size:</b></text>
<text top="342" left="249" width="4" height="16" font="3"> </text>
<text top="342" left="252" width="52" height="15" font="21">n=466 pts </text>
<text top="296" left="344" width="164" height="15" font="26"><b>Inclusion criteria:</b> Pts treated at </text>
<text top="311" left="344" width="129" height="15" font="21">hospitals in Stockholm for </text>
<text top="327" left="344" width="144" height="15" font="21">complaints in the lower limbs </text>
<text top="342" left="344" width="149" height="15" font="21">causing a suspicion of arterial </text>
<text top="358" left="344" width="63" height="15" font="21">insufficiency </text>
<text top="373" left="344" width="3" height="15" font="21"> </text>
<text top="389" left="344" width="164" height="15" font="26"><b>Exclusion criteria: </b>Embolic ALI, </text>
<text top="404" left="344" width="174" height="15" font="21">peripheral arterial insufficiency that </text>
<text top="420" left="344" width="155" height="15" font="21">appeared in the final stage of a </text>
<text top="435" left="344" width="180" height="15" font="21">severe disease (e.g., heart failure or </text>
<text top="451" left="344" width="43" height="15" font="21">cancer). </text>
<text top="297" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="296" left="546" width="5" height="16" font="27"></text>
<text top="297" left="552" width="263" height="15" font="26"><b> endpoint:</b> Survival, amputation, adverse CV events. </text>
<text top="312" left="540" width="3" height="15" font="21"> </text>
<text top="328" left="540" width="265" height="15" font="26"><b>Results: </b>36/294 (1.5%) of pts whose symptoms were </text>
<text top="343" left="540" width="286" height="15" font="21">attributed to arteriosclerosis had an amputation during the </text>
<text top="359" left="540" width="285" height="15" font="21">observation period. Amputation rate among this subgroup </text>
<text top="374" left="540" width="284" height="15" font="21">was 2.24/1000 mo for men and 1.23/1000 mo for women.<b> </b></text>
<text top="296" left="851" width="7" height="18" font="7"></text>
<text top="297" left="857" width="3" height="17" font="0"> </text>
<text top="298" left="861" width="237" height="15" font="21">Study included pts suspected to have Beurger’s </text>
<text top="314" left="851" width="47" height="15" font="21">disease.  </text>
<text top="330" left="851" width="7" height="18" font="7"></text>
<text top="331" left="857" width="3" height="17" font="0"> </text>
<text top="332" left="861" width="236" height="15" font="21">Classified pts with DM separate from those with </text>
<text top="348" left="851" width="81" height="15" font="21">atherosclerosis. </text>
<text top="364" left="851" width="7" height="18" font="7"></text>
<text top="365" left="857" width="3" height="17" font="0"> </text>
<text top="366" left="861" width="243" height="15" font="21">Included pts with CLI but did not stratify results in </text>
<text top="382" left="851" width="86" height="15" font="21">a similar fashion. </text>
<text top="397" left="851" width="7" height="18" font="7"></text>
<text top="399" left="857" width="3" height="17" font="0"> </text>
<text top="400" left="861" width="205" height="15" font="21">Authors concluded that “the course of the </text>
<text top="416" left="851" width="223" height="15" font="21">disease in the lower limbs does not affect life </text>
<text top="431" left="851" width="198" height="15" font="21">expectancy to any considerable extent.” </text>
<text top="467" left="95" width="85" height="17" font="0">Jelnes R, et al. </text>
<text top="484" left="95" width="59" height="17" font="0">1986(321) </text>
<text top="501" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3094806">3094806</a></text>
<text top="501" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3094806"> </a></text>
<text top="519" left="95" width="3" height="17" font="0"> </text>
<text top="467" left="223" width="82" height="15" font="26"><b>Study type:</b> NR </text>
<text top="482" left="223" width="3" height="15" font="21"> </text>
<text top="498" left="223" width="81" height="15" font="26"><b>Size:</b> n=257 pts </text>
<text top="467" left="344" width="156" height="15" font="26"><b>Inclusion criteria:</b> Pts referred </text>
<text top="482" left="344" width="165" height="15" font="21">consecutively for the first time for </text>
<text top="498" left="344" width="159" height="15" font="21">claudication during a 1 y period. </text>
<text top="513" left="344" width="3" height="15" font="21"> </text>
<text top="529" left="344" width="152" height="15" font="26"><b>Exclusion criteria: </b>Rest pain, </text>
<text top="544" left="344" width="123" height="15" font="21">ulcers, or foot gangrene. </text>
<text top="468" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="467" left="546" width="5" height="16" font="27"></text>
<text top="468" left="552" width="267" height="15" font="26"><b> endpoint:</b> Rate of clinical progression (to rest pain or </text>
<text top="483" left="540" width="57" height="15" font="21">gangrene). </text>
<text top="499" left="540" width="3" height="15" font="21"> </text>
<text top="514" left="540" width="290" height="15" font="26"><b>Results: </b>7.5% rate of progression in the worst affected leg </text>
<text top="530" left="540" width="247" height="15" font="21">during first yr after referral; 2.2% per yr thereafter. </text>
<text top="467" left="851" width="7" height="18" font="7"></text>
<text top="468" left="857" width="3" height="17" font="0"> </text>
<text top="469" left="861" width="215" height="15" font="21">Unclear whether design was prospective or </text>
<text top="485" left="851" width="69" height="15" font="21">retrospective. </text>
<text top="501" left="851" width="7" height="18" font="7"></text>
<text top="502" left="857" width="3" height="17" font="0"> </text>
<text top="503" left="861" width="224" height="15" font="21">Recruitment occurred from the department of </text>
<text top="519" left="851" width="232" height="15" font="21">clinical physiology at a single hospital over 1 y. </text>
<text top="535" left="851" width="7" height="18" font="7"></text>
<text top="536" left="857" width="3" height="17" font="0"> </text>
<text top="537" left="861" width="236" height="15" font="21">At a mean follow up of 6.5 ± 0.5 yts, 44% of pts </text>
<text top="553" left="851" width="49" height="15" font="21">had died. </text>
<text top="569" left="95" width="44" height="17" font="0">Bloor K </text>
<text top="587" left="95" width="59" height="17" font="0">1961(322) </text>
<text top="604" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19310276">19310276</a></text>
<text top="604" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19310276"> </a></text>
<text top="621" left="95" width="3" height="17" font="0"> </text>
<text top="569" left="223" width="104" height="17" font="2"><b>Study type:</b> Topic </text>
<text top="587" left="223" width="52" height="17" font="0">overview </text>
<text top="604" left="223" width="3" height="17" font="0"> </text>
<text top="621" left="223" width="56" height="17" font="2"><b>Size:</b> N/A </text>
<text top="569" left="344" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="587" left="344" width="3" height="17" font="0"> </text>
<text top="604" left="344" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="570" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="569" left="547" width="6" height="18" font="7"></text>
<text top="570" left="553" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="588" left="540" width="3" height="17" font="0"> </text>
<text top="605" left="540" width="76" height="17" font="2"><b>Results: </b>N/A<b> </b></text>
<text top="569" left="851" width="24" height="17" font="0">N/A </text>
<text top="639" left="95" width="103" height="17" font="0">Dormandy J, et al. </text>
<text top="656" left="95" width="63" height="17" font="0">1989 (323) </text>
<text top="673" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2647761">2647761</a></text>
<text top="673" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2647761"> </a></text>
<text top="691" left="95" width="3" height="17" font="0"> </text>
<text top="639" left="223" width="82" height="15" font="26"><b>Study type:</b> NR </text>
<text top="654" left="223" width="47" height="15" font="21">(Review) </text>
<text top="670" left="223" width="3" height="15" font="21"> </text>
<text top="685" left="223" width="95" height="15" font="26"><b>Size:</b> n=52 studies </text>
<text top="701" left="223" width="95" height="15" font="21">published between </text>
<text top="716" left="223" width="59" height="15" font="21">1958–1986 </text>
<text top="639" left="344" width="135" height="15" font="26"><b>Inclusion criteria:</b> English </text>
<text top="654" left="344" width="124" height="15" font="21">language published data </text>
<text top="670" left="344" width="3" height="15" font="21"> </text>
<text top="685" left="344" width="162" height="15" font="26"><b>Exclusion criteria:</b> Publications </text>
<text top="701" left="344" width="167" height="15" font="21">based on small numbers of pts or </text>
<text top="716" left="344" width="88" height="15" font="21">inconclusive data </text>
<text top="640" left="540" width="6" height="15" font="26"><b>1</b></text>
<text top="639" left="546" width="5" height="16" font="27"></text>
<text top="640" left="552" width="246" height="15" font="26"><b> endpoint:</b> Fate of pts presenting with chronic leg </text>
<text top="655" left="540" width="47" height="15" font="21">ischemia </text>
<text top="671" left="540" width="3" height="15" font="21"> </text>
<text top="686" left="540" width="278" height="15" font="26"><b>Results: </b>Reported prevalence of claudication in general </text>
<text top="702" left="540" width="296" height="15" font="21">population ranges from 0.4%–6.9% in men and 0.2%–3% in </text>
<text top="717" left="540" width="269" height="15" font="21">women. 25% of pts with claudication had worsening of </text>
<text top="733" left="540" width="260" height="15" font="21">symptoms after presentation, and 1.5–5% had major </text>
<text top="748" left="540" width="61" height="15" font="21">amputation.<b> </b></text>
<text top="639" left="851" width="24" height="17" font="0">N/A </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">143 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="990" height="17" font="0">ABF indicates aortobifemoral; ABI, ankle-brachial index; ALI, acute limb ischemia; ACS NSQIP, American College of Surgeons National Surgical Quality Improvement Program; AFB, </text>
<text top="104" left="86" width="1000" height="17" font="0">aortobifemoral bypass; AHRQ, Agency for Healthcare Research and Quality; AIOD, aortoiliac occlusive disease; APP, assisted primary patency; AS, aortoiliac stenting; ASA, American </text>
<text top="121" left="86" width="1003" height="17" font="0">Society of Anesthesiologist; BPG, bypass graft; CFA, common femoral artery; CFE, common femoral endarterectomy; CIA, common iliac artery; CI, confidence interval; CLI, critical limb </text>
<text top="138" left="86" width="994" height="17" font="0">ischemia; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; EIA, external iliac artery; ePTFE, expanded polytetrafluoroethylene; EVT, endovascular treatment; GSV, </text>
<text top="155" left="86" width="1000" height="17" font="0">greater saphenous vein; HBD, heparain bonded Dacron; HR, hazard ratio; HRQoL, heath-related quality of life; HUV, human umbilical vein; ICD, International Classification of Disease; </text>
<text top="172" left="86" width="976" height="17" font="0">IC, intermittent claudication; LEB, lower extremity bypass; LE, lower extremity; LS, limb salvage; N/A, not applicable; NIS, National Impatient Sample; NR, nonrandomized; NSQIP, </text>
<text top="190" left="86" width="1007" height="17" font="0">National Surgical Quality Improvement Program, NS, not significant; NYHA, New York Heart Association; OR, odds ratio; PAD, peripheral artery disease; PCIS, percutaneous iliac stent; </text>
<text top="207" left="86" width="1017" height="17" font="0">PP, primary patency; PTAS, percutaneous angioplasty/stent; PTFE, polytetrafluoroethylene; pt, patient; QoL, quality of life; RC, routine care; RCT, randomized controlled trial; RR, relative </text>
<text top="224" left="86" width="993" height="17" font="0">risk; RSFAE, remote superficial artery endarterectomy; SA RIEA, Stent-assisted remote iliac endarterectomy; SE, supervised exercise; SFA, superficial femoral artery; SIA, subintimal </text>
<text top="241" left="86" width="369" height="17" font="0">angioplasty; TASC, transatlantic inter-society consensus; and TcPO</text>
<text top="247" left="456" width="4" height="11" font="11">2</text>
<text top="241" left="460" width="192" height="17" font="0">, transcutaneous oxygen pressure. </text>
<text top="258" left="86" width="3" height="17" font="0"> </text>
<text top="276" left="86" width="3" height="17" font="0"> </text>
<text top="293" left="86" width="693" height="21" font="1"><b>Evidence Table 39. RCTs Comparing Endovascular Revascularization for Chronic CLI–Section 8.2. </b></text>
<text top="314" left="123" width="38" height="17" font="2"><b>Study </b></text>
<text top="332" left="112" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="349" left="118" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="366" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="314" left="208" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="332" left="213" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="349" left="207" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="314" left="367" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="314" left="572" width="38" height="17" font="2"><b>Study </b></text>
<text top="332" left="554" width="77" height="17" font="2"><b>Intervention  </b></text>
<text top="349" left="553" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="366" left="572" width="38" height="17" font="2"><b>Study </b></text>
<text top="383" left="554" width="77" height="17" font="2"><b>Comparator  </b></text>
<text top="400" left="557" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="314" left="660" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="332" left="664" width="97" height="17" font="2"><b>(Absolute Event </b></text>
<text top="349" left="648" width="129" height="17" font="2"><b>Rates, P value; OR or </b></text>
<text top="366" left="694" width="41" height="17" font="2"><b>RR; &amp;  </b></text>
<text top="383" left="689" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="315" left="861" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="314" left="923" width="6" height="18" font="7"></text>
<text top="315" left="929" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="333" left="893" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="350" left="901" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="418" left="95" width="79" height="17" font="0">Werk M, et al. </text>
<text top="436" left="95" width="59" height="17" font="0">2012(232)<b> </b></text>
<text top="453" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23192918">23192918 </a></text>
<text top="470" left="95" width="3" height="17" font="0"> </text>
<text top="418" left="203" width="88" height="17" font="2"><b>Aim: </b>SFA DCB </text>
<text top="436" left="203" width="46" height="17" font="0">vs. PTA </text>
<text top="453" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="470" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="487" left="203" width="29" height="17" font="0">RCT </text>
<text top="504" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="522" left="203" width="84" height="17" font="2"><b>Size: n=</b>85 pts<b> </b></text>
<text top="418" left="311" width="215" height="17" font="2"><b>Inclusion criteria: </b>Sx femoro-popliteal </text>
<text top="436" left="311" width="129" height="17" font="0">atherosclerotic disease </text>
<text top="453" left="311" width="3" height="17" font="0"> </text>
<text top="470" left="311" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="487" left="311" width="7" height="18" font="7"></text>
<text top="488" left="317" width="198" height="17" font="0"> Acute thrombus or aneurysm in the </text>
<text top="506" left="311" width="73" height="17" font="0">target vessel </text>
<text top="523" left="311" width="7" height="18" font="7"></text>
<text top="524" left="317" width="207" height="17" font="0"> Failure to cross the target lesion with </text>
<text top="541" left="311" width="66" height="17" font="0">a guidewire </text>
<text top="558" left="311" width="7" height="18" font="7"></text>
<text top="559" left="317" width="162" height="17" font="0"> Inflow lesions that cannot be </text>
<text top="577" left="311" width="129" height="17" font="0">successfully pretreated </text>
<text top="594" left="311" width="7" height="18" font="7"></text>
<text top="595" left="317" width="149" height="17" font="0"> Significant disease of all 3 </text>
<text top="612" left="311" width="118" height="17" font="0">infrapopliteal vessels </text>
<text top="630" left="311" width="7" height="18" font="7"></text>
<text top="631" left="317" width="202" height="17" font="0"> Renal failure (serum creatinine &gt;2.0 </text>
<text top="648" left="311" width="42" height="17" font="0">mg/dL) </text>
<text top="665" left="311" width="7" height="18" font="7"></text>
<text top="666" left="317" width="208" height="17" font="0"> Known intolerance or allergy to study </text>
<text top="684" left="311" width="63" height="17" font="0">medication </text>
<text top="701" left="311" width="7" height="18" font="7"></text>
<text top="702" left="317" width="119" height="17" font="0"> Life expectancy &lt;2 y<b> </b></text>
<text top="418" left="547" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="436" left="547" width="29" height="17" font="0">DCB<b> </b></text>
<text top="453" left="547" width="3" height="17" font="2"><b> </b></text>
<text top="470" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="487" left="547" width="27" height="17" font="0">PTA<b> </b></text>
<text top="419" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="418" left="655" width="6" height="18" font="7"></text>
<text top="419" left="661" width="87" height="17" font="2"><b> endpoint: </b>The </text>
<text top="437" left="648" width="120" height="17" font="0">primary endpoint was </text>
<text top="454" left="648" width="109" height="17" font="0">late lumen loss at 6 </text>
<text top="471" left="648" width="92" height="17" font="0">mo assessed by </text>
<text top="488" left="648" width="117" height="17" font="0">blinded angiographic </text>
<text top="506" left="648" width="110" height="17" font="0">corelab quantitative </text>
<text top="523" left="648" width="52" height="17" font="0">analyses </text>
<text top="418" left="790" width="7" height="18" font="7"></text>
<text top="419" left="797" width="133" height="17" font="2"><b> </b>DEB is superior to PTA </text>
<text top="437" left="790" width="7" height="18" font="7"></text>
<text top="438" left="797" width="286" height="17" font="0"> Pts with sx femoro-popliteal atherosclerotic disease </text>
<text top="455" left="790" width="308" height="17" font="0">undergoing percutaneous transluminal angioplasty were </text>
<text top="472" left="790" width="283" height="17" font="0">randomized to paclitaxel-coated IN.PACT Pacific or </text>
<text top="490" left="790" width="315" height="17" font="0">uncoated Pacific balloons. The primary endpoint was late </text>
<text top="507" left="790" width="295" height="17" font="0">lumen loss at 6 mo assessed by blinded angiographic </text>
<text top="524" left="790" width="315" height="17" font="0">corelab quantitative analyses. Secondary endpoints were </text>
<text top="541" left="790" width="305" height="17" font="0">binary restenosis and Rutherford class change at 6 mo, </text>
<text top="558" left="790" width="282" height="17" font="0">and target lesion revascularization + major adverse </text>
<text top="576" left="790" width="307" height="17" font="0">clinical events (major adverse events=death, target limb </text>
<text top="593" left="790" width="317" height="17" font="0">amputation, or target lesion revascularization) at 6 and 12 </text>
<text top="610" left="790" width="297" height="17" font="0">mo. 85 pts (91 cases=interventional procedures) were </text>
<text top="627" left="790" width="315" height="17" font="0">randomized in 3 hospitals (44 to DEB and 47 to uncoated </text>
<text top="645" left="790" width="274" height="17" font="0">balloons). Average lesion length was 7.0±5.3 and </text>
<text top="662" left="790" width="276" height="17" font="0">6.6±5.5 cm for DEB and control arm, respectively. </text>
<text top="679" left="790" width="285" height="17" font="0">Procedural success was obtained in all cases. 6 mo </text>
<text top="696" left="790" width="266" height="17" font="0">quantitative angiography showed that DEB were </text>
<text top="713" left="790" width="308" height="17" font="0">associated with significantly lower late lumen loss (-0.01 </text>
<text top="731" left="790" width="289" height="17" font="0">mm; 95% CI: -0.29–0.26 vs. 0.65 mm; 95% CI: 0.37–</text>
<text top="748" left="790" width="313" height="17" font="0">0.93; p=0.001) and fewer binary restenoses (3 [8.6%] vs. </text>
<text top="765" left="790" width="281" height="17" font="0">11 [32.4%]; p=0.01). This translated into a clinically </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">144 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="790" width="295" height="17" font="0">relevant benefit with significantly fewer major adverse </text>
<text top="104" left="790" width="291" height="17" font="0">events for DEB vs. uncoated balloons up to 12 mo (3 </text>
<text top="122" left="790" width="296" height="17" font="0">[7.1%] vs. 15 [34.9%]; p&lt;0.01) as well as target lesion </text>
<text top="139" left="790" width="288" height="17" font="0">revascularizations (3 [7.1%] vs. 12 [27.9%]; p=0.02). </text>
<text top="157" left="95" width="56" height="17" font="2"><b>IN.PACT</b>  </text>
<text top="174" left="95" width="78" height="17" font="0">Tepe G, et al. </text>
<text top="191" left="95" width="59" height="17" font="0">2015(229)<b> </b></text>
<text top="208" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25472980">25472980 </a></text>
<text top="226" left="95" width="3" height="17" font="0"> </text>
<text top="157" left="203" width="88" height="17" font="2"><b>Aim: </b>SFA DCB </text>
<text top="174" left="203" width="46" height="17" font="0">vs. PTA<b> </b></text>
<text top="191" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="208" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="226" left="203" width="29" height="17" font="0">RCT </text>
<text top="243" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="260" left="203" width="90" height="17" font="2"><b>Size: </b>n=331 pts<b> </b></text>
<text top="157" left="311" width="211" height="17" font="2"><b>Inclusion criteria: </b>IC or ischemic rest </text>
<text top="174" left="311" width="208" height="17" font="0">pain attributable to superficial femoral </text>
<text top="191" left="311" width="102" height="17" font="0">and popliteal PAD<b> </b></text>
<text top="208" left="311" width="3" height="17" font="2"><b> </b></text>
<text top="226" left="311" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="243" left="311" width="7" height="18" font="7"></text>
<text top="244" left="317" width="213" height="17" font="0"> Lesion and/or occlusions located in or </text>
<text top="261" left="311" width="189" height="17" font="0">extending to the popliteal artery or </text>
<text top="278" left="311" width="151" height="17" font="0">below the ankle joint space </text>
<text top="296" left="311" width="7" height="18" font="7"></text>
<text top="297" left="317" width="177" height="17" font="0"> Inflow lesion or occlusion in the </text>
<text top="314" left="311" width="222" height="17" font="0">ipsilateral iliac, SFA, or popliteal arteries </text>
<text top="331" left="311" width="107" height="17" font="0">with length ≥15 cm </text>
<text top="348" left="311" width="7" height="18" font="7"></text>
<text top="349" left="317" width="213" height="17" font="0"> Significant (≥50% DS) inflow lesion or </text>
<text top="367" left="311" width="217" height="17" font="0">occlusion in the ipsilateral iliac, SFA, or </text>
<text top="384" left="311" width="169" height="17" font="0">popliteal arteries left untreated </text>
<text top="401" left="311" width="7" height="18" font="7"></text>
<text top="402" left="317" width="216" height="17" font="0"> Previously implanted stent in the TL(s) </text>
<text top="420" left="311" width="7" height="18" font="7"></text>
<text top="421" left="317" width="207" height="17" font="0"> Aneurysm in the target vessel. Acute </text>
<text top="438" left="311" width="109" height="17" font="0">thrombus in the TL  </text>
<text top="157" left="547" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="174" left="547" width="29" height="17" font="0">DCB </text>
<text top="191" left="547" width="3" height="17" font="2"><b> </b></text>
<text top="208" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="226" left="547" width="27" height="17" font="0">PTA<b> </b></text>
<text top="158" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="157" left="655" width="6" height="18" font="7"></text>
<text top="158" left="661" width="100" height="17" font="2"><b> endpoint: </b>12 mo </text>
<text top="175" left="648" width="91" height="17" font="0">primary patency </text>
<text top="157" left="790" width="7" height="18" font="7"></text>
<text top="158" left="797" width="122" height="17" font="2"><b> </b>DCB superior to PTA </text>
<text top="175" left="790" width="7" height="18" font="7"></text>
<text top="176" left="797" width="294" height="17" font="0"> The IN.PACT SFA Trial is a prospective, multicenter, </text>
<text top="194" left="790" width="306" height="17" font="0">single-blinded, randomized trial in which 331 pts with IC </text>
<text top="211" left="790" width="297" height="17" font="0">or ischemic rest pain attributable to superficial femoral </text>
<text top="228" left="790" width="310" height="17" font="0">and popliteal PAD were randomly assigned in a 2:1 ratio </text>
<text top="245" left="790" width="283" height="17" font="0">to treatment with DCB or PTA. The primary efficacy </text>
<text top="262" left="790" width="307" height="17" font="0">endpoint was primary patency, defined as freedom from </text>
<text top="280" left="790" width="230" height="17" font="0">restenosis or clinically driven target lesion </text>
<text top="297" left="790" width="313" height="17" font="0">revascularization at 12 mo. Baseline characteristics were </text>
<text top="314" left="790" width="315" height="17" font="0">similar between the 2 groups. Mean lesion length and the </text>
<text top="331" left="790" width="316" height="17" font="0">percentage of total occlusions for the DCB and PTA arms </text>
<text top="348" left="790" width="305" height="17" font="0">were 8.94±4.89 and 8.81±5.12 cm (p=0.82) and 25.8% </text>
<text top="366" left="790" width="314" height="17" font="0">and 19.5% (p=0.22), respectively. DCB resulted in higher </text>
<text top="383" left="790" width="296" height="17" font="0">primary patency vs. PTA (82.2% vs. 52.4%; p&lt;0.001). </text>
<text top="400" left="790" width="315" height="17" font="0">The rate of clinically driven target lesion revascularization </text>
<text top="417" left="790" width="301" height="17" font="0">was 2.4% in the DCB arm in comparison with 20.6% in </text>
<text top="434" left="790" width="302" height="17" font="0">the PTA arm (p&lt;0.001). There was a low rate of vessel </text>
<text top="452" left="790" width="311" height="17" font="0">thrombosis in both arms (1.4% after DCB and 3.7% after </text>
<text top="469" left="790" width="283" height="17" font="0">PTA [p=0.10]). There were no device- or procedure-</text>
<text top="486" left="790" width="227" height="17" font="0">related deaths and no major amputations </text>
<text top="504" left="95" width="75" height="17" font="2"><b>ABSOLUTE </b> </text>
<text top="521" left="95" width="91" height="17" font="0">Schillinger M, et </text>
<text top="539" left="95" width="20" height="17" font="0">al.  </text>
<text top="556" left="95" width="59" height="17" font="0">2007(225) </text>
<text top="573" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17502568">17502568 </a></text>
<text top="590" left="95" width="3" height="17" font="0"> </text>
<text top="504" left="203" width="94" height="17" font="2"><b>Aim:</b> SFA PTAS </text>
<text top="521" left="203" width="46" height="17" font="0">vs. PTA </text>
<text top="539" left="203" width="3" height="17" font="0"> </text>
<text top="556" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="573" left="203" width="29" height="17" font="0">RCT </text>
<text top="590" left="203" width="3" height="17" font="0"> </text>
<text top="607" left="203" width="90" height="17" font="2"><b>Size:</b> n=104 pts </text>
<text top="504" left="311" width="174" height="17" font="2"><b>Inclusion criteria:</b> Rutherford 3</text>
<text top="504" left="485" width="7" height="17" font="19">–</text>
<text top="504" left="492" width="34" height="17" font="0">5 and </text>
<text top="521" left="311" width="76" height="17" font="0">SFA stenosis </text>
<text top="539" left="311" width="3" height="17" font="0"> </text>
<text top="556" left="311" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="573" left="311" width="7" height="18" font="7"></text>
<text top="574" left="317" width="22" height="17" font="0">ALI </text>
<text top="591" left="311" width="7" height="18" font="7"></text>
<text top="592" left="317" width="206" height="17" font="0"> Previous bypass surgery, or stenting </text>
<text top="610" left="311" width="62" height="17" font="0">of the SFA </text>
<text top="627" left="311" width="7" height="18" font="7"></text>
<text top="628" left="317" width="176" height="17" font="0"> Untreated inflow disease of the </text>
<text top="645" left="311" width="222" height="17" font="0">ipsilateral pelvic arteries (&gt;50% stenosis </text>
<text top="663" left="311" width="79" height="17" font="0">or occlusions) </text>
<text top="504" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="521" left="547" width="36" height="17" font="0">PTAS </text>
<text top="539" left="547" width="3" height="17" font="0"> </text>
<text top="556" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="573" left="547" width="27" height="17" font="0">PTA </text>
<text top="505" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="504" left="655" width="6" height="18" font="7"></text>
<text top="505" left="661" width="63" height="17" font="2"><b> endpoint:</b> </text>
<text top="522" left="648" width="120" height="17" font="0">Restenosis by duplex </text>
<text top="540" left="648" width="33" height="17" font="0">at 2 y </text>
<text top="504" left="790" width="7" height="18" font="7"></text>
<text top="505" left="797" width="303" height="17" font="0"> PTAS is superior to PTA for long lesions (lesion length </text>
<text top="522" left="790" width="180" height="17" font="0">112 mm PTAS and 93 mm PTA) </text>
<text top="540" left="790" width="7" height="18" font="7"></text>
<text top="541" left="797" width="261" height="17" font="0"> Of 104 pts with chronic limb ischemia and SFA </text>
<text top="558" left="790" width="316" height="17" font="0">obstructions, 98 (94%) could be followed up until 2 y after </text>
<text top="575" left="790" width="282" height="17" font="0">intervention for occurrence of restenosis (&gt;50%) by </text>
<text top="593" left="790" width="286" height="17" font="0">duplex ultrasound and for clinical and hemodynamic </text>
<text top="610" left="790" width="261" height="17" font="0">outcome by treadmill walking distance and ABI. </text>
<text top="627" left="790" width="310" height="17" font="0">Restenosis rates at 2 y were 45.7% (21 of 46) vs. 69.2% </text>
<text top="644" left="790" width="288" height="17" font="0">(36 of 52) in favor of primary stenting compared with </text>
<text top="661" left="790" width="303" height="17" font="0">balloon angioplasty with optional secondary stenting by </text>
<text top="679" left="790" width="267" height="17" font="0">an ITT analysis (p=0.031). Consistently, stenting </text>
<text top="696" left="790" width="296" height="17" font="0">(whether primary or secondary; n=63) was superior to </text>
<text top="713" left="790" width="281" height="17" font="0">plain balloon angioplasty (n=35) with respect to the </text>
<text top="730" left="790" width="309" height="17" font="0">occurrence of restenosis (49.2% vs. 74.3%; p=0.028) by </text>
<text top="747" left="790" width="276" height="17" font="0">a treatment-received analysis. Clinically, pts in the </text>
<text top="765" left="790" width="272" height="17" font="0">primary stent group showed a trend toward better </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">145 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="790" width="282" height="17" font="0">treadmill walking capacity (average, 302 vs. 196 m; </text>
<text top="104" left="790" width="299" height="17" font="0">p=0.12) and better ABI values (average, 0.88 vs. 0.78; </text>
<text top="122" left="790" width="309" height="17" font="0">p=0.09) at 2 y, respectively. Reintervention rates tended </text>
<text top="139" left="790" width="316" height="17" font="0">to be lower after primary stenting (17 of 46 [37.0%] vs. 28 </text>
<text top="156" left="790" width="125" height="17" font="0">of 52 [53.8%]; p=0.14) </text>
<text top="174" left="95" width="36" height="17" font="2"><b>FAST</b> </text>
<text top="191" left="95" width="90" height="17" font="0">Krankenberg H, </text>
<text top="208" left="95" width="33" height="17" font="0">et al.  </text>
<text top="226" left="95" width="59" height="17" font="0">2007(226) </text>
<text top="243" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17592075">17592075 </a></text>
<text top="260" left="95" width="3" height="17" font="0"> </text>
<text top="174" left="203" width="86" height="17" font="2"><b>Aim:</b> SFA PTA </text>
<text top="191" left="203" width="55" height="17" font="0">vs. PTAS </text>
<text top="208" left="203" width="3" height="17" font="0"> </text>
<text top="226" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="243" left="203" width="32" height="17" font="0">RCT  </text>
<text top="260" left="203" width="3" height="17" font="0"> </text>
<text top="277" left="203" width="90" height="17" font="2"><b>Size:</b> n=244 pts </text>
<text top="174" left="311" width="194" height="17" font="2"><b>Inclusion criteria:</b> SFA stenosis &amp; </text>
<text top="191" left="311" width="105" height="17" font="0">claudication or CLI </text>
<text top="208" left="311" width="3" height="17" font="0"> </text>
<text top="226" left="311" width="199" height="17" font="2"><b>Exclusion criteria:</b> Major exclusion </text>
<text top="243" left="311" width="74" height="17" font="0">criteria were: </text>
<text top="260" left="311" width="7" height="18" font="7"></text>
<text top="261" left="317" width="204" height="17" font="0"> A TL that required pretreatment with </text>
<text top="278" left="311" width="200" height="17" font="0">adjunctive devices such as lasers or </text>
<text top="296" left="311" width="110" height="17" font="0">debulking catheters </text>
<text top="313" left="311" width="7" height="18" font="7"></text>
<text top="314" left="317" width="204" height="17" font="0"> A TL that extended into the popliteal </text>
<text top="331" left="311" width="35" height="17" font="0">artery </text>
<text top="348" left="311" width="7" height="18" font="7"></text>
<text top="349" left="317" width="188" height="17" font="0"> Previous stent implantation in the </text>
<text top="367" left="311" width="76" height="17" font="0">targeted SFA </text>
<text top="384" left="311" width="7" height="18" font="7"></text>
<text top="385" left="317" width="187" height="17" font="0"> Multiple lesions exceeding a total </text>
<text top="402" left="311" width="88" height="17" font="0">length of 10 cm </text>
<text top="420" left="311" width="7" height="18" font="7"></text>
<text top="421" left="317" width="212" height="17" font="0"> Acute or subacute (≤4 wk) thrombotic </text>
<text top="438" left="311" width="55" height="17" font="0">occlusion </text>
<text top="455" left="311" width="7" height="18" font="7"></text>
<text top="456" left="317" width="176" height="17" font="0"> Untreated ipsilateral iliac artery </text>
<text top="474" left="311" width="49" height="17" font="0">stenosis </text>
<text top="491" left="311" width="7" height="18" font="7"></text>
<text top="492" left="317" width="152" height="17" font="0"> Ongoing dialysis treatment </text>
<text top="509" left="311" width="7" height="18" font="7"></text>
<text top="510" left="317" width="195" height="17" font="0"> Treatment with oral anticoagulants </text>
<text top="528" left="311" width="166" height="17" font="0">other than antiplatelet agents. </text>
<text top="174" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="191" left="547" width="36" height="17" font="0">PTAS </text>
<text top="208" left="547" width="3" height="17" font="0"> </text>
<text top="226" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="243" left="547" width="27" height="17" font="0">PTA </text>
<text top="175" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="174" left="655" width="6" height="18" font="7"></text>
<text top="175" left="661" width="63" height="17" font="2"><b> endpoint:</b> </text>
<text top="192" left="648" width="127" height="17" font="0">Technical success, 1 y </text>
<text top="210" left="648" width="99" height="17" font="0">duplex restenosis </text>
<text top="227" left="648" width="3" height="17" font="0"> </text>
<text top="174" left="790" width="7" height="18" font="7"></text>
<text top="175" left="797" width="284" height="17" font="0"> For short lesions mean length 45mm, no difference </text>
<text top="192" left="790" width="137" height="17" font="0">between PTAS and PTA </text>
<text top="210" left="790" width="7" height="18" font="7"></text>
<text top="211" left="797" width="279" height="17" font="0"> Overall, stent fractures were detected in 45 of 121 </text>
<text top="228" left="790" width="315" height="17" font="0">treated legs (37.2%). In a stent-based analysis, 64 of 261 </text>
<text top="245" left="790" width="302" height="17" font="0">stents (24.5%) showed fractures, which were classified </text>
<text top="262" left="790" width="282" height="17" font="0">as minor (single strut fracture) in 31 cases (48.4%), </text>
<text top="280" left="790" width="307" height="17" font="0">moderate (fracture of &gt;1 strut) in 17 cases (26.6%), and </text>
<text top="297" left="790" width="293" height="17" font="0">severe (complete separation of stent segments) in 16 </text>
<text top="314" left="790" width="295" height="17" font="0">cases (25.0%). Fracture rates were 13.2% for stented </text>
<text top="331" left="790" width="301" height="17" font="0">length ≤8 cm, 42.4% for stented length &gt;8–16 cm, and </text>
<text top="348" left="790" width="297" height="17" font="0">52.0% for stented length &gt;16 cm. In 21 cases (32.8%) </text>
<text top="366" left="790" width="315" height="17" font="0">there was a restenosis of &gt;50% diameter reduction at the </text>
<text top="383" left="790" width="283" height="17" font="0">site of stent fracture. In 22 cases (34.4%) with stent </text>
<text top="400" left="790" width="310" height="17" font="0">fracture there was a total stent reocclusion. According to </text>
<text top="417" left="790" width="303" height="17" font="0">Kaplan-Meier estimates, the primary patency rate at 12 </text>
<text top="434" left="790" width="290" height="17" font="0">mo was significantly lower for pts with stent fractures </text>
<text top="452" left="790" width="166" height="17" font="0">(41.1% vs. 84.3%, p&lt;0.0001). </text>
<text top="546" left="95" width="92" height="17" font="0">Gandini R, et al. </text>
<text top="563" left="95" width="59" height="17" font="0">2013(324) </text>
<text top="580" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24325697">24325697</a></text>
<text top="580" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24325697"> </a></text>
<text top="597" left="95" width="3" height="17" font="0"> </text>
<text top="546" left="203" width="92" height="17" font="2"><b>Aim:</b> CLI &amp; SFA </text>
<text top="563" left="203" width="76" height="17" font="0">ISR: DCB vs. </text>
<text top="580" left="203" width="63" height="17" font="0">laser+DCB </text>
<text top="597" left="203" width="3" height="17" font="0"> </text>
<text top="614" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="632" left="203" width="29" height="17" font="0">RCT </text>
<text top="649" left="203" width="3" height="17" font="0"> </text>
<text top="666" left="203" width="90" height="17" font="2"><b>Size:</b> n=448 pts </text>
<text top="546" left="311" width="223" height="17" font="2"><b>Inclusion criteria:</b> CLI and chronic SFA </text>
<text top="563" left="311" width="98" height="17" font="0">in-stent occlusion </text>
<text top="580" left="311" width="3" height="17" font="0"> </text>
<text top="597" left="311" width="204" height="17" font="2"><b>Exclusion criteria:</b> Denovo stenosis </text>
<text top="614" left="311" width="66" height="17" font="0">without ISR </text>
<text top="546" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="563" left="547" width="67" height="17" font="0">Laser+DCB </text>
<text top="580" left="547" width="3" height="17" font="0"> </text>
<text top="597" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="614" left="547" width="29" height="17" font="0">DCB </text>
<text top="547" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="546" left="655" width="6" height="18" font="7"></text>
<text top="547" left="661" width="100" height="17" font="2"><b> endpoint:</b> 12 mo </text>
<text top="564" left="648" width="91" height="17" font="0">primary patency </text>
<text top="581" left="648" width="3" height="17" font="0"> </text>
<text top="546" left="790" width="7" height="18" font="7"></text>
<text top="547" left="797" width="194" height="17" font="0"> Laser+DEB superior to DEB alone </text>
<text top="564" left="790" width="7" height="18" font="7"></text>
<text top="565" left="797" width="305" height="17" font="0"> In the Laser+DEB group, the patency rates at 6 and 12 </text>
<text top="582" left="790" width="298" height="17" font="0">mo (91.7% and 66.7%, respectively) were significantly </text>
<text top="599" left="790" width="289" height="17" font="0">higher (p=0.01) than in the DEB only pts (58.3% and </text>
<text top="617" left="790" width="293" height="17" font="0">37.5%, respectively). TLR at 12 mo was 16.7% in the </text>
<text top="634" left="790" width="277" height="17" font="0">Laser+DEB group and 50% in the DEB only group </text>
<text top="651" left="790" width="295" height="17" font="0">(p=0.01). 2 (8%) pts needed major amputations in the </text>
<text top="668" left="790" width="311" height="17" font="0">Laser+DEB group vs. 11 (46%) in the DEB only group at </text>
<text top="686" left="790" width="97" height="17" font="0">12 mo (p=0.003). </text>
<text top="703" left="95" width="86" height="17" font="2"><b>DEBATE-SFA  </b></text>
<text top="721" left="95" width="81" height="17" font="0">Liistro F, et al. </text>
<text top="738" left="95" width="59" height="17" font="0">2013(230) </text>
<text top="755" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24239203">24239203 </a></text>
<text top="772" left="95" width="3" height="17" font="0"> </text>
<text top="703" left="203" width="93" height="17" font="2"><b>Aim:</b> PEB+BMS </text>
<text top="721" left="203" width="84" height="17" font="0">vs. PTA+BMS  </text>
<text top="738" left="203" width="3" height="17" font="0"> </text>
<text top="755" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="772" left="203" width="29" height="17" font="0">RCT </text>
<text top="703" left="311" width="214" height="17" font="2"><b>Inclusion criteria:</b> Claudication or CLI </text>
<text top="721" left="311" width="100" height="17" font="0">and SFA stenosis </text>
<text top="738" left="311" width="3" height="17" font="0"> </text>
<text top="755" left="311" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="772" left="311" width="7" height="18" font="7"></text>
<text top="773" left="317" width="119" height="17" font="0"> Life expectancy &lt;1 y </text>
<text top="703" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="721" left="547" width="62" height="17" font="0">PEB+BMS </text>
<text top="738" left="547" width="3" height="17" font="0"> </text>
<text top="755" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="772" left="547" width="61" height="17" font="0">PTA+BMS </text>
<text top="705" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="704" left="655" width="6" height="18" font="7"></text>
<text top="705" left="661" width="100" height="17" font="2"><b> endpoint:</b> 12 mo </text>
<text top="722" left="648" width="96" height="17" font="0">binary restenosis </text>
<text top="704" left="790" width="7" height="18" font="7"></text>
<text top="705" left="797" width="200" height="17" font="0"> PEB+BMS is superior to PTA+BMS </text>
<text top="722" left="790" width="7" height="18" font="7"></text>
<text top="723" left="797" width="290" height="17" font="0"> Mean lesion length was 94±60 vs. 96±69 mm in the </text>
<text top="740" left="790" width="306" height="17" font="0">PEB+BMS and PTA+BMS groups (p=0.8), respectively. </text>
<text top="757" left="790" width="313" height="17" font="0">The primary endpoint occurred in 9 (17%) vs. 26 (47.3%) </text>
<text top="775" left="790" width="277" height="17" font="0">of lesions in the PEB+BMS and PTA+BMS groups </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">146 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="3" height="17" font="0"> </text>
<text top="104" left="203" width="90" height="17" font="2"><b>Size:</b> n=104 pts </text>
<text top="87" left="311" width="7" height="18" font="7"></text>
<text top="88" left="317" width="170" height="17" font="0"> Contraindication for combined </text>
<text top="106" left="311" width="107" height="17" font="0">antiplatelet therapy </text>
<text top="123" left="311" width="7" height="18" font="7"></text>
<text top="124" left="317" width="202" height="17" font="0"> Known allergy to nickel or paclitaxel </text>
<text top="141" left="311" width="7" height="18" font="7"></text>
<text top="142" left="317" width="213" height="17" font="0"> Need for major amputation at the time </text>
<text top="159" left="311" width="75" height="17" font="0">of enrollment </text>
<text top="177" left="311" width="7" height="18" font="7"></text>
<text top="178" left="317" width="204" height="17" font="0"> Failure to recanalize intended below-</text>
<text top="195" left="311" width="201" height="17" font="0">the-knee arteries in CLI pts at risk of </text>
<text top="212" left="311" width="213" height="17" font="0">major amputation was also considered </text>
<text top="230" left="311" width="119" height="17" font="0">an exclusion criterion </text>
<text top="87" left="790" width="300" height="17" font="0">(p=0.008), respectively. A near-significant (p=0.07) 1-y </text>
<text top="104" left="790" width="304" height="17" font="0">freedom from target lesion revascularization advantage </text>
<text top="122" left="790" width="266" height="17" font="0">was observed in the PEB+BMS group. No major </text>
<text top="139" left="790" width="279" height="17" font="0">amputation occurred. No significant difference was </text>
<text top="156" left="790" width="308" height="17" font="0">observed according to lesion characteristics or technical </text>
<text top="173" left="790" width="58" height="17" font="0">approach. </text>
<text top="248" left="95" width="93" height="17" font="2"><b>IN.PACT DEEP</b>  </text>
<text top="265" left="95" width="79" height="17" font="0">Zeller T, et al. </text>
<text top="282" left="95" width="63" height="17" font="0">2014 (325) </text>
<text top="299" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25301459">25301459 </a></text>
<text top="316" left="95" width="3" height="17" font="0"> </text>
<text top="248" left="203" width="83" height="17" font="2"><b>Aim:</b> Infrapop: </text>
<text top="265" left="203" width="76" height="17" font="0">DCB vs. PTA </text>
<text top="282" left="203" width="3" height="17" font="0"> </text>
<text top="299" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="316" left="203" width="29" height="17" font="0">RCT </text>
<text top="334" left="203" width="3" height="17" font="0"> </text>
<text top="351" left="203" width="90" height="17" font="2"><b>Size:</b> n=358 pts </text>
<text top="248" left="311" width="214" height="17" font="2"><b>Inclusion criteria:</b> CLI due to infrapop </text>
<text top="265" left="311" width="29" height="17" font="0">PAD </text>
<text top="282" left="311" width="3" height="17" font="0"> </text>
<text top="299" left="311" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="316" left="311" width="7" height="18" font="7"></text>
<text top="317" left="317" width="213" height="17" font="0"> Lesion and/or occlusions located in or </text>
<text top="335" left="311" width="189" height="17" font="0">extending to the popliteal artery or </text>
<text top="352" left="311" width="155" height="17" font="0">below the ankle joint space  </text>
<text top="369" left="311" width="7" height="18" font="7"></text>
<text top="370" left="317" width="177" height="17" font="0"> Inflow lesion or occlusion in the </text>
<text top="387" left="311" width="222" height="17" font="0">ipsilateral iliac, SFA, or popliteal arteries </text>
<text top="405" left="311" width="111" height="17" font="0">with length ≥15 cm  </text>
<text top="422" left="311" width="7" height="18" font="7"></text>
<text top="423" left="317" width="213" height="17" font="0"> Significant (≥50% DS) inflow lesion or </text>
<text top="440" left="311" width="217" height="17" font="0">occlusion in the ipsilateral iliac, SFA, or </text>
<text top="457" left="311" width="172" height="17" font="0">popliteal arteries left untreated  </text>
<text top="475" left="311" width="7" height="18" font="7"></text>
<text top="476" left="317" width="177" height="17" font="0"> Failure to obtain &lt;30% residual </text>
<text top="493" left="311" width="132" height="17" font="0">stenosis in pre-existing, </text>
<text top="510" left="311" width="217" height="17" font="0">hemodynamically significant (≥50% DS </text>
<text top="528" left="311" width="219" height="17" font="0">and &lt;15 cm length) inflow lesions in the </text>
<text top="545" left="311" width="213" height="17" font="0">ipsilateral iliac, SFA, or popliteal artery </text>
<text top="562" left="311" width="7" height="18" font="7"></text>
<text top="563" left="317" width="208" height="17" font="0"> DES and/or DEB was not allowed for </text>
<text top="580" left="311" width="220" height="17" font="0">the treatment of inflow lesions GFR &lt;30 </text>
<text top="598" left="311" width="202" height="17" font="0">mL/min except for pts with renal end-</text>
<text top="615" left="311" width="217" height="17" font="0">stage disease on chronic hemodialysis  </text>
<text top="248" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="265" left="547" width="29" height="17" font="0">DCB </text>
<text top="282" left="547" width="3" height="17" font="0"> </text>
<text top="299" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="316" left="547" width="27" height="17" font="0">PTA </text>
<text top="249" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="248" left="655" width="6" height="18" font="7"></text>
<text top="249" left="661" width="115" height="17" font="2"><b> endpoint:</b> Clinically </text>
<text top="266" left="648" width="107" height="17" font="0">driven target lesion </text>
<text top="283" left="648" width="122" height="17" font="0">revascularization (CD-</text>
<text top="300" left="648" width="115" height="17" font="0">TLR) and late lumen </text>
<text top="318" left="648" width="61" height="17" font="0">loss (LLL). </text>
<text top="335" left="648" width="3" height="17" font="0"> </text>
<text top="352" left="648" width="124" height="17" font="2"><b>Safety endpoint:</b> The </text>
<text top="369" left="648" width="81" height="17" font="0">primary safety </text>
<text top="386" left="648" width="127" height="17" font="0">endpoint through 6 mo </text>
<text top="404" left="648" width="125" height="17" font="0">was a composite of all-</text>
<text top="421" left="648" width="124" height="17" font="0">cause mortality, major </text>
<text top="438" left="648" width="114" height="17" font="0">amputation, and CD-</text>
<text top="455" left="648" width="30" height="17" font="0">TLR. </text>
<text top="248" left="790" width="7" height="18" font="7"></text>
<text top="249" left="797" width="179" height="17" font="0"> Increased amputation with DEB </text>
<text top="266" left="790" width="7" height="18" font="7"></text>
<text top="267" left="797" width="278" height="17" font="0"> Clinical characteristics were similar between the 2 </text>
<text top="284" left="790" width="304" height="17" font="0">groups. Significant baseline differences between the IA-</text>
<text top="301" left="790" width="318" height="17" font="0">DEB and PTA arms included mean lesion length (10.2 cm </text>
<text top="319" left="790" width="314" height="17" font="0">vs. 12.9 cm; p=0.002), impaired inflow (40.7% vs. 28.8%; </text>
<text top="336" left="790" width="286" height="17" font="0">p=0.035), and previous target limb revascularization </text>
<text top="353" left="790" width="303" height="17" font="0">(32.2% vs. 21.8%; p=0.047). Primary efficacy results of </text>
<text top="370" left="790" width="272" height="17" font="0">IA-DEB vs. PTA were CD-TLR of 9.2% vs. 13.1% </text>
<text top="387" left="790" width="304" height="17" font="0">(p=0.291) and LLL of 0.61±0.78 mm vs. 0.62±0.78 mm </text>
<text top="405" left="790" width="286" height="17" font="0">(p=0.950). Primary safety endpoints were 17.7% vs. </text>
<text top="422" left="790" width="314" height="17" font="0">15.8% (p=0.021) and met the noninferiority hypothesis. A </text>
<text top="439" left="790" width="312" height="17" font="0">safety signal driven by major amputations through 12 mo </text>
<text top="456" left="790" width="309" height="17" font="0">was observed in the IA-DEB arm vs. the PTA arm (8.8% </text>
<text top="474" left="790" width="110" height="17" font="0">vs. 3.6%; p=0.080). </text>
<text top="633" left="95" width="65" height="17" font="2"><b>ACHILLES</b> </text>
<text top="650" left="95" width="85" height="17" font="0">Scheinert D, et </text>
<text top="667" left="95" width="16" height="17" font="0">al. </text>
<text top="684" left="95" width="59" height="17" font="0">2012(326) </text>
<text top="702" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23194941">23194941 </a></text>
<text top="719" left="95" width="3" height="17" font="0"> </text>
<text top="633" left="203" width="83" height="17" font="2"><b>Aim:</b> Infrapop: </text>
<text top="650" left="203" width="75" height="17" font="0">DES vs. PTA </text>
<text top="667" left="203" width="3" height="17" font="0"> </text>
<text top="684" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="702" left="203" width="29" height="17" font="0">RCT </text>
<text top="719" left="203" width="3" height="17" font="0"> </text>
<text top="736" left="203" width="90" height="17" font="2"><b>Size:</b> n=200 pts </text>
<text top="633" left="311" width="214" height="17" font="2"><b>Inclusion criteria:</b> CLI due to infrapop </text>
<text top="650" left="311" width="29" height="17" font="0">PAD </text>
<text top="667" left="311" width="3" height="17" font="0"> </text>
<text top="684" left="311" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="702" left="311" width="7" height="18" font="7"></text>
<text top="703" left="317" width="205" height="17" font="0"> Significant stenoses (&gt;50%) distal to </text>
<text top="720" left="311" width="138" height="17" font="0">the TL that might require </text>
<text top="737" left="311" width="189" height="17" font="0">revascularization or impede runoff </text>
<text top="754" left="311" width="7" height="18" font="7"></text>
<text top="755" left="317" width="209" height="17" font="0"> Angiographically evident thrombus or </text>
<text top="773" left="311" width="167" height="17" font="0">Hx of thrombolysis within 72 h </text>
<text top="633" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="650" left="547" width="29" height="17" font="0">DES </text>
<text top="667" left="547" width="3" height="17" font="0"> </text>
<text top="684" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="702" left="547" width="27" height="17" font="0">PTA </text>
<text top="634" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="633" left="655" width="6" height="18" font="7"></text>
<text top="634" left="661" width="83" height="17" font="2"><b> endpoint:</b> 1 y </text>
<text top="651" left="648" width="74" height="17" font="0">angiographic </text>
<text top="668" left="648" width="98" height="17" font="0">restenosis vessel </text>
<text top="686" left="648" width="122" height="17" font="0">patency death, repeat </text>
<text top="703" left="648" width="99" height="17" font="0">revascularization, </text>
<text top="720" left="648" width="124" height="17" font="0">index-limb amputation </text>
<text top="737" left="648" width="31" height="17" font="0">rates </text>
<text top="633" left="790" width="7" height="18" font="7"></text>
<text top="634" left="797" width="210" height="17" font="0"> Infrapop DES superior to PTA for CLI </text>
<text top="651" left="790" width="7" height="18" font="7"></text>
<text top="652" left="797" width="276" height="17" font="0"> 99 and 101 pts (mean age 73.4 y; 64% DM) were </text>
<text top="669" left="790" width="304" height="17" font="0">randomized to SES and PTA, respectively (8 crossover </text>
<text top="687" left="790" width="257" height="17" font="0">bailout cases to SES). At 1 y, there were lower </text>
<text top="704" left="790" width="267" height="17" font="0">angiographic restenosis rates (22.4% vs. 41.9%, </text>
<text top="721" left="790" width="286" height="17" font="0">p=0.019), greater vessel patency (75.0% vs. 57.1%, </text>
<text top="738" left="790" width="294" height="17" font="0">p=0.025), and similar death, repeat revascularization, </text>
<text top="756" left="790" width="306" height="17" font="0">index-limb amputation rates, and proportions of pts with </text>
<text top="773" left="790" width="243" height="17" font="0">improved Rutherford class for SES vs. PTA. </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">147 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="311" width="7" height="18" font="7"></text>
<text top="88" left="317" width="207" height="17" font="0"> Untreated lesions (&gt;75% stenosis) in </text>
<text top="106" left="311" width="157" height="17" font="0">the common or external iliac </text>
<text top="123" left="311" width="7" height="18" font="7"></text>
<text top="124" left="317" width="198" height="17" font="0"> Common or superficial femoral and </text>
<text top="141" left="311" width="84" height="17" font="0">popliteal artery </text>
<text top="158" left="311" width="7" height="18" font="7"></text>
<text top="159" left="317" width="180" height="17" font="0"> Infrapopliteal trifurcation lesions </text>
<text top="177" left="311" width="187" height="17" font="0">requiring 2- or 3-branch treatment </text>
<text top="194" left="311" width="7" height="18" font="7"></text>
<text top="195" left="317" width="215" height="17" font="0"> Stent placement across or within 1 cm </text>
<text top="212" left="311" width="212" height="17" font="0">of the knee joint or in an artery subject </text>
<text top="230" left="311" width="134" height="17" font="0">to external compression </text>
<text top="247" left="311" width="7" height="18" font="7"></text>
<text top="248" left="317" width="170" height="17" font="0"> Prior stenting within the target </text>
<text top="265" left="311" width="200" height="17" font="0">vessel(s) or aneurysm in the SFA or </text>
<text top="282" left="311" width="84" height="17" font="0">popliteal artery </text>
<text top="300" left="311" width="7" height="18" font="7"></text>
<text top="301" left="317" width="206" height="17" font="0"> Hx of thrombophlebitis, deep venous </text>
<text top="318" left="311" width="209" height="17" font="0">thrombosis, or impaired renal function </text>
<text top="335" left="311" width="86" height="17" font="0">(Cr &gt;2.5 mg/dl) </text>
<text top="352" left="311" width="7" height="18" font="7"></text>
<text top="353" left="317" width="137" height="17" font="0"> Life expectancy &lt;12 mo </text>
<text top="371" left="311" width="7" height="18" font="7"></text>
<text top="372" left="317" width="185" height="17" font="0"> Known intolerance to antiplatelet </text>
<text top="389" left="311" width="66" height="17" font="0">medication. </text>
<text top="407" left="95" width="65" height="17" font="2"><b>ACHILLES</b> </text>
<text top="424" left="95" width="83" height="17" font="0">Katsanos K, et </text>
<text top="441" left="95" width="16" height="17" font="0">al. </text>
<text top="459" left="95" width="59" height="17" font="0">2016(327) </text>
<text top="476" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26777329">26777329</a></text>
<text top="476" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26777329"> </a></text>
<text top="407" left="203" width="83" height="17" font="2"><b>Aim:</b> Infrapop: </text>
<text top="424" left="203" width="75" height="17" font="0">DES vs. PTA </text>
<text top="441" left="203" width="3" height="17" font="0"> </text>
<text top="459" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="476" left="203" width="29" height="17" font="0">RCT </text>
<text top="493" left="203" width="3" height="17" font="0"> </text>
<text top="510" left="203" width="90" height="17" font="2"><b>Size:</b> n=200 pts </text>
<text top="407" left="311" width="216" height="17" font="2"><b>Inclusion criteria:</b> Refer to ACHILLES </text>
<text top="424" left="311" width="60" height="17" font="0">trial above </text>
<text top="441" left="311" width="3" height="17" font="0"> </text>
<text top="459" left="311" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="476" left="311" width="7" height="18" font="7"></text>
<text top="477" left="317" width="174" height="17" font="0"> Refer to ACHILLES trial above </text>
<text top="407" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="424" left="547" width="29" height="17" font="0">DES </text>
<text top="441" left="547" width="3" height="17" font="0"> </text>
<text top="459" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="476" left="547" width="27" height="17" font="0">PTA </text>
<text top="408" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="407" left="655" width="6" height="18" font="7"></text>
<text top="408" left="661" width="83" height="17" font="2"><b> endpoint:</b> 1 y </text>
<text top="425" left="648" width="74" height="17" font="0">angiographic </text>
<text top="443" left="648" width="98" height="17" font="0">restenosis vessel </text>
<text top="460" left="648" width="122" height="17" font="0">patency death, repeat </text>
<text top="477" left="648" width="99" height="17" font="0">revascularization, </text>
<text top="494" left="648" width="124" height="17" font="0">index-limb amputation </text>
<text top="512" left="648" width="31" height="17" font="0">rates </text>
<text top="407" left="790" width="7" height="18" font="7"></text>
<text top="408" left="797" width="288" height="17" font="0"> Infrapop SES axcellerates wound healing and is ES </text>
<text top="425" left="790" width="129" height="17" font="0">superior to PTA for CLI </text>
<text top="443" left="790" width="7" height="18" font="7"></text>
<text top="444" left="797" width="291" height="17" font="0">  There was a trend of more QALYs gained with SES </text>
<text top="461" left="790" width="274" height="17" font="0">compared with PTA up to 1 y after randomization. </text>
<text top="478" left="790" width="280" height="17" font="0">Relative QALY gain was 0.10 (95% CI: -0.01–0.21; </text>
<text top="495" left="790" width="316" height="17" font="0">p=0.08) in the whole study and 0.17 (95% CI: -0.03–0.35; </text>
<text top="513" left="790" width="250" height="17" font="0">p=0.09) in the wound subgroups comparison. </text>
<text top="531" left="95" width="40" height="17" font="2"><b>BASIL</b> </text>
<text top="548" left="95" width="87" height="17" font="0">Adam DJ, et al. </text>
<text top="565" left="95" width="63" height="17" font="0">2005 (328) </text>
<text top="582" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16325694">16325694 </a></text>
<text top="599" left="95" width="3" height="17" font="0"> </text>
<text top="531" left="203" width="94" height="17" font="2"><b>Aim:</b> Bypass vs. </text>
<text top="548" left="203" width="68" height="17" font="0">PTA for CLI </text>
<text top="565" left="203" width="3" height="17" font="0"> </text>
<text top="582" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="599" left="203" width="29" height="17" font="0">RCT </text>
<text top="617" left="203" width="3" height="17" font="0"> </text>
<text top="634" left="203" width="90" height="17" font="2"><b>Size:</b> n=452 pts </text>
<text top="531" left="311" width="166" height="17" font="2"><b>Inclusion criteria:</b> CLI due to </text>
<text top="548" left="311" width="98" height="17" font="0">infrainguinal PAD </text>
<text top="565" left="311" width="3" height="17" font="0"> </text>
<text top="582" left="311" width="222" height="17" font="2"><b>Exclusion criteria:</b> Pt who could not be </text>
<text top="599" left="311" width="204" height="17" font="0">treated equally well with infrainguinal </text>
<text top="617" left="311" width="223" height="17" font="0">bypass or angioplasty in the opinion of a </text>
<text top="634" left="311" width="198" height="17" font="0">vascular surgeon and interventional </text>
<text top="651" left="311" width="59" height="17" font="0">radiologist </text>
<text top="531" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="548" left="547" width="27" height="17" font="0">PTA </text>
<text top="565" left="547" width="3" height="17" font="0"> </text>
<text top="582" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="599" left="547" width="44" height="17" font="0">Bypass </text>
<text top="532" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="531" left="655" width="6" height="18" font="7"></text>
<text top="532" left="661" width="63" height="17" font="2"><b> endpoint:</b> </text>
<text top="549" left="648" width="90" height="17" font="0">Amputation free </text>
<text top="566" left="648" width="45" height="17" font="0">survival </text>
<text top="531" left="790" width="7" height="18" font="7"></text>
<text top="532" left="797" width="95" height="17" font="0"> Equal outcomes </text>
<text top="549" left="790" width="7" height="18" font="7"></text>
<text top="550" left="797" width="299" height="17" font="0"> The trial ran for 5.5 y, and follow-up finished when pts </text>
<text top="567" left="790" width="298" height="17" font="0">reached an endpoint (amputation of trial leg above the </text>
<text top="585" left="790" width="307" height="17" font="0">ankle or death). 7 individuals were lost to follow-up after </text>
<text top="602" left="790" width="293" height="17" font="0">randomization (3 assigned angioplasty, 2 surgery); of </text>
<text top="619" left="790" width="300" height="17" font="0">these, 3 were lost (1 angioplasty, 2 surgery) during the </text>
<text top="636" left="790" width="286" height="17" font="0">first y of follow-up. 195 (86%) of 228 pts assigned to </text>
<text top="653" left="790" width="265" height="17" font="0">bypass surgery and 216 (96%) of 224 to balloon </text>
<text top="671" left="790" width="282" height="17" font="0">angioplasty underwent an attempt at their allocated </text>
<text top="688" left="790" width="315" height="17" font="0">intervention at a median (IQR) of 6 (3–16) and 6 (2–20) d </text>
<text top="705" left="790" width="313" height="17" font="0">after randomization, respectively. At the end of follow-up, </text>
<text top="722" left="790" width="314" height="17" font="0">248 (55%) pts were alive without amputation (of trial leg), </text>
<text top="739" left="790" width="273" height="17" font="0">38 (8%) alive with amputation, 36 (8%) dead after </text>
<text top="757" left="790" width="293" height="17" font="0">amputation, and 130 (29%) dead without amputation. </text>
<text top="774" left="790" width="302" height="17" font="0">After 6 mo, the 2 strategies did not differ significantly in </text>
</page>
<page number="148" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">148 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="790" width="304" height="17" font="0">amputation-free survival (48 vs. 60 pts; unadjusted HR: </text>
<text top="104" left="790" width="285" height="17" font="0">1.07; 95% CI: 0.72–1.6; adjusted HR: 0.73; 95% CI: </text>
<text top="122" left="790" width="279" height="17" font="0">0.49–1.07). We saw no difference in health-related </text>
<text top="139" left="790" width="304" height="17" font="0">quality of life between the 2 strategies, but for the first y </text>
<text top="156" left="790" width="312" height="17" font="0">the hospital costs associated with a surgery-first strategy </text>
<text top="173" left="790" width="315" height="17" font="0">were about 1/3 higher than those with an angioplasty-first </text>
<text top="190" left="790" width="51" height="17" font="0">strategy. </text>
<text top="208" left="95" width="40" height="17" font="2"><b>BASIL </b></text>
<text top="226" left="95" width="94" height="17" font="0">Bradbury AW, et </text>
<text top="243" left="95" width="20" height="17" font="0">al.  </text>
<text top="260" left="95" width="63" height="17" font="0">2010 (329) </text>
<text top="277" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20307380">20307380</a></text>
<text top="277" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20307380"> </a></text>
<text top="294" left="95" width="3" height="17" font="0"> </text>
<text top="208" left="203" width="94" height="17" font="2"><b>Aim:</b> Bypass vs. </text>
<text top="226" left="203" width="68" height="17" font="0">PTA for CLI </text>
<text top="243" left="203" width="3" height="17" font="0"> </text>
<text top="260" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="277" left="203" width="29" height="17" font="0">RCT </text>
<text top="294" left="203" width="3" height="17" font="0"> </text>
<text top="312" left="203" width="90" height="17" font="2"><b>Size:</b> n=452 pts </text>
<text top="208" left="311" width="166" height="17" font="2"><b>Inclusion criteria:</b> CLI due to </text>
<text top="226" left="311" width="98" height="17" font="0">infrainguinal PAD </text>
<text top="243" left="311" width="3" height="17" font="0"> </text>
<text top="260" left="311" width="222" height="17" font="2"><b>Exclusion criteria:</b> Pt who could not be </text>
<text top="277" left="311" width="204" height="17" font="0">treated equally well with infrainguinal </text>
<text top="294" left="311" width="223" height="17" font="0">bypass or angioplasty in the opinion of a </text>
<text top="312" left="311" width="198" height="17" font="0">vascular surgeon and interventional </text>
<text top="329" left="311" width="59" height="17" font="0">radiologist </text>
<text top="208" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="226" left="547" width="27" height="17" font="0">PTA </text>
<text top="243" left="547" width="3" height="17" font="0"> </text>
<text top="260" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="277" left="547" width="44" height="17" font="0">Bypass </text>
<text top="209" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="208" left="655" width="6" height="18" font="7"></text>
<text top="209" left="661" width="90" height="17" font="2"><b> endpoint:</b> AFS </text>
<text top="208" left="790" width="24" height="17" font="0">N/A </text>
<text top="347" left="95" width="40" height="17" font="2"><b>BASIL </b></text>
<text top="364" left="95" width="94" height="17" font="0">Bradbury AW, et </text>
<text top="381" left="95" width="16" height="17" font="0">al. </text>
<text top="398" left="95" width="63" height="17" font="0">2014 (330) </text>
<text top="416" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20435259">20435259</a></text>
<text top="416" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20435259"> </a></text>
<text top="347" left="203" width="94" height="17" font="2"><b>Aim:</b> Bypass vs. </text>
<text top="364" left="203" width="89" height="17" font="0">angiography for </text>
<text top="381" left="203" width="23" height="17" font="0">CLI </text>
<text top="398" left="203" width="3" height="17" font="0"> </text>
<text top="416" left="203" width="92" height="17" font="2"><b>Study type:</b> ITT </text>
<text top="433" left="203" width="72" height="17" font="0">analysis of a </text>
<text top="450" left="203" width="29" height="17" font="0">RCT </text>
<text top="467" left="203" width="3" height="17" font="0"> </text>
<text top="485" left="203" width="90" height="17" font="2"><b>Size:</b> n=452 pts </text>
<text top="347" left="311" width="166" height="17" font="2"><b>Inclusion criteria:</b> CLI due to </text>
<text top="364" left="311" width="98" height="17" font="0">infrainguinal PAD </text>
<text top="381" left="311" width="3" height="17" font="0"> </text>
<text top="398" left="311" width="222" height="17" font="2"><b>Exclusion criteria:</b> Pt who could not be </text>
<text top="416" left="311" width="204" height="17" font="0">treated equally well with infrainguinal </text>
<text top="433" left="311" width="223" height="17" font="0">bypass or angioplasty in the opinion of a </text>
<text top="450" left="311" width="198" height="17" font="0">vascular surgeon and interventional </text>
<text top="467" left="311" width="59" height="17" font="0">radiologist </text>
<text top="347" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="364" left="547" width="27" height="17" font="0">PTA </text>
<text top="381" left="547" width="3" height="17" font="0"> </text>
<text top="398" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="416" left="547" width="44" height="17" font="0">Bypass </text>
<text top="348" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="347" left="655" width="6" height="18" font="7"></text>
<text top="348" left="661" width="114" height="17" font="2"><b> endpoint:</b> AFS and </text>
<text top="365" left="648" width="21" height="17" font="0">OS </text>
<text top="347" left="790" width="295" height="17" font="0">Bypass was associated with improvements in OS and </text>
<text top="364" left="790" width="294" height="17" font="0">AFS of about 7 and 6 mo, but long term no significant </text>
<text top="381" left="790" width="189" height="17" font="0">difference between the treatments </text>
<text top="503" left="95" width="63" height="17" font="2"><b>LEVANT 1 </b></text>
<text top="520" left="95" width="85" height="17" font="0">Schienert D, et </text>
<text top="537" left="95" width="16" height="17" font="0">al. </text>
<text top="554" left="95" width="63" height="17" font="0">2014 (231) </text>
<text top="571" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24456716">24456716</a></text>
<text top="571" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24456716"> </a></text>
<text top="589" left="95" width="3" height="17" font="2"><b> </b></text>
<text top="503" left="203" width="74" height="17" font="2"><b>Aim: </b>Assess </text>
<text top="520" left="203" width="87" height="17" font="0">efficacy of DEB </text>
<text top="537" left="203" width="72" height="17" font="0">vs. PTA with </text>
<text top="554" left="203" width="86" height="17" font="0">bailout stenting<b> </b></text>
<text top="571" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="589" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="606" left="203" width="29" height="17" font="0">RCT </text>
<text top="623" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="640" left="203" width="82" height="17" font="2"><b>Size: </b>DEB=49 </text>
<text top="657" left="203" width="23" height="17" font="0">pts; </text>
<text top="675" left="203" width="53" height="17" font="0">Standard </text>
<text top="692" left="203" width="68" height="17" font="0">PTA=52 pts<b> </b></text>
<text top="503" left="311" width="176" height="17" font="2"><b>Inclusion Criteria: </b>Rutherford 2</text>
<text top="503" left="487" width="7" height="17" font="19">–</text>
<text top="503" left="494" width="10" height="17" font="0">5 </text>
<text top="520" left="311" width="59" height="17" font="0">symptoms<b> </b></text>
<text top="537" left="311" width="3" height="17" font="2"><b> </b></text>
<text top="554" left="311" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="571" left="311" width="7" height="18" font="7"></text>
<text top="572" left="317" width="103" height="17" font="0"> Listed in methods </text>
<text top="590" left="311" width="7" height="18" font="7"></text>
<text top="591" left="317" width="174" height="17" font="0"> Notably highly calcified lesions<b> </b></text>
<text top="503" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="520" left="547" width="29" height="17" font="0">DEB </text>
<text top="537" left="547" width="3" height="17" font="0"> </text>
<text top="554" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="571" left="547" width="81" height="17" font="0">Standard PTA </text>
<text top="589" left="547" width="65" height="17" font="0">with bailout </text>
<text top="606" left="547" width="47" height="17" font="0">stenting<b> </b></text>
<text top="504" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="503" left="655" width="6" height="18" font="7"></text>
<text top="504" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="521" left="648" width="7" height="18" font="7"></text>
<text top="522" left="655" width="113" height="17" font="2"><b> </b>Angiography lumen </text>
<text top="539" left="648" width="70" height="17" font="0">loss at 6 mo </text>
<text top="557" left="648" width="7" height="18" font="7"></text>
<text top="558" left="655" width="102" height="17" font="2"><b> </b>At 6 mo DEB had </text>
<text top="575" left="648" width="122" height="17" font="0">lower lumen loss than </text>
<text top="592" left="648" width="79" height="17" font="0">standard PTA </text>
<text top="609" left="648" width="56" height="17" font="0">(p&lt;0.016) </text>
<text top="503" left="790" width="67" height="17" font="0">Small study </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">149 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="72" height="17" font="2"><b>DEBELLUM </b></text>
<text top="104" left="95" width="84" height="17" font="0">Fanelli F, et al. </text>
<text top="122" left="95" width="63" height="17" font="0">2012 (331) </text>
<text top="139" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23046320">23046320</a></text>
<text top="139" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23046320"> </a></text>
<text top="156" left="95" width="3" height="17" font="2"><b> </b></text>
<text top="87" left="203" width="74" height="17" font="2"><b>Aim: </b>Assess </text>
<text top="104" left="203" width="87" height="17" font="0">efficacy of DEB </text>
<text top="122" left="203" width="50" height="17" font="0">vs. PTA <b> </b></text>
<text top="139" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="156" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="173" left="203" width="29" height="17" font="0">RCT<b> </b></text>
<text top="190" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="208" left="203" width="82" height="17" font="2"><b>Size: </b>DEB=25 </text>
<text top="225" left="203" width="77" height="17" font="0">pts; Standard </text>
<text top="242" left="203" width="68" height="17" font="0">PTA=25 pts<b> </b></text>
<text top="87" left="311" width="185" height="17" font="2"><b>Inclusion criteria: </b>Fontaine 2b-4 </text>
<text top="104" left="311" width="59" height="17" font="0">symptoms </text>
<text top="122" left="311" width="3" height="17" font="0"> </text>
<text top="139" left="311" width="183" height="17" font="2"><b>Exclusion criteria:</b> Pts requiring </text>
<text top="156" left="311" width="202" height="17" font="0">provisional stenting after angioplasty </text>
<text top="173" left="311" width="214" height="17" font="0">secondary to flow-limiting dissection or </text>
<text top="190" left="311" width="130" height="17" font="0">residual stenosis &gt;50%<b> </b></text>
<text top="87" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="104" left="547" width="29" height="17" font="0">DEB </text>
<text top="122" left="547" width="3" height="17" font="0"> </text>
<text top="139" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="156" left="547" width="84" height="17" font="0">Standard PTA <b> </b></text>
<text top="88" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="655" width="6" height="18" font="7"></text>
<text top="88" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="106" left="648" width="7" height="18" font="7"></text>
<text top="107" left="655" width="113" height="17" font="2"><b> </b>Angiography lumen </text>
<text top="124" left="648" width="70" height="17" font="0">loss at 6 mo </text>
<text top="141" left="648" width="7" height="18" font="7"></text>
<text top="142" left="655" width="118" height="17" font="2"><b> </b>Late lumen loss was </text>
<text top="159" left="648" width="95" height="17" font="0">lower in the DEB </text>
<text top="177" left="648" width="84" height="17" font="0">group (p&lt;0.01) </text>
<text top="87" left="790" width="67" height="17" font="0">Small study </text>
<text top="260" left="95" width="64" height="17" font="2"><b>LEVANT-2 </b></text>
<text top="277" left="95" width="90" height="17" font="0">Rosenfield K, et </text>
<text top="294" left="95" width="20" height="17" font="0">al.  </text>
<text top="312" left="95" width="63" height="17" font="0">2015 (332) </text>
<text top="329" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26106946">26106946</a></text>
<text top="329" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26106946"> </a></text>
<text top="346" left="95" width="3" height="17" font="0"> </text>
<text top="260" left="203" width="74" height="17" font="2"><b>Aim: </b>Assess </text>
<text top="277" left="203" width="90" height="17" font="0">efficiacy of DEB </text>
<text top="294" left="203" width="72" height="17" font="0">vs. PTA with </text>
<text top="312" left="203" width="86" height="17" font="0">bailout stenting<b> </b></text>
<text top="329" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="346" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="363" left="203" width="29" height="17" font="0">RCT<b> </b></text>
<text top="381" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="398" left="203" width="90" height="17" font="2"><b>Size: </b>n=476 pts<b> </b></text>
<text top="260" left="311" width="181" height="17" font="2"><b>Inclusion criteria: </b>Fontaine 2–4 </text>
<text top="277" left="311" width="59" height="17" font="0">symptoms </text>
<text top="294" left="311" width="3" height="17" font="0"> </text>
<text top="312" left="311" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="329" left="311" width="7" height="18" font="7"></text>
<text top="330" left="317" width="125" height="17" font="0"> Lesion length ≥15 cm </text>
<text top="347" left="311" width="7" height="18" font="7"></text>
<text top="348" left="317" width="102" height="17" font="0"> Detailed in NEJM </text>
<text top="260" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="277" left="547" width="29" height="17" font="0">DEB </text>
<text top="294" left="547" width="3" height="17" font="0"> </text>
<text top="312" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="329" left="547" width="81" height="17" font="0">Standard PTA<b> </b></text>
<text top="261" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="260" left="655" width="6" height="18" font="7"></text>
<text top="261" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="278" left="648" width="7" height="18" font="7"></text>
<text top="279" left="655" width="109" height="17" font="2"><b> </b>Primary patency of </text>
<text top="297" left="648" width="122" height="17" font="0">target lesion at 12 mo </text>
<text top="314" left="648" width="7" height="18" font="7"></text>
<text top="315" left="655" width="80" height="17" font="2"><b> </b>DEB superior </text>
<text top="332" left="648" width="50" height="17" font="0">(p&lt;0.02) </text>
<text top="350" left="648" width="7" height="18" font="7"></text>
<text top="351" left="655" width="119" height="17" font="2"><b> </b>DEB noninferior with </text>
<text top="368" left="648" width="89" height="17" font="0">regard to safety </text>
<text top="385" left="648" width="57" height="17" font="0">endpoints </text>
<text top="260" left="790" width="24" height="17" font="0">N/A </text>
<text top="416" left="95" width="57" height="17" font="2"><b>DESTINY </b></text>
<text top="433" left="95" width="92" height="17" font="0">Bosiers M, et al. </text>
<text top="450" left="95" width="63" height="17" font="0">2012 (333) </text>
<text top="467" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22169682">22169682</a></text>
<text top="467" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22169682"> </a></text>
<text top="485" left="95" width="3" height="17" font="0"> </text>
<text top="416" left="203" width="74" height="17" font="2"><b>Aim: </b>Assess </text>
<text top="433" left="203" width="73" height="17" font="0">infrapopliteal </text>
<text top="450" left="203" width="90" height="17" font="0">PTAS with DES </text>
<text top="467" left="203" width="90" height="17" font="0">vs. BMS for CLI </text>
<text top="485" left="203" width="3" height="17" font="0"> </text>
<text top="502" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="519" left="203" width="29" height="17" font="0">RCT<b> </b></text>
<text top="536" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="553" left="203" width="90" height="17" font="2"><b>Size: </b>n=140 pts </text>
<text top="416" left="311" width="200" height="17" font="2"><b>Inclusion criteria: </b>CLI and infrapop </text>
<text top="433" left="311" width="49" height="17" font="0">stenosis </text>
<text top="450" left="311" width="3" height="17" font="0"> </text>
<text top="467" left="311" width="210" height="17" font="2"><b>Exclusion criteria: </b>Lack of ≥1 vessel </text>
<text top="485" left="311" width="101" height="17" font="0">outflow to the foot </text>
<text top="416" left="547" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="433" left="547" width="29" height="17" font="0">DES </text>
<text top="450" left="547" width="3" height="17" font="0"> </text>
<text top="467" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="485" left="547" width="30" height="17" font="0">BMS<b> </b></text>
<text top="417" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="416" left="655" width="6" height="18" font="7"></text>
<text top="417" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="434" left="648" width="7" height="18" font="7"></text>
<text top="435" left="655" width="115" height="17" font="2"><b> </b>Binary restenosis of </text>
<text top="452" left="648" width="122" height="17" font="0">the target lesion at 12 </text>
<text top="470" left="648" width="21" height="17" font="0">mo </text>
<text top="487" left="648" width="7" height="18" font="7"></text>
<text top="488" left="655" width="119" height="17" font="2"><b> </b>DES was superior to </text>
<text top="505" left="648" width="86" height="17" font="0">BMS (p=0.001) </text>
<text top="416" left="790" width="283" height="17" font="0">Reduced restenosis and the need for reintervention </text>
<text top="433" left="790" width="181" height="17" font="0">compared with bare metal stents </text>
<text top="571" left="95" width="88" height="17" font="0">Rastan A, et al. </text>
<text top="589" left="95" width="63" height="17" font="0">2011 (334) </text>
<text top="606" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21622669">21622669</a></text>
<text top="606" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21622669"> </a></text>
<text top="571" left="203" width="91" height="17" font="2"><b>Aim: </b>Determine </text>
<text top="589" left="203" width="91" height="17" font="0">if SES improves </text>
<text top="606" left="203" width="91" height="17" font="0">primary patency </text>
<text top="623" left="203" width="59" height="17" font="0">rates after </text>
<text top="640" left="203" width="77" height="17" font="0">interventional </text>
<text top="657" left="203" width="88" height="17" font="0">therapy of focal </text>
<text top="675" left="203" width="55" height="17" font="0">lesions of </text>
<text top="692" left="203" width="73" height="17" font="0">infrapopliteal </text>
<text top="709" left="203" width="35" height="17" font="0">artery </text>
<text top="726" left="203" width="3" height="17" font="0"> </text>
<text top="744" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="761" left="203" width="71" height="17" font="0">Prospective, </text>
<text top="571" left="311" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="589" left="311" width="7" height="18" font="7"></text>
<text top="590" left="318" width="64" height="17" font="2"><b> </b>Age ≥21 y </text>
<text top="607" left="311" width="7" height="18" font="7"></text>
<text top="608" left="318" width="206" height="17" font="2"><b> </b>PAD with Rutherford-Becker class 3–</text>
<text top="625" left="311" width="10" height="17" font="0">5 </text>
<text top="643" left="311" width="7" height="18" font="7"></text>
<text top="644" left="317" width="158" height="17" font="0"> lifestyle-limiting claudication </text>
<text top="661" left="311" width="222" height="17" font="0">Rutherford-Becker classs 2 if successful </text>
<text top="678" left="311" width="216" height="17" font="0">intervention of TASC A femoropopliteal </text>
<text top="695" left="311" width="174" height="17" font="0">lesions to improve runoff status </text>
<text top="713" left="311" width="7" height="18" font="7"></text>
<text top="714" left="317" width="198" height="17" font="0"> Presence of a single primary target </text>
<text top="731" left="311" width="203" height="17" font="0">lesion in a native infrapopliteal artery </text>
<text top="748" left="311" width="209" height="17" font="0">that was 2.5–3.5 mm in diameter, and </text>
<text top="765" left="311" width="99" height="17" font="0">≤44 mm in length </text>
<text top="571" left="547" width="75" height="17" font="2"><b>Intervention:</b></text>
<text top="573" left="621" width="4" height="16" font="3"> </text>
<text top="589" left="547" width="74" height="17" font="0">Polymer-free </text>
<text top="606" left="547" width="53" height="17" font="0">sirolimus-</text>
<text top="623" left="547" width="73" height="17" font="0">eluting stent  </text>
<text top="640" left="547" width="3" height="17" font="0"> </text>
<text top="657" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="675" left="547" width="48" height="17" font="0">Placebo-</text>
<text top="692" left="547" width="69" height="17" font="0">coated bare-</text>
<text top="709" left="547" width="64" height="17" font="0">metal stent<b> </b></text>
<text top="572" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="571" left="655" width="6" height="18" font="7"></text>
<text top="572" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="590" left="648" width="7" height="18" font="7"></text>
<text top="591" left="655" width="115" height="17" font="2"><b> </b>1-y primary patency </text>
<text top="608" left="648" width="25" height="17" font="0">rate </text>
<text top="625" left="648" width="3" height="17" font="0"> </text>
<text top="644" left="648" width="7" height="17" font="2"><b>2</b></text>
<text top="643" left="655" width="6" height="18" font="7"></text>
<text top="644" left="661" width="73" height="17" font="2"><b> endpoints:</b>  </text>
<text top="661" left="648" width="7" height="18" font="7"></text>
<text top="662" left="655" width="79" height="17" font="2"><b> </b>6-mo primary </text>
<text top="679" left="648" width="71" height="17" font="0">patency rate </text>
<text top="697" left="648" width="7" height="18" font="7"></text>
<text top="698" left="655" width="112" height="17" font="2"><b> </b>Secondary patency </text>
<text top="715" left="648" width="25" height="17" font="0">rate </text>
<text top="732" left="648" width="7" height="18" font="7"></text>
<text top="733" left="655" width="69" height="17" font="2"><b> </b>Changes in </text>
<text top="750" left="648" width="104" height="17" font="0">Rutherford-Becker </text>
<text top="768" left="648" width="121" height="17" font="0">classification after 1 y </text>
<text top="571" left="790" width="313" height="17" font="0">SES improved mid-term patency rates compared to BMS </text>
<text top="589" left="790" width="3" height="17" font="0"> </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">150 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="71" height="17" font="0">randomized, </text>
<text top="104" left="203" width="71" height="17" font="0">multi-centre, </text>
<text top="122" left="203" width="94" height="17" font="0">double-blind trial<b> </b></text>
<text top="139" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="156" left="203" width="90" height="17" font="2"><b>Size: </b>n=161 pts </text>
<text top="87" left="311" width="7" height="18" font="7"></text>
<text top="88" left="317" width="159" height="17" font="0"> Diameter stenosis of ≥70%  </text>
<text top="106" left="311" width="3" height="17" font="0"> </text>
<text top="123" left="311" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="140" left="311" width="7" height="18" font="7"></text>
<text top="141" left="318" width="77" height="17" font="2"><b> </b>Pregnant pts </text>
<text top="158" left="311" width="7" height="18" font="7"></text>
<text top="159" left="317" width="203" height="17" font="0"> Visible thrombus within target lesion </text>
<text top="177" left="311" width="7" height="18" font="7"></text>
<text top="178" left="317" width="172" height="17" font="0"> Known systemic coagulopathy </text>
<text top="195" left="311" width="7" height="18" font="7"></text>
<text top="196" left="317" width="105" height="17" font="0"> Buerger's disease </text>
<text top="214" left="311" width="7" height="18" font="7"></text>
<text top="215" left="317" width="25" height="17" font="0"> ALI </text>
<text top="232" left="311" width="7" height="18" font="7"></text>
<text top="233" left="317" width="120" height="17" font="0"> Life expentency &lt;1 y </text>
<text top="250" left="311" width="7" height="18" font="7"></text>
<text top="251" left="317" width="215" height="17" font="0"> Intolerance of aspirin, clopidogrel, and </text>
<text top="269" left="311" width="44" height="17" font="0">heparin </text>
<text top="287" left="95" width="86" height="17" font="0">Siablis D, et al. </text>
<text top="304" left="95" width="63" height="17" font="0">2014 (335) </text>
<text top="321" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25234679">25234679</a></text>
<text top="321" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25234679"> </a></text>
<text top="287" left="203" width="49" height="17" font="2"><b>Aim: </b>To </text>
<text top="304" left="203" width="80" height="17" font="0">compare PCB </text>
<text top="321" left="203" width="87" height="17" font="0">vs. DES in long </text>
<text top="338" left="203" width="73" height="17" font="0">infrapopliteal </text>
<text top="355" left="203" width="42" height="17" font="0">lesions </text>
<text top="373" left="203" width="3" height="17" font="0"> </text>
<text top="390" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="407" left="203" width="68" height="17" font="0">Prospective </text>
<text top="424" left="203" width="28" height="17" font="0">PCT<b> </b></text>
<text top="441" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="459" left="203" width="83" height="17" font="2"><b>Size: </b>n=50 pts </text>
<text top="287" left="311" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="304" left="311" width="7" height="18" font="7"></text>
<text top="305" left="318" width="133" height="17" font="2"><b> </b>Rutherford classes 3–6 </text>
<text top="322" left="311" width="7" height="18" font="7"></text>
<text top="323" left="318" width="168" height="17" font="2"><b> </b>Angiographically documented </text>
<text top="340" left="311" width="168" height="17" font="0">infrapopliteal disease ≥70 mm </text>
<text top="358" left="311" width="3" height="17" font="0"> </text>
<text top="375" left="311" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="392" left="311" width="3" height="17" font="0"> </text>
<text top="287" left="547" width="75" height="17" font="2"><b>Intervention:</b></text>
<text top="288" left="621" width="4" height="16" font="3"> </text>
<text top="304" left="547" width="74" height="17" font="0">Polymer-free </text>
<text top="321" left="547" width="53" height="17" font="0">sirolimus-</text>
<text top="338" left="547" width="73" height="17" font="0">eluting stent  </text>
<text top="355" left="547" width="3" height="17" font="0"> </text>
<text top="373" left="547" width="77" height="17" font="2"><b>Comparator:</b> </text>
<text top="390" left="547" width="48" height="17" font="0">Placebo-</text>
<text top="407" left="547" width="69" height="17" font="0">coated bare-</text>
<text top="424" left="547" width="64" height="17" font="0">metal stent<b> </b></text>
<text top="288" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="287" left="655" width="6" height="18" font="7"></text>
<text top="288" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="305" left="648" width="7" height="18" font="7"></text>
<text top="306" left="655" width="78" height="17" font="2"><b> </b>Target lesion </text>
<text top="323" left="648" width="119" height="17" font="0">restenosis &gt;50% at 6 </text>
<text top="340" left="648" width="21" height="17" font="0">mo </text>
<text top="358" left="648" width="3" height="17" font="0"> </text>
<text top="376" left="648" width="7" height="17" font="2"><b>2</b></text>
<text top="375" left="655" width="6" height="18" font="7"></text>
<text top="376" left="661" width="73" height="17" font="2"><b> endpoints:</b>  </text>
<text top="393" left="648" width="7" height="18" font="7"></text>
<text top="394" left="655" width="91" height="17" font="2"><b> </b>Immediate post-</text>
<text top="412" left="648" width="107" height="17" font="0">procedure stenosis </text>
<text top="429" left="648" width="7" height="18" font="7"></text>
<text top="430" left="655" width="78" height="17" font="2"><b> </b>Target lesion </text>
<text top="447" left="648" width="96" height="17" font="0">revascularization </text>
<text top="287" left="790" width="7" height="18" font="7"></text>
<text top="288" left="797" width="289" height="17" font="2"><b> </b>Significant lower residual immediate post-procedure </text>
<text top="305" left="790" width="315" height="17" font="0">stenosis in DES compared with PCB in long infrapopliteal </text>
<text top="322" left="790" width="36" height="17" font="0">lesion </text>
<text top="339" left="790" width="7" height="18" font="7"></text>
<text top="340" left="797" width="307" height="17" font="2"><b> </b>At 6 mo, significantly reduced vessel restenosis in DES </text>
<text top="358" left="790" width="112" height="17" font="0">compared with PCB </text>
<text top="477" left="95" width="78" height="17" font="0">Tepe G, et al. </text>
<text top="494" left="95" width="63" height="17" font="0">2015 (336) </text>
<text top="511" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25616822">25616822</a></text>
<text top="511" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25616822"> </a></text>
<text top="477" left="203" width="82" height="17" font="2"><b>Aim: </b>Evaluate </text>
<text top="494" left="203" width="87" height="17" font="0">5-y follow-up of </text>
<text top="511" left="203" width="66" height="17" font="0">PCB on the </text>
<text top="528" left="203" width="84" height="17" font="0">restenosis rate </text>
<text top="546" left="203" width="86" height="17" font="0">after peripheral </text>
<text top="563" left="203" width="41" height="17" font="0">arterial </text>
<text top="580" left="203" width="77" height="17" font="0">interventions. </text>
<text top="597" left="203" width="3" height="17" font="0"> </text>
<text top="614" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="632" left="203" width="92" height="17" font="0">multicenter RCT<b> </b></text>
<text top="649" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="666" left="203" width="90" height="17" font="2"><b>Size: </b>n=154 pts </text>
<text top="477" left="311" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="494" left="311" width="7" height="18" font="7"></text>
<text top="495" left="318" width="183" height="17" font="2"><b> </b>Included in the THUNDER study </text>
<text top="512" left="311" width="3" height="17" font="0"> </text>
<text top="530" left="311" width="3" height="17" font="0"> </text>
<text top="547" left="311" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="564" left="311" width="3" height="17" font="0"> </text>
<text top="477" left="547" width="75" height="17" font="2"><b>Intervention:</b></text>
<text top="478" left="621" width="4" height="16" font="3"> </text>
<text top="477" left="625" width="3" height="17" font="0"> </text>
<text top="494" left="547" width="7" height="18" font="7"></text>
<text top="495" left="554" width="56" height="17" font="0"> PCB and </text>
<text top="512" left="547" width="51" height="17" font="0">standard </text>
<text top="530" left="547" width="49" height="17" font="0">nonionic </text>
<text top="547" left="547" width="47" height="17" font="0">contrast </text>
<text top="564" left="547" width="80" height="17" font="0">medium (PCB </text>
<text top="581" left="547" width="39" height="17" font="0">group) </text>
<text top="598" left="547" width="7" height="18" font="7"></text>
<text top="599" left="554" width="54" height="17" font="2"><b> </b>Plain old </text>
<text top="617" left="547" width="43" height="17" font="0">balloon </text>
<text top="634" left="547" width="66" height="17" font="0">angioplasty </text>
<text top="651" left="547" width="81" height="17" font="0">and paclicaxel </text>
<text top="668" left="547" width="51" height="17" font="0">added to </text>
<text top="686" left="547" width="87" height="17" font="0">standard nionic </text>
<text top="703" left="547" width="47" height="17" font="0">contrast </text>
<text top="720" left="547" width="47" height="17" font="0">medium </text>
<text top="737" left="547" width="73" height="17" font="0">(paclitaxel-in-</text>
<text top="754" left="547" width="64" height="17" font="0">CM Group) </text>
<text top="772" left="547" width="3" height="17" font="0"> </text>
<text top="478" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="477" left="655" width="6" height="18" font="7"></text>
<text top="478" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="495" left="648" width="7" height="18" font="7"></text>
<text top="496" left="655" width="102" height="17" font="2"><b> </b>Angiographic LLL </text>
<text top="513" left="648" width="111" height="17" font="0">(difference between </text>
<text top="531" left="648" width="105" height="17" font="0">the postprocedural </text>
<text top="548" left="648" width="107" height="17" font="0">and 6-mo follow up </text>
<text top="565" left="648" width="83" height="17" font="0">minimal lumen </text>
<text top="582" left="648" width="55" height="17" font="0">diameter, </text>
<text top="599" left="648" width="73" height="17" font="0">evaluated by </text>
<text top="617" left="648" width="66" height="17" font="0">quantitative </text>
<text top="634" left="648" width="75" height="17" font="0">angiography) </text>
<text top="651" left="648" width="3" height="17" font="0"> </text>
<text top="669" left="648" width="7" height="17" font="2"><b>2</b></text>
<text top="668" left="655" width="6" height="18" font="7"></text>
<text top="669" left="661" width="73" height="17" font="2"><b> endpoints:</b>  </text>
<text top="687" left="648" width="7" height="18" font="7"></text>
<text top="688" left="655" width="98" height="17" font="2"><b> </b>freedom from TL </text>
<text top="705" left="648" width="99" height="17" font="0">revascularization, </text>
<text top="722" left="648" width="124" height="17" font="0">binary restenosis rate, </text>
<text top="739" left="648" width="88" height="17" font="0">and amputation </text>
<text top="477" left="790" width="7" height="18" font="7"></text>
<text top="478" left="797" width="303" height="17" font="2"><b> </b>5-y follow up period resulted in maintained reduced TL </text>
<text top="495" left="790" width="307" height="17" font="0">revascularizationrate following PCB treatment. No signs </text>
<text top="512" left="790" width="311" height="17" font="0">of drug-related local vessel abnormalities were detected. </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">151 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="547" width="77" height="17" font="2"><b>Comparator: </b></text>
<text top="104" left="547" width="51" height="17" font="0">Plain old </text>
<text top="122" left="547" width="43" height="17" font="0">balloon </text>
<text top="139" left="547" width="68" height="17" font="0">angioplastic </text>
<text top="156" left="547" width="75" height="17" font="0">and standard </text>
<text top="173" left="547" width="72" height="17" font="0">nonionic CM </text>
<text top="190" left="547" width="86" height="17" font="0">(Control group) </text>
<text top="208" left="86" width="1007" height="17" font="0">ABI indicates ankle-brachial index; AFS, amputation-free surivival; ALI, acute limb ischemia; BMS indicates bare metal stent; CD-TLR, clinically driven target lesion revascularization; CI, </text>
<text top="226" left="86" width="1009" height="17" font="0">confidence interval; CLI, critical limb ischemia; DCB, drug coated balloon; DEB, drug eluting balloon; DES, drug eluting stent; DM, diabetes mellitus; HR, hazard ratio; IA-DEB, apmhirion-</text>
<text top="243" left="86" width="978" height="17" font="0">drug eluting balloon; IC, intermittent claudication; ISR, in stent restenosis; IQR, interquartile range; JACC, Journal of American College of Cardiology; LLL, late lumen loss; N/A, not </text>
<text top="260" left="86" width="993" height="17" font="0">applicable; OR, odds ratio; OS, overall survival; PAD, periphery artery disease; PCB, paclitaxel-coated blaoon; PEB, paclitaxel eluting balloon; PTA, percutaneous angioplasty, PTAS, </text>
<text top="277" left="86" width="511" height="17" font="0">percutaneous angioplasty stent; pt, patient; RCT, randomized controlled trial; RR, relative risk;</text>
<text top="277" left="598" width="3" height="17" font="9"> </text>
<text top="277" left="601" width="470" height="17" font="0">SES, self-expanding stents; and SFA, superficial femoral artery; and TL, target lesion. </text>
<text top="294" left="86" width="3" height="17" font="0"> </text>
<text top="312" left="86" width="3" height="17" font="0"> </text>
<text top="329" left="86" width="1014" height="21" font="1"><b>Evidence Table 40. Nonrandomized Trials, Observational Studies, and/or Registries of Endovascular Revascularization for Chromic CLI–Section </b></text>
<text top="350" left="86" width="41" height="21" font="1"><b>8.2.1. </b></text>
<text top="371" left="103" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="388" left="128" width="48" height="17" font="2"><b>Author; </b></text>
<text top="405" left="106" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="371" left="228" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="388" left="254" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="371" left="402" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="371" left="570" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="388" left="577" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="405" left="629" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="371" left="872" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="388" left="900" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="423" left="95" width="105" height="17" font="0">Kashyap VS, et al. </text>
<text top="441" left="95" width="63" height="17" font="0">2008 (224) </text>
<text top="458" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18804943">18804943 </a></text>
<text top="475" left="95" width="3" height="17" font="0"> </text>
<text top="423" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="441" left="223" width="111" height="17" font="0">Retrospective Endo </text>
<text top="458" left="223" width="46" height="17" font="0">vs. ABF </text>
<text top="475" left="223" width="3" height="17" font="0"> </text>
<text top="492" left="223" width="90" height="17" font="2"><b>Size:</b> n=189 pts </text>
<text top="423" left="365" width="157" height="17" font="2"><b>Inclusion criteria:</b> Sx AIOD </text>
<text top="441" left="365" width="161" height="17" font="0">(claudication, 53%; rest pain, </text>
<text top="458" left="365" width="178" height="17" font="0">28%; tissue loss, 12%; ALI, 7%) </text>
<text top="475" left="365" width="3" height="17" font="0"> </text>
<text top="492" left="365" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="509" left="365" width="7" height="18" font="7"></text>
<text top="511" left="371" width="166" height="17" font="0"> Pts undergoing endovascular </text>
<text top="528" left="365" width="143" height="17" font="0">treatment such as PTA or </text>
<text top="545" left="365" width="142" height="17" font="0">stenting for iliac stenoses </text>
<text top="562" left="365" width="7" height="18" font="7"></text>
<text top="563" left="371" width="153" height="17" font="0"> Pts with iliac dissection, an </text>
<text top="581" left="365" width="133" height="17" font="0">associated AAA, or iliac </text>
<text top="598" left="365" width="170" height="17" font="0">recanalization before or during </text>
<text top="615" left="365" width="147" height="17" font="0">AAA endograft placement.<b> </b></text>
<text top="424" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="423" left="571" width="6" height="18" font="7"></text>
<text top="424" left="577" width="170" height="17" font="2"><b> endpoint:</b> Technical success, </text>
<text top="442" left="564" width="124" height="17" font="0">primary patency at 3 y </text>
<text top="459" left="564" width="3" height="17" font="0"> </text>
<text top="476" left="564" width="188" height="17" font="2"><b>Results: </b>3 y primary patency was </text>
<text top="493" left="564" width="133" height="17" font="0">higher in ABF group but </text>
<text top="511" left="564" width="125" height="17" font="0">population was biased </text>
<text top="423" left="767" width="7" height="18" font="7"></text>
<text top="424" left="774" width="79" height="17" font="0"> ABF superior </text>
<text top="442" left="767" width="7" height="18" font="7"></text>
<text top="443" left="774" width="83" height="17" font="0"> Selection bias </text>
<text top="460" left="767" width="7" height="18" font="7"></text>
<text top="461" left="774" width="326" height="17" font="0"> The ABF pts were younger than the R/PTAS pts (60 vs. 65 </text>
<text top="478" left="767" width="335" height="17" font="0">y; p=0.003) and had higher rates of hyperlipidemia (p=0.009) </text>
<text top="496" left="767" width="330" height="17" font="0">and smoking (p&lt;0.001). All other clinical variables, including </text>
<text top="513" left="767" width="332" height="17" font="0">cardiac status, DM, symptoms at presentation, TransAtlantic </text>
<text top="530" left="767" width="330" height="17" font="0">Inter-Society Consensus stratification, and presence of poor </text>
<text top="547" left="767" width="319" height="17" font="0">outflow were similar between the 2 groups. Pts underwent </text>
<text top="565" left="767" width="325" height="17" font="0">ABF with general anesthesia (96%), often with concomitant </text>
<text top="582" left="767" width="275" height="17" font="0">treatment of femoral or infrainguinal disease (61% </text>
<text top="599" left="767" width="332" height="17" font="0">endarterectomy, profundaplasty, or distal bypass). Technical </text>
<text top="616" left="767" width="310" height="17" font="0">success was universal, with marked improvement in ABI </text>
<text top="633" left="767" width="305" height="17" font="0">(0.48–0.84; p&lt;0.001). Pts underwent R/PTAS with local </text>
<text top="651" left="767" width="340" height="17" font="0">anesthesia/sedation (78%), with a 96% technical success rate </text>
<text top="668" left="767" width="339" height="17" font="0">and similar hemodynamic improvement (0.36–0.82; p&lt;0.001). </text>
<text top="685" left="767" width="294" height="17" font="0">At the time of R/PTAS, 21% of pts underwent femoral </text>
<text top="702" left="767" width="280" height="17" font="0">endarterectomy/profundaplasty or bypass (n=5) for </text>
<text top="719" left="767" width="301" height="17" font="0">concomitant infrainguinal disease. Limb-based primary </text>
<text top="737" left="767" width="300" height="17" font="0">patency at 3 y was significantly higher for ABF than for </text>
<text top="754" left="767" width="326" height="17" font="0">R/PTAS (93% vs. 74%, p=0.002). Secondary patency rates </text>
<text top="771" left="767" width="325" height="17" font="0">(97% vs. 95%), limb salvage (98% vs. 98%), and long-term </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">152 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="767" width="337" height="17" font="0">survival (80% vs. 80%) were similar. DM and the requirement </text>
<text top="104" left="767" width="313" height="17" font="0">of distal bypass were associated with decreased patency </text>
<text top="122" left="767" width="340" height="17" font="0">(p&lt;0.001). CLI at presentation (tissue loss, HR: 8.1; p&lt;0.001), </text>
<text top="139" left="767" width="313" height="17" font="0">poor outflow (HR: 2; p=0.023), and renal failure (HR: 2.5; </text>
<text top="156" left="767" width="273" height="17" font="0">p=0.02) were associated with decreased survival. </text>
<text top="174" left="95" width="98" height="17" font="0">Ferraresi R, et al. </text>
<text top="191" left="95" width="63" height="17" font="0">2009 (337) </text>
<text top="208" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19112033">19112033 </a></text>
<text top="226" left="95" width="3" height="17" font="0"> </text>
<text top="174" left="223" width="103" height="17" font="2"><b>Study type:</b> Case </text>
<text top="191" left="223" width="115" height="17" font="0">series: infrapop PTA </text>
<text top="208" left="223" width="40" height="17" font="0">for CLI </text>
<text top="226" left="223" width="3" height="17" font="0"> </text>
<text top="243" left="223" width="90" height="17" font="2"><b>Size:</b> n=101 pts </text>
<text top="174" left="365" width="175" height="17" font="2"><b>Inclusion criteria:</b> Pts with DM </text>
<text top="191" left="365" width="162" height="17" font="0">with CLI due to infrapop PAD </text>
<text top="208" left="365" width="3" height="17" font="0"> </text>
<text top="226" left="365" width="169" height="17" font="2"><b>Exclusion criteria:</b> Above the </text>
<text top="243" left="365" width="114" height="17" font="0">knee &gt;70% stenosis<b> </b></text>
<text top="175" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="174" left="571" width="6" height="18" font="7"></text>
<text top="175" left="577" width="139" height="17" font="2"><b> endpoint:</b> Limb salvage </text>
<text top="192" left="564" width="3" height="17" font="0"> </text>
<text top="210" left="564" width="180" height="17" font="2"><b>Results: </b>93% limb salvage rate; </text>
<text top="227" left="564" width="83" height="17" font="0">no comparator </text>
<text top="174" left="767" width="7" height="18" font="7"></text>
<text top="175" left="774" width="167" height="17" font="0"> Proof of concept; poor quality </text>
<text top="192" left="767" width="7" height="18" font="7"></text>
<text top="193" left="774" width="317" height="17" font="0"> The limb salvage rate was 93% after a mean follow-up of </text>
<text top="211" left="767" width="315" height="17" font="0">1048±525 d (2.9±1.4 y). Transcutaneous oxygen tension </text>
<text top="228" left="767" width="328" height="17" font="0">significantly increased after 1 mo (18.1±11.2 vs. 39.6±15.1; </text>
<text top="245" left="767" width="327" height="17" font="0">p&lt;0.05). After 1 y, target-vessel re-stenosis had occurred in </text>
<text top="262" left="767" width="294" height="17" font="0">42% of the non-amputated limbs, 9 pts (9%) had died </text>
<text top="280" left="767" width="318" height="17" font="0">because of medical conditions unrelated to PTA and 3 pts </text>
<text top="297" left="767" width="248" height="17" font="0">had undergone repeat PTA for recurrent CLI. </text>
<text top="315" left="95" width="89" height="17" font="0">Park, SW, et al. </text>
<text top="332" left="95" width="63" height="17" font="0">2013 (338) </text>
<text top="349" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23975668">23975668 </a></text>
<text top="366" left="95" width="3" height="17" font="0"> </text>
<text top="315" left="223" width="103" height="17" font="2"><b>Study type:</b> Case </text>
<text top="332" left="223" width="36" height="17" font="0">series </text>
<text top="349" left="223" width="3" height="17" font="0"> </text>
<text top="366" left="223" width="83" height="17" font="2"><b>Size:</b> n=64 pts </text>
<text top="315" left="365" width="166" height="17" font="2"><b>Inclusion criteria:</b> CLI due to </text>
<text top="332" left="365" width="167" height="17" font="0">CTO in below the knee artery  </text>
<text top="349" left="365" width="3" height="17" font="0"> </text>
<text top="366" left="365" width="157" height="17" font="2"><b>Exclusion criteria: </b>Pts with </text>
<text top="384" left="365" width="179" height="17" font="0">concomitant above-knee arterial </text>
<text top="401" left="365" width="182" height="17" font="0">steno-occlusive lesions including </text>
<text top="418" left="365" width="185" height="17" font="0">the aortoiliac and femoropopliteal </text>
<text top="435" left="365" width="141" height="17" font="0">arterial lesions, clinical or </text>
<text top="452" left="365" width="138" height="17" font="0">imaging signs of embolic </text>
<text top="470" left="365" width="176" height="17" font="0">disease, or who had undergone </text>
<text top="487" left="365" width="114" height="17" font="0">thrombolysis prior to </text>
<text top="504" left="365" width="137" height="17" font="0">endovascular or surgical </text>
<text top="521" left="365" width="68" height="17" font="0">procedures.<b> </b></text>
<text top="316" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="315" left="571" width="6" height="18" font="7"></text>
<text top="316" left="577" width="139" height="17" font="2"><b> endpoint:</b> Limb salvage </text>
<text top="333" left="564" width="3" height="17" font="0"> </text>
<text top="350" left="564" width="187" height="17" font="2"><b>Results: </b>90.6% limb salvage rate </text>
<text top="368" left="564" width="178" height="17" font="0">and 59.1% primary patency rate </text>
<text top="385" left="564" width="160" height="17" font="0">at 1 y. No comparator group. </text>
<text top="315" left="767" width="7" height="18" font="7"></text>
<text top="316" left="774" width="144" height="17" font="0"> Reasonable limb salvage </text>
<text top="333" left="767" width="7" height="18" font="7"></text>
<text top="334" left="774" width="151" height="17" font="0"> Poor vessel patency at 1 y </text>
<text top="351" left="767" width="7" height="18" font="7"></text>
<text top="353" left="774" width="293" height="17" font="0"> The BTK EVT was performed on 64 limbs. Technical </text>
<text top="370" left="767" width="334" height="17" font="0">success rate was 93.8% and limb salvage rate was 90.6%. 3 </text>
<text top="387" left="767" width="293" height="17" font="0">of 4 limbs with technical failure and 3 of 60 limbs with </text>
<text top="404" left="767" width="297" height="17" font="0">technical success underwent BTK amputation and the </text>
<text top="421" left="767" width="322" height="17" font="0">comparison of these rates were significantly different (75% </text>
<text top="439" left="767" width="323" height="17" font="0">vs. 5%; p=0.002). Primary patency rates for the limbs were </text>
<text top="456" left="767" width="324" height="17" font="0">75% and 59.1% at 6 mo and 12 mo follow-up, respectively. </text>
<text top="473" left="767" width="302" height="17" font="0">Minor complications disappeared through the follow-up </text>
<text top="490" left="767" width="306" height="17" font="0">periods and there was no 30 d complication or systemic </text>
<text top="508" left="767" width="209" height="17" font="0">adverse events for the treated vessel. </text>
<text top="539" left="95" width="82" height="17" font="0">Faglia E, et al. </text>
<text top="557" left="95" width="63" height="17" font="0">2006 (339) </text>
<text top="574" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16730466">16730466 </a></text>
<text top="591" left="95" width="3" height="17" font="0"> </text>
<text top="539" left="223" width="103" height="17" font="2"><b>Study type:</b> Case </text>
<text top="557" left="223" width="36" height="17" font="0">series </text>
<text top="574" left="223" width="3" height="17" font="0"> </text>
<text top="591" left="223" width="120" height="17" font="2"><b>Size:</b> n=564 total pts: </text>
<text top="608" left="223" width="124" height="17" font="0">420 PTA, 117 bypass, </text>
<text top="625" left="223" width="44" height="17" font="0">27 both </text>
<text top="539" left="365" width="175" height="17" font="2"><b>Inclusion criteria:</b> Pts with DM </text>
<text top="557" left="365" width="51" height="17" font="0">with CLI  </text>
<text top="574" left="365" width="3" height="17" font="0"> </text>
<text top="591" left="365" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="608" left="365" width="7" height="18" font="7"></text>
<text top="609" left="371" width="90" height="17" font="0"> Pts without DM </text>
<text top="627" left="365" width="7" height="18" font="7"></text>
<text top="628" left="371" width="110" height="17" font="0"> No stenosis &gt;50% <b> </b></text>
<text top="540" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="539" left="571" width="6" height="18" font="7"></text>
<text top="540" left="577" width="139" height="17" font="2"><b> endpoint:</b> Limb salvage </text>
<text top="558" left="564" width="3" height="17" font="0"> </text>
<text top="575" left="564" width="176" height="17" font="2"><b>Results: </b>Major amputation was </text>
<text top="592" left="564" width="151" height="17" font="0">associated with absence of </text>
<text top="609" left="564" width="156" height="17" font="0">revascularization (OR: 35.9; </text>
<text top="627" left="564" width="165" height="17" font="0">p&lt;0.001; 95% CI: 12.9–99.7), </text>
<text top="644" left="564" width="177" height="17" font="0">occlusion of each of the 3 crural </text>
<text top="661" left="564" width="184" height="17" font="0">arteries (OR: 8.20; p=0.022; 95% </text>
<text top="678" left="564" width="174" height="17" font="0">CI: 1.35–49.6), wound infection </text>
<text top="695" left="564" width="176" height="17" font="0">(OR: 2.1; p=0.004; 95% CI: 1.3–</text>
<text top="713" left="564" width="177" height="17" font="0">3.6), dialysis (OR: 4.7; p=0.001; </text>
<text top="730" left="564" width="165" height="17" font="0">95% CI: 1.9–11.7) increase in </text>
<text top="747" left="564" width="32" height="17" font="0">TcPO</text>
<text top="753" left="596" width="4" height="11" font="11">2</text>
<text top="747" left="600" width="127" height="17" font="0"> after revascularization </text>
<text top="764" left="564" width="159" height="17" font="0">(OR: 0.80; p&lt;0.001; 95% CI: </text>
<text top="539" left="767" width="7" height="18" font="7"></text>
<text top="540" left="774" width="317" height="17" font="0"> PTA was carried out in 420 (74.5%), BPG in 117 (20.7%) </text>
<text top="558" left="767" width="324" height="17" font="0">pts. In 27 (4.8%) pts both PTA and BPG were not possible. </text>
<text top="575" left="767" width="339" height="17" font="0">23 above-the-ankle amputations (4.1%) were performed at 30 </text>
<text top="592" left="767" width="334" height="17" font="0">d: 6 in PTA pts, 3 in BPG pts, 14 in nonrevascularized pts. In </text>
<text top="609" left="767" width="317" height="17" font="0">the follow-up of 558 pts (98.9%), 62 repeated PTAs and 9 </text>
<text top="627" left="767" width="327" height="17" font="0">new BPGs, 32 new major amputations (16 in PTA pts, 14 in </text>
<text top="644" left="767" width="317" height="17" font="0">BPG pts and 2 in nonrevascularized pts) were performed. </text>
<text top="661" left="767" width="275" height="17" font="0">Major amputation was associated with absence of </text>
<text top="678" left="767" width="320" height="17" font="0">revascularization (OR: 35.9; p&lt;0.001; 95% CI: 12.9–99.7), </text>
<text top="695" left="767" width="333" height="17" font="0">occlusion of each of the 3 crural arteries (OR: 8.20; p=0.022; </text>
<text top="713" left="767" width="335" height="17" font="0">95% CI: 1.35–49.6), wound infection (OR: 2.1; p=0.004; 95% </text>
<text top="730" left="767" width="322" height="17" font="0">CI: 1.3–3.6), dialysis (OR: 4.7; p=0.001; 95% CI: 1.9–11.7) </text>
<text top="747" left="767" width="94" height="17" font="0">increase in TcPO</text>
<text top="753" left="861" width="4" height="11" font="11">2</text>
<text top="747" left="866" width="239" height="17" font="0"> after revascularization (OR: 0.80; p&lt;0.001; </text>
<text top="764" left="767" width="320" height="17" font="0">95% CI: 0.74–0.87). 173 pts died during follow-up and this </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">153 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="564" width="66" height="17" font="0">0.74–0.87). </text>
<text top="87" left="767" width="326" height="17" font="0">was associated with age (HR: 1.05; p&lt;0.001; 95% CI: 1.03–</text>
<text top="104" left="767" width="314" height="17" font="0">1.07), Hx of cardiac disease (HR: 2.16; p&lt;0.001; 95% CI: </text>
<text top="122" left="767" width="333" height="17" font="0">1.53–3.06), dialysis (HR: 3.52; p&lt;0.001; 95% CI: 2.08–5.97), </text>
<text top="139" left="767" width="318" height="17" font="0">absence of revascularization (HR: 1.68; p&lt;0.001; 95% CI: </text>
<text top="156" left="767" width="338" height="17" font="0">1.29–2.19) and impaired ejection fraction (HR: 1.08; p&lt;0.001; </text>
<text top="173" left="767" width="113" height="17" font="0">95% CI: 1.05–1.09). </text>
<text top="191" left="95" width="82" height="17" font="0">Faglia E, et al. </text>
<text top="208" left="95" width="66" height="17" font="0">2005. (340) </text>
<text top="226" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15878541">15878541 </a></text>
<text top="243" left="95" width="3" height="17" font="0"> </text>
<text top="191" left="223" width="103" height="17" font="2"><b>Study type:</b> Case </text>
<text top="208" left="223" width="36" height="17" font="0">series </text>
<text top="226" left="223" width="3" height="17" font="0"> </text>
<text top="243" left="223" width="90" height="17" font="2"><b>Size:</b> n=993 pts </text>
<text top="191" left="365" width="170" height="17" font="2"><b>Inclusion criteria:</b> CLI treated </text>
<text top="208" left="365" width="56" height="17" font="0">with endo </text>
<text top="226" left="365" width="3" height="17" font="0"> </text>
<text top="243" left="365" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="260" left="365" width="7" height="18" font="7"></text>
<text top="261" left="371" width="90" height="17" font="0"> Pts without DM </text>
<text top="278" left="365" width="7" height="18" font="7"></text>
<text top="279" left="371" width="106" height="17" font="0"> No stenosis &gt;50%<b> </b></text>
<text top="192" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="191" left="571" width="6" height="18" font="7"></text>
<text top="192" left="577" width="139" height="17" font="2"><b> endpoint:</b> Limb salvage </text>
<text top="210" left="564" width="3" height="17" font="0"> </text>
<text top="227" left="564" width="182" height="17" font="2"><b>Results: </b>1.7% major amputation </text>
<text top="244" left="564" width="151" height="17" font="0">rate at variable follow-up of </text>
<text top="261" left="564" width="148" height="17" font="0">26±15 mo. No comparator </text>
<text top="191" left="767" width="7" height="18" font="7"></text>
<text top="192" left="774" width="80" height="17" font="0"> PTA effective </text>
<text top="210" left="767" width="7" height="18" font="7"></text>
<text top="211" left="774" width="327" height="17" font="0"> PTA was successful performed in 993 pts. 17 (1.7%) major </text>
<text top="228" left="767" width="298" height="17" font="0">amputations were carried out. 1 death and 33 nonfatal </text>
<text top="245" left="767" width="341" height="17" font="0">complications were observed. Mean follow-up was 26±15 mo. </text>
<text top="262" left="767" width="324" height="17" font="0">Clinical restenosis was observed in 87 pts. The 5 y primary </text>
<text top="280" left="767" width="313" height="17" font="0">patency was 88%, 95% CI 86-91%. During follow-up 119 </text>
<text top="297" left="767" width="221" height="17" font="0">(12.0%) pts died at a rate of 6.7% per y. </text>
<text top="315" left="95" width="70" height="17" font="0">Iida O, et al. </text>
<text top="332" left="95" width="63" height="17" font="0">2012 (341) </text>
<text top="349" left="95" width="62" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22051875">22051875  </a></text>
<text top="366" left="95" width="3" height="17" font="0"> </text>
<text top="315" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="332" left="223" width="126" height="17" font="0">Retrospective analysis </text>
<text top="349" left="223" width="72" height="17" font="0">of BTK PTA: </text>
<text top="366" left="223" width="107" height="17" font="0">angiosome vs. non-</text>
<text top="384" left="223" width="64" height="17" font="0">angiosome </text>
<text top="401" left="223" width="3" height="17" font="0"> </text>
<text top="418" left="223" width="102" height="17" font="2"><b>Size: </b>n=369 limbs </text>
<text top="435" left="223" width="120" height="17" font="0">from 329 consecutive </text>
<text top="452" left="223" width="20" height="17" font="0">pts<b> </b></text>
<text top="315" left="365" width="170" height="17" font="2"><b>Inclusion criteria:</b> CLI treated </text>
<text top="332" left="365" width="56" height="17" font="0">with endo </text>
<text top="349" left="365" width="3" height="17" font="0"> </text>
<text top="366" left="365" width="187" height="17" font="2"><b>Exclusion criteria: </b>Unsuccessful </text>
<text top="384" left="365" width="184" height="17" font="0">recanalization of ≥1 vessel to the </text>
<text top="401" left="365" width="61" height="17" font="0">pedal arch<b> </b></text>
<text top="316" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="315" left="571" width="6" height="18" font="7"></text>
<text top="316" left="577" width="139" height="17" font="2"><b> endpoint:</b> Limb salvage </text>
<text top="333" left="564" width="3" height="17" font="0"> </text>
<text top="350" left="564" width="167" height="17" font="2"><b>Results: </b>Freedom from major </text>
<text top="368" left="564" width="163" height="17" font="0">amputation at 18±16 mo was </text>
<text top="385" left="564" width="182" height="17" font="0">higher in the angiosome directed </text>
<text top="402" left="564" width="165" height="17" font="0">group 51%±8% vs. 28%±8%, </text>
<text top="419" left="564" width="48" height="17" font="0">p=0.008 </text>
<text top="315" left="767" width="7" height="18" font="7"></text>
<text top="316" left="774" width="258" height="17" font="0"> AFS higher in angiosome directed endo group </text>
<text top="333" left="767" width="7" height="18" font="7"></text>
<text top="334" left="774" width="290" height="17" font="0"> During follow-up (mean, 18±16 mo), the overall limb </text>
<text top="351" left="767" width="323" height="17" font="0">salvage rate was 81% (300 of 369), death occurred in 36% </text>
<text top="369" left="767" width="315" height="17" font="0">(119 of 329), and the reintervention rate was 31% (114 of </text>
<text top="386" left="767" width="315" height="17" font="0">369). After propensity score adjustment, the estimated (± </text>
<text top="403" left="767" width="295" height="17" font="0">standard error) rates for AFS (49%±8% vs. 29%±6%; </text>
<text top="420" left="767" width="311" height="17" font="0">p=0.0002), freedom from MALE (51%±8% vs. 28%±8%, </text>
<text top="438" left="767" width="313" height="17" font="0">p=0.008), and major amputation (82%±5% vs. 68%±5%, </text>
<text top="455" left="767" width="322" height="17" font="0">p=0.01) were significantly higher in the direct group than in </text>
<text top="472" left="767" width="340" height="17" font="0">the indirect group for up to 4 y after the index procedure. After </text>
<text top="489" left="767" width="309" height="17" font="0">multivariable Cox proportional analysis, the independent </text>
<text top="506" left="767" width="323" height="17" font="0">factors associated with major amputation were hemoglobin </text>
<text top="524" left="767" width="339" height="17" font="0">A(1c) level (HR: 1.4; 95% CI: 1.1–1.9; p=0.006) and cilostazol </text>
<text top="541" left="767" width="334" height="17" font="0">administration (HR: 0.28; 95% CI: 0.11–0.70; p=0.006) in the </text>
<text top="558" left="767" width="325" height="17" font="0">direct group, and C-reactive protein level (HR: 1.2; 95% CI: </text>
<text top="575" left="767" width="212" height="17" font="0">1.1–1.4; p=0.002) in the indirect group </text>
<text top="593" left="95" width="92" height="17" font="0">Feiring AJ, et al. </text>
<text top="610" left="95" width="63" height="17" font="0">2010 (342) </text>
<text top="628" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20378075">20378075</a></text>
<text top="628" left="149" width="3" height="17" font="2"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20378075"><b> </b></a></text>
<text top="645" left="95" width="3" height="17" font="0"> </text>
<text top="593" left="223" width="103" height="17" font="2"><b>Study type:</b> Case </text>
<text top="610" left="223" width="36" height="17" font="0">series </text>
<text top="628" left="223" width="3" height="17" font="0"> </text>
<text top="645" left="223" width="90" height="17" font="2"><b>Size:</b> n=105 pts </text>
<text top="593" left="365" width="183" height="17" font="2"><b>Inclusion criteria:</b> Infrapop DES </text>
<text top="610" left="365" width="40" height="17" font="0">for CLI </text>
<text top="628" left="365" width="3" height="17" font="0"> </text>
<text top="645" left="365" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="662" left="365" width="7" height="18" font="7"></text>
<text top="663" left="371" width="69" height="17" font="0"> Lack of CLI </text>
<text top="680" left="365" width="7" height="18" font="7"></text>
<text top="682" left="371" width="133" height="17" font="0"> No exclusions for other </text>
<text top="699" left="365" width="76" height="17" font="0">comorbidities<b> </b></text>
<text top="594" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="593" left="571" width="6" height="18" font="7"></text>
<text top="594" left="577" width="161" height="17" font="2"><b> endpoint:</b> Major amputation </text>
<text top="612" left="564" width="74" height="17" font="0">and mortality </text>
<text top="629" left="564" width="3" height="17" font="0"> </text>
<text top="646" left="564" width="159" height="17" font="2"><b>Results: </b>The 3 y cumulative </text>
<text top="663" left="564" width="159" height="17" font="0">incidence of amputation was </text>
<text top="680" left="564" width="181" height="17" font="0">6±2%, survival was 71±5%, and </text>
<text top="698" left="564" width="161" height="17" font="0">amputation-free-survival was </text>
<text top="715" left="564" width="43" height="17" font="0">68±5%<b> </b></text>
<text top="593" left="767" width="7" height="18" font="7"></text>
<text top="594" left="774" width="218" height="17" font="0"> Infrapop DES for CLI appears effective </text>
<text top="612" left="767" width="7" height="18" font="7"></text>
<text top="613" left="774" width="289" height="17" font="0"> The mean pt age was 74±9 y. There were 228 DES </text>
<text top="630" left="767" width="340" height="17" font="0">implanted (83% Cypher [Cordis, Johnson &amp; Johnson, Warren, </text>
<text top="647" left="767" width="318" height="17" font="0">New Jersey], 17% Taxus [Boston Scientific, Maple Grove, </text>
<text top="664" left="767" width="337" height="17" font="0">Minnesota]). The number of stents per limb was 1.9±0.9, and </text>
<text top="682" left="767" width="313" height="17" font="0">35% of limbs received overlapping DES (length of 60±13 </text>
<text top="699" left="767" width="335" height="17" font="0">mm). There were no procedural deaths, and 96% of pts were </text>
<text top="716" left="767" width="305" height="17" font="0">discharged within 24 h. The 3 y cumulative incidence of </text>
<text top="733" left="767" width="335" height="17" font="0">amputation was 6±2%, survival was 71±5%, and amputation-</text>
<text top="750" left="767" width="319" height="17" font="0">free-survival was 68±5%. Only 12% of pts who died had a </text>
<text top="768" left="767" width="302" height="17" font="0">preceding major amputation. Rutherford category, age, </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">154 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="767" width="332" height="17" font="0">creatinine level, and dialysis (p≤0.001–0.04) were predictors </text>
<text top="104" left="767" width="317" height="17" font="0">of death but not amputation. Target limb revascularization </text>
<text top="122" left="767" width="337" height="17" font="0">occurred in 15% of pts, and repeat angiography in 35% of pts </text>
<text top="139" left="767" width="202" height="17" font="0">revealed a binary restenosis in 12%. </text>
<text top="157" left="95" width="86" height="17" font="0">Siablis D, et al. </text>
<text top="174" left="95" width="63" height="17" font="0">2009 (343) </text>
<text top="191" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19620014">19620014 </a></text>
<text top="208" left="95" width="3" height="17" font="0"> </text>
<text top="157" left="223" width="122" height="17" font="2"><b>Study type:</b> Registry: </text>
<text top="174" left="223" width="126" height="17" font="0">Infrapop DES vs. BMS </text>
<text top="191" left="223" width="3" height="17" font="0"> </text>
<text top="208" left="223" width="90" height="17" font="2"><b>Size:</b> n=103 pts </text>
<text top="157" left="365" width="170" height="17" font="2"><b>Inclusion criteria:</b> CLI treated </text>
<text top="174" left="365" width="146" height="17" font="0">with infrapop DES or BMS </text>
<text top="191" left="365" width="3" height="17" font="0"> </text>
<text top="208" left="365" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="226" left="365" width="7" height="18" font="7"></text>
<text top="227" left="371" width="123" height="17" font="0"> Hx of severe contrast </text>
<text top="244" left="365" width="127" height="17" font="0">allergy/hypersensitivity </text>
<text top="261" left="365" width="7" height="18" font="7"></text>
<text top="262" left="371" width="173" height="17" font="0"> Hypersensitivity to ASA and/or </text>
<text top="280" left="365" width="63" height="17" font="0">clopidogrel </text>
<text top="297" left="365" width="7" height="18" font="7"></text>
<text top="298" left="371" width="148" height="17" font="0"> Systemic coagulopathy or </text>
<text top="315" left="365" width="151" height="17" font="0">hypercoagulation disorders </text>
<text top="332" left="365" width="7" height="18" font="7"></text>
<text top="333" left="371" width="25" height="17" font="0"> ALI </text>
<text top="351" left="365" width="7" height="18" font="7"></text>
<text top="352" left="371" width="96" height="17" font="0"> Buerger disease </text>
<text top="369" left="365" width="7" height="18" font="7"></text>
<text top="370" left="371" width="126" height="17" font="0"> Deep vein thrombosis </text>
<text top="387" left="365" width="7" height="18" font="7"></text>
<text top="389" left="371" width="164" height="17" font="0"> Bifurcation and/or trifurcation </text>
<text top="406" left="365" width="42" height="17" font="0">lesions </text>
<text top="423" left="365" width="7" height="18" font="7"></text>
<text top="424" left="371" width="176" height="17" font="0"> Previous use of other DES (not </text>
<text top="441" left="365" width="32" height="17" font="0">SES) </text>
<text top="459" left="365" width="7" height="18" font="7"></text>
<text top="460" left="371" width="141" height="17" font="0"> Stenting indications after </text>
<text top="477" left="365" width="170" height="17" font="0">suboptimal and/or complicated </text>
<text top="494" left="365" width="109" height="17" font="0">balloon angioplasty </text>
<text top="512" left="365" width="7" height="18" font="7"></text>
<text top="513" left="371" width="76" height="17" font="0"> Elastic recoil </text>
<text top="530" left="365" width="130" height="17" font="0">Flow-limiting dissection </text>
<text top="547" left="365" width="7" height="18" font="7"></text>
<text top="548" left="371" width="138" height="17" font="0"> Residual stenosis &gt;30%<b> </b></text>
<text top="158" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="157" left="571" width="6" height="18" font="7"></text>
<text top="158" left="577" width="173" height="17" font="2"><b> endpoint:</b> Primary clinical and </text>
<text top="175" left="564" width="180" height="17" font="0">angiographic endpoints included </text>
<text top="192" left="564" width="173" height="17" font="0">mortality, limb salvage, primary </text>
<text top="210" left="564" width="161" height="17" font="0">patency, binary angiographic </text>
<text top="227" left="564" width="173" height="17" font="0">restenosis, and clinically driven </text>
<text top="244" left="564" width="183" height="17" font="0">repeat intervention-free survival.  </text>
<text top="261" left="564" width="3" height="17" font="0"> </text>
<text top="278" left="564" width="161" height="17" font="2"><b>Results: </b>At 3 y, SES-treated </text>
<text top="296" left="564" width="159" height="17" font="0">lesions were associated with </text>
<text top="313" left="564" width="146" height="17" font="0">significantly better primary </text>
<text top="330" left="564" width="184" height="17" font="0">patency (HR: 4.81; 95% CI: 2.91–</text>
<text top="347" left="564" width="171" height="17" font="0">7.94; p&lt;0.001), reduced binary </text>
<text top="365" left="564" width="166" height="17" font="0">restenosis (HR: 0.38; 95% CI: </text>
<text top="382" left="564" width="176" height="17" font="0">0.25–0.58; p&lt;0.001), and better </text>
<text top="399" left="564" width="176" height="17" font="0">repeat intervention-free survival </text>
<text top="416" left="564" width="168" height="17" font="0">(HR: 2.56; 95% CI: 1.30–5.00; </text>
<text top="433" left="564" width="178" height="17" font="0">p=0.006) vs. BMS-treated ones. </text>
<text top="451" left="564" width="171" height="17" font="0">No significant differences were </text>
<text top="468" left="564" width="161" height="17" font="0">identified between SESs and </text>
<text top="485" left="564" width="187" height="17" font="0">BMSs with regard to overall 3 y pt </text>
<text top="502" left="564" width="153" height="17" font="0">mortality (29.3% vs. 32.0%; </text>
<text top="519" left="564" width="148" height="17" font="0">p=0.205) and limb salvage </text>
<text top="537" left="564" width="159" height="17" font="0">(80.3% vs. 82.0%; p=0.507).<b> </b></text>
<text top="157" left="767" width="7" height="18" font="7"></text>
<text top="158" left="774" width="218" height="17" font="0"> Infrapop DES for CLI appears effective </text>
<text top="175" left="767" width="7" height="18" font="7"></text>
<text top="176" left="774" width="314" height="17" font="0"> In total, 103 pts were included in the analysis; 41 (75.6% </text>
<text top="194" left="767" width="333" height="17" font="0">with DM) were treated with a BMS (47 limbs; 77 lesions) and </text>
<text top="211" left="767" width="337" height="17" font="0">62 (87.1% with DM) with an SES (75 limbs; 153 lesions). At 3 </text>
<text top="228" left="767" width="310" height="17" font="0">y, SES-treated lesions were associated with significantly </text>
<text top="245" left="767" width="294" height="17" font="0">better primary patency (HR: 4.81; 95% CI: 2.91–7.94; </text>
<text top="262" left="767" width="307" height="17" font="0">p&lt;0.001), reduced binary restenosis (HR: 0.38; 95% CI: </text>
<text top="280" left="767" width="307" height="17" font="0">0.25–0.58; p&lt;0.001), and better repeat intervention-free </text>
<text top="297" left="767" width="316" height="17" font="0">survival (HR: 2.56; 95% CI: 1.30–5.00; p=0.006) vs. BMS-</text>
<text top="314" left="767" width="299" height="17" font="0">treated ones. No significant differences were identified </text>
<text top="331" left="767" width="295" height="17" font="0">between SESs and BMSs with regard to overall 3 y pt </text>
<text top="348" left="767" width="301" height="17" font="0">mortality (29.3% vs. 32.0%; p=0.205) and limb salvage </text>
<text top="366" left="767" width="159" height="17" font="0">(80.3% vs. 82.0%; p=0.507). </text>
<text top="566" left="95" width="91" height="17" font="0">Werner M, et al. </text>
<text top="583" left="95" width="63" height="17" font="0">2012 (344) </text>
<text top="601" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22313195">22313195 </a></text>
<text top="618" left="95" width="3" height="17" font="0"> </text>
<text top="566" left="223" width="103" height="17" font="2"><b>Study type:</b> Case </text>
<text top="583" left="223" width="36" height="17" font="0">series </text>
<text top="601" left="223" width="3" height="17" font="0"> </text>
<text top="618" left="223" width="90" height="17" font="2"><b>Size:</b> n=158 pts </text>
<text top="566" left="365" width="183" height="17" font="2"><b>Inclusion criteria:</b> Infrapop DES </text>
<text top="583" left="365" width="40" height="17" font="0">for CLI </text>
<text top="601" left="365" width="3" height="17" font="0"> </text>
<text top="618" left="365" width="153" height="17" font="2"><b>Exclusion criteria: </b>Lack of </text>
<text top="635" left="365" width="96" height="17" font="0">infrapop stenosis<b> </b></text>
<text top="567" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="566" left="571" width="6" height="18" font="7"></text>
<text top="567" left="577" width="175" height="17" font="2"><b> endpoint:</b> Angiographic binary </text>
<text top="585" left="564" width="177" height="17" font="0">restenosis; freedom from death, </text>
<text top="602" left="564" width="134" height="17" font="0">amputation, and bypass </text>
<text top="619" left="564" width="3" height="17" font="0"> </text>
<text top="636" left="564" width="187" height="17" font="2"><b>Results:</b> Results in column to the </text>
<text top="653" left="564" width="148" height="17" font="0">right; no comparator group </text>
<text top="566" left="767" width="7" height="18" font="7"></text>
<text top="567" left="774" width="191" height="17" font="0"> Proof of concept for infrapop DES </text>
<text top="585" left="767" width="7" height="18" font="7"></text>
<text top="586" left="774" width="322" height="17" font="0"> Technical success was achieved in all cases. The primary </text>
<text top="603" left="767" width="339" height="17" font="0">patency rates were 97.0% after 6 mo, 87.0% after 12 mo, and </text>
<text top="620" left="767" width="292" height="17" font="0">83.8% at 60 mo. In-stent stenosis was predominantly </text>
<text top="637" left="767" width="328" height="17" font="0">observed in the first y after stent placement. Female gender </text>
<text top="655" left="767" width="305" height="17" font="0">was associated with a higher rate of ISS. During clinical </text>
<text top="672" left="767" width="333" height="17" font="0">follow-up of 144 (91%) pts over a mean 31.1±20.3 mo, there </text>
<text top="689" left="767" width="302" height="17" font="0">were 27 (18.8%) deaths, 4 (2.8%) amputations, and no </text>
<text top="706" left="767" width="319" height="17" font="0">bypass surgery. Clinical status improved in 92% of the pts </text>
<text top="723" left="767" width="301" height="17" font="0">with CLI and 77% of the pts suffering from claudication </text>
<text top="741" left="767" width="60" height="17" font="0">(p=0.022). </text>
<text top="759" left="95" width="75" height="17" font="0">Acin F, et al.  </text>
<text top="776" left="95" width="63" height="17" font="0">2014 (345) </text>
<text top="759" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="776" left="223" width="108" height="17" font="0">Retrospective case </text>
<text top="759" left="365" width="155" height="17" font="2"><b>Inclusion criteria:</b> Infrapop </text>
<text top="776" left="365" width="165" height="17" font="0">intervention for CLI in pts with </text>
<text top="760" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="759" left="571" width="6" height="18" font="7"></text>
<text top="760" left="577" width="145" height="17" font="2"><b> endpoint: </b>Ischemic ulcer </text>
<text top="777" left="564" width="170" height="17" font="0">healing and limb salvage rates<b> </b></text>
<text top="759" left="767" width="24" height="17" font="0">N/A </text>
</page>
<page number="155" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">155 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24527215">24527215</a></text>
<text top="87" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24527215"> </a></text>
<text top="104" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="117" height="17" font="0">series assessing CLI </text>
<text top="104" left="223" width="126" height="17" font="0">treatment with number </text>
<text top="122" left="223" width="106" height="17" font="0">of infrapop vessels </text>
<text top="139" left="223" width="88" height="17" font="0">and angiosome </text>
<text top="156" left="223" width="66" height="17" font="0">relationship </text>
<text top="173" left="223" width="3" height="17" font="0"> </text>
<text top="190" left="223" width="70" height="17" font="2"><b>Size:</b> n=101 </text>
<text top="208" left="223" width="105" height="17" font="0">procedures; 92 pts<b> </b></text>
<text top="87" left="365" width="23" height="17" font="0">DM </text>
<text top="87" left="564" width="3" height="17" font="2"><b> </b></text>
<text top="104" left="564" width="189" height="17" font="2"><b>Results:</b> No difference between 1 </text>
<text top="122" left="564" width="147" height="17" font="0">vessel run-off and multiple </text>
<text top="139" left="564" width="170" height="17" font="0">vessels; no difference is single </text>
<text top="156" left="564" width="154" height="17" font="0">vessel was in angiosome of </text>
<text top="173" left="564" width="40" height="17" font="0">wound </text>
<text top="226" left="95" width="115" height="17" font="0">Alexandrescu VA, et </text>
<text top="243" left="95" width="20" height="17" font="0">al.  </text>
<text top="260" left="95" width="63" height="17" font="0">2008 (346) </text>
<text top="277" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18840046">18840046</a></text>
<text top="277" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18840046"> </a></text>
<text top="294" left="95" width="3" height="17" font="0"> </text>
<text top="226" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="243" left="223" width="108" height="17" font="0">Retrospective case </text>
<text top="260" left="223" width="117" height="17" font="0">series assessing CLI </text>
<text top="277" left="223" width="81" height="17" font="0">treatment with </text>
<text top="294" left="223" width="64" height="17" font="0">angiosome </text>
<text top="312" left="223" width="66" height="17" font="0">relationship </text>
<text top="329" left="223" width="3" height="17" font="0"> </text>
<text top="346" left="223" width="83" height="17" font="2"><b>Size:</b> n=98 pts<b> </b></text>
<text top="226" left="365" width="155" height="17" font="2"><b>Inclusion criteria:</b> Infrapop </text>
<text top="243" left="365" width="165" height="17" font="0">intervention for CLI in pts with </text>
<text top="260" left="365" width="23" height="17" font="0">DM </text>
<text top="227" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="226" left="571" width="6" height="18" font="7"></text>
<text top="227" left="577" width="145" height="17" font="2"><b> endpoint: </b>Ischemic ulcer </text>
<text top="244" left="564" width="170" height="17" font="0">healing and limb salvage rates </text>
<text top="261" left="564" width="3" height="17" font="2"><b> </b></text>
<text top="278" left="564" width="148" height="17" font="2"><b>Results:</b> Limb salving and </text>
<text top="296" left="564" width="150" height="17" font="0">healing rates typical of that </text>
<text top="313" left="564" width="146" height="17" font="0">described for endo for CLI<b> </b></text>
<text top="226" left="767" width="120" height="17" font="0">No comparator group </text>
<text top="364" left="95" width="109" height="17" font="0">Fossacaca R, et al. </text>
<text top="381" left="95" width="63" height="17" font="0">2013 (347) </text>
<text top="398" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23358605">23358605</a></text>
<text top="398" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23358605"> </a></text>
<text top="416" left="95" width="3" height="17" font="0"> </text>
<text top="364" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="381" left="223" width="108" height="17" font="0">Retrospective case </text>
<text top="398" left="223" width="117" height="17" font="0">series assessing CLI </text>
<text top="416" left="223" width="81" height="17" font="0">treatment with </text>
<text top="433" left="223" width="64" height="17" font="0">angiosome </text>
<text top="450" left="223" width="66" height="17" font="0">relationship </text>
<text top="467" left="223" width="3" height="17" font="0"> </text>
<text top="485" left="223" width="90" height="17" font="2"><b>Size:</b> n=201 pts<b> </b></text>
<text top="364" left="365" width="155" height="17" font="2"><b>Inclusion criteria:</b> Infrapop </text>
<text top="381" left="365" width="165" height="17" font="0">intervention for CLI in pts with </text>
<text top="398" left="365" width="23" height="17" font="0">DM </text>
<text top="365" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="364" left="571" width="6" height="18" font="7"></text>
<text top="365" left="577" width="145" height="17" font="2"><b> endpoint: </b>Ischemic ulcer </text>
<text top="382" left="564" width="183" height="17" font="0">healing and limb salvage rates at </text>
<text top="400" left="564" width="86" height="17" font="0">1,6, and 12 mo </text>
<text top="417" left="564" width="3" height="17" font="2"><b> </b></text>
<text top="434" left="564" width="141" height="17" font="2"><b>Results:</b> No difference in </text>
<text top="451" left="564" width="178" height="17" font="0">therapeutic efficacy with indirect </text>
<text top="468" left="564" width="170" height="17" font="0">revasc vs. angiosome directed </text>
<text top="486" left="564" width="40" height="17" font="0">revasc<b> </b></text>
<text top="364" left="767" width="71" height="17" font="0">Higher TcPO</text>
<text top="370" left="838" width="4" height="11" font="11">2</text>
<text top="364" left="843" width="243" height="17" font="0"> in angiosome group but no clinical outcome </text>
<text top="381" left="767" width="57" height="17" font="0">difference </text>
<text top="504" left="95" width="81" height="17" font="0">Kabra A, et al. </text>
<text top="521" left="95" width="63" height="17" font="0">2013 (348) </text>
<text top="538" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23058724">23058724</a></text>
<text top="538" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23058724"> </a></text>
<text top="555" left="95" width="3" height="17" font="0"> </text>
<text top="504" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="521" left="223" width="97" height="17" font="0">Prospective case </text>
<text top="538" left="223" width="117" height="17" font="0">series assessing CLI </text>
<text top="555" left="223" width="81" height="17" font="0">treatment with </text>
<text top="573" left="223" width="64" height="17" font="0">angiosome </text>
<text top="590" left="223" width="66" height="17" font="0">relationship </text>
<text top="607" left="223" width="3" height="17" font="0"> </text>
<text top="624" left="223" width="83" height="17" font="2"><b>Size:</b> n=64 pts<b> </b></text>
<text top="504" left="365" width="155" height="17" font="2"><b>Inclusion criteria:</b> Infrapop </text>
<text top="521" left="365" width="140" height="17" font="0">intervention for CLI in pts </text>
<text top="505" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="504" left="571" width="6" height="18" font="7"></text>
<text top="505" left="577" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="522" left="564" width="7" height="18" font="7"></text>
<text top="523" left="571" width="178" height="17" font="0"> Ischemic ulcer healing and limb </text>
<text top="540" left="564" width="169" height="17" font="0">salvage rates at 1,3, and 6 mo </text>
<text top="558" left="564" width="7" height="18" font="7"></text>
<text top="559" left="571" width="163" height="17" font="0"> The difference in the rates of </text>
<text top="576" left="564" width="189" height="17" font="0">ulcer healing between the DR and </text>
<text top="593" left="564" width="145" height="17" font="0">IR groups was statistically </text>
<text top="610" left="564" width="169" height="17" font="0">significant (p=0.021). The limb </text>
<text top="628" left="564" width="172" height="17" font="0">salvage in the DR group (84%) </text>
<text top="645" left="564" width="157" height="17" font="0">and IR group (75%) was not </text>
<text top="662" left="564" width="171" height="17" font="0">statistically significant (p=0.06) </text>
<text top="504" left="767" width="67" height="17" font="0">Small study </text>
<text top="680" left="95" width="86" height="17" font="0">Kret MR, et al.  </text>
<text top="697" left="95" width="63" height="17" font="0">2014 (349) </text>
<text top="714" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23972526">23972526</a></text>
<text top="714" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23972526"> </a></text>
<text top="732" left="95" width="3" height="17" font="0"> </text>
<text top="680" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="697" left="223" width="108" height="17" font="0">Retrospective case </text>
<text top="714" left="223" width="117" height="17" font="0">series assessing CLI </text>
<text top="732" left="223" width="81" height="17" font="0">treatment with </text>
<text top="749" left="223" width="64" height="17" font="0">angiosome </text>
<text top="766" left="223" width="66" height="17" font="0">relationship </text>
<text top="680" left="365" width="155" height="17" font="2"><b>Inclusion criteria:</b> Infrapop </text>
<text top="697" left="365" width="140" height="17" font="0">intervention for CLI in pts </text>
<text top="681" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="680" left="571" width="6" height="18" font="7"></text>
<text top="681" left="577" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="698" left="564" width="7" height="18" font="7"></text>
<text top="700" left="571" width="166" height="17" font="0"> Complete wound healing and </text>
<text top="717" left="564" width="133" height="17" font="0">time to complete wound </text>
<text top="734" left="564" width="7" height="18" font="7"></text>
<text top="735" left="571" width="130" height="17" font="0"> No difference between </text>
<text top="752" left="564" width="165" height="17" font="0">angiosome group and indirect </text>
<text top="770" left="564" width="75" height="17" font="0">revasc group </text>
<text top="680" left="767" width="24" height="17" font="0">N/A </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">156 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="223" width="3" height="17" font="0"> </text>
<text top="104" left="223" width="83" height="17" font="2"><b>Size:</b> n=97 pts<b> </b></text>
<text top="122" left="95" width="81" height="17" font="0">Lejay A, et al.  </text>
<text top="139" left="95" width="63" height="17" font="0">2014 (350) </text>
<text top="157" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24333196">24333196</a></text>
<text top="157" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24333196"> </a></text>
<text top="174" left="95" width="3" height="17" font="0"> </text>
<text top="122" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="139" left="223" width="108" height="17" font="0">Retrospective case </text>
<text top="157" left="223" width="117" height="17" font="0">series assessing CLI </text>
<text top="174" left="223" width="81" height="17" font="0">treatment with </text>
<text top="191" left="223" width="64" height="17" font="0">angiosome </text>
<text top="208" left="223" width="66" height="17" font="0">relationship </text>
<text top="226" left="223" width="3" height="17" font="0"> </text>
<text top="243" left="223" width="83" height="17" font="2"><b>Size:</b> n=54 pts </text>
<text top="122" left="365" width="155" height="17" font="2"><b>Inclusion criteria:</b> Infrapop </text>
<text top="139" left="365" width="116" height="17" font="0">bypass for CLI in pts </text>
<text top="123" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="122" left="571" width="6" height="18" font="7"></text>
<text top="123" left="577" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="141" left="564" width="7" height="18" font="7"></text>
<text top="142" left="571" width="151" height="17" font="0"> Median ulcer-healing time, </text>
<text top="159" left="564" width="167" height="17" font="0">survival, primary patency, and </text>
<text top="176" left="564" width="152" height="17" font="0">limb salvage rates between </text>
<text top="194" left="564" width="168" height="17" font="0">angiosome vs. indirect bypass </text>
<text top="211" left="564" width="35" height="17" font="0">group </text>
<text top="228" left="564" width="7" height="18" font="7"></text>
<text top="229" left="571" width="182" height="17" font="0"> Angiosome directed bypass had </text>
<text top="246" left="564" width="185" height="17" font="0">higher limb salvage at 1, 3, and 5 </text>
<text top="264" left="564" width="174" height="17" font="0">y (p=0.03) compared to indirect </text>
<text top="281" left="564" width="40" height="17" font="0">revasc<b> </b></text>
<text top="122" left="767" width="67" height="17" font="0">Small study </text>
<text top="299" left="95" width="97" height="17" font="0">Neville RF, et al.  </text>
<text top="316" left="95" width="63" height="17" font="0">2009 (351) </text>
<text top="333" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19179041">19179041</a></text>
<text top="333" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19179041"> </a></text>
<text top="350" left="95" width="3" height="17" font="0"> </text>
<text top="299" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="316" left="223" width="108" height="17" font="0">Retrospective case </text>
<text top="333" left="223" width="117" height="17" font="0">series assessing CLI </text>
<text top="350" left="223" width="81" height="17" font="0">treatment with </text>
<text top="368" left="223" width="64" height="17" font="0">angiosome </text>
<text top="385" left="223" width="66" height="17" font="0">relationship </text>
<text top="402" left="223" width="3" height="17" font="0"> </text>
<text top="419" left="223" width="83" height="17" font="2"><b>Size:</b> n=48 pts </text>
<text top="299" left="365" width="155" height="17" font="2"><b>Inclusion criteria:</b> Infrapop </text>
<text top="316" left="365" width="116" height="17" font="0">bypass for CLI in pts </text>
<text top="300" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="299" left="571" width="6" height="18" font="7"></text>
<text top="300" left="577" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="317" left="564" width="7" height="18" font="7"></text>
<text top="318" left="571" width="166" height="17" font="0"> Complete wound healing and </text>
<text top="335" left="564" width="133" height="17" font="0">time to complete wound </text>
<text top="353" left="564" width="7" height="18" font="7"></text>
<text top="354" left="571" width="159" height="17" font="0"> Angiosome group had more </text>
<text top="371" left="564" width="184" height="17" font="0">complete wound healing ; among </text>
<text top="388" left="564" width="173" height="17" font="0">wounds that did heal there was </text>
<text top="405" left="564" width="171" height="17" font="0">no difference in time to healing </text>
<text top="423" left="564" width="122" height="17" font="0">between the 2 groups </text>
<text top="299" left="767" width="67" height="17" font="0">Small study </text>
<text top="441" left="95" width="87" height="17" font="0">Osawa S, et al. </text>
<text top="458" left="95" width="63" height="17" font="0">2013 (352) </text>
<text top="475" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23822940">23822940</a></text>
<text top="475" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23822940"> </a></text>
<text top="492" left="95" width="3" height="17" font="0"> </text>
<text top="441" left="223" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="458" left="223" width="108" height="17" font="0">Retrospective case </text>
<text top="475" left="223" width="117" height="17" font="0">series assessing CLI </text>
<text top="492" left="223" width="89" height="17" font="0">with angiosome </text>
<text top="510" left="223" width="66" height="17" font="0">relationship </text>
<text top="527" left="223" width="3" height="17" font="0"> </text>
<text top="544" left="223" width="125" height="17" font="2"><b>Size:</b> n=111 pts (n=57 </text>
<text top="561" left="223" width="97" height="17" font="0">for endo therapy) </text>
<text top="441" left="365" width="132" height="17" font="2"><b>Inclusion criteria:</b> CLI  </text>
<text top="442" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="441" left="571" width="6" height="18" font="7"></text>
<text top="442" left="577" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="459" left="564" width="7" height="18" font="7"></text>
<text top="460" left="571" width="174" height="17" font="0"> Time to complete wound in pts </text>
<text top="477" left="564" width="171" height="17" font="0">who had angiosome or indirect </text>
<text top="495" left="564" width="43" height="17" font="0">revasc  </text>
<text top="512" left="564" width="7" height="18" font="7"></text>
<text top="513" left="571" width="173" height="17" font="0"> Wound healing rate was faster </text>
<text top="530" left="564" width="163" height="17" font="0">for angiosome directed group </text>
<text top="441" left="767" width="67" height="17" font="0">Small study </text>
<text top="579" left="95" width="101" height="17" font="0">Abu Dabrh AM, et </text>
<text top="596" left="95" width="16" height="17" font="0">al. </text>
<text top="614" left="95" width="63" height="17" font="0">2015 (353) </text>
<text top="631" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26391460">26391460</a></text>
<text top="631" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26391460"> </a></text>
<text top="648" left="95" width="3" height="17" font="0"> </text>
<text top="579" left="223" width="111" height="17" font="2"><b>Aim:</b> To investigate </text>
<text top="596" left="223" width="127" height="17" font="0">natural hx of untreated </text>
<text top="614" left="223" width="103" height="17" font="0">CLI or severe limb </text>
<text top="631" left="223" width="52" height="17" font="0">ischemia </text>
<text top="648" left="223" width="3" height="17" font="0"> </text>
<text top="665" left="223" width="126" height="17" font="2"><b>Study type:</b> SR/MA of </text>
<text top="682" left="223" width="119" height="17" font="0">observational studies </text>
<text top="700" left="223" width="3" height="17" font="0"> </text>
<text top="717" left="223" width="106" height="17" font="2"><b>Size:</b> n=13 studies </text>
<text top="734" left="223" width="42" height="17" font="0">(1,527)<b> </b></text>
<text top="579" left="365" width="113" height="17" font="2"><b>Inclusion criteria:</b>   </text>
<text top="596" left="365" width="7" height="18" font="7"></text>
<text top="597" left="371" width="172" height="17" font="0"> Studies with pts. reporting rest </text>
<text top="615" left="365" width="142" height="17" font="0">pain, tissue loss, ulcer, or </text>
<text top="632" left="365" width="55" height="17" font="0">gangrene </text>
<text top="649" left="365" width="7" height="18" font="7"></text>
<text top="650" left="371" width="120" height="17" font="0"> Rutherford class 4–6 </text>
<text top="668" left="365" width="7" height="18" font="7"></text>
<text top="669" left="371" width="175" height="17" font="0"> Or ankle pressure &lt;70 mm Hg, </text>
<text top="686" left="365" width="139" height="17" font="0">toe pressure &lt;50 mm Hg </text>
<text top="703" left="365" width="7" height="18" font="7"></text>
<text top="704" left="371" width="158" height="17" font="0"> Flat pulse volume recording </text>
<text top="722" left="365" width="7" height="18" font="7"></text>
<text top="723" left="371" width="100" height="17" font="0"> transcutaneous O</text>
<text top="728" left="472" width="4" height="11" font="11">2</text>
<text top="723" left="476" width="55" height="17" font="0"> pressure </text>
<text top="740" left="365" width="113" height="17" font="0">&lt;40 mmHg for ≥1 y. </text>
<text top="757" left="365" width="7" height="18" font="7"></text>
<text top="758" left="371" width="121" height="17" font="0"> No revasc treatment. </text>
<text top="775" left="365" width="3" height="17" font="0"> </text>
<text top="580" left="564" width="7" height="17" font="2"><b>1</b></text>
<text top="579" left="571" width="6" height="18" font="7"></text>
<text top="580" left="577" width="150" height="17" font="2"><b> endpoint:</b> Mortality, Major </text>
<text top="597" left="564" width="151" height="17" font="0">amputation, wound healing </text>
<text top="615" left="564" width="3" height="17" font="0"> </text>
<text top="632" left="564" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="649" left="564" width="7" height="18" font="7"></text>
<text top="650" left="571" width="171" height="17" font="0"> All-cause mortality: 22% (95% </text>
<text top="667" left="564" width="86" height="17" font="0">CI: 12%–33%)  </text>
<text top="685" left="564" width="7" height="18" font="7"></text>
<text top="686" left="571" width="158" height="17" font="0"> Major amputation rate: 22% </text>
<text top="703" left="564" width="108" height="17" font="0">(95% CI: 2%–42%) </text>
<text top="720" left="564" width="7" height="18" font="7"></text>
<text top="721" left="571" width="178" height="17" font="0"> Worsened wound or ulcer: 35% </text>
<text top="739" left="564" width="115" height="17" font="0">(95% CI: 10%–62%) </text>
<text top="579" left="767" width="327" height="17" font="0">Trend towards improvement in the current era probably due </text>
<text top="596" left="767" width="141" height="17" font="0">to improved medical care </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">157 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="365" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="104" left="365" width="173" height="17" font="0">Revascularization treated arms </text>
<text top="122" left="86" width="982" height="17" font="0">AAA indicates abdominal aortic aneurysm; ABF, aortobifemoral bypass; ABI, ankle-brachial index; AFS, amputation free survival; AIOD, aortoiliac occlusive disease; ALI, acute limb </text>
<text top="139" left="86" width="969" height="17" font="0">ischemia; ASA, aspirin; BMS, bare metal stent; BPG, bypass graft; BTK, below the knee; BPG, bypass graft; CI, confidence interval; CLI, critical limb ischemia; CTO, chronic total </text>
<text top="157" left="86" width="1015" height="17" font="0">occlusion; DES, drug eluting stent; DM, diabetes mellitus; DR, direct revascularization; EVT, endovascular treatment; HR, hazard ratio; IR, indirect revascularization; MALE major adverse </text>
<text top="174" left="86" width="1016" height="17" font="0">limb event; N/A, not applicable; OR, odds ratio; PTA, percutaneous angioplasty; pt, patient; R/PTAS, recanalization, percutaneous transluminal angioplasty, and stenting; RR, relative risk; </text>
<text top="191" left="86" width="210" height="17" font="0">SES, self-expanding stents; and TcPO</text>
<text top="197" left="296" width="7" height="11" font="11">2,</text>
<text top="191" left="303" width="192" height="17" font="0"> transcutaneous oxygen pressure.  </text>
<text top="208" left="86" width="3" height="17" font="0"> </text>
<text top="226" left="86" width="3" height="17" font="0"> </text>
<text top="243" left="86" width="591" height="21" font="1"><b>Evidence Table 41. RCTs of Surgical Revascularization for Chronic CLI–Section 8.2. </b></text>
<text top="264" left="96" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="281" left="122" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="299" left="99" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="264" left="225" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="281" left="230" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="299" left="224" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="264" left="350" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="264" left="505" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="281" left="523" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="299" left="505" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="316" left="526" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="264" left="718" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="281" left="676" width="191" height="17" font="2"><b>(Absolute Event Rates, P value;  </b></text>
<text top="299" left="732" width="79" height="17" font="2"><b>OR or RR; &amp;  </b></text>
<text top="316" left="746" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="265" left="918" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="264" left="980" width="6" height="18" font="7"></text>
<text top="265" left="986" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="283" left="951" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="300" left="958" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="334" left="95" width="83" height="17" font="0">Abidia A, et al. </text>
<text top="351" left="95" width="63" height="17" font="0">2003 (354) </text>
<text top="368" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12787692">12787692 </a></text>
<text top="385" left="95" width="3" height="17" font="0"> </text>
<text top="334" left="209" width="82" height="17" font="2"><b>Aim:</b> Evaluate </text>
<text top="351" left="209" width="104" height="17" font="0">hyperbaric oxygen </text>
<text top="368" left="209" width="106" height="17" font="0">in pts with DM with </text>
<text top="385" left="209" width="115" height="17" font="0">ischemic nonhealing </text>
<text top="403" left="209" width="33" height="17" font="0">ulcer. </text>
<text top="420" left="209" width="3" height="17" font="0"> </text>
<text top="437" left="209" width="113" height="17" font="2"><b>Study type:</b> Double </text>
<text top="454" left="209" width="58" height="17" font="0">blind RCT </text>
<text top="472" left="209" width="3" height="17" font="0"> </text>
<text top="489" left="209" width="83" height="17" font="2"><b>Size:</b> n=18 pts </text>
<text top="334" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="351" left="338" width="7" height="18" font="7"></text>
<text top="352" left="344" width="121" height="17" font="0"> Ulcer &gt;1 cm and &lt;10 </text>
<text top="369" left="338" width="89" height="17" font="0">cm in maximum </text>
<text top="387" left="338" width="131" height="17" font="0">diameter which had not </text>
<text top="404" left="338" width="108" height="17" font="0">shown any signs of </text>
<text top="421" left="338" width="89" height="17" font="0">healing, despite </text>
<text top="438" left="338" width="96" height="17" font="0">optimum medical </text>
<text top="455" left="338" width="124" height="17" font="0">management for more </text>
<text top="473" left="338" width="88" height="17" font="0">than 6 wk since </text>
<text top="490" left="338" width="64" height="17" font="0">presenting. </text>
<text top="507" left="338" width="7" height="18" font="7"></text>
<text top="508" left="344" width="127" height="17" font="0"> ABI &lt;0.8 (or great TBI </text>
<text top="526" left="338" width="134" height="17" font="0">&lt;0.7 if calf vessels were </text>
<text top="543" left="338" width="93" height="17" font="0">incompressible). </text>
<text top="560" left="338" width="7" height="18" font="7"></text>
<text top="561" left="344" width="123" height="17" font="0"> Pts with DM, HgbA1c </text>
<text top="578" left="338" width="42" height="17" font="0">&lt;8.5%. </text>
<text top="595" left="338" width="3" height="17" font="0"> </text>
<text top="613" left="338" width="131" height="17" font="2"><b>Exclusion criteria:</b> Pts </text>
<text top="630" left="338" width="103" height="17" font="0">for whom vascular </text>
<text top="647" left="338" width="128" height="17" font="0">surgery, angioplasty or </text>
<text top="664" left="338" width="98" height="17" font="0">thrombolysis was </text>
<text top="682" left="338" width="51" height="17" font="0">planned  </text>
<text top="334" left="486" width="113" height="17" font="2"><b>Intervention:</b> 100% </text>
<text top="351" left="486" width="98" height="17" font="0">oxygen (Tx at 2.4 </text>
<text top="368" left="486" width="139" height="17" font="0">Atmospheres of absolute </text>
<text top="385" left="486" width="138" height="17" font="0">pressure for 90 min daily </text>
<text top="403" left="486" width="90" height="17" font="0">(30 treatments). </text>
<text top="420" left="486" width="3" height="17" font="0"> </text>
<text top="437" left="486" width="147" height="17" font="2"><b>Comparator:</b> Air Tx at 2.4 </text>
<text top="454" left="486" width="139" height="17" font="0">Atmospheres of absolute </text>
<text top="472" left="486" width="138" height="17" font="0">pressure for 90 min daily </text>
<text top="489" left="486" width="90" height="17" font="0">(30 treatments). </text>
<text top="335" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="334" left="655" width="6" height="18" font="7"></text>
<text top="335" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="352" left="648" width="7" height="18" font="7"></text>
<text top="353" left="655" width="225" height="17" font="0"> At 6 wk follow-up, complete healing was </text>
<text top="371" left="648" width="222" height="17" font="0">achieved in 5 of 8 ulcers in the Tx group </text>
<text top="388" left="648" width="228" height="17" font="0">compared with 1 of 8 ulcers in the control </text>
<text top="405" left="648" width="42" height="17" font="0">group.  </text>
<text top="422" left="648" width="7" height="18" font="7"></text>
<text top="423" left="655" width="213" height="17" font="0"> The respective results at 1 y follow-up </text>
<text top="441" left="648" width="186" height="17" font="0">were 5 of 8 and 0 of 8 (p=0.026 )  </text>
<text top="458" left="648" width="7" height="18" font="7"></text>
<text top="459" left="655" width="217" height="17" font="0"> 6 wk follow-up the median decrease of </text>
<text top="476" left="648" width="240" height="17" font="0">the wound areas in the Tx group was 100% </text>
<text top="493" left="648" width="220" height="17" font="0">compared with 52% in the control group </text>
<text top="511" left="648" width="234" height="17" font="0">(p=0.027). However, values at 6 mo follow-</text>
<text top="528" left="648" width="206" height="17" font="0">up were 100% and 95% respectively. </text>
<text top="334" left="905" width="24" height="17" font="0">N/A </text>
<text top="700" left="95" width="38" height="17" font="2"><b>STILE </b></text>
<text top="717" left="95" width="98" height="17" font="0">Weaver FA, et al. </text>
<text top="734" left="95" width="63" height="17" font="0">1996 (355) </text>
<text top="751" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8911400">8911400</a></text>
<text top="751" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8911400"> </a></text>
<text top="768" left="95" width="3" height="17" font="0"> </text>
<text top="700" left="209" width="96" height="17" font="2"><b>Aim:</b> LE lysis vs. </text>
<text top="717" left="209" width="46" height="17" font="0">surgical </text>
<text top="734" left="209" width="96" height="17" font="0">revascularization </text>
<text top="751" left="209" width="92" height="17" font="0">with and without </text>
<text top="768" left="209" width="105" height="17" font="0">prior endovascular </text>
<text top="700" left="338" width="124" height="17" font="2"><b>Inclusion criteria:</b> LE </text>
<text top="717" left="338" width="52" height="17" font="0">ischemia </text>
<text top="734" left="338" width="3" height="17" font="0"> </text>
<text top="751" left="338" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="700" left="486" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="717" left="486" width="80" height="17" font="0">Thrombolysis  </text>
<text top="734" left="486" width="3" height="17" font="0"> </text>
<text top="751" left="486" width="125" height="17" font="2"><b>Comparator:</b> Surgical </text>
<text top="768" left="486" width="96" height="17" font="0">revascularization </text>
<text top="701" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="700" left="655" width="6" height="18" font="7"></text>
<text top="701" left="661" width="191" height="17" font="2"><b> endpoint:</b> At 1 y, the incidence of </text>
<text top="718" left="648" width="187" height="17" font="0">recurrent ischemia (64% vs. 35%; </text>
<text top="735" left="648" width="233" height="17" font="0">p&lt;0.0001) and major amputation (10% vs. </text>
<text top="752" left="648" width="225" height="17" font="0">0%; p=0.0024) was increased in pts who </text>
<text top="770" left="648" width="146" height="17" font="0">were randomized to lysis.  </text>
<text top="700" left="905" width="7" height="18" font="7"></text>
<text top="701" left="911" width="174" height="17" font="0"> Factors associated with a poor </text>
<text top="718" left="905" width="202" height="17" font="0">lytic outcome included FP occlusion, </text>
<text top="735" left="905" width="171" height="17" font="0">diabetes, and critical ischemia. </text>
<text top="752" left="905" width="7" height="18" font="7"></text>
<text top="753" left="911" width="180" height="17" font="0"> No differences in mortality rates </text>
<text top="771" left="905" width="188" height="17" font="0">were observed at 1 y between the </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">158 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="209" width="67" height="17" font="0">intervention </text>
<text top="104" left="209" width="3" height="17" font="0"> </text>
<text top="122" left="209" width="102" height="17" font="2"><b>Study type</b> : RCT </text>
<text top="139" left="209" width="3" height="17" font="0"> </text>
<text top="156" left="209" width="90" height="17" font="2"><b>Size:</b> n=237 pts </text>
<text top="87" left="905" width="141" height="17" font="0">lysis and surgical groups. </text>
<text top="174" left="95" width="46" height="17" font="2"><b>TOPAS</b> </text>
<text top="191" left="95" width="81" height="17" font="0">Ouriel K, et al. </text>
<text top="208" left="95" width="63" height="17" font="0">1998 (356) </text>
<text top="226" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9545358">9545358</a></text>
<text top="226" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9545358"> </a></text>
<text top="243" left="95" width="7" height="17" font="0">  </text>
<text top="174" left="209" width="96" height="17" font="2"><b>Aim:</b> LE lysis vs. </text>
<text top="191" left="209" width="46" height="17" font="0">surgical </text>
<text top="208" left="209" width="96" height="17" font="0">revascularization </text>
<text top="226" left="209" width="92" height="17" font="0">with and without </text>
<text top="243" left="209" width="105" height="17" font="0">prior endovascular </text>
<text top="260" left="209" width="67" height="17" font="0">intervention </text>
<text top="277" left="209" width="3" height="17" font="0"> </text>
<text top="294" left="209" width="102" height="17" font="2"><b>Study type</b> : RCT </text>
<text top="312" left="209" width="64" height="17" font="0">Multicenter </text>
<text top="329" left="209" width="3" height="17" font="0"> </text>
<text top="346" left="209" width="90" height="17" font="2"><b>Size:</b> n=544 pts<b> </b></text>
<text top="174" left="338" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="191" left="338" width="110" height="17" font="0">Acute thrombotic or </text>
<text top="208" left="338" width="124" height="17" font="0">embolic occlusion of a </text>
<text top="226" left="338" width="109" height="17" font="0">leg (native artery or </text>
<text top="243" left="338" width="126" height="17" font="0">bypass graft) within 14 </text>
<text top="260" left="338" width="129" height="17" font="0">d before randomization </text>
<text top="277" left="338" width="127" height="17" font="0">that met the guidelines </text>
<text top="294" left="338" width="101" height="17" font="0">for reversible limb-</text>
<text top="312" left="338" width="117" height="17" font="0">threatening ischemia </text>
<text top="329" left="338" width="3" height="17" font="0"> </text>
<text top="346" left="338" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="363" left="338" width="102" height="17" font="0">Women who were </text>
<text top="381" left="338" width="116" height="17" font="0">pregnant or in whom </text>
<text top="398" left="338" width="96" height="17" font="0">pregnancy was a </text>
<text top="415" left="338" width="60" height="17" font="0">possibility.<b> </b></text>
<text top="174" left="486" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="191" left="486" width="102" height="17" font="0">Thrombolysis with </text>
<text top="208" left="486" width="57" height="17" font="0">urokinase </text>
<text top="226" left="486" width="3" height="17" font="0"> </text>
<text top="243" left="486" width="125" height="17" font="2"><b>Comparator:</b> Surgical </text>
<text top="260" left="486" width="96" height="17" font="0">revascularization<b> </b></text>
<text top="175" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="174" left="655" width="6" height="18" font="7"></text>
<text top="175" left="661" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="192" left="648" width="7" height="18" font="7"></text>
<text top="193" left="655" width="221" height="17" font="0"> Final angiograms, which were available </text>
<text top="211" left="648" width="239" height="17" font="0">for 246 pts treated with urokinase, revealed </text>
<text top="228" left="648" width="240" height="17" font="0">recanalization in 196 (79.7%) and complete </text>
<text top="245" left="648" width="220" height="17" font="0">dissolution of thrombus in 167 (67.9%).  </text>
<text top="262" left="648" width="7" height="18" font="7"></text>
<text top="263" left="655" width="211" height="17" font="0"> Both Tx groups had similar significant </text>
<text top="281" left="648" width="155" height="17" font="0">improvements in mean ABI. </text>
<text top="298" left="648" width="7" height="18" font="7"></text>
<text top="299" left="655" width="204" height="17" font="0"> Amputation-free survival rates in the </text>
<text top="316" left="648" width="228" height="17" font="0">urokinase group were 71.8% at 6 mo and </text>
<text top="334" left="648" width="234" height="17" font="0">65.0% at 1 y, as compared with respective </text>
<text top="351" left="648" width="223" height="17" font="0">rates of 74.8% and 69.9% in the surgery </text>
<text top="368" left="648" width="38" height="17" font="0">group; </text>
<text top="385" left="648" width="7" height="18" font="7"></text>
<text top="386" left="655" width="222" height="17" font="0"> 6 mo differences 95% CI: 10.5%–4.5%; </text>
<text top="404" left="648" width="45" height="17" font="0">p=0.43. </text>
<text top="421" left="648" width="7" height="18" font="7"></text>
<text top="422" left="655" width="215" height="17" font="0"> 1 y differences 95% CI: -12.9%–3.1%; </text>
<text top="439" left="648" width="45" height="17" font="0">p=0.23. </text>
<text top="456" left="648" width="7" height="18" font="7"></text>
<text top="457" left="655" width="235" height="17" font="0"> At 6 mo the surgery group had undergone </text>
<text top="475" left="648" width="233" height="17" font="0">551 open operative procedures (excluding </text>
<text top="492" left="648" width="235" height="17" font="0">amputations), as compared with 315 in the </text>
<text top="509" left="648" width="114" height="17" font="0">thrombolysis group. <b> </b></text>
<text top="174" left="905" width="185" height="17" font="0">Major hemorrhage occurred in 32 </text>
<text top="191" left="905" width="191" height="17" font="0">pts in the urokinase group (12.5%) </text>
<text top="208" left="905" width="170" height="17" font="0">as compared with 14 pts in the </text>
<text top="226" left="905" width="119" height="17" font="0">surgery group (5.5%) </text>
<text top="243" left="905" width="202" height="17" font="0">(p=0.005). There were 4 episodes of </text>
<text top="260" left="905" width="167" height="17" font="0">intracranial hemorrhage in the </text>
<text top="277" left="905" width="194" height="17" font="0">urokinase group (1.6%), 1 of which </text>
<text top="294" left="905" width="202" height="17" font="0">was fatal. By contrast, there were no </text>
<text top="312" left="905" width="200" height="17" font="0">episodes of intracranial hemorrhage </text>
<text top="329" left="905" width="116" height="17" font="0">in the surgery group. </text>
<text top="527" left="95" width="93" height="17" font="0">Dutch Iliac Stent </text>
<text top="544" left="95" width="100" height="17" font="0">Trial Study Group </text>
<text top="562" left="95" width="94" height="17" font="0">Tetteroo E, et al. </text>
<text top="579" left="95" width="63" height="17" font="0">1998 (221) </text>
<text top="596" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9643685">9643685</a></text>
<text top="596" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9643685"> </a></text>
<text top="613" left="95" width="3" height="17" font="0"> </text>
<text top="527" left="209" width="107" height="17" font="2"><b>Aim:</b> To determine </text>
<text top="544" left="209" width="107" height="17" font="0">outcomes between </text>
<text top="562" left="209" width="83" height="17" font="0">direct stent vs. </text>
<text top="579" left="209" width="77" height="17" font="0">delayed stent </text>
<text top="596" left="209" width="88" height="17" font="0">placement after </text>
<text top="613" left="209" width="69" height="17" font="0">angioplasty  </text>
<text top="630" left="209" width="3" height="17" font="0"> </text>
<text top="648" left="209" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="665" left="209" width="3" height="17" font="0"> </text>
<text top="682" left="209" width="93" height="17" font="2"><b>Size:</b> n=279  pts </text>
<text top="527" left="338" width="122" height="17" font="2"><b>Inclusion criteria:</b> IC </text>
<text top="544" left="338" width="109" height="17" font="0">on the basis of iliac-</text>
<text top="562" left="338" width="129" height="17" font="0">artery stenosis of more </text>
<text top="579" left="338" width="116" height="17" font="0">than 50%, proven by </text>
<text top="596" left="338" width="71" height="17" font="0">angiography </text>
<text top="613" left="338" width="3" height="17" font="0"> </text>
<text top="630" left="338" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="648" left="338" width="102" height="17" font="0">Women who were </text>
<text top="665" left="338" width="116" height="17" font="0">pregnant or in whom </text>
<text top="682" left="338" width="96" height="17" font="0">pregnancy was a </text>
<text top="699" left="338" width="87" height="17" font="0">possibility were </text>
<text top="716" left="338" width="56" height="17" font="0">excluded. </text>
<text top="527" left="486" width="124" height="17" font="2"><b>Intervention:</b> Primary </text>
<text top="544" left="486" width="91" height="17" font="0">angioplasty with </text>
<text top="562" left="486" width="97" height="17" font="0">subsequent stent </text>
<text top="579" left="486" width="126" height="17" font="0">placement in case of a </text>
<text top="596" left="486" width="132" height="17" font="0">residual mean pressure </text>
<text top="613" left="486" width="115" height="17" font="0">gradient &gt;10 mm Hg </text>
<text top="630" left="486" width="124" height="17" font="0">across the treated site </text>
<text top="648" left="486" width="45" height="17" font="0">group II </text>
<text top="665" left="486" width="3" height="17" font="0"> </text>
<text top="682" left="486" width="143" height="17" font="2"><b>Comparator:</b> Direct stent </text>
<text top="699" left="486" width="105" height="17" font="0">placement, group I </text>
<text top="528" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="527" left="655" width="6" height="18" font="7"></text>
<text top="528" left="661" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="546" left="648" width="7" height="18" font="7"></text>
<text top="547" left="655" width="232" height="17" font="0"> In group II, selective stent placement was </text>
<text top="564" left="648" width="237" height="17" font="0">done in 59 (43%) of the 136 pts. The mean </text>
<text top="581" left="648" width="228" height="17" font="0">follow-up was 9.3 mo (range 3–24). Initial </text>
<text top="598" left="648" width="223" height="17" font="0">hemodynamic success and complication </text>
<text top="616" left="648" width="225" height="17" font="0">rates were 119 (81%) of 149 limbs and 6 </text>
<text top="633" left="648" width="242" height="17" font="0">(4%) of 143 limbs (group I) vs. 103 (82%) of </text>
<text top="650" left="648" width="235" height="17" font="0">126 limbs and 10 (7%) of 136 limbs (group </text>
<text top="667" left="648" width="93" height="17" font="0">II), respectively.  </text>
<text top="684" left="648" width="7" height="18" font="7"></text>
<text top="685" left="655" width="206" height="17" font="0"> Clinical success rates at 2 y were 29 </text>
<text top="703" left="648" width="228" height="17" font="0">(78%) of 37 pts and 26 (77%) of 34 pts in </text>
<text top="720" left="648" width="200" height="17" font="0">groups I and II, respectively (p=0.6); </text>
<text top="737" left="648" width="191" height="17" font="0">however, 43% and 35% of the pts, </text>
<text top="754" left="648" width="183" height="17" font="0">respectively, still had symptoms.  </text>
<text top="772" left="648" width="7" height="18" font="7"></text>
<text top="773" left="655" width="179" height="17" font="0"> QoL improved significantly after </text>
<text top="527" left="905" width="24" height="17" font="0">N/A </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">159 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="648" width="208" height="17" font="0">intervention (p&lt;0.05) but we found no </text>
<text top="104" left="648" width="207" height="17" font="0">difference between the groups during </text>
<text top="122" left="648" width="215" height="17" font="0">follow-up. 2 y cumulative patency rates </text>
<text top="139" left="648" width="204" height="17" font="0">were similar at 71% vs. 70% (p=0.2), </text>
<text top="156" left="648" width="241" height="17" font="0">respectively, as were reintervention rates at </text>
<text top="173" left="648" width="220" height="17" font="0">7% vs. 4%, respectively (95% CI -2% to </text>
<text top="190" left="648" width="29" height="17" font="0">9%). </text>
<text top="208" left="95" width="62" height="17" font="2"><b>CRISP-US </b></text>
<text top="226" left="95" width="84" height="17" font="0">Ponec D, et el. </text>
<text top="243" left="95" width="63" height="17" font="0">2004 (357) </text>
<text top="260" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15361558">15361558</a></text>
<text top="260" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15361558"> </a></text>
<text top="277" left="95" width="3" height="17" font="0"> </text>
<text top="208" left="209" width="85" height="17" font="2"><b>Aim: </b>Compare </text>
<text top="226" left="209" width="96" height="17" font="0">SMART stent vs. </text>
<text top="243" left="209" width="82" height="17" font="0">Wallstent after </text>
<text top="260" left="209" width="94" height="17" font="0">suboptimal PTA. </text>
<text top="277" left="209" width="3" height="17" font="0"> </text>
<text top="294" left="209" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="312" left="209" width="64" height="17" font="0">multicenter </text>
<text top="329" left="209" width="3" height="17" font="0"> </text>
<text top="346" left="209" width="90" height="17" font="2"><b>Size:</b> n=203 pts </text>
<text top="208" left="338" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="226" left="338" width="124" height="17" font="0">Chronic limb ischemia </text>
<text top="243" left="338" width="3" height="17" font="0"> </text>
<text top="260" left="338" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="208" left="486" width="146" height="17" font="2"><b>Intervention:</b> Smart Stent </text>
<text top="226" left="486" width="3" height="17" font="0"> </text>
<text top="243" left="486" width="135" height="17" font="2"><b>Comparator:</b> Wall stent </text>
<text top="209" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="208" left="655" width="6" height="18" font="7"></text>
<text top="209" left="661" width="207" height="17" font="2"><b> endpoint:</b> 9 mo composite end point </text>
<text top="227" left="648" width="224" height="17" font="0">rate was equivalent for the SMART stent </text>
<text top="244" left="648" width="219" height="17" font="0">and Wallstent (6.9% vs. 5.9%), with low </text>
<text top="261" left="648" width="232" height="17" font="0">rates of restenosis (3.5% vs. 2.7%), death </text>
<text top="278" left="648" width="213" height="17" font="0">(2.0% vs. 0.0%), and revascularization </text>
<text top="296" left="648" width="224" height="17" font="0">(2.0% vs. 4.0%) in the 2 groups. Primary </text>
<text top="313" left="648" width="224" height="17" font="0">patency at 12 mo was 94.7% and 91.1% </text>
<text top="330" left="648" width="204" height="17" font="0">with the SMART stent and Wallstent, </text>
<text top="347" left="648" width="236" height="17" font="0">respectively. Functional and hemodynamic </text>
<text top="365" left="648" width="243" height="17" font="0">improvement was also comparable between </text>
<text top="382" left="648" width="242" height="17" font="0">the groups. The frequency of major adverse </text>
<text top="399" left="648" width="231" height="17" font="0">events was similar at 1 y (4.9% vs. 5.9%). </text>
<text top="208" left="905" width="192" height="17" font="0">The acute procedural success rate </text>
<text top="226" left="905" width="173" height="17" font="0">was higher in the SMART stent </text>
<text top="243" left="905" width="194" height="17" font="0">group (98.2% vs. 87.5%; p=0.002). </text>
<text top="417" left="95" width="62" height="17" font="2"><b>CRISP-US </b></text>
<text top="434" left="95" width="91" height="17" font="0">Schillinger M, et </text>
<text top="451" left="95" width="16" height="17" font="0">al. </text>
<text top="468" left="95" width="63" height="17" font="0">2006 (358) </text>
<text top="486" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16672699">16672699</a></text>
<text top="486" left="149" width="7" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16672699">  </a></text>
<text top="503" left="95" width="3" height="17" font="0"> </text>
<text top="417" left="209" width="109" height="17" font="2"><b>Aim:</b> Primary Stent </text>
<text top="434" left="209" width="86" height="17" font="0">vs. Angioplasty </text>
<text top="451" left="209" width="3" height="17" font="0"> </text>
<text top="468" left="209" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="486" left="209" width="64" height="17" font="0">multicenter </text>
<text top="503" left="209" width="3" height="17" font="0"> </text>
<text top="520" left="209" width="90" height="17" font="2"><b>Size:</b> n=104 pts </text>
<text top="417" left="338" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="434" left="338" width="125" height="17" font="0">Severe claudication or </text>
<text top="451" left="338" width="121" height="17" font="0">chronic limb ischemia </text>
<text top="468" left="338" width="101" height="17" font="0">due to stenosis or </text>
<text top="486" left="338" width="116" height="17" font="0">occlusion of the SFA </text>
<text top="503" left="338" width="3" height="17" font="0"> </text>
<text top="520" left="338" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="417" left="486" width="103" height="17" font="2"><b>Intervention:</b> Self-</text>
<text top="434" left="486" width="126" height="17" font="0">expanding nitinol stent </text>
<text top="451" left="486" width="3" height="17" font="0"> </text>
<text top="468" left="486" width="144" height="17" font="2"><b>Comparator:</b> Angioplasty </text>
<text top="418" left="648" width="7" height="17" font="0">1</text>
<text top="417" left="655" width="6" height="18" font="7"></text>
<text top="418" left="661" width="225" height="17" font="0"> endpoint: At 6 mo, the rate of restenosis </text>
<text top="435" left="648" width="240" height="17" font="0">on angiography was 24% in the stent group </text>
<text top="452" left="648" width="239" height="17" font="0">and 43% in the angioplasty group (p=0.05); </text>
<text top="470" left="648" width="159" height="17" font="0">at 12 mo the rates on duplex </text>
<text top="487" left="648" width="205" height="17" font="0">ultrasonography were 37% and 63%, </text>
<text top="504" left="648" width="241" height="17" font="0">respectively (p=0.01). Pts in the stent group </text>
<text top="521" left="648" width="232" height="17" font="0">were able to walk significantly farther on a </text>
<text top="539" left="648" width="230" height="17" font="0">treadmill at 6 and 12 mo than those in the </text>
<text top="556" left="648" width="104" height="17" font="0">angioplasty group. </text>
<text top="417" left="905" width="174" height="17" font="0">Angiographic follow-up was not </text>
<text top="434" left="905" width="185" height="17" font="0">done in all pts, resulting in lack of </text>
<text top="451" left="905" width="202" height="17" font="0">quantitative data on lumen diameter, </text>
<text top="468" left="905" width="125" height="17" font="0">residual stenosis, etc.  </text>
<text top="574" left="95" width="42" height="17" font="0">BASIL  </text>
<text top="591" left="95" width="91" height="17" font="0">Adam DJ, et al.  </text>
<text top="608" left="95" width="63" height="17" font="0">2005 (328) </text>
<text top="625" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16325694">16325694 </a></text>
<text top="643" left="95" width="3" height="17" font="25"> </text>
<text top="574" left="209" width="101" height="17" font="2"><b>Aim:</b> Infrainguinal </text>
<text top="591" left="209" width="107" height="17" font="0">surgical bypass vs. </text>
<text top="608" left="209" width="68" height="17" font="0">PTA for CLI </text>
<text top="625" left="209" width="3" height="17" font="0"> </text>
<text top="643" left="209" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="660" left="209" width="3" height="17" font="0"> </text>
<text top="677" left="209" width="93" height="17" font="2"><b>Size:</b> n= 452 pts </text>
<text top="574" left="338" width="129" height="17" font="2"><b>Inclusion criteria:</b> CLI </text>
<text top="591" left="338" width="107" height="17" font="0">due to infrainguinal </text>
<text top="608" left="338" width="29" height="17" font="0">PAD </text>
<text top="625" left="338" width="3" height="17" font="0"> </text>
<text top="643" left="338" width="137" height="17" font="2"><b>Exclusion criteria:</b> N/A  </text>
<text top="574" left="486" width="105" height="17" font="2"><b>Intervention:</b> PTA </text>
<text top="591" left="486" width="48" height="17" font="0">(N=224) </text>
<text top="608" left="486" width="3" height="17" font="0"> </text>
<text top="625" left="486" width="121" height="17" font="2"><b>Comparator:</b> Bypass </text>
<text top="643" left="486" width="48" height="17" font="0">(N=228) </text>
<text top="575" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="574" left="655" width="6" height="18" font="7"></text>
<text top="575" left="661" width="198" height="17" font="2"><b> endpoint:</b> Amputation free survival </text>
<text top="592" left="648" width="3" height="17" font="0"> </text>
<text top="609" left="648" width="150" height="17" font="2"><b>Safety endpoint:</b> Mortality </text>
<text top="574" left="905" width="7" height="18" font="7"></text>
<text top="575" left="911" width="95" height="17" font="0"> Equal outcomes </text>
<text top="592" left="905" width="7" height="18" font="7"></text>
<text top="593" left="911" width="183" height="17" font="0"> The trial ran for 5.5 y, and follow-</text>
<text top="610" left="905" width="181" height="17" font="0">up finished when pts reached an </text>
<text top="628" left="905" width="176" height="17" font="0">endpoint (amputation of trial leg </text>
<text top="645" left="905" width="177" height="17" font="0">above the ankle or death). 7 pts </text>
<text top="662" left="905" width="147" height="17" font="0">were lost to follow-up after </text>
<text top="679" left="905" width="148" height="17" font="0">randomization (3 assigned </text>
<text top="697" left="905" width="192" height="17" font="0">angioplasty, 2 surgery); of these, 3 </text>
<text top="714" left="905" width="195" height="17" font="0">were lost (1 angioplasty, 2 surgery) </text>
<text top="731" left="905" width="185" height="17" font="0">during the first y of follow-up. 195 </text>
<text top="748" left="905" width="202" height="17" font="0">(86%) of 228 pts assigned to bypass </text>
<text top="765" left="905" width="180" height="17" font="0">surgery and 216 (96%) of 224 to </text>
</page>
<page number="160" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">160 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="905" width="187" height="17" font="0">balloon angioplasty underwent an </text>
<text top="104" left="905" width="138" height="17" font="0">attempt at their allocated </text>
<text top="122" left="905" width="192" height="17" font="0">intervention at a median (IQR) of 6 </text>
<text top="139" left="905" width="151" height="17" font="0">(3–16) and 6 (2–20) d after </text>
<text top="156" left="905" width="191" height="17" font="0">randomization, respectively. At the </text>
<text top="173" left="905" width="174" height="17" font="0">end of follow-up, 248 (55%) pts </text>
<text top="190" left="905" width="183" height="17" font="0">were alive without amputation (of </text>
<text top="208" left="905" width="151" height="17" font="0">trial leg), 38 (8%) alive with </text>
<text top="225" left="905" width="173" height="17" font="0">amputation, 36 (8%) dead after </text>
<text top="242" left="905" width="182" height="17" font="0">amputation, and 130 (29%) dead </text>
<text top="259" left="905" width="194" height="17" font="0">without amputation. After 6 mo, the </text>
<text top="276" left="905" width="138" height="17" font="0">2 strategies did not differ </text>
<text top="294" left="905" width="170" height="17" font="0">significantly in amputation-free </text>
<text top="311" left="905" width="189" height="17" font="0">survival (48 vs. 60 pts; unadjusted </text>
<text top="328" left="905" width="157" height="17" font="0">HR: 1.07; 95% CI: 0.72–1.6; </text>
<text top="345" left="905" width="183" height="17" font="0">adjusted HR: 0.73; 95% CI: 0.49–</text>
<text top="363" left="905" width="203" height="17" font="0">1.07). No difference in health-related </text>
<text top="380" left="905" width="153" height="17" font="0">quality of life between the 2 </text>
<text top="397" left="905" width="172" height="17" font="0">strategies, but for the first y the </text>
<text top="414" left="905" width="176" height="17" font="0">hospital costs associated with a </text>
<text top="431" left="905" width="200" height="17" font="0">surgery-first strategy were about 1/3 </text>
<text top="449" left="905" width="141" height="17" font="0">higher than those with an </text>
<text top="466" left="905" width="140" height="17" font="0">angioplasty-first strategy. </text>
<text top="484" left="95" width="75" height="17" font="2"><b>PREVENT III </b></text>
<text top="501" left="95" width="95" height="17" font="0">Conte MS, et al.  </text>
<text top="518" left="95" width="63" height="17" font="0">2006 (359) </text>
<text top="535" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16616230">16616230 </a></text>
<text top="553" left="95" width="3" height="17" font="0"> </text>
<text top="484" left="209" width="77" height="17" font="2"><b>Aim: </b>Reduce </text>
<text top="501" left="209" width="109" height="17" font="0">stenosis in Surgical </text>
<text top="518" left="209" width="83" height="17" font="0">bypass for CLI </text>
<text top="535" left="209" width="95" height="17" font="0">using E2F decoy </text>
<text top="553" left="209" width="3" height="17" font="0"> </text>
<text top="570" left="209" width="70" height="17" font="2"><b>Study type: </b></text>
<text top="587" left="209" width="71" height="17" font="0">Prospective, </text>
<text top="604" left="209" width="111" height="17" font="0">randomized, double </text>
<text top="621" left="209" width="97" height="17" font="0">blinded, phase III<b> </b></text>
<text top="639" left="209" width="29" height="17" font="0">RCT </text>
<text top="656" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="673" left="209" width="100" height="17" font="2"><b>Size: </b>n=1,404 pts<b> </b></text>
<text top="484" left="338" width="127" height="17" font="2"><b>Inclusion criteria: </b>Pts </text>
<text top="501" left="338" width="112" height="17" font="0">with CLI (R4-6) who </text>
<text top="518" left="338" width="113" height="17" font="0">had autologous vein </text>
<text top="535" left="338" width="109" height="17" font="0">graft randomized to </text>
<text top="553" left="338" width="123" height="17" font="0">placebo or E2F decoy<b> </b></text>
<text top="570" left="338" width="3" height="17" font="2"><b> </b></text>
<text top="587" left="338" width="129" height="17" font="2"><b>Exclusion criteria:</b> IC, </text>
<text top="604" left="338" width="127" height="17" font="0">hypercoagulable state, </text>
<text top="621" left="338" width="135" height="17" font="0">revisions of infrainguinal </text>
<text top="639" left="338" width="80" height="17" font="0">bypass grafts<b>  </b></text>
<text top="484" left="486" width="105" height="17" font="2"><b>Intervention: </b>PTA </text>
<text top="501" left="486" width="48" height="17" font="0">(N=517)<b> </b></text>
<text top="518" left="486" width="7" height="17" font="2"><b>  </b></text>
<text top="535" left="486" width="121" height="17" font="2"><b>Comparator: </b>Bypass </text>
<text top="553" left="486" width="48" height="17" font="0">(N=341)<b> </b></text>
<text top="485" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="484" left="655" width="6" height="18" font="7"></text>
<text top="485" left="661" width="198" height="17" font="2"><b> endpoint: </b>Nontechnical index graft </text>
<text top="502" left="648" width="194" height="17" font="0">failure resulting in revision or major </text>
<text top="519" left="648" width="64" height="17" font="0">amputation<b> </b></text>
<text top="537" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="554" left="648" width="222" height="17" font="2"><b>Safety endpoint: </b>All-cause graft failure, </text>
<text top="571" left="648" width="196" height="17" font="0">freedom from significant index graft </text>
<text top="588" left="648" width="217" height="17" font="0">stenosis, amputation, index graft failure </text>
<text top="605" left="648" width="222" height="17" font="0">survival, graft patency, and limb salvage<b> </b></text>
<text top="484" left="905" width="7" height="18" font="7"></text>
<text top="485" left="912" width="112" height="17" font="2"><b> </b>2.7% 30 d mortality </text>
<text top="502" left="905" width="7" height="18" font="7"></text>
<text top="503" left="912" width="52" height="17" font="2"><b> </b>4.7% MI </text>
<text top="521" left="905" width="7" height="18" font="7"></text>
<text top="522" left="912" width="148" height="17" font="2"><b> </b>5.2% early graft occlusion </text>
<text top="539" left="905" width="7" height="18" font="7"></text>
<text top="540" left="912" width="161" height="17" font="2"><b> </b>Primary patency at 1 y: 61% </text>
<text top="557" left="905" width="7" height="18" font="7"></text>
<text top="558" left="912" width="176" height="17" font="2"><b> </b>Primary assisted patency: 77% </text>
<text top="576" left="905" width="7" height="18" font="7"></text>
<text top="577" left="912" width="143" height="17" font="2"><b> </b>Secondary patency: 80% </text>
<text top="594" left="905" width="7" height="18" font="7"></text>
<text top="595" left="912" width="111" height="17" font="2"><b> </b>Limb salvage: 88% </text>
<text top="691" left="95" width="60" height="17" font="2"><b>BEST-CLI </b></text>
<text top="708" left="95" width="85" height="17" font="0">Farber A, et al. </text>
<text top="726" left="95" width="63" height="17" font="0">2014 (360) </text>
<text top="743" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25241324">25241324 </a></text>
<text top="760" left="95" width="3" height="17" font="0"> </text>
<text top="691" left="209" width="100" height="17" font="2"><b>Aim: </b>To compare </text>
<text top="708" left="209" width="103" height="17" font="0">best endovascular </text>
<text top="726" left="209" width="92" height="17" font="0">vs. best surgical </text>
<text top="743" left="209" width="103" height="17" font="0">therapy in pts with </text>
<text top="760" left="209" width="80" height="17" font="0">CLI. Compare </text>
<text top="777" left="209" width="104" height="17" font="0">treatment efficacy, </text>
<text top="691" left="338" width="127" height="17" font="2"><b>Inclusion criteria: </b>Pts </text>
<text top="708" left="338" width="90" height="17" font="0">with CLI (R4-6) <b> </b></text>
<text top="726" left="338" width="3" height="17" font="2"><b> </b></text>
<text top="743" left="338" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="691" left="486" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="708" left="486" width="95" height="17" font="0">Endovascular Tx </text>
<text top="726" left="486" width="56" height="17" font="0">(n=1,050)<b> </b></text>
<text top="743" left="486" width="3" height="17" font="2"><b> </b></text>
<text top="760" left="486" width="121" height="17" font="2"><b>Comparator: </b>Bypass </text>
<text top="777" left="486" width="58" height="17" font="0">(N=1,050)<b> </b></text>
<text top="692" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="691" left="655" width="6" height="18" font="7"></text>
<text top="692" left="661" width="170" height="17" font="2"><b> endpoint: </b>MALE-free survival </text>
<text top="710" left="648" width="3" height="17" font="2"><b> </b></text>
<text top="727" left="648" width="103" height="17" font="2"><b>Safety endpoint:  </b></text>
<text top="744" left="648" width="7" height="18" font="7"></text>
<text top="745" left="655" width="208" height="17" font="2"><b> </b>MALE-POD (i.e., death within 30 d of </text>
<text top="762" left="648" width="63" height="17" font="0">procedure) </text>
<text top="691" left="905" width="24" height="17" font="0">N/A </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="28" size="13" family="Times" color="#333333"/>
	<fontspec id="29" size="7" family="Times" color="#333333"/>
<text top="795" left="1081" width="24" height="17" font="0">161 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="209" width="56" height="17" font="0">functional </text>
<text top="104" left="209" width="110" height="17" font="0">outcomes, and cost </text>
<text top="122" left="209" width="81" height="17" font="0">in pts with CLI </text>
<text top="139" left="209" width="92" height="17" font="0">undergoing best </text>
<text top="156" left="209" width="91" height="17" font="0">open surgical or </text>
<text top="173" left="209" width="103" height="17" font="0">best endovascular </text>
<text top="190" left="209" width="96" height="17" font="0">revascularization </text>
<text top="208" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="225" left="209" width="82" height="17" font="2"><b>Study type: </b>A </text>
<text top="242" left="209" width="70" height="17" font="0">prospective, </text>
<text top="259" left="209" width="99" height="17" font="0">multicenter, RCT. </text>
<text top="276" left="209" width="90" height="17" font="0">CLI trial has a 2-</text>
<text top="294" left="209" width="105" height="17" font="0">cohort design. The </text>
<text top="311" left="209" width="99" height="17" font="0">first cohort (1,620 </text>
<text top="328" left="209" width="80" height="17" font="0">pts) evaluates </text>
<text top="345" left="209" width="89" height="17" font="0">outcomes in pts </text>
<text top="363" left="209" width="111" height="17" font="0">who have adequate </text>
<text top="380" left="209" width="86" height="17" font="0">single segment </text>
<text top="397" left="209" width="95" height="17" font="0">great saphenous </text>
<text top="414" left="209" width="97" height="17" font="0">vein. The second </text>
<text top="431" left="209" width="110" height="17" font="0">cohort (480 pts) will </text>
<text top="449" left="209" width="96" height="17" font="0">study pts who do </text>
<text top="466" left="209" width="105" height="17" font="0">not have adequate </text>
<text top="483" left="209" width="86" height="17" font="0">single segment </text>
<text top="500" left="209" width="95" height="17" font="0">great saphenous </text>
<text top="517" left="209" width="33" height="17" font="0">vein. <b> </b></text>
<text top="535" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="552" left="209" width="100" height="17" font="2"><b>Size: </b>n=2,100 pts<b> </b></text>
<text top="87" left="648" width="7" height="18" font="7"></text>
<text top="88" left="655" width="193" height="17" font="2"><b> </b>Freedom from perioperative death </text>
<text top="106" left="648" width="7" height="18" font="7"></text>
<text top="107" left="655" width="101" height="17" font="2"><b> </b>Freedom from MI </text>
<text top="124" left="648" width="7" height="18" font="7"></text>
<text top="125" left="655" width="201" height="17" font="2"><b> </b>Freedom from stroke, freedom from </text>
<text top="142" left="648" width="230" height="17" font="0">reinterventions (major and minor) in index </text>
<text top="159" left="648" width="228" height="17" font="0">leg, number of reinterventions (major and </text>
<text top="177" left="648" width="138" height="17" font="0">minor) per limb salvaged </text>
<text top="194" left="648" width="154" height="17" font="0">freedom from clinical failure </text>
<text top="211" left="648" width="7" height="18" font="7"></text>
<text top="212" left="655" width="107" height="17" font="2"><b> </b>Freedom from CLI </text>
<text top="230" left="648" width="7" height="18" font="7"></text>
<text top="231" left="655" width="186" height="17" font="2"><b> </b>Freedom from all-cause mortality </text>
<text top="248" left="648" width="7" height="18" font="7"></text>
<text top="249" left="655" width="204" height="17" font="2"><b> </b>Freedom from hemodynamic failure.<b> </b></text>
<text top="570" left="95" width="83" height="17" font="0">Veves A, et al. </text>
<text top="587" left="95" width="63" height="17" font="0">2002 (361) </text>
<text top="604" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12093340">12093340</a></text>
<text top="604" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12093340"> </a></text>
<text top="621" left="95" width="3" height="17" font="0"> </text>
<text top="570" left="209" width="110" height="17" font="2"><b>Aim: </b>To compare a </text>
<text top="587" left="209" width="73" height="17" font="0">collagen and </text>
<text top="604" left="209" width="100" height="17" font="0">oxidized cellulose </text>
<text top="621" left="209" width="64" height="17" font="0">dressing to </text>
<text top="639" left="209" width="97" height="17" font="0">moistened gauze </text>
<text top="656" left="209" width="84" height="17" font="0">with regards to </text>
<text top="673" left="209" width="90" height="17" font="0">wound healing.<b>  </b></text>
<text top="690" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="708" left="209" width="102" height="17" font="2"><b>Study Type: </b>RCT </text>
<text top="725" left="209" width="3" height="17" font="2"><b> </b></text>
<text top="742" left="209" width="90" height="17" font="2"><b>Size:</b> n=276 pts<b> </b></text>
<text top="570" left="338" width="114" height="17" font="2"><b>Inclusion criteria: </b>≥</text>
<text top="570" left="452" width="20" height="17" font="28">8 y </text>
<text top="587" left="338" width="119" height="17" font="28">of age with a diabetic </text>
<text top="604" left="338" width="90" height="17" font="28">foot ulcer ≥30 d </text>
<text top="621" left="338" width="133" height="17" font="28">duration, Wagner grade </text>
<text top="639" left="338" width="129" height="17" font="28">1–2, and an area of ≥1 </text>
<text top="656" left="338" width="16" height="17" font="28">cm</text>
<text top="657" left="354" width="4" height="11" font="29">2</text>
<text top="656" left="358" width="103" height="17" font="28"> (greatest length × </text>
<text top="673" left="338" width="133" height="17" font="28">greatest width). Pts had </text>
<text top="690" left="338" width="114" height="17" font="28">adequate circulation </text>
<text top="708" left="338" width="112" height="17" font="28">with an oscillometer </text>
<text top="725" left="338" width="129" height="17" font="28">reading of the limb that </text>
<text top="742" left="338" width="133" height="17" font="28">had the target wound of </text>
<text top="759" left="338" width="129" height="17" font="28">≥1 U and a wound that </text>
<text top="776" left="338" width="90" height="17" font="28">was debrided of </text>
<text top="570" left="486" width="78" height="17" font="2"><b>Intervention: </b></text>
<text top="570" left="564" width="68" height="17" font="28">Promogran, </text>
<text top="587" left="486" width="100" height="17" font="28">a wound dressing </text>
<text top="604" left="486" width="145" height="17" font="28">consisting of collagen and </text>
<text top="621" left="486" width="118" height="17" font="28">oxidized regenerated </text>
<text top="639" left="486" width="115" height="17" font="28">cellulose for diabetic </text>
<text top="656" left="486" width="77" height="17" font="28">plantar ulcers.</text>
<text top="656" left="563" width="3" height="17" font="2"><b> </b></text>
<text top="673" left="486" width="7" height="17" font="2"><b>  </b></text>
<text top="690" left="486" width="137" height="17" font="2"><b>Comparator: </b>Moistened </text>
<text top="708" left="486" width="125" height="17" font="0">Gauze with secondary </text>
<text top="725" left="486" width="57" height="17" font="0">dressing.<b>  </b></text>
<text top="571" left="648" width="7" height="17" font="2"><b>1</b></text>
<text top="570" left="655" width="6" height="18" font="7"></text>
<text top="571" left="661" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="588" left="648" width="7" height="18" font="7"></text>
<text top="589" left="655" width="3" height="17" font="2"><b> </b></text>
<text top="589" left="658" width="196" height="17" font="28">Complete healing of the study ulcer </text>
<text top="607" left="648" width="44" height="17" font="28">(wound)</text>
<text top="607" left="693" width="3" height="17" font="2"><b> </b></text>
<text top="624" left="648" width="7" height="18" font="7"></text>
<text top="625" left="655" width="3" height="17" font="2"><b> </b></text>
<text top="625" left="659" width="201" height="17" font="28">After 12 wk of treatment, 51 (37.0%) </text>
<text top="642" left="648" width="243" height="17" font="28">Promogran treated pts had complete wound </text>
<text top="659" left="648" width="230" height="17" font="28">closure compared with 39 (28.3%) control </text>
<text top="677" left="648" width="232" height="17" font="28">pts, but this difference was not statistically </text>
<text top="694" left="648" width="115" height="17" font="28">significant (p=0.12).  </text>
<text top="711" left="648" width="7" height="18" font="7"></text>
<text top="712" left="655" width="3" height="17" font="2"><b> </b></text>
<text top="712" left="658" width="205" height="17" font="28">The difference in healing between Tx </text>
<text top="729" left="648" width="232" height="17" font="28">groups achieved borderline significance in </text>
<text top="747" left="648" width="231" height="17" font="28">the subgroup of pts with wounds of &lt;6 mo </text>
<text top="764" left="648" width="236" height="17" font="28">duration. In pts with ulcers &lt;6 mo duration, </text>
<text top="570" left="905" width="141" height="17" font="0">Limitations: Study did not </text>
<text top="587" left="905" width="188" height="17" font="0">standardize frequency of dressing </text>
<text top="604" left="905" width="57" height="17" font="0">changes.  </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">162 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="338" width="103" height="17" font="28">necrotic/nonviable </text>
<text top="104" left="338" width="110" height="17" font="28">tissue at enrollment.</text>
<text top="104" left="448" width="3" height="17" font="2"><b> </b></text>
<text top="122" left="338" width="3" height="17" font="2"><b> </b></text>
<text top="139" left="338" width="113" height="17" font="2"><b>Exclusion criteria:  </b></text>
<text top="156" left="338" width="7" height="18" font="7"></text>
<text top="157" left="345" width="3" height="17" font="2"><b> </b></text>
<text top="157" left="348" width="89" height="17" font="28">Clinical signs of </text>
<text top="174" left="338" width="49" height="17" font="28">infection </text>
<text top="192" left="338" width="7" height="18" font="7"></text>
<text top="193" left="345" width="3" height="17" font="2"><b> </b></text>
<text top="193" left="348" width="110" height="17" font="28">A target wound that </text>
<text top="210" left="338" width="105" height="17" font="28">had exposed bone </text>
<text top="227" left="338" width="7" height="18" font="7"></text>
<text top="228" left="345" width="3" height="17" font="2"><b> </b></text>
<text top="228" left="348" width="125" height="17" font="28">A concurrent illness or </text>
<text top="246" left="338" width="113" height="17" font="28">a condition that may </text>
<text top="263" left="338" width="111" height="17" font="28">have interfered with </text>
<text top="280" left="338" width="125" height="17" font="28">wound healing, known </text>
<text top="297" left="338" width="124" height="17" font="28">hypersensitivity to any </text>
<text top="314" left="338" width="84" height="17" font="28">of the dressing </text>
<text top="332" left="338" width="70" height="17" font="28">components </text>
<text top="349" left="338" width="7" height="18" font="7"></text>
<text top="350" left="345" width="3" height="17" font="2"><b> </b></text>
<text top="350" left="348" width="93" height="17" font="28">Unwillingness or </text>
<text top="367" left="338" width="75" height="17" font="28">inability of an </text>
<text top="384" left="338" width="109" height="17" font="28">ambulatory pt to be </text>
<text top="402" left="338" width="121" height="17" font="28">fitted with appropriate </text>
<text top="419" left="338" width="107" height="17" font="28">shoe gear or an off-</text>
<text top="436" left="338" width="82" height="17" font="28">loading device </text>
<text top="453" left="338" width="7" height="18" font="7"></text>
<text top="454" left="345" width="3" height="17" font="2"><b> </b></text>
<text top="454" left="348" width="91" height="17" font="28">Multiple diabetic </text>
<text top="472" left="338" width="107" height="17" font="28">ulcers on the same </text>
<text top="489" left="338" width="27" height="17" font="28">foot. </text>
<text top="489" left="365" width="3" height="17" font="2"><b> </b></text>
<text top="87" left="648" width="211" height="17" font="28">43 (45%) of 95 Promogran-treated pts </text>
<text top="104" left="648" width="208" height="17" font="28">healed compared with 29 (33%) of 89 </text>
<text top="122" left="648" width="201" height="17" font="28">controls (p=0.056). In the group with </text>
<text top="139" left="648" width="239" height="17" font="28">wounds &lt;6 mo duration, similar numbers of </text>
<text top="156" left="648" width="189" height="17" font="28">pts healed in the Promogran (8/43 </text>
<text top="173" left="648" width="241" height="17" font="28">[19%]; p=0.83) groups. No differences were </text>
<text top="190" left="648" width="235" height="17" font="28">seen in the safety measurements between </text>
<text top="208" left="648" width="48" height="17" font="28">groups.  </text>
<text top="507" left="86" width="1013" height="17" font="0">ABI indicates ankle-brachial index; CI, confidence interval; CLI, critical limb ischemia; DM, diabetes mellitus; E2F, egifoligide; FP, femoral popliteal; HgbA1c, hemoglobin A1c; HR, hazard </text>
<text top="524" left="86" width="989" height="17" font="0">ratio; IC, intermittent claudication; IQR, interquartile range; LE, lower extremity; MALE, major adverse limb event; MALE-POD, major adverse limb event perioperative death; N/A, not </text>
<text top="541" left="86" width="991" height="17" font="0">applicable; PTA, percutaneous angioplasty; pt, patient; QoL, quality of life; RCT, randomized controlled trial; SFA, superficial femoral artery; TBI, toe-brachial index; and tx, treatment. </text>
<text top="562" left="86" width="4" height="16" font="3"> </text>
<text top="599" left="86" width="759" height="17" font="2"><b>Evidence Table 42. Nonrandomized Trials, Observational Studies, and/or Registries for Surgical Revascularization for Chronic CLI</b></text>
<text top="597" left="846" width="8" height="21" font="1"><b>–</b></text>
<text top="599" left="854" width="72" height="17" font="2"><b>Section 8.2. </b></text>
<text top="618" left="95" width="94" height="17" font="2"><b>Study Acronym </b></text>
<text top="635" left="101" width="86" height="17" font="2"><b>(if applicable)  </b></text>
<text top="652" left="120" width="44" height="17" font="2"><b>Author </b></text>
<text top="670" left="127" width="33" height="17" font="2"><b>Year  </b></text>
<text top="618" left="211" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="635" left="238" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="618" left="370" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="618" left="579" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="635" left="587" width="168" height="17" font="2"><b>(include P value; OR or RR;  </b></text>
<text top="652" left="632" width="73" height="17" font="2"><b>and 95% CI) </b></text>
<text top="618" left="908" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="635" left="935" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="688" left="95" width="83" height="17" font="0">Biancari F and </text>
<text top="705" left="95" width="61" height="17" font="0">Juvonen T </text>
<text top="722" left="95" width="56" height="17" font="0">2014 (60) </text>
<text top="739" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24491282">24491282 </a></text>
<text top="756" left="95" width="3" height="17" font="0"> </text>
<text top="688" left="203" width="118" height="17" font="2"><b>Aim:</b> Compare direct </text>
<text top="705" left="203" width="62" height="17" font="0">vs. indirect </text>
<text top="722" left="203" width="114" height="17" font="0">revascularization for </text>
<text top="739" left="203" width="133" height="17" font="0">wound healing and limb </text>
<text top="756" left="203" width="53" height="17" font="0">salvage.  </text>
<text top="774" left="203" width="3" height="17" font="0"> </text>
<text top="688" left="351" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="705" left="351" width="92" height="17" font="0">Prospective and </text>
<text top="722" left="351" width="74" height="17" font="0">retrospective </text>
<text top="739" left="351" width="144" height="17" font="0">observational studies with </text>
<text top="756" left="351" width="143" height="17" font="0">surgical, endovascular, or </text>
<text top="774" left="351" width="140" height="17" font="0">hybrid revascularization.  </text>
<text top="688" left="513" width="222" height="17" font="2"><b>Intervention:</b> Indirect Revascularization </text>
<text top="705" left="513" width="3" height="17" font="0"> </text>
<text top="722" left="513" width="213" height="17" font="2"><b>Comparator:</b> Direct Revascularization </text>
<text top="739" left="513" width="3" height="17" font="0"> </text>
<text top="758" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="757" left="520" width="6" height="18" font="7"></text>
<text top="758" left="526" width="243" height="17" font="2"><b> endpoint:</b> The risk of unhealed wound was </text>
<text top="775" left="513" width="286" height="17" font="0">significantly lower after direct revascularization (HR: </text>
<text top="688" left="837" width="7" height="18" font="7"></text>
<text top="689" left="844" width="233" height="17" font="0"> Pooled limb salvage rates after direct and </text>
<text top="706" left="837" width="260" height="17" font="0">indirect revascularization were at 1 y 86.2% vs. </text>
<text top="723" left="837" width="270" height="17" font="0">77.8% and at 2 y 84.9% vs. 70.1%, respectively.  </text>
<text top="741" left="837" width="7" height="18" font="7"></text>
<text top="742" left="844" width="257" height="17" font="0"> The analysis of 3 studies reporting only on pts </text>
<text top="759" left="837" width="213" height="17" font="0">with DM confirmed the benefit of direct </text>
<text top="776" left="837" width="257" height="17" font="0">revascularization in terms of limb salvage (HR: </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">163 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="116" height="17" font="2"><b>Study type:</b> 9 Study </text>
<text top="104" left="203" width="81" height="17" font="0">Meta-Analysis </text>
<text top="122" left="203" width="3" height="17" font="0"> </text>
<text top="139" left="203" width="114" height="17" font="2"><b>Size:</b> n=1,290 Legs  </text>
<text top="87" left="351" width="3" height="17" font="2"><b> </b></text>
<text top="104" left="351" width="140" height="17" font="2"><b>Exclusion criteria:</b> Data </text>
<text top="122" left="351" width="133" height="17" font="0">in abstracts alone, trials </text>
<text top="139" left="351" width="137" height="17" font="0">not reporting 6 mo data.  </text>
<text top="87" left="513" width="137" height="17" font="0">0.64; 95% CI: 0.52–0.8; r</text>
<text top="88" left="650" width="4" height="11" font="11">2</text>
<text top="87" left="654" width="137" height="17" font="0">: 0%; 4 studies included) </text>
<text top="104" left="513" width="229" height="17" font="0">compared with indirect revascularization.  </text>
<text top="122" left="513" width="3" height="17" font="0"> </text>
<text top="139" left="513" width="270" height="17" font="0">Direct revascularization was also associated with </text>
<text top="156" left="513" width="294" height="17" font="0">significantly lower risk of major amputation (HR: 0.44; </text>
<text top="173" left="513" width="113" height="17" font="0">95% CI: 0.26–0.75; r</text>
<text top="174" left="626" width="4" height="11" font="11">2</text>
<text top="173" left="630" width="148" height="17" font="0">: 62%; 8 studies included). </text>
<text top="87" left="837" width="144" height="17" font="0">0.48; 95% CI: 0.31–0.75; r</text>
<text top="88" left="981" width="4" height="11" font="11">2</text>
<text top="87" left="985" width="84" height="17" font="0">: 0%; 4 studies </text>
<text top="104" left="837" width="57" height="17" font="0">included)  </text>
<text top="191" left="95" width="90" height="17" font="0">Fogle MA, et al. </text>
<text top="208" left="95" width="63" height="17" font="0">1987 (362) </text>
<text top="226" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3795391">3795391 </a></text>
<text top="243" left="95" width="3" height="17" font="0"> </text>
<text top="191" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="208" left="203" width="79" height="17" font="0">Retrospective </text>
<text top="226" left="203" width="109" height="17" font="0">observational study </text>
<text top="243" left="203" width="3" height="17" font="0"> </text>
<text top="260" left="203" width="132" height="17" font="2"><b>Size:</b> n=675 grafts, 582 </text>
<text top="277" left="203" width="20" height="17" font="0">pts </text>
<text top="191" left="351" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="208" left="351" width="122" height="17" font="0">Disabling claudication </text>
<text top="226" left="351" width="113" height="17" font="0">and/or limb salvage, </text>
<text top="243" left="351" width="135" height="17" font="0">defined by the presence </text>
<text top="260" left="351" width="116" height="17" font="0">ischemic rest pain or </text>
<text top="277" left="351" width="148" height="17" font="0">tissue necrosis or schemic </text>
<text top="294" left="351" width="101" height="17" font="0">rest pain or tissue </text>
<text top="312" left="351" width="53" height="17" font="0">necrosis. </text>
<text top="329" left="351" width="3" height="17" font="0"> </text>
<text top="346" left="351" width="131" height="17" font="2"><b>Exclusion criteria:</b> Pts </text>
<text top="363" left="351" width="132" height="17" font="0">undergoing intervention </text>
<text top="381" left="351" width="138" height="17" font="0">for indications other than </text>
<text top="398" left="351" width="136" height="17" font="0">atherosclerotic disease.  </text>
<text top="191" left="513" width="175" height="17" font="2"><b>Intervention:</b> In Situ Vein Graft </text>
<text top="208" left="513" width="3" height="17" font="0"> </text>
<text top="226" left="513" width="191" height="17" font="2"><b>Comparator: </b>Reversed vein graft  </text>
<text top="243" left="513" width="3" height="17" font="0"> </text>
<text top="261" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="260" left="520" width="6" height="18" font="7"></text>
<text top="261" left="526" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="278" left="513" width="145" height="17" font="0">In situ cumulative patency </text>
<text top="296" left="513" width="48" height="17" font="0">1 y 85% </text>
<text top="313" left="513" width="48" height="17" font="0">3 y 85% </text>
<text top="330" left="513" width="3" height="17" font="0"> </text>
<text top="347" left="513" width="191" height="17" font="0">Reversed vein cumulative patency </text>
<text top="365" left="513" width="48" height="17" font="0">1 y 81% </text>
<text top="382" left="513" width="48" height="17" font="0">3 y 73% </text>
<text top="191" left="837" width="7" height="18" font="7"></text>
<text top="192" left="844" width="194" height="17" font="0"> Reversed vein patency at 5 y 63% </text>
<text top="210" left="837" width="7" height="18" font="7"></text>
<text top="211" left="844" width="263" height="17" font="0"> Infrapopliteal reversed vein cumulative patency </text>
<text top="228" left="837" width="48" height="17" font="0">3 y 62% </text>
<text top="245" left="837" width="7" height="18" font="7"></text>
<text top="246" left="844" width="222" height="17" font="0"> Infrapopliteal in situ cumulative patency </text>
<text top="264" left="837" width="48" height="17" font="0">3 y 87% </text>
<text top="281" left="837" width="7" height="18" font="7"></text>
<text top="282" left="844" width="243" height="17" font="0"> Limitation: Study only examined cumulative </text>
<text top="299" left="837" width="185" height="17" font="0">patency not primary patency, etc. </text>
<text top="416" left="95" width="87" height="17" font="0">Rashid H, et al. </text>
<text top="433" left="95" width="63" height="17" font="0">2013 (363) </text>
<text top="450" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23523278">23523278 </a></text>
<text top="467" left="95" width="3" height="17" font="0"> </text>
<text top="416" left="203" width="103" height="17" font="2"><b>Aim:</b> The effect of </text>
<text top="433" left="203" width="117" height="17" font="0">pedal arch quality on </text>
<text top="450" left="203" width="110" height="17" font="0">the amputation-free </text>
<text top="467" left="203" width="115" height="17" font="0">survival and patency </text>
<text top="485" left="203" width="119" height="17" font="0">rates of distal bypass </text>
<text top="502" left="203" width="107" height="17" font="0">grafts and its direct </text>
<text top="519" left="203" width="116" height="17" font="0">impact on the rate of </text>
<text top="536" left="203" width="107" height="17" font="0">healing and time to </text>
<text top="553" left="203" width="118" height="17" font="0">healing of tissue loss </text>
<text top="571" left="203" width="125" height="17" font="0">after direct angiosome </text>
<text top="588" left="203" width="129" height="17" font="0">revascularization in pts </text>
<text top="605" left="203" width="51" height="17" font="0">with CLI. </text>
<text top="622" left="203" width="3" height="17" font="0"> </text>
<text top="639" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="657" left="203" width="85" height="17" font="0">Restrospective </text>
<text top="674" left="203" width="3" height="17" font="0"> </text>
<text top="691" left="203" width="90" height="17" font="2"><b>Size:</b> n=154 pts </text>
<text top="416" left="351" width="129" height="17" font="2"><b>Inclusion criteria:</b> CLI </text>
<text top="433" left="351" width="103" height="17" font="0">Rutherford Class 4</text>
<text top="433" left="454" width="7" height="17" font="19">–</text>
<text top="433" left="460" width="10" height="17" font="0">6 </text>
<text top="450" left="351" width="3" height="17" font="0"> </text>
<text top="467" left="351" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="416" left="513" width="81" height="17" font="2"><b>Intervention:</b>  </text>
<text top="433" left="513" width="248" height="17" font="0">Pts with a CPA, IPA, and NPA, all underwent </text>
<text top="450" left="513" width="122" height="17" font="0">infrapopliteal bypass.  </text>
<text top="467" left="513" width="3" height="17" font="0"> </text>
<text top="486" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="485" left="520" width="6" height="18" font="7"></text>
<text top="486" left="526" width="63" height="17" font="2"><b> endpoint:</b> </text>
<text top="503" left="513" width="7" height="18" font="7"></text>
<text top="504" left="520" width="299" height="17" font="2"><b> </b>The primary patency rates at 1 y in the CPA, IPA, and </text>
<text top="521" left="513" width="249" height="17" font="0">NPA groups were 58.4%, 54.6%, and 63.8%, </text>
<text top="539" left="513" width="135" height="17" font="0">respectively (p=0.5168)  </text>
<text top="556" left="513" width="7" height="18" font="7"></text>
<text top="557" left="520" width="280" height="17" font="2"><b> </b>Secondary patency rates were 86.0%, 84.7%, and </text>
<text top="574" left="513" width="173" height="17" font="0">88.8%, respectively (p=0.8940) </text>
<text top="591" left="513" width="7" height="18" font="7"></text>
<text top="592" left="520" width="299" height="17" font="2"><b> </b>Amputation-free survival at 48 mo was 67.2%, 69.7%, </text>
<text top="610" left="513" width="197" height="17" font="0">and 45.9%, respectively (p=0.3883) </text>
<text top="416" left="837" width="7" height="18" font="7"></text>
<text top="417" left="844" width="233" height="17" font="0"> Tissue loss was present in 141 of the 167 </text>
<text top="434" left="837" width="262" height="17" font="0">bypasses. In the CPA group, 83% of tissue loss </text>
<text top="451" left="837" width="265" height="17" font="0">with DAR healed compared with 92% in the non-</text>
<text top="468" left="837" width="235" height="17" font="0">DAR (median time to healing, 66 vs. 74 d). </text>
<text top="486" left="837" width="7" height="18" font="7"></text>
<text top="487" left="844" width="234" height="17" font="0"> Similarly, in the IPA group, 90% with DAR </text>
<text top="504" left="837" width="239" height="17" font="0">healed compared with 81% in the non-DAR </text>
<text top="521" left="837" width="269" height="17" font="0">(median time to healing, 96 vs. 86 d). In the NPA </text>
<text top="539" left="837" width="246" height="17" font="0">group, only 75% with DAR healed compared </text>
<text top="556" left="837" width="229" height="17" font="0">with 73% in the non-DAR (median time to </text>
<text top="573" left="837" width="254" height="17" font="0">healing, 90 vs. 135 d). There was a significant </text>
<text top="590" left="837" width="221" height="17" font="0">difference in healing and time to healing </text>
<text top="607" left="837" width="216" height="17" font="0">between the CPA/IPA and NPA groups </text>
<text top="625" left="837" width="67" height="17" font="0">(p=0.0264). </text>
<text top="642" left="837" width="7" height="18" font="7"></text>
<text top="643" left="844" width="223" height="17" font="0"> Limitation: Study did not stratify pts with </text>
<text top="660" left="837" width="210" height="17" font="0">underlying renal disease. Wound care </text>
<text top="677" left="837" width="253" height="17" font="0">techniques were not completely standardized. </text>
<text top="709" left="95" width="96" height="17" font="0">Nolan BW, et al.  </text>
<text top="726" left="95" width="63" height="17" font="0">2011 (364) </text>
<text top="744" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21802888">21802888 </a></text>
<text top="761" left="95" width="3" height="17" font="0"> </text>
<text top="709" left="203" width="117" height="17" font="2"><b>Aim:</b> LE bypass with </text>
<text top="726" left="203" width="94" height="17" font="0">and without prior </text>
<text top="744" left="203" width="76" height="17" font="0">endovascular </text>
<text top="761" left="203" width="67" height="17" font="0">intervention </text>
<text top="709" left="351" width="129" height="17" font="2"><b>Inclusion criteria:</b> CLI </text>
<text top="726" left="351" width="134" height="17" font="0">(rest pain or tissue loss) </text>
<text top="744" left="351" width="3" height="17" font="0"> </text>
<text top="761" left="351" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="709" left="513" width="242" height="17" font="2"><b>Intervention:</b> LE bypass post endovascular </text>
<text top="726" left="513" width="74" height="17" font="0">intervention.  </text>
<text top="744" left="513" width="3" height="17" font="0"> </text>
<text top="761" left="513" width="184" height="17" font="2"><b>Comparator:</b> Primary LE bypass </text>
<text top="709" left="837" width="24" height="17" font="0">N/A </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">164 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="3" height="17" font="0"> </text>
<text top="104" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="122" left="203" width="116" height="17" font="0">Retrospective cohort </text>
<text top="139" left="203" width="123" height="17" font="0">analysis (10 Centers)  </text>
<text top="156" left="203" width="3" height="17" font="0"> </text>
<text top="173" left="203" width="99" height="17" font="2"><b>Size:</b> n=1,880 LE </text>
<text top="190" left="203" width="55" height="17" font="0">bypasses </text>
<text top="87" left="513" width="3" height="17" font="0"> </text>
<text top="105" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="104" left="520" width="6" height="18" font="7"></text>
<text top="105" left="526" width="292" height="17" font="2"><b> endpoint:</b> Major amputation and graft occlusion at 1 </text>
<text top="123" left="513" width="281" height="17" font="0">y postoperatively. Secondary outcomes included in-</text>
<text top="140" left="513" width="296" height="17" font="0">hospital MAE, 1 y mortality, and composite 1 y MALE. </text>
<text top="157" left="513" width="3" height="17" font="0"> </text>
<text top="174" left="513" width="278" height="17" font="0">Prior PVI or bypass did not alter 30 d MAE and 1 y </text>
<text top="192" left="513" width="181" height="17" font="0">mortality after the index bypass.  </text>
<text top="209" left="567" width="3" height="17" font="0"> </text>
<text top="226" left="513" width="306" height="17" font="0">1 y major amputation and 1 y graft occlusion rates were </text>
<text top="243" left="513" width="302" height="17" font="0">significantly higher in pts who had prior iPVI than those </text>
<text top="260" left="513" width="276" height="17" font="0">without (31% vs. 20%; p=0.046 and 28% vs. 18%; </text>
<text top="278" left="513" width="272" height="17" font="0">p=0.009), similar to pts who had a prior ipsilateral </text>
<text top="295" left="513" width="309" height="17" font="0">bypass (1 y major amputation, 29% vs. 20%; p=0.022; 1 </text>
<text top="312" left="513" width="230" height="17" font="0">y graft occlusion, 33% vs. 18%; p=0.001). </text>
<text top="330" left="95" width="90" height="17" font="0">Santo VJ, et al.  </text>
<text top="347" left="95" width="63" height="17" font="0">2014 (365) </text>
<text top="365" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24613692">24613692 </a></text>
<text top="382" left="95" width="3" height="17" font="0"> </text>
<text top="330" left="203" width="117" height="17" font="2"><b>Aim:</b> LE bypass with </text>
<text top="347" left="203" width="94" height="17" font="0">and without prior </text>
<text top="365" left="203" width="76" height="17" font="0">endovascular </text>
<text top="382" left="203" width="67" height="17" font="0">intervention </text>
<text top="399" left="203" width="3" height="17" font="0"> </text>
<text top="416" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="433" left="203" width="79" height="17" font="0">Retrospective </text>
<text top="451" left="203" width="3" height="17" font="0"> </text>
<text top="468" left="203" width="67" height="17" font="2"><b>Size:</b> n=314</text>
<text top="469" left="269" width="4" height="16" font="3"> </text>
<text top="468" left="273" width="64" height="17" font="0">autologous </text>
<text top="485" left="203" width="100" height="17" font="0">vein LE bypasses </text>
<text top="330" left="351" width="129" height="17" font="2"><b>Inclusion criteria:</b> CLI </text>
<text top="347" left="351" width="140" height="17" font="0">LEBs were performed for </text>
<text top="365" left="351" width="136" height="17" font="0">CLI, 71% for tissue loss. </text>
<text top="382" left="351" width="139" height="17" font="0">TASC II type D or type C </text>
<text top="399" left="351" width="129" height="17" font="0">lesions were present in </text>
<text top="416" left="351" width="83" height="17" font="0">62% and 25%, </text>
<text top="433" left="351" width="75" height="17" font="0">respectively.  </text>
<text top="451" left="351" width="3" height="17" font="0"> </text>
<text top="468" left="351" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="330" left="513" width="242" height="17" font="2"><b>Intervention:</b> LE bypass post endovascular </text>
<text top="347" left="513" width="97" height="17" font="0">intervention. PEI  </text>
<text top="365" left="513" width="3" height="17" font="0"> </text>
<text top="382" left="513" width="216" height="17" font="2"><b>Comparator:</b> Primary LE bypass NPEI </text>
<text top="399" left="513" width="3" height="17" font="0"> </text>
<text top="417" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="416" left="520" width="6" height="18" font="7"></text>
<text top="417" left="526" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="434" left="513" width="7" height="18" font="7"></text>
<text top="436" left="520" width="207" height="17" font="0"> The 30-day mortality rate was 3.5%.  </text>
<text top="453" left="513" width="7" height="18" font="7"></text>
<text top="454" left="520" width="280" height="17" font="0"> Overall, Primary patency rates at 1 y and 5 y were </text>
<text top="471" left="513" width="87" height="17" font="0">61% and 45%.  </text>
<text top="489" left="513" width="7" height="18" font="7"></text>
<text top="490" left="520" width="265" height="17" font="0"> The 5 y limb salvage rate was 89%, and the 5 y </text>
<text top="507" left="513" width="191" height="17" font="0">amputation-free survival was 49%. </text>
<text top="524" left="513" width="7" height="18" font="7"></text>
<text top="525" left="520" width="286" height="17" font="0"> The 1 y primary patency rate was 62% for NPEI pts </text>
<text top="542" left="513" width="171" height="17" font="0">vs. 59% for PEI pts (p=0.759).  </text>
<text top="560" left="513" width="311" height="17" font="0">The 3 y limb salvage rate was 89% for NPEI pts vs. 92% </text>
<text top="577" left="513" width="124" height="17" font="0">for PEI pts (p=0.445).  </text>
<text top="594" left="513" width="7" height="18" font="7"></text>
<text top="595" left="520" width="286" height="17" font="0"> The 3 y amputation-free survival was 59% for NPEI </text>
<text top="612" left="513" width="311" height="17" font="0">pts vs. 52% for PEI pts (p=0.399). Median follow-up time </text>
<text top="630" left="513" width="305" height="17" font="0">was 323 d for NPEI pts (IQR: 83–918) vs. 463 d for PEI </text>
<text top="647" left="513" width="167" height="17" font="0">pts (IQR: 145–946; p=0.275).  </text>
<text top="330" left="837" width="24" height="17" font="0">N/A </text>
<text top="665" left="95" width="68" height="17" font="0">Uhl C, et al. </text>
<text top="682" left="95" width="63" height="17" font="0">2014 (366) </text>
<text top="699" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24418639">24418639 </a></text>
<text top="716" left="95" width="3" height="17" font="0"> </text>
<text top="665" left="203" width="108" height="17" font="2"><b>Aim:</b> Pedal bypass </text>
<text top="682" left="203" width="94" height="17" font="0">surgery with and </text>
<text top="699" left="203" width="70" height="17" font="0">without prior </text>
<text top="716" left="203" width="76" height="17" font="0">endovascular </text>
<text top="734" left="203" width="71" height="17" font="0">intervention  </text>
<text top="751" left="203" width="3" height="17" font="0"> </text>
<text top="768" left="203" width="71" height="17" font="2"><b>Study type:</b> </text>
<text top="665" left="351" width="129" height="17" font="2"><b>Inclusion criteria:</b> CLI </text>
<text top="682" left="351" width="133" height="17" font="0">with rest pain, ulcers, or </text>
<text top="699" left="351" width="128" height="17" font="0">gangrene (Rutherford 4</text>
<text top="699" left="479" width="7" height="17" font="19">–</text>
<text top="716" left="351" width="120" height="17" font="0">6), who then required </text>
<text top="734" left="351" width="127" height="17" font="0">pedal bypass either as </text>
<text top="751" left="351" width="131" height="17" font="0">primary therapy or after </text>
<text top="768" left="351" width="105" height="17" font="0">prior endovascular </text>
<text top="665" left="513" width="277" height="17" font="2"><b>Intervention:</b> Pedal Bypass post intervention. PEI </text>
<text top="682" left="513" width="3" height="17" font="0"> </text>
<text top="699" left="513" width="230" height="17" font="2"><b>Comparator:</b> Primary pedal bypass. BSF </text>
<text top="716" left="513" width="3" height="17" font="0"> </text>
<text top="735" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="734" left="520" width="6" height="18" font="7"></text>
<text top="735" left="526" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="752" left="513" width="7" height="18" font="7"></text>
<text top="753" left="520" width="265" height="17" font="0"> Overall, primary patency at 1 y was 58.3%, and </text>
<text top="770" left="513" width="177" height="17" font="0">secondary patency was 61.3%.  </text>
<text top="665" left="837" width="24" height="17" font="0">N/A </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">165 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="79" height="17" font="0">Retrospective </text>
<text top="104" left="203" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="97" height="17" font="2"><b>Size:</b> n=75 pedal </text>
<text top="139" left="203" width="133" height="17" font="0">bypass operations in 71 </text>
<text top="156" left="203" width="20" height="17" font="0">pts </text>
<text top="87" left="351" width="74" height="17" font="0">intervention.  </text>
<text top="104" left="351" width="3" height="17" font="0"> </text>
<text top="122" left="351" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="513" width="7" height="18" font="7"></text>
<text top="88" left="520" width="276" height="17" font="0"> Limb salvage was 76.8% and survival was 80.4% </text>
<text top="106" left="513" width="7" height="18" font="7"></text>
<text top="107" left="520" width="282" height="17" font="0"> Graft occlusion within 30 d was 18.7%. Revision in </text>
<text top="124" left="513" width="306" height="17" font="0">those cases was futile and 78.6% of pts had to undergo </text>
<text top="141" left="513" width="105" height="17" font="0">major amputation.  </text>
<text top="158" left="513" width="7" height="18" font="7"></text>
<text top="159" left="520" width="283" height="17" font="0"> Primary patency at 1 y was 67.0% in PEI group vs. </text>
<text top="177" left="513" width="301" height="17" font="0">48.3% in BSF group (p=0.409) and secondary patency </text>
<text top="194" left="513" width="184" height="17" font="0">was 73.5% vs. 48.6% (p=0.100).  </text>
<text top="211" left="513" width="7" height="18" font="7"></text>
<text top="212" left="520" width="276" height="17" font="0"> Prior endovascular intervention had no significant </text>
<text top="230" left="513" width="299" height="17" font="0">impact on either limb salvage (82.3% vs. 71.6% at 1 y; </text>
<text top="247" left="513" width="279" height="17" font="0">p=0.515) or graft occlusions within 30 d (19.4% vs. </text>
<text top="264" left="513" width="101" height="17" font="0">17.9%; p=0.547).  </text>
<text top="281" left="513" width="7" height="18" font="7"></text>
<text top="282" left="520" width="267" height="17" font="0"> Survival rate at 1 y was 79.5% in PEI group and </text>
<text top="300" left="513" width="173" height="17" font="0">81.3% in BSF group (p=0.765). </text>
<text top="318" left="95" width="88" height="17" font="0">Korhonen M, et </text>
<text top="335" left="95" width="16" height="17" font="0">al. </text>
<text top="352" left="95" width="63" height="17" font="0">2011 (367) </text>
<text top="369" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21195637">21195637 </a></text>
<text top="386" left="95" width="3" height="17" font="0"> </text>
<text top="318" left="203" width="114" height="17" font="2"><b>Aim: </b>Compare Fem-</text>
<text top="335" left="203" width="116" height="17" font="0">pop PTA vs. surgical </text>
<text top="352" left="203" width="83" height="17" font="0">bypass for CLI </text>
<text top="369" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="386" left="203" width="71" height="17" font="2"><b>Study type: </b></text>
<text top="404" left="203" width="115" height="17" font="0">Observational single </text>
<text top="421" left="203" width="38" height="17" font="0">center<b> </b></text>
<text top="438" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="455" left="203" width="90" height="17" font="2"><b>Size: </b>n=858 pts<b> </b></text>
<text top="318" left="351" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="335" left="351" width="141" height="17" font="0">Consecutive pts enrolled <b> </b></text>
<text top="352" left="351" width="3" height="17" font="2"><b> </b></text>
<text top="369" left="351" width="137" height="17" font="2"><b>Exclusion criteria: </b>N/A<b>  </b></text>
<text top="318" left="513" width="153" height="17" font="2"><b>Intervention: </b>PTA (N=517)<b> </b></text>
<text top="335" left="513" width="7" height="17" font="2"><b>  </b></text>
<text top="352" left="513" width="173" height="17" font="2"><b>Comparator: </b>Bypass (N=341)<b>  </b></text>
<text top="369" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="387" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="386" left="520" width="6" height="18" font="7"></text>
<text top="387" left="526" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="405" left="513" width="7" height="18" font="7"></text>
<text top="406" left="520" width="282" height="17" font="0"> Mortality, limb salvage, AFS, Freedom from repeat </text>
<text top="423" left="513" width="67" height="17" font="0">intervention<b> </b></text>
<text top="440" left="513" width="7" height="18" font="7"></text>
<text top="441" left="520" width="293" height="17" font="0"> Mortality: (30 d, 1 y, 3 y): Endo: 5.1%, 24.3%, 41.1% </text>
<text top="459" left="513" width="7" height="18" font="7"></text>
<text top="460" left="520" width="158" height="17" font="0"> Surgery: 2.4%, 17.8%, 35% </text>
<text top="477" left="513" width="7" height="18" font="7"></text>
<text top="478" left="520" width="276" height="17" font="0"> LIMB SALVAGE: (1 y, 3 y, 5 y): Endo: 87%, 77%, </text>
<text top="495" left="513" width="38" height="17" font="0">75.3% </text>
<text top="513" left="513" width="7" height="18" font="7"></text>
<text top="514" left="520" width="155" height="17" font="0"> Surgery: 95%, 77%, 75.3% </text>
<text top="531" left="513" width="7" height="18" font="7"></text>
<text top="532" left="520" width="300" height="17" font="0"> No significant difference in AFS after propensity score </text>
<text top="549" left="513" width="64" height="17" font="0">adjustment<b> </b></text>
<text top="318" left="837" width="24" height="17" font="0">N/A </text>
<text top="567" left="95" width="94" height="17" font="0">Kasemi H, et al.  </text>
<text top="585" left="95" width="63" height="17" font="0">2016 (368) </text>
<text top="602" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26370748">26370748</a></text>
<text top="602" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26370748"> </a></text>
<text top="619" left="95" width="3" height="17" font="0"> </text>
<text top="567" left="203" width="98" height="17" font="2"><b>Aim: </b>To evaluate </text>
<text top="585" left="203" width="132" height="17" font="0">endovascular treatment </text>
<text top="602" left="203" width="47" height="17" font="0">of AIOD<b> </b></text>
<text top="619" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="636" left="203" width="70" height="17" font="2"><b>Study Type </b></text>
<text top="653" left="203" width="82" height="17" font="0">Retrospective <b> </b></text>
<text top="671" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="688" left="203" width="90" height="17" font="2"><b>Size: </b>n=22 pts.<b>  </b></text>
<text top="567" left="351" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="585" left="351" width="129" height="17" font="0">Indication for treatment </text>
<text top="602" left="351" width="136" height="17" font="0">were long-segment (&gt;10 </text>
<text top="619" left="351" width="99" height="17" font="0">cm) TASC type D </text>
<text top="636" left="351" width="122" height="17" font="0">aortoiliac occlusion (2 </text>
<text top="653" left="351" width="135" height="17" font="0">suprarenal, 4 juxtarenal, </text>
<text top="671" left="351" width="103" height="17" font="0">and 16 infrarenal), </text>
<text top="688" left="351" width="142" height="17" font="0">extending to the common </text>
<text top="705" left="351" width="124" height="17" font="0">or iliac arteries (EIAs). </text>
<text top="722" left="351" width="116" height="17" font="0">Clinical indication for </text>
<text top="739" left="351" width="146" height="17" font="0">endovascular therapy was </text>
<text top="757" left="351" width="149" height="17" font="0">severe claudication or CLI. </text>
<text top="774" left="351" width="3" height="17" font="2"><b> </b></text>
<text top="567" left="513" width="308" height="17" font="0">A total of 22 pts underwent total endovascular treatment </text>
<text top="585" left="513" width="75" height="17" font="0">of AIOD from </text>
<text top="602" left="513" width="269" height="17" font="0">January 2008–September 2014. BMSs in kissing </text>
<text top="619" left="513" width="157" height="17" font="0">configuration were deployed </text>
<text top="636" left="513" width="297" height="17" font="0">in 9 cases, covered stents in kissing configuration in 9 </text>
<text top="653" left="513" width="158" height="17" font="0">pts and the aortic bifurcation </text>
<text top="671" left="513" width="272" height="17" font="0">Teconstruction with the Y-guidewire configuration </text>
<text top="688" left="513" width="231" height="17" font="0">technique was performed in the last 4 pts. </text>
<text top="705" left="513" width="3" height="17" font="0"> </text>
<text top="723" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="722" left="520" width="6" height="18" font="7"></text>
<text top="723" left="526" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="741" left="513" width="7" height="18" font="7"></text>
<text top="742" left="520" width="297" height="17" font="0"> Technical success was 100%. Perioperative mortality </text>
<text top="759" left="513" width="309" height="17" font="0">rate was 4.5%. ABI improved from 0.49 ± 0.19 to 0.96 ± </text>
<text top="776" left="513" width="233" height="17" font="0">0.05 at the right side and from 0.53 ± 0.17 </text>
<text top="567" left="837" width="24" height="17" font="0">N/A </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">166 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="351" width="131" height="17" font="2"><b>Exclusion criteria:</b> Pts </text>
<text top="104" left="351" width="99" height="17" font="0">with inflammatory </text>
<text top="122" left="351" width="54" height="17" font="0">occlusive </text>
<text top="139" left="351" width="119" height="17" font="0">vascular disease and </text>
<text top="156" left="351" width="143" height="17" font="0">aortoiliac thromboembolic </text>
<text top="173" left="351" width="137" height="17" font="0">occlusion were excluded </text>
<text top="190" left="351" width="85" height="17" font="0">from the study. </text>
<text top="87" left="513" width="7" height="18" font="7"></text>
<text top="88" left="520" width="290" height="17" font="0"> 0.98 ± 0.04 at the left side (p&lt;0.01). Mean follow-up </text>
<text top="106" left="513" width="174" height="17" font="0">was 39.5 mo (range, 5–80 mo). </text>
<text top="123" left="513" width="7" height="18" font="7"></text>
<text top="124" left="520" width="303" height="17" font="0"> The primary patency rate was 95.2% at 1 y and 90.5% </text>
<text top="141" left="513" width="33" height="17" font="0">at 3 y<b> </b></text>
<text top="208" left="95" width="94" height="17" font="0">Bredahl K, et al.  </text>
<text top="226" left="95" width="63" height="17" font="0">2015 (369) </text>
<text top="243" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26115920">26115920</a></text>
<text top="243" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26115920"> </a></text>
<text top="260" left="95" width="3" height="17" font="0"> </text>
<text top="208" left="203" width="111" height="17" font="2"><b>Aim: </b>To identify the </text>
<text top="226" left="203" width="94" height="17" font="0">effect of growing </text>
<text top="243" left="203" width="129" height="17" font="0">endovascular repair on </text>
<text top="260" left="203" width="99" height="17" font="0">open aortic repair </text>
<text top="277" left="203" width="64" height="17" font="0">outcomes. <b> </b></text>
<text top="294" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="312" left="203" width="74" height="17" font="2"><b>Study Type: </b></text>
<text top="329" left="203" width="79" height="17" font="0">Retrospective<b> </b></text>
<text top="346" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="363" left="203" width="80" height="17" font="2"><b>Size: </b>n=3,623 </text>
<text top="381" left="203" width="130" height="17" font="0">aortobifemoral and 144 </text>
<text top="398" left="203" width="105" height="17" font="0">aortobiiliac bypass </text>
<text top="415" left="203" width="65" height="17" font="0">procedures<b> </b></text>
<text top="208" left="351" width="106" height="17" font="2"><b>Inclusion criteria: </b></text>
<text top="226" left="351" width="109" height="17" font="0">Bypass procedures </text>
<text top="243" left="351" width="126" height="17" font="0">performed in Denmark </text>
<text top="260" left="351" width="111" height="17" font="0">due to chronic IC or </text>
<text top="277" left="351" width="66" height="17" font="0">chronic CLI </text>
<text top="294" left="351" width="3" height="17" font="2"><b> </b></text>
<text top="312" left="351" width="132" height="17" font="2"><b>Exclusion criteria: </b>We </text>
<text top="329" left="351" width="131" height="17" font="0">excluded pts with acute </text>
<text top="346" left="351" width="26" height="17" font="0">limb </text>
<text top="363" left="351" width="116" height="17" font="0">ischemia, secondary </text>
<text top="381" left="351" width="74" height="17" font="0">renovascular </text>
<text top="398" left="351" width="81" height="17" font="0">hypertension,  </text>
<text top="415" left="351" width="124" height="17" font="0">secondary mesenteric </text>
<text top="432" left="351" width="116" height="17" font="0">ischemia, secondary </text>
<text top="449" left="351" width="131" height="17" font="0">aneurysm, and pts who </text>
<text top="467" left="351" width="145" height="17" font="0">had previously undergone </text>
<text top="484" left="351" width="137" height="17" font="0">intra-abdominal vascular </text>
<text top="501" left="351" width="48" height="17" font="0">surgery.<b> </b></text>
<text top="208" left="513" width="155" height="17" font="2"><b>Intervention: </b>Open Bypass </text>
<text top="226" left="513" width="3" height="17" font="0"> </text>
<text top="244" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="243" left="520" width="6" height="18" font="7"></text>
<text top="244" left="526" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="261" left="513" width="7" height="18" font="7"></text>
<text top="262" left="520" width="288" height="17" font="0"> The annual caseload fell from 323 to 106 during the </text>
<text top="280" left="513" width="289" height="17" font="0">study period, but the 30 d mortality at 3.6% (95% CI: </text>
<text top="297" left="513" width="306" height="17" font="0">3.0–4.1) and the 30 d major complication rate remained </text>
<text top="314" left="513" width="188" height="17" font="0">constant at 20% (95% CI: 18–21). </text>
<text top="331" left="513" width="7" height="18" font="7"></text>
<text top="332" left="520" width="288" height="17" font="0"> Gangrene (OR: 3.3; 95% CI: 1.7–6.5; p=0.005) was </text>
<text top="350" left="513" width="278" height="17" font="0">the most significant risk factor for 30-day mortality, </text>
<text top="367" left="513" width="288" height="17" font="0">followed by renal insufficiency (OR, 2.5; 95% CI, 1.1-</text>
<text top="384" left="513" width="290" height="17" font="0">5.8; p=0.035) and cardiac disease (OR: 2.1; 95% CI: </text>
<text top="401" left="513" width="107" height="17" font="0">1.4–3.1; p&lt;0.001).  </text>
<text top="418" left="513" width="7" height="18" font="7"></text>
<text top="419" left="520" width="272" height="17" font="0"> Multiorgan failure, mesenteric ischemia, need for </text>
<text top="437" left="513" width="302" height="17" font="0">dialysis and cardiac complications were the most lethal </text>
<text top="454" left="513" width="295" height="17" font="0">complications, with mortality rates of 94%, 44%, 38%, </text>
<text top="471" left="513" width="127" height="17" font="0">and 34%, respectively.<b> </b></text>
<text top="208" left="837" width="24" height="17" font="0">N/A </text>
<text top="519" left="95" width="89" height="17" font="0">Chew DK, et al. </text>
<text top="536" left="95" width="63" height="17" font="0">2001 (370) </text>
<text top="553" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11174776">11174776</a></text>
<text top="553" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11174776"> </a></text>
<text top="571" left="95" width="3" height="17" font="0"> </text>
<text top="519" left="203" width="119" height="17" font="2"><b>Aim: </b>To evaluate the </text>
<text top="536" left="203" width="109" height="17" font="0">long-term results of </text>
<text top="553" left="203" width="68" height="17" font="0">autogenous </text>
<text top="571" left="203" width="120" height="17" font="0">composite vein grafts </text>
<text top="588" left="203" width="118" height="17" font="0">used for infrainguinal </text>
<text top="605" left="203" width="128" height="17" font="0">arterial bypass grafting </text>
<text top="622" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="639" left="203" width="74" height="17" font="2"><b>Study Type: </b></text>
<text top="657" left="203" width="79" height="17" font="0">Retrospective<b> </b></text>
<text top="674" left="203" width="3" height="17" font="2"><b> </b></text>
<text top="691" left="203" width="90" height="17" font="2"><b>Size:</b> n=154 pts<b> </b></text>
<text top="519" left="351" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="536" left="351" width="7" height="18" font="7"></text>
<text top="537" left="358" width="126" height="17" font="0"> 90% of the operations </text>
<text top="555" left="351" width="133" height="17" font="0">were performed for limb </text>
<text top="572" left="351" width="135" height="17" font="0">salvage (rest pain: 36%; </text>
<text top="589" left="351" width="124" height="17" font="0">ulcer: 33%; gangrene: </text>
<text top="606" left="351" width="128" height="17" font="0">21%); the rest were for </text>
<text top="623" left="351" width="112" height="17" font="0">severe claudication. </text>
<text top="641" left="351" width="7" height="18" font="7"></text>
<text top="642" left="358" width="122" height="17" font="0"> 48% of bypass grafts </text>
<text top="659" left="351" width="118" height="17" font="0">were performed after </text>
<text top="676" left="351" width="83" height="17" font="0">failed previous </text>
<text top="693" left="351" width="90" height="17" font="0">reconstructions.<b> </b></text>
<text top="519" left="513" width="296" height="17" font="2"><b>Intervention: </b>Infrainguinal bypasses using composite </text>
<text top="536" left="513" width="147" height="17" font="0">vein grafts were examined </text>
<text top="553" left="513" width="3" height="17" font="2"><b> </b></text>
<text top="572" left="513" width="7" height="17" font="2"><b>1</b></text>
<text top="571" left="520" width="6" height="18" font="7"></text>
<text top="572" left="526" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="589" left="513" width="7" height="18" font="7"></text>
<text top="590" left="520" width="244" height="17" font="0"> The 30 d operative mortality rate was 1.8%. </text>
<text top="607" left="513" width="307" height="17" font="0">Perioperative graft failure (&lt;30 d) occurred in 18 bypass </text>
<text top="625" left="513" width="287" height="17" font="0">grafts (11%), resulting in early amputation (&lt;30 d) in </text>
<text top="642" left="513" width="38" height="17" font="0">1.2%.  </text>
<text top="659" left="513" width="7" height="18" font="7"></text>
<text top="660" left="520" width="299" height="17" font="0"> Overall, 5 y cumulative patency rates were 44% ± 5% </text>
<text top="677" left="513" width="307" height="17" font="0">for primary patency, 63% ± 5% for PAP, and 65% ± 5% </text>
<text top="695" left="513" width="151" height="17" font="0">for secondary patency SP.  </text>
<text top="712" left="513" width="7" height="18" font="7"></text>
<text top="713" left="520" width="282" height="17" font="0"> A high revision rate for stenosis or thrombosis was </text>
<text top="730" left="513" width="283" height="17" font="0">required during follow-up to maintain patency of the </text>
<text top="747" left="513" width="77" height="17" font="0">grafts (27%).  </text>
<text top="765" left="513" width="202" height="17" font="0">Limb salvage was 81% ± 5% at 5 y.  </text>
<text top="519" left="837" width="24" height="17" font="0">N/A </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">167 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="513" width="7" height="18" font="7"></text>
<text top="88" left="520" width="278" height="17" font="0"> Primary reconstructions with composite vein fared </text>
<text top="106" left="513" width="300" height="17" font="0">significantly better than secondary reconstructions (SP </text>
<text top="123" left="513" width="165" height="17" font="0">76% vs. 54% at 5 y; p&lt;0.01).  </text>
<text top="140" left="513" width="7" height="18" font="7"></text>
<text top="141" left="520" width="261" height="17" font="0"> Arm vein composites showed superior patency </text>
<text top="158" left="513" width="305" height="17" font="0">compared with greater saphenous vein composites (SP </text>
<text top="176" left="513" width="161" height="17" font="0">79% vs. 61% at 5 y, p&lt;0.05).<b> </b></text>
<text top="194" left="86" width="1002" height="17" font="0">ABI indicates ankle-brachial index; AFS, amputation free survival; AIOD, aortoiliac occlusive disease; BMS, bare metal stent; BSF, bypass surgery as first-line treatment; CI, confidence </text>
<text top="211" left="86" width="1012" height="17" font="0">interval; CLI, critical limb ischemia; CPA, complete pedal arch; DAR, direct angiosome revascularization; DM, diabetes mellitus; EIA, external iliac artery; HR, hazard ratio; IC, intermittent </text>
<text top="230" left="86" width="222" height="17" font="0">claudication; IPA, incomplete pedal arch;</text>
<text top="231" left="309" width="37" height="16" font="3"> iPVI, </text>
<text top="230" left="346" width="736" height="17" font="0">ipsilateral peripheral endovascular intervention; IQR, interquartile range; LEB, lower extremity bypass; LE, lower extremity; MAE, major </text>
<text top="248" left="86" width="918" height="17" font="0">adverse event; MALE, major adverse limb event; N/A, not applicable; NPA, no pedal arch; NPEI, no prior endovascular intervention; PAP, primary assisted patency; PEI,</text>
<text top="250" left="1004" width="4" height="16" font="3"> </text>
<text top="248" left="1008" width="28" height="17" font="0">prior </text>
<text top="265" left="86" width="962" height="17" font="0">endovascular intervention; PTA, percutaneous angioplasty; pt, patient; PVI, peripheral endovascular intervention; SP, secondary patency; and TASC, TransAtlantic Inter-Society </text>
<text top="283" left="86" width="68" height="17" font="0">Consensus. </text>
<text top="303" left="86" width="4" height="16" font="3"> </text>
<text top="338" left="86" width="729" height="21" font="1"><b>Evidence Table 43. RCT Comparing Prostanoids for End-Stage Peripheral Artery Disease–Section 8.2.3. </b></text>
<text top="359" left="100" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="376" left="125" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="394" left="103" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="359" left="241" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="376" left="245" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="394" left="239" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="359" left="381" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="359" left="538" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="376" left="556" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="394" left="539" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="411" left="559" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="359" left="725" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="376" left="683" width="188" height="17" font="2"><b>(Absolute Event Rates, P value; </b></text>
<text top="394" left="740" width="79" height="17" font="2"><b>OR or RR; &amp;  </b></text>
<text top="411" left="753" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="360" left="912" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="359" left="973" width="6" height="18" font="7"></text>
<text top="360" left="979" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="378" left="944" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="395" left="952" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="429" left="95" width="94" height="17" font="0">Ruffolo AJ, et al. </text>
<text top="446" left="95" width="63" height="17" font="0">2010 (371) </text>
<text top="463" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20091595">20091595 </a></text>
<text top="481" left="95" width="3" height="17" font="0"> </text>
<text top="429" left="216" width="126" height="17" font="2"><b>Aim:</b> Evaluation of the </text>
<text top="446" left="216" width="103" height="17" font="0">“effectiveness and </text>
<text top="463" left="216" width="130" height="17" font="0">safety of prostanoids in </text>
<text top="481" left="216" width="72" height="17" font="0">pts with CLI” </text>
<text top="498" left="216" width="3" height="17" font="0"> </text>
<text top="515" left="216" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="532" left="216" width="72" height="17" font="0">analysis and </text>
<text top="549" left="216" width="114" height="17" font="0">systematic review of </text>
<text top="567" left="216" width="97" height="17" font="0">randomized trials </text>
<text top="584" left="216" width="3" height="17" font="0"> </text>
<text top="601" left="216" width="128" height="17" font="2"><b>Size:</b> n=2,724 pts from </text>
<text top="618" left="216" width="118" height="17" font="0">20 randomized trials  </text>
<text top="429" left="361" width="129" height="17" font="2"><b>Inclusion criteria:</b> CLI </text>
<text top="446" left="361" width="144" height="17" font="0">“without chance of rescue </text>
<text top="463" left="361" width="94" height="17" font="0">or reconstructive </text>
<text top="481" left="361" width="71" height="17" font="0">intervention” </text>
<text top="498" left="361" width="3" height="17" font="0"> </text>
<text top="515" left="361" width="144" height="17" font="2"><b>Exclusion criteria:</b> Trials </text>
<text top="532" left="361" width="103" height="17" font="0">in which treatment </text>
<text top="549" left="361" width="112" height="17" font="0">assignment was not </text>
<text top="567" left="361" width="125" height="17" font="0">masked; withdrawal of </text>
<text top="584" left="361" width="146" height="17" font="0">≥10% of study population; </text>
<text top="601" left="361" width="90" height="17" font="0">no ITT analysis. </text>
<text top="429" left="524" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="446" left="524" width="62" height="17" font="0">Prostanoid </text>
<text top="463" left="524" width="136" height="17" font="0">administration (including </text>
<text top="481" left="524" width="99" height="17" font="0">prostaglandin E1, </text>
<text top="498" left="524" width="118" height="17" font="0">prostacyclin, iloprost, </text>
<text top="515" left="524" width="115" height="17" font="0">betaprost, cisaprost) </text>
<text top="532" left="524" width="3" height="17" font="0"> </text>
<text top="549" left="524" width="125" height="17" font="2"><b>Comparator:</b> Placebo </text>
<text top="567" left="524" width="129" height="17" font="0">or other pharmacologic </text>
<text top="584" left="524" width="40" height="17" font="0">control<b> </b></text>
<text top="430" left="676" width="7" height="17" font="2"><b>1</b></text>
<text top="429" left="683" width="6" height="18" font="7"></text>
<text top="430" left="689" width="182" height="17" font="2"><b> endpoint:</b> Decrease in rest pain </text>
<text top="447" left="676" width="199" height="17" font="0">relief (RR: 1.32; 95% CI: 1.10–1.57) </text>
<text top="464" left="676" width="185" height="17" font="0">and ulcer healing (RR: 1.54; 95% </text>
<text top="482" left="676" width="201" height="17" font="0">CI: 1.22–1.96) but no class effect on </text>
<text top="499" left="676" width="187" height="17" font="0">amputations (24.8 vs. 26.7%; RR: </text>
<text top="516" left="676" width="187" height="17" font="0">0.89; 95% CI: 0.76–1.04). Iloprost </text>
<text top="533" left="676" width="150" height="17" font="0">specifically associated with </text>
<text top="551" left="676" width="179" height="17" font="0">decreased amputation rate (RR: </text>
<text top="568" left="676" width="140" height="17" font="0">0.69; 95% CI: 0.52–0.93) </text>
<text top="585" left="676" width="3" height="17" font="0"> </text>
<text top="603" left="676" width="7" height="17" font="2"><b>1</b></text>
<text top="602" left="683" width="6" height="18" font="7"></text>
<text top="603" left="689" width="173" height="17" font="2"><b> Safety endpoint:</b> No effect on </text>
<text top="621" left="676" width="187" height="17" font="0">mortality (RR: 1.07; 95% CI: 0.65–</text>
<text top="638" left="676" width="196" height="17" font="0">1.75); higher risk of adverse events </text>
<text top="655" left="676" width="169" height="17" font="0">(RR: 2.35; 95% CI: 1.99–2.78)<b> </b></text>
<text top="429" left="891" width="7" height="18" font="7"></text>
<text top="430" left="898" width="202" height="17" font="0"> Adverse events included headache, </text>
<text top="447" left="891" width="198" height="17" font="0">flushing, nausea, vomiting, diarrhea </text>
<text top="465" left="891" width="7" height="18" font="7"></text>
<text top="466" left="898" width="204" height="17" font="0"> “Amputation” not specifically defined </text>
<text top="483" left="891" width="202" height="17" font="0">if major only or total) in 9 of the trials </text>
<text top="500" left="891" width="7" height="18" font="7"></text>
<text top="501" left="898" width="189" height="17" font="0"> Amputation rate of placebo group </text>
<text top="518" left="891" width="207" height="17" font="0">notably higher in iloprost studies (147 </text>
<text top="536" left="891" width="192" height="17" font="0">of 383, 38.4%) than overall (201 of </text>
<text top="553" left="891" width="70" height="17" font="0">753, 26.7%) </text>
<text top="570" left="891" width="3" height="17" font="0"> </text>
<text top="587" left="891" width="198" height="17" font="2"><b>Summary</b>: Review “did not find any </text>
<text top="604" left="891" width="204" height="17" font="0">conclusive evidence that prostanoids </text>
<text top="622" left="891" width="154" height="17" font="0">provided long-term benefit.” </text>
<text top="673" left="86" width="788" height="17" font="0">CI indicates confidence interval; CLI, critical limb ischemia; ITT, intent to treat; pt, patient; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="693" left="86" width="4" height="16" font="3"> </text>
<text top="728" left="86" width="947" height="21" font="1"><b>Evidence Table 44. Nonrandomized Trials, Observational Studies, and/or Registries for Would Healing Therapies for CLI–Section 8.2.3. </b></text>
<text top="750" left="93" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="767" left="119" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="750" left="240" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="767" left="245" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="750" left="394" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="750" left="603" width="105" height="17" font="2"><b>Endpoint Results </b></text>
<text top="767" left="550" width="210" height="17" font="2"><b>(Absolute Event Rates, P value; OR </b></text>
<text top="751" left="785" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="750" left="847" width="6" height="18" font="7"></text>
<text top="751" left="853" width="108" height="17" font="2"><b> Endpoint (if any); </b></text>
<text top="768" left="818" width="111" height="17" font="2"><b>Study Limitations; </b></text>
</page>
<page number="168" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">168 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="87" left="239" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="87" left="605" width="101" height="17" font="2"><b>or RR; &amp; 95% CI) </b></text>
<text top="87" left="825" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="105" left="86" width="92" height="17" font="0">Moran PS, et al. </text>
<text top="122" left="86" width="63" height="17" font="0">2015 (372) </text>
<text top="139" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25270409">25270409</a></text>
<text top="139" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25270409"> </a></text>
<text top="157" left="86" width="3" height="17" font="0"> </text>
<text top="105" left="212" width="129" height="17" font="2"><b>Aim:</b> Evaluation of IPC </text>
<text top="122" left="212" width="121" height="17" font="0">and standard medical </text>
<text top="139" left="212" width="138" height="17" font="0">therapy for pts who were </text>
<text top="157" left="212" width="73" height="17" font="0">“ineligible for </text>
<text top="174" left="212" width="100" height="17" font="0">revascularization” </text>
<text top="191" left="212" width="3" height="17" font="0"> </text>
<text top="208" left="212" width="102" height="17" font="2"><b>Study type:</b> Meta-</text>
<text top="226" left="212" width="133" height="17" font="0">analysis and systematic </text>
<text top="243" left="212" width="98" height="17" font="0">review of studies  </text>
<text top="260" left="212" width="3" height="17" font="0"> </text>
<text top="277" left="212" width="125" height="17" font="2"><b>Size:</b> n=409 limbs in 8 </text>
<text top="294" left="212" width="124" height="17" font="0">series; no randomized </text>
<text top="312" left="212" width="82" height="17" font="0">trials identified </text>
<text top="105" left="365" width="129" height="17" font="2"><b>Inclusion criteria:</b> CLI </text>
<text top="122" left="365" width="73" height="17" font="0">“ineligible for </text>
<text top="139" left="365" width="161" height="17" font="0">revascularization”; see Table </text>
<text top="157" left="365" width="143" height="17" font="0">1 of publication for details </text>
<text top="174" left="365" width="3" height="17" font="0"> </text>
<text top="191" left="365" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="106" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="105" left="554" width="6" height="18" font="7"></text>
<text top="106" left="560" width="204" height="17" font="2"><b> endpoint:</b> Significant improvements </text>
<text top="123" left="547" width="191" height="17" font="0">in limb salvage and wound healing </text>
<text top="141" left="547" width="213" height="17" font="0">rates (58 vs. 17% at 18 mo for both) in </text>
<text top="158" left="547" width="161" height="17" font="0">1 controlled study; significant </text>
<text top="175" left="547" width="196" height="17" font="0">improvement in SF-36 quality of life </text>
<text top="192" left="547" width="201" height="17" font="0">domains in another controlled study; </text>
<text top="210" left="547" width="212" height="17" font="0">10–15 mm Hg average increase in toe </text>
<text top="227" left="547" width="57" height="17" font="0">pressures </text>
<text top="244" left="547" width="3" height="17" font="0"> </text>
<text top="262" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="261" left="554" width="6" height="18" font="7"></text>
<text top="262" left="560" width="179" height="17" font="2"><b> Safety endpoint:</b> Compression </text>
<text top="280" left="547" width="215" height="17" font="0">therapy not completed because of pain </text>
<text top="297" left="547" width="68" height="17" font="0">in 7% of pts<b> </b></text>
<text top="105" left="776" width="7" height="18" font="7"></text>
<text top="106" left="783" width="175" height="17" font="0"> No randomized trials available; </text>
<text top="123" left="776" width="136" height="17" font="0">only 2 case series made </text>
<text top="141" left="776" width="164" height="17" font="0">comparisons to controls (total </text>
<text top="158" left="776" width="35" height="17" font="0">n=32) </text>
<text top="175" left="776" width="3" height="17" font="0"> </text>
<text top="192" left="776" width="162" height="17" font="2"><b>Summary</b>: “Limited available </text>
<text top="210" left="776" width="178" height="17" font="0">results suggest that IPC may be </text>
<text top="227" left="776" width="167" height="17" font="0">associated with improved limb </text>
<text top="244" left="776" width="186" height="17" font="0">salvage, wound healing, and pain </text>
<text top="261" left="776" width="83" height="17" font="0">management”. </text>
<text top="330" left="86" width="107" height="17" font="0">Kobayashi N, et al. </text>
<text top="347" left="86" width="63" height="17" font="0">2015 (373) </text>
<text top="364" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25542618">25542618</a></text>
<text top="364" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25542618"> </a></text>
<text top="381" left="86" width="3" height="17" font="0"> </text>
<text top="330" left="212" width="100" height="17" font="2"><b>Aim:</b> Determine if </text>
<text top="347" left="212" width="121" height="17" font="0">endovascular therapy </text>
<text top="364" left="212" width="127" height="17" font="0">improves tissue loss in </text>
<text top="381" left="212" width="42" height="17" font="0">CLI pts </text>
<text top="398" left="212" width="3" height="17" font="0"> </text>
<text top="416" left="212" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="433" left="212" width="3" height="17" font="0"> </text>
<text top="450" left="212" width="140" height="17" font="2"><b>Size:</b> n=187 CLI pts; 113 </text>
<text top="467" left="212" width="118" height="17" font="0">with complete wound </text>
<text top="485" left="212" width="43" height="17" font="0">healing </text>
<text top="330" left="365" width="152" height="17" font="0"> <b>Inclusion criteria:</b> CLI pts </text>
<text top="347" left="365" width="83" height="17" font="0">with tissue loss</text>
<text top="349" left="447" width="4" height="16" font="3"> </text>
<text top="347" left="451" width="79" height="17" font="0">who achieved </text>
<text top="364" left="365" width="164" height="17" font="0">complete wound healing after </text>
<text top="381" left="365" width="76" height="17" font="0">endovascular </text>
<text top="398" left="365" width="96" height="17" font="0">revascularization </text>
<text top="416" left="365" width="3" height="17" font="0"> </text>
<text top="433" left="365" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="331" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="330" left="554" width="6" height="18" font="7"></text>
<text top="331" left="560" width="196" height="17" font="2"><b> endpoint:</b> Survival rate at 3 y 74% </text>
<text top="331" left="776" width="7" height="17" font="2"><b>2</b></text>
<text top="330" left="783" width="6" height="18" font="7"></text>
<text top="331" left="789" width="163" height="17" font="2"><b> endpoint:</b> Limb salvage rate </text>
<text top="348" left="776" width="179" height="17" font="0">and recurrence rate at 3 y 100% </text>
<text top="365" left="776" width="3" height="17" font="0"> </text>
<text top="382" left="776" width="183" height="17" font="0">Recurrance rate of CLI at 3 y 9%<b> </b></text>
<text top="503" left="86" width="99" height="17" font="0">Armstrong DG, et </text>
<text top="520" left="86" width="16" height="17" font="0">al. </text>
<text top="537" left="86" width="63" height="17" font="0">2012 (205) </text>
<text top="554" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22431496">22431496 </a></text>
<text top="571" left="86" width="3" height="17" font="0"> </text>
<text top="503" left="212" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="520" left="212" width="112" height="17" font="0">retrospective cohort </text>
<text top="537" left="212" width="3" height="17" font="0"> </text>
<text top="554" left="212" width="140" height="17" font="2"><b>Size:</b> n=790 diabetic foot </text>
<text top="571" left="212" width="64" height="17" font="0">operations  </text>
<text top="503" left="365" width="169" height="17" font="2"><b>Inclusion criteria:</b> All diabetic </text>
<text top="520" left="365" width="169" height="17" font="0">foot operations 2006–2008 vs. </text>
<text top="537" left="365" width="62" height="17" font="0">2008-2010 </text>
<text top="504" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="503" left="554" width="6" height="18" font="7"></text>
<text top="504" left="560" width="190" height="17" font="2"><b> endpoint:</b> Amputation level, case </text>
<text top="521" left="547" width="23" height="17" font="0">mix </text>
<text top="538" left="547" width="3" height="17" font="0"> </text>
<text top="555" left="547" width="213" height="17" font="2"><b>Results:</b> 37.5% reduction in transtibial </text>
<text top="573" left="547" width="214" height="17" font="0">amputations; 44% increase in vascular </text>
<text top="590" left="547" width="73" height="17" font="0">interventions </text>
<text top="503" left="776" width="178" height="17" font="0">Interdisciplinary care as a “rapid </text>
<text top="520" left="776" width="186" height="17" font="0">and sustained impact in changing </text>
<text top="537" left="776" width="159" height="17" font="0">surgery type from reactive to </text>
<text top="554" left="776" width="163" height="17" font="0">proactive” and reduces major </text>
<text top="571" left="776" width="70" height="17" font="0">amputations </text>
<text top="608" left="86" width="83" height="17" font="0">Chung J, et al. </text>
<text top="625" left="86" width="63" height="17" font="0">2015 (206) </text>
<text top="642" left="86" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25073577">25073577 </a></text>
<text top="659" left="86" width="3" height="17" font="0"> </text>
<text top="608" left="212" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="625" left="212" width="112" height="17" font="0">retrospective cohort </text>
<text top="642" left="212" width="3" height="17" font="0"> </text>
<text top="659" left="212" width="83" height="17" font="2"><b>Size:</b> n=85 pts </text>
<text top="608" left="365" width="127" height="17" font="2"><b>Inclusion criteria:</b> “All </text>
<text top="625" left="365" width="147" height="17" font="0">consecutive pts” with R5/6 </text>
<text top="642" left="365" width="128" height="17" font="0">CLI at a single hospital </text>
<text top="659" left="365" width="86" height="17" font="0">8/2010–6/2012 </text>
<text top="609" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="608" left="554" width="6" height="18" font="7"></text>
<text top="609" left="560" width="172" height="17" font="2"><b> endpoint:</b> 1 y amputation-free </text>
<text top="626" left="547" width="45" height="17" font="0">survival </text>
<text top="643" left="547" width="3" height="17" font="0"> </text>
<text top="661" left="547" width="179" height="17" font="2"><b>Results:</b> 67 vs. 42% at 1 y; also </text>
<text top="678" left="547" width="180" height="17" font="0">higher mean limb salvage times. </text>
<text top="695" left="547" width="172" height="17" font="0">Multidisciplinary care remained </text>
<text top="712" left="547" width="189" height="17" font="0">significant on multivariate analysis </text>
<text top="608" left="776" width="171" height="17" font="0">Multidisciplinary care improves </text>
<text top="625" left="776" width="193" height="17" font="0">amputation-free survival in pts with </text>
<text top="642" left="776" width="52" height="17" font="0">R5/6 CLI </text>
<text top="730" left="86" width="86" height="17" font="0">Vartanian et al. </text>
<text top="747" left="86" width="63" height="17" font="0">2015 (211) </text>
<text top="764" left="86" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25596408">25596408</a></text>
<text top="764" left="141" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25596408"> </a></text>
<text top="730" left="212" width="95" height="17" font="2"><b>Study type:</b> NR, </text>
<text top="747" left="212" width="113" height="17" font="0">retrospective review </text>
<text top="764" left="212" width="3" height="17" font="0"> </text>
<text top="730" left="365" width="152" height="17" font="2"><b>Inclusion criteria:</b> Pts with </text>
<text top="747" left="365" width="129" height="17" font="0">neuroischemic wounds </text>
<text top="764" left="365" width="166" height="17" font="0">treated at a signle institutional </text>
<text top="731" left="547" width="7" height="17" font="2"><b>1</b></text>
<text top="730" left="554" width="6" height="18" font="7"></text>
<text top="731" left="560" width="193" height="17" font="2"><b> endpoint:</b> Time to wound healing, </text>
<text top="748" left="547" width="184" height="17" font="0">reulceration rate, and ambulatory </text>
<text top="766" left="547" width="40" height="17" font="0">status. </text>
<text top="730" left="776" width="150" height="17" font="0">Multidisciplinary care helps </text>
<text top="747" left="776" width="155" height="17" font="0">effectively heal wounds and </text>
<text top="764" left="776" width="183" height="17" font="0">maintain ambulatory status in pts </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">169 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="212" width="123" height="17" font="2"><b>Size:</b> n=91 limbs from </text>
<text top="104" left="212" width="37" height="17" font="0">89 pts </text>
<text top="87" left="365" width="156" height="17" font="0">amputation prevention clinic </text>
<text top="104" left="365" width="159" height="17" font="0">from March 2012–July 2013. </text>
<text top="122" left="365" width="144" height="17" font="0">Pts at highest risk for limb </text>
<text top="139" left="365" width="140" height="17" font="0">loss, defined as ischemic </text>
<text top="156" left="365" width="146" height="17" font="0">wounds (ischemic ulcer or </text>
<text top="173" left="365" width="144" height="17" font="0">gangrene) or diabetic foot </text>
<text top="190" left="365" width="43" height="17" font="0">ulcers.  </text>
<text top="208" left="365" width="3" height="17" font="0"> </text>
<text top="225" left="365" width="158" height="17" font="2"><b>Exclusion criteria: </b>New pts </text>
<text top="242" left="365" width="115" height="17" font="0">evaluated for benign </text>
<text top="259" left="365" width="137" height="17" font="0">conditions (e.g., arthritis, </text>
<text top="276" left="365" width="132" height="17" font="0">overuse injuries, simple </text>
<text top="294" left="365" width="144" height="17" font="0">infections in nondiabetics, </text>
<text top="311" left="365" width="162" height="17" font="0">venous ulcers, minor trauma, </text>
<text top="328" left="365" width="87" height="17" font="0">radiculopathy).  </text>
<text top="87" left="547" width="3" height="17" font="0"> </text>
<text top="104" left="547" width="214" height="17" font="2"><b>Results:</b> 67% of wounds were present </text>
<text top="122" left="547" width="196" height="17" font="0">&gt;6 wk before referral. A total of 151 </text>
<text top="139" left="547" width="213" height="17" font="0">podiatric and 86 vascular interventions </text>
<text top="156" left="547" width="162" height="17" font="0">were prformed, with an equal </text>
<text top="173" left="547" width="208" height="17" font="0">distribution of endovascular and open </text>
<text top="190" left="547" width="201" height="17" font="0">revascularizations. Complete wound </text>
<text top="208" left="547" width="201" height="17" font="0">healing observed in 59% of wounds, </text>
<text top="225" left="547" width="200" height="17" font="0">and average time to full healing was </text>
<text top="242" left="547" width="207" height="17" font="0">12 wk. Hindfood wounds predictive of </text>
<text top="259" left="547" width="210" height="17" font="0">failure to heal (OR: 0.21; p&lt;0.01; 95% </text>
<text top="276" left="547" width="85" height="17" font="0">CI: 0.06–0.68). </text>
<text top="87" left="776" width="116" height="17" font="0">with limb threatening </text>
<text top="104" left="776" width="181" height="17" font="0">neuroischemic wounds. Hindfoot </text>
<text top="122" left="776" width="172" height="17" font="0">or ankle wounds can adversely </text>
<text top="139" left="776" width="172" height="17" font="0">influence the outcome. Healing </text>
<text top="156" left="776" width="133" height="17" font="0">can be prolonged and a </text>
<text top="173" left="776" width="180" height="17" font="0">substancial proportion of pts can </text>
<text top="190" left="776" width="190" height="17" font="0">be expected to have a recurrence, </text>
<text top="208" left="776" width="133" height="17" font="0">therefore surveillance is </text>
<text top="225" left="776" width="144" height="17" font="0">mandatory. A coordinated </text>
<text top="242" left="776" width="174" height="17" font="0">amputation prevention program </text>
<text top="259" left="776" width="165" height="17" font="0">may help to minimize hospital </text>
<text top="276" left="776" width="159" height="17" font="0">readmissions in the high-risk </text>
<text top="294" left="776" width="67" height="17" font="0">population.  </text>
<text top="346" left="86" width="557" height="17" font="0">CLI indicates critical limb ischemia; IPC, intermittent pneumatic compression; and N/A, not applicable. </text>
<text top="381" left="86" width="4" height="21" font="1"><b> </b></text>
<text top="402" left="86" width="848" height="21" font="1"><b>Evidence Table 45. Nonrandomized Trials, Observational Studies, and/or Registries of Acute Limb Ischemia–Section 9.1. </b></text>
<text top="423" left="109" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="440" left="134" width="48" height="17" font="2"><b>Author; </b></text>
<text top="457" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="423" left="241" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="440" left="267" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="423" left="397" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="423" left="582" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="440" left="590" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="457" left="642" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="423" left="865" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="440" left="892" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="475" left="95" width="115" height="17" font="0">Rutherford RB, et al. </text>
<text top="493" left="95" width="60" height="17" font="0">1992 (374)</text>
<text top="494" left="154" width="4" height="16" font="3"> </text>
<text top="493" left="158" width="3" height="17" font="0"> </text>
<text top="510" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9308598">9308598</a></text>
<text top="510" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9308598"> </a></text>
<text top="527" left="95" width="3" height="17" font="0"> </text>
<text top="475" left="235" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="493" left="235" width="124" height="17" font="0">Consensus Document </text>
<text top="510" left="235" width="3" height="17" font="0"> </text>
<text top="527" left="235" width="56" height="17" font="2"><b>Size: </b>N/A </text>
<text top="475" left="378" width="130" height="17" font="2"><b>Inclusion criteria: </b>N/A </text>
<text top="493" left="378" width="3" height="17" font="0"> </text>
<text top="510" left="378" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="476" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="475" left="547" width="6" height="18" font="7"></text>
<text top="476" left="553" width="196" height="17" font="2"><b> endpoint:</b> Scoring Scheme for ALI </text>
<text top="494" left="540" width="3" height="17" font="0"> </text>
<text top="511" left="540" width="79" height="17" font="2"><b>Results: </b>N/A<b>  </b></text>
<text top="475" left="817" width="24" height="17" font="0">N/A </text>
<text top="545" left="95" width="100" height="17" font="0">Nypaver TJ, et al. </text>
<text top="562" left="95" width="63" height="17" font="0">1998 (375) </text>
<text top="579" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9737621">9737621 </a></text>
<text top="597" left="95" width="3" height="17" font="0"> </text>
<text top="545" left="235" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="562" left="235" width="129" height="17" font="0">institution retrospective </text>
<text top="579" left="235" width="38" height="17" font="0">cohort </text>
<text top="597" left="235" width="3" height="17" font="0"> </text>
<text top="614" left="235" width="83" height="17" font="2"><b>Size:</b> n=71 pts </text>
<text top="545" left="378" width="141" height="17" font="2"><b>Inclusion criteria:</b> Acute </text>
<text top="562" left="378" width="117" height="17" font="0">arterial ischemia and </text>
<text top="579" left="378" width="66" height="17" font="0">required an </text>
<text top="597" left="378" width="112" height="17" font="0">urgent/emergent LE </text>
<text top="614" left="378" width="83" height="17" font="0">arterial bypass </text>
<text top="631" left="378" width="81" height="17" font="0">reconstruction </text>
<text top="648" left="378" width="3" height="17" font="0"> </text>
<text top="665" left="378" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="546" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="545" left="547" width="6" height="18" font="7"></text>
<text top="546" left="553" width="213" height="17" font="2"><b> endpoint:</b> Outcome of arterial bypass </text>
<text top="563" left="540" width="242" height="17" font="0">reconstruction in the setting of acute arterial </text>
<text top="581" left="540" width="52" height="17" font="0">ischemia </text>
<text top="598" left="540" width="3" height="17" font="0"> </text>
<text top="615" left="540" width="76" height="17" font="2"><b>Results: </b>N/A<b> </b></text>
<text top="632" left="540" width="7" height="18" font="7"></text>
<text top="633" left="547" width="211" height="17" font="0"> Mean duration of symptoms was 43 h </text>
<text top="651" left="540" width="231" height="17" font="0">(median 24), and mean time from hospital </text>
<text top="668" left="540" width="244" height="17" font="0">presentation to the operating room was 36 h </text>
<text top="685" left="540" width="69" height="17" font="0">(median 12) </text>
<text top="702" left="540" width="7" height="18" font="7"></text>
<text top="703" left="547" width="235" height="17" font="0"> Death, limb loss, or both, were associated </text>
<text top="721" left="540" width="253" height="17" font="0">with a paralytic limb (p=0.001) and congestive </text>
<text top="738" left="540" width="118" height="17" font="0">heart failure (p=0.03) </text>
<text top="545" left="817" width="24" height="17" font="0">N/A </text>
<text top="756" left="95" width="86" height="17" font="0">Fogarty TJ and </text>
<text top="773" left="95" width="62" height="17" font="0">Cranley JJ </text>
<text top="756" left="235" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="773" left="235" width="64" height="17" font="0">Descriptive </text>
<text top="756" left="378" width="130" height="17" font="2"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="773" left="378" width="3" height="17" font="0"> </text>
<text top="757" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="756" left="547" width="6" height="18" font="7"></text>
<text top="757" left="553" width="87" height="17" font="2"><b> endpoint: </b>N/A<b> </b></text>
<text top="774" left="540" width="3" height="17" font="0"> </text>
<text top="756" left="817" width="7" height="18" font="7"></text>
<text top="757" left="824" width="184" height="17" font="0"> First description of embolectomy </text>
<text top="774" left="817" width="48" height="17" font="0">catheter </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">170 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="63" height="17" font="0">1965 (376) </text>
<text top="104" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14263952">14263952 </a></text>
<text top="122" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="235" width="3" height="17" font="0"> </text>
<text top="104" left="235" width="129" height="17" font="2"><b>Size</b>: n=56 episodes of </text>
<text top="122" left="235" width="123" height="17" font="0">embolism occurring in </text>
<text top="139" left="235" width="37" height="17" font="0">50 pts </text>
<text top="87" left="378" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="87" left="540" width="76" height="17" font="2"><b>Results: </b>N/A<b> </b></text>
<text top="104" left="540" width="3" height="17" font="0"> </text>
<text top="157" left="95" width="82" height="17" font="0">Shin HS, et al. </text>
<text top="174" left="95" width="63" height="17" font="0">2013 (377) </text>
<text top="191" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24436594">24436594 </a></text>
<text top="208" left="95" width="3" height="17" font="0"> </text>
<text top="157" left="235" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="174" left="235" width="59" height="17" font="0">institution  </text>
<text top="191" left="235" width="3" height="17" font="0"> </text>
<text top="208" left="235" width="106" height="17" font="2"><b>Size:</b> n=18 acutely </text>
<text top="226" left="235" width="114" height="17" font="0">ischemic limbs in 14 </text>
<text top="243" left="235" width="88" height="17" font="0">consecutive pts </text>
<text top="157" left="378" width="143" height="17" font="2"><b>Inclusion criteria:</b> All pts </text>
<text top="174" left="378" width="47" height="17" font="0">with ALI </text>
<text top="191" left="378" width="3" height="17" font="0"> </text>
<text top="208" left="378" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="158" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="157" left="547" width="6" height="18" font="7"></text>
<text top="158" left="553" width="236" height="17" font="2"><b> endpoint:</b> Limb salvage via novel surgical </text>
<text top="175" left="540" width="55" height="17" font="0">approach </text>
<text top="192" left="540" width="3" height="17" font="0"> </text>
<text top="210" left="540" width="241" height="17" font="2"><b>Results: </b>Of 14 pts, 1 died and 1 underwent </text>
<text top="227" left="540" width="226" height="17" font="0">amputation. After 1 wk of anticoagulation </text>
<text top="244" left="540" width="261" height="17" font="0">therapy, ≥2 arterial pulses were detected at the </text>
<text top="261" left="540" width="263" height="17" font="0">ankles in all 15 limbs from the remaining 12 pts. </text>
<text top="278" left="540" width="226" height="17" font="0">All 15 limbs were salvaged successfully.<b> </b> </text>
<text top="157" left="817" width="7" height="18" font="7"></text>
<text top="158" left="824" width="68" height="17" font="0"> CTA for Dx </text>
<text top="175" left="817" width="7" height="18" font="7"></text>
<text top="176" left="824" width="115" height="17" font="10"> 71% heart disease:  </text>
<text top="194" left="817" width="117" height="17" font="10">57% atrial fibrillation  </text>
<text top="211" left="817" width="161" height="17" font="10">14% had a Hx of previous MI </text>
<text top="228" left="817" width="7" height="18" font="7"></text>
<text top="229" left="824" width="217" height="17" font="0"> 86% of pts with mixed thromboembolic </text>
<text top="246" left="817" width="46" height="17" font="0">disease </text>
<text top="264" left="817" width="7" height="18" font="7"></text>
<text top="265" left="824" width="197" height="17" font="0"> Below-knee exposure and 1 vessel </text>
<text top="282" left="817" width="35" height="17" font="0">runoff </text>
<text top="300" left="95" width="107" height="17" font="0">de Donato G, et al. </text>
<text top="317" left="95" width="63" height="17" font="0">2014 (378) </text>
<text top="334" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24342067">24342067 </a></text>
<text top="351" left="95" width="3" height="17" font="0"> </text>
<text top="300" left="235" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="317" left="235" width="93" height="17" font="0">institution cohort </text>
<text top="334" left="235" width="3" height="17" font="0"> </text>
<text top="351" left="235" width="90" height="17" font="2"><b>Size:</b> n=322 pts </text>
<text top="300" left="378" width="143" height="17" font="2"><b>Inclusion criteria:</b> All pts </text>
<text top="317" left="378" width="34" height="17" font="0">w ALI </text>
<text top="334" left="378" width="3" height="17" font="0"> </text>
<text top="351" left="378" width="132" height="17" font="2"><b>Exclusion criteria:</b> ALI </text>
<text top="369" left="378" width="120" height="17" font="0">from graft thrombosis </text>
<text top="301" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="300" left="547" width="6" height="18" font="7"></text>
<text top="301" left="553" width="63" height="17" font="2"><b> endpoint: </b></text>
<text top="318" left="540" width="7" height="18" font="7"></text>
<text top="319" left="547" width="142" height="17" font="0"> In-hospital complications </text>
<text top="337" left="540" width="7" height="18" font="7"></text>
<text top="338" left="547" width="81" height="17" font="0"> 30 d mortality </text>
<text top="355" left="540" width="7" height="18" font="7"></text>
<text top="356" left="547" width="180" height="17" font="0"> Primary and secondary patency </text>
<text top="373" left="540" width="7" height="18" font="7"></text>
<text top="374" left="547" width="111" height="17" font="0"> Reintervention rate </text>
<text top="392" left="540" width="7" height="18" font="7"></text>
<text top="393" left="547" width="79" height="17" font="0"> Limb salvage </text>
<text top="410" left="540" width="7" height="18" font="7"></text>
<text top="411" left="547" width="122" height="17" font="0"> Overall survival rates </text>
<text top="428" left="540" width="3" height="17" font="0"> </text>
<text top="446" left="540" width="234" height="17" font="2"><b>Results:</b> Reduction in complications when </text>
<text top="463" left="540" width="245" height="17" font="0">hybrid techniques utilized as opposed to just </text>
<text top="480" left="540" width="122" height="17" font="0">thromboembolectomy </text>
<text top="300" left="817" width="7" height="18" font="7"></text>
<text top="301" left="824" width="204" height="17" font="0"> Thromboembolectomy alone in 35% </text>
<text top="318" left="817" width="7" height="18" font="7"></text>
<text top="319" left="824" width="89" height="17" font="0"> 45.5% via CFA </text>
<text top="337" left="817" width="7" height="18" font="7"></text>
<text top="338" left="824" width="112" height="17" font="0"> 30 d mortality 4.4% </text>
<text top="355" left="817" width="7" height="18" font="7"></text>
<text top="356" left="824" width="168" height="17" font="0"> 15% in hospital complications </text>
<text top="373" left="817" width="7" height="18" font="7"></text>
<text top="374" left="824" width="194" height="17" font="0"> 8 pts w complication from catheter </text>
<text top="498" left="95" width="82" height="17" font="2"><b>VS.GNNE ALI </b></text>
<text top="515" left="95" width="81" height="17" font="0">Baril DT, et al. </text>
<text top="533" left="95" width="63" height="17" font="0">2013 (379) </text>
<text top="550" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23714364">23714364 </a></text>
<text top="567" left="95" width="3" height="17" font="0"> </text>
<text top="498" left="235" width="119" height="17" font="2"><b>Study type:</b> Registry </text>
<text top="515" left="235" width="39" height="17" font="0">review </text>
<text top="533" left="235" width="3" height="17" font="0"> </text>
<text top="550" left="235" width="90" height="17" font="2"><b>Size:</b> n=323 pts </text>
<text top="498" left="378" width="143" height="17" font="2"><b>Inclusion criteria:</b> All pts </text>
<text top="515" left="378" width="135" height="17" font="0">undergoing infrainguinal </text>
<text top="533" left="378" width="128" height="17" font="0">lower extremity bypass </text>
<text top="550" left="378" width="136" height="17" font="0">between 2003 and 2011 </text>
<text top="567" left="378" width="72" height="17" font="0">(ALI vs. CLI) </text>
<text top="584" left="378" width="3" height="17" font="0"> </text>
<text top="601" left="378" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="499" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="498" left="547" width="6" height="18" font="7"></text>
<text top="499" left="553" width="235" height="17" font="2"><b> endpoint:</b> Major amputation and mortality </text>
<text top="516" left="540" width="3" height="17" font="0"> </text>
<text top="534" left="540" width="264" height="17" font="2"><b>Results</b>: ALI predictor of both major amputation </text>
<text top="551" left="540" width="216" height="17" font="0">(HR: 2.16; CI: 1.38–3.40; p=0.001) and </text>
<text top="568" left="540" width="256" height="17" font="0">mortality (HR: 1.41; CI: 1.09–1.83; p=0.009) at </text>
<text top="585" left="540" width="20" height="17" font="0">1 y </text>
<text top="498" left="817" width="7" height="18" font="7"></text>
<text top="499" left="824" width="170" height="17" font="0"> Age and gender similar to CLI </text>
<text top="516" left="817" width="7" height="18" font="7"></text>
<text top="518" left="824" width="208" height="17" font="0"> ALI less likely to be on ASA (63% vs. </text>
<text top="535" left="817" width="199" height="17" font="0">75%; p&lt;0.0001) or a statin (55% vs. </text>
<text top="552" left="817" width="91" height="17" font="0">68%; p&lt;0.0001) </text>
<text top="569" left="817" width="7" height="18" font="7"></text>
<text top="570" left="824" width="210" height="17" font="0"> ALI more likely to be current smokers </text>
<text top="588" left="817" width="32" height="17" font="0">(49% </text>
<text top="605" left="817" width="219" height="17" font="0">vs. 39%; p&lt;0.0001), to have had a prior </text>
<text top="622" left="817" width="181" height="17" font="0">ipsilateral bypass (33% vs. 24%; </text>
<text top="639" left="817" width="160" height="17" font="0">p=0.004) or a prior ipsilateral </text>
<text top="656" left="817" width="196" height="17" font="0">percutaneous intervention (41% vs. </text>
<text top="674" left="817" width="87" height="17" font="0">29%; p=0.001]) </text>
<text top="692" left="95" width="107" height="17" font="0">Manojlović V, et al. </text>
<text top="709" left="95" width="63" height="17" font="0">2013 (380) </text>
<text top="726" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23534299">23534299</a></text>
<text top="726" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23534299"> </a></text>
<text top="743" left="95" width="3" height="17" font="0"> </text>
<text top="692" left="235" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="709" left="235" width="111" height="17" font="0">Retrospective study </text>
<text top="726" left="235" width="3" height="17" font="0"> </text>
<text top="743" left="235" width="83" height="17" font="2"><b>Size:</b> n=95 pts </text>
<text top="692" left="378" width="127" height="17" font="2"><b>Inclusion criteria:</b> Pts </text>
<text top="709" left="378" width="126" height="17" font="0">operated on ≤6 h after </text>
<text top="726" left="378" width="146" height="17" font="0">onset of symptoms of ALI. </text>
<text top="743" left="378" width="3" height="17" font="0"> </text>
<text top="761" left="378" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="693" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="692" left="547" width="6" height="18" font="7"></text>
<text top="693" left="553" width="247" height="17" font="2"><b> endpoint:</b> Preserved extremity, amputation, </text>
<text top="710" left="540" width="101" height="17" font="0">and fatal outcome </text>
<text top="727" left="540" width="3" height="17" font="0"> </text>
<text top="745" left="540" width="55" height="17" font="2"><b>Results</b>:  </text>
<text top="762" left="540" width="7" height="18" font="7"></text>
<text top="763" left="547" width="220" height="17" font="0"> More pts had embolism of blood vessel </text>
<text top="692" left="817" width="7" height="18" font="7"></text>
<text top="693" left="824" width="142" height="17" font="0"> Majority of pts age ≥70 y </text>
<text top="710" left="817" width="7" height="18" font="7"></text>
<text top="711" left="824" width="179" height="17" font="0"> Surgical procedures showed no </text>
<text top="728" left="817" width="220" height="17" font="0">difference when final outcome analyzed </text>
<text top="746" left="817" width="7" height="18" font="7"></text>
<text top="747" left="824" width="213" height="17" font="0"> Mortality rate was 10.5% and 7/10 pts </text>
<text top="764" left="817" width="204" height="17" font="0">with this outcome had severe form of </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">171 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="378" width="131" height="17" font="0">Previous reconstructive </text>
<text top="104" left="378" width="116" height="17" font="0">procedures on blood </text>
<text top="122" left="378" width="139" height="17" font="0">vessels and where acute </text>
<text top="139" left="378" width="107" height="17" font="0">ischemia had been </text>
<text top="156" left="378" width="119" height="17" font="0">induced by trauma or </text>
<text top="173" left="378" width="147" height="17" font="0">aneurysmal disease of the </text>
<text top="190" left="378" width="136" height="17" font="0">peripheral blood vessels<b> </b></text>
<text top="87" left="540" width="257" height="17" font="0">(73.7%) compared to a chronic lesion (26.3%); </text>
<text top="104" left="540" width="41" height="17" font="0">p&lt;0.05 </text>
<text top="122" left="540" width="7" height="18" font="7"></text>
<text top="123" left="547" width="189" height="17" font="0"> 86.2% of pts achieved successful </text>
<text top="140" left="540" width="96" height="17" font="0">revascularization </text>
<text top="157" left="540" width="7" height="18" font="7"></text>
<text top="158" left="547" width="248" height="17" font="0"> 3.2% of pts had mputating treatment ≤30 d.  </text>
<text top="176" left="540" width="7" height="18" font="7"></text>
<text top="177" left="547" width="187" height="17" font="0"> 10.5% of pts had a fatal outcome </text>
<text top="87" left="817" width="213" height="17" font="0">chronic myocardiopathy and metabolic </text>
<text top="104" left="817" width="94" height="17" font="0">decompensation </text>
<text top="122" left="817" width="7" height="18" font="7"></text>
<text top="123" left="824" width="194" height="17" font="0"> High success rate, with successful </text>
<text top="140" left="817" width="225" height="17" font="0">revascularization of LE achieved in 85%. </text>
<text top="157" left="817" width="195" height="17" font="0">This demonstrates benefits of early </text>
<text top="174" left="817" width="222" height="17" font="0">operative treatment in ALI, regardless of </text>
<text top="192" left="817" width="207" height="17" font="0">the clause of ischemia (thrombosis or </text>
<text top="209" left="817" width="60" height="17" font="0">embolism) </text>
<text top="227" left="95" width="80" height="17" font="0">Duval S, et al. </text>
<text top="244" left="95" width="63" height="17" font="0">2014 (381) </text>
<text top="261" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25262269">25262269 </a></text>
<text top="278" left="95" width="3" height="17" font="0"> </text>
<text top="227" left="235" width="119" height="17" font="2"><b>Study type:</b> Registry </text>
<text top="244" left="235" width="3" height="17" font="0"> </text>
<text top="261" left="235" width="90" height="17" font="2"><b>Size:</b> n=200 pts </text>
<text top="227" left="378" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="244" left="378" width="7" height="18" font="7"></text>
<text top="245" left="385" width="98" height="17" font="0"> Limb threatening </text>
<text top="262" left="378" width="52" height="17" font="0">ischemia </text>
<text top="280" left="378" width="7" height="18" font="7"></text>
<text top="281" left="385" width="85" height="17" font="0"> Enrolled in the </text>
<text top="298" left="378" width="101" height="17" font="0">FRIENDS registry </text>
<text top="315" left="378" width="3" height="17" font="0"> </text>
<text top="332" left="378" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="350" left="378" width="7" height="18" font="7"></text>
<text top="351" left="385" width="27" height="17" font="0"> N/A </text>
<text top="228" left="540" width="7" height="17" font="2"><b>1</b></text>
<text top="227" left="547" width="6" height="18" font="7"></text>
<text top="228" left="553" width="202" height="17" font="2"><b> endpoint:</b> Amputation and mortality </text>
<text top="245" left="540" width="3" height="17" font="0"> </text>
<text top="262" left="540" width="55" height="17" font="2"><b>Results</b>:  </text>
<text top="280" left="540" width="7" height="18" font="7"></text>
<text top="281" left="547" width="250" height="17" font="0"> Duration of limb ischemia in pts with ALI was </text>
<text top="298" left="540" width="226" height="17" font="0">associated with much higher rates of first </text>
<text top="315" left="540" width="256" height="17" font="0">amputation (p= o.0002) and worse amputation-</text>
<text top="332" left="540" width="207" height="17" font="0">free survival (p=0.037). No significant </text>
<text top="350" left="540" width="239" height="17" font="0">associations were observed in pts with CLI. </text>
<text top="367" left="540" width="7" height="18" font="7"></text>
<text top="368" left="547" width="233" height="17" font="0"> Increased duration of limb ischemia in pts </text>
<text top="385" left="540" width="236" height="17" font="0">with ALI was associated with progressively </text>
<text top="402" left="540" width="239" height="17" font="0">increased 30-day ambputation (p=0.028 for </text>
<text top="420" left="540" width="36" height="17" font="0">trend) </text>
<text top="227" left="817" width="7" height="18" font="7"></text>
<text top="228" left="824" width="211" height="17" font="0"> The longer lower extremity symptoms </text>
<text top="245" left="817" width="226" height="17" font="0">in ALI occur, the less likely the possibility </text>
<text top="262" left="817" width="59" height="17" font="0">of salvage </text>
<text top="280" left="817" width="7" height="18" font="7"></text>
<text top="281" left="824" width="186" height="17" font="0"> Limb ALI episodes are extreamly </text>
<text top="298" left="817" width="220" height="17" font="0">deadly, even with limb revascularization </text>
<text top="315" left="817" width="3" height="17" font="0"> </text>
<text top="438" left="86" width="1015" height="17" font="0">ALI indicates acute limb ischemia; CI, confidence interval; CFA, common femoral artery; CLI, critical limb; CTA, computed tomography angiography; HR, hazard ratio; LE, lower extremity; </text>
<text top="455" left="86" width="447" height="17" font="0">MI, myocardial infarction; N/A, not applicable; OR, odds ratio; and RR, relative risk</text>
<text top="455" left="534" width="7" height="17" font="9">. </text>
<text top="472" left="86" width="3" height="17" font="9"> </text>
<text top="489" left="86" width="3" height="17" font="9"> </text>
<text top="506" left="86" width="925" height="21" font="1"><b>Evidence Table 46. Nonrandomized Trials, Observational studies, and/or Registries Comparing Evaluating Noninvasive Testing and </b></text>
<text top="527" left="86" width="237" height="21" font="1"><b>Angiography for ALI–Section 9.1. </b></text>
<text top="548" left="104" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="566" left="129" width="48" height="17" font="2"><b>Author; </b></text>
<text top="583" left="107" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="548" left="242" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="566" left="269" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="548" left="417" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="548" left="606" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="566" left="614" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="583" left="666" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="548" left="874" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="566" left="901" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="601" left="95" width="109" height="17" font="0">Morris-Stiff G, et al. </text>
<text top="618" left="95" width="63" height="17" font="0">2009 (382) </text>
<text top="635" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19785938">19785938 </a></text>
<text top="653" left="95" width="3" height="17" font="0"> </text>
<text top="601" left="224" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="618" left="224" width="145" height="17" font="0">review comparing pts with </text>
<text top="635" left="224" width="131" height="17" font="0">ALI from 2 time periods </text>
<text top="653" left="224" width="3" height="17" font="0"> </text>
<text top="670" left="224" width="90" height="17" font="2"><b>Size:</b> n=205 pts </text>
<text top="601" left="392" width="127" height="17" font="2"><b>Inclusion criteria:</b> Pts </text>
<text top="618" left="392" width="146" height="17" font="0">presenting with ALI during </text>
<text top="635" left="392" width="116" height="17" font="0">specified time period </text>
<text top="653" left="392" width="3" height="17" font="0"> </text>
<text top="670" left="392" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="601" left="567" width="230" height="17" font="2"><b>Results:</b> Despite increased pre-operative </text>
<text top="618" left="567" width="246" height="17" font="0">(15% vs. 47%; p&lt;0.05) and on-table imaging </text>
<text top="635" left="567" width="241" height="17" font="0">(0% vs. 16%; p&lt;0.05) technical success did </text>
<text top="653" left="567" width="71" height="17" font="0">not improve. </text>
<text top="601" left="837" width="7" height="18" font="7"></text>
<text top="602" left="844" width="167" height="17" font="0"> Delay from symptom onset to </text>
<text top="619" left="837" width="183" height="17" font="0">surgery is a major determinant of </text>
<text top="636" left="837" width="54" height="17" font="0">outcome. </text>
<text top="688" left="95" width="101" height="17" font="0">Londero LS, et al. </text>
<text top="705" left="95" width="63" height="17" font="0">2014 (383) </text>
<text top="722" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25400690">25400690 </a></text>
<text top="739" left="95" width="3" height="17" font="0"> </text>
<text top="688" left="224" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="705" left="224" width="123" height="17" font="0">cross-sectional cohort </text>
<text top="722" left="224" width="120" height="17" font="0">study including all pts </text>
<text top="739" left="224" width="107" height="17" font="0">suspected with ALI </text>
<text top="757" left="224" width="3" height="17" font="0"> </text>
<text top="774" left="224" width="86" height="17" font="2"><b>Size:</b> n=42 pts  </text>
<text top="688" left="392" width="126" height="17" font="2"><b>Inclusion criteria:</b> All  </text>
<text top="705" left="392" width="3" height="17" font="0"> </text>
<text top="722" left="392" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="689" left="567" width="7" height="17" font="2"><b>1</b></text>
<text top="688" left="574" width="6" height="18" font="7"></text>
<text top="689" left="580" width="204" height="17" font="2"><b> endpoint:</b> 30 pts needed immediate </text>
<text top="706" left="567" width="240" height="17" font="0">intervention. In the group of 14 pts who had </text>
<text top="723" left="567" width="237" height="17" font="0">immediate operation, the median time from </text>
<text top="740" left="567" width="243" height="17" font="0">vascular evaluation to revascularization was </text>
<text top="758" left="567" width="253" height="17" font="0">324.5 (122–873) min and in the group of 8 pts </text>
<text top="775" left="567" width="221" height="17" font="0">that went through an imaging procedure </text>
<text top="688" left="837" width="7" height="18" font="7"></text>
<text top="689" left="844" width="154" height="17" font="0"> If CT or MRA was used the </text>
<text top="706" left="837" width="176" height="17" font="0">intervention was delayed by 3 h </text>
<text top="723" left="837" width="7" height="18" font="7"></text>
<text top="724" left="844" width="194" height="17" font="0"> No clear delay to angiography, but </text>
<text top="742" left="837" width="183" height="17" font="0">thrombolysis duration was longer </text>
<text top="759" left="837" width="72" height="17" font="0">than surgery<b> </b></text>
</page>
<page number="172" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">172 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="567" width="256" height="17" font="0">before an operation the median delay was 822 </text>
<text top="104" left="567" width="254" height="17" font="0">(494–1185) min from specialist assessment to </text>
<text top="122" left="567" width="212" height="17" font="0">revascularization. The median time for </text>
<text top="139" left="567" width="226" height="17" font="0">revascularization among 4 pts, who were </text>
<text top="156" left="567" width="237" height="17" font="0">treated with arterial thrombolysis was 5621 </text>
<text top="173" left="567" width="100" height="17" font="0">(1686–8376) min. </text>
<text top="191" left="86" width="1006" height="17" font="0">ALI indicates acute limb ischemia; CI, confidence interval; CLI, critical limb ischemia; CT, computed tomography; DSA, digital subtraction angiography; DUAM, duplex ultrasound arterial </text>
<text top="208" left="86" width="748" height="17" font="0">mapping; HR, hazard ratio; N/A, not applicable; MRA, magnetic resonance angiography; OR, odds ratio; pt, patient; and RR, relative risk. </text>
<text top="226" left="86" width="3" height="17" font="0"> </text>
<text top="243" left="86" width="3" height="17" font="0"> </text>
<text top="260" left="86" width="544" height="21" font="1"><b>Evidence Table 47. RCTs of Revascularization Strategy for ALI–Section 9.2.2. </b></text>
<text top="281" left="123" width="38" height="17" font="2"><b>Study </b></text>
<text top="299" left="112" width="61" height="17" font="2"><b>Acronym; </b></text>
<text top="316" left="118" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="333" left="96" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="281" left="222" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="299" left="227" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="316" left="221" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="281" left="394" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="281" left="583" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="299" left="600" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="316" left="583" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="333" left="604" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="281" left="768" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="299" left="716" width="210" height="17" font="2"><b>(Absolute Event Rates, P value; OR </b></text>
<text top="316" left="794" width="57" height="17" font="2"><b>or RR; &amp;  </b></text>
<text top="333" left="797" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="283" left="940" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="281" left="1002" width="6" height="18" font="7"></text>
<text top="283" left="1008" width="60" height="17" font="2"><b> Endpoint </b></text>
<text top="300" left="980" width="48" height="17" font="2"><b>(if any); </b></text>
<text top="317" left="949" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="334" left="956" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="352" left="95" width="81" height="17" font="0">Ouriel K, et al. </text>
<text top="369" left="95" width="63" height="17" font="0">1994 (384) </text>
<text top="387" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8201703">8201703 </a></text>
<text top="404" left="95" width="3" height="17" font="0"> </text>
<text top="352" left="203" width="81" height="17" font="2"><b>Aim:</b> Catheter </text>
<text top="369" left="203" width="117" height="17" font="0">directed Intra-arterial </text>
<text top="387" left="203" width="120" height="17" font="0">urokinase vs. surgery </text>
<text top="404" left="203" width="3" height="17" font="0"> </text>
<text top="421" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="438" left="203" width="3" height="17" font="0"> </text>
<text top="455" left="203" width="106" height="17" font="2"><b>Size:</b> n=57 pts IAT </text>
<text top="473" left="203" width="115" height="17" font="0">vs. n=57 pts surgery </text>
<text top="352" left="338" width="156" height="17" font="2"><b>Inclusion criteria:</b> ALI &lt;7 d </text>
<text top="369" left="338" width="3" height="17" font="0"> </text>
<text top="387" left="338" width="214" height="17" font="2"><b>Exclusion criteria:</b> Pts were excluded </text>
<text top="404" left="338" width="171" height="17" font="0">from study if they manifested a </text>
<text top="421" left="338" width="221" height="17" font="0">contraindication to thrombolytic therapy, </text>
<text top="438" left="338" width="221" height="17" font="0">including one or more of the following: a </text>
<text top="455" left="338" width="213" height="17" font="0">major operative procedure within 14 d, </text>
<text top="473" left="338" width="168" height="17" font="0">active peptic ulcer disease, an </text>
<text top="490" left="338" width="191" height="17" font="0">intracranial neoplasm, or a Hx of a </text>
<text top="507" left="338" width="221" height="17" font="0">cerebrovascular accident. Pts were also </text>
<text top="524" left="338" width="213" height="17" font="0">excluded if they had a contraindication </text>
<text top="542" left="338" width="191" height="17" font="0">to operative revascularization; non-</text>
<text top="559" left="338" width="183" height="17" font="0">ambulatory prior to ALI or Cr&gt;2.5<b> </b></text>
<text top="352" left="574" width="129" height="17" font="2"><b>Intervention:</b> Catheter </text>
<text top="369" left="574" width="104" height="17" font="0">directed urokinase </text>
<text top="387" left="574" width="3" height="17" font="0"> </text>
<text top="404" left="574" width="124" height="17" font="2"><b>Comparator:</b> Surgery </text>
<text top="353" left="716" width="7" height="17" font="2"><b>1</b></text>
<text top="352" left="722" width="6" height="18" font="7"></text>
<text top="353" left="729" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="371" left="716" width="7" height="18" font="7"></text>
<text top="372" left="722" width="186" height="17" font="0"> Limb salvage 82% at 12 mo both </text>
<text top="389" left="716" width="41" height="17" font="0">groups </text>
<text top="406" left="716" width="7" height="18" font="7"></text>
<text top="407" left="722" width="193" height="17" font="0"> Survival 84% IAT vs. 58% surgery </text>
<text top="425" left="716" width="96" height="17" font="0">at 12 mo, p=0.01 </text>
<text top="352" left="938" width="7" height="18" font="7"></text>
<text top="353" left="945" width="61" height="17" font="0"> Increased </text>
<text top="371" left="938" width="94" height="17" font="0">cardiopulmonary </text>
<text top="388" left="938" width="91" height="17" font="0">complications in </text>
<text top="405" left="938" width="126" height="17" font="0">surgery group 49% vs. </text>
<text top="422" left="938" width="80" height="17" font="0">16%, p=0.001 </text>
<text top="439" left="938" width="3" height="17" font="0"> </text>
<text top="577" left="95" width="46" height="17" font="2"><b>TOPAS</b> </text>
<text top="594" left="95" width="81" height="17" font="0">Ouriel K, et al. </text>
<text top="611" left="95" width="63" height="17" font="0">1998 (356) </text>
<text top="628" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9545358">9545358 </a></text>
<text top="646" left="95" width="3" height="17" font="0"> </text>
<text top="577" left="203" width="81" height="17" font="2"><b>Aim:</b> Catheter </text>
<text top="594" left="203" width="117" height="17" font="0">directed Intra-arterial </text>
<text top="611" left="203" width="120" height="17" font="0">urokinase vs. surgery </text>
<text top="628" left="203" width="3" height="17" font="0"> </text>
<text top="646" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="663" left="203" width="3" height="17" font="0"> </text>
<text top="680" left="203" width="113" height="17" font="2"><b>Size:</b> n=272 pts IAT </text>
<text top="697" left="203" width="121" height="17" font="0">vs. n=272 pts surgery </text>
<text top="577" left="338" width="163" height="17" font="2"><b>Inclusion criteria:</b> ALI ≤14 d </text>
<text top="594" left="338" width="3" height="17" font="0"> </text>
<text top="611" left="338" width="199" height="17" font="2"><b>Exclusion criteria:</b> pts ineligible for </text>
<text top="628" left="338" width="79" height="17" font="0">thrombolytics <b> </b></text>
<text top="577" left="574" width="129" height="17" font="2"><b>Intervention:</b> Catheter </text>
<text top="594" left="574" width="115" height="17" font="0">directered urokinase </text>
<text top="611" left="574" width="3" height="17" font="0"> </text>
<text top="628" left="574" width="124" height="17" font="2"><b>Comparator:</b> Surgery </text>
<text top="578" left="716" width="7" height="17" font="2"><b>1</b></text>
<text top="577" left="722" width="6" height="18" font="7"></text>
<text top="578" left="729" width="182" height="17" font="2"><b> endpoint:</b> 6 mo amputation free </text>
<text top="595" left="716" width="193" height="17" font="0">survival 71.68 IAT vs. 74.8 surgery </text>
<text top="612" left="716" width="41" height="17" font="0">p=0.43 </text>
<text top="629" left="716" width="3" height="17" font="0"> </text>
<text top="647" left="716" width="209" height="17" font="2"><b>Safety endpoint:</b> Mortality at hospital </text>
<text top="664" left="716" width="184" height="17" font="0">discharge 8.8 IAT vs. 5.9 surgery </text>
<text top="681" left="716" width="45" height="17" font="0">p=0.19  </text>
<text top="577" left="938" width="24" height="17" font="0">N/A </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">173 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="42" height="17" font="2"><b>STILE</b>  </text>
<text top="104" left="95" width="89" height="17" font="0">Graor RA, et al. </text>
<text top="122" left="95" width="63" height="17" font="0">1994 (385) </text>
<text top="139" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8092895">8092895 </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="81" height="17" font="2"><b>Aim:</b> Catheter </text>
<text top="104" left="203" width="117" height="17" font="0">directed Intra-arterial </text>
<text top="122" left="203" width="113" height="17" font="0">tPA or urokinase vs. </text>
<text top="139" left="203" width="44" height="17" font="0">surgery </text>
<text top="156" left="203" width="3" height="17" font="0"> </text>
<text top="173" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="190" left="203" width="3" height="17" font="0"> </text>
<text top="208" left="203" width="117" height="17" font="2"><b>Size:</b> n=137 pts tPA, </text>
<text top="225" left="203" width="101" height="17" font="0">n=112 pts UK, N= </text>
<text top="242" left="203" width="92" height="17" font="0">144 pts surgery  </text>
<text top="87" left="338" width="109" height="17" font="2"><b>Inclusion criteria:  </b></text>
<text top="104" left="338" width="7" height="18" font="7"></text>
<text top="105" left="344" width="54" height="17" font="0"> 18–90 y  </text>
<text top="123" left="338" width="7" height="18" font="7"></text>
<text top="124" left="344" width="210" height="17" font="0"> Signs or symptoms of worsening limb </text>
<text top="141" left="338" width="191" height="17" font="0">ischemia within the past 6 mo who </text>
<text top="158" left="338" width="119" height="17" font="0">required intervention  </text>
<text top="176" left="338" width="7" height="18" font="7"></text>
<text top="177" left="344" width="168" height="17" font="0"> Angiographically documented </text>
<text top="194" left="338" width="192" height="17" font="0">nonembolic arterial or bypass graft </text>
<text top="211" left="338" width="58" height="17" font="0">occlusion  </text>
<text top="228" left="338" width="3" height="17" font="0"> </text>
<text top="246" left="338" width="205" height="17" font="2"><b>Exclusion criteria:</b> infected grafts or </text>
<text top="263" left="338" width="144" height="17" font="0">contraindications to lytics <b> </b></text>
<text top="87" left="574" width="129" height="17" font="2"><b>Intervention:</b> Catheter </text>
<text top="104" left="574" width="118" height="17" font="0">directed urokinase or </text>
<text top="122" left="574" width="23" height="17" font="0">tPA </text>
<text top="139" left="574" width="3" height="17" font="0"> </text>
<text top="156" left="574" width="127" height="17" font="2"><b>Comparator:</b> Surgery  </text>
<text top="88" left="716" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="722" width="6" height="18" font="7"></text>
<text top="88" left="729" width="165" height="17" font="2"><b> endpoint:</b> Composite clinical </text>
<text top="106" left="716" width="146" height="17" font="0">outcome (see page 255 of </text>
<text top="123" left="716" width="176" height="17" font="0">mansuscript) 22.6% surgery vs. </text>
<text top="140" left="716" width="113" height="17" font="0">38.3% IAT, p=0.011 </text>
<text top="87" left="938" width="7" height="18" font="7"></text>
<text top="88" left="945" width="87" height="17" font="0"> Note: failure of </text>
<text top="106" left="938" width="108" height="17" font="0">catheter placement </text>
<text top="123" left="938" width="129" height="17" font="0">occurred in 28% of IAT </text>
<text top="140" left="938" width="129" height="17" font="0">group resulting in large </text>
<text top="157" left="938" width="62" height="17" font="0">failure rate </text>
<text top="174" left="938" width="7" height="18" font="7"></text>
<text top="175" left="945" width="105" height="17" font="0"> Poor quality study </text>
<text top="281" left="95" width="92" height="17" font="0">Comerota AJ, et </text>
<text top="298" left="95" width="16" height="17" font="0">al. </text>
<text top="315" left="95" width="63" height="17" font="0">1996 (386) </text>
<text top="332" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8795509">8795509 </a></text>
<text top="350" left="95" width="3" height="17" font="0"> </text>
<text top="281" left="203" width="96" height="17" font="2"><b>Aim:</b> Surgery vs. </text>
<text top="298" left="203" width="99" height="17" font="0">CDT for occluded </text>
<text top="315" left="203" width="77" height="17" font="0">bypass grafts </text>
<text top="332" left="203" width="3" height="17" font="0"> </text>
<text top="350" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="367" left="203" width="3" height="17" font="0"> </text>
<text top="384" left="203" width="114" height="17" font="2"><b>Size:</b> Surgery (n=46 </text>
<text top="401" left="203" width="102" height="17" font="0">pts) or CDT (n=78 </text>
<text top="418" left="203" width="24" height="17" font="0">pts) </text>
<text top="281" left="338" width="220" height="17" font="2"><b>Inclusion criteria:</b> ALI &lt;14 d or chronic </text>
<text top="298" left="338" width="86" height="17" font="0">ischemia &gt;14 d </text>
<text top="315" left="338" width="3" height="17" font="0"> </text>
<text top="332" left="338" width="210" height="17" font="2"><b>Exclusion criteria:</b> contra-indications </text>
<text top="350" left="338" width="90" height="17" font="0">to thrombolysis <b> </b></text>
<text top="281" left="574" width="107" height="17" font="2"><b>Intervention:</b> CDT </text>
<text top="298" left="574" width="3" height="17" font="0"> </text>
<text top="315" left="574" width="124" height="17" font="2"><b>Comparator:</b> Surgery </text>
<text top="282" left="716" width="7" height="17" font="2"><b>1</b></text>
<text top="281" left="722" width="6" height="18" font="7"></text>
<text top="282" left="729" width="66" height="17" font="2"><b> endpoint:  </b></text>
<text top="299" left="716" width="7" height="18" font="7"></text>
<text top="300" left="722" width="165" height="17" font="0"> A composite clinical outcome </text>
<text top="318" left="716" width="157" height="17" font="0">including death, amputation, </text>
<text top="335" left="716" width="179" height="17" font="0">ongoing/recurrent ischemia, and </text>
<text top="352" left="716" width="200" height="17" font="0">major morbidity was analyzed on an </text>
<text top="369" left="716" width="197" height="17" font="0">intent-to-treat basis at 30 d and 1 y. </text>
<text top="386" left="716" width="7" height="18" font="7"></text>
<text top="387" left="722" width="167" height="17" font="0"> Acutely ischemic pts (0–14 d) </text>
<text top="405" left="716" width="198" height="17" font="0">randomized to lysis demonstrated a </text>
<text top="422" left="716" width="149" height="17" font="0">trend toward a lower major </text>
<text top="439" left="716" width="186" height="17" font="0">amputation rate at 30 d (p=0.074) </text>
<text top="456" left="716" width="181" height="17" font="0">and significantly at 1 y (p=0.026) </text>
<text top="474" left="716" width="184" height="17" font="0">compared with surgical pts, while </text>
<text top="491" left="716" width="208" height="17" font="0">those with &gt;14 d ischemia showed no </text>
<text top="508" left="716" width="200" height="17" font="0">difference in limb salvage but higher </text>
<text top="525" left="716" width="209" height="17" font="0">ongoing/recurrent ischemia in lytic pts </text>
<text top="542" left="716" width="56" height="17" font="0">(p&lt;0.001) </text>
<text top="281" left="938" width="7" height="18" font="7"></text>
<text top="282" left="945" width="123" height="17" font="0"> For ALI &lt;14 d CDT is </text>
<text top="299" left="938" width="97" height="17" font="0">similar to surgery </text>
<text top="560" left="95" width="77" height="17" font="0">Diffin DC and </text>
<text top="578" left="95" width="68" height="17" font="0">Kandarpa K </text>
<text top="595" left="95" width="63" height="17" font="0">1996 (387) </text>
<text top="612" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8773976">8773976</a></text>
<text top="612" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8773976"> </a></text>
<text top="629" left="95" width="3" height="17" font="0"> </text>
<text top="560" left="203" width="95" height="17" font="2"><b>Aim:</b> Review the </text>
<text top="578" left="203" width="113" height="17" font="0">risks and benefits of </text>
<text top="595" left="203" width="118" height="17" font="0">PIAT vs. SR as initial </text>
<text top="612" left="203" width="60" height="17" font="0">tx for ALLI </text>
<text top="629" left="203" width="3" height="17" font="0"> </text>
<text top="646" left="203" width="120" height="17" font="2"><b>Study type:</b> Analysis </text>
<text top="664" left="203" width="59" height="17" font="0">of 2 RCTs </text>
<text top="681" left="203" width="3" height="17" font="0"> </text>
<text top="698" left="203" width="105" height="17" font="2"><b>Size:</b> SR (n=1,051 </text>
<text top="715" left="203" width="111" height="17" font="0">pts) or PIAT (n=895 </text>
<text top="733" left="203" width="24" height="17" font="0">pts) </text>
<text top="560" left="338" width="222" height="17" font="2"><b>Inclusion criteria:</b> Published RCTs that </text>
<text top="578" left="338" width="203" height="17" font="0">compared PIAT with SR as the initial </text>
<text top="595" left="338" width="98" height="17" font="0">treatment of ALLI </text>
<text top="612" left="338" width="3" height="17" font="0"> </text>
<text top="629" left="338" width="179" height="17" font="2"><b>Exclusion criteria:</b> Studied that </text>
<text top="646" left="338" width="203" height="17" font="0">included &gt;1 disease category but did </text>
<text top="664" left="338" width="179" height="17" font="0">not specifically stratify results by </text>
<text top="681" left="338" width="51" height="17" font="0">category<b> </b></text>
<text top="560" left="574" width="109" height="17" font="2"><b>Intervention:</b> PIAT </text>
<text top="578" left="574" width="3" height="17" font="0"> </text>
<text top="595" left="574" width="98" height="17" font="2"><b>Comparator:</b> SR </text>
<text top="561" left="716" width="7" height="17" font="2"><b>1</b></text>
<text top="560" left="722" width="6" height="18" font="7"></text>
<text top="561" left="729" width="163" height="17" font="2"><b> endpoint: </b>Limb salvage and </text>
<text top="579" left="716" width="166" height="17" font="0">mortality at 30 d and 6–12 mo<b> </b></text>
<text top="560" left="938" width="7" height="18" font="7"></text>
<text top="561" left="945" width="124" height="17" font="0"> Limb salvage rates at </text>
<text top="579" left="938" width="119" height="17" font="0">30 d for PIAT vs. SR: </text>
<text top="596" left="938" width="82" height="17" font="0">93%; vs. 89%  </text>
<text top="613" left="938" width="7" height="18" font="7"></text>
<text top="614" left="945" width="124" height="17" font="0"> Limb salvage rates at </text>
<text top="632" left="938" width="119" height="17" font="0">6–12 mo for PIAT vs. </text>
<text top="649" left="938" width="103" height="17" font="0">SR: 89%; vs. 73% </text>
<text top="666" left="938" width="7" height="18" font="7"></text>
<text top="667" left="945" width="96" height="17" font="0"> PIAT better limb-</text>
<text top="684" left="938" width="94" height="17" font="0">salvage rate and </text>
<text top="702" left="938" width="131" height="17" font="0">mortality than SR in the </text>
<text top="719" left="938" width="98" height="17" font="0">treatment of ALLI </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">174 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="94" height="17" font="0">Schrijver AM,, et </text>
<text top="104" left="95" width="16" height="17" font="0">al. </text>
<text top="122" left="95" width="63" height="17" font="0">2011 (388) </text>
<text top="139" left="95" width="75" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033836/">PMC3033836</a></text>
<text top="139" left="170" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033836/"> </a></text>
<text top="156" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="203" width="99" height="17" font="2"><b>Study type:</b> RCT </text>
<text top="104" left="203" width="3" height="17" font="0"> </text>
<text top="122" left="203" width="83" height="17" font="2"><b>Size:</b> n=60 pts </text>
<text top="87" left="338" width="109" height="17" font="2"><b>Inclusion criteria:</b>  </text>
<text top="104" left="338" width="7" height="18" font="7"></text>
<text top="105" left="344" width="140" height="17" font="0"> Pts age &gt;18 y and &lt;85 y </text>
<text top="123" left="338" width="7" height="18" font="7"></text>
<text top="124" left="344" width="206" height="17" font="0"> Pts with thrombosed femoropopliteal </text>
<text top="141" left="338" width="182" height="17" font="0">or femorocrural native arteries or </text>
<text top="158" left="338" width="217" height="17" font="0">femoropopliteal or femorocrural venous </text>
<text top="176" left="338" width="173" height="17" font="0">or prosthetic bypass grafts with </text>
<text top="193" left="338" width="212" height="17" font="0">ischemic complaints between 1–7 wks </text>
<text top="210" left="338" width="7" height="18" font="7"></text>
<text top="211" left="344" width="201" height="17" font="0"> Pts with acute lower limb ischaemia </text>
<text top="228" left="338" width="211" height="17" font="0">class I and IIa according to Rutherford </text>
<text top="246" left="338" width="73" height="17" font="0">classification </text>
<text top="263" left="338" width="7" height="18" font="7"></text>
<text top="264" left="344" width="183" height="17" font="0"> Pts understand the nature of the </text>
<text top="281" left="338" width="217" height="17" font="0">procedure and provide written informed </text>
<text top="298" left="338" width="47" height="17" font="0">consent </text>
<text top="316" left="338" width="3" height="17" font="0"> </text>
<text top="333" left="338" width="113" height="17" font="2"><b>Exclusion criteria:</b>  </text>
<text top="350" left="338" width="7" height="18" font="7"></text>
<text top="351" left="344" width="180" height="17" font="0"> Isolated common femoral artery </text>
<text top="368" left="338" width="64" height="17" font="0">thrombosis </text>
<text top="386" left="338" width="7" height="18" font="7"></text>
<text top="387" left="344" width="215" height="17" font="0"> localized emboli (&lt;5 cm) or occlusions </text>
<text top="404" left="338" width="202" height="17" font="0">in the native femoropopliteal arteries </text>
<text top="421" left="338" width="7" height="18" font="7"></text>
<text top="422" left="344" width="182" height="17" font="0"> Clinical complaints of ALI due to </text>
<text top="440" left="338" width="200" height="17" font="0">thrombosis of the femoropopliteal or </text>
<text top="457" left="338" width="171" height="17" font="0">femorocrural native arteries, or </text>
<text top="474" left="338" width="217" height="17" font="0">femoropopliteal or femorocrural venous </text>
<text top="491" left="338" width="219" height="17" font="0">or prothetic bypass grafts &lt;1 wk and &gt;7 </text>
<text top="508" left="338" width="18" height="17" font="0">wk </text>
<text top="526" left="338" width="7" height="18" font="7"></text>
<text top="527" left="344" width="173" height="17" font="0"> ALI class IIb and III Rutherford </text>
<text top="544" left="338" width="73" height="17" font="0">classification </text>
<text top="561" left="338" width="213" height="17" font="0">Antiplatelet therapy, anticoagulants, or </text>
<text top="578" left="338" width="212" height="17" font="0">thrombolytic drugs are contraindicated </text>
<text top="596" left="338" width="7" height="18" font="7"></text>
<text top="597" left="344" width="190" height="17" font="0"> &lt;6 wk ischemic stroke or cerebral </text>
<text top="614" left="338" width="50" height="17" font="0">bleeding </text>
<text top="631" left="338" width="7" height="18" font="7"></text>
<text top="632" left="344" width="70" height="17" font="0"> 6 wk surger </text>
<text top="650" left="338" width="7" height="18" font="7"></text>
<text top="651" left="344" width="215" height="17" font="0"> DBP &gt;110 mm HG, SBP &gt;200 mm Hg </text>
<text top="668" left="338" width="7" height="18" font="7"></text>
<text top="669" left="344" width="113" height="17" font="0"> Current malignancy </text>
<text top="686" left="338" width="7" height="18" font="7"></text>
<text top="687" left="344" width="181" height="17" font="0"> Hx of life-threatening reaction to </text>
<text top="705" left="338" width="94" height="17" font="0">contrast medium </text>
<text top="722" left="338" width="7" height="18" font="7"></text>
<text top="723" left="344" width="178" height="17" font="0"> Uncorrected bleeding disorders </text>
<text top="740" left="338" width="7" height="18" font="7"></text>
<text top="741" left="344" width="198" height="17" font="0"> Women with child-bearing potential </text>
<text top="759" left="338" width="185" height="17" font="0">not on contraceptives or currently </text>
<text top="776" left="338" width="78" height="17" font="0">breastfeeding </text>
<text top="87" left="574" width="78" height="17" font="2"><b>Intervention:</b> </text>
<text top="104" left="574" width="126" height="17" font="0">Standard thrombolysis </text>
<text top="122" left="574" width="3" height="17" font="0"> </text>
<text top="139" left="574" width="98" height="17" font="2"><b>Comparator:</b> US-</text>
<text top="156" left="574" width="67" height="17" font="0">accelerated </text>
<text top="173" left="574" width="72" height="17" font="0">thrombolysis </text>
<text top="88" left="716" width="7" height="17" font="2"><b>1</b></text>
<text top="87" left="722" width="6" height="18" font="7"></text>
<text top="88" left="729" width="175" height="17" font="2"><b> endpoint:</b> Duration of catheter-</text>
<text top="106" left="716" width="182" height="17" font="0">directed thrombolysis needed for </text>
<text top="123" left="716" width="203" height="17" font="0">uninterrupted flow in the thrombosed </text>
<text top="140" left="716" width="198" height="17" font="0">infrainguinal native artery or bypass </text>
<text top="157" left="716" width="197" height="17" font="0">graft, with outflow through ≥1 crural </text>
<text top="174" left="716" width="35" height="17" font="0">artery </text>
<text top="192" left="716" width="3" height="17" font="0"> </text>
<text top="87" left="938" width="7" height="18" font="7"></text>
<text top="88" left="945" width="115" height="17" font="0"> RCT comparing this </text>
<text top="106" left="938" width="122" height="17" font="0">technique to standard </text>
<text top="123" left="938" width="86" height="17" font="0">catheter-based </text>
<text top="140" left="938" width="114" height="17" font="0">thrombolytic therapy </text>
<text top="157" left="938" width="129" height="17" font="0">failed to demonstrate a </text>
<text top="174" left="938" width="127" height="17" font="0">difference in outcomes </text>
<text top="192" left="938" width="102" height="17" font="0">including bleeding </text>
<text top="209" left="938" width="113" height="17" font="0">despite a lower total </text>
<text top="226" left="938" width="83" height="17" font="0">amount of lytic </text>
<text top="243" left="938" width="53" height="17" font="0">delivered </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">175 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="338" width="7" height="18" font="7"></text>
<text top="88" left="344" width="64" height="17" font="0"> pregnancy </text>
<text top="106" left="338" width="7" height="18" font="7"></text>
<text top="107" left="344" width="188" height="17" font="0"> Hemodynamically unstable at the </text>
<text top="124" left="338" width="127" height="17" font="0">onset of the procedure </text>
<text top="141" left="338" width="7" height="18" font="7"></text>
<text top="142" left="344" width="144" height="17" font="0"> Pts who refuse treatment </text>
<text top="160" left="338" width="7" height="18" font="7"></text>
<text top="161" left="344" width="185" height="17" font="0"> Currently participating in another </text>
<text top="178" left="338" width="33" height="17" font="0">study </text>
<text top="195" left="338" width="7" height="18" font="7"></text>
<text top="196" left="344" width="144" height="17" font="0"> Life expectancy of &lt;1 mo </text>
<text top="214" left="338" width="7" height="18" font="7"></text>
<text top="215" left="344" width="139" height="17" font="0"> Contraindication for MRI </text>
<text top="233" left="86" width="986" height="17" font="0">ALI indicates acute limb ischemia; ALLI, acute lower-limb ischemia; CDT, catheter-directed thrombolysis; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; hx, </text>
<text top="250" left="86" width="980" height="17" font="0">history; IAT, intra-arterial treatment; MRI, magnetic resonance imaging; N/A, not applicable; OR, odds ratio; PIAT, peripheral intraarterial thrombolysis; pt, patient; RCT, randomized </text>
<text top="267" left="86" width="911" height="17" font="0">controlled trail; RR, relative risk; SR, surgical revascularization; SBP, systolic blood pressure; STILE, Surgery Versus Thrombolysis for Ischemia of the Lower Extremity;</text>
<text top="267" left="998" width="3" height="17" font="9"> </text>
<text top="267" left="1001" width="49" height="17" font="0">TOPAS, </text>
<text top="284" left="86" width="452" height="17" font="0">Thrombolysis or Peripheral Arterial Surgery; and tPA, tissue plasminogen activator </text>
<text top="301" left="86" width="3" height="17" font="0"> </text>
<text top="319" left="86" width="3" height="17" font="0"> </text>
<text top="336" left="86" width="905" height="21" font="1"><b>Evidence Table 48. Nonrandomized Trials, Observational Studies, and/or Registries of Clinical Presentation of ALI–Section 9.2.2. </b></text>
<text top="357" left="100" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="374" left="125" width="48" height="17" font="2"><b>Author; </b></text>
<text top="392" left="103" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="357" left="228" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="374" left="254" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="357" left="383" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="357" left="569" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="374" left="576" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="392" left="628" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="357" left="862" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="374" left="889" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="410" left="95" width="104" height="17" font="0">Fagundes C, et al. </text>
<text top="427" left="95" width="63" height="17" font="0">2005 (389) </text>
<text top="444" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17315606">17315606 </a></text>
<text top="461" left="95" width="3" height="17" font="0"> </text>
<text top="410" left="216" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="427" left="216" width="122" height="17" font="0">institution prospective </text>
<text top="444" left="216" width="122" height="17" font="0">cohort (observational) </text>
<text top="461" left="216" width="3" height="17" font="0"> </text>
<text top="479" left="216" width="83" height="17" font="2"><b>Size: </b>n=83 pts </text>
<text top="410" left="371" width="131" height="17" font="2"><b>Inclusion criteria: </b>ALI, </text>
<text top="427" left="371" width="70" height="17" font="0">and etiology </text>
<text top="444" left="371" width="3" height="17" font="0"> </text>
<text top="461" left="371" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="479" left="371" width="94" height="17" font="0">Stage I ischemia </text>
<text top="411" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="410" left="527" width="6" height="18" font="7"></text>
<text top="411" left="533" width="201" height="17" font="2"><b> endpoint:</b> Mortality and amputation </text>
<text top="428" left="520" width="3" height="17" font="0"> </text>
<text top="445" left="520" width="52" height="17" font="2"><b>Results: </b></text>
<text top="462" left="520" width="7" height="18" font="7"></text>
<text top="464" left="527" width="261" height="17" font="0"> Male gender, smoking, and comorbidities were </text>
<text top="481" left="520" width="257" height="17" font="0">more frequent among pts with thrombosis, and </text>
<text top="498" left="520" width="254" height="17" font="0">atrial fibrillation was more common among pts </text>
<text top="515" left="520" width="81" height="17" font="0">with embolism </text>
<text top="533" left="520" width="7" height="18" font="7"></text>
<text top="534" left="527" width="254" height="17" font="0"> Occlusion longer than 24 h (OR: 2.6; 95% CI: </text>
<text top="551" left="520" width="220" height="17" font="0">1.1–7.6) was associated with death and </text>
<text top="568" left="520" width="212" height="17" font="0">amputation in the multivariate analysis </text>
<text top="585" left="520" width="7" height="18" font="7"></text>
<text top="586" left="527" width="120" height="17" font="0"> Mortality 15 (18.1%)  </text>
<text top="604" left="520" width="7" height="18" font="7"></text>
<text top="605" left="527" width="133" height="17" font="0"> Amputation 24 (28.9%) </text>
<text top="410" left="810" width="7" height="18" font="7"></text>
<text top="411" left="817" width="169" height="17" font="0"> Comorbidities were also more </text>
<text top="428" left="810" width="198" height="17" font="0">frequent among pts with thrombosis </text>
<text top="623" left="95" width="99" height="17" font="0">Rutherford RB, et </text>
<text top="640" left="95" width="16" height="17" font="0">al.<b> </b></text>
<text top="657" left="95" width="56" height="17" font="0">1997 (46) </text>
<text top="674" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9308598">9308598</a></text>
<text top="674" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9308598"> </a></text>
<text top="692" left="95" width="3" height="17" font="0"> </text>
<text top="623" left="216" width="135" height="17" font="2"><b>Study type:</b> Consensus </text>
<text top="640" left="216" width="57" height="17" font="0">document </text>
<text top="657" left="216" width="3" height="17" font="0"> </text>
<text top="674" left="216" width="56" height="17" font="2"><b>Size:</b> N/A </text>
<text top="623" left="371" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="640" left="371" width="3" height="17" font="0"> </text>
<text top="657" left="371" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="624" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="623" left="527" width="6" height="18" font="7"></text>
<text top="624" left="533" width="196" height="17" font="2"><b> endpoint:</b> Scoring Scheme for ALI </text>
<text top="641" left="520" width="3" height="17" font="0"> </text>
<text top="658" left="520" width="76" height="17" font="2"><b>Results:</b> N/A </text>
<text top="623" left="810" width="24" height="17" font="0">N/A </text>
<text top="710" left="95" width="100" height="17" font="0">Nypaver TJ, et al. </text>
<text top="727" left="95" width="63" height="17" font="0">1998 (375) </text>
<text top="744" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9737621">9737621</a></text>
<text top="744" left="142" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9737621"> </a></text>
<text top="761" left="95" width="3" height="17" font="0"> </text>
<text top="710" left="216" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="727" left="216" width="129" height="17" font="0">institution retrospective </text>
<text top="744" left="216" width="38" height="17" font="0">cohort </text>
<text top="761" left="216" width="3" height="17" font="0"> </text>
<text top="710" left="371" width="106" height="17" font="2"><b>Inclusion criteria:</b> </text>
<text top="727" left="371" width="128" height="17" font="0">Acute arterial ischemia </text>
<text top="744" left="371" width="90" height="17" font="0">and required an </text>
<text top="761" left="371" width="127" height="17" font="0">urgent/emergent lower-</text>
<text top="711" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="710" left="527" width="6" height="18" font="7"></text>
<text top="711" left="533" width="213" height="17" font="2"><b> endpoint:</b> Outcome of arterial bypass </text>
<text top="728" left="520" width="242" height="17" font="0">reconstruction in the setting of acute arterial </text>
<text top="745" left="520" width="52" height="17" font="0">ischemia </text>
<text top="762" left="520" width="3" height="17" font="0"> </text>
<text top="710" left="810" width="24" height="17" font="0">N/A </text>
</page>
<page number="176" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">176 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="216" width="67" height="17" font="2"><b>Size:</b> n= 71 </text>
<text top="87" left="371" width="94" height="17" font="0">extremity arterial </text>
<text top="104" left="371" width="123" height="17" font="0">bypass reconstruction </text>
<text top="122" left="371" width="3" height="17" font="0"> </text>
<text top="139" left="371" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="520" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="104" left="520" width="7" height="18" font="7"></text>
<text top="105" left="527" width="259" height="17" font="0"> Mean duration of symptoms was 43 h (median </text>
<text top="123" left="520" width="268" height="17" font="0">24), and mean time from hospital presentation to </text>
<text top="140" left="520" width="228" height="17" font="0">the operating room was 36 h (median 12) </text>
<text top="157" left="520" width="7" height="18" font="7"></text>
<text top="158" left="527" width="260" height="17" font="0"> Death, limb loss, or both, were associated with </text>
<text top="176" left="520" width="259" height="17" font="0">a paralytic limb (p=0.001) and congestive heart </text>
<text top="193" left="520" width="86" height="17" font="0">failure (p=0.03) </text>
<text top="211" left="95" width="96" height="17" font="0">Fogarty TJ, et al.<b> </b></text>
<text top="228" left="95" width="63" height="17" font="0">1963 (390) </text>
<text top="245" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13945714">13945714</a></text>
<text top="245" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13945714"> </a></text>
<text top="211" left="216" width="135" height="17" font="2"><b>Study type:</b> Descriptive </text>
<text top="228" left="216" width="3" height="17" font="0"> </text>
<text top="245" left="216" width="56" height="17" font="2"><b>Size:</b> N/A </text>
<text top="211" left="371" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="228" left="371" width="3" height="17" font="0"> </text>
<text top="245" left="371" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="212" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="211" left="527" width="6" height="18" font="7"></text>
<text top="212" left="533" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="229" left="520" width="3" height="17" font="0"> </text>
<text top="246" left="520" width="76" height="17" font="2"><b>Results:</b> N/A </text>
<text top="211" left="810" width="7" height="18" font="7"></text>
<text top="212" left="817" width="184" height="17" font="0"> First description of embolectomy </text>
<text top="229" left="810" width="48" height="17" font="0">catheter </text>
<text top="264" left="95" width="82" height="17" font="0">Shin HS, et al.<b> </b></text>
<text top="281" left="95" width="63" height="17" font="0">2013 (377) </text>
<text top="299" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24436594">24436594</a></text>
<text top="299" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24436594"> </a></text>
<text top="316" left="95" width="3" height="17" font="0"> </text>
<text top="264" left="216" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="281" left="216" width="59" height="17" font="0">institution  </text>
<text top="299" left="216" width="3" height="17" font="0"> </text>
<text top="316" left="216" width="125" height="17" font="2"><b>Size:</b> n=18 limbs in 14 </text>
<text top="333" left="216" width="88" height="17" font="0">consecutive pts </text>
<text top="264" left="371" width="123" height="17" font="2"><b>Inclusion criteria:</b> All </text>
<text top="281" left="371" width="67" height="17" font="0">pts with ALI </text>
<text top="299" left="371" width="3" height="17" font="0"> </text>
<text top="316" left="371" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="265" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="264" left="527" width="6" height="18" font="7"></text>
<text top="265" left="533" width="236" height="17" font="2"><b> endpoint:</b> Limb salvage via novel surgical </text>
<text top="283" left="520" width="55" height="17" font="0">approach </text>
<text top="300" left="520" width="3" height="17" font="0"> </text>
<text top="317" left="520" width="76" height="17" font="2"><b>Results:</b> N/A </text>
<text top="264" left="810" width="7" height="18" font="7"></text>
<text top="265" left="817" width="68" height="17" font="0"> CTA for Dx </text>
<text top="283" left="810" width="7" height="18" font="7"></text>
<text top="284" left="817" width="115" height="17" font="10"> 71% heart disease:  </text>
<text top="301" left="810" width="117" height="17" font="10">57% atrial fibrillation  </text>
<text top="318" left="810" width="161" height="17" font="10">14% had a Hx of previous MI </text>
<text top="335" left="810" width="7" height="18" font="7"></text>
<text top="337" left="817" width="217" height="17" font="0"> 86% of pts with mixed thromboembolic </text>
<text top="354" left="810" width="46" height="17" font="0">disease </text>
<text top="371" left="810" width="7" height="18" font="7"></text>
<text top="372" left="817" width="197" height="17" font="0"> Below knee exposure and 1 vessel </text>
<text top="389" left="810" width="35" height="17" font="0">runoff </text>
<text top="407" left="95" width="84" height="17" font="0">Eliason JL and </text>
<text top="425" left="95" width="80" height="17" font="0">Wakefield TW<b> </b></text>
<text top="442" left="95" width="63" height="17" font="0">2009 (391) </text>
<text top="459" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19298933">19298933</a></text>
<text top="459" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19298933"> </a></text>
<text top="476" left="95" width="3" height="17" font="0"> </text>
<text top="407" left="216" width="114" height="17" font="2"><b>Study type:</b> Review </text>
<text top="425" left="216" width="40" height="17" font="0">article  </text>
<text top="442" left="216" width="3" height="17" font="0"> </text>
<text top="459" left="216" width="106" height="17" font="2"><b>Size:</b> n=18 studies </text>
<text top="407" left="371" width="130" height="17" font="2"><b>Inclusion criteria:</b> N/A </text>
<text top="425" left="371" width="3" height="17" font="0"> </text>
<text top="442" left="371" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="408" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="407" left="527" width="6" height="18" font="7"></text>
<text top="408" left="533" width="87" height="17" font="2"><b> endpoint:</b> N/A </text>
<text top="426" left="520" width="3" height="17" font="0"> </text>
<text top="443" left="520" width="76" height="17" font="2"><b>Results:</b> N/A </text>
<text top="460" left="520" width="3" height="17" font="0"> </text>
<text top="407" left="810" width="7" height="18" font="7"></text>
<text top="408" left="817" width="3" height="17" font="0"> </text>
<text top="408" left="820" width="191" height="17" font="10">Compartment pressures are easily </text>
<text top="426" left="810" width="213" height="17" font="10">measured through multiple methods of </text>
<text top="443" left="810" width="122" height="17" font="10">pressure transduction </text>
<text top="460" left="810" width="7" height="18" font="7"></text>
<text top="461" left="817" width="181" height="17" font="0"> The majority of the lethal events </text>
<text top="479" left="810" width="228" height="17" font="0">associated with IR injury occur with acute </text>
<text top="496" left="810" width="222" height="17" font="0">lung injury as a prominent component of </text>
<text top="513" left="810" width="224" height="17" font="0">the multiple organ dysfunction syndrome </text>
<text top="531" left="95" width="107" height="17" font="0">de Donato G, et al.<b> </b></text>
<text top="548" left="95" width="63" height="17" font="0">2014 (378) </text>
<text top="565" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24342067">24342067</a></text>
<text top="565" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24342067"> </a></text>
<text top="583" left="95" width="3" height="17" font="0"> </text>
<text top="531" left="216" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="548" left="216" width="93" height="17" font="0">institution cohort </text>
<text top="565" left="216" width="3" height="17" font="0"> </text>
<text top="583" left="216" width="90" height="17" font="2"><b>Size:</b> n=322 pts </text>
<text top="531" left="371" width="123" height="17" font="2"><b>Inclusion criteria:</b> All </text>
<text top="548" left="371" width="54" height="17" font="0">pts w ALI </text>
<text top="565" left="371" width="3" height="17" font="0"> </text>
<text top="583" left="371" width="132" height="17" font="2"><b>Exclusion criteria:</b> ALI </text>
<text top="600" left="371" width="120" height="17" font="0">from graft thrombosis </text>
<text top="532" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="531" left="527" width="6" height="18" font="7"></text>
<text top="532" left="533" width="66" height="17" font="2"><b> endpoint:</b>  </text>
<text top="549" left="520" width="7" height="18" font="7"></text>
<text top="550" left="527" width="142" height="17" font="0"> In-hospital complications </text>
<text top="568" left="520" width="7" height="18" font="7"></text>
<text top="569" left="527" width="81" height="17" font="0"> 30 d mortality </text>
<text top="586" left="520" width="7" height="18" font="7"></text>
<text top="587" left="527" width="180" height="17" font="0"> Primary and secondary patency </text>
<text top="604" left="520" width="103" height="17" font="0">reintervention rate </text>
<text top="622" left="520" width="7" height="18" font="7"></text>
<text top="623" left="527" width="79" height="17" font="0"> Limb salvage </text>
<text top="640" left="520" width="7" height="18" font="7"></text>
<text top="641" left="527" width="122" height="17" font="0"> Overall survival rates </text>
<text top="658" left="520" width="3" height="17" font="0"> </text>
<text top="676" left="520" width="271" height="17" font="2"><b>Results:</b> Reduction in complications when hybrid </text>
<text top="693" left="520" width="208" height="17" font="0">techniques utilized as opposed to just </text>
<text top="710" left="520" width="122" height="17" font="0">thromboembolectomy </text>
<text top="531" left="810" width="7" height="18" font="7"></text>
<text top="532" left="817" width="204" height="17" font="0"> Thromboembolectomy alone in 35% </text>
<text top="549" left="810" width="7" height="18" font="7"></text>
<text top="550" left="817" width="89" height="17" font="0"> 45.5% via CFA </text>
<text top="568" left="810" width="7" height="18" font="7"></text>
<text top="569" left="817" width="112" height="17" font="0"> 30 d mortality 4.4% </text>
<text top="586" left="810" width="7" height="18" font="7"></text>
<text top="587" left="817" width="168" height="17" font="0"> 15% in hospital complications </text>
<text top="604" left="810" width="203" height="17" font="0">8 pts with complication from catheter </text>
<text top="728" left="95" width="81" height="17" font="0">Baril DT, et al.<b> </b></text>
<text top="745" left="95" width="63" height="17" font="0">2013 (379) </text>
<text top="762" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23714364">23714364</a></text>
<text top="762" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23714364"> </a></text>
<text top="728" left="216" width="119" height="17" font="2"><b>Study type:</b> Registry </text>
<text top="745" left="216" width="39" height="17" font="0">review </text>
<text top="762" left="216" width="3" height="17" font="0"> </text>
<text top="728" left="371" width="123" height="17" font="2"><b>Inclusion criteria:</b> All </text>
<text top="745" left="371" width="85" height="17" font="0">pts undergoing </text>
<text top="762" left="371" width="103" height="17" font="0">infrainguinal lower </text>
<text top="729" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="728" left="527" width="6" height="18" font="7"></text>
<text top="729" left="533" width="235" height="17" font="2"><b> endpoint:</b> Major amputation and mortality </text>
<text top="746" left="520" width="3" height="17" font="0"> </text>
<text top="764" left="520" width="265" height="17" font="2"><b>Results:</b> ALI predictor of both major amputation </text>
<text top="728" left="810" width="7" height="18" font="7"></text>
<text top="729" left="817" width="170" height="17" font="0"> Age and gender similar to CLI </text>
<text top="746" left="810" width="7" height="18" font="7"></text>
<text top="747" left="817" width="208" height="17" font="0"> ALI less likely to be on ASA (63% vs. </text>
<text top="765" left="810" width="231" height="17" font="0">75%; p&lt;0.0001) or a statin (55% vs. 68%; </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">177 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="216" width="112" height="17" font="2"><b>Size:</b> n=323 bypass </text>
<text top="104" left="216" width="65" height="17" font="0">procedures </text>
<text top="87" left="371" width="96" height="17" font="0">extremity bypass </text>
<text top="104" left="371" width="136" height="17" font="0">between 2003 and 2011 </text>
<text top="122" left="371" width="72" height="17" font="0">(ALI vs. CLI) </text>
<text top="139" left="371" width="3" height="17" font="0"> </text>
<text top="156" left="371" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="520" width="266" height="17" font="0">(HR: 2.16; CI: 1.38–3.40; p=0.001) and mortality </text>
<text top="104" left="520" width="222" height="17" font="0">(HR: 1.41; CI: 1.09–1.83; p=0.009 at 1 y </text>
<text top="87" left="810" width="59" height="17" font="0">p&lt;0.0001) </text>
<text top="104" left="810" width="7" height="18" font="7"></text>
<text top="105" left="817" width="210" height="17" font="0"> ALI more likely to be current smokers </text>
<text top="123" left="810" width="32" height="17" font="0">(49% </text>
<text top="140" left="810" width="223" height="17" font="0">vs. 39%; p&lt;0 .0001), to have had a prior </text>
<text top="157" left="810" width="233" height="17" font="0">ipsilateral bypass (33% vs. 24%; p=0.004) </text>
<text top="174" left="810" width="186" height="17" font="0">or a prior ipsilateral percutaneous </text>
<text top="192" left="810" width="202" height="17" font="0">intervention (41% vs. 29%; p=0.001) </text>
<text top="210" left="95" width="75" height="17" font="0">Lurie F, et al.<b> </b></text>
<text top="227" left="95" width="63" height="17" font="0">2015 (392) </text>
<text top="244" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25154566">25154566</a></text>
<text top="244" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25154566"> </a></text>
<text top="261" left="95" width="3" height="17" font="0"> </text>
<text top="210" left="216" width="116" height="17" font="2"><b>Study type:</b> Multiple </text>
<text top="227" left="216" width="94" height="17" font="0">institution review </text>
<text top="244" left="216" width="3" height="17" font="0"> </text>
<text top="261" left="216" width="100" height="17" font="2"><b>Size:</b> n=1,074 pts </text>
<text top="210" left="371" width="127" height="17" font="2"><b>Inclusion criteria:</b> Pts </text>
<text top="227" left="371" width="118" height="17" font="0">treated within 14 d of </text>
<text top="244" left="371" width="134" height="17" font="0">onset of their symptoms </text>
<text top="261" left="371" width="102" height="17" font="0">of nonembolic ALI </text>
<text top="278" left="371" width="3" height="17" font="0"> </text>
<text top="296" left="371" width="110" height="17" font="2"><b>Exclusion criteria:</b> </text>
<text top="313" left="371" width="126" height="17" font="0">Elective admission, no </text>
<text top="330" left="371" width="44" height="17" font="0">therapy </text>
<text top="211" left="520" width="7" height="17" font="2"><b>1</b></text>
<text top="210" left="527" width="6" height="18" font="7"></text>
<text top="211" left="533" width="242" height="17" font="2"><b> endpoint:</b> Clinical and technical outcomes, </text>
<text top="228" left="520" width="197" height="17" font="0">number and type of reinterventions, </text>
<text top="245" left="520" width="256" height="17" font="0">complications, relief of ischemia, limb salvage, </text>
<text top="262" left="520" width="51" height="17" font="0">and AFS </text>
<text top="280" left="520" width="3" height="17" font="0"> </text>
<text top="297" left="520" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="314" left="520" width="7" height="18" font="7"></text>
<text top="315" left="527" width="242" height="17" font="0"> No association between the choice of initial </text>
<text top="332" left="520" width="238" height="17" font="0">treatment, pt characteristics, location of the </text>
<text top="350" left="520" width="271" height="17" font="0">occlusion, or the class of ischemia, individually or </text>
<text top="367" left="520" width="83" height="17" font="0">in combination </text>
<text top="384" left="520" width="7" height="18" font="7"></text>
<text top="385" left="527" width="248" height="17" font="0"> Combined endpoint of readmission and AFS </text>
<text top="402" left="520" width="92" height="17" font="0">was significantly </text>
<text top="420" left="520" width="197" height="17" font="0">lower in the CDT and CDTA groups </text>
<text top="210" left="810" width="7" height="18" font="7"></text>
<text top="211" left="817" width="195" height="17" font="0"> The cause of ALI was an occluded </text>
<text top="228" left="810" width="219" height="17" font="0">native vessel in 115 pts (56.1%) and an </text>
<text top="245" left="810" width="203" height="17" font="0">occluded bypass graft in 90 (43.9%). </text>
<text top="262" left="810" width="7" height="18" font="7"></text>
<text top="263" left="817" width="208" height="17" font="0"> Initial treatment resulted in an overall </text>
<text top="281" left="810" width="231" height="17" font="0">primary success of 67.3%. 60 pts (29.7%) </text>
<text top="298" left="810" width="229" height="17" font="0">required a second intervention, 11 (5.4%) </text>
<text top="315" left="810" width="206" height="17" font="0">required a third intervention, 5 (2.4%) </text>
<text top="332" left="810" width="206" height="17" font="0">required amputation, and 2 (1%) died </text>
<text top="438" left="86" width="981" height="17" font="0">ALI indicates acute limb ischemia; AFS, amputation-free survival; ASA, acetylsalicylic Acid; CA, contrast arteriography; CDTA, catheter directed thrombolysis and angioplasty; CDT, </text>
<text top="455" left="86" width="973" height="17" font="0">catheter directed thrombolysis; CFA, common femoral artery; CI, confidence interval; CLI, critical limb ischemia; CTA, computed tomography angiography; DSA, digital subtraction </text>
<text top="472" left="86" width="1000" height="17" font="0">angiography; DUAM, duplex ultrasound arterial mapping; HR, hazard ratio; MI, myocardial infarction; MRA, magnetic resonance angiography; N/A, not applicable; NEJM, New England </text>
<text top="489" left="86" width="553" height="17" font="0">Journal of Medicine; NIS, National Inpatient Sample; OR, odds ratio; pt, patient; and RR, relative risk. </text>
<text top="506" left="86" width="3" height="17" font="0"> </text>
<text top="524" left="86" width="3" height="17" font="0"> </text>
<text top="541" left="86" width="1006" height="21" font="1"><b>Evidence Table 49. Nonrandomized Trials, Observational Studies, and/or Registries of Diagnostic Evaluation of the Cause of ALI–Section 9.2.2. </b></text>
<text top="562" left="86" width="983" height="17" font="0">(There is no literature specifically addressing the diagnostic work up for the cause of ALI. This large single-center series does give etiologies. Echocardiography and telemetry seem </text>
<text top="579" left="86" width="823" height="17" font="0">reasonable for those without underlying PAD. Focused evaluation for hypercoagulable state seems reasonable in those with native artery thrombosis.)  </text>
<text top="597" left="109" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="614" left="134" width="48" height="17" font="2"><b>Author; </b></text>
<text top="631" left="112" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="597" left="248" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="614" left="274" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="597" left="417" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="597" left="582" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="614" left="589" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="631" left="641" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="597" left="851" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="614" left="879" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="649" left="95" width="32" height="17" font="0">Taha </text>
<text top="666" left="95" width="63" height="17" font="0">2015 (393) </text>
<text top="683" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25080883">25080883</a></text>
<text top="683" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25080883"> </a></text>
<text top="701" left="95" width="3" height="17" font="0"> </text>
<text top="649" left="234" width="108" height="17" font="2"><b>Study type:</b> Single </text>
<text top="666" left="234" width="111" height="17" font="0">center retrospective </text>
<text top="683" left="234" width="131" height="17" font="0">review comparing open </text>
<text top="701" left="234" width="135" height="17" font="0">and endovascular repair </text>
<text top="718" left="234" width="35" height="17" font="0">in ALI </text>
<text top="735" left="234" width="3" height="17" font="0"> </text>
<text top="752" left="234" width="90" height="17" font="2"><b>Size:</b> n=473 pts </text>
<text top="649" left="392" width="148" height="17" font="2"><b>Inclusion criteria:</b> ALI pts </text>
<text top="666" left="392" width="121" height="17" font="0">cared for my vascular </text>
<text top="683" left="392" width="156" height="17" font="0">surgeons. All with embolism </text>
<text top="701" left="392" width="144" height="17" font="0">or thrombosis as etiology. </text>
<text top="718" left="392" width="3" height="17" font="0"> </text>
<text top="735" left="392" width="156" height="17" font="2"><b>Exclusion criteria:</b> Trauma </text>
<text top="752" left="392" width="148" height="17" font="0">as etiology of ALI, blue toe </text>
<text top="770" left="392" width="57" height="17" font="0">syndrome </text>
<text top="650" left="566" width="7" height="17" font="2"><b>1</b></text>
<text top="649" left="573" width="6" height="18" font="7"></text>
<text top="650" left="579" width="170" height="17" font="2"><b> endpoint:</b> Technical success, </text>
<text top="667" left="566" width="146" height="17" font="0">incidence of postoperative </text>
<text top="685" left="566" width="207" height="17" font="0">complications, length of hospital stay, </text>
<text top="702" left="566" width="172" height="17" font="0">loss of primary patency, loss of </text>
<text top="719" left="566" width="206" height="17" font="0">assisted primary patency, and loss of </text>
<text top="736" left="566" width="164" height="17" font="0">secondary patency as well as </text>
<text top="754" left="566" width="210" height="17" font="0">amputation and mortality rates at 30 d </text>
<text top="771" left="566" width="47" height="17" font="0">and 1 y  </text>
<text top="649" left="790" width="7" height="18" font="7"></text>
<text top="650" left="797" width="217" height="17" font="0"> Underlying cause of ALI retrieved from </text>
<text top="667" left="790" width="231" height="17" font="0">medical record, cause by percent: cardiac </text>
<text top="685" left="790" width="252" height="17" font="0">embolism 17.7; native artery thrombosis 26.2; </text>
<text top="702" left="790" width="228" height="17" font="0">failed stent 17.9; failed bypass graft 33.5; </text>
<text top="719" left="790" width="204" height="17" font="0">thrombosed peripheral aneurysm 4.7 </text>
</page>
<page number="178" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">178 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="566" width="3" height="17" font="0"> </text>
<text top="104" left="566" width="76" height="17" font="2"><b>Results:</b> N/A </text>
<text top="122" left="86" width="558" height="17" font="0">ALI indicates acute limb ischemia; N/A, not applicable; PAD, peripheral artery disease; and pt, patient. </text>
<text top="139" left="86" width="3" height="17" font="0"> </text>
<text top="157" left="86" width="3" height="17" font="0"> </text>
<text top="174" left="86" width="953" height="21" font="1"><b>Evidence Table 50. Nonrandomized Trials, Observational Studies, and/or Registries of Revascularization Strategy for ALI–Section 9.2.2. </b></text>
<text top="195" left="96" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="213" left="122" width="48" height="17" font="2"><b>Author; </b></text>
<text top="230" left="99" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="195" left="228" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="213" left="254" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="195" left="437" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="195" left="670" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="213" left="678" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="230" left="730" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="195" left="922" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="213" left="949" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="248" left="95" width="73" height="17" font="0">Gupta R and </text>
<text top="265" left="95" width="76" height="17" font="0">Hennebry TA </text>
<text top="282" left="95" width="63" height="17" font="0">2012 (394) </text>
<text top="299" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22511320">22511320 </a></text>
<text top="317" left="95" width="3" height="17" font="0"> </text>
<text top="248" left="210" width="139" height="17" font="2"><b>Study type:</b> Case series </text>
<text top="265" left="210" width="3" height="17" font="0"> </text>
<text top="282" left="210" width="83" height="17" font="2"><b>Size:</b> n=24 pts </text>
<text top="248" left="379" width="204" height="17" font="2"><b>Inclusion criteria:</b> ALI &lt;14 d treated </text>
<text top="265" left="379" width="100" height="17" font="0">with Trellis device </text>
<text top="282" left="379" width="3" height="17" font="0"> </text>
<text top="299" left="379" width="228" height="17" font="2"><b>Exclusion criteria:</b> Vessel size less than </text>
<text top="317" left="379" width="192" height="17" font="0">3 mm diameter or distal location or </text>
<text top="334" left="379" width="223" height="17" font="0">contrast intolerance, as assessed by the </text>
<text top="351" left="379" width="156" height="17" font="0">treating clinician's discretion </text>
<text top="249" left="622" width="7" height="17" font="2"><b>1</b></text>
<text top="248" left="628" width="6" height="18" font="7"></text>
<text top="249" left="635" width="177" height="17" font="2"><b> endpoint:</b> Limb salvage=100% </text>
<text top="266" left="622" width="3" height="17" font="0"> </text>
<text top="283" left="622" width="255" height="17" font="2"><b>Results:</b> In hospital and 30 d mortality=4.16% </text>
<text top="248" left="912" width="7" height="18" font="7"></text>
<text top="249" left="919" width="96" height="17" font="0"> Proof of concept </text>
<text top="266" left="912" width="7" height="18" font="7"></text>
<text top="267" left="919" width="76" height="17" font="0"> Level C data </text>
<text top="369" left="95" width="91" height="17" font="0">Ansel GM, et al.<b> </b></text>
<text top="386" left="95" width="59" height="17" font="0">2008(395) </text>
<text top="403" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18726955">18726955 </a></text>
<text top="421" left="95" width="3" height="17" font="0"> </text>
<text top="369" left="210" width="139" height="17" font="2"><b>Study type:</b> Case series </text>
<text top="386" left="210" width="3" height="17" font="0"> </text>
<text top="403" left="210" width="150" height="17" font="2"><b>Size:</b> n=29 limbs treated in </text>
<text top="421" left="210" width="44" height="17" font="0">119 pts </text>
<text top="369" left="379" width="204" height="17" font="2"><b>Inclusion criteria:</b> ALI &lt;14 d treated </text>
<text top="386" left="379" width="150" height="17" font="0">with pharmaco-mechanical </text>
<text top="403" left="379" width="209" height="17" font="0">thrombectomy±catheter directed lysis </text>
<text top="421" left="379" width="3" height="17" font="0"> </text>
<text top="438" left="379" width="195" height="17" font="2"><b>Exclusion criteria:</b> Pts felt to have </text>
<text top="455" left="379" width="215" height="17" font="0">possibly experienced a cardio embolic, </text>
<text top="472" left="379" width="193" height="17" font="0">and evaluated pts with only arterial </text>
<text top="490" left="379" width="179" height="17" font="0">thrombosis as the inciting event. </text>
<text top="370" left="622" width="7" height="17" font="2"><b>1</b></text>
<text top="369" left="628" width="6" height="18" font="7"></text>
<text top="370" left="635" width="142" height="17" font="2"><b> endpoint:</b> Limb salvage  </text>
<text top="387" left="622" width="3" height="17" font="0"> </text>
<text top="405" left="622" width="257" height="17" font="2"><b>Results:</b> In-hospital success with limb salvage </text>
<text top="422" left="622" width="252" height="17" font="0">was attained in 96.5% (n=55) with mortality of </text>
<text top="439" left="622" width="270" height="17" font="0">3.5% (n=2). 30 d limb salvage and mortality were </text>
<text top="456" left="622" width="256" height="17" font="0">94.7% (n=54) and 5.3% (n=3), respectively. At </text>
<text top="473" left="622" width="254" height="17" font="0">mean 5 y follow-up (mean=62 mo), 3 pts have </text>
<text top="491" left="622" width="235" height="17" font="0">been lost to follow-up. The results of 54/57 </text>
<text top="508" left="622" width="258" height="17" font="0">(94.7%) are available. Amputation free survival </text>
<text top="525" left="622" width="275" height="17" font="0">was 94.7% (n=36/38) with long-term mortality rate </text>
<text top="542" left="622" width="112" height="17" font="0">of 29.6% (n=16/54). </text>
<text top="369" left="912" width="7" height="18" font="7"></text>
<text top="370" left="919" width="79" height="17" font="0"> Level C data  </text>
<text top="560" left="95" width="92" height="17" font="0">Byrne RM, et al. </text>
<text top="577" left="95" width="63" height="17" font="0">2014 (396) </text>
<text top="595" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24360240">24360240 </a></text>
<text top="612" left="95" width="3" height="17" font="0"> </text>
<text top="560" left="210" width="139" height="17" font="2"><b>Study type:</b> Case series </text>
<text top="577" left="210" width="3" height="17" font="0"> </text>
<text top="595" left="210" width="132" height="17" font="2"><b>Size:</b> n=154 limbs were </text>
<text top="612" left="210" width="98" height="17" font="0">treated in 147 pts </text>
<text top="560" left="379" width="195" height="17" font="2"><b>Inclusion criteria:</b> ALI treated with </text>
<text top="577" left="379" width="63" height="17" font="0">PMT±CDT </text>
<text top="595" left="379" width="3" height="17" font="0"> </text>
<text top="612" left="379" width="195" height="17" font="2"><b>Exclusion criteria:</b> None reported  </text>
<text top="561" left="622" width="7" height="17" font="2"><b>1</b></text>
<text top="560" left="628" width="6" height="18" font="7"></text>
<text top="561" left="635" width="257" height="17" font="2"><b> endpoint:</b> Technical success was achieved in </text>
<text top="579" left="622" width="274" height="17" font="0">83.8% of cases, with a 30 d mortality rate of 5.2% </text>
<text top="596" left="622" width="3" height="17" font="0"> </text>
<text top="613" left="622" width="256" height="17" font="2"><b>Results:</b> Overall rate of major amputation was </text>
<text top="630" left="622" width="246" height="17" font="0">15.0% (18.1% for CDT only, 11.3% for PMT; </text>
<text top="647" left="622" width="39" height="17" font="0">p=NS) </text>
<text top="665" left="622" width="3" height="17" font="0"> </text>
<text top="560" left="912" width="7" height="18" font="7"></text>
<text top="561" left="919" width="76" height="17" font="0"> Level C data </text>
<text top="683" left="95" width="86" height="17" font="0">Taha AG, et al. </text>
<text top="700" left="95" width="63" height="17" font="0">2015 (393) </text>
<text top="717" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25080883">25080883 </a></text>
<text top="734" left="95" width="3" height="17" font="0"> </text>
<text top="683" left="210" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="700" left="210" width="152" height="17" font="0">comparison of endo vs. OR </text>
<text top="717" left="210" width="3" height="17" font="0"> </text>
<text top="734" left="210" width="132" height="17" font="2"><b>Size:</b> n=154 limbs were </text>
<text top="752" left="210" width="152" height="17" font="0">treated in 147 pts in the ER </text>
<text top="769" left="210" width="146" height="17" font="0">group, compared with 326 </text>
<text top="683" left="379" width="128" height="17" font="2"><b>Inclusion criteria:</b> ALI </text>
<text top="700" left="379" width="3" height="17" font="0"> </text>
<text top="717" left="379" width="216" height="17" font="2"><b>Exclusion criteria:</b> Blue toe syndrome </text>
<text top="734" left="379" width="225" height="17" font="0">and acute ischemia secondary to trauma </text>
<text top="752" left="379" width="155" height="17" font="0">or dissection were excluded </text>
<text top="684" left="622" width="7" height="17" font="2"><b>1</b></text>
<text top="683" left="628" width="6" height="18" font="7"></text>
<text top="684" left="635" width="236" height="17" font="2"><b> endpoint:</b> Amputation and mortality at 1 y </text>
<text top="701" left="622" width="3" height="17" font="0"> </text>
<text top="718" left="622" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="735" left="622" width="7" height="18" font="7"></text>
<text top="737" left="629" width="258" height="17" font="0"> Overall amputation rates were 13.5% (OR) vs. </text>
<text top="754" left="622" width="269" height="17" font="0">6.5% (ER) at 30 d (p=0.023) and 19.6% (OR) vs. </text>
<text top="771" left="622" width="157" height="17" font="0">13.0% (ER) at 1 y (p=0.074) </text>
<text top="683" left="912" width="7" height="18" font="7"></text>
<text top="684" left="919" width="133" height="17" font="0"> Equal amputation rates </text>
<text top="701" left="912" width="7" height="18" font="7"></text>
<text top="702" left="919" width="120" height="17" font="0"> Endo had lower 30 d </text>
<text top="719" left="912" width="50" height="17" font="0">mortality </text>
<text top="737" left="912" width="7" height="18" font="7"></text>
<text top="738" left="919" width="76" height="17" font="0"> Level C data </text>
</page>
<page number="179" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="30" size="13" family="Times" color="#272727"/>
<text top="795" left="1081" width="24" height="17" font="0">179 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="210" width="144" height="17" font="0">limbs in 296 pts in the OR </text>
<text top="104" left="210" width="35" height="17" font="0">group </text>
<text top="87" left="622" width="7" height="18" font="7"></text>
<text top="88" left="629" width="254" height="17" font="0"> 30 d mortality rate was 13.2% (OR) and 5.4% </text>
<text top="106" left="622" width="85" height="17" font="0">(ER) (p=0.012) </text>
<text top="123" left="95" width="77" height="17" font="0">Schernthaner </text>
<text top="141" left="95" width="55" height="17" font="0">MB, et al. </text>
<text top="158" left="95" width="63" height="17" font="0">2014 (397) </text>
<text top="175" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24933285">24933285 </a></text>
<text top="192" left="95" width="3" height="17" font="0"> </text>
<text top="123" left="210" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="141" left="210" width="143" height="17" font="0">series; UAT and standard </text>
<text top="158" left="210" width="144" height="17" font="0">CDT in pts with acute and </text>
<text top="175" left="210" width="135" height="17" font="0">subacute limb ischemia. </text>
<text top="192" left="210" width="3" height="17" font="0"> </text>
<text top="210" left="210" width="99" height="17" font="2"><b>Size:</b> n=UAT was </text>
<text top="227" left="210" width="137" height="17" font="0">performed in 75 pts, and </text>
<text top="244" left="210" width="144" height="17" font="0">CDT was performed in 27 </text>
<text top="261" left="210" width="20" height="17" font="0">pts </text>
<text top="123" left="379" width="221" height="17" font="2"><b>Inclusion criteria:</b> ALI or subacute limb </text>
<text top="141" left="379" width="52" height="17" font="0">ischemia </text>
<text top="158" left="379" width="3" height="17" font="0"> </text>
<text top="175" left="379" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported </text>
<text top="125" left="622" width="7" height="17" font="2"><b>1</b></text>
<text top="123" left="628" width="6" height="18" font="7"></text>
<text top="125" left="635" width="139" height="17" font="2"><b> endpoint:</b> Limb salvage </text>
<text top="142" left="622" width="3" height="17" font="0"> </text>
<text top="159" left="622" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="176" left="622" width="7" height="18" font="7"></text>
<text top="177" left="629" width="165" height="17" font="0"> No difference in limb salvage </text>
<text top="195" left="622" width="7" height="18" font="7"></text>
<text top="196" left="629" width="264" height="17" font="0"> Major and minor bleeding combined was lower: </text>
<text top="213" left="622" width="261" height="17" font="0">6.7% (UAT) vs. 22.2% (CDT) (p=0.025) despite </text>
<text top="230" left="622" width="142" height="17" font="0">no difference in lytic dose </text>
<text top="123" left="912" width="7" height="18" font="7"></text>
<text top="125" left="919" width="109" height="17" font="0"> Pilot data – level C </text>
<text top="279" left="95" width="81" height="17" font="0">Silva JA, et al.<b> </b></text>
<text top="296" left="95" width="63" height="17" font="0">1998 (398) </text>
<text top="314" left="95" width="51" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9863742">9863742 </a></text>
<text top="331" left="95" width="3" height="17" font="9"> </text>
<text top="279" left="209" width="139" height="17" font="2"><b>Study type:</b> Case series </text>
<text top="296" left="209" width="3" height="17" font="0"> </text>
<text top="314" left="209" width="80" height="17" font="2"><b>Size:</b> n=21 pts</text>
<text top="314" left="289" width="3" height="17" font="9"> </text>
<text top="279" left="378" width="205" height="17" font="2"><b>Inclusion criteria:</b> ALI ≤14 d treated </text>
<text top="296" left="378" width="156" height="17" font="0">with rheolytic thrombectomy </text>
<text top="314" left="378" width="3" height="17" font="0"> </text>
<text top="331" left="378" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported </text>
<text top="331" left="570" width="3" height="17" font="9"> </text>
<text top="280" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="279" left="628" width="6" height="18" font="7"></text>
<text top="280" left="634" width="139" height="17" font="2"><b> endpoint:</b> Limb salvage </text>
<text top="298" left="621" width="3" height="17" font="0"> </text>
<text top="315" left="621" width="267" height="17" font="2"><b>Results:</b> The overall 6 mo survival was 81% (17 </text>
<text top="332" left="621" width="267" height="17" font="0">pts), and limb salvage occurred in 16 of 18 limbs </text>
<text top="349" left="621" width="110" height="17" font="0">(89% ) in the 17 pts </text>
<text top="279" left="911" width="7" height="18" font="7"></text>
<text top="280" left="918" width="96" height="17" font="0"> Proof of concept </text>
<text top="298" left="911" width="7" height="18" font="7"></text>
<text top="299" left="918" width="76" height="17" font="0"> Level C data </text>
<text top="367" left="95" width="100" height="17" font="0">Kasirajan K, et al.<b> </b></text>
<text top="384" left="95" width="63" height="17" font="0">2001 (399) </text>
<text top="402" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11287526">11287526 </a></text>
<text top="419" left="95" width="3" height="17" font="9"> </text>
<text top="367" left="209" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="384" left="209" width="48" height="17" font="0">analysis </text>
<text top="402" left="209" width="3" height="17" font="0"> </text>
<text top="419" left="209" width="124" height="17" font="2"><b>Size:</b> n=86 pts (acute, </text>
<text top="436" left="209" width="130" height="17" font="0">n=65; subacute, n=21); </text>
<text top="453" left="209" width="149" height="17" font="0">acute &lt;14 d; suacute 14 d–</text>
<text top="470" left="209" width="27" height="17" font="0">4 mo</text>
<text top="470" left="237" width="3" height="17" font="9"> </text>
<text top="367" left="378" width="180" height="17" font="2"><b>Inclusion criteria:</b> ALI (acute or </text>
<text top="384" left="378" width="57" height="17" font="0">subacute) </text>
<text top="402" left="378" width="3" height="17" font="0"> </text>
<text top="419" left="378" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported </text>
<text top="419" left="570" width="3" height="17" font="9"> </text>
<text top="368" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="367" left="628" width="6" height="18" font="7"></text>
<text top="368" left="634" width="228" height="17" font="2"><b> endpoint:</b> Angiographic success=61.4% </text>
<text top="385" left="621" width="3" height="17" font="0"> </text>
<text top="403" left="621" width="252" height="17" font="2"><b>Results:</b> 1 mo amputation and mortality rates </text>
<text top="420" left="621" width="124" height="17" font="0">were 11.6% and 9.3% </text>
<text top="367" left="911" width="7" height="18" font="7"></text>
<text top="368" left="918" width="76" height="17" font="0"> Level C data </text>
<text top="386" left="911" width="7" height="18" font="7"></text>
<text top="387" left="918" width="100" height="17" font="0"> Mixed population </text>
<text top="488" left="95" width="81" height="17" font="0">Allie DE, et al.<b> </b></text>
<text top="506" left="95" width="63" height="17" font="0">2004 (400) </text>
<text top="523" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15558768">15558768 </a></text>
<text top="540" left="95" width="3" height="17" font="0"> </text>
<text top="488" left="209" width="139" height="17" font="2"><b>Study type:</b> Case series </text>
<text top="506" left="209" width="3" height="17" font="0"> </text>
<text top="523" left="209" width="80" height="17" font="2"><b>Size:</b> n=49 pts</text>
<text top="523" left="289" width="3" height="17" font="9"> </text>
<text top="488" left="378" width="195" height="17" font="2"><b>Inclusion criteria:</b> ALI treated with </text>
<text top="506" left="378" width="204" height="17" font="0">rheolytic thrombectomy catheter with </text>
<text top="523" left="378" width="197" height="17" font="0">thrombolytic solution priming agent  </text>
<text top="540" left="378" width="3" height="17" font="0"> </text>
<text top="557" left="378" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported </text>
<text top="557" left="570" width="3" height="17" font="9"> </text>
<text top="489" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="488" left="628" width="6" height="18" font="7"></text>
<text top="489" left="634" width="194" height="17" font="2"><b> endpoint:</b> 30 d limb salvage=91% </text>
<text top="507" left="621" width="3" height="17" font="0"> </text>
<text top="524" left="621" width="273" height="17" font="2"><b>Results:</b> No significant difference between power </text>
<text top="541" left="621" width="257" height="17" font="0">pulse with UK or TNK; however no comparator </text>
<text top="558" left="621" width="230" height="17" font="0">group using catheter directed lytic delivery</text>
<text top="558" left="851" width="3" height="17" font="9"> </text>
<text top="488" left="911" width="7" height="18" font="7"></text>
<text top="489" left="918" width="96" height="17" font="0"> Proof of concept </text>
<text top="507" left="911" width="7" height="18" font="7"></text>
<text top="508" left="918" width="76" height="17" font="0"> Level C data </text>
<text top="576" left="95" width="92" height="17" font="0">Elmahdy MG, et </text>
<text top="594" left="95" width="16" height="17" font="0">al. </text>
<text top="611" left="95" width="63" height="17" font="0">2010 (401) </text>
<text top="628" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20934653">20934653 </a></text>
<text top="645" left="95" width="3" height="17" font="0"> </text>
<text top="576" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="594" left="209" width="3" height="17" font="0"> </text>
<text top="611" left="209" width="83" height="17" font="2"><b>Size:</b> n=97 pts </text>
<text top="576" left="378" width="208" height="17" font="2"><b>Inclusion criteria:</b> Non traumatic ALI </text>
<text top="594" left="378" width="3" height="17" font="0"> </text>
<text top="611" left="378" width="118" height="17" font="2"><b>Exclusion criteria:</b> P</text>
<text top="611" left="496" width="110" height="17" font="30">ast Hx of peripheral </text>
<text top="628" left="378" width="208" height="17" font="30">arterial graft, traumatic limb ischemia, </text>
<text top="645" left="378" width="212" height="17" font="30">dissection, and thrombosis induced by </text>
<text top="662" left="378" width="208" height="17" font="30">vasospasm, arteritis, popliteal cyst, or </text>
<text top="680" left="378" width="66" height="17" font="30">entrapment.</text>
<text top="680" left="444" width="3" height="17" font="0"> </text>
<text top="577" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="576" left="628" width="6" height="18" font="7"></text>
<text top="577" left="634" width="197" height="17" font="2"><b> endpoint:</b> Agreement with surgical </text>
<text top="595" left="621" width="213" height="17" font="0">determination of embolic or thrombotic </text>
<text top="612" left="621" width="3" height="17" font="0"> </text>
<text top="629" left="621" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="646" left="621" width="7" height="18" font="7"></text>
<text top="647" left="628" width="250" height="17" font="0"> Clinical characteristics similar in embolic and </text>
<text top="665" left="621" width="102" height="17" font="0">thrombotic groups </text>
<text top="682" left="621" width="7" height="18" font="7"></text>
<text top="683" left="628" width="219" height="17" font="0"> Greater difference in diameter of artery </text>
<text top="700" left="621" width="241" height="17" font="0">compared with contralateral artery diameter </text>
<text top="718" left="621" width="144" height="17" font="0">identified embolic etiology </text>
<text top="576" left="911" width="7" height="18" font="7"></text>
<text top="577" left="918" width="96" height="17" font="0"> Duplex provided </text>
<text top="595" left="911" width="127" height="17" font="0">information on etiology </text>
<text top="612" left="911" width="146" height="17" font="0">that could guide treatment </text>
<text top="736" left="95" width="72" height="17" font="0">Ascher et al. </text>
<text top="753" left="95" width="63" height="17" font="0">1999 (402) </text>
<text top="770" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12712369">12712369</a></text>
<text top="770" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12712369"> </a></text>
<text top="736" left="209" width="152" height="17" font="2"><b>Study type:</b> Retrospective, </text>
<text top="753" left="209" width="142" height="17" font="0">bypass for CLI performed </text>
<text top="770" left="209" width="142" height="17" font="0">using ultrasound alone or </text>
<text top="736" left="378" width="230" height="17" font="2"><b>Inclusion criteria:</b> Need for infra inguinal </text>
<text top="753" left="378" width="83" height="17" font="0">arterial bypass </text>
<text top="770" left="378" width="3" height="17" font="0"> </text>
<text top="737" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="736" left="628" width="6" height="18" font="7"></text>
<text top="737" left="634" width="262" height="17" font="2"><b> endpoint:</b> Adequacy of ultrasound to diagnose </text>
<text top="754" left="621" width="49" height="17" font="0">stenosis </text>
<text top="771" left="621" width="3" height="17" font="0"> </text>
<text top="736" left="911" width="7" height="18" font="7"></text>
<text top="737" left="918" width="122" height="17" font="0"> Duplex took 100 min  </text>
<text top="754" left="911" width="143" height="17" font="0">angiography required in 2 </text>
<text top="771" left="911" width="99" height="17" font="0">pts due to arterial </text>
</page>
<page number="180" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">180 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="209" width="143" height="17" font="0">ultrasound + angiography </text>
<text top="104" left="209" width="3" height="17" font="0"> </text>
<text top="122" left="209" width="83" height="17" font="2"><b>Size:</b> n=27 pts </text>
<text top="87" left="378" width="200" height="17" font="2"><b>Exclusion criteria:</b> Contrast allergy </text>
<text top="87" left="621" width="259" height="17" font="2"><b>Results:</b> Adequate map by ultrasound alone in </text>
<text top="104" left="621" width="100" height="17" font="0">the majority of pts </text>
<text top="87" left="911" width="67" height="17" font="0">calcification </text>
<text top="104" left="911" width="7" height="18" font="7"></text>
<text top="105" left="918" width="133" height="17" font="0"> Not clear if any pts had </text>
<text top="123" left="911" width="22" height="17" font="0">ALI </text>
<text top="141" left="95" width="94" height="17" font="0">Lowery AJ, et al. </text>
<text top="158" left="95" width="63" height="17" font="0">2007 (403)<b> </b></text>
<text top="175" left="95" width="58" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17628263">17628263 </a></text>
<text top="192" left="95" width="3" height="17" font="0"> </text>
<text top="141" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="158" left="209" width="131" height="17" font="0">evaluation of US, MRA, </text>
<text top="175" left="209" width="29" height="17" font="0">DSA </text>
<text top="192" left="209" width="3" height="17" font="0"> </text>
<text top="210" left="209" width="90" height="17" font="2"><b>Size:</b> n=465 pts </text>
<text top="141" left="378" width="224" height="17" font="2"><b>Inclusion criteria:</b> All pts with CLI being </text>
<text top="158" left="378" width="158" height="17" font="0">considered for endovascular </text>
<text top="175" left="378" width="96" height="17" font="0">revascularization </text>
<text top="192" left="378" width="3" height="17" font="0"> </text>
<text top="210" left="378" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="142" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="141" left="628" width="6" height="18" font="7"></text>
<text top="142" left="634" width="72" height="17" font="2"><b> endpoint:</b> C</text>
<text top="142" left="706" width="163" height="17" font="30">ompared clinical pragmatism, </text>
<text top="159" left="621" width="266" height="17" font="30">hemodynamic outcomes, and cost-effectiveness </text>
<text top="176" left="621" width="254" height="17" font="30">when using DUAM alone compared to DSA or </text>
<text top="194" left="621" width="185" height="17" font="30">MRA as preoperative assessment</text>
<text top="194" left="806" width="3" height="17" font="0"> </text>
<text top="211" left="621" width="3" height="17" font="0"> </text>
<text top="228" left="621" width="52" height="17" font="2"><b>Results:</b> </text>
<text top="228" left="673" width="201" height="17" font="30">In the DUAM group, 43 lesions were </text>
<text top="245" left="621" width="267" height="17" font="30">identified and marked at the time of preoperative </text>
<text top="262" left="621" width="275" height="17" font="30">DUAM, all of which were treated at angioplasty. In </text>
<text top="280" left="621" width="199" height="17" font="30">the DSA group, 53 lesions identified </text>
<text top="297" left="621" width="269" height="17" font="30">preoperatively were treated at angioplasty. In the </text>
<text top="314" left="621" width="227" height="17" font="30">MRA group, 58 lesions were identified as </text>
<text top="331" left="621" width="250" height="17" font="30">requiring treatment on the preoperative MRA. </text>
<text top="348" left="621" width="207" height="17" font="30">Only 50 of these required angioplasty.</text>
<text top="348" left="828" width="3" height="17" font="0"> </text>
<text top="141" left="911" width="7" height="18" font="7"></text>
<text top="142" left="918" width="98" height="17" font="0"> US and DSA are </text>
<text top="159" left="911" width="125" height="17" font="0">reasonable, MRA may </text>
<text top="176" left="911" width="111" height="17" font="0">have overestimated </text>
<text top="194" left="911" width="49" height="17" font="0">stenosis </text>
<text top="211" left="911" width="7" height="18" font="7"></text>
<text top="212" left="918" width="133" height="17" font="0"> Not clear if any pts had </text>
<text top="229" left="911" width="22" height="17" font="0">ALI </text>
<text top="246" left="911" width="7" height="18" font="7"></text>
<text top="247" left="918" width="112" height="17" font="0"> Similar results from </text>
<text top="265" left="911" width="118" height="17" font="0">Hingorani and Soule, </text>
<text top="282" left="911" width="126" height="17" font="0">different from Cambria </text>
<text top="366" left="95" width="92" height="17" font="0">Leung DA, et al. </text>
<text top="384" left="95" width="63" height="17" font="0">2015 (404) </text>
<text top="401" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26109628">26109628</a></text>
<text top="401" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26109628"> </a></text>
<text top="366" left="209" width="124" height="17" font="2"><b>Study type:</b> Rheolytic </text>
<text top="384" left="209" width="125" height="17" font="0">thrombectomy registry </text>
<text top="401" left="209" width="33" height="17" font="0">study </text>
<text top="418" left="209" width="3" height="17" font="0"> </text>
<text top="435" left="209" width="90" height="17" font="2"><b>Size:</b> n=283 pts </text>
<text top="366" left="378" width="174" height="17" font="2"><b>Inclusion criteria:</b> Pts with ALI </text>
<text top="384" left="378" width="217" height="17" font="0">undergoing treatment with the AngioJet </text>
<text top="401" left="378" width="44" height="17" font="0">System </text>
<text top="418" left="378" width="3" height="17" font="0"> </text>
<text top="435" left="378" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="367" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="366" left="628" width="6" height="18" font="7"></text>
<text top="367" left="634" width="213" height="17" font="2"><b> endpoint:</b> Procedure success, 12-mo </text>
<text top="385" left="621" width="252" height="17" font="0">amputation free survival, 12-mo freedom from </text>
<text top="402" left="621" width="64" height="17" font="0">amputation </text>
<text top="419" left="621" width="3" height="17" font="0"> </text>
<text top="436" left="621" width="271" height="17" font="2"><b>Results:</b> 83% achieved procedure success. 52% </text>
<text top="454" left="621" width="250" height="17" font="0">of procedures completed without the need for </text>
<text top="471" left="621" width="213" height="17" font="0">adjunctive CDT. 12-mo follow-up, 81% </text>
<text top="488" left="621" width="263" height="17" font="0">amputation free survival and 91% freedom from </text>
<text top="505" left="621" width="259" height="17" font="0">mortality, 91% freedom from bleeding requiring </text>
<text top="522" left="621" width="246" height="17" font="0">transfusion, 95% freedom from renal failure.  </text>
<text top="540" left="621" width="236" height="17" font="0">Significantly better outcomes in pts without </text>
<text top="557" left="621" width="226" height="17" font="0">infrapopliteal involvement and those who </text>
<text top="574" left="621" width="168" height="17" font="0">underwent PMT without CDT.  </text>
<text top="591" left="621" width="268" height="17" font="0">Higher rates of procedure success (p=0.021), 12-</text>
<text top="609" left="621" width="277" height="17" font="0">mo amputation free survival (p=0.028), and 12-mo </text>
<text top="626" left="621" width="253" height="17" font="0">freedom from amputation (p=0.01) in the PMT </text>
<text top="643" left="621" width="106" height="17" font="0">without CDT group </text>
<text top="366" left="911" width="7" height="18" font="7"></text>
<text top="367" left="918" width="133" height="17" font="0"> PMT had more positive </text>
<text top="385" left="911" width="112" height="17" font="0">results as a first line </text>
<text top="402" left="911" width="98" height="17" font="0">treatment for ALI  </text>
<text top="661" left="95" width="90" height="17" font="0">Schrijver AM, et </text>
<text top="678" left="95" width="16" height="17" font="0">al. </text>
<text top="695" left="95" width="63" height="17" font="0">2012 (405) </text>
<text top="713" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21534002">21534002</a></text>
<text top="713" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21534002"> </a></text>
<text top="730" left="95" width="3" height="17" font="0"> </text>
<text top="661" left="209" width="138" height="17" font="2"><b>Study type:</b> Prospective </text>
<text top="678" left="209" width="38" height="17" font="0">cohort </text>
<text top="695" left="209" width="3" height="17" font="0"> </text>
<text top="713" left="209" width="151" height="17" font="2"><b>Size:</b> n=21 consecutive pts </text>
<text top="661" left="378" width="225" height="17" font="2"><b>Inclusion criteria:</b> Pts with aotrofemoral </text>
<text top="678" left="378" width="202" height="17" font="0">arterial thromboembolic obstructions </text>
<text top="695" left="378" width="3" height="17" font="0"> </text>
<text top="713" left="378" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="662" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="661" left="628" width="6" height="18" font="7"></text>
<text top="662" left="634" width="258" height="17" font="2"><b> endpoint:</b> 30-d technical and clinical outcome </text>
<text top="679" left="621" width="174" height="17" font="0">of US-accelerated thrombolysis </text>
<text top="697" left="621" width="3" height="17" font="0"> </text>
<text top="714" left="621" width="261" height="17" font="2"><b>Results:</b> Complete thrombolysis (&gt;95% lysis of </text>
<text top="731" left="621" width="268" height="17" font="0">thrombus) was achieved in 20 pts; in 9 pts within </text>
<text top="748" left="621" width="243" height="17" font="0">24 hours. Median ankle-brachial index (ABI) </text>
<text top="765" left="621" width="238" height="17" font="0">increased from 0.28 (range, 0-0.85) to 0.91 </text>
<text top="661" left="911" width="7" height="18" font="7"></text>
<text top="662" left="918" width="117" height="17" font="0"> This feasibility study </text>
<text top="679" left="911" width="135" height="17" font="0">showed a high technical </text>
<text top="697" left="911" width="107" height="17" font="0">success rate of US-</text>
<text top="714" left="911" width="139" height="17" font="0">accelerated thrombolysis </text>
<text top="731" left="911" width="131" height="17" font="0">for aortofemoral arterial </text>
<text top="748" left="911" width="94" height="17" font="0">obstructions. US-</text>
<text top="765" left="911" width="139" height="17" font="0">accelerated thrombolysis </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">181 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="621" width="271" height="17" font="0">(range, 0.58-1.35). One pt had a thromboembolic </text>
<text top="104" left="621" width="276" height="17" font="0">complication and needed surgical intervention. No </text>
<text top="122" left="621" width="231" height="17" font="0">hemorrhagic complications and no deaths </text>
<text top="139" left="621" width="271" height="17" font="0">occurred. At 30-day follow-up, 17 of 21 pts (81%) </text>
<text top="156" left="621" width="167" height="17" font="0">had a patent artery or bypass. </text>
<text top="173" left="621" width="3" height="17" font="0"> </text>
<text top="87" left="911" width="149" height="17" font="0">led to complete lysis within </text>
<text top="104" left="911" width="140" height="17" font="0">24 h in almost half of pts, </text>
<text top="122" left="911" width="120" height="17" font="0">with a low 30-d major </text>
<text top="139" left="911" width="100" height="17" font="0">complication rate. </text>
<text top="191" left="95" width="96" height="17" font="0">Schrijver A, et al. </text>
<text top="208" left="95" width="63" height="17" font="0">2011 (406) </text>
<text top="226" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21792154">21792154</a></text>
<text top="226" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21792154"> </a></text>
<text top="243" left="95" width="3" height="17" font="0"> </text>
<text top="191" left="209" width="149" height="17" font="2"><b>Study type:</b> Retrospective </text>
<text top="208" left="209" width="38" height="17" font="0">cohort </text>
<text top="226" left="209" width="3" height="17" font="0"> </text>
<text top="243" left="209" width="83" height="17" font="2"><b>Size:</b> n=57 pts </text>
<text top="191" left="378" width="213" height="17" font="2"><b>Inclusion criteria:</b> Pts undergoing US-</text>
<text top="208" left="378" width="151" height="17" font="0">acelerated thrombolysis for </text>
<text top="226" left="378" width="227" height="17" font="0">thromboembolic arterial occlusions of the </text>
<text top="243" left="378" width="96" height="17" font="0">lower extremities </text>
<text top="260" left="378" width="3" height="17" font="0"> </text>
<text top="277" left="378" width="134" height="17" font="2"><b>Exclusion criteria:</b> N/A </text>
<text top="192" left="621" width="7" height="17" font="2"><b>1</b></text>
<text top="191" left="628" width="6" height="18" font="7"></text>
<text top="192" left="634" width="199" height="17" font="2"><b> endpoint:</b> 30-d and 6-mo follow-up </text>
<text top="210" left="621" width="3" height="17" font="0"> </text>
<text top="227" left="621" width="245" height="17" font="2"><b>Results:</b> The 30-day patency rate was 81%, </text>
<text top="244" left="621" width="256" height="17" font="0">without additional mortality. During a median 6-</text>
<text top="261" left="621" width="262" height="17" font="0">month (range, 2-14) follow-up, 9 reinterventions </text>
<text top="278" left="621" width="235" height="17" font="0">were performed. Two pts underwent major </text>
<text top="296" left="621" width="212" height="17" font="0">amputation and 3 pts died; because of </text>
<text top="313" left="621" width="199" height="17" font="0">malignancy (N=2) and stroke (N=1). </text>
<text top="191" left="911" width="7" height="18" font="7"></text>
<text top="192" left="918" width="128" height="17" font="0"> Initial success rates of </text>
<text top="210" left="911" width="129" height="17" font="0">ultrasound-accelerated </text>
<text top="227" left="911" width="144" height="17" font="0">thrombolysis are high and </text>
<text top="244" left="911" width="134" height="17" font="0">complication rate is low. </text>
<text top="261" left="911" width="133" height="17" font="0">However, reintervention </text>
<text top="278" left="911" width="122" height="17" font="0">rate during short-term </text>
<text top="296" left="911" width="123" height="17" font="0">follow-up for recurrent </text>
<text top="313" left="911" width="130" height="17" font="0">ischemia is substantial. </text>
<text top="331" left="86" width="1004" height="17" font="0">ALI indicates acute limb ischemia; CI, confidence interval; CDT, catheter-directed thrombolysis; CLI, critical limb ischemia; CT, computed tomography; DUAM, duplex ultrasound arterial </text>
<text top="348" left="86" width="1009" height="17" font="0">mapping; DSA, digital-subtraction angiography; ER, endovascular revascularization; HR, hazard ratio; MRA, magnetic resonance angiography; N/A, not applicable; OR, odds ratio; PMT, </text>
<text top="365" left="86" width="950" height="17" font="0">percutaneous mechanical thrombectomy; P-PS, power-pulse spray; pt, patient; RR, relative risk; RT, rheolytic thrombectomy; TNK, tenecteplase; UAT, ultrasound accelerated </text>
<text top="382" left="86" width="508" height="17" font="0">thrombolysis; UAT, ultrasound-accelerated thrombolysis; UK, urokinase; and US, ultrasound. </text>
<text top="400" left="86" width="3" height="17" font="0"> </text>
<text top="417" left="86" width="3" height="17" font="0"> </text>
<text top="434" left="86" width="457" height="21" font="1"><b>Evidence Table 51. RCTs for Longitudinal Follow-Up–Section 10. </b></text>
<text top="455" left="98" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="473" left="123" width="51" height="17" font="2"><b>Author;  </b></text>
<text top="490" left="101" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="455" left="244" width="83" height="17" font="2"><b>Aim of Study; </b></text>
<text top="473" left="248" width="74" height="17" font="2"><b>Study Type; </b></text>
<text top="490" left="242" width="86" height="17" font="2"><b>Study Size (N) </b></text>
<text top="455" left="394" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="455" left="552" width="115" height="17" font="2"><b>Study Intervention  </b></text>
<text top="473" left="570" width="79" height="17" font="2"><b>(# patients) /  </b></text>
<text top="490" left="552" width="114" height="17" font="2"><b>Study Comparator  </b></text>
<text top="507" left="573" width="69" height="17" font="2"><b>(# patients) </b></text>
<text top="455" left="741" width="104" height="17" font="2"><b>Endpoint Results </b></text>
<text top="473" left="689" width="210" height="17" font="2"><b>(Absolute Event Rates, P value; OR </b></text>
<text top="490" left="767" width="57" height="17" font="2"><b>or RR; &amp;  </b></text>
<text top="507" left="770" width="48" height="17" font="2"><b>95% CI) </b></text>
<text top="457" left="927" width="62" height="17" font="2"><b>Relevant 2</b></text>
<text top="456" left="988" width="6" height="18" font="7"></text>
<text top="457" left="994" width="63" height="17" font="2"><b> Endpoint  </b></text>
<text top="474" left="967" width="48" height="17" font="2"><b>(if any); </b></text>
<text top="491" left="935" width="111" height="17" font="2"><b>Study Limitations; </b></text>
<text top="508" left="943" width="96" height="17" font="2"><b>Adverse Events </b></text>
<text top="526" left="95" width="85" height="17" font="0">Ihlberg L, et al. </text>
<text top="543" left="95" width="63" height="17" font="0">1999 (407) </text>
<text top="561" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10610828">10610828</a></text>
<text top="561" left="149" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10610828"> </a></text>
<text top="578" left="95" width="3" height="17" font="0"> </text>
<text top="526" left="212" width="145" height="17" font="2"><b>Aim: </b>To evaluate benefits </text>
<text top="543" left="212" width="121" height="17" font="0">of duplex over clinical </text>
<text top="561" left="212" width="133" height="17" font="0">surveillance with ABI, in </text>
<text top="578" left="212" width="116" height="17" font="0">preventing vein-graft </text>
<text top="595" left="212" width="40" height="17" font="0">failure. </text>
<text top="612" left="212" width="3" height="17" font="2"><b> </b></text>
<text top="629" left="212" width="143" height="17" font="2"><b>Study type: </b>Randomized </text>
<text top="647" left="212" width="3" height="17" font="0"> </text>
<text top="664" left="212" width="118" height="17" font="2"><b>Size: </b>n=304 pts (362 </text>
<text top="681" left="212" width="129" height="17" font="0">infrainguinal bypasses) </text>
<text top="526" left="371" width="123" height="17" font="2"><b>Inclusion criteria: </b>All </text>
<text top="543" left="371" width="114" height="17" font="0">primary infrainguinal </text>
<text top="561" left="371" width="136" height="17" font="0">bypass autogenous vein </text>
<text top="578" left="371" width="135" height="17" font="0">grafts between 1/91 and </text>
<text top="595" left="371" width="34" height="17" font="0">12/95 </text>
<text top="612" left="371" width="3" height="17" font="0"> </text>
<text top="629" left="371" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="526" left="540" width="101" height="17" font="2"><b>Intervention:</b> ABI </text>
<text top="543" left="540" width="67" height="17" font="0">group (183) </text>
<text top="561" left="540" width="3" height="17" font="0"> </text>
<text top="578" left="540" width="115" height="17" font="2"><b>Comparator:</b>Duplex </text>
<text top="595" left="540" width="67" height="17" font="0">group (179) </text>
<text top="612" left="540" width="3" height="17" font="0"> </text>
<text top="629" left="540" width="133" height="17" font="0">Surveillance time points </text>
<text top="647" left="540" width="124" height="17" font="0">for groups at 1, 3, 6, 9 </text>
<text top="664" left="540" width="68" height="17" font="0">and 12 mo.  </text>
<text top="527" left="689" width="7" height="17" font="2"><b>1</b></text>
<text top="526" left="695" width="6" height="18" font="7"></text>
<text top="527" left="702" width="70" height="17" font="2"><b> endpoint:</b>   </text>
<text top="545" left="689" width="7" height="18" font="7"></text>
<text top="546" left="695" width="148" height="17" font="0"> Primary assisted patency, </text>
<text top="563" left="689" width="202" height="17" font="0">secondary patency and limb salvage </text>
<text top="580" left="689" width="190" height="17" font="0">rates were 67%, 74% and 85% for </text>
<text top="597" left="689" width="207" height="17" font="0">ABI group vs. 67%, 73% and 81% for </text>
<text top="615" left="689" width="197" height="17" font="0">the Duplex group, respectively. (NS </text>
<text top="632" left="689" width="62" height="17" font="0">difference) </text>
<text top="649" left="689" width="7" height="18" font="7"></text>
<text top="650" left="695" width="135" height="17" font="0"> Similar outcomes at 1y. </text>
<text top="667" left="689" width="3" height="17" font="0"> </text>
<text top="685" left="689" width="124" height="17" font="2"><b>Safety endpoint:</b> N/A </text>
<text top="526" left="911" width="129" height="17" font="0">Grafts were more often </text>
<text top="543" left="911" width="153" height="17" font="0">redone in the duplex group. </text>
<text top="561" left="911" width="3" height="17" font="0"> </text>
<text top="578" left="911" width="151" height="17" font="2"><b>Limitations:</b> Low power. A </text>
<text top="595" left="911" width="130" height="17" font="0">large multicenter trial is </text>
<text top="612" left="911" width="49" height="17" font="0">required </text>
<text top="703" left="95" width="88" height="17" font="0">Lundell A, et al. </text>
<text top="720" left="95" width="63" height="17" font="0">1995<b> </b>(408)<b> </b></text>
<text top="737" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7823359">7823359</a></text>
<text top="737" left="142" width="3" height="17" font="2"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7823359"><b> </b></a></text>
<text top="754" left="95" width="3" height="17" font="0"> </text>
<text top="703" left="212" width="38" height="17" font="2"><b>Aim:   </b></text>
<text top="720" left="212" width="127" height="17" font="0">To investigate whether </text>
<text top="737" left="212" width="120" height="17" font="0">intensive surveillance </text>
<text top="754" left="212" width="97" height="17" font="0">(Duplex and ABI) </text>
<text top="771" left="212" width="53" height="17" font="0">improves </text>
<text top="703" left="371" width="127" height="17" font="2"><b>Inclusion criteria: </b>Pts </text>
<text top="720" left="371" width="146" height="17" font="0">undergoing reconstruction </text>
<text top="737" left="371" width="124" height="17" font="0">surgery (CLI, popliteal </text>
<text top="754" left="371" width="141" height="17" font="0">aneurysm, IC diminishing </text>
<text top="771" left="371" width="31" height="17" font="0">QoL) </text>
<text top="703" left="540" width="131" height="17" font="2"><b>Intervention:</b> Intensive </text>
<text top="720" left="540" width="94" height="17" font="0">surveillance (79) </text>
<text top="737" left="540" width="3" height="17" font="2"><b> </b></text>
<text top="754" left="540" width="123" height="17" font="2"><b>Comparator: </b>Routine </text>
<text top="771" left="540" width="77" height="17" font="0">follow up (77) </text>
<text top="704" left="689" width="7" height="17" font="2"><b>1</b></text>
<text top="703" left="695" width="6" height="18" font="7"></text>
<text top="704" left="702" width="157" height="17" font="2"><b> endpoint: </b>Assisted primary </text>
<text top="721" left="689" width="206" height="17" font="0">cumulative vein graft patency rates in </text>
<text top="738" left="689" width="202" height="17" font="0">the intensive group vs. routine group </text>
<text top="755" left="689" width="152" height="17" font="0">(78% vs. 53%; p&lt;0.05) and </text>
<text top="773" left="689" width="189" height="17" font="0">secondary patency rates (82% vs. </text>
<text top="703" left="911" width="7" height="18" font="7"></text>
<text top="704" left="918" width="137" height="17" font="0"> Most of the failing grafts </text>
<text top="721" left="911" width="147" height="17" font="0">and graft occlusions found </text>
<text top="738" left="911" width="93" height="17" font="0">in first postop. y. </text>
<text top="755" left="911" width="7" height="18" font="7"></text>
<text top="756" left="918" width="105" height="17" font="0"> More failing grafts </text>
<text top="774" left="911" width="132" height="17" font="0">identified if the intervals </text>
</page>
<page number="182" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">182 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="212" width="122" height="17" font="0">femoropopliteal/crural </text>
<text top="104" left="212" width="91" height="17" font="0">graft patency as </text>
<text top="122" left="212" width="113" height="17" font="0">compared to routine </text>
<text top="139" left="212" width="55" height="17" font="0">follow up. </text>
<text top="156" left="212" width="3" height="17" font="0"> </text>
<text top="173" left="212" width="143" height="17" font="2"><b>Study type: </b>Randomized </text>
<text top="190" left="212" width="3" height="17" font="2"><b> </b></text>
<text top="208" left="212" width="90" height="17" font="2"><b>Size: </b>n=156 pts<b> </b></text>
<text top="87" left="371" width="3" height="17" font="2"><b> </b></text>
<text top="104" left="371" width="134" height="17" font="2"><b>Exclusion criteria: </b>N/A </text>
<text top="87" left="689" width="77" height="17" font="0">56%; p&lt;0.05) </text>
<text top="104" left="689" width="3" height="17" font="0"> </text>
<text top="122" left="689" width="198" height="17" font="0">Assisted primary cumulative ePTFE </text>
<text top="139" left="689" width="192" height="17" font="0">and composite graft patency in the </text>
<text top="156" left="689" width="202" height="17" font="0">intensive group vs. the routine group </text>
<text top="173" left="689" width="191" height="17" font="0">(57% vs. 50%; NS) and secondary </text>
<text top="190" left="689" width="166" height="17" font="0">patency results were also NS. </text>
<text top="208" left="689" width="3" height="17" font="0"> </text>
<text top="225" left="689" width="124" height="17" font="2"><b>Safety endpoint: </b>N/A </text>
<text top="87" left="911" width="152" height="17" font="0">between visits was 6 wk for </text>
<text top="104" left="911" width="51" height="17" font="0">first 6mo </text>
<text top="243" left="86" width="1015" height="17" font="0">ABI indicates ankle brachial index; CLI, critical limb ischemia; ePTFE, Polytetrafluoroethylene; IC, intermittent claudication; N/A, not applicable; NS, not significant; pt, patient; QoL, quality </text>
<text top="263" left="86" width="243" height="17" font="0">of life; and RCT, randomized controlled trial; </text>
<text top="297" left="86" width="3" height="17" font="0"> </text>
<text top="315" left="86" width="866" height="21" font="1"><b>Evidence Table 52. Nonrandomized Trials, Observational Studies, and/or Registries for Longitudinal Follow-Up–Section 10. </b></text>
<text top="336" left="96" width="98" height="17" font="2"><b>Study Acronym; </b></text>
<text top="353" left="122" width="48" height="17" font="2"><b>Author; </b></text>
<text top="370" left="99" width="92" height="17" font="2"><b>Year Published </b></text>
<text top="336" left="211" width="118" height="17" font="2"><b>Study Type/Design; </b></text>
<text top="353" left="238" width="66" height="17" font="2"><b>Study Size </b></text>
<text top="336" left="394" width="111" height="17" font="2"><b>Patient Population </b></text>
<text top="336" left="616" width="179" height="17" font="2"><b>Primary Endpoint and Results </b></text>
<text top="353" left="624" width="164" height="17" font="2"><b>(include P value; OR or RR; </b></text>
<text top="370" left="676" width="60" height="17" font="2"><b>&amp; 95% CI) </b></text>
<text top="336" left="895" width="130" height="17" font="2"><b>Summary/Conclusion </b></text>
<text top="353" left="923" width="75" height="17" font="2"><b>Comment(s) </b></text>
<text top="388" left="95" width="99" height="17" font="0">Jongsma H, et al. </text>
<text top="406" left="95" width="63" height="17" font="0">2016 (409) </text>
<text top="423" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26482995">26482995</a></text>
<text top="423" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26482995"> </a></text>
<text top="440" left="95" width="3" height="17" font="0"> </text>
<text top="388" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="406" left="210" width="116" height="17" font="0">Retrospective cohort </text>
<text top="423" left="210" width="33" height="17" font="0">study </text>
<text top="440" left="210" width="3" height="17" font="0"> </text>
<text top="457" left="210" width="83" height="17" font="2"><b>Size:</b> n=69 pts </text>
<text top="388" left="345" width="113" height="17" font="2"><b>Inclusion criteria:</b>   </text>
<text top="406" left="345" width="200" height="17" font="0">Pts with primary PTA for autologous </text>
<text top="423" left="345" width="209" height="17" font="0">infrainguinal bypasses monitored with </text>
<text top="440" left="345" width="94" height="17" font="0">duplex u/s for 1y </text>
<text top="457" left="345" width="3" height="17" font="0"> </text>
<text top="475" left="345" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported </text>
<text top="390" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="388" left="574" width="6" height="18" font="7"></text>
<text top="390" left="581" width="230" height="17" font="2"><b> endpoint:</b> Number of study interventions </text>
<text top="407" left="568" width="3" height="17" font="0"> </text>
<text top="424" left="568" width="59" height="17" font="2"><b>Results:</b>   </text>
<text top="441" left="568" width="7" height="18" font="7"></text>
<text top="442" left="575" width="253" height="17" font="0"> 43% free of major stenosis/ bypass occlusion </text>
<text top="460" left="568" width="7" height="18" font="7"></text>
<text top="461" left="575" width="133" height="17" font="0"> 42% recurrent stenosis </text>
<text top="478" left="568" width="7" height="18" font="7"></text>
<text top="479" left="575" width="84" height="17" font="0"> 14% occluded </text>
<text top="388" left="858" width="7" height="18" font="7"></text>
<text top="390" left="865" width="160" height="17" font="0"> Secondary interventions are </text>
<text top="407" left="858" width="178" height="17" font="0">common however such frequent </text>
<text top="424" left="858" width="197" height="17" font="0">interventions result in patency rates </text>
<text top="441" left="858" width="65" height="17" font="0">&gt;80% at 1y </text>
<text top="497" left="95" width="83" height="17" font="0">Carter A, et al. </text>
<text top="514" left="95" width="63" height="17" font="0">2007 (410) </text>
<text top="532" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17980793">17980793</a></text>
<text top="532" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17980793"> </a></text>
<text top="549" left="95" width="3" height="17" font="0"> </text>
<text top="497" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="514" left="210" width="83" height="17" font="0">Observational  </text>
<text top="532" left="210" width="3" height="17" font="0"> </text>
<text top="549" left="210" width="104" height="17" font="2"><b>Size:</b> n=212 grafts </text>
<text top="566" left="210" width="52" height="17" font="0">(197 pts) </text>
<text top="497" left="345" width="176" height="17" font="2"><b>Inclusion criteria:</b> Infrainguinal </text>
<text top="514" left="345" width="178" height="17" font="0">lower limb grafts with duplex u/s </text>
<text top="532" left="345" width="185" height="17" font="0">surveillance (0, 1, 3, 6, 12 and 18 </text>
<text top="549" left="345" width="25" height="17" font="0">mo) </text>
<text top="566" left="345" width="3" height="17" font="0"> </text>
<text top="583" left="345" width="192" height="17" font="2"><b>Exclusion criteria: </b>None reported </text>
<text top="498" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="497" left="574" width="6" height="18" font="7"></text>
<text top="498" left="581" width="224" height="17" font="2"><b> endpoint:</b> Graft failures and time points </text>
<text top="515" left="568" width="3" height="17" font="0"> </text>
<text top="533" left="568" width="59" height="17" font="2"><b>Results:</b>   </text>
<text top="550" left="568" width="7" height="18" font="7"></text>
<text top="551" left="575" width="106" height="17" font="0"> Occlusions-21.6% </text>
<text top="568" left="568" width="7" height="18" font="7"></text>
<text top="569" left="575" width="260" height="17" font="0"> Salvage procedure-16% (40.5% done at 6 mo) </text>
<text top="587" left="568" width="7" height="18" font="7"></text>
<text top="588" left="575" width="216" height="17" font="0"> 56.6% occlusion preceded by stenosis </text>
<text top="605" left="568" width="7" height="18" font="7"></text>
<text top="606" left="575" width="242" height="17" font="0"> Primary occlusions: 95.9% in the prosthetic </text>
<text top="623" left="568" width="238" height="17" font="0">group and 66.5% in the femorocrural group </text>
<text top="641" left="568" width="7" height="18" font="7"></text>
<text top="642" left="575" width="243" height="17" font="0"> Twice as many stenosis in venous conduits </text>
<text top="659" left="568" width="135" height="17" font="0">than the prosthetic ones </text>
<text top="498" left="858" width="6" height="16" font="27"></text>
<text top="499" left="864" width="3" height="15" font="21"> </text>
<text top="497" left="867" width="189" height="17" font="0">Surveillance effective for AKV and </text>
<text top="514" left="858" width="165" height="17" font="0">BKV groups (for detecting the </text>
<text top="532" left="858" width="181" height="17" font="0">presence of significant lesions at </text>
<text top="549" left="858" width="142" height="17" font="0">high risk of failure without </text>
<text top="566" left="858" width="71" height="17" font="0">intervention) </text>
<text top="583" left="858" width="7" height="18" font="7"></text>
<text top="584" left="865" width="172" height="17" font="0"> Statins protective against graft </text>
<text top="602" left="858" width="37" height="17" font="0">failure </text>
<text top="677" left="95" width="98" height="17" font="0">Westerband A, et </text>
<text top="694" left="95" width="16" height="17" font="0">al. </text>
<text top="711" left="95" width="63" height="17" font="0">1997 (411) </text>
<text top="729" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9061138">9061138</a></text>
<text top="729" left="143" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9061138"> </a></text>
<text top="746" left="95" width="3" height="17" font="0"> </text>
<text top="677" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="694" left="210" width="83" height="17" font="0">Observational  </text>
<text top="711" left="210" width="3" height="17" font="0"> </text>
<text top="729" left="210" width="111" height="17" font="2"><b>Size:</b> n=98 pts (101 </text>
<text top="746" left="210" width="96" height="17" font="0">infrainguinal vein </text>
<text top="763" left="210" width="38" height="17" font="0">grafts) </text>
<text top="677" left="345" width="190" height="17" font="2"><b>Inclusion criteria:</b> CFDS and ABI </text>
<text top="694" left="345" width="190" height="17" font="0">every 3 mo for 1 y and every 6 mo </text>
<text top="711" left="345" width="132" height="17" font="0">thereafter for another y  </text>
<text top="729" left="345" width="3" height="17" font="0"> </text>
<text top="746" left="345" width="202" height="17" font="2"><b>Exclusion criteria:</b> Lost to follow up </text>
<text top="763" left="345" width="20" height="17" font="0">pts </text>
<text top="678" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="677" left="574" width="6" height="18" font="7"></text>
<text top="678" left="581" width="262" height="17" font="2"><b> endpoint:</b> No. of evaluations and interventions </text>
<text top="695" left="568" width="243" height="17" font="0">to prevent graft occlusion after the threshold </text>
<text top="713" left="568" width="269" height="17" font="0">criteria based on existent literature (HVC defined </text>
<text top="730" left="568" width="276" height="17" font="0">as PSV &gt;300 cm/sec and Vr &gt;3.5; LVC defined as </text>
<text top="747" left="568" width="231" height="17" font="0">PSV &lt;45 cm/sec; an ABI decrease &gt;0.15) </text>
<text top="764" left="568" width="3" height="17" font="0"> </text>
<text top="677" left="858" width="7" height="18" font="7"></text>
<text top="678" left="865" width="159" height="17" font="0"> Infrainguinal vein grafts with </text>
<text top="695" left="858" width="160" height="17" font="0">normal CFDS and ABI are at </text>
<text top="713" left="858" width="160" height="17" font="0">minimal risk for spontaneous </text>
<text top="730" left="858" width="185" height="17" font="0">occlusion prospectively validating </text>
<text top="747" left="858" width="118" height="17" font="0">the threshold criteria. </text>
<text top="764" left="858" width="7" height="18" font="7"></text>
<text top="765" left="865" width="145" height="17" font="0"> High risk of bias being an </text>
</page>
<page number="183" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">183 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="568" width="55" height="17" font="2"><b>Results:</b>  </text>
<text top="104" left="568" width="232" height="17" font="0">-51 grafts didn't occlude and didn't require </text>
<text top="122" left="568" width="49" height="17" font="0">revision. </text>
<text top="139" left="568" width="235" height="17" font="0">-43 had stenosis (20 underwent revision, 2 </text>
<text top="156" left="568" width="235" height="17" font="0">stenosed, 10 regressed spontaneously, 10 </text>
<text top="173" left="568" width="95" height="17" font="0">remained stable)<b> </b></text>
<text top="87" left="858" width="135" height="17" font="0">observational validation. </text>
<text top="191" left="95" width="78" height="17" font="0">Mills JL, et al. </text>
<text top="208" left="95" width="63" height="17" font="0">1990 (412) </text>
<text top="226" left="95" width="48" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2214034">2214034</a></text>
<text top="226" left="143" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2214034"> </a></text>
<text top="243" left="95" width="3" height="17" font="0"> </text>
<text top="191" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="208" left="210" width="79" height="17" font="0">Observational </text>
<text top="226" left="210" width="3" height="17" font="0"> </text>
<text top="243" left="210" width="118" height="17" font="2"><b>Size:</b> n=292 pts (379 </text>
<text top="260" left="210" width="116" height="17" font="0">reversed vein grafts)<b> </b></text>
<text top="191" left="345" width="176" height="17" font="2"><b>Inclusion criteria:</b> Infrainguinal </text>
<text top="208" left="345" width="181" height="17" font="0">reversed vein bypasses subjects </text>
<text top="226" left="345" width="200" height="17" font="0">undergoing prospective surveillance </text>
<text top="243" left="345" width="47" height="17" font="0">protocol </text>
<text top="260" left="345" width="3" height="17" font="0"> </text>
<text top="277" left="345" width="192" height="17" font="2"><b>Exclusion criteria: </b>None reported<b> </b></text>
<text top="192" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="191" left="574" width="6" height="18" font="7"></text>
<text top="192" left="581" width="135" height="17" font="2"><b> endpoint and results:</b>  </text>
<text top="210" left="568" width="7" height="18" font="7"></text>
<text top="211" left="575" width="247" height="17" font="0"> Mean of 3.2 surveillance exams/ graft with a </text>
<text top="228" left="568" width="163" height="17" font="0">mean follow up was 21.5 mo. </text>
<text top="245" left="568" width="7" height="18" font="7"></text>
<text top="246" left="575" width="261" height="17" font="0"> -2.1% of 280 grafts with GFV &gt;45cm/sec failed </text>
<text top="264" left="568" width="238" height="17" font="0">within 6 mo of surveillance exam. GFV &lt;45 </text>
<text top="281" left="568" width="273" height="17" font="0">cm/sec in 99 grafts resulted in arteriography in 75 </text>
<text top="298" left="568" width="255" height="17" font="0">grafts, identifying 50 stenoses in 48 bypasses. </text>
<text top="315" left="568" width="248" height="17" font="0">-29% of grafts diagnosed as failing by duplex </text>
<text top="332" left="568" width="249" height="17" font="0">scans were related to decrease in ABI &gt;0.15. </text>
<text top="191" left="858" width="7" height="18" font="7"></text>
<text top="192" left="865" width="183" height="17" font="0"> Duplex surveillance appeared to </text>
<text top="210" left="858" width="195" height="17" font="0">be more reliable in the failing grafts </text>
<text top="227" left="858" width="51" height="17" font="0">than ABI </text>
<text top="244" left="858" width="7" height="18" font="7"></text>
<text top="245" left="865" width="192" height="17" font="0"> Dupex surveillance identified graft-</text>
<text top="262" left="858" width="185" height="17" font="0">threatening lesions in 13% of 379 </text>
<text top="280" left="858" width="179" height="17" font="0">grafts and repair was successful </text>
<text top="350" left="95" width="95" height="17" font="0">Brumberg RS, et </text>
<text top="368" left="95" width="16" height="17" font="0">al. </text>
<text top="385" left="95" width="63" height="17" font="0">2007 (413) </text>
<text top="402" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17920227">17920227</a></text>
<text top="402" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17920227"> </a></text>
<text top="419" left="95" width="3" height="17" font="0"> </text>
<text top="350" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="368" left="210" width="79" height="17" font="0">Observational </text>
<text top="385" left="210" width="3" height="17" font="0"> </text>
<text top="402" left="210" width="118" height="17" font="2"><b>Size:</b> n=121 pts (130 </text>
<text top="419" left="210" width="105" height="17" font="0">PTFE infrainguinal </text>
<text top="436" left="210" width="59" height="17" font="0">bypasses)<b> </b></text>
<text top="350" left="345" width="170" height="17" font="2"><b>Inclusion criteria:</b> Pts with no </text>
<text top="368" left="345" width="202" height="17" font="0">usable saphenous veins. Lower limb </text>
<text top="385" left="345" width="174" height="17" font="0">ischemia (rest pain, tissue loss, </text>
<text top="402" left="345" width="208" height="17" font="0">disabling claudication/and or popliteal </text>
<text top="419" left="345" width="181" height="17" font="0">aneurysm, pts requiring a repeat </text>
<text top="436" left="345" width="198" height="17" font="0">bypass). Duplex surveillance at 1, 4 </text>
<text top="454" left="345" width="150" height="17" font="0">and 7 mo. and twice yearly </text>
<text top="471" left="345" width="64" height="17" font="0">afterwards. </text>
<text top="488" left="345" width="3" height="17" font="0"> </text>
<text top="505" left="345" width="195" height="17" font="2"><b>Exclusion criteria:</b> Cadaveric vein </text>
<text top="351" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="350" left="574" width="6" height="18" font="7"></text>
<text top="351" left="581" width="135" height="17" font="2"><b> endpoint and results:</b>  </text>
<text top="369" left="568" width="7" height="18" font="7"></text>
<text top="374" left="575" width="4" height="12" font="21"> </text>
<text top="370" left="578" width="243" height="17" font="0">3y primary patency, assisted and secondary </text>
<text top="387" left="568" width="231" height="17" font="0">patency results were 39%, 43% and 59%, </text>
<text top="404" left="568" width="72" height="17" font="0">respectively. </text>
<text top="422" left="568" width="7" height="18" font="7"></text>
<text top="427" left="575" width="4" height="12" font="21"> </text>
<text top="423" left="578" width="259" height="17" font="0">NS differences noted between above knee and </text>
<text top="440" left="568" width="103" height="17" font="0">below knee grafts. </text>
<text top="457" left="568" width="7" height="18" font="7"></text>
<text top="463" left="575" width="4" height="12" font="21"> </text>
<text top="458" left="578" width="260" height="17" font="0">At 3 y, freedom from limb loss was 75% and pt. </text>
<text top="476" left="568" width="102" height="17" font="0">survival was 75%. </text>
<text top="493" left="568" width="7" height="18" font="7"></text>
<text top="498" left="575" width="4" height="12" font="21"> </text>
<text top="494" left="578" width="238" height="17" font="0">Distal anastomotic adjunct with below knee </text>
<text top="511" left="568" width="271" height="17" font="0">bypasses reduced graft thrombosis (35% with vs. </text>
<text top="528" left="568" width="223" height="17" font="0">60% without) but no patency advantage. </text>
<text top="546" left="568" width="7" height="18" font="7"></text>
<text top="551" left="575" width="4" height="12" font="21"> </text>
<text top="547" left="578" width="246" height="17" font="0">Multivariate analysis: low graft flow (OR: 6.1; </text>
<text top="564" left="568" width="271" height="17" font="0">95% CI: 1.9–19.2), use of warfarin (OR: 8.4; 95% </text>
<text top="581" left="568" width="239" height="17" font="0">CI: 2.1–34.5) and therapeutic warfarin (OR; </text>
<text top="598" left="568" width="272" height="17" font="0">24.6%; CI: 5.7–106) to be independent predictors </text>
<text top="616" left="568" width="64" height="17" font="0">of patency.<b> </b></text>
<text top="350" left="858" width="7" height="18" font="7"></text>
<text top="356" left="865" width="4" height="12" font="21"> </text>
<text top="351" left="869" width="176" height="17" font="0">Low graft flow endangered graft </text>
<text top="369" left="858" width="163" height="17" font="0">patency more frequently than </text>
<text top="386" left="858" width="157" height="17" font="0">development of duplex scan </text>
<text top="403" left="858" width="107" height="17" font="0">detected stenoses. </text>
<text top="420" left="858" width="7" height="18" font="7"></text>
<text top="421" left="865" width="159" height="17" font="0"> Early duplex scanning more </text>
<text top="439" left="858" width="191" height="17" font="0">important for diagnosing MGV and </text>
<text top="456" left="858" width="135" height="17" font="0">the thrombotic potential. </text>
<text top="633" left="95" width="90" height="17" font="0">Calligaro KD, et </text>
<text top="651" left="95" width="16" height="17" font="0">al. </text>
<text top="668" left="95" width="63" height="17" font="0">2001 (414) </text>
<text top="685" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11665434">11665434</a></text>
<text top="685" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11665434"> </a></text>
<text top="702" left="95" width="3" height="17" font="0"> </text>
<text top="633" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="651" left="210" width="79" height="17" font="0">Observational </text>
<text top="668" left="210" width="3" height="17" font="0"> </text>
<text top="685" left="210" width="108" height="17" font="2"><b>Size:</b> n= 66 pts (89 </text>
<text top="702" left="210" width="70" height="17" font="0">infrainguinal </text>
<text top="720" left="210" width="59" height="17" font="0">bypasses)<b> </b></text>
<text top="633" left="345" width="170" height="17" font="2"><b>Inclusion criteria:</b> Infringuinal </text>
<text top="651" left="345" width="179" height="17" font="0">prosthetic bypasses with Duplex </text>
<text top="668" left="345" width="166" height="17" font="0">surveillance and entered graft </text>
<text top="685" left="345" width="116" height="17" font="0">surveillance protocol </text>
<text top="702" left="345" width="3" height="17" font="0"> </text>
<text top="720" left="345" width="169" height="17" font="2"><b>Exclusion criteria:</b> No duplex </text>
<text top="737" left="345" width="188" height="17" font="0">surveillance, inadequate follow up </text>
<text top="754" left="345" width="46" height="17" font="0">(&lt;3 mo)<b> </b></text>
<text top="635" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="633" left="574" width="6" height="18" font="7"></text>
<text top="635" left="581" width="135" height="17" font="2"><b> endpoint and results:</b>  </text>
<text top="652" left="568" width="204" height="17" font="0">-22 thrombosed and 25 failing grafts  </text>
<text top="669" left="568" width="166" height="17" font="0">-25 failing grafts were redone. </text>
<text top="686" left="568" width="261" height="17" font="0">-Sensitivity of duplex correctly identifying failing </text>
<text top="703" left="568" width="32" height="17" font="0">graft: </text>
<text top="721" left="568" width="205" height="17" font="0">88% for FT vs. 57% for FP (p = 0.04) </text>
<text top="738" left="568" width="227" height="17" font="0">-PPV was 95% FT vs. 65% FP (p = 0.04) </text>
<text top="633" left="858" width="7" height="18" font="7"></text>
<text top="639" left="865" width="4" height="12" font="21"> </text>
<text top="635" left="869" width="169" height="17" font="0">The surveillance and follow up </text>
<text top="652" left="858" width="166" height="17" font="0">management not shown to be </text>
<text top="669" left="858" width="194" height="17" font="0">correlated with improved outcomes </text>
<text top="686" left="858" width="7" height="18" font="7"></text>
<text top="687" left="865" width="176" height="17" font="0"> Prosthetic grafts more prone to </text>
<text top="705" left="858" width="67" height="17" font="0">thrombosis. </text>
<text top="772" left="95" width="89" height="17" font="0">Stone PA, et al. </text>
<text top="772" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="772" left="345" width="163" height="17" font="2"><b>Inclusion criteria:</b> Bypasses </text>
<text top="773" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="772" left="574" width="6" height="18" font="7"></text>
<text top="773" left="581" width="135" height="17" font="2"><b> endpoint and results:</b>  </text>
<text top="772" left="858" width="184" height="17" font="0">Duplex surveillance with repair of </text>
</page>
<page number="184" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">184 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="63" height="17" font="0">2006 (415) </text>
<text top="104" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16950423">16950423</a></text>
<text top="104" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16950423"> </a></text>
<text top="122" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="210" width="83" height="17" font="0">Observational  </text>
<text top="104" left="210" width="3" height="17" font="0"> </text>
<text top="122" left="210" width="36" height="17" font="2"><b>Size:</b>  </text>
<text top="139" left="210" width="61" height="17" font="0">n=108 pts. </text>
<text top="156" left="210" width="118" height="17" font="0">(femorofemoral: 100; </text>
<text top="173" left="210" width="99" height="17" font="0">vein: 8 bypasses)<b> </b></text>
<text top="87" left="345" width="175" height="17" font="0">undergoing Duplex surveillance </text>
<text top="104" left="345" width="47" height="17" font="0">protocol </text>
<text top="122" left="345" width="3" height="17" font="0"> </text>
<text top="139" left="345" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported<b> </b></text>
<text top="87" left="568" width="7" height="18" font="7"></text>
<text top="88" left="575" width="160" height="17" font="0"> 29% bypasses were revised </text>
<text top="106" left="568" width="7" height="18" font="7"></text>
<text top="107" left="575" width="258" height="17" font="0"> Primary patency at 1, 3 and 5y was 86%, 78% </text>
<text top="124" left="568" width="127" height="17" font="0">and 62%, respectively. </text>
<text top="141" left="568" width="7" height="18" font="7"></text>
<text top="142" left="575" width="262" height="17" font="0"> Duplex assisted-primary patency was 95% at 1 </text>
<text top="159" left="568" width="223" height="17" font="0">y, 88% at 3 and 5 y (p&lt;0.0001, log rank) </text>
<text top="177" left="568" width="7" height="18" font="7"></text>
<text top="178" left="575" width="258" height="17" font="0"> Secondary graft patency was 98% at 1 y, 93% </text>
<text top="195" left="568" width="71" height="17" font="0">at 3 and 5 y.<b> </b></text>
<text top="87" left="858" width="162" height="17" font="0">lesions with PSVs &gt;300 cm/s </text>
<text top="104" left="858" width="169" height="17" font="0">improved long term patency of </text>
<text top="122" left="858" width="120" height="17" font="0">femorofemoral grafts. </text>
<text top="213" left="95" width="87" height="17" font="0">Back MR, et al. </text>
<text top="230" left="95" width="63" height="17" font="0">2001 (416) </text>
<text top="248" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11797981">11797981</a></text>
<text top="248" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11797981"> </a></text>
<text top="265" left="95" width="3" height="17" font="0"> </text>
<text top="213" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="230" left="210" width="83" height="17" font="0">Observational  </text>
<text top="248" left="210" width="3" height="17" font="0"> </text>
<text top="265" left="210" width="104" height="17" font="2"><b>Size:</b> n=64 pts (84 </text>
<text top="282" left="210" width="65" height="17" font="0">iliac stents)<b> </b></text>
<text top="213" left="345" width="113" height="17" font="2"><b>Inclusion criteria:</b>   </text>
<text top="230" left="345" width="178" height="17" font="0">Iliac PTA and stents undergoing </text>
<text top="248" left="345" width="208" height="17" font="0">aortoiliac duplex surveillance protocol </text>
<text top="265" left="345" width="197" height="17" font="0">at &lt;1 mo, 3 mo. and 6 mo. intervals </text>
<text top="282" left="345" width="59" height="17" font="0">for 36 mo. </text>
<text top="299" left="345" width="3" height="17" font="0"> </text>
<text top="316" left="345" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported </text>
<text top="214" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="213" left="574" width="6" height="18" font="7"></text>
<text top="214" left="581" width="142" height="17" font="2"><b> endpoints and results:</b>  </text>
<text top="231" left="568" width="7" height="18" font="7"></text>
<text top="232" left="575" width="58" height="17" font="0"> 73 patent </text>
<text top="250" left="568" width="7" height="18" font="7"></text>
<text top="251" left="575" width="75" height="17" font="0"> 3 occlusions </text>
<text top="268" left="568" width="7" height="18" font="7"></text>
<text top="269" left="575" width="105" height="17" font="0"> 2 failing by duplex </text>
<text top="287" left="568" width="7" height="18" font="7"></text>
<text top="288" left="575" width="72" height="17" font="0"> 6 re-stented </text>
<text top="213" left="858" width="7" height="18" font="7"></text>
<text top="214" left="865" width="163" height="17" font="0"> Duplex surveillance with iliac </text>
<text top="231" left="858" width="170" height="17" font="0">stenting localized deteriorating </text>
<text top="249" left="858" width="201" height="17" font="0">inflow segments, enhanced assisted </text>
<text top="266" left="858" width="50" height="17" font="0">patency. </text>
<text top="283" left="858" width="7" height="18" font="7"></text>
<text top="284" left="865" width="171" height="17" font="0"> Superior efficacy for multilevel </text>
<text top="301" left="858" width="166" height="17" font="0">occlusive disease and outflow </text>
<text top="319" left="858" width="90" height="17" font="0">reconstructions. </text>
<text top="337" left="95" width="72" height="17" font="0">Baril DT and </text>
<text top="354" left="95" width="64" height="17" font="0">Marone LK </text>
<text top="371" left="95" width="63" height="17" font="0">2012 (417) </text>
<text top="388" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22609972">22609972</a></text>
<text top="388" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22609972"> </a></text>
<text top="405" left="95" width="3" height="17" font="0"> </text>
<text top="337" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="354" left="210" width="83" height="17" font="0">Observational  </text>
<text top="371" left="210" width="3" height="17" font="0"> </text>
<text top="388" left="210" width="102" height="17" font="2"><b>Size:</b> n=330 limbs<b> </b></text>
<text top="337" left="345" width="198" height="17" font="2"><b>Inclusion criteria:</b> Femoropopliteal </text>
<text top="354" left="345" width="159" height="17" font="0">angioplasty and stenting pts. </text>
<text top="371" left="345" width="205" height="17" font="0">undergoing surveillance at 1, 3 and 6 </text>
<text top="388" left="345" width="172" height="17" font="0">mo. and then at 6 mo. intervals </text>
<text top="405" left="345" width="152" height="17" font="0">indefinitely after procedure. </text>
<text top="423" left="345" width="3" height="17" font="0"> </text>
<text top="440" left="345" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported </text>
<text top="338" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="337" left="574" width="6" height="18" font="7"></text>
<text top="338" left="581" width="142" height="17" font="2"><b> endpoints and results:</b>  </text>
<text top="355" left="568" width="7" height="18" font="7"></text>
<text top="356" left="575" width="232" height="17" font="0"> Data pairs of duplex and angiographically </text>
<text top="373" left="568" width="274" height="17" font="0">measured stenosis within 30 d of each underwent </text>
<text top="391" left="568" width="55" height="17" font="0">analyses. </text>
<text top="408" left="568" width="7" height="18" font="7"></text>
<text top="409" left="575" width="267" height="17" font="0"> Linear regression analyses were performed and </text>
<text top="426" left="568" width="241" height="17" font="0">ROC curves were used to ascertain optimal </text>
<text top="443" left="568" width="229" height="17" font="0">criteria associating to ≥50% and ≥80% in-</text>
<text top="461" left="568" width="256" height="17" font="0">stenosis. A linear regression model of PSV vs. </text>
<text top="478" left="568" width="191" height="17" font="0">degree of angiographic stenosis (R</text>
<text top="479" left="758" width="4" height="11" font="11">2</text>
<text top="478" left="763" width="38" height="17" font="0">=0.60; </text>
<text top="495" left="568" width="56" height="17" font="0">p&lt;0.001); </text>
<text top="512" left="568" width="13" height="17" font="0">(R</text>
<text top="513" left="581" width="4" height="11" font="11">2</text>
<text top="512" left="585" width="254" height="17" font="0">=0.55; p&lt;0.001) for velocity ratio vs. degree of </text>
<text top="530" left="568" width="273" height="17" font="0">angiographic stenosis showing strong correlation, </text>
<text top="547" left="568" width="176" height="17" font="0">a moderate adjusted correlation </text>
<text top="564" left="568" width="79" height="17" font="0">Co-efficient (R</text>
<text top="565" left="646" width="4" height="11" font="11">2</text>
<text top="564" left="651" width="192" height="17" font="0">=0.31; p&lt;0.02) for decrease in ABI </text>
<text top="581" left="568" width="200" height="17" font="0">vs. degree of angiographic stenosis. </text>
<text top="337" left="858" width="7" height="18" font="7"></text>
<text top="338" left="865" width="179" height="17" font="0"> Applying duplex criteria for both </text>
<text top="355" left="858" width="189" height="17" font="0">≥50% and ≥80% in-stent stenosis </text>
<text top="372" left="858" width="156" height="17" font="0">during follow up may help in </text>
<text top="389" left="858" width="137" height="17" font="0">preventing endovascular </text>
<text top="407" left="858" width="113" height="17" font="0">intervention failures. </text>
<text top="599" left="95" width="94" height="17" font="0">Troutman DA, et </text>
<text top="616" left="95" width="16" height="17" font="0">al. </text>
<text top="633" left="95" width="63" height="17" font="0">2014 (418) </text>
<text top="651" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25256612">25256612</a></text>
<text top="651" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25256612"> </a></text>
<text top="668" left="95" width="3" height="17" font="0"> </text>
<text top="599" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="616" left="210" width="79" height="17" font="0">Observational </text>
<text top="633" left="210" width="82" height="17" font="0">(retrospective) </text>
<text top="651" left="210" width="3" height="17" font="0"> </text>
<text top="668" left="210" width="100" height="17" font="2"><b>Size:</b> n=142 stent </text>
<text top="685" left="210" width="96" height="17" font="0">grafts (92 arterial </text>
<text top="702" left="210" width="111" height="17" font="0">segments in 79 pts) </text>
<text top="599" left="345" width="200" height="17" font="2"><b>Inclusion criteria:</b> DU protocol with </text>
<text top="616" left="345" width="198" height="17" font="0">at least 1 study documenting patent </text>
<text top="633" left="345" width="186" height="17" font="0">stent graft, at 1wk, every 3 mo for </text>
<text top="651" left="345" width="181" height="17" font="0">first y and every 6 mo thereafter. </text>
<text top="668" left="345" width="3" height="17" font="0"> </text>
<text top="685" left="345" width="192" height="17" font="2"><b>Exclusion criteria:</b> None reported<b> </b></text>
<text top="600" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="599" left="574" width="6" height="18" font="7"></text>
<text top="600" left="581" width="142" height="17" font="2"><b> endpoints and results:</b>  </text>
<text top="617" left="568" width="7" height="18" font="7"></text>
<text top="619" left="575" width="250" height="17" font="0"> 15 of 20 pts with ≥1 of abnormal DU findings </text>
<text top="636" left="568" width="271" height="17" font="0">underwent prophylactic treatment (8) or occluded </text>
<text top="653" left="568" width="262" height="17" font="0">without treatment (7), whereas only 2 of 72 with </text>
<text top="670" left="568" width="227" height="17" font="0">normal DU findings occluded (p=0.0001). </text>
<text top="687" left="568" width="7" height="18" font="7"></text>
<text top="689" left="575" width="208" height="17" font="0"> Senstivity of DU for total cohort: 58% </text>
<text top="706" left="568" width="7" height="18" font="7"></text>
<text top="707" left="575" width="129" height="17" font="0"> Specificity of DU: 97% </text>
<text top="724" left="568" width="7" height="18" font="7"></text>
<text top="725" left="575" width="64" height="17" font="0"> NPV: 78% </text>
<text top="743" left="568" width="7" height="18" font="7"></text>
<text top="744" left="575" width="63" height="17" font="0"> PPV: 93% </text>
<text top="599" left="858" width="7" height="18" font="7"></text>
<text top="600" left="865" width="193" height="17" font="0"> DU surveillance can predict failure </text>
<text top="617" left="858" width="78" height="17" font="0">of stent grafts </text>
<text top="635" left="858" width="7" height="18" font="7"></text>
<text top="636" left="865" width="177" height="17" font="0"> Statistically reliable markers for </text>
<text top="653" left="858" width="182" height="17" font="0">predicting stent graft thrombosis: </text>
<text top="670" left="858" width="202" height="17" font="0">Focal PSVs &gt;300 cm/s, Vr &gt;3.0, and </text>
<text top="687" left="858" width="195" height="17" font="0">uniform PSVs &lt;50 cm/s throughout </text>
<text top="705" left="858" width="79" height="17" font="0">the stent graft </text>
<text top="762" left="95" width="96" height="17" font="0">Connors G, et al. </text>
<text top="762" left="210" width="70" height="17" font="2"><b>Study type:</b> </text>
<text top="762" left="345" width="168" height="17" font="2"><b>Inclusion criteria:</b> Pts with IC </text>
<text top="763" left="568" width="7" height="17" font="2"><b>1</b></text>
<text top="762" left="574" width="6" height="18" font="7"></text>
<text top="763" left="581" width="142" height="17" font="2"><b> endpoints and results:</b>  </text>
<text top="762" left="858" width="7" height="18" font="7"></text>
<text top="763" left="865" width="179" height="17" font="0"> Long-term primary patency with </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">185 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="87" left="95" width="63" height="17" font="0">2011 (419) </text>
<text top="104" left="95" width="55" height="17" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20853355">20853355</a></text>
<text top="104" left="150" width="3" height="17" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20853355"> </a></text>
<text top="122" left="95" width="3" height="17" font="0"> </text>
<text top="87" left="210" width="83" height="17" font="0">Observational  </text>
<text top="104" left="210" width="3" height="17" font="0"> </text>
<text top="122" left="210" width="115" height="17" font="2"><b>Size:</b> n=142 limbs in </text>
<text top="139" left="210" width="112" height="17" font="0">111 consecutive pts </text>
<text top="87" left="345" width="131" height="17" font="0">(Rutherford category 3) </text>
<text top="104" left="345" width="3" height="17" font="0"> </text>
<text top="122" left="345" width="157" height="17" font="2"><b>Exclusion criteria:</b> Pts with </text>
<text top="139" left="345" width="136" height="17" font="0">revascularization for CLI<b> </b></text>
<text top="87" left="568" width="7" height="18" font="7"></text>
<text top="88" left="575" width="257" height="17" font="0"> Compared to lesions &lt;100 mm, longer lesions </text>
<text top="106" left="568" width="268" height="17" font="0">had higher failed primary patency (100–200 mm; </text>
<text top="123" left="568" width="262" height="17" font="0">HR: 2.0; p=0.16 vs. &gt;200 mm: HR=2.6; p=0.03) </text>
<text top="140" left="568" width="7" height="18" font="7"></text>
<text top="141" left="575" width="269" height="17" font="0"> Short and intermediate lesions had similar failed </text>
<text top="158" left="568" width="199" height="17" font="0">secondary patency (&lt;5% incidence) </text>
<text top="176" left="568" width="7" height="18" font="7"></text>
<text top="177" left="575" width="243" height="17" font="0"> Lesions &gt;200 mm had higher trend in failed </text>
<text top="194" left="568" width="205" height="17" font="0">secondary patency (HR=4.2; p=0.06) </text>
<text top="211" left="568" width="7" height="18" font="7"></text>
<text top="212" left="575" width="255" height="17" font="0"> Compared to lesions &gt;100 mm, higher gain in </text>
<text top="230" left="568" width="253" height="17" font="0">long-term patency with outpatient surveillance </text>
<text top="247" left="568" width="223" height="17" font="0">and reintervention for longer lesions and </text>
<text top="264" left="568" width="269" height="17" font="0">significantly so for intermediate lesions (100–200 </text>
<text top="281" left="568" width="211" height="17" font="0">mm=23% vs. &lt;100 mm=8%; p=0.041) </text>
<text top="87" left="858" width="192" height="17" font="0">percutaneous treatment of femoral </text>
<text top="104" left="858" width="179" height="17" font="0">artery lesions was lower for long </text>
<text top="122" left="858" width="112" height="17" font="0">lesions (&gt;100mm).   </text>
<text top="139" left="858" width="7" height="18" font="7"></text>
<text top="140" left="865" width="150" height="17" font="0"> Outpatient surveillance for </text>
<text top="157" left="858" width="149" height="17" font="0">restenosis requiring repeat </text>
<text top="174" left="858" width="194" height="17" font="0">intervention had a greater effect on </text>
<text top="192" left="858" width="187" height="17" font="0">long-term patency in pts receiving </text>
<text top="209" left="858" width="187" height="17" font="0">initial treatment for longer femoral </text>
<text top="226" left="858" width="180" height="17" font="0">artery lesions (&gt;100 mm length). </text>
<text top="299" left="86" width="1018" height="17" font="0">ABI indicates ankle-brachial index; AKV, above knee venous graft; BKV, below knee venous graft; CFDS, color flow duplex surveillance; CI, confidence interval; CLI, critical limb ischemia; </text>
<text top="316" left="86" width="975" height="17" font="0">DU, duplex ultrasound; FP, femoropopliteal graft; FT, femorotibial graft; GFV, graft flow velocity; HVC, high-velocity criteria; IC, intermittent claudication; LCV; MGV; NPV, negative </text>
<text top="334" left="86" width="902" height="17" font="0">predictive value; NS, not significant; OR, odds ratio; PPV, positive predictive value; PSV, peak systolic velocities; PTA, percutaneous transluminal angioplasty; PTFE, </text>
<text top="351" left="86" width="638" height="17" font="0">polytetrafluoroethylene; pt, patient; PSV; u/s, ultrasound; ROC, receiver operating characteristic;and Vr, velocity ratio.</text>
</page>
<page number="186" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">186 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="86" left="86" width="3" height="17" font="0"> </text>
<text top="104" left="86" width="3" height="17" font="0"> </text>
<text top="121" left="86" width="84" height="21" font="1"><b>References </b></text>
<text top="145" left="594" width="4" height="14" font="0"> </text>
<text top="162" left="86" width="4" height="14" font="0"> </text>
<text top="162" left="116" width="867" height="14" font="0">1.   ROSE GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27:645-58. </text>
<text top="179" left="86" width="4" height="14" font="0"> </text>
<text top="179" left="116" width="982" height="14" font="0">2.   Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J </text>
<text top="197" left="140" width="203" height="14" font="0">Clin Epidemiol. 1992;45:1101-9. </text>
<text top="214" left="86" width="4" height="14" font="0"> </text>
<text top="214" left="116" width="968" height="14" font="0">3.   Criqui MH, Denenberg JO, Bird CE, et al. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease </text>
<text top="231" left="140" width="205" height="14" font="0">testing. Vasc Med. 1996;1:65-71. </text>
<text top="249" left="86" width="4" height="14" font="0"> </text>
<text top="249" left="116" width="970" height="14" font="0">4.   McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern </text>
<text top="266" left="140" width="146" height="14" font="0">Med. 1999;159:387-92. </text>
<text top="283" left="86" width="4" height="14" font="0"> </text>
<text top="283" left="116" width="978" height="14" font="0">5.   McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. </text>
<text top="300" left="140" width="126" height="14" font="0">2001;286:1599-606. </text>
<text top="317" left="86" width="4" height="14" font="0"> </text>
<text top="317" left="116" width="958" height="14" font="0">6.   Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-24. </text>
<text top="335" left="86" width="4" height="14" font="0"> </text>
<text top="335" left="116" width="912" height="14" font="0">7.   Khan NA, Rahim SA, Anand SS, et al. Does the clinical examination predict lower extremity peripheral arterial disease? JAMA. 2006;295:536-46. </text>
<text top="352" left="86" width="4" height="14" font="0"> </text>
<text top="352" left="116" width="970" height="14" font="0">8.   Grøndal N, Sogaard R, Lindholt JS. Baseline prevalence of abdominal aortic aneurysm, peripheral arterial disease and hypertension in men aged 65-74 years </text>
<text top="369" left="140" width="459" height="14" font="0">from a population screening study (VIVA trial). Br J Surg. 2015;102:902-6. </text>
<text top="386" left="86" width="4" height="14" font="0"> </text>
<text top="386" left="116" width="975" height="14" font="0">9.   Wassel CL, Loomba R, Ix JH, et al. Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease: the San </text>
<text top="404" left="140" width="381" height="14" font="0">Diego Population Study. J Am Coll Cardiol. 2011;58:1386-92. </text>
<text top="421" left="86" width="4" height="14" font="0"> </text>
<text top="421" left="108" width="972" height="14" font="0">10.   Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic </text>
<text top="438" left="140" width="319" height="14" font="0">review and meta-analysis. Lancet. 2012;379:905-14. </text>
<text top="456" left="86" width="4" height="14" font="0"> </text>
<text top="456" left="108" width="979" height="14" font="0">11.   Singh S, Sethi A, Singh M, et al. Simultaneously measured inter-arm and inter-leg systolic blood pressure differences and cardiovascular risk stratification: a </text>
<text top="473" left="140" width="469" height="14" font="0">systemic review and meta-analysis. J Am Soc Hypertens. 2015;9:640-50.e12. </text>
<text top="490" left="86" width="4" height="14" font="0"> </text>
<text top="490" left="108" width="953" height="14" font="0">12.   Shadman R, Criqui MH, Bundens WP, et al. Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. J Am Coll </text>
<text top="507" left="140" width="156" height="14" font="0">Cardiol. 2004;44:618-23. </text>
<text top="524" left="86" width="4" height="14" font="0"> </text>
<text top="524" left="108" width="997" height="14" font="0">13.   Cournot M, Boccalon H, Cambou JP, et al. Accuracy of the screening physical examination to identify subclinical atherosclerosis and peripheral arterial disease </text>
<text top="542" left="140" width="349" height="14" font="0">in asymptomatic subjects. J Vasc Surg. 2007;46:1215-21. </text>
<text top="559" left="86" width="4" height="14" font="0"> </text>
<text top="559" left="108" width="950" height="14" font="0">14.   Armstrong DWJ, Tobin C, Matangi MF. The accuracy of the physical examination for the detection of lower extremity peripheral arterial disease. Can J </text>
<text top="576" left="140" width="163" height="14" font="0">Cardiol. 2010;26:e346-50. </text>
<text top="594" left="86" width="4" height="14" font="0"> </text>
<text top="594" left="108" width="962" height="14" font="0">15.   Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a </text>
<text top="611" left="140" width="323" height="14" font="0">randomized controlled trial. JAMA. 2010;303:841-8. </text>
<text top="628" left="86" width="4" height="14" font="0"> </text>
<text top="628" left="108" width="955" height="14" font="0">16.   Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo </text>
<text top="645" left="140" width="822" height="14" font="0">controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. </text>
<text top="662" left="86" width="4" height="14" font="0"> </text>
<text top="662" left="108" width="943" height="14" font="0">17.   McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA. </text>
<text top="680" left="140" width="103" height="14" font="0">2013;310:57-65. </text>
<text top="697" left="86" width="4" height="14" font="0"> </text>
<text top="697" left="108" width="929" height="14" font="0">18.   Criqui MH, Vargas V, Denenberg JO, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005;112:2703-7. </text>
<text top="714" left="86" width="4" height="14" font="0"> </text>
<text top="714" left="108" width="937" height="14" font="0">19.   Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition </text>
<text top="731" left="140" width="389" height="14" font="0">Examination Survey, 1999-2000. Circulation. 2004;110:738-43. </text>
<text top="749" left="86" width="4" height="14" font="0"> </text>
<text top="749" left="108" width="993" height="14" font="0">20.   Guo X, Li J, Pang W, et al. Sensitivity and specificity of ankle-brachial index for detecting angiographic stenosis of peripheral arteries. Circ J. 2008;72:605-10. </text>
</page>
<page number="187" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">187 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="4" height="14" font="0"> </text>
<text top="90" left="108" width="940" height="14" font="0">21.   Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart </text>
<text top="107" left="140" width="279" height="14" font="0">Association. Circulation. 2012;126:2890-909. </text>
<text top="124" left="86" width="4" height="14" font="0"> </text>
<text top="124" left="108" width="959" height="14" font="0">22.   Aboyans V, Ho E, Denenberg JO, et al. The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and </text>
<text top="142" left="140" width="327" height="14" font="0">nondiabetic subjects. J Vasc Surg. 2008;48:1197-203. </text>
<text top="159" left="86" width="4" height="14" font="0"> </text>
<text top="159" left="108" width="956" height="14" font="0">23.   Schröder F, Diehm N, Kareem S, et al. A modified calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial </text>
<text top="176" left="140" width="226" height="14" font="0">disease. J Vasc Surg. 2006;44:531-6. </text>
<text top="193" left="86" width="4" height="14" font="0"> </text>
<text top="193" left="108" width="981" height="14" font="0">24.   Premalatha G, Ravikumar R, Sanjay R, et al. Comparison of colour duplex ultrasound and ankle-brachial pressure index measurements in peripheral vascular </text>
<text top="211" left="140" width="590" height="14" font="0">disease in type 2 diabetic patients with foot infections. J Assoc Physicians India. 2002;50:1240-4. </text>
<text top="228" left="86" width="4" height="14" font="0"> </text>
<text top="228" left="108" width="935" height="14" font="0">25.   Allen J, Oates CP, Henderson J, et al. Comparison of lower limb arterial assessments using color-duplex ultrasound and ankle/brachial pressure index </text>
<text top="245" left="140" width="268" height="14" font="0">measurements. Angiology. 1996;47:225-32. </text>
<text top="262" left="86" width="4" height="14" font="0"> </text>
<text top="262" left="108" width="959" height="14" font="0">26.   Lijmer JG, Hunink MG, van den Dungen JJ, et al. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol. 1996;22:391-8. </text>
<text top="280" left="86" width="4" height="14" font="0"> </text>
<text top="280" left="108" width="983" height="14" font="0">27.   Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-</text>
<text top="297" left="140" width="223" height="14" font="0">analysis. JAMA. 2008;300:197-208. </text>
<text top="314" left="86" width="4" height="14" font="0"> </text>
<text top="314" left="108" width="981" height="14" font="0">28.   Fowkes FG, Murray GD, Butcher I, et al. Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. Eur J </text>
<text top="331" left="140" width="187" height="14" font="0">Prev Cardiol. 2014;21:310-20. </text>
<text top="349" left="86" width="4" height="14" font="0"> </text>
<text top="349" left="108" width="969" height="14" font="0">29.   Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. </text>
<text top="366" left="140" width="193" height="14" font="0">Circulation. 2009;120:2053-61. </text>
<text top="383" left="86" width="4" height="14" font="0"> </text>
<text top="383" left="108" width="919" height="14" font="0">30.   Lin JS, Olson CM, Johnson ES, et al. The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among </text>
<text top="400" left="140" width="768" height="14" font="0">asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern med. 2013;333-41. </text>
<text top="418" left="86" width="4" height="14" font="0"> </text>
<text top="418" left="108" width="931" height="14" font="0">31.   Alahdab F, Wang AT, Elraiyah TA, et al. A systematic review for the screening for peripheral arterial disease in asymptomatic patients. J Vasc Surg. </text>
<text top="435" left="140" width="113" height="14" font="0">2015;61:42S-53S. </text>
<text top="452" left="86" width="4" height="14" font="0"> </text>
<text top="452" left="108" width="966" height="14" font="0">32.   Hiramoto JS, Katz R, Ix JH, et al. Sex differences in the prevalence and clinical outcomes of subclinical peripheral artery disease in the Health, Aging, and </text>
<text top="469" left="140" width="402" height="14" font="0">Body Composition (Health ABC) study. Vascular. 2014;22:142-8. </text>
<text top="487" left="86" width="4" height="14" font="0"> </text>
<text top="487" left="108" width="973" height="14" font="0">33.   Bundó M, Muñoz L, Pérez C, et al. Asymptomatic peripheral arterial disease in type 2 diabetes patients: a 10-year follow-up study of the utility of the ankle </text>
<text top="504" left="140" width="590" height="14" font="0">brachial index as a prognostic marker of cardiovascular disease. Ann Vasc Surg. 2010;24:985-93. </text>
<text top="521" left="86" width="4" height="14" font="0"> </text>
<text top="521" left="108" width="940" height="14" font="0">34.   Tsivgoulis G, Bogiatzi C, Heliopoulos I, et al. Low ankle-brachial index predicts early risk of recurrent stroke in patients with acute cerebral ischemia. </text>
<text top="538" left="140" width="212" height="14" font="0">Atherosclerosis. 2012;220:407-12. </text>
<text top="556" left="86" width="4" height="14" font="0"> </text>
<text top="556" left="108" width="953" height="14" font="0">35.   Bouisset F, Bongard V, Ruidavets JB, et al. Prognostic usefulness of clinical and subclinical peripheral arterial disease in men with stable coronary heart </text>
<text top="573" left="140" width="257" height="14" font="0">disease. Am J Cardiol. 2012;110:197-202. </text>
<text top="590" left="86" width="4" height="14" font="0"> </text>
<text top="590" left="108" width="970" height="14" font="0">36.   Sen S, Lynch DR, Kaltsas E, et al. Association of asymptomatic peripheral arterial disease with vascular events in patients with stroke or transient ischemic </text>
<text top="607" left="140" width="193" height="14" font="0">attack. Stroke. 2009;40:3472-7. </text>
<text top="625" left="86" width="4" height="14" font="0"> </text>
<text top="625" left="108" width="973" height="14" font="0">37.   Ratanakorn D, Keandoungchun J, Tegeler CH. Prevalence and association between risk factors, stroke subtypes, and abnormal ankle brachial index in acute </text>
<text top="642" left="140" width="372" height="14" font="0">ischemic stroke. J Stroke Cerebrovasc Dis. 2012;21:498-503. </text>
<text top="659" left="86" width="4" height="14" font="0"> </text>
<text top="659" left="108" width="997" height="14" font="0">38.   Ramos R, García-Gil M, Comas-Cufí M, et al. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. J Am Coll </text>
<text top="676" left="140" width="156" height="14" font="0">Cardiol. 2016;67:630-40. </text>
<text top="694" left="86" width="4" height="14" font="0"> </text>
<text top="694" left="108" width="989" height="14" font="0">39.   Jiménez M, Dorado L, Hernández-Pérez M, et al. Ankle-brachial index in screening for asymptomatic carotid and intracranial atherosclerosis. Atherosclerosis. </text>
<text top="711" left="140" width="96" height="14" font="0">2014;233:72-5. </text>
<text top="728" left="86" width="4" height="14" font="0"> </text>
<text top="728" left="108" width="990" height="14" font="0">40.   McDermott MM, Fried L, Simonsick E, et al. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: </text>
<text top="745" left="140" width="428" height="14" font="0">the Women's Health and Aging Study. Circulation. 2000;101:1007-12. </text>
<text top="763" left="86" width="4" height="14" font="0"> </text>
<text top="763" left="108" width="961" height="14" font="0">41.   McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. </text>
<text top="780" left="140" width="159" height="14" font="0">JAMA. 2004;292:453-61. </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">188 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="4" height="14" font="0"> </text>
<text top="90" left="108" width="978" height="14" font="0">42.   McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern </text>
<text top="107" left="140" width="137" height="14" font="0">med. 2006;144:10-20. </text>
<text top="124" left="86" width="4" height="14" font="0"> </text>
<text top="124" left="108" width="991" height="14" font="0">43.   McDermott MM, Ferrucci L, Liu K, et al. Leg symptom categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr Soc. 2010;58:1256-</text>
<text top="142" left="140" width="22" height="14" font="0">62. </text>
<text top="159" left="86" width="4" height="14" font="0"> </text>
<text top="159" left="108" width="985" height="14" font="0">44.   McDermott MM, Applegate WB, Bonds DE, et al. Ankle brachial index values, leg symptoms, and functional performance among community-dwelling older </text>
<text top="176" left="140" width="721" height="14" font="0">men and women in the Lifestyle Interventions and Independence for Elders Study. J Am Heart Assoc. 2013;2:e000257. </text>
<text top="193" left="86" width="4" height="14" font="0"> </text>
<text top="193" left="108" width="991" height="14" font="0">45.   Niazi K, Khan TH, Easley KA. Diagnostic utility of the two methods of ankle brachial index in the detection of peripheral arterial disease of lower extremities. </text>
<text top="211" left="140" width="272" height="14" font="0">Catheter Cardiovasc Interv. 2006;68:788-92. </text>
<text top="228" left="86" width="4" height="14" font="0"> </text>
<text top="228" left="108" width="916" height="14" font="0">46.   Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. </text>
<text top="245" left="140" width="103" height="14" font="0">1997;26:517-38. </text>
<text top="262" left="86" width="4" height="14" font="0"> </text>
<text top="262" left="108" width="926" height="14" font="0">47.   Eslahpazir BA, Allemang MT, Lakin RO, et al. Pulse volume recording does not enhance segmental pressure readings for peripheral arterial disease </text>
<text top="280" left="140" width="278" height="14" font="0">stratification. Ann Vasc Surg. 2014;28:18-27. </text>
<text top="297" left="86" width="4" height="14" font="0"> </text>
<text top="297" left="108" width="940" height="14" font="0">48.   Ouriel K, McDonnell AE, Metz CE, et al. Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery. 1982;91:686-93. </text>
<text top="314" left="86" width="4" height="14" font="0"> </text>
<text top="314" left="108" width="895" height="14" font="0">49.   Aerden D, Massaad D, von KK, et al. The ankle--brachial index and the diabetic foot: a troublesome marriage. Ann Vasc Surg. 2011;25:770-7. </text>
<text top="331" left="86" width="4" height="14" font="0"> </text>
<text top="331" left="108" width="858" height="14" font="0">50.   Park SC, Choi CY, Ha YI, et al. Utility of toe-brachial index for diagnosis of peripheral artery disease. Arch Plast Surg. 2012;39:227-31. </text>
<text top="349" left="86" width="4" height="14" font="0"> </text>
<text top="349" left="108" width="901" height="14" font="0">51.   Weinberg I, Giri J, Calfon MA, et al. Anatomic correlates of supra-normal ankle brachial indices. Catheter Cardiovasc Interv. 2013;81:1025-30. </text>
<text top="366" left="86" width="4" height="14" font="0"> </text>
<text top="366" left="108" width="981" height="14" font="0">52.   Suominen V, Rantanen T, Venermo M, et al. Prevalence and risk factors of PAD among patients with elevated ABI. Eur J Vasc Endovasc Surg. 2008;35:709-</text>
<text top="383" left="140" width="22" height="14" font="0">14. </text>
<text top="400" left="86" width="4" height="14" font="0"> </text>
<text top="400" left="108" width="724" height="14" font="0">53.   Wagener JS, Hendricker C. Intra-subject variability of noninvasive oxygen measurements. Chest. 1987;92:1047-9. </text>
<text top="418" left="86" width="4" height="14" font="0"> </text>
<text top="418" left="108" width="985" height="14" font="0">54.   Tsai FW, Tulsyan N, Jones DN, et al. Skin perfusion pressure of the foot is a good substitute for toe pressure in the assessment of limb ischemia. J Vasc Surg. </text>
<text top="435" left="140" width="88" height="14" font="0">2000;32:32-6. </text>
<text top="452" left="86" width="4" height="14" font="0"> </text>
<text top="452" left="108" width="942" height="14" font="0">55.   Yamada T, Ohta T, Ishibashi H, et al. Clinical reliability and utility of skin perfusion pressure measurement in ischemic limbs—comparison with other </text>
<text top="469" left="140" width="383" height="14" font="0">noninvasive diagnostic methods. J Vasc Surg. 2008;47:318-23. </text>
<text top="487" left="86" width="4" height="14" font="0"> </text>
<text top="487" left="108" width="972" height="14" font="0">56.   Bosanquet DC, Glasbey JC, Williams IM, et al. Systematic review and meta-analysis of direct versus indirect angiosomal revascularisation of infrapopliteal </text>
<text top="504" left="140" width="314" height="14" font="0">arteries. Eur J Vasc Endovasc Surg. 2014;48:88-97. </text>
<text top="521" left="86" width="4" height="14" font="0"> </text>
<text top="521" left="108" width="768" height="14" font="0">57.   Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive disease. JAMA. 1969;207:1869-74. </text>
<text top="538" left="86" width="4" height="14" font="0"> </text>
<text top="538" left="108" width="979" height="14" font="0">58.   Carter SA, Tate RB. Value of toe pulse waves in addition to systolic pressures in the assessment of the severity of peripheral arterial disease and critical limb </text>
<text top="556" left="140" width="243" height="14" font="0">ischemia. J Vasc Surg. 1996;24:258-65. </text>
<text top="573" left="86" width="4" height="14" font="0"> </text>
<text top="573" left="108" width="944" height="14" font="0">59.   Ramsey DE, Manke DA, Sumner DS. Toe blood pressure. A valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease. J </text>
<text top="590" left="140" width="250" height="14" font="0">Cardiovasc Surg (Torino). 1983;24:43-8. </text>
<text top="607" left="86" width="4" height="14" font="0"> </text>
<text top="607" left="108" width="993" height="14" font="0">60.   Biancari F, Juvonen T. Angiosome-targeted lower limb revascularization for ischemic foot wounds: systematic review and meta-analysis. Eur J Vasc Endovasc </text>
<text top="625" left="140" width="139" height="14" font="0">Surg. 2014;47:517-22. </text>
<text top="642" left="86" width="4" height="14" font="0"> </text>
<text top="642" left="108" width="985" height="14" font="0">61.   Vincent DG, Salles-Cunha SX, Bernhard VM, et al. Noninvasive assessment of toe systolic pressures with special reference to diabetes mellitus. J Cardiovasc </text>
<text top="659" left="140" width="179" height="14" font="0">Surg (Torino). 1983;24:22-8. </text>
<text top="676" left="86" width="4" height="14" font="0"> </text>
<text top="676" left="108" width="945" height="14" font="0">62.   Mahe G, Pollak AW, Liedl DA, et al. Discordant diagnosis of lower extremity peripheral artery disease using American Heart Association postexercise </text>
<text top="694" left="140" width="308" height="14" font="0">guidelines. Medicine (Baltimore ). 2015;94:e1277. </text>
<text top="711" left="86" width="4" height="14" font="0"> </text>
<text top="711" left="108" width="942" height="14" font="0">63.   Nicolaï SP, Viechtbauer W, Kruidenier LM, et al. Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis. J Vasc Surg. </text>
<text top="728" left="140" width="96" height="14" font="0">2009;50:322-9. </text>
<text top="745" left="86" width="4" height="14" font="0"> </text>
<text top="745" left="108" width="711" height="14" font="0">64.   Laing SP, Greenhalgh RM. Standard exercise test to assess peripheral arterial disease. Br Med J. 1980;280:13-6. </text>
<text top="763" left="86" width="4" height="14" font="0"> </text>
<text top="763" left="108" width="937" height="14" font="0">65.   Raines JK, Darling RC, Buth J, et al. Vascular laboratory criteria for the management of peripheral vascular disease of the lower extremities. Surgery. </text>
<text top="780" left="140" width="88" height="14" font="0">1976;79:21-9. </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">189 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="4" height="14" font="0"> </text>
<text top="90" left="108" width="915" height="14" font="0">66.   Sumner DS, Strandness DE. The relationship between calf blood flow and ankle blood pressure in patients with intermittent claudication. Surgery. </text>
<text top="107" left="140" width="103" height="14" font="0">1969;65:763-71. </text>
<text top="124" left="86" width="4" height="14" font="0"> </text>
<text top="124" left="108" width="935" height="14" font="0">67.   Castronuovo JJ, Adera HM, Smiell JM, et al. Skin perfusion pressure measurement is valuable in the diagnosis of critical limb ischemia. J Vasc Surg. </text>
<text top="142" left="140" width="103" height="14" font="0">1997;26:629-37. </text>
<text top="159" left="86" width="4" height="14" font="0"> </text>
<text top="159" left="108" width="991" height="14" font="0">68.   Biotteau E, Mahe G, Rousseau P, et al. Transcutaneous oxygen pressure measurements in diabetic and non-diabetic patients clinically suspected of severe limb </text>
<text top="176" left="140" width="477" height="14" font="0">ischemia: a matched paired retrospective analysis. Int Angiol. 2009;28:479-83. </text>
<text top="193" left="86" width="4" height="14" font="0"> </text>
<text top="193" left="108" width="966" height="14" font="0">69.   Bunte MC, Jacob J, Nudelman B, et al. Validation of the relationship between ankle-brachial and toe-brachial indices and infragenicular arterial patency in </text>
<text top="211" left="140" width="294" height="14" font="0">critical limb ischemia. Vasc Med. 2015;20:23-9. </text>
<text top="228" left="86" width="4" height="14" font="0"> </text>
<text top="228" left="108" width="938" height="14" font="0">70.   Stein R, Hriljac I, Halperin JL, et al. Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease. Vasc Med. </text>
<text top="245" left="140" width="96" height="14" font="0">2006;11:29-33. </text>
<text top="262" left="86" width="4" height="14" font="0"> </text>
<text top="262" left="108" width="958" height="14" font="0">71.   Shishehbor MH, Hammad TA, Zeller T, et al. An analysis of IN.PACT DEEP randomized trial on the limitations of the societal guidelines-recommended </text>
<text top="280" left="140" width="551" height="14" font="0">hemodynamic parameters to diagnose critical limb ischemia. J Vasc Surg. 2016;63:1311-7. </text>
<text top="297" left="86" width="4" height="14" font="0"> </text>
<text top="297" left="108" width="989" height="14" font="0">72.   Wikström J, Hansen T, Johansson L, et al. Ankle brachial index &lt;0.9 underestimates the prevalence of peripheral artery occlusive disease assessed with whole-</text>
<text top="314" left="140" width="497" height="14" font="0">body magnetic resonance angiography in the elderly. Acta Radiol. 2008;49:143-9. </text>
<text top="331" left="86" width="4" height="14" font="0"> </text>
<text top="331" left="108" width="978" height="14" font="0">73.   Wikström J, Hansen T, Johansson L, et al. Lower extremity artery stenosis distribution in an unselected elderly population and its relation to a reduced ankle-</text>
<text top="349" left="140" width="268" height="14" font="0">brachial index. J Vasc Surg. 2009;50:330-4. </text>
<text top="366" left="86" width="4" height="14" font="0"> </text>
<text top="366" left="108" width="941" height="14" font="0">74.   Clairotte C, Retout S, Potier L, et al. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in </text>
<text top="383" left="140" width="400" height="14" font="0">nondiabetic and diabetic patients. Diabetes Care. 2009;32:1231-6. </text>
<text top="400" left="86" width="4" height="14" font="0"> </text>
<text top="400" left="108" width="972" height="14" font="0">75.   Burbelko M, Augsten M, Kalinowski MO, et al. Comparison of contrast-enhanced multi-station MR angiography and digital subtraction angiography of the </text>
<text top="418" left="140" width="454" height="14" font="0">lower extremity arterial disease. J Magn Reson Imaging. 2013;37:1427-35. </text>
<text top="435" left="86" width="4" height="14" font="0"> </text>
<text top="435" left="108" width="946" height="14" font="0">76.   Shareghi S, Gopal A, Gul K, et al. Diagnostic accuracy of 64 multidetector computed tomographic angiography in peripheral vascular disease. Catheter </text>
<text top="452" left="140" width="210" height="14" font="0">Cardiovasc Interv. 2010;75:23-31. </text>
<text top="469" left="86" width="4" height="14" font="0"> </text>
<text top="469" left="108" width="995" height="14" font="0">77.   de Vries SO, Hunink MG, Polak JF. Summary receiver operating characteristic curves as a technique for meta-analysis of the diagnostic performance of duplex </text>
<text top="487" left="140" width="449" height="14" font="0">ultrasonography in peripheral arterial disease. Acad Radiol. 1996;3:361-9. </text>
<text top="504" left="86" width="4" height="14" font="0"> </text>
<text top="504" left="108" width="940" height="14" font="0">78.   Ota H, Takase K, Igarashi K, et al. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: </text>
<text top="521" left="140" width="540" height="14" font="0">importance of reviewing cross-sectional images. AJR Am J Roentgenol. 2004;182:201-9. </text>
<text top="538" left="86" width="4" height="14" font="0"> </text>
<text top="538" left="108" width="982" height="14" font="0">79.   He C, Yang JG, Li YM, et al. Comparison of lower extremity atherosclerosis in diabetic and non-diabetic patients using multidetector computed tomography. </text>
<text top="556" left="140" width="240" height="14" font="0">BMC Cardiovasc Disord. 2014;14:125. </text>
<text top="573" left="86" width="4" height="14" font="0"> </text>
<text top="573" left="108" width="942" height="14" font="0">80.   Philip F, Shishehbor MH, Desai MY, et al. Characterization of internal pudendal artery atherosclerosis using aortography and multi-detector computed </text>
<text top="590" left="140" width="381" height="14" font="0">angiography. Catheter Cardiovasc Interv. 2013;82:E516-E521. </text>
<text top="607" left="86" width="4" height="14" font="0"> </text>
<text top="607" left="108" width="969" height="14" font="0">81.   Kayhan A, Palabiyik F, Serinsöz S, et al. Multidetector CT angiography versus arterial duplex USG in diagnosis of mild lower extremity peripheral arterial </text>
<text top="625" left="140" width="510" height="14" font="0">disease: is multidetector CT a valuable screening tool? Eur J Radiol. 2012;81:542-6. </text>
<text top="642" left="86" width="4" height="14" font="0"> </text>
<text top="642" left="108" width="942" height="14" font="0">82.   Joshi SB, Mendoza DD, Steinberg DH, et al. Ultra-low-dose intra-arterial contrast injection for iliofemoral computed tomographic angiography. JACC </text>
<text top="659" left="140" width="232" height="14" font="0">Cardiovasc Imaging. 2009;2:1404-11. </text>
<text top="676" left="86" width="4" height="14" font="0"> </text>
<text top="676" left="108" width="952" height="14" font="0">83.   Mesurolle B, Qanadli SD, El HM, et al. Occlusive arterial disease of abdominal aorta and lower extremities: comparison of helical CT angiography with </text>
<text top="694" left="140" width="353" height="14" font="0">transcatheter angiography. Clin Imaging. 2004;28:252-60. </text>
<text top="711" left="86" width="4" height="14" font="0"> </text>
<text top="711" left="108" width="995" height="14" font="0">84.   Romano M, Mainenti PP, Imbriaco M, et al. Multidetector row CT angiography of the abdominal aorta and lower extremities in patients with peripheral arterial </text>
<text top="728" left="140" width="591" height="14" font="0">occlusive disease: diagnostic accuracy and interobserver agreement. Eur J Radiol. 2004;50:303-8. </text>
<text top="745" left="86" width="4" height="14" font="0"> </text>
<text top="745" left="108" width="942" height="14" font="0">85.   Martin ML, Tay KH, Flak B, et al. Multidetector CT angiography of the aortoiliac system and lower extremities: a prospective comparison with digital </text>
<text top="763" left="140" width="414" height="14" font="0">subtraction angiography. AJR Am J Roentgenol. 2003;180:1085-91. </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">190 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="4" height="14" font="0"> </text>
<text top="90" left="108" width="911" height="14" font="0">86.   Andreucci M, Solomon R, Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int. </text>
<text top="107" left="140" width="121" height="14" font="0">2014;2014:741018. </text>
<text top="124" left="86" width="4" height="14" font="0"> </text>
<text top="124" left="108" width="935" height="14" font="0">87.   Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. </text>
<text top="142" left="140" width="111" height="14" font="0">2011;21:2527-41. </text>
<text top="159" left="86" width="4" height="14" font="0"> </text>
<text top="159" left="108" width="964" height="14" font="0">88.   Meyer BC, Klein S, Krix M, et al. Comparison of a standard and a high-concentration contrast medium protocol for MDCT angiography of the lower limb </text>
<text top="176" left="140" width="200" height="14" font="0">arteries. Rofo. 2012;184:527-34. </text>
<text top="193" left="86" width="4" height="14" font="0"> </text>
<text top="193" left="108" width="965" height="14" font="0">89.   Fraioli F, Catalano C, Napoli A, et al. Low-dose multidetector-row CT angiography of the infra-renal aorta and lower extremity vessels: image quality and </text>
<text top="211" left="140" width="510" height="14" font="0">diagnostic accuracy in comparison with standard DSA. Eur Radiol. 2006;16:137-46. </text>
<text top="228" left="86" width="4" height="14" font="0"> </text>
<text top="228" left="108" width="962" height="14" font="0">90.   Met R, Bipat S, Legemate DA, et al. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and </text>
<text top="245" left="140" width="249" height="14" font="0">meta-analysis. JAMA. 2009;301:415-24. </text>
<text top="262" left="86" width="4" height="14" font="0"> </text>
<text top="262" left="108" width="986" height="14" font="0">91.   Favaretto E, Pili C, Amato A, et al. Analysis of agreement between Duplex ultrasound scanning and arteriography in patients with lower limb artery disease. J </text>
<text top="280" left="140" width="288" height="14" font="0">Cardiovasc Med (Hagerstown). 2007;8:337-41. </text>
<text top="297" left="86" width="4" height="14" font="0"> </text>
<text top="297" left="108" width="987" height="14" font="0">92.   Kau T, Eicher W, Reiterer C, et al. Dual-energy CT angiography in peripheral arterial occlusive disease-accuracy of maximum intensity projections in clinical </text>
<text top="314" left="140" width="371" height="14" font="0">routine and subgroup analysis. Eur Radiol. 2011;21:1677-86. </text>
<text top="331" left="86" width="4" height="14" font="0"> </text>
<text top="331" left="108" width="980" height="14" font="0">93.   McCullough PA, Capasso P. Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized </text>
<text top="349" left="140" width="304" height="14" font="0">controlled trials. BMC Med Imaging. 2011;11:12. </text>
<text top="366" left="86" width="4" height="14" font="0"> </text>
<text top="366" left="108" width="979" height="14" font="0">94.   Sultan S, Chua BY, Hamada N, et al. Preoperative vascular screening in the presence of aortic, carotid and peripheral pathology for patients undergoing their </text>
<text top="383" left="140" width="455" height="14" font="0">first arterial intervention: 18 month follow-up. Int Angiol. 2013;32:281-90. </text>
<text top="400" left="86" width="4" height="14" font="0"> </text>
<text top="400" left="108" width="950" height="14" font="0">95.   Kurvers HA, van der Graaf Y, Blankensteijn JD, et al. Screening for asymptomatic internal carotid artery stenosis and aneurysm of the abdominal aorta: </text>
<text top="418" left="140" width="922" height="14" font="0">comparing the yield between patients with manifest atherosclerosis and patients with risk factors for atherosclerosis only. J Vasc Surg. 2003;37:1226-33. </text>
<text top="435" left="86" width="4" height="14" font="0"> </text>
<text top="435" left="108" width="971" height="14" font="0">96.   Giugliano G, Laurenzano E, Rengo C, et al. Abdominal aortic aneurysm in patients affected by intermittent claudication: prevalence and clinical predictors. </text>
<text top="452" left="140" width="211" height="14" font="0">BMC Surg. 2012;12(suppl 1):S17. </text>
<text top="469" left="86" width="4" height="14" font="0"> </text>
<text top="469" left="108" width="930" height="14" font="0">97.   Barba A, Estallo L, Rodríguez L, et al. Detection of abdominal aortic aneurysm in patients with peripheral artery disease. Eur J Vasc Endovasc Surg. </text>
<text top="487" left="140" width="96" height="14" font="0">2005;30:504-8. </text>
<text top="504" left="86" width="4" height="14" font="0"> </text>
<text top="504" left="108" width="935" height="14" font="0">98.   Lee JY, Lee SW, Lee WS, et al. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with </text>
<text top="521" left="140" width="472" height="14" font="0">significant coronary artery disease. JACC Cardiovasc Interv. 2013;6:1303-13. </text>
<text top="538" left="86" width="4" height="14" font="0"> </text>
<text top="538" left="108" width="992" height="14" font="0">99.   Moyer VA. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services </text>
<text top="556" left="140" width="448" height="14" font="0">Task Force recommendation statement. Ann Intern Med. 2013;159:342-8. </text>
<text top="573" left="86" width="964" height="14" font="0">  100.   McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351:2795-804. </text>
<text top="590" left="86" width="1019" height="14" font="0">  101.   Olin JW, Melia M, Young JR, et al. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med. 1990;88:46N-51N. </text>
<text top="607" left="86" width="993" height="14" font="0">  102.   Leertouwer TC, Pattynama PM, van den Berg-Huysmans A. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? Kidney Int. </text>
<text top="625" left="140" width="103" height="14" font="0">2001;59:1480-3. </text>
<text top="642" left="86" width="958" height="14" font="0">  103.   Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg. 2002;36:443-51. </text>
<text top="659" left="86" width="1010" height="14" font="0">  104.   Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. </text>
<text top="676" left="140" width="195" height="14" font="0">J Intern Med. 2007;261:276-84. </text>
<text top="694" left="86" width="945" height="14" font="0">  105.   Horrocks M, Horrocks EH, Murphy P, et al. The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty. Int Angiol. </text>
<text top="711" left="140" width="96" height="14" font="0">1997;16:101-6. </text>
<text top="728" left="86" width="963" height="14" font="0">  106.   Minar E, Ahmadi A, Koppensteiner R, et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous </text>
<text top="745" left="140" width="341" height="14" font="0">transluminal angioplasty. Circulation. 1995;91:2167-73. </text>
<text top="763" left="86" width="934" height="14" font="0">  107.   CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. </text>
<text top="780" left="140" width="118" height="14" font="0">1996;348:1329-39. </text>
</page>
<page number="191" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">191 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="860" height="14" font="0">  108.   Cacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192-201. </text>
<text top="107" left="86" width="1005" height="14" font="0">  109.   Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J </text>
<text top="124" left="140" width="212" height="14" font="0">Am Coll Cardiol. 2007;49:1982-8. </text>
<text top="142" left="86" width="979" height="14" font="0">  110.   Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for </text>
<text top="159" left="140" width="947" height="14" font="0">vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. </text>
<text top="176" left="140" width="193" height="14" font="0">Circulation. 2010;121:2575-83. </text>
<text top="193" left="86" width="1011" height="14" font="0">  111.   Cassar K, Ford I, Greaves M, et al. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb </text>
<text top="211" left="140" width="244" height="14" font="0">angioplasty. Br J Surg. 2005;92:159-65. </text>
<text top="228" left="86" width="995" height="14" font="0">  112.   Belch JJ, Dormandy J, CASPAR Writing CommitteeBiasi GM, et al. Results of the randomized, placebo-controlled Clopidogrel and Acetylsalicylic Acid in </text>
<text top="245" left="140" width="572" height="14" font="0">Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial. J Vasc Surg. 2010;52:825-33. </text>
<text top="262" left="86" width="949" height="14" font="0">  113.   Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a </text>
<text top="280" left="140" width="472" height="14" font="0">randomised and double-blinded clinical trial. Eur Radiol. 2012;22:1998-2006. </text>
<text top="297" left="86" width="755" height="14" font="0">  114.   Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2</text>
<text top="294" left="841" width="5" height="9" font="11">o</text>
<text top="297" left="846" width="258" height="14" font="0">P-TIMI 50. Circulation. 2013;127:1522-9. </text>
<text top="314" left="86" width="997" height="14" font="0">  115.   Strobl FF, Brechtel K, Schmehl J, et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated </text>
<text top="331" left="140" width="453" height="14" font="0">patients with peripheral artery disease. J Endovasc Ther. 2013;20:699-706. </text>
<text top="349" left="86" width="994" height="14" font="0">  116.   Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet </text>
<text top="366" left="140" width="293" height="14" font="0">Trialists' Collaboration. BMJ. 1994;308:159-68. </text>
<text top="383" left="86" width="1009" height="14" font="0">  117.   Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, </text>
<text top="400" left="140" width="332" height="14" font="0">and stroke in high risk patients. BMJ. 2002;324:71-86. </text>
<text top="418" left="86" width="949" height="14" font="0">  118.   Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404-13. </text>
<text top="435" left="86" width="977" height="14" font="0">  119.   Bohula EA, Aylward PE, Bonaca MP, et al. Efficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with </text>
<text top="452" left="140" width="624" height="14" font="0">previous myocardial infarction and no history of stroke or transient ischemic attack: results from TRA 2</text>
<text top="449" left="765" width="5" height="9" font="11">o</text>
<text top="452" left="770" width="258" height="14" font="0">P-TIMI 50. Circulation. 2015;132:1871-9. </text>
<text top="469" left="86" width="989" height="14" font="0">  120.   Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the </text>
<text top="487" left="140" width="933" height="14" font="0">Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 </text>
<text top="504" left="140" width="43" height="14" font="0">(TRA2</text>
<text top="501" left="183" width="5" height="9" font="11">o</text>
<text top="504" left="188" width="251" height="14" font="0">P-TIMI 50). Circulation. 2016;997-1005. </text>
<text top="521" left="86" width="1002" height="14" font="0">  121.   Jones WS, Dolor RJ, Hasselblad V, et al. Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease </text>
<text top="538" left="140" width="756" height="14" font="0">and critical limb ischemia: systematic review of revascularization in critical limb ischemia. Am Heart J. 2014;167:489-98.e7. </text>
<text top="556" left="86" width="1018" height="14" font="0">  122.   Katsanos K, Spiliopoulos S, Saha P, et al. Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and </text>
<text top="573" left="140" width="877" height="14" font="0">Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. PLoS One. 2015;10:e0135692. </text>
<text top="590" left="86" width="937" height="14" font="0">  123.   Magnani G, Bonaca MP, Braunwald E, et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. </text>
<text top="607" left="140" width="105" height="14" font="0">2015;4:e001505. </text>
<text top="625" left="86" width="983" height="14" font="0">  124.   Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of </text>
<text top="642" left="140" width="279" height="14" font="0">randomized trials. JAMA. 2009;301:1909-19. </text>
<text top="659" left="86" width="967" height="14" font="0">  125.   Armstrong EJ, Anderson DR, Yeo KK, et al. Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with </text>
<text top="676" left="140" width="425" height="14" font="0">symptomatic peripheral arterial disease. J Vasc Surg. 2015;62:157-65. </text>
<text top="694" left="86" width="998" height="14" font="0">  126.   Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major </text>
<text top="711" left="140" width="778" height="14" font="0">vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645-54. </text>
<text top="728" left="86" width="944" height="14" font="0">  127.   Mohler ER3, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. </text>
<text top="745" left="140" width="186" height="14" font="0">Circulation. 2003;108:1481-6. </text>
<text top="763" left="86" width="969" height="14" font="0">  128.   Hiatt WR, Hirsch AT, Creager MA, et al. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vasc Med. </text>
<text top="780" left="140" width="96" height="14" font="0">2010;15:171-9. </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">192 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="968" height="14" font="0">  129.   Giri J, McDermott MM, Greenland P, et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol. </text>
<text top="107" left="140" width="118" height="14" font="0">2006;47:998-1004. </text>
<text top="124" left="86" width="995" height="14" font="0">  130.   West AM, Anderson JD, Meyer CH, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. </text>
<text top="142" left="140" width="111" height="14" font="0">2011;218:156-62. </text>
<text top="159" left="86" width="996" height="14" font="0">  131.   Stoekenbroek RM, Boekholdt SM, Fayyad R, et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. </text>
<text top="176" left="140" width="152" height="14" font="0">Heart. 2015;101:356-62. </text>
<text top="193" left="86" width="981" height="14" font="0">  132.   Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007;CD000123. </text>
<text top="211" left="86" width="985" height="14" font="0">  133.   Kumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the </text>
<text top="228" left="140" width="295" height="14" font="0">REACH registry. Eur Heart J. 2014;35:2864-72. </text>
<text top="245" left="86" width="992" height="14" font="0">  134.   Vogel TR, Dombrovskiy VY, Galiñanes EL, et al. Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. </text>
<text top="262" left="140" width="248" height="14" font="0">Circ Cardiovasc Interv. 2013;6:694-700. </text>
<text top="280" left="86" width="980" height="14" font="0">  135.   Westin GG, Armstrong EJ, Bang H, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free </text>
<text top="297" left="140" width="507" height="14" font="0">survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63:682-90. </text>
<text top="314" left="86" width="1010" height="14" font="0">  136.   Feringa HH, Karagiannis SE, van Waning VH, et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial </text>
<text top="331" left="140" width="233" height="14" font="0">disease. J Vasc Surg. 2007;45:936-43. </text>
<text top="349" left="86" width="957" height="14" font="0">  137.   Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. </text>
<text top="366" left="140" width="96" height="14" font="0">2004;25:17-24. </text>
<text top="383" left="86" width="993" height="14" font="0">  138.   Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart </text>
<text top="400" left="140" width="528" height="14" font="0">Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. </text>
<text top="418" left="86" width="903" height="14" font="0">  139.   Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. </text>
<text top="435" left="86" width="1000" height="14" font="0">  140.   Bavry AA, Anderson RD, Gong Y, et al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the </text>
<text top="452" left="140" width="488" height="14" font="0">INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48-53. </text>
<text top="469" left="86" width="1005" height="14" font="0">  141.   Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis </text>
<text top="487" left="140" width="392" height="14" font="0">of findings from the VALUE trial. J Hypertens. 2006;24:2163-8. </text>
<text top="504" left="86" width="996" height="14" font="0">  142.   Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J </text>
<text top="521" left="140" width="180" height="14" font="0">Hypertens. 2011;29:1448-56. </text>
<text top="538" left="86" width="1010" height="14" font="0">  143.   Espinola-Klein C, Weisser G, Jagodzinski A, et al. b-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or </text>
<text top="556" left="140" width="462" height="14" font="0">metoprolol in arterial occlusive disease trial. Hypertension. 2011;58:148-54. </text>
<text top="573" left="86" width="870" height="14" font="0">  144.   Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;CD005508. </text>
<text top="590" left="86" width="971" height="14" font="0">  145.   ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to </text>
<text top="607" left="140" width="956" height="14" font="0">angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack </text>
<text top="625" left="140" width="277" height="14" font="0">Trial (ALLHAT). JAMA. 2002;288:2981-97. </text>
<text top="642" left="86" width="1010" height="14" font="0">  146.   Feringa HH, van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am </text>
<text top="659" left="140" width="185" height="14" font="0">Coll Cardiol. 2006;47:1182-7. </text>
<text top="676" left="86" width="803" height="14" font="0">  147.   Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst. 2000;1:18-20. </text>
<text top="694" left="86" width="1003" height="14" font="0">  148.   Rigotti NA, Regan S, Levy DE, et al. Sustained care intervention and postdischarge smoking cessation among hospitalized adults: a randomized clinical trial. </text>
<text top="711" left="140" width="159" height="14" font="0">JAMA. 2014;312:719-28. </text>
<text top="728" left="86" width="1005" height="14" font="0">  149.   Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. </text>
<text top="745" left="140" width="178" height="14" font="0">Circulation. 2010;121:221-9. </text>
<text top="763" left="86" width="1016" height="14" font="0">  150.   Hennrikus D, Joseph AM, Lando HA, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J </text>
<text top="780" left="140" width="219" height="14" font="0">Am Coll Cardiol. 2010;56:2105-12. </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">193 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="1018" height="14" font="0">  151.   Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart </text>
<text top="107" left="140" width="117" height="14" font="0">J. 2003;24:946-55. </text>
<text top="124" left="86" width="831" height="14" font="0">  152.   Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013;CD000165. </text>
<text top="142" left="86" width="974" height="14" font="0">  153.   Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-</text>
<text top="159" left="140" width="197" height="14" font="0">analysis. BMJ. 2012;344:e2856. </text>
<text top="176" left="86" width="976" height="14" font="0">  154.   Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. </text>
<text top="193" left="140" width="103" height="14" font="0">2014;129:28-41. </text>
<text top="211" left="86" width="966" height="14" font="0">  155.   Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without </text>
<text top="228" left="140" width="223" height="14" font="0">diabetes. JAMA. 2013;309:1014-21. </text>
<text top="245" left="86" width="842" height="14" font="0">  156.   Hoel AW, Nolan BW, Goodney PP, et al. Variation in smoking cessation after vascular operations. J Vasc Surg. 2013;57:1338-44. </text>
<text top="262" left="86" width="953" height="14" font="0">  157.   Selvarajah S, Black JH3, Malas MB, et al. Preoperative smoking is associated with early graft failure after infrainguinal bypass surgery. J Vasc Surg. </text>
<text top="280" left="140" width="111" height="14" font="0">2014;59:1308-14. </text>
<text top="297" left="86" width="996" height="14" font="0">  158.   Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with </text>
<text top="314" left="140" width="425" height="14" font="0">symptomatic peripheral artery disease. J Vasc Surg. 2014;60:1565-71. </text>
<text top="331" left="86" width="994" height="14" font="0">  159.   Lu L, Mackay DF, Pell JP. Association between level of exposure to secondhand smoke and peripheral arterial disease: cross-sectional study of 5,686 never </text>
<text top="349" left="140" width="262" height="14" font="0">smokers. Atherosclerosis. 2013;229:273-6. </text>
<text top="366" left="86" width="993" height="14" font="0">  160.   Tan CE, Glantz SA. Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: a meta-analysis. </text>
<text top="383" left="140" width="193" height="14" font="0">Circulation. 2012;126:2177-83. </text>
<text top="400" left="86" width="967" height="14" font="0">  161.   Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study </text>
<text top="418" left="140" width="765" height="14" font="0">(PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89. </text>
<text top="435" left="86" width="994" height="14" font="0">  162.   Singh S, Armstrong EJ, Sherif W, et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients </text>
<text top="452" left="140" width="538" height="14" font="0">with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med. 2014;19:307-14. </text>
<text top="469" left="86" width="946" height="14" font="0">  163.   Takahara M, Kaneto H, Iida O, et al. The influence of glycemic control on the prognosis of Japanese patients undergoing percutaneous transluminal </text>
<text top="487" left="140" width="434" height="14" font="0">angioplasty for critical limb ischemia. Diabetes Care. 2010;33:2538-42. </text>
<text top="504" left="86" width="977" height="14" font="0">  164.   Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the </text>
<text top="521" left="140" width="302" height="14" font="0">Strong Heart Study. Circulation. 2004;109:733-9. </text>
<text top="538" left="86" width="894" height="14" font="0">  165.   Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217-27. </text>
<text top="556" left="86" width="954" height="14" font="0">  166.   Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a </text>
<text top="573" left="140" width="265" height="14" font="0">randomised trial. Lancet. 2000;355:346-51. </text>
<text top="590" left="86" width="946" height="14" font="0">  167.   Johnson WC, Williford WO, Department of Veterans Affairs Cooporative Study #362. Benefits, morbidity, and mortality associated with long-term </text>
<text top="607" left="140" width="950" height="14" font="0">administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg. 2002;35:413-</text>
<text top="625" left="140" width="22" height="14" font="0">21. </text>
<text top="642" left="86" width="998" height="14" font="0">  168.   Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg. 1998;28:446-</text>
<text top="659" left="140" width="22" height="14" font="0">57. </text>
<text top="676" left="86" width="948" height="14" font="0">  169.   Antonicelli R, Sardina M, Scotti A, et al. Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and </text>
<text top="694" left="140" width="415" height="14" font="0">claudication. Italian CAP Study Group. Am J Med. 1999;107:234-9. </text>
<text top="711" left="86" width="1013" height="14" font="0">  170.   Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, </text>
<text top="728" left="140" width="733" height="14" font="0">9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e669S-90S. </text>
<text top="745" left="86" width="1000" height="14" font="0">  171.   Bedenis R, Lethaby A, Maxwell H, et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. </text>
<text top="763" left="140" width="107" height="14" font="0">2015;CD000535. </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">194 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="962" height="14" font="0">  172.   Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane </text>
<text top="107" left="140" width="228" height="14" font="0">Database Syst Rev. 2001;CD001999. </text>
<text top="124" left="86" width="837" height="14" font="0">  173.   Bedenis R, Stewart M, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014;CD003748. </text>
<text top="142" left="86" width="986" height="14" font="0">  174.   Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-30. </text>
<text top="159" left="86" width="994" height="14" font="0">  175.   Goldenberg NA, Krantz MJ, Hiatt WR. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery </text>
<text top="176" left="140" width="620" height="14" font="0">disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vasc Med. 2012;17:145-54. </text>
<text top="193" left="86" width="951" height="14" font="0">  176.   Warner CJ, Greaves SW, Larson RJ, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. </text>
<text top="211" left="140" width="111" height="14" font="0">2014;59:1607-14. </text>
<text top="228" left="86" width="1014" height="14" font="0">  177.   Iida O, Yokoi H, Soga Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of </text>
<text top="245" left="140" width="459" height="14" font="0">Peripheral Intervention by Cilostazol study. Circulation. 2013;127:2307-15. </text>
<text top="262" left="86" width="921" height="14" font="0">  178.   Salhiyyah K, Senanayake E, Abdel-Hadi M, et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2012;1:CD005262. </text>
<text top="280" left="86" width="894" height="14" font="0">  179.   Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2002;CD002785. </text>
<text top="297" left="86" width="991" height="14" font="0">  180.   Khandanpour N, Loke YK, Meyer FJ, et al. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg. </text>
<text top="314" left="140" width="103" height="14" font="0">2009;38:316-22. </text>
<text top="331" left="86" width="930" height="14" font="0">  181.   Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77. </text>
<text top="349" left="86" width="1019" height="14" font="0">  182.   Lonn E, Held C, Arnold JM, et al. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and </text>
<text top="366" left="140" width="701" height="14" font="0">B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Can J Cardiol. 2006;22:47-53. </text>
<text top="383" left="86" width="1018" height="14" font="0">  183.   Gurfinkel EP, Leo de la Fuente R, Mendiz O, et al. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) </text>
<text top="400" left="140" width="214" height="14" font="0">Study. Eur Heart J. 2004;25:25-31. </text>
<text top="418" left="86" width="964" height="14" font="0">  184.   Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: </text>
<text top="435" left="140" width="283" height="14" font="0">FLUCAD study. Eur Heart J. 2008;29:1350-8. </text>
<text top="452" left="86" width="1010" height="14" font="0">  185.   Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart </text>
<text top="469" left="140" width="516" height="14" font="0">Association/American College of Cardiology. J Am Coll Cardiol. 2006;48:1498-502. </text>
<text top="487" left="86" width="988" height="14" font="0">  186.   Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral </text>
<text top="504" left="140" width="450" height="14" font="0">artery disease: the CLEVER study. J Am Coll Cardiol. 2015;65:999-1009. </text>
<text top="521" left="86" width="1009" height="14" font="0">  187.   Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: </text>
<text top="538" left="140" width="832" height="14" font="0">six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125:130-9. </text>
<text top="556" left="86" width="998" height="14" font="0">  188.   McDermott MM, Guralnik JM, Criqui MH, et al. Home-based walking exercise in peripheral artery disease: 12-month follow-up of the GOALS randomized </text>
<text top="573" left="140" width="254" height="14" font="0">trial. J Am Heart Assoc. 2014;3:e000711. </text>
<text top="590" left="86" width="979" height="14" font="0">  189.   Collins TC, Lunos S, Carlson T, et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral </text>
<text top="607" left="140" width="474" height="14" font="0">arterial disease: a randomized controlled trial. Diabetes Care. 2011;34:2174-9. </text>
<text top="625" left="86" width="1011" height="14" font="0">  190.   Gardner AW, Parker DE, Montgomery PS, et al. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: </text>
<text top="642" left="140" width="360" height="14" font="0">a randomized controlled trial. Circulation. 2011;123:491-8. </text>
<text top="659" left="86" width="998" height="14" font="0">  191.   Saxton JM, Zwierska I, Blagojevic M, et al. Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic </text>
<text top="676" left="140" width="352" height="14" font="0">peripheral arterial disease. J Vasc Surg. 2011;53:1265-73. </text>
<text top="694" left="86" width="942" height="14" font="0">  192.   Treat-Jacobson D, Bronas UG, Leon AS. Efficacy of arm-ergometry versus treadmill exercise training to improve walking distance in patients with </text>
<text top="711" left="140" width="253" height="14" font="0">claudication. Vasc Med. 2009;14:203-13. </text>
<text top="728" left="86" width="1014" height="14" font="0">  193.   Mika P, Konik A, Januszek R, et al. Comparison of two treadmill training programs on walking ability and endothelial function in intermittent claudication. Int </text>
<text top="745" left="140" width="173" height="14" font="0">J Cardiol. 2013;168:838-42. </text>
<text top="763" left="86" width="949" height="14" font="0">  194.   Fakhry F, Rouwet EV, den Hoed PT, et al. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for </text>
<text top="780" left="140" width="531" height="14" font="0">intermittent claudication from a randomized clinical trial. Br J Surg. 2013;100:1164-71. </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">195 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="984" height="14" font="0">  195.   Mazari FA, Gulati S, Rahman MN, et al. Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in </text>
<text top="107" left="140" width="349" height="14" font="0">intermittent claudication. Ann Vasc Surg. 2010;24:69-79. </text>
<text top="124" left="86" width="1011" height="14" font="0">  196.   Fakhry F, Spronk S, van der Laan L, et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a </text>
<text top="142" left="140" width="321" height="14" font="0">randomized clinical trial. JAMA. 2015;314:1936-44. </text>
<text top="159" left="86" width="979" height="14" font="0">  197.   Guidon M, McGee H. One-year effect of a supervised exercise programme on functional capacity and quality of life in peripheral arterial disease. Disabil </text>
<text top="176" left="140" width="165" height="14" font="0">Rehabil. 2013;35:397-404. </text>
<text top="193" left="86" width="988" height="14" font="0">  198.   Gardner AW, Parker DE, Montgomery PS, et al. Step-monitored home exercise improves ambulation, vascular function, and inflammation in symptomatic </text>
<text top="211" left="140" width="639" height="14" font="0">patients with peripheral artery disease: a randomized controlled trial. J Am Heart Assoc. 2014;3:e001107. </text>
<text top="228" left="86" width="943" height="14" font="0">  199.   Langbein WE, Collins EG, Orebaugh C, et al. Increasing exercise tolerance of persons limited by claudication pain using polestriding. J Vasc Surg. </text>
<text top="245" left="140" width="103" height="14" font="0">2002;35:887-93. </text>
<text top="262" left="86" width="1003" height="14" font="0">  200.   Walker RD, Nawaz S, Wilkinson CH, et al. Influence of upper- and lower-limb exercise training on cardiovascular function and walking distances in patients </text>
<text top="280" left="140" width="360" height="14" font="0">with intermittent claudication. J Vasc Surg. 2000;31:662-9. </text>
<text top="297" left="86" width="1010" height="14" font="0">  201.   Pilz M, Kandioler-Honetz E, Wenkstetten-Holub A, et al. Evaluation of 6- and 12-month supervised exercise training on strength and endurance parameters in </text>
<text top="314" left="140" width="495" height="14" font="0">patients with peripheral arterial disease. Wien Klin Wochenschr. 2014;126:383-9. </text>
<text top="331" left="86" width="917" height="14" font="0">  202.   Mays RJ, Rogers RK, Hiatt WR, et al. Community walking programs for treatment of peripheral artery disease. J Vasc Surg. 2013;58:1678-87. </text>
<text top="349" left="86" width="893" height="14" font="0">  203.   Crane M, Werber B. Critical pathway approach to diabetic pedal infections in a multidisciplinary setting. J Foot Ankle Surg. 1999;38:30-3. </text>
<text top="366" left="86" width="997" height="14" font="0">  204.   Larsson J, Apelqvist J, Agardh CD, et al. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team </text>
<text top="383" left="140" width="240" height="14" font="0">approach? Diabet Med. 1995;12:770-6. </text>
<text top="400" left="86" width="1006" height="14" font="0">  205.   Armstrong DG, Bharara M, White M, et al. The impact and outcomes of establishing an integrated interdisciplinary surgical team to care for the diabetic foot. </text>
<text top="418" left="140" width="252" height="14" font="0">Diabetes Metab Res Rev. 2012;28:514-8. </text>
<text top="435" left="86" width="977" height="14" font="0">  206.   Chung J, Modrall JG, Ahn C, et al. Multidisciplinary care improves amputation-free survival in patients with chronic critical limb ischemia. J Vasc Surg. </text>
<text top="452" left="140" width="96" height="14" font="0">2015;61:162-9. </text>
<text top="469" left="86" width="998" height="14" font="0">  207.   Canavan RJ, Unwin NC, Kelly WF, et al. Diabetes- and nondiabetes-related lower extremity amputation incidence before and after the introduction of better </text>
<text top="487" left="140" width="742" height="14" font="0">organized diabetes foot care: continuous longitudinal monitoring using a standard method. Diabetes Care. 2008;31:459-63. </text>
<text top="504" left="86" width="1002" height="14" font="0">  208.   Williams DT, Majeed MU, Shingler G, et al. A diabetic foot service established by a department of vascular surgery: an observational study. Ann Vasc Surg. </text>
<text top="521" left="140" width="96" height="14" font="0">2012;26:700-6. </text>
<text top="538" left="86" width="989" height="14" font="0">  209.   Driver VR, Madsen J, Goodman RA. Reducing amputation rates in patients with diabetes at a military medical center: the limb preservation service model. </text>
<text top="556" left="140" width="195" height="14" font="0">Diabetes Care. 2005;28:248-53. </text>
<text top="573" left="86" width="988" height="14" font="0">  210.   Wrobel JS, Charns MP, Diehr P, et al. The relationship between provider coordination and diabetes-related foot outcomes. Diabetes Care. 2003;26:3042-7. </text>
<text top="590" left="86" width="1011" height="14" font="0">  211.   Vartanian SM, Robinson KD, Ofili K, et al. Outcomes of neuroischemic wounds treated by a multidisciplinary amputation prevention service. Ann Vasc Surg. </text>
<text top="607" left="140" width="103" height="14" font="0">2015;29:534-42. </text>
<text top="625" left="86" width="909" height="14" font="0">  212.   Gardner SE, Hillis SL, Frantz RA. Clinical signs of infection in diabetic foot ulcers with high microbial load. Biol Res Nurs. 2009;11:119-28. </text>
<text top="642" left="86" width="1000" height="14" font="0">  213.   Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic </text>
<text top="659" left="140" width="301" height="14" font="0">foot infections. Clin Infect Dis. 2012;54:e132-73. </text>
<text top="676" left="86" width="1008" height="14" font="0">  214.   Pickwell K, Siersma V, Kars M, et al. Predictors of lower-extremity amputation in patients with an infected diabetic foot ulcer. Diabetes Care. 2015;38:852-7. </text>
<text top="694" left="86" width="977" height="14" font="0">  215.   Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-</text>
<text top="711" left="140" width="256" height="14" font="0">analysis. Clin Infect Dis. 2008;47:519-27. </text>
<text top="728" left="86" width="1014" height="14" font="0">  216.   Prompers L, Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and </text>
<text top="745" left="140" width="559" height="14" font="0">without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008;51:747-55. </text>
<text top="763" left="86" width="1006" height="14" font="0">  217.   Rogers LC, Andros G, Caporusso J, et al. Toe and flow: essential components and structure of the amputation prevention team. J Vasc Surg. 2010;52:23S-7S. </text>
</page>
<page number="196" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">196 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="997" height="14" font="0">  218.   Sumpio BE, Armstrong DG, Lavery LA, et al. The role of interdisciplinary team approach in the management of the diabetic foot: a joint statement from the </text>
<text top="107" left="140" width="660" height="14" font="0">Society for Vascular Surgery and the American Podiatric Medical Association. J Vasc Surg. 2010;51:1504-6. </text>
<text top="124" left="86" width="960" height="14" font="0">  219.   Fitzgerald RH, Mills JL, Joseph W, et al. The diabetic rapid response acute foot team: 7 essential skills for targeted limb salvage. Eplasty. 2009;9:e15. </text>
<text top="142" left="86" width="932" height="14" font="0">  220.   Wrobel JS, Robbins JM, Charns MP, et al. Diabetes-related foot care at 10 Veterans Affairs medical centers: must do's associated with successful </text>
<text top="159" left="140" width="367" height="14" font="0">microsystems. Jt Comm J Qual Patient Saf. 2006;32:206-13. </text>
<text top="176" left="86" width="974" height="14" font="0">  221.   Tetteroo E, van der Graaf Y, Bosch JL, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent </text>
<text top="193" left="140" width="724" height="14" font="0">placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet. 1998;351:1153-9. </text>
<text top="211" left="86" width="1000" height="14" font="0">  222.   Klein WM, van der Graaf Y, Seegers J, et al. Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with </text>
<text top="228" left="140" width="501" height="14" font="0">iliac artery disease: The Dutch Iliac Stent Trial Study. Radiology. 2004;232:491-8. </text>
<text top="245" left="86" width="1004" height="14" font="0">  223.   Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. </text>
<text top="262" left="140" width="103" height="14" font="0">1997;204:87-96. </text>
<text top="280" left="86" width="1017" height="14" font="0">  224.   Kashyap VS, Pavkov ML, Bena JF, et al. The management of severe aortoiliac occlusive disease: endovascular therapy rivals open reconstruction. J Vasc Surg. </text>
<text top="297" left="140" width="141" height="14" font="0">2008;48:1451-7, 1457. </text>
<text top="314" left="86" width="969" height="14" font="0">  225.   Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional </text>
<text top="331" left="140" width="241" height="14" font="0">stenting. Circulation. 2007;115:2745-9. </text>
<text top="349" left="86" width="1005" height="14" font="0">  226.   Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions </text>
<text top="366" left="140" width="581" height="14" font="0">up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation. 2007;116:285-92. </text>
<text top="383" left="86" width="963" height="14" font="0">  227.   Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal </text>
<text top="400" left="140" width="710" height="14" font="0">popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-76. </text>
<text top="418" left="86" width="987" height="14" font="0">  228.   Dick P, Wallner H, Sabeti S, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter </text>
<text top="435" left="140" width="218" height="14" font="0">Cardiovasc Interv. 2009;74:1090-5. </text>
<text top="452" left="86" width="990" height="14" font="0">  229.   Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and </text>
<text top="469" left="140" width="763" height="14" font="0">popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495-502. </text>
<text top="487" left="86" width="997" height="14" font="0">  230.   Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug </text>
<text top="504" left="140" width="724" height="14" font="0">eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295-302. </text>
<text top="521" left="86" width="929" height="14" font="0">  231.   Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for </text>
<text top="538" left="140" width="939" height="14" font="0">femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc </text>
<text top="556" left="140" width="124" height="14" font="0">Interv. 2014;7:10-9. </text>
<text top="573" left="86" width="957" height="14" font="0">  232.   Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized </text>
<text top="590" left="140" width="342" height="14" font="0">PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831-40. </text>
<text top="607" left="86" width="1007" height="14" font="0">  233.   Lammer J, Zeller T, Hausegger KA, et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized </text>
<text top="625" left="140" width="926" height="14" font="0">VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial </text>
<text top="642" left="140" width="427" height="14" font="0">femoral artery occlusive disease). J Am Coll Cardiol. 2013;62:1320-7. </text>
<text top="659" left="86" width="1003" height="14" font="0">  234.   Geraghty PJ, Mewissen MW, Jaff MR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for </text>
<text top="676" left="140" width="505" height="14" font="0">complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58:386-95. </text>
<text top="694" left="86" width="998" height="14" font="0">  235.   Saxon RR, Dake MD, Volgelzang RL, et al. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement </text>
<text top="711" left="140" width="880" height="14" font="0">with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008;19:823-32. </text>
<text top="728" left="86" width="1018" height="14" font="0">  236.   Kedora J, Hohmann S, Garrett W, et al. Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of </text>
<text top="745" left="140" width="442" height="14" font="0">superficial femoral arterial occlusive disease. J Vasc Surg. 2007;45:10-6. </text>
<text top="763" left="86" width="1011" height="14" font="0">  237.   Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-</text>
<text top="780" left="140" width="520" height="14" font="0">month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495-504. </text>
</page>
<page number="197" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">197 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="1016" height="14" font="0">  238.   Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX </text>
<text top="107" left="140" width="310" height="14" font="0">Randomized Trial. Circulation. 2016;133:1472-83. </text>
<text top="124" left="86" width="991" height="14" font="0">  239.   Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-</text>
<text top="142" left="140" width="440" height="14" font="0">term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-10. </text>
<text top="159" left="86" width="941" height="14" font="0">  240.   Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-99. </text>
<text top="176" left="86" width="998" height="14" font="0">  241.   Dippel EJ, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial </text>
<text top="193" left="140" width="954" height="14" font="0">results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc </text>
<text top="211" left="140" width="139" height="14" font="0">Interv. 2015;8:92-101. </text>
<text top="228" left="86" width="982" height="14" font="0">  242.   Banerjee S, Das TS, Abu-Fadel MS, et al. Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral </text>
<text top="245" left="140" width="440" height="14" font="0">arterial segments: the COBRA trial. J Am Coll Cardiol. 2012;60:1352-9. </text>
<text top="262" left="86" width="1014" height="14" font="0">  243.   Whyman MR, Fowkes FG, Kerracher EM, et al. Randomised controlled trial of percutaneous transluminal angioplasty for intermittent claudication. Eur J Vasc </text>
<text top="280" left="140" width="201" height="14" font="0">Endovasc Surg. 1996;12:167-72. </text>
<text top="297" left="86" width="988" height="14" font="0">  244.   Whyman MR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled </text>
<text top="314" left="140" width="207" height="14" font="0">trial. J Vasc Surg. 1997;26:551-7. </text>
<text top="331" left="86" width="974" height="14" font="0">  245.   Perkins JM, Collin J, Creasy TS, et al. Reprinted article &#34;Exercise training versus angioplasty for stable claudication. Long and medium term results of a </text>
<text top="349" left="140" width="505" height="14" font="0">prospective, randomised trial&#34;. Eur J Vasc Endovasc Surg. 2011;42(suppl 1):S41-5. </text>
<text top="366" left="86" width="992" height="14" font="0">  246.   Spronk S, Bosch JL, den Hoed PT, et al. Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based </text>
<text top="383" left="140" width="456" height="14" font="0">exercise training-randomized controlled trial. Radiology. 2009;250:586-95. </text>
<text top="400" left="86" width="976" height="14" font="0">  247.   Spronk S, Bosch JL, den Hoed PT, et al. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in </text>
<text top="418" left="140" width="607" height="14" font="0">patients with intermittent claudication: a randomized controlled trial. J Vasc Surg. 2008;48:1472-80. </text>
<text top="435" left="86" width="1011" height="14" font="0">  248.   Gelin J, Jivegård L, Taft C, et al. Treatment efficacy of intermittent claudication by surgical intervention, supervised physical exercise training compared to no </text>
<text top="452" left="140" width="936" height="14" font="0">treatment in unselected randomised patients, I: one year results of functional and physiological improvements. Eur J Vasc Endovasc Surg. 2001;22:107-13. </text>
<text top="469" left="86" width="985" height="14" font="0">  249.   Taft C, Karlsson J, Gelin J, et al. Treatment efficacy of intermittent claudication by invasive therapy, supervised physical exercise training compared to no </text>
<text top="487" left="140" width="850" height="14" font="0">treatment in unselected randomised patients, II: one-year results of health-related quality of life. Eur J Vasc Endovasc Surg. 2001;22:114-23. </text>
<text top="504" left="86" width="998" height="14" font="0">  250.   Hobbs SD, Marshall T, Fegan C, et al. The constitutive procoagulant and hypofibrinolytic state in patients with intermittent claudication due to infrainguinal </text>
<text top="521" left="140" width="670" height="14" font="0">disease significantly improves with percutaneous transluminal balloon angioplasty. J Vasc Surg. 2006;43:40-6. </text>
<text top="538" left="86" width="1001" height="14" font="0">  251.   Nylaende M, Abdelnoor M, Stranden E, et al. The Oslo Balloon Angioplasty versus Conservative Treatment study (OBACT)—the 2-years results of a single </text>
<text top="556" left="140" width="737" height="14" font="0">centre, prospective, randomised study in patients with intermittent claudication. Eur J Vasc Endovasc Surg. 2007;33:3-12. </text>
<text top="573" left="86" width="1009" height="14" font="0">  252.   Greenhalgh RM, Belch JJ, Brown LC, et al. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed </text>
<text top="590" left="140" width="924" height="14" font="0">by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac </text>
<text top="607" left="140" width="360" height="14" font="0">arterial disease. Eur J Vasc Endovasc Surg. 2008;36:680-8. </text>
<text top="625" left="86" width="1011" height="14" font="0">  253.   Kruidenier LM, Nicolai SP, Rouwet EV, et al. Additional supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: </text>
<text top="642" left="140" width="391" height="14" font="0">a randomized clinical trial. J Vasc Interv Radiol. 2011;22:961-8. </text>
<text top="659" left="86" width="1001" height="14" font="0">  254.   Mazari FA, Khan JA, Carradice D, et al. Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for </text>
<text top="676" left="140" width="548" height="14" font="0">intermittent claudication due to femoropopliteal arterial disease. Br J Surg. 2012;99:39-48. </text>
<text top="694" left="86" width="989" height="14" font="0">  255.   Nordanstig J, Gelin J, Hensäter M, et al. Walking performance and health-related quality of life after surgical or endovascular invasive versus non-invasive </text>
<text top="711" left="140" width="695" height="14" font="0">treatment for intermittent claudication—a prospective randomised trial. Eur J Vasc Endovasc Surg. 2011;42:220-7. </text>
<text top="728" left="86" width="1004" height="14" font="0">  256.   Nordanstig J, Taft C, Hensäter M, et al. Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year </text>
<text top="745" left="140" width="748" height="14" font="0">results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial. Circulation. 2014;130:939-47. </text>
<text top="763" left="86" width="996" height="14" font="0">  257.   Malgor RD, Alahdab F, Elraiyah TA, et al. A systematic review of treatment of intermittent claudication in the lower extremities. J Vasc Surg. 2015;61:54S-</text>
<text top="780" left="140" width="31" height="14" font="0">73S. </text>
</page>
<page number="198" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">198 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="972" height="14" font="0">  258.   Vemulapalli S, Dolor RJ, Hasselblad V, et al. Comparative effectiveness of medical therapy, supervised exercise, and revascularization for patients with </text>
<text top="107" left="140" width="494" height="14" font="0">intermittent claudication: a network meta-analysis. Clin Cardiol. 2015;38:378-86. </text>
<text top="124" left="86" width="919" height="14" font="0">  259.   McPhail IR, Spittell PC, Weston SA, et al. Intermittent claudication: an objective office-based assessment. J Am Coll Cardiol. 2001;37:1381-5. </text>
<text top="142" left="86" width="977" height="14" font="0">  260.   Schulte KL, Pilger E, Schellong S, et al. Primary self-expanding nitinol stenting vs balloon angioplasty with optional bailout stenting for the treatment of </text>
<text top="159" left="140" width="930" height="14" font="0">infrapopliteal artery disease in patients with severe intermittent claudication or critical limb ischemia (EXPAND Study). J Endovasc Ther. 2015;22:690-7. </text>
<text top="176" left="86" width="973" height="14" font="0">  261.   Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-5. </text>
<text top="193" left="86" width="1007" height="14" font="0">  262.   Sakamoto Y, Hirano K, Iida O, et al. Five-year outcomes of self-expanding nitinol stent implantation for chronic total occlusion of the superficial femoral and </text>
<text top="211" left="140" width="455" height="14" font="0">proximal popliteal artery. Catheter Cardiovasc Interv. 2013;82:E251-E256. </text>
<text top="228" left="86" width="971" height="14" font="0">  263.   Feinglass J, McCarthy WJ, Slavensky R, et al. Functional status and walking ability after lower extremity bypass grafting or angioplasty for intermittent </text>
<text top="245" left="140" width="524" height="14" font="0">claudication: results from a prospective outcomes study. J Vasc Surg. 2000;31:93-103. </text>
<text top="262" left="86" width="956" height="14" font="0">  264.   Giugliano G, Di SL, Perrino C, et al. Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with </text>
<text top="280" left="140" width="362" height="14" font="0">peripheral arterial disease. Int J Cardiol. 2013;167:2566-71. </text>
<text top="297" left="86" width="1010" height="14" font="0">  265.   Koivunen K, Lukkarinen H. One-year prospective health-related quality-of-life outcomes in patients treated with conservative method, endovascular treatment </text>
<text top="314" left="140" width="651" height="14" font="0">or open surgery for symptomatic lower limb atherosclerotic disease. Eur J Cardiovasc Nurs. 2008;7:247-56. </text>
<text top="331" left="86" width="1013" height="14" font="0">  266.   Pell JP, Lee AJ. Impact of angioplasty and arterial reconstructive surgery on the quality of life of claudicants. The Scottish Vascular Audit Group. Scott Med J. </text>
<text top="349" left="140" width="88" height="14" font="0">1997;42:47-8. </text>
<text top="366" left="86" width="1014" height="14" font="0">  267.   Kalbaugh CA, Taylor SM, Blackhurst DW, et al. One-year prospective quality-of-life outcomes in patients treated with angioplasty for symptomatic peripheral </text>
<text top="383" left="140" width="287" height="14" font="0">arterial disease. J Vasc Surg. 2006;44:296-302. </text>
<text top="400" left="86" width="1016" height="14" font="0">  268.   Sachs T, Pomposelli F, Hamdan A, et al. Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft. </text>
<text top="418" left="140" width="190" height="14" font="0">J Vasc Surg. 2011;54:1021-31. </text>
<text top="435" left="86" width="979" height="14" font="0">  269.   Shammas NW, Shammas GA, Dippel EJ, et al. Predictors of distal embolization in peripheral percutaneous interventions: a report from a large peripheral </text>
<text top="452" left="140" width="327" height="14" font="0">vascular registry. J Invasive Cardiol. 2009;21:628-31. </text>
<text top="469" left="86" width="985" height="14" font="0">  270.   Matsi PJ, Manninen HI. Complications of lower-limb percutaneous transluminal angioplasty: a prospective analysis of 410 procedures on 295 consecutive </text>
<text top="487" left="140" width="327" height="14" font="0">patients. Cardiovasc Intervent Radiol. 1998;21:361-6. </text>
<text top="504" left="86" width="977" height="14" font="0">  271.   Linni K, Ugurluoglu A, Hitzl W, et al. Bioabsorbable stent implantation vs. common femoral artery endarterectomy: early results of a randomized trial. J </text>
<text top="521" left="140" width="209" height="14" font="0">Endovasc Ther. 2014;21:493-502. </text>
<text top="538" left="86" width="1010" height="14" font="0">  272.   Gabrielli R, Rosati MS, Vitale S, et al. Randomized controlled trial of remote endarterectomy versus endovascular intervention for TransAtlantic Inter-Society </text>
<text top="556" left="140" width="442" height="14" font="0">Consensus II D femoropopliteal lesions. J Vasc Surg. 2012;56:1598-605. </text>
<text top="573" left="86" width="981" height="14" font="0">  273.   Gisbertz SS, Tutein Nolthenius RP, de Borst GJ, et al. Remote endarterectomy versus supragenicular bypass surgery for long occlusions of the superficial </text>
<text top="590" left="140" width="742" height="14" font="0">femoral artery: medium-term results of a randomized controlled trial (the REVAS trial). Ann Vasc Surg. 2010;24:1015-23. </text>
<text top="607" left="86" width="1009" height="14" font="0">  274.   van Det RJ, Vriens BH, van der Palen J, et al. Dacron or ePTFE for femoro-popliteal above-knee bypass grafting: short- and long-term results of a multicentre </text>
<text top="625" left="140" width="375" height="14" font="0">randomised trial. Eur J Vasc Endovasc Surg. 2009;37:457-63. </text>
<text top="642" left="86" width="991" height="14" font="0">  275.   Gisbertz SS, Ramzan M, Tutein Nolthenius RP, et al. Short-term results of a randomized trial comparing remote endarterectomy and supragenicular bypass </text>
<text top="659" left="140" width="741" height="14" font="0">surgery for long occlusions of the superficial femoral artery [the REVAS trial]. Eur J Vasc Endovasc Surg. 2009;37:68-76. </text>
<text top="676" left="86" width="1006" height="14" font="0">  276.   Ricco JB, Probst H. Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease. J Vasc </text>
<text top="694" left="140" width="132" height="14" font="0">Surg. 2008;47:45-53. </text>
<text top="711" left="86" width="984" height="14" font="0">  277.   Jensen LP, Lepäntalo M, Fossdal JE, et al. Dacron or PTFE for above-knee femoropopliteal bypass. a multicenter randomised study. Eur J Vasc Endovasc </text>
<text top="728" left="140" width="124" height="14" font="0">Surg. 2007;34:44-9. </text>
<text top="745" left="86" width="988" height="14" font="0">  278.   AbuRahma AF, Robinson PA, Holt SM. Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral </text>
<text top="763" left="140" width="405" height="14" font="0">above knee femoropopliteal bypasses. Surgery. 1999;126:594-602. </text>
</page>
<page number="199" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">199 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="976" height="14" font="0">  279.   Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg. </text>
<text top="107" left="140" width="103" height="14" font="0">2000;31:417-25. </text>
<text top="124" left="86" width="963" height="14" font="0">  280.   Johnson WC, Lee KK. Comparative evaluation of externally supported Dacron and polytetrafluoroethylene prosthetic bypasses for femorofemoral and </text>
<text top="142" left="140" width="676" height="14" font="0">axillofemoral arterial reconstructions. Veterans Affairs Cooperative Study #141. J Vasc Surg. 1999;30:1077-83. </text>
<text top="159" left="86" width="1017" height="14" font="0">  281.   Klinkert P, Schepers A, Burger DH, et al. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized </text>
<text top="176" left="140" width="279" height="14" font="0">controlled trial. J Vasc Surg. 2003;37:149-55. </text>
<text top="193" left="86" width="884" height="14" font="0">  282.   Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded </text>
<text top="211" left="140" width="599" height="14" font="0">polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986;3:104-14. </text>
<text top="228" left="86" width="931" height="14" font="0">  283.   Nguyen BN, Amdur RL, Abugideiri M, et al. Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015;61:1489-94. </text>
<text top="245" left="86" width="1017" height="14" font="0">  284.   Lo RC, Bensley RP, Dahlberg SE, et al. Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation </text>
<text top="262" left="140" width="464" height="14" font="0">for lower extremity peripheral arterial disease. J Vasc Surg. 2014;59:409-18. </text>
<text top="280" left="86" width="1001" height="14" font="0">  285.   Siracuse JJ, Gill HL, Schneider DB, et al. Assessing the perioperative safety of common femoral endarterectomy in the endovascular era. Vasc Endovascular </text>
<text top="297" left="140" width="132" height="14" font="0">Surg. 2014;48:27-33. </text>
<text top="314" left="86" width="1018" height="14" font="0">  286.   Aihara H, Soga Y, Mii S, et al. Comparison of long-term outcome after endovascular therapy versus bypass surgery in claudication patients with Trans-Atlantic </text>
<text top="331" left="140" width="515" height="14" font="0">Inter-Society Consensus-II C and D femoropopliteal disease. Circ J. 2014;78:457-64. </text>
<text top="349" left="86" width="1016" height="14" font="0">  287.   Boufi M, Azghari A, Belahda K, et al. Subintimal recanalization plus stenting or bypass for management of claudicants with femoro-popliteal occlusions. Eur J </text>
<text top="366" left="140" width="235" height="14" font="0">Vasc Endovasc Surg. 2013;46:347-52. </text>
<text top="383" left="86" width="963" height="14" font="0">  288.   Sachwani GR, Hans SS, Khoury MD, et al. Results of iliac stenting and aortofemoral grafting for iliac artery occlusions. J Vasc Surg. 2013;57:1030-7. </text>
<text top="400" left="86" width="994" height="14" font="0">  289.   Jones WS, Schmit KM, Vemulapalli S, et al. Treatment Strategies for Patients With Peripheral Artery Disease. Comparative Effectiveness Review No. 118. </text>
<text top="418" left="140" width="606" height="14" font="0">The Duke Evidence-based Practice Center under Contract No 290-2007-10066-I. 2013;Available at: </text>
<text top="435" left="140" width="687" height="14" font="6"><a href="http://www.effectivehealthcare.ahrq.gov/ehc/products/368/1415/Peripheral-Artery-Disease-Treatment-130301.pdf">http://www.effectivehealthcare.ahrq.gov/ehc/products/368/1415/Peripheral-Artery-Disease-Treatment-130301.pdf</a></text>
<text top="435" left="827" width="196" height="14" font="0"><a href="http://www.effectivehealthcare.ahrq.gov/ehc/products/368/1415/Peripheral-Artery-Disease-Treatment-130301.pdf">. Ac</a>cessed September 25, 2016. </text>
<text top="452" left="86" width="991" height="14" font="0">  290.   Antoniou GA, Chalmers N, Georgiadis GS, et al. A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc </text>
<text top="469" left="140" width="139" height="14" font="0">Surg. 2013;57:242-53. </text>
<text top="487" left="86" width="1001" height="14" font="0">  291.   Malgor RD, Ricotta JJ, Bower TC, et al. Common femoral artery endarterectomy for lower-extremity ischemia: evaluating the need for additional distal limb </text>
<text top="504" left="140" width="312" height="14" font="0">revascularization. Ann Vasc Surg. 2012;26:946-56. </text>
<text top="521" left="86" width="974" height="14" font="0">  292.   Simons JP, Schanzer A, Nolan BW, et al. Outcomes and practice patterns in patients undergoing lower extremity bypass. J Vasc Surg. 2012;55:1629-36. </text>
<text top="538" left="86" width="1016" height="14" font="0">  293.   Siracuse JJ, Giles KA, Pomposelli FB, et al. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral </text>
<text top="556" left="140" width="332" height="14" font="0">artery occlusive disease. J Vasc Surg. 2012;55:1001-7. </text>
<text top="573" left="86" width="969" height="14" font="0">  294.   Kakkos SK, Haurani MJ, Shepard AD, et al. Patterns and outcomes of aortofemoral bypass grafting in the era of endovascular interventions. Eur J Vasc </text>
<text top="590" left="140" width="201" height="14" font="0">Endovasc Surg. 2011;42:658-66. </text>
<text top="607" left="86" width="1006" height="14" font="0">  295.   Simó G, Banga P, Darabos G, et al. Stent-assisted remote iliac artery endarterectomy: an alternative approach to treating combined external iliac and common </text>
<text top="625" left="140" width="410" height="14" font="0">femoral artery disease. Eur J Vasc Endovasc Surg. 2011;42:648-55. </text>
<text top="642" left="86" width="1009" height="14" font="0">  296.   Eugster T, Marti R, Gurke L, et al. Ten years after arterial bypass surgery for claudication: venous bypass is the primary procedure for TASC C and D lesions. </text>
<text top="659" left="140" width="198" height="14" font="0">World J Surg. 2011;35:2328-31. </text>
<text top="676" left="86" width="979" height="14" font="0">  297.   Piazza M, Ricotta JJ, Bower TC, et al. Iliac artery stenting combined with open femoral endarterectomy is as effective as open surgical reconstruction for </text>
<text top="694" left="140" width="497" height="14" font="0">severe iliac and common femoral occlusive disease. J Vasc Surg. 2011;54:402-11. </text>
<text top="711" left="86" width="1016" height="14" font="0">  298.   Derksen WJ, Gisbertz SS, Hellings WE, et al. Predictive risk factors for restenosis after remote superficial femoral artery endarterectomy. Eur J Vasc Endovasc </text>
<text top="728" left="140" width="147" height="14" font="0">Surg. 2010;39:597-603. </text>
<text top="745" left="86" width="1005" height="14" font="0">  299.   Koscielny A, Putz U, Willinek W, et al. Case-control comparison of profundaplasty and femoropopliteal supragenicular bypass for peripheral arterial disease. </text>
<text top="763" left="140" width="160" height="14" font="0">Br J Surg. 2010;97:344-8. </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">200 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="988" height="14" font="0">  300.   Ballotta E, Gruppo M, Mazzalai F, et al. Common femoral artery endarterectomy for occlusive disease: an 8-year single-center prospective study. Surgery. </text>
<text top="107" left="140" width="111" height="14" font="0">2010;147:268-74. </text>
<text top="124" left="86" width="1000" height="14" font="0">  301.   Burke CR, Henke PK, Hernandez R, et al. A contemporary comparison of aortofemoral bypass and aortoiliac stenting in the treatment of aortoiliac occlusive </text>
<text top="142" left="140" width="238" height="14" font="0">disease. Ann Vasc Surg. 2010;24:4-13. </text>
<text top="159" left="86" width="779" height="14" font="0">  302.   Twine CP, McLain AD. Graft type for femoro-popliteal bypass surgery. Cochrane Database Syst Rev. 2010;CD001487. </text>
<text top="176" left="86" width="980" height="14" font="0">  303.   Chiesa R, Marone EM, Tshomba Y, et al. Aortobifemoral bypass grafting using expanded polytetrafluoroethylene stretch grafts in patients with occlusive </text>
<text top="193" left="140" width="338" height="14" font="0">atherosclerotic disease. Ann Vasc Surg. 2009;23:764-9. </text>
<text top="211" left="86" width="965" height="14" font="0">  304.   Al-Khoury G, Marone L, Chaer R, et al. Isolated femoral endarterectomy: impact of SFA TASC classification on recurrence of symptoms and need for </text>
<text top="228" left="140" width="319" height="14" font="0">additional intervention. J Vasc Surg. 2009;50:784-9. </text>
<text top="245" left="86" width="936" height="14" font="0">  305.   Goodney PP, Likosky DS, Cronenwett JL, et al. Predicting ambulation status one year after lower extremity bypass. J Vasc Surg. 2009;49:1431-9. </text>
<text top="262" left="86" width="968" height="14" font="0">  306.   Chang RW, Goodney PP, Baek JH, et al. Long-term results of combined common femoral endarterectomy and iliac stenting/stent grafting for occlusive </text>
<text top="280" left="140" width="226" height="14" font="0">disease. J Vasc Surg. 2008;48:362-7. </text>
<text top="297" left="86" width="947" height="14" font="0">  307.   Jaquinandi V, Picquet J, Bouye P, et al. High prevalence of proximal claudication among patients with patent aortobifemoral bypasses. J Vasc Surg. </text>
<text top="314" left="140" width="96" height="14" font="0">2007;45:312-8. </text>
<text top="331" left="86" width="774" height="14" font="0">  308.   Fowkes F, Leng GC. Bypass surgery for chronic lower limb ischaemia. Cochrane Database Syst Rev. 2008;CD002000. </text>
<text top="349" left="86" width="1004" height="14" font="0">  309.   Pereira CE, Albers M, Romiti M, et al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg. 2006;44:510-7. </text>
<text top="366" left="86" width="1004" height="14" font="0">  310.   Rosenthal D, Martin JD, Smeets L, et al. Remote superficial femoral artery endarterectomy and distal aSpire stenting: results of a multinational study at three-</text>
<text top="383" left="140" width="374" height="14" font="0">year follow-up. J Cardiovasc Surg (Torino ). 2006;47:385-91. </text>
<text top="400" left="86" width="872" height="14" font="0">  311.   Martin JD, Hupp JA, Peeler MO, et al. Remote endarterectomy: lessons learned after more than 100 cases. J Vasc Surg. 2006;43:320-6. </text>
<text top="418" left="86" width="1010" height="14" font="0">  312.   Mori E, Komori K, Kume M, et al. Comparison of the long-term results between surgical and conservative treatment in patients with intermittent claudication. </text>
<text top="435" left="140" width="174" height="14" font="0">Surgery. 2002;131:S269-74. </text>
<text top="452" left="86" width="1009" height="14" font="0">  313.   Archie JP. Femoropopliteal bypass with either adequate ipsilateral reversed saphenous vein or obligatory polytetrafluoroethylene. Ann Vasc Surg. 1994;8:475-</text>
<text top="469" left="140" width="22" height="14" font="0">84. </text>
<text top="487" left="86" width="994" height="14" font="0">  314.   Hunink MG, Wong JB, Donaldson MC, et al. Patency results of percutaneous and surgical revascularization for femoropopliteal arterial disease. Med Decis </text>
<text top="504" left="140" width="150" height="14" font="0">Making. 1994;14:71-81. </text>
<text top="521" left="86" width="973" height="14" font="0">  315.   Schweiger H, Klein P, Lang W. Tibial bypass grafting for limb salvage with ringed polytetrafluoroethylene prostheses: results of primary and secondary </text>
<text top="538" left="140" width="256" height="14" font="0">procedures. J Vasc Surg. 1993;18:867-74. </text>
<text top="556" left="86" width="794" height="14" font="0">  316.   Baldwin ZK, Pearce BJ, Curi MA, et al. Limb salvage after infrainguinal bypass graft failure. J Vasc Surg. 2004;39:951-7. </text>
<text top="573" left="86" width="998" height="14" font="0">  317.   Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the </text>
<text top="590" left="140" width="330" height="14" font="0">general population. Int J Epidemiol. 1996;25:1172-81. </text>
<text top="607" left="86" width="878" height="14" font="0">  318.   Kannel WB, Skinner JJ, Schwartz MJ, et al. Intermittent claudication. Incidence in the Framingham Study. Circulation. 1970;41:875-83. </text>
<text top="625" left="86" width="696" height="14" font="0">  319.   Kannel WB, Shurtleff D. The natural history of arteriosclerosis obliterans. Cardiovasc Clin. 1971;3:37-52. </text>
<text top="642" left="86" width="918" height="14" font="0">  320.   TILLGREN C. Obliterative Arterial Disease of the Lower Limbs. II. A Study of the Course of the Disease. Acta Med Scand. 1965;178:103-19. </text>
<text top="659" left="86" width="981" height="14" font="0">  321.   Jelnes R, Gaardsting O, Hougaard Jensen K, et al. Fate in intermittent claudication: outcome and risk factors. Br Med J (Clin Res Ed). 1986;293:1137-40. </text>
<text top="676" left="86" width="994" height="14" font="0">  322.   Bloor K. Natural history of arteriosclerosis of the lower extremities: Hunterian lecture delivered at the Royal College of Surgeons of England on 22nd April </text>
<text top="694" left="140" width="274" height="14" font="0">1960. Ann R Coll Surg Engl. 1961;28:36-52. </text>
<text top="711" left="86" width="945" height="14" font="0">  323.   Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino ). 1989;30:50-7. </text>
<text top="728" left="86" width="993" height="14" font="0">  324.   Gandini R, Del GC, Merolla S, et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in </text>
<text top="745" left="140" width="716" height="14" font="0">patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther. 2013;20:805-14. </text>
<text top="763" left="86" width="1015" height="14" font="0">  325.   Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb </text>
<text top="780" left="140" width="659" height="14" font="0">ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568-76. </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">201 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="958" height="14" font="0">  326.   Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the </text>
<text top="107" left="140" width="923" height="14" font="0">sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60:2290-5. </text>
<text top="124" left="86" width="977" height="14" font="0">  327.   Katsanos K, Spiliopoulos S, Diamantopoulos A, et al. Wound healing outcomes and health-related quality-of-life changes in the ACHILLES trial: 1-year </text>
<text top="142" left="140" width="901" height="14" font="0">results from a prospective randomized controlled trial of infrapopliteal balloon angioplasty versus sirolimus-eluting stenting in patients with ischemic </text>
<text top="159" left="140" width="412" height="14" font="0">peripheral arterial disease. JACC Cardiovasc Interv. 2016;9:259-67. </text>
<text top="176" left="86" width="995" height="14" font="0">  328.   Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. </text>
<text top="193" left="140" width="118" height="14" font="0">2005;366:1925-34. </text>
<text top="211" left="86" width="1002" height="14" font="0">  329.   Bradbury AW, Adam DJ, Bell J, et al. Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-</text>
<text top="228" left="140" width="946" height="14" font="0">angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the </text>
<text top="245" left="140" width="393" height="14" font="0">Leg (BASIL) trial. Health Technol Assess. 2010;14:1-210, iii-iv. </text>
<text top="262" left="86" width="973" height="14" font="0">  330.   Bradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall </text>
<text top="280" left="140" width="381" height="14" font="0">survival by treatment received. J Vasc Surg. 2010;51:18S-31S. </text>
<text top="297" left="86" width="1013" height="14" font="0">  331.   Fanelli F, Cannavale A, Boatta E, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J </text>
<text top="314" left="140" width="201" height="14" font="0">Endovasc Ther. 2012;19:571-80. </text>
<text top="331" left="86" width="922" height="14" font="0">  332.   Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145-53. </text>
<text top="349" left="86" width="988" height="14" font="0">  333.   Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and </text>
<text top="366" left="140" width="417" height="14" font="0">infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55:390-8. </text>
<text top="383" left="86" width="999" height="14" font="0">  334.   Rastan A, Tepe G, Krankenberg H, et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, </text>
<text top="400" left="140" width="422" height="14" font="0">multi-centre, randomized clinical trial. Eur Heart J. 2011;32:2274-81. </text>
<text top="418" left="86" width="1007" height="14" font="0">  335.   Siablis D, Kitrou PM, Spiliopoulos S, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment </text>
<text top="435" left="140" width="657" height="14" font="0">arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048-56. </text>
<text top="452" left="86" width="985" height="14" font="0">  336.   Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC </text>
<text top="469" left="140" width="203" height="14" font="0">Cardiovasc Interv. 2015;8:102-8. </text>
<text top="487" left="86" width="970" height="14" font="0">  337.   Ferraresi R, Centola M, Ferlini M, et al. Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb </text>
<text top="504" left="140" width="337" height="14" font="0">ischaemia. Eur J Vasc Endovasc Surg. 2009;37:336-42. </text>
<text top="521" left="86" width="1000" height="14" font="0">  338.   Park SW, Kim JS, Yun IJ, et al. Clinical outcomes of endovascular treatments for critical limb ischemia with chronic total occlusive lesions limited to below-</text>
<text top="538" left="140" width="282" height="14" font="0">the-knee arteries. Acta Radiol. 2013;54:785-9. </text>
<text top="556" left="86" width="1001" height="14" font="0">  339.   Faglia E, Clerici G, Clerissi J, et al. Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: data of a cohort study of </text>
<text top="573" left="140" width="350" height="14" font="0">564 patients. Eur J Vasc Endovasc Surg. 2006;32:484-90. </text>
<text top="590" left="86" width="973" height="14" font="0">  340.   Faglia E, Dalla PL, Clerici G, et al. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: </text>
<text top="607" left="140" width="848" height="14" font="0">prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg. 2005;29:620-7. </text>
<text top="625" left="86" width="1016" height="14" font="0">  341.   Iida O, Soga Y, Hirano K, et al. Long-term results of direct and indirect endovascular revascularization based on the angiosome concept in patients with critical </text>
<text top="642" left="140" width="564" height="14" font="0">limb ischemia presenting with isolated below-the-knee lesions. J Vasc Surg. 2012;55:363-70. </text>
<text top="659" left="86" width="943" height="14" font="0">  342.   Feiring AJ, Krahn M, Nelson L, et al. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE </text>
<text top="676" left="140" width="577" height="14" font="0">(PReventing Amputations using Drug eluting StEnts) trial. J Am Coll Cardiol. 2010;55:1580-9. </text>
<text top="694" left="86" width="1010" height="14" font="0">  343.   Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-</text>
<text top="711" left="140" width="487" height="14" font="0">term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20:1141-50. </text>
<text top="728" left="86" width="984" height="14" font="0">  344.   Werner M, Schmidt A, Freyer M, et al. Sirolimus-eluting stents for the treatment of infrapopliteal arteries in chronic limb ischemia: long-term clinical and </text>
<text top="745" left="140" width="345" height="14" font="0">angiographic follow-up. J Endovasc Ther. 2012;19:12-9. </text>
<text top="763" left="86" width="1004" height="14" font="0">  345.   Acín F, Varela C, López de Maturana I, et al. Results of infrapopliteal endovascular procedures performed in diabetic patients with critical limb ischemia and </text>
<text top="780" left="140" width="730" height="14" font="0">tissue loss from the perspective of an angiosome-oriented revascularization strategy. Int J Vasc Med. 2014;2014:270539. </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">202 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="1007" height="14" font="0">  346.   Alexandrescu VA, Hubermont G, Philips Y, et al. Selective primary angioplasty following an angiosome model of reperfusion in the treatment of Wagner 1-4 </text>
<text top="107" left="140" width="655" height="14" font="0">diabetic foot lesions: practice in a multidisciplinary diabetic limb service. J Endovasc Ther. 2008;15:580-93. </text>
<text top="124" left="86" width="971" height="14" font="0">  347.   Fossaceca R, Guzzardi G, Cerini P, et al. Endovascular treatment of diabetic foot in a selected population of patients with below-the-knee disease: is the </text>
<text top="142" left="140" width="453" height="14" font="0">angiosome model effective? Cardiovasc Intervent Radiol. 2013;36:637-44. </text>
<text top="159" left="86" width="1012" height="14" font="0">  348.   Kabra A, Suresh KR, Vivekanand V, et al. Outcomes of angiosome and non-angiosome targeted revascularization in critical lower limb ischemia. J Vasc Surg. </text>
<text top="176" left="140" width="88" height="14" font="0">2013;57:44-9. </text>
<text top="193" left="86" width="946" height="14" font="0">  349.   Kret MR, Cheng D, Azarbal AF, et al. Utility of direct angiosome revascularization and runoff scores in predicting outcomes in patients undergoing </text>
<text top="211" left="140" width="440" height="14" font="0">revascularization for critical limb ischemia. J Vasc Surg. 2014;59:121-8. </text>
<text top="228" left="86" width="985" height="14" font="0">  350.   Lejay A, Georg Y, Tartaglia E, et al. Long-term outcomes of direct and indirect below-the-knee open revascularization based on the angiosome concept in </text>
<text top="245" left="140" width="464" height="14" font="0">diabetic patients with critical limb ischemia. Ann Vasc Surg. 2014;28:983-9. </text>
<text top="262" left="86" width="943" height="14" font="0">  351.   Neville RF, Attinger CE, Bulan EJ, et al. Revascularization of a specific angiosome for limb salvage: does the target artery matter? Ann Vasc Surg. </text>
<text top="280" left="140" width="103" height="14" font="0">2009;23:367-73. </text>
<text top="297" left="86" width="963" height="14" font="0">  352.   Osawa S, Terashi H, Tsuji Y, et al. Importance of the six angiosomes concept through arterial-arterial connections in CLI. Int Angiol. 2013;32:375-85. </text>
<text top="314" left="86" width="931" height="14" font="0">  353.   Abu Dabrh AM, Steffen MW, Undavalli C, et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62:1642-51. </text>
<text top="331" left="86" width="1010" height="14" font="0">  354.   Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled </text>
<text top="349" left="140" width="294" height="14" font="0">trial. Eur J Vasc Endovasc Surg. 2003;25:513-8. </text>
<text top="366" left="86" width="980" height="14" font="0">  355.   Weaver FA, Comerota AJ, Youngblood M, et al. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: </text>
<text top="383" left="140" width="892" height="14" font="0">results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity. J Vasc Surg. </text>
<text top="400" left="140" width="103" height="14" font="0">1996;24:513-21. </text>
<text top="418" left="86" width="987" height="14" font="0">  356.   Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. </text>
<text top="435" left="140" width="626" height="14" font="0">Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med. 1998;338:1105-11. </text>
<text top="452" left="86" width="981" height="14" font="0">  357.   Ponec D, Jaff MR, Swischuk J, et al. The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. J Vasc Interv </text>
<text top="469" left="140" width="143" height="14" font="0">Radiol. 2004;15:911-8. </text>
<text top="487" left="86" width="928" height="14" font="0">  358.   Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. </text>
<text top="504" left="140" width="118" height="14" font="0">2006;354:1879-88. </text>
<text top="521" left="86" width="993" height="14" font="0">  359.   Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in </text>
<text top="538" left="140" width="379" height="14" font="0">lower extremity bypass surgery. J Vasc Surg. 2006;43:742-51. </text>
<text top="556" left="86" width="1016" height="14" font="0">  360.   Farber A, Rosenfield K, Menard M. The BEST-CLI trial: a multidisciplinary effort to assess which therapy is best for patients with critical limb ischemia. Tech </text>
<text top="573" left="140" width="217" height="14" font="0">Vasc Interv Radiol. 2014;17:221-4. </text>
<text top="590" left="86" width="1006" height="14" font="0">  361.   Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the </text>
<text top="607" left="140" width="392" height="14" font="0">management of diabetic foot ulcers. Arch Surg. 2002;137:822-7. </text>
<text top="625" left="86" width="965" height="14" font="0">  362.   Fogle MA, Whittemore AD, Couch NP, et al. A comparison of in situ and reversed saphenous vein grafts for infrainguinal reconstruction. J Vasc Surg. </text>
<text top="642" left="140" width="88" height="14" font="0">1987;5:46-52. </text>
<text top="659" left="86" width="976" height="14" font="0">  363.   Rashid H, Slim H, Zayed H, et al. The impact of arterial pedal arch quality and angiosome revascularization on foot tissue loss healing and infrapopliteal </text>
<text top="676" left="140" width="294" height="14" font="0">bypass outcome. J Vasc Surg. 2013;57:1219-26. </text>
<text top="694" left="86" width="1016" height="14" font="0">  364.   Nolan BW, De Martino RR, Stone DH, et al. Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor </text>
<text top="711" left="140" width="409" height="14" font="0">outcome after lower extremity bypass. J Vasc Surg. 2011;54:730-5. </text>
<text top="728" left="86" width="979" height="14" font="0">  365.   Santo VJ, Dargon P, Azarbal AF, et al. Lower extremity autologous vein bypass for critical limb ischemia is not adversely affected by prior endovascular </text>
<text top="745" left="140" width="250" height="14" font="0">procedure. J Vasc Surg. 2014;60:129-35. </text>
<text top="763" left="86" width="778" height="14" font="0">  366.   Uhl C, Hock C, Betz T, et al. Pedal bypass surgery after crural endovascular intervention. J Vasc Surg. 2014;59:1583-7. </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">203 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="965" height="14" font="0">  367.   Korhonen M, Biancari F, Söderström M, et al. Femoropopliteal balloon angioplasty vs. bypass surgery for CLI: a propensity score analysis. Eur J Vasc </text>
<text top="107" left="140" width="201" height="14" font="0">Endovasc Surg. 2011;41:378-84. </text>
<text top="124" left="86" width="940" height="14" font="0">  368.   Kasemi H, Marino M, Dionisi CP, et al. Seven-year approach evolution of the aortoiliac occlusive disease endovascular treatment. Ann Vasc Surg. </text>
<text top="142" left="140" width="103" height="14" font="0">2016;30:277-85. </text>
<text top="159" left="86" width="990" height="14" font="0">  369.   Bredahl K, Jensen LP, Schroeder TV, et al. Mortality and complications after aortic bifurcated bypass procedures for chronic aortoiliac occlusive disease. J </text>
<text top="176" left="140" width="165" height="14" font="0">Vasc Surg. 2015;62:75-82. </text>
<text top="193" left="86" width="996" height="14" font="0">  370.   Chew DK, Conte MS, Donaldson MC, et al. Autogenous composite vein bypass graft for infrainguinal arterial reconstruction. J Vasc Surg. 2001;33:259-64. </text>
<text top="211" left="86" width="809" height="14" font="0">  371.   Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev. 2010;CD006544. </text>
<text top="228" left="86" width="997" height="14" font="0">  372.   Moran PS, Teljeur C, Harrington P, et al. A systematic review of intermittent pneumatic compression for critical limb ischaemia. Vasc Med. 2015;20:41-50. </text>
<text top="245" left="86" width="964" height="14" font="0">  373.   Kobayashi N, Hirano K, Nakano M, et al. Prognosis of critical limb ischemia patients with tissue loss after achievement of complete wound healing by </text>
<text top="262" left="140" width="310" height="14" font="0">endovascular therapy. J Vasc Surg. 2015;61:951-9. </text>
<text top="280" left="86" width="767" height="14" font="0">  374.   Rutherford RB. Acute limb ischemia: Clinical assessment and standards for reporting. Semin Vasc Surg. 1992;5:4-10. </text>
<text top="297" left="86" width="824" height="14" font="0">  375.   Nypaver TJ, Whyte BR, Endean ED, et al. Nontraumatic lower-extremity acute arterial ischemia. Am J Surg. 1998;176:147-52. </text>
<text top="314" left="86" width="691" height="14" font="0">  376.   FOGARTY TJ, CRANLEY JJ. Catheter Technic for Arterial Embolectomy. Ann Surg. 1965;161:325-30. </text>
<text top="331" left="86" width="988" height="14" font="0">  377.   Shin HS, Kyoung KH, Suh BJ, et al. Acute limb ischemia: surgical thromboembolectomy and the clinical course of arterial revascularization at ankle. Int J </text>
<text top="349" left="140" width="152" height="14" font="0">Angiol. 2013;22:109-14. </text>
<text top="366" left="86" width="988" height="14" font="0">  378.   de Donato G, Setacci F, Sirignano P, et al. The combination of surgical embolectomy and endovascular techniques may improve outcomes of patients with </text>
<text top="383" left="140" width="348" height="14" font="0">acute lower limb ischemia. J Vasc Surg. 2014;59:729-36. </text>
<text top="400" left="86" width="912" height="14" font="0">  379.   Baril DT, Patel VI, Judelson DR, et al. Outcomes of lower extremity bypass performed for acute limb ischemia. J Vasc Surg. 2013;58:949-56. </text>
<text top="418" left="86" width="973" height="14" font="0">  380.   Manojlovic V, Popovic V, Nikolic D, et al. Analysis of associated diseases in patients with acute critical lower limb ischemia. Med Pregl. 2013;66:41-5. </text>
<text top="435" left="86" width="1006" height="14" font="0">  381.   Duval S, Keo HH, Oldenburg NC, et al. The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: the FRIENDS registry. </text>
<text top="452" left="140" width="187" height="14" font="0">Am Heart J. 2014;168:577-87. </text>
<text top="469" left="86" width="1017" height="14" font="0">  382.   Morris-Stiff G, D'Souza J, Raman S, et al. Update experience of surgery for acute limb ischaemia in a district general hospital-are we getting any better? Ann R </text>
<text top="487" left="140" width="201" height="14" font="0">Coll Surg Engl. 2009;91:637-40. </text>
<text top="504" left="86" width="994" height="14" font="0">  383.   Londero LS, Nørgaard B, Houlind K. Patient delay is the main cause of treatment delay in acute limb ischemia: an investigation of pre- and in-hospital time </text>
<text top="521" left="140" width="239" height="14" font="0">delay. World J Emerg Surg. 2014;9:56. </text>
<text top="538" left="86" width="996" height="14" font="0">  384.   Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral </text>
<text top="556" left="140" width="297" height="14" font="0">arterial ischemia. J Vasc Surg. 1994;19:1021-30. </text>
<text top="573" left="86" width="931" height="14" font="0">  385.   Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. </text>
<text top="590" left="140" width="103" height="14" font="0">1994;220:266-8. </text>
<text top="607" left="86" width="995" height="14" font="0">  386.   Comerota AJ, Weaver FA, Hosking JD, et al. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass </text>
<text top="625" left="140" width="224" height="14" font="0">grafts. Am J Surg. 1996;172:105-12. </text>
<text top="642" left="86" width="1000" height="14" font="0">  387.   Diffin DC, Kandarpa K. Assessment of peripheral intraarterial thrombolysis versus surgical revascularization in acute lower-limb ischemia: a review of limb-</text>
<text top="659" left="140" width="411" height="14" font="0">salvage and mortality statistics. J Vasc Interv Radiol. 1996;7:57-63. </text>
<text top="676" left="86" width="1005" height="14" font="0">  388.   Schrijver AM, Reijnen MM, van Oostayen JA, et al. Dutch randomized trial comparing standard catheter-directed thrombolysis versus ultrasound-accelerated </text>
<text top="694" left="140" width="639" height="14" font="0">thrombolysis for thromboembolic infrainguinal disease (DUET): design and rationale. Trials. 2011;12:20. </text>
<text top="711" left="86" width="998" height="14" font="0">  389.   Fagundes C, Fuchs FD, Fagundes A, et al. Prognostic factors for amputation or death in patients submitted to vascular surgery for acute limb ischemia. Vasc </text>
<text top="728" left="140" width="212" height="14" font="0">Health Risk Manag. 2005;1:345-9. </text>
<text top="745" left="86" width="938" height="14" font="0">  390.   FOGARTY TJ, CRANLEY JJ, KRAUSE RJ, et al. A method for extraction of arterial emboli and thrombi. Surg Gynecol Obstet. 1963;116:241-4. </text>
<text top="763" left="86" width="907" height="14" font="0">  391.   Eliason JL, Wakefield TW. Metabolic consequences of acute limb ischemia and their clinical implications. Semin Vasc Surg. 2009;22:29-33. </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">204 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="1017" height="14" font="0">  392.   Lurie F, Vaidya V, Comerota AJ. Clinical outcomes and cost-effectiveness of initial treatment strategies for nonembolic acute limb ischemia in real-life clinical </text>
<text top="107" left="140" width="236" height="14" font="0">settings. J Vasc Surg. 2015;61:138-46. </text>
<text top="124" left="86" width="1003" height="14" font="0">  393.   Taha AG, Byrne RM, Avgerinos ED, et al. Comparative effectiveness of endovascular versus surgical revascularization for acute lower extremity ischemia. J </text>
<text top="142" left="140" width="173" height="14" font="0">Vasc Surg. 2015;61:147-54. </text>
<text top="159" left="86" width="1006" height="14" font="0">  394.   Gupta R, Hennebry TA. Percutaneous isolated pharmaco-mechanical thrombolysis-thrombectomy system for the management of acute arterial limb ischemia: </text>
<text top="176" left="140" width="558" height="14" font="0">30-day results from a single-center experience. Catheter Cardiovasc Interv. 2012;80:636-43. </text>
<text top="193" left="86" width="1001" height="14" font="0">  395.   Ansel GM, Botti CF, Silver MJ. Treatment of acute limb ischemia with a percutaneous mechanical thrombectomy-based endovascular approach: 5-year limb </text>
<text top="211" left="140" width="607" height="14" font="0">salvage and survival results from a single center series. Catheter Cardiovasc Interv. 2008;72:325-30. </text>
<text top="228" left="86" width="968" height="14" font="0">  396.   Byrne RM, Taha AG, Avgerinos E, et al. Contemporary outcomes of endovascular interventions for acute limb ischemia. J Vasc Surg. 2014;59:988-95. </text>
<text top="245" left="86" width="1000" height="14" font="0">  397.   Schernthaner MB, Samuels S, Biegler P, et al. Ultrasound-accelerated versus standard catheter-directed thrombolysis in 102 patients with acute and subacute </text>
<text top="262" left="140" width="333" height="14" font="0">limb ischemia. J Vasc Interv Radiol. 2014;25:1149-56. </text>
<text top="280" left="86" width="1017" height="14" font="0">  398.   Silva JA, Ramee SR, Collins TJ, et al. Rheolytic thrombectomy in the treatment of acute limb-threatening ischemia: immediate results and six-month follow-up </text>
<text top="297" left="140" width="829" height="14" font="0">of the multicenter AngioJet registry. Possis Peripheral AngioJet Study AngioJet Investigators. Cathet Cardiovasc Diagn. 1998;45:386-93. </text>
<text top="314" left="86" width="993" height="14" font="0">  399.   Kasirajan K, Gray B, Beavers FP, et al. Rheolytic thrombectomy in the management of acute and subacute limb-threatening ischemia. J Vasc Interv Radiol. </text>
<text top="331" left="140" width="103" height="14" font="0">2001;12:413-21. </text>
<text top="349" left="86" width="979" height="14" font="0">  400.   Allie DE, Hebert CJ, Lirtzman MD, et al. Novel simultaneous combination chemical thrombolysis/rheolytic thrombectomy therapy for acute critical limb </text>
<text top="366" left="140" width="536" height="14" font="0">ischemia: the power-pulse spray technique. Catheter Cardiovasc Interv. 2004;63:512-22. </text>
<text top="383" left="86" width="995" height="14" font="0">  401.   Elmahdy MF, Ghareeb MS, Baligh EE, et al. Value of duplex scanning in differentiating embolic from thrombotic arterial occlusion in acute limb ischemia. </text>
<text top="400" left="140" width="249" height="14" font="0">Cardiovasc Revasc Med. 2010;11:223-6. </text>
<text top="418" left="86" width="983" height="14" font="0">  402.   Ascher E, Hingorani A, Markevich N, et al. Acute lower limb ischemia: the value of duplex ultrasound arterial mapping (DUAM) as the sole preoperative </text>
<text top="435" left="140" width="314" height="14" font="0">imaging technique. Ann Vasc Surg. 2003;17:284-9. </text>
<text top="452" left="86" width="1005" height="14" font="0">  403.   Lowery AJ, Hynes N, Manning BJ, et al. A prospective feasibility study of duplex ultrasound arterial mapping, digital-subtraction angiography, and magnetic </text>
<text top="469" left="140" width="840" height="14" font="0">resonance angiography in management of critical lower limb ischemia by endovascular revascularization. Ann Vasc Surg. 2007;21:443-51. </text>
<text top="487" left="86" width="982" height="14" font="0">  404.   Leung DA, Blitz LR, Nelson T, et al. Rheolytic pharmacomechanical thrombectomy for the management of acute limb ischemia: results from the PEARL </text>
<text top="504" left="140" width="269" height="14" font="0">Registry. J Endovasc Ther. 2015;22:546-57. </text>
<text top="521" left="86" width="1014" height="14" font="0">  405.   Schrijver AM, Reijnen MM, van Oostayen JA, et al. Initial results of catheter-directed ultrasound-accelerated thrombolysis for thromboembolic obstructions of </text>
<text top="538" left="140" width="549" height="14" font="0">the aortofemoral arteries: a feasibility study. Cardiovasc Intervent Radiol. 2012;35:279-85. </text>
<text top="556" left="86" width="1003" height="14" font="0">  406.   Schrijver A, Vos J, Hoksbergen AW, et al. Ultrasound-accelerated thrombolysis for lower extremity ischemia: multicenter experience and literature review. J </text>
<text top="573" left="140" width="269" height="14" font="0">Cardiovasc Surg (Torino ). 2011;52:467-76. </text>
<text top="590" left="86" width="970" height="14" font="0">  407.   Ihlberg L, Luther M, Albäck A, et al. Does a completely accomplished duplex-based surveillance prevent vein-graft failure? Eur J Vasc Endovasc Surg. </text>
<text top="607" left="140" width="111" height="14" font="0">1999;18:395-400. </text>
<text top="625" left="86" width="999" height="14" font="0">  408.   Lundell A, Lindblad B, Bergqvist D, et al. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized </text>
<text top="642" left="140" width="215" height="14" font="0">study. J Vasc Surg. 1995;21:26-33. </text>
<text top="659" left="86" width="1011" height="14" font="0">  409.   Jongsma H, Bekken JA, van Buchem F, et al. Secondary interventions in patients with autologous infrainguinal bypass grafts strongly improve patency rates. J </text>
<text top="676" left="140" width="173" height="14" font="0">Vasc Surg. 2016;63:385-90. </text>
<text top="694" left="86" width="1002" height="14" font="0">  410.   Carter A, Murphy MO, Halka AT, et al. The natural history of stenoses within lower limb arterial bypass grafts using a graft surveillance program. Ann Vasc </text>
<text top="711" left="140" width="147" height="14" font="0">Surg. 2007;21:695-703. </text>
<text top="728" left="86" width="1017" height="14" font="0">  411.   Westerband A, Mills JL, Kistler S, et al. Prospective validation of threshold criteria for intervention in infrainguinal vein grafts undergoing duplex surveillance. </text>
<text top="745" left="140" width="187" height="14" font="0">Ann Vasc Surg. 1997;11:44-8. </text>
<text top="763" left="86" width="1015" height="14" font="0">  412.   Mills JL, Harris EJ, Taylor LM, et al. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. J </text>
<text top="780" left="140" width="173" height="14" font="0">Vasc Surg. 1990;12:379-86. </text>
</page>
<page number="205" position="absolute" top="0" left="0" height="918" width="1188">
<text top="795" left="1081" width="24" height="17" font="0">205 </text>
<text top="812" left="86" width="460" height="17" font="0">© American Heart Association, Inc. and American College of Cardiology Foundation </text>
<text top="830" left="1102" width="3" height="17" font="0"> </text>
<text top="847" left="86" width="3" height="17" font="0"> </text>
<text top="90" left="86" width="999" height="14" font="0">  413.   Brumberg RS, Back MR, Armstrong PA, et al. The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure. J </text>
<text top="107" left="140" width="173" height="14" font="0">Vasc Surg. 2007;46:1160-6. </text>
<text top="124" left="86" width="997" height="14" font="0">  414.   Calligaro KD, Doerr K, McAffee-Bennett S, et al. Should duplex ultrasonography be performed for surveillance of femoropopliteal and femorotibial arterial </text>
<text top="142" left="140" width="322" height="14" font="0">prosthetic bypasses? Ann Vasc Surg. 2001;15:520-4. </text>
<text top="159" left="86" width="891" height="14" font="0">  415.   Stone PA, Armstrong PA, Bandyk DF, et al. Duplex ultrasound criteria for femorofemoral bypass revision. J Vasc Surg. 2006;44:496-502. </text>
<text top="176" left="86" width="1016" height="14" font="0">  416.   Back MR, Novotney M, Roth SM, et al. Utility of duplex surveillance following iliac artery angioplasty and primary stenting. J Endovasc Ther. 2001;8:629-37. </text>
<text top="193" left="86" width="985" height="14" font="0">  417.   Baril DT, Marone LK. Duplex evaluation following femoropopliteal angioplasty and stenting: criteria and utility of surveillance. Vasc Endovascular Surg. </text>
<text top="211" left="140" width="96" height="14" font="0">2012;46:353-7. </text>
<text top="228" left="86" width="1013" height="14" font="0">  418.   Troutman DA, Madden NJ, Dougherty MJ, et al. Duplex ultrasound diagnosis of failing stent grafts placed for occlusive disease. J Vasc Surg. 2014;60:1580-4. </text>
<text top="245" left="86" width="1014" height="14" font="0">  419.   Connors G, Todoran TM, Engelson BA, et al. Percutaneous revascularization of long femoral artery lesions for claudication: patency over 2.5 years and impact </text>
<text top="262" left="140" width="443" height="14" font="0">of systematic surveillance. Catheter Cardiovasc Interv. 2011;77:1055-62. </text>
<text top="280" left="86" width="4" height="14" font="0"> </text>
<text top="293" left="86" width="3" height="17" font="0"> </text>
</page>
</pdf2xml>
